[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fKl_iiq75zjpnCB2GZGMspRhAoAo-DHf6N7HxkxRUIe4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":88,"rows":95},"Boehringer Ingelheim",[4],2275,false,96,399,15710388,106,131,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Healthy",798,{"name":18,"count":19},"Pulmonary Disease, Chronic Obstructive",232,{"name":21,"count":22},"Diabetes Mellitus, Type 2",126,{"name":24,"count":25},"Hypertension",122,{"name":27,"count":28},"HIV Infections",67,{"name":30,"count":31},"Asthma",62,{"name":33,"count":34},"Neoplasms",57,{"name":36,"count":37},"Carcinoma, Non-Small-Cell Lung",56,[39,44,49,54,59,64,69,74,79,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05249426","A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","2024-07-15","BI 765063",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05327946","A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated","2024-07-16","BI 770371",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05879978","A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","2025-06-11","Obrixtamig",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04958239","A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer","2026-04-27","BI 765179",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06077864","A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)","2026-05-08","survodutide",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07413913","A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector","2026-05-28","Survodutide formulation A",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT03363464","Comparative Effectiveness of Empagliflozin in the US","2026-05-31","Empagliflozin",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04325217","Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan","2026-06-30","Nintedanib",{"nctId":80,"briefTitle":81,"date":77,"intervention":82},"NCT05990738","DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","BI 764532",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT06013969","A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares","2026-07-23","Spesolimab",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,345,910,1080,1194,1338,1448,1511,1563,1594,1742,1790,1816,1844,1957,2043,2073,2152,2189,2270,2288,2315,2333,2351,2369,2440,2615,2674,2743,2810,2868,2907,2944,2976,3006,3041,3068,3086,3104,3131,3149,3167,3194,3212,3230,3248,3266,3284,3302,3320,3344,3362,3457,3633,3681,3716,3775,3823,3858,3910,3958,4199,4306,4375,4402,4538,4572,4601,4619,4637,4662,4680,4704,4722,4745,4763,4781,4803,4827,4845,4863,4884,4902,4929,4947,4965,4983,5001,5019,5037,5055,5073,5097,5122,5140,5163,5186,5204,5589,5651,5694,5730,5748,5772,5790,5808,5831,5981,6105,6195,6288,6359,6419,6483,6548,6613,6688,6746,6796,6844,6889,6939,6978,7028,7058,7099,7138,7173,7201,7230,7256,7285,7318,7344,7368,7402,7438,7460,7492,7530,7558,7590,7623,7646,7664,7686,7710,7728,7746,7769,7787,7810,7828,7853,7871,7889,7907,7932,7950,7968,7986,8008,8026,8051,8069,8091,8115,8133,8156,8174,8192,8210,8228,8246,8264,8287,8309,8327,8350,8368,8386,8404,8422,8440,8462,8485,8503,8521,8545,8563,8588,8606,8624,8642,8660,8683,8706,8724,8746,8764,8786,8809,8832,8850,8871,8894,8918,8936,8954,8978,8996,9014,9032,9050,9075,9098,9124,9142,9160,9178,9196,9218,9241,9259,9283,9301,9322,9569,9742,9871,9984,10062,10132,10227,10284,10367,10453,10506,10583,10637,10711,10759,10801,10853,10895,10939,10992,11033,11078,11112,11153,11190,11220,11259,11285,11311,11344,11379,11426,11468,11494,11522,11563,11595,11631,11673,11710,11749,11778,11804,11835,11872,11907,11936,11968,11997,12028,12050,12072,12096,12118,12147,12174,12206,12236,12263,12298,12331,12357,12385,12413,12439,12469,12498,12528,12562,12587,12621,12643,12674,12702,12732,12762,12794,12816,12838,12867,12899,12921,12948,12974,12996,13027,13049,13071,13093,13127,13149,13181,13203,13237,13270,13299,13321,13350,13372,13400,13428,13450,13472,13500,13529,13556,13578,13601,13619,13637,13655,13673,13691,13709,13727,13745,13763,13786,13804,13822,13840,13858,13876,13894,13912,13938,13956,13980,13998,14016,14034,14052,14070,14088,14106,14124,14142,14166,14184,14202,14224,14246,14264,14282,14300,14318,14336,14354,14377,14395,14420,14438,14456,14474,14498,14520,14538,14564,14582,14600,14618,14636,14654,14677,14695,14718,14736,14760,14778,14796,14814,14837,14855,14881,14899,14917,14935,14953,14975,14993,15011,15029,15047,15065,15083,15106,15124,15149,15173,15191,15212,15230,15248,15270,15288,15306,15324,15342,15360,15385,15403,15424,15446,15464,15485,15503,15525,15543,15567,15585,15603,15627,15645,15663,15685,15709,15727,15745,15766,15787,15809,15840,15858,15876,15894,15912,15930,15948,15966,15984,16002,16020,16038,16056,16074,16092,16110,16132,16158,16176,16198,16216,16234,16252,16275,16293,16311,16329,16352,16370,16388,16409,16427,16455,16473,16491,16509,16527,16545,16563,16581,16599,16622,16640,16661,16685,16706,16724,16742,16764,16782,16808,16826,16844,16862,16880,16898,16916,16938,16964,16982,17000,17018,17036,17054,17077,17095,17113,17136,17154,17172,17190,17208,17232,17255,17278,17296,17318,17336,17354,17372,17394,17412,17435,17456,17474,17492,17510,17528,17546,17564,17582,17600,17618,17636,17654,17672,17694,17719,17741,17759,17783,17801,17819,17837,17855,17873,17891,17909,17927,17952,17970,17988,18013,18031,18049,18067,18085,18108,18126,18144,18162,18180,18203,18221,18239,18263,18281,18303,18321,18339,18362,18387,18405,18423,18446,18464,18482,18500,18518,18536,18554,18576,18594,18612,18630,18795,18923,19058,19151,19259,19359,19451,19521,19574,19634,19699,19762,19817,19885,19948,19997,20060,20109,20167,20216,20280,20334,20384,20429,20480,20514,20553,20590,20620,20660,20706,20744,20792,20822,20857,20887,20933,20973,21015,21058,21096,21122,21162,21201,21235,21268,21306,21337,21370,21396,21430,21467,21498,21528,21565,21587,21609,21634,21664,21691,21716,21746,21774,21799,21829,21851,21880,21909,21935,21957,21981,22008,22030,22052,22088,22110,22147,22169,22191,22213,22247,22269,22293,22321,22346,22368,22386,22404,22422,22440,22458,22476,22494,22512,22535,22553,22574,22592,22614,22632,22654,22672,22690,22711,22729,22747,22765,22783,22801,22819,22837,22855,22873,22891,22909,22933,22951,22978,22996,23014,23032,23050,23068,23086,23112,23130,23148,23166,23184,23202,23223,23246,23264,23282,23300,23318,23342,23360,23378,23396,23419,23437,23455,23479,23497,23515,23533,23555,23573,23591,23609,23627,23650,23674,23692,23710,23734,23752,23774,23792,23810,23828,23846,23864,23886,23908,23926,23949,23967,23985,24007,24025,24043,24061,24079,24097,24115,24140,24158,24176,24194,24215,24245,24263,24281,24299,24317,24335,24353,24371,24389,24407,24429,24447,24471,24489,24507,24530,24556,24574,24592,24610,24628,24646,24664,24682,24700,24718,24736,24761,24779,24797,24820,24838,24856,24874,24897,24915,24933,24951,24969,24987,25010,25028,25046,25064,25082,25100,25118,25136,25160,25178,25196,25214,25236,25254,25275,25293,25314,25340,25358,25376,25399,25417,25435,25453,25471,25489,25507,25525,25547,25565,25587,25605,25629,25647,25665,25690,25708,25726,25749,25771,25789,25807,25830,25848,25871,25889,25907,25931,25949,25977,25995,26013,26031,26049,26067,26085,26103,26121,26146,26164,26182,26200,26218,26236,26254,26276,26294,26316,26334,26357,26375,26393,26411,26438,26456,26474,26492,26514,26532,26554,26576,26594,26612,26630,26648,26666,26684,26707,26725,26743,26766,26784,26807,26825,26843,26861,26879,26903,26921,26939,26961,26987,27005,27023,27041,27059,27077,27098,27116,27253,27313,27370,27417,27468,27514,27557,27598,27646,27691,27736,27782,27819,27864,27894,27935,27977,28017,28061,28099,28134,28164,28199,28235,28266,28305,28340,28377,28403,28437,28469,28504,28545,28578,28604,28638,28664,28692,28718,28751,28782,28816,28849,28882,28914,28940,28974,29000,29030,29064,29097,29123,29155,29188,29212,29236,29258,29280,29308,29336,29363,29387,29409,29438,29466,29493,29515,29544,29566,29597,29619,29641,29663,29687,29714,29745,29767,29796,29824,29852,29874,29902,29924,29946,29968,29995,30023,30048,30070,30098,30125,30152,30179,30203,30231,30253,30280,30302,30328,30356,30384,30415,30437,30471,30501,30523,30551,30578,30600,30627,30654,30678,30700,30731,30759,30784,30802,30820,30841,30859,30880,30903,30921,30939,30957,30975,30993,31011,31036,31054,31076,31094,31117,31135,31153,31175,31193,31216,31234,31252,31270,31294,31312,31333,31356,31374,31392,31414,31436,31454,31472,31494,31512,31534,31552,31570,31593,31611,31632,31650,31673,31691,31709,31727,31751,31769,31790,31808,31826,31848,31866,31884,31902,31920,31938,31956,31974,31996,32014,32035,32053,32071,32094,32112,32130,32152,32170,32193,32211,32232,32250,32268,32286,32304,32325,32348,32366,32384,32402,32425,32443,32461,32479,32501,32519,32537,32560,32578,32596,32618,32636,32657,32679,32697,32718,32736,32759,32777,32795,32819,32837,32855,32873,32896,32914,32932,32953,32980,32998,33016,33034,33052,33070,33088,33111,33129,33147,33165,33183,33207,33232,33250,33268,33286,33304,33322,33349,33367,33385,33403,33421,33439,33457,33475,33496,33518,33536,33554,33572,33590,33608,33631,33649,33667,33685,33703,33721,33739,33757,33780,33798,33816,33838,33856,33878,33896,33920,33938,33956,33974,34001,34019,34037,34055,34077,34095,34117,34135,34153,34171,34192,34214,34232,34256,34277,34299,34317,34339,34357,34381,34399,34417,34435,34453,34471,34489,34507,34529,34547,34565,34583,34601,34619,34637,34663,34681,34699,34717,34742,34760,34778,34796,34814,34835,34856,34874,34892,34910,34931,34953,34971,34989,35011,35029,35047,35065,35083,35104,35126,35144,35162,35180,35202,35220,35243,35267,35285,35303,35321,35339,35357,35375,35396,35418,35436,35458,35476,35500,35518,35536,35554,35582,35600,35618,35636,35654,35672,35690,35708,35730,35748,35772,35790,35808,35826,35847,35865,35887,35905,35928,35953,35971,35989,36007,36028,36046,36064,36085,36107,36125,36147,36165,36187,36205,36223,36241,36259,36280,36303,36321,36339,36360,36388,36406,36424,36442,36460,36478,36496,36514,36536,36554,36577,36595,36613,36631,36652,36670,36688,36706,36727,36745,36767,36785,36808,36826,36844,36869,36887,36905,36923,36941,36959,36977,36995,37013,37031,37049,37067,37085,37103,37125,37147,37165,37190,37208,37230,37251,37273,37291,37320,37338,37356,37374,37392,37410,37428,37446,37464,37485,37507,37525,37547,37565,37587,37605,37628,37646,37664,37682,37700,37718,37739,37760,37778,37800,37818,37840,37858,37879,37897,37915,37936,37957,37979,37997,38019,38037,38055,38076,38099,38117,38135,38157,38175,38198,38216,38234,38252,38270,38291,38312,38336,38354,38372,38390,38408,38434,38452,38470,38492,38510,38531,38549,38570,38588,38606,38629,38647,38665,38683,38705,38723,38747,38765,38783,38808,38826,38844,38865,38887,38905,38929,38947,38965,38983,39001,39025,39043,39061,39079,39102,39120,39138,39156,39174,39195,39223,39241,39259,39277,39295,39313,39331,39349,39371,39389,39410,39433,39451,39469,39492,39510,39528,39552,39570,39588,39612,39630,39648,39666,39690,39708,39726,39744,39768,39786,39804,39822,39844,39862,39886,39904,39922,39940,39958,39976,39994,40015,40040,40058,40076,40094,40115,40133,40151,40169,40187,40210,40228,40246,40268,40290,40308,40326,40347,40370,40388,40409,40427,40448,40469,40491,40509,40532,40550,40568,40590,40608,40626,40644,40662,40680,40698,40716,40734,40757,40775,40793,40814,40836,40854,40872,40894,40912,40933,40951,40973,40991,41013,41031,41049,41067,41085,41108,41131,41149,41174,41192,41210,41228,41246,41264,41285,41303,41321,41339,41357,41379,41397,41415,41433,41451,41476,41494,41512,41533,41555,41573,41591,41612,41635,41653,41671,41693,41714,41732,41750,41768,41786,41804,41822,41840,41858,41876,41894,41916,41934,41956,41974,41992,42010,42028,42046,42067,42090,42108,42126,42144,42169,42187,42205,42223,42241,42265,42283,42301,42319,42340,42362,42380,42403,42421,42439,42460,42481,42505,42523,42550,42568,42586,42604,42622,42644,42662,42680,42698,42716,42734,42755,42776,42797,42818,42836,42858,42876,42901,42919,42941,42959,42977,42995,43013,43035,43053,43075,43093,43111,43129,43147,43165,43186,43207,43233,43251,43269,43287,43305,43323,43344,43368,43386,43404,43422,43440,43458,43481,43499,43517,43535,43553,43574,43592,43617,43635,43653,43671,43689,43707,43725,43743,43761,43779,43804,43822,43840,43865,43883,43901,43919,43937,43960,43978,43996,44019,44037,44055,44078,44096,44119,44137,44159,44177,44200,44218,44236,44254,44272,44290,44313,44331,44349,44367,44385,44403,44421,44439,44462,44480,44498,44516,44534,44552,44575,44593,44611,44632,44650,44668,44686,44707,44728,44746,44764,44782,44800,44828,44846,44864,44882,44900,44918,44936,44954,44975,44997,45028,45046,45064,45082,45100,45118,45136,45154,45172,45190,45208,45229,45255,45273,45291,45309,45327,45345,45368,45386,45409,45427,45445,45471,45489,45507,45525,45543,45561,45579,45597,45615,45636,45658,45676,45699,45717,45735,45753,45771,45792,45815,45839,45857,45882,45900,45918,45936,45954,45977,45995,46013,46031,46052,46073,46091,46109,46135,46153,46171,46189,46207,46225,46243,46261,46279,46301,46319,46337,46359,46377,46399,46417,46442,46460,46478,46496,46521,46539,46557,46575,46593,46616,46634,46652,46674,46692,46710,46733,46751,46772,46794,46812,46835,46853,46878,46896,46914,46932,46953,46971,46994,47012,47030,47051,47069,47092,47115,47133,47151,47172,47190,47223,47241,47259,47277,47295,47313,47331,47349,47367,47385,47403,47421,47439,47461,47479,47501,47519,47540,47558,47581,47599,47617,47635,47653,47671,47695,47718,47736,47754,47772,47793,47811,47833,47851,47869,47887,47905,47923,47941,47965,47983,48001,48019,48037,48064,48082,48100,48118,48136,48154,48175,48200,48218,48236,48254,48272,48290,48313,48331,48349,48370,48394,48412,48430,48448,48474,48492,48510,48528,48546,48564,48582,48607,48625,48643,48664,48687,48705,48723,48741,48759,48777,48795,48813,48831,48849,48867,48885,48903,48921,48939,48963,48981,48999,49017,49038,49061,49079,49101,49119,49137,49159,49181,49199,49217,49235,49253,49271,49289,49628,50008,50247,50455,50711,50893,51150,51334,51464,51609,51800,51943,52072,52177,52280,52358,52429,52506,52564,52622,52690,52765,52819,52869,52950,53014,53074,53136,53178,53216,53264,53300,53337,53378,53408,53448,53478,53527,53563,53596,53632,53669,53705,53733,53765,53800,53826,53853,53887,53915,53949,53978,54006,54035,54057,54085,54111,54136,54164,54193,54215,54237,54259,54281,54309,54331,54353,54381,54405,54432,54460,54492,54518,54545,54567,54589,54611,54633,54657,54675,54693,54714,54732,54753,54771,54794,54816,54840,54864,54882,54900,54923,54946,54969,54991,55009,55032,55050,55075,55093,55115,55136,55158,55176,55194,55212,55233,55251,55269,55291,55313,55338,55356,55374,55399,55422,55440,55463,55481,55506,55524,55548,55566,55584,55602,55626,55644,55662,55680,55698,55724,55742,55760,55778,55800,55824,55842,55865,55883,55901,55919,55937,55961,55983,56001,56023,56045,56067,56090,56112,56133,56151,56175,56199,56217,56235,56258,56276,56302,56320,56338,56356,56374,56397,56415,56433,56455,56477,56495,56513,56531,56554,56577,56601,56619,56637,56655,56679,56697,56715,56733,56754,56772,56790,56812,56830,56851,56874,56896,56914,56932,56958,56976,56994,57012,57034,57056,57074,57097,57118,57136,57158,57183,57205,57228,57246,57264,57287,57309,57327,57345,57363,57385,57408,57426,57449,57470,57488,57512,57535],{"intervention":87,"totalTrials":97,"cells":98},23,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":135,"PHASE3":273,"PHASE4":325,"NA":334},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104,116,126],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT02978690","Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis","COMPLETED",[90],"2017-09-20","2018-01-10","2016-12-19",7,[114],"Psoriasis",[87],{"nctId":117,"briefTitle":118,"status":107,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":125},"NCT06520514","A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways",[90],"2025-01-15","2025-02-04","2024-08-07",60,[15],[87],{"nctId":127,"briefTitle":128,"status":107,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT03123094","Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects",[90],"2018-01-04","2017-05-16",32,[15],[87],{"trials":136,"activeCount":272,"soonestReadout":142},[137,148,159,170,181,192,203,213,224,234,244,254,263],{"nctId":138,"briefTitle":139,"status":140,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":12,"conditions":145,"interventions":147},"NCT03886246","Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study","ACTIVE_NOT_RECRUITING",[91],"2027-09-30","2028-04-27","2019-05-29",[146],"Generalized Pustular Psoriasis",[87,87],{"nctId":149,"briefTitle":150,"status":107,"phases":151,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NCT03100864","This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients",[91],"2019-08-05","2019-10-24","2017-05-22",8,[157],"Colitis, Ulcerative",[87],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT05013385","A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction","TERMINATED",[91],"2022-05-31","2021-11-09",5,[168],"Fibrostenotic Crohn´s Disease",[87],{"nctId":171,"briefTitle":172,"status":162,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT04086121","A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032",[91],"2021-04-28","2022-02-23","2019-09-24",14,[179],"Dermatitis, Atopic",[87],{"nctId":182,"briefTitle":183,"status":162,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT04362254","A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials",[91],"2022-05-14","2022-09-23","2020-05-15",12,[190],"Crohn Disease",[87],{"nctId":193,"briefTitle":194,"status":107,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":202},"NCT04015518","A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis",[91],"2020-08-06","2021-07-28","2019-07-31",152,[201],"Palmoplantar Pustulosis (PPP)",[87,87,87,87,87],{"nctId":204,"briefTitle":205,"status":107,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"NCT03123120","A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy",[91],"2020-03-26","2020-09-16","2017-06-07",22,[157],[87],{"nctId":214,"briefTitle":215,"status":162,"phases":216,"primaryCompletion":217,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT04493424","A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab",[91],"2023-01-16","2023-05-15","2020-09-04",108,[222],"Palmoplantar Pustulosis",[87],{"nctId":225,"briefTitle":226,"status":107,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":233},"NCT03782792","Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis",[91],"2020-09-23","2021-01-05","2019-01-31",53,[146],[87],{"nctId":235,"briefTitle":236,"status":107,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT03135548","Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients",[91],"2018-07-12","2018-11-14","2017-05-30",59,[114],[87,87],{"nctId":245,"briefTitle":246,"status":107,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT03752970","A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease",[91],"2021-12-01","2022-07-04","2019-02-05",27,[190],[87],{"nctId":255,"briefTitle":256,"status":107,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT04399837","A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis",[91],"2022-11-23","2020-06-04",123,[146],[87],{"nctId":264,"briefTitle":265,"status":107,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT03648541","BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis",[91],"2023-05-03","2018-10-29",79,[157],[87],1,{"trials":274,"activeCount":272,"soonestReadout":317},[275,285,294,303,312],{"nctId":276,"briefTitle":277,"status":107,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT05200247","An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options",[92],"2023-03-20","2022-02-17",11,[146],[284],"spesolimab",{"nctId":286,"briefTitle":287,"status":107,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT05239039","An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options",[92],"2023-07-17","2022-03-15",39,[146],[284],{"nctId":295,"briefTitle":296,"status":107,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT03482635","BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis",[91,92],"2020-05-18","2018-03-27",98,[157],[87],{"nctId":304,"briefTitle":305,"status":162,"phases":306,"primaryCompletion":307,"completion":307,"start":308,"enrollment":291,"conditions":309,"interventions":311},"NCT06241573","A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab",[91,92],"2025-04-11","2024-05-08",[310],"Hidradenitis Suppurativa (HS)",[87],{"nctId":313,"briefTitle":314,"status":315,"phases":316,"primaryCompletion":317,"completion":318,"start":121,"enrollment":319,"conditions":320,"interventions":322},"NCT06624670","A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum","RECRUITING",[92],"2027-11-12","2028-08-19",90,[321],"Pyoderma Gangrenosum",[87,323,324],"Prednisone","Prednisolone",{"trials":326,"activeCount":272,"soonestReadout":86},[327],{"nctId":84,"briefTitle":85,"status":140,"phases":328,"primaryCompletion":86,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},[93],"2026-08-14","2023-10-22",42,[146],[87],{"trials":335,"activeCount":101},[336],{"nctId":337,"briefTitle":338,"status":107,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT05670821","PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms",[],"2025-10-06","2023-04-18",52,[146],[87],{"intervention":73,"totalTrials":37,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":487,"PHASE3":554,"PHASE4":738,"NA":760},{"trials":348,"activeCount":101},[],{"trials":350,"activeCount":101},[351,363,374,386,395,404,415,424,433,442,452,461,470,478],{"nctId":352,"briefTitle":353,"status":107,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT03629054","This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills",[90],"2018-11-05","2018-08-27",30,[15],[360,73,361,362],"Empagliflozin, Metformin HCl, Linagliptin","Linagliptin","Metformin HCl",{"nctId":364,"briefTitle":365,"status":107,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":132,"conditions":370,"interventions":371},"NCT05083949","A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin\u002FMetformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together",[90],"2021-08-06","2021-09-09","2021-07-23",[15],[372,73,373],"FDC 12.5mg empagliflozin\u002F850mg metformin","Glifage®",{"nctId":375,"briefTitle":376,"status":107,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":382},"NCT01844531","Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets",[90],"2013-11","2013-04",24,[15],[383,384,384,383,385,385],"empagliflozin","metformin","empagliflozin and metformin",{"nctId":387,"briefTitle":388,"status":107,"phases":389,"primaryCompletion":390,"start":391,"enrollment":392,"conditions":393,"interventions":394},"NCT01451775","Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.",[90],"2011-11","2011-10",18,[15],[73,73,73],{"nctId":396,"briefTitle":397,"status":107,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":403},"NCT02782624","Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers",[90],"2009-11","2009-09",16,[15],[73,73],{"nctId":405,"briefTitle":406,"status":107,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT01811953","Equivalence of Resorption of Empagliflozin\u002FMetformin Administered as Combination Tablet Compared With Empagliflozin\u002FMetformin as Single Tablets Administered Together",[90],"2013-05","2013-03",48,[15],[73,413,73,414,413,414,73,413,414],"Metformin","Empagliflozin\u002FMetformin",{"nctId":416,"briefTitle":417,"status":107,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":357,"conditions":421,"interventions":422},"NCT02230995","Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin\u002FMetformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects",[90],"2014-10","2014-09",[15],[384,423,383],"empagliflozin\u002Fmetformin",{"nctId":425,"briefTitle":426,"status":107,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":357,"conditions":430,"interventions":431},"NCT03259490","This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood",[90],"2017-11-13","2017-08-31",[15],[432,73,361,362],"Empagliflozin\u002Flinagliptin\u002Fmetformin HCl",{"nctId":434,"briefTitle":435,"status":107,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT02577315","Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin\u002F500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions",[90],"2015-10","2015-09",25,[15],[73,413,73,413],{"nctId":443,"briefTitle":444,"status":107,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":450},"NCT01672788","Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets",[90],"2012-11","2012-08",36,[15],[73,451,413,413,451,73],"Empagliflozin + Metformin",{"nctId":453,"briefTitle":454,"status":107,"phases":455,"primaryCompletion":447,"completion":447,"start":456,"enrollment":392,"conditions":457,"interventions":458},"NCT01634100","Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid",[90],"2012-06",[15],[459,460,73,73,460,459,73],"Probenecid","Rifampicin",{"nctId":462,"briefTitle":463,"status":107,"phases":464,"primaryCompletion":465,"completion":466,"start":467,"enrollment":177,"conditions":468,"interventions":469},"NCT06962826","A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food",[90],"2025-06-26","2025-09-12","2025-05-27",[15],[73],{"nctId":471,"briefTitle":472,"status":107,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":357,"conditions":476,"interventions":477},"NCT02266472","Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin\u002FMetformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female",[90],"2014-12","2014-11",[15],[384,423,383],{"nctId":479,"briefTitle":480,"status":107,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":37,"conditions":485,"interventions":486},"NCT02758171","Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin\u002FLinagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects",[90],"2016-07-29","2016-08-03","2016-05-17",[15],[73,361],{"trials":488,"activeCount":272,"soonestReadout":493},[489,500,512,521,529,542],{"nctId":490,"briefTitle":491,"status":140,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT06926660","A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease",[91],"2026-08-20","2025-07-18",492,[497],"Chronic Kidney Disease",[499,73],"Vicadrostat",{"nctId":501,"briefTitle":502,"status":107,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT05182840","A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease",[91],"2023-06-19","2023-07-10","2022-01-11",714,[509],"Kidney Disease, Chronic",[511,73],"BI 690517",{"nctId":513,"briefTitle":514,"status":107,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":520},"NCT01649297","A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy",[91],"2013-12","2012-10",983,[21],[383,73,383,383],{"nctId":522,"briefTitle":523,"status":107,"phases":524,"primaryCompletion":437,"completion":437,"start":525,"enrollment":291,"conditions":526,"interventions":527},"NCT01867307","Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls",[91],"2013-06",[21,15],[73,528],"BI 10773",{"nctId":530,"briefTitle":531,"status":107,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":540},"NCT02632747","Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study",[91],"2017-12-19","2019-07-02","2016-05-10",31,[538,21,539],"Diabetes Mellitus, Type 1","Obesity",[73,541],"ramipril",{"nctId":543,"briefTitle":544,"status":162,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":319,"conditions":549,"interventions":552},"NCT05282121","A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)",[91],"2024-04-23","2024-06-07","2022-06-28",[550,551],"Liver Diseases","Hypertension, Portal",[553,73],"Avenciguat",{"trials":555,"activeCount":166,"soonestReadout":569},[556,565,576,587,597,607,614,624,634,644,653,664,674,683,692,701,710,719,728],{"nctId":557,"briefTitle":558,"status":107,"phases":559,"primaryCompletion":560,"completion":561,"start":230,"enrollment":562,"conditions":563,"interventions":564},"NCT03594110","EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)",[92],"2022-07-05","2024-07-02",6609,[497],[73],{"nctId":566,"briefTitle":567,"status":315,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT06424288","A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure",[92],"2028-05-22","2024-06-17",6000,[573],"Heart Failure",[575,383],"vicadrostat",{"nctId":577,"briefTitle":578,"status":107,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":584,"interventions":585},"NCT03429543","Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM",[92],"2022-10-19","2023-05-31","2018-03-20",175,[21],[413,586,361,73],"Insulin",{"nctId":588,"briefTitle":589,"status":315,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":596},"NCT06935370","A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart",[92],"2029-02-04","2029-02-22","2025-05-20",4200,[573],[575,383],{"nctId":598,"briefTitle":599,"status":600,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":101,"conditions":604,"interventions":605},"NCT01984606","Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes","WITHDRAWN",[92],"2017-02","2015-01",[21],[73,606],"Sitagliptin",{"nctId":608,"briefTitle":609,"status":107,"phases":610,"primaryCompletion":516,"completion":516,"start":611,"enrollment":123,"conditions":612,"interventions":613},"NCT01947855","Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus",[92],"2013-09",[21],[73,73],{"nctId":615,"briefTitle":616,"status":107,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT02414958","Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)",[92],"2017-04-20","2017-10-23","2015-06-30",730,[538],[73,73],{"nctId":625,"briefTitle":626,"status":107,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT04509674","EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)",[92],"2023-11-05","2020-12-16",6522,[632],"Myocardial Infarction",[73],{"nctId":635,"briefTitle":636,"status":315,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":643},"NCT07107945","A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)",[92],"2028-06-26","2029-06-25","2025-12-09",120,[497],[73],{"nctId":645,"briefTitle":646,"status":107,"phases":647,"primaryCompletion":648,"completion":649,"start":582,"enrollment":650,"conditions":651,"interventions":652},"NCT03448406","This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.",[92],"2019-10-04","2019-10-09",315,[573],[73],{"nctId":654,"briefTitle":655,"status":315,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":663},"NCT07064473","EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease",[92],"2029-12-14","2029-12-21","2025-07-22",11800,[21,24,662],"Cardiovascular Diseases",[499,73],{"nctId":665,"briefTitle":666,"status":107,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":673},"NCT03057977","EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)",[92],"2020-05-01","2020-05-28","2017-03-06",3730,[573],[73],{"nctId":675,"briefTitle":676,"status":107,"phases":677,"primaryCompletion":678,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":682},"NCT03057951","EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)",[92],"2021-04-26","2017-03-02",5988,[573],[73],{"nctId":684,"briefTitle":685,"status":107,"phases":686,"primaryCompletion":687,"completion":688,"start":298,"enrollment":689,"conditions":690,"interventions":691},"NCT04157751","A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure",[92],"2021-05-28","2021-06-02",530,[573],[73],{"nctId":693,"briefTitle":694,"status":107,"phases":695,"primaryCompletion":696,"completion":697,"start":582,"enrollment":698,"conditions":699,"interventions":700},"NCT03448419","This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms",[92],"2019-09-30","2019-10-07",312,[573],[73],{"nctId":702,"briefTitle":703,"status":315,"phases":704,"primaryCompletion":705,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":709},"NCT06531824","EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)",[92],"2028-08-30","2024-08-30",11000,[509],[511,73],{"nctId":711,"briefTitle":712,"status":107,"phases":713,"primaryCompletion":714,"completion":669,"start":715,"enrollment":716,"conditions":717,"interventions":718},"NCT03332212","A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin",[92],"2020-05-21","2018-03-01",72,[573],[73],{"nctId":720,"briefTitle":721,"status":107,"phases":722,"primaryCompletion":723,"completion":109,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT02580591","Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)",[92],"2017-09-12","2015-12-22",977,[538],[73],{"nctId":729,"briefTitle":730,"status":107,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":737},"NCT04233801","A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin",[92],"2022-03-03","2022-03-10","2020-04-15",219,[21],[73],{"trials":739,"activeCount":101},[740,750],{"nctId":741,"briefTitle":742,"status":107,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT04531462","A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years",[93],"2022-08-19","2022-08-26","2020-10-05",129,[21],[73],{"nctId":751,"briefTitle":752,"status":107,"phases":753,"primaryCompletion":754,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":759},"NCT02589639","Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus",[93],"2017-04-18","2018-01-05","2015-10-28",269,[21],[73],{"trials":761,"activeCount":272,"soonestReadout":72},[762,771,780,790,800,812,820,830,840,849,860,872,882,892,901],{"nctId":763,"briefTitle":764,"status":600,"phases":765,"primaryCompletion":766,"completion":766,"start":767,"enrollment":101,"conditions":768,"interventions":769},"NCT05102071","Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas",[],"2022-06-15","2021-11-01",[21,662],[383,384,770],"sulfonylurea",{"nctId":772,"briefTitle":773,"status":107,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":779},"NCT04098575","A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes",[],"2019-12-31","2019-09-16",9571,[21],[73],{"nctId":781,"briefTitle":782,"status":107,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":788},"NCT03764631","Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration",[],"2021-01-11","2018-09-26",1502,[21],[73,789],"Dipeptidyl-peptidase 4 (DPP-4) inhibitors",{"nctId":791,"briefTitle":792,"status":107,"phases":793,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":798},"NCT03993132","A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes",[],"2022-06-16","2018-10-01",26774,[21],[73,799],"Liraglutide",{"nctId":801,"briefTitle":802,"status":107,"phases":803,"primaryCompletion":804,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":808},"NCT03807440","DIA_CENTRAL:T2D Treatment Pattern in Central Europe",[],"2021-08-31","2019-08-26",4083,[21],[73,809,810,811],"Sodium Glucose Transporter 2 inhibitor","Dipeptidyl-peptidase 4 inhibitor","Glucagon-like peptide 1 agonist",{"nctId":70,"briefTitle":71,"status":140,"phases":813,"primaryCompletion":72,"completion":72,"start":814,"enrollment":815,"conditions":816,"interventions":817},[],"2017-10-16",230000,[21],[73,818,819],"DPP-4 inhibitor","GLP-1 receptor agonist",{"nctId":821,"briefTitle":822,"status":107,"phases":823,"primaryCompletion":824,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":829},"NCT04927858","A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017",[],"2018-11-15","2018-04-02",460558,[828],"Type 2 Diabetes Mellitus",[73],{"nctId":831,"briefTitle":832,"status":107,"phases":833,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":838},"NCT05465317","Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease",[],"2023-05-02","2022-08-08",62197,[21],[73,839],"Dipeptidyl Peptidate-4 inhibitors",{"nctId":841,"briefTitle":842,"status":107,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":848},"NCT04937816","This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations",[],"2021-07-13","2021-06-01",16746,[21],[73],{"nctId":850,"briefTitle":851,"status":107,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":857},"NCT04295005","A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists",[],"2021-09-30","2020-11-16",24500,[21],[73,858,859],"DPP-4i","GLP-1-RA",{"nctId":861,"briefTitle":862,"status":107,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT03050619","Characteristics of Empagliflozin Initiators",[],"2016-10-14","2016-09-10",31908,[868],"Type 2 Diabetes",[73,870,871],"Other SGLT2 inhibitors","Other non-insulin GLDs",{"nctId":873,"briefTitle":874,"status":107,"phases":875,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":879,"interventions":880},"NCT02864914","Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors",[],"2022-07-29","2016-03-15",333580,[21],[73,881],"DPP-4 inhibitors",{"nctId":883,"briefTitle":884,"status":107,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":890},"NCT05162014","To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin",[],"2022-09-12","2021-12-20",494679,[21],[383,891],"Oral non-incretin\u002Fnon-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents",{"nctId":893,"briefTitle":894,"status":107,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":900},"NCT05350202","Emp-Activity: Empagliflozin Functional Capacity",[],"2024-07-25","2022-12-18",3431,[573],[73],{"nctId":902,"briefTitle":903,"status":107,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":909},"NCT03464045","Empa PASS on Urinary Tract Malignancies",[],"2024-03-11","2016-11-16",344995,[21],[383,881],{"intervention":911,"totalTrials":912,"cells":913},"Zongertinib",13,{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":996,"PHASE3":1045,"PHASE4":1076,"NA":1078},{"trials":915,"activeCount":101},[],{"trials":917,"activeCount":272,"soonestReadout":934},[918,930,941,950,959,972,979,988],{"nctId":919,"briefTitle":920,"status":107,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":401,"conditions":924,"interventions":925},"NCT06494761","A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body",[90],"2024-10-16","2024-07-30",[15],[926,927,928,929],"zongertinib","midazolam","omeprazole","repaglinide",{"nctId":931,"briefTitle":932,"status":140,"phases":933,"primaryCompletion":934,"completion":705,"start":935,"enrollment":936,"conditions":937,"interventions":940},"NCT04886804","Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)",[90],"2026-12-30","2021-07-02",608,[938,939],"Neoplasm Metastasis","Non-Small Cell Lung Cancer",[926],{"nctId":942,"briefTitle":943,"status":107,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":401,"conditions":947,"interventions":948},"NCT05833139","A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood",[90],"2023-06-12","2023-04-14",[15],[911,949],"Itraconazole",{"nctId":951,"briefTitle":952,"status":107,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":958},"NCT05879991","A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body",[90],"2023-10-19","2023-08-10",15,[15],[926,926,926],{"nctId":960,"briefTitle":961,"status":107,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":132,"conditions":966,"interventions":967},"NCT06504862","A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood",[90],"2024-10-03","2024-12-18","2024-08-20",[15],[911,968,969,970,971],"Dabigatran-etexilate","Rosuvastatin","Metformin hydrochloride","Furosemide",{"nctId":973,"briefTitle":974,"status":107,"phases":975,"primaryCompletion":976,"completion":976,"start":954,"enrollment":401,"conditions":977,"interventions":978},"NCT06075277","A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food",[90],"2024-01-02",[15],[926],{"nctId":980,"briefTitle":981,"status":107,"phases":982,"primaryCompletion":983,"completion":983,"start":984,"enrollment":401,"conditions":985,"interventions":986},"NCT06028464","A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood",[90],"2023-12-08","2023-09-11",[15],[911,987],"Carbamazepine",{"nctId":989,"briefTitle":990,"status":107,"phases":991,"primaryCompletion":992,"completion":992,"start":120,"enrollment":993,"conditions":994,"interventions":995},"NCT06692322","A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems",[90],"2025-06-20",29,[550,15],[911],{"trials":997,"activeCount":1044,"soonestReadout":1003},[998,1013,1024],{"nctId":999,"briefTitle":1000,"status":1001,"phases":1002,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":123,"conditions":1006,"interventions":1008},"NCT07486817","Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","NOT_YET_RECRUITING",[91],"2027-08-12","2029-08-25","2026-06-22",[1007],"Lung Cancer, Non-squamous, Non-small Cell",[911,1009,1010,1011,1012],"Cisplatin","Carboplatin","Pemetrexed","Pembrolizumab",{"nctId":1014,"briefTitle":1015,"status":315,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT06581432","Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations",[91],"2027-12-31","2028-12-29","2024-10-11",430,[1022],"Solid Tumours",[911],{"nctId":1025,"briefTitle":1026,"status":315,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1037},"NCT06324357","Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",[90,91],"2029-01-08","2024-06-03",768,[1032,1033,1034,1035,1036],"Metastatic Breast Cancer","Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Colorectal Cancer",[911,1038,1039,1040,1041,1042,1043],"Trastuzumab deruxtecan","Trastuzumab emtansine","Trastuzumab","Capecitabine","mFOLFOX6","zanidatamab",3,{"trials":1046,"activeCount":1075,"soonestReadout":1065},[1047,1061],{"nctId":1048,"briefTitle":1049,"status":315,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT07195695","Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations",[92],"2032-02-26","2036-09-02","2026-01-16",400,[1056],"Non-small Cell Lung Cancer",[911,1012,1058,1059,1060],"Atezolizumab","Durvalumab","Nivolumab",{"nctId":1062,"briefTitle":1063,"status":140,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1070},"NCT06151574","Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment",[92],"2026-09-02","2028-01-28","2024-02-09",428,[1007],[926,1071,1072,1073,1074],"pembrolizumab","cisplatin","carboplatin","pemetrexed",2,{"trials":1077,"activeCount":101},[],{"trials":1079,"activeCount":101},[],{"intervention":1010,"totalTrials":1081,"cells":1082},10,{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1141,"PHASE3":1147,"PHASE4":1190,"NA":1192},{"trials":1084,"activeCount":101},[],{"trials":1086,"activeCount":1075,"soonestReadout":1091},[1087,1099,1110,1121,1132],{"nctId":1088,"briefTitle":1089,"status":140,"phases":1090,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1097},"NCT06077500","DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer",[90],"2026-09-01","2027-04-01","2024-02-14",46,[1096],"Small Cell Lung Carcinoma (SCLC)",[82,1010,1098,1058],"Etoposide",{"nctId":1100,"briefTitle":1101,"status":315,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT06132113","DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers",[90],"2027-02-09","2027-04-25","2024-01-22",55,[1108],"Neuroendocrine Neoplasms",[82,1010,1098,1009],{"nctId":1111,"briefTitle":1112,"status":107,"phases":1113,"primaryCompletion":1114,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1118},"NCT02182232","A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer",[90],"2007-05","2005-06",33,[36],[1119,1120,1010],"BIBF 1120","Paclitaxel",{"nctId":1122,"briefTitle":1123,"status":107,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1114,"enrollment":1126,"conditions":1127,"interventions":1128},"NCT00809133","Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours",[90],"2015-02",83,[33],[1120,1010,1129,1120,1130,1120,1010,1131,1129,1129],"BIBW 2992","BIBW2992","Bevacizumab",{"nctId":1133,"briefTitle":1134,"status":107,"phases":1135,"primaryCompletion":1136,"start":1137,"enrollment":210,"conditions":1138,"interventions":1140},"NCT02182245","Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies",[90],"2007-01-01","2005-10-01",[1139],"Genital Neoplasms, Female",[1119,1120,1010],{"trials":1142,"activeCount":272,"soonestReadout":1003},[1143],{"nctId":999,"briefTitle":1000,"status":1001,"phases":1144,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":123,"conditions":1145,"interventions":1146},[91],[1007],[911,1009,1010,1011,1012],{"trials":1148,"activeCount":1044,"soonestReadout":1065},[1149,1159,1163,1178],{"nctId":1150,"briefTitle":1151,"status":1001,"phases":1152,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":1155,"conditions":1156,"interventions":1158},"NCT07544654","DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy",[92],"2029-12-13","2026-06-15",390,[1157],"Extrapulmonary Neuroendocrine Cancer",[53,1010,1098],{"nctId":1062,"briefTitle":1063,"status":140,"phases":1160,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1161,"interventions":1162},[92],[1007],[926,1071,1072,1073,1074],{"nctId":1164,"briefTitle":1165,"status":315,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1171,"interventions":1174},"NCT07472517","DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy",[92],"2028-09-09","2029-07-30","2026-04-13",670,[1172,1173],"Small Cell Lung Cancer (SCLC)","Extensive-stage Small Cell Lung Cancer (ES-SCLC)",[1175,1176,1073,1177],"obrixtamig","atezolizumab","etoposide",{"nctId":1179,"briefTitle":1180,"status":107,"phases":1181,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1189},"NCT01015118","LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer",[92],"2013-04-01","2016-09-15","2009-11-17",1366,[1187,1188],"Ovarian Neoplasms","Peritoneal Neoplasms",[1120,1119,1010,1120,1010],{"trials":1191,"activeCount":101},[],{"trials":1193,"activeCount":101},[],{"intervention":1195,"totalTrials":912,"cells":1196},"Survodutide",{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1243,"PHASE3":1256,"PHASE4":1334,"NA":1336},{"trials":1198,"activeCount":101},[],{"trials":1200,"activeCount":1075,"soonestReadout":1216},[1201,1212,1221,1230],{"nctId":1202,"briefTitle":1203,"status":140,"phases":1204,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1210},"NCT06745284","A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity",[90],"2027-01-08","2027-01-10","2025-03-26",64,[539],[1195,1211],"Semaglutide",{"nctId":1213,"briefTitle":1214,"status":140,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT07221591","A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body",[90],"2026-08-04","2025-11-05",100,[15],[63],{"nctId":1222,"briefTitle":1223,"status":107,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":357,"conditions":1227,"interventions":1229},"NCT06492135","A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body",[90],"2025-04-15","2024-08-12",[1228,539],"Overweight",[63],{"nctId":1231,"briefTitle":1232,"status":107,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1239},"NCT06564441","A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity",[90],"2025-12-16","2026-01-05","2024-10-01",34,[1228,539],[1195,1240,1241,1242],"Bupropion","Caffeine","Midazolam",{"trials":1244,"activeCount":101},[1245],{"nctId":1246,"briefTitle":1247,"status":107,"phases":1248,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},"NCT04771273","A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)",[91],"2023-11-09","2023-12-21","2021-04-27",295,[1254],"Non-alcoholic Steatohepatitis (NASH)",[1195],{"trials":1257,"activeCount":1044,"soonestReadout":62},[1258,1267,1278,1288,1299,1309,1319,1328],{"nctId":1259,"briefTitle":1260,"status":107,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT06176365","A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease",[92],"2025-12-03","2024-01-16",274,[539],[1195],{"nctId":1268,"briefTitle":1269,"status":107,"phases":1270,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT06309992","A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)",[92],"2025-10-09","2025-12-02","2024-04-02",218,[539,1276],"Non-Alcoholic SteatoHepatitis (NASH)",[1195],{"nctId":1279,"briefTitle":1280,"status":107,"phases":1281,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1287},"NCT06214741","A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight",[92],"2025-07-29","2026-01-28","2024-02-06",307,[539,1228],[63],{"nctId":1289,"briefTitle":1290,"status":315,"phases":1291,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1298},"NCT06632444","LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\u002FMASH Who Have Moderate or Advanced Liver Fibrosis",[92],"2031-12-27","2024-09-17",1800,[1296,1297],"Metabolic Dysfunction Associated Steatohepatitis (MASH)","Liver Fibrosis",[1195],{"nctId":1300,"briefTitle":1301,"status":315,"phases":1302,"primaryCompletion":1303,"completion":1303,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1308},"NCT06632457","LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\u002FMASH Who Have Cirrhosis",[92],"2029-06-05","2024-11-07",1590,[1307],"Metabolic Dysfunction Associated Steatohepatitis",[1195],{"nctId":1310,"briefTitle":1311,"status":107,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1318},"NCT06066528","A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight",[92],"2025-12-12","2026-03-27","2023-11-27",755,[539,21],[1195],{"nctId":1320,"briefTitle":1321,"status":107,"phases":1322,"primaryCompletion":1272,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1327},"NCT06066515","A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight",[92],"2026-02-20","2023-11-25",726,[539],[63],{"nctId":60,"briefTitle":61,"status":140,"phases":1329,"primaryCompletion":62,"completion":1005,"start":1330,"enrollment":1331,"conditions":1332,"interventions":1333},[92],"2023-11-20",5531,[539],[63],{"trials":1335,"activeCount":101},[],{"trials":1337,"activeCount":101},[],{"intervention":1339,"totalTrials":1340,"cells":1341},"Nerandomilast",9,{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1384,"PHASE3":1386,"PHASE4":1444,"NA":1446},{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":101},[1346,1354,1363,1374],{"nctId":1347,"briefTitle":1348,"status":107,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":1208,"conditions":1352,"interventions":1353},"NCT06393127","A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body",[90],"2024-09-10","2024-06-04",[15],[1339,1339],{"nctId":1355,"briefTitle":1356,"status":107,"phases":1357,"primaryCompletion":1358,"completion":1359,"start":1360,"enrollment":188,"conditions":1361,"interventions":1362},"NCT06139302","A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men",[90],"2024-02-07","2024-02-13","2023-12-20",[15],[1339],{"nctId":1364,"briefTitle":1365,"status":107,"phases":1366,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":401,"conditions":1370,"interventions":1371},"NCT07100964","A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood",[90],"2025-09-20","2025-10-01","2025-08-11",[15],[1372,1373],"nerandomilast","carbamazepine",{"nctId":1375,"briefTitle":1376,"status":107,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":401,"conditions":1381,"interventions":1382},"NCT07081932","A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood",[90],"2025-09-27","2025-10-08","2025-08-26",[15],[1339,1383],"Bosentan",{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":166,"soonestReadout":1392},[1388,1400,1411,1422,1434],{"nctId":1389,"briefTitle":1390,"status":315,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1399},"NCT06238622","A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast",[92],"2027-04-28","2027-05-05","2024-05-06",1700,[1397,1398],"Idiopathic Pulmonary Fibrosis","Progressive Pulmonary Fibrosis",[1339],{"nctId":1401,"briefTitle":1402,"status":1001,"phases":1403,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1410},"NCT07540988","FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression",[92],"2028-12-05","2028-12-12","2026-08-28",466,[1409],"Interstitial Lung Diseases",[1339],{"nctId":1412,"briefTitle":1413,"status":1001,"phases":1414,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1421},"NCT07366034","A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)",[92],"2029-04-27","2031-04-14","2026-07-27",35,[1420],"Fibrosing Interstitial Lung Disease",[1339],{"nctId":1423,"briefTitle":1424,"status":315,"phases":1425,"primaryCompletion":1426,"completion":1427,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1433},"NCT07201922","A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis",[92],"2029-05-14","2029-05-23","2026-02-10",80,[1431,1432,1409],"Familial Pulmonary Fibrosis","Interstitial Lung Abnormalities",[1339],{"nctId":1435,"briefTitle":1436,"status":315,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":1054,"conditions":1441,"interventions":1443},"NCT06806592","A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases",[92],"2027-07-17","2027-07-30","2025-09-13",[1409,1442],"Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases",[1339],{"trials":1445,"activeCount":101},[],{"trials":1447,"activeCount":101},[],{"intervention":1012,"totalTrials":112,"cells":1449},{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1482,"PHASE3":1497,"PHASE4":1507,"NA":1509},{"trials":1451,"activeCount":101},[],{"trials":1453,"activeCount":1075,"soonestReadout":57},[1454,1462,1473],{"nctId":55,"briefTitle":56,"status":140,"phases":1455,"primaryCompletion":57,"completion":1456,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1460},[90],"2028-02-17","2021-10-18",151,[33],[58,1461,1012],"Ezabenlimab",{"nctId":1463,"briefTitle":1464,"status":140,"phases":1465,"primaryCompletion":1466,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1471},"NCT06806852","A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone",[90],"2027-08-31","2025-05-14",85,[1470],"Head and Neck Squamous Cell Carcinoma",[48,1012,1472],"Cetuximab",{"nctId":1474,"briefTitle":1475,"status":162,"phases":1476,"primaryCompletion":1477,"completion":1478,"start":1479,"enrollment":1075,"conditions":1480,"interventions":1481},"NCT05446129","A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery",[90],"2023-08-11","2023-11-08","2022-09-27",[1036],[1461,43,1012],{"trials":1483,"activeCount":272,"soonestReadout":1003},[1484,1493],{"nctId":1485,"briefTitle":1486,"status":107,"phases":1487,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":380,"conditions":1490,"interventions":1491},"NCT03157089","Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung",[91],"2020-01-13","2017-11-02",[36],[1492,1071],"Afatinib",{"nctId":999,"briefTitle":1000,"status":1001,"phases":1494,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":123,"conditions":1495,"interventions":1496},[91],[1007],[911,1009,1010,1011,1012],{"trials":1498,"activeCount":1075,"soonestReadout":1065},[1499,1503],{"nctId":1048,"briefTitle":1049,"status":315,"phases":1500,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1501,"interventions":1502},[92],[1056],[911,1012,1058,1059,1060],{"nctId":1062,"briefTitle":1063,"status":140,"phases":1504,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1505,"interventions":1506},[92],[1007],[926,1071,1072,1073,1074],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"intervention":499,"totalTrials":1512,"cells":1513},6,{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1539,"PHASE3":1545,"PHASE4":1559,"NA":1561},{"trials":1515,"activeCount":101},[],{"trials":1517,"activeCount":272,"soonestReadout":1532},[1518,1528],{"nctId":1519,"briefTitle":1520,"status":107,"phases":1521,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":956,"conditions":1525,"interventions":1526},"NCT07035457","A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together",[90],"2025-08-07","2025-08-15","2025-07-02",[15],[499,1527],"Jardiance®",{"nctId":1529,"briefTitle":1530,"status":315,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1537},"NCT07513207","A Study in Healthy People to Test How Vicadrostat Affects the Heart",[90],"2026-07-24","2026-08-21","2026-04-22",45,[15],[499,1538],"Moxifloxacin",{"trials":1540,"activeCount":272,"soonestReadout":493},[1541],{"nctId":490,"briefTitle":491,"status":140,"phases":1542,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":1543,"interventions":1544},[91],[497],[499,73],{"trials":1546,"activeCount":1044,"soonestReadout":569},[1547,1551,1555],{"nctId":566,"briefTitle":567,"status":315,"phases":1548,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":1549,"interventions":1550},[92],[573],[575,383],{"nctId":588,"briefTitle":589,"status":315,"phases":1552,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":1553,"interventions":1554},[92],[573],[575,383],{"nctId":654,"briefTitle":655,"status":315,"phases":1556,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":1557,"interventions":1558},[92],[21,24,662],[499,73],{"trials":1560,"activeCount":101},[],{"trials":1562,"activeCount":101},[],{"intervention":1098,"totalTrials":1564,"cells":1565},4,{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1578,"PHASE3":1580,"PHASE4":1590,"NA":1592},{"trials":1567,"activeCount":101},[],{"trials":1569,"activeCount":1075,"soonestReadout":1091},[1570,1574],{"nctId":1088,"briefTitle":1089,"status":140,"phases":1571,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":1572,"interventions":1573},[90],[1096],[82,1010,1098,1058],{"nctId":1100,"briefTitle":1101,"status":315,"phases":1575,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1576,"interventions":1577},[90],[1108],[82,1010,1098,1009],{"trials":1579,"activeCount":101},[],{"trials":1581,"activeCount":1075,"soonestReadout":1167},[1582,1586],{"nctId":1150,"briefTitle":1151,"status":1001,"phases":1583,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":1155,"conditions":1584,"interventions":1585},[92],[1157],[53,1010,1098],{"nctId":1164,"briefTitle":1165,"status":315,"phases":1587,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1588,"interventions":1589},[92],[1172,1173],[1175,1176,1073,1177],{"trials":1591,"activeCount":101},[],{"trials":1593,"activeCount":101},[],{"intervention":1595,"totalTrials":956,"cells":1596},"BI 1291583",{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1695,"PHASE3":1726,"PHASE4":1738,"NA":1740},{"trials":1598,"activeCount":101},[],{"trials":1600,"activeCount":272,"soonestReadout":1690},[1601,1609,1617,1625,1634,1642,1650,1658,1666,1676,1686],{"nctId":1602,"briefTitle":1603,"status":107,"phases":1604,"primaryCompletion":1605,"completion":1467,"start":1606,"enrollment":357,"conditions":1607,"interventions":1608},"NCT06631417","A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations",[90],"2025-01-10","2024-10-22",[15],[1595,1595,1595],{"nctId":1610,"briefTitle":1611,"status":107,"phases":1612,"primaryCompletion":1613,"completion":1613,"start":1614,"enrollment":188,"conditions":1615,"interventions":1616},"NCT03837964","A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men",[90],"2019-04-24","2019-02-27",[15],[1595],{"nctId":1618,"briefTitle":1619,"status":107,"phases":1620,"primaryCompletion":1358,"completion":1358,"start":1621,"enrollment":177,"conditions":1622,"interventions":1623},"NCT06166992","A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body",[90],"2023-12-12",[15],[1595,1624],"[14C]-BI 1291583",{"nctId":1626,"briefTitle":1627,"status":162,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":1631,"conditions":1632,"interventions":1633},"NCT03414008","This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated",[90],"2019-11-18","2018-02-05",54,[15],[1595],{"nctId":1635,"briefTitle":1636,"status":107,"phases":1637,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":380,"conditions":1640,"interventions":1641},"NCT04866160","A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated",[90],"2021-11-30","2021-05-17",[15],[1595],{"nctId":1643,"briefTitle":1644,"status":107,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":448,"conditions":1648,"interventions":1649},"NCT05183347","A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated",[90],"2022-07-27","2022-02-04",[15],[1595],{"nctId":1651,"briefTitle":1652,"status":162,"phases":1653,"primaryCompletion":1654,"completion":1654,"start":1655,"enrollment":380,"conditions":1656,"interventions":1657},"NCT03868540","A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated",[90],"2019-11-25","2019-03-28",[15],[1595],{"nctId":1659,"briefTitle":1660,"status":107,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":177,"conditions":1664,"interventions":1665},"NCT03890887","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood",[90],"2019-07-29","2019-04-12",[15],[1595,949],{"nctId":1667,"briefTitle":1668,"status":107,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT06917872","A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood",[90],"2025-09-09","2025-04-29",20,[15],[1595,1675],"erythromycin",{"nctId":1677,"briefTitle":1678,"status":107,"phases":1679,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":177,"conditions":1683,"interventions":1684},"NCT06791187","A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body",[90],"2025-02-21","2025-03-27","2025-01-23",[15],[1685,1595],"dabigatran etexilate",{"nctId":1687,"briefTitle":1688,"status":315,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":132,"conditions":1692,"interventions":1694},"NCT07023354","A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems",[90],"2026-08-01","2025-07-17",[15,1693],"Hepatic Impairment",[1595],{"trials":1696,"activeCount":272,"soonestReadout":1712},[1697,1708,1717],{"nctId":1698,"briefTitle":1699,"status":107,"phases":1700,"primaryCompletion":1701,"completion":1702,"start":1703,"enrollment":1704,"conditions":1705,"interventions":1707},"NCT05238675","A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis",[91],"2024-05-01","2024-05-30","2022-04-28",322,[1706],"Bronchiectasis",[1595],{"nctId":1709,"briefTitle":1710,"status":140,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1716},"NCT05846230","Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine",[91],"2027-03-31","2023-09-08",268,[1706],[1595],{"nctId":1718,"briefTitle":1719,"status":107,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":210,"conditions":1723,"interventions":1725},"NCT05865886","A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)",[91],"2024-10-07","2024-04-05",[1724,1706],"Cystic Fibrosis",[1595],{"trials":1727,"activeCount":272,"soonestReadout":1732},[1728],{"nctId":1729,"briefTitle":1730,"status":315,"phases":1731,"primaryCompletion":1732,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1737},"NCT06872892","The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis",[92],"2028-09-14","2028-10-12","2025-06-09",1755,[1706],[1595],{"trials":1739,"activeCount":101},[],{"trials":1741,"activeCount":101},[],{"intervention":1009,"totalTrials":166,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1752,"PHASE3":1758,"PHASE4":1786,"NA":1788},{"trials":1745,"activeCount":101},[],{"trials":1747,"activeCount":272,"soonestReadout":1103},[1748],{"nctId":1100,"briefTitle":1101,"status":315,"phases":1749,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1750,"interventions":1751},[90],[1108],[82,1010,1098,1009],{"trials":1753,"activeCount":272,"soonestReadout":1003},[1754],{"nctId":999,"briefTitle":1000,"status":1001,"phases":1755,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":123,"conditions":1756,"interventions":1757},[91],[1007],[911,1009,1010,1011,1012],{"trials":1759,"activeCount":272,"soonestReadout":1065},[1760,1764,1775],{"nctId":1062,"briefTitle":1063,"status":140,"phases":1761,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1762,"interventions":1763},[92],[1007],[926,1071,1072,1073,1074],{"nctId":1765,"briefTitle":1766,"status":107,"phases":1767,"primaryCompletion":1768,"completion":1769,"start":1770,"enrollment":1771,"conditions":1772,"interventions":1774},"NCT00949650","BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation",[92],"2012-02-09","2017-03-16","2009-08-14",345,[36,1773],"Adenocarcinoma",[1011,1129,1009],{"nctId":1776,"briefTitle":1777,"status":162,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":1783,"interventions":1785},"NCT01907100","Nintedanib (BIBF 1120) in Mesothelioma",[91,92],"2018-03-16","2018-08-31","2013-09-19",545,[1784],"Mesothelioma",[78,1011,1009,1009,1011],{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":101},[],{"intervention":1058,"totalTrials":1044,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1800,"PHASE3":1802,"PHASE4":1812,"NA":1814},{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":272,"soonestReadout":1091},[1796],{"nctId":1088,"briefTitle":1089,"status":140,"phases":1797,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":1798,"interventions":1799},[90],[1096],[82,1010,1098,1058],{"trials":1801,"activeCount":101},[],{"trials":1803,"activeCount":1075,"soonestReadout":1167},[1804,1808],{"nctId":1048,"briefTitle":1049,"status":315,"phases":1805,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1806,"interventions":1807},[92],[1056],[911,1012,1058,1059,1060],{"nctId":1164,"briefTitle":1165,"status":315,"phases":1809,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1810,"interventions":1811},[92],[1172,1173],[1175,1176,1073,1177],{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[],{"intervention":53,"totalTrials":1044,"cells":1817},{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1828,"PHASE3":1830,"PHASE4":1840,"NA":1842},{"trials":1819,"activeCount":101},[],{"trials":1821,"activeCount":272,"soonestReadout":52},[1822],{"nctId":50,"briefTitle":51,"status":140,"phases":1823,"primaryCompletion":52,"completion":1824,"start":1825,"enrollment":1535,"conditions":1826,"interventions":1827},[90],"2026-12-31","2023-06-27",[1096,1108],[53,1461],{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":1075,"soonestReadout":1167},[1832,1836],{"nctId":1150,"briefTitle":1151,"status":1001,"phases":1833,"primaryCompletion":1153,"completion":1153,"start":1154,"enrollment":1155,"conditions":1834,"interventions":1835},[92],[1157],[53,1010,1098],{"nctId":1164,"briefTitle":1165,"status":315,"phases":1837,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":1170,"conditions":1838,"interventions":1839},[92],[1172,1173],[1175,1176,1073,1177],{"trials":1841,"activeCount":101},[],{"trials":1843,"activeCount":101},[],{"intervention":1845,"totalTrials":281,"cells":1846},"BI 764198",{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1909,"PHASE3":1940,"PHASE4":1953,"NA":1955},{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":101},[1851,1859,1868,1877,1885,1894,1903],{"nctId":1852,"briefTitle":1853,"status":107,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":716,"conditions":1857,"interventions":1858},"NCT03854552","A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.",[90],"2019-08-07","2019-03-15",[15],[1845],{"nctId":1860,"briefTitle":1861,"status":107,"phases":1862,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":1865,"conditions":1866,"interventions":1867},"NCT04176536","A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body",[90],"2020-11-17","2019-12-10",28,[15,497],[1845],{"nctId":1869,"briefTitle":1870,"status":107,"phases":1871,"primaryCompletion":1872,"completion":1873,"start":1874,"enrollment":177,"conditions":1875,"interventions":1876},"NCT07368569","A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body",[90],"2026-03-14","2026-03-17","2026-02-06",[15],[970,1845],{"nctId":1878,"briefTitle":1879,"status":107,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":342,"conditions":1883,"interventions":1884},"NCT04102462","A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198",[90],"2020-10-08","2019-10-29",[15],[1845],{"nctId":1886,"briefTitle":1887,"status":107,"phases":1888,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1893},"NCT04665700","A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated",[90],"2021-10-16","2021-02-06",44,[15],[1845],{"nctId":1895,"briefTitle":1896,"status":107,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":177,"conditions":1901,"interventions":1902},"NCT07308652","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood",[90],"2026-03-24","2026-04-10","2026-02-09",[15],[1845,949],{"nctId":1904,"briefTitle":1905,"status":107,"phases":1906,"primaryCompletion":1249,"completion":1249,"start":267,"enrollment":380,"conditions":1907,"interventions":1908},"NCT05863130","A Study in Healthy Men to Test How BI 764198 is Processed in the Body",[90],[15],[1845,1845],{"trials":1910,"activeCount":272,"soonestReadout":1926},[1911,1922,1932],{"nctId":1912,"briefTitle":1913,"status":162,"phases":1914,"primaryCompletion":1915,"completion":1916,"start":1917,"enrollment":1918,"conditions":1919,"interventions":1921},"NCT04604184","ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19",[91],"2021-03-24","2021-05-31","2020-11-03",133,[1920],"COVID-19",[1845],{"nctId":1923,"briefTitle":1924,"status":315,"phases":1925,"primaryCompletion":1926,"completion":1456,"start":1927,"enrollment":1928,"conditions":1929,"interventions":1931},"NCT07355296","PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease",[91],"2028-01-20","2026-03-23",132,[1930],"Proteinuric Kidney Diseases",[1845],{"nctId":1933,"briefTitle":1934,"status":107,"phases":1935,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":28,"conditions":1938,"interventions":1939},"NCT05213624","A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis",[91],"2025-01-03","2022-05-03",[509],[1845],{"trials":1941,"activeCount":272,"soonestReadout":1946},[1942],{"nctId":1943,"briefTitle":1944,"status":315,"phases":1945,"primaryCompletion":1946,"completion":1947,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1952},"NCT07220083","A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)",[92],"2029-11-20","2029-12-18","2026-02-16",286,[1951],"Focal Segmental Glomerulosclerosis",[1845],{"trials":1954,"activeCount":101},[],{"trials":1956,"activeCount":101},[],{"intervention":1011,"totalTrials":1340,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1995,"PHASE3":2012,"PHASE4":2039,"NA":2041},{"trials":1960,"activeCount":101},[],{"trials":1962,"activeCount":101},[1963,1976,1985],{"nctId":1964,"briefTitle":1965,"status":107,"phases":1966,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":1968,"interventions":1969},"NCT01169675","BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours",[90],"2010-07",[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],"BIBW 2992 low dose","BIBW 2992 high dose","BIBW 2992 high dose 6 day","BIBW 2992 low dose 6 day","BIBW 2992 medium dose 6 day","BIBW 2992 medium dose",{"nctId":1977,"briefTitle":1978,"status":107,"phases":1979,"primaryCompletion":1980,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1984},"NCT02182102","Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer",[90],"2010-05","2005-09",26,[36],[1119,1011],{"nctId":1986,"briefTitle":1987,"status":107,"phases":1988,"primaryCompletion":1989,"start":1990,"enrollment":1991,"conditions":1992,"interventions":1993},"NCT02211833","Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer",[90],"2009-02","2006-10",41,[36],[1994,1011],"BI 2536",{"trials":1996,"activeCount":272,"soonestReadout":1003},[1997,2008],{"nctId":1998,"briefTitle":1999,"status":107,"phases":2000,"primaryCompletion":2001,"completion":2002,"start":2003,"enrollment":2004,"conditions":2005,"interventions":2006},"NCT00824408","Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC",[91],"2012-09","2015-08","2009-03",143,[36],[1074,1074,2007],"BI 6727",{"nctId":999,"briefTitle":1000,"status":1001,"phases":2009,"primaryCompletion":1003,"completion":1004,"start":1005,"enrollment":123,"conditions":2010,"interventions":2011},[91],[1007],[911,1009,1010,1011,1012],{"trials":2013,"activeCount":272,"soonestReadout":1065},[2014,2018,2022,2026],{"nctId":1062,"briefTitle":1063,"status":140,"phases":2015,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":2016,"interventions":2017},[92],[1007],[926,1071,1072,1073,1074],{"nctId":1765,"briefTitle":1766,"status":107,"phases":2019,"primaryCompletion":1768,"completion":1769,"start":1770,"enrollment":1771,"conditions":2020,"interventions":2021},[92],[36,1773],[1011,1129,1009],{"nctId":1776,"briefTitle":1777,"status":162,"phases":2023,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":2024,"interventions":2025},[91,92],[1784],[78,1011,1009,1009,1011],{"nctId":2027,"briefTitle":2028,"status":107,"phases":2029,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2034,"interventions":2035},"NCT00806819","Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC",[92],"2011-06","2015-12","2008-12",718,[36],[78,1011,1074,2036,2037,2037,2036,2038,2036,2037,2038,2038,78,1011],"B12","dexamethasone","Folic Acid",{"trials":2040,"activeCount":101},[],{"trials":2042,"activeCount":101},[],{"intervention":1060,"totalTrials":1075,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2061,"PHASE3":2063,"PHASE4":2069,"NA":2071},{"trials":2046,"activeCount":101},[],{"trials":2048,"activeCount":272,"soonestReadout":2053},[2049],{"nctId":2050,"briefTitle":2051,"status":1001,"phases":2052,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":1094,"conditions":2056,"interventions":2058},"NCT07176975","A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers",[90],"2028-12-19","2029-05-22","2027-08-03",[2057],"Solid Tumors",[2059,2060],"BI 1831169","nivolumab",{"trials":2062,"activeCount":101},[],{"trials":2064,"activeCount":272,"soonestReadout":1051},[2065],{"nctId":1048,"briefTitle":1049,"status":315,"phases":2066,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":2067,"interventions":2068},[92],[1056],[911,1012,1058,1059,1060],{"trials":2070,"activeCount":101},[],{"trials":2072,"activeCount":101},[],{"intervention":2074,"totalTrials":1512,"cells":2075},"Tenecteplase",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2082,"PHASE4":2139,"NA":2150},{"trials":2077,"activeCount":101},[],{"trials":2079,"activeCount":101},[],{"trials":2081,"activeCount":101},[],{"trials":2083,"activeCount":272,"soonestReadout":2132},[2084,2096,2107,2117,2128],{"nctId":2085,"briefTitle":2086,"status":107,"phases":2087,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":2091,"interventions":2093},"NCT04915729","A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity",[92],"2023-10-08","2021-06-22",1489,[2092],"Stroke",[2094,2095],"tenecteplase","alteplase",{"nctId":2097,"briefTitle":2098,"status":107,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2104},"NCT00623623","STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction",[92],"2012-09-01","2008-03-01",1899,[632],[2105,2094,2106],"enoxaparin","clopidogrel",{"nctId":2108,"briefTitle":2109,"status":162,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":2113,"conditions":2114,"interventions":2116},"NCT00157261","Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial",[92],"2006-06","2004-01",1050,[2115],"Heart Arrest",[2094],{"nctId":2118,"briefTitle":2119,"status":107,"phases":2120,"primaryCompletion":2121,"start":2122,"enrollment":2123,"conditions":2124,"interventions":2125},"NCT02182011","A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)",[92],"2001-06","2000-05",49,[632],[2074,2126,2127],"Alteplase","Streptokinase",{"nctId":2129,"briefTitle":2130,"status":315,"phases":2131,"primaryCompletion":2132,"completion":2132,"start":2133,"enrollment":2134,"conditions":2135,"interventions":2137},"NCT07361302","A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well",[92],"2027-10-02","2026-02-17",1325,[2136],"Acute Ischemic Stroke",[2074,2138],"Standard of care treatment",{"trials":2140,"activeCount":101},[2141],{"nctId":2142,"briefTitle":2143,"status":162,"phases":2144,"primaryCompletion":2145,"start":2146,"enrollment":2147,"conditions":2148,"interventions":2149},"NCT00168792","A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)",[93],"2006-07","2003-11",1671,[632],[2074],{"trials":2151,"activeCount":101},[],{"intervention":323,"totalTrials":1044,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2167,"PHASE3":2169,"PHASE4":2175,"NA":2187},{"trials":2155,"activeCount":101},[],{"trials":2157,"activeCount":101},[2158],{"nctId":2159,"briefTitle":2160,"status":107,"phases":2161,"primaryCompletion":2162,"start":2163,"enrollment":1672,"conditions":2164,"interventions":2165},"NCT02268149","Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects",[90],"2000-07","2000-04",[15],[2166,323],"BIIL 284 BS",{"trials":2168,"activeCount":101},[],{"trials":2170,"activeCount":272,"soonestReadout":317},[2171],{"nctId":313,"briefTitle":314,"status":315,"phases":2172,"primaryCompletion":317,"completion":318,"start":121,"enrollment":319,"conditions":2173,"interventions":2174},[92],[321],[87,323,324],{"trials":2176,"activeCount":101},[2177],{"nctId":2178,"briefTitle":2179,"status":107,"phases":2180,"primaryCompletion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2185},"NCT02184299","Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients",[93],"2000-01","1999-04",138,[27],[2186,323],"Nevirapine",{"trials":2188,"activeCount":101},[],{"intervention":511,"totalTrials":1340,"cells":2190},{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2254,"PHASE3":2260,"PHASE4":2266,"NA":2268},{"trials":2192,"activeCount":101},[],{"trials":2194,"activeCount":101},[2195,2206,2214,2222,2229,2238,2246],{"nctId":2196,"briefTitle":2197,"status":107,"phases":2198,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":31,"conditions":2202,"interventions":2204},"NCT03165240","This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated",[90],"2020-04-16","2020-05-07","2017-10-05",[2203],"Diabetic Nephropathies",[511,2205],"Eplerenone",{"nctId":2207,"briefTitle":2208,"status":107,"phases":2209,"primaryCompletion":2210,"completion":2210,"start":2211,"enrollment":716,"conditions":2212,"interventions":2213},"NCT03100916","This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood",[90],"2017-11-24","2017-05-05",[15],[511,511,511],{"nctId":2215,"briefTitle":2216,"status":107,"phases":2217,"primaryCompletion":2218,"completion":2218,"start":2219,"enrollment":37,"conditions":2220,"interventions":2221},"NCT03206632","This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated",[90],"2017-10-13","2017-07-17",[15],[511],{"nctId":2223,"briefTitle":2224,"status":107,"phases":2225,"primaryCompletion":230,"completion":230,"start":2226,"enrollment":448,"conditions":2227,"interventions":2228},"NCT03608072","A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated",[90],"2018-08-06",[15],[511],{"nctId":2230,"briefTitle":2231,"status":107,"phases":2232,"primaryCompletion":2233,"completion":2233,"start":2234,"enrollment":2235,"conditions":2236,"interventions":2237},"NCT02891148","Single Rising Dose Study of BI 690517 in Healthy Volunteers",[90],"2016-12-12","2016-09-29",50,[15],[511],{"nctId":2239,"briefTitle":2240,"status":107,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":1865,"conditions":2244,"interventions":2245},"NCT05731908","A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems",[90],"2023-04-13","2023-02-21",[550,15],[511],{"nctId":2247,"briefTitle":2248,"status":107,"phases":2249,"primaryCompletion":2250,"completion":2250,"start":2251,"enrollment":177,"conditions":2252,"interventions":2253},"NCT05515588","A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body",[90],"2022-11-17","2022-09-19",[15],[511,511],{"trials":2255,"activeCount":101},[2256],{"nctId":501,"briefTitle":502,"status":107,"phases":2257,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":2258,"interventions":2259},[91],[509],[511,73],{"trials":2261,"activeCount":272,"soonestReadout":705},[2262],{"nctId":702,"briefTitle":703,"status":315,"phases":2263,"primaryCompletion":705,"completion":705,"start":706,"enrollment":707,"conditions":2264,"interventions":2265},[92],[509],[511,73],{"trials":2267,"activeCount":101},[],{"trials":2269,"activeCount":101},[],{"intervention":1059,"totalTrials":272,"cells":2271},{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2278,"PHASE4":2284,"NA":2286},{"trials":2273,"activeCount":101},[],{"trials":2275,"activeCount":101},[],{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":272,"soonestReadout":1051},[2280],{"nctId":1048,"briefTitle":1049,"status":315,"phases":2281,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":2282,"interventions":2283},[92],[1056],[911,1012,1058,1059,1060],{"trials":2285,"activeCount":101},[],{"trials":2287,"activeCount":101},[],{"intervention":2289,"totalTrials":272,"cells":2290},"Nerandomilast formulation 1",{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2295,"PHASE3":2297,"PHASE4":2311,"NA":2313},{"trials":2292,"activeCount":101},[],{"trials":2294,"activeCount":101},[],{"trials":2296,"activeCount":101},[],{"trials":2298,"activeCount":272,"soonestReadout":2303},[2299],{"nctId":2300,"briefTitle":2301,"status":1001,"phases":2302,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2307,"interventions":2309},"NCT07497087","A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis",[92],"2030-02-26","2030-03-17","2026-06-09",448,[2308],"Systemic Sclerosis",[2289,2310],"Nerandomilast formulation 2",{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[],{"intervention":2310,"totalTrials":272,"cells":2316},{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2329,"NA":2331},{"trials":2318,"activeCount":101},[],{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":272,"soonestReadout":2303},[2325],{"nctId":2300,"briefTitle":2301,"status":1001,"phases":2326,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2327,"interventions":2328},[92],[2308],[2289,2310],{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":101},[],{"intervention":2138,"totalTrials":272,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2347,"NA":2349},{"trials":2336,"activeCount":101},[],{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":272,"soonestReadout":2132},[2343],{"nctId":2129,"briefTitle":2130,"status":315,"phases":2344,"primaryCompletion":2132,"completion":2132,"start":2133,"enrollment":2134,"conditions":2345,"interventions":2346},[92],[2136],[2074,2138],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[],{"intervention":324,"totalTrials":272,"cells":2352},{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2365,"NA":2367},{"trials":2354,"activeCount":101},[],{"trials":2356,"activeCount":101},[],{"trials":2358,"activeCount":101},[],{"trials":2360,"activeCount":272,"soonestReadout":317},[2361],{"nctId":313,"briefTitle":314,"status":315,"phases":2362,"primaryCompletion":317,"completion":318,"start":121,"enrollment":319,"conditions":2363,"interventions":2364},[92],[321],[87,323,324],{"trials":2366,"activeCount":101},[],{"trials":2368,"activeCount":101},[],{"intervention":2370,"totalTrials":1512,"cells":2371},"BI 3000202",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2422,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2373,"activeCount":101},[],{"trials":2375,"activeCount":272,"soonestReadout":2417},[2376,2385,2394,2403,2413],{"nctId":2377,"briefTitle":2378,"status":107,"phases":2379,"primaryCompletion":2380,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2384},"NCT06327256","A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam",[90],"2024-09-27","2024-04-09",40,[15],[2370,1242],{"nctId":2386,"briefTitle":2387,"status":107,"phases":2388,"primaryCompletion":2389,"completion":2390,"start":1217,"enrollment":177,"conditions":2391,"interventions":2392},"NCT07215260","A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body",[90],"2025-12-07","2025-12-18",[15],[2370,969,2393],"Digoxin",{"nctId":2395,"briefTitle":2396,"status":107,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":2399,"enrollment":2400,"conditions":2401,"interventions":2402},"NCT05945888","A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood",[90],"2023-11-13","2023-07-25",68,[15],[2370],{"nctId":2404,"briefTitle":2405,"status":107,"phases":2406,"primaryCompletion":2407,"completion":2408,"start":2409,"enrollment":188,"conditions":2410,"interventions":2411},"NCT07273474","A Study in Healthy Men and Women to Test How BI 3000202 is Taken up and Processed by the Body",[90],"2026-03-05","2026-03-25","2025-12-30",[15],[2370,2412],"BI 3000202 [14C]-labelled",{"nctId":2414,"briefTitle":2415,"status":315,"phases":2416,"primaryCompletion":2417,"completion":2418,"start":2419,"enrollment":1891,"conditions":2420,"interventions":2421},"NCT07486102","A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems",[90],"2027-02-26","2027-02-27","2026-05-01",[15,1693],[2370],{"trials":2423,"activeCount":272,"soonestReadout":591},[2424],{"nctId":2425,"briefTitle":2426,"status":315,"phases":2427,"primaryCompletion":591,"completion":2428,"start":2429,"enrollment":2430,"conditions":2431,"interventions":2433},"NCT07409181","A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)",[91],"2029-07-08","2026-04-20",405,[2432],"Systemic Lupus Erythematosus",[2370],{"trials":2435,"activeCount":101},[],{"trials":2437,"activeCount":101},[],{"trials":2439,"activeCount":101},[],{"intervention":2441,"totalTrials":2442,"cells":2443},"BI 1015550",19,{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2570,"PHASE3":2589,"PHASE4":2611,"NA":2613},{"trials":2445,"activeCount":101},[],{"trials":2447,"activeCount":101},[2448,2455,2462,2469,2478,2486,2494,2502,2511,2519,2528,2536,2543,2552,2561],{"nctId":2449,"briefTitle":2450,"status":107,"phases":2451,"primaryCompletion":525,"completion":525,"start":379,"enrollment":380,"conditions":2452,"interventions":2453},"NCT01835899","Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution",[90],[15],[2441,2441,2454,2441],"BI1015550",{"nctId":2456,"briefTitle":2457,"status":107,"phases":2458,"primaryCompletion":2459,"completion":2459,"start":814,"enrollment":188,"conditions":2460,"interventions":2461},"NCT03302078","Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects",[90],"2017-12-13",[15],[2441],{"nctId":2463,"briefTitle":2464,"status":107,"phases":2465,"primaryCompletion":896,"completion":896,"start":2466,"enrollment":1094,"conditions":2467,"interventions":2468},"NCT06107036","A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities",[90],"2024-03-06",[15],[2441,1538],{"nctId":2470,"briefTitle":2471,"status":107,"phases":2472,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":380,"conditions":2476,"interventions":2477},"NCT05633862","A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body",[90],"2023-03-16","2023-03-17","2023-01-13",[15],[2441],{"nctId":2479,"briefTitle":2480,"status":107,"phases":2481,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":392,"conditions":2484,"interventions":2485},"NCT06415045","A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food",[90],"2024-07-24","2024-05-28",[15],[2441],{"nctId":2487,"briefTitle":2488,"status":107,"phases":2489,"primaryCompletion":2490,"completion":2490,"start":1478,"enrollment":177,"conditions":2491,"interventions":2492},"NCT06070610","A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood",[90],"2023-12-14",[15],[2441,78,2493],"Pirfenidone",{"nctId":2495,"briefTitle":2496,"status":107,"phases":2497,"primaryCompletion":2498,"completion":2498,"start":2499,"enrollment":1208,"conditions":2500,"interventions":2501},"NCT06408870","A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body",[90],"2024-08-28","2024-06-06",[15],[2441],{"nctId":2503,"briefTitle":2504,"status":107,"phases":2505,"primaryCompletion":2001,"completion":2001,"start":2506,"enrollment":2507,"conditions":2508,"interventions":2509},"NCT01594515","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers",[90],"2012-05",70,[15],[2441,2441,2441,2441,2441,2510,2441,2441,2441],"BI 101550",{"nctId":2512,"briefTitle":2513,"status":107,"phases":2514,"primaryCompletion":2515,"completion":2516,"start":1779,"enrollment":956,"conditions":2517,"interventions":2518},"NCT03422068","This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.",[90],"2019-07-01","2019-07-10",[1397],[2441],{"nctId":2520,"briefTitle":2521,"status":107,"phases":2522,"primaryCompletion":2523,"completion":2523,"start":2524,"enrollment":1865,"conditions":2525,"interventions":2527},"NCT05661344","A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems",[90],"2023-09-13","2023-02-07",[2526],"Hepatic Insufficiency",[2441],{"nctId":2529,"briefTitle":2530,"status":107,"phases":2531,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":956,"conditions":2534,"interventions":2535},"NCT05550636","A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood",[90],"2022-12-19","2022-10-11",[15],[2441,927],{"nctId":2537,"briefTitle":2538,"status":107,"phases":2539,"primaryCompletion":1639,"completion":1639,"start":2540,"enrollment":1512,"conditions":2541,"interventions":2542},"NCT04771286","A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body",[90],"2021-03-25",[15],[2441],{"nctId":2544,"briefTitle":2545,"status":107,"phases":2546,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":1982,"conditions":2549,"interventions":2551},"NCT05718648","A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems",[90],"2023-08-15","2023-02-09",[2550,15],"Renal Insufficiency",[2441],{"nctId":2553,"briefTitle":2554,"status":107,"phases":2555,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":401,"conditions":2558,"interventions":2559},"NCT03403439","This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood",[90],"2018-07-20","2018-05-03",[15],[2441,2560],"itraconazole",{"nctId":2562,"briefTitle":2563,"status":107,"phases":2564,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":155,"conditions":2567,"interventions":2568},"NCT05707403","A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body",[90],"2023-03-28","2023-02-14",[15],[2441,2569],"BI 1015550 mixed with [C-14]-BI 1015550",{"trials":2571,"activeCount":272,"soonestReadout":1216},[2572,2579],{"nctId":2573,"briefTitle":2574,"status":315,"phases":2575,"primaryCompletion":1216,"completion":2576,"start":2407,"enrollment":1672,"conditions":2577,"interventions":2578},"NCT06241560","A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood",[91],"2026-08-06",[1397],[2441,2493],{"nctId":2580,"briefTitle":2581,"status":107,"phases":2582,"primaryCompletion":2583,"completion":2584,"start":2585,"enrollment":2586,"conditions":2587,"interventions":2588},"NCT04419506","A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)",[91],"2021-10-06","2021-10-15","2020-07-28",147,[1397],[2441],{"trials":2590,"activeCount":101},[2591,2601],{"nctId":2592,"briefTitle":2593,"status":107,"phases":2594,"primaryCompletion":964,"completion":2595,"start":2596,"enrollment":2597,"conditions":2598,"interventions":2600},"NCT05321082","A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)",[92],"2025-04-14","2022-11-16",1178,[2599],"Lung Diseases, Interstitial",[2441],{"nctId":2602,"briefTitle":2603,"status":107,"phases":2604,"primaryCompletion":2605,"completion":2606,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2610},"NCT05321069","A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)",[92],"2024-08-16","2024-12-17","2022-10-06",1177,[1397],[2441],{"trials":2612,"activeCount":101},[],{"trials":2614,"activeCount":101},[],{"intervention":2616,"totalTrials":166,"cells":2617},"trastuzumab",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2642,"PHASE3":2657,"PHASE4":2670,"NA":2672},{"trials":2619,"activeCount":101},[],{"trials":2621,"activeCount":101},[2622,2634],{"nctId":2623,"briefTitle":2624,"status":107,"phases":2625,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":912,"conditions":2628,"interventions":2631},"NCT01649271","Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.",[90],"2016-06-23","2012-07-23",[2629,2630],"Breast Neoplasms","Stomach Neoplasms",[2632,2633,2616,2632,2633,2633],"Herceptin","afatinib",{"nctId":2635,"briefTitle":2636,"status":107,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":392,"conditions":2640,"interventions":2641},"NCT00950742","Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.",[90],"2013-10-01","2009-08-01",[2629],[1040,1129],{"trials":2643,"activeCount":272,"soonestReadout":1028},[2644,2653],{"nctId":2645,"briefTitle":2646,"status":107,"phases":2647,"primaryCompletion":2648,"start":2649,"enrollment":993,"conditions":2650,"interventions":2651},"NCT00826267","6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab",[91],"2011-08","2009-01",[2629],[2652,1129,2616],"lapatinib",{"nctId":1025,"briefTitle":1026,"status":315,"phases":2654,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":2655,"interventions":2656},[90,91],[1032,1033,1034,1035,1036],[911,1038,1039,1040,1041,1042,1043],{"trials":2658,"activeCount":101},[2659],{"nctId":2660,"briefTitle":2661,"status":107,"phases":2662,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":2667,"interventions":2668},"NCT01125566","LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment",[92],"2013-06-08","2018-07-06","2010-06-22",508,[2629],[1129,2616,2669,2669],"vinorelbine",{"trials":2671,"activeCount":101},[],{"trials":2673,"activeCount":101},[],{"intervention":2675,"totalTrials":166,"cells":2676},"Brigimadlin",{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2705,"PHASE4":2739,"NA":2741},{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":272,"soonestReadout":2701},[2683,2697],{"nctId":2684,"briefTitle":2685,"status":162,"phases":2686,"primaryCompletion":2687,"completion":2687,"start":2688,"enrollment":2689,"conditions":2690,"interventions":2695},"NCT05512377","Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder",[91],"2025-09-25","2022-12-13",99,[2691,2057,2692,2693,2694],"Pancreatic Neoplasms","Biliary Tract Cancer","Lung Neoplasms","Bladder Cancer",[2696],"brigimadlin",{"nctId":2698,"briefTitle":2699,"status":140,"phases":2700,"primaryCompletion":2701,"completion":2701,"start":2702,"enrollment":319,"conditions":2703,"interventions":2704},"NCT06619509","A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine",[91],"2030-12-30","2024-12-30",[1022],[2675],{"trials":2706,"activeCount":101},[2707,2718,2732],{"nctId":2708,"briefTitle":2709,"status":107,"phases":2710,"primaryCompletion":2711,"completion":2712,"start":2713,"enrollment":1054,"conditions":2714,"interventions":2716},"NCT05218499","Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma",[91,92],"2024-04-16","2026-01-26","2022-03-31",[2715],"Liposarcoma, Dedifferentiated",[2675,2717],"Doxorubicin",{"nctId":2719,"briefTitle":2720,"status":600,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":101,"conditions":2725,"interventions":2729},"NCT06370871","Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma",[92],"2026-07-03","2028-10-13","2024-06-27",[2726,2727,2728],"Advanced Soft Tissue Sarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Myxofibrosarcoma (MFS)",[2675,1461,2730,2731],"Gemcitabine","Docetaxel",{"nctId":2733,"briefTitle":2734,"status":107,"phases":2735,"primaryCompletion":1313,"completion":1313,"start":2736,"enrollment":2183,"conditions":2737,"interventions":2738},"NCT06058793","Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma",[92],"2023-12-13",[2715],[2675],{"trials":2740,"activeCount":101},[],{"trials":2742,"activeCount":101},[],{"intervention":2744,"totalTrials":1512,"cells":2745},"BI 1584862",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2792,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2747,"activeCount":101},[],{"trials":2749,"activeCount":101},[2750,2758,2766,2775,2783],{"nctId":2751,"briefTitle":2752,"status":107,"phases":2753,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":177,"conditions":2756,"interventions":2757},"NCT06041438","A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood",[90],"2023-11-10","2023-09-29",[15],[2744,2560],{"nctId":2759,"briefTitle":2760,"status":107,"phases":2761,"primaryCompletion":2762,"completion":2762,"start":2763,"enrollment":132,"conditions":2764,"interventions":2765},"NCT06148948","A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated",[90],"2024-05-21","2023-12-25",[15],[2744],{"nctId":2767,"briefTitle":2768,"status":107,"phases":2769,"primaryCompletion":2770,"completion":2770,"start":2771,"enrollment":2772,"conditions":2773,"interventions":2774},"NCT05520827","A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food",[90],"2023-03-06","2022-09-29",77,[15],[2744],{"nctId":2776,"briefTitle":2777,"status":107,"phases":2778,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":2235,"conditions":2781,"interventions":2782},"NCT06006598","A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men",[90],"2024-05-05","2023-08-28",[15],[2744,927],{"nctId":2784,"briefTitle":2785,"status":107,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":2789,"conditions":2790,"interventions":2791},"NCT06957756","A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems",[90],"2026-05-21","2025-08-06",43,[2526],[2744],{"trials":2793,"activeCount":272,"soonestReadout":2798},[2794],{"nctId":2795,"briefTitle":2796,"status":140,"phases":2797,"primaryCompletion":2798,"completion":2417,"start":2799,"enrollment":2800,"conditions":2801,"interventions":2803},"NCT06769048","A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy",[91],"2027-02-15","2025-01-31",150,[2802],"Geographic Atrophy",[2744],{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[],{"trials":2809,"activeCount":101},[],{"intervention":2811,"totalTrials":166,"cells":2812},"BI 1815368",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2849,"PHASE3":2862,"PHASE4":2864,"NA":2866},{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":101},[2817,2826,2834,2842],{"nctId":2818,"briefTitle":2819,"status":107,"phases":2820,"primaryCompletion":2821,"completion":2822,"start":2823,"enrollment":177,"conditions":2824,"interventions":2825},"NCT06655220","A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body",[90],"2024-12-08","2025-01-13","2024-11-08",[15],[970,2811],{"nctId":2827,"briefTitle":2828,"status":107,"phases":2829,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":177,"conditions":2832,"interventions":2833},"NCT05965583","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the Blood",[90],"2023-10-24","2023-08-02",[15],[2811,949],{"nctId":2835,"briefTitle":2836,"status":107,"phases":2837,"primaryCompletion":2838,"completion":2838,"start":2839,"enrollment":1982,"conditions":2840,"interventions":2841},"NCT06494774","A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men",[90],"2024-11-13","2024-08-19",[15],[2811],{"nctId":2843,"briefTitle":2844,"status":107,"phases":2845,"primaryCompletion":2499,"completion":2499,"start":2846,"enrollment":241,"conditions":2847,"interventions":2848},"NCT05857878","A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men",[90],"2023-06-23",[15],[2811],{"trials":2850,"activeCount":272,"soonestReadout":2855},[2851],{"nctId":2852,"briefTitle":2853,"status":315,"phases":2854,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":2858,"conditions":2859,"interventions":2861},"NCT06962839","A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema",[91],"2027-09-01","2027-09-29","2025-06-05",300,[2860],"Macular Edema",[2811],{"trials":2863,"activeCount":101},[],{"trials":2865,"activeCount":101},[],{"trials":2867,"activeCount":101},[],{"intervention":2869,"totalTrials":1044,"cells":2870},"BI 765423",{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2890,"PHASE3":2901,"PHASE4":2903,"NA":2905},{"trials":2872,"activeCount":101},[],{"trials":2874,"activeCount":101},[2875,2882],{"nctId":2876,"briefTitle":2877,"status":107,"phases":2878,"primaryCompletion":2879,"completion":2879,"start":217,"enrollment":1208,"conditions":2880,"interventions":2881},"NCT05658107","A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men",[90],"2024-03-19",[15],[2869],{"nctId":2883,"briefTitle":2884,"status":107,"phases":2885,"primaryCompletion":2886,"completion":1671,"start":1394,"enrollment":2887,"conditions":2888,"interventions":2889},"NCT06232252","A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men",[90],"2025-04-25",38,[15],[2869],{"trials":2891,"activeCount":272,"soonestReadout":1392},[2892],{"nctId":2893,"briefTitle":2894,"status":315,"phases":2895,"primaryCompletion":1392,"completion":2896,"start":2897,"enrollment":2898,"conditions":2899,"interventions":2900},"NCT07036523","A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment",[91],"2027-11-01","2025-11-13",71,[1397],[2869],{"trials":2902,"activeCount":101},[],{"trials":2904,"activeCount":101},[],{"trials":2906,"activeCount":101},[],{"intervention":2908,"totalTrials":1075,"cells":2909},"BI 764524",{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":101},[],{"trials":2915,"activeCount":272,"soonestReadout":2920},[2916,2929],{"nctId":2917,"briefTitle":2918,"status":140,"phases":2919,"primaryCompletion":2920,"completion":2921,"start":2922,"enrollment":2923,"conditions":2924,"interventions":2926},"NCT06321302","A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy",[91],"2027-03-05","2027-08-20","2024-05-15",188,[2925],"Diabetic Retinopathy",[2908,2927,2928],"Sham comparator to BI 764524","Aflibercept (Eylea®) - US only",{"nctId":2930,"briefTitle":2931,"status":107,"phases":2932,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":1535,"conditions":2935,"interventions":2936},"NCT04424290","HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia",[90,91],"2023-04-28","2020-06-12",[2925],[2908,2937],"Sham control of BI 764524",{"trials":2939,"activeCount":101},[],{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"intervention":2945,"totalTrials":1075,"cells":2946},"BI 3802876",{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2959,"PHASE3":2970,"PHASE4":2972,"NA":2974},{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[2951],{"nctId":2952,"briefTitle":2953,"status":107,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":241,"conditions":2957,"interventions":2958},"NCT06081530","A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated",[90],"2025-03-20","2023-10-27",[15],[2945],{"trials":2960,"activeCount":272,"soonestReadout":2965},[2961],{"nctId":2962,"briefTitle":2963,"status":315,"phases":2964,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":357,"conditions":2967,"interventions":2969},"NCT07325526","A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)",[91],"2027-03-29","2026-02-27",[2968],"Liver Cirrhosis",[2945],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[],{"trials":2975,"activeCount":101},[],{"intervention":2977,"totalTrials":1075,"cells":2978},"BI 3720931",{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":3000,"PHASE4":3002,"NA":3004},{"trials":2980,"activeCount":101},[],{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":272,"soonestReadout":2989},[2985,2992],{"nctId":2986,"briefTitle":2987,"status":140,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":593,"enrollment":166,"conditions":2990,"interventions":2991},"NCT06962852","A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)",[90,91],"2040-10-29",[1724],[2977],{"nctId":2993,"briefTitle":2994,"status":162,"phases":2995,"primaryCompletion":2996,"completion":2996,"start":2997,"enrollment":166,"conditions":2998,"interventions":2999},"NCT06515002","A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)",[90,91],"2026-02-03","2024-11-04",[1724],[2977],{"trials":3001,"activeCount":101},[],{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[],{"intervention":3007,"totalTrials":1075,"cells":3008},"BI 771716",{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3021,"PHASE3":3035,"PHASE4":3037,"NA":3039},{"trials":3010,"activeCount":101},[],{"trials":3012,"activeCount":101},[3013],{"nctId":3014,"briefTitle":3015,"status":107,"phases":3016,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1672,"conditions":3019,"interventions":3020},"NCT06006585","A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy",[90],"2024-05-24","2023-10-06",[2802],[3007],{"trials":3022,"activeCount":272,"soonestReadout":3027},[3023],{"nctId":3024,"briefTitle":3025,"status":140,"phases":3026,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3029,"conditions":3030,"interventions":3032},"NCT06722157","A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy",[91],"2026-10-28","2025-01-06",202,[3031,2802],"Macular Degeneration, Age-related",[3007,3033,3034],"Pegcetacoplan","Sham comparator to BI 771716",{"trials":3036,"activeCount":101},[],{"trials":3038,"activeCount":101},[],{"trials":3040,"activeCount":101},[],{"intervention":1041,"totalTrials":1075,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":272,"soonestReadout":1028},[3049,3053],{"nctId":1025,"briefTitle":1026,"status":315,"phases":3050,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":3051,"interventions":3052},[90,91],[1032,1033,1034,1035,1036],[911,1038,1039,1040,1041,1042,1043],{"nctId":3054,"briefTitle":3055,"status":162,"phases":3056,"primaryCompletion":3057,"completion":3057,"start":3058,"enrollment":272,"conditions":3059,"interventions":3061},"NCT02780700","Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]",[91],"2016-09-09","2016-07-05",[3060],"Colorectal Neoplasms",[78,1041],{"trials":3063,"activeCount":101},[],{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":101},[],{"intervention":2927,"totalTrials":272,"cells":3069},{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3080,"PHASE4":3082,"NA":3084},{"trials":3071,"activeCount":101},[],{"trials":3073,"activeCount":101},[],{"trials":3075,"activeCount":272,"soonestReadout":2920},[3076],{"nctId":2917,"briefTitle":2918,"status":140,"phases":3077,"primaryCompletion":2920,"completion":2921,"start":2922,"enrollment":2923,"conditions":3078,"interventions":3079},[91],[2925],[2908,2927,2928],{"trials":3081,"activeCount":101},[],{"trials":3083,"activeCount":101},[],{"trials":3085,"activeCount":101},[],{"intervention":2928,"totalTrials":272,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3098,"PHASE4":3100,"NA":3102},{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":272,"soonestReadout":2920},[3094],{"nctId":2917,"briefTitle":2918,"status":140,"phases":3095,"primaryCompletion":2920,"completion":2921,"start":2922,"enrollment":2923,"conditions":3096,"interventions":3097},[91],[2925],[2908,2927,2928],{"trials":3099,"activeCount":101},[],{"trials":3101,"activeCount":101},[],{"trials":3103,"activeCount":101},[],{"intervention":3105,"totalTrials":272,"cells":3106},"Low dose BI 3812465",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3108,"activeCount":101},[],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":272,"soonestReadout":3117},[3113],{"nctId":3114,"briefTitle":3115,"status":1001,"phases":3116,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":2123,"conditions":3120,"interventions":3122},"NCT07553429","A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated",[90,91],"2027-03-23","2027-07-06","2026-05-14",[3121],"Diabetic Macular Edema",[3105,3123,3124],"Medium dose BI 3812465","High dose BI 3812465",{"trials":3126,"activeCount":101},[],{"trials":3128,"activeCount":101},[],{"trials":3130,"activeCount":101},[],{"intervention":3123,"totalTrials":272,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":101},[],{"trials":3136,"activeCount":101},[],{"trials":3138,"activeCount":272,"soonestReadout":3117},[3139],{"nctId":3114,"briefTitle":3115,"status":1001,"phases":3140,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":2123,"conditions":3141,"interventions":3142},[90,91],[3121],[3105,3123,3124],{"trials":3144,"activeCount":101},[],{"trials":3146,"activeCount":101},[],{"trials":3148,"activeCount":101},[],{"intervention":3124,"totalTrials":272,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":101},[],{"trials":3154,"activeCount":101},[],{"trials":3156,"activeCount":272,"soonestReadout":3117},[3157],{"nctId":3114,"briefTitle":3115,"status":1001,"phases":3158,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":2123,"conditions":3159,"interventions":3160},[90,91],[3121],[3105,3123,3124],{"trials":3162,"activeCount":101},[],{"trials":3164,"activeCount":101},[],{"trials":3166,"activeCount":101},[],{"intervention":3168,"totalTrials":272,"cells":3169},"BI 764532, dose 1",{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3174,"PHASE3":3188,"PHASE4":3190,"NA":3192},{"trials":3171,"activeCount":101},[],{"trials":3173,"activeCount":101},[],{"trials":3175,"activeCount":272,"soonestReadout":2855},[3176],{"nctId":3177,"briefTitle":3178,"status":315,"phases":3179,"primaryCompletion":2855,"completion":3180,"start":3181,"enrollment":3182,"conditions":3183,"interventions":3186},"NCT05882058","DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers",[91],"2028-02-24","2023-10-13",204,[3184,1108,3185],"Small Cell Lung Carcinoma","Extra-pulmonary Neuroendocrine Carcinoma",[3168,3187],"BI 764532, dose 2",{"trials":3189,"activeCount":101},[],{"trials":3191,"activeCount":101},[],{"trials":3193,"activeCount":101},[],{"intervention":3187,"totalTrials":272,"cells":3195},{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":272,"soonestReadout":2855},[3202],{"nctId":3177,"briefTitle":3178,"status":315,"phases":3203,"primaryCompletion":2855,"completion":3180,"start":3181,"enrollment":3182,"conditions":3204,"interventions":3205},[91],[3184,1108,3185],[3168,3187],{"trials":3207,"activeCount":101},[],{"trials":3209,"activeCount":101},[],{"trials":3211,"activeCount":101},[],{"intervention":1038,"totalTrials":272,"cells":3213},{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3224,"PHASE4":3226,"NA":3228},{"trials":3215,"activeCount":101},[],{"trials":3217,"activeCount":101},[],{"trials":3219,"activeCount":272,"soonestReadout":1028},[3220],{"nctId":1025,"briefTitle":1026,"status":315,"phases":3221,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":3222,"interventions":3223},[90,91],[1032,1033,1034,1035,1036],[911,1038,1039,1040,1041,1042,1043],{"trials":3225,"activeCount":101},[],{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[],{"intervention":1039,"totalTrials":272,"cells":3231},{"EARLY_PHASE1":3232,"PHASE1":3234,"PHASE2":3236,"PHASE3":3242,"PHASE4":3244,"NA":3246},{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[],{"trials":3237,"activeCount":272,"soonestReadout":1028},[3238],{"nctId":1025,"briefTitle":1026,"status":315,"phases":3239,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":3240,"interventions":3241},[90,91],[1032,1033,1034,1035,1036],[911,1038,1039,1040,1041,1042,1043],{"trials":3243,"activeCount":101},[],{"trials":3245,"activeCount":101},[],{"trials":3247,"activeCount":101},[],{"intervention":1042,"totalTrials":272,"cells":3249},{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3254,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3251,"activeCount":101},[],{"trials":3253,"activeCount":101},[],{"trials":3255,"activeCount":272,"soonestReadout":1028},[3256],{"nctId":1025,"briefTitle":1026,"status":315,"phases":3257,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":3258,"interventions":3259},[90,91],[1032,1033,1034,1035,1036],[911,1038,1039,1040,1041,1042,1043],{"trials":3261,"activeCount":101},[],{"trials":3263,"activeCount":101},[],{"trials":3265,"activeCount":101},[],{"intervention":1043,"totalTrials":272,"cells":3267},{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3278,"PHASE4":3280,"NA":3282},{"trials":3269,"activeCount":101},[],{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":272,"soonestReadout":1028},[3274],{"nctId":1025,"briefTitle":1026,"status":315,"phases":3275,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":3276,"interventions":3277},[90,91],[1032,1033,1034,1035,1036],[911,1038,1039,1040,1041,1042,1043],{"trials":3279,"activeCount":101},[],{"trials":3281,"activeCount":101},[],{"trials":3283,"activeCount":101},[],{"intervention":3033,"totalTrials":272,"cells":3285},{"EARLY_PHASE1":3286,"PHASE1":3288,"PHASE2":3290,"PHASE3":3296,"PHASE4":3298,"NA":3300},{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":272,"soonestReadout":3027},[3292],{"nctId":3024,"briefTitle":3025,"status":140,"phases":3293,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3029,"conditions":3294,"interventions":3295},[91],[3031,2802],[3007,3033,3034],{"trials":3297,"activeCount":101},[],{"trials":3299,"activeCount":101},[],{"trials":3301,"activeCount":101},[],{"intervention":3034,"totalTrials":272,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3314,"PHASE4":3316,"NA":3318},{"trials":3305,"activeCount":101},[],{"trials":3307,"activeCount":101},[],{"trials":3309,"activeCount":272,"soonestReadout":3027},[3310],{"nctId":3024,"briefTitle":3025,"status":140,"phases":3311,"primaryCompletion":3027,"completion":3027,"start":3028,"enrollment":3029,"conditions":3312,"interventions":3313},[91],[3031,2802],[3007,3033,3034],{"trials":3315,"activeCount":101},[],{"trials":3317,"activeCount":101},[],{"trials":3319,"activeCount":101},[],{"intervention":3321,"totalTrials":272,"cells":3322},"BI 3032950 intravenous",{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":272,"soonestReadout":1439},[3329],{"nctId":3330,"briefTitle":3331,"status":315,"phases":3332,"primaryCompletion":1439,"completion":1168,"start":3333,"enrollment":1429,"conditions":3334,"interventions":3336},"NCT06636656","A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis",[91],"2024-12-11",[3335],"Ulcerative Colitis",[3321,3337],"BI 3032950 subcutaneous",{"trials":3339,"activeCount":101},[],{"trials":3341,"activeCount":101},[],{"trials":3343,"activeCount":101},[],{"intervention":3337,"totalTrials":272,"cells":3345},{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3356,"PHASE4":3358,"NA":3360},{"trials":3347,"activeCount":101},[],{"trials":3349,"activeCount":101},[],{"trials":3351,"activeCount":272,"soonestReadout":1439},[3352],{"nctId":3330,"briefTitle":3331,"status":315,"phases":3353,"primaryCompletion":1439,"completion":1168,"start":3333,"enrollment":1429,"conditions":3354,"interventions":3355},[91],[3335],[3321,3337],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"intervention":2493,"totalTrials":1081,"cells":3363},{"EARLY_PHASE1":3364,"PHASE1":3366,"PHASE2":3372,"PHASE3":3378,"PHASE4":3380,"NA":3403},{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[3368],{"nctId":2487,"briefTitle":2488,"status":107,"phases":3369,"primaryCompletion":2490,"completion":2490,"start":1478,"enrollment":177,"conditions":3370,"interventions":3371},[90],[15],[2441,78,2493],{"trials":3373,"activeCount":272,"soonestReadout":1216},[3374],{"nctId":2573,"briefTitle":2574,"status":315,"phases":3375,"primaryCompletion":1216,"completion":2576,"start":2407,"enrollment":1672,"conditions":3376,"interventions":3377},[91],[1397],[2441,2493],{"trials":3379,"activeCount":101},[],{"trials":3381,"activeCount":101},[3382,3392],{"nctId":3383,"briefTitle":3384,"status":107,"phases":3385,"primaryCompletion":3386,"completion":3387,"start":3388,"enrollment":3389,"conditions":3390,"interventions":3391},"NCT02579603","Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF",[93],"2017-01-03","2017-01-31","2015-10-16",105,[1397],[78,2493],{"nctId":3393,"briefTitle":3394,"status":107,"phases":3395,"primaryCompletion":3396,"completion":3396,"start":3397,"enrollment":3398,"conditions":3399,"interventions":3400},"NCT02606877","A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination",[93],"2017-03-22","2016-04-19",37,[1397],[3401,3402],"nintedanib","pirfenidone",{"trials":3404,"activeCount":101},[3405,3413,3421,3430,3439,3448],{"nctId":3406,"briefTitle":3407,"status":107,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":341,"enrollment":3410,"conditions":3411,"interventions":3412},"NCT05779007","Dose Reduction and Discontinuation With Anti-Fibrotic Medications",[],"2023-07-14",2778,[1397],[2493,78],{"nctId":3414,"briefTitle":3415,"status":107,"phases":3416,"primaryCompletion":3417,"completion":3417,"start":922,"enrollment":3418,"conditions":3419,"interventions":3420},"NCT06485635","Real-life-persistence to Antifibrotic Treatments",[],"2026-04-07",10646,[1397],[78,2493],{"nctId":3422,"briefTitle":3423,"status":600,"phases":3424,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":101,"conditions":3427,"interventions":3429},"NCT05676112","Safety of Nintedanib in Real World in China",[],"2026-09-30","2023-12-29",[3428],"Pulmonary Fibrosis",[3401,3402],{"nctId":3431,"briefTitle":3432,"status":107,"phases":3433,"primaryCompletion":3434,"completion":3434,"start":3435,"enrollment":3436,"conditions":3437,"interventions":3438},"NCT03242759","Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan",[],"2020-02-18","2017-08-17",101,[3428],[3401,3402],{"nctId":3440,"briefTitle":3441,"status":107,"phases":3442,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":3445,"conditions":3446,"interventions":3447},"NCT03958071","A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking",[],"2019-05-31","2019-02-01",13264,[1397],[78,2493],{"nctId":3449,"briefTitle":3450,"status":107,"phases":3451,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":3454,"conditions":3455,"interventions":3456},"NCT03047031","Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis",[],"2022-07-21","2017-04-05",21,[1397],[78,2493],{"intervention":1461,"totalTrials":392,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3471,"PHASE2":3610,"PHASE3":3623,"PHASE4":3629,"NA":3631},{"trials":3460,"activeCount":101},[3461],{"nctId":3462,"briefTitle":3463,"status":107,"phases":3464,"primaryCompletion":3465,"completion":3465,"start":3466,"enrollment":3467,"conditions":3468,"interventions":3469},"NCT03433898","This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer",[89],"2023-07-20","2018-02-23",146,[33],[1461,3470],"BI 754111",{"trials":3472,"activeCount":1340,"soonestReadout":42},[3473,3485,3491,3502,3512,3520,3524,3535,3545,3559,3569,3579,3583,3596,3606],{"nctId":3474,"briefTitle":3475,"status":140,"phases":3476,"primaryCompletion":3477,"completion":3477,"start":732,"enrollment":177,"conditions":3478,"interventions":3482},"NCT05068102","A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab",[90],"2026-09-16",[3479,3480,3481],"Carcinoma, Squamous Cell of Head and Neck (HNSCC)","Melanoma","Non-small Cell Lung Cancer (NSCLC)",[43,1461,3483,48,3484],"[89Zr]Zr- BI 765063","[89Zr]Zr- BI 770371",{"nctId":45,"briefTitle":46,"status":140,"phases":3486,"primaryCompletion":47,"completion":3425,"start":3487,"enrollment":448,"conditions":3488,"interventions":3489},[90],"2022-05-17",[2057],[48,3490],"ezabenlimab",{"nctId":3492,"briefTitle":3493,"status":315,"phases":3494,"primaryCompletion":3495,"completion":3496,"start":2419,"enrollment":123,"conditions":3497,"interventions":3500},"NCT07607678","A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab",[90],"2028-06-05","2030-10-15",[3498,3499],"Advanced Solid Cancer","Metastatic Solid Cancer",[3501,1461],"BI 3819026",{"nctId":3503,"briefTitle":3504,"status":107,"phases":3505,"primaryCompletion":3506,"completion":3507,"start":3508,"enrollment":3509,"conditions":3510,"interventions":3511},"NCT03156114","This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.",[90],"2023-03-09","2023-06-06","2017-06-13",172,[33,36],[1461,3470],{"nctId":40,"briefTitle":41,"status":140,"phases":3513,"primaryCompletion":42,"completion":3514,"start":3515,"enrollment":410,"conditions":3516,"interventions":3518},[90],"2026-07-31","2022-04-12",[3517],"Head and Neck Squamous Cell Carcinoma (HNSCC)",[43,1461,3519,1472],"BI 836880",{"nctId":50,"briefTitle":51,"status":140,"phases":3521,"primaryCompletion":52,"completion":1824,"start":1825,"enrollment":1535,"conditions":3522,"interventions":3523},[90],[1096,1108],[53,1461],{"nctId":3525,"briefTitle":3526,"status":107,"phases":3527,"primaryCompletion":3528,"completion":3529,"start":3530,"enrollment":3531,"conditions":3532,"interventions":3534},"NCT03468426","A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours",[90],"2024-07-31","2024-09-12","2018-07-05",252,[3533,33],"Non-squamous, Non-Small-Cell Lung Cancer",[3519,1461],{"nctId":3536,"briefTitle":3537,"status":107,"phases":3538,"primaryCompletion":3539,"completion":2606,"start":3540,"enrollment":28,"conditions":3541,"interventions":3543},"NCT04752215","A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface",[90],"2024-11-19","2021-05-18",[3542],"Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms",[3544,3490],"BI 765049",{"nctId":3546,"briefTitle":3547,"status":140,"phases":3548,"primaryCompletion":3549,"completion":3549,"start":3550,"enrollment":3551,"conditions":3552,"interventions":3554},"NCT05846516","A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer",[90],"2027-06-27","2023-05-11",58,[3553],"Pancreatic Ductal Adenocarcinoma",[3555,3556,3557,1461,3558],"VSV-GP154","ATP150","ATP152","ATP162",{"nctId":3560,"briefTitle":3561,"status":315,"phases":3562,"primaryCompletion":3563,"completion":3563,"start":3564,"enrollment":3565,"conditions":3566,"interventions":3567},"NCT05471856","A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)",[90],"2028-09-13","2023-02-24",66,[2057],[3568,1461],"BI 1703880",{"nctId":3570,"briefTitle":3571,"status":107,"phases":3572,"primaryCompletion":3573,"completion":1874,"start":3574,"enrollment":3575,"conditions":3576,"interventions":3577},"NCT03964233","A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)",[90],"2024-09-05","2019-06-20",119,[33],[3578,3490,3470],"BI 907828",{"nctId":55,"briefTitle":56,"status":140,"phases":3580,"primaryCompletion":57,"completion":1456,"start":1457,"enrollment":1458,"conditions":3581,"interventions":3582},[90],[33],[58,1461,1012],{"nctId":3584,"briefTitle":3585,"status":107,"phases":3586,"primaryCompletion":1523,"completion":3587,"start":3588,"enrollment":3454,"conditions":3589,"interventions":3595},"NCT06091930","A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6",[90],"2025-10-03","2024-02-16",[3590,3591,3592,1036,3593,3594],"Gastrointestinal Cancer","Lung Cancer","Pancreatic Cancer","Head and Neck Cancer","Liver Cancer",[3544,1461],{"nctId":3597,"briefTitle":3598,"status":315,"phases":3599,"primaryCompletion":3600,"completion":3601,"start":3602,"enrollment":123,"conditions":3603,"interventions":3604},"NCT07395258","A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)",[90],"2028-02-20","2032-02-12","2026-04-02",[2057],[3605,1461],"BI 3923948",{"nctId":1474,"briefTitle":1475,"status":162,"phases":3607,"primaryCompletion":1477,"completion":1478,"start":1479,"enrollment":1075,"conditions":3608,"interventions":3609},[90],[1036],[1461,43,1012],{"trials":3611,"activeCount":101},[3612],{"nctId":3613,"briefTitle":3614,"status":107,"phases":3615,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":3618,"conditions":3619,"interventions":3622},"NCT03697304","Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced\u002FMetastatic Solid Tumours",[91],"2024-12-03","2019-03-19",211,[938,3620,3621],"Advanced Tumors","Metastatic Solid Tumors",[1461,3470,3519],{"trials":3624,"activeCount":101},[3625],{"nctId":2719,"briefTitle":2720,"status":600,"phases":3626,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":101,"conditions":3627,"interventions":3628},[92],[2726,2727,2728],[2675,1461,2730,2731],{"trials":3630,"activeCount":101},[],{"trials":3632,"activeCount":101},[],{"intervention":82,"totalTrials":166,"cells":3634},{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3673,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3636,"activeCount":101},[],{"trials":3638,"activeCount":166,"soonestReadout":77},[3639,3643,3653,3657,3664],{"nctId":1088,"briefTitle":1089,"status":140,"phases":3640,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":3641,"interventions":3642},[90],[1096],[82,1010,1098,1058],{"nctId":3644,"briefTitle":3645,"status":315,"phases":3646,"primaryCompletion":3647,"completion":3648,"start":3649,"enrollment":188,"conditions":3650,"interventions":3651},"NCT05963867","A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer",[90],"2026-08-10","2026-11-25","2024-08-06",[1096,1108],[82,3652],"[89Zr]Zr-BI 764532",{"nctId":1100,"briefTitle":1101,"status":315,"phases":3654,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":3655,"interventions":3656},[90],[1108],[82,1010,1098,1009],{"nctId":80,"briefTitle":81,"status":140,"phases":3658,"primaryCompletion":77,"completion":1439,"start":1093,"enrollment":3659,"conditions":3660,"interventions":3661},[90],69,[1096],[82,3662,3663],"Topotecan","Single agent chemotherapy",{"nctId":3665,"briefTitle":3666,"status":140,"phases":3667,"primaryCompletion":3668,"completion":142,"start":3669,"enrollment":392,"conditions":3670,"interventions":3672},"NCT05916313","A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3",[90],"2027-08-09","2024-01-30",[3671],"Glioma",[82],{"trials":3674,"activeCount":101},[],{"trials":3676,"activeCount":101},[],{"trials":3678,"activeCount":101},[],{"trials":3680,"activeCount":101},[],{"intervention":48,"totalTrials":1564,"cells":3682},{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3699,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3684,"activeCount":101},[],{"trials":3686,"activeCount":1044,"soonestReadout":47},[3687,3691,3695],{"nctId":3474,"briefTitle":3475,"status":140,"phases":3688,"primaryCompletion":3477,"completion":3477,"start":732,"enrollment":177,"conditions":3689,"interventions":3690},[90],[3479,3480,3481],[43,1461,3483,48,3484],{"nctId":45,"briefTitle":46,"status":140,"phases":3692,"primaryCompletion":47,"completion":3425,"start":3487,"enrollment":448,"conditions":3693,"interventions":3694},[90],[2057],[48,3490],{"nctId":1463,"briefTitle":1464,"status":140,"phases":3696,"primaryCompletion":1466,"completion":1466,"start":1467,"enrollment":1468,"conditions":3697,"interventions":3698},[90],[1470],[48,1012,1472],{"trials":3700,"activeCount":101},[3701],{"nctId":3702,"briefTitle":3703,"status":107,"phases":3704,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":1865,"conditions":3707,"interventions":3709},"NCT06675929","A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH",[91],"2026-01-13","2025-01-20",[3708,1296],"Compensated Liver Cirrhosis",[48],{"trials":3711,"activeCount":101},[],{"trials":3713,"activeCount":101},[],{"trials":3715,"activeCount":101},[],{"intervention":1472,"totalTrials":1512,"cells":3717},{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3747,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3719,"activeCount":101},[],{"trials":3721,"activeCount":1075,"soonestReadout":42},[3722,3726,3736,3740],{"nctId":40,"briefTitle":41,"status":140,"phases":3723,"primaryCompletion":42,"completion":3514,"start":3515,"enrollment":410,"conditions":3724,"interventions":3725},[90],[3517],[43,1461,3519,1472],{"nctId":3727,"briefTitle":3728,"status":107,"phases":3729,"primaryCompletion":3730,"completion":3731,"start":3732,"enrollment":3733,"conditions":3734,"interventions":3735},"NCT01090011","Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer",[90],"2013-01","2014-08","2010-03",171,[36],[1472,1472,1129,1129],{"nctId":1463,"briefTitle":1464,"status":140,"phases":3737,"primaryCompletion":1466,"completion":1466,"start":1467,"enrollment":1468,"conditions":3738,"interventions":3739},[90],[1470],[48,1012,1472],{"nctId":3741,"briefTitle":3742,"status":107,"phases":3743,"primaryCompletion":603,"completion":3744,"start":516,"enrollment":3551,"conditions":3745,"interventions":3746},"NCT02020577","Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours",[90],"2016-04",[33],[1472,1492],{"trials":3748,"activeCount":101},[3749,3758],{"nctId":3750,"briefTitle":3751,"status":107,"phases":3752,"primaryCompletion":3753,"start":3754,"enrollment":3755,"conditions":3756,"interventions":3757},"NCT01152437","A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer",[91],"2012-03","2010-06",94,[3060],[1129,1472],{"nctId":3759,"briefTitle":3760,"status":107,"phases":3761,"primaryCompletion":3732,"completion":3762,"start":3763,"enrollment":3764,"conditions":3765,"interventions":3768},"NCT00514943","BIBW 2992 (Afatinib) in Head & Neck Cancer",[91],"2013-07","2007-08",124,[3766,3767],"Head and Neck Neoplasms","Carcinoma, Squamous Cell",[1129,1472],{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":101},[],{"trials":3774,"activeCount":101},[],{"intervention":1211,"totalTrials":1564,"cells":3776},{"EARLY_PHASE1":3777,"PHASE1":3779,"PHASE2":3805,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3778,"activeCount":101},[],{"trials":3780,"activeCount":1075,"soonestReadout":3801},[3781,3785,3797],{"nctId":1202,"briefTitle":1203,"status":140,"phases":3782,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":3783,"interventions":3784},[90],[539],[1195,1211],{"nctId":3786,"briefTitle":3787,"status":107,"phases":3788,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":3791,"conditions":3792,"interventions":3793},"NCT05751226","A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906",[90],"2024-08-01","2023-04-11",88,[15,539],[3794,3795,3796],"BI 1820237","semaglutide","BI 456906",{"nctId":3798,"briefTitle":3799,"status":315,"phases":3800,"primaryCompletion":3801,"completion":3802,"start":1236,"enrollment":357,"conditions":3803,"interventions":3804},"NCT05202353","A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver",[90],"2026-12-02","2027-01-01",[539],[3796,1211],{"trials":3806,"activeCount":101},[3807],{"nctId":3808,"briefTitle":3809,"status":107,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3816},"NCT04153929","A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.",[91],"2021-10-08","2021-11-04","2020-04-30",413,[21],[3796,1211],{"trials":3818,"activeCount":101},[],{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"intervention":43,"totalTrials":1564,"cells":3824},{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3850,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3826,"activeCount":101},[],{"trials":3828,"activeCount":1075,"soonestReadout":42},[3829,3833,3837,3846],{"nctId":3474,"briefTitle":3475,"status":140,"phases":3830,"primaryCompletion":3477,"completion":3477,"start":732,"enrollment":177,"conditions":3831,"interventions":3832},[90],[3479,3480,3481],[43,1461,3483,48,3484],{"nctId":40,"briefTitle":41,"status":140,"phases":3834,"primaryCompletion":42,"completion":3514,"start":3515,"enrollment":410,"conditions":3835,"interventions":3836},[90],[3517],[43,1461,3519,1472],{"nctId":3838,"briefTitle":3839,"status":107,"phases":3840,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":392,"conditions":3843,"interventions":3844},"NCT04653142","A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)",[90],"2022-04-20","2020-12-15",[2057],[43,3845],"BI 754091",{"nctId":1474,"briefTitle":1475,"status":162,"phases":3847,"primaryCompletion":1477,"completion":1478,"start":1479,"enrollment":1075,"conditions":3848,"interventions":3849},[90],[1036],[1461,43,1012],{"trials":3851,"activeCount":101},[],{"trials":3853,"activeCount":101},[],{"trials":3855,"activeCount":101},[],{"trials":3857,"activeCount":101},[],{"intervention":3859,"totalTrials":1564,"cells":3860},"BI 1701963",{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3902,"PHASE3":3904,"PHASE4":3906,"NA":3908},{"trials":3862,"activeCount":101},[],{"trials":3864,"activeCount":1075,"soonestReadout":3888},[3865,3875,3884,3893],{"nctId":3866,"briefTitle":3867,"status":162,"phases":3868,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":155,"conditions":3871,"interventions":3873},"NCT04835714","A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])",[90],"2022-01-18","2021-04-20",[3872],"Solid Tumors, KRAS Mutation",[3859,3874],"BI 3011441",{"nctId":3876,"briefTitle":3877,"status":140,"phases":3878,"primaryCompletion":1017,"completion":1017,"start":3879,"enrollment":2898,"conditions":3880,"interventions":3882},"NCT04111458","A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)",[90],"2019-11-04",[3881],"Solid Tumors, KRAS Mutation; SOS1",[3859,3883],"Trametinib",{"nctId":3885,"briefTitle":3886,"status":140,"phases":3887,"primaryCompletion":3888,"completion":3889,"start":368,"enrollment":357,"conditions":3890,"interventions":3891},"NCT04973163","A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation",[90],"2026-11-29","2026-12-27",[3872],[3892,3859,1242],"BI 1823911",{"nctId":3894,"briefTitle":3895,"status":162,"phases":3896,"primaryCompletion":3869,"completion":3869,"start":3897,"enrollment":956,"conditions":3898,"interventions":3900},"NCT04627142","A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation",[90],"2020-11-23",[3899],"Metastatic Colorectal Cancer (CRC)",[3859,3901],"Camptosar®",{"trials":3903,"activeCount":101},[],{"trials":3905,"activeCount":101},[],{"trials":3907,"activeCount":101},[],{"trials":3909,"activeCount":101},[],{"intervention":3911,"totalTrials":1564,"cells":3912},"BI 3031185",{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3950,"PHASE3":3952,"PHASE4":3954,"NA":3956},{"trials":3914,"activeCount":101},[],{"trials":3916,"activeCount":1075,"soonestReadout":3946},[3917,3928,3935,3942],{"nctId":3918,"briefTitle":3919,"status":315,"phases":3920,"primaryCompletion":3921,"completion":3922,"start":3923,"enrollment":8,"conditions":3924,"interventions":3927},"NCT07001475","A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit\u002FHyperactivity Disorder",[90],"2026-10-27","2026-11-27","2025-08-12",[3925,3926],"Borderline Personality Disorder","Attention Deficit Hyperactivity Disorder",[3911],{"nctId":3929,"briefTitle":3930,"status":107,"phases":3931,"primaryCompletion":3932,"completion":3932,"start":1379,"enrollment":177,"conditions":3933,"interventions":3934},"NCT07211425","A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood",[90],"2026-01-21",[15],[3911,949],{"nctId":3936,"briefTitle":3937,"status":107,"phases":3938,"primaryCompletion":2498,"completion":2498,"start":905,"enrollment":3939,"conditions":3940,"interventions":3941},"NCT06255340","A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood",[90],75,[15],[3911],{"nctId":3943,"briefTitle":3944,"status":315,"phases":3945,"primaryCompletion":3946,"completion":3946,"start":3947,"enrollment":1218,"conditions":3948,"interventions":3949},"NCT06916702","A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women",[90],"2026-10-07","2025-04-07",[15],[3911,1242],{"trials":3951,"activeCount":101},[],{"trials":3953,"activeCount":101},[],{"trials":3955,"activeCount":101},[],{"trials":3957,"activeCount":101},[],{"intervention":1242,"totalTrials":251,"cells":3959},{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":4181,"PHASE3":4183,"PHASE4":4185,"NA":4187},{"trials":3961,"activeCount":101},[],{"trials":3963,"activeCount":1075,"soonestReadout":3946},[3964,3974,3982,3986,3997,4001,4016,4025,4034,4049,4058,4067,4078,4082,4086,4096,4100,4110,4114,4124,4135,4143,4151,4159,4168,4177],{"nctId":3965,"briefTitle":3966,"status":107,"phases":3967,"primaryCompletion":3968,"completion":3969,"start":3879,"enrollment":3970,"conditions":3971,"interventions":3972},"NCT04107805","A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated",[90],"2021-03-05","2021-03-26",87,[15],[3973,1242],"BI 1323495",{"nctId":3975,"briefTitle":3976,"status":107,"phases":3977,"primaryCompletion":3978,"start":1115,"enrollment":1672,"conditions":3979,"interventions":3980},"NCT02256748","Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers",[90],"2005-08",[15],[3981,1242],"BIRT 2584 XX",{"nctId":2377,"briefTitle":2378,"status":107,"phases":3983,"primaryCompletion":2380,"completion":2380,"start":2381,"enrollment":2382,"conditions":3984,"interventions":3985},[90],[15],[2370,1242],{"nctId":3987,"briefTitle":3988,"status":162,"phases":3989,"primaryCompletion":3990,"start":3991,"enrollment":3398,"conditions":3992,"interventions":3993},"NCT02182401","Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers",[90],"2009-08","2009-07",[15],[3994,3995,1242,3996],"BI 207127 NA","BI 201335 NA","Tolbutamide",{"nctId":919,"briefTitle":920,"status":107,"phases":3998,"primaryCompletion":922,"completion":922,"start":923,"enrollment":401,"conditions":3999,"interventions":4000},[90],[15],[926,927,928,929],{"nctId":4002,"briefTitle":4003,"status":107,"phases":4004,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":4006,"interventions":4007},"NCT02243553","Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers",[90],"2006-01",[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],"Tipranavir","Tipranavir solution","Ritonavir","Warfarin sodium","Vitamin K","Omeprazole","Dextromethorphan hydrobromide","Midazolam oral solution",{"nctId":4017,"briefTitle":4018,"status":107,"phases":4019,"primaryCompletion":4020,"completion":4020,"start":4021,"enrollment":357,"conditions":4022,"interventions":4023},"NCT04789304","A Study to Test How Healthy Men Tolerate Different Doses of BI 1595043",[90],"2022-01-14","2021-04-01",[15],[4024,1242],"BI 1595043",{"nctId":4026,"briefTitle":4027,"status":107,"phases":4028,"primaryCompletion":4029,"completion":4029,"start":4030,"enrollment":291,"conditions":4031,"interventions":4032},"NCT04241458","A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321",[90],"2020-11-24","2020-01-30",[15],[4033,1242],"BI 703621",{"nctId":4035,"briefTitle":4036,"status":107,"phases":4037,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":4039,"interventions":4041},"NCT01525628","Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients",[90],"2012-04",[4040],"Hepatitis C, Chronic",[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],"BI 201335","tenofovir","caffeine","tolbutamide","pegylated interferon","BI 207127","ribavirin",{"nctId":4050,"briefTitle":4051,"status":107,"phases":4052,"primaryCompletion":4053,"completion":4053,"start":4054,"enrollment":123,"conditions":4055,"interventions":4056},"NCT03325712","This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam",[90],"2018-11-26","2017-11-17",[15],[4057,1242],"BI 705564",{"nctId":4059,"briefTitle":4060,"status":107,"phases":4061,"primaryCompletion":4062,"completion":4062,"start":4063,"enrollment":2507,"conditions":4064,"interventions":4065},"NCT04537897","A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated",[90],"2021-10-07","2020-10-06",[15],[4066,1242],"BI 474121",{"nctId":4068,"briefTitle":4069,"status":107,"phases":4070,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":28,"conditions":4073,"interventions":4074},"NCT05738291","A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood",[90],"2024-06-14","2023-05-01",[15],[4075,927,4076,4077],"BI 1839100","digoxin","rosuvastatin",{"nctId":1231,"briefTitle":1232,"status":107,"phases":4079,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":4080,"interventions":4081},[90],[1228,539],[1195,1240,1241,1242],{"nctId":2776,"briefTitle":2777,"status":107,"phases":4083,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":2235,"conditions":4084,"interventions":4085},[90],[15],[2744,927],{"nctId":4087,"briefTitle":4088,"status":107,"phases":4089,"primaryCompletion":4090,"completion":4090,"start":4091,"enrollment":912,"conditions":4092,"interventions":4093},"NCT02783040","Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin",[90],"2015-10-30","2015-09-07",[15],[1242,4094,4013,2393,4095],"Warfarin","BI 425809",{"nctId":3885,"briefTitle":3886,"status":140,"phases":4097,"primaryCompletion":3888,"completion":3889,"start":368,"enrollment":357,"conditions":4098,"interventions":4099},[90],[3872],[3892,3859,1242],{"nctId":4101,"briefTitle":4102,"status":107,"phases":4103,"primaryCompletion":4104,"completion":4105,"start":4106,"enrollment":1126,"conditions":4107,"interventions":4108},"NCT03279978","This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357",[90],"2018-08-24","2018-08-30","2018-01-09",[15,114],[4109,1242],"BI 730357",{"nctId":2529,"briefTitle":2530,"status":107,"phases":4111,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":956,"conditions":4112,"interventions":4113},[90],[15],[2441,927],{"nctId":4115,"briefTitle":4116,"status":600,"phases":4117,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":101,"conditions":4121,"interventions":4122},"NCT02345304","Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin",[90],"2015-04","2015-05","2015-03",[15],[4013,4094,4123,1242,4013,4123,1242,1242,4094,4123,2393,2393],"BI 1181181",{"nctId":4125,"briefTitle":4126,"status":107,"phases":4127,"primaryCompletion":4128,"start":4129,"enrollment":410,"conditions":4130,"interventions":4131},"NCT02217514","Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers",[90],"2008-03","2008-02",[15],[1242,4132,4133,4134],"BI 44370 low dose","BI 44370 medium dose","BI 44370 high dose",{"nctId":4136,"briefTitle":4137,"status":162,"phases":4138,"primaryCompletion":4139,"completion":2857,"start":964,"enrollment":357,"conditions":4140,"interventions":4141},"NCT06716190","A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People",[90],"2025-05-19",[15],[4142,1242],"BI 3731579",{"nctId":4144,"briefTitle":4145,"status":107,"phases":4146,"primaryCompletion":965,"completion":965,"start":2922,"enrollment":392,"conditions":4147,"interventions":4148},"NCT06367153","A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood",[90],[15],[4149,4150,1242,1240],"BI 1569912","Repaglinide",{"nctId":4152,"briefTitle":4153,"status":107,"phases":4154,"primaryCompletion":164,"completion":164,"start":4155,"enrollment":956,"conditions":4156,"interventions":4157},"NCT05258110","A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood",[90],"2022-03-18",[15],[927,4158],"iclepertin",{"nctId":4160,"briefTitle":4161,"status":107,"phases":4162,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":4163,"interventions":4164},"NCT02254148","The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)",[90],[15],[927,4044,4076,4165,928,4166,4167],"warfarin","BI 187004","metoprolol",{"nctId":4169,"briefTitle":4170,"status":107,"phases":4171,"primaryCompletion":4172,"completion":4172,"start":4173,"enrollment":2235,"conditions":4174,"interventions":4175},"NCT03754959","This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down Midazolam",[90],"2019-07-22","2018-12-18",[15],[4176,1242],"BI 1358894",{"nctId":3943,"briefTitle":3944,"status":315,"phases":4178,"primaryCompletion":3946,"completion":3946,"start":3947,"enrollment":1218,"conditions":4179,"interventions":4180},[90],[15],[3911,1242],{"trials":4182,"activeCount":101},[],{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[],{"trials":4188,"activeCount":101},[4189],{"nctId":4190,"briefTitle":4191,"status":107,"phases":4192,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":1564,"conditions":4196,"interventions":4197},"NCT05741385","A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis",[94],"2024-08-09","2024-08-23","2023-10-10",[2968],[1241,4011,4013,4198,1242],"Metoprolol",{"intervention":3796,"totalTrials":912,"cells":4200},{"EARLY_PHASE1":4201,"PHASE1":4203,"PHASE2":4284,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4202,"activeCount":101},[],{"trials":4204,"activeCount":272,"soonestReadout":3801},[4205,4213,4222,4230,4236,4240,4248,4256,4264,4268,4276],{"nctId":4206,"briefTitle":4207,"status":107,"phases":4208,"primaryCompletion":4209,"completion":4209,"start":4210,"enrollment":1672,"conditions":4211,"interventions":4212},"NCT03175211","Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers",[90],"2018-02-19","2017-06-30",[15],[3796],{"nctId":4214,"briefTitle":4215,"status":107,"phases":4216,"primaryCompletion":4217,"completion":4217,"start":4218,"enrollment":4219,"conditions":4220,"interventions":4221},"NCT06200467","A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity",[90],"2025-10-22","2024-03-13",110,[1228,539],[3796,1538],{"nctId":4223,"briefTitle":4224,"status":107,"phases":4225,"primaryCompletion":4226,"completion":3813,"start":4227,"enrollment":12,"conditions":4228,"interventions":4229},"NCT03591718","A Study to Test Different Doses of BI 456906 in Patients With Obesity",[90],"2020-04-20","2018-07-26",[539],[3796],{"nctId":4231,"briefTitle":4232,"status":107,"phases":4233,"primaryCompletion":2250,"completion":2250,"start":249,"enrollment":1512,"conditions":4234,"interventions":4235},"NCT05421338","A Study in Healthy Men to Test How BI 456906 is Processed in the Body",[90],[15],[3796],{"nctId":3786,"briefTitle":3787,"status":107,"phases":4237,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":3791,"conditions":4238,"interventions":4239},[90],[15,539],[3794,3795,3796],{"nctId":4241,"briefTitle":4242,"status":107,"phases":4243,"primaryCompletion":4244,"completion":4244,"start":4245,"enrollment":97,"conditions":4246,"interventions":4247},"NCT06352424","A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity",[90],"2025-02-24","2024-04-30",[539],[3796,3794],{"nctId":4249,"briefTitle":4250,"status":107,"phases":4251,"primaryCompletion":1863,"completion":4252,"start":4253,"enrollment":3398,"conditions":4254,"interventions":4255},"NCT04384081","A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg\u002Fm2",[90],"2021-01-20","2020-06-01",[15],[3796],{"nctId":4257,"briefTitle":4258,"status":107,"phases":4259,"primaryCompletion":4260,"completion":4260,"start":2922,"enrollment":331,"conditions":4261,"interventions":4263},"NCT06352411","A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems",[90],"2025-09-16",[15,4262],"Renal Impairment",[3796],{"nctId":3798,"briefTitle":3799,"status":315,"phases":4265,"primaryCompletion":3801,"completion":3802,"start":1236,"enrollment":357,"conditions":4266,"interventions":4267},[90],[539],[3796,1211],{"nctId":4269,"briefTitle":4270,"status":107,"phases":4271,"primaryCompletion":3426,"completion":3426,"start":4272,"enrollment":4273,"conditions":4274,"interventions":4275},"NCT05296733","A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906",[90],"2022-04-27",82,[15,550,539],[3796],{"nctId":4277,"briefTitle":4278,"status":107,"phases":4279,"primaryCompletion":4280,"completion":1207,"start":1250,"enrollment":132,"conditions":4281,"interventions":4282},"NCT05896384","A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood",[90],"2025-02-14",[15],[3796,4283],"Microgynon®",{"trials":4285,"activeCount":101},[4286,4296],{"nctId":4287,"briefTitle":4288,"status":107,"phases":4289,"primaryCompletion":4290,"completion":4291,"start":4292,"enrollment":4293,"conditions":4294,"interventions":4295},"NCT04667377","A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight",[91],"2022-09-15","2022-10-07","2021-03-08",387,[539],[3796],{"nctId":3808,"briefTitle":3809,"status":107,"phases":4297,"primaryCompletion":3811,"completion":3812,"start":3813,"enrollment":3814,"conditions":4298,"interventions":4299},[91],[21],[3796,1211],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[],{"intervention":3519,"totalTrials":155,"cells":4307},{"EARLY_PHASE1":4308,"PHASE1":4310,"PHASE2":4345,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4309,"activeCount":101},[],{"trials":4311,"activeCount":272,"soonestReadout":42},[4312,4321,4328,4332,4341],{"nctId":4313,"briefTitle":4314,"status":107,"phases":4315,"primaryCompletion":4316,"completion":4317,"start":4318,"enrollment":993,"conditions":4319,"interventions":4320},"NCT02674152","Dose Finding Study of BI 836880 in Patients With Solid Tumors",[90],"2018-09-12","2020-11-04","2016-01-05",[33],[3519],{"nctId":4322,"briefTitle":4323,"status":107,"phases":4324,"primaryCompletion":198,"completion":198,"start":4325,"enrollment":380,"conditions":4326,"interventions":4327},"NCT02689505","Weekly BI 836880 in Patients With Advanced Solid Tumors",[90],"2016-04-04",[33],[3519],{"nctId":40,"briefTitle":41,"status":140,"phases":4329,"primaryCompletion":42,"completion":3514,"start":3515,"enrollment":410,"conditions":4330,"interventions":4331},[90],[3517],[43,1461,3519,1472],{"nctId":4333,"briefTitle":4334,"status":107,"phases":4335,"primaryCompletion":4336,"completion":4337,"start":4338,"enrollment":3454,"conditions":4339,"interventions":4340},"NCT03972150","A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer",[90],"2020-10-27","2022-03-28","2019-06-12",[33],[3519,3845],{"nctId":3525,"briefTitle":3526,"status":107,"phases":4342,"primaryCompletion":3528,"completion":3529,"start":3530,"enrollment":3531,"conditions":4343,"interventions":4344},[90],[3533,33],[3519,1461],{"trials":4346,"activeCount":101},[4347,4356,4360],{"nctId":4348,"briefTitle":4349,"status":600,"phases":4350,"primaryCompletion":4351,"completion":4351,"start":4352,"enrollment":101,"conditions":4353,"interventions":4355},"NCT04499352","A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer",[91],"2020-10-19","2020-09-14",[4354],"Anal Canal Squamous Cell Carcinoma",[3845,3519],{"nctId":3613,"briefTitle":3614,"status":107,"phases":4357,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":3618,"conditions":4358,"interventions":4359},[91],[938,3620,3621],[1461,3470,3519],{"nctId":4361,"briefTitle":4362,"status":107,"phases":4363,"primaryCompletion":4364,"completion":4364,"start":4365,"enrollment":2789,"conditions":4366,"interventions":4368},"NCT03861234","A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)",[90,91],"2023-11-01","2019-06-27",[4367],"Wet Macular Degeneration",[3519],{"trials":4370,"activeCount":101},[],{"trials":4372,"activeCount":101},[],{"trials":4374,"activeCount":101},[],{"intervention":3662,"totalTrials":1075,"cells":4376},{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4385,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4378,"activeCount":101},[],{"trials":4380,"activeCount":272,"soonestReadout":77},[4381],{"nctId":80,"briefTitle":81,"status":140,"phases":4382,"primaryCompletion":77,"completion":1439,"start":1093,"enrollment":3659,"conditions":4383,"interventions":4384},[90],[1096],[82,3662,3663],{"trials":4386,"activeCount":101},[4387],{"nctId":4388,"briefTitle":4389,"status":107,"phases":4390,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":4219,"conditions":4393,"interventions":4394},"NCT01121406","BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer",[91],"2014-06","2010-04",[1187],[1120,2730,3662,4395,2007],"Pegylated liposomal doxorubicin",{"trials":4397,"activeCount":101},[],{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":101},[],{"intervention":1538,"totalTrials":177,"cells":4403},{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4530,"PHASE3":4532,"PHASE4":4534,"NA":4536},{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":272,"soonestReadout":1532},[4408,4419,4423,4427,4437,4446,4457,4469,4480,4490,4494,4503,4512,4521],{"nctId":4409,"briefTitle":4410,"status":107,"phases":4411,"primaryCompletion":4412,"start":4413,"enrollment":37,"conditions":4414,"interventions":4415},"NCT02182310","Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects",[90],"2008-10","2008-06",[15],[4416,4417,1538,4418],"BI 201335 low dose","BI 201335 placebo","BI 201335 high dose",{"nctId":4214,"briefTitle":4215,"status":107,"phases":4420,"primaryCompletion":4217,"completion":4217,"start":4218,"enrollment":4219,"conditions":4421,"interventions":4422},[90],[1228,539],[3796,1538],{"nctId":2463,"briefTitle":2464,"status":107,"phases":4424,"primaryCompletion":896,"completion":896,"start":2466,"enrollment":1094,"conditions":4425,"interventions":4426},[90],[15],[2441,1538],{"nctId":4428,"briefTitle":4429,"status":107,"phases":4430,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":4433,"conditions":4434,"interventions":4435},"NCT03934203","This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)",[90],"2019-09-06","2019-05-09",47,[15],[4436,1538],"BI 409306",{"nctId":4438,"briefTitle":4439,"status":107,"phases":4440,"primaryCompletion":4441,"start":4442,"enrollment":357,"conditions":4443,"interventions":4444},"NCT01195675","Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects",[90],"2010-11","2010-08",[15],[528,1538,4445,528],"BI 10773 Placebo",{"nctId":4447,"briefTitle":4448,"status":107,"phases":4449,"primaryCompletion":4450,"completion":4450,"start":4451,"enrollment":37,"conditions":4452,"interventions":4453},"NCT06070597","A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety",[90],"2024-06-05","2024-01-25",[15],[4454,4455,1538,4456],"Iclepertin","Iclepertin Placebo","Moxifloxacin Placebo",{"nctId":4458,"briefTitle":4459,"status":107,"phases":4460,"primaryCompletion":4461,"start":4462,"enrollment":4463,"conditions":4464,"interventions":4465},"NCT02248883","Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects",[90],"2006-03","2005-12",81,[15],[4466,1538,4467,4468],"TPV low","TPV high","RTV",{"nctId":4470,"briefTitle":4471,"status":107,"phases":4472,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":410,"conditions":4475,"interventions":4476},"NCT01965431","Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.",[90],"2014-01","2013-10",[15],[4047,4477,4478,4479,1538],"BI 207127 placebo","Faldaprevir placebo","Faldaprevir",{"nctId":4481,"briefTitle":4482,"status":107,"phases":4483,"primaryCompletion":4462,"start":3978,"enrollment":291,"conditions":4484,"interventions":4485},"NCT02256735","Study to Investigate the Effect of KUC 7483 CL on the QT\u002FQTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers",[90],[15],[4486,4487,4488,4489,1538],"Treatment A","Treatment B","Treatment C","Treatment D",{"nctId":1529,"briefTitle":1530,"status":315,"phases":4491,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":4492,"interventions":4493},[90],[15],[499,1538],{"nctId":4495,"briefTitle":4496,"status":107,"phases":4497,"primaryCompletion":4498,"start":4461,"enrollment":2382,"conditions":4499,"interventions":4500},"NCT02170987","Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.",[90],"2006-05",[15],[4501,4502,1538],"Dabigatran etexilate low","Dabigatran etexilate high",{"nctId":4504,"briefTitle":4505,"status":107,"phases":4506,"primaryCompletion":4413,"start":4507,"enrollment":1891,"conditions":4508,"interventions":4509},"NCT02183467","Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects",[90],"2008-01",[15],[4510,4511,1538],"BI 1356, low dose","BI 1356, high dose",{"nctId":4513,"briefTitle":4514,"status":107,"phases":4515,"primaryCompletion":4516,"start":4517,"enrollment":380,"conditions":4518,"interventions":4519},"NCT02172144","Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers",[90],"2007-10","2007-06",[15],[4520,1538],"BI 1744 CL solution for inhalation",{"nctId":4522,"briefTitle":4523,"status":107,"phases":4524,"primaryCompletion":4516,"start":1114,"enrollment":123,"conditions":4525,"interventions":4526},"NCT02262546","Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers",[90],[15],[4527,4528,1538,4529,4456],"Pramipexole extended-release (ER)","Pramipexole immediate-release (IR)","Pramipexole Placebo",{"trials":4531,"activeCount":101},[],{"trials":4533,"activeCount":101},[],{"trials":4535,"activeCount":101},[],{"trials":4537,"activeCount":101},[],{"intervention":3544,"totalTrials":1044,"cells":4539},{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4541,"activeCount":101},[],{"trials":4543,"activeCount":272,"soonestReadout":4548},[4544,4556,4560],{"nctId":4545,"briefTitle":4546,"status":315,"phases":4547,"primaryCompletion":4548,"completion":4549,"start":4550,"enrollment":4551,"conditions":4552,"interventions":4555},"NCT06882746","A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas",[90],"2026-12-11","2027-05-12","2025-03-28",135,[4553,4554,3553],"Colorectal Carcinoma","Gastric Carcinoma",[3544],{"nctId":3536,"briefTitle":3537,"status":107,"phases":4557,"primaryCompletion":3539,"completion":2606,"start":3540,"enrollment":28,"conditions":4558,"interventions":4559},[90],[3542],[3544,3490],{"nctId":3584,"briefTitle":3585,"status":107,"phases":4561,"primaryCompletion":1523,"completion":3587,"start":3588,"enrollment":3454,"conditions":4562,"interventions":4563},[90],[3590,3591,3592,1036,3593,3594],[3544,1461],{"trials":4565,"activeCount":101},[],{"trials":4567,"activeCount":101},[],{"trials":4569,"activeCount":101},[],{"trials":4571,"activeCount":101},[],{"intervention":2059,"totalTrials":1075,"cells":4573},{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4575,"activeCount":101},[],{"trials":4577,"activeCount":272,"soonestReadout":2053},[4578,4589],{"nctId":4579,"briefTitle":4580,"status":4581,"phases":4582,"primaryCompletion":4583,"completion":4584,"start":4337,"enrollment":4585,"conditions":4586,"interventions":4587},"NCT05155332","A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)","SUSPENDED",[90],"2027-12-13","2028-10-31",190,[2057],[2059,4588],"anti-PD-1 antibody",{"nctId":2050,"briefTitle":2051,"status":1001,"phases":4590,"primaryCompletion":2053,"completion":2054,"start":2055,"enrollment":1094,"conditions":4591,"interventions":4592},[90],[2057],[2059,2060],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[],{"intervention":3483,"totalTrials":272,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":101},[],{"trials":4606,"activeCount":272,"soonestReadout":3477},[4607],{"nctId":3474,"briefTitle":3475,"status":140,"phases":4608,"primaryCompletion":3477,"completion":3477,"start":732,"enrollment":177,"conditions":4609,"interventions":4610},[90],[3479,3480,3481],[43,1461,3483,48,3484],{"trials":4612,"activeCount":101},[],{"trials":4614,"activeCount":101},[],{"trials":4616,"activeCount":101},[],{"trials":4618,"activeCount":101},[],{"intervention":3484,"totalTrials":272,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4629,"PHASE3":4631,"PHASE4":4633,"NA":4635},{"trials":4622,"activeCount":101},[],{"trials":4624,"activeCount":272,"soonestReadout":3477},[4625],{"nctId":3474,"briefTitle":3475,"status":140,"phases":4626,"primaryCompletion":3477,"completion":3477,"start":732,"enrollment":177,"conditions":4627,"interventions":4628},[90],[3479,3480,3481],[43,1461,3483,48,3484],{"trials":4630,"activeCount":101},[],{"trials":4632,"activeCount":101},[],{"trials":4634,"activeCount":101},[],{"trials":4636,"activeCount":101},[],{"intervention":4638,"totalTrials":272,"cells":4639},"BI 3000202_low dose",{"EARLY_PHASE1":4640,"PHASE1":4642,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":272,"soonestReadout":4648},[4644],{"nctId":4645,"briefTitle":4646,"status":140,"phases":4647,"primaryCompletion":4648,"completion":4649,"start":1282,"enrollment":401,"conditions":4650,"interventions":4652},"NCT06878365","A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies",[90],"2026-12-06","2026-12-07",[4651],"Type 1 Interferonopathies",[4638,4653],"BI 3000202_high dose",{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":101},[],{"intervention":4653,"totalTrials":272,"cells":4663},{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4672,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":272,"soonestReadout":4648},[4668],{"nctId":4645,"briefTitle":4646,"status":140,"phases":4669,"primaryCompletion":4648,"completion":4649,"start":1282,"enrollment":401,"conditions":4670,"interventions":4671},[90],[4651],[4638,4653],{"trials":4673,"activeCount":101},[],{"trials":4675,"activeCount":101},[],{"trials":4677,"activeCount":101},[],{"trials":4679,"activeCount":101},[],{"intervention":4681,"totalTrials":272,"cells":4682},"Obrixtamig - parenteral 1",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4696,"PHASE3":4698,"PHASE4":4700,"NA":4702},{"trials":4684,"activeCount":101},[],{"trials":4686,"activeCount":272,"soonestReadout":1091},[4687],{"nctId":4688,"briefTitle":4689,"status":315,"phases":4690,"primaryCompletion":1091,"completion":2798,"start":4691,"enrollment":2858,"conditions":4692,"interventions":4694},"NCT04429087","A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",[90],"2020-07-29",[4693],"Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3",[4681,4695],"Obrixtamig - parenteral 2",{"trials":4697,"activeCount":101},[],{"trials":4699,"activeCount":101},[],{"trials":4701,"activeCount":101},[],{"trials":4703,"activeCount":101},[],{"intervention":4695,"totalTrials":272,"cells":4705},{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4714,"PHASE3":4716,"PHASE4":4718,"NA":4720},{"trials":4707,"activeCount":101},[],{"trials":4709,"activeCount":272,"soonestReadout":1091},[4710],{"nctId":4688,"briefTitle":4689,"status":315,"phases":4711,"primaryCompletion":1091,"completion":2798,"start":4691,"enrollment":2858,"conditions":4712,"interventions":4713},[90],[4693],[4681,4695],{"trials":4715,"activeCount":101},[],{"trials":4717,"activeCount":101},[],{"trials":4719,"activeCount":101},[],{"trials":4721,"activeCount":101},[],{"intervention":4723,"totalTrials":272,"cells":4724},"Verducatib",{"EARLY_PHASE1":4725,"PHASE1":4727,"PHASE2":4737,"PHASE3":4739,"PHASE4":4741,"NA":4743},{"trials":4726,"activeCount":101},[],{"trials":4728,"activeCount":272,"soonestReadout":3647},[4729],{"nctId":4730,"briefTitle":4731,"status":1001,"phases":4732,"primaryCompletion":3647,"completion":4733,"start":4734,"enrollment":188,"conditions":4735,"interventions":4736},"NCT07531628","A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants",[90],"2026-10-14","2026-07-13",[15],[4723],{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":101},[],{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"intervention":3501,"totalTrials":272,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4755,"PHASE3":4757,"PHASE4":4759,"NA":4761},{"trials":4748,"activeCount":101},[],{"trials":4750,"activeCount":272,"soonestReadout":3495},[4751],{"nctId":3492,"briefTitle":3493,"status":315,"phases":4752,"primaryCompletion":3495,"completion":3496,"start":2419,"enrollment":123,"conditions":4753,"interventions":4754},[90],[3498,3499],[3501,1461],{"trials":4756,"activeCount":101},[],{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[],{"trials":4762,"activeCount":101},[],{"intervention":3652,"totalTrials":272,"cells":4764},{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4773,"PHASE3":4775,"PHASE4":4777,"NA":4779},{"trials":4766,"activeCount":101},[],{"trials":4768,"activeCount":272,"soonestReadout":3647},[4769],{"nctId":3644,"briefTitle":3645,"status":315,"phases":4770,"primaryCompletion":3647,"completion":3648,"start":3649,"enrollment":188,"conditions":4771,"interventions":4772},[90],[1096,1108],[82,3652],{"trials":4774,"activeCount":101},[],{"trials":4776,"activeCount":101},[],{"trials":4778,"activeCount":101},[],{"trials":4780,"activeCount":101},[],{"intervention":4782,"totalTrials":272,"cells":4783},"BI 3821001",{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4795,"PHASE3":4797,"PHASE4":4799,"NA":4801},{"trials":4785,"activeCount":101},[],{"trials":4787,"activeCount":272,"soonestReadout":4792},[4788],{"nctId":4789,"briefTitle":4790,"status":315,"phases":4791,"primaryCompletion":4792,"completion":4792,"start":1534,"enrollment":716,"conditions":4793,"interventions":4794},"NCT07526194","A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated",[90],"2026-10-02",[15],[4782],{"trials":4796,"activeCount":101},[],{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":101},[],{"trials":4802,"activeCount":101},[],{"intervention":4804,"totalTrials":272,"cells":4805},"BI 3776528",{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4819,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4807,"activeCount":101},[],{"trials":4809,"activeCount":272,"soonestReadout":4814},[4810],{"nctId":4811,"briefTitle":4812,"status":315,"phases":4813,"primaryCompletion":4814,"completion":4814,"start":1682,"enrollment":4815,"conditions":4816,"interventions":4817},"NCT06745297","A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated",[90],"2026-08-25",142,[15],[4804,4818],"short-acting benzodiazepine",{"trials":4820,"activeCount":101},[],{"trials":4822,"activeCount":101},[],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"intervention":4818,"totalTrials":272,"cells":4828},{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4837,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4830,"activeCount":101},[],{"trials":4832,"activeCount":272,"soonestReadout":4814},[4833],{"nctId":4811,"briefTitle":4812,"status":315,"phases":4834,"primaryCompletion":4814,"completion":4814,"start":1682,"enrollment":4815,"conditions":4835,"interventions":4836},[90],[15],[4804,4818],{"trials":4838,"activeCount":101},[],{"trials":4840,"activeCount":101},[],{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":101},[],{"intervention":3663,"totalTrials":272,"cells":4846},{"EARLY_PHASE1":4847,"PHASE1":4849,"PHASE2":4855,"PHASE3":4857,"PHASE4":4859,"NA":4861},{"trials":4848,"activeCount":101},[],{"trials":4850,"activeCount":272,"soonestReadout":77},[4851],{"nctId":80,"briefTitle":81,"status":140,"phases":4852,"primaryCompletion":77,"completion":1439,"start":1093,"enrollment":3659,"conditions":4853,"interventions":4854},[90],[1096],[82,3662,3663],{"trials":4856,"activeCount":101},[],{"trials":4858,"activeCount":101},[],{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":101},[],{"intervention":68,"totalTrials":272,"cells":4864},{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4876,"PHASE3":4878,"PHASE4":4880,"NA":4882},{"trials":4866,"activeCount":101},[],{"trials":4868,"activeCount":272,"soonestReadout":67},[4869],{"nctId":65,"briefTitle":66,"status":140,"phases":4870,"primaryCompletion":67,"completion":4871,"start":4872,"enrollment":37,"conditions":4873,"interventions":4874},[90],"2026-06-08","2026-03-03",[15,539],[68,4875],"Survodutide formulation B2",{"trials":4877,"activeCount":101},[],{"trials":4879,"activeCount":101},[],{"trials":4881,"activeCount":101},[],{"trials":4883,"activeCount":101},[],{"intervention":4875,"totalTrials":272,"cells":4885},{"EARLY_PHASE1":4886,"PHASE1":4888,"PHASE2":4894,"PHASE3":4896,"PHASE4":4898,"NA":4900},{"trials":4887,"activeCount":101},[],{"trials":4889,"activeCount":272,"soonestReadout":67},[4890],{"nctId":65,"briefTitle":66,"status":140,"phases":4891,"primaryCompletion":67,"completion":4871,"start":4872,"enrollment":37,"conditions":4892,"interventions":4893},[90],[15,539],[68,4875],{"trials":4895,"activeCount":101},[],{"trials":4897,"activeCount":101},[],{"trials":4899,"activeCount":101},[],{"trials":4901,"activeCount":101},[],{"intervention":4903,"totalTrials":272,"cells":4904},"BI 3820768",{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4921,"PHASE3":4923,"PHASE4":4925,"NA":4927},{"trials":4906,"activeCount":101},[],{"trials":4908,"activeCount":272,"soonestReadout":4913},[4909],{"nctId":4910,"briefTitle":4911,"status":315,"phases":4912,"primaryCompletion":4913,"completion":4914,"start":2966,"enrollment":4915,"conditions":4916,"interventions":4920},"NCT07306559","A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)",[90],"2029-04-21","2029-12-31",187,[4917,4918,4919],"Advanced Relapsed or Refractory Germ Cell Tumours","Advanced Relapsed or Refractory Endometrial Cancer","Advanced Relapsed or Refractory Ovarian Cancer",[4903],{"trials":4922,"activeCount":101},[],{"trials":4924,"activeCount":101},[],{"trials":4926,"activeCount":101},[],{"trials":4928,"activeCount":101},[],{"intervention":3555,"totalTrials":272,"cells":4930},{"EARLY_PHASE1":4931,"PHASE1":4933,"PHASE2":4939,"PHASE3":4941,"PHASE4":4943,"NA":4945},{"trials":4932,"activeCount":101},[],{"trials":4934,"activeCount":272,"soonestReadout":3549},[4935],{"nctId":3546,"briefTitle":3547,"status":140,"phases":4936,"primaryCompletion":3549,"completion":3549,"start":3550,"enrollment":3551,"conditions":4937,"interventions":4938},[90],[3553],[3555,3556,3557,1461,3558],{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[],{"trials":4944,"activeCount":101},[],{"trials":4946,"activeCount":101},[],{"intervention":3556,"totalTrials":272,"cells":4948},{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4957,"PHASE3":4959,"PHASE4":4961,"NA":4963},{"trials":4950,"activeCount":101},[],{"trials":4952,"activeCount":272,"soonestReadout":3549},[4953],{"nctId":3546,"briefTitle":3547,"status":140,"phases":4954,"primaryCompletion":3549,"completion":3549,"start":3550,"enrollment":3551,"conditions":4955,"interventions":4956},[90],[3553],[3555,3556,3557,1461,3558],{"trials":4958,"activeCount":101},[],{"trials":4960,"activeCount":101},[],{"trials":4962,"activeCount":101},[],{"trials":4964,"activeCount":101},[],{"intervention":3557,"totalTrials":272,"cells":4966},{"EARLY_PHASE1":4967,"PHASE1":4969,"PHASE2":4975,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4968,"activeCount":101},[],{"trials":4970,"activeCount":272,"soonestReadout":3549},[4971],{"nctId":3546,"briefTitle":3547,"status":140,"phases":4972,"primaryCompletion":3549,"completion":3549,"start":3550,"enrollment":3551,"conditions":4973,"interventions":4974},[90],[3553],[3555,3556,3557,1461,3558],{"trials":4976,"activeCount":101},[],{"trials":4978,"activeCount":101},[],{"trials":4980,"activeCount":101},[],{"trials":4982,"activeCount":101},[],{"intervention":3558,"totalTrials":272,"cells":4984},{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4993,"PHASE3":4995,"PHASE4":4997,"NA":4999},{"trials":4986,"activeCount":101},[],{"trials":4988,"activeCount":272,"soonestReadout":3549},[4989],{"nctId":3546,"briefTitle":3547,"status":140,"phases":4990,"primaryCompletion":3549,"completion":3549,"start":3550,"enrollment":3551,"conditions":4991,"interventions":4992},[90],[3553],[3555,3556,3557,1461,3558],{"trials":4994,"activeCount":101},[],{"trials":4996,"activeCount":101},[],{"trials":4998,"activeCount":101},[],{"trials":5000,"activeCount":101},[],{"intervention":3883,"totalTrials":272,"cells":5002},{"EARLY_PHASE1":5003,"PHASE1":5005,"PHASE2":5011,"PHASE3":5013,"PHASE4":5015,"NA":5017},{"trials":5004,"activeCount":101},[],{"trials":5006,"activeCount":272,"soonestReadout":1017},[5007],{"nctId":3876,"briefTitle":3877,"status":140,"phases":5008,"primaryCompletion":1017,"completion":1017,"start":3879,"enrollment":2898,"conditions":5009,"interventions":5010},[90],[3881],[3859,3883],{"trials":5012,"activeCount":101},[],{"trials":5014,"activeCount":101},[],{"trials":5016,"activeCount":101},[],{"trials":5018,"activeCount":101},[],{"intervention":3892,"totalTrials":272,"cells":5020},{"EARLY_PHASE1":5021,"PHASE1":5023,"PHASE2":5029,"PHASE3":5031,"PHASE4":5033,"NA":5035},{"trials":5022,"activeCount":101},[],{"trials":5024,"activeCount":272,"soonestReadout":3888},[5025],{"nctId":3885,"briefTitle":3886,"status":140,"phases":5026,"primaryCompletion":3888,"completion":3889,"start":368,"enrollment":357,"conditions":5027,"interventions":5028},[90],[3872],[3892,3859,1242],{"trials":5030,"activeCount":101},[],{"trials":5032,"activeCount":101},[],{"trials":5034,"activeCount":101},[],{"trials":5036,"activeCount":101},[],{"intervention":3568,"totalTrials":272,"cells":5038},{"EARLY_PHASE1":5039,"PHASE1":5041,"PHASE2":5047,"PHASE3":5049,"PHASE4":5051,"NA":5053},{"trials":5040,"activeCount":101},[],{"trials":5042,"activeCount":272,"soonestReadout":3563},[5043],{"nctId":3560,"briefTitle":3561,"status":315,"phases":5044,"primaryCompletion":3563,"completion":3563,"start":3564,"enrollment":3565,"conditions":5045,"interventions":5046},[90],[2057],[3568,1461],{"trials":5048,"activeCount":101},[],{"trials":5050,"activeCount":101},[],{"trials":5052,"activeCount":101},[],{"trials":5054,"activeCount":101},[],{"intervention":58,"totalTrials":272,"cells":5056},{"EARLY_PHASE1":5057,"PHASE1":5059,"PHASE2":5065,"PHASE3":5067,"PHASE4":5069,"NA":5071},{"trials":5058,"activeCount":101},[],{"trials":5060,"activeCount":272,"soonestReadout":57},[5061],{"nctId":55,"briefTitle":56,"status":140,"phases":5062,"primaryCompletion":57,"completion":1456,"start":1457,"enrollment":1458,"conditions":5063,"interventions":5064},[90],[33],[58,1461,1012],{"trials":5066,"activeCount":101},[],{"trials":5068,"activeCount":101},[],{"trials":5070,"activeCount":101},[],{"trials":5072,"activeCount":101},[],{"intervention":5074,"totalTrials":272,"cells":5075},"BI 3814916",{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5089,"PHASE3":5091,"PHASE4":5093,"NA":5095},{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":272,"soonestReadout":5084},[5080],{"nctId":5081,"briefTitle":5082,"status":315,"phases":5083,"primaryCompletion":5084,"completion":5084,"start":5085,"enrollment":5086,"conditions":5087,"interventions":5088},"NCT07486115","A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People",[90],"2027-07-12","2026-05-20",136,[15],[5074],{"trials":5090,"activeCount":101},[],{"trials":5092,"activeCount":101},[],{"trials":5094,"activeCount":101},[],{"trials":5096,"activeCount":101},[],{"intervention":5098,"totalTrials":272,"cells":5099},"Formulation A",{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5114,"PHASE3":5116,"PHASE4":5118,"NA":5120},{"trials":5101,"activeCount":101},[],{"trials":5103,"activeCount":272,"soonestReadout":5108},[5104],{"nctId":5105,"briefTitle":5106,"status":315,"phases":5107,"primaryCompletion":5108,"completion":5109,"start":5110,"enrollment":1429,"conditions":5111,"interventions":5112},"NCT07407348","A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body",[90],"2027-01-26","2027-03-02","2026-02-26",[15,539,1228],[5098,5113],"Formulation B6",{"trials":5115,"activeCount":101},[],{"trials":5117,"activeCount":101},[],{"trials":5119,"activeCount":101},[],{"trials":5121,"activeCount":101},[],{"intervention":5113,"totalTrials":272,"cells":5123},{"EARLY_PHASE1":5124,"PHASE1":5126,"PHASE2":5132,"PHASE3":5134,"PHASE4":5136,"NA":5138},{"trials":5125,"activeCount":101},[],{"trials":5127,"activeCount":272,"soonestReadout":5108},[5128],{"nctId":5105,"briefTitle":5106,"status":315,"phases":5129,"primaryCompletion":5108,"completion":5109,"start":5110,"enrollment":1429,"conditions":5130,"interventions":5131},[90],[15,539,1228],[5098,5113],{"trials":5133,"activeCount":101},[],{"trials":5135,"activeCount":101},[],{"trials":5137,"activeCount":101},[],{"trials":5139,"activeCount":101},[],{"intervention":5141,"totalTrials":272,"cells":5142},"BI 3810944",{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5155,"PHASE3":5157,"PHASE4":5159,"NA":5161},{"trials":5144,"activeCount":101},[],{"trials":5146,"activeCount":272,"soonestReadout":5151},[5147],{"nctId":5148,"briefTitle":5149,"status":315,"phases":5150,"primaryCompletion":5151,"completion":5151,"start":5152,"enrollment":3659,"conditions":5153,"interventions":5154},"NCT07224425","A Study of BI 3810944 in Patients With Advanced Cancer",[90],"2029-10-05","2026-02-24",[1022,3480],[5141],{"trials":5156,"activeCount":101},[],{"trials":5158,"activeCount":101},[],{"trials":5160,"activeCount":101},[],{"trials":5162,"activeCount":101},[],{"intervention":5164,"totalTrials":272,"cells":5165},"BI 3804379",{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5178,"PHASE3":5180,"PHASE4":5182,"NA":5184},{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":272,"soonestReadout":5174},[5170],{"nctId":5171,"briefTitle":5172,"status":315,"phases":5173,"primaryCompletion":5174,"completion":5175,"start":3529,"enrollment":11,"conditions":5176,"interventions":5177},"NCT06575400","A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People",[90],"2028-02-02","2028-03-20",[15],[5164],{"trials":5179,"activeCount":101},[],{"trials":5181,"activeCount":101},[],{"trials":5183,"activeCount":101},[],{"trials":5185,"activeCount":101},[],{"intervention":3605,"totalTrials":272,"cells":5187},{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5196,"PHASE3":5198,"PHASE4":5200,"NA":5202},{"trials":5189,"activeCount":101},[],{"trials":5191,"activeCount":272,"soonestReadout":3600},[5192],{"nctId":3597,"briefTitle":3598,"status":315,"phases":5193,"primaryCompletion":3600,"completion":3601,"start":3602,"enrollment":123,"conditions":5194,"interventions":5195},[90],[2057],[3605,1461],{"trials":5197,"activeCount":101},[],{"trials":5199,"activeCount":101},[],{"trials":5201,"activeCount":101},[],{"trials":5203,"activeCount":101},[],{"intervention":78,"totalTrials":5205,"cells":5206},51,{"EARLY_PHASE1":5207,"PHASE1":5209,"PHASE2":5286,"PHASE3":5300,"PHASE4":5419,"NA":5447},{"trials":5208,"activeCount":101},[],{"trials":5210,"activeCount":101},[5211,5220,5229,5236,5246,5250,5258,5265,5271,5278],{"nctId":5212,"briefTitle":5213,"status":107,"phases":5214,"primaryCompletion":5215,"completion":5216,"start":5217,"enrollment":1081,"conditions":5218,"interventions":5219},"NCT02300298","Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy",[90],"2016-01-15","2017-10-27","2014-12-24",[36],[78,2731],{"nctId":5221,"briefTitle":5222,"status":162,"phases":5223,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":1075,"conditions":5226,"interventions":5227},"NCT02751385","Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer",[90],"2017-11-28","2016-05-20",[36],[5228,78],"Microgynon",{"nctId":5230,"briefTitle":5231,"status":107,"phases":5232,"primaryCompletion":474,"completion":603,"start":5233,"enrollment":1116,"conditions":5234,"interventions":5235},"NCT02191865","Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers",[90],"2014-07",[2526],[78,78,78],{"nctId":5237,"briefTitle":5238,"status":107,"phases":5239,"primaryCompletion":649,"completion":5240,"start":5241,"enrollment":5242,"conditions":5243,"interventions":5245},"NCT03675581","A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)",[90],"2019-10-10","2018-11-08",17,[5244],"Scleroderma, Systemic",[5228,78],{"nctId":2487,"briefTitle":2488,"status":107,"phases":5247,"primaryCompletion":2490,"completion":2490,"start":1478,"enrollment":177,"conditions":5248,"interventions":5249},[90],[15],[2441,78,2493],{"nctId":5251,"briefTitle":5252,"status":107,"phases":5253,"primaryCompletion":5254,"completion":5254,"start":5255,"enrollment":177,"conditions":5256,"interventions":5257},"NCT02668393","Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma",[90],"2019-11-27","2016-03-07",[36],[2731,78,78,78,78],{"nctId":5259,"briefTitle":5260,"status":107,"phases":5261,"primaryCompletion":446,"completion":446,"start":2001,"enrollment":1237,"conditions":5262,"interventions":5263},"NCT01679613","Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers",[90],[15],[78,78,5264,78,78,5264],"Ketoconazole",{"nctId":5266,"briefTitle":5267,"status":107,"phases":5268,"primaryCompletion":409,"completion":409,"start":3730,"enrollment":1982,"conditions":5269,"interventions":5270},"NCT01770392","Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin",[90],[15],[78,460,78],{"nctId":5272,"briefTitle":5273,"status":107,"phases":5274,"primaryCompletion":5275,"completion":5275,"start":2002,"enrollment":2507,"conditions":5276,"interventions":5277},"NCT02572752","Relative Bioavailability of 2 Oral Formulations of Nintedanib",[90],"2015-11",[15],[78,78,78],{"nctId":5279,"briefTitle":5280,"status":107,"phases":5281,"primaryCompletion":5282,"completion":5282,"start":5283,"enrollment":912,"conditions":5284,"interventions":5285},"NCT02667704","Influence of Bosentan on the Pharmacokinetics of Nintedanib",[90],"2016-03","2016-02",[15],[1383,78],{"trials":5287,"activeCount":101},[5288,5292],{"nctId":3054,"briefTitle":3055,"status":162,"phases":5289,"primaryCompletion":3057,"completion":3057,"start":3058,"enrollment":272,"conditions":5290,"interventions":5291},[91],[3060],[78,1041],{"nctId":5293,"briefTitle":5294,"status":107,"phases":5295,"primaryCompletion":437,"completion":437,"start":5296,"enrollment":1672,"conditions":5297,"interventions":5298},"NCT01417156","Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)",[91],"2011-09",[3428],[78,5299],"Pirfenidoneone",{"trials":5301,"activeCount":101},[5302,5310,5318,5328,5338,5347,5356,5364,5373,5383,5393,5397,5401,5410],{"nctId":5303,"briefTitle":5304,"status":107,"phases":5305,"primaryCompletion":5306,"completion":5306,"start":5307,"enrollment":1631,"conditions":5308,"interventions":5309},"NCT05285982","A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)",[92],"2025-08-13","2022-04-06",[2599],[78],{"nctId":5311,"briefTitle":5312,"status":107,"phases":5313,"primaryCompletion":4245,"completion":5314,"start":5315,"enrollment":4463,"conditions":5316,"interventions":5317},"NCT05065190","A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis",[92],"2024-05-07","2021-11-25",[2599],[78],{"nctId":5319,"briefTitle":5320,"status":107,"phases":5321,"primaryCompletion":5322,"completion":5323,"start":5324,"enrollment":5325,"conditions":5326,"interventions":5327},"NCT02999178","Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)",[92],"2019-04-23","2019-08-12","2017-01-17",663,[2599],[78],{"nctId":5329,"briefTitle":5330,"status":107,"phases":5331,"primaryCompletion":5332,"completion":5333,"start":5334,"enrollment":5335,"conditions":5336,"interventions":5337},"NCT01619085","Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis",[92],"2017-07-05","2021-02-01","2012-06-06",752,[1397],[78],{"nctId":5339,"briefTitle":5340,"status":107,"phases":5341,"primaryCompletion":5342,"completion":5342,"start":5343,"enrollment":5344,"conditions":5345,"interventions":5346},"NCT03313180","A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis",[92],"2023-01-25","2017-11-27",444,[2599],[78],{"nctId":5348,"briefTitle":5349,"status":162,"phases":5350,"primaryCompletion":5351,"completion":5351,"start":5352,"enrollment":188,"conditions":5353,"interventions":5354},"NCT02231164","LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research",[92],"2015-12-24","2014-10-14",[36],[5355,5355,3401],"docetaxel",{"nctId":5357,"briefTitle":5358,"status":107,"phases":5359,"primaryCompletion":5360,"completion":5360,"start":5361,"enrollment":291,"conditions":5362,"interventions":5363},"NCT04093024","A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)",[92],"2022-05-24","2019-12-03",[2599],[78],{"nctId":5365,"briefTitle":5366,"status":107,"phases":5367,"primaryCompletion":5368,"completion":5368,"start":5369,"enrollment":5370,"conditions":5371,"interventions":5372},"NCT03820726","A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)",[92],"2022-08-30","2019-04-16",435,[2599],[78],{"nctId":5374,"briefTitle":5375,"status":107,"phases":5376,"primaryCompletion":5377,"completion":5378,"start":5379,"enrollment":1030,"conditions":5380,"interventions":5381},"NCT02149108","Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)",[92],"2016-05-13","2016-08-25","2014-09-25",[3060],[78,5382,5382],"BSC",{"nctId":5384,"briefTitle":5385,"status":107,"phases":5386,"primaryCompletion":5387,"completion":5388,"start":5389,"enrollment":5390,"conditions":5391,"interventions":5392},"NCT02597933","A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis",[92],"2018-10-31","2018-11-28","2015-11-12",580,[5244],[78],{"nctId":1776,"briefTitle":1777,"status":162,"phases":5394,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":1782,"conditions":5395,"interventions":5396},[91,92],[1784],[78,1011,1009,1009,1011],{"nctId":2027,"briefTitle":2028,"status":107,"phases":5398,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":5399,"interventions":5400},[92],[36],[78,1011,1074,2036,2037,2037,2036,2038,2036,2037,2038,2038,78,1011],{"nctId":5402,"briefTitle":5403,"status":107,"phases":5404,"primaryCompletion":5405,"completion":5405,"start":5406,"enrollment":5407,"conditions":5408,"interventions":5409},"NCT01979952","Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)",[92],"2016-10-27","2013-11-26",113,[1397],[78],{"nctId":5411,"briefTitle":5412,"status":107,"phases":5413,"primaryCompletion":533,"completion":5414,"start":5415,"enrollment":1264,"conditions":5416,"interventions":5417},"NCT02802345","Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment",[92],"2018-04-13","2016-06-30",[1397],[78,5418],"Sildenafil",{"trials":5420,"activeCount":101},[5421,5425,5429,5437],{"nctId":3383,"briefTitle":3384,"status":107,"phases":5422,"primaryCompletion":3386,"completion":3387,"start":3388,"enrollment":3389,"conditions":5423,"interventions":5424},[93],[1397],[78,2493],{"nctId":3393,"briefTitle":3394,"status":107,"phases":5426,"primaryCompletion":3396,"completion":3396,"start":3397,"enrollment":3398,"conditions":5427,"interventions":5428},[93],[1397],[3401,3402],{"nctId":5430,"briefTitle":5431,"status":162,"phases":5432,"primaryCompletion":5433,"completion":5434,"start":824,"enrollment":2442,"conditions":5435,"interventions":5436},"NCT03717012","Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[93],"2020-03-27","2020-06-10",[1397],[78],{"nctId":5438,"briefTitle":5439,"status":107,"phases":5440,"primaryCompletion":5441,"completion":5442,"start":5443,"enrollment":5444,"conditions":5445,"interventions":5446},"NCT02788474","Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment",[93],"2017-08-04","2018-06-08","2016-06-09",347,[1397],[3401],{"trials":5448,"activeCount":272,"soonestReadout":77},[5449,5456,5460,5469,5478,5485,5491,5500,5508,5512,5519,5527,5535,5539,5547,5553,5562,5571,5575,5581,5585],{"nctId":5450,"briefTitle":5451,"status":107,"phases":5452,"primaryCompletion":1671,"completion":1671,"start":47,"enrollment":392,"conditions":5453,"interventions":5455},"NCT06200714","A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib",[],[1397,5454],"Diarrhoea",[78],{"nctId":3406,"briefTitle":3407,"status":107,"phases":5457,"primaryCompletion":3409,"completion":3409,"start":341,"enrollment":3410,"conditions":5458,"interventions":5459},[],[1397],[2493,78],{"nctId":5461,"briefTitle":5462,"status":107,"phases":5463,"primaryCompletion":5464,"completion":5464,"start":5465,"enrollment":5466,"conditions":5467,"interventions":5468},"NCT03710824","Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib",[],"2023-02-22","2019-02-28",180,[1397],[78],{"nctId":5470,"briefTitle":5471,"status":107,"phases":5472,"primaryCompletion":5473,"completion":5474,"start":5475,"enrollment":2507,"conditions":5476,"interventions":5477},"NCT04525547","Safety and Effectiveness of Nintedanib in Korean Patients",[],"2022-08-02","2022-08-18","2021-01-13",[1397],[78],{"nctId":5479,"briefTitle":5480,"status":5481,"phases":5482,"conditions":5483,"interventions":5484},"NCT04739150","An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options","NO_LONGER_AVAILABLE",[],[2599],[3401],{"nctId":75,"briefTitle":76,"status":140,"phases":5486,"primaryCompletion":77,"completion":77,"start":5487,"enrollment":5488,"conditions":5489,"interventions":5490},[],"2020-05-27",586,[2599],[78],{"nctId":5492,"briefTitle":5493,"status":107,"phases":5494,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":5497,"conditions":5498,"interventions":5499},"NCT05022784","Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients",[],"2021-12-30","2021-08-23",1798,[1397],[78],{"nctId":5501,"briefTitle":5502,"status":107,"phases":5503,"primaryCompletion":5504,"completion":5504,"start":5505,"enrollment":5497,"conditions":5506,"interventions":5507},"NCT05870956","Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients",[],"2023-06-30","2023-05-16",[1397],[78],{"nctId":3414,"briefTitle":3415,"status":107,"phases":5509,"primaryCompletion":3417,"completion":3417,"start":922,"enrollment":3418,"conditions":5510,"interventions":5511},[],[1397],[78,2493],{"nctId":5513,"briefTitle":5514,"status":5515,"phases":5516,"conditions":5517,"interventions":5518},"NCT02171156","Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)","APPROVED_FOR_MARKETING",[],[1397],[3401],{"nctId":5520,"briefTitle":5521,"status":5481,"phases":5522,"conditions":5523,"interventions":5526},"NCT05624281","A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)",[],[5524,5525],"Lung Diseases, Interstitial (in Pediatric Populations)","Childhood Interstitial Lung Disease (chILD)",[3401],{"nctId":5528,"briefTitle":5529,"status":107,"phases":5530,"primaryCompletion":834,"completion":834,"start":5531,"enrollment":5532,"conditions":5533,"interventions":5534},"NCT02607722","All-Case Surveillance of Ofev in Patients With IPF in Japan",[],"2015-08-31",10117,[1397],[78],{"nctId":3422,"briefTitle":3423,"status":600,"phases":5536,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":101,"conditions":5537,"interventions":5538},[],[3428],[3401,3402],{"nctId":5540,"briefTitle":5541,"status":107,"phases":5542,"primaryCompletion":5543,"completion":5543,"start":5544,"enrollment":3791,"conditions":5545,"interventions":5546},"NCT05503030","Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients",[],"2026-05-13","2022-12-21",[2599],[78],{"nctId":5548,"briefTitle":5549,"status":5481,"phases":5550,"conditions":5551,"interventions":5552},"NCT02230982","Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis",[],[1397],[3401],{"nctId":5554,"briefTitle":5555,"status":107,"phases":5556,"primaryCompletion":964,"completion":5557,"start":5558,"enrollment":5559,"conditions":5560,"interventions":5561},"NCT04559581","Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan",[],"2025-01-22","2020-10-02",425,[2599],[78],{"nctId":5563,"briefTitle":5564,"status":107,"phases":5565,"primaryCompletion":5566,"completion":5566,"start":5567,"enrollment":5568,"conditions":5569,"interventions":5570},"NCT05151640","INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation",[],"2025-09-05","2023-02-08",158,[2599],[78],{"nctId":3431,"briefTitle":3432,"status":107,"phases":5572,"primaryCompletion":3434,"completion":3434,"start":3435,"enrollment":3436,"conditions":5573,"interventions":5574},[],[3428],[3401,3402],{"nctId":5576,"briefTitle":5577,"status":107,"phases":5578,"primaryCompletion":2381,"completion":2381,"start":687,"enrollment":220,"conditions":5579,"interventions":5580},"NCT04702893","INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation",[],[2599],[78],{"nctId":3440,"briefTitle":3441,"status":107,"phases":5582,"primaryCompletion":3443,"completion":3443,"start":3444,"enrollment":3445,"conditions":5583,"interventions":5584},[],[1397],[78,2493],{"nctId":3449,"briefTitle":3450,"status":107,"phases":5586,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":3454,"conditions":5587,"interventions":5588},[],[1397],[78,2493],{"intervention":5590,"totalTrials":1512,"cells":5591},"JARDIANCE®",{"EARLY_PHASE1":5592,"PHASE1":5594,"PHASE2":5600,"PHASE3":5602,"PHASE4":5604,"NA":5606},{"trials":5593,"activeCount":101},[],{"trials":5595,"activeCount":101},[5596],{"nctId":1519,"briefTitle":1520,"status":107,"phases":5597,"primaryCompletion":1522,"completion":1523,"start":1524,"enrollment":956,"conditions":5598,"interventions":5599},[90],[15],[499,1527],{"trials":5601,"activeCount":101},[],{"trials":5603,"activeCount":101},[],{"trials":5605,"activeCount":101},[],{"trials":5607,"activeCount":272,"soonestReadout":1712},[5608,5618,5627,5636,5643],{"nctId":5609,"briefTitle":5610,"status":107,"phases":5611,"primaryCompletion":5612,"completion":5613,"start":5614,"enrollment":5615,"conditions":5616,"interventions":5617},"NCT05262764","Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)",[],"2024-06-21","2024-06-28","2022-04-15",1200,[573],[5590],{"nctId":5619,"briefTitle":5620,"status":107,"phases":5621,"primaryCompletion":5622,"completion":5622,"start":5623,"enrollment":5624,"conditions":5625,"interventions":5626},"NCT05236673","Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure",[],"2025-04-30","2022-07-28",610,[573],[5590],{"nctId":5628,"briefTitle":5629,"status":107,"phases":5630,"primaryCompletion":5631,"completion":5631,"start":5632,"enrollment":5633,"conditions":5634,"interventions":5635},"NCT02367131","Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus",[],"2016-09-27","2015-02-24",419,[21],[5590],{"nctId":5637,"briefTitle":5638,"status":140,"phases":5639,"primaryCompletion":1712,"completion":1712,"start":1606,"enrollment":5640,"conditions":5641,"interventions":5642},"NCT06527846","Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease",[],1024,[509],[5590],{"nctId":5644,"briefTitle":5645,"status":107,"phases":5646,"primaryCompletion":5622,"completion":5622,"start":5647,"enrollment":5648,"conditions":5649,"interventions":5650},"NCT06287073","JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)",[],"2024-03-29",299,[509],[5590],{"intervention":5652,"totalTrials":1044,"cells":5653},"Ofev®",{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5667,"PHASE3":5669,"PHASE4":5671,"NA":5673},{"trials":5655,"activeCount":101},[],{"trials":5657,"activeCount":101},[5658],{"nctId":5659,"briefTitle":5660,"status":107,"phases":5661,"primaryCompletion":5662,"completion":5662,"start":4337,"enrollment":3454,"conditions":5663,"interventions":5664},"NCT05262751","A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib",[90],"2022-11-30",[15],[5652,5665,5666],"Nintedanib formulation 1","Nintedanib formulation 2",{"trials":5668,"activeCount":101},[],{"trials":5670,"activeCount":101},[],{"trials":5672,"activeCount":101},[],{"trials":5674,"activeCount":272,"soonestReadout":5688},[5675,5684],{"nctId":5676,"briefTitle":5677,"status":107,"phases":5678,"primaryCompletion":1467,"completion":1467,"start":5679,"enrollment":5680,"conditions":5681,"interventions":5682},"NCT04614441","NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib",[],"2021-01-21",214,[1397],[5683],"OFEV®",{"nctId":5685,"briefTitle":5686,"status":140,"phases":5687,"primaryCompletion":5688,"completion":5688,"start":5689,"enrollment":5690,"conditions":5691,"interventions":5693},"NCT07080125","A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis",[],"2033-12-31","2025-06-17",2000,[1409,5692],"Systemic Sclerosis Associated Interstitial Lung Disease",[5652],{"intervention":5695,"totalTrials":1075,"cells":5696},"Jardiance",{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5698,"activeCount":101},[],{"trials":5700,"activeCount":101},[],{"trials":5702,"activeCount":101},[],{"trials":5704,"activeCount":101},[],{"trials":5706,"activeCount":101},[],{"trials":5708,"activeCount":272,"soonestReadout":5713},[5709,5720],{"nctId":5710,"briefTitle":5711,"status":1001,"phases":5712,"primaryCompletion":5713,"completion":5713,"start":5714,"enrollment":5715,"conditions":5716,"interventions":5718},"NCT07044700","Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction",[],"2028-12-31","2028-01-31",5000,[5717],"Heart Failure of Reduced Ejection Fraction (HFrEF)",[5695,5719],"non-SGLT2 inhibitors",{"nctId":5721,"briefTitle":5722,"status":107,"phases":5723,"primaryCompletion":5724,"completion":5725,"start":5726,"enrollment":5727,"conditions":5728,"interventions":5729},"NCT02489942","Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus",[],"2020-11-11","2020-12-04","2015-06-12",8145,[21],[5695],{"intervention":5719,"totalTrials":272,"cells":5731},{"EARLY_PHASE1":5732,"PHASE1":5734,"PHASE2":5736,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5733,"activeCount":101},[],{"trials":5735,"activeCount":101},[],{"trials":5737,"activeCount":101},[],{"trials":5739,"activeCount":101},[],{"trials":5741,"activeCount":101},[],{"trials":5743,"activeCount":272,"soonestReadout":5713},[5744],{"nctId":5710,"briefTitle":5711,"status":1001,"phases":5745,"primaryCompletion":5713,"completion":5713,"start":5714,"enrollment":5715,"conditions":5746,"interventions":5747},[],[5717],[5695,5719],{"intervention":5749,"totalTrials":272,"cells":5750},"SGLT2 inhibitor",{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5755,"PHASE3":5757,"PHASE4":5759,"NA":5761},{"trials":5752,"activeCount":101},[],{"trials":5754,"activeCount":101},[],{"trials":5756,"activeCount":101},[],{"trials":5758,"activeCount":101},[],{"trials":5760,"activeCount":101},[],{"trials":5762,"activeCount":272,"soonestReadout":5767},[5763],{"nctId":5764,"briefTitle":5765,"status":140,"phases":5766,"primaryCompletion":5767,"completion":5767,"start":5768,"enrollment":5769,"conditions":5770,"interventions":5771},"NCT07063316","SGLT2 Inhibitors and Renal Anemia in Japan: RWD",[],"2026-12-25","2025-07-23",15000,[497],[5749],{"intervention":818,"totalTrials":272,"cells":5773},{"EARLY_PHASE1":5774,"PHASE1":5776,"PHASE2":5778,"PHASE3":5780,"PHASE4":5782,"NA":5784},{"trials":5775,"activeCount":101},[],{"trials":5777,"activeCount":101},[],{"trials":5779,"activeCount":101},[],{"trials":5781,"activeCount":101},[],{"trials":5783,"activeCount":101},[],{"trials":5785,"activeCount":272,"soonestReadout":72},[5786],{"nctId":70,"briefTitle":71,"status":140,"phases":5787,"primaryCompletion":72,"completion":72,"start":814,"enrollment":815,"conditions":5788,"interventions":5789},[],[21],[73,818,819],{"intervention":819,"totalTrials":272,"cells":5791},{"EARLY_PHASE1":5792,"PHASE1":5794,"PHASE2":5796,"PHASE3":5798,"PHASE4":5800,"NA":5802},{"trials":5793,"activeCount":101},[],{"trials":5795,"activeCount":101},[],{"trials":5797,"activeCount":101},[],{"trials":5799,"activeCount":101},[],{"trials":5801,"activeCount":101},[],{"trials":5803,"activeCount":272,"soonestReadout":72},[5804],{"nctId":70,"briefTitle":71,"status":140,"phases":5805,"primaryCompletion":72,"completion":72,"start":814,"enrollment":815,"conditions":5806,"interventions":5807},[],[21],[73,818,819],{"intervention":5809,"totalTrials":272,"cells":5810},"Sodium\u002Fglucose cotransporter-2 inhibitors",{"EARLY_PHASE1":5811,"PHASE1":5813,"PHASE2":5815,"PHASE3":5817,"PHASE4":5819,"NA":5821},{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[],{"trials":5818,"activeCount":101},[],{"trials":5820,"activeCount":101},[],{"trials":5822,"activeCount":272,"soonestReadout":3514},[5823],{"nctId":5824,"briefTitle":5825,"status":140,"phases":5826,"primaryCompletion":3514,"completion":3514,"start":5827,"enrollment":5828,"conditions":5829,"interventions":5830},"NCT05882071","Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France",[],"2023-11-15",547150,[21],[5809],{"intervention":5832,"totalTrials":177,"cells":5833},"Salmeterol",{"EARLY_PHASE1":5834,"PHASE1":5836,"PHASE2":5850,"PHASE3":5873,"PHASE4":5947,"NA":5979},{"trials":5835,"activeCount":101},[],{"trials":5837,"activeCount":101},[5838],{"nctId":5839,"briefTitle":5840,"status":107,"phases":5841,"primaryCompletion":5842,"start":5843,"enrollment":188,"conditions":5844,"interventions":5845},"NCT02256722","In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects",[90],"2005-11","2005-10",[15],[5846,5847,5848,5849,5832],"KUC 7483 CL","Bisoprolol","Propranolol","Acipimox",{"trials":5851,"activeCount":101},[5852,5864],{"nctId":5853,"briefTitle":5854,"status":107,"phases":5855,"primaryCompletion":5856,"start":4516,"enrollment":5857,"conditions":5858,"interventions":5859},"NCT00535366","Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD",[91],"2008-09",103,[18],[5860,5832,5861,5862,5863],"Tiotropium","Fluticasone","Ciclesonide low","Ciclesonide high",{"nctId":5865,"briefTitle":5866,"status":107,"phases":5867,"primaryCompletion":5868,"start":5869,"enrollment":5870,"conditions":5871,"interventions":5872},"NCT02242253","Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],"2004-07","2003-09",97,[18],[5860,5832],{"trials":5874,"activeCount":101},[5875,5883,5890,5901,5910,5919,5927,5938],{"nctId":5876,"briefTitle":5877,"status":107,"phases":5878,"completion":5879,"start":5880,"enrollment":448,"conditions":5881,"interventions":5882},"NCT00274534","A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.",[92],"2003-07","2000-12",[18],[5860,5832],{"nctId":5884,"briefTitle":5885,"status":107,"phases":5886,"primaryCompletion":5843,"start":5887,"enrollment":410,"conditions":5888,"interventions":5889},"NCT02172794","Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)",[92],"2002-05",[18],[5860,5832],{"nctId":5891,"briefTitle":5892,"status":107,"phases":5893,"primaryCompletion":603,"completion":1125,"start":4474,"enrollment":5894,"conditions":5895,"interventions":5896},"NCT01969721","Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients",[92],229,[18],[5897,5898,5899,5900,5900,5899,5897,5898],"fluticasone propionate","salmeterol","tiotropium","olodaterol",{"nctId":5902,"briefTitle":5903,"status":107,"phases":5904,"primaryCompletion":5905,"start":5906,"enrollment":2235,"conditions":5907,"interventions":5908},"NCT00673478","Tiotropium and Salmeterol PK Study in COPD Patients",[92],"2009-06","2008-05",[18],[5909,5832,5860],"Tiotropium+Salmeterol",{"nctId":5911,"briefTitle":5912,"status":107,"phases":5913,"primaryCompletion":5914,"start":5915,"enrollment":5916,"conditions":5917,"interventions":5918},"NCT00274560","A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.",[92],"2003-03-27","2002-05-01",653,[18],[5860,5832],{"nctId":5920,"briefTitle":5921,"status":107,"phases":5922,"primaryCompletion":2122,"start":5923,"enrollment":5924,"conditions":5925,"interventions":5926},"NCT02172287","Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],"1999-02",623,[18],[5860,5832],{"nctId":5928,"briefTitle":5929,"status":162,"phases":5930,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5933,"conditions":5934,"interventions":5935},"NCT00662740","Tiotropium\u002FSalmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)",[92],"2008-11-21","2008-04-15",220,[18],[5936,5832,5937,5860],"Tiotropium\u002FSalmeterol QD","Tiotropium\u002FSalmeterol QD+ Salmeterol",{"nctId":5939,"briefTitle":5940,"status":162,"phases":5941,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5942,"conditions":5943,"interventions":5944},"NCT00668772","Tiotropium\u002FSalmeterol Inhalation Powder in COPD",[92],207,[18],[5945,5946,5832,5860],"Tiotropium\u002FSalmeterol","Tiotropium\u002FSalmeterol QD + Salmeterol",{"trials":5948,"activeCount":101},[5949,5961,5971],{"nctId":5950,"briefTitle":5951,"status":107,"phases":5952,"primaryCompletion":5953,"completion":5954,"start":5955,"enrollment":5956,"conditions":5957,"interventions":5958},"NCT03055988","Cardiovascular Function in COPD Patients",[93],"2018-03-05","2018-03-26","2017-03-29",76,[18],[5860,5959,5960,5832],"Olodaterol","Fluticasone propionate",{"nctId":5962,"briefTitle":5963,"status":107,"phases":5964,"primaryCompletion":5965,"completion":5966,"start":5967,"enrollment":5968,"conditions":5969,"interventions":5970},"NCT03240575","The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus",[93],"2019-04-08","2019-05-06","2017-08-14",302,[18],[5860,5959,5960,5832],{"nctId":5972,"briefTitle":5973,"status":107,"phases":5974,"primaryCompletion":4392,"start":4507,"enrollment":5975,"conditions":5976,"interventions":5977},"NCT00563381","Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.",[93],7376,[18],[5978,5832],"Tiotropium bromide",{"trials":5980,"activeCount":101},[],{"intervention":5982,"totalTrials":281,"cells":5983},"Pantoprazole",{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":6085,"PHASE3":6087,"PHASE4":6089,"NA":6103},{"trials":5985,"activeCount":101},[],{"trials":5987,"activeCount":101},[5988,6001,6011,6018,6025,6036,6049,6060,6070,6077],{"nctId":5989,"briefTitle":5990,"status":107,"phases":5991,"primaryCompletion":5992,"start":5993,"enrollment":956,"conditions":5994,"interventions":5995},"NCT02170636","Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects",[90],"2002-03","2002-01",[15],[5996,5997,5998,5999,6000,5982],"BIBR 1048 MS Capsule E","BIBR 1048 MS Capsule F","BIBR 1048 MS Capsule G","BIBR 1048 MS Tablet H","BIBR 1048 MS Drinking solution",{"nctId":6002,"briefTitle":6003,"status":107,"phases":6004,"primaryCompletion":2121,"start":6005,"enrollment":380,"conditions":6006,"interventions":6007},"NCT02170805","Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects",[90],"2001-04",[15],[6008,6009,6010,5982],"BIBR 1048 MS capsule formulation A","BIBR 1048 MS capsule formulation B","BIBR 1048 MS powder plus solution",{"nctId":6012,"briefTitle":6013,"status":107,"phases":6014,"primaryCompletion":5993,"start":6015,"enrollment":210,"conditions":6016,"interventions":6017},"NCT02209831","Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers",[90],"2001-11",[15],[5982],{"nctId":6019,"briefTitle":6020,"status":107,"phases":6021,"primaryCompletion":5887,"start":5992,"enrollment":392,"conditions":6022,"interventions":6023},"NCT02170610","Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects",[90],[15],[6024,5982],"BIBR 1048 MS",{"nctId":6026,"briefTitle":6027,"status":107,"phases":6028,"primaryCompletion":6029,"start":6030,"enrollment":188,"conditions":6031,"interventions":6032},"NCT02170623","Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects",[90],"2002-04","2002-02",[15],[6033,6034,5982,6035],"BIBR 1048 MS Capsule I","BIBR 1048 MS Capsule K","BIBR 1048 MS drinking solution",{"nctId":6037,"briefTitle":6038,"status":107,"phases":6039,"primaryCompletion":6040,"start":6041,"enrollment":401,"conditions":6042,"interventions":6043},"NCT02170896","Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects",[90],"2001-12","2001-10",[15],[6044,6045,6046,6047,6048,5982],"BIBR 1048 MS Capsule A","BIBR 1048 MS Capsule B","BIBR 1048 MS Capsule C","BIBR 1048 MS Capsule D","BIBR 1048 MS tartaric acid solution",{"nctId":6050,"briefTitle":6051,"status":107,"phases":6052,"primaryCompletion":5880,"start":6053,"enrollment":410,"conditions":6054,"interventions":6055},"NCT02170766","Bioavailability of BIBR 953 ZW in Healthy Subjects",[90],"2000-10",[15],[6056,6057,6058,6059,5982],"BIBR 1048 low1","BIBR 1048 low2","BIBR 1048 medium","BIBR 1048 high",{"nctId":6061,"briefTitle":6062,"status":107,"phases":6063,"primaryCompletion":6064,"start":6065,"enrollment":188,"conditions":6066,"interventions":6067},"NCT02264106","Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects",[90],"1998-06","1998-04",[15],[6068,6069,5982],"Lefradafiban","Lefradafiban double chamber sachet",{"nctId":6071,"briefTitle":6072,"status":107,"phases":6073,"primaryCompletion":6074,"start":6065,"enrollment":188,"conditions":6075,"interventions":6076},"NCT02264119","Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects",[90],"1998-07",[15],[6068,5982],{"nctId":6078,"briefTitle":6079,"status":107,"phases":6080,"primaryCompletion":6081,"start":6082,"enrollment":448,"conditions":6083,"interventions":6084},"NCT02173730","BIBR 953 ZW in Healthy Elderly Subjects",[90],"2003-02","2002-11",[15],[6024,5982],{"trials":6086,"activeCount":101},[],{"trials":6088,"activeCount":101},[],{"trials":6090,"activeCount":101},[6091],{"nctId":6092,"briefTitle":6093,"status":107,"phases":6094,"primaryCompletion":5233,"completion":5233,"start":6095,"enrollment":6096,"conditions":6097,"interventions":6099},"NCT01493557","A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation",[93],"2011-12",1067,[6098],"Atrial Fibrillation",[6100,6101,6102,6101],"pantoprazole","Pradaxa","Pradaxa, within 30 minutes after a meal",{"trials":6104,"activeCount":101},[],{"intervention":6106,"totalTrials":1081,"cells":6107},"Ramipril",{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6143,"PHASE3":6149,"PHASE4":6160,"NA":6193},{"trials":6109,"activeCount":101},[],{"trials":6111,"activeCount":101},[6112,6122,6128,6136],{"nctId":6113,"briefTitle":6114,"status":107,"phases":6115,"primaryCompletion":4517,"start":6116,"enrollment":6117,"conditions":6118,"interventions":6119},"NCT02214979","Bioequivalence of Telmisartan \u002F Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers",[90],"2007-03",84,[15],[6120,6121,6106,6106],"Telmisartan\u002FRamipril","Telmisartan",{"nctId":6123,"briefTitle":6124,"status":107,"phases":6125,"primaryCompletion":4517,"start":6116,"enrollment":6117,"conditions":6126,"interventions":6127},"NCT02214992","Bioequivalence of Telmisartan\u002Fg Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers",[90],[15],[6120,6121,6106,6106],{"nctId":6129,"briefTitle":6130,"status":107,"phases":6131,"primaryCompletion":6132,"start":6133,"enrollment":97,"conditions":6134,"interventions":6135},"NCT01284621","Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers",[90],"2011-03","2011-01",[15],[528,6106,528,6106,6106,6106],{"nctId":6137,"briefTitle":6138,"status":107,"phases":6139,"primaryCompletion":6140,"start":4517,"enrollment":331,"conditions":6141,"interventions":6142},"NCT02215005","Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers",[90],"2007-09",[15],[6121,6106],{"trials":6144,"activeCount":101},[6145],{"nctId":530,"briefTitle":531,"status":107,"phases":6146,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":6147,"interventions":6148},[91],[538,21,539],[73,541],{"trials":6150,"activeCount":101},[6151],{"nctId":6152,"briefTitle":6153,"status":107,"phases":6154,"primaryCompletion":6155,"start":6156,"enrollment":6157,"conditions":6158,"interventions":6159},"NCT00281593","Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension",[92],"2007-04","2006-04",1354,[24],[6121,6106],{"trials":6161,"activeCount":101},[6162,6168,6177,6185],{"nctId":6163,"briefTitle":6164,"status":107,"phases":6165,"completion":5868,"start":6081,"enrollment":8,"conditions":6166,"interventions":6167},"NCT00240422","Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes",[93],[21,24],[6121,6106],{"nctId":6169,"briefTitle":6170,"status":107,"phases":6171,"primaryCompletion":6172,"start":6173,"enrollment":6174,"conditions":6175,"interventions":6176},"NCT00274599","PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN",[93],"2003-11-30","2002-10-09",812,[24],[6121,6106],{"nctId":6178,"briefTitle":6179,"status":107,"phases":6180,"primaryCompletion":4413,"start":6015,"enrollment":6181,"conditions":6182,"interventions":6183},"NCT00153101","Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.",[93],31546,[662],[6121,6184,6106],"Combination of Telmisartan and Ramipril",{"nctId":6186,"briefTitle":6187,"status":107,"phases":6188,"primaryCompletion":2146,"completion":2146,"start":6189,"enrollment":6190,"conditions":6191,"interventions":6192},"NCT00274612","Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM",[93],"2002-10",801,[24],[6121,6106],{"trials":6194,"activeCount":101},[],{"intervention":6196,"totalTrials":1340,"cells":6197},"Hydrochlorothiazide",{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6229,"PHASE3":6240,"PHASE4":6269,"NA":6286},{"trials":6199,"activeCount":101},[],{"trials":6201,"activeCount":101},[6202,6211,6219],{"nctId":6203,"briefTitle":6204,"status":107,"phases":6205,"primaryCompletion":6206,"start":6207,"enrollment":132,"conditions":6208,"interventions":6209},"NCT02187523","Relative Oral Bioavailability of Telmisartan \u002F Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects",[90],"1999-12","1999-10",[15],[6196,6121,6210],"Telmisartan\u002FHCTZ FDC",{"nctId":6212,"briefTitle":6213,"status":107,"phases":6214,"primaryCompletion":2030,"start":6133,"enrollment":97,"conditions":6215,"interventions":6216},"NCT01276288","Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes",[90],[21],[528,6217,6218,528,6218,528,6217],"hydrochlorothiazide","torasemide",{"nctId":6220,"briefTitle":6221,"status":107,"phases":6222,"primaryCompletion":6223,"start":6224,"enrollment":132,"conditions":6225,"interventions":6226},"NCT02276378","Influence of Food on the Bioavailability of Two Doses of Telmisartan\u002FHCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers",[90],"2008-08","2008-07",[15],[6227,6228,6196],"Telmisartan low","Telmisartan high",{"trials":6230,"activeCount":101},[6231],{"nctId":6232,"briefTitle":6233,"status":107,"phases":6234,"primaryCompletion":1115,"completion":1115,"start":6235,"enrollment":6236,"conditions":6237,"interventions":6238},"NCT00153049","3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension",[91],"2004-06",583,[24],[6121,6196,6239],"Telmisartan + Hydrochlorothiazide",{"trials":6241,"activeCount":101},[6242,6250,6258],{"nctId":6243,"briefTitle":6244,"status":107,"phases":6245,"primaryCompletion":6246,"start":6064,"enrollment":6247,"conditions":6248,"interventions":6249},"NCT02177422","Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension",[92],"1999-11",489,[24],[6121,6196],{"nctId":6251,"briefTitle":6252,"status":107,"phases":6253,"primaryCompletion":4391,"completion":5233,"start":378,"enrollment":6254,"conditions":6255,"interventions":6256},"NCT01975246","Add-on to Micamlo BP Trial",[92],309,[24],[6257,6217,6257],"Telmisartan + amlodipine",{"nctId":6259,"briefTitle":6260,"status":107,"phases":6261,"primaryCompletion":6262,"start":6207,"enrollment":6263,"conditions":6264,"interventions":6265},"NCT02175355","Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)",[92],"2000-08",1039,[24],[6266,6267,6268,6196],"Low dose of Micardis®","Medium dose of Micardis®","High dose of Micardis®",{"trials":6270,"activeCount":101},[6271,6278],{"nctId":6272,"briefTitle":6273,"status":107,"phases":6274,"primaryCompletion":4392,"start":5905,"enrollment":6275,"conditions":6276,"interventions":6277},"NCT00926289","Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension",[93],894,[24],[6121,6121,6196],{"nctId":6279,"briefTitle":6280,"status":107,"phases":6281,"primaryCompletion":5993,"start":2181,"enrollment":6282,"conditions":6283,"interventions":6284},"NCT02172586","Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients",[93],363,[24],[6121,6285,6196],"Losartan",{"trials":6287,"activeCount":101},[],{"intervention":5960,"totalTrials":155,"cells":6289},{"EARLY_PHASE1":6290,"PHASE1":6292,"PHASE2":6294,"PHASE3":6332,"PHASE4":6338,"NA":6357},{"trials":6291,"activeCount":101},[],{"trials":6293,"activeCount":101},[],{"trials":6295,"activeCount":101},[6296,6305,6317,6324],{"nctId":6297,"briefTitle":6298,"status":162,"phases":6299,"primaryCompletion":6300,"completion":6300,"start":6301,"enrollment":357,"conditions":6302,"interventions":6303},"NCT01397201","Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)",[91],"2011-12-23","2011-07-01",[30],[6304,5960],"BI 54903",{"nctId":6306,"briefTitle":6307,"status":107,"phases":6308,"primaryCompletion":6309,"completion":6309,"start":6310,"enrollment":6311,"conditions":6312,"interventions":6313},"NCT01092143","BI 671800 ED in Steroid-naive Asthmatic Patients",[91],"2011-03-26","2010-03-18",389,[30],[6314,6315,5960,6316],"BI 671800","Fluticasone propionate placebo","BI 671800 Placebo",{"nctId":6318,"briefTitle":6319,"status":162,"phases":6320,"primaryCompletion":6300,"completion":6300,"start":6321,"enrollment":993,"conditions":6322,"interventions":6323},"NCT01397162","Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy",[91],"2011-07-21",[30],[5960,6304],{"nctId":6325,"briefTitle":6326,"status":162,"phases":6327,"primaryCompletion":6328,"completion":6329,"start":6301,"enrollment":1340,"conditions":6330,"interventions":6331},"NCT01396278","Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).",[91],"2011-12-01","2011-12-14",[30],[5960,6304],{"trials":6333,"activeCount":101},[6334],{"nctId":5891,"briefTitle":5892,"status":107,"phases":6335,"primaryCompletion":603,"completion":1125,"start":4474,"enrollment":5894,"conditions":6336,"interventions":6337},[92],[18],[5897,5898,5899,5900,5900,5899,5897,5898],{"trials":6339,"activeCount":101},[6340,6344,6353],{"nctId":5950,"briefTitle":5951,"status":107,"phases":6341,"primaryCompletion":5953,"completion":5954,"start":5955,"enrollment":5956,"conditions":6342,"interventions":6343},[93],[18],[5860,5959,5960,5832],{"nctId":6345,"briefTitle":6346,"status":107,"phases":6347,"primaryCompletion":3762,"completion":3762,"start":1989,"enrollment":6348,"conditions":6349,"interventions":6350},"NCT00975195","Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease",[93],2488,[18],[6351,6352,5897],"tiotropium inhalation","salmeterol xinafoate",{"nctId":5962,"briefTitle":5963,"status":107,"phases":6354,"primaryCompletion":5965,"completion":5966,"start":5967,"enrollment":5968,"conditions":6355,"interventions":6356},[93],[18],[5860,5959,5960,5832],{"trials":6358,"activeCount":101},[],{"intervention":6360,"totalTrials":1512,"cells":6361},"Tiotropium inhalation",{"EARLY_PHASE1":6362,"PHASE1":6364,"PHASE2":6366,"PHASE3":6368,"PHASE4":6395,"NA":6417},{"trials":6363,"activeCount":101},[],{"trials":6365,"activeCount":101},[],{"trials":6367,"activeCount":101},[],{"trials":6369,"activeCount":101},[6370,6379,6386],{"nctId":6371,"briefTitle":6372,"status":107,"phases":6373,"primaryCompletion":6374,"completion":6374,"start":6375,"enrollment":1928,"conditions":6376,"interventions":6377},"NCT00274092","Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],"2003-10","2002-09",[18],[6351,6378],"Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients",{"nctId":6380,"briefTitle":6381,"status":107,"phases":6382,"primaryCompletion":5993,"start":2122,"enrollment":6383,"conditions":6384,"interventions":6385},"NCT02172378","12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales",[92],116,[18],[6360],{"nctId":6387,"briefTitle":6388,"status":107,"phases":6389,"primaryCompletion":6390,"start":6391,"enrollment":6392,"conditions":6393,"interventions":6394},"NCT02172300","Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],"2000-11","1999-06",198,[18],[6360],{"trials":6396,"activeCount":101},[6397,6405,6409],{"nctId":6398,"briefTitle":6399,"status":162,"phases":6400,"primaryCompletion":6401,"start":2112,"enrollment":956,"conditions":6402,"interventions":6403},"NCT02172508","Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation",[93],"2004-03",[18],[6404],"Tiotropium Inhalation",{"nctId":6345,"briefTitle":6346,"status":107,"phases":6406,"primaryCompletion":3762,"completion":3762,"start":1989,"enrollment":6348,"conditions":6407,"interventions":6408},[93],[18],[6351,6352,5897],{"nctId":6410,"briefTitle":6411,"status":107,"phases":6412,"primaryCompletion":6156,"completion":6156,"start":6413,"enrollment":6414,"conditions":6415,"interventions":6416},"NCT00152984","Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma",[93],"2004-12",472,[18,30],[6360],{"trials":6418,"activeCount":101},[],{"intervention":6420,"totalTrials":1512,"cells":6421},"Clopidogrel",{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6457,"PHASE3":6459,"PHASE4":6465,"NA":6481},{"trials":6423,"activeCount":101},[],{"trials":6425,"activeCount":101},[6426,6434,6441,6449],{"nctId":6427,"briefTitle":6428,"status":107,"phases":6429,"primaryCompletion":3991,"start":1989,"enrollment":1891,"conditions":6430,"interventions":6431},"NCT02171598","Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects",[90],[15],[6420,6432,6433],"Dabigatran high dose","Dabigatran low dose",{"nctId":6435,"briefTitle":6436,"status":107,"phases":6437,"primaryCompletion":5923,"start":6438,"enrollment":177,"conditions":6439,"interventions":6440},"NCT02265289","Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects",[90],"1999-01",[15],[6068,6420],{"nctId":6442,"briefTitle":6443,"status":107,"phases":6444,"primaryCompletion":6445,"start":6446,"enrollment":380,"conditions":6447,"interventions":6448},"NCT02262650","Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects",[90],"2004-05","2004-04",[15],[6121,6420],{"nctId":6450,"briefTitle":6451,"status":107,"phases":6452,"primaryCompletion":6453,"start":5923,"enrollment":177,"conditions":6454,"interventions":6455},"NCT02222987","Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects",[90],"1999-03",[15],[6456,6420],"Terbogrel",{"trials":6458,"activeCount":101},[],{"trials":6460,"activeCount":101},[6461],{"nctId":2097,"briefTitle":2098,"status":107,"phases":6462,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":2102,"conditions":6463,"interventions":6464},[92],[632],[2105,2094,2106],{"trials":6466,"activeCount":101},[6467],{"nctId":6468,"briefTitle":6469,"status":107,"phases":6470,"primaryCompletion":6471,"start":6472,"enrollment":6473,"conditions":6474,"interventions":6475},"NCT00153062","PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes",[93],"2008-04","2003-08",20332,[2092],[6476,6476,6477,6477,6478,6478,6479,6479,6420,6420,6480,6480],"Aggrenox","Clopidogrel placebo","Micardis","Aggrenox placebo","Micardis placebo",{"trials":6482,"activeCount":101},[],{"intervention":6484,"totalTrials":166,"cells":6485},"Aspirin",{"EARLY_PHASE1":6486,"PHASE1":6488,"PHASE2":6506,"PHASE3":6508,"PHASE4":6526,"NA":6546},{"trials":6487,"activeCount":101},[],{"trials":6489,"activeCount":101},[6490,6499],{"nctId":6491,"briefTitle":6492,"status":107,"phases":6493,"primaryCompletion":6494,"start":6495,"enrollment":401,"conditions":6496,"interventions":6497},"NCT02187562","Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females",[90],"2002-08","2002-07",[15],[6498,6484],"Meloxicam",{"nctId":6500,"briefTitle":6501,"status":107,"phases":6502,"primaryCompletion":4413,"start":3763,"enrollment":342,"conditions":6503,"interventions":6504},"NCT02251795","Effects of Steady State Tipranavir\u002FRitonavir or Darunavir\u002FRitonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects",[90],[15],[4008,4010,6505,6484],"Darunavir",{"trials":6507,"activeCount":101},[],{"trials":6509,"activeCount":101},[6510],{"nctId":6511,"briefTitle":6512,"status":107,"phases":6513,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":6517,"interventions":6519},"NCT02164864","Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)",[92],"2017-06-05","2014-07-22",2725,[6098,6518],"Percutaneous Coronary Intervention",[6520,6521,6484,6522,6523,6523,6524,6523,6525],"Dabigatran Etexilate 110mg","Warfarin 3mg","Dabigatran Etexilate 150mg","Clopidogrel or Ticagrelor","Warfarin 5mg","Warfarin 1mg",{"trials":6527,"activeCount":101},[6528,6538],{"nctId":6529,"briefTitle":6530,"status":107,"phases":6531,"primaryCompletion":1136,"start":6532,"enrollment":281,"conditions":6533,"interventions":6535},"NCT00129038","Modified-release Dipyridamole\u002FAspirin (200mg\u002F25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients",[93],"2004-04-01",[6534],"Coronary Arteriosclerosis",[6536,6537],"modified-release dipyridamole\u002Faspirin","aspirin",{"nctId":6539,"briefTitle":6540,"status":107,"phases":6541,"primaryCompletion":6390,"start":6053,"enrollment":536,"conditions":6542,"interventions":6543},"NCT02251184","Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH",[93],[15],[6476,6544,6484,6545],"Dipyridamole","Lansoprazole",{"trials":6547,"activeCount":101},[],{"intervention":6549,"totalTrials":166,"cells":6550},"Diclofenac",{"EARLY_PHASE1":6551,"PHASE1":6553,"PHASE2":6562,"PHASE3":6564,"PHASE4":6578,"NA":6611},{"trials":6552,"activeCount":101},[],{"trials":6554,"activeCount":101},[6555],{"nctId":6556,"briefTitle":6557,"status":107,"phases":6558,"primaryCompletion":2145,"start":4498,"enrollment":380,"conditions":6559,"interventions":6560},"NCT02171507","Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers",[90],[15],[6561,6549],"Dabigatran etexilate",{"trials":6563,"activeCount":101},[],{"trials":6565,"activeCount":101},[6566],{"nctId":6567,"briefTitle":6568,"status":107,"phases":6569,"primaryCompletion":6570,"completion":6571,"start":6572,"enrollment":6573,"conditions":6574,"interventions":6576},"NCT02700815","Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain",[92],"2017-07-13","2017-07-21","2016-05-09",746,[6575],"Acute Pain",[6549,6577],"Capsaicin",{"trials":6579,"activeCount":101},[6580,6590,6601],{"nctId":6581,"briefTitle":6582,"status":107,"phases":6583,"primaryCompletion":6030,"start":6584,"enrollment":6585,"conditions":6586,"interventions":6588},"NCT02229747","Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis",[93],"2001-08",128,[6587],"Pharyngitis",[6498,6549,6589],"Nimesulide",{"nctId":6591,"briefTitle":6592,"status":162,"phases":6593,"primaryCompletion":6390,"start":6594,"enrollment":1512,"conditions":6595,"interventions":6597},"NCT02181920","Metamizol for the Treatment of Neoplastic Chronic Pain",[93],"2000-03",[6596],"Pain",[6598,6549,6599,6600],"Metamizole","Diclofenac placebo","Metamizole placebo",{"nctId":6602,"briefTitle":6603,"status":107,"phases":6604,"primaryCompletion":6605,"start":6606,"enrollment":6607,"conditions":6608,"interventions":6610},"NCT02183129","Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee",[93],"1999-11-01","1999-04-01",91,[6609],"Osteoarthritis",[6549,6498],{"trials":6612,"activeCount":101},[],{"intervention":6614,"totalTrials":166,"cells":6615},"linagliptin placebo",{"EARLY_PHASE1":6616,"PHASE1":6618,"PHASE2":6620,"PHASE3":6622,"PHASE4":6676,"NA":6686},{"trials":6617,"activeCount":101},[],{"trials":6619,"activeCount":101},[],{"trials":6621,"activeCount":101},[],{"trials":6623,"activeCount":101},[6624,6636,6651,6660],{"nctId":6625,"briefTitle":6626,"status":107,"phases":6627,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":6630,"conditions":6631,"interventions":6632},"NCT01243424","CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes",[92],"2018-08-21","2010-11-11",6103,[21],[6633,6634,6614,6635],"linagliptin","glimepiride","glimepiride placebo",{"nctId":6637,"briefTitle":6638,"status":107,"phases":6639,"primaryCompletion":6640,"completion":6641,"start":6642,"enrollment":6643,"conditions":6644,"interventions":6645},"NCT02453555","Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus",[92],"2016-08-26","2017-03-27","2015-05-14",275,[21],[361,6646,6647,6648,6649,6650],"Empagliflozin placebo + linagliptin placebo low dose","Empagliflozin + linagliptin low dose","Linagliptin placebo","Empagliflozin + linagliptin high dose","Empa + lina highdose placebo",{"nctId":6652,"briefTitle":6653,"status":107,"phases":6654,"primaryCompletion":4442,"start":6223,"enrollment":6655,"conditions":6656,"interventions":6657},"NCT00740051","A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",[92],227,[21],[361,6658,6659],"Linagliptin Placebo","Glimepiride",{"nctId":6661,"briefTitle":6662,"status":107,"phases":6663,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":6665,"interventions":6666},"NCT01422876","Efficacy and Safety of Empagliflozin (BI 10773) \u002F Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients",[92],1405,[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],"high dose FDC","BI 10773 high dose","high dose FDC placebo","low dose FDC placebo","high dose BI 10773 placebo","low dose FDC","BI 10773 low dose","BI 10773 low dose placebo","low dose BI 10773 placebo",{"trials":6677,"activeCount":101},[6678],{"nctId":6679,"briefTitle":6680,"status":107,"phases":6681,"primaryCompletion":409,"completion":409,"start":390,"enrollment":6682,"conditions":6683,"interventions":6684},"NCT01438814","Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control",[93],689,[21],[6685,6614,384,384,6633],"metformin placebo",{"trials":6687,"activeCount":101},[],{"intervention":6689,"totalTrials":166,"cells":6690},"tamsulosin hydrochloride",{"EARLY_PHASE1":6691,"PHASE1":6693,"PHASE2":6695,"PHASE3":6713,"PHASE4":6732,"NA":6744},{"trials":6692,"activeCount":101},[],{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[6697,6706],{"nctId":6698,"briefTitle":6699,"status":107,"phases":6700,"primaryCompletion":2146,"start":6701,"enrollment":6702,"conditions":6703,"interventions":6705},"NCT02244281","Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms",[91],"2001-05",74,[6704],"Lower Urinary Tract Symptoms",[6689],{"nctId":6707,"briefTitle":6708,"status":107,"phases":6709,"primaryCompletion":5905,"completion":5905,"start":6156,"enrollment":2004,"conditions":6710,"interventions":6712},"NCT00340704","PK\u002FPD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder",[91],[6711],"Bladder, Neurogenic",[6689],{"trials":6714,"activeCount":101},[6715,6722],{"nctId":6716,"briefTitle":6717,"status":107,"phases":6718,"primaryCompletion":1989,"completion":1989,"start":4507,"enrollment":6719,"conditions":6720,"interventions":6721},"NCT00796614","Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder",[91,92],231,[6711],[6689],{"nctId":6723,"briefTitle":6724,"status":107,"phases":6725,"primaryCompletion":6726,"completion":6726,"start":6727,"enrollment":6728,"conditions":6729,"interventions":6731},"NCT02573311","Actual Use Study of Tamsulosin in Men",[92],"2016-08-01","2015-09-23",1117,[6730],"Urological Manifestations",[6689],{"trials":6733,"activeCount":101},[6734],{"nctId":6735,"briefTitle":6736,"status":107,"phases":6737,"primaryCompletion":6738,"start":6074,"enrollment":6739,"conditions":6740,"interventions":6742},"NCT02244242","Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia",[93],"1999-08",493,[6741],"Prostatic Hyperplasia",[6743],"Tamsulosin hydrochloride",{"trials":6745,"activeCount":101},[],{"intervention":6747,"totalTrials":1564,"cells":6748},"Telmisartan 40 mg",{"EARLY_PHASE1":6749,"PHASE1":6751,"PHASE2":6753,"PHASE3":6755,"PHASE4":6785,"NA":6794},{"trials":6750,"activeCount":101},[],{"trials":6752,"activeCount":101},[],{"trials":6754,"activeCount":101},[],{"trials":6756,"activeCount":101},[6757,6769,6778],{"nctId":6758,"briefTitle":6759,"status":107,"phases":6760,"primaryCompletion":6116,"start":6156,"enrollment":6761,"conditions":6762,"interventions":6763},"NCT00281580","Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension",[92],1461,[24],[6764,6765,6747,6766,6765,6767,6766,6765,6764,6764,6765,6764,6764,6768,6768,6766,6768,6767,6767,6764,6768,6747,6747,6764,6764,6747,6767,6766],"Amlodipine 5 mg","Telmisartan 20 mg","Amlodipine 10 mg","Telmisartan 80 mg","Amlodipine 2.5 mg",{"nctId":6770,"briefTitle":6771,"status":107,"phases":6772,"primaryCompletion":3763,"completion":3763,"start":4498,"enrollment":6773,"conditions":6774,"interventions":6775},"NCT00326768","Trial of Telmisartan 80 mg\u002FHCTZ 12.5 mg and Telmisartan 40 mg\u002FHCTZ 12.5 mg in Patients With Hypertension",[92],184,[24],[6776,6747,6777],"Telmisartan 40 mg\u002FHCTZ 12.5 mg","Telmisartan 80 mg\u002FHCTZ 12.5 mg",{"nctId":6779,"briefTitle":6780,"status":107,"phases":6781,"primaryCompletion":3978,"completion":3978,"start":6782,"enrollment":1274,"conditions":6783,"interventions":6784},"NCT00144222","Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy",[92],"2005-01",[24],[6776,6747],{"trials":6786,"activeCount":101},[6787],{"nctId":6788,"briefTitle":6789,"status":107,"phases":6790,"primaryCompletion":6401,"completion":6445,"start":6040,"enrollment":331,"conditions":6791,"interventions":6792},"NCT00274144","Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism",[93],[24,6534],[6793],"telmisartan 40 mg",{"trials":6795,"activeCount":101},[],{"intervention":6797,"totalTrials":1564,"cells":6798},"tiotropium 18 mcg",{"EARLY_PHASE1":6799,"PHASE1":6801,"PHASE2":6803,"PHASE3":6805,"PHASE4":6832,"NA":6842},{"trials":6800,"activeCount":101},[],{"trials":6802,"activeCount":101},[],{"trials":6804,"activeCount":101},[],{"trials":6806,"activeCount":101},[6807,6817,6826],{"nctId":6808,"briefTitle":6809,"status":107,"phases":6810,"primaryCompletion":6133,"start":6811,"enrollment":25,"conditions":6812,"interventions":6813},"NCT01040728","A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease",[92],"2010-01",[18],[6814,6815,6816],"Olodaterol (BI1744) Low","Olodaterol (BI1744) High","Tiotropium 18 mcg",{"nctId":6818,"briefTitle":6819,"status":107,"phases":6820,"primaryCompletion":408,"completion":408,"start":1980,"enrollment":6821,"conditions":6822,"interventions":6823},"NCT01126437","Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease",[92],17183,[18],[6797,6824,6825],"tiotropium 1.25 mcg","tiotropium 2.5 mcg",{"nctId":6827,"briefTitle":6828,"status":107,"phases":6829,"primaryCompletion":6133,"start":6811,"enrollment":220,"conditions":6830,"interventions":6831},"NCT01040689","Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease",[92],[18],[6814,6815,6816],{"trials":6833,"activeCount":101},[6834],{"nctId":6835,"briefTitle":6836,"status":107,"phases":6837,"primaryCompletion":3754,"start":3763,"enrollment":6838,"conditions":6839,"interventions":6841},"NCT00525512","Tiotropium In Exercise",[93],519,[18,6840],"Exercise",[6797],{"trials":6843,"activeCount":101},[],{"intervention":6845,"totalTrials":1564,"cells":6846},"Fluconazole",{"EARLY_PHASE1":6847,"PHASE1":6849,"PHASE2":6874,"PHASE3":6876,"PHASE4":6878,"NA":6887},{"trials":6848,"activeCount":101},[],{"trials":6850,"activeCount":101},[6851,6860,6867],{"nctId":6852,"briefTitle":6853,"status":107,"phases":6854,"primaryCompletion":6855,"completion":6855,"start":6856,"enrollment":956,"conditions":6857,"interventions":6858},"NCT05076409","A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood",[90],"2022-01-10","2021-10-19",[15],[4095,6859],"fluconazole",{"nctId":6861,"briefTitle":6862,"status":107,"phases":6863,"primaryCompletion":1967,"start":1980,"enrollment":1418,"conditions":6864,"interventions":6865},"NCT01153724","Relative Bioavailability of Olodaterol and Fluconazole",[90],[15,18],[6866,6845],"BI 1744",{"nctId":6868,"briefTitle":6869,"status":107,"phases":6870,"primaryCompletion":5879,"start":6871,"enrollment":1672,"conditions":6872,"interventions":6873},"NCT02195466","Effects of Single-dose and Steady-state TPV\u002FRTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers",[90],"2003-06",[15],[4008,4010,6845],{"trials":6875,"activeCount":101},[],{"trials":6877,"activeCount":101},[],{"trials":6879,"activeCount":101},[6880],{"nctId":6881,"briefTitle":6882,"status":107,"phases":6883,"primaryCompletion":6884,"start":6701,"enrollment":380,"conditions":6885,"interventions":6886},"NCT02181946","Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients",[93],"2001-07",[27],[6845,2186],{"trials":6888,"activeCount":101},[],{"intervention":6890,"totalTrials":1564,"cells":6891},"Pramipexole IR",{"EARLY_PHASE1":6892,"PHASE1":6894,"PHASE2":6921,"PHASE3":6923,"PHASE4":6925,"NA":6937},{"trials":6893,"activeCount":101},[],{"trials":6895,"activeCount":101},[6896,6906,6915],{"nctId":6897,"briefTitle":6898,"status":107,"phases":6899,"primaryCompletion":4462,"start":5843,"enrollment":956,"conditions":6900,"interventions":6901},"NCT02260024","In Vitro\u002Fin Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers",[90],[15],[6890,6902,6903,6904,6905],"Pramipexole SR C","Pramipexole SR C2","Pramipexole SR C2A","Pramipexole SR C2B",{"nctId":6907,"briefTitle":6908,"status":107,"phases":6909,"primaryCompletion":6910,"start":6911,"enrollment":380,"conditions":6912,"interventions":6913},"NCT02264132","Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers",[90],"2006-11","2006-09",[15],[6914,6890],"Pramipexole ER",{"nctId":6916,"briefTitle":6917,"status":107,"phases":6918,"primaryCompletion":2145,"start":6156,"enrollment":291,"conditions":6919,"interventions":6920},"NCT02261103","Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers",[90],[15],[6914,6890],{"trials":6922,"activeCount":101},[],{"trials":6924,"activeCount":101},[],{"trials":6926,"activeCount":101},[6927],{"nctId":6928,"briefTitle":6929,"status":107,"phases":6930,"primaryCompletion":6931,"completion":6931,"start":6932,"enrollment":300,"conditions":6933,"interventions":6935},"NCT03521635","The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa",[93],"2020-01-07","2018-07-03",[6934],"Parkinson Disease",[6936,6890],"Pramipexole SR",{"trials":6938,"activeCount":101},[],{"intervention":6476,"totalTrials":1564,"cells":6940},{"EARLY_PHASE1":6941,"PHASE1":6943,"PHASE2":6954,"PHASE3":6956,"PHASE4":6966,"NA":6976},{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[6945],{"nctId":6946,"briefTitle":6947,"status":107,"phases":6948,"primaryCompletion":6949,"start":2162,"enrollment":956,"conditions":6950,"interventions":6951},"NCT02226926","Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers",[90],"2000-09",[15],[6476,6952,6953],"Persantin Retard","Acetylsalicylic acid",{"trials":6955,"activeCount":101},[],{"trials":6957,"activeCount":101},[6958],{"nctId":6959,"briefTitle":6960,"status":107,"phases":6961,"primaryCompletion":2003,"start":6156,"enrollment":6962,"conditions":6963,"interventions":6965},"NCT00311402","JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme",[92],1295,[6964],"Cerebrovascular Accident",[6476],{"trials":6967,"activeCount":101},[6968,6972],{"nctId":6468,"briefTitle":6469,"status":107,"phases":6969,"primaryCompletion":6471,"start":6472,"enrollment":6473,"conditions":6970,"interventions":6971},[93],[2092],[6476,6476,6477,6477,6478,6478,6479,6479,6420,6420,6480,6480],{"nctId":6539,"briefTitle":6540,"status":107,"phases":6973,"primaryCompletion":6390,"start":6053,"enrollment":536,"conditions":6974,"interventions":6975},[93],[15],[6476,6544,6484,6545],{"trials":6977,"activeCount":101},[],{"intervention":6979,"totalTrials":1564,"cells":6980},"Low dose of telmisartan",{"EARLY_PHASE1":6981,"PHASE1":6983,"PHASE2":6995,"PHASE3":6997,"PHASE4":7009,"NA":7026},{"trials":6982,"activeCount":101},[],{"trials":6984,"activeCount":101},[6985],{"nctId":6986,"briefTitle":6987,"status":107,"phases":6988,"primaryCompletion":6989,"start":6990,"enrollment":1672,"conditions":6991,"interventions":6992},"NCT02262780","Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan \u002F Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers",[90],"2004-02-15","2003-12-01",[15],[6979,6993,6994],"High dose of telmisartan","HCTZ",{"trials":6996,"activeCount":101},[],{"trials":6998,"activeCount":101},[6999],{"nctId":7000,"briefTitle":7001,"status":107,"phases":7002,"primaryCompletion":7003,"start":2162,"enrollment":7004,"conditions":7005,"interventions":7006},"NCT02269176","Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension",[92],"2001-01",330,[24],[6979,6993,7007,7008],"Low dose of losartan","High dose of losartan",{"trials":7010,"activeCount":101},[7011,7018],{"nctId":7012,"briefTitle":7013,"status":107,"phases":7014,"primaryCompletion":6495,"start":6594,"enrollment":7015,"conditions":7016,"interventions":7017},"NCT02260089","Telmisartan in Mild to Moderate Hypertensive Patients",[93],134,[24],[6979,6993],{"nctId":7019,"briefTitle":7020,"status":107,"phases":7021,"primaryCompletion":6390,"start":7022,"enrollment":7023,"conditions":7024,"interventions":7025},"NCT02242370","Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension",[93],"1999-09",3045,[24],[6979,6993],{"trials":7027,"activeCount":101},[],{"intervention":6993,"totalTrials":1564,"cells":7029},{"EARLY_PHASE1":7030,"PHASE1":7032,"PHASE2":7038,"PHASE3":7040,"PHASE4":7046,"NA":7056},{"trials":7031,"activeCount":101},[],{"trials":7033,"activeCount":101},[7034],{"nctId":6986,"briefTitle":6987,"status":107,"phases":7035,"primaryCompletion":6989,"start":6990,"enrollment":1672,"conditions":7036,"interventions":7037},[90],[15],[6979,6993,6994],{"trials":7039,"activeCount":101},[],{"trials":7041,"activeCount":101},[7042],{"nctId":7000,"briefTitle":7001,"status":107,"phases":7043,"primaryCompletion":7003,"start":2162,"enrollment":7004,"conditions":7044,"interventions":7045},[92],[24],[6979,6993,7007,7008],{"trials":7047,"activeCount":101},[7048,7052],{"nctId":7012,"briefTitle":7013,"status":107,"phases":7049,"primaryCompletion":6495,"start":6594,"enrollment":7015,"conditions":7050,"interventions":7051},[93],[24],[6979,6993],{"nctId":7019,"briefTitle":7020,"status":107,"phases":7053,"primaryCompletion":6390,"start":7022,"enrollment":7023,"conditions":7054,"interventions":7055},[93],[24],[6979,6993],{"trials":7057,"activeCount":101},[],{"intervention":7059,"totalTrials":1044,"cells":7060},"Ipratropium bromide",{"EARLY_PHASE1":7061,"PHASE1":7063,"PHASE2":7065,"PHASE3":7067,"PHASE4":7078,"NA":7097},{"trials":7062,"activeCount":101},[],{"trials":7064,"activeCount":101},[],{"trials":7066,"activeCount":101},[],{"trials":7068,"activeCount":101},[7069],{"nctId":7070,"briefTitle":7071,"status":107,"phases":7072,"primaryCompletion":6401,"start":6189,"enrollment":7073,"conditions":7074,"interventions":7075},"NCT02177253","Ipratropium Bromide\u002FSalbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease",[92],1118,[18],[7076,7059,7077],"Ipratropium bromide \u002F Salbutamol","COMBIVENT Inhalation Aerosol",{"trials":7079,"activeCount":101},[7080,7088],{"nctId":7081,"briefTitle":7082,"status":162,"phases":7083,"primaryCompletion":7084,"start":7084,"enrollment":1044,"conditions":7085,"interventions":7086},"NCT02235428","Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children",[93],"1998-09",[30],[7059,7087],"Salbutamol",{"nctId":7089,"briefTitle":7090,"status":107,"phases":7091,"primaryCompletion":7092,"completion":2002,"start":4474,"enrollment":7093,"conditions":7094,"interventions":7095},"NCT01943552","Ipratropium Bromide in Peri-Operative COPD",[93],"2015-07",192,[18],[7096],"ipratropium bromide",{"trials":7098,"activeCount":101},[],{"intervention":7100,"totalTrials":1044,"cells":7101},"Valsartan",{"EARLY_PHASE1":7102,"PHASE1":7104,"PHASE2":7106,"PHASE3":7108,"PHASE4":7118,"NA":7136},{"trials":7103,"activeCount":101},[],{"trials":7105,"activeCount":101},[],{"trials":7107,"activeCount":101},[],{"trials":7109,"activeCount":101},[7110],{"nctId":7111,"briefTitle":7112,"status":107,"phases":7113,"primaryCompletion":7114,"start":6065,"enrollment":7115,"conditions":7116,"interventions":7117},"NCT02177396","MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring",[92],"1998-12",426,[24],[6121,7100],{"trials":7119,"activeCount":101},[7120,7128],{"nctId":7121,"briefTitle":7122,"status":107,"phases":7123,"primaryCompletion":4462,"completion":4462,"start":7124,"enrollment":7125,"conditions":7126,"interventions":7127},"NCT00153023","1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy",[93],"2003-04",885,[2203,24],[6121,7100],{"nctId":7129,"briefTitle":7130,"status":107,"phases":7131,"primaryCompletion":6375,"start":7132,"enrollment":7133,"conditions":7134,"interventions":7135},"NCT02242318","Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring",[93],"2001-09",440,[24],[6121,7100],{"trials":7137,"activeCount":101},[],{"intervention":7139,"totalTrials":1044,"cells":7140},"Salmeterol xinafoate",{"EARLY_PHASE1":7141,"PHASE1":7143,"PHASE2":7145,"PHASE3":7163,"PHASE4":7165,"NA":7171},{"trials":7142,"activeCount":101},[],{"trials":7144,"activeCount":101},[],{"trials":7146,"activeCount":101},[7147,7156],{"nctId":7148,"briefTitle":7149,"status":107,"phases":7150,"primaryCompletion":7151,"start":1981,"enrollment":7152,"conditions":7153,"interventions":7154},"NCT02242227","Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],"2006-02",111,[18],[7139,7155],"Serevent® Diskus®",{"nctId":7157,"briefTitle":7158,"status":107,"phases":7159,"primaryCompletion":5856,"start":2145,"enrollment":7160,"conditions":7161,"interventions":7162},"NCT00350207","Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg\u002FArg",[91],388,[30],[5978,7139],{"trials":7164,"activeCount":101},[],{"trials":7166,"activeCount":101},[7167],{"nctId":6345,"briefTitle":6346,"status":107,"phases":7168,"primaryCompletion":3762,"completion":3762,"start":1989,"enrollment":6348,"conditions":7169,"interventions":7170},[93],[18],[6351,6352,5897],{"trials":7172,"activeCount":101},[],{"intervention":6522,"totalTrials":1075,"cells":7174},{"EARLY_PHASE1":7175,"PHASE1":7177,"PHASE2":7179,"PHASE3":7181,"PHASE4":7187,"NA":7199},{"trials":7176,"activeCount":101},[],{"trials":7178,"activeCount":101},[],{"trials":7180,"activeCount":101},[],{"trials":7182,"activeCount":101},[7183],{"nctId":6511,"briefTitle":6512,"status":107,"phases":7184,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":7185,"interventions":7186},[92],[6098,6518],[6520,6521,6484,6522,6523,6523,6524,6523,6525],{"trials":7188,"activeCount":101},[7189],{"nctId":7190,"briefTitle":7191,"status":107,"phases":7192,"primaryCompletion":7193,"completion":7194,"start":7195,"enrollment":7196,"conditions":7197,"interventions":7198},"NCT02348723","Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)",[93],"2016-11-11","2016-11-14","2015-04-28",678,[6098],[4094,6522],{"trials":7200,"activeCount":101},[],{"intervention":7202,"totalTrials":1075,"cells":7203},"Combivent",{"EARLY_PHASE1":7204,"PHASE1":7206,"PHASE2":7208,"PHASE3":7217,"PHASE4":7219,"NA":7228},{"trials":7205,"activeCount":101},[],{"trials":7207,"activeCount":101},[],{"trials":7209,"activeCount":101},[7210],{"nctId":7211,"briefTitle":7212,"status":107,"phases":7213,"primaryCompletion":6584,"start":6053,"enrollment":3565,"conditions":7214,"interventions":7215},"NCT02182674","A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[7216,7202],"Combivent HFA",{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[7221],{"nctId":7222,"briefTitle":7223,"status":107,"phases":7224,"primaryCompletion":6471,"start":2145,"enrollment":7225,"conditions":7226,"interventions":7227},"NCT00359788","A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.",[93],349,[18],[5899,7202],{"trials":7229,"activeCount":101},[],{"intervention":7087,"totalTrials":1075,"cells":7231},{"EARLY_PHASE1":7232,"PHASE1":7234,"PHASE2":7236,"PHASE3":7238,"PHASE4":7240,"NA":7254},{"trials":7233,"activeCount":101},[],{"trials":7235,"activeCount":101},[],{"trials":7237,"activeCount":101},[],{"trials":7239,"activeCount":101},[],{"trials":7241,"activeCount":101},[7242,7246],{"nctId":7081,"briefTitle":7082,"status":162,"phases":7243,"primaryCompletion":7084,"start":7084,"enrollment":1044,"conditions":7244,"interventions":7245},[93],[30],[7059,7087],{"nctId":7247,"briefTitle":7248,"status":107,"phases":7249,"primaryCompletion":7084,"start":7250,"enrollment":357,"conditions":7251,"interventions":7252},"NCT02182713","Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm",[93],"1998-05",[30],[7253,7087],"Salbutamol sulfate\u002FIpratropium bromide",{"trials":7255,"activeCount":101},[],{"intervention":6285,"totalTrials":1075,"cells":7257},{"EARLY_PHASE1":7258,"PHASE1":7260,"PHASE2":7262,"PHASE3":7264,"PHASE4":7266,"NA":7283},{"trials":7259,"activeCount":101},[],{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"trials":7265,"activeCount":101},[],{"trials":7267,"activeCount":101},[7268,7272],{"nctId":6279,"briefTitle":6280,"status":107,"phases":7269,"primaryCompletion":5993,"start":2181,"enrollment":6282,"conditions":7270,"interventions":7271},[93],[24],[6121,6285,6196],{"nctId":7273,"briefTitle":7274,"status":107,"phases":7275,"primaryCompletion":7276,"start":7277,"enrollment":7278,"conditions":7279,"interventions":7280},"NCT00168857","A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)",[93],"2006-06-01","2003-07-09",860,[24,2203],[7281,7282],"telmisartan","losartan",{"trials":7284,"activeCount":101},[],{"intervention":7286,"totalTrials":1075,"cells":7287},"Duloxetine",{"EARLY_PHASE1":7288,"PHASE1":7290,"PHASE2":7292,"PHASE3":7294,"PHASE4":7305,"NA":7316},{"trials":7289,"activeCount":101},[],{"trials":7291,"activeCount":101},[],{"trials":7293,"activeCount":101},[],{"trials":7295,"activeCount":101},[7296],{"nctId":7297,"briefTitle":7298,"status":107,"phases":7299,"primaryCompletion":4498,"start":7300,"enrollment":7301,"conditions":7302,"interventions":7304},"NCT02232555","Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain",[92],"2005-05",327,[7303],"Depressive Disorder, Major",[7286],{"trials":7306,"activeCount":101},[7307],{"nctId":7308,"briefTitle":7309,"status":107,"phases":7310,"primaryCompletion":7311,"completion":7311,"start":7312,"enrollment":7313,"conditions":7314,"interventions":7315},"NCT02229825","Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression",[93],"2008-08-26","2007-02-09",339,[7303],[7286],{"trials":7317,"activeCount":101},[],{"intervention":6685,"totalTrials":1075,"cells":7319},{"EARLY_PHASE1":7320,"PHASE1":7322,"PHASE2":7324,"PHASE3":7326,"PHASE4":7328,"NA":7342},{"trials":7321,"activeCount":101},[],{"trials":7323,"activeCount":101},[],{"trials":7325,"activeCount":101},[],{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[7330,7334],{"nctId":6679,"briefTitle":6680,"status":107,"phases":7331,"primaryCompletion":409,"completion":409,"start":390,"enrollment":6682,"conditions":7332,"interventions":7333},[93],[21],[6685,6614,384,384,6633],{"nctId":7335,"briefTitle":7336,"status":107,"phases":7337,"primaryCompletion":379,"completion":379,"start":7338,"enrollment":7339,"conditions":7340,"interventions":7341},"NCT01512979","Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes",[93],"2012-01",316,[21],[384,6633,6685,6685],{"trials":7343,"activeCount":101},[],{"intervention":6598,"totalTrials":1075,"cells":7345},{"EARLY_PHASE1":7346,"PHASE1":7348,"PHASE2":7350,"PHASE3":7352,"PHASE4":7354,"NA":7366},{"trials":7347,"activeCount":101},[],{"trials":7349,"activeCount":101},[],{"trials":7351,"activeCount":101},[],{"trials":7353,"activeCount":101},[],{"trials":7355,"activeCount":101},[7356,7360],{"nctId":6591,"briefTitle":6592,"status":162,"phases":7357,"primaryCompletion":6390,"start":6594,"enrollment":1512,"conditions":7358,"interventions":7359},[93],[6596],[6598,6549,6599,6600],{"nctId":7361,"briefTitle":7362,"status":162,"phases":7363,"primaryCompletion":5887,"start":7114,"enrollment":3551,"conditions":7364,"interventions":7365},"NCT02184260","Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke",[93],[2092],[6598],{"trials":7367,"activeCount":101},[],{"intervention":7369,"totalTrials":1075,"cells":7370},"FLOMAX®",{"EARLY_PHASE1":7371,"PHASE1":7373,"PHASE2":7375,"PHASE3":7386,"PHASE4":7388,"NA":7400},{"trials":7372,"activeCount":101},[],{"trials":7374,"activeCount":101},[],{"trials":7376,"activeCount":101},[7377],{"nctId":7378,"briefTitle":7379,"status":107,"phases":7380,"primaryCompletion":1115,"start":7381,"enrollment":7382,"conditions":7383,"interventions":7385},"NCT02244294","FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)",[91],"2001-03",176,[7384],"Prostate Hyperplasia",[7369],{"trials":7387,"activeCount":101},[],{"trials":7389,"activeCount":101},[7390],{"nctId":7391,"briefTitle":7392,"status":107,"phases":7393,"primaryCompletion":7394,"start":7395,"enrollment":7396,"conditions":7397,"interventions":7398},"NCT02244255","FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia",[93],"2000-06","1998-08",1993,[6741],[7369,7399],"Ascending doses of HYTRIN®",{"trials":7401,"activeCount":101},[],{"intervention":7403,"totalTrials":1075,"cells":7404},"High dose of MICARDIS®, once daily",{"EARLY_PHASE1":7405,"PHASE1":7407,"PHASE2":7409,"PHASE3":7411,"PHASE4":7413,"NA":7436},{"trials":7406,"activeCount":101},[],{"trials":7408,"activeCount":101},[],{"trials":7410,"activeCount":101},[],{"trials":7412,"activeCount":101},[],{"trials":7414,"activeCount":101},[7415,7425],{"nctId":7416,"briefTitle":7417,"status":107,"phases":7418,"primaryCompletion":7419,"start":2122,"enrollment":4293,"conditions":7420,"interventions":7421},"NCT02200653","A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® \u002F LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)",[93],"2001-02",[24],[7403,7422,7423,7424],"Low dose of MICARDIS®, once daily","Low dose of COZAAR® \u002F LORZAAR®, once daily","High dose of COZAAR® \u002F LORZAAR®, once daily",{"nctId":7426,"briefTitle":7427,"status":107,"phases":7428,"primaryCompletion":5880,"start":6594,"enrollment":7429,"conditions":7430,"interventions":7431},"NCT02200640","A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)",[93],333,[24],[7432,7433,7434,7435],"High dose of Micardis®, once daily","Low dose of Micardis®, once daily","Low dose of COZAAR®, once daily","High dose of COZAAR®, once daily",{"trials":7437,"activeCount":101},[],{"intervention":7422,"totalTrials":1075,"cells":7439},{"EARLY_PHASE1":7440,"PHASE1":7442,"PHASE2":7444,"PHASE3":7446,"PHASE4":7448,"NA":7458},{"trials":7441,"activeCount":101},[],{"trials":7443,"activeCount":101},[],{"trials":7445,"activeCount":101},[],{"trials":7447,"activeCount":101},[],{"trials":7449,"activeCount":101},[7450,7454],{"nctId":7416,"briefTitle":7417,"status":107,"phases":7451,"primaryCompletion":7419,"start":2122,"enrollment":4293,"conditions":7452,"interventions":7453},[93],[24],[7403,7422,7423,7424],{"nctId":7426,"briefTitle":7427,"status":107,"phases":7455,"primaryCompletion":5880,"start":6594,"enrollment":7429,"conditions":7456,"interventions":7457},[93],[24],[7432,7433,7434,7435],{"trials":7459,"activeCount":101},[],{"intervention":7461,"totalTrials":1075,"cells":7462},"enalapril",{"EARLY_PHASE1":7463,"PHASE1":7465,"PHASE2":7467,"PHASE3":7469,"PHASE4":7479,"NA":7490},{"trials":7464,"activeCount":101},[],{"trials":7466,"activeCount":101},[],{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[7471],{"nctId":7472,"briefTitle":7473,"status":107,"phases":7474,"primaryCompletion":2112,"completion":2112,"start":7475,"enrollment":7476,"conditions":7477,"interventions":7478},"NCT00274118","DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril",[92],"1997-07",250,[24,21],[7281,7461],{"trials":7480,"activeCount":101},[7481],{"nctId":7482,"briefTitle":7483,"status":107,"phases":7484,"primaryCompletion":6494,"start":2163,"enrollment":7485,"conditions":7486,"interventions":7487},"NCT02177461","Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension",[93],374,[24],[6121,7488,7489],"Enalapril","Clonidine",{"trials":7491,"activeCount":101},[],{"intervention":7493,"totalTrials":1075,"cells":7494},"empagliflozin 25 mg",{"EARLY_PHASE1":7495,"PHASE1":7497,"PHASE2":7499,"PHASE3":7501,"PHASE4":7516,"NA":7528},{"trials":7496,"activeCount":101},[],{"trials":7498,"activeCount":101},[],{"trials":7500,"activeCount":101},[],{"trials":7502,"activeCount":101},[7503],{"nctId":7504,"briefTitle":7505,"status":107,"phases":7506,"primaryCompletion":7507,"completion":7508,"start":7509,"enrollment":7510,"conditions":7511,"interventions":7512},"NCT02489968","Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus",[92],"2016-11-18","2017-06-16","2015-05-12",880,[21],[7513,7514,7515,7493],"empagliflozin 10 mg + linagliptin 5 mg","empagliflozin 10 mg","empagliflozin 25 mg + linagliptin 5 mg",{"trials":7517,"activeCount":101},[7518],{"nctId":7519,"briefTitle":7520,"status":107,"phases":7521,"primaryCompletion":7522,"completion":7522,"start":7523,"enrollment":7524,"conditions":7525,"interventions":7526},"NCT02589626","Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA",[93],"2017-06-02","2015-10-29",65,[21],[7527,7493],"empagliflozin 10mg",{"trials":7529,"activeCount":101},[],{"intervention":7531,"totalTrials":1075,"cells":7532},"Rifabutin",{"EARLY_PHASE1":7533,"PHASE1":7535,"PHASE2":7543,"PHASE3":7545,"PHASE4":7547,"NA":7556},{"trials":7534,"activeCount":101},[],{"trials":7536,"activeCount":101},[7537],{"nctId":7538,"briefTitle":7539,"status":107,"phases":7540,"primaryCompletion":6374,"start":6472,"enrollment":380,"conditions":7541,"interventions":7542},"NCT02251171","Effects of Steady-state TPV\u002FRTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers",[90],[15],[4008,4010,7531],{"trials":7544,"activeCount":101},[],{"trials":7546,"activeCount":101},[],{"trials":7548,"activeCount":101},[7549],{"nctId":7550,"briefTitle":7551,"status":107,"phases":7552,"primaryCompletion":7114,"start":7553,"enrollment":2442,"conditions":7554,"interventions":7555},"NCT02184078","Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients",[93],"1998-10",[27],[2186,7531],{"trials":7557,"activeCount":101},[],{"intervention":7559,"totalTrials":1075,"cells":7560},"3TC",{"EARLY_PHASE1":7561,"PHASE1":7563,"PHASE2":7565,"PHASE3":7567,"PHASE4":7580,"NA":7588},{"trials":7562,"activeCount":101},[],{"trials":7564,"activeCount":101},[],{"trials":7566,"activeCount":101},[],{"trials":7568,"activeCount":101},[7569],{"nctId":7570,"briefTitle":7571,"status":107,"phases":7572,"primaryCompletion":7573,"completion":7573,"start":7574,"enrollment":7575,"conditions":7576,"interventions":7578},"NCT00144183","A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)",[92],"2007-01","2003-01",407,[7577],"Acquired Immunodeficiency Syndrome",[2186,7579,7559],"Zidovudine",{"trials":7581,"activeCount":101},[7582],{"nctId":7583,"briefTitle":7584,"status":107,"phases":7585,"primaryCompletion":2145,"completion":2145,"start":6871,"enrollment":231,"conditions":7586,"interventions":7587},"NCT00144157","Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV",[93],[7577],[2186,7579,7559],{"trials":7589,"activeCount":101},[],{"intervention":7591,"totalTrials":1075,"cells":7592},"Metoprolol succinate",{"EARLY_PHASE1":7593,"PHASE1":7595,"PHASE2":7608,"PHASE3":7610,"PHASE4":7612,"NA":7621},{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[7597],{"nctId":7598,"briefTitle":7599,"status":107,"phases":7600,"primaryCompletion":2146,"start":6081,"enrollment":3575,"conditions":7601,"interventions":7602},"NCT02264002","Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers",[90],[15],[7603,7604,7605,7606,7607,7591],"Cilobradine low dose 1","Cilobradine low dose 2","Cilobradine medium dose","Cilobradine high dose 1","Cilobradine high dose 2",{"trials":7609,"activeCount":101},[],{"trials":7611,"activeCount":101},[],{"trials":7613,"activeCount":101},[7614],{"nctId":7615,"briefTitle":7616,"status":162,"phases":7617,"primaryCompletion":7618,"start":5869,"enrollment":380,"conditions":7619,"interventions":7620},"NCT02242812","Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension",[93],"2004-10",[24],[6121,7591],{"trials":7622,"activeCount":101},[],{"intervention":7624,"totalTrials":272,"cells":7625},"telmisartan 80 mg\u002Fhydrochlorothiazide 25 mg",{"EARLY_PHASE1":7626,"PHASE1":7628,"PHASE2":7630,"PHASE3":7632,"PHASE4":7634,"NA":7644},{"trials":7627,"activeCount":101},[],{"trials":7629,"activeCount":101},[],{"trials":7631,"activeCount":101},[],{"trials":7633,"activeCount":101},[],{"trials":7635,"activeCount":101},[7636],{"nctId":7637,"briefTitle":7638,"status":107,"phases":7639,"primaryCompletion":6235,"start":5869,"enrollment":7640,"conditions":7641,"interventions":7642},"NCT00240448","A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I\u002FII Patients",[93],1109,[24],[7624,7643],"valsartan 160 mg\u002Fhydrochlorothiazide 25 mg",{"trials":7645,"activeCount":101},[],{"intervention":7643,"totalTrials":272,"cells":7647},{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7662},{"trials":7649,"activeCount":101},[],{"trials":7651,"activeCount":101},[],{"trials":7653,"activeCount":101},[],{"trials":7655,"activeCount":101},[],{"trials":7657,"activeCount":101},[7658],{"nctId":7637,"briefTitle":7638,"status":107,"phases":7659,"primaryCompletion":6235,"start":5869,"enrollment":7640,"conditions":7660,"interventions":7661},[93],[24],[7624,7643],{"trials":7663,"activeCount":101},[],{"intervention":7665,"totalTrials":272,"cells":7666},"Tiotropium Bromide Inhalation Powder",{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7671,"PHASE3":7673,"PHASE4":7675,"NA":7684},{"trials":7668,"activeCount":101},[],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[],{"trials":7676,"activeCount":101},[7677],{"nctId":7678,"briefTitle":7679,"status":107,"phases":7680,"primaryCompletion":3978,"start":6235,"enrollment":7681,"conditions":7682,"interventions":7683},"NCT00106821","Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease",[93],166,[18],[7665],{"trials":7685,"activeCount":101},[],{"intervention":7687,"totalTrials":272,"cells":7688},"Mirapex",{"EARLY_PHASE1":7689,"PHASE1":7691,"PHASE2":7693,"PHASE3":7695,"PHASE4":7697,"NA":7708},{"trials":7690,"activeCount":101},[],{"trials":7692,"activeCount":101},[],{"trials":7694,"activeCount":101},[],{"trials":7696,"activeCount":101},[],{"trials":7698,"activeCount":101},[7699],{"nctId":7700,"briefTitle":7701,"status":107,"phases":7702,"primaryCompletion":7703,"start":6782,"enrollment":7704,"conditions":7705,"interventions":7706},"NCT00144300","Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients",[93],"2010-09",246,[6934],[7687,7707],"Requip",{"trials":7709,"activeCount":101},[],{"intervention":7707,"totalTrials":272,"cells":7711},{"EARLY_PHASE1":7712,"PHASE1":7714,"PHASE2":7716,"PHASE3":7718,"PHASE4":7720,"NA":7726},{"trials":7713,"activeCount":101},[],{"trials":7715,"activeCount":101},[],{"trials":7717,"activeCount":101},[],{"trials":7719,"activeCount":101},[],{"trials":7721,"activeCount":101},[7722],{"nctId":7700,"briefTitle":7701,"status":107,"phases":7723,"primaryCompletion":7703,"start":6782,"enrollment":7704,"conditions":7724,"interventions":7725},[93],[6934],[7687,7707],{"trials":7727,"activeCount":101},[],{"intervention":6589,"totalTrials":272,"cells":7729},{"EARLY_PHASE1":7730,"PHASE1":7732,"PHASE2":7734,"PHASE3":7736,"PHASE4":7738,"NA":7744},{"trials":7731,"activeCount":101},[],{"trials":7733,"activeCount":101},[],{"trials":7735,"activeCount":101},[],{"trials":7737,"activeCount":101},[],{"trials":7739,"activeCount":101},[7740],{"nctId":6581,"briefTitle":6582,"status":107,"phases":7741,"primaryCompletion":6030,"start":6584,"enrollment":6585,"conditions":7742,"interventions":7743},[93],[6587],[6498,6549,6589],{"trials":7745,"activeCount":101},[],{"intervention":7747,"totalTrials":272,"cells":7748},"Telmisartan & Hydrochlorothiazide",{"EARLY_PHASE1":7749,"PHASE1":7751,"PHASE2":7753,"PHASE3":7755,"PHASE4":7757,"NA":7767},{"trials":7750,"activeCount":101},[],{"trials":7752,"activeCount":101},[],{"trials":7754,"activeCount":101},[],{"trials":7756,"activeCount":101},[],{"trials":7758,"activeCount":101},[7759],{"nctId":7760,"briefTitle":7761,"status":107,"phases":7762,"primaryCompletion":5879,"start":6495,"enrollment":7763,"conditions":7764,"interventions":7765},"NCT00274638","PROBE Parallel 6-week Treatment Comparing Telmisartan\u002FHydrochlorothiazide (HCT) (40\u002F12.5 or 80\u002F12.5) With Losartan\u002FHCT (50\u002F12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)",[93],805,[24],[7747,7766],"Losartan & Hydrochlorothiazide",{"trials":7768,"activeCount":101},[],{"intervention":7766,"totalTrials":272,"cells":7770},{"EARLY_PHASE1":7771,"PHASE1":7773,"PHASE2":7775,"PHASE3":7777,"PHASE4":7779,"NA":7785},{"trials":7772,"activeCount":101},[],{"trials":7774,"activeCount":101},[],{"trials":7776,"activeCount":101},[],{"trials":7778,"activeCount":101},[],{"trials":7780,"activeCount":101},[7781],{"nctId":7760,"briefTitle":7761,"status":107,"phases":7782,"primaryCompletion":5879,"start":6495,"enrollment":7763,"conditions":7783,"interventions":7784},[93],[24],[7747,7766],{"trials":7786,"activeCount":101},[],{"intervention":7788,"totalTrials":272,"cells":7789},"Telmisartan capsule 40 mg",{"EARLY_PHASE1":7790,"PHASE1":7792,"PHASE2":7794,"PHASE3":7796,"PHASE4":7798,"NA":7808},{"trials":7791,"activeCount":101},[],{"trials":7793,"activeCount":101},[],{"trials":7795,"activeCount":101},[],{"trials":7797,"activeCount":101},[],{"trials":7799,"activeCount":101},[7800],{"nctId":7801,"briefTitle":7802,"status":107,"phases":7803,"primaryCompletion":5842,"completion":5842,"start":7574,"enrollment":7804,"conditions":7805,"interventions":7806},"NCT00153088","INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy",[93],527,[2203],[7788,7807],"Telmisartan capsule 80 mg",{"trials":7809,"activeCount":101},[],{"intervention":7807,"totalTrials":272,"cells":7811},{"EARLY_PHASE1":7812,"PHASE1":7814,"PHASE2":7816,"PHASE3":7818,"PHASE4":7820,"NA":7826},{"trials":7813,"activeCount":101},[],{"trials":7815,"activeCount":101},[],{"trials":7817,"activeCount":101},[],{"trials":7819,"activeCount":101},[],{"trials":7821,"activeCount":101},[7822],{"nctId":7801,"briefTitle":7802,"status":107,"phases":7823,"primaryCompletion":5842,"completion":5842,"start":7574,"enrollment":7804,"conditions":7824,"interventions":7825},[93],[2203],[7788,7807],{"trials":7827,"activeCount":101},[],{"intervention":7829,"totalTrials":272,"cells":7830},"Duloxetine 60 mg QD",{"EARLY_PHASE1":7831,"PHASE1":7833,"PHASE2":7835,"PHASE3":7837,"PHASE4":7839,"NA":7851},{"trials":7832,"activeCount":101},[],{"trials":7834,"activeCount":101},[],{"trials":7836,"activeCount":101},[],{"trials":7838,"activeCount":101},[],{"trials":7840,"activeCount":101},[7841],{"nctId":7842,"briefTitle":7843,"status":107,"phases":7844,"primaryCompletion":3754,"start":1989,"enrollment":220,"conditions":7845,"interventions":7847},"NCT00844194","Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder",[93],[7846,7303],"Diabetic Neuropathies",[7829,7829,7848,7848,7849,7849,7829,7829,7850,7848,7848,7850],"Duloxetine 30 mg QD","Duloxetine 90 mg QD","Duloxetine 120 mg QD",{"trials":7852,"activeCount":101},[],{"intervention":7848,"totalTrials":272,"cells":7854},{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7861,"PHASE4":7863,"NA":7869},{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[],{"trials":7862,"activeCount":101},[],{"trials":7864,"activeCount":101},[7865],{"nctId":7842,"briefTitle":7843,"status":107,"phases":7866,"primaryCompletion":3754,"start":1989,"enrollment":220,"conditions":7867,"interventions":7868},[93],[7846,7303],[7829,7829,7848,7848,7849,7849,7829,7829,7850,7848,7848,7850],{"trials":7870,"activeCount":101},[],{"intervention":7849,"totalTrials":272,"cells":7872},{"EARLY_PHASE1":7873,"PHASE1":7875,"PHASE2":7877,"PHASE3":7879,"PHASE4":7881,"NA":7887},{"trials":7874,"activeCount":101},[],{"trials":7876,"activeCount":101},[],{"trials":7878,"activeCount":101},[],{"trials":7880,"activeCount":101},[],{"trials":7882,"activeCount":101},[7883],{"nctId":7842,"briefTitle":7843,"status":107,"phases":7884,"primaryCompletion":3754,"start":1989,"enrollment":220,"conditions":7885,"interventions":7886},[93],[7846,7303],[7829,7829,7848,7848,7849,7849,7829,7829,7850,7848,7848,7850],{"trials":7888,"activeCount":101},[],{"intervention":7850,"totalTrials":272,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7895,"PHASE3":7897,"PHASE4":7899,"NA":7905},{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":101},[],{"trials":7896,"activeCount":101},[],{"trials":7898,"activeCount":101},[],{"trials":7900,"activeCount":101},[7901],{"nctId":7842,"briefTitle":7843,"status":107,"phases":7902,"primaryCompletion":3754,"start":1989,"enrollment":220,"conditions":7903,"interventions":7904},[93],[7846,7303],[7829,7829,7848,7848,7849,7849,7829,7829,7850,7848,7848,7850],{"trials":7906,"activeCount":101},[],{"intervention":7908,"totalTrials":272,"cells":7909},"Ipratropium bromide 500 µg\u002Fsalbutamol sulphate 3 mg",{"EARLY_PHASE1":7910,"PHASE1":7912,"PHASE2":7914,"PHASE3":7916,"PHASE4":7918,"NA":7930},{"trials":7911,"activeCount":101},[],{"trials":7913,"activeCount":101},[],{"trials":7915,"activeCount":101},[],{"trials":7917,"activeCount":101},[],{"trials":7919,"activeCount":101},[7920],{"nctId":7921,"briefTitle":7922,"status":107,"phases":7923,"primaryCompletion":2162,"start":7924,"enrollment":1116,"conditions":7925,"interventions":7926},"NCT02182856","Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD",[93],"1998-02",[18],[7908,7927,7928,7929],"Ipratropium 500 µg","Salbutamol sulphate 3 mg","Salbutamol sulphate 6 mg",{"trials":7931,"activeCount":101},[],{"intervention":7927,"totalTrials":272,"cells":7933},{"EARLY_PHASE1":7934,"PHASE1":7936,"PHASE2":7938,"PHASE3":7940,"PHASE4":7942,"NA":7948},{"trials":7935,"activeCount":101},[],{"trials":7937,"activeCount":101},[],{"trials":7939,"activeCount":101},[],{"trials":7941,"activeCount":101},[],{"trials":7943,"activeCount":101},[7944],{"nctId":7921,"briefTitle":7922,"status":107,"phases":7945,"primaryCompletion":2162,"start":7924,"enrollment":1116,"conditions":7946,"interventions":7947},[93],[18],[7908,7927,7928,7929],{"trials":7949,"activeCount":101},[],{"intervention":7928,"totalTrials":272,"cells":7951},{"EARLY_PHASE1":7952,"PHASE1":7954,"PHASE2":7956,"PHASE3":7958,"PHASE4":7960,"NA":7966},{"trials":7953,"activeCount":101},[],{"trials":7955,"activeCount":101},[],{"trials":7957,"activeCount":101},[],{"trials":7959,"activeCount":101},[],{"trials":7961,"activeCount":101},[7962],{"nctId":7921,"briefTitle":7922,"status":107,"phases":7963,"primaryCompletion":2162,"start":7924,"enrollment":1116,"conditions":7964,"interventions":7965},[93],[18],[7908,7927,7928,7929],{"trials":7967,"activeCount":101},[],{"intervention":7929,"totalTrials":272,"cells":7969},{"EARLY_PHASE1":7970,"PHASE1":7972,"PHASE2":7974,"PHASE3":7976,"PHASE4":7978,"NA":7984},{"trials":7971,"activeCount":101},[],{"trials":7973,"activeCount":101},[],{"trials":7975,"activeCount":101},[],{"trials":7977,"activeCount":101},[],{"trials":7979,"activeCount":101},[7980],{"nctId":7921,"briefTitle":7922,"status":107,"phases":7981,"primaryCompletion":2162,"start":7924,"enrollment":1116,"conditions":7982,"interventions":7983},[93],[18],[7908,7927,7928,7929],{"trials":7985,"activeCount":101},[],{"intervention":7987,"totalTrials":272,"cells":7988},"telmisartan, valsartan",{"EARLY_PHASE1":7989,"PHASE1":7991,"PHASE2":7993,"PHASE3":7995,"PHASE4":7997,"NA":8006},{"trials":7990,"activeCount":101},[],{"trials":7992,"activeCount":101},[],{"trials":7994,"activeCount":101},[],{"trials":7996,"activeCount":101},[],{"trials":7998,"activeCount":101},[7999],{"nctId":8000,"briefTitle":8001,"status":107,"phases":8002,"primaryCompletion":6494,"completion":6494,"start":6041,"enrollment":8003,"conditions":8004,"interventions":8005},"NCT00034840","Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose",[93],490,[24],[7987],{"trials":8007,"activeCount":101},[],{"intervention":6936,"totalTrials":272,"cells":8009},{"EARLY_PHASE1":8010,"PHASE1":8012,"PHASE2":8014,"PHASE3":8016,"PHASE4":8018,"NA":8024},{"trials":8011,"activeCount":101},[],{"trials":8013,"activeCount":101},[],{"trials":8015,"activeCount":101},[],{"trials":8017,"activeCount":101},[],{"trials":8019,"activeCount":101},[8020],{"nctId":6928,"briefTitle":6929,"status":107,"phases":8021,"primaryCompletion":6931,"completion":6931,"start":6932,"enrollment":300,"conditions":8022,"interventions":8023},[93],[6934],[6936,6890],{"trials":8025,"activeCount":101},[],{"intervention":8027,"totalTrials":272,"cells":8028},"Combivent Respimat via tee adapter",{"EARLY_PHASE1":8029,"PHASE1":8031,"PHASE2":8033,"PHASE3":8035,"PHASE4":8037,"NA":8049},{"trials":8030,"activeCount":101},[],{"trials":8032,"activeCount":101},[],{"trials":8034,"activeCount":101},[],{"trials":8036,"activeCount":101},[],{"trials":8038,"activeCount":101},[8039],{"nctId":8040,"briefTitle":8041,"status":162,"phases":8042,"primaryCompletion":8043,"completion":8044,"start":8045,"enrollment":281,"conditions":8046,"interventions":8047},"NCT01969539","Ventilator Adapters for Combivent Respimat",[93],"2014-11-20","2014-11-21","2013-10-14",[18],[8027,8048],"Combivent Respimat via ventilator adapter",{"trials":8050,"activeCount":101},[],{"intervention":8048,"totalTrials":272,"cells":8052},{"EARLY_PHASE1":8053,"PHASE1":8055,"PHASE2":8057,"PHASE3":8059,"PHASE4":8061,"NA":8067},{"trials":8054,"activeCount":101},[],{"trials":8056,"activeCount":101},[],{"trials":8058,"activeCount":101},[],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[8063],{"nctId":8040,"briefTitle":8041,"status":162,"phases":8064,"primaryCompletion":8043,"completion":8044,"start":8045,"enrollment":281,"conditions":8065,"interventions":8066},[93],[18],[8027,8048],{"trials":8068,"activeCount":101},[],{"intervention":8070,"totalTrials":272,"cells":8071},"BI-Sifrol®",{"EARLY_PHASE1":8072,"PHASE1":8074,"PHASE2":8076,"PHASE3":8078,"PHASE4":8080,"NA":8089},{"trials":8073,"activeCount":101},[],{"trials":8075,"activeCount":101},[],{"trials":8077,"activeCount":101},[],{"trials":8079,"activeCount":101},[],{"trials":8081,"activeCount":101},[8082],{"nctId":8083,"briefTitle":8084,"status":107,"phases":8085,"primaryCompletion":8086,"start":2112,"enrollment":993,"conditions":8087,"interventions":8088},"NCT02231905","Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease",[93],"2004-11",[6934],[8070],{"trials":8090,"activeCount":101},[],{"intervention":8092,"totalTrials":272,"cells":8093},"Telmisartan 80 mg + hydrochlorothiazide 12.5 mg",{"EARLY_PHASE1":8094,"PHASE1":8096,"PHASE2":8098,"PHASE3":8100,"PHASE4":8102,"NA":8113},{"trials":8095,"activeCount":101},[],{"trials":8097,"activeCount":101},[],{"trials":8099,"activeCount":101},[],{"trials":8101,"activeCount":101},[],{"trials":8103,"activeCount":101},[8104],{"nctId":8105,"briefTitle":8106,"status":107,"phases":8107,"primaryCompletion":6401,"completion":6401,"start":8108,"enrollment":8109,"conditions":8110,"interventions":8111},"NCT00240474","A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)",[93],"2002-12",1000,[24],[8092,8112],"Amlodipine 10 mg + hydrochlorothiazide 12.5 mg",{"trials":8114,"activeCount":101},[],{"intervention":8112,"totalTrials":272,"cells":8116},{"EARLY_PHASE1":8117,"PHASE1":8119,"PHASE2":8121,"PHASE3":8123,"PHASE4":8125,"NA":8131},{"trials":8118,"activeCount":101},[],{"trials":8120,"activeCount":101},[],{"trials":8122,"activeCount":101},[],{"trials":8124,"activeCount":101},[],{"trials":8126,"activeCount":101},[8127],{"nctId":8105,"briefTitle":8106,"status":107,"phases":8128,"primaryCompletion":6401,"completion":6401,"start":8108,"enrollment":8109,"conditions":8129,"interventions":8130},[93],[24],[8092,8112],{"trials":8132,"activeCount":101},[],{"intervention":8134,"totalTrials":272,"cells":8135},"Tiotropium plus Salmeterol",{"EARLY_PHASE1":8136,"PHASE1":8138,"PHASE2":8140,"PHASE3":8142,"PHASE4":8144,"NA":8154},{"trials":8137,"activeCount":101},[],{"trials":8139,"activeCount":101},[],{"trials":8141,"activeCount":101},[],{"trials":8143,"activeCount":101},[],{"trials":8145,"activeCount":101},[8146],{"nctId":8147,"briefTitle":8148,"status":107,"phases":8149,"primaryCompletion":2649,"start":6140,"enrollment":8150,"conditions":8151,"interventions":8152},"NCT00530842","Effect of Tiotropium Plus Salmeterol vs. Fluticasone\u002FSalmeterol on Static Lung Volumes and Exercise Endurance in COPD",[93],344,[18],[8134,8153],"Fluticasone\u002FSalmeterol",{"trials":8155,"activeCount":101},[],{"intervention":8153,"totalTrials":272,"cells":8157},{"EARLY_PHASE1":8158,"PHASE1":8160,"PHASE2":8162,"PHASE3":8164,"PHASE4":8166,"NA":8172},{"trials":8159,"activeCount":101},[],{"trials":8161,"activeCount":101},[],{"trials":8163,"activeCount":101},[],{"trials":8165,"activeCount":101},[],{"trials":8167,"activeCount":101},[8168],{"nctId":8147,"briefTitle":8148,"status":107,"phases":8169,"primaryCompletion":2649,"start":6140,"enrollment":8150,"conditions":8170,"interventions":8171},[93],[18],[8134,8153],{"trials":8173,"activeCount":101},[],{"intervention":6477,"totalTrials":272,"cells":8175},{"EARLY_PHASE1":8176,"PHASE1":8178,"PHASE2":8180,"PHASE3":8182,"PHASE4":8184,"NA":8190},{"trials":8177,"activeCount":101},[],{"trials":8179,"activeCount":101},[],{"trials":8181,"activeCount":101},[],{"trials":8183,"activeCount":101},[],{"trials":8185,"activeCount":101},[8186],{"nctId":6468,"briefTitle":6469,"status":107,"phases":8187,"primaryCompletion":6471,"start":6472,"enrollment":6473,"conditions":8188,"interventions":8189},[93],[2092],[6476,6476,6477,6477,6478,6478,6479,6479,6420,6420,6480,6480],{"trials":8191,"activeCount":101},[],{"intervention":6479,"totalTrials":272,"cells":8193},{"EARLY_PHASE1":8194,"PHASE1":8196,"PHASE2":8198,"PHASE3":8200,"PHASE4":8202,"NA":8208},{"trials":8195,"activeCount":101},[],{"trials":8197,"activeCount":101},[],{"trials":8199,"activeCount":101},[],{"trials":8201,"activeCount":101},[],{"trials":8203,"activeCount":101},[8204],{"nctId":6468,"briefTitle":6469,"status":107,"phases":8205,"primaryCompletion":6471,"start":6472,"enrollment":6473,"conditions":8206,"interventions":8207},[93],[2092],[6476,6476,6477,6477,6478,6478,6479,6479,6420,6420,6480,6480],{"trials":8209,"activeCount":101},[],{"intervention":6480,"totalTrials":272,"cells":8211},{"EARLY_PHASE1":8212,"PHASE1":8214,"PHASE2":8216,"PHASE3":8218,"PHASE4":8220,"NA":8226},{"trials":8213,"activeCount":101},[],{"trials":8215,"activeCount":101},[],{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[],{"trials":8221,"activeCount":101},[8222],{"nctId":6468,"briefTitle":6469,"status":107,"phases":8223,"primaryCompletion":6471,"start":6472,"enrollment":6473,"conditions":8224,"interventions":8225},[93],[2092],[6476,6476,6477,6477,6478,6478,6479,6479,6420,6420,6480,6480],{"trials":8227,"activeCount":101},[],{"intervention":6599,"totalTrials":272,"cells":8229},{"EARLY_PHASE1":8230,"PHASE1":8232,"PHASE2":8234,"PHASE3":8236,"PHASE4":8238,"NA":8244},{"trials":8231,"activeCount":101},[],{"trials":8233,"activeCount":101},[],{"trials":8235,"activeCount":101},[],{"trials":8237,"activeCount":101},[],{"trials":8239,"activeCount":101},[8240],{"nctId":6591,"briefTitle":6592,"status":162,"phases":8241,"primaryCompletion":6390,"start":6594,"enrollment":1512,"conditions":8242,"interventions":8243},[93],[6596],[6598,6549,6599,6600],{"trials":8245,"activeCount":101},[],{"intervention":6600,"totalTrials":272,"cells":8247},{"EARLY_PHASE1":8248,"PHASE1":8250,"PHASE2":8252,"PHASE3":8254,"PHASE4":8256,"NA":8262},{"trials":8249,"activeCount":101},[],{"trials":8251,"activeCount":101},[],{"trials":8253,"activeCount":101},[],{"trials":8255,"activeCount":101},[],{"trials":8257,"activeCount":101},[8258],{"nctId":6591,"briefTitle":6592,"status":162,"phases":8259,"primaryCompletion":6390,"start":6594,"enrollment":1512,"conditions":8260,"interventions":8261},[93],[6596],[6598,6549,6599,6600],{"trials":8263,"activeCount":101},[],{"intervention":8265,"totalTrials":272,"cells":8266},"valsartan combined with hydrochlorothiazide",{"EARLY_PHASE1":8267,"PHASE1":8269,"PHASE2":8271,"PHASE3":8273,"PHASE4":8275,"NA":8285},{"trials":8268,"activeCount":101},[],{"trials":8270,"activeCount":101},[],{"trials":8272,"activeCount":101},[],{"trials":8274,"activeCount":101},[],{"trials":8276,"activeCount":101},[8277],{"nctId":8278,"briefTitle":8279,"status":107,"phases":8280,"primaryCompletion":6413,"completion":6413,"start":7574,"enrollment":8281,"conditions":8282,"interventions":8283},"NCT00239538","SMOOTH - Blood Pressure Control in Diabetic\u002FObese Patients",[93],840,[24,21],[8284,8265],"telmisartan combined with hydrochlorothiazide",{"trials":8286,"activeCount":101},[],{"intervention":8288,"totalTrials":272,"cells":8289},"Pradaxa, dabigatran etexilate",{"EARLY_PHASE1":8290,"PHASE1":8292,"PHASE2":8294,"PHASE3":8296,"PHASE4":8298,"NA":8307},{"trials":8291,"activeCount":101},[],{"trials":8293,"activeCount":101},[],{"trials":8295,"activeCount":101},[],{"trials":8297,"activeCount":101},[],{"trials":8299,"activeCount":101},[8300],{"nctId":8301,"briefTitle":8302,"status":107,"phases":8303,"primaryCompletion":437,"completion":437,"start":3762,"enrollment":8304,"conditions":8305,"interventions":8306},"NCT01896297","Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function",[93],63,[6098],[8288],{"trials":8308,"activeCount":101},[],{"intervention":7253,"totalTrials":272,"cells":8310},{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8315,"PHASE3":8317,"PHASE4":8319,"NA":8325},{"trials":8312,"activeCount":101},[],{"trials":8314,"activeCount":101},[],{"trials":8316,"activeCount":101},[],{"trials":8318,"activeCount":101},[],{"trials":8320,"activeCount":101},[8321],{"nctId":7247,"briefTitle":7248,"status":107,"phases":8322,"primaryCompletion":7084,"start":7250,"enrollment":357,"conditions":8323,"interventions":8324},[93],[30],[7253,7087],{"trials":8326,"activeCount":101},[],{"intervention":8328,"totalTrials":272,"cells":8329},"ipratropium plus salbutamol UDV",{"EARLY_PHASE1":8330,"PHASE1":8332,"PHASE2":8334,"PHASE3":8336,"PHASE4":8338,"NA":8348},{"trials":8331,"activeCount":101},[],{"trials":8333,"activeCount":101},[],{"trials":8335,"activeCount":101},[],{"trials":8337,"activeCount":101},[],{"trials":8339,"activeCount":101},[8340],{"nctId":8341,"briefTitle":8342,"status":107,"phases":8343,"primaryCompletion":2146,"completion":2146,"start":5887,"enrollment":8344,"conditions":8345,"interventions":8346},"NCT00273962","A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)",[93],500,[30],[8328,8347],"salbutamol UDV",{"trials":8349,"activeCount":101},[],{"intervention":8347,"totalTrials":272,"cells":8351},{"EARLY_PHASE1":8352,"PHASE1":8354,"PHASE2":8356,"PHASE3":8358,"PHASE4":8360,"NA":8366},{"trials":8353,"activeCount":101},[],{"trials":8355,"activeCount":101},[],{"trials":8357,"activeCount":101},[],{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":101},[8362],{"nctId":8341,"briefTitle":8342,"status":107,"phases":8363,"primaryCompletion":2146,"completion":2146,"start":5887,"enrollment":8344,"conditions":8364,"interventions":8365},[93],[30],[8328,8347],{"trials":8367,"activeCount":101},[],{"intervention":7399,"totalTrials":272,"cells":8369},{"EARLY_PHASE1":8370,"PHASE1":8372,"PHASE2":8374,"PHASE3":8376,"PHASE4":8378,"NA":8384},{"trials":8371,"activeCount":101},[],{"trials":8373,"activeCount":101},[],{"trials":8375,"activeCount":101},[],{"trials":8377,"activeCount":101},[],{"trials":8379,"activeCount":101},[8380],{"nctId":7391,"briefTitle":7392,"status":107,"phases":8381,"primaryCompletion":7394,"start":7395,"enrollment":7396,"conditions":8382,"interventions":8383},[93],[6741],[7369,7399],{"trials":8385,"activeCount":101},[],{"intervention":7423,"totalTrials":272,"cells":8387},{"EARLY_PHASE1":8388,"PHASE1":8390,"PHASE2":8392,"PHASE3":8394,"PHASE4":8396,"NA":8402},{"trials":8389,"activeCount":101},[],{"trials":8391,"activeCount":101},[],{"trials":8393,"activeCount":101},[],{"trials":8395,"activeCount":101},[],{"trials":8397,"activeCount":101},[8398],{"nctId":7416,"briefTitle":7417,"status":107,"phases":8399,"primaryCompletion":7419,"start":2122,"enrollment":4293,"conditions":8400,"interventions":8401},[93],[24],[7403,7422,7423,7424],{"trials":8403,"activeCount":101},[],{"intervention":7424,"totalTrials":272,"cells":8405},{"EARLY_PHASE1":8406,"PHASE1":8408,"PHASE2":8410,"PHASE3":8412,"PHASE4":8414,"NA":8420},{"trials":8407,"activeCount":101},[],{"trials":8409,"activeCount":101},[],{"trials":8411,"activeCount":101},[],{"trials":8413,"activeCount":101},[],{"trials":8415,"activeCount":101},[8416],{"nctId":7416,"briefTitle":7417,"status":107,"phases":8417,"primaryCompletion":7419,"start":2122,"enrollment":4293,"conditions":8418,"interventions":8419},[93],[24],[7403,7422,7423,7424],{"trials":8421,"activeCount":101},[],{"intervention":6536,"totalTrials":272,"cells":8423},{"EARLY_PHASE1":8424,"PHASE1":8426,"PHASE2":8428,"PHASE3":8430,"PHASE4":8432,"NA":8438},{"trials":8425,"activeCount":101},[],{"trials":8427,"activeCount":101},[],{"trials":8429,"activeCount":101},[],{"trials":8431,"activeCount":101},[],{"trials":8433,"activeCount":101},[8434],{"nctId":6529,"briefTitle":6530,"status":107,"phases":8435,"primaryCompletion":1136,"start":6532,"enrollment":281,"conditions":8436,"interventions":8437},[93],[6534],[6536,6537],{"trials":8439,"activeCount":101},[],{"intervention":8441,"totalTrials":272,"cells":8442},"Antistax film coated",{"EARLY_PHASE1":8443,"PHASE1":8445,"PHASE2":8447,"PHASE3":8449,"PHASE4":8451,"NA":8460},{"trials":8444,"activeCount":101},[],{"trials":8446,"activeCount":101},[],{"trials":8448,"activeCount":101},[],{"trials":8450,"activeCount":101},[],{"trials":8452,"activeCount":101},[8453],{"nctId":8454,"briefTitle":8455,"status":107,"phases":8456,"primaryCompletion":6041,"start":2121,"enrollment":7524,"conditions":8457,"interventions":8459},"NCT02184234","Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)",[93],[8458],"Venous Insufficiency",[8441],{"trials":8461,"activeCount":101},[],{"intervention":8463,"totalTrials":272,"cells":8464},"Salmeterol plus Fluticasone",{"EARLY_PHASE1":8465,"PHASE1":8467,"PHASE2":8469,"PHASE3":8471,"PHASE4":8473,"NA":8483},{"trials":8466,"activeCount":101},[],{"trials":8468,"activeCount":101},[],{"trials":8470,"activeCount":101},[],{"trials":8472,"activeCount":101},[],{"trials":8474,"activeCount":101},[8475],{"nctId":8476,"briefTitle":8477,"status":107,"phases":8478,"primaryCompletion":8479,"completion":8479,"start":5869,"enrollment":8480,"conditions":8481,"interventions":8482},"NCT00239499","Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)",[93],"2004-08",107,[18],[5860,8463],{"trials":8484,"activeCount":101},[],{"intervention":7434,"totalTrials":272,"cells":8486},{"EARLY_PHASE1":8487,"PHASE1":8489,"PHASE2":8491,"PHASE3":8493,"PHASE4":8495,"NA":8501},{"trials":8488,"activeCount":101},[],{"trials":8490,"activeCount":101},[],{"trials":8492,"activeCount":101},[],{"trials":8494,"activeCount":101},[],{"trials":8496,"activeCount":101},[8497],{"nctId":7426,"briefTitle":7427,"status":107,"phases":8498,"primaryCompletion":5880,"start":6594,"enrollment":7429,"conditions":8499,"interventions":8500},[93],[24],[7432,7433,7434,7435],{"trials":8502,"activeCount":101},[],{"intervention":7435,"totalTrials":272,"cells":8504},{"EARLY_PHASE1":8505,"PHASE1":8507,"PHASE2":8509,"PHASE3":8511,"PHASE4":8513,"NA":8519},{"trials":8506,"activeCount":101},[],{"trials":8508,"activeCount":101},[],{"trials":8510,"activeCount":101},[],{"trials":8512,"activeCount":101},[],{"trials":8514,"activeCount":101},[8515],{"nctId":7426,"briefTitle":7427,"status":107,"phases":8516,"primaryCompletion":5880,"start":6594,"enrollment":7429,"conditions":8517,"interventions":8518},[93],[24],[7432,7433,7434,7435],{"trials":8520,"activeCount":101},[],{"intervention":8522,"totalTrials":272,"cells":8523},"Hylan G-F 20",{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8528,"PHASE3":8530,"PHASE4":8532,"NA":8543},{"trials":8525,"activeCount":101},[],{"trials":8527,"activeCount":101},[],{"trials":8529,"activeCount":101},[],{"trials":8531,"activeCount":101},[],{"trials":8533,"activeCount":101},[8534],{"nctId":8535,"briefTitle":8536,"status":107,"phases":8537,"primaryCompletion":8538,"start":7553,"enrollment":8539,"conditions":8540,"interventions":8541},"NCT02197026","Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis",[93],"2000-02",518,[6609],[8522,8542],"Standard treatment",{"trials":8544,"activeCount":101},[],{"intervention":8542,"totalTrials":272,"cells":8546},{"EARLY_PHASE1":8547,"PHASE1":8549,"PHASE2":8551,"PHASE3":8553,"PHASE4":8555,"NA":8561},{"trials":8548,"activeCount":101},[],{"trials":8550,"activeCount":101},[],{"trials":8552,"activeCount":101},[],{"trials":8554,"activeCount":101},[],{"trials":8556,"activeCount":101},[8557],{"nctId":8535,"briefTitle":8536,"status":107,"phases":8558,"primaryCompletion":8538,"start":7553,"enrollment":8539,"conditions":8559,"interventions":8560},[93],[6609],[8522,8542],{"trials":8562,"activeCount":101},[],{"intervention":8564,"totalTrials":272,"cells":8565},"Stiolto Respimat",{"EARLY_PHASE1":8566,"PHASE1":8568,"PHASE2":8570,"PHASE3":8572,"PHASE4":8574,"NA":8586},{"trials":8567,"activeCount":101},[],{"trials":8569,"activeCount":101},[],{"trials":8571,"activeCount":101},[],{"trials":8573,"activeCount":101},[],{"trials":8575,"activeCount":101},[8576],{"nctId":8577,"briefTitle":8578,"status":107,"phases":8579,"primaryCompletion":8580,"completion":8580,"start":109,"enrollment":507,"conditions":8581,"interventions":8582},"NCT03265145","Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]",[93],"2020-09-30",[18],[8564,8583,8584,8585],"ICS","LABA","LAMA",{"trials":8587,"activeCount":101},[],{"intervention":8584,"totalTrials":272,"cells":8589},{"EARLY_PHASE1":8590,"PHASE1":8592,"PHASE2":8594,"PHASE3":8596,"PHASE4":8598,"NA":8604},{"trials":8591,"activeCount":101},[],{"trials":8593,"activeCount":101},[],{"trials":8595,"activeCount":101},[],{"trials":8597,"activeCount":101},[],{"trials":8599,"activeCount":101},[8600],{"nctId":8577,"briefTitle":8578,"status":107,"phases":8601,"primaryCompletion":8580,"completion":8580,"start":109,"enrollment":507,"conditions":8602,"interventions":8603},[93],[18],[8564,8583,8584,8585],{"trials":8605,"activeCount":101},[],{"intervention":6544,"totalTrials":272,"cells":8607},{"EARLY_PHASE1":8608,"PHASE1":8610,"PHASE2":8612,"PHASE3":8614,"PHASE4":8616,"NA":8622},{"trials":8609,"activeCount":101},[],{"trials":8611,"activeCount":101},[],{"trials":8613,"activeCount":101},[],{"trials":8615,"activeCount":101},[],{"trials":8617,"activeCount":101},[8618],{"nctId":6539,"briefTitle":6540,"status":107,"phases":8619,"primaryCompletion":6390,"start":6053,"enrollment":536,"conditions":8620,"interventions":8621},[93],[15],[6476,6544,6484,6545],{"trials":8623,"activeCount":101},[],{"intervention":6545,"totalTrials":272,"cells":8625},{"EARLY_PHASE1":8626,"PHASE1":8628,"PHASE2":8630,"PHASE3":8632,"PHASE4":8634,"NA":8640},{"trials":8627,"activeCount":101},[],{"trials":8629,"activeCount":101},[],{"trials":8631,"activeCount":101},[],{"trials":8633,"activeCount":101},[],{"trials":8635,"activeCount":101},[8636],{"nctId":6539,"briefTitle":6540,"status":107,"phases":8637,"primaryCompletion":6390,"start":6053,"enrollment":536,"conditions":8638,"interventions":8639},[93],[15],[6476,6544,6484,6545],{"trials":8641,"activeCount":101},[],{"intervention":6184,"totalTrials":272,"cells":8643},{"EARLY_PHASE1":8644,"PHASE1":8646,"PHASE2":8648,"PHASE3":8650,"PHASE4":8652,"NA":8658},{"trials":8645,"activeCount":101},[],{"trials":8647,"activeCount":101},[],{"trials":8649,"activeCount":101},[],{"trials":8651,"activeCount":101},[],{"trials":8653,"activeCount":101},[8654],{"nctId":6178,"briefTitle":6179,"status":107,"phases":8655,"primaryCompletion":4413,"start":6015,"enrollment":6181,"conditions":8656,"interventions":8657},[93],[662],[6121,6184,6106],{"trials":8659,"activeCount":101},[],{"intervention":8661,"totalTrials":272,"cells":8662},"Bromocriptine and other dopamine agonists",{"EARLY_PHASE1":8663,"PHASE1":8665,"PHASE2":8667,"PHASE3":8669,"PHASE4":8671,"NA":8681},{"trials":8664,"activeCount":101},[],{"trials":8666,"activeCount":101},[],{"trials":8668,"activeCount":101},[],{"trials":8670,"activeCount":101},[],{"trials":8672,"activeCount":101},[8673],{"nctId":8674,"briefTitle":8675,"status":107,"phases":8676,"primaryCompletion":7394,"start":6064,"enrollment":8677,"conditions":8678,"interventions":8679},"NCT02233023","Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease",[93],705,[6934],[8680,8661],"Pramipexole",{"trials":8682,"activeCount":101},[],{"intervention":8684,"totalTrials":272,"cells":8685},"Bendrofluazide",{"EARLY_PHASE1":8686,"PHASE1":8688,"PHASE2":8690,"PHASE3":8692,"PHASE4":8694,"NA":8704},{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[],{"trials":8691,"activeCount":101},[],{"trials":8693,"activeCount":101},[],{"trials":8695,"activeCount":101},[8696],{"nctId":8697,"briefTitle":8698,"status":107,"phases":8699,"primaryCompletion":6594,"start":8700,"enrollment":1982,"conditions":8701,"interventions":8702},"NCT02235402","A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients",[93],"1997-12",[24],[8703,8684],"Lacidipine",{"trials":8705,"activeCount":101},[],{"intervention":6102,"totalTrials":272,"cells":8707},{"EARLY_PHASE1":8708,"PHASE1":8710,"PHASE2":8712,"PHASE3":8714,"PHASE4":8716,"NA":8722},{"trials":8709,"activeCount":101},[],{"trials":8711,"activeCount":101},[],{"trials":8713,"activeCount":101},[],{"trials":8715,"activeCount":101},[],{"trials":8717,"activeCount":101},[8718],{"nctId":6092,"briefTitle":6093,"status":107,"phases":8719,"primaryCompletion":5233,"completion":5233,"start":6095,"enrollment":6096,"conditions":8720,"interventions":8721},[93],[6098],[6100,6101,6102,6101],{"trials":8723,"activeCount":101},[],{"intervention":8725,"totalTrials":272,"cells":8726},"Telmisartan low dose",{"EARLY_PHASE1":8727,"PHASE1":8729,"PHASE2":8731,"PHASE3":8733,"PHASE4":8735,"NA":8744},{"trials":8728,"activeCount":101},[],{"trials":8730,"activeCount":101},[],{"trials":8732,"activeCount":101},[],{"trials":8734,"activeCount":101},[],{"trials":8736,"activeCount":101},[8737],{"nctId":8738,"briefTitle":8739,"status":107,"phases":8740,"primaryCompletion":6029,"start":6949,"enrollment":4273,"conditions":8741,"interventions":8742},"NCT02178306","Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild\u002FModerate or Severe Renal Impairment or Requiring Hemodialysis",[93],[24],[8725,8743],"Telmisartan high dose",{"trials":8745,"activeCount":101},[],{"intervention":8743,"totalTrials":272,"cells":8747},{"EARLY_PHASE1":8748,"PHASE1":8750,"PHASE2":8752,"PHASE3":8754,"PHASE4":8756,"NA":8762},{"trials":8749,"activeCount":101},[],{"trials":8751,"activeCount":101},[],{"trials":8753,"activeCount":101},[],{"trials":8755,"activeCount":101},[],{"trials":8757,"activeCount":101},[8758],{"nctId":8738,"briefTitle":8739,"status":107,"phases":8759,"primaryCompletion":6029,"start":6949,"enrollment":4273,"conditions":8760,"interventions":8761},[93],[24],[8725,8743],{"trials":8763,"activeCount":101},[],{"intervention":8765,"totalTrials":272,"cells":8766},"Tamsulosin HCl controlled release",{"EARLY_PHASE1":8767,"PHASE1":8769,"PHASE2":8771,"PHASE3":8773,"PHASE4":8775,"NA":8784},{"trials":8768,"activeCount":101},[],{"trials":8770,"activeCount":101},[],{"trials":8772,"activeCount":101},[],{"trials":8774,"activeCount":101},[],{"trials":8776,"activeCount":101},[8777],{"nctId":8778,"briefTitle":8779,"status":107,"phases":8780,"primaryCompletion":6446,"start":7574,"enrollment":8781,"conditions":8782,"interventions":8783},"NCT02245490","Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms",[93],153,[6741],[8765],{"trials":8785,"activeCount":101},[],{"intervention":8787,"totalTrials":272,"cells":8788},"Tiotropium Handihaler®",{"EARLY_PHASE1":8789,"PHASE1":8791,"PHASE2":8793,"PHASE3":8795,"PHASE4":8797,"NA":8807},{"trials":8790,"activeCount":101},[],{"trials":8792,"activeCount":101},[],{"trials":8794,"activeCount":101},[],{"trials":8796,"activeCount":101},[],{"trials":8798,"activeCount":101},[8799],{"nctId":8800,"briefTitle":8801,"status":107,"phases":8802,"primaryCompletion":6856,"completion":8803,"start":1654,"enrollment":716,"conditions":8804,"interventions":8805},"NCT03964207","A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)",[93],"2021-11-16",[18],[8806,8787],"Tiotropium Respimat®",{"trials":8808,"activeCount":101},[],{"intervention":8810,"totalTrials":272,"cells":8811},"telmisartan 80 mg \u002F hydrochlorothiazide 25 mg",{"EARLY_PHASE1":8812,"PHASE1":8814,"PHASE2":8816,"PHASE3":8818,"PHASE4":8820,"NA":8830},{"trials":8813,"activeCount":101},[],{"trials":8815,"activeCount":101},[],{"trials":8817,"activeCount":101},[],{"trials":8819,"activeCount":101},[],{"trials":8821,"activeCount":101},[8822],{"nctId":8823,"briefTitle":8824,"status":107,"phases":8825,"primaryCompletion":2145,"completion":2145,"start":1981,"enrollment":8826,"conditions":8827,"interventions":8828},"NCT00168779","Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension",[93],1185,[24],[8810,8829],"valsartan 160 mg \u002F hydrochlorothiazide 25 mg",{"trials":8831,"activeCount":101},[],{"intervention":8829,"totalTrials":272,"cells":8833},{"EARLY_PHASE1":8834,"PHASE1":8836,"PHASE2":8838,"PHASE3":8840,"PHASE4":8842,"NA":8848},{"trials":8835,"activeCount":101},[],{"trials":8837,"activeCount":101},[],{"trials":8839,"activeCount":101},[],{"trials":8841,"activeCount":101},[],{"trials":8843,"activeCount":101},[8844],{"nctId":8823,"briefTitle":8824,"status":107,"phases":8845,"primaryCompletion":2145,"completion":2145,"start":1981,"enrollment":8826,"conditions":8846,"interventions":8847},[93],[24],[8810,8829],{"trials":8849,"activeCount":101},[],{"intervention":8851,"totalTrials":272,"cells":8852},"Candesartan",{"EARLY_PHASE1":8853,"PHASE1":8855,"PHASE2":8857,"PHASE3":8859,"PHASE4":8861,"NA":8869},{"trials":8854,"activeCount":101},[],{"trials":8856,"activeCount":101},[],{"trials":8858,"activeCount":101},[],{"trials":8860,"activeCount":101},[],{"trials":8862,"activeCount":101},[8863],{"nctId":8864,"briefTitle":8865,"status":107,"phases":8866,"primaryCompletion":6494,"start":6029,"enrollment":380,"conditions":8867,"interventions":8868},"NCT02261116","Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers",[93],[15],[6121,8851],{"trials":8870,"activeCount":101},[],{"intervention":8872,"totalTrials":272,"cells":8873},"ipratropium bromide \u002F albuterol",{"EARLY_PHASE1":8874,"PHASE1":8876,"PHASE2":8878,"PHASE3":8880,"PHASE4":8882,"NA":8892},{"trials":8875,"activeCount":101},[],{"trials":8877,"activeCount":101},[],{"trials":8879,"activeCount":101},[],{"trials":8881,"activeCount":101},[],{"trials":8883,"activeCount":101},[8884],{"nctId":8885,"briefTitle":8886,"status":107,"phases":8887,"primaryCompletion":8888,"start":8889,"enrollment":7301,"conditions":8890,"interventions":8891},"NCT00388882","Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.",[93],"2007-10-08","2006-10-04",[18],[5899,8872],{"trials":8893,"activeCount":101},[],{"intervention":8895,"totalTrials":272,"cells":8896},"Aggrenox bid",{"EARLY_PHASE1":8897,"PHASE1":8899,"PHASE2":8901,"PHASE3":8903,"PHASE4":8905,"NA":8916},{"trials":8898,"activeCount":101},[],{"trials":8900,"activeCount":101},[],{"trials":8902,"activeCount":101},[],{"trials":8904,"activeCount":101},[],{"trials":8906,"activeCount":101},[8907],{"nctId":8908,"briefTitle":8909,"status":107,"phases":8910,"primaryCompletion":1989,"start":8911,"enrollment":8912,"conditions":8913,"interventions":8914},"NCT00562588","EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA",[93],"2007-07",551,[6964],[8895,8915],"ASA 100 mg qd",{"trials":8917,"activeCount":101},[],{"intervention":8915,"totalTrials":272,"cells":8919},{"EARLY_PHASE1":8920,"PHASE1":8922,"PHASE2":8924,"PHASE3":8926,"PHASE4":8928,"NA":8934},{"trials":8921,"activeCount":101},[],{"trials":8923,"activeCount":101},[],{"trials":8925,"activeCount":101},[],{"trials":8927,"activeCount":101},[],{"trials":8929,"activeCount":101},[8930],{"nctId":8908,"briefTitle":8909,"status":107,"phases":8931,"primaryCompletion":1989,"start":8911,"enrollment":8912,"conditions":8932,"interventions":8933},[93],[6964],[8895,8915],{"trials":8935,"activeCount":101},[],{"intervention":7489,"totalTrials":272,"cells":8937},{"EARLY_PHASE1":8938,"PHASE1":8940,"PHASE2":8942,"PHASE3":8944,"PHASE4":8946,"NA":8952},{"trials":8939,"activeCount":101},[],{"trials":8941,"activeCount":101},[],{"trials":8943,"activeCount":101},[],{"trials":8945,"activeCount":101},[],{"trials":8947,"activeCount":101},[8948],{"nctId":7482,"briefTitle":7483,"status":107,"phases":8949,"primaryCompletion":6494,"start":2163,"enrollment":7485,"conditions":8950,"interventions":8951},[93],[24],[6121,7488,7489],{"trials":8953,"activeCount":101},[],{"intervention":8955,"totalTrials":272,"cells":8956},"Meloxicam - low",{"EARLY_PHASE1":8957,"PHASE1":8959,"PHASE2":8961,"PHASE3":8963,"PHASE4":8965,"NA":8976},{"trials":8958,"activeCount":101},[],{"trials":8960,"activeCount":101},[],{"trials":8962,"activeCount":101},[],{"trials":8964,"activeCount":101},[],{"trials":8966,"activeCount":101},[8967],{"nctId":8968,"briefTitle":8969,"status":107,"phases":8970,"primaryCompletion":6949,"start":2122,"enrollment":4273,"conditions":8971,"interventions":8972},"NCT02183155","Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects",[93],[15],[8955,8973,8974,8975],"Meloxicam - medium","Meloxicam - high","Extended-release indomethacin",{"trials":8977,"activeCount":101},[],{"intervention":8973,"totalTrials":272,"cells":8979},{"EARLY_PHASE1":8980,"PHASE1":8982,"PHASE2":8984,"PHASE3":8986,"PHASE4":8988,"NA":8994},{"trials":8981,"activeCount":101},[],{"trials":8983,"activeCount":101},[],{"trials":8985,"activeCount":101},[],{"trials":8987,"activeCount":101},[],{"trials":8989,"activeCount":101},[8990],{"nctId":8968,"briefTitle":8969,"status":107,"phases":8991,"primaryCompletion":6949,"start":2122,"enrollment":4273,"conditions":8992,"interventions":8993},[93],[15],[8955,8973,8974,8975],{"trials":8995,"activeCount":101},[],{"intervention":8974,"totalTrials":272,"cells":8997},{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9002,"PHASE3":9004,"PHASE4":9006,"NA":9012},{"trials":8999,"activeCount":101},[],{"trials":9001,"activeCount":101},[],{"trials":9003,"activeCount":101},[],{"trials":9005,"activeCount":101},[],{"trials":9007,"activeCount":101},[9008],{"nctId":8968,"briefTitle":8969,"status":107,"phases":9009,"primaryCompletion":6949,"start":2122,"enrollment":4273,"conditions":9010,"interventions":9011},[93],[15],[8955,8973,8974,8975],{"trials":9013,"activeCount":101},[],{"intervention":8975,"totalTrials":272,"cells":9015},{"EARLY_PHASE1":9016,"PHASE1":9018,"PHASE2":9020,"PHASE3":9022,"PHASE4":9024,"NA":9030},{"trials":9017,"activeCount":101},[],{"trials":9019,"activeCount":101},[],{"trials":9021,"activeCount":101},[],{"trials":9023,"activeCount":101},[],{"trials":9025,"activeCount":101},[9026],{"nctId":8968,"briefTitle":8969,"status":107,"phases":9027,"primaryCompletion":6949,"start":2122,"enrollment":4273,"conditions":9028,"interventions":9029},[93],[15],[8955,8973,8974,8975],{"trials":9031,"activeCount":101},[],{"intervention":7527,"totalTrials":272,"cells":9033},{"EARLY_PHASE1":9034,"PHASE1":9036,"PHASE2":9038,"PHASE3":9040,"PHASE4":9042,"NA":9048},{"trials":9035,"activeCount":101},[],{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[],{"trials":9041,"activeCount":101},[],{"trials":9043,"activeCount":101},[9044],{"nctId":7519,"briefTitle":7520,"status":107,"phases":9045,"primaryCompletion":7522,"completion":7522,"start":7523,"enrollment":7524,"conditions":9046,"interventions":9047},[93],[21],[7527,7493],{"trials":9049,"activeCount":101},[],{"intervention":9051,"totalTrials":272,"cells":9052},"FDC of tiotropium + olodaterol",{"EARLY_PHASE1":9053,"PHASE1":9055,"PHASE2":9057,"PHASE3":9059,"PHASE4":9061,"NA":9073},{"trials":9054,"activeCount":101},[],{"trials":9056,"activeCount":101},[],{"trials":9058,"activeCount":101},[],{"trials":9060,"activeCount":101},[],{"trials":9062,"activeCount":101},[9063],{"nctId":9064,"briefTitle":9065,"status":107,"phases":9066,"primaryCompletion":9067,"completion":9068,"start":9069,"enrollment":9070,"conditions":9071,"interventions":9072},"NCT02683109","Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD",[93],"2017-01-09","2017-01-30","2016-03-08",221,[18],[9051,5860,5959],{"trials":9074,"activeCount":101},[],{"intervention":9076,"totalTrials":272,"cells":9077},"Finasteride",{"EARLY_PHASE1":9078,"PHASE1":9080,"PHASE2":9082,"PHASE3":9084,"PHASE4":9086,"NA":9096},{"trials":9079,"activeCount":101},[],{"trials":9081,"activeCount":101},[],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[],{"trials":9087,"activeCount":101},[9088],{"nctId":9089,"briefTitle":9090,"status":107,"phases":9091,"primaryCompletion":6390,"start":6065,"enrollment":9092,"conditions":9093,"interventions":9094},"NCT02244229","Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients",[93],403,[6741],[9095,9076],"Tamsulosin",{"trials":9097,"activeCount":101},[],{"intervention":9099,"totalTrials":272,"cells":9100},"tenofovir DF 300 mg QD",{"EARLY_PHASE1":9101,"PHASE1":9103,"PHASE2":9105,"PHASE3":9107,"PHASE4":9109,"NA":9122},{"trials":9102,"activeCount":101},[],{"trials":9104,"activeCount":101},[],{"trials":9106,"activeCount":101},[],{"trials":9108,"activeCount":101},[],{"trials":9110,"activeCount":101},[9111],{"nctId":9112,"briefTitle":9113,"status":107,"phases":9114,"primaryCompletion":3732,"start":6140,"enrollment":9115,"conditions":9116,"interventions":9117},"NCT00552240","Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)",[93],154,[27],[9099,9099,9118,9118,9119,9120,9121],"emtricitabine 200 mg QD","Nevirapine 200 mg BID","Atazanavir 300 mg","Ritonavir 100 mg",{"trials":9123,"activeCount":101},[],{"intervention":9118,"totalTrials":272,"cells":9125},{"EARLY_PHASE1":9126,"PHASE1":9128,"PHASE2":9130,"PHASE3":9132,"PHASE4":9134,"NA":9140},{"trials":9127,"activeCount":101},[],{"trials":9129,"activeCount":101},[],{"trials":9131,"activeCount":101},[],{"trials":9133,"activeCount":101},[],{"trials":9135,"activeCount":101},[9136],{"nctId":9112,"briefTitle":9113,"status":107,"phases":9137,"primaryCompletion":3732,"start":6140,"enrollment":9115,"conditions":9138,"interventions":9139},[93],[27],[9099,9099,9118,9118,9119,9120,9121],{"trials":9141,"activeCount":101},[],{"intervention":9119,"totalTrials":272,"cells":9143},{"EARLY_PHASE1":9144,"PHASE1":9146,"PHASE2":9148,"PHASE3":9150,"PHASE4":9152,"NA":9158},{"trials":9145,"activeCount":101},[],{"trials":9147,"activeCount":101},[],{"trials":9149,"activeCount":101},[],{"trials":9151,"activeCount":101},[],{"trials":9153,"activeCount":101},[9154],{"nctId":9112,"briefTitle":9113,"status":107,"phases":9155,"primaryCompletion":3732,"start":6140,"enrollment":9115,"conditions":9156,"interventions":9157},[93],[27],[9099,9099,9118,9118,9119,9120,9121],{"trials":9159,"activeCount":101},[],{"intervention":9120,"totalTrials":272,"cells":9161},{"EARLY_PHASE1":9162,"PHASE1":9164,"PHASE2":9166,"PHASE3":9168,"PHASE4":9170,"NA":9176},{"trials":9163,"activeCount":101},[],{"trials":9165,"activeCount":101},[],{"trials":9167,"activeCount":101},[],{"trials":9169,"activeCount":101},[],{"trials":9171,"activeCount":101},[9172],{"nctId":9112,"briefTitle":9113,"status":107,"phases":9173,"primaryCompletion":3732,"start":6140,"enrollment":9115,"conditions":9174,"interventions":9175},[93],[27],[9099,9099,9118,9118,9119,9120,9121],{"trials":9177,"activeCount":101},[],{"intervention":9121,"totalTrials":272,"cells":9179},{"EARLY_PHASE1":9180,"PHASE1":9182,"PHASE2":9184,"PHASE3":9186,"PHASE4":9188,"NA":9194},{"trials":9181,"activeCount":101},[],{"trials":9183,"activeCount":101},[],{"trials":9185,"activeCount":101},[],{"trials":9187,"activeCount":101},[],{"trials":9189,"activeCount":101},[9190],{"nctId":9112,"briefTitle":9113,"status":107,"phases":9191,"primaryCompletion":3732,"start":6140,"enrollment":9115,"conditions":9192,"interventions":9193},[93],[27],[9099,9099,9118,9118,9119,9120,9121],{"trials":9195,"activeCount":101},[],{"intervention":9197,"totalTrials":272,"cells":9198},"Spiriva HandiHaler",{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9203,"PHASE3":9205,"PHASE4":9207,"NA":9216},{"trials":9200,"activeCount":101},[],{"trials":9202,"activeCount":101},[],{"trials":9204,"activeCount":101},[],{"trials":9206,"activeCount":101},[],{"trials":9208,"activeCount":101},[9209],{"nctId":9210,"briefTitle":9211,"status":107,"phases":9212,"primaryCompletion":409,"completion":409,"start":390,"enrollment":9213,"conditions":9214,"interventions":9215},"NCT01644734","Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test",[93],1328,[18],[9197],{"trials":9217,"activeCount":101},[],{"intervention":9219,"totalTrials":272,"cells":9220},"Benzidamine hydrochloride",{"EARLY_PHASE1":9221,"PHASE1":9223,"PHASE2":9225,"PHASE3":9227,"PHASE4":9229,"NA":9239},{"trials":9222,"activeCount":101},[],{"trials":9224,"activeCount":101},[],{"trials":9226,"activeCount":101},[],{"trials":9228,"activeCount":101},[],{"trials":9230,"activeCount":101},[9231],{"nctId":9232,"briefTitle":9233,"status":107,"phases":9234,"primaryCompletion":9235,"start":7084,"enrollment":5680,"conditions":9236,"interventions":9237},"NCT02178293","Ketoprofen Lysine Salt as Mouthwash in Acute Phlogosis of the Pharyngeal Cavity Versus Benzidamine Hydrochloride",[93],"1999-05",[6587],[9219,9238],"Ketoprofen lysine salt",{"trials":9240,"activeCount":101},[],{"intervention":9238,"totalTrials":272,"cells":9242},{"EARLY_PHASE1":9243,"PHASE1":9245,"PHASE2":9247,"PHASE3":9249,"PHASE4":9251,"NA":9257},{"trials":9244,"activeCount":101},[],{"trials":9246,"activeCount":101},[],{"trials":9248,"activeCount":101},[],{"trials":9250,"activeCount":101},[],{"trials":9252,"activeCount":101},[9253],{"nctId":9232,"briefTitle":9233,"status":107,"phases":9254,"primaryCompletion":9235,"start":7084,"enrollment":5680,"conditions":9255,"interventions":9256},[93],[6587],[9219,9238],{"trials":9258,"activeCount":101},[],{"intervention":9260,"totalTrials":272,"cells":9261},"Test: Tiotropium 18 µg per day",{"EARLY_PHASE1":9262,"PHASE1":9264,"PHASE2":9266,"PHASE3":9268,"PHASE4":9270,"NA":9281},{"trials":9263,"activeCount":101},[],{"trials":9265,"activeCount":101},[],{"trials":9267,"activeCount":101},[],{"trials":9269,"activeCount":101},[],{"trials":9271,"activeCount":101},[9272],{"nctId":9273,"briefTitle":9274,"status":107,"phases":9275,"primaryCompletion":9276,"completion":9276,"start":2146,"enrollment":9277,"conditions":9278,"interventions":9279},"NCT00239421","A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)",[93],"2004-09",605,[18],[9260,9280],"Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.",{"trials":9282,"activeCount":101},[],{"intervention":9280,"totalTrials":272,"cells":9284},{"EARLY_PHASE1":9285,"PHASE1":9287,"PHASE2":9289,"PHASE3":9291,"PHASE4":9293,"NA":9299},{"trials":9286,"activeCount":101},[],{"trials":9288,"activeCount":101},[],{"trials":9290,"activeCount":101},[],{"trials":9292,"activeCount":101},[],{"trials":9294,"activeCount":101},[9295],{"nctId":9273,"briefTitle":9274,"status":107,"phases":9296,"primaryCompletion":9276,"completion":9276,"start":2146,"enrollment":9277,"conditions":9297,"interventions":9298},[93],[18],[9260,9280],{"trials":9300,"activeCount":101},[],{"intervention":9302,"totalTrials":272,"cells":9303},"Magnesium metamizol",{"EARLY_PHASE1":9304,"PHASE1":9306,"PHASE2":9308,"PHASE3":9310,"PHASE4":9312,"NA":9320},{"trials":9305,"activeCount":101},[],{"trials":9307,"activeCount":101},[],{"trials":9309,"activeCount":101},[],{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":101},[9314],{"nctId":9315,"briefTitle":9316,"status":107,"phases":9317,"primaryCompletion":6401,"start":5992,"enrollment":25,"conditions":9318,"interventions":9319},"NCT02184273","Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery",[93],[6596],[9302],{"trials":9321,"activeCount":101},[],{"intervention":528,"totalTrials":1237,"cells":9323},{"EARLY_PHASE1":9324,"PHASE1":9326,"PHASE2":9431,"PHASE3":9485,"PHASE4":9565,"NA":9567},{"trials":9325,"activeCount":101},[],{"trials":9327,"activeCount":101},[9328,9336,9344,9352,9358,9364,9371,9377,9384,9388,9392,9400,9407,9414,9421,9425],{"nctId":9329,"briefTitle":9330,"status":107,"phases":9331,"primaryCompletion":9332,"start":6133,"enrollment":401,"conditions":9333,"interventions":9334},"NCT01276301","DDI Between BI Empagliflozin (10773) and Verapamil",[90],"2011-02",[15],[9335,528,528],"Verapamil",{"nctId":9337,"briefTitle":9338,"status":107,"phases":9339,"primaryCompletion":9340,"start":9332,"enrollment":392,"conditions":9341,"interventions":9342},"NCT01304329","Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin",[90],"2011-04",[15],[528,9343,9343,528],"simvastatin",{"nctId":9345,"briefTitle":9346,"status":107,"phases":9347,"primaryCompletion":9348,"start":9332,"enrollment":392,"conditions":9349,"interventions":9350},"NCT01301742","Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers",[90],"2011-05",[15],[528,9351,528],"Gemfibrozil",{"nctId":9353,"briefTitle":9354,"status":107,"phases":9355,"primaryCompletion":4129,"start":4507,"enrollment":177,"conditions":9356,"interventions":9357},"NCT02172209","Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers",[90],[15],[528],{"nctId":9359,"briefTitle":9360,"status":107,"phases":9361,"primaryCompletion":2003,"start":2649,"enrollment":401,"conditions":9362,"interventions":9363},"NCT02172248","Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers",[90],[15],[528,413],{"nctId":9365,"briefTitle":9366,"status":107,"phases":9367,"primaryCompletion":3991,"start":5905,"enrollment":1672,"conditions":9368,"interventions":9369},"NCT02276365","Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers",[90],[15],[528,9370],"Pioglitazone",{"nctId":9372,"briefTitle":9373,"status":107,"phases":9374,"primaryCompletion":400,"start":3991,"enrollment":401,"conditions":9375,"interventions":9376},"NCT02172222","Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers",[90],[15],[528,361],{"nctId":9378,"briefTitle":9379,"status":107,"phases":9380,"primaryCompletion":9381,"completion":9381,"start":3991,"enrollment":2382,"conditions":9382,"interventions":9383},"NCT01907113","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment",[90],"2009-12",[21],[528,528,528,528,528],{"nctId":4438,"briefTitle":4439,"status":107,"phases":9385,"primaryCompletion":4441,"start":4442,"enrollment":357,"conditions":9386,"interventions":9387},[90],[15],[528,1538,4445,528],{"nctId":6212,"briefTitle":6213,"status":107,"phases":9389,"primaryCompletion":2030,"start":6133,"enrollment":97,"conditions":9390,"interventions":9391},[90],[21],[528,6217,6218,528,6218,528,6217],{"nctId":9393,"briefTitle":9394,"status":107,"phases":9395,"primaryCompletion":9396,"start":4441,"enrollment":380,"conditions":9397,"interventions":9398},"NCT01242176","Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers",[90],"2010-12",[15],[9399,528],"BI 10773 XX",{"nctId":9401,"briefTitle":9402,"status":107,"phases":9403,"primaryCompletion":5905,"start":9404,"enrollment":401,"conditions":9405,"interventions":9406},"NCT02172261","Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers",[90],"2009-04",[15],[528,6659],{"nctId":9408,"briefTitle":9409,"status":107,"phases":9410,"primaryCompletion":3991,"start":9411,"enrollment":401,"conditions":9412,"interventions":9413},"NCT02172196","Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers",[90],"2009-05",[15],[528,606],{"nctId":9415,"briefTitle":9416,"status":107,"phases":9417,"primaryCompletion":9418,"completion":9418,"start":8911,"enrollment":410,"conditions":9419,"interventions":9420},"NCT01924767","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets",[90],"2007-11",[21],[4445,528,4445,528,4445,4445,528,528],{"nctId":6129,"briefTitle":6130,"status":107,"phases":9422,"primaryCompletion":6132,"start":6133,"enrollment":97,"conditions":9423,"interventions":9424},[90],[15],[528,6106,528,6106,6106,6106],{"nctId":9426,"briefTitle":9427,"status":107,"phases":9428,"primaryCompletion":4441,"start":1967,"enrollment":448,"conditions":9429,"interventions":9430},"NCT01111318","Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function",[90],[2526,15],[528],{"trials":9432,"activeCount":101},[9433,9439,9446,9452,9460,9467,9471,9478],{"nctId":9434,"briefTitle":9435,"status":107,"phases":9436,"primaryCompletion":447,"completion":447,"start":2030,"enrollment":342,"conditions":9437,"interventions":9438},"NCT01392560","Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration",[91],[538],[528],{"nctId":9440,"briefTitle":9441,"status":107,"phases":9442,"primaryCompletion":9443,"start":9404,"enrollment":1218,"conditions":9444,"interventions":9445},"NCT00885118","4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)",[91],"2009-10",[21],[528,528,528,528],{"nctId":9447,"briefTitle":9448,"status":107,"phases":9449,"primaryCompletion":3762,"completion":3762,"start":4441,"enrollment":6607,"conditions":9450,"interventions":9451},"NCT01248364","A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects",[91],[21],[528],{"nctId":9453,"briefTitle":9454,"status":107,"phases":9455,"primaryCompletion":9443,"start":6223,"enrollment":9456,"conditions":9457,"interventions":9458},"NCT00749190","BI 10773 add-on to Metformin in Patients With Type 2 Diabetes",[91],495,[21],[528,9459],"sitagliptin",{"nctId":9461,"briefTitle":9462,"status":107,"phases":9463,"primaryCompletion":9443,"start":4412,"enrollment":9464,"conditions":9465,"interventions":9466},"NCT00789035","12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients",[91],408,[21],[528,384],{"nctId":522,"briefTitle":523,"status":107,"phases":9468,"primaryCompletion":437,"completion":437,"start":525,"enrollment":291,"conditions":9469,"interventions":9470},[91],[21,15],[73,528],{"nctId":9472,"briefTitle":9473,"status":107,"phases":9474,"primaryCompletion":9348,"start":2003,"enrollment":9475,"conditions":9476,"interventions":9477},"NCT00881530","Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension",[91],660,[21],[528,413,528,606],{"nctId":9479,"briefTitle":9480,"status":107,"phases":9481,"primaryCompletion":456,"completion":456,"start":7703,"enrollment":9482,"conditions":9483,"interventions":9484},"NCT01193218","Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus",[91],547,[21],[528,528,528,528],{"trials":9486,"activeCount":101},[9487,9495,9502,9511,9519,9527,9534,9542,9549,9556],{"nctId":9488,"briefTitle":9489,"status":107,"phases":9490,"primaryCompletion":9491,"completion":9491,"start":2030,"enrollment":9492,"conditions":9493,"interventions":9494},"NCT01370005","12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus",[92],"2012-07",825,[21,24],[528,528],{"nctId":9496,"briefTitle":9497,"status":107,"phases":9498,"primaryCompletion":379,"completion":379,"start":9332,"enrollment":9499,"conditions":9500,"interventions":9501},"NCT01306214","Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus",[92],566,[21,539],[528,528],{"nctId":9503,"briefTitle":9504,"status":107,"phases":9505,"primaryCompletion":4120,"completion":4120,"start":3730,"enrollment":9506,"conditions":9507,"interventions":9508},"NCT01778049","Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes",[92],708,[21],[528,4445,9509,528,9509,9510,528,528,528,9510,4445,9510,528,9510],"BI 10773 \u002F BI 1356","BI 10773 \u002F BI 1356 Placebo",{"nctId":9512,"briefTitle":9513,"status":107,"phases":9514,"primaryCompletion":9515,"completion":2002,"start":4442,"enrollment":9516,"conditions":9517,"interventions":9518},"NCT01167881","Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes",[92],"2013-08",1549,[21],[528,6659],{"nctId":9520,"briefTitle":9521,"status":107,"phases":9522,"primaryCompletion":408,"completion":408,"start":9332,"enrollment":9523,"conditions":9524,"interventions":9525},"NCT01289990","Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes",[92],2705,[21],[528,528,528,528,528,528,528,9526,528],"Sitagliptin 100mg",{"nctId":9528,"briefTitle":9529,"status":107,"phases":9530,"primaryCompletion":379,"completion":379,"start":9348,"enrollment":9531,"conditions":9532,"interventions":9533},"NCT01368081","Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus",[92],1162,[21],[413,528,528],{"nctId":9535,"briefTitle":9536,"status":107,"phases":9537,"primaryCompletion":9538,"start":1967,"enrollment":9539,"conditions":9540,"interventions":9541},"NCT01159600","Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes",[92],"2012-02",1504,[21],[528,528,528],{"nctId":9543,"briefTitle":9544,"status":107,"phases":9545,"primaryCompletion":4038,"start":7703,"enrollment":9546,"conditions":9547,"interventions":9548},"NCT01210001","Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin",[92],499,[21],[528,528],{"nctId":9550,"briefTitle":9551,"status":107,"phases":9552,"primaryCompletion":9491,"completion":9491,"start":1967,"enrollment":9553,"conditions":9554,"interventions":9555},"NCT01164501","Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment",[92],741,[21,2550],[528,528],{"nctId":9557,"briefTitle":9558,"status":107,"phases":9559,"primaryCompletion":3753,"start":1967,"enrollment":9560,"conditions":9561,"interventions":9562},"NCT01177813","Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes",[92],986,[21],[528,9563,9564,606],"BI 10773 open label","BI10773",{"trials":9566,"activeCount":101},[],{"trials":9568,"activeCount":101},[],{"intervention":1119,"totalTrials":97,"cells":9570},{"EARLY_PHASE1":9571,"PHASE1":9573,"PHASE2":9657,"PHASE3":9719,"PHASE4":9738,"NA":9740},{"trials":9572,"activeCount":101},[],{"trials":9574,"activeCount":101},[9575,9583,9589,9596,9602,9610,9617,9624,9628,9634,9640,9644,9653],{"nctId":9576,"briefTitle":9577,"status":107,"phases":9578,"primaryCompletion":9579,"completion":5324,"start":9580,"enrollment":401,"conditions":9581,"interventions":9582},"NCT01346540","A Phase I\u002FII Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine\u002FCisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.",[90],"2013-04-25","2011-04-14",[36],[1119],{"nctId":9584,"briefTitle":9585,"status":107,"phases":9586,"primaryCompletion":400,"start":7618,"enrollment":1991,"conditions":9587,"interventions":9588},"NCT00715403","A Phase I\u002FII Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120",[90],[33],[1119],{"nctId":9590,"briefTitle":9591,"status":107,"phases":9592,"primaryCompletion":9593,"completion":5233,"start":9443,"enrollment":2507,"conditions":9594,"interventions":9595},"NCT00998296","Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.",[90],"2012-12",[33],[1129,1119],{"nctId":9597,"briefTitle":9598,"status":107,"phases":9599,"primaryCompletion":3990,"start":7573,"enrollment":1865,"conditions":9600,"interventions":9601},"NCT00730821","Phase I of BIBW 2992\u002FBIBF 1120 Combination Therapy in Solid Tumors",[90],[33],[1129,1119],{"nctId":9603,"briefTitle":9604,"status":107,"phases":9605,"primaryCompletion":8086,"start":6082,"enrollment":9606,"conditions":9607,"interventions":9609},"NCT01951846","To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours",[90],61,[9608],"Malignant Solid Tumour",[1119],{"nctId":9611,"briefTitle":9612,"status":107,"phases":9613,"primaryCompletion":9614,"completion":9614,"start":9381,"enrollment":357,"conditions":9615,"interventions":9616},"NCT01022853","Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors",[90],"2013-02",[33],[2007,1119],{"nctId":9618,"briefTitle":9619,"status":107,"phases":9620,"primaryCompletion":1115,"start":6871,"enrollment":2235,"conditions":9621,"interventions":9623},"NCT02182206","An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours",[90],[9622],"Tumors",[1119],{"nctId":1977,"briefTitle":1978,"status":107,"phases":9625,"primaryCompletion":1980,"start":1981,"enrollment":1982,"conditions":9626,"interventions":9627},[90],[36],[1119,1011],{"nctId":9629,"briefTitle":9630,"status":107,"phases":9631,"primaryCompletion":5905,"start":2111,"enrollment":380,"conditions":9632,"interventions":9633},"NCT02182128","A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours",[90],[9622],[1119],{"nctId":9635,"briefTitle":9636,"status":107,"phases":9637,"primaryCompletion":5842,"start":5843,"enrollment":956,"conditions":9638,"interventions":9639},"NCT02182076","Pharmacokinetics\u002FBioavailability of BIBF 1120 Administered to Healthy Male Volunteers",[90],[15],[1119],{"nctId":1111,"briefTitle":1112,"status":107,"phases":9641,"primaryCompletion":1114,"start":1115,"enrollment":1116,"conditions":9642,"interventions":9643},[90],[36],[1119,1120,1010],{"nctId":9645,"briefTitle":9646,"status":107,"phases":9647,"primaryCompletion":9648,"start":9649,"enrollment":3454,"conditions":9650,"interventions":9652},"NCT02182219","Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer",[90],"2007-04-01","2005-11-01",[9651],"Prostatic Neoplasms",[1119],{"nctId":1133,"briefTitle":1134,"status":107,"phases":9654,"primaryCompletion":1136,"start":1137,"enrollment":210,"conditions":9655,"interventions":9656},[90],[1139],[1119,1120,1010],{"trials":9658,"activeCount":101},[9659,9667,9673,9684,9693,9703,9712],{"nctId":9660,"briefTitle":9661,"status":107,"phases":9662,"primaryCompletion":9663,"completion":9663,"start":9664,"enrollment":6392,"conditions":9665,"interventions":9666},"NCT01170065","Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)",[91],"2016-09-26","2010-06-25",[3428],[1119,1119,1119,1119],{"nctId":9668,"briefTitle":9669,"status":107,"phases":9670,"primaryCompletion":6132,"start":1980,"enrollment":2235,"conditions":9671,"interventions":9672},"NCT01136174","Safety and PK Study of BIBF 1120 in Japanese Patients With IPF",[91],[1397],[1119,1119,1119],{"nctId":9674,"briefTitle":9675,"status":107,"phases":9676,"primaryCompletion":9677,"completion":9678,"start":9679,"enrollment":2689,"conditions":9680,"interventions":9682},"NCT01024920","Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.",[91],"2011-11-08","2020-06-19","2009-12-16",[9681],"Carcinoma, Renal Cell",[1119,9683],"sunitinib",{"nctId":9685,"briefTitle":9686,"status":107,"phases":9687,"primaryCompletion":5233,"completion":9688,"start":9443,"enrollment":7015,"conditions":9689,"interventions":9691},"NCT00987935","A Phase I \u002F II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients",[91],"2016-01",[9690],"Carcinoma, Hepatocellular",[9692,1119],"Sorafenib",{"nctId":9694,"briefTitle":9695,"status":107,"phases":9696,"primaryCompletion":9697,"completion":9698,"start":9699,"enrollment":9700,"conditions":9701,"interventions":9702},"NCT01004003","Phase I\u002FII Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma",[91],"2014-07-14","2016-10-12","2009-10-22",125,[9690],[9692,1119],{"nctId":9704,"briefTitle":9705,"status":107,"phases":9706,"primaryCompletion":7338,"completion":7338,"start":9411,"enrollment":6585,"conditions":9707,"interventions":9708},"NCT00904839","BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer",[91],[3060],[1119,1119,9709,1131,9710,9711],"mFolfox","mFolfox 6","bevacizumab",{"nctId":9713,"briefTitle":9714,"status":107,"phases":9715,"primaryCompletion":2032,"start":4461,"enrollment":3970,"conditions":9716,"interventions":9717},"NCT00706628","A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer",[91],[9651],[1119,1129,9718],"Sequential BIBF 1120 + BIBW 2992",{"trials":9720,"activeCount":101},[9721,9728,9734],{"nctId":9722,"briefTitle":9723,"status":107,"phases":9724,"primaryCompletion":4474,"completion":4474,"start":9340,"enrollment":9725,"conditions":9726,"interventions":9727},"NCT01335464","Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients",[92],515,[3428],[1119],{"nctId":9729,"briefTitle":9730,"status":107,"phases":9731,"primaryCompletion":4474,"completion":4474,"start":9348,"enrollment":8912,"conditions":9732,"interventions":9733},"NCT01335477","Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II",[92],[3428],[1119],{"nctId":1179,"briefTitle":1180,"status":107,"phases":9735,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":9736,"interventions":9737},[92],[1187,1188],[1120,1119,1010,1120,1010],{"trials":9739,"activeCount":101},[],{"trials":9741,"activeCount":101},[],{"intervention":4042,"totalTrials":401,"cells":9743},{"EARLY_PHASE1":9744,"PHASE1":9746,"PHASE2":9792,"PHASE3":9811,"PHASE4":9867,"NA":9869},{"trials":9745,"activeCount":101},[],{"trials":9747,"activeCount":101},[9748,9755,9759,9766,9772,9778,9786],{"nctId":9749,"briefTitle":9750,"status":107,"phases":9751,"primaryCompletion":9752,"start":2030,"enrollment":177,"conditions":9753,"interventions":9754},"NCT01374802","Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers",[90],"2011-07",[27],[6505,4010,4042],{"nctId":4035,"briefTitle":4036,"status":107,"phases":9756,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":9757,"interventions":9758},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"nctId":9760,"briefTitle":9761,"status":107,"phases":9762,"primaryCompletion":456,"completion":456,"start":4038,"enrollment":132,"conditions":9763,"interventions":9765},"NCT01580306","Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment",[90],[9764],"Hepatitis C",[4042,4042],{"nctId":9767,"briefTitle":9768,"status":107,"phases":9769,"primaryCompletion":446,"completion":446,"start":447,"enrollment":1237,"conditions":9770,"interventions":9771},"NCT01637922","Drug Interaction Study With BI 201335 and Methadone or Buprenorphine\u002FNaloxone",[90],[9764],[4042,4042],{"nctId":9773,"briefTitle":9774,"status":107,"phases":9775,"primaryCompletion":4412,"completion":4412,"start":4413,"enrollment":1075,"conditions":9776,"interventions":9777},"NCT01909778","Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis",[90],[9764,2968],[4042],{"nctId":9779,"briefTitle":9780,"status":107,"phases":9781,"primaryCompletion":447,"completion":447,"start":4038,"enrollment":401,"conditions":9782,"interventions":9783},"NCT01570244","Drug-drug Interaction of BI 201335 and Microgynon",[90],[4040],[9784,9785,9784,4042,9785],"levonorgestrel","Ethinylestradiol",{"nctId":9787,"briefTitle":9788,"status":107,"phases":9789,"primaryCompletion":409,"completion":409,"start":3730,"enrollment":37,"conditions":9790,"interventions":9791},"NCT01764945","Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions",[90],[15],[4042,4042,4042,4042,4042,4042,4042,4042],{"trials":9793,"activeCount":101},[9794,9803],{"nctId":9795,"briefTitle":9796,"status":107,"phases":9797,"primaryCompletion":419,"completion":419,"start":1980,"enrollment":9798,"conditions":9799,"interventions":9800},"NCT01132313","Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +\u002F- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection",[91],488,[4040],[4047,4042,4047,4042,9801,9801,9801,4047,4047,4047,4042,9801,9801,4047,4047,4042,4042,9801,4042,4042,4047,4042,4042,4047,4042,9801,9801,9802,4042,4047,9801,4047,4042,9801,9801],"Ribavirin","BI 207217",{"nctId":9804,"briefTitle":9805,"status":107,"phases":9806,"primaryCompletion":9340,"start":400,"enrollment":9807,"conditions":9808,"interventions":9809},"NCT00984620","Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)",[91],160,[9764],[4042,4042,9810,9801],"Pegylated Interferon-alpha",{"trials":9812,"activeCount":101},[9813,9820,9829,9838,9845,9855,9861],{"nctId":9814,"briefTitle":9815,"status":107,"phases":9816,"primaryCompletion":603,"completion":603,"start":9593,"enrollment":9817,"conditions":9818,"interventions":9819},"NCT01732796","IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1",[92],470,[4040],[9801,4042,9801,4047,4042,9801,4047,4479,4047],{"nctId":9821,"briefTitle":9822,"status":107,"phases":9823,"primaryCompletion":9824,"completion":9824,"start":9340,"enrollment":9825,"conditions":9826,"interventions":9827},"NCT01343888","Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)",[92],"2014-03",656,[9764],[9828,4042,4042],"PegIFN\u002FRBV",{"nctId":9830,"briefTitle":9831,"status":600,"phases":9832,"primaryCompletion":9833,"completion":9833,"start":408,"enrollment":101,"conditions":9834,"interventions":9835},"NCT01858961","Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients",[92],"2016-07",[4040],[4042,4048,4047,9836,4048,9837],"Telaprevir","Pegylated Interferon",{"nctId":9839,"briefTitle":9840,"status":107,"phases":9841,"primaryCompletion":9614,"completion":9842,"start":2030,"enrollment":7196,"conditions":9843,"interventions":9844},"NCT01358864","Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)",[92],"2014-05",[4040],[4042,9810,9801],{"nctId":9846,"briefTitle":9847,"status":107,"phases":9848,"primaryCompletion":611,"completion":4391,"start":5296,"enrollment":9849,"conditions":9850,"interventions":9851},"NCT01399619","Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)",[92],310,[4040],[9828,9828,9852,9853,9828,9854],"BI201335","BI201335 24W","Bi 201335",{"nctId":9856,"briefTitle":9857,"status":107,"phases":9858,"primaryCompletion":4391,"completion":4391,"start":9752,"enrollment":3575,"conditions":9859,"interventions":9860},"NCT01330316","A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients",[92],[9764],[4042,9828],{"nctId":9862,"briefTitle":9863,"status":600,"phases":9864,"primaryCompletion":437,"start":2001,"enrollment":101,"conditions":9865,"interventions":9866},"NCT01608737","A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection",[92],[4040],[9828,4042,4042,9828,4042],{"trials":9868,"activeCount":101},[],{"trials":9870,"activeCount":101},[],{"intervention":9872,"totalTrials":177,"cells":9873},"BI 1356",{"EARLY_PHASE1":9874,"PHASE1":9876,"PHASE2":9937,"PHASE3":9939,"PHASE4":9980,"NA":9982},{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[9878,9886,9892,9898,9906,9912,9918,9924,9930],{"nctId":9879,"briefTitle":9880,"status":107,"phases":9881,"primaryCompletion":6224,"start":5906,"enrollment":1672,"conditions":9882,"interventions":9883},"NCT02183428","Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers",[90],[15],[9872,9884,9885],"Glyburide","BI 1356 + Glyburide",{"nctId":9887,"briefTitle":9888,"status":107,"phases":9889,"primaryCompletion":5856,"start":4413,"enrollment":1672,"conditions":9890,"interventions":9891},"NCT02183402","Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers",[90],[15],[2393,9872],{"nctId":9893,"briefTitle":9894,"status":107,"phases":9895,"primaryCompletion":4412,"start":5906,"enrollment":392,"conditions":9896,"interventions":9897},"NCT02183389","Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers",[90],[15],[4094,9872],{"nctId":9899,"briefTitle":9900,"status":107,"phases":9901,"primaryCompletion":6155,"start":9902,"enrollment":1672,"conditions":9903,"interventions":9904},"NCT02183337","Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers",[90],"2007-02",[15],[9872,9905,9370],"BI 1356 + Pioglitazone",{"nctId":9907,"briefTitle":9908,"status":107,"phases":9909,"primaryCompletion":2003,"start":6224,"enrollment":1116,"conditions":9910,"interventions":9911},"NCT02183376","Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects",[90],[2526],[9872],{"nctId":9913,"briefTitle":9914,"status":107,"phases":9915,"primaryCompletion":4412,"start":6224,"enrollment":392,"conditions":9916,"interventions":9917},"NCT02175394","Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects",[90],[15],[4283,9872],{"nctId":9919,"briefTitle":9920,"status":107,"phases":9921,"primaryCompletion":2032,"start":4412,"enrollment":132,"conditions":9922,"interventions":9923},"NCT02183493","Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects",[90],[15],[9872],{"nctId":9925,"briefTitle":9926,"status":107,"phases":9927,"primaryCompletion":4413,"start":6471,"enrollment":188,"conditions":9928,"interventions":9929},"NCT02183441","Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers",[90],[15],[9872,4010],{"nctId":9931,"briefTitle":9932,"status":107,"phases":9933,"primaryCompletion":5905,"start":9404,"enrollment":1672,"conditions":9934,"interventions":9935},"NCT02173639","Bioavailability of Combination Tablet BI 1356\u002FMetformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects",[90],[15],[9936,9872,413],"BI 1356\u002Fmetformin",{"trials":9938,"activeCount":101},[],{"trials":9940,"activeCount":101},[9941,9948,9955,9964,9970],{"nctId":9942,"briefTitle":9943,"status":107,"phases":9944,"primaryCompletion":6811,"start":2032,"enrollment":9945,"conditions":9946,"interventions":9947},"NCT00819091","Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",[92],245,[21],[9872],{"nctId":9949,"briefTitle":9950,"status":107,"phases":9951,"primaryCompletion":9396,"start":4129,"enrollment":9952,"conditions":9953,"interventions":9954},"NCT00622284","Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes",[92],1560,[21],[9872,6659],{"nctId":9956,"briefTitle":9957,"status":107,"phases":9958,"primaryCompletion":1980,"start":2032,"enrollment":9959,"conditions":9960,"interventions":9961},"NCT00798161","Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design",[92],857,[21],[9872,9962,9963,413,384],"BI 1356 + metformin","Bi 1356 + metformin",{"nctId":9965,"briefTitle":9966,"status":107,"phases":9967,"primaryCompletion":6133,"start":2032,"enrollment":1918,"conditions":9968,"interventions":9969},"NCT00800683","Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive",[92],[21],[9872],{"nctId":9971,"briefTitle":9972,"status":107,"phases":9973,"primaryCompletion":6811,"start":6471,"enrollment":9974,"conditions":9975,"interventions":9976},"NCT00654381","Japanese P III vs Voglibose and Placebo",[92],561,[21],[9872,9872,9977,9978,9979],"voglibose placebo","BI 1356 placebo","voglibose",{"trials":9981,"activeCount":101},[],{"trials":9983,"activeCount":101},[],{"intervention":4479,"totalTrials":1081,"cells":9985},{"EARLY_PHASE1":9986,"PHASE1":9988,"PHASE2":10042,"PHASE3":10052,"PHASE4":10058,"NA":10060},{"trials":9987,"activeCount":101},[],{"trials":9989,"activeCount":101},[9990,9997,10003,10010,10014,10020,10029,10035],{"nctId":9991,"briefTitle":9992,"status":162,"phases":9993,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":1564,"conditions":9994,"interventions":9995},"NCT01957657","Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients",[90],[2550],[4047,9996,4047,4047,4047,9996,9996,9996],"faldaprevir",{"nctId":9998,"briefTitle":9999,"status":107,"phases":10000,"primaryCompletion":408,"completion":408,"start":409,"enrollment":439,"conditions":10001,"interventions":10002},"NCT01821937","Pharmacokinetics of Faldaprevir of Soft Capsule",[90],[15],[9996,4479],{"nctId":10004,"briefTitle":10005,"status":107,"phases":10006,"primaryCompletion":409,"completion":409,"start":9614,"enrollment":439,"conditions":10007,"interventions":10008},"NCT01785160","Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir",[90],[15],[10009,10009,4479],"Raltegravir",{"nctId":4470,"briefTitle":4471,"status":107,"phases":10011,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":410,"conditions":10012,"interventions":10013},[90],[15],[4047,4477,4478,4479,1538],{"nctId":10015,"briefTitle":10016,"status":107,"phases":10017,"primaryCompletion":9593,"completion":9593,"start":2001,"enrollment":956,"conditions":10018,"interventions":10019},"NCT01694706","Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir",[90],[15],[9996,9996,928,9996],{"nctId":10021,"briefTitle":10022,"status":107,"phases":10023,"primaryCompletion":10024,"completion":10024,"start":516,"enrollment":132,"conditions":10025,"interventions":10026},"NCT02016625","Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus",[90],"2014-04",[15],[4479,4479,10027,10028],"Cyclosporine","Tacrolimus",{"nctId":10030,"briefTitle":10031,"status":162,"phases":10032,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":392,"conditions":10033,"interventions":10034},"NCT01941615","Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel",[90],[15],[9996,4283,4047],{"nctId":10036,"briefTitle":10037,"status":107,"phases":10038,"primaryCompletion":409,"completion":409,"start":9614,"enrollment":5205,"conditions":10039,"interventions":10040},"NCT01795937","Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin",[90],[15],[949,10041,4479,969,4479],"Atorvastatin",{"trials":10043,"activeCount":101},[10044],{"nctId":10045,"briefTitle":10046,"status":107,"phases":10047,"primaryCompletion":419,"completion":419,"start":379,"enrollment":1418,"conditions":10048,"interventions":10049},"NCT01830127","BI 207127 \u002F Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3",[91],[4040],[9801,10050,4479,9801,10051,4479],"BI 207127 high dose","BI 207127 low dose",{"trials":10053,"activeCount":101},[10054],{"nctId":9814,"briefTitle":9815,"status":107,"phases":10055,"primaryCompletion":603,"completion":603,"start":9593,"enrollment":9817,"conditions":10056,"interventions":10057},[92],[4040],[9801,4042,9801,4047,4042,9801,4047,4479,4047],{"trials":10059,"activeCount":101},[],{"trials":10061,"activeCount":101},[],{"intervention":9801,"totalTrials":1081,"cells":10063},{"EARLY_PHASE1":10064,"PHASE1":10066,"PHASE2":10081,"PHASE3":10114,"PHASE4":10128,"NA":10130},{"trials":10065,"activeCount":101},[],{"trials":10067,"activeCount":101},[10068,10072],{"nctId":4035,"briefTitle":4036,"status":107,"phases":10069,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":10070,"interventions":10071},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"nctId":10073,"briefTitle":10074,"status":107,"phases":10075,"primaryCompletion":10076,"start":10077,"enrollment":448,"conditions":10078,"interventions":10079},"NCT02259855","Pharmacokinetics (PK) of Tipranavir\u002FRitonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment",[90],"2008-10-01","2006-01-01",[2526],[4008,4010,10080,9801],"Pegylated interferon",{"trials":10082,"activeCount":101},[10083,10087,10094,10106,10110],{"nctId":9795,"briefTitle":9796,"status":107,"phases":10084,"primaryCompletion":419,"completion":419,"start":1980,"enrollment":9798,"conditions":10085,"interventions":10086},[91],[4040],[4047,4042,4047,4042,9801,9801,9801,4047,4047,4047,4042,9801,9801,4047,4047,4042,4042,9801,4042,4042,4047,4042,4042,4047,4042,9801,9801,9802,4042,4047,9801,4047,4042,9801,9801],{"nctId":10088,"briefTitle":10089,"status":107,"phases":10090,"primaryCompletion":9515,"completion":9515,"start":9538,"enrollment":439,"conditions":10091,"interventions":10092},"NCT01528735","This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C",[91],[4040],[3994,10093,9801,9801,3994,3995,3995,10093],"peginterferon",{"nctId":10095,"briefTitle":10096,"status":107,"phases":10097,"primaryCompletion":2648,"completion":2648,"start":3991,"enrollment":210,"conditions":10098,"interventions":10100},"NCT00947349","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients",[91],[9764,10099],"Pharmacokinetics",[4048,10101,10101,4048,10102,10101,4048,10103,10104,10105,10103],"pegylated interferon (PegIFN) alfa-2a","BI 201335 NA low placebo","BI 201335 NA high","BI 201335 NA low","BI 201335 NA high placebo",{"nctId":9804,"briefTitle":9805,"status":107,"phases":10107,"primaryCompletion":9340,"start":400,"enrollment":9807,"conditions":10108,"interventions":10109},[91],[9764],[4042,4042,9810,9801],{"nctId":10045,"briefTitle":10046,"status":107,"phases":10111,"primaryCompletion":419,"completion":419,"start":379,"enrollment":1418,"conditions":10112,"interventions":10113},[91],[4040],[9801,10050,4479,9801,10051,4479],{"trials":10115,"activeCount":101},[10116,10120,10124],{"nctId":9814,"briefTitle":9815,"status":107,"phases":10117,"primaryCompletion":603,"completion":603,"start":9593,"enrollment":9817,"conditions":10118,"interventions":10119},[92],[4040],[9801,4042,9801,4047,4042,9801,4047,4479,4047],{"nctId":9830,"briefTitle":9831,"status":600,"phases":10121,"primaryCompletion":9833,"completion":9833,"start":408,"enrollment":101,"conditions":10122,"interventions":10123},[92],[4040],[4042,4048,4047,9836,4048,9837],{"nctId":9839,"briefTitle":9840,"status":107,"phases":10125,"primaryCompletion":9614,"completion":9842,"start":2030,"enrollment":7196,"conditions":10126,"interventions":10127},[92],[4040],[4042,9810,9801],{"trials":10129,"activeCount":101},[],{"trials":10131,"activeCount":101},[],{"intervention":10133,"totalTrials":1340,"cells":10134},"Volasertib",{"EARLY_PHASE1":10135,"PHASE1":10137,"PHASE2":10200,"PHASE3":10212,"PHASE4":10223,"NA":10225},{"trials":10136,"activeCount":101},[],{"trials":10138,"activeCount":101},[10139,10149,10160,10166,10177,10185,10194],{"nctId":10140,"briefTitle":10141,"status":600,"phases":10142,"primaryCompletion":10143,"completion":10144,"start":10145,"enrollment":101,"conditions":10146,"interventions":10148},"NCT02722135","A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed",[90],"2018-05","2018-09","2016-11",[10147],"Leukemia, Myeloid, Acute",[10133],{"nctId":10150,"briefTitle":10151,"status":162,"phases":10152,"primaryCompletion":10153,"completion":10153,"start":10154,"enrollment":401,"conditions":10155,"interventions":10158},"NCT01957644","Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML",[90],"2016-12-16","2013-11-06",[10156,10157],"Myelodysplastic Syndromes","Leukemia, Myelomonocytic, Chronic",[10159,10133],"Azacitidine",{"nctId":10161,"briefTitle":10162,"status":107,"phases":10163,"primaryCompletion":4119,"completion":4119,"start":447,"enrollment":2442,"conditions":10164,"interventions":10165},"NCT01662505","Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)",[90],[10147],[10133],{"nctId":10167,"briefTitle":10168,"status":107,"phases":10169,"primaryCompletion":10170,"completion":10171,"start":10172,"enrollment":210,"conditions":10173,"interventions":10175},"NCT01971476","Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known",[90],"2015-06-01","2017-01-27","2013-10-22",[10174,33],"Leukemia",[10176],"volasertib",{"nctId":10178,"briefTitle":10179,"status":162,"phases":10180,"primaryCompletion":10181,"completion":482,"start":10182,"enrollment":272,"conditions":10183,"interventions":10184},"NCT02721875","Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes",[90],"2016-06-29","2016-04-28",[10156],[10133,10133,10159],{"nctId":10186,"briefTitle":10187,"status":107,"phases":10188,"primaryCompletion":10189,"completion":10190,"start":10191,"enrollment":1865,"conditions":10192,"interventions":10193},"NCT01772563","Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours",[90],"2014-05-30","2021-04-22","2013-02-04",[33],[10176,2560],{"nctId":10195,"briefTitle":10196,"status":107,"phases":10197,"primaryCompletion":603,"completion":438,"start":3731,"enrollment":166,"conditions":10198,"interventions":10199},"NCT02201329","Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",[90],[10156,10157],[10159,10133],{"trials":10201,"activeCount":101},[10202],{"nctId":10203,"briefTitle":10204,"status":107,"phases":10205,"primaryCompletion":10206,"completion":10207,"start":10208,"enrollment":5466,"conditions":10209,"interventions":10210},"NCT00804856","Phase I\u002FIIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia",[91],"2012-03-09","2021-04-23","2008-11-27",[10147],[10133,10211],"Cytarabine",{"trials":10213,"activeCount":101},[10214],{"nctId":10215,"briefTitle":10216,"status":107,"phases":10217,"primaryCompletion":10218,"completion":687,"start":10219,"enrollment":10220,"conditions":10221,"interventions":10222},"NCT01721876","Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)",[92],"2014-08-12","2013-01-29",666,[10147],[10133,10211],{"trials":10224,"activeCount":101},[],{"trials":10226,"activeCount":101},[],{"intervention":4047,"totalTrials":1340,"cells":10228},{"EARLY_PHASE1":10229,"PHASE1":10231,"PHASE2":10264,"PHASE3":10270,"PHASE4":10280,"NA":10282},{"trials":10230,"activeCount":101},[],{"trials":10232,"activeCount":101},[10233,10237,10241,10247,10251,10260],{"nctId":9991,"briefTitle":9992,"status":162,"phases":10234,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":1564,"conditions":10235,"interventions":10236},[90],[2550],[4047,9996,4047,4047,4047,9996,9996,9996],{"nctId":4035,"briefTitle":4036,"status":107,"phases":10238,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":10239,"interventions":10240},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"nctId":10242,"briefTitle":10243,"status":107,"phases":10244,"primaryCompletion":3753,"start":9538,"enrollment":392,"conditions":10245,"interventions":10246},"NCT01535638","Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers",[90],[15],[4047,4047,4047],{"nctId":4470,"briefTitle":4471,"status":107,"phases":10248,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":410,"conditions":10249,"interventions":10250},[90],[15],[4047,4477,4478,4479,1538],{"nctId":10252,"briefTitle":10253,"status":162,"phases":10254,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":401,"conditions":10255,"interventions":10256},"NCT01983566","Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects",[90],[15],[10257,10258,4047,10259],"BI 207127 high fat","BI 207127 with Omeprazole","BI 207127 low fat",{"nctId":10030,"briefTitle":10031,"status":162,"phases":10261,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":392,"conditions":10262,"interventions":10263},[90],[15],[9996,4283,4047],{"trials":10265,"activeCount":101},[10266],{"nctId":9795,"briefTitle":9796,"status":107,"phases":10267,"primaryCompletion":419,"completion":419,"start":1980,"enrollment":9798,"conditions":10268,"interventions":10269},[91],[4040],[4047,4042,4047,4042,9801,9801,9801,4047,4047,4047,4042,9801,9801,4047,4047,4042,4042,9801,4042,4042,4047,4042,4042,4047,4042,9801,9801,9802,4042,4047,9801,4047,4042,9801,9801],{"trials":10271,"activeCount":101},[10272,10276],{"nctId":9814,"briefTitle":9815,"status":107,"phases":10273,"primaryCompletion":603,"completion":603,"start":9593,"enrollment":9817,"conditions":10274,"interventions":10275},[92],[4040],[9801,4042,9801,4047,4042,9801,4047,4479,4047],{"nctId":9830,"briefTitle":9831,"status":600,"phases":10277,"primaryCompletion":9833,"completion":9833,"start":408,"enrollment":101,"conditions":10278,"interventions":10279},[92],[4040],[4042,4048,4047,9836,4048,9837],{"trials":10281,"activeCount":101},[],{"trials":10283,"activeCount":101},[],{"intervention":10285,"totalTrials":155,"cells":10286},"Enoxaparin",{"EARLY_PHASE1":10287,"PHASE1":10289,"PHASE2":10291,"PHASE3":10302,"PHASE4":10363,"NA":10365},{"trials":10288,"activeCount":101},[],{"trials":10290,"activeCount":101},[],{"trials":10292,"activeCount":101},[10293],{"nctId":10294,"briefTitle":10295,"status":107,"phases":10296,"primaryCompletion":6472,"start":6082,"enrollment":10297,"conditions":10298,"interventions":10300},"NCT01225822","BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery",[91],1973,[10299],"Venous Thromboembolism",[10285,10301,10301,10301,10301],"BIBR 1048",{"trials":10303,"activeCount":101},[10304,10315,10319,10326,10335,10344,10352],{"nctId":10305,"briefTitle":10306,"status":107,"phases":10307,"primaryCompletion":6005,"start":2122,"enrollment":10308,"conditions":10309,"interventions":10310},"NCT02181985","Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)",[92],5989,[632],[10311,10312,10313,10285,10314],"Full dose TNK-tPA","Half dose TNK-tPA","Heparin","Abciximab",{"nctId":2097,"briefTitle":2098,"status":107,"phases":10316,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":2102,"conditions":10317,"interventions":10318},[92],[632],[2105,2094,2106],{"nctId":10320,"briefTitle":10321,"status":107,"phases":10322,"primaryCompletion":400,"start":4128,"enrollment":10323,"conditions":10324,"interventions":10325},"NCT00657150","Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty",[92],2055,[10299],[10285,6561],{"nctId":10327,"briefTitle":10328,"status":107,"phases":10329,"primaryCompletion":2145,"start":8086,"enrollment":10330,"conditions":10331,"interventions":10334},"NCT00168818","Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery",[92],3494,[10332,10333],"Thromboembolism","Arthroplasty, Replacement, Hip",[1685,1685,2105],{"nctId":10336,"briefTitle":10337,"status":107,"phases":10338,"primaryCompletion":6494,"start":2162,"enrollment":10339,"conditions":10340,"interventions":10341},"NCT02181998","A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting",[92],1606,[632],[10342,10343,10285],"Full dose tenecteplase","Unfractioned heparin",{"nctId":10345,"briefTitle":10346,"status":107,"phases":10347,"primaryCompletion":4498,"start":8086,"enrollment":10348,"conditions":10349,"interventions":10351},"NCT00168805","RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery",[92],2101,[10350,10332],"Arthroplasty, Replacement, Knee",[2105,1685,1685],{"nctId":10353,"briefTitle":10354,"status":107,"phases":10355,"primaryCompletion":2111,"start":8086,"enrollment":10356,"conditions":10357,"interventions":10358},"NCT00152971","Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement",[92],2615,[10350,10332],[10359,10360,10361,10362,10285],"Dabigatran Dose 1 - day 2 to completion","Dabigatran Dose 1 - day 1","Dabigatran Dose 2 - day 2 to completion","Dabigatran Dose 2 - day 1",{"trials":10364,"activeCount":101},[],{"trials":10366,"activeCount":101},[],{"intervention":10368,"totalTrials":155,"cells":10369},"Ibuprofen",{"EARLY_PHASE1":10370,"PHASE1":10372,"PHASE2":10411,"PHASE3":10425,"PHASE4":10449,"NA":10451},{"trials":10371,"activeCount":101},[],{"trials":10373,"activeCount":101},[10374,10381,10387,10394,10402],{"nctId":10375,"briefTitle":10376,"status":107,"phases":10377,"primaryCompletion":3762,"completion":3762,"start":525,"enrollment":448,"conditions":10378,"interventions":10379},"NCT01879371","Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate",[90],[15],[10380,10368,10368],"Ibuprofen+caffeine FDC",{"nctId":10382,"briefTitle":10383,"status":107,"phases":10384,"primaryCompletion":9688,"completion":9688,"start":5275,"enrollment":448,"conditions":10385,"interventions":10386},"NCT02629354","To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet",[90],[15],[10368,1241,10368],{"nctId":10388,"briefTitle":10389,"status":107,"phases":10390,"primaryCompletion":7703,"start":1967,"enrollment":4433,"conditions":10391,"interventions":10392},"NCT01170637","Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.",[90],[15],[10368,10368,10393,10393],"Pseudoephedrine-HCl",{"nctId":10395,"briefTitle":10396,"status":107,"phases":10397,"primaryCompletion":6189,"start":6494,"enrollment":448,"conditions":10398,"interventions":10399},"NCT02183012","Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers",[90],[15],[10400,10401,10368],"Ibuprofen extrudate","Ibuprofen lysinate",{"nctId":10403,"briefTitle":10404,"status":107,"phases":10405,"primaryCompletion":3387,"completion":10406,"start":10407,"enrollment":37,"conditions":10408,"interventions":10410},"NCT02963701","Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects",[90],"2017-02-08","2016-12-20",[10409],"Healthy Volunteers",[10368,10393],{"trials":10412,"activeCount":101},[10413],{"nctId":10414,"briefTitle":10415,"status":107,"phases":10416,"primaryCompletion":9235,"start":7924,"enrollment":10417,"conditions":10418,"interventions":10419},"NCT02187588","Study to Assess the Kinetic of the Analgesic Effect and Tolerability of Eschscholtzia Californica Versus Ibuprofen and Placebo in the Treatment of Pain After Surgery of the Third Molar",[91],200,[6596],[10420,10421,10368,10422,10423,10424],"Eschscholtzia Californica - low dose","Eschscholtzia Californica - high dose","Eschscholtzia Californica - low dose Placebo","Eschscholtzia Californica - high dose Placebo","Ibuprofen Placebo",{"trials":10426,"activeCount":101},[10427,10439],{"nctId":10428,"briefTitle":10429,"status":107,"phases":10430,"primaryCompletion":10431,"completion":10432,"start":10407,"enrollment":10433,"conditions":10434,"interventions":10437},"NCT03003000","Ibuprofen\u002FCaffeine Lower Back or Neck Pain Study",[92],"2017-09-24","2017-09-28",635,[10435,10436],"Back Pain","Neck Pain",[10438,4044],"ibuprofen",{"nctId":10440,"briefTitle":10441,"status":107,"phases":10442,"primaryCompletion":9824,"completion":9824,"start":9515,"enrollment":10443,"conditions":10444,"interventions":10447},"NCT01929031","Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain",[92],562,[10445,10446],"Pain, Postoperative","Tooth Diseases",[10448,10438,10438,4044,10448,4044,10438,10448],"ibuprofen + caffeine",{"trials":10450,"activeCount":101},[],{"trials":10452,"activeCount":101},[],{"intervention":6659,"totalTrials":155,"cells":10454},{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10469,"PHASE3":10477,"PHASE4":10502,"NA":10504},{"trials":10456,"activeCount":101},[],{"trials":10458,"activeCount":101},[10459,10463],{"nctId":9401,"briefTitle":9402,"status":107,"phases":10460,"primaryCompletion":5905,"start":9404,"enrollment":401,"conditions":10461,"interventions":10462},[90],[15],[528,6659],{"nctId":10464,"briefTitle":10465,"status":107,"phases":10466,"primaryCompletion":4473,"completion":4473,"start":517,"enrollment":331,"conditions":10467,"interventions":10468},"NCT01703286","Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)",[90],[21],[361,6659],{"trials":10470,"activeCount":101},[10471],{"nctId":10472,"briefTitle":10473,"status":107,"phases":10474,"primaryCompletion":3763,"start":6156,"enrollment":7429,"conditions":10475,"interventions":10476},"NCT00309608","Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes",[91],[21],[361,361,361,6659],{"trials":10478,"activeCount":101},[10479,10486,10490,10494,10498],{"nctId":10480,"briefTitle":10481,"status":107,"phases":10482,"primaryCompletion":2506,"start":3732,"enrollment":10483,"conditions":10484,"interventions":10485},"NCT01087502","Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment",[92],241,[21],[6659,361],{"nctId":9949,"briefTitle":9950,"status":107,"phases":10487,"primaryCompletion":9396,"start":4129,"enrollment":9952,"conditions":10488,"interventions":10489},[92],[21],[9872,6659],{"nctId":6625,"briefTitle":6626,"status":107,"phases":10491,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":6630,"conditions":10492,"interventions":10493},[92],[21],[6633,6634,6614,6635],{"nctId":6652,"briefTitle":6653,"status":107,"phases":10495,"primaryCompletion":4442,"start":6223,"enrollment":6655,"conditions":10496,"interventions":10497},[92],[21],[361,6658,6659],{"nctId":9512,"briefTitle":9513,"status":107,"phases":10499,"primaryCompletion":9515,"completion":2002,"start":4442,"enrollment":9516,"conditions":10500,"interventions":10501},[92],[21],[528,6659],{"trials":10503,"activeCount":101},[],{"trials":10505,"activeCount":101},[],{"intervention":4454,"totalTrials":155,"cells":10507},{"EARLY_PHASE1":10508,"PHASE1":10510,"PHASE2":10536,"PHASE3":10538,"PHASE4":10579,"NA":10581},{"trials":10509,"activeCount":101},[],{"trials":10511,"activeCount":101},[10512,10520,10528,10532],{"nctId":10513,"briefTitle":10514,"status":107,"phases":10515,"primaryCompletion":10516,"completion":10516,"start":10517,"enrollment":2442,"conditions":10518,"interventions":10519},"NCT05613777","A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood",[90],"2023-10-04","2022-11-24",[15],[4283,4454],{"nctId":10521,"briefTitle":10522,"status":107,"phases":10523,"primaryCompletion":10524,"completion":10524,"start":10525,"enrollment":993,"conditions":10526,"interventions":10527},"NCT05731895","A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems",[90],"2023-12-11","2023-03-08",[2526],[4454],{"nctId":4447,"briefTitle":4448,"status":107,"phases":10529,"primaryCompletion":4450,"completion":4450,"start":4451,"enrollment":37,"conditions":10530,"interventions":10531},[90],[15],[4454,4455,1538,4456],{"nctId":4152,"briefTitle":4153,"status":107,"phases":10533,"primaryCompletion":164,"completion":164,"start":4155,"enrollment":956,"conditions":10534,"interventions":10535},[90],[15],[927,4158],{"trials":10537,"activeCount":101},[],{"trials":10539,"activeCount":101},[10540,10551,10561,10569],{"nctId":10541,"briefTitle":10542,"status":162,"phases":10543,"primaryCompletion":10544,"completion":10545,"start":10546,"enrollment":10547,"conditions":10548,"interventions":10550},"NCT05211947","A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study",[92],"2025-02-26","2025-03-18","2022-03-21",1356,[10549],"Schizophrenia",[4454],{"nctId":10552,"briefTitle":10553,"status":107,"phases":10554,"primaryCompletion":10555,"completion":10556,"start":10557,"enrollment":10558,"conditions":10559,"interventions":10560},"NCT04860830","CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia",[92],"2024-10-28","2024-11-20","2021-08-09",609,[10549],[4454],{"nctId":10562,"briefTitle":10563,"status":107,"phases":10564,"primaryCompletion":1293,"completion":1236,"start":10565,"enrollment":10566,"conditions":10567,"interventions":10568},"NCT04846868","Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)",[92],"2021-09-08",620,[10549],[4454],{"nctId":10570,"briefTitle":10571,"status":107,"phases":10572,"primaryCompletion":10573,"completion":10574,"start":10575,"enrollment":10576,"conditions":10577,"interventions":10578},"NCT04846881","Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)",[92],"2024-10-18","2024-11-17","2021-08-24",611,[10549],[4454],{"trials":10580,"activeCount":101},[],{"trials":10582,"activeCount":101},[],{"intervention":1120,"totalTrials":112,"cells":10584},{"EARLY_PHASE1":10585,"PHASE1":10587,"PHASE2":10613,"PHASE3":10627,"PHASE4":10633,"NA":10635},{"trials":10586,"activeCount":101},[],{"trials":10588,"activeCount":101},[10589,10601,10605,10609],{"nctId":10590,"briefTitle":10591,"status":107,"phases":10592,"primaryCompletion":10593,"completion":10594,"start":10595,"enrollment":319,"conditions":10596,"interventions":10597},"NCT01938846","BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and\u002For Metastatic Solid Tumors",[90],"2016-07-30","2017-06-22","2013-09-05",[33],[10598,10599,10598,10598,10600],"BI 860585","exemestane","paclitaxel",{"nctId":1111,"briefTitle":1112,"status":107,"phases":10602,"primaryCompletion":1114,"start":1115,"enrollment":1116,"conditions":10603,"interventions":10604},[90],[36],[1119,1120,1010],{"nctId":1122,"briefTitle":1123,"status":107,"phases":10606,"primaryCompletion":1125,"completion":1125,"start":1114,"enrollment":1126,"conditions":10607,"interventions":10608},[90],[33],[1120,1010,1129,1120,1130,1120,1010,1131,1129,1129],{"nctId":1133,"briefTitle":1134,"status":107,"phases":10610,"primaryCompletion":1136,"start":1137,"enrollment":210,"conditions":10611,"interventions":10612},[90],[1139],[1119,1120,1010],{"trials":10614,"activeCount":101},[10615,10623],{"nctId":10616,"briefTitle":10617,"status":107,"phases":10618,"primaryCompletion":10619,"completion":10619,"start":10620,"enrollment":392,"conditions":10621,"interventions":10622},"NCT02597946","Afatinib in NSCLC With HER2 Mutation",[91],"2018-07-22","2016-03-18",[36],[2633,10600],{"nctId":4388,"briefTitle":4389,"status":107,"phases":10624,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":4219,"conditions":10625,"interventions":10626},[91],[1187],[1120,2730,3662,4395,2007],{"trials":10628,"activeCount":101},[10629],{"nctId":1179,"briefTitle":1180,"status":107,"phases":10630,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":10631,"interventions":10632},[92],[1187,1188],[1120,1119,1010,1120,1010],{"trials":10634,"activeCount":101},[],{"trials":10636,"activeCount":101},[],{"intervention":10638,"totalTrials":1512,"cells":10639},"BI 695501",{"EARLY_PHASE1":10640,"PHASE1":10642,"PHASE2":10654,"PHASE3":10656,"PHASE4":10707,"NA":10709},{"trials":10641,"activeCount":101},[],{"trials":10643,"activeCount":101},[10644],{"nctId":10645,"briefTitle":10646,"status":107,"phases":10647,"primaryCompletion":10648,"completion":10648,"start":10649,"enrollment":7301,"conditions":10650,"interventions":10651},"NCT02045979","Pharmacokinetics and Safety in Healthy Volunteers",[90],"2014-06-20","2014-01-31",[15],[10638,10652,10653],"adalimumab-EU source","adalimumab-US source",{"trials":10655,"activeCount":101},[],{"trials":10657,"activeCount":101},[10658,10670,10678,10688,10697],{"nctId":10659,"briefTitle":10660,"status":107,"phases":10661,"primaryCompletion":10662,"completion":10663,"start":10664,"enrollment":10665,"conditions":10666,"interventions":10668},"NCT02137226","BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis",[92],"2016-03-03","2016-10-18","2015-01-26",645,[10667],"Arthritis, Rheumatoid",[10638,10669],"US-licensed Humira®",{"nctId":10671,"briefTitle":10672,"status":107,"phases":10673,"primaryCompletion":10674,"completion":10674,"start":10675,"enrollment":1020,"conditions":10676,"interventions":10677},"NCT02640612","Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis",[92],"2017-11-01","2016-01-22",[10667],[10638],{"nctId":10679,"briefTitle":10680,"status":107,"phases":10681,"primaryCompletion":10682,"completion":10683,"start":10684,"enrollment":2586,"conditions":10685,"interventions":10686},"NCT02871635","BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity",[92],"2019-04-30","2019-05-13","2016-09-28",[190],[10638,10687],"HUMIRA",{"nctId":10689,"briefTitle":10690,"status":107,"phases":10691,"primaryCompletion":5369,"completion":5369,"start":10692,"enrollment":10693,"conditions":10694,"interventions":10695},"NCT03210259","The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis",[92],"2017-07-10",259,[114],[10696,10638],"Humira®",{"nctId":10698,"briefTitle":10699,"status":107,"phases":10700,"primaryCompletion":10701,"completion":10701,"start":10702,"enrollment":10703,"conditions":10704,"interventions":10705},"NCT02850965","Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis",[92],"2018-01-17","2016-08-17",318,[114],[10638,10706],"Humira",{"trials":10708,"activeCount":101},[],{"trials":10710,"activeCount":101},[],{"intervention":9828,"totalTrials":1512,"cells":10712},{"EARLY_PHASE1":10713,"PHASE1":10715,"PHASE2":10717,"PHASE3":10730,"PHASE4":10755,"NA":10757},{"trials":10714,"activeCount":101},[],{"trials":10716,"activeCount":101},[],{"trials":10718,"activeCount":101},[10719],{"nctId":10720,"briefTitle":10721,"status":107,"phases":10722,"primaryCompletion":390,"start":4412,"enrollment":10723,"conditions":10724,"interventions":10725},"NCT00774397","Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN\u002FRBV in HCV-GT1 (SILEN-C1&2)",[91],719,[4040],[10726,9828,10727,9828,10728,9828,10728,9828,10729,9828,9828,10728,9828],"BI 201335 NA 240 mg QD \u002F LI","BI 201335 NA 120mg QD \u002F LI","BI 201335 NA 240 mg QD","BI 201335 NA 240 mg BID",{"trials":10731,"activeCount":101},[10732,10736,10743,10747,10751],{"nctId":9821,"briefTitle":9822,"status":107,"phases":10733,"primaryCompletion":9824,"completion":9824,"start":9340,"enrollment":9825,"conditions":10734,"interventions":10735},[92],[9764],[9828,4042,4042],{"nctId":10737,"briefTitle":10738,"status":107,"phases":10739,"primaryCompletion":10024,"completion":10024,"start":9340,"enrollment":10740,"conditions":10741,"interventions":10742},"NCT01297270","Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)",[92],658,[9764],[9852,9828,9852],{"nctId":9846,"briefTitle":9847,"status":107,"phases":10744,"primaryCompletion":611,"completion":4391,"start":5296,"enrollment":9849,"conditions":10745,"interventions":10746},[92],[4040],[9828,9828,9852,9853,9828,9854],{"nctId":9856,"briefTitle":9857,"status":107,"phases":10748,"primaryCompletion":4391,"completion":4391,"start":9752,"enrollment":3575,"conditions":10749,"interventions":10750},[92],[9764],[4042,9828],{"nctId":9862,"briefTitle":9863,"status":600,"phases":10752,"primaryCompletion":437,"start":2001,"enrollment":101,"conditions":10753,"interventions":10754},[92],[4040],[9828,4042,4042,9828,4042],{"trials":10756,"activeCount":101},[],{"trials":10758,"activeCount":101},[],{"intervention":606,"totalTrials":1512,"cells":10760},{"EARLY_PHASE1":10761,"PHASE1":10763,"PHASE2":10769,"PHASE3":10787,"PHASE4":10797,"NA":10799},{"trials":10762,"activeCount":101},[],{"trials":10764,"activeCount":101},[10765],{"nctId":9408,"briefTitle":9409,"status":107,"phases":10766,"primaryCompletion":3991,"start":9411,"enrollment":401,"conditions":10767,"interventions":10768},[90],[15],[528,606],{"trials":10770,"activeCount":101},[10771,10779,10783],{"nctId":10772,"briefTitle":10773,"status":107,"phases":10774,"primaryCompletion":10775,"start":6224,"enrollment":10776,"conditions":10777,"interventions":10778},"NCT00716092","The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients",[91],"2008-11",121,[21],[606,361],{"nctId":9453,"briefTitle":9454,"status":107,"phases":10780,"primaryCompletion":9443,"start":6223,"enrollment":9456,"conditions":10781,"interventions":10782},[91],[21],[528,9459],{"nctId":9472,"briefTitle":9473,"status":107,"phases":10784,"primaryCompletion":9348,"start":2003,"enrollment":9475,"conditions":10785,"interventions":10786},[91],[21],[528,413,528,606],{"trials":10788,"activeCount":101},[10789,10793],{"nctId":598,"briefTitle":599,"status":600,"phases":10790,"primaryCompletion":602,"completion":602,"start":603,"enrollment":101,"conditions":10791,"interventions":10792},[92],[21],[73,606],{"nctId":9557,"briefTitle":9558,"status":107,"phases":10794,"primaryCompletion":3753,"start":1967,"enrollment":9560,"conditions":10795,"interventions":10796},[92],[21],[528,9563,9564,606],{"trials":10798,"activeCount":101},[],{"trials":10800,"activeCount":101},[],{"intervention":10802,"totalTrials":166,"cells":10803},"Tiotropium inhalation powder",{"EARLY_PHASE1":10804,"PHASE1":10806,"PHASE2":10808,"PHASE3":10810,"PHASE4":10849,"NA":10851},{"trials":10805,"activeCount":101},[],{"trials":10807,"activeCount":101},[],{"trials":10809,"activeCount":101},[],{"trials":10811,"activeCount":101},[10812,10820,10828,10835,10843],{"nctId":10813,"briefTitle":10814,"status":107,"phases":10815,"completion":6401,"start":6871,"enrollment":10417,"conditions":10816,"interventions":10817},"NCT00239434","A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[10818,10819],"tiotropium inhalation powder","ipratropium bromide Metered Dose Inhaler",{"nctId":10821,"briefTitle":10822,"status":107,"phases":10823,"primaryCompletion":6029,"start":6701,"enrollment":10824,"conditions":10825,"interventions":10826},"NCT02172469","Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[92],215,[18],[10802,10827],"Ipratropium Bromide Metered Dose Inhaler",{"nctId":10829,"briefTitle":10830,"status":107,"phases":10831,"primaryCompletion":5887,"start":2121,"enrollment":2235,"conditions":10832,"interventions":10833},"NCT02172443","Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease",[92],[18],[10818,10834],"Atrovent",{"nctId":10836,"briefTitle":10837,"status":107,"phases":10838,"primaryCompletion":2122,"start":5923,"enrollment":10839,"conditions":10840,"interventions":10841},"NCT02173691","Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)",[92],584,[18],[10802,10842],"Salmeterol inhalation aerosol",{"nctId":10844,"briefTitle":10845,"status":107,"phases":10846,"primaryCompletion":6584,"start":6390,"enrollment":4463,"conditions":10847,"interventions":10848},"NCT02172391","Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[10802],{"trials":10850,"activeCount":101},[],{"trials":10852,"activeCount":101},[],{"intervention":10854,"totalTrials":1564,"cells":10855},"Lamivudine",{"EARLY_PHASE1":10856,"PHASE1":10858,"PHASE2":10860,"PHASE3":10876,"PHASE4":10891,"NA":10893},{"trials":10857,"activeCount":101},[],{"trials":10859,"activeCount":101},[],{"trials":10861,"activeCount":101},[10862,10870],{"nctId":10863,"briefTitle":10864,"status":107,"phases":10865,"primaryCompletion":2163,"start":6453,"enrollment":392,"conditions":10866,"interventions":10867},"NCT02249130","Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir",[91],[27],[4008,4010,10868,7579,10854,10869],"Delavirdine","Stavudine",{"nctId":10871,"briefTitle":10872,"status":107,"phases":10873,"primaryCompletion":6413,"completion":6413,"start":5993,"enrollment":260,"conditions":10874,"interventions":10875},"NCT00273975","Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients",[91],[27],[2186,10854,7579],{"trials":10877,"activeCount":101},[10878,10885],{"nctId":10879,"briefTitle":10880,"status":107,"phases":10881,"primaryCompletion":7003,"start":2182,"enrollment":10882,"conditions":10883,"interventions":10884},"NCT02181933","Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women",[92],2648,[27],[2186,7579,10854],{"nctId":10886,"briefTitle":10887,"status":107,"phases":10888,"enrollment":5690,"conditions":10889,"interventions":10890},"NCT00002368","The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs",[92],[27],[2186,10854],{"trials":10892,"activeCount":101},[],{"trials":10894,"activeCount":101},[],{"intervention":10896,"totalTrials":1564,"cells":10897},"Telmisartan\u002FAmlodipine",{"EARLY_PHASE1":10898,"PHASE1":10900,"PHASE2":10923,"PHASE3":10925,"PHASE4":10935,"NA":10937},{"trials":10899,"activeCount":101},[],{"trials":10901,"activeCount":101},[10902,10909,10915],{"nctId":10903,"briefTitle":10904,"status":107,"phases":10905,"primaryCompletion":9418,"start":6140,"enrollment":6117,"conditions":10906,"interventions":10907},"NCT02259829","Bioequivalence Study of Telmisartan\u002FAmlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers",[90],[15],[10896,6121,10908],"Amlodipine",{"nctId":10910,"briefTitle":10911,"status":107,"phases":10912,"primaryCompletion":9418,"start":6140,"enrollment":2382,"conditions":10913,"interventions":10914},"NCT02259777","Bioavailability of Telmisartan\u002FAmlodipine Fixed Dose Combination in Healthy Male and Female Volunteers",[90],[15],[10896],{"nctId":10916,"briefTitle":10917,"status":107,"phases":10918,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":448,"conditions":10919,"interventions":10920},"NCT02183675","Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers",[90],[15],[10896,10921,10922],"Telmisartan\u002FAmlodipine\u002FHCTZ","Telmisartan\u002FHCTZ",{"trials":10924,"activeCount":101},[],{"trials":10926,"activeCount":101},[10927],{"nctId":10928,"briefTitle":10929,"status":107,"phases":10930,"primaryCompletion":9348,"start":1980,"enrollment":10931,"conditions":10932,"interventions":10933},"NCT01134393","TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch",[92],502,[24],[10934],"telmisartan\u002Famlodipine",{"trials":10936,"activeCount":101},[],{"trials":10938,"activeCount":101},[],{"intervention":10940,"totalTrials":1564,"cells":10941},"BI 695500",{"EARLY_PHASE1":10942,"PHASE1":10944,"PHASE2":10956,"PHASE3":10958,"PHASE4":10988,"NA":10990},{"trials":10943,"activeCount":101},[],{"trials":10945,"activeCount":101},[10946],{"nctId":10947,"briefTitle":10948,"status":107,"phases":10949,"primaryCompletion":724,"completion":724,"start":10950,"enrollment":10951,"conditions":10952,"interventions":10954},"NCT01950273","Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma",[90],"2013-09-27",95,[10953],"Lymphoma, Follicular",[10940,10955],"MabThera",{"trials":10957,"activeCount":101},[],{"trials":10959,"activeCount":101},[10960,10971,10979],{"nctId":10961,"briefTitle":10962,"status":162,"phases":10963,"primaryCompletion":10964,"completion":9698,"start":10965,"enrollment":10966,"conditions":10967,"interventions":10968},"NCT01682512","Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis",[92],"2015-11-17","2012-09-05",294,[10667],[10940,10940,10969,10969,10970],"Rituxan®","MabThera®",{"nctId":10972,"briefTitle":10973,"status":162,"phases":10974,"primaryCompletion":2031,"completion":2031,"start":4118,"enrollment":1075,"conditions":10975,"interventions":10977},"NCT02417129","BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma",[92],[10976],"Lymphoma, Non-Hodgkin",[10978,10940],"Rituximab",{"nctId":10980,"briefTitle":10981,"status":162,"phases":10982,"primaryCompletion":10983,"completion":10984,"start":10985,"enrollment":6607,"conditions":10986,"interventions":10987},"NCT01955733","Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis",[92],"2015-11-18","2016-11-07","2013-05-31",[10667],[10940],{"trials":10989,"activeCount":101},[],{"trials":10991,"activeCount":101},[],{"intervention":9343,"totalTrials":1564,"cells":10993},{"EARLY_PHASE1":10994,"PHASE1":10996,"PHASE2":11017,"PHASE3":11019,"PHASE4":11029,"NA":11031},{"trials":10995,"activeCount":101},[],{"trials":10997,"activeCount":101},[10998,11002,11010],{"nctId":9337,"briefTitle":9338,"status":107,"phases":10999,"primaryCompletion":9340,"start":9332,"enrollment":392,"conditions":11000,"interventions":11001},[90],[15],[528,9343,9343,528],{"nctId":11003,"briefTitle":11004,"status":107,"phases":11005,"primaryCompletion":5843,"start":1981,"enrollment":1672,"conditions":11006,"interventions":11007},"NCT02183623","The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers",[90],[15],[11008,11009],"Simvastatin","10 mg BI 1356 BS",{"nctId":11011,"briefTitle":11012,"status":107,"phases":11013,"primaryCompletion":2122,"start":2163,"enrollment":401,"conditions":11014,"interventions":11015},"NCT02187536","Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects",[90],[15],[6121,11008,11016],"Telmisartan placebo",{"trials":11018,"activeCount":101},[],{"trials":11020,"activeCount":101},[11021],{"nctId":11022,"briefTitle":11023,"status":107,"phases":11024,"primaryCompletion":3763,"completion":3763,"start":6156,"enrollment":11025,"conditions":11026,"interventions":11028},"NCT00316095","Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia",[92],1695,[24,11027],"Dyslipidemias",[7281,9343],{"trials":11030,"activeCount":101},[],{"trials":11032,"activeCount":101},[],{"intervention":11034,"totalTrials":1564,"cells":11035},"Brotizolam",{"EARLY_PHASE1":11036,"PHASE1":11038,"PHASE2":11061,"PHASE3":11063,"PHASE4":11074,"NA":11076},{"trials":11037,"activeCount":101},[],{"trials":11039,"activeCount":101},[11040,11047,11054],{"nctId":11041,"briefTitle":11042,"status":107,"phases":11043,"primaryCompletion":6949,"start":6262,"enrollment":357,"conditions":11044,"interventions":11045},"NCT02218645","Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) Taken With Water in Healthy Adult Males",[90],[15],[11046,11034],"WE 941 OD",{"nctId":11048,"briefTitle":11049,"status":107,"phases":11050,"primaryCompletion":6262,"start":2162,"enrollment":357,"conditions":11051,"interventions":11052},"NCT02218658","Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males",[90],[15],[11053,11034],"WE941 OD",{"nctId":11055,"briefTitle":11056,"status":107,"phases":11057,"primaryCompletion":390,"start":2648,"enrollment":380,"conditions":11058,"interventions":11059},"NCT01361022","To Assess the Bioequivalence of Brotizolam Tablets 250 Mcg vs. Lendormin Tablets 250 Mcg Administered to Healthy Adult Volunteers",[90],[15],[11060,11034],"Lendormin",{"trials":11062,"activeCount":101},[],{"trials":11064,"activeCount":101},[11065],{"nctId":11066,"briefTitle":11067,"status":107,"phases":11068,"primaryCompletion":7573,"completion":7573,"start":2111,"enrollment":11069,"conditions":11070,"interventions":11072},"NCT00347295","Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.",[92],253,[11071],"Sleep Initiation and Maintenance Disorders",[11034,11073],"Estazolam",{"trials":11075,"activeCount":101},[],{"trials":11077,"activeCount":101},[],{"intervention":4445,"totalTrials":1564,"cells":11079},{"EARLY_PHASE1":11080,"PHASE1":11082,"PHASE2":11092,"PHASE3":11102,"PHASE4":11108,"NA":11110},{"trials":11081,"activeCount":101},[],{"trials":11083,"activeCount":101},[11084,11088],{"nctId":4438,"briefTitle":4439,"status":107,"phases":11085,"primaryCompletion":4441,"start":4442,"enrollment":357,"conditions":11086,"interventions":11087},[90],[15],[528,1538,4445,528],{"nctId":9415,"briefTitle":9416,"status":107,"phases":11089,"primaryCompletion":9418,"completion":9418,"start":8911,"enrollment":410,"conditions":11090,"interventions":11091},[90],[21],[4445,528,4445,528,4445,4445,528,528],{"trials":11093,"activeCount":101},[11094],{"nctId":11095,"briefTitle":11096,"status":107,"phases":11097,"primaryCompletion":2506,"start":399,"enrollment":11098,"conditions":11099,"interventions":11100},"NCT01011868","Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes",[91],494,[21],[11101,6673,6668,11101],"BI 10773 placebo",{"trials":11103,"activeCount":101},[11104],{"nctId":9503,"briefTitle":9504,"status":107,"phases":11105,"primaryCompletion":4120,"completion":4120,"start":3730,"enrollment":9506,"conditions":11106,"interventions":11107},[92],[21],[528,4445,9509,528,9509,9510,528,528,528,9510,4445,9510,528,9510],{"trials":11109,"activeCount":101},[],{"trials":11111,"activeCount":101},[],{"intervention":11113,"totalTrials":1564,"cells":11114},"Talsaclidine",{"EARLY_PHASE1":11115,"PHASE1":11117,"PHASE2":11132,"PHASE3":11141,"PHASE4":11149,"NA":11151},{"trials":11116,"activeCount":101},[],{"trials":11118,"activeCount":101},[11119,11126],{"nctId":11120,"briefTitle":11121,"status":107,"phases":11122,"primaryCompletion":11123,"start":6074,"enrollment":448,"conditions":11124,"interventions":11125},"NCT02264067","Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers",[90],"1998-11",[15],[11113],{"nctId":11127,"briefTitle":11128,"status":107,"phases":11129,"primaryCompletion":8538,"start":6246,"enrollment":188,"conditions":11130,"interventions":11131},"NCT02264093","Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers",[90],[15],[5848,11113],{"trials":11133,"activeCount":101},[11134],{"nctId":11135,"briefTitle":11136,"status":162,"phases":11137,"primaryCompletion":2122,"start":6206,"enrollment":1631,"conditions":11138,"interventions":11140},"NCT02249351","Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type",[91],[11139],"Alzheimer Disease",[11113],{"trials":11142,"activeCount":101},[11143],{"nctId":11144,"briefTitle":11145,"status":162,"phases":11146,"primaryCompletion":6949,"start":9235,"enrollment":6392,"conditions":11147,"interventions":11148},"NCT02248116","Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type",[91,92],[11139],[11113],{"trials":11150,"activeCount":101},[],{"trials":11152,"activeCount":101},[],{"intervention":6673,"totalTrials":1564,"cells":11154},{"EARLY_PHASE1":11155,"PHASE1":11157,"PHASE2":11167,"PHASE3":11173,"PHASE4":11186,"NA":11188},{"trials":11156,"activeCount":101},[],{"trials":11158,"activeCount":101},[11159],{"nctId":11160,"briefTitle":11161,"status":107,"phases":11162,"primaryCompletion":6471,"start":4507,"enrollment":11163,"conditions":11164,"interventions":11165},"NCT00558571","4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes",[90],78,[21],[6673,11166,6668],"BI 10773 medium dose",{"trials":11168,"activeCount":101},[11169],{"nctId":11095,"briefTitle":11096,"status":107,"phases":11170,"primaryCompletion":2506,"start":399,"enrollment":11098,"conditions":11171,"interventions":11172},[91],[21],[11101,6673,6668,11101],{"trials":11174,"activeCount":101},[11175,11182],{"nctId":11176,"briefTitle":11177,"status":107,"phases":11178,"primaryCompletion":4118,"completion":4118,"start":1967,"enrollment":11179,"conditions":11180,"interventions":11181},"NCT01131676","BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).",[92],7064,[21],[6673,6668],{"nctId":6661,"briefTitle":6662,"status":107,"phases":11183,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":11184,"interventions":11185},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":11187,"activeCount":101},[],{"trials":11189,"activeCount":101},[],{"intervention":6668,"totalTrials":1564,"cells":11191},{"EARLY_PHASE1":11192,"PHASE1":11194,"PHASE2":11200,"PHASE3":11206,"PHASE4":11216,"NA":11218},{"trials":11193,"activeCount":101},[],{"trials":11195,"activeCount":101},[11196],{"nctId":11160,"briefTitle":11161,"status":107,"phases":11197,"primaryCompletion":6471,"start":4507,"enrollment":11163,"conditions":11198,"interventions":11199},[90],[21],[6673,11166,6668],{"trials":11201,"activeCount":101},[11202],{"nctId":11095,"briefTitle":11096,"status":107,"phases":11203,"primaryCompletion":2506,"start":399,"enrollment":11098,"conditions":11204,"interventions":11205},[91],[21],[11101,6673,6668,11101],{"trials":11207,"activeCount":101},[11208,11212],{"nctId":11176,"briefTitle":11177,"status":107,"phases":11209,"primaryCompletion":4118,"completion":4118,"start":1967,"enrollment":11179,"conditions":11210,"interventions":11211},[92],[21],[6673,6668],{"nctId":6661,"briefTitle":6662,"status":107,"phases":11213,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":11214,"interventions":11215},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":11217,"activeCount":101},[],{"trials":11219,"activeCount":101},[],{"intervention":11221,"totalTrials":1044,"cells":11222},"warfarin 3mg",{"EARLY_PHASE1":11223,"PHASE1":11225,"PHASE2":11227,"PHASE3":11249,"PHASE4":11255,"NA":11257},{"trials":11224,"activeCount":101},[],{"trials":11226,"activeCount":101},[],{"trials":11228,"activeCount":101},[11229,11241],{"nctId":11230,"briefTitle":11231,"status":162,"phases":11232,"primaryCompletion":525,"completion":525,"start":6095,"enrollment":5568,"conditions":11233,"interventions":11235},"NCT01505881","Follow on Study From RE-ALIGN",[91],[10332,11234],"Heart Valve Prosthesis",[11236,11237,11238,11239,11240,11221],"dabigatran etexilate low dose","warfarin 5mg","dabigatran etexilate intermediate dose","warfarin 1mg","dabigatran etexilate high dose",{"nctId":11242,"briefTitle":11243,"status":162,"phases":11244,"primaryCompletion":525,"completion":525,"start":391,"enrollment":11245,"conditions":11246,"interventions":11248},"NCT01452347","Dabigatran Etexilate in Patients With Mechanical Heart Valves",[91],328,[11247],"Heart Valve Diseases",[11239,11238,11236,11237,11240,11221],{"trials":11250,"activeCount":101},[11251],{"nctId":6511,"briefTitle":6512,"status":107,"phases":11252,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":11253,"interventions":11254},[92],[6098,6518],[6520,6521,6484,6522,6523,6523,6524,6523,6525],{"trials":11256,"activeCount":101},[],{"trials":11258,"activeCount":101},[],{"intervention":11237,"totalTrials":1044,"cells":11260},{"EARLY_PHASE1":11261,"PHASE1":11263,"PHASE2":11265,"PHASE3":11275,"PHASE4":11281,"NA":11283},{"trials":11262,"activeCount":101},[],{"trials":11264,"activeCount":101},[],{"trials":11266,"activeCount":101},[11267,11271],{"nctId":11230,"briefTitle":11231,"status":162,"phases":11268,"primaryCompletion":525,"completion":525,"start":6095,"enrollment":5568,"conditions":11269,"interventions":11270},[91],[10332,11234],[11236,11237,11238,11239,11240,11221],{"nctId":11242,"briefTitle":11243,"status":162,"phases":11272,"primaryCompletion":525,"completion":525,"start":391,"enrollment":11245,"conditions":11273,"interventions":11274},[91],[11247],[11239,11238,11236,11237,11240,11221],{"trials":11276,"activeCount":101},[11277],{"nctId":6511,"briefTitle":6512,"status":107,"phases":11278,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":11279,"interventions":11280},[92],[6098,6518],[6520,6521,6484,6522,6523,6523,6524,6523,6525],{"trials":11282,"activeCount":101},[],{"trials":11284,"activeCount":101},[],{"intervention":11239,"totalTrials":1044,"cells":11286},{"EARLY_PHASE1":11287,"PHASE1":11289,"PHASE2":11291,"PHASE3":11301,"PHASE4":11307,"NA":11309},{"trials":11288,"activeCount":101},[],{"trials":11290,"activeCount":101},[],{"trials":11292,"activeCount":101},[11293,11297],{"nctId":11230,"briefTitle":11231,"status":162,"phases":11294,"primaryCompletion":525,"completion":525,"start":6095,"enrollment":5568,"conditions":11295,"interventions":11296},[91],[10332,11234],[11236,11237,11238,11239,11240,11221],{"nctId":11242,"briefTitle":11243,"status":162,"phases":11298,"primaryCompletion":525,"completion":525,"start":391,"enrollment":11245,"conditions":11299,"interventions":11300},[91],[11247],[11239,11238,11236,11237,11240,11221],{"trials":11302,"activeCount":101},[11303],{"nctId":6511,"briefTitle":6512,"status":107,"phases":11304,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":11305,"interventions":11306},[92],[6098,6518],[6520,6521,6484,6522,6523,6523,6524,6523,6525],{"trials":11308,"activeCount":101},[],{"trials":11310,"activeCount":101},[],{"intervention":5945,"totalTrials":1044,"cells":11312},{"EARLY_PHASE1":11313,"PHASE1":11315,"PHASE2":11324,"PHASE3":11326,"PHASE4":11340,"NA":11342},{"trials":11314,"activeCount":101},[],{"trials":11316,"activeCount":101},[11317],{"nctId":11318,"briefTitle":11319,"status":107,"phases":11320,"primaryCompletion":2145,"start":4461,"enrollment":448,"conditions":11321,"interventions":11322},"NCT02254174","Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers",[90],[15],[5945,7155,11323],"Spiriva®",{"trials":11325,"activeCount":101},[],{"trials":11327,"activeCount":101},[11328,11336],{"nctId":11329,"briefTitle":11330,"status":107,"phases":11331,"primaryCompletion":11332,"completion":11332,"start":5932,"enrollment":2586,"conditions":11333,"interventions":11334},"NCT00662792","Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD",[92],"2009-07-22",[18],[5860,11335,5860,5945],"Salmeterol MDPI",{"nctId":5939,"briefTitle":5940,"status":162,"phases":11337,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5942,"conditions":11338,"interventions":11339},[92],[18],[5945,5946,5832,5860],{"trials":11341,"activeCount":101},[],{"trials":11343,"activeCount":101},[],{"intervention":11345,"totalTrials":1044,"cells":11346},"Ba253BINEB",{"EARLY_PHASE1":11347,"PHASE1":11349,"PHASE2":11351,"PHASE3":11353,"PHASE4":11375,"NA":11377},{"trials":11348,"activeCount":101},[],{"trials":11350,"activeCount":101},[],{"trials":11352,"activeCount":101},[],{"trials":11354,"activeCount":101},[11355,11361,11369],{"nctId":11356,"briefTitle":11357,"status":107,"phases":11358,"primaryCompletion":2122,"start":6074,"enrollment":3791,"conditions":11359,"interventions":11360},"NCT02182661","A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma",[92],[30],[11345],{"nctId":11362,"briefTitle":11363,"status":107,"phases":11364,"primaryCompletion":7394,"start":7553,"enrollment":11365,"conditions":11366,"interventions":11367},"NCT02182583","Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],163,[18],[11368,11345],"Ba253MDI",{"nctId":11370,"briefTitle":11371,"status":107,"phases":11372,"primaryCompletion":6453,"start":7395,"enrollment":6702,"conditions":11373,"interventions":11374},"NCT02182635","Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[11345],{"trials":11376,"activeCount":101},[],{"trials":11378,"activeCount":101},[],{"intervention":11380,"totalTrials":1044,"cells":11381},"Linagliptin 5mg",{"EARLY_PHASE1":11382,"PHASE1":11384,"PHASE2":11386,"PHASE3":11388,"PHASE4":11422,"NA":11424},{"trials":11383,"activeCount":101},[],{"trials":11385,"activeCount":101},[],{"trials":11387,"activeCount":101},[],{"trials":11389,"activeCount":101},[11390,11403,11415],{"nctId":11391,"briefTitle":11392,"status":107,"phases":11393,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":11395,"interventions":11396},"NCT01183013","30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",[92],936,[21],[11397,11398,11399,11400,11401,11380,11402],"Pioglitazone 15 mg","Pioglitazone 45 mg","Pioglitazone 30 mg","Linagliptin 5mg \u002F Pioglitazone 45 mg FDC","Linagliptin 5mg \u002F Pioglitazone 30 mg FDC","Linagliptin 5mg \u002F Pioglitazone 15 mg FDC",{"nctId":11404,"briefTitle":11405,"status":107,"phases":11406,"primaryCompletion":10024,"completion":10024,"start":517,"enrollment":11407,"conditions":11408,"interventions":11409},"NCT01708902","Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients",[92],876,[21],[11410,11410,11411,11412,11413,11413,11411,11414],"linagliptin2.5mg\u002Fmetformin1000mg","linagliptin 5mg","Metformin 500mg","linagliptin2.5mg\u002Fmetformin500mg","Metformin 1000mg",{"nctId":11416,"briefTitle":11417,"status":107,"phases":11418,"primaryCompletion":5275,"completion":2031,"start":9614,"enrollment":11419,"conditions":11420,"interventions":11421},"NCT01792518","MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",[92],360,[21],[11380],{"trials":11423,"activeCount":101},[],{"trials":11425,"activeCount":101},[],{"intervention":11427,"totalTrials":1044,"cells":11428},"empagliflozin high dose",{"EARLY_PHASE1":11429,"PHASE1":11431,"PHASE2":11441,"PHASE3":11452,"PHASE4":11464,"NA":11466},{"trials":11430,"activeCount":101},[],{"trials":11432,"activeCount":101},[11433],{"nctId":11434,"briefTitle":11435,"status":107,"phases":11436,"primaryCompletion":5283,"completion":5283,"start":4391,"enrollment":251,"conditions":11437,"interventions":11438},"NCT02121483","Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus",[90],[21],[11439,11427,11440],"empagliflozin medium dose","empagliflozin low dose",{"trials":11442,"activeCount":101},[11443],{"nctId":11444,"briefTitle":11445,"status":107,"phases":11446,"primaryCompletion":11447,"completion":11448,"start":11449,"enrollment":410,"conditions":11450,"interventions":11451},"NCT02702011","Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus",[91],"2016-09-05","2016-10-03","2016-03-20",[538],[11439,11440,11427],{"trials":11453,"activeCount":101},[11454],{"nctId":11455,"briefTitle":11456,"status":107,"phases":11457,"primaryCompletion":11458,"completion":11458,"start":11459,"enrollment":7681,"conditions":11460,"interventions":11461},"NCT02182830","24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black\u002FAfrican American Patients With Type 2 Diabetes Mellitus and Hypertension",[92],"2017-05-18","2014-07-25",[21,24],[11462,11463],"Empagliflozin low dose","Empagliflozin high dose",{"trials":11465,"activeCount":101},[],{"trials":11467,"activeCount":101},[],{"intervention":11440,"totalTrials":1044,"cells":11469},{"EARLY_PHASE1":11470,"PHASE1":11472,"PHASE2":11478,"PHASE3":11484,"PHASE4":11490,"NA":11492},{"trials":11471,"activeCount":101},[],{"trials":11473,"activeCount":101},[11474],{"nctId":11434,"briefTitle":11435,"status":107,"phases":11475,"primaryCompletion":5283,"completion":5283,"start":4391,"enrollment":251,"conditions":11476,"interventions":11477},[90],[21],[11439,11427,11440],{"trials":11479,"activeCount":101},[11480],{"nctId":11444,"briefTitle":11445,"status":107,"phases":11481,"primaryCompletion":11447,"completion":11448,"start":11449,"enrollment":410,"conditions":11482,"interventions":11483},[91],[538],[11439,11440,11427],{"trials":11485,"activeCount":101},[11486],{"nctId":11455,"briefTitle":11456,"status":107,"phases":11487,"primaryCompletion":11458,"completion":11458,"start":11459,"enrollment":7681,"conditions":11488,"interventions":11489},[92],[21,24],[11462,11463],{"trials":11491,"activeCount":101},[],{"trials":11493,"activeCount":101},[],{"intervention":6505,"totalTrials":1044,"cells":11495},{"EARLY_PHASE1":11496,"PHASE1":11498,"PHASE2":11508,"PHASE3":11510,"PHASE4":11518,"NA":11520},{"trials":11497,"activeCount":101},[],{"trials":11499,"activeCount":101},[11500,11504],{"nctId":9749,"briefTitle":9750,"status":107,"phases":11501,"primaryCompletion":9752,"start":2030,"enrollment":177,"conditions":11502,"interventions":11503},[90],[27],[6505,4010,4042],{"nctId":6500,"briefTitle":6501,"status":107,"phases":11505,"primaryCompletion":4413,"start":3763,"enrollment":342,"conditions":11506,"interventions":11507},[90],[15],[4008,4010,6505,6484],{"trials":11509,"activeCount":101},[],{"trials":11511,"activeCount":101},[11512],{"nctId":11513,"briefTitle":11514,"status":162,"phases":11515,"primaryCompletion":5856,"start":6140,"enrollment":2382,"conditions":11516,"interventions":11517},"NCT00517192","Comparison of TPV\u002Fr to DRV\u002Fr in Triple Class Experienced Patient With Resistance to > 1 PI",[92],[27],[4008,6505,4010],{"trials":11519,"activeCount":101},[],{"trials":11521,"activeCount":101},[],{"intervention":11523,"totalTrials":1044,"cells":11524},"BI 695502",{"EARLY_PHASE1":11525,"PHASE1":11527,"PHASE2":11537,"PHASE3":11539,"PHASE4":11559,"NA":11561},{"trials":11526,"activeCount":101},[],{"trials":11528,"activeCount":101},[11529],{"nctId":11530,"briefTitle":11531,"status":107,"phases":11532,"primaryCompletion":11533,"completion":11533,"start":11534,"enrollment":6607,"conditions":11535,"interventions":11536},"NCT01608087","Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects",[90],"2012-11-01","2012-05-01",[15],[11523,9711,9711],{"trials":11538,"activeCount":101},[],{"trials":11540,"activeCount":101},[11541,11551],{"nctId":11542,"briefTitle":11543,"status":107,"phases":11544,"primaryCompletion":4210,"completion":11545,"start":11546,"enrollment":11547,"conditions":11548,"interventions":11549},"NCT02272413","Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer",[92],"2018-11-16","2015-07-08",671,[36],[11523,11550],"Avastin",{"nctId":11552,"briefTitle":11553,"status":107,"phases":11554,"primaryCompletion":11555,"completion":11555,"start":11556,"enrollment":260,"conditions":11557,"interventions":11558},"NCT02776683","Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer",[92],"2018-10-03","2016-06-08",[3060],[11523,11550],{"trials":11560,"activeCount":101},[],{"trials":11562,"activeCount":101},[],{"intervention":10922,"totalTrials":1044,"cells":11564},{"EARLY_PHASE1":11565,"PHASE1":11567,"PHASE2":11573,"PHASE3":11575,"PHASE4":11591,"NA":11593},{"trials":11566,"activeCount":101},[],{"trials":11568,"activeCount":101},[11569],{"nctId":10916,"briefTitle":10917,"status":107,"phases":11570,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":448,"conditions":11571,"interventions":11572},[90],[15],[10896,10921,10922],{"trials":11574,"activeCount":101},[],{"trials":11576,"activeCount":101},[11577,11584],{"nctId":11578,"briefTitle":11579,"status":107,"phases":11580,"primaryCompletion":6911,"completion":6911,"start":11581,"enrollment":1771,"conditions":11582,"interventions":11583},"NCT00146341","Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg",[92],"2005-04",[24],[10922,6121],{"nctId":11585,"briefTitle":11586,"status":107,"phases":11587,"primaryCompletion":11588,"completion":11588,"start":5842,"enrollment":993,"conditions":11589,"interventions":11590},"NCT00257491","Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg\u002FHydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension",[92],"2006-08",[24],[6121,10922],{"trials":11592,"activeCount":101},[],{"trials":11594,"activeCount":101},[],{"intervention":11596,"totalTrials":1044,"cells":11597},"Formoterol",{"EARLY_PHASE1":11598,"PHASE1":11600,"PHASE2":11602,"PHASE3":11611,"PHASE4":11627,"NA":11629},{"trials":11599,"activeCount":101},[],{"trials":11601,"activeCount":101},[],{"trials":11603,"activeCount":101},[11604],{"nctId":11605,"briefTitle":11606,"status":107,"phases":11607,"primaryCompletion":6494,"start":6030,"enrollment":6702,"conditions":11608,"interventions":11609},"NCT02238119","Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[11610,5860,11596],"Tiotropium + formoterol combination",{"trials":11612,"activeCount":101},[11613,11620],{"nctId":11614,"briefTitle":11615,"status":107,"phases":11616,"primaryCompletion":9396,"start":2649,"enrollment":11617,"conditions":11618,"interventions":11619},"NCT00796653","Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II",[92],937,[18],[5959,5959,11596],{"nctId":11621,"briefTitle":11622,"status":107,"phases":11623,"primaryCompletion":9396,"start":1989,"enrollment":11624,"conditions":11625,"interventions":11626},"NCT00793624","Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I",[92],906,[18],[5959,5959,11596],{"trials":11628,"activeCount":101},[],{"trials":11630,"activeCount":101},[],{"intervention":11632,"totalTrials":1044,"cells":11633},"Atazanavir",{"EARLY_PHASE1":11634,"PHASE1":11636,"PHASE2":11655,"PHASE3":11657,"PHASE4":11669,"NA":11671},{"trials":11635,"activeCount":101},[],{"trials":11637,"activeCount":101},[11638,11645],{"nctId":11639,"briefTitle":11640,"status":107,"phases":11641,"primaryCompletion":11642,"start":6782,"enrollment":3454,"conditions":11643,"interventions":11644},"NCT02253836","Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir",[90],"2005-07",[15],[4008,4010,11632],{"nctId":11646,"briefTitle":11647,"status":107,"phases":11648,"primaryCompletion":11649,"start":11650,"enrollment":1891,"conditions":11651,"interventions":11652},"NCT02257008","Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers",[90],"2003-12","2003-03",[15],[11653,11654,11632,4010],"BILR 355 BS","Nelfinavir",{"trials":11656,"activeCount":101},[],{"trials":11658,"activeCount":101},[11659],{"nctId":11660,"briefTitle":11661,"status":107,"phases":11662,"primaryCompletion":9332,"start":1990,"enrollment":11663,"conditions":11664,"interventions":11665},"NCT00389207","Nevirapine or Atazanavir\u002FRitonavir Given With Emtricitabine\u002FTenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults",[92],576,[27],[11666,11667,11668],"nevirapine bid","nevirapine qd","atazanavir",{"trials":11670,"activeCount":101},[],{"trials":11672,"activeCount":101},[],{"intervention":11674,"totalTrials":1044,"cells":11675},"Meloxicam ampoule",{"EARLY_PHASE1":11676,"PHASE1":11678,"PHASE2":11686,"PHASE3":11688,"PHASE4":11706,"NA":11708},{"trials":11677,"activeCount":101},[],{"trials":11679,"activeCount":101},[11680],{"nctId":11681,"briefTitle":11682,"status":107,"phases":11683,"primaryCompletion":7114,"start":11123,"enrollment":188,"conditions":11684,"interventions":11685},"NCT02183090","Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects",[90],[15],[11674,6498],{"trials":11687,"activeCount":101},[],{"trials":11689,"activeCount":101},[11690,11697],{"nctId":11691,"briefTitle":11692,"status":107,"phases":11693,"primaryCompletion":6413,"completion":6413,"start":5868,"enrollment":11694,"conditions":11695,"interventions":11696},"NCT00239395","A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis",[92],168,[6609],[11674,6498],{"nctId":11698,"briefTitle":11699,"status":107,"phases":11700,"primaryCompletion":11701,"completion":11702,"start":11703,"enrollment":2800,"conditions":11704,"interventions":11705},"NCT00239382","A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis",[92],"2004-12-01","2004-12-31","2004-07-01",[10667],[11674,6498],{"trials":11707,"activeCount":101},[],{"trials":11709,"activeCount":101},[],{"intervention":11711,"totalTrials":1044,"cells":11712},"Pramipexole 0.125 mg",{"EARLY_PHASE1":11713,"PHASE1":11715,"PHASE2":11717,"PHASE3":11727,"PHASE4":11745,"NA":11747},{"trials":11714,"activeCount":101},[],{"trials":11716,"activeCount":101},[],{"trials":11718,"activeCount":101},[11719],{"nctId":11720,"briefTitle":11721,"status":107,"phases":11722,"primaryCompletion":4462,"start":8479,"enrollment":1991,"conditions":11723,"interventions":11725},"NCT00152997","Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome",[91],[11724],"Restless Legs Syndrome",[11711,11726],"Pramipexole 0.125 mg tablets Placebo",{"trials":11728,"activeCount":101},[11729,11738],{"nctId":11730,"briefTitle":11731,"status":107,"phases":11732,"completion":11733,"start":7114,"enrollment":11734,"conditions":11735,"interventions":11736},"NCT00274131","Long-term Administration Study of SND 919 Tablets in Parkinson's Disease",[92],"2004-02",170,[6934],[11711,11737],"Pramipexole 0.5 mg",{"nctId":11739,"briefTitle":11740,"status":107,"phases":11741,"primaryCompletion":4128,"start":1990,"enrollment":9115,"conditions":11742,"interventions":11744},"NCT00390689","A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.",[92],[11743],"Idiopathic Restless Legs Syndrome",[11711,11737],{"trials":11746,"activeCount":101},[],{"trials":11748,"activeCount":101},[],{"intervention":10211,"totalTrials":1044,"cells":11750},{"EARLY_PHASE1":11751,"PHASE1":11753,"PHASE2":11755,"PHASE3":11768,"PHASE4":11774,"NA":11776},{"trials":11752,"activeCount":101},[],{"trials":11754,"activeCount":101},[],{"trials":11756,"activeCount":101},[11757,11761],{"nctId":10203,"briefTitle":10204,"status":107,"phases":11758,"primaryCompletion":10206,"completion":10207,"start":10208,"enrollment":5466,"conditions":11759,"interventions":11760},[91],[10147],[10133,10211],{"nctId":11762,"briefTitle":11763,"status":107,"phases":11764,"primaryCompletion":9824,"completion":9824,"start":5906,"enrollment":2400,"conditions":11765,"interventions":11766},"NCT00632749","BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment",[91],[10147],[11767,10211,11767,10211],"BI 811283",{"trials":11769,"activeCount":101},[11770],{"nctId":10215,"briefTitle":10216,"status":107,"phases":11771,"primaryCompletion":10218,"completion":687,"start":10219,"enrollment":10220,"conditions":11772,"interventions":11773},[92],[10147],[10133,10211],{"trials":11775,"activeCount":101},[],{"trials":11777,"activeCount":101},[],{"intervention":4046,"totalTrials":1044,"cells":11779},{"EARLY_PHASE1":11780,"PHASE1":11782,"PHASE2":11792,"PHASE3":11794,"PHASE4":11800,"NA":11802},{"trials":11781,"activeCount":101},[],{"trials":11783,"activeCount":101},[11784,11788],{"nctId":4035,"briefTitle":4036,"status":107,"phases":11785,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":11786,"interventions":11787},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"nctId":10073,"briefTitle":10074,"status":107,"phases":11789,"primaryCompletion":10076,"start":10077,"enrollment":448,"conditions":11790,"interventions":11791},[90],[2526],[4008,4010,10080,9801],{"trials":11793,"activeCount":101},[],{"trials":11795,"activeCount":101},[11796],{"nctId":9830,"briefTitle":9831,"status":600,"phases":11797,"primaryCompletion":9833,"completion":9833,"start":408,"enrollment":101,"conditions":11798,"interventions":11799},[92],[4040],[4042,4048,4047,9836,4048,9837],{"trials":11801,"activeCount":101},[],{"trials":11803,"activeCount":101},[],{"intervention":9564,"totalTrials":1044,"cells":11805},{"EARLY_PHASE1":11806,"PHASE1":11808,"PHASE2":11823,"PHASE3":11825,"PHASE4":11831,"NA":11833},{"trials":11807,"activeCount":101},[],{"trials":11809,"activeCount":101},[11810,11817],{"nctId":11811,"briefTitle":11812,"status":107,"phases":11813,"primaryCompletion":11533,"completion":11533,"start":11814,"enrollment":132,"conditions":11815,"interventions":11816},"NCT01581658","Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes",[90],"2012-04-01",[21],[9564,9564,9564,9564],{"nctId":11818,"briefTitle":11819,"status":107,"phases":11820,"primaryCompletion":7338,"start":6132,"enrollment":380,"conditions":11821,"interventions":11822},"NCT01316341","Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus",[90],[21],[9564,9564],{"trials":11824,"activeCount":101},[],{"trials":11826,"activeCount":101},[11827],{"nctId":9557,"briefTitle":9558,"status":107,"phases":11828,"primaryCompletion":3753,"start":1967,"enrollment":9560,"conditions":11829,"interventions":11830},[92],[21],[528,9563,9564,606],{"trials":11832,"activeCount":101},[],{"trials":11834,"activeCount":101},[],{"intervention":11836,"totalTrials":1044,"cells":11837},"Epinastine",{"EARLY_PHASE1":11838,"PHASE1":11840,"PHASE2":11857,"PHASE3":11859,"PHASE4":11868,"NA":11870},{"trials":11839,"activeCount":101},[],{"trials":11841,"activeCount":101},[11842,11850],{"nctId":11843,"briefTitle":11844,"status":107,"phases":11845,"primaryCompletion":6207,"start":6738,"enrollment":439,"conditions":11846,"interventions":11847},"NCT02182531","Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers",[90],[15],[11836,11848,11849],"Pseudoephedrine","Epinastine + Pseudoephedrine combination",{"nctId":11851,"briefTitle":11852,"status":107,"phases":11853,"primaryCompletion":6438,"start":11123,"enrollment":380,"conditions":11854,"interventions":11855},"NCT02260063","Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers",[90],[15],[11856,11836],"Epinastine syrup",{"trials":11858,"activeCount":101},[],{"trials":11860,"activeCount":101},[11861],{"nctId":11862,"briefTitle":11863,"status":107,"phases":11864,"primaryCompletion":6884,"start":2122,"enrollment":3436,"conditions":11865,"interventions":11867},"NCT02182518","Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis",[92],[11866],"Rhinitis, Allergic, Perennial",[11836,11848],{"trials":11869,"activeCount":101},[],{"trials":11871,"activeCount":101},[],{"intervention":11873,"totalTrials":1044,"cells":11874},"Porfiromycin",{"EARLY_PHASE1":11875,"PHASE1":11877,"PHASE2":11885,"PHASE3":11887,"PHASE4":11903,"NA":11905},{"trials":11876,"activeCount":101},[],{"trials":11878,"activeCount":101},[11879],{"nctId":11880,"briefTitle":11881,"status":162,"phases":11882,"primaryCompletion":2162,"start":6206,"enrollment":1044,"conditions":11883,"interventions":11884},"NCT02209701","Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors",[90],[3766],[11873],{"trials":11886,"activeCount":101},[],{"trials":11888,"activeCount":101},[11889,11895],{"nctId":11890,"briefTitle":11891,"status":162,"phases":11892,"primaryCompletion":5880,"start":2122,"enrollment":1044,"conditions":11893,"interventions":11894},"NCT02183246","Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients",[92],[3766],[11873],{"nctId":11896,"briefTitle":11897,"status":107,"phases":11898,"start":8700,"enrollment":11899,"conditions":11900,"interventions":11901},"NCT00003328","Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[92],600,[3593],[11902],"porfiromycin",{"trials":11904,"activeCount":101},[],{"trials":11906,"activeCount":101},[],{"intervention":9852,"totalTrials":1044,"cells":11908},{"EARLY_PHASE1":11909,"PHASE1":11911,"PHASE2":11920,"PHASE3":11922,"PHASE4":11932,"NA":11934},{"trials":11910,"activeCount":101},[],{"trials":11912,"activeCount":101},[11913],{"nctId":11914,"briefTitle":11915,"status":107,"phases":11916,"primaryCompletion":6133,"completion":11917,"start":6140,"enrollment":8,"conditions":11918,"interventions":11919},"NCT00793793","Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced",[90],"2011-01-25",[4040],[9852,9852,9852,9852],{"trials":11921,"activeCount":101},[],{"trials":11923,"activeCount":101},[11924,11928],{"nctId":10737,"briefTitle":10738,"status":107,"phases":11925,"primaryCompletion":10024,"completion":10024,"start":9340,"enrollment":10740,"conditions":11926,"interventions":11927},[92],[9764],[9852,9828,9852],{"nctId":9846,"briefTitle":9847,"status":107,"phases":11929,"primaryCompletion":611,"completion":4391,"start":5296,"enrollment":9849,"conditions":11930,"interventions":11931},[92],[4040],[9828,9828,9852,9853,9828,9854],{"trials":11933,"activeCount":101},[],{"trials":11935,"activeCount":101},[],{"intervention":6866,"totalTrials":1044,"cells":11937},{"EARLY_PHASE1":11938,"PHASE1":11940,"PHASE2":11952,"PHASE3":11954,"PHASE4":11964,"NA":11966},{"trials":11939,"activeCount":101},[],{"trials":11941,"activeCount":101},[11942,11946],{"nctId":6861,"briefTitle":6862,"status":107,"phases":11943,"primaryCompletion":1967,"start":1980,"enrollment":1418,"conditions":11944,"interventions":11945},[90],[15,18],[6866,6845],{"nctId":11947,"briefTitle":11948,"status":107,"phases":11949,"primaryCompletion":4442,"start":1980,"enrollment":132,"conditions":11950,"interventions":11951},"NCT01153711","Relative Bioavailability of of Olodaterol and Ketoconazole",[90],[15,18],[6866,6866,5264,5264],{"trials":11953,"activeCount":101},[],{"trials":11955,"activeCount":101},[11956],{"nctId":11957,"briefTitle":11958,"status":107,"phases":11959,"primaryCompletion":4392,"start":5905,"enrollment":2689,"conditions":11960,"interventions":11961},"NCT00931385","Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease",[92],[18],[6866,11962,11963],"bi1744","Foradil",{"trials":11965,"activeCount":101},[],{"trials":11967,"activeCount":101},[],{"intervention":11969,"totalTrials":1075,"cells":11970},"Telmisartan\u002Fhydrochlorothiazide",{"EARLY_PHASE1":11971,"PHASE1":11973,"PHASE2":11975,"PHASE3":11977,"PHASE4":11993,"NA":11995},{"trials":11972,"activeCount":101},[],{"trials":11974,"activeCount":101},[],{"trials":11976,"activeCount":101},[],{"trials":11978,"activeCount":101},[11979,11985],{"nctId":11980,"briefTitle":11981,"status":107,"phases":11982,"primaryCompletion":2181,"start":6391,"enrollment":1218,"conditions":11983,"interventions":11984},"NCT02177487","Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension",[92],[24],[11969],{"nctId":11986,"briefTitle":11987,"status":107,"phases":11988,"primaryCompletion":7022,"start":5923,"enrollment":11989,"conditions":11990,"interventions":11991},"NCT02177435","Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension",[92],491,[24],[6121,11992],"Telmisartan\u002FHydrochlorothiazide",{"trials":11994,"activeCount":101},[],{"trials":11996,"activeCount":101},[],{"intervention":11998,"totalTrials":1075,"cells":11999},"Pramipexol Extended Release",{"EARLY_PHASE1":12000,"PHASE1":12002,"PHASE2":12004,"PHASE3":12006,"PHASE4":12024,"NA":12026},{"trials":12001,"activeCount":101},[],{"trials":12003,"activeCount":101},[],{"trials":12005,"activeCount":101},[],{"trials":12007,"activeCount":101},[12008,12016],{"nctId":12009,"briefTitle":12010,"status":107,"phases":12011,"primaryCompletion":10775,"start":6155,"enrollment":12012,"conditions":12013,"interventions":12014},"NCT00466167","Pivotal Study in Advanced Parkinsons Disease Patients",[92],517,[6934],[11998,12015],"Pramipexol Immediate Release",{"nctId":12017,"briefTitle":12018,"status":107,"phases":12019,"primaryCompletion":10775,"start":1114,"enrollment":12020,"conditions":12021,"interventions":12023},"NCT00479401","Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",[92],539,[12022],"Early Parkinson Disease (Early PD)",[11998,12015],{"trials":12025,"activeCount":101},[],{"trials":12027,"activeCount":101},[],{"intervention":12015,"totalTrials":1075,"cells":12029},{"EARLY_PHASE1":12030,"PHASE1":12032,"PHASE2":12034,"PHASE3":12036,"PHASE4":12046,"NA":12048},{"trials":12031,"activeCount":101},[],{"trials":12033,"activeCount":101},[],{"trials":12035,"activeCount":101},[],{"trials":12037,"activeCount":101},[12038,12042],{"nctId":12009,"briefTitle":12010,"status":107,"phases":12039,"primaryCompletion":10775,"start":6155,"enrollment":12012,"conditions":12040,"interventions":12041},[92],[6934],[11998,12015],{"nctId":12017,"briefTitle":12018,"status":107,"phases":12043,"primaryCompletion":10775,"start":1114,"enrollment":12020,"conditions":12044,"interventions":12045},[92],[12022],[11998,12015],{"trials":12047,"activeCount":101},[],{"trials":12049,"activeCount":101},[],{"intervention":10819,"totalTrials":1075,"cells":12051},{"EARLY_PHASE1":12052,"PHASE1":12054,"PHASE2":12056,"PHASE3":12058,"PHASE4":12068,"NA":12070},{"trials":12053,"activeCount":101},[],{"trials":12055,"activeCount":101},[],{"trials":12057,"activeCount":101},[],{"trials":12059,"activeCount":101},[12060,12064],{"nctId":10813,"briefTitle":10814,"status":107,"phases":12061,"completion":6401,"start":6871,"enrollment":10417,"conditions":12062,"interventions":12063},[92],[18],[10818,10819],{"nctId":10821,"briefTitle":10822,"status":107,"phases":12065,"primaryCompletion":6029,"start":6701,"enrollment":10824,"conditions":12066,"interventions":12067},[92],[18],[10802,10827],{"trials":12069,"activeCount":101},[],{"trials":12071,"activeCount":101},[],{"intervention":4416,"totalTrials":1075,"cells":12073},{"EARLY_PHASE1":12074,"PHASE1":12076,"PHASE2":12082,"PHASE3":12084,"PHASE4":12092,"NA":12094},{"trials":12075,"activeCount":101},[],{"trials":12077,"activeCount":101},[12078],{"nctId":4409,"briefTitle":4410,"status":107,"phases":12079,"primaryCompletion":4412,"start":4413,"enrollment":37,"conditions":12080,"interventions":12081},[90],[15],[4416,4417,1538,4418],{"trials":12083,"activeCount":101},[],{"trials":12085,"activeCount":101},[12086],{"nctId":12087,"briefTitle":12088,"status":107,"phases":12089,"primaryCompletion":516,"completion":516,"start":4038,"enrollment":12,"conditions":12090,"interventions":12091},"NCT01579474","Japanese Pegylated Interferon (PegIFN) Alfa-2b\u002FRibavirin (RBV) Combination Trial",[92],[9764],[4418,4416,4418,4418],{"trials":12093,"activeCount":101},[],{"trials":12095,"activeCount":101},[],{"intervention":4418,"totalTrials":1075,"cells":12097},{"EARLY_PHASE1":12098,"PHASE1":12100,"PHASE2":12106,"PHASE3":12108,"PHASE4":12114,"NA":12116},{"trials":12099,"activeCount":101},[],{"trials":12101,"activeCount":101},[12102],{"nctId":4409,"briefTitle":4410,"status":107,"phases":12103,"primaryCompletion":4412,"start":4413,"enrollment":37,"conditions":12104,"interventions":12105},[90],[15],[4416,4417,1538,4418],{"trials":12107,"activeCount":101},[],{"trials":12109,"activeCount":101},[12110],{"nctId":12087,"briefTitle":12088,"status":107,"phases":12111,"primaryCompletion":516,"completion":516,"start":4038,"enrollment":12,"conditions":12112,"interventions":12113},[92],[9764],[4418,4416,4418,4418],{"trials":12115,"activeCount":101},[],{"trials":12117,"activeCount":101},[],{"intervention":12119,"totalTrials":1075,"cells":12120},"tiotropium 5mcg\u002Fday",{"EARLY_PHASE1":12121,"PHASE1":12123,"PHASE2":12125,"PHASE3":12127,"PHASE4":12143,"NA":12145},{"trials":12122,"activeCount":101},[],{"trials":12124,"activeCount":101},[],{"trials":12126,"activeCount":101},[],{"trials":12128,"activeCount":101},[12129,12136],{"nctId":12130,"briefTitle":12131,"status":107,"phases":12132,"primaryCompletion":9752,"start":4412,"enrollment":12133,"conditions":12134,"interventions":12135},"NCT00772538","Evaluation of Tiotropium 5 µg\u002FDay Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)",[92],459,[30],[12119],{"nctId":12137,"briefTitle":12138,"status":107,"phases":12139,"primaryCompletion":9752,"start":4412,"enrollment":12140,"conditions":12141,"interventions":12142},"NCT00776984","Evaluation of Tiotropium 5 µg\u002FDay Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)",[92],453,[30],[12119],{"trials":12144,"activeCount":101},[],{"trials":12146,"activeCount":101},[],{"intervention":2669,"totalTrials":1075,"cells":12148},{"EARLY_PHASE1":12149,"PHASE1":12151,"PHASE2":12153,"PHASE3":12164,"PHASE4":12170,"NA":12172},{"trials":12150,"activeCount":101},[],{"trials":12152,"activeCount":101},[],{"trials":12154,"activeCount":101},[12155],{"nctId":12156,"briefTitle":12157,"status":107,"phases":12158,"primaryCompletion":12159,"completion":3731,"start":391,"enrollment":10776,"conditions":12160,"interventions":12161},"NCT01441596","Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases",[91],"2014-02",[2629,938],[12162,12163,2633,2633],"Vinorelbine","Investigator's choice of treatment",{"trials":12165,"activeCount":101},[12166],{"nctId":2660,"briefTitle":2661,"status":107,"phases":12167,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":12168,"interventions":12169},[92],[2629],[1129,2616,2669,2669],{"trials":12171,"activeCount":101},[],{"trials":12173,"activeCount":101},[],{"intervention":12175,"totalTrials":1075,"cells":12176},"Tiotropium high dose",{"EARLY_PHASE1":12177,"PHASE1":12179,"PHASE2":12181,"PHASE3":12183,"PHASE4":12202,"NA":12204},{"trials":12178,"activeCount":101},[],{"trials":12180,"activeCount":101},[],{"trials":12182,"activeCount":101},[],{"trials":12184,"activeCount":101},[12185,12193],{"nctId":12186,"briefTitle":12187,"status":107,"phases":12188,"primaryCompletion":4119,"completion":4119,"start":9491,"enrollment":12189,"conditions":12190,"interventions":12191},"NCT01634152","Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma",[92],401,[30],[12192,12175],"Tiotropium low dose mcg",{"nctId":12194,"briefTitle":12195,"status":107,"phases":12196,"primaryCompletion":4474,"completion":4474,"start":6133,"enrollment":12197,"conditions":12198,"interventions":12199},"NCT01277523","Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma",[92],392,[30],[12200,12201],"tiotropium high dose","tiotropium low dose",{"trials":12203,"activeCount":101},[],{"trials":12205,"activeCount":101},[],{"intervention":12207,"totalTrials":1075,"cells":12208},"telmisartan+amlodipine",{"EARLY_PHASE1":12209,"PHASE1":12211,"PHASE2":12213,"PHASE3":12215,"PHASE4":12232,"NA":12234},{"trials":12210,"activeCount":101},[],{"trials":12212,"activeCount":101},[],{"trials":12214,"activeCount":101},[],{"trials":12216,"activeCount":101},[12217,12225],{"nctId":12218,"briefTitle":12219,"status":107,"phases":12220,"primaryCompletion":5856,"start":4516,"enrollment":12221,"conditions":12222,"interventions":12223},"NCT00558064","Filtered Trial for Amlodipine Non-responder",[92],531,[24],[12207,12224],"amlodipine",{"nctId":12226,"briefTitle":12227,"status":107,"phases":12228,"primaryCompletion":6224,"start":4516,"enrollment":12229,"conditions":12230,"interventions":12231},"NCT00550953","Filtered Trial for Telmisartan 40mg Non-responder",[92],314,[24],[12207,7281],{"trials":12233,"activeCount":101},[],{"trials":12235,"activeCount":101},[],{"intervention":10834,"totalTrials":1075,"cells":12237},{"EARLY_PHASE1":12238,"PHASE1":12240,"PHASE2":12242,"PHASE3":12244,"PHASE4":12259,"NA":12261},{"trials":12239,"activeCount":101},[],{"trials":12241,"activeCount":101},[],{"trials":12243,"activeCount":101},[],{"trials":12245,"activeCount":101},[12246,12255],{"nctId":12247,"briefTitle":12248,"status":107,"phases":12249,"primaryCompletion":6207,"start":7395,"enrollment":12250,"conditions":12251,"interventions":12252},"NCT02177344","Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease",[92],646,[18],[12253,12254,10834],"Low dose of Ipratropium bromide","High dose of Ipratropium bromide",{"nctId":10829,"briefTitle":10830,"status":107,"phases":12256,"primaryCompletion":5887,"start":2121,"enrollment":2235,"conditions":12257,"interventions":12258},[92],[18],[10818,10834],{"trials":12260,"activeCount":101},[],{"trials":12262,"activeCount":101},[],{"intervention":12264,"totalTrials":1075,"cells":12265},"Methotrexate",{"EARLY_PHASE1":12266,"PHASE1":12268,"PHASE2":12270,"PHASE3":12272,"PHASE4":12294,"NA":12296},{"trials":12267,"activeCount":101},[],{"trials":12269,"activeCount":101},[],{"trials":12271,"activeCount":101},[],{"trials":12273,"activeCount":101},[12274,12284],{"nctId":12275,"briefTitle":12276,"status":107,"phases":12277,"primaryCompletion":12278,"completion":12279,"start":12280,"enrollment":12281,"conditions":12282,"interventions":12283},"NCT01345682","LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and\u002For Metastatic (R\u002FM) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy",[92],"2014-03-15","2016-12-06","2012-01-05",483,[3766,3767],[1492,12264],{"nctId":12285,"briefTitle":12286,"status":107,"phases":12287,"primaryCompletion":12288,"completion":12289,"start":12290,"enrollment":12291,"conditions":12292,"interventions":12293},"NCT01856478","LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and\u002For Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy",[92],"2018-08-22","2024-10-02","2013-06-07",340,[3766],[12264,1492],{"trials":12295,"activeCount":101},[],{"trials":12297,"activeCount":101},[],{"intervention":12299,"totalTrials":1075,"cells":12300},"Buscopan®",{"EARLY_PHASE1":12301,"PHASE1":12303,"PHASE2":12305,"PHASE3":12317,"PHASE4":12327,"NA":12329},{"trials":12302,"activeCount":101},[],{"trials":12304,"activeCount":101},[],{"trials":12306,"activeCount":101},[12307],{"nctId":12308,"briefTitle":12309,"status":107,"phases":12310,"primaryCompletion":6207,"start":7924,"enrollment":12311,"conditions":12312,"interventions":12314},"NCT02229786","Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms",[91],1637,[12313],"Gastrointestinal Diseases",[12315,12299,12316],"Buscopan® plus","Paracetamol",{"trials":12318,"activeCount":101},[12319],{"nctId":12320,"briefTitle":12321,"status":107,"phases":12322,"primaryCompletion":1125,"completion":1125,"start":9515,"enrollment":5648,"conditions":12323,"interventions":12325},"NCT01929044","Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain",[92],[12324],"Intestinal Diseases",[12326,12299],"654-II",{"trials":12328,"activeCount":101},[],{"trials":12330,"activeCount":101},[],{"intervention":11963,"totalTrials":1075,"cells":12332},{"EARLY_PHASE1":12333,"PHASE1":12335,"PHASE2":12337,"PHASE3":12339,"PHASE4":12353,"NA":12355},{"trials":12334,"activeCount":101},[],{"trials":12336,"activeCount":101},[],{"trials":12338,"activeCount":101},[],{"trials":12340,"activeCount":101},[12341,12349],{"nctId":12342,"briefTitle":12343,"status":107,"phases":12344,"primaryCompletion":1980,"start":5905,"enrollment":1218,"conditions":12345,"interventions":12346},"NCT00932646","Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease",[92],[18],[12347,12348,11963],"BI 1744 (Olodaterol) Low Dose","BI 1744 (Olodaterol) Medium Dose",{"nctId":11957,"briefTitle":11958,"status":107,"phases":12350,"primaryCompletion":4392,"start":5905,"enrollment":2689,"conditions":12351,"interventions":12352},[92],[18],[6866,11962,11963],{"trials":12354,"activeCount":101},[],{"trials":12356,"activeCount":101},[],{"intervention":12358,"totalTrials":1075,"cells":12359},"Bromocriptine",{"EARLY_PHASE1":12360,"PHASE1":12362,"PHASE2":12364,"PHASE3":12366,"PHASE4":12381,"NA":12383},{"trials":12361,"activeCount":101},[],{"trials":12363,"activeCount":101},[],{"trials":12365,"activeCount":101},[],{"trials":12367,"activeCount":101},[12368,12374],{"nctId":12369,"briefTitle":12370,"status":107,"phases":12371,"primaryCompletion":2162,"start":2182,"enrollment":650,"conditions":12372,"interventions":12373},"NCT02172573","Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease",[92],[6934],[8680,12358],{"nctId":12375,"briefTitle":12376,"status":107,"phases":12377,"primaryCompletion":8479,"completion":8479,"start":5879,"enrollment":12378,"conditions":12379,"interventions":12380},"NCT00240409","Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease",[92],208,[6934],[8680,12358],{"trials":12382,"activeCount":101},[],{"trials":12384,"activeCount":101},[],{"intervention":12386,"totalTrials":1075,"cells":12387},"loperamide",{"EARLY_PHASE1":12388,"PHASE1":12390,"PHASE2":12399,"PHASE3":12401,"PHASE4":12409,"NA":12411},{"trials":12389,"activeCount":101},[],{"trials":12391,"activeCount":101},[12392],{"nctId":12393,"briefTitle":12394,"status":107,"phases":12395,"primaryCompletion":7574,"start":6495,"enrollment":380,"conditions":12396,"interventions":12397},"NCT02251119","The Pharmacodynamic\u002FPharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers",[90],[15],[4008,4010,12398],"Loperamide",{"trials":12400,"activeCount":101},[],{"trials":12402,"activeCount":101},[12403],{"nctId":12404,"briefTitle":12405,"status":107,"phases":12406,"primaryCompletion":7092,"completion":7092,"start":379,"enrollment":2382,"conditions":12407,"interventions":12408},"NCT01814553","ADAM-Afatinib Diarrhea Assessment and Management",[92],[36],[2633,12386],{"trials":12410,"activeCount":101},[],{"trials":12412,"activeCount":101},[],{"intervention":6825,"totalTrials":1075,"cells":12414},{"EARLY_PHASE1":12415,"PHASE1":12417,"PHASE2":12419,"PHASE3":12421,"PHASE4":12435,"NA":12437},{"trials":12416,"activeCount":101},[],{"trials":12418,"activeCount":101},[],{"trials":12420,"activeCount":101},[],{"trials":12422,"activeCount":101},[12423,12431],{"nctId":12424,"briefTitle":12425,"status":107,"phases":12426,"primaryCompletion":4038,"completion":4038,"start":6132,"enrollment":12427,"conditions":12428,"interventions":12429},"NCT01316380","Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma",[92],465,[30],[6825,12430],"tiotropium 5 mcg",{"nctId":6818,"briefTitle":6819,"status":107,"phases":12432,"primaryCompletion":408,"completion":408,"start":1980,"enrollment":6821,"conditions":12433,"interventions":12434},[92],[18],[6797,6824,6825],{"trials":12436,"activeCount":101},[],{"trials":12438,"activeCount":101},[],{"intervention":12440,"totalTrials":1075,"cells":12441},"Ambroxol Lozenge",{"EARLY_PHASE1":12442,"PHASE1":12444,"PHASE2":12455,"PHASE3":12457,"PHASE4":12465,"NA":12467},{"trials":12443,"activeCount":101},[],{"trials":12445,"activeCount":101},[12446],{"nctId":12447,"briefTitle":12448,"status":107,"phases":12449,"primaryCompletion":2032,"start":4412,"enrollment":188,"conditions":12450,"interventions":12451},"NCT02194257","Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers",[90],[15],[12452,12453,12454],"[14C]-cyclohexane ambroxol oral solution","[14C]-benzyl ambroxol oral solution","Ambroxol lozenge",{"trials":12456,"activeCount":101},[],{"trials":12458,"activeCount":101},[12459],{"nctId":12460,"briefTitle":12461,"status":107,"phases":12462,"primaryCompletion":5842,"completion":5842,"start":11581,"enrollment":5933,"conditions":12463,"interventions":12464},"NCT00144274","Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis",[92],[6587],[12440],{"trials":12466,"activeCount":101},[],{"trials":12468,"activeCount":101},[],{"intervention":12470,"totalTrials":1075,"cells":12471},"Linagliptin + pioglitazone",{"EARLY_PHASE1":12472,"PHASE1":12474,"PHASE2":12484,"PHASE3":12486,"PHASE4":12494,"NA":12496},{"trials":12473,"activeCount":101},[],{"trials":12475,"activeCount":101},[12476],{"nctId":12477,"briefTitle":12478,"status":107,"phases":12479,"primaryCompletion":9348,"start":6133,"enrollment":1208,"conditions":12480,"interventions":12481},"NCT01276327","Bioequivalence of a Fixed Dose Combination Tablet Linagliptin\u002FPioglitazone Compared With Its Mono-components",[90],[15],[12482,12482,12483,12483],"Linagliptin + Pioglitazone","Linagliptin\u002FPioglitazone",{"trials":12485,"activeCount":101},[],{"trials":12487,"activeCount":101},[12488],{"nctId":12489,"briefTitle":12490,"status":107,"phases":12491,"primaryCompletion":5905,"start":4128,"enrollment":6311,"conditions":12492,"interventions":12493},"NCT00641043","Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone",[92],[21],[12470],{"trials":12495,"activeCount":101},[],{"trials":12497,"activeCount":101},[],{"intervention":12499,"totalTrials":1075,"cells":12500},"Comparator Protease Inhibitor",{"EARLY_PHASE1":12501,"PHASE1":12503,"PHASE2":12505,"PHASE3":12507,"PHASE4":12524,"NA":12526},{"trials":12502,"activeCount":101},[],{"trials":12504,"activeCount":101},[],{"trials":12506,"activeCount":101},[],{"trials":12508,"activeCount":101},[12509,12516],{"nctId":12510,"briefTitle":12511,"status":107,"phases":12512,"primaryCompletion":5856,"start":7574,"enrollment":12513,"conditions":12514,"interventions":12515},"NCT00054717","Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)",[92],630,[27],[4008,4010,12499],{"nctId":12517,"briefTitle":12518,"status":107,"phases":12519,"primaryCompletion":4412,"start":6081,"enrollment":12520,"conditions":12521,"interventions":12522},"NCT00144170","Tipranavir\u002FRitonavir vs. Genotypically Defined Protease Inhibitor\u002FRitonavir in HIV Patients (RESIST-2)",[92],882,[27],[4008,12523],"Comparator protease inhibitor",{"trials":12525,"activeCount":101},[],{"trials":12527,"activeCount":101},[],{"intervention":12529,"totalTrials":1075,"cells":12530},"BI 767551 intravenous",{"EARLY_PHASE1":12531,"PHASE1":12533,"PHASE2":12535,"PHASE3":12537,"PHASE4":12558,"NA":12560},{"trials":12532,"activeCount":101},[],{"trials":12534,"activeCount":101},[],{"trials":12536,"activeCount":101},[],{"trials":12538,"activeCount":101},[12539,12548],{"nctId":12540,"briefTitle":12541,"status":162,"phases":12542,"primaryCompletion":935,"completion":12543,"start":12544,"enrollment":166,"conditions":12545,"interventions":12546},"NCT04822701","A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19",[91,92],"2021-10-04","2021-04-21",[1920],[12529,12547],"BI 767551 inhaled",{"nctId":12549,"briefTitle":12550,"status":600,"phases":12551,"primaryCompletion":12552,"completion":12553,"start":12554,"enrollment":101,"conditions":12555,"interventions":12556},"NCT04894474","A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2",[91,92],"2022-05-23","2022-07-24","2021-06-17",[1920],[12529,12557],"BI 767551 inhalation",{"trials":12559,"activeCount":101},[],{"trials":12561,"activeCount":101},[],{"intervention":12563,"totalTrials":1075,"cells":12564},"Telmisartan + hydrochlorothiazide",{"EARLY_PHASE1":12565,"PHASE1":12567,"PHASE2":12569,"PHASE3":12575,"PHASE4":12583,"NA":12585},{"trials":12566,"activeCount":101},[],{"trials":12568,"activeCount":101},[],{"trials":12570,"activeCount":101},[12571],{"nctId":6232,"briefTitle":6233,"status":107,"phases":12572,"primaryCompletion":1115,"completion":1115,"start":6235,"enrollment":6236,"conditions":12573,"interventions":12574},[91],[24],[6121,6196,6239],{"trials":12576,"activeCount":101},[12577],{"nctId":12578,"briefTitle":12579,"status":107,"phases":12580,"primaryCompletion":2122,"start":2181,"enrollment":7301,"conditions":12581,"interventions":12582},"NCT02177500","Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy",[92],[24],[12563,6121],{"trials":12584,"activeCount":101},[],{"trials":12586,"activeCount":101},[],{"intervention":12588,"totalTrials":1075,"cells":12589},"Tiotropium low",{"EARLY_PHASE1":12590,"PHASE1":12592,"PHASE2":12594,"PHASE3":12607,"PHASE4":12617,"NA":12619},{"trials":12591,"activeCount":101},[],{"trials":12593,"activeCount":101},[],{"trials":12595,"activeCount":101},[12596],{"nctId":12597,"briefTitle":12598,"status":107,"phases":12599,"primaryCompletion":390,"start":12600,"enrollment":9115,"conditions":12601,"interventions":12602},"NCT01222533","Tiotropium Respimat Pharmacokinetic Study in COPD",[91],"2010-10",[18],[12603,12588,12604,12605,12606],"Tiotropium medium","Tiotropium high","Tiotropium 18mcg","Tiotropium placebo",{"trials":12608,"activeCount":101},[12609],{"nctId":12610,"briefTitle":12611,"status":107,"phases":12612,"primaryCompletion":7132,"start":5880,"enrollment":12613,"conditions":12614,"interventions":12615},"NCT02172807","Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],201,[18],[12588,12604,12616],"Oxitropium",{"trials":12618,"activeCount":101},[],{"trials":12620,"activeCount":101},[],{"intervention":12604,"totalTrials":1075,"cells":12622},{"EARLY_PHASE1":12623,"PHASE1":12625,"PHASE2":12627,"PHASE3":12633,"PHASE4":12639,"NA":12641},{"trials":12624,"activeCount":101},[],{"trials":12626,"activeCount":101},[],{"trials":12628,"activeCount":101},[12629],{"nctId":12597,"briefTitle":12598,"status":107,"phases":12630,"primaryCompletion":390,"start":12600,"enrollment":9115,"conditions":12631,"interventions":12632},[91],[18],[12603,12588,12604,12605,12606],{"trials":12634,"activeCount":101},[12635],{"nctId":12610,"briefTitle":12611,"status":107,"phases":12636,"primaryCompletion":7132,"start":5880,"enrollment":12613,"conditions":12637,"interventions":12638},[92],[18],[12588,12604,12616],{"trials":12640,"activeCount":101},[],{"trials":12642,"activeCount":101},[],{"intervention":12644,"totalTrials":1075,"cells":12645},"nonivamide + nicoboxil",{"EARLY_PHASE1":12646,"PHASE1":12648,"PHASE2":12650,"PHASE3":12652,"PHASE4":12670,"NA":12672},{"trials":12647,"activeCount":101},[],{"trials":12649,"activeCount":101},[],{"trials":12651,"activeCount":101},[],{"trials":12653,"activeCount":101},[12654,12661],{"nctId":12655,"briefTitle":12656,"status":107,"phases":12657,"primaryCompletion":4119,"completion":4119,"start":603,"enrollment":2183,"conditions":12658,"interventions":12660},"NCT02300311","Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain",[92],[12659],"Low Back Pain",[12644],{"nctId":12662,"briefTitle":12663,"status":107,"phases":12664,"primaryCompletion":379,"completion":379,"start":517,"enrollment":7763,"conditions":12665,"interventions":12667},"NCT01708915","Nonivamide\u002FNicoboxil Ointment in Acute Low Back Pain",[92],[12666],"Acute Low Back Pain",[12668,12644,12669],"nicoboxil","nonivamide",{"trials":12671,"activeCount":101},[],{"trials":12673,"activeCount":101},[],{"intervention":12675,"totalTrials":1075,"cells":12676},"Red Vine Leaf Extract",{"EARLY_PHASE1":12677,"PHASE1":12679,"PHASE2":12687,"PHASE3":12689,"PHASE4":12698,"NA":12700},{"trials":12678,"activeCount":101},[],{"trials":12680,"activeCount":101},[12681],{"nctId":12682,"briefTitle":12683,"status":107,"phases":12684,"primaryCompletion":9276,"start":6584,"enrollment":188,"conditions":12685,"interventions":12686},"NCT02191241","Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)",[90],[15],[12675],{"trials":12688,"activeCount":101},[],{"trials":12690,"activeCount":101},[12691],{"nctId":12692,"briefTitle":12693,"status":107,"phases":12694,"primaryCompletion":399,"start":2003,"enrollment":7476,"conditions":12695,"interventions":12696},"NCT00855179","Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency",[92],[8458],[12697],"Red vine leaf extract",{"trials":12699,"activeCount":101},[],{"trials":12701,"activeCount":101},[],{"intervention":12703,"totalTrials":1075,"cells":12704},"telmisartan and amlodipine",{"EARLY_PHASE1":12705,"PHASE1":12707,"PHASE2":12709,"PHASE3":12711,"PHASE4":12728,"NA":12730},{"trials":12706,"activeCount":101},[],{"trials":12708,"activeCount":101},[],{"trials":12710,"activeCount":101},[],{"trials":12712,"activeCount":101},[12713,12720],{"nctId":12714,"briefTitle":12715,"status":107,"phases":12716,"primaryCompletion":9381,"start":2003,"enrollment":12717,"conditions":12718,"interventions":12719},"NCT00860262","Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension",[92],858,[24],[12224,7281,12703],{"nctId":12721,"briefTitle":12722,"status":107,"phases":12723,"primaryCompletion":2030,"start":12600,"enrollment":12724,"conditions":12725,"interventions":12726},"NCT01222520","Telmisartan 80mg Non-responder Trial",[92],174,[24],[12727,6121],"Telmisartan and amlodipine",{"trials":12729,"activeCount":101},[],{"trials":12731,"activeCount":101},[],{"intervention":12733,"totalTrials":1075,"cells":12734},"Bisacodyl",{"EARLY_PHASE1":12735,"PHASE1":12737,"PHASE2":12746,"PHASE3":12748,"PHASE4":12758,"NA":12760},{"trials":12736,"activeCount":101},[],{"trials":12738,"activeCount":101},[12739],{"nctId":12740,"briefTitle":12741,"status":107,"phases":12742,"primaryCompletion":5906,"start":4129,"enrollment":401,"conditions":12743,"interventions":12744},"NCT02211911","Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females",[90],[15],[12733,12745],"Sodium picosulfate",{"trials":12747,"activeCount":101},[],{"trials":12749,"activeCount":101},[12750],{"nctId":12751,"briefTitle":12752,"status":107,"phases":12753,"primaryCompletion":2146,"start":6374,"enrollment":357,"conditions":12754,"interventions":12756},"NCT02211976","Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness",[92],[12755],"Constipation",[12733,12757],"Simeticone",{"trials":12759,"activeCount":101},[],{"trials":12761,"activeCount":101},[],{"intervention":12763,"totalTrials":1075,"cells":12764},"WAL 801 CL dry syrup",{"EARLY_PHASE1":12765,"PHASE1":12767,"PHASE2":12769,"PHASE3":12771,"PHASE4":12790,"NA":12792},{"trials":12766,"activeCount":101},[],{"trials":12768,"activeCount":101},[],{"trials":12770,"activeCount":101},[],{"trials":12772,"activeCount":101},[12773,12779],{"nctId":12774,"briefTitle":12775,"status":107,"phases":12776,"primaryCompletion":6030,"start":2121,"enrollment":31,"conditions":12777,"interventions":12778},"NCT02182570","WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients",[92],[179],[12763],{"nctId":12780,"briefTitle":12781,"status":107,"phases":12782,"primaryCompletion":5993,"start":2121,"enrollment":12783,"conditions":12784,"interventions":12785},"NCT02182557","WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients",[92],162,[179],[12786,12787,12788,12789],"WAL 801 CL Dry Syrup","Ketotifen Fumarate Dry Syrup","WAL 801 CL Dry Syrup placebo","Ketotifen Fumarate Dry Syrup placebo",{"trials":12791,"activeCount":101},[],{"trials":12793,"activeCount":101},[],{"intervention":6814,"totalTrials":1075,"cells":12795},{"EARLY_PHASE1":12796,"PHASE1":12798,"PHASE2":12800,"PHASE3":12802,"PHASE4":12812,"NA":12814},{"trials":12797,"activeCount":101},[],{"trials":12799,"activeCount":101},[],{"trials":12801,"activeCount":101},[],{"trials":12803,"activeCount":101},[12804,12808],{"nctId":6808,"briefTitle":6809,"status":107,"phases":12805,"primaryCompletion":6133,"start":6811,"enrollment":25,"conditions":12806,"interventions":12807},[92],[18],[6814,6815,6816],{"nctId":6827,"briefTitle":6828,"status":107,"phases":12809,"primaryCompletion":6133,"start":6811,"enrollment":220,"conditions":12810,"interventions":12811},[92],[18],[6814,6815,6816],{"trials":12813,"activeCount":101},[],{"trials":12815,"activeCount":101},[],{"intervention":6815,"totalTrials":1075,"cells":12817},{"EARLY_PHASE1":12818,"PHASE1":12820,"PHASE2":12822,"PHASE3":12824,"PHASE4":12834,"NA":12836},{"trials":12819,"activeCount":101},[],{"trials":12821,"activeCount":101},[],{"trials":12823,"activeCount":101},[],{"trials":12825,"activeCount":101},[12826,12830],{"nctId":6808,"briefTitle":6809,"status":107,"phases":12827,"primaryCompletion":6133,"start":6811,"enrollment":25,"conditions":12828,"interventions":12829},[92],[18],[6814,6815,6816],{"nctId":6827,"briefTitle":6828,"status":107,"phases":12831,"primaryCompletion":6133,"start":6811,"enrollment":220,"conditions":12832,"interventions":12833},[92],[18],[6814,6815,6816],{"trials":12835,"activeCount":101},[],{"trials":12837,"activeCount":101},[],{"intervention":12201,"totalTrials":1075,"cells":12839},{"EARLY_PHASE1":12840,"PHASE1":12842,"PHASE2":12844,"PHASE3":12857,"PHASE4":12863,"NA":12865},{"trials":12841,"activeCount":101},[],{"trials":12843,"activeCount":101},[],{"trials":12845,"activeCount":101},[12846],{"nctId":12847,"briefTitle":12848,"status":107,"phases":12849,"primaryCompletion":12850,"start":12851,"enrollment":10776,"conditions":12852,"interventions":12853},"NCT02242266","Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],"2006-06-04","2005-07-28",[18],[12854,12855,12856],"Tiotropium low dose","Tiotropium medium dose","Spiriva® HandiHaler® high dose",{"trials":12858,"activeCount":101},[12859],{"nctId":12194,"briefTitle":12195,"status":107,"phases":12860,"primaryCompletion":4474,"completion":4474,"start":6133,"enrollment":12197,"conditions":12861,"interventions":12862},[92],[30],[12200,12201],{"trials":12864,"activeCount":101},[],{"trials":12866,"activeCount":101},[],{"intervention":12868,"totalTrials":1075,"cells":12869},"nevirapine IR",{"EARLY_PHASE1":12870,"PHASE1":12872,"PHASE2":12874,"PHASE3":12876,"PHASE4":12895,"NA":12897},{"trials":12871,"activeCount":101},[],{"trials":12873,"activeCount":101},[],{"trials":12875,"activeCount":101},[],{"trials":12877,"activeCount":101},[12878,12886],{"nctId":12879,"briefTitle":12880,"status":107,"phases":12881,"primaryCompletion":390,"start":9418,"enrollment":12882,"conditions":12883,"interventions":12884},"NCT00561925","VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients",[92],1068,[27],[12868,12885],"nevirapine XR",{"nctId":12887,"briefTitle":12888,"status":107,"phases":12889,"primaryCompletion":7338,"completion":7338,"start":2032,"enrollment":12890,"conditions":12891,"interventions":12892},"NCT00819052","Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients",[92],445,[27],[12893,12893,12894],"Nevirapine XR","Nevirapine IR",{"trials":12896,"activeCount":101},[],{"trials":12898,"activeCount":101},[],{"intervention":12885,"totalTrials":1075,"cells":12900},{"EARLY_PHASE1":12901,"PHASE1":12903,"PHASE2":12905,"PHASE3":12907,"PHASE4":12917,"NA":12919},{"trials":12902,"activeCount":101},[],{"trials":12904,"activeCount":101},[],{"trials":12906,"activeCount":101},[],{"trials":12908,"activeCount":101},[12909,12913],{"nctId":12879,"briefTitle":12880,"status":107,"phases":12910,"primaryCompletion":390,"start":9418,"enrollment":12882,"conditions":12911,"interventions":12912},[92],[27],[12868,12885],{"nctId":12887,"briefTitle":12888,"status":107,"phases":12914,"primaryCompletion":7338,"completion":7338,"start":2032,"enrollment":12890,"conditions":12915,"interventions":12916},[92],[27],[12893,12893,12894],{"trials":12918,"activeCount":101},[],{"trials":12920,"activeCount":101},[],{"intervention":12922,"totalTrials":1075,"cells":12923},"Tiotropium Inhalation Solution",{"EARLY_PHASE1":12924,"PHASE1":12926,"PHASE2":12928,"PHASE3":12930,"PHASE4":12944,"NA":12946},{"trials":12925,"activeCount":101},[],{"trials":12927,"activeCount":101},[],{"trials":12929,"activeCount":101},[],{"trials":12931,"activeCount":101},[12932,12939],{"nctId":12933,"briefTitle":12934,"status":107,"phases":12935,"primaryCompletion":1115,"start":6081,"enrollment":12936,"conditions":12937,"interventions":12938},"NCT00168831","Tiotropium \u002F Respimat One-Year Study",[92],1007,[18],[12922],{"nctId":12940,"briefTitle":12934,"status":107,"phases":12941,"primaryCompletion":1115,"start":7574,"enrollment":518,"conditions":12942,"interventions":12943},"NCT00168844",[92],[18],[12922],{"trials":12945,"activeCount":101},[],{"trials":12947,"activeCount":101},[],{"intervention":12949,"totalTrials":1075,"cells":12950},"COMBIVENT HFA",{"EARLY_PHASE1":12951,"PHASE1":12953,"PHASE2":12955,"PHASE3":12961,"PHASE4":12970,"NA":12972},{"trials":12952,"activeCount":101},[],{"trials":12954,"activeCount":101},[],{"trials":12956,"activeCount":101},[12957],{"nctId":7211,"briefTitle":7212,"status":107,"phases":12958,"primaryCompletion":6584,"start":6053,"enrollment":3565,"conditions":12959,"interventions":12960},[91],[18],[7216,7202],{"trials":12962,"activeCount":101},[12963],{"nctId":12964,"briefTitle":12965,"status":162,"phases":12966,"primaryCompletion":2121,"start":6053,"enrollment":11419,"conditions":12967,"interventions":12968},"NCT02194205","Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[12949,12969],"COMBIVENT CFC",{"trials":12971,"activeCount":101},[],{"trials":12973,"activeCount":101},[],{"intervention":10687,"totalTrials":1075,"cells":12975},{"EARLY_PHASE1":12976,"PHASE1":12978,"PHASE2":12980,"PHASE3":12982,"PHASE4":12992,"NA":12994},{"trials":12977,"activeCount":101},[],{"trials":12979,"activeCount":101},[],{"trials":12981,"activeCount":101},[],{"trials":12983,"activeCount":101},[12984,12988],{"nctId":10679,"briefTitle":10680,"status":107,"phases":12985,"primaryCompletion":10682,"completion":10683,"start":10684,"enrollment":2586,"conditions":12986,"interventions":12987},[92],[190],[10638,10687],{"nctId":10698,"briefTitle":10699,"status":107,"phases":12989,"primaryCompletion":10701,"completion":10701,"start":10702,"enrollment":10703,"conditions":12990,"interventions":12991},[92],[114],[10638,10706],{"trials":12993,"activeCount":101},[],{"trials":12995,"activeCount":101},[],{"intervention":12997,"totalTrials":1075,"cells":12998},"tiotropium Respimat® low dose",{"EARLY_PHASE1":12999,"PHASE1":13001,"PHASE2":13003,"PHASE3":13005,"PHASE4":13023,"NA":13025},{"trials":13000,"activeCount":101},[],{"trials":13002,"activeCount":101},[],{"trials":13004,"activeCount":101},[],{"trials":13006,"activeCount":101},[13007,13016],{"nctId":13008,"briefTitle":13009,"status":107,"phases":13010,"primaryCompletion":446,"completion":446,"start":4442,"enrollment":13011,"conditions":13012,"interventions":13013},"NCT01172821","Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II",[92],1032,[30],[12997,13014,13015],"tiotropium Respimat® high dose","50 mcg salmeterol HFA MDI",{"nctId":13017,"briefTitle":13018,"status":107,"phases":13019,"primaryCompletion":446,"completion":446,"start":4442,"enrollment":13020,"conditions":13021,"interventions":13022},"NCT01172808","Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I",[92],1071,[30],[12997,13014,13015],{"trials":13024,"activeCount":101},[],{"trials":13026,"activeCount":101},[],{"intervention":13014,"totalTrials":1075,"cells":13028},{"EARLY_PHASE1":13029,"PHASE1":13031,"PHASE2":13033,"PHASE3":13035,"PHASE4":13045,"NA":13047},{"trials":13030,"activeCount":101},[],{"trials":13032,"activeCount":101},[],{"trials":13034,"activeCount":101},[],{"trials":13036,"activeCount":101},[13037,13041],{"nctId":13008,"briefTitle":13009,"status":107,"phases":13038,"primaryCompletion":446,"completion":446,"start":4442,"enrollment":13011,"conditions":13039,"interventions":13040},[92],[30],[12997,13014,13015],{"nctId":13017,"briefTitle":13018,"status":107,"phases":13042,"primaryCompletion":446,"completion":446,"start":4442,"enrollment":13020,"conditions":13043,"interventions":13044},[92],[30],[12997,13014,13015],{"trials":13046,"activeCount":101},[],{"trials":13048,"activeCount":101},[],{"intervention":13015,"totalTrials":1075,"cells":13050},{"EARLY_PHASE1":13051,"PHASE1":13053,"PHASE2":13055,"PHASE3":13057,"PHASE4":13067,"NA":13069},{"trials":13052,"activeCount":101},[],{"trials":13054,"activeCount":101},[],{"trials":13056,"activeCount":101},[],{"trials":13058,"activeCount":101},[13059,13063],{"nctId":13008,"briefTitle":13009,"status":107,"phases":13060,"primaryCompletion":446,"completion":446,"start":4442,"enrollment":13011,"conditions":13061,"interventions":13062},[92],[30],[12997,13014,13015],{"nctId":13017,"briefTitle":13018,"status":107,"phases":13064,"primaryCompletion":446,"completion":446,"start":4442,"enrollment":13020,"conditions":13065,"interventions":13066},[92],[30],[12997,13014,13015],{"trials":13068,"activeCount":101},[],{"trials":13070,"activeCount":101},[],{"intervention":6776,"totalTrials":1075,"cells":13072},{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13077,"PHASE3":13079,"PHASE4":13089,"NA":13091},{"trials":13074,"activeCount":101},[],{"trials":13076,"activeCount":101},[],{"trials":13078,"activeCount":101},[],{"trials":13080,"activeCount":101},[13081,13085],{"nctId":6770,"briefTitle":6771,"status":107,"phases":13082,"primaryCompletion":3763,"completion":3763,"start":4498,"enrollment":6773,"conditions":13083,"interventions":13084},[92],[24],[6776,6747,6777],{"nctId":6779,"briefTitle":6780,"status":107,"phases":13086,"primaryCompletion":3978,"completion":3978,"start":6782,"enrollment":1274,"conditions":13087,"interventions":13088},[92],[24],[6776,6747],{"trials":13090,"activeCount":101},[],{"trials":13092,"activeCount":101},[],{"intervention":13094,"totalTrials":1075,"cells":13095},"Berodual® MDI",{"EARLY_PHASE1":13096,"PHASE1":13098,"PHASE2":13100,"PHASE3":13102,"PHASE4":13123,"NA":13125},{"trials":13097,"activeCount":101},[],{"trials":13099,"activeCount":101},[],{"trials":13101,"activeCount":101},[],{"trials":13103,"activeCount":101},[13104,13113],{"nctId":13105,"briefTitle":13106,"status":107,"phases":13107,"primaryCompletion":2182,"start":7924,"enrollment":13108,"conditions":13109,"interventions":13110},"NCT02173782","Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],892,[18],[13111,13112,13094],"Berodual® Respimat ® high dose","Berodual® Respimat ® low dose",{"nctId":13114,"briefTitle":13115,"status":107,"phases":13116,"primaryCompletion":13117,"start":7084,"enrollment":13118,"conditions":13119,"interventions":13120},"NCT02182505","Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma",[92],"1999-07",535,[30],[13121,13122,13094],"Berodual® Respimat®, low dose","Berodual® Respimat®, high dose",{"trials":13124,"activeCount":101},[],{"trials":13126,"activeCount":101},[],{"intervention":9810,"totalTrials":1075,"cells":13128},{"EARLY_PHASE1":13129,"PHASE1":13131,"PHASE2":13133,"PHASE3":13139,"PHASE4":13145,"NA":13147},{"trials":13130,"activeCount":101},[],{"trials":13132,"activeCount":101},[],{"trials":13134,"activeCount":101},[13135],{"nctId":9804,"briefTitle":9805,"status":107,"phases":13136,"primaryCompletion":9340,"start":400,"enrollment":9807,"conditions":13137,"interventions":13138},[91],[9764],[4042,4042,9810,9801],{"trials":13140,"activeCount":101},[13141],{"nctId":9839,"briefTitle":9840,"status":107,"phases":13142,"primaryCompletion":9614,"completion":9842,"start":2030,"enrollment":7196,"conditions":13143,"interventions":13144},[92],[4040],[4042,9810,9801],{"trials":13146,"activeCount":101},[],{"trials":13148,"activeCount":101},[],{"intervention":13150,"totalTrials":1075,"cells":13151},"Dabigatran dose 1",{"EARLY_PHASE1":13152,"PHASE1":13154,"PHASE2":13156,"PHASE3":13158,"PHASE4":13177,"NA":13179},{"trials":13153,"activeCount":101},[],{"trials":13155,"activeCount":101},[],{"trials":13157,"activeCount":101},[],{"trials":13159,"activeCount":101},[13160,13168],{"nctId":13161,"briefTitle":13162,"status":107,"phases":13163,"primaryCompletion":9404,"start":4462,"enrollment":13164,"conditions":13165,"interventions":13166},"NCT00262600","Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate",[92],18113,[6098,2092],[4165,13150,13167],"Dabigatran dose 2",{"nctId":13169,"briefTitle":13170,"status":107,"phases":13171,"primaryCompletion":9593,"completion":9593,"start":10775,"enrollment":13172,"conditions":13173,"interventions":13174},"NCT00808067","RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial",[92],5897,[6098],[13175,13176],"dabigatran dose 1","dabigatran dose 2",{"trials":13178,"activeCount":101},[],{"trials":13180,"activeCount":101},[],{"intervention":13167,"totalTrials":1075,"cells":13182},{"EARLY_PHASE1":13183,"PHASE1":13185,"PHASE2":13187,"PHASE3":13189,"PHASE4":13199,"NA":13201},{"trials":13184,"activeCount":101},[],{"trials":13186,"activeCount":101},[],{"trials":13188,"activeCount":101},[],{"trials":13190,"activeCount":101},[13191,13195],{"nctId":13161,"briefTitle":13162,"status":107,"phases":13192,"primaryCompletion":9404,"start":4462,"enrollment":13164,"conditions":13193,"interventions":13194},[92],[6098,2092],[4165,13150,13167],{"nctId":13169,"briefTitle":13170,"status":107,"phases":13196,"primaryCompletion":9593,"completion":9593,"start":10775,"enrollment":13172,"conditions":13197,"interventions":13198},[92],[6098],[13175,13176],{"trials":13200,"activeCount":101},[],{"trials":13202,"activeCount":101},[],{"intervention":13204,"totalTrials":1075,"cells":13205},"Spesolimab - solution for",{"EARLY_PHASE1":13206,"PHASE1":13208,"PHASE2":13210,"PHASE3":13223,"PHASE4":13233,"NA":13235},{"trials":13207,"activeCount":101},[],{"trials":13209,"activeCount":101},[],{"trials":13211,"activeCount":101},[13212],{"nctId":13213,"briefTitle":13214,"status":107,"phases":13215,"primaryCompletion":13216,"completion":13217,"start":13218,"enrollment":342,"conditions":13219,"interventions":13221},"NCT04762277","A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa",[91],"2022-01-19","2022-04-21","2021-04-06",[13220],"Hidradenitis Suppurativa",[13204,13222],"Spesolimab- solution for",{"trials":13224,"activeCount":101},[13225],{"nctId":13226,"briefTitle":13227,"status":162,"phases":13228,"primaryCompletion":2822,"completion":13229,"start":945,"enrollment":2789,"conditions":13230,"interventions":13232},"NCT05856526","A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome",[91,92],"2025-07-31",[13231],"Netherton Syndrome",[13204,13204],{"trials":13234,"activeCount":101},[],{"trials":13236,"activeCount":101},[],{"intervention":13238,"totalTrials":1075,"cells":13239},"Amlodipine 5mg",{"EARLY_PHASE1":13240,"PHASE1":13242,"PHASE2":13252,"PHASE3":13254,"PHASE4":13266,"NA":13268},{"trials":13241,"activeCount":101},[],{"trials":13243,"activeCount":101},[13244],{"nctId":13245,"briefTitle":13246,"status":107,"phases":13247,"primaryCompletion":3731,"completion":420,"start":9842,"enrollment":716,"conditions":13248,"interventions":13249},"NCT02129192","Bioequivalence Study of Telmisartan Between Telmisartan 80 mg\u002FAmlodipine 5 mg\u002FHydrochlorothiazide 12.5 mg (T80\u002FA5\u002FH12.5 mg) Fixed-dose Combination (FDC) Tablet and T80\u002FH12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use",[90],[15],[13238,13250,13251],"T80\u002FH12.5 mg FDC","T80\u002FA5\u002FH12.5 mg FDC",{"trials":13253,"activeCount":101},[],{"trials":13255,"activeCount":101},[13256],{"nctId":13257,"briefTitle":13258,"status":107,"phases":13259,"primaryCompletion":2648,"start":1967,"enrollment":13260,"conditions":13261,"interventions":13262},"NCT01103960","An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy",[92],324,[24],[13263,13264,13265],"Telmisartan80mg+Amlodipine5mg","amlodipine 5mg","Telmisartan80mg+Amlodipine 5mg",{"trials":13267,"activeCount":101},[],{"trials":13269,"activeCount":101},[],{"intervention":6953,"totalTrials":1075,"cells":13271},{"EARLY_PHASE1":13272,"PHASE1":13274,"PHASE2":13280,"PHASE3":13282,"PHASE4":13295,"NA":13297},{"trials":13273,"activeCount":101},[],{"trials":13275,"activeCount":101},[13276],{"nctId":6946,"briefTitle":6947,"status":107,"phases":13277,"primaryCompletion":6949,"start":2162,"enrollment":956,"conditions":13278,"interventions":13279},[90],[15],[6476,6952,6953],{"trials":13281,"activeCount":101},[],{"trials":13283,"activeCount":101},[13284],{"nctId":13285,"briefTitle":13286,"status":107,"phases":13287,"primaryCompletion":13117,"start":7553,"enrollment":13288,"conditions":13289,"interventions":13291},"NCT02183220","Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache",[92],417,[13290],"Migraine Disorders",[13292,6953,13293,13294],"Metamizol","Metamizol placebo","ASA placebo",{"trials":13296,"activeCount":101},[],{"trials":13298,"activeCount":101},[],{"intervention":11737,"totalTrials":1075,"cells":13300},{"EARLY_PHASE1":13301,"PHASE1":13303,"PHASE2":13305,"PHASE3":13307,"PHASE4":13317,"NA":13319},{"trials":13302,"activeCount":101},[],{"trials":13304,"activeCount":101},[],{"trials":13306,"activeCount":101},[],{"trials":13308,"activeCount":101},[13309,13313],{"nctId":11730,"briefTitle":11731,"status":107,"phases":13310,"completion":11733,"start":7114,"enrollment":11734,"conditions":13311,"interventions":13312},[92],[6934],[11711,11737],{"nctId":11739,"briefTitle":11740,"status":107,"phases":13314,"primaryCompletion":4128,"start":1990,"enrollment":9115,"conditions":13315,"interventions":13316},[92],[11743],[11711,11737],{"trials":13318,"activeCount":101},[],{"trials":13320,"activeCount":101},[],{"intervention":13322,"totalTrials":1075,"cells":13323},"fixed dose combination of telmisartan+amlodipine",{"EARLY_PHASE1":13324,"PHASE1":13326,"PHASE2":13328,"PHASE3":13330,"PHASE4":13346,"NA":13348},{"trials":13325,"activeCount":101},[],{"trials":13327,"activeCount":101},[],{"trials":13329,"activeCount":101},[],{"trials":13331,"activeCount":101},[13332,13339],{"nctId":13333,"briefTitle":13334,"status":107,"phases":13335,"primaryCompletion":4412,"start":9418,"enrollment":13336,"conditions":13337,"interventions":13338},"NCT00553267","Telmisartan\u002FAmlodipine (80\u002F10) vs. Telmisartan\u002FAmlodipine (40\u002F10) vs. amlodipine10 in Resistant Hypertension",[92],947,[24],[13322,12224],{"nctId":13340,"briefTitle":13341,"status":107,"phases":13342,"primaryCompletion":5856,"start":4516,"enrollment":13343,"conditions":13344,"interventions":13345},"NCT00558428","Telmisartan\u002FAmlodipine (80\u002F5) vs. Telmisartan\u002FAmlodipine (40\u002F5) vs. Amlodipine 10 or 5 in Resistant Hypertension",[92],1098,[24],[13322,12224],{"trials":13347,"activeCount":101},[],{"trials":13349,"activeCount":101},[],{"intervention":11848,"totalTrials":1075,"cells":13351},{"EARLY_PHASE1":13352,"PHASE1":13354,"PHASE2":13360,"PHASE3":13362,"PHASE4":13368,"NA":13370},{"trials":13353,"activeCount":101},[],{"trials":13355,"activeCount":101},[13356],{"nctId":11843,"briefTitle":11844,"status":107,"phases":13357,"primaryCompletion":6207,"start":6738,"enrollment":439,"conditions":13358,"interventions":13359},[90],[15],[11836,11848,11849],{"trials":13361,"activeCount":101},[],{"trials":13363,"activeCount":101},[13364],{"nctId":11862,"briefTitle":11863,"status":107,"phases":13365,"primaryCompletion":6884,"start":2122,"enrollment":3436,"conditions":13366,"interventions":13367},[92],[11866],[11836,11848],{"trials":13369,"activeCount":101},[],{"trials":13371,"activeCount":101},[],{"intervention":7514,"totalTrials":1075,"cells":13373},{"EARLY_PHASE1":13374,"PHASE1":13376,"PHASE2":13388,"PHASE3":13390,"PHASE4":13396,"NA":13398},{"trials":13375,"activeCount":101},[],{"trials":13377,"activeCount":101},[13378],{"nctId":13379,"briefTitle":13380,"status":107,"phases":13381,"primaryCompletion":12159,"completion":12159,"start":4473,"enrollment":132,"conditions":13382,"interventions":13383},"NCT02028767","Bioequivalence Study in Healthy Volunteers for Empagliflozin\u002FMetformin Fixed Dose Combination Compared to Separate Tablets",[90],[15],[13384,13385,13386,13387],"Empagliflozin 2.5 mg","Empagliflozin 10 mg","Metformin 500 mg","Empagliflozin\u002FMetformin FDC",{"trials":13389,"activeCount":101},[],{"trials":13391,"activeCount":101},[13392],{"nctId":7504,"briefTitle":7505,"status":107,"phases":13393,"primaryCompletion":7507,"completion":7508,"start":7509,"enrollment":7510,"conditions":13394,"interventions":13395},[92],[21],[7513,7514,7515,7493],{"trials":13397,"activeCount":101},[],{"trials":13399,"activeCount":101},[],{"intervention":12787,"totalTrials":1075,"cells":13401},{"EARLY_PHASE1":13402,"PHASE1":13404,"PHASE2":13406,"PHASE3":13408,"PHASE4":13424,"NA":13426},{"trials":13403,"activeCount":101},[],{"trials":13405,"activeCount":101},[],{"trials":13407,"activeCount":101},[],{"trials":13409,"activeCount":101},[13410,13414],{"nctId":12780,"briefTitle":12781,"status":107,"phases":13411,"primaryCompletion":5993,"start":2121,"enrollment":12783,"conditions":13412,"interventions":13413},[92],[179],[12786,12787,12788,12789],{"nctId":13415,"briefTitle":13416,"status":107,"phases":13417,"primaryCompletion":6040,"start":2121,"enrollment":1458,"conditions":13418,"interventions":13419},"NCT02182544","WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis",[92],[11866],[13420,13421,13422,13423],"WAL801CL dry syrup","Ketotifen fumarate dry syrup","Ketotifen fumarate dry syrup placebo","WAL 801 CL dry syrup placebo",{"trials":13425,"activeCount":101},[],{"trials":13427,"activeCount":101},[],{"intervention":12788,"totalTrials":1075,"cells":13429},{"EARLY_PHASE1":13430,"PHASE1":13432,"PHASE2":13434,"PHASE3":13436,"PHASE4":13446,"NA":13448},{"trials":13431,"activeCount":101},[],{"trials":13433,"activeCount":101},[],{"trials":13435,"activeCount":101},[],{"trials":13437,"activeCount":101},[13438,13442],{"nctId":12780,"briefTitle":12781,"status":107,"phases":13439,"primaryCompletion":5993,"start":2121,"enrollment":12783,"conditions":13440,"interventions":13441},[92],[179],[12786,12787,12788,12789],{"nctId":13415,"briefTitle":13416,"status":107,"phases":13443,"primaryCompletion":6040,"start":2121,"enrollment":1458,"conditions":13444,"interventions":13445},[92],[11866],[13420,13421,13422,13423],{"trials":13447,"activeCount":101},[],{"trials":13449,"activeCount":101},[],{"intervention":12789,"totalTrials":1075,"cells":13451},{"EARLY_PHASE1":13452,"PHASE1":13454,"PHASE2":13456,"PHASE3":13458,"PHASE4":13468,"NA":13470},{"trials":13453,"activeCount":101},[],{"trials":13455,"activeCount":101},[],{"trials":13457,"activeCount":101},[],{"trials":13459,"activeCount":101},[13460,13464],{"nctId":12780,"briefTitle":12781,"status":107,"phases":13461,"primaryCompletion":5993,"start":2121,"enrollment":12783,"conditions":13462,"interventions":13463},[92],[179],[12786,12787,12788,12789],{"nctId":13415,"briefTitle":13416,"status":107,"phases":13465,"primaryCompletion":6040,"start":2121,"enrollment":1458,"conditions":13466,"interventions":13467},[92],[11866],[13420,13421,13422,13423],{"trials":13469,"activeCount":101},[],{"trials":13471,"activeCount":101},[],{"intervention":10978,"totalTrials":1075,"cells":13473},{"EARLY_PHASE1":13474,"PHASE1":13476,"PHASE2":13478,"PHASE3":13490,"PHASE4":13496,"NA":13498},{"trials":13475,"activeCount":101},[],{"trials":13477,"activeCount":101},[],{"trials":13479,"activeCount":101},[13480],{"nctId":13481,"briefTitle":13482,"status":107,"phases":13483,"primaryCompletion":1779,"completion":1779,"start":13484,"enrollment":3454,"conditions":13485,"interventions":13487},"NCT02624492","To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed\u002FRefractory DLBCL",[91],"2016-01-28",[13486],"Lymphoma, Large B-Cell, Diffuse",[13488,13489,10978,13489],"BI 836826","GemOx",{"trials":13491,"activeCount":101},[13492],{"nctId":10972,"briefTitle":10973,"status":162,"phases":13493,"primaryCompletion":2031,"completion":2031,"start":4118,"enrollment":1075,"conditions":13494,"interventions":13495},[92],[10976],[10978,10940],{"trials":13497,"activeCount":101},[],{"trials":13499,"activeCount":101},[],{"intervention":13501,"totalTrials":1075,"cells":13502},"Olodaterol (BI 1744) placebo",{"EARLY_PHASE1":13503,"PHASE1":13505,"PHASE2":13507,"PHASE3":13509,"PHASE4":13525,"NA":13527},{"trials":13504,"activeCount":101},[],{"trials":13506,"activeCount":101},[],{"trials":13508,"activeCount":101},[],{"trials":13510,"activeCount":101},[13511,13518],{"nctId":13512,"briefTitle":13513,"status":107,"phases":13514,"primaryCompletion":9340,"start":6811,"enrollment":13515,"conditions":13516,"interventions":13517},"NCT01040793","Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II",[92],157,[18],[5959,5959,5959,13501],{"nctId":13519,"briefTitle":13520,"status":107,"phases":13521,"primaryCompletion":9340,"start":6811,"enrollment":1458,"conditions":13522,"interventions":13523},"NCT01040130","Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I",[92],[18],[5959,5959,5959,13524],"Olodaterol (BI 1744) Placebo",{"trials":13526,"activeCount":101},[],{"trials":13528,"activeCount":101},[],{"intervention":13530,"totalTrials":1075,"cells":13531},"Antistax®",{"EARLY_PHASE1":13532,"PHASE1":13534,"PHASE2":13536,"PHASE3":13544,"PHASE4":13552,"NA":13554},{"trials":13533,"activeCount":101},[],{"trials":13535,"activeCount":101},[],{"trials":13537,"activeCount":101},[13538],{"nctId":13539,"briefTitle":13540,"status":107,"phases":13541,"primaryCompletion":6494,"start":6029,"enrollment":2898,"conditions":13542,"interventions":13543},"NCT02191163","Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency",[91],[8458],[13530],{"trials":13545,"activeCount":101},[13546],{"nctId":13547,"briefTitle":13548,"status":107,"phases":13549,"primaryCompletion":7618,"start":6446,"enrollment":9945,"conditions":13550,"interventions":13551},"NCT02191254","Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency",[92],[8458],[13530],{"trials":13553,"activeCount":101},[],{"trials":13555,"activeCount":101},[],{"intervention":11550,"totalTrials":1075,"cells":13557},{"EARLY_PHASE1":13558,"PHASE1":13560,"PHASE2":13562,"PHASE3":13564,"PHASE4":13574,"NA":13576},{"trials":13559,"activeCount":101},[],{"trials":13561,"activeCount":101},[],{"trials":13563,"activeCount":101},[],{"trials":13565,"activeCount":101},[13566,13570],{"nctId":11542,"briefTitle":11543,"status":107,"phases":13567,"primaryCompletion":4210,"completion":11545,"start":11546,"enrollment":11547,"conditions":13568,"interventions":13569},[92],[36],[11523,11550],{"nctId":11552,"briefTitle":11553,"status":107,"phases":13571,"primaryCompletion":11555,"completion":11555,"start":11556,"enrollment":260,"conditions":13572,"interventions":13573},[92],[3060],[11523,11550],{"trials":13575,"activeCount":101},[],{"trials":13577,"activeCount":101},[],{"intervention":13579,"totalTrials":272,"cells":13580},"Roxanes's clotrimazole troches",{"EARLY_PHASE1":13581,"PHASE1":13583,"PHASE2":13585,"PHASE3":13587,"PHASE4":13597,"NA":13599},{"trials":13582,"activeCount":101},[],{"trials":13584,"activeCount":101},[],{"trials":13586,"activeCount":101},[],{"trials":13588,"activeCount":101},[13589],{"nctId":13590,"briefTitle":13591,"status":107,"phases":13592,"primaryCompletion":6015,"start":6701,"enrollment":4915,"conditions":13593,"interventions":13595},"NCT02184351","Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis",[92],[13594],"Candidiasis, Oral",[13579,13596],"Mycelex® troches",{"trials":13598,"activeCount":101},[],{"trials":13600,"activeCount":101},[],{"intervention":13596,"totalTrials":272,"cells":13602},{"EARLY_PHASE1":13603,"PHASE1":13605,"PHASE2":13607,"PHASE3":13609,"PHASE4":13615,"NA":13617},{"trials":13604,"activeCount":101},[],{"trials":13606,"activeCount":101},[],{"trials":13608,"activeCount":101},[],{"trials":13610,"activeCount":101},[13611],{"nctId":13590,"briefTitle":13591,"status":107,"phases":13612,"primaryCompletion":6015,"start":6701,"enrollment":4915,"conditions":13613,"interventions":13614},[92],[13594],[13579,13596],{"trials":13616,"activeCount":101},[],{"trials":13618,"activeCount":101},[],{"intervention":10311,"totalTrials":272,"cells":13620},{"EARLY_PHASE1":13621,"PHASE1":13623,"PHASE2":13625,"PHASE3":13627,"PHASE4":13633,"NA":13635},{"trials":13622,"activeCount":101},[],{"trials":13624,"activeCount":101},[],{"trials":13626,"activeCount":101},[],{"trials":13628,"activeCount":101},[13629],{"nctId":10305,"briefTitle":10306,"status":107,"phases":13630,"primaryCompletion":6005,"start":2122,"enrollment":10308,"conditions":13631,"interventions":13632},[92],[632],[10311,10312,10313,10285,10314],{"trials":13634,"activeCount":101},[],{"trials":13636,"activeCount":101},[],{"intervention":10312,"totalTrials":272,"cells":13638},{"EARLY_PHASE1":13639,"PHASE1":13641,"PHASE2":13643,"PHASE3":13645,"PHASE4":13651,"NA":13653},{"trials":13640,"activeCount":101},[],{"trials":13642,"activeCount":101},[],{"trials":13644,"activeCount":101},[],{"trials":13646,"activeCount":101},[13647],{"nctId":10305,"briefTitle":10306,"status":107,"phases":13648,"primaryCompletion":6005,"start":2122,"enrollment":10308,"conditions":13649,"interventions":13650},[92],[632],[10311,10312,10313,10285,10314],{"trials":13652,"activeCount":101},[],{"trials":13654,"activeCount":101},[],{"intervention":10313,"totalTrials":272,"cells":13656},{"EARLY_PHASE1":13657,"PHASE1":13659,"PHASE2":13661,"PHASE3":13663,"PHASE4":13669,"NA":13671},{"trials":13658,"activeCount":101},[],{"trials":13660,"activeCount":101},[],{"trials":13662,"activeCount":101},[],{"trials":13664,"activeCount":101},[13665],{"nctId":10305,"briefTitle":10306,"status":107,"phases":13666,"primaryCompletion":6005,"start":2122,"enrollment":10308,"conditions":13667,"interventions":13668},[92],[632],[10311,10312,10313,10285,10314],{"trials":13670,"activeCount":101},[],{"trials":13672,"activeCount":101},[],{"intervention":10314,"totalTrials":272,"cells":13674},{"EARLY_PHASE1":13675,"PHASE1":13677,"PHASE2":13679,"PHASE3":13681,"PHASE4":13687,"NA":13689},{"trials":13676,"activeCount":101},[],{"trials":13678,"activeCount":101},[],{"trials":13680,"activeCount":101},[],{"trials":13682,"activeCount":101},[13683],{"nctId":10305,"briefTitle":10306,"status":107,"phases":13684,"primaryCompletion":6005,"start":2122,"enrollment":10308,"conditions":13685,"interventions":13686},[92],[632],[10311,10312,10313,10285,10314],{"trials":13688,"activeCount":101},[],{"trials":13690,"activeCount":101},[],{"intervention":6520,"totalTrials":272,"cells":13692},{"EARLY_PHASE1":13693,"PHASE1":13695,"PHASE2":13697,"PHASE3":13699,"PHASE4":13705,"NA":13707},{"trials":13694,"activeCount":101},[],{"trials":13696,"activeCount":101},[],{"trials":13698,"activeCount":101},[],{"trials":13700,"activeCount":101},[13701],{"nctId":6511,"briefTitle":6512,"status":107,"phases":13702,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":13703,"interventions":13704},[92],[6098,6518],[6520,6521,6484,6522,6523,6523,6524,6523,6525],{"trials":13706,"activeCount":101},[],{"trials":13708,"activeCount":101},[],{"intervention":6523,"totalTrials":272,"cells":13710},{"EARLY_PHASE1":13711,"PHASE1":13713,"PHASE2":13715,"PHASE3":13717,"PHASE4":13723,"NA":13725},{"trials":13712,"activeCount":101},[],{"trials":13714,"activeCount":101},[],{"trials":13716,"activeCount":101},[],{"trials":13718,"activeCount":101},[13719],{"nctId":6511,"briefTitle":6512,"status":107,"phases":13720,"primaryCompletion":6514,"completion":6514,"start":6515,"enrollment":6516,"conditions":13721,"interventions":13722},[92],[6098,6518],[6520,6521,6484,6522,6523,6523,6524,6523,6525],{"trials":13724,"activeCount":101},[],{"trials":13726,"activeCount":101},[],{"intervention":10669,"totalTrials":272,"cells":13728},{"EARLY_PHASE1":13729,"PHASE1":13731,"PHASE2":13733,"PHASE3":13735,"PHASE4":13741,"NA":13743},{"trials":13730,"activeCount":101},[],{"trials":13732,"activeCount":101},[],{"trials":13734,"activeCount":101},[],{"trials":13736,"activeCount":101},[13737],{"nctId":10659,"briefTitle":10660,"status":107,"phases":13738,"primaryCompletion":10662,"completion":10663,"start":10664,"enrollment":10665,"conditions":13739,"interventions":13740},[92],[10667],[10638,10669],{"trials":13742,"activeCount":101},[],{"trials":13744,"activeCount":101},[],{"intervention":6378,"totalTrials":272,"cells":13746},{"EARLY_PHASE1":13747,"PHASE1":13749,"PHASE2":13751,"PHASE3":13753,"PHASE4":13759,"NA":13761},{"trials":13748,"activeCount":101},[],{"trials":13750,"activeCount":101},[],{"trials":13752,"activeCount":101},[],{"trials":13754,"activeCount":101},[13755],{"nctId":6371,"briefTitle":6372,"status":107,"phases":13756,"primaryCompletion":6374,"completion":6374,"start":6375,"enrollment":1928,"conditions":13757,"interventions":13758},[92],[18],[6351,6378],{"trials":13760,"activeCount":101},[],{"trials":13762,"activeCount":101},[],{"intervention":13764,"totalTrials":272,"cells":13765},"linagliptine 5 mg",{"EARLY_PHASE1":13766,"PHASE1":13768,"PHASE2":13770,"PHASE3":13772,"PHASE4":13782,"NA":13784},{"trials":13767,"activeCount":101},[],{"trials":13769,"activeCount":101},[],{"trials":13771,"activeCount":101},[],{"trials":13773,"activeCount":101},[13774],{"nctId":13775,"briefTitle":13776,"status":107,"phases":13777,"primaryCompletion":9396,"start":6223,"enrollment":13778,"conditions":13779,"interventions":13780},"NCT00736099","Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM",[92],2122,[21],[13764,13781],"linagliptine 5 mg and pioglitazone 30 mg",{"trials":13783,"activeCount":101},[],{"trials":13785,"activeCount":101},[],{"intervention":13781,"totalTrials":272,"cells":13787},{"EARLY_PHASE1":13788,"PHASE1":13790,"PHASE2":13792,"PHASE3":13794,"PHASE4":13800,"NA":13802},{"trials":13789,"activeCount":101},[],{"trials":13791,"activeCount":101},[],{"trials":13793,"activeCount":101},[],{"trials":13795,"activeCount":101},[13796],{"nctId":13775,"briefTitle":13776,"status":107,"phases":13797,"primaryCompletion":9396,"start":6223,"enrollment":13778,"conditions":13798,"interventions":13799},[92],[21],[13764,13781],{"trials":13801,"activeCount":101},[],{"trials":13803,"activeCount":101},[],{"intervention":11335,"totalTrials":272,"cells":13805},{"EARLY_PHASE1":13806,"PHASE1":13808,"PHASE2":13810,"PHASE3":13812,"PHASE4":13818,"NA":13820},{"trials":13807,"activeCount":101},[],{"trials":13809,"activeCount":101},[],{"trials":13811,"activeCount":101},[],{"trials":13813,"activeCount":101},[13814],{"nctId":11329,"briefTitle":11330,"status":107,"phases":13815,"primaryCompletion":11332,"completion":11332,"start":5932,"enrollment":2586,"conditions":13816,"interventions":13817},[92],[18],[5860,11335,5860,5945],{"trials":13819,"activeCount":101},[],{"trials":13821,"activeCount":101},[],{"intervention":6764,"totalTrials":272,"cells":13823},{"EARLY_PHASE1":13824,"PHASE1":13826,"PHASE2":13828,"PHASE3":13830,"PHASE4":13836,"NA":13838},{"trials":13825,"activeCount":101},[],{"trials":13827,"activeCount":101},[],{"trials":13829,"activeCount":101},[],{"trials":13831,"activeCount":101},[13832],{"nctId":6758,"briefTitle":6759,"status":107,"phases":13833,"primaryCompletion":6116,"start":6156,"enrollment":6761,"conditions":13834,"interventions":13835},[92],[24],[6764,6765,6747,6766,6765,6767,6766,6765,6764,6764,6765,6764,6764,6768,6768,6766,6768,6767,6767,6764,6768,6747,6747,6764,6764,6747,6767,6766],{"trials":13837,"activeCount":101},[],{"trials":13839,"activeCount":101},[],{"intervention":6765,"totalTrials":272,"cells":13841},{"EARLY_PHASE1":13842,"PHASE1":13844,"PHASE2":13846,"PHASE3":13848,"PHASE4":13854,"NA":13856},{"trials":13843,"activeCount":101},[],{"trials":13845,"activeCount":101},[],{"trials":13847,"activeCount":101},[],{"trials":13849,"activeCount":101},[13850],{"nctId":6758,"briefTitle":6759,"status":107,"phases":13851,"primaryCompletion":6116,"start":6156,"enrollment":6761,"conditions":13852,"interventions":13853},[92],[24],[6764,6765,6747,6766,6765,6767,6766,6765,6764,6764,6765,6764,6764,6768,6768,6766,6768,6767,6767,6764,6768,6747,6747,6764,6764,6747,6767,6766],{"trials":13855,"activeCount":101},[],{"trials":13857,"activeCount":101},[],{"intervention":6766,"totalTrials":272,"cells":13859},{"EARLY_PHASE1":13860,"PHASE1":13862,"PHASE2":13864,"PHASE3":13866,"PHASE4":13872,"NA":13874},{"trials":13861,"activeCount":101},[],{"trials":13863,"activeCount":101},[],{"trials":13865,"activeCount":101},[],{"trials":13867,"activeCount":101},[13868],{"nctId":6758,"briefTitle":6759,"status":107,"phases":13869,"primaryCompletion":6116,"start":6156,"enrollment":6761,"conditions":13870,"interventions":13871},[92],[24],[6764,6765,6747,6766,6765,6767,6766,6765,6764,6764,6765,6764,6764,6768,6768,6766,6768,6767,6767,6764,6768,6747,6747,6764,6764,6747,6767,6766],{"trials":13873,"activeCount":101},[],{"trials":13875,"activeCount":101},[],{"intervention":6767,"totalTrials":272,"cells":13877},{"EARLY_PHASE1":13878,"PHASE1":13880,"PHASE2":13882,"PHASE3":13884,"PHASE4":13890,"NA":13892},{"trials":13879,"activeCount":101},[],{"trials":13881,"activeCount":101},[],{"trials":13883,"activeCount":101},[],{"trials":13885,"activeCount":101},[13886],{"nctId":6758,"briefTitle":6759,"status":107,"phases":13887,"primaryCompletion":6116,"start":6156,"enrollment":6761,"conditions":13888,"interventions":13889},[92],[24],[6764,6765,6747,6766,6765,6767,6766,6765,6764,6764,6765,6764,6764,6768,6768,6766,6768,6767,6767,6764,6768,6747,6747,6764,6764,6747,6767,6766],{"trials":13891,"activeCount":101},[],{"trials":13893,"activeCount":101},[],{"intervention":6768,"totalTrials":272,"cells":13895},{"EARLY_PHASE1":13896,"PHASE1":13898,"PHASE2":13900,"PHASE3":13902,"PHASE4":13908,"NA":13910},{"trials":13897,"activeCount":101},[],{"trials":13899,"activeCount":101},[],{"trials":13901,"activeCount":101},[],{"trials":13903,"activeCount":101},[13904],{"nctId":6758,"briefTitle":6759,"status":107,"phases":13905,"primaryCompletion":6116,"start":6156,"enrollment":6761,"conditions":13906,"interventions":13907},[92],[24],[6764,6765,6747,6766,6765,6767,6766,6765,6764,6764,6765,6764,6764,6768,6768,6766,6768,6767,6767,6764,6768,6747,6747,6764,6764,6747,6767,6766],{"trials":13909,"activeCount":101},[],{"trials":13911,"activeCount":101},[],{"intervention":13913,"totalTrials":272,"cells":13914},"Alteplase low dose",{"EARLY_PHASE1":13915,"PHASE1":13917,"PHASE2":13919,"PHASE3":13921,"PHASE4":13934,"NA":13936},{"trials":13916,"activeCount":101},[],{"trials":13918,"activeCount":101},[],{"trials":13920,"activeCount":101},[],{"trials":13922,"activeCount":101},[13923],{"nctId":13924,"briefTitle":13925,"status":107,"phases":13926,"primaryCompletion":13927,"completion":13928,"start":629,"enrollment":13929,"conditions":13930,"interventions":13932},"NCT04640194","A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19",[91,92],"2022-07-19","2022-07-25",104,[13931],"Acute Respiratory Distress Syndrome",[13913,13933],"Alteplase high dose",{"trials":13935,"activeCount":101},[],{"trials":13937,"activeCount":101},[],{"intervention":13933,"totalTrials":272,"cells":13939},{"EARLY_PHASE1":13940,"PHASE1":13942,"PHASE2":13944,"PHASE3":13946,"PHASE4":13952,"NA":13954},{"trials":13941,"activeCount":101},[],{"trials":13943,"activeCount":101},[],{"trials":13945,"activeCount":101},[],{"trials":13947,"activeCount":101},[13948],{"nctId":13924,"briefTitle":13925,"status":107,"phases":13949,"primaryCompletion":13927,"completion":13928,"start":629,"enrollment":13929,"conditions":13950,"interventions":13951},[91,92],[13931],[13913,13933],{"trials":13953,"activeCount":101},[],{"trials":13955,"activeCount":101},[],{"intervention":13957,"totalTrials":272,"cells":13958},"Atrovent Respimat",{"EARLY_PHASE1":13959,"PHASE1":13961,"PHASE2":13963,"PHASE3":13965,"PHASE4":13976,"NA":13978},{"trials":13960,"activeCount":101},[],{"trials":13962,"activeCount":101},[],{"trials":13964,"activeCount":101},[],{"trials":13966,"activeCount":101},[13967],{"nctId":13968,"briefTitle":13969,"status":107,"phases":13970,"primaryCompletion":6471,"start":6910,"enrollment":13971,"conditions":13972,"interventions":13973},"NCT00400153","Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)",[92],1480,[18],[13957,13974,13975],"COMBIVENT MDI","Combivent Respimat",{"trials":13977,"activeCount":101},[],{"trials":13979,"activeCount":101},[],{"intervention":13974,"totalTrials":272,"cells":13981},{"EARLY_PHASE1":13982,"PHASE1":13984,"PHASE2":13986,"PHASE3":13988,"PHASE4":13994,"NA":13996},{"trials":13983,"activeCount":101},[],{"trials":13985,"activeCount":101},[],{"trials":13987,"activeCount":101},[],{"trials":13989,"activeCount":101},[13990],{"nctId":13968,"briefTitle":13969,"status":107,"phases":13991,"primaryCompletion":6471,"start":6910,"enrollment":13971,"conditions":13992,"interventions":13993},[92],[18],[13957,13974,13975],{"trials":13995,"activeCount":101},[],{"trials":13997,"activeCount":101},[],{"intervention":13975,"totalTrials":272,"cells":13999},{"EARLY_PHASE1":14000,"PHASE1":14002,"PHASE2":14004,"PHASE3":14006,"PHASE4":14012,"NA":14014},{"trials":14001,"activeCount":101},[],{"trials":14003,"activeCount":101},[],{"trials":14005,"activeCount":101},[],{"trials":14007,"activeCount":101},[14008],{"nctId":13968,"briefTitle":13969,"status":107,"phases":14009,"primaryCompletion":6471,"start":6910,"enrollment":13971,"conditions":14010,"interventions":14011},[92],[18],[13957,13974,13975],{"trials":14013,"activeCount":101},[],{"trials":14015,"activeCount":101},[],{"intervention":11397,"totalTrials":272,"cells":14017},{"EARLY_PHASE1":14018,"PHASE1":14020,"PHASE2":14022,"PHASE3":14024,"PHASE4":14030,"NA":14032},{"trials":14019,"activeCount":101},[],{"trials":14021,"activeCount":101},[],{"trials":14023,"activeCount":101},[],{"trials":14025,"activeCount":101},[14026],{"nctId":11391,"briefTitle":11392,"status":107,"phases":14027,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":14028,"interventions":14029},[92],[21],[11397,11398,11399,11400,11401,11380,11402],{"trials":14031,"activeCount":101},[],{"trials":14033,"activeCount":101},[],{"intervention":11398,"totalTrials":272,"cells":14035},{"EARLY_PHASE1":14036,"PHASE1":14038,"PHASE2":14040,"PHASE3":14042,"PHASE4":14048,"NA":14050},{"trials":14037,"activeCount":101},[],{"trials":14039,"activeCount":101},[],{"trials":14041,"activeCount":101},[],{"trials":14043,"activeCount":101},[14044],{"nctId":11391,"briefTitle":11392,"status":107,"phases":14045,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":14046,"interventions":14047},[92],[21],[11397,11398,11399,11400,11401,11380,11402],{"trials":14049,"activeCount":101},[],{"trials":14051,"activeCount":101},[],{"intervention":11399,"totalTrials":272,"cells":14053},{"EARLY_PHASE1":14054,"PHASE1":14056,"PHASE2":14058,"PHASE3":14060,"PHASE4":14066,"NA":14068},{"trials":14055,"activeCount":101},[],{"trials":14057,"activeCount":101},[],{"trials":14059,"activeCount":101},[],{"trials":14061,"activeCount":101},[14062],{"nctId":11391,"briefTitle":11392,"status":107,"phases":14063,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":14064,"interventions":14065},[92],[21],[11397,11398,11399,11400,11401,11380,11402],{"trials":14067,"activeCount":101},[],{"trials":14069,"activeCount":101},[],{"intervention":11400,"totalTrials":272,"cells":14071},{"EARLY_PHASE1":14072,"PHASE1":14074,"PHASE2":14076,"PHASE3":14078,"PHASE4":14084,"NA":14086},{"trials":14073,"activeCount":101},[],{"trials":14075,"activeCount":101},[],{"trials":14077,"activeCount":101},[],{"trials":14079,"activeCount":101},[14080],{"nctId":11391,"briefTitle":11392,"status":107,"phases":14081,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":14082,"interventions":14083},[92],[21],[11397,11398,11399,11400,11401,11380,11402],{"trials":14085,"activeCount":101},[],{"trials":14087,"activeCount":101},[],{"intervention":11401,"totalTrials":272,"cells":14089},{"EARLY_PHASE1":14090,"PHASE1":14092,"PHASE2":14094,"PHASE3":14096,"PHASE4":14102,"NA":14104},{"trials":14091,"activeCount":101},[],{"trials":14093,"activeCount":101},[],{"trials":14095,"activeCount":101},[],{"trials":14097,"activeCount":101},[14098],{"nctId":11391,"briefTitle":11392,"status":107,"phases":14099,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":14100,"interventions":14101},[92],[21],[11397,11398,11399,11400,11401,11380,11402],{"trials":14103,"activeCount":101},[],{"trials":14105,"activeCount":101},[],{"intervention":11402,"totalTrials":272,"cells":14107},{"EARLY_PHASE1":14108,"PHASE1":14110,"PHASE2":14112,"PHASE3":14114,"PHASE4":14120,"NA":14122},{"trials":14109,"activeCount":101},[],{"trials":14111,"activeCount":101},[],{"trials":14113,"activeCount":101},[],{"trials":14115,"activeCount":101},[14116],{"nctId":11391,"briefTitle":11392,"status":107,"phases":14117,"primaryCompletion":9614,"completion":9614,"start":4442,"enrollment":11394,"conditions":14118,"interventions":14119},[92],[21],[11397,11398,11399,11400,11401,11380,11402],{"trials":14121,"activeCount":101},[],{"trials":14123,"activeCount":101},[],{"intervention":586,"totalTrials":272,"cells":14125},{"EARLY_PHASE1":14126,"PHASE1":14128,"PHASE2":14130,"PHASE3":14132,"PHASE4":14138,"NA":14140},{"trials":14127,"activeCount":101},[],{"trials":14129,"activeCount":101},[],{"trials":14131,"activeCount":101},[],{"trials":14133,"activeCount":101},[14134],{"nctId":577,"briefTitle":578,"status":107,"phases":14135,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":14136,"interventions":14137},[92],[21],[413,586,361,73],{"trials":14139,"activeCount":101},[],{"trials":14141,"activeCount":101},[],{"intervention":14143,"totalTrials":272,"cells":14144},"Loxoprofen sodium",{"EARLY_PHASE1":14145,"PHASE1":14147,"PHASE2":14149,"PHASE3":14151,"PHASE4":14162,"NA":14164},{"trials":14146,"activeCount":101},[],{"trials":14148,"activeCount":101},[],{"trials":14150,"activeCount":101},[],{"trials":14152,"activeCount":101},[14153],{"nctId":14154,"briefTitle":14155,"status":107,"phases":14156,"primaryCompletion":14157,"completion":14157,"start":14158,"enrollment":1429,"conditions":14159,"interventions":14160},"NCT02831569","Japanese IP-TN Trial",[92],"2016-10-19","2016-07-27",[6596],[14143,14161],"Methocarbamol",{"trials":14163,"activeCount":101},[],{"trials":14165,"activeCount":101},[],{"intervention":14161,"totalTrials":272,"cells":14167},{"EARLY_PHASE1":14168,"PHASE1":14170,"PHASE2":14172,"PHASE3":14174,"PHASE4":14180,"NA":14182},{"trials":14169,"activeCount":101},[],{"trials":14171,"activeCount":101},[],{"trials":14173,"activeCount":101},[],{"trials":14175,"activeCount":101},[14176],{"nctId":14154,"briefTitle":14155,"status":107,"phases":14177,"primaryCompletion":14157,"completion":14157,"start":14158,"enrollment":1429,"conditions":14178,"interventions":14179},[92],[6596],[14143,14161],{"trials":14181,"activeCount":101},[],{"trials":14183,"activeCount":101},[],{"intervention":12192,"totalTrials":272,"cells":14185},{"EARLY_PHASE1":14186,"PHASE1":14188,"PHASE2":14190,"PHASE3":14192,"PHASE4":14198,"NA":14200},{"trials":14187,"activeCount":101},[],{"trials":14189,"activeCount":101},[],{"trials":14191,"activeCount":101},[],{"trials":14193,"activeCount":101},[14194],{"nctId":12186,"briefTitle":12187,"status":107,"phases":14195,"primaryCompletion":4119,"completion":4119,"start":9491,"enrollment":12189,"conditions":14196,"interventions":14197},[92],[30],[12192,12175],{"trials":14199,"activeCount":101},[],{"trials":14201,"activeCount":101},[],{"intervention":14203,"totalTrials":272,"cells":14204},"dabigatran etexilate 150 mg twice daily",{"EARLY_PHASE1":14205,"PHASE1":14207,"PHASE2":14209,"PHASE3":14211,"PHASE4":14220,"NA":14222},{"trials":14206,"activeCount":101},[],{"trials":14208,"activeCount":101},[],{"trials":14210,"activeCount":101},[],{"trials":14212,"activeCount":101},[14213],{"nctId":14214,"briefTitle":14215,"status":107,"phases":14216,"primaryCompletion":9332,"start":9418,"enrollment":14217,"conditions":14218,"interventions":14219},"NCT00558259","Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE",[92],1353,[10299],[14203],{"trials":14221,"activeCount":101},[],{"trials":14223,"activeCount":101},[],{"intervention":14225,"totalTrials":272,"cells":14226},"Tiotropium Respimat",{"EARLY_PHASE1":14227,"PHASE1":14229,"PHASE2":14231,"PHASE3":14233,"PHASE4":14242,"NA":14244},{"trials":14228,"activeCount":101},[],{"trials":14230,"activeCount":101},[],{"trials":14232,"activeCount":101},[],{"trials":14234,"activeCount":101},[14235],{"nctId":14236,"briefTitle":14237,"status":107,"phases":14238,"primaryCompletion":379,"completion":379,"start":9340,"enrollment":14239,"conditions":14240,"interventions":14241},"NCT01340209","Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma",[92],285,[30],[14225,14225],{"trials":14243,"activeCount":101},[],{"trials":14245,"activeCount":101},[],{"intervention":12253,"totalTrials":272,"cells":14247},{"EARLY_PHASE1":14248,"PHASE1":14250,"PHASE2":14252,"PHASE3":14254,"PHASE4":14260,"NA":14262},{"trials":14249,"activeCount":101},[],{"trials":14251,"activeCount":101},[],{"trials":14253,"activeCount":101},[],{"trials":14255,"activeCount":101},[14256],{"nctId":12247,"briefTitle":12248,"status":107,"phases":14257,"primaryCompletion":6207,"start":7395,"enrollment":12250,"conditions":14258,"interventions":14259},[92],[18],[12253,12254,10834],{"trials":14261,"activeCount":101},[],{"trials":14263,"activeCount":101},[],{"intervention":12254,"totalTrials":272,"cells":14265},{"EARLY_PHASE1":14266,"PHASE1":14268,"PHASE2":14270,"PHASE3":14272,"PHASE4":14278,"NA":14280},{"trials":14267,"activeCount":101},[],{"trials":14269,"activeCount":101},[],{"trials":14271,"activeCount":101},[],{"trials":14273,"activeCount":101},[14274],{"nctId":12247,"briefTitle":12248,"status":107,"phases":14275,"primaryCompletion":6207,"start":7395,"enrollment":12250,"conditions":14276,"interventions":14277},[92],[18],[12253,12254,10834],{"trials":14279,"activeCount":101},[],{"trials":14281,"activeCount":101},[],{"intervention":11368,"totalTrials":272,"cells":14283},{"EARLY_PHASE1":14284,"PHASE1":14286,"PHASE2":14288,"PHASE3":14290,"PHASE4":14296,"NA":14298},{"trials":14285,"activeCount":101},[],{"trials":14287,"activeCount":101},[],{"trials":14289,"activeCount":101},[],{"trials":14291,"activeCount":101},[14292],{"nctId":11362,"briefTitle":11363,"status":107,"phases":14293,"primaryCompletion":7394,"start":7553,"enrollment":11365,"conditions":14294,"interventions":14295},[92],[18],[11368,11345],{"trials":14297,"activeCount":101},[],{"trials":14299,"activeCount":101},[],{"intervention":12347,"totalTrials":272,"cells":14301},{"EARLY_PHASE1":14302,"PHASE1":14304,"PHASE2":14306,"PHASE3":14308,"PHASE4":14314,"NA":14316},{"trials":14303,"activeCount":101},[],{"trials":14305,"activeCount":101},[],{"trials":14307,"activeCount":101},[],{"trials":14309,"activeCount":101},[14310],{"nctId":12342,"briefTitle":12343,"status":107,"phases":14311,"primaryCompletion":1980,"start":5905,"enrollment":1218,"conditions":14312,"interventions":14313},[92],[18],[12347,12348,11963],{"trials":14315,"activeCount":101},[],{"trials":14317,"activeCount":101},[],{"intervention":12348,"totalTrials":272,"cells":14319},{"EARLY_PHASE1":14320,"PHASE1":14322,"PHASE2":14324,"PHASE3":14326,"PHASE4":14332,"NA":14334},{"trials":14321,"activeCount":101},[],{"trials":14323,"activeCount":101},[],{"trials":14325,"activeCount":101},[],{"trials":14327,"activeCount":101},[14328],{"nctId":12342,"briefTitle":12343,"status":107,"phases":14329,"primaryCompletion":1980,"start":5905,"enrollment":1218,"conditions":14330,"interventions":14331},[92],[18],[12347,12348,11963],{"trials":14333,"activeCount":101},[],{"trials":14335,"activeCount":101},[],{"intervention":6257,"totalTrials":272,"cells":14337},{"EARLY_PHASE1":14338,"PHASE1":14340,"PHASE2":14342,"PHASE3":14344,"PHASE4":14350,"NA":14352},{"trials":14339,"activeCount":101},[],{"trials":14341,"activeCount":101},[],{"trials":14343,"activeCount":101},[],{"trials":14345,"activeCount":101},[14346],{"nctId":6251,"briefTitle":6252,"status":107,"phases":14347,"primaryCompletion":4391,"completion":5233,"start":378,"enrollment":6254,"conditions":14348,"interventions":14349},[92],[24],[6257,6217,6257],{"trials":14351,"activeCount":101},[],{"trials":14353,"activeCount":101},[],{"intervention":14355,"totalTrials":272,"cells":14356},"TNK-tPA",{"EARLY_PHASE1":14357,"PHASE1":14359,"PHASE2":14361,"PHASE3":14363,"PHASE4":14373,"NA":14375},{"trials":14358,"activeCount":101},[],{"trials":14360,"activeCount":101},[],{"trials":14362,"activeCount":101},[],{"trials":14364,"activeCount":101},[14365],{"nctId":14366,"briefTitle":14367,"status":107,"phases":14368,"completion":7151,"start":7381,"enrollment":14369,"conditions":14370,"interventions":14371},"NCT00148460","Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction",[92],270,[632],[14355,14372],"rt-PA",{"trials":14374,"activeCount":101},[],{"trials":14376,"activeCount":101},[],{"intervention":12430,"totalTrials":272,"cells":14378},{"EARLY_PHASE1":14379,"PHASE1":14381,"PHASE2":14383,"PHASE3":14385,"PHASE4":14391,"NA":14393},{"trials":14380,"activeCount":101},[],{"trials":14382,"activeCount":101},[],{"trials":14384,"activeCount":101},[],{"trials":14386,"activeCount":101},[14387],{"nctId":12424,"briefTitle":12425,"status":107,"phases":14388,"primaryCompletion":4038,"completion":4038,"start":6132,"enrollment":12427,"conditions":14389,"interventions":14390},[92],[30],[6825,12430],{"trials":14392,"activeCount":101},[],{"trials":14394,"activeCount":101},[],{"intervention":14396,"totalTrials":272,"cells":14397},"Low dose ASA",{"EARLY_PHASE1":14398,"PHASE1":14400,"PHASE2":14402,"PHASE3":14404,"PHASE4":14416,"NA":14418},{"trials":14399,"activeCount":101},[],{"trials":14401,"activeCount":101},[],{"trials":14403,"activeCount":101},[],{"trials":14405,"activeCount":101},[14406],{"nctId":14407,"briefTitle":14408,"status":107,"phases":14409,"primaryCompletion":7574,"start":7084,"enrollment":14410,"conditions":14411,"interventions":14412},"NCT02183688","Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients",[92],1889,[13290],[14396,14413,14414,14415,1241],"High dose ASA","Low dose paracetamol","High dose paracetamol",{"trials":14417,"activeCount":101},[],{"trials":14419,"activeCount":101},[],{"intervention":14413,"totalTrials":272,"cells":14421},{"EARLY_PHASE1":14422,"PHASE1":14424,"PHASE2":14426,"PHASE3":14428,"PHASE4":14434,"NA":14436},{"trials":14423,"activeCount":101},[],{"trials":14425,"activeCount":101},[],{"trials":14427,"activeCount":101},[],{"trials":14429,"activeCount":101},[14430],{"nctId":14407,"briefTitle":14408,"status":107,"phases":14431,"primaryCompletion":7574,"start":7084,"enrollment":14410,"conditions":14432,"interventions":14433},[92],[13290],[14396,14413,14414,14415,1241],{"trials":14435,"activeCount":101},[],{"trials":14437,"activeCount":101},[],{"intervention":14414,"totalTrials":272,"cells":14439},{"EARLY_PHASE1":14440,"PHASE1":14442,"PHASE2":14444,"PHASE3":14446,"PHASE4":14452,"NA":14454},{"trials":14441,"activeCount":101},[],{"trials":14443,"activeCount":101},[],{"trials":14445,"activeCount":101},[],{"trials":14447,"activeCount":101},[14448],{"nctId":14407,"briefTitle":14408,"status":107,"phases":14449,"primaryCompletion":7574,"start":7084,"enrollment":14410,"conditions":14450,"interventions":14451},[92],[13290],[14396,14413,14414,14415,1241],{"trials":14453,"activeCount":101},[],{"trials":14455,"activeCount":101},[],{"intervention":14415,"totalTrials":272,"cells":14457},{"EARLY_PHASE1":14458,"PHASE1":14460,"PHASE2":14462,"PHASE3":14464,"PHASE4":14470,"NA":14472},{"trials":14459,"activeCount":101},[],{"trials":14461,"activeCount":101},[],{"trials":14463,"activeCount":101},[],{"trials":14465,"activeCount":101},[14466],{"nctId":14407,"briefTitle":14408,"status":107,"phases":14467,"primaryCompletion":7574,"start":7084,"enrollment":14410,"conditions":14468,"interventions":14469},[92],[13290],[14396,14413,14414,14415,1241],{"trials":14471,"activeCount":101},[],{"trials":14473,"activeCount":101},[],{"intervention":14475,"totalTrials":272,"cells":14476},"Ambroxol",{"EARLY_PHASE1":14477,"PHASE1":14479,"PHASE2":14481,"PHASE3":14483,"PHASE4":14494,"NA":14496},{"trials":14478,"activeCount":101},[],{"trials":14480,"activeCount":101},[],{"trials":14482,"activeCount":101},[],{"trials":14484,"activeCount":101},[14485],{"nctId":14486,"briefTitle":14487,"status":107,"phases":14488,"primaryCompletion":14489,"completion":14489,"start":14490,"enrollment":14491,"conditions":14492,"interventions":14493},"NCT00525044","Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat",[92],"2008-01-01","2007-08-01",249,[6587],[14475],{"trials":14495,"activeCount":101},[],{"trials":14497,"activeCount":101},[],{"intervention":14499,"totalTrials":272,"cells":14500},"Berodual® Respimat® inhaler",{"EARLY_PHASE1":14501,"PHASE1":14503,"PHASE2":14505,"PHASE3":14507,"PHASE4":14516,"NA":14518},{"trials":14502,"activeCount":101},[],{"trials":14504,"activeCount":101},[],{"trials":14506,"activeCount":101},[],{"trials":14508,"activeCount":101},[14509],{"nctId":14510,"briefTitle":14511,"status":162,"phases":14512,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14513,"interventions":14514},"NCT02176187","Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease",[92],[18],[14499,14515],"Berodual® metered dose inhaler",{"trials":14517,"activeCount":101},[],{"trials":14519,"activeCount":101},[],{"intervention":14515,"totalTrials":272,"cells":14521},{"EARLY_PHASE1":14522,"PHASE1":14524,"PHASE2":14526,"PHASE3":14528,"PHASE4":14534,"NA":14536},{"trials":14523,"activeCount":101},[],{"trials":14525,"activeCount":101},[],{"trials":14527,"activeCount":101},[],{"trials":14529,"activeCount":101},[14530],{"nctId":14510,"briefTitle":14511,"status":162,"phases":14531,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14532,"interventions":14533},[92],[18],[14499,14515],{"trials":14535,"activeCount":101},[],{"trials":14537,"activeCount":101},[],{"intervention":14539,"totalTrials":272,"cells":14540},"Berodual® Respimat®, low inspiratory flow rate",{"EARLY_PHASE1":14541,"PHASE1":14543,"PHASE2":14545,"PHASE3":14547,"PHASE4":14560,"NA":14562},{"trials":14542,"activeCount":101},[],{"trials":14544,"activeCount":101},[],{"trials":14546,"activeCount":101},[],{"trials":14548,"activeCount":101},[14549],{"nctId":14550,"briefTitle":14551,"status":162,"phases":14552,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14553,"interventions":14554},"NCT02176200","Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[14539,14555,14556,14557,14558,14559],"Berodual® Respimat®, medium inspiratory flow rate","Berodual® Respimat®, high inspiratory flow rate","Berodual® HFA-MDI, low inspiratory flow rate","Berodual® HFA-MDI, medium inspiratory flow rate","Berodual® HFA-MDI, high inspiratory flow rate",{"trials":14561,"activeCount":101},[],{"trials":14563,"activeCount":101},[],{"intervention":14555,"totalTrials":272,"cells":14565},{"EARLY_PHASE1":14566,"PHASE1":14568,"PHASE2":14570,"PHASE3":14572,"PHASE4":14578,"NA":14580},{"trials":14567,"activeCount":101},[],{"trials":14569,"activeCount":101},[],{"trials":14571,"activeCount":101},[],{"trials":14573,"activeCount":101},[14574],{"nctId":14550,"briefTitle":14551,"status":162,"phases":14575,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14576,"interventions":14577},[92],[18],[14539,14555,14556,14557,14558,14559],{"trials":14579,"activeCount":101},[],{"trials":14581,"activeCount":101},[],{"intervention":14556,"totalTrials":272,"cells":14583},{"EARLY_PHASE1":14584,"PHASE1":14586,"PHASE2":14588,"PHASE3":14590,"PHASE4":14596,"NA":14598},{"trials":14585,"activeCount":101},[],{"trials":14587,"activeCount":101},[],{"trials":14589,"activeCount":101},[],{"trials":14591,"activeCount":101},[14592],{"nctId":14550,"briefTitle":14551,"status":162,"phases":14593,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14594,"interventions":14595},[92],[18],[14539,14555,14556,14557,14558,14559],{"trials":14597,"activeCount":101},[],{"trials":14599,"activeCount":101},[],{"intervention":14557,"totalTrials":272,"cells":14601},{"EARLY_PHASE1":14602,"PHASE1":14604,"PHASE2":14606,"PHASE3":14608,"PHASE4":14614,"NA":14616},{"trials":14603,"activeCount":101},[],{"trials":14605,"activeCount":101},[],{"trials":14607,"activeCount":101},[],{"trials":14609,"activeCount":101},[14610],{"nctId":14550,"briefTitle":14551,"status":162,"phases":14611,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14612,"interventions":14613},[92],[18],[14539,14555,14556,14557,14558,14559],{"trials":14615,"activeCount":101},[],{"trials":14617,"activeCount":101},[],{"intervention":14558,"totalTrials":272,"cells":14619},{"EARLY_PHASE1":14620,"PHASE1":14622,"PHASE2":14624,"PHASE3":14626,"PHASE4":14632,"NA":14634},{"trials":14621,"activeCount":101},[],{"trials":14623,"activeCount":101},[],{"trials":14625,"activeCount":101},[],{"trials":14627,"activeCount":101},[14628],{"nctId":14550,"briefTitle":14551,"status":162,"phases":14629,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14630,"interventions":14631},[92],[18],[14539,14555,14556,14557,14558,14559],{"trials":14633,"activeCount":101},[],{"trials":14635,"activeCount":101},[],{"intervention":14559,"totalTrials":272,"cells":14637},{"EARLY_PHASE1":14638,"PHASE1":14640,"PHASE2":14642,"PHASE3":14644,"PHASE4":14650,"NA":14652},{"trials":14639,"activeCount":101},[],{"trials":14641,"activeCount":101},[],{"trials":14643,"activeCount":101},[],{"trials":14645,"activeCount":101},[14646],{"nctId":14550,"briefTitle":14551,"status":162,"phases":14647,"primaryCompletion":6413,"start":7124,"enrollment":1044,"conditions":14648,"interventions":14649},[92],[18],[14539,14555,14556,14557,14558,14559],{"trials":14651,"activeCount":101},[],{"trials":14653,"activeCount":101},[],{"intervention":14655,"totalTrials":272,"cells":14656},"fixed-dose combination of telmisartan 40mg+amlodipine 10mg",{"EARLY_PHASE1":14657,"PHASE1":14659,"PHASE2":14661,"PHASE3":14663,"PHASE4":14673,"NA":14675},{"trials":14658,"activeCount":101},[],{"trials":14660,"activeCount":101},[],{"trials":14662,"activeCount":101},[],{"trials":14664,"activeCount":101},[14665],{"nctId":14666,"briefTitle":14667,"status":107,"phases":14668,"primaryCompletion":5905,"start":4128,"enrollment":14669,"conditions":14670,"interventions":14671},"NCT00624052","26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension",[92],838,[24],[14655,14672],"fixed-dose combination of telmisartan 80mg+amlodipine10mg",{"trials":14674,"activeCount":101},[],{"trials":14676,"activeCount":101},[],{"intervention":14672,"totalTrials":272,"cells":14678},{"EARLY_PHASE1":14679,"PHASE1":14681,"PHASE2":14683,"PHASE3":14685,"PHASE4":14691,"NA":14693},{"trials":14680,"activeCount":101},[],{"trials":14682,"activeCount":101},[],{"trials":14684,"activeCount":101},[],{"trials":14686,"activeCount":101},[14687],{"nctId":14666,"briefTitle":14667,"status":107,"phases":14688,"primaryCompletion":5905,"start":4128,"enrollment":14669,"conditions":14689,"interventions":14690},[92],[24],[14655,14672],{"trials":14692,"activeCount":101},[],{"trials":14694,"activeCount":101},[],{"intervention":14696,"totalTrials":272,"cells":14697},"tiotropium Respimat low dose",{"EARLY_PHASE1":14698,"PHASE1":14700,"PHASE2":14702,"PHASE3":14704,"PHASE4":14714,"NA":14716},{"trials":14699,"activeCount":101},[],{"trials":14701,"activeCount":101},[],{"trials":14703,"activeCount":101},[],{"trials":14705,"activeCount":101},[14706],{"nctId":14707,"briefTitle":14708,"status":107,"phases":14709,"primaryCompletion":516,"completion":516,"start":9396,"enrollment":14710,"conditions":14711,"interventions":14712},"NCT01257230","Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma",[92],398,[30],[14696,14713],"tiotropium Respimat high dose",{"trials":14715,"activeCount":101},[],{"trials":14717,"activeCount":101},[],{"intervention":14713,"totalTrials":272,"cells":14719},{"EARLY_PHASE1":14720,"PHASE1":14722,"PHASE2":14724,"PHASE3":14726,"PHASE4":14732,"NA":14734},{"trials":14721,"activeCount":101},[],{"trials":14723,"activeCount":101},[],{"trials":14725,"activeCount":101},[],{"trials":14727,"activeCount":101},[14728],{"nctId":14707,"briefTitle":14708,"status":107,"phases":14729,"primaryCompletion":516,"completion":516,"start":9396,"enrollment":14710,"conditions":14730,"interventions":14731},[92],[30],[14696,14713],{"trials":14733,"activeCount":101},[],{"trials":14735,"activeCount":101},[],{"intervention":14737,"totalTrials":272,"cells":14738},"Respimat® Budesonide low dose",{"EARLY_PHASE1":14739,"PHASE1":14741,"PHASE2":14743,"PHASE3":14745,"PHASE4":14756,"NA":14758},{"trials":14740,"activeCount":101},[],{"trials":14742,"activeCount":101},[],{"trials":14744,"activeCount":101},[],{"trials":14746,"activeCount":101},[14747],{"nctId":14748,"briefTitle":14749,"status":107,"phases":14750,"primaryCompletion":2121,"start":7553,"enrollment":14751,"conditions":14752,"interventions":14753},"NCT02181335","Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy",[92],684,[30],[14737,14754,14755],"Respimat® Budesonide high dose","Turbohaler® Budesonide",{"trials":14757,"activeCount":101},[],{"trials":14759,"activeCount":101},[],{"intervention":14754,"totalTrials":272,"cells":14761},{"EARLY_PHASE1":14762,"PHASE1":14764,"PHASE2":14766,"PHASE3":14768,"PHASE4":14774,"NA":14776},{"trials":14763,"activeCount":101},[],{"trials":14765,"activeCount":101},[],{"trials":14767,"activeCount":101},[],{"trials":14769,"activeCount":101},[14770],{"nctId":14748,"briefTitle":14749,"status":107,"phases":14771,"primaryCompletion":2121,"start":7553,"enrollment":14751,"conditions":14772,"interventions":14773},[92],[30],[14737,14754,14755],{"trials":14775,"activeCount":101},[],{"trials":14777,"activeCount":101},[],{"intervention":14755,"totalTrials":272,"cells":14779},{"EARLY_PHASE1":14780,"PHASE1":14782,"PHASE2":14784,"PHASE3":14786,"PHASE4":14792,"NA":14794},{"trials":14781,"activeCount":101},[],{"trials":14783,"activeCount":101},[],{"trials":14785,"activeCount":101},[],{"trials":14787,"activeCount":101},[14788],{"nctId":14748,"briefTitle":14749,"status":107,"phases":14789,"primaryCompletion":2121,"start":7553,"enrollment":14751,"conditions":14790,"interventions":14791},[92],[30],[14737,14754,14755],{"trials":14793,"activeCount":101},[],{"trials":14795,"activeCount":101},[],{"intervention":12547,"totalTrials":272,"cells":14797},{"EARLY_PHASE1":14798,"PHASE1":14800,"PHASE2":14802,"PHASE3":14804,"PHASE4":14810,"NA":14812},{"trials":14799,"activeCount":101},[],{"trials":14801,"activeCount":101},[],{"trials":14803,"activeCount":101},[],{"trials":14805,"activeCount":101},[14806],{"nctId":12540,"briefTitle":12541,"status":162,"phases":14807,"primaryCompletion":935,"completion":12543,"start":12544,"enrollment":166,"conditions":14808,"interventions":14809},[91,92],[1920],[12529,12547],{"trials":14811,"activeCount":101},[],{"trials":14813,"activeCount":101},[],{"intervention":14815,"totalTrials":272,"cells":14816},"meloxicam oral suspension",{"EARLY_PHASE1":14817,"PHASE1":14819,"PHASE2":14821,"PHASE3":14823,"PHASE4":14833,"NA":14835},{"trials":14818,"activeCount":101},[],{"trials":14820,"activeCount":101},[],{"trials":14822,"activeCount":101},[],{"trials":14824,"activeCount":101},[14825],{"nctId":14826,"briefTitle":14827,"status":107,"phases":14828,"primaryCompletion":6871,"start":5880,"enrollment":5466,"conditions":14829,"interventions":14831},"NCT00034853","Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)",[92],[14830],"Arthritis, Juvenile Rheumatoid",[14815,14832],"naproxen oral suspension",{"trials":14834,"activeCount":101},[],{"trials":14836,"activeCount":101},[],{"intervention":14832,"totalTrials":272,"cells":14838},{"EARLY_PHASE1":14839,"PHASE1":14841,"PHASE2":14843,"PHASE3":14845,"PHASE4":14851,"NA":14853},{"trials":14840,"activeCount":101},[],{"trials":14842,"activeCount":101},[],{"trials":14844,"activeCount":101},[],{"trials":14846,"activeCount":101},[14847],{"nctId":14826,"briefTitle":14827,"status":107,"phases":14848,"primaryCompletion":6871,"start":5880,"enrollment":5466,"conditions":14849,"interventions":14850},[92],[14830],[14815,14832],{"trials":14852,"activeCount":101},[],{"trials":14854,"activeCount":101},[],{"intervention":14856,"totalTrials":272,"cells":14857},"pramipexole 0.125 mg BID",{"EARLY_PHASE1":14858,"PHASE1":14860,"PHASE2":14862,"PHASE3":14864,"PHASE4":14877,"NA":14879},{"trials":14859,"activeCount":101},[],{"trials":14861,"activeCount":101},[],{"trials":14863,"activeCount":101},[],{"trials":14865,"activeCount":101},[14866],{"nctId":14867,"briefTitle":14868,"status":162,"phases":14869,"primaryCompletion":9443,"start":5906,"enrollment":1535,"conditions":14870,"interventions":14872},"NCT00681863","Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome",[92],[14871],"Tourette Syndrome",[14856,14873,14874,14875,14876],"pramipexole 0.0625 mg QD","pramipexole 0.125 mg TID","pramipexole 0.25 mg BID","pramipexole 0.0625 mg BID",{"trials":14878,"activeCount":101},[],{"trials":14880,"activeCount":101},[],{"intervention":14873,"totalTrials":272,"cells":14882},{"EARLY_PHASE1":14883,"PHASE1":14885,"PHASE2":14887,"PHASE3":14889,"PHASE4":14895,"NA":14897},{"trials":14884,"activeCount":101},[],{"trials":14886,"activeCount":101},[],{"trials":14888,"activeCount":101},[],{"trials":14890,"activeCount":101},[14891],{"nctId":14867,"briefTitle":14868,"status":162,"phases":14892,"primaryCompletion":9443,"start":5906,"enrollment":1535,"conditions":14893,"interventions":14894},[92],[14871],[14856,14873,14874,14875,14876],{"trials":14896,"activeCount":101},[],{"trials":14898,"activeCount":101},[],{"intervention":14874,"totalTrials":272,"cells":14900},{"EARLY_PHASE1":14901,"PHASE1":14903,"PHASE2":14905,"PHASE3":14907,"PHASE4":14913,"NA":14915},{"trials":14902,"activeCount":101},[],{"trials":14904,"activeCount":101},[],{"trials":14906,"activeCount":101},[],{"trials":14908,"activeCount":101},[14909],{"nctId":14867,"briefTitle":14868,"status":162,"phases":14910,"primaryCompletion":9443,"start":5906,"enrollment":1535,"conditions":14911,"interventions":14912},[92],[14871],[14856,14873,14874,14875,14876],{"trials":14914,"activeCount":101},[],{"trials":14916,"activeCount":101},[],{"intervention":14875,"totalTrials":272,"cells":14918},{"EARLY_PHASE1":14919,"PHASE1":14921,"PHASE2":14923,"PHASE3":14925,"PHASE4":14931,"NA":14933},{"trials":14920,"activeCount":101},[],{"trials":14922,"activeCount":101},[],{"trials":14924,"activeCount":101},[],{"trials":14926,"activeCount":101},[14927],{"nctId":14867,"briefTitle":14868,"status":162,"phases":14928,"primaryCompletion":9443,"start":5906,"enrollment":1535,"conditions":14929,"interventions":14930},[92],[14871],[14856,14873,14874,14875,14876],{"trials":14932,"activeCount":101},[],{"trials":14934,"activeCount":101},[],{"intervention":14876,"totalTrials":272,"cells":14936},{"EARLY_PHASE1":14937,"PHASE1":14939,"PHASE2":14941,"PHASE3":14943,"PHASE4":14949,"NA":14951},{"trials":14938,"activeCount":101},[],{"trials":14940,"activeCount":101},[],{"trials":14942,"activeCount":101},[],{"trials":14944,"activeCount":101},[14945],{"nctId":14867,"briefTitle":14868,"status":162,"phases":14946,"primaryCompletion":9443,"start":5906,"enrollment":1535,"conditions":14947,"interventions":14948},[92],[14871],[14856,14873,14874,14875,14876],{"trials":14950,"activeCount":101},[],{"trials":14952,"activeCount":101},[],{"intervention":14954,"totalTrials":272,"cells":14955},"telmisartan40\u002Famlodipine5",{"EARLY_PHASE1":14956,"PHASE1":14958,"PHASE2":14960,"PHASE3":14962,"PHASE4":14971,"NA":14973},{"trials":14957,"activeCount":101},[],{"trials":14959,"activeCount":101},[],{"trials":14961,"activeCount":101},[],{"trials":14963,"activeCount":101},[14964],{"nctId":14965,"briefTitle":14966,"status":107,"phases":14967,"primaryCompletion":9443,"start":4507,"enrollment":10693,"conditions":14968,"interventions":14969},"NCT00618774","An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination",[92],[24],[14954,14970],"telmisartan80\u002Famlodipine5",{"trials":14972,"activeCount":101},[],{"trials":14974,"activeCount":101},[],{"intervention":14970,"totalTrials":272,"cells":14976},{"EARLY_PHASE1":14977,"PHASE1":14979,"PHASE2":14981,"PHASE3":14983,"PHASE4":14989,"NA":14991},{"trials":14978,"activeCount":101},[],{"trials":14980,"activeCount":101},[],{"trials":14982,"activeCount":101},[],{"trials":14984,"activeCount":101},[14985],{"nctId":14965,"briefTitle":14966,"status":107,"phases":14986,"primaryCompletion":9443,"start":4507,"enrollment":10693,"conditions":14987,"interventions":14988},[92],[24],[14954,14970],{"trials":14990,"activeCount":101},[],{"trials":14992,"activeCount":101},[],{"intervention":6635,"totalTrials":272,"cells":14994},{"EARLY_PHASE1":14995,"PHASE1":14997,"PHASE2":14999,"PHASE3":15001,"PHASE4":15007,"NA":15009},{"trials":14996,"activeCount":101},[],{"trials":14998,"activeCount":101},[],{"trials":15000,"activeCount":101},[],{"trials":15002,"activeCount":101},[15003],{"nctId":6625,"briefTitle":6626,"status":107,"phases":15004,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":6630,"conditions":15005,"interventions":15006},[92],[21],[6633,6634,6614,6635],{"trials":15008,"activeCount":101},[],{"trials":15010,"activeCount":101},[],{"intervention":12616,"totalTrials":272,"cells":15012},{"EARLY_PHASE1":15013,"PHASE1":15015,"PHASE2":15017,"PHASE3":15019,"PHASE4":15025,"NA":15027},{"trials":15014,"activeCount":101},[],{"trials":15016,"activeCount":101},[],{"trials":15018,"activeCount":101},[],{"trials":15020,"activeCount":101},[15021],{"nctId":12610,"briefTitle":12611,"status":107,"phases":15022,"primaryCompletion":7132,"start":5880,"enrollment":12613,"conditions":15023,"interventions":15024},[92],[18],[12588,12604,12616],{"trials":15026,"activeCount":101},[],{"trials":15028,"activeCount":101},[],{"intervention":9962,"totalTrials":272,"cells":15030},{"EARLY_PHASE1":15031,"PHASE1":15033,"PHASE2":15035,"PHASE3":15037,"PHASE4":15043,"NA":15045},{"trials":15032,"activeCount":101},[],{"trials":15034,"activeCount":101},[],{"trials":15036,"activeCount":101},[],{"trials":15038,"activeCount":101},[15039],{"nctId":9956,"briefTitle":9957,"status":107,"phases":15040,"primaryCompletion":1980,"start":2032,"enrollment":9959,"conditions":15041,"interventions":15042},[92],[21],[9872,9962,9963,413,384],{"trials":15044,"activeCount":101},[],{"trials":15046,"activeCount":101},[],{"intervention":12668,"totalTrials":272,"cells":15048},{"EARLY_PHASE1":15049,"PHASE1":15051,"PHASE2":15053,"PHASE3":15055,"PHASE4":15061,"NA":15063},{"trials":15050,"activeCount":101},[],{"trials":15052,"activeCount":101},[],{"trials":15054,"activeCount":101},[],{"trials":15056,"activeCount":101},[15057],{"nctId":12662,"briefTitle":12663,"status":107,"phases":15058,"primaryCompletion":379,"completion":379,"start":517,"enrollment":7763,"conditions":15059,"interventions":15060},[92],[12666],[12668,12644,12669],{"trials":15062,"activeCount":101},[],{"trials":15064,"activeCount":101},[],{"intervention":12669,"totalTrials":272,"cells":15066},{"EARLY_PHASE1":15067,"PHASE1":15069,"PHASE2":15071,"PHASE3":15073,"PHASE4":15079,"NA":15081},{"trials":15068,"activeCount":101},[],{"trials":15070,"activeCount":101},[],{"trials":15072,"activeCount":101},[],{"trials":15074,"activeCount":101},[15075],{"nctId":12662,"briefTitle":12663,"status":107,"phases":15076,"primaryCompletion":379,"completion":379,"start":517,"enrollment":7763,"conditions":15077,"interventions":15078},[92],[12666],[12668,12644,12669],{"trials":15080,"activeCount":101},[],{"trials":15082,"activeCount":101},[],{"intervention":15084,"totalTrials":272,"cells":15085},"Telmisartan 80",{"EARLY_PHASE1":15086,"PHASE1":15088,"PHASE2":15090,"PHASE3":15092,"PHASE4":15102,"NA":15104},{"trials":15087,"activeCount":101},[],{"trials":15089,"activeCount":101},[],{"trials":15091,"activeCount":101},[],{"trials":15093,"activeCount":101},[15094],{"nctId":15095,"briefTitle":15096,"status":107,"phases":15097,"primaryCompletion":1980,"start":1989,"enrollment":15098,"conditions":15099,"interventions":15100},"NCT00877929","Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus",[92],706,[24],[15084,15101,15101],"Amlodipine 10",{"trials":15103,"activeCount":101},[],{"trials":15105,"activeCount":101},[],{"intervention":15101,"totalTrials":272,"cells":15107},{"EARLY_PHASE1":15108,"PHASE1":15110,"PHASE2":15112,"PHASE3":15114,"PHASE4":15120,"NA":15122},{"trials":15109,"activeCount":101},[],{"trials":15111,"activeCount":101},[],{"trials":15113,"activeCount":101},[],{"trials":15115,"activeCount":101},[15116],{"nctId":15095,"briefTitle":15096,"status":107,"phases":15117,"primaryCompletion":1980,"start":1989,"enrollment":15098,"conditions":15118,"interventions":15119},[92],[24],[15084,15101,15101],{"trials":15121,"activeCount":101},[],{"trials":15123,"activeCount":101},[],{"intervention":15125,"totalTrials":272,"cells":15126},"Pharmaton PHL 00749",{"EARLY_PHASE1":15127,"PHASE1":15129,"PHASE2":15131,"PHASE3":15133,"PHASE4":15145,"NA":15147},{"trials":15128,"activeCount":101},[],{"trials":15130,"activeCount":101},[],{"trials":15132,"activeCount":101},[],{"trials":15134,"activeCount":101},[15135],{"nctId":15136,"briefTitle":15137,"status":107,"phases":15138,"primaryCompletion":11642,"completion":11642,"start":15139,"enrollment":15140,"conditions":15141,"interventions":15144},"NCT00144235","Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue",[92],"2005-03",412,[15142,15143],"Mental Competency","Mental Fatigue",[15125],{"trials":15146,"activeCount":101},[],{"trials":15148,"activeCount":101},[],{"intervention":15150,"totalTrials":272,"cells":15151},"Meloxicam suppository",{"EARLY_PHASE1":15152,"PHASE1":15154,"PHASE2":15156,"PHASE3":15158,"PHASE4":15169,"NA":15171},{"trials":15153,"activeCount":101},[],{"trials":15155,"activeCount":101},[],{"trials":15157,"activeCount":101},[],{"trials":15159,"activeCount":101},[15160],{"nctId":15161,"briefTitle":15162,"status":107,"phases":15163,"primaryCompletion":5915,"start":15164,"enrollment":7093,"conditions":15165,"interventions":15167},"NCT02183168","Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis",[92],"2001-07-01",[15166],"Spondylitis, Ankylosing",[15150,6498,15168],"Indomethacin",{"trials":15170,"activeCount":101},[],{"trials":15172,"activeCount":101},[],{"intervention":15168,"totalTrials":272,"cells":15174},{"EARLY_PHASE1":15175,"PHASE1":15177,"PHASE2":15179,"PHASE3":15181,"PHASE4":15187,"NA":15189},{"trials":15176,"activeCount":101},[],{"trials":15178,"activeCount":101},[],{"trials":15180,"activeCount":101},[],{"trials":15182,"activeCount":101},[15183],{"nctId":15161,"briefTitle":15162,"status":107,"phases":15184,"primaryCompletion":5915,"start":15164,"enrollment":7093,"conditions":15185,"interventions":15186},[92],[15166],[15150,6498,15168],{"trials":15188,"activeCount":101},[],{"trials":15190,"activeCount":101},[],{"intervention":15192,"totalTrials":272,"cells":15193},"telmisartan+amlodipine fixed dose combination",{"EARLY_PHASE1":15194,"PHASE1":15196,"PHASE2":15198,"PHASE3":15200,"PHASE4":15208,"NA":15210},{"trials":15195,"activeCount":101},[],{"trials":15197,"activeCount":101},[],{"trials":15199,"activeCount":101},[],{"trials":15201,"activeCount":101},[15202],{"nctId":15203,"briefTitle":15204,"status":107,"phases":15205,"primaryCompletion":9752,"start":4441,"enrollment":251,"conditions":15206,"interventions":15207},"NCT01204398","Telmisartan+Amlodipine Fixed Dose Combination in Hypertension",[92],[24],[15192],{"trials":15209,"activeCount":101},[],{"trials":15211,"activeCount":101},[],{"intervention":9509,"totalTrials":272,"cells":15213},{"EARLY_PHASE1":15214,"PHASE1":15216,"PHASE2":15218,"PHASE3":15220,"PHASE4":15226,"NA":15228},{"trials":15215,"activeCount":101},[],{"trials":15217,"activeCount":101},[],{"trials":15219,"activeCount":101},[],{"trials":15221,"activeCount":101},[15222],{"nctId":9503,"briefTitle":9504,"status":107,"phases":15223,"primaryCompletion":4120,"completion":4120,"start":3730,"enrollment":9506,"conditions":15224,"interventions":15225},[92],[21],[528,4445,9509,528,9509,9510,528,528,528,9510,4445,9510,528,9510],{"trials":15227,"activeCount":101},[],{"trials":15229,"activeCount":101},[],{"intervention":9510,"totalTrials":272,"cells":15231},{"EARLY_PHASE1":15232,"PHASE1":15234,"PHASE2":15236,"PHASE3":15238,"PHASE4":15244,"NA":15246},{"trials":15233,"activeCount":101},[],{"trials":15235,"activeCount":101},[],{"trials":15237,"activeCount":101},[],{"trials":15239,"activeCount":101},[15240],{"nctId":9503,"briefTitle":9504,"status":107,"phases":15241,"primaryCompletion":4120,"completion":4120,"start":3730,"enrollment":9506,"conditions":15242,"interventions":15243},[92],[21],[528,4445,9509,528,9509,9510,528,528,528,9510,4445,9510,528,9510],{"trials":15245,"activeCount":101},[],{"trials":15247,"activeCount":101},[],{"intervention":15249,"totalTrials":272,"cells":15250},"Telmisartan, low dose",{"EARLY_PHASE1":15251,"PHASE1":15253,"PHASE2":15255,"PHASE3":15257,"PHASE4":15266,"NA":15268},{"trials":15252,"activeCount":101},[],{"trials":15254,"activeCount":101},[],{"trials":15256,"activeCount":101},[],{"trials":15258,"activeCount":101},[15259],{"nctId":15260,"briefTitle":15261,"status":107,"phases":15262,"primaryCompletion":13117,"start":5923,"enrollment":1982,"conditions":15263,"interventions":15264},"NCT02176499","Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension",[92],[24],[15249,15265],"Telmisartan, high dose",{"trials":15267,"activeCount":101},[],{"trials":15269,"activeCount":101},[],{"intervention":15265,"totalTrials":272,"cells":15271},{"EARLY_PHASE1":15272,"PHASE1":15274,"PHASE2":15276,"PHASE3":15278,"PHASE4":15284,"NA":15286},{"trials":15273,"activeCount":101},[],{"trials":15275,"activeCount":101},[],{"trials":15277,"activeCount":101},[],{"trials":15279,"activeCount":101},[15280],{"nctId":15260,"briefTitle":15261,"status":107,"phases":15281,"primaryCompletion":13117,"start":5923,"enrollment":1982,"conditions":15282,"interventions":15283},[92],[24],[15249,15265],{"trials":15285,"activeCount":101},[],{"trials":15287,"activeCount":101},[],{"intervention":6646,"totalTrials":272,"cells":15289},{"EARLY_PHASE1":15290,"PHASE1":15292,"PHASE2":15294,"PHASE3":15296,"PHASE4":15302,"NA":15304},{"trials":15291,"activeCount":101},[],{"trials":15293,"activeCount":101},[],{"trials":15295,"activeCount":101},[],{"trials":15297,"activeCount":101},[15298],{"nctId":6637,"briefTitle":6638,"status":107,"phases":15299,"primaryCompletion":6640,"completion":6641,"start":6642,"enrollment":6643,"conditions":15300,"interventions":15301},[92],[21],[361,6646,6647,6648,6649,6650],{"trials":15303,"activeCount":101},[],{"trials":15305,"activeCount":101},[],{"intervention":6647,"totalTrials":272,"cells":15307},{"EARLY_PHASE1":15308,"PHASE1":15310,"PHASE2":15312,"PHASE3":15314,"PHASE4":15320,"NA":15322},{"trials":15309,"activeCount":101},[],{"trials":15311,"activeCount":101},[],{"trials":15313,"activeCount":101},[],{"trials":15315,"activeCount":101},[15316],{"nctId":6637,"briefTitle":6638,"status":107,"phases":15317,"primaryCompletion":6640,"completion":6641,"start":6642,"enrollment":6643,"conditions":15318,"interventions":15319},[92],[21],[361,6646,6647,6648,6649,6650],{"trials":15321,"activeCount":101},[],{"trials":15323,"activeCount":101},[],{"intervention":6649,"totalTrials":272,"cells":15325},{"EARLY_PHASE1":15326,"PHASE1":15328,"PHASE2":15330,"PHASE3":15332,"PHASE4":15338,"NA":15340},{"trials":15327,"activeCount":101},[],{"trials":15329,"activeCount":101},[],{"trials":15331,"activeCount":101},[],{"trials":15333,"activeCount":101},[15334],{"nctId":6637,"briefTitle":6638,"status":107,"phases":15335,"primaryCompletion":6640,"completion":6641,"start":6642,"enrollment":6643,"conditions":15336,"interventions":15337},[92],[21],[361,6646,6647,6648,6649,6650],{"trials":15339,"activeCount":101},[],{"trials":15341,"activeCount":101},[],{"intervention":6650,"totalTrials":272,"cells":15343},{"EARLY_PHASE1":15344,"PHASE1":15346,"PHASE2":15348,"PHASE3":15350,"PHASE4":15356,"NA":15358},{"trials":15345,"activeCount":101},[],{"trials":15347,"activeCount":101},[],{"trials":15349,"activeCount":101},[],{"trials":15351,"activeCount":101},[15352],{"nctId":6637,"briefTitle":6638,"status":107,"phases":15353,"primaryCompletion":6640,"completion":6641,"start":6642,"enrollment":6643,"conditions":15354,"interventions":15355},[92],[21],[361,6646,6647,6648,6649,6650],{"trials":15357,"activeCount":101},[],{"trials":15359,"activeCount":101},[],{"intervention":15361,"totalTrials":272,"cells":15362},"Spesolimab i.v.",{"EARLY_PHASE1":15363,"PHASE1":15365,"PHASE2":15367,"PHASE3":15369,"PHASE4":15381,"NA":15383},{"trials":15364,"activeCount":101},[],{"trials":15366,"activeCount":101},[],{"trials":15368,"activeCount":101},[],{"trials":15370,"activeCount":101},[15371],{"nctId":15372,"briefTitle":15373,"status":107,"phases":15374,"primaryCompletion":3789,"completion":15375,"start":15376,"enrollment":15377,"conditions":15378,"interventions":15379},"NCT05819398","Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa",[91,92],"2025-03-31","2023-04-17",209,[13220],[15361,15380],"Spesolimab s.c.",{"trials":15382,"activeCount":101},[],{"trials":15384,"activeCount":101},[],{"intervention":15380,"totalTrials":272,"cells":15386},{"EARLY_PHASE1":15387,"PHASE1":15389,"PHASE2":15391,"PHASE3":15393,"PHASE4":15399,"NA":15401},{"trials":15388,"activeCount":101},[],{"trials":15390,"activeCount":101},[],{"trials":15392,"activeCount":101},[],{"trials":15394,"activeCount":101},[15395],{"nctId":15372,"briefTitle":15373,"status":107,"phases":15396,"primaryCompletion":3789,"completion":15375,"start":15376,"enrollment":15377,"conditions":15397,"interventions":15398},[91,92],[13220],[15361,15380],{"trials":15400,"activeCount":101},[],{"trials":15402,"activeCount":101},[],{"intervention":15404,"totalTrials":272,"cells":15405},"salbutamol sulfate + ipratropium bromide",{"EARLY_PHASE1":15406,"PHASE1":15408,"PHASE2":15410,"PHASE3":15412,"PHASE4":15420,"NA":15422},{"trials":15407,"activeCount":101},[],{"trials":15409,"activeCount":101},[],{"trials":15411,"activeCount":101},[],{"trials":15413,"activeCount":101},[15414],{"nctId":15415,"briefTitle":15416,"status":162,"phases":15417,"primaryCompletion":6206,"start":6074,"enrollment":4433,"conditions":15418,"interventions":15419},"NCT02182700","Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis",[92],[30],[15404],{"trials":15421,"activeCount":101},[],{"trials":15423,"activeCount":101},[],{"intervention":15425,"totalTrials":272,"cells":15426},"99mTc-radiolabelled tiotropium",{"EARLY_PHASE1":15427,"PHASE1":15429,"PHASE2":15431,"PHASE3":15433,"PHASE4":15442,"NA":15444},{"trials":15428,"activeCount":101},[],{"trials":15430,"activeCount":101},[],{"trials":15432,"activeCount":101},[],{"trials":15434,"activeCount":101},[15435],{"nctId":15436,"briefTitle":15437,"status":107,"phases":15438,"primaryCompletion":6189,"start":5887,"enrollment":210,"conditions":15439,"interventions":15440},"NCT02172456","Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[15425,15441],"non-radiolabelled tiotropium",{"trials":15443,"activeCount":101},[],{"trials":15445,"activeCount":101},[],{"intervention":15441,"totalTrials":272,"cells":15447},{"EARLY_PHASE1":15448,"PHASE1":15450,"PHASE2":15452,"PHASE3":15454,"PHASE4":15460,"NA":15462},{"trials":15449,"activeCount":101},[],{"trials":15451,"activeCount":101},[],{"trials":15453,"activeCount":101},[],{"trials":15455,"activeCount":101},[15456],{"nctId":15436,"briefTitle":15437,"status":107,"phases":15457,"primaryCompletion":6189,"start":5887,"enrollment":210,"conditions":15458,"interventions":15459},[92],[18],[15425,15441],{"trials":15461,"activeCount":101},[],{"trials":15463,"activeCount":101},[],{"intervention":15465,"totalTrials":272,"cells":15466},"Read vine leaf extract",{"EARLY_PHASE1":15467,"PHASE1":15469,"PHASE2":15471,"PHASE3":15473,"PHASE4":15481,"NA":15483},{"trials":15468,"activeCount":101},[],{"trials":15470,"activeCount":101},[],{"trials":15472,"activeCount":101},[],{"trials":15474,"activeCount":101},[15475],{"nctId":15476,"briefTitle":15477,"status":107,"phases":15478,"primaryCompletion":1990,"start":4461,"enrollment":3029,"conditions":15479,"interventions":15480},"NCT00292435","Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)",[92],[8458],[15465],{"trials":15482,"activeCount":101},[],{"trials":15484,"activeCount":101},[],{"intervention":12757,"totalTrials":272,"cells":15486},{"EARLY_PHASE1":15487,"PHASE1":15489,"PHASE2":15491,"PHASE3":15493,"PHASE4":15499,"NA":15501},{"trials":15488,"activeCount":101},[],{"trials":15490,"activeCount":101},[],{"trials":15492,"activeCount":101},[],{"trials":15494,"activeCount":101},[15495],{"nctId":12751,"briefTitle":12752,"status":107,"phases":15496,"primaryCompletion":2146,"start":6374,"enrollment":357,"conditions":15497,"interventions":15498},[92],[12755],[12733,12757],{"trials":15500,"activeCount":101},[],{"trials":15502,"activeCount":101},[],{"intervention":15504,"totalTrials":272,"cells":15505},"Bisacodyl 10 mg",{"EARLY_PHASE1":15506,"PHASE1":15508,"PHASE2":15510,"PHASE3":15512,"PHASE4":15521,"NA":15523},{"trials":15507,"activeCount":101},[],{"trials":15509,"activeCount":101},[],{"trials":15511,"activeCount":101},[],{"trials":15513,"activeCount":101},[15514],{"nctId":15515,"briefTitle":15516,"status":107,"phases":15517,"primaryCompletion":5905,"start":6140,"enrollment":15518,"conditions":15519,"interventions":15520},"NCT00526097","Dulcolax vs Placebo in Functional Constipation",[92],368,[12755],[15504],{"trials":15522,"activeCount":101},[],{"trials":15524,"activeCount":101},[],{"intervention":10842,"totalTrials":272,"cells":15526},{"EARLY_PHASE1":15527,"PHASE1":15529,"PHASE2":15531,"PHASE3":15533,"PHASE4":15539,"NA":15541},{"trials":15528,"activeCount":101},[],{"trials":15530,"activeCount":101},[],{"trials":15532,"activeCount":101},[],{"trials":15534,"activeCount":101},[15535],{"nctId":10836,"briefTitle":10837,"status":107,"phases":15536,"primaryCompletion":2122,"start":5923,"enrollment":10839,"conditions":15537,"interventions":15538},[92],[18],[10802,10842],{"trials":15540,"activeCount":101},[],{"trials":15542,"activeCount":101},[],{"intervention":15544,"totalTrials":272,"cells":15545},"40 mg telmisartan",{"EARLY_PHASE1":15546,"PHASE1":15548,"PHASE2":15550,"PHASE3":15552,"PHASE4":15563,"NA":15565},{"trials":15547,"activeCount":101},[],{"trials":15549,"activeCount":101},[],{"trials":15551,"activeCount":101},[],{"trials":15553,"activeCount":101},[15554],{"nctId":15555,"briefTitle":15556,"status":107,"phases":15557,"primaryCompletion":5296,"start":6133,"enrollment":15558,"conditions":15559,"interventions":15560},"NCT01286558","Comparison in Japan T80\u002FA5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40\u002FA5 (Telmisartan 40 mg and Amlodipine 5 mg)",[92],225,[24],[15544,15561,15561,15562],"5 mg amlodipine","80 mg telmisartan",{"trials":15564,"activeCount":101},[],{"trials":15566,"activeCount":101},[],{"intervention":15561,"totalTrials":272,"cells":15568},{"EARLY_PHASE1":15569,"PHASE1":15571,"PHASE2":15573,"PHASE3":15575,"PHASE4":15581,"NA":15583},{"trials":15570,"activeCount":101},[],{"trials":15572,"activeCount":101},[],{"trials":15574,"activeCount":101},[],{"trials":15576,"activeCount":101},[15577],{"nctId":15555,"briefTitle":15556,"status":107,"phases":15578,"primaryCompletion":5296,"start":6133,"enrollment":15558,"conditions":15579,"interventions":15580},[92],[24],[15544,15561,15561,15562],{"trials":15582,"activeCount":101},[],{"trials":15584,"activeCount":101},[],{"intervention":15562,"totalTrials":272,"cells":15586},{"EARLY_PHASE1":15587,"PHASE1":15589,"PHASE2":15591,"PHASE3":15593,"PHASE4":15599,"NA":15601},{"trials":15588,"activeCount":101},[],{"trials":15590,"activeCount":101},[],{"trials":15592,"activeCount":101},[],{"trials":15594,"activeCount":101},[15595],{"nctId":15555,"briefTitle":15556,"status":107,"phases":15596,"primaryCompletion":5296,"start":6133,"enrollment":15558,"conditions":15597,"interventions":15598},[92],[24],[15544,15561,15561,15562],{"trials":15600,"activeCount":101},[],{"trials":15602,"activeCount":101},[],{"intervention":15604,"totalTrials":272,"cells":15605},"meloxicam 0.25 mg\u002Fkg",{"EARLY_PHASE1":15606,"PHASE1":15608,"PHASE2":15610,"PHASE3":15612,"PHASE4":15623,"NA":15625},{"trials":15607,"activeCount":101},[],{"trials":15609,"activeCount":101},[],{"trials":15611,"activeCount":101},[],{"trials":15613,"activeCount":101},[15614],{"nctId":15615,"briefTitle":15616,"status":107,"phases":15617,"primaryCompletion":7574,"completion":7574,"start":6949,"enrollment":15618,"conditions":15619,"interventions":15620},"NCT00279747","A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA\u002FJIA)",[92],226,[14830],[15604,15621,15622],"meloxicam 0.125 mg\u002Fkg","naproxen 10 mg\u002Fkg",{"trials":15624,"activeCount":101},[],{"trials":15626,"activeCount":101},[],{"intervention":15621,"totalTrials":272,"cells":15628},{"EARLY_PHASE1":15629,"PHASE1":15631,"PHASE2":15633,"PHASE3":15635,"PHASE4":15641,"NA":15643},{"trials":15630,"activeCount":101},[],{"trials":15632,"activeCount":101},[],{"trials":15634,"activeCount":101},[],{"trials":15636,"activeCount":101},[15637],{"nctId":15615,"briefTitle":15616,"status":107,"phases":15638,"primaryCompletion":7574,"completion":7574,"start":6949,"enrollment":15618,"conditions":15639,"interventions":15640},[92],[14830],[15604,15621,15622],{"trials":15642,"activeCount":101},[],{"trials":15644,"activeCount":101},[],{"intervention":15622,"totalTrials":272,"cells":15646},{"EARLY_PHASE1":15647,"PHASE1":15649,"PHASE2":15651,"PHASE3":15653,"PHASE4":15659,"NA":15661},{"trials":15648,"activeCount":101},[],{"trials":15650,"activeCount":101},[],{"trials":15652,"activeCount":101},[],{"trials":15654,"activeCount":101},[15655],{"nctId":15615,"briefTitle":15616,"status":107,"phases":15656,"primaryCompletion":7574,"completion":7574,"start":6949,"enrollment":15618,"conditions":15657,"interventions":15658},[92],[14830],[15604,15621,15622],{"trials":15660,"activeCount":101},[],{"trials":15662,"activeCount":101},[],{"intervention":15664,"totalTrials":272,"cells":15665},"Ipratropium",{"EARLY_PHASE1":15666,"PHASE1":15668,"PHASE2":15670,"PHASE3":15672,"PHASE4":15681,"NA":15683},{"trials":15667,"activeCount":101},[],{"trials":15669,"activeCount":101},[],{"trials":15671,"activeCount":101},[],{"trials":15673,"activeCount":101},[15674],{"nctId":15675,"briefTitle":15676,"status":107,"phases":15677,"primaryCompletion":11650,"completion":11650,"start":6495,"enrollment":15678,"conditions":15679,"interventions":15680},"NCT00274040","Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD",[92],141,[18],[5860,15664],{"trials":15682,"activeCount":101},[],{"trials":15684,"activeCount":101},[],{"intervention":15686,"totalTrials":272,"cells":15687},"Berodual® via Respimat®, high dose",{"EARLY_PHASE1":15688,"PHASE1":15690,"PHASE2":15692,"PHASE3":15694,"PHASE4":15705,"NA":15707},{"trials":15689,"activeCount":101},[],{"trials":15691,"activeCount":101},[],{"trials":15693,"activeCount":101},[],{"trials":15695,"activeCount":101},[15696],{"nctId":15697,"briefTitle":15698,"status":107,"phases":15699,"primaryCompletion":6391,"start":6065,"enrollment":15700,"conditions":15701,"interventions":15702},"NCT02182479","Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients",[92],631,[30],[15686,15703,15704],"Berodual® via Respimat®, low dose","Berodual® via MDI, high dose",{"trials":15706,"activeCount":101},[],{"trials":15708,"activeCount":101},[],{"intervention":15703,"totalTrials":272,"cells":15710},{"EARLY_PHASE1":15711,"PHASE1":15713,"PHASE2":15715,"PHASE3":15717,"PHASE4":15723,"NA":15725},{"trials":15712,"activeCount":101},[],{"trials":15714,"activeCount":101},[],{"trials":15716,"activeCount":101},[],{"trials":15718,"activeCount":101},[15719],{"nctId":15697,"briefTitle":15698,"status":107,"phases":15720,"primaryCompletion":6391,"start":6065,"enrollment":15700,"conditions":15721,"interventions":15722},[92],[30],[15686,15703,15704],{"trials":15724,"activeCount":101},[],{"trials":15726,"activeCount":101},[],{"intervention":15704,"totalTrials":272,"cells":15728},{"EARLY_PHASE1":15729,"PHASE1":15731,"PHASE2":15733,"PHASE3":15735,"PHASE4":15741,"NA":15743},{"trials":15730,"activeCount":101},[],{"trials":15732,"activeCount":101},[],{"trials":15734,"activeCount":101},[],{"trials":15736,"activeCount":101},[15737],{"nctId":15697,"briefTitle":15698,"status":107,"phases":15738,"primaryCompletion":6391,"start":6065,"enrollment":15700,"conditions":15739,"interventions":15740},[92],[30],[15686,15703,15704],{"trials":15742,"activeCount":101},[],{"trials":15744,"activeCount":101},[],{"intervention":15746,"totalTrials":272,"cells":15747},"Gingko biloba",{"EARLY_PHASE1":15748,"PHASE1":15750,"PHASE2":15752,"PHASE3":15754,"PHASE4":15762,"NA":15764},{"trials":15749,"activeCount":101},[],{"trials":15751,"activeCount":101},[],{"trials":15753,"activeCount":101},[],{"trials":15755,"activeCount":101},[15756],{"nctId":15757,"briefTitle":15758,"status":107,"phases":15759,"primaryCompletion":6082,"start":5887,"enrollment":641,"conditions":15760,"interventions":15761},"NCT02181972","Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults",[92],[15],[15746],{"trials":15763,"activeCount":101},[],{"trials":15765,"activeCount":101},[],{"intervention":15767,"totalTrials":272,"cells":15768},"Songha Night ®",{"EARLY_PHASE1":15769,"PHASE1":15771,"PHASE2":15773,"PHASE3":15775,"PHASE4":15783,"NA":15785},{"trials":15770,"activeCount":101},[],{"trials":15772,"activeCount":101},[],{"trials":15774,"activeCount":101},[],{"trials":15776,"activeCount":101},[15777],{"nctId":15778,"briefTitle":15779,"status":107,"phases":15780,"primaryCompletion":7114,"start":7250,"enrollment":3467,"conditions":15781,"interventions":15782},"NCT02183714","The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances",[92],[11071],[15767],{"trials":15784,"activeCount":101},[],{"trials":15786,"activeCount":101},[],{"intervention":15788,"totalTrials":272,"cells":15789},"tiotropium Respimat® inhaler",{"EARLY_PHASE1":15790,"PHASE1":15792,"PHASE2":15794,"PHASE3":15796,"PHASE4":15805,"NA":15807},{"trials":15791,"activeCount":101},[],{"trials":15793,"activeCount":101},[],{"trials":15795,"activeCount":101},[],{"trials":15797,"activeCount":101},[15798],{"nctId":15799,"briefTitle":15800,"status":107,"phases":15801,"primaryCompletion":3753,"start":7703,"enrollment":15802,"conditions":15803,"interventions":15804},"NCT01179347","Tiotropium Bromide in Cystic Fibrosis",[92],464,[1724],[15788],{"trials":15806,"activeCount":101},[],{"trials":15808,"activeCount":101},[],{"intervention":15810,"totalTrials":272,"cells":15811},"BI 207127-placebo: 8-week treatment",{"EARLY_PHASE1":15812,"PHASE1":15814,"PHASE2":15816,"PHASE3":15818,"PHASE4":15836,"NA":15838},{"trials":15813,"activeCount":101},[],{"trials":15815,"activeCount":101},[],{"trials":15817,"activeCount":101},[],{"trials":15819,"activeCount":101},[15820],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15823,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15825,"interventions":15826},"NCT01728324","Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2",[92],496,[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],"Ribavirin: 24-week treatment","BI 207127: 24-week treatment","Faldaprevir: 24-week treatment","Ribavirin-placebo: 8-week treatment","Faldaprevir-placebo: 8-week treatment","Faldaprevir: 16-week treatment","Ribavirin: 16-week treatment","RBV: 24-week treatment","BI 207127: 16-week treatment",{"trials":15837,"activeCount":101},[],{"trials":15839,"activeCount":101},[],{"intervention":15827,"totalTrials":272,"cells":15841},{"EARLY_PHASE1":15842,"PHASE1":15844,"PHASE2":15846,"PHASE3":15848,"PHASE4":15854,"NA":15856},{"trials":15843,"activeCount":101},[],{"trials":15845,"activeCount":101},[],{"trials":15847,"activeCount":101},[],{"trials":15849,"activeCount":101},[15850],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15851,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15852,"interventions":15853},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15855,"activeCount":101},[],{"trials":15857,"activeCount":101},[],{"intervention":15828,"totalTrials":272,"cells":15859},{"EARLY_PHASE1":15860,"PHASE1":15862,"PHASE2":15864,"PHASE3":15866,"PHASE4":15872,"NA":15874},{"trials":15861,"activeCount":101},[],{"trials":15863,"activeCount":101},[],{"trials":15865,"activeCount":101},[],{"trials":15867,"activeCount":101},[15868],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15869,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15870,"interventions":15871},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15873,"activeCount":101},[],{"trials":15875,"activeCount":101},[],{"intervention":15829,"totalTrials":272,"cells":15877},{"EARLY_PHASE1":15878,"PHASE1":15880,"PHASE2":15882,"PHASE3":15884,"PHASE4":15890,"NA":15892},{"trials":15879,"activeCount":101},[],{"trials":15881,"activeCount":101},[],{"trials":15883,"activeCount":101},[],{"trials":15885,"activeCount":101},[15886],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15887,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15888,"interventions":15889},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15891,"activeCount":101},[],{"trials":15893,"activeCount":101},[],{"intervention":15830,"totalTrials":272,"cells":15895},{"EARLY_PHASE1":15896,"PHASE1":15898,"PHASE2":15900,"PHASE3":15902,"PHASE4":15908,"NA":15910},{"trials":15897,"activeCount":101},[],{"trials":15899,"activeCount":101},[],{"trials":15901,"activeCount":101},[],{"trials":15903,"activeCount":101},[15904],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15905,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15906,"interventions":15907},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15909,"activeCount":101},[],{"trials":15911,"activeCount":101},[],{"intervention":15831,"totalTrials":272,"cells":15913},{"EARLY_PHASE1":15914,"PHASE1":15916,"PHASE2":15918,"PHASE3":15920,"PHASE4":15926,"NA":15928},{"trials":15915,"activeCount":101},[],{"trials":15917,"activeCount":101},[],{"trials":15919,"activeCount":101},[],{"trials":15921,"activeCount":101},[15922],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15923,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15924,"interventions":15925},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15927,"activeCount":101},[],{"trials":15929,"activeCount":101},[],{"intervention":15832,"totalTrials":272,"cells":15931},{"EARLY_PHASE1":15932,"PHASE1":15934,"PHASE2":15936,"PHASE3":15938,"PHASE4":15944,"NA":15946},{"trials":15933,"activeCount":101},[],{"trials":15935,"activeCount":101},[],{"trials":15937,"activeCount":101},[],{"trials":15939,"activeCount":101},[15940],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15941,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15942,"interventions":15943},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15945,"activeCount":101},[],{"trials":15947,"activeCount":101},[],{"intervention":15833,"totalTrials":272,"cells":15949},{"EARLY_PHASE1":15950,"PHASE1":15952,"PHASE2":15954,"PHASE3":15956,"PHASE4":15962,"NA":15964},{"trials":15951,"activeCount":101},[],{"trials":15953,"activeCount":101},[],{"trials":15955,"activeCount":101},[],{"trials":15957,"activeCount":101},[15958],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15959,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15960,"interventions":15961},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15963,"activeCount":101},[],{"trials":15965,"activeCount":101},[],{"intervention":15834,"totalTrials":272,"cells":15967},{"EARLY_PHASE1":15968,"PHASE1":15970,"PHASE2":15972,"PHASE3":15974,"PHASE4":15980,"NA":15982},{"trials":15969,"activeCount":101},[],{"trials":15971,"activeCount":101},[],{"trials":15973,"activeCount":101},[],{"trials":15975,"activeCount":101},[15976],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15977,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15978,"interventions":15979},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15981,"activeCount":101},[],{"trials":15983,"activeCount":101},[],{"intervention":15835,"totalTrials":272,"cells":15985},{"EARLY_PHASE1":15986,"PHASE1":15988,"PHASE2":15990,"PHASE3":15992,"PHASE4":15998,"NA":16000},{"trials":15987,"activeCount":101},[],{"trials":15989,"activeCount":101},[],{"trials":15991,"activeCount":101},[],{"trials":15993,"activeCount":101},[15994],{"nctId":15821,"briefTitle":15822,"status":107,"phases":15995,"primaryCompletion":12159,"completion":603,"start":446,"enrollment":15824,"conditions":15996,"interventions":15997},[92],[4040],[15810,15827,15828,15829,15829,15830,15828,15831,15832,15833,15834,15835],{"trials":15999,"activeCount":101},[],{"trials":16001,"activeCount":101},[],{"intervention":12969,"totalTrials":272,"cells":16003},{"EARLY_PHASE1":16004,"PHASE1":16006,"PHASE2":16008,"PHASE3":16010,"PHASE4":16016,"NA":16018},{"trials":16005,"activeCount":101},[],{"trials":16007,"activeCount":101},[],{"trials":16009,"activeCount":101},[],{"trials":16011,"activeCount":101},[16012],{"nctId":12964,"briefTitle":12965,"status":162,"phases":16013,"primaryCompletion":2121,"start":6053,"enrollment":11419,"conditions":16014,"interventions":16015},[92],[18],[12949,12969],{"trials":16017,"activeCount":101},[],{"trials":16019,"activeCount":101},[],{"intervention":6824,"totalTrials":272,"cells":16021},{"EARLY_PHASE1":16022,"PHASE1":16024,"PHASE2":16026,"PHASE3":16028,"PHASE4":16034,"NA":16036},{"trials":16023,"activeCount":101},[],{"trials":16025,"activeCount":101},[],{"trials":16027,"activeCount":101},[],{"trials":16029,"activeCount":101},[16030],{"nctId":6818,"briefTitle":6819,"status":107,"phases":16031,"primaryCompletion":408,"completion":408,"start":1980,"enrollment":6821,"conditions":16032,"interventions":16033},[92],[18],[6797,6824,6825],{"trials":16035,"activeCount":101},[],{"trials":16037,"activeCount":101},[],{"intervention":11410,"totalTrials":272,"cells":16039},{"EARLY_PHASE1":16040,"PHASE1":16042,"PHASE2":16044,"PHASE3":16046,"PHASE4":16052,"NA":16054},{"trials":16041,"activeCount":101},[],{"trials":16043,"activeCount":101},[],{"trials":16045,"activeCount":101},[],{"trials":16047,"activeCount":101},[16048],{"nctId":11404,"briefTitle":11405,"status":107,"phases":16049,"primaryCompletion":10024,"completion":10024,"start":517,"enrollment":11407,"conditions":16050,"interventions":16051},[92],[21],[11410,11410,11411,11412,11413,11413,11411,11414],{"trials":16053,"activeCount":101},[],{"trials":16055,"activeCount":101},[],{"intervention":11412,"totalTrials":272,"cells":16057},{"EARLY_PHASE1":16058,"PHASE1":16060,"PHASE2":16062,"PHASE3":16064,"PHASE4":16070,"NA":16072},{"trials":16059,"activeCount":101},[],{"trials":16061,"activeCount":101},[],{"trials":16063,"activeCount":101},[],{"trials":16065,"activeCount":101},[16066],{"nctId":11404,"briefTitle":11405,"status":107,"phases":16067,"primaryCompletion":10024,"completion":10024,"start":517,"enrollment":11407,"conditions":16068,"interventions":16069},[92],[21],[11410,11410,11411,11412,11413,11413,11411,11414],{"trials":16071,"activeCount":101},[],{"trials":16073,"activeCount":101},[],{"intervention":11413,"totalTrials":272,"cells":16075},{"EARLY_PHASE1":16076,"PHASE1":16078,"PHASE2":16080,"PHASE3":16082,"PHASE4":16088,"NA":16090},{"trials":16077,"activeCount":101},[],{"trials":16079,"activeCount":101},[],{"trials":16081,"activeCount":101},[],{"trials":16083,"activeCount":101},[16084],{"nctId":11404,"briefTitle":11405,"status":107,"phases":16085,"primaryCompletion":10024,"completion":10024,"start":517,"enrollment":11407,"conditions":16086,"interventions":16087},[92],[21],[11410,11410,11411,11412,11413,11413,11411,11414],{"trials":16089,"activeCount":101},[],{"trials":16091,"activeCount":101},[],{"intervention":11414,"totalTrials":272,"cells":16093},{"EARLY_PHASE1":16094,"PHASE1":16096,"PHASE2":16098,"PHASE3":16100,"PHASE4":16106,"NA":16108},{"trials":16095,"activeCount":101},[],{"trials":16097,"activeCount":101},[],{"trials":16099,"activeCount":101},[],{"trials":16101,"activeCount":101},[16102],{"nctId":11404,"briefTitle":11405,"status":107,"phases":16103,"primaryCompletion":10024,"completion":10024,"start":517,"enrollment":11407,"conditions":16104,"interventions":16105},[92],[21],[11410,11410,11411,11412,11413,11413,11411,11414],{"trials":16107,"activeCount":101},[],{"trials":16109,"activeCount":101},[],{"intervention":16111,"totalTrials":272,"cells":16112},"dabigatran etexilate 150 mg",{"EARLY_PHASE1":16113,"PHASE1":16115,"PHASE2":16117,"PHASE3":16119,"PHASE4":16128,"NA":16130},{"trials":16114,"activeCount":101},[],{"trials":16116,"activeCount":101},[],{"trials":16118,"activeCount":101},[],{"trials":16120,"activeCount":101},[16121],{"nctId":16122,"briefTitle":16123,"status":107,"phases":16124,"primaryCompletion":9411,"start":7151,"enrollment":16125,"conditions":16126,"interventions":16127},"NCT00291330","Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism",[92],2564,[10332],[16111,4165],{"trials":16129,"activeCount":101},[],{"trials":16131,"activeCount":101},[],{"intervention":16133,"totalTrials":272,"cells":16134},"optional ASA as comedication",{"EARLY_PHASE1":16135,"PHASE1":16137,"PHASE2":16139,"PHASE3":16141,"PHASE4":16154,"NA":16156},{"trials":16136,"activeCount":101},[],{"trials":16138,"activeCount":101},[],{"trials":16140,"activeCount":101},[],{"trials":16142,"activeCount":101},[16143],{"nctId":16144,"briefTitle":16145,"status":107,"phases":16146,"primaryCompletion":16147,"completion":16147,"start":16148,"enrollment":16149,"conditions":16150,"interventions":16152},"NCT02239120","Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)",[92],"2018-08-14","2014-11-27",5390,[2092,16151],"Secondary Prevention",[16133,16153,1685],"ASA 100 mg",{"trials":16155,"activeCount":101},[],{"trials":16157,"activeCount":101},[],{"intervention":16153,"totalTrials":272,"cells":16159},{"EARLY_PHASE1":16160,"PHASE1":16162,"PHASE2":16164,"PHASE3":16166,"PHASE4":16172,"NA":16174},{"trials":16161,"activeCount":101},[],{"trials":16163,"activeCount":101},[],{"trials":16165,"activeCount":101},[],{"trials":16167,"activeCount":101},[16168],{"nctId":16144,"briefTitle":16145,"status":107,"phases":16169,"primaryCompletion":16147,"completion":16147,"start":16148,"enrollment":16149,"conditions":16170,"interventions":16171},[92],[2092,16151],[16133,16153,1685],{"trials":16173,"activeCount":101},[],{"trials":16175,"activeCount":101},[],{"intervention":16177,"totalTrials":272,"cells":16178},"telmisartan 40 mg\u002Fhydrochlorothiazide 12.5 mg",{"EARLY_PHASE1":16179,"PHASE1":16181,"PHASE2":16183,"PHASE3":16185,"PHASE4":16194,"NA":16196},{"trials":16180,"activeCount":101},[],{"trials":16182,"activeCount":101},[],{"trials":16184,"activeCount":101},[],{"trials":16186,"activeCount":101},[16187],{"nctId":16188,"briefTitle":16189,"status":107,"phases":16190,"primaryCompletion":15139,"completion":15139,"start":6401,"enrollment":536,"conditions":16191,"interventions":16192},"NCT00133185","A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension",[92],[24],[16177,16193],"losartan 50 mg\u002Fhydrochlorothiazide 12.5 mg",{"trials":16195,"activeCount":101},[],{"trials":16197,"activeCount":101},[],{"intervention":16193,"totalTrials":272,"cells":16199},{"EARLY_PHASE1":16200,"PHASE1":16202,"PHASE2":16204,"PHASE3":16206,"PHASE4":16212,"NA":16214},{"trials":16201,"activeCount":101},[],{"trials":16203,"activeCount":101},[],{"trials":16205,"activeCount":101},[],{"trials":16207,"activeCount":101},[16208],{"nctId":16188,"briefTitle":16189,"status":107,"phases":16209,"primaryCompletion":15139,"completion":15139,"start":6401,"enrollment":536,"conditions":16210,"interventions":16211},[92],[24],[16177,16193],{"trials":16213,"activeCount":101},[],{"trials":16215,"activeCount":101},[],{"intervention":6777,"totalTrials":272,"cells":16217},{"EARLY_PHASE1":16218,"PHASE1":16220,"PHASE2":16222,"PHASE3":16224,"PHASE4":16230,"NA":16232},{"trials":16219,"activeCount":101},[],{"trials":16221,"activeCount":101},[],{"trials":16223,"activeCount":101},[],{"trials":16225,"activeCount":101},[16226],{"nctId":6770,"briefTitle":6771,"status":107,"phases":16227,"primaryCompletion":3763,"completion":3763,"start":4498,"enrollment":6773,"conditions":16228,"interventions":16229},[92],[24],[6776,6747,6777],{"trials":16231,"activeCount":101},[],{"trials":16233,"activeCount":101},[],{"intervention":9836,"totalTrials":272,"cells":16235},{"EARLY_PHASE1":16236,"PHASE1":16238,"PHASE2":16240,"PHASE3":16242,"PHASE4":16248,"NA":16250},{"trials":16237,"activeCount":101},[],{"trials":16239,"activeCount":101},[],{"trials":16241,"activeCount":101},[],{"trials":16243,"activeCount":101},[16244],{"nctId":9830,"briefTitle":9831,"status":600,"phases":16245,"primaryCompletion":9833,"completion":9833,"start":408,"enrollment":101,"conditions":16246,"interventions":16247},[92],[4040],[4042,4048,4047,9836,4048,9837],{"trials":16249,"activeCount":101},[],{"trials":16251,"activeCount":101},[],{"intervention":16253,"totalTrials":272,"cells":16254},"Fixed dose combination telmisartan 80 mg + HCTZ 25 mg",{"EARLY_PHASE1":16255,"PHASE1":16257,"PHASE2":16259,"PHASE3":16261,"PHASE4":16271,"NA":16273},{"trials":16256,"activeCount":101},[],{"trials":16258,"activeCount":101},[],{"trials":16260,"activeCount":101},[],{"trials":16262,"activeCount":101},[16263],{"nctId":16264,"briefTitle":16265,"status":107,"phases":16266,"primaryCompletion":11588,"completion":11588,"start":5843,"enrollment":16267,"conditions":16268,"interventions":16269},"NCT00239369","Telmisartan80\u002FHCTZ25 Versus Telmisartan80\u002FHCTZ12.5 in Hypertension Not Responding to Telmisartan80\u002FHCTZ12.5",[92],713,[24],[16253,16270],"Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg",{"trials":16272,"activeCount":101},[],{"trials":16274,"activeCount":101},[],{"intervention":16270,"totalTrials":272,"cells":16276},{"EARLY_PHASE1":16277,"PHASE1":16279,"PHASE2":16281,"PHASE3":16283,"PHASE4":16289,"NA":16291},{"trials":16278,"activeCount":101},[],{"trials":16280,"activeCount":101},[],{"trials":16282,"activeCount":101},[],{"trials":16284,"activeCount":101},[16285],{"nctId":16264,"briefTitle":16265,"status":107,"phases":16286,"primaryCompletion":11588,"completion":11588,"start":5843,"enrollment":16267,"conditions":16287,"interventions":16288},[92],[24],[16253,16270],{"trials":16290,"activeCount":101},[],{"trials":16292,"activeCount":101},[],{"intervention":13111,"totalTrials":272,"cells":16294},{"EARLY_PHASE1":16295,"PHASE1":16297,"PHASE2":16299,"PHASE3":16301,"PHASE4":16307,"NA":16309},{"trials":16296,"activeCount":101},[],{"trials":16298,"activeCount":101},[],{"trials":16300,"activeCount":101},[],{"trials":16302,"activeCount":101},[16303],{"nctId":13105,"briefTitle":13106,"status":107,"phases":16304,"primaryCompletion":2182,"start":7924,"enrollment":13108,"conditions":16305,"interventions":16306},[92],[18],[13111,13112,13094],{"trials":16308,"activeCount":101},[],{"trials":16310,"activeCount":101},[],{"intervention":13112,"totalTrials":272,"cells":16312},{"EARLY_PHASE1":16313,"PHASE1":16315,"PHASE2":16317,"PHASE3":16319,"PHASE4":16325,"NA":16327},{"trials":16314,"activeCount":101},[],{"trials":16316,"activeCount":101},[],{"trials":16318,"activeCount":101},[],{"trials":16320,"activeCount":101},[16321],{"nctId":13105,"briefTitle":13106,"status":107,"phases":16322,"primaryCompletion":2182,"start":7924,"enrollment":13108,"conditions":16323,"interventions":16324},[92],[18],[13111,13112,13094],{"trials":16326,"activeCount":101},[],{"trials":16328,"activeCount":101},[],{"intervention":16330,"totalTrials":272,"cells":16331},"Combivent CFC-MDI",{"EARLY_PHASE1":16332,"PHASE1":16334,"PHASE2":16336,"PHASE3":16338,"PHASE4":16348,"NA":16350},{"trials":16333,"activeCount":101},[],{"trials":16335,"activeCount":101},[],{"trials":16337,"activeCount":101},[],{"trials":16339,"activeCount":101},[16340],{"nctId":16341,"briefTitle":16342,"status":107,"phases":16343,"primaryCompletion":9340,"start":399,"enrollment":9817,"conditions":16344,"interventions":16345},"NCT01019694","Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease",[92],[18],[16330,16346,16347],"Combivent Respimat 20\u002F100 mcg","Atrovent HFA 42 mcg + Albuterol HFA 200 mcg",{"trials":16349,"activeCount":101},[],{"trials":16351,"activeCount":101},[],{"intervention":16346,"totalTrials":272,"cells":16353},{"EARLY_PHASE1":16354,"PHASE1":16356,"PHASE2":16358,"PHASE3":16360,"PHASE4":16366,"NA":16368},{"trials":16355,"activeCount":101},[],{"trials":16357,"activeCount":101},[],{"trials":16359,"activeCount":101},[],{"trials":16361,"activeCount":101},[16362],{"nctId":16341,"briefTitle":16342,"status":107,"phases":16363,"primaryCompletion":9340,"start":399,"enrollment":9817,"conditions":16364,"interventions":16365},[92],[18],[16330,16346,16347],{"trials":16367,"activeCount":101},[],{"trials":16369,"activeCount":101},[],{"intervention":16347,"totalTrials":272,"cells":16371},{"EARLY_PHASE1":16372,"PHASE1":16374,"PHASE2":16376,"PHASE3":16378,"PHASE4":16384,"NA":16386},{"trials":16373,"activeCount":101},[],{"trials":16375,"activeCount":101},[],{"trials":16377,"activeCount":101},[],{"trials":16379,"activeCount":101},[16380],{"nctId":16341,"briefTitle":16342,"status":107,"phases":16381,"primaryCompletion":9340,"start":399,"enrollment":9817,"conditions":16382,"interventions":16383},[92],[18],[16330,16346,16347],{"trials":16385,"activeCount":101},[],{"trials":16387,"activeCount":101},[],{"intervention":16389,"totalTrials":272,"cells":16390},"BNS003",{"EARLY_PHASE1":16391,"PHASE1":16393,"PHASE2":16395,"PHASE3":16397,"PHASE4":16405,"NA":16407},{"trials":16392,"activeCount":101},[],{"trials":16394,"activeCount":101},[],{"trials":16396,"activeCount":101},[],{"trials":16398,"activeCount":101},[16399],{"nctId":16400,"briefTitle":16401,"status":107,"phases":16402,"primaryCompletion":6782,"start":5868,"enrollment":5466,"conditions":16403,"interventions":16404},"NCT02211898","Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux",[92],[8458],[16389],{"trials":16406,"activeCount":101},[],{"trials":16408,"activeCount":101},[],{"intervention":12326,"totalTrials":272,"cells":16410},{"EARLY_PHASE1":16411,"PHASE1":16413,"PHASE2":16415,"PHASE3":16417,"PHASE4":16423,"NA":16425},{"trials":16412,"activeCount":101},[],{"trials":16414,"activeCount":101},[],{"trials":16416,"activeCount":101},[],{"trials":16418,"activeCount":101},[16419],{"nctId":12320,"briefTitle":12321,"status":107,"phases":16420,"primaryCompletion":1125,"completion":1125,"start":9515,"enrollment":5648,"conditions":16421,"interventions":16422},[92],[12324],[12326,12299],{"trials":16424,"activeCount":101},[],{"trials":16426,"activeCount":101},[],{"intervention":16428,"totalTrials":272,"cells":16429},"Metformin 500 mg bid",{"EARLY_PHASE1":16430,"PHASE1":16432,"PHASE2":16434,"PHASE3":16436,"PHASE4":16451,"NA":16453},{"trials":16431,"activeCount":101},[],{"trials":16433,"activeCount":101},[],{"trials":16435,"activeCount":101},[],{"trials":16437,"activeCount":101},[16438],{"nctId":16439,"briefTitle":16440,"status":107,"phases":16441,"primaryCompletion":475,"completion":474,"start":517,"enrollment":16442,"conditions":16443,"interventions":16445},"NCT01719003","Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes",[92],1413,[21,16444],"Hyperglycemia",[16428,16446,16447,16448,16449,16428,16450,16449,16446,16428,16446,16450,16446,16450],"Metformin 1000 mg bid","Empagliflozin low dose qd","Empagliflozin high dose qd","Empagliflozin low dose bid","Empagliflozin high dose bid",{"trials":16452,"activeCount":101},[],{"trials":16454,"activeCount":101},[],{"intervention":16446,"totalTrials":272,"cells":16456},{"EARLY_PHASE1":16457,"PHASE1":16459,"PHASE2":16461,"PHASE3":16463,"PHASE4":16469,"NA":16471},{"trials":16458,"activeCount":101},[],{"trials":16460,"activeCount":101},[],{"trials":16462,"activeCount":101},[],{"trials":16464,"activeCount":101},[16465],{"nctId":16439,"briefTitle":16440,"status":107,"phases":16466,"primaryCompletion":475,"completion":474,"start":517,"enrollment":16442,"conditions":16467,"interventions":16468},[92],[21,16444],[16428,16446,16447,16448,16449,16428,16450,16449,16446,16428,16446,16450,16446,16450],{"trials":16470,"activeCount":101},[],{"trials":16472,"activeCount":101},[],{"intervention":16447,"totalTrials":272,"cells":16474},{"EARLY_PHASE1":16475,"PHASE1":16477,"PHASE2":16479,"PHASE3":16481,"PHASE4":16487,"NA":16489},{"trials":16476,"activeCount":101},[],{"trials":16478,"activeCount":101},[],{"trials":16480,"activeCount":101},[],{"trials":16482,"activeCount":101},[16483],{"nctId":16439,"briefTitle":16440,"status":107,"phases":16484,"primaryCompletion":475,"completion":474,"start":517,"enrollment":16442,"conditions":16485,"interventions":16486},[92],[21,16444],[16428,16446,16447,16448,16449,16428,16450,16449,16446,16428,16446,16450,16446,16450],{"trials":16488,"activeCount":101},[],{"trials":16490,"activeCount":101},[],{"intervention":16448,"totalTrials":272,"cells":16492},{"EARLY_PHASE1":16493,"PHASE1":16495,"PHASE2":16497,"PHASE3":16499,"PHASE4":16505,"NA":16507},{"trials":16494,"activeCount":101},[],{"trials":16496,"activeCount":101},[],{"trials":16498,"activeCount":101},[],{"trials":16500,"activeCount":101},[16501],{"nctId":16439,"briefTitle":16440,"status":107,"phases":16502,"primaryCompletion":475,"completion":474,"start":517,"enrollment":16442,"conditions":16503,"interventions":16504},[92],[21,16444],[16428,16446,16447,16448,16449,16428,16450,16449,16446,16428,16446,16450,16446,16450],{"trials":16506,"activeCount":101},[],{"trials":16508,"activeCount":101},[],{"intervention":16449,"totalTrials":272,"cells":16510},{"EARLY_PHASE1":16511,"PHASE1":16513,"PHASE2":16515,"PHASE3":16517,"PHASE4":16523,"NA":16525},{"trials":16512,"activeCount":101},[],{"trials":16514,"activeCount":101},[],{"trials":16516,"activeCount":101},[],{"trials":16518,"activeCount":101},[16519],{"nctId":16439,"briefTitle":16440,"status":107,"phases":16520,"primaryCompletion":475,"completion":474,"start":517,"enrollment":16442,"conditions":16521,"interventions":16522},[92],[21,16444],[16428,16446,16447,16448,16449,16428,16450,16449,16446,16428,16446,16450,16446,16450],{"trials":16524,"activeCount":101},[],{"trials":16526,"activeCount":101},[],{"intervention":16450,"totalTrials":272,"cells":16528},{"EARLY_PHASE1":16529,"PHASE1":16531,"PHASE2":16533,"PHASE3":16535,"PHASE4":16541,"NA":16543},{"trials":16530,"activeCount":101},[],{"trials":16532,"activeCount":101},[],{"trials":16534,"activeCount":101},[],{"trials":16536,"activeCount":101},[16537],{"nctId":16439,"briefTitle":16440,"status":107,"phases":16538,"primaryCompletion":475,"completion":474,"start":517,"enrollment":16442,"conditions":16539,"interventions":16540},[92],[21,16444],[16428,16446,16447,16448,16449,16428,16450,16449,16446,16428,16446,16450,16446,16450],{"trials":16542,"activeCount":101},[],{"trials":16544,"activeCount":101},[],{"intervention":13292,"totalTrials":272,"cells":16546},{"EARLY_PHASE1":16547,"PHASE1":16549,"PHASE2":16551,"PHASE3":16553,"PHASE4":16559,"NA":16561},{"trials":16548,"activeCount":101},[],{"trials":16550,"activeCount":101},[],{"trials":16552,"activeCount":101},[],{"trials":16554,"activeCount":101},[16555],{"nctId":13285,"briefTitle":13286,"status":107,"phases":16556,"primaryCompletion":13117,"start":7553,"enrollment":13288,"conditions":16557,"interventions":16558},[92],[13290],[13292,6953,13293,13294],{"trials":16560,"activeCount":101},[],{"trials":16562,"activeCount":101},[],{"intervention":13293,"totalTrials":272,"cells":16564},{"EARLY_PHASE1":16565,"PHASE1":16567,"PHASE2":16569,"PHASE3":16571,"PHASE4":16577,"NA":16579},{"trials":16566,"activeCount":101},[],{"trials":16568,"activeCount":101},[],{"trials":16570,"activeCount":101},[],{"trials":16572,"activeCount":101},[16573],{"nctId":13285,"briefTitle":13286,"status":107,"phases":16574,"primaryCompletion":13117,"start":7553,"enrollment":13288,"conditions":16575,"interventions":16576},[92],[13290],[13292,6953,13293,13294],{"trials":16578,"activeCount":101},[],{"trials":16580,"activeCount":101},[],{"intervention":13294,"totalTrials":272,"cells":16582},{"EARLY_PHASE1":16583,"PHASE1":16585,"PHASE2":16587,"PHASE3":16589,"PHASE4":16595,"NA":16597},{"trials":16584,"activeCount":101},[],{"trials":16586,"activeCount":101},[],{"trials":16588,"activeCount":101},[],{"trials":16590,"activeCount":101},[16591],{"nctId":13285,"briefTitle":13286,"status":107,"phases":16592,"primaryCompletion":13117,"start":7553,"enrollment":13288,"conditions":16593,"interventions":16594},[92],[13290],[13292,6953,13293,13294],{"trials":16596,"activeCount":101},[],{"trials":16598,"activeCount":101},[],{"intervention":16600,"totalTrials":272,"cells":16601},"telmisartan\u002Famlodipine 40\u002F5 mg fixed combination",{"EARLY_PHASE1":16602,"PHASE1":16604,"PHASE2":16606,"PHASE3":16608,"PHASE4":16618,"NA":16620},{"trials":16603,"activeCount":101},[],{"trials":16605,"activeCount":101},[],{"trials":16607,"activeCount":101},[],{"trials":16609,"activeCount":101},[16610],{"nctId":16611,"briefTitle":16612,"status":107,"phases":16613,"primaryCompletion":2003,"start":4507,"enrollment":16614,"conditions":16615,"interventions":16616},"NCT00614380","Open Label Study Telmisartan and Amlodipine in Hypertension",[92],976,[24],[16600,16617],"telmisartan\u002Famlodipine 80\u002F5 mg fixed combination",{"trials":16619,"activeCount":101},[],{"trials":16621,"activeCount":101},[],{"intervention":16617,"totalTrials":272,"cells":16623},{"EARLY_PHASE1":16624,"PHASE1":16626,"PHASE2":16628,"PHASE3":16630,"PHASE4":16636,"NA":16638},{"trials":16625,"activeCount":101},[],{"trials":16627,"activeCount":101},[],{"trials":16629,"activeCount":101},[],{"trials":16631,"activeCount":101},[16632],{"nctId":16611,"briefTitle":16612,"status":107,"phases":16633,"primaryCompletion":2003,"start":4507,"enrollment":16614,"conditions":16634,"interventions":16635},[92],[24],[16600,16617],{"trials":16637,"activeCount":101},[],{"trials":16639,"activeCount":101},[],{"intervention":16641,"totalTrials":272,"cells":16642},"Aggrenox® modified release",{"EARLY_PHASE1":16643,"PHASE1":16645,"PHASE2":16647,"PHASE3":16649,"PHASE4":16657,"NA":16659},{"trials":16644,"activeCount":101},[],{"trials":16646,"activeCount":101},[],{"trials":16648,"activeCount":101},[],{"trials":16650,"activeCount":101},[16651],{"nctId":16652,"briefTitle":16653,"status":107,"phases":16654,"primaryCompletion":7124,"completion":7124,"start":6375,"enrollment":1218,"conditions":16655,"interventions":16656},"NCT00274586","Headache Study to Compare Aggrenox Full Dose and Reduced Dose",[92],[6964],[16641],{"trials":16658,"activeCount":101},[],{"trials":16660,"activeCount":101},[],{"intervention":16662,"totalTrials":272,"cells":16663},"BIBF 1120 plus docetaxel",{"EARLY_PHASE1":16664,"PHASE1":16666,"PHASE2":16668,"PHASE3":16670,"PHASE4":16681,"NA":16683},{"trials":16665,"activeCount":101},[],{"trials":16667,"activeCount":101},[],{"trials":16669,"activeCount":101},[],{"trials":16671,"activeCount":101},[16672],{"nctId":16673,"briefTitle":16674,"status":107,"phases":16675,"primaryCompletion":16676,"completion":428,"start":16677,"enrollment":16678,"conditions":16679,"interventions":16680},"NCT00805194","LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer",[92],"2010-11-02","2008-12-03",1314,[36],[16662],{"trials":16682,"activeCount":101},[],{"trials":16684,"activeCount":101},[],{"intervention":16686,"totalTrials":272,"cells":16687},"telmisartan + HCTZ",{"EARLY_PHASE1":16688,"PHASE1":16690,"PHASE2":16692,"PHASE3":16694,"PHASE4":16702,"NA":16704},{"trials":16689,"activeCount":101},[],{"trials":16691,"activeCount":101},[],{"trials":16693,"activeCount":101},[],{"trials":16695,"activeCount":101},[16696],{"nctId":16697,"briefTitle":16698,"status":107,"phases":16699,"primaryCompletion":603,"completion":603,"start":3762,"enrollment":1928,"conditions":16700,"interventions":16701},"NCT01911780","Compare Efficacy and Safety of Telmisartan\u002FHydrochlorothiazide With Telmisartan\u002FHydrochlorothiazide Plus Amlodipine",[92],[24],[16686,16686,12224],{"trials":16703,"activeCount":101},[],{"trials":16705,"activeCount":101},[],{"intervention":10969,"totalTrials":272,"cells":16707},{"EARLY_PHASE1":16708,"PHASE1":16710,"PHASE2":16712,"PHASE3":16714,"PHASE4":16720,"NA":16722},{"trials":16709,"activeCount":101},[],{"trials":16711,"activeCount":101},[],{"trials":16713,"activeCount":101},[],{"trials":16715,"activeCount":101},[16716],{"nctId":10961,"briefTitle":10962,"status":162,"phases":16717,"primaryCompletion":10964,"completion":9698,"start":10965,"enrollment":10966,"conditions":16718,"interventions":16719},[92],[10667],[10940,10940,10969,10969,10970],{"trials":16721,"activeCount":101},[],{"trials":16723,"activeCount":101},[],{"intervention":10970,"totalTrials":272,"cells":16725},{"EARLY_PHASE1":16726,"PHASE1":16728,"PHASE2":16730,"PHASE3":16732,"PHASE4":16738,"NA":16740},{"trials":16727,"activeCount":101},[],{"trials":16729,"activeCount":101},[],{"trials":16731,"activeCount":101},[],{"trials":16733,"activeCount":101},[16734],{"nctId":10961,"briefTitle":10962,"status":162,"phases":16735,"primaryCompletion":10964,"completion":9698,"start":10965,"enrollment":10966,"conditions":16736,"interventions":16737},[92],[10667],[10940,10940,10969,10969,10970],{"trials":16739,"activeCount":101},[],{"trials":16741,"activeCount":101},[],{"intervention":16743,"totalTrials":272,"cells":16744},"telmisartan 80 mg + hydrochlorothiazide 25 mg",{"EARLY_PHASE1":16745,"PHASE1":16747,"PHASE2":16749,"PHASE3":16751,"PHASE4":16760,"NA":16762},{"trials":16746,"activeCount":101},[],{"trials":16748,"activeCount":101},[],{"trials":16750,"activeCount":101},[],{"trials":16752,"activeCount":101},[16753],{"nctId":16754,"briefTitle":16755,"status":107,"phases":16756,"primaryCompletion":7573,"completion":7573,"start":4005,"enrollment":16757,"conditions":16758,"interventions":16759},"NCT00267943","Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients",[92],639,[24],[16743],{"trials":16761,"activeCount":101},[],{"trials":16763,"activeCount":101},[],{"intervention":5909,"totalTrials":272,"cells":16765},{"EARLY_PHASE1":16766,"PHASE1":16768,"PHASE2":16770,"PHASE3":16772,"PHASE4":16778,"NA":16780},{"trials":16767,"activeCount":101},[],{"trials":16769,"activeCount":101},[],{"trials":16771,"activeCount":101},[],{"trials":16773,"activeCount":101},[16774],{"nctId":5902,"briefTitle":5903,"status":107,"phases":16775,"primaryCompletion":5905,"start":5906,"enrollment":2235,"conditions":16776,"interventions":16777},[92],[18],[5909,5832,5860],{"trials":16779,"activeCount":101},[],{"trials":16781,"activeCount":101},[],{"intervention":16783,"totalTrials":272,"cells":16784},"BIBR277 low dose",{"EARLY_PHASE1":16785,"PHASE1":16787,"PHASE2":16789,"PHASE3":16791,"PHASE4":16804,"NA":16806},{"trials":16786,"activeCount":101},[],{"trials":16788,"activeCount":101},[],{"trials":16790,"activeCount":101},[],{"trials":16792,"activeCount":101},[16793],{"nctId":16794,"briefTitle":16795,"status":107,"phases":16796,"primaryCompletion":7022,"start":7084,"enrollment":15558,"conditions":16797,"interventions":16798},"NCT02177448","BIBR 277 Capsule in Patients With Essential Hypertension",[92],[24],[16783,16799,16800,16801,16802,16803],"BIBR277 medium dose","BIBR277 high dose","Enalapril low dose","Enalapril medium dose","Enalapril high dose",{"trials":16805,"activeCount":101},[],{"trials":16807,"activeCount":101},[],{"intervention":16799,"totalTrials":272,"cells":16809},{"EARLY_PHASE1":16810,"PHASE1":16812,"PHASE2":16814,"PHASE3":16816,"PHASE4":16822,"NA":16824},{"trials":16811,"activeCount":101},[],{"trials":16813,"activeCount":101},[],{"trials":16815,"activeCount":101},[],{"trials":16817,"activeCount":101},[16818],{"nctId":16794,"briefTitle":16795,"status":107,"phases":16819,"primaryCompletion":7022,"start":7084,"enrollment":15558,"conditions":16820,"interventions":16821},[92],[24],[16783,16799,16800,16801,16802,16803],{"trials":16823,"activeCount":101},[],{"trials":16825,"activeCount":101},[],{"intervention":16800,"totalTrials":272,"cells":16827},{"EARLY_PHASE1":16828,"PHASE1":16830,"PHASE2":16832,"PHASE3":16834,"PHASE4":16840,"NA":16842},{"trials":16829,"activeCount":101},[],{"trials":16831,"activeCount":101},[],{"trials":16833,"activeCount":101},[],{"trials":16835,"activeCount":101},[16836],{"nctId":16794,"briefTitle":16795,"status":107,"phases":16837,"primaryCompletion":7022,"start":7084,"enrollment":15558,"conditions":16838,"interventions":16839},[92],[24],[16783,16799,16800,16801,16802,16803],{"trials":16841,"activeCount":101},[],{"trials":16843,"activeCount":101},[],{"intervention":16801,"totalTrials":272,"cells":16845},{"EARLY_PHASE1":16846,"PHASE1":16848,"PHASE2":16850,"PHASE3":16852,"PHASE4":16858,"NA":16860},{"trials":16847,"activeCount":101},[],{"trials":16849,"activeCount":101},[],{"trials":16851,"activeCount":101},[],{"trials":16853,"activeCount":101},[16854],{"nctId":16794,"briefTitle":16795,"status":107,"phases":16855,"primaryCompletion":7022,"start":7084,"enrollment":15558,"conditions":16856,"interventions":16857},[92],[24],[16783,16799,16800,16801,16802,16803],{"trials":16859,"activeCount":101},[],{"trials":16861,"activeCount":101},[],{"intervention":16802,"totalTrials":272,"cells":16863},{"EARLY_PHASE1":16864,"PHASE1":16866,"PHASE2":16868,"PHASE3":16870,"PHASE4":16876,"NA":16878},{"trials":16865,"activeCount":101},[],{"trials":16867,"activeCount":101},[],{"trials":16869,"activeCount":101},[],{"trials":16871,"activeCount":101},[16872],{"nctId":16794,"briefTitle":16795,"status":107,"phases":16873,"primaryCompletion":7022,"start":7084,"enrollment":15558,"conditions":16874,"interventions":16875},[92],[24],[16783,16799,16800,16801,16802,16803],{"trials":16877,"activeCount":101},[],{"trials":16879,"activeCount":101},[],{"intervention":16803,"totalTrials":272,"cells":16881},{"EARLY_PHASE1":16882,"PHASE1":16884,"PHASE2":16886,"PHASE3":16888,"PHASE4":16894,"NA":16896},{"trials":16883,"activeCount":101},[],{"trials":16885,"activeCount":101},[],{"trials":16887,"activeCount":101},[],{"trials":16889,"activeCount":101},[16890],{"nctId":16794,"briefTitle":16795,"status":107,"phases":16891,"primaryCompletion":7022,"start":7084,"enrollment":15558,"conditions":16892,"interventions":16893},[92],[24],[16783,16799,16800,16801,16802,16803],{"trials":16895,"activeCount":101},[],{"trials":16897,"activeCount":101},[],{"intervention":11073,"totalTrials":272,"cells":16899},{"EARLY_PHASE1":16900,"PHASE1":16902,"PHASE2":16904,"PHASE3":16906,"PHASE4":16912,"NA":16914},{"trials":16901,"activeCount":101},[],{"trials":16903,"activeCount":101},[],{"trials":16905,"activeCount":101},[],{"trials":16907,"activeCount":101},[16908],{"nctId":11066,"briefTitle":11067,"status":107,"phases":16909,"primaryCompletion":7573,"completion":7573,"start":2111,"enrollment":11069,"conditions":16910,"interventions":16911},[92],[11071],[11034,11073],{"trials":16913,"activeCount":101},[],{"trials":16915,"activeCount":101},[],{"intervention":16917,"totalTrials":272,"cells":16918},"NSAID",{"EARLY_PHASE1":16919,"PHASE1":16921,"PHASE2":16923,"PHASE3":16925,"PHASE4":16934,"NA":16936},{"trials":16920,"activeCount":101},[],{"trials":16922,"activeCount":101},[],{"trials":16924,"activeCount":101},[],{"trials":16926,"activeCount":101},[16927],{"nctId":16928,"briefTitle":16929,"status":107,"phases":16930,"primaryCompletion":6390,"start":7553,"enrollment":16931,"conditions":16932,"interventions":16933},"NCT02183064","Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis",[92],1309,[6609],[6498,16917],{"trials":16935,"activeCount":101},[],{"trials":16937,"activeCount":101},[],{"intervention":16939,"totalTrials":272,"cells":16940},"Low dose of Klimadynon®",{"EARLY_PHASE1":16941,"PHASE1":16943,"PHASE2":16945,"PHASE3":16947,"PHASE4":16960,"NA":16962},{"trials":16942,"activeCount":101},[],{"trials":16944,"activeCount":101},[],{"trials":16946,"activeCount":101},[],{"trials":16948,"activeCount":101},[16949],{"nctId":16950,"briefTitle":16951,"status":107,"phases":16952,"primaryCompletion":6949,"start":11123,"enrollment":16953,"conditions":16954,"interventions":16956},"NCT02184364","Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints",[92],161,[16955],"Menopause",[16939,16957,16958,16959],"Medium dose of Klimadynon®","High dose of Klimadynon®","Oestrofeminal®",{"trials":16961,"activeCount":101},[],{"trials":16963,"activeCount":101},[],{"intervention":16957,"totalTrials":272,"cells":16965},{"EARLY_PHASE1":16966,"PHASE1":16968,"PHASE2":16970,"PHASE3":16972,"PHASE4":16978,"NA":16980},{"trials":16967,"activeCount":101},[],{"trials":16969,"activeCount":101},[],{"trials":16971,"activeCount":101},[],{"trials":16973,"activeCount":101},[16974],{"nctId":16950,"briefTitle":16951,"status":107,"phases":16975,"primaryCompletion":6949,"start":11123,"enrollment":16953,"conditions":16976,"interventions":16977},[92],[16955],[16939,16957,16958,16959],{"trials":16979,"activeCount":101},[],{"trials":16981,"activeCount":101},[],{"intervention":16958,"totalTrials":272,"cells":16983},{"EARLY_PHASE1":16984,"PHASE1":16986,"PHASE2":16988,"PHASE3":16990,"PHASE4":16996,"NA":16998},{"trials":16985,"activeCount":101},[],{"trials":16987,"activeCount":101},[],{"trials":16989,"activeCount":101},[],{"trials":16991,"activeCount":101},[16992],{"nctId":16950,"briefTitle":16951,"status":107,"phases":16993,"primaryCompletion":6949,"start":11123,"enrollment":16953,"conditions":16994,"interventions":16995},[92],[16955],[16939,16957,16958,16959],{"trials":16997,"activeCount":101},[],{"trials":16999,"activeCount":101},[],{"intervention":16959,"totalTrials":272,"cells":17001},{"EARLY_PHASE1":17002,"PHASE1":17004,"PHASE2":17006,"PHASE3":17008,"PHASE4":17014,"NA":17016},{"trials":17003,"activeCount":101},[],{"trials":17005,"activeCount":101},[],{"trials":17007,"activeCount":101},[],{"trials":17009,"activeCount":101},[17010],{"nctId":16950,"briefTitle":16951,"status":107,"phases":17011,"primaryCompletion":6949,"start":11123,"enrollment":16953,"conditions":17012,"interventions":17013},[92],[16955],[16939,16957,16958,16959],{"trials":17015,"activeCount":101},[],{"trials":17017,"activeCount":101},[],{"intervention":7513,"totalTrials":272,"cells":17019},{"EARLY_PHASE1":17020,"PHASE1":17022,"PHASE2":17024,"PHASE3":17026,"PHASE4":17032,"NA":17034},{"trials":17021,"activeCount":101},[],{"trials":17023,"activeCount":101},[],{"trials":17025,"activeCount":101},[],{"trials":17027,"activeCount":101},[17028],{"nctId":7504,"briefTitle":7505,"status":107,"phases":17029,"primaryCompletion":7507,"completion":7508,"start":7509,"enrollment":7510,"conditions":17030,"interventions":17031},[92],[21],[7513,7514,7515,7493],{"trials":17033,"activeCount":101},[],{"trials":17035,"activeCount":101},[],{"intervention":7515,"totalTrials":272,"cells":17037},{"EARLY_PHASE1":17038,"PHASE1":17040,"PHASE2":17042,"PHASE3":17044,"PHASE4":17050,"NA":17052},{"trials":17039,"activeCount":101},[],{"trials":17041,"activeCount":101},[],{"trials":17043,"activeCount":101},[],{"trials":17045,"activeCount":101},[17046],{"nctId":7504,"briefTitle":7505,"status":107,"phases":17047,"primaryCompletion":7507,"completion":7508,"start":7509,"enrollment":7510,"conditions":17048,"interventions":17049},[92],[21],[7513,7514,7515,7493],{"trials":17051,"activeCount":101},[],{"trials":17053,"activeCount":101},[],{"intervention":17055,"totalTrials":272,"cells":17056},"tiotropium +olodaterol",{"EARLY_PHASE1":17057,"PHASE1":17059,"PHASE2":17061,"PHASE3":17063,"PHASE4":17073,"NA":17075},{"trials":17058,"activeCount":101},[],{"trials":17060,"activeCount":101},[],{"trials":17062,"activeCount":101},[],{"trials":17064,"activeCount":101},[17065],{"nctId":17066,"briefTitle":17067,"status":107,"phases":17068,"primaryCompletion":2002,"completion":437,"start":9824,"enrollment":17069,"conditions":17070,"interventions":17071},"NCT02085161","To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways",[92],304,[18],[17072,17055,5899],"tiotropium+olodaterol",{"trials":17074,"activeCount":101},[],{"trials":17076,"activeCount":101},[],{"intervention":9853,"totalTrials":272,"cells":17078},{"EARLY_PHASE1":17079,"PHASE1":17081,"PHASE2":17083,"PHASE3":17085,"PHASE4":17091,"NA":17093},{"trials":17080,"activeCount":101},[],{"trials":17082,"activeCount":101},[],{"trials":17084,"activeCount":101},[],{"trials":17086,"activeCount":101},[17087],{"nctId":9846,"briefTitle":9847,"status":107,"phases":17088,"primaryCompletion":611,"completion":4391,"start":5296,"enrollment":9849,"conditions":17089,"interventions":17090},[92],[4040],[9828,9828,9852,9853,9828,9854],{"trials":17092,"activeCount":101},[],{"trials":17094,"activeCount":101},[],{"intervention":10696,"totalTrials":272,"cells":17096},{"EARLY_PHASE1":17097,"PHASE1":17099,"PHASE2":17101,"PHASE3":17103,"PHASE4":17109,"NA":17111},{"trials":17098,"activeCount":101},[],{"trials":17100,"activeCount":101},[],{"trials":17102,"activeCount":101},[],{"trials":17104,"activeCount":101},[17105],{"nctId":10689,"briefTitle":10690,"status":107,"phases":17106,"primaryCompletion":5369,"completion":5369,"start":10692,"enrollment":10693,"conditions":17107,"interventions":17108},[92],[114],[10696,10638],{"trials":17110,"activeCount":101},[],{"trials":17112,"activeCount":101},[],{"intervention":17114,"totalTrials":272,"cells":17115},"Tiotropium + placebo",{"EARLY_PHASE1":17116,"PHASE1":17118,"PHASE2":17120,"PHASE3":17122,"PHASE4":17132,"NA":17134},{"trials":17117,"activeCount":101},[],{"trials":17119,"activeCount":101},[],{"trials":17121,"activeCount":101},[],{"trials":17123,"activeCount":101},[17124],{"nctId":17125,"briefTitle":17126,"status":107,"phases":17127,"primaryCompletion":5869,"completion":5869,"start":6189,"enrollment":7524,"conditions":17128,"interventions":17129},"NCT00274066","Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva",[92],[18],[17114,17130,17131],"Tiotropium + ipratropium","Tiotropium + fenoterol",{"trials":17133,"activeCount":101},[],{"trials":17135,"activeCount":101},[],{"intervention":17130,"totalTrials":272,"cells":17137},{"EARLY_PHASE1":17138,"PHASE1":17140,"PHASE2":17142,"PHASE3":17144,"PHASE4":17150,"NA":17152},{"trials":17139,"activeCount":101},[],{"trials":17141,"activeCount":101},[],{"trials":17143,"activeCount":101},[],{"trials":17145,"activeCount":101},[17146],{"nctId":17125,"briefTitle":17126,"status":107,"phases":17147,"primaryCompletion":5869,"completion":5869,"start":6189,"enrollment":7524,"conditions":17148,"interventions":17149},[92],[18],[17114,17130,17131],{"trials":17151,"activeCount":101},[],{"trials":17153,"activeCount":101},[],{"intervention":17131,"totalTrials":272,"cells":17155},{"EARLY_PHASE1":17156,"PHASE1":17158,"PHASE2":17160,"PHASE3":17162,"PHASE4":17168,"NA":17170},{"trials":17157,"activeCount":101},[],{"trials":17159,"activeCount":101},[],{"trials":17161,"activeCount":101},[],{"trials":17163,"activeCount":101},[17164],{"nctId":17125,"briefTitle":17126,"status":107,"phases":17165,"primaryCompletion":5869,"completion":5869,"start":6189,"enrollment":7524,"conditions":17166,"interventions":17167},[92],[18],[17114,17130,17131],{"trials":17169,"activeCount":101},[],{"trials":17171,"activeCount":101},[],{"intervention":5382,"totalTrials":272,"cells":17173},{"EARLY_PHASE1":17174,"PHASE1":17176,"PHASE2":17178,"PHASE3":17180,"PHASE4":17186,"NA":17188},{"trials":17175,"activeCount":101},[],{"trials":17177,"activeCount":101},[],{"trials":17179,"activeCount":101},[],{"trials":17181,"activeCount":101},[17182],{"nctId":5374,"briefTitle":5375,"status":107,"phases":17183,"primaryCompletion":5377,"completion":5378,"start":5379,"enrollment":1030,"conditions":17184,"interventions":17185},[92],[3060],[78,5382,5382],{"trials":17187,"activeCount":101},[],{"trials":17189,"activeCount":101},[],{"intervention":9526,"totalTrials":272,"cells":17191},{"EARLY_PHASE1":17192,"PHASE1":17194,"PHASE2":17196,"PHASE3":17198,"PHASE4":17204,"NA":17206},{"trials":17193,"activeCount":101},[],{"trials":17195,"activeCount":101},[],{"trials":17197,"activeCount":101},[],{"trials":17199,"activeCount":101},[17200],{"nctId":9520,"briefTitle":9521,"status":107,"phases":17201,"primaryCompletion":408,"completion":408,"start":9332,"enrollment":9523,"conditions":17202,"interventions":17203},[92],[21],[528,528,528,528,528,528,528,9526,528],{"trials":17205,"activeCount":101},[],{"trials":17207,"activeCount":101},[],{"intervention":17209,"totalTrials":272,"cells":17210},"Saline solution",{"EARLY_PHASE1":17211,"PHASE1":17213,"PHASE2":17215,"PHASE3":17217,"PHASE4":17228,"NA":17230},{"trials":17212,"activeCount":101},[],{"trials":17214,"activeCount":101},[],{"trials":17216,"activeCount":101},[],{"trials":17218,"activeCount":101},[17219],{"nctId":17220,"briefTitle":17221,"status":107,"phases":17222,"primaryCompletion":10024,"completion":10024,"start":611,"enrollment":401,"conditions":17223,"interventions":17226},"NCT01958164","Efficacy and Safety of Actilyse 2 mg\u002F 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion",[92],[17224,17225],"Catheter Obstruction","Vascular Access Devices",[17227,17209,17227,17227],"Actilyse",{"trials":17229,"activeCount":101},[],{"trials":17231,"activeCount":101},[],{"intervention":17233,"totalTrials":272,"cells":17234},"levodopa in combination with benserazide",{"EARLY_PHASE1":17235,"PHASE1":17237,"PHASE2":17239,"PHASE3":17241,"PHASE4":17251,"NA":17253},{"trials":17236,"activeCount":101},[],{"trials":17238,"activeCount":101},[],{"trials":17240,"activeCount":101},[],{"trials":17242,"activeCount":101},[17243],{"nctId":17244,"briefTitle":17245,"status":107,"phases":17246,"primaryCompletion":17247,"completion":17247,"start":6081,"enrollment":3551,"conditions":17248,"interventions":17249},"NCT00144209","Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa \u002F Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome",[92],"2005-02",[11724],[17250,17233],"pramipexole",{"trials":17252,"activeCount":101},[],{"trials":17254,"activeCount":101},[],{"intervention":17256,"totalTrials":272,"cells":17257},"Eschscholtzia Californica",{"EARLY_PHASE1":17258,"PHASE1":17260,"PHASE2":17262,"PHASE3":17264,"PHASE4":17274,"NA":17276},{"trials":17259,"activeCount":101},[],{"trials":17261,"activeCount":101},[],{"trials":17263,"activeCount":101},[],{"trials":17265,"activeCount":101},[17266],{"nctId":17267,"briefTitle":17268,"status":162,"phases":17269,"primaryCompletion":6064,"start":17270,"enrollment":2123,"conditions":17271,"interventions":17272},"NCT02183233","Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia",[92],"1998-01",[11071],[17256,17273],"Eschscholtzia Californica Placebo",{"trials":17275,"activeCount":101},[],{"trials":17277,"activeCount":101},[],{"intervention":17273,"totalTrials":272,"cells":17279},{"EARLY_PHASE1":17280,"PHASE1":17282,"PHASE2":17284,"PHASE3":17286,"PHASE4":17292,"NA":17294},{"trials":17281,"activeCount":101},[],{"trials":17283,"activeCount":101},[],{"trials":17285,"activeCount":101},[],{"trials":17287,"activeCount":101},[17288],{"nctId":17267,"briefTitle":17268,"status":162,"phases":17289,"primaryCompletion":6064,"start":17270,"enrollment":2123,"conditions":17290,"interventions":17291},[92],[11071],[17256,17273],{"trials":17293,"activeCount":101},[],{"trials":17295,"activeCount":101},[],{"intervention":17297,"totalTrials":272,"cells":17298},"Tipranavir\u002FRitonavir",{"EARLY_PHASE1":17299,"PHASE1":17301,"PHASE2":17303,"PHASE3":17305,"PHASE4":17314,"NA":17316},{"trials":17300,"activeCount":101},[],{"trials":17302,"activeCount":101},[],{"trials":17304,"activeCount":101},[],{"trials":17306,"activeCount":101},[17307],{"nctId":17308,"briefTitle":17309,"status":107,"phases":17310,"primaryCompletion":6156,"completion":6156,"start":6445,"enrollment":17311,"conditions":17312,"interventions":17313},"NCT00144287","Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV\u002Fr) in Patients With Advanced HIV-1 Infection and Limited Treatment Options",[92],255,[27],[17297],{"trials":17315,"activeCount":101},[],{"trials":17317,"activeCount":101},[],{"intervention":7007,"totalTrials":272,"cells":17319},{"EARLY_PHASE1":17320,"PHASE1":17322,"PHASE2":17324,"PHASE3":17326,"PHASE4":17332,"NA":17334},{"trials":17321,"activeCount":101},[],{"trials":17323,"activeCount":101},[],{"trials":17325,"activeCount":101},[],{"trials":17327,"activeCount":101},[17328],{"nctId":7000,"briefTitle":7001,"status":107,"phases":17329,"primaryCompletion":7003,"start":2162,"enrollment":7004,"conditions":17330,"interventions":17331},[92],[24],[6979,6993,7007,7008],{"trials":17333,"activeCount":101},[],{"trials":17335,"activeCount":101},[],{"intervention":7008,"totalTrials":272,"cells":17337},{"EARLY_PHASE1":17338,"PHASE1":17340,"PHASE2":17342,"PHASE3":17344,"PHASE4":17350,"NA":17352},{"trials":17339,"activeCount":101},[],{"trials":17341,"activeCount":101},[],{"trials":17343,"activeCount":101},[],{"trials":17345,"activeCount":101},[17346],{"nctId":7000,"briefTitle":7001,"status":107,"phases":17347,"primaryCompletion":7003,"start":2162,"enrollment":7004,"conditions":17348,"interventions":17349},[92],[24],[6979,6993,7007,7008],{"trials":17351,"activeCount":101},[],{"trials":17353,"activeCount":101},[],{"intervention":6577,"totalTrials":272,"cells":17355},{"EARLY_PHASE1":17356,"PHASE1":17358,"PHASE2":17360,"PHASE3":17362,"PHASE4":17368,"NA":17370},{"trials":17357,"activeCount":101},[],{"trials":17359,"activeCount":101},[],{"trials":17361,"activeCount":101},[],{"trials":17363,"activeCount":101},[17364],{"nctId":6567,"briefTitle":6568,"status":107,"phases":17365,"primaryCompletion":6570,"completion":6571,"start":6572,"enrollment":6573,"conditions":17366,"interventions":17367},[92],[6575],[6549,6577],{"trials":17369,"activeCount":101},[],{"trials":17371,"activeCount":101},[],{"intervention":17373,"totalTrials":272,"cells":17374},"rt-PA 0.9 mg\u002Fkg verum or placebo Intravenous",{"EARLY_PHASE1":17375,"PHASE1":17377,"PHASE2":17379,"PHASE3":17381,"PHASE4":17390,"NA":17392},{"trials":17376,"activeCount":101},[],{"trials":17378,"activeCount":101},[],{"trials":17380,"activeCount":101},[],{"trials":17382,"activeCount":101},[17383],{"nctId":17384,"briefTitle":17385,"status":107,"phases":17386,"primaryCompletion":4129,"start":7124,"enrollment":17387,"conditions":17388,"interventions":17389},"NCT00153036","Rt-PA in the Treatment of Acute Ischemic Stroke",[92],821,[6964],[17373],{"trials":17391,"activeCount":101},[],{"trials":17393,"activeCount":101},[],{"intervention":2127,"totalTrials":272,"cells":17395},{"EARLY_PHASE1":17396,"PHASE1":17398,"PHASE2":17400,"PHASE3":17402,"PHASE4":17408,"NA":17410},{"trials":17397,"activeCount":101},[],{"trials":17399,"activeCount":101},[],{"trials":17401,"activeCount":101},[],{"trials":17403,"activeCount":101},[17404],{"nctId":2118,"briefTitle":2119,"status":107,"phases":17405,"primaryCompletion":2121,"start":2122,"enrollment":2123,"conditions":17406,"interventions":17407},[92],[632],[2074,2126,2127],{"trials":17409,"activeCount":101},[],{"trials":17411,"activeCount":101},[],{"intervention":17413,"totalTrials":272,"cells":17414},"Investigator´s choice of chemotherapy",{"EARLY_PHASE1":17415,"PHASE1":17417,"PHASE2":17419,"PHASE3":17421,"PHASE4":17431,"NA":17433},{"trials":17416,"activeCount":101},[],{"trials":17418,"activeCount":101},[],{"trials":17420,"activeCount":101},[],{"trials":17422,"activeCount":101},[17423],{"nctId":17424,"briefTitle":17425,"status":107,"phases":17426,"primaryCompletion":4474,"completion":9688,"start":17427,"enrollment":17428,"conditions":17429,"interventions":17430},"NCT01085136","LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib",[92],"2010-02",1154,[36],[17413,1129],{"trials":17432,"activeCount":101},[],{"trials":17434,"activeCount":101},[],{"intervention":17436,"totalTrials":272,"cells":17437},"Tiotropium inhalation capsules for oral inhalation",{"EARLY_PHASE1":17438,"PHASE1":17440,"PHASE2":17442,"PHASE3":17444,"PHASE4":17452,"NA":17454},{"trials":17439,"activeCount":101},[],{"trials":17441,"activeCount":101},[],{"trials":17443,"activeCount":101},[],{"trials":17445,"activeCount":101},[17446],{"nctId":17447,"briefTitle":17448,"status":107,"phases":17449,"primaryCompletion":7084,"start":7924,"enrollment":993,"conditions":17450,"interventions":17451},"NCT02172326","Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)",[92],[18],[17436],{"trials":17453,"activeCount":101},[],{"trials":17455,"activeCount":101},[],{"intervention":5936,"totalTrials":272,"cells":17457},{"EARLY_PHASE1":17458,"PHASE1":17460,"PHASE2":17462,"PHASE3":17464,"PHASE4":17470,"NA":17472},{"trials":17459,"activeCount":101},[],{"trials":17461,"activeCount":101},[],{"trials":17463,"activeCount":101},[],{"trials":17465,"activeCount":101},[17466],{"nctId":5928,"briefTitle":5929,"status":162,"phases":17467,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5933,"conditions":17468,"interventions":17469},[92],[18],[5936,5832,5937,5860],{"trials":17471,"activeCount":101},[],{"trials":17473,"activeCount":101},[],{"intervention":5937,"totalTrials":272,"cells":17475},{"EARLY_PHASE1":17476,"PHASE1":17478,"PHASE2":17480,"PHASE3":17482,"PHASE4":17488,"NA":17490},{"trials":17477,"activeCount":101},[],{"trials":17479,"activeCount":101},[],{"trials":17481,"activeCount":101},[],{"trials":17483,"activeCount":101},[17484],{"nctId":5928,"briefTitle":5929,"status":162,"phases":17485,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5933,"conditions":17486,"interventions":17487},[92],[18],[5936,5832,5937,5860],{"trials":17489,"activeCount":101},[],{"trials":17491,"activeCount":101},[],{"intervention":11666,"totalTrials":272,"cells":17493},{"EARLY_PHASE1":17494,"PHASE1":17496,"PHASE2":17498,"PHASE3":17500,"PHASE4":17506,"NA":17508},{"trials":17495,"activeCount":101},[],{"trials":17497,"activeCount":101},[],{"trials":17499,"activeCount":101},[],{"trials":17501,"activeCount":101},[17502],{"nctId":11660,"briefTitle":11661,"status":107,"phases":17503,"primaryCompletion":9332,"start":1990,"enrollment":11663,"conditions":17504,"interventions":17505},[92],[27],[11666,11667,11668],{"trials":17507,"activeCount":101},[],{"trials":17509,"activeCount":101},[],{"intervention":11667,"totalTrials":272,"cells":17511},{"EARLY_PHASE1":17512,"PHASE1":17514,"PHASE2":17516,"PHASE3":17518,"PHASE4":17524,"NA":17526},{"trials":17513,"activeCount":101},[],{"trials":17515,"activeCount":101},[],{"trials":17517,"activeCount":101},[],{"trials":17519,"activeCount":101},[17520],{"nctId":11660,"briefTitle":11661,"status":107,"phases":17521,"primaryCompletion":9332,"start":1990,"enrollment":11663,"conditions":17522,"interventions":17523},[92],[27],[11666,11667,11668],{"trials":17525,"activeCount":101},[],{"trials":17527,"activeCount":101},[],{"intervention":2717,"totalTrials":272,"cells":17529},{"EARLY_PHASE1":17530,"PHASE1":17532,"PHASE2":17534,"PHASE3":17536,"PHASE4":17542,"NA":17544},{"trials":17531,"activeCount":101},[],{"trials":17533,"activeCount":101},[],{"trials":17535,"activeCount":101},[],{"trials":17537,"activeCount":101},[17538],{"nctId":2708,"briefTitle":2709,"status":107,"phases":17539,"primaryCompletion":2711,"completion":2712,"start":2713,"enrollment":1054,"conditions":17540,"interventions":17541},[91,92],[2715],[2675,2717],{"trials":17543,"activeCount":101},[],{"trials":17545,"activeCount":101},[],{"intervention":10342,"totalTrials":272,"cells":17547},{"EARLY_PHASE1":17548,"PHASE1":17550,"PHASE2":17552,"PHASE3":17554,"PHASE4":17560,"NA":17562},{"trials":17549,"activeCount":101},[],{"trials":17551,"activeCount":101},[],{"trials":17553,"activeCount":101},[],{"trials":17555,"activeCount":101},[17556],{"nctId":10336,"briefTitle":10337,"status":107,"phases":17557,"primaryCompletion":6494,"start":2162,"enrollment":10339,"conditions":17558,"interventions":17559},[92],[632],[10342,10343,10285],{"trials":17561,"activeCount":101},[],{"trials":17563,"activeCount":101},[],{"intervention":10343,"totalTrials":272,"cells":17565},{"EARLY_PHASE1":17566,"PHASE1":17568,"PHASE2":17570,"PHASE3":17572,"PHASE4":17578,"NA":17580},{"trials":17567,"activeCount":101},[],{"trials":17569,"activeCount":101},[],{"trials":17571,"activeCount":101},[],{"trials":17573,"activeCount":101},[17574],{"nctId":10336,"briefTitle":10337,"status":107,"phases":17575,"primaryCompletion":6494,"start":2162,"enrollment":10339,"conditions":17576,"interventions":17577},[92],[632],[10342,10343,10285],{"trials":17579,"activeCount":101},[],{"trials":17581,"activeCount":101},[],{"intervention":2036,"totalTrials":272,"cells":17583},{"EARLY_PHASE1":17584,"PHASE1":17586,"PHASE2":17588,"PHASE3":17590,"PHASE4":17596,"NA":17598},{"trials":17585,"activeCount":101},[],{"trials":17587,"activeCount":101},[],{"trials":17589,"activeCount":101},[],{"trials":17591,"activeCount":101},[17592],{"nctId":2027,"briefTitle":2028,"status":107,"phases":17593,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":17594,"interventions":17595},[92],[36],[78,1011,1074,2036,2037,2037,2036,2038,2036,2037,2038,2038,78,1011],{"trials":17597,"activeCount":101},[],{"trials":17599,"activeCount":101},[],{"intervention":2037,"totalTrials":272,"cells":17601},{"EARLY_PHASE1":17602,"PHASE1":17604,"PHASE2":17606,"PHASE3":17608,"PHASE4":17614,"NA":17616},{"trials":17603,"activeCount":101},[],{"trials":17605,"activeCount":101},[],{"trials":17607,"activeCount":101},[],{"trials":17609,"activeCount":101},[17610],{"nctId":2027,"briefTitle":2028,"status":107,"phases":17611,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":17612,"interventions":17613},[92],[36],[78,1011,1074,2036,2037,2037,2036,2038,2036,2037,2038,2038,78,1011],{"trials":17615,"activeCount":101},[],{"trials":17617,"activeCount":101},[],{"intervention":2038,"totalTrials":272,"cells":17619},{"EARLY_PHASE1":17620,"PHASE1":17622,"PHASE2":17624,"PHASE3":17626,"PHASE4":17632,"NA":17634},{"trials":17621,"activeCount":101},[],{"trials":17623,"activeCount":101},[],{"trials":17625,"activeCount":101},[],{"trials":17627,"activeCount":101},[17628],{"nctId":2027,"briefTitle":2028,"status":107,"phases":17629,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":17630,"interventions":17631},[92],[36],[78,1011,1074,2036,2037,2037,2036,2038,2036,2037,2038,2038,78,1011],{"trials":17633,"activeCount":101},[],{"trials":17635,"activeCount":101},[],{"intervention":12557,"totalTrials":272,"cells":17637},{"EARLY_PHASE1":17638,"PHASE1":17640,"PHASE2":17642,"PHASE3":17644,"PHASE4":17650,"NA":17652},{"trials":17639,"activeCount":101},[],{"trials":17641,"activeCount":101},[],{"trials":17643,"activeCount":101},[],{"trials":17645,"activeCount":101},[17646],{"nctId":12549,"briefTitle":12550,"status":600,"phases":17647,"primaryCompletion":12552,"completion":12553,"start":12554,"enrollment":101,"conditions":17648,"interventions":17649},[91,92],[1920],[12529,12557],{"trials":17651,"activeCount":101},[],{"trials":17653,"activeCount":101},[],{"intervention":10448,"totalTrials":272,"cells":17655},{"EARLY_PHASE1":17656,"PHASE1":17658,"PHASE2":17660,"PHASE3":17662,"PHASE4":17668,"NA":17670},{"trials":17657,"activeCount":101},[],{"trials":17659,"activeCount":101},[],{"trials":17661,"activeCount":101},[],{"trials":17663,"activeCount":101},[17664],{"nctId":10440,"briefTitle":10441,"status":107,"phases":17665,"primaryCompletion":9824,"completion":9824,"start":9515,"enrollment":10443,"conditions":17666,"interventions":17667},[92],[10445,10446],[10448,10438,10438,4044,10448,4044,10438,10448],{"trials":17669,"activeCount":101},[],{"trials":17671,"activeCount":101},[],{"intervention":17673,"totalTrials":272,"cells":17674},"Losartan + Hydrochlorothiazide",{"EARLY_PHASE1":17675,"PHASE1":17677,"PHASE2":17679,"PHASE3":17681,"PHASE4":17690,"NA":17692},{"trials":17676,"activeCount":101},[],{"trials":17678,"activeCount":101},[],{"trials":17680,"activeCount":101},[],{"trials":17682,"activeCount":101},[17683],{"nctId":17684,"briefTitle":17685,"status":107,"phases":17686,"primaryCompletion":7114,"start":6065,"enrollment":17687,"conditions":17688,"interventions":17689},"NCT02183701","Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension",[92],715,[24],[6121,17673],{"trials":17691,"activeCount":101},[],{"trials":17693,"activeCount":101},[],{"intervention":17695,"totalTrials":272,"cells":17696},"standard of care",{"EARLY_PHASE1":17697,"PHASE1":17699,"PHASE2":17701,"PHASE3":17703,"PHASE4":17715,"NA":17717},{"trials":17698,"activeCount":101},[],{"trials":17700,"activeCount":101},[],{"trials":17702,"activeCount":101},[],{"trials":17704,"activeCount":101},[17705],{"nctId":17706,"briefTitle":17707,"status":107,"phases":17708,"primaryCompletion":17709,"completion":17710,"start":17711,"enrollment":17712,"conditions":17713,"interventions":17714},"NCT01895777","Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)",[92],"2019-10-16","2019-11-14","2013-09-25",267,[10299],[1685,17695],{"trials":17716,"activeCount":101},[],{"trials":17718,"activeCount":101},[],{"intervention":17720,"totalTrials":272,"cells":17721},"Tiotropium powder inhalation",{"EARLY_PHASE1":17722,"PHASE1":17724,"PHASE2":17726,"PHASE3":17728,"PHASE4":17737,"NA":17739},{"trials":17723,"activeCount":101},[],{"trials":17725,"activeCount":101},[],{"trials":17727,"activeCount":101},[],{"trials":17729,"activeCount":101},[17730],{"nctId":17731,"briefTitle":17732,"status":107,"phases":17733,"primaryCompletion":5887,"start":6949,"enrollment":16953,"conditions":17734,"interventions":17735},"NCT02172430","Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[17720,17736],"Tersigan®",{"trials":17738,"activeCount":101},[],{"trials":17740,"activeCount":101},[],{"intervention":17736,"totalTrials":272,"cells":17742},{"EARLY_PHASE1":17743,"PHASE1":17745,"PHASE2":17747,"PHASE3":17749,"PHASE4":17755,"NA":17757},{"trials":17744,"activeCount":101},[],{"trials":17746,"activeCount":101},[],{"trials":17748,"activeCount":101},[],{"trials":17750,"activeCount":101},[17751],{"nctId":17731,"briefTitle":17732,"status":107,"phases":17752,"primaryCompletion":5887,"start":6949,"enrollment":16953,"conditions":17753,"interventions":17754},[92],[18],[17720,17736],{"trials":17756,"activeCount":101},[],{"trials":17758,"activeCount":101},[],{"intervention":17760,"totalTrials":272,"cells":17761},"Hyoscine Butylbromide -",{"EARLY_PHASE1":17762,"PHASE1":17764,"PHASE2":17766,"PHASE3":17768,"PHASE4":17779,"NA":17781},{"trials":17763,"activeCount":101},[],{"trials":17765,"activeCount":101},[],{"trials":17767,"activeCount":101},[],{"trials":17769,"activeCount":101},[17770],{"nctId":17771,"briefTitle":17772,"status":107,"phases":17773,"primaryCompletion":17774,"completion":17774,"start":17775,"enrollment":5968,"conditions":17776,"interventions":17778},"NCT02242305","Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort",[92],"2009-07-20","2008-11-01",[17777],"Abdominal Pain",[17760,17760],{"trials":17780,"activeCount":101},[],{"trials":17782,"activeCount":101},[],{"intervention":5946,"totalTrials":272,"cells":17784},{"EARLY_PHASE1":17785,"PHASE1":17787,"PHASE2":17789,"PHASE3":17791,"PHASE4":17797,"NA":17799},{"trials":17786,"activeCount":101},[],{"trials":17788,"activeCount":101},[],{"trials":17790,"activeCount":101},[],{"trials":17792,"activeCount":101},[17793],{"nctId":5939,"briefTitle":5940,"status":162,"phases":17794,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5942,"conditions":17795,"interventions":17796},[92],[18],[5945,5946,5832,5860],{"trials":17798,"activeCount":101},[],{"trials":17800,"activeCount":101},[],{"intervention":6667,"totalTrials":272,"cells":17802},{"EARLY_PHASE1":17803,"PHASE1":17805,"PHASE2":17807,"PHASE3":17809,"PHASE4":17815,"NA":17817},{"trials":17804,"activeCount":101},[],{"trials":17806,"activeCount":101},[],{"trials":17808,"activeCount":101},[],{"trials":17810,"activeCount":101},[17811],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17812,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17813,"interventions":17814},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17816,"activeCount":101},[],{"trials":17818,"activeCount":101},[],{"intervention":6669,"totalTrials":272,"cells":17820},{"EARLY_PHASE1":17821,"PHASE1":17823,"PHASE2":17825,"PHASE3":17827,"PHASE4":17833,"NA":17835},{"trials":17822,"activeCount":101},[],{"trials":17824,"activeCount":101},[],{"trials":17826,"activeCount":101},[],{"trials":17828,"activeCount":101},[17829],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17830,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17831,"interventions":17832},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17834,"activeCount":101},[],{"trials":17836,"activeCount":101},[],{"intervention":6670,"totalTrials":272,"cells":17838},{"EARLY_PHASE1":17839,"PHASE1":17841,"PHASE2":17843,"PHASE3":17845,"PHASE4":17851,"NA":17853},{"trials":17840,"activeCount":101},[],{"trials":17842,"activeCount":101},[],{"trials":17844,"activeCount":101},[],{"trials":17846,"activeCount":101},[17847],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17848,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17849,"interventions":17850},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17852,"activeCount":101},[],{"trials":17854,"activeCount":101},[],{"intervention":6671,"totalTrials":272,"cells":17856},{"EARLY_PHASE1":17857,"PHASE1":17859,"PHASE2":17861,"PHASE3":17863,"PHASE4":17869,"NA":17871},{"trials":17858,"activeCount":101},[],{"trials":17860,"activeCount":101},[],{"trials":17862,"activeCount":101},[],{"trials":17864,"activeCount":101},[17865],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17866,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17867,"interventions":17868},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17870,"activeCount":101},[],{"trials":17872,"activeCount":101},[],{"intervention":6672,"totalTrials":272,"cells":17874},{"EARLY_PHASE1":17875,"PHASE1":17877,"PHASE2":17879,"PHASE3":17881,"PHASE4":17887,"NA":17889},{"trials":17876,"activeCount":101},[],{"trials":17878,"activeCount":101},[],{"trials":17880,"activeCount":101},[],{"trials":17882,"activeCount":101},[17883],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17884,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17885,"interventions":17886},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17888,"activeCount":101},[],{"trials":17890,"activeCount":101},[],{"intervention":6674,"totalTrials":272,"cells":17892},{"EARLY_PHASE1":17893,"PHASE1":17895,"PHASE2":17897,"PHASE3":17899,"PHASE4":17905,"NA":17907},{"trials":17894,"activeCount":101},[],{"trials":17896,"activeCount":101},[],{"trials":17898,"activeCount":101},[],{"trials":17900,"activeCount":101},[17901],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17902,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17903,"interventions":17904},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17906,"activeCount":101},[],{"trials":17908,"activeCount":101},[],{"intervention":6675,"totalTrials":272,"cells":17910},{"EARLY_PHASE1":17911,"PHASE1":17913,"PHASE2":17915,"PHASE3":17917,"PHASE4":17923,"NA":17925},{"trials":17912,"activeCount":101},[],{"trials":17914,"activeCount":101},[],{"trials":17916,"activeCount":101},[],{"trials":17918,"activeCount":101},[17919],{"nctId":6661,"briefTitle":6662,"status":107,"phases":17920,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":17921,"interventions":17922},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"trials":17924,"activeCount":101},[],{"trials":17926,"activeCount":101},[],{"intervention":17928,"totalTrials":272,"cells":17929},"Gemcitabine+Cisplatin",{"EARLY_PHASE1":17930,"PHASE1":17932,"PHASE2":17934,"PHASE3":17936,"PHASE4":17948,"NA":17950},{"trials":17931,"activeCount":101},[],{"trials":17933,"activeCount":101},[],{"trials":17935,"activeCount":101},[],{"trials":17937,"activeCount":101},[17938],{"nctId":17939,"briefTitle":17940,"status":107,"phases":17941,"primaryCompletion":17942,"completion":17943,"start":17944,"enrollment":17945,"conditions":17946,"interventions":17947},"NCT01121393","BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)",[92],"2017-11-23","2017-11-26","2010-04-19",364,[36,1773],[17928,1129],{"trials":17949,"activeCount":101},[],{"trials":17951,"activeCount":101},[],{"intervention":13121,"totalTrials":272,"cells":17953},{"EARLY_PHASE1":17954,"PHASE1":17956,"PHASE2":17958,"PHASE3":17960,"PHASE4":17966,"NA":17968},{"trials":17955,"activeCount":101},[],{"trials":17957,"activeCount":101},[],{"trials":17959,"activeCount":101},[],{"trials":17961,"activeCount":101},[17962],{"nctId":13114,"briefTitle":13115,"status":107,"phases":17963,"primaryCompletion":13117,"start":7084,"enrollment":13118,"conditions":17964,"interventions":17965},[92],[30],[13121,13122,13094],{"trials":17967,"activeCount":101},[],{"trials":17969,"activeCount":101},[],{"intervention":13122,"totalTrials":272,"cells":17971},{"EARLY_PHASE1":17972,"PHASE1":17974,"PHASE2":17976,"PHASE3":17978,"PHASE4":17984,"NA":17986},{"trials":17973,"activeCount":101},[],{"trials":17975,"activeCount":101},[],{"trials":17977,"activeCount":101},[],{"trials":17979,"activeCount":101},[17980],{"nctId":13114,"briefTitle":13115,"status":107,"phases":17981,"primaryCompletion":13117,"start":7084,"enrollment":13118,"conditions":17982,"interventions":17983},[92],[30],[13121,13122,13094],{"trials":17985,"activeCount":101},[],{"trials":17987,"activeCount":101},[],{"intervention":17989,"totalTrials":272,"cells":17990},"Empagliflozin + Linagliptin",{"EARLY_PHASE1":17991,"PHASE1":17993,"PHASE2":17995,"PHASE3":17997,"PHASE4":18009,"NA":18011},{"trials":17992,"activeCount":101},[],{"trials":17994,"activeCount":101},[],{"trials":17996,"activeCount":101},[],{"trials":17998,"activeCount":101},[17999],{"nctId":18000,"briefTitle":18001,"status":107,"phases":18002,"primaryCompletion":18003,"completion":18003,"start":18004,"enrollment":18005,"conditions":18006,"interventions":18007},"NCT01734785","Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes",[92],"2015-03-23","2013-02-08",607,[21],[361,17989,17989,17989,18008,17989],"Empagliflozin placebo + Linagliptin placebo",{"trials":18010,"activeCount":101},[],{"trials":18012,"activeCount":101},[],{"intervention":18008,"totalTrials":272,"cells":18014},{"EARLY_PHASE1":18015,"PHASE1":18017,"PHASE2":18019,"PHASE3":18021,"PHASE4":18027,"NA":18029},{"trials":18016,"activeCount":101},[],{"trials":18018,"activeCount":101},[],{"trials":18020,"activeCount":101},[],{"trials":18022,"activeCount":101},[18023],{"nctId":18000,"briefTitle":18001,"status":107,"phases":18024,"primaryCompletion":18003,"completion":18003,"start":18004,"enrollment":18005,"conditions":18025,"interventions":18026},[92],[21],[361,17989,17989,17989,18008,17989],{"trials":18028,"activeCount":101},[],{"trials":18030,"activeCount":101},[],{"intervention":9977,"totalTrials":272,"cells":18032},{"EARLY_PHASE1":18033,"PHASE1":18035,"PHASE2":18037,"PHASE3":18039,"PHASE4":18045,"NA":18047},{"trials":18034,"activeCount":101},[],{"trials":18036,"activeCount":101},[],{"trials":18038,"activeCount":101},[],{"trials":18040,"activeCount":101},[18041],{"nctId":9971,"briefTitle":9972,"status":107,"phases":18042,"primaryCompletion":6811,"start":6471,"enrollment":9974,"conditions":18043,"interventions":18044},[92],[21],[9872,9872,9977,9978,9979],{"trials":18046,"activeCount":101},[],{"trials":18048,"activeCount":101},[],{"intervention":9978,"totalTrials":272,"cells":18050},{"EARLY_PHASE1":18051,"PHASE1":18053,"PHASE2":18055,"PHASE3":18057,"PHASE4":18063,"NA":18065},{"trials":18052,"activeCount":101},[],{"trials":18054,"activeCount":101},[],{"trials":18056,"activeCount":101},[],{"trials":18058,"activeCount":101},[18059],{"nctId":9971,"briefTitle":9972,"status":107,"phases":18060,"primaryCompletion":6811,"start":6471,"enrollment":9974,"conditions":18061,"interventions":18062},[92],[21],[9872,9872,9977,9978,9979],{"trials":18064,"activeCount":101},[],{"trials":18066,"activeCount":101},[],{"intervention":9979,"totalTrials":272,"cells":18068},{"EARLY_PHASE1":18069,"PHASE1":18071,"PHASE2":18073,"PHASE3":18075,"PHASE4":18081,"NA":18083},{"trials":18070,"activeCount":101},[],{"trials":18072,"activeCount":101},[],{"trials":18074,"activeCount":101},[],{"trials":18076,"activeCount":101},[18077],{"nctId":9971,"briefTitle":9972,"status":107,"phases":18078,"primaryCompletion":6811,"start":6471,"enrollment":9974,"conditions":18079,"interventions":18080},[92],[21],[9872,9872,9977,9978,9979],{"trials":18082,"activeCount":101},[],{"trials":18084,"activeCount":101},[],{"intervention":18086,"totalTrials":272,"cells":18087},"Tiotropium low dose QD",{"EARLY_PHASE1":18088,"PHASE1":18090,"PHASE2":18092,"PHASE3":18094,"PHASE4":18104,"NA":18106},{"trials":18089,"activeCount":101},[],{"trials":18091,"activeCount":101},[],{"trials":18093,"activeCount":101},[],{"trials":18095,"activeCount":101},[18096],{"nctId":18097,"briefTitle":18098,"status":107,"phases":18099,"primaryCompletion":18100,"completion":2031,"start":9491,"enrollment":9092,"conditions":18101,"interventions":18102},"NCT01634139","Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma",[92],"2015-06",[30],[18086,18103],"Tiotropium high dose QD",{"trials":18105,"activeCount":101},[],{"trials":18107,"activeCount":101},[],{"intervention":18103,"totalTrials":272,"cells":18109},{"EARLY_PHASE1":18110,"PHASE1":18112,"PHASE2":18114,"PHASE3":18116,"PHASE4":18122,"NA":18124},{"trials":18111,"activeCount":101},[],{"trials":18113,"activeCount":101},[],{"trials":18115,"activeCount":101},[],{"trials":18117,"activeCount":101},[18118],{"nctId":18097,"briefTitle":18098,"status":107,"phases":18119,"primaryCompletion":18100,"completion":2031,"start":9491,"enrollment":9092,"conditions":18120,"interventions":18121},[92],[30],[18086,18103],{"trials":18123,"activeCount":101},[],{"trials":18125,"activeCount":101},[],{"intervention":6266,"totalTrials":272,"cells":18127},{"EARLY_PHASE1":18128,"PHASE1":18130,"PHASE2":18132,"PHASE3":18134,"PHASE4":18140,"NA":18142},{"trials":18129,"activeCount":101},[],{"trials":18131,"activeCount":101},[],{"trials":18133,"activeCount":101},[],{"trials":18135,"activeCount":101},[18136],{"nctId":6259,"briefTitle":6260,"status":107,"phases":18137,"primaryCompletion":6262,"start":6207,"enrollment":6263,"conditions":18138,"interventions":18139},[92],[24],[6266,6267,6268,6196],{"trials":18141,"activeCount":101},[],{"trials":18143,"activeCount":101},[],{"intervention":6267,"totalTrials":272,"cells":18145},{"EARLY_PHASE1":18146,"PHASE1":18148,"PHASE2":18150,"PHASE3":18152,"PHASE4":18158,"NA":18160},{"trials":18147,"activeCount":101},[],{"trials":18149,"activeCount":101},[],{"trials":18151,"activeCount":101},[],{"trials":18153,"activeCount":101},[18154],{"nctId":6259,"briefTitle":6260,"status":107,"phases":18155,"primaryCompletion":6262,"start":6207,"enrollment":6263,"conditions":18156,"interventions":18157},[92],[24],[6266,6267,6268,6196],{"trials":18159,"activeCount":101},[],{"trials":18161,"activeCount":101},[],{"intervention":6268,"totalTrials":272,"cells":18163},{"EARLY_PHASE1":18164,"PHASE1":18166,"PHASE2":18168,"PHASE3":18170,"PHASE4":18176,"NA":18178},{"trials":18165,"activeCount":101},[],{"trials":18167,"activeCount":101},[],{"trials":18169,"activeCount":101},[],{"trials":18171,"activeCount":101},[18172],{"nctId":6259,"briefTitle":6260,"status":107,"phases":18173,"primaryCompletion":6262,"start":6207,"enrollment":6263,"conditions":18174,"interventions":18175},[92],[24],[6266,6267,6268,6196],{"trials":18177,"activeCount":101},[],{"trials":18179,"activeCount":101},[],{"intervention":18181,"totalTrials":272,"cells":18182},"Linagliptin + metformin",{"EARLY_PHASE1":18183,"PHASE1":18185,"PHASE2":18187,"PHASE3":18189,"PHASE4":18199,"NA":18201},{"trials":18184,"activeCount":101},[],{"trials":18186,"activeCount":101},[],{"trials":18188,"activeCount":101},[],{"trials":18190,"activeCount":101},[18191],{"nctId":18192,"briefTitle":18193,"status":107,"phases":18194,"primaryCompletion":2030,"start":5905,"enrollment":18195,"conditions":18196,"interventions":18197},"NCT00915772","Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid",[92],567,[21],[18181,18198,413],"Linagliptin+metformin",{"trials":18200,"activeCount":101},[],{"trials":18202,"activeCount":101},[],{"intervention":18198,"totalTrials":272,"cells":18204},{"EARLY_PHASE1":18205,"PHASE1":18207,"PHASE2":18209,"PHASE3":18211,"PHASE4":18217,"NA":18219},{"trials":18206,"activeCount":101},[],{"trials":18208,"activeCount":101},[],{"trials":18210,"activeCount":101},[],{"trials":18212,"activeCount":101},[18213],{"nctId":18192,"briefTitle":18193,"status":107,"phases":18214,"primaryCompletion":2030,"start":5905,"enrollment":18195,"conditions":18215,"interventions":18216},[92],[21],[18181,18198,413],{"trials":18218,"activeCount":101},[],{"trials":18220,"activeCount":101},[],{"intervention":9563,"totalTrials":272,"cells":18222},{"EARLY_PHASE1":18223,"PHASE1":18225,"PHASE2":18227,"PHASE3":18229,"PHASE4":18235,"NA":18237},{"trials":18224,"activeCount":101},[],{"trials":18226,"activeCount":101},[],{"trials":18228,"activeCount":101},[],{"trials":18230,"activeCount":101},[18231],{"nctId":9557,"briefTitle":9558,"status":107,"phases":18232,"primaryCompletion":3753,"start":1967,"enrollment":9560,"conditions":18233,"interventions":18234},[92],[21],[528,9563,9564,606],{"trials":18236,"activeCount":101},[],{"trials":18238,"activeCount":101},[],{"intervention":18240,"totalTrials":272,"cells":18241},"Fenoterol MDI",{"EARLY_PHASE1":18242,"PHASE1":18244,"PHASE2":18246,"PHASE3":18248,"PHASE4":18259,"NA":18261},{"trials":18243,"activeCount":101},[],{"trials":18245,"activeCount":101},[],{"trials":18247,"activeCount":101},[],{"trials":18249,"activeCount":101},[18250],{"nctId":18251,"briefTitle":18252,"status":162,"phases":18253,"primaryCompletion":18254,"start":18255,"enrollment":2442,"conditions":18256,"interventions":18257},"NCT02177370","Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma",[92],"1996-10","1990-02",[30],[18240,18258],"DSCG MDI",{"trials":18260,"activeCount":101},[],{"trials":18262,"activeCount":101},[],{"intervention":18258,"totalTrials":272,"cells":18264},{"EARLY_PHASE1":18265,"PHASE1":18267,"PHASE2":18269,"PHASE3":18271,"PHASE4":18277,"NA":18279},{"trials":18266,"activeCount":101},[],{"trials":18268,"activeCount":101},[],{"trials":18270,"activeCount":101},[],{"trials":18272,"activeCount":101},[18273],{"nctId":18251,"briefTitle":18252,"status":162,"phases":18274,"primaryCompletion":18254,"start":18255,"enrollment":2442,"conditions":18275,"interventions":18276},[92],[30],[18240,18258],{"trials":18278,"activeCount":101},[],{"trials":18280,"activeCount":101},[],{"intervention":18282,"totalTrials":272,"cells":18283},"sodium picosulphate",{"EARLY_PHASE1":18284,"PHASE1":18286,"PHASE2":18288,"PHASE3":18290,"PHASE4":18299,"NA":18301},{"trials":18285,"activeCount":101},[],{"trials":18287,"activeCount":101},[],{"trials":18289,"activeCount":101},[],{"trials":18291,"activeCount":101},[18292],{"nctId":18293,"briefTitle":18294,"status":107,"phases":18295,"primaryCompletion":2649,"start":4516,"enrollment":18296,"conditions":18297,"interventions":18298},"NCT00576810","Sodium Picosulphate vs. Placebo in Functional Constipation",[92],367,[12755],[18282],{"trials":18300,"activeCount":101},[],{"trials":18302,"activeCount":101},[],{"intervention":13263,"totalTrials":272,"cells":18304},{"EARLY_PHASE1":18305,"PHASE1":18307,"PHASE2":18309,"PHASE3":18311,"PHASE4":18317,"NA":18319},{"trials":18306,"activeCount":101},[],{"trials":18308,"activeCount":101},[],{"trials":18310,"activeCount":101},[],{"trials":18312,"activeCount":101},[18313],{"nctId":13257,"briefTitle":13258,"status":107,"phases":18314,"primaryCompletion":2648,"start":1967,"enrollment":13260,"conditions":18315,"interventions":18316},[92],[24],[13263,13264,13265],{"trials":18318,"activeCount":101},[],{"trials":18320,"activeCount":101},[],{"intervention":13265,"totalTrials":272,"cells":18322},{"EARLY_PHASE1":18323,"PHASE1":18325,"PHASE2":18327,"PHASE3":18329,"PHASE4":18335,"NA":18337},{"trials":18324,"activeCount":101},[],{"trials":18326,"activeCount":101},[],{"trials":18328,"activeCount":101},[],{"trials":18330,"activeCount":101},[18331],{"nctId":13257,"briefTitle":13258,"status":107,"phases":18332,"primaryCompletion":2648,"start":1967,"enrollment":13260,"conditions":18333,"interventions":18334},[92],[24],[13263,13264,13265],{"trials":18336,"activeCount":101},[],{"trials":18338,"activeCount":101},[],{"intervention":18340,"totalTrials":272,"cells":18341},"Optimized Background Regimen",{"EARLY_PHASE1":18342,"PHASE1":18344,"PHASE2":18346,"PHASE3":18348,"PHASE4":18358,"NA":18360},{"trials":18343,"activeCount":101},[],{"trials":18345,"activeCount":101},[],{"trials":18347,"activeCount":101},[],{"trials":18349,"activeCount":101},[18350],{"nctId":18351,"briefTitle":18352,"status":162,"phases":18353,"primaryCompletion":4412,"start":9902,"enrollment":1116,"conditions":18354,"interventions":18355},"NCT00440271","SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir\u002Fr IN Race\u002FGender HIV+ Patients Randomized to TDM or SoC",[92],[27],[18356,18357,18340],"tipranavir","ritonavir",{"trials":18359,"activeCount":101},[],{"trials":18361,"activeCount":101},[],{"intervention":18363,"totalTrials":272,"cells":18364},"background therapy",{"EARLY_PHASE1":18365,"PHASE1":18367,"PHASE2":18369,"PHASE3":18371,"PHASE4":18383,"NA":18385},{"trials":18366,"activeCount":101},[],{"trials":18368,"activeCount":101},[],{"trials":18370,"activeCount":101},[],{"trials":18372,"activeCount":101},[18373],{"nctId":18374,"briefTitle":18375,"status":107,"phases":18376,"primaryCompletion":18377,"completion":18378,"start":18379,"enrollment":18380,"conditions":18381,"interventions":18382},"NCT02897349","Linagliptin Add-on to Insulin Background Therapy",[92],"2019-01-11","2019-01-18","2016-09-30",206,[21],[6633,18363],{"trials":18384,"activeCount":101},[],{"trials":18386,"activeCount":101},[],{"intervention":11962,"totalTrials":272,"cells":18388},{"EARLY_PHASE1":18389,"PHASE1":18391,"PHASE2":18393,"PHASE3":18395,"PHASE4":18401,"NA":18403},{"trials":18390,"activeCount":101},[],{"trials":18392,"activeCount":101},[],{"trials":18394,"activeCount":101},[],{"trials":18396,"activeCount":101},[18397],{"nctId":11957,"briefTitle":11958,"status":107,"phases":18398,"primaryCompletion":4392,"start":5905,"enrollment":2689,"conditions":18399,"interventions":18400},[92],[18],[6866,11962,11963],{"trials":18402,"activeCount":101},[],{"trials":18404,"activeCount":101},[],{"intervention":13420,"totalTrials":272,"cells":18406},{"EARLY_PHASE1":18407,"PHASE1":18409,"PHASE2":18411,"PHASE3":18413,"PHASE4":18419,"NA":18421},{"trials":18408,"activeCount":101},[],{"trials":18410,"activeCount":101},[],{"trials":18412,"activeCount":101},[],{"trials":18414,"activeCount":101},[18415],{"nctId":13415,"briefTitle":13416,"status":107,"phases":18416,"primaryCompletion":6040,"start":2121,"enrollment":1458,"conditions":18417,"interventions":18418},[92],[11866],[13420,13421,13422,13423],{"trials":18420,"activeCount":101},[],{"trials":18422,"activeCount":101},[],{"intervention":18424,"totalTrials":272,"cells":18425},"Ambroxol hydrochloride",{"EARLY_PHASE1":18426,"PHASE1":18428,"PHASE2":18430,"PHASE3":18432,"PHASE4":18442,"NA":18444},{"trials":18427,"activeCount":101},[],{"trials":18429,"activeCount":101},[],{"trials":18431,"activeCount":101},[],{"trials":18433,"activeCount":101},[18434],{"nctId":18435,"briefTitle":18436,"status":107,"phases":18437,"primaryCompletion":2111,"completion":2111,"start":5843,"enrollment":18438,"conditions":18439,"interventions":18440},"NCT00148499","Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute\u002FViralpharyngitis",[92],751,[6587],[18424,18441],"benzocaine",{"trials":18443,"activeCount":101},[],{"trials":18445,"activeCount":101},[],{"intervention":18441,"totalTrials":272,"cells":18447},{"EARLY_PHASE1":18448,"PHASE1":18450,"PHASE2":18452,"PHASE3":18454,"PHASE4":18460,"NA":18462},{"trials":18449,"activeCount":101},[],{"trials":18451,"activeCount":101},[],{"trials":18453,"activeCount":101},[],{"trials":18455,"activeCount":101},[18456],{"nctId":18435,"briefTitle":18436,"status":107,"phases":18457,"primaryCompletion":2111,"completion":2111,"start":5843,"enrollment":18438,"conditions":18458,"interventions":18459},[92],[6587],[18424,18441],{"trials":18461,"activeCount":101},[],{"trials":18463,"activeCount":101},[],{"intervention":10359,"totalTrials":272,"cells":18465},{"EARLY_PHASE1":18466,"PHASE1":18468,"PHASE2":18470,"PHASE3":18472,"PHASE4":18478,"NA":18480},{"trials":18467,"activeCount":101},[],{"trials":18469,"activeCount":101},[],{"trials":18471,"activeCount":101},[],{"trials":18473,"activeCount":101},[18474],{"nctId":10353,"briefTitle":10354,"status":107,"phases":18475,"primaryCompletion":2111,"start":8086,"enrollment":10356,"conditions":18476,"interventions":18477},[92],[10350,10332],[10359,10360,10361,10362,10285],{"trials":18479,"activeCount":101},[],{"trials":18481,"activeCount":101},[],{"intervention":10360,"totalTrials":272,"cells":18483},{"EARLY_PHASE1":18484,"PHASE1":18486,"PHASE2":18488,"PHASE3":18490,"PHASE4":18496,"NA":18498},{"trials":18485,"activeCount":101},[],{"trials":18487,"activeCount":101},[],{"trials":18489,"activeCount":101},[],{"trials":18491,"activeCount":101},[18492],{"nctId":10353,"briefTitle":10354,"status":107,"phases":18493,"primaryCompletion":2111,"start":8086,"enrollment":10356,"conditions":18494,"interventions":18495},[92],[10350,10332],[10359,10360,10361,10362,10285],{"trials":18497,"activeCount":101},[],{"trials":18499,"activeCount":101},[],{"intervention":10361,"totalTrials":272,"cells":18501},{"EARLY_PHASE1":18502,"PHASE1":18504,"PHASE2":18506,"PHASE3":18508,"PHASE4":18514,"NA":18516},{"trials":18503,"activeCount":101},[],{"trials":18505,"activeCount":101},[],{"trials":18507,"activeCount":101},[],{"trials":18509,"activeCount":101},[18510],{"nctId":10353,"briefTitle":10354,"status":107,"phases":18511,"primaryCompletion":2111,"start":8086,"enrollment":10356,"conditions":18512,"interventions":18513},[92],[10350,10332],[10359,10360,10361,10362,10285],{"trials":18515,"activeCount":101},[],{"trials":18517,"activeCount":101},[],{"intervention":10362,"totalTrials":272,"cells":18519},{"EARLY_PHASE1":18520,"PHASE1":18522,"PHASE2":18524,"PHASE3":18526,"PHASE4":18532,"NA":18534},{"trials":18521,"activeCount":101},[],{"trials":18523,"activeCount":101},[],{"trials":18525,"activeCount":101},[],{"trials":18527,"activeCount":101},[18528],{"nctId":10353,"briefTitle":10354,"status":107,"phases":18529,"primaryCompletion":2111,"start":8086,"enrollment":10356,"conditions":18530,"interventions":18531},[92],[10350,10332],[10359,10360,10361,10362,10285],{"trials":18533,"activeCount":101},[],{"trials":18535,"activeCount":101},[],{"intervention":5418,"totalTrials":272,"cells":18537},{"EARLY_PHASE1":18538,"PHASE1":18540,"PHASE2":18542,"PHASE3":18544,"PHASE4":18550,"NA":18552},{"trials":18539,"activeCount":101},[],{"trials":18541,"activeCount":101},[],{"trials":18543,"activeCount":101},[],{"trials":18545,"activeCount":101},[18546],{"nctId":5411,"briefTitle":5412,"status":107,"phases":18547,"primaryCompletion":533,"completion":5414,"start":5415,"enrollment":1264,"conditions":18548,"interventions":18549},[92],[1397],[78,5418],{"trials":18551,"activeCount":101},[],{"trials":18553,"activeCount":101},[],{"intervention":18555,"totalTrials":272,"cells":18556},"Berodual® Respimat®",{"EARLY_PHASE1":18557,"PHASE1":18559,"PHASE2":18561,"PHASE3":18563,"PHASE4":18572,"NA":18574},{"trials":18558,"activeCount":101},[],{"trials":18560,"activeCount":101},[],{"trials":18562,"activeCount":101},[],{"trials":18564,"activeCount":101},[18565],{"nctId":18566,"briefTitle":18567,"status":107,"phases":18568,"primaryCompletion":6871,"start":6189,"enrollment":9945,"conditions":18569,"interventions":18570},"NCT02173795","Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition",[92],[18,30],[18555,18571],"Berodual® MA HFA",{"trials":18573,"activeCount":101},[],{"trials":18575,"activeCount":101},[],{"intervention":18571,"totalTrials":272,"cells":18577},{"EARLY_PHASE1":18578,"PHASE1":18580,"PHASE2":18582,"PHASE3":18584,"PHASE4":18590,"NA":18592},{"trials":18579,"activeCount":101},[],{"trials":18581,"activeCount":101},[],{"trials":18583,"activeCount":101},[],{"trials":18585,"activeCount":101},[18586],{"nctId":18566,"briefTitle":18567,"status":107,"phases":18587,"primaryCompletion":6871,"start":6189,"enrollment":9945,"conditions":18588,"interventions":18589},[92],[18,30],[18555,18571],{"trials":18591,"activeCount":101},[],{"trials":18593,"activeCount":101},[],{"intervention":7076,"totalTrials":272,"cells":18595},{"EARLY_PHASE1":18596,"PHASE1":18598,"PHASE2":18600,"PHASE3":18602,"PHASE4":18608,"NA":18610},{"trials":18597,"activeCount":101},[],{"trials":18599,"activeCount":101},[],{"trials":18601,"activeCount":101},[],{"trials":18603,"activeCount":101},[18604],{"nctId":7070,"briefTitle":7071,"status":107,"phases":18605,"primaryCompletion":6401,"start":6189,"enrollment":7073,"conditions":18606,"interventions":18607},[92],[18],[7076,7059,7077],{"trials":18609,"activeCount":101},[],{"trials":18611,"activeCount":101},[],{"intervention":7077,"totalTrials":272,"cells":18613},{"EARLY_PHASE1":18614,"PHASE1":18616,"PHASE2":18618,"PHASE3":18620,"PHASE4":18626,"NA":18628},{"trials":18615,"activeCount":101},[],{"trials":18617,"activeCount":101},[],{"trials":18619,"activeCount":101},[],{"trials":18621,"activeCount":101},[18622],{"nctId":7070,"briefTitle":7071,"status":107,"phases":18623,"primaryCompletion":6401,"start":6189,"enrollment":7073,"conditions":18624,"interventions":18625},[92],[18],[7076,7059,7077],{"trials":18627,"activeCount":101},[],{"trials":18629,"activeCount":101},[],{"intervention":4436,"totalTrials":392,"cells":18631},{"EARLY_PHASE1":18632,"PHASE1":18634,"PHASE2":18748,"PHASE3":18789,"PHASE4":18791,"NA":18793},{"trials":18633,"activeCount":101},[],{"trials":18635,"activeCount":101},[18636,18644,18648,18657,18665,18674,18682,18689,18696,18706,18714,18723,18731,18739],{"nctId":18637,"briefTitle":18638,"status":107,"phases":18639,"primaryCompletion":18640,"completion":18640,"start":18641,"enrollment":1340,"conditions":18642,"interventions":18643},"NCT03505151","This Study in Healthy Men and Women Tests How the Body Takes up BI 409306",[90],"2018-05-19","2018-04-27",[15],[4436,4436],{"nctId":4428,"briefTitle":4429,"status":107,"phases":18645,"primaryCompletion":4431,"completion":4431,"start":4432,"enrollment":4433,"conditions":18646,"interventions":18647},[90],[15],[4436,1538],{"nctId":18649,"briefTitle":18650,"status":107,"phases":18651,"primaryCompletion":18652,"completion":18652,"start":18653,"enrollment":401,"conditions":18654,"interventions":18655},"NCT03193307","This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other",[90],"2017-12-01","2017-06-29",[15],[18656,4436],"Microgynon® 30",{"nctId":18658,"briefTitle":18659,"status":107,"phases":18660,"primaryCompletion":18661,"completion":18661,"start":18662,"enrollment":392,"conditions":18663,"interventions":18664},"NCT02222168","Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers",[90],"2014-10-31","2014-09-04",[15],[4436],{"nctId":18666,"briefTitle":18667,"status":107,"phases":18668,"primaryCompletion":18669,"completion":18670,"start":18671,"enrollment":1429,"conditions":18672,"interventions":18673},"NCT01343706","Safety Tolerability and Pharmacokinetic of BI 409306",[90],"2011-08-01","2011-08-05","2011-04-01",[15],[4436,4436],{"nctId":18675,"briefTitle":18676,"status":107,"phases":18677,"primaryCompletion":18678,"completion":4325,"start":5215,"enrollment":132,"conditions":18679,"interventions":18680},"NCT02635750","Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects",[90],"2016-03-16",[15],[4436,18681],"Donepezil",{"nctId":18683,"briefTitle":18684,"status":107,"phases":18685,"primaryCompletion":18686,"completion":18686,"start":240,"enrollment":956,"conditions":18687,"interventions":18688},"NCT03151499","Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers",[90],"2017-07-11",[15],[4436,460],{"nctId":18690,"briefTitle":18691,"status":107,"phases":18692,"primaryCompletion":18693,"completion":18693,"start":11534,"enrollment":2382,"conditions":18694,"interventions":18695},"NCT01611311","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306",[90],"2012-08-01",[15],[4436],{"nctId":18697,"briefTitle":18698,"status":107,"phases":18699,"primaryCompletion":18700,"completion":18701,"start":18702,"enrollment":2382,"conditions":18703,"interventions":18704},"NCT04602221","A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine",[90],"2022-08-01","2022-08-12","2020-12-01",[15],[18705,4436,4095],"Lamotrigine",{"nctId":18707,"briefTitle":18708,"status":107,"phases":18709,"primaryCompletion":18710,"completion":18710,"start":18711,"enrollment":2382,"conditions":18712,"interventions":18713},"NCT01892384","Safety and Tolerability of BI 409306 in Patients With Schizophrenia",[90],"2013-12-05","2013-06-28",[10549],[4436],{"nctId":18715,"briefTitle":18716,"status":107,"phases":18717,"primaryCompletion":18718,"completion":18719,"start":18720,"enrollment":439,"conditions":18721,"interventions":18722},"NCT02248259","Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers",[90],"2015-01-07","2015-01-08","2014-10-08",[15],[4436,949],{"nctId":18724,"briefTitle":18725,"status":107,"phases":18726,"primaryCompletion":18727,"completion":18727,"start":18728,"enrollment":1126,"conditions":18729,"interventions":18730},"NCT01505894","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses",[90],"2012-07-01","2012-01-01",[15],[4436],{"nctId":18732,"briefTitle":18733,"status":107,"phases":18734,"primaryCompletion":18735,"completion":18736,"start":6328,"enrollment":1672,"conditions":18737,"interventions":18738},"NCT01493570","Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers",[90],"2012-02-01","2012-02-21",[15],[4436],{"nctId":18740,"briefTitle":18741,"status":107,"phases":18742,"primaryCompletion":18743,"completion":18744,"start":18745,"enrollment":1672,"conditions":18746,"interventions":18747},"NCT02438683","BI 409306 Cardiac Safety Trial in Healthy Volunteers",[90],"2015-08-12","2015-08-13","2015-05-04",[15],[4436,4436],{"trials":18749,"activeCount":101},[18750,18760,18769,18779],{"nctId":18751,"briefTitle":18752,"status":162,"phases":18753,"primaryCompletion":18754,"completion":18755,"start":18756,"enrollment":18757,"conditions":18758,"interventions":18759},"NCT03351244","This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months",[91],"2021-03-10","2021-03-31","2017-12-07",264,[10549],[4436],{"nctId":18761,"briefTitle":18762,"status":107,"phases":18763,"primaryCompletion":18764,"completion":18765,"start":18766,"enrollment":6585,"conditions":18767,"interventions":18768},"NCT02240693","Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo",[91],"2017-09-18","2017-10-09","2015-01-15",[11139],[4436,4436,4436,4436],{"nctId":18770,"briefTitle":18771,"status":162,"phases":18772,"primaryCompletion":18773,"completion":18774,"start":18775,"enrollment":2235,"conditions":18776,"interventions":18778},"NCT03230097","This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year",[91],"2021-03-17","2021-04-07","2017-09-29",[18777],"Psychotic Disorders",[4436],{"nctId":18780,"briefTitle":18781,"status":107,"phases":18782,"primaryCompletion":18783,"completion":18784,"start":18785,"enrollment":18786,"conditions":18787,"interventions":18788},"NCT02337907","BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.",[91],"2017-09-15","2017-10-10","2015-01-21",329,[11139],[4436,18681],{"trials":18790,"activeCount":101},[],{"trials":18792,"activeCount":101},[],{"trials":18794,"activeCount":101},[],{"intervention":4095,"totalTrials":401,"cells":18796},{"EARLY_PHASE1":18797,"PHASE1":18799,"PHASE2":18906,"PHASE3":18917,"PHASE4":18919,"NA":18921},{"trials":18798,"activeCount":101},[],{"trials":18800,"activeCount":101},[18801,18810,18819,18823,18830,18836,18845,18852,18859,18866,18874,18878,18886,18890,18898],{"nctId":18802,"briefTitle":18803,"status":107,"phases":18804,"primaryCompletion":18805,"completion":18805,"start":18806,"enrollment":401,"conditions":18807,"interventions":18808},"NCT03988803","A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other",[90],"2019-10-30","2019-07-17",[15],[4095,18809],"Memantine",{"nctId":18811,"briefTitle":18812,"status":107,"phases":18813,"primaryCompletion":18814,"completion":18814,"start":18815,"enrollment":1512,"conditions":18816,"interventions":18817},"NCT03783000","A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet",[90],"2019-03-06","2019-01-15",[15],[4095,18818],"[C-14]-BI 425809",{"nctId":6852,"briefTitle":6853,"status":107,"phases":18820,"primaryCompletion":6855,"completion":6855,"start":6856,"enrollment":956,"conditions":18821,"interventions":18822},[90],[15],[4095,6859],{"nctId":18824,"briefTitle":18825,"status":107,"phases":18826,"primaryCompletion":18827,"completion":18827,"start":2770,"enrollment":177,"conditions":18828,"interventions":18829},"NCT05723874","A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood",[90],"2023-05-26",[15],[4095,1383],{"nctId":18831,"briefTitle":18832,"status":107,"phases":18833,"primaryCompletion":4120,"completion":4120,"start":603,"enrollment":401,"conditions":18834,"interventions":18835},"NCT02342717","Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects",[90],[15],[4095,949,4095],{"nctId":18837,"briefTitle":18838,"status":107,"phases":18839,"primaryCompletion":18840,"completion":18840,"start":18841,"enrollment":1126,"conditions":18842,"interventions":18843},"NCT02068690","Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809",[90],"2014-09-10","2014-03-20",[15],[18844,4095],"BI 425809 PfOS",{"nctId":18846,"briefTitle":18847,"status":107,"phases":18848,"primaryCompletion":2830,"completion":2830,"start":18849,"enrollment":448,"conditions":18850,"interventions":18851},"NCT05718843","A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems",[90],"2023-02-01",[2550],[4095],{"nctId":18853,"briefTitle":18854,"status":107,"phases":18855,"primaryCompletion":18856,"completion":18856,"start":18766,"enrollment":8,"conditions":18857,"interventions":18858},"NCT02337283","Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)",[90],"2015-11-16",[15],[4095],{"nctId":18860,"briefTitle":18861,"status":107,"phases":18862,"primaryCompletion":18863,"completion":18863,"start":1663,"enrollment":132,"conditions":18864,"interventions":18865},"NCT03905096","A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other",[90],"2019-08-30",[15],[4095,18681],{"nctId":18867,"briefTitle":18868,"status":107,"phases":18869,"primaryCompletion":18870,"completion":18870,"start":18871,"enrollment":439,"conditions":18872,"interventions":18873},"NCT02362516","Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809",[90],"2015-06-19","2015-02-23",[15],[4095],{"nctId":4087,"briefTitle":4088,"status":107,"phases":18875,"primaryCompletion":4090,"completion":4090,"start":4091,"enrollment":912,"conditions":18876,"interventions":18877},[90],[15],[1242,4094,4013,2393,4095],{"nctId":18879,"briefTitle":18880,"status":107,"phases":18881,"primaryCompletion":18882,"completion":18882,"start":18883,"enrollment":401,"conditions":18884,"interventions":18885},"NCT05347004","A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food",[90],"2022-12-28","2022-10-25",[15],[4095],{"nctId":18697,"briefTitle":18698,"status":107,"phases":18887,"primaryCompletion":18700,"completion":18701,"start":18702,"enrollment":2382,"conditions":18888,"interventions":18889},[90],[15],[18705,4436,4095],{"nctId":18891,"briefTitle":18892,"status":107,"phases":18893,"primaryCompletion":18894,"completion":18894,"start":18895,"enrollment":2123,"conditions":18896,"interventions":18897},"NCT02383888","Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects",[90],"2015-08-06","2015-05-11",[15],[4095],{"nctId":18899,"briefTitle":18900,"status":107,"phases":18901,"primaryCompletion":18902,"completion":18902,"start":18903,"enrollment":401,"conditions":18904,"interventions":18905},"NCT03082183","A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood",[90],"2017-06-20","2017-03-28",[15],[460,4095],{"trials":18907,"activeCount":101},[18908],{"nctId":18909,"briefTitle":18910,"status":107,"phases":18911,"primaryCompletion":18912,"completion":18913,"start":18914,"enrollment":10417,"conditions":18915,"interventions":18916},"NCT03859973","This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia",[91],"2022-09-30","2022-11-04","2019-04-15",[10549],[4095],{"trials":18918,"activeCount":101},[],{"trials":18920,"activeCount":101},[],{"trials":18922,"activeCount":101},[],{"intervention":4176,"totalTrials":956,"cells":18924},{"EARLY_PHASE1":18925,"PHASE1":18927,"PHASE2":19014,"PHASE3":19052,"PHASE4":19054,"NA":19056},{"trials":18926,"activeCount":101},[],{"trials":18928,"activeCount":101},[18929,18936,18944,18952,18961,18967,18975,18983,18992,18999,19010],{"nctId":18930,"briefTitle":18931,"status":107,"phases":18932,"primaryCompletion":18933,"completion":18933,"start":3617,"enrollment":401,"conditions":18934,"interventions":18935},"NCT03843151","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood",[90],"2019-06-03",[15],[4176,949],{"nctId":18937,"briefTitle":18938,"status":107,"phases":18939,"primaryCompletion":18940,"completion":18940,"start":4351,"enrollment":956,"conditions":18941,"interventions":18942},"NCT04567316","A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body",[90],"2021-01-10",[15],[18943,4176],"[14C]-radiolabelled BI 1358894",{"nctId":18945,"briefTitle":18946,"status":107,"phases":18947,"primaryCompletion":18948,"completion":18948,"start":18949,"enrollment":1672,"conditions":18950,"interventions":18951},"NCT03904576","A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms",[90],"2019-08-29","2019-04-18",[15],[4176],{"nctId":18953,"briefTitle":18954,"status":107,"phases":18955,"primaryCompletion":18956,"completion":18956,"start":18957,"enrollment":392,"conditions":18958,"interventions":18959},"NCT04899674","A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood",[90],"2021-09-02","2021-06-30",[15],[18960,4176],"Elontril",{"nctId":18962,"briefTitle":18963,"status":107,"phases":18964,"primaryCompletion":1864,"completion":1864,"start":697,"enrollment":1982,"conditions":18965,"interventions":18966},"NCT04099732","A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood",[90],[15],[969,4176],{"nctId":18968,"briefTitle":18969,"status":107,"phases":18970,"primaryCompletion":18971,"completion":18971,"start":18972,"enrollment":1126,"conditions":18973,"interventions":18974},"NCT03210272","This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood",[90],"2019-02-18","2017-07-18",[15],[4176,4176,4176],{"nctId":18976,"briefTitle":18977,"status":162,"phases":18978,"primaryCompletion":18979,"completion":18979,"start":1713,"enrollment":993,"conditions":18980,"interventions":18981},"NCT05934942","A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood",[90],"2024-02-08",[15],[18982,4176],"Yasmin®",{"nctId":18984,"briefTitle":18985,"status":107,"phases":18986,"primaryCompletion":18987,"completion":18987,"start":18988,"enrollment":188,"conditions":18989,"interventions":18990},"NCT04426851","A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood",[90],"2020-10-12","2020-07-13",[15],[4176,18991,4176],"BI 1358894 (C-14) intravenous solution",{"nctId":18993,"briefTitle":18994,"status":107,"phases":18995,"primaryCompletion":18996,"completion":18996,"start":5965,"enrollment":380,"conditions":18997,"interventions":18998},"NCT03892616","A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood",[90],"2019-07-03",[15],[4176,4176,4176,4176,4176],{"nctId":19000,"briefTitle":19001,"status":107,"phases":19002,"primaryCompletion":19003,"completion":19004,"start":19005,"enrollment":19006,"conditions":19007,"interventions":19008},"NCT03854578","A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions",[90],"2019-08-27","2019-09-23","2019-03-12",73,[7303],[4176,19009],"Citalopram",{"nctId":4169,"briefTitle":4170,"status":107,"phases":19011,"primaryCompletion":4172,"completion":4172,"start":4173,"enrollment":2235,"conditions":19012,"interventions":19013},[90],[15],[4176,1242],{"trials":19015,"activeCount":101},[19016,19025,19033,19043],{"nctId":19017,"briefTitle":19018,"status":107,"phases":19019,"primaryCompletion":19020,"completion":1330,"start":19021,"enrollment":10703,"conditions":19022,"interventions":19024},"NCT05103657","A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder",[91],"2023-10-12","2021-12-07",[19023],"Post-Traumatic Stress Disorder",[4176],{"nctId":19026,"briefTitle":19027,"status":107,"phases":19028,"primaryCompletion":19029,"completion":5342,"start":19030,"enrollment":1155,"conditions":19031,"interventions":19032},"NCT04566601","A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder",[91],"2022-12-09","2020-11-13",[3925],[4176],{"nctId":19034,"briefTitle":19035,"status":107,"phases":19036,"primaryCompletion":19037,"completion":19038,"start":19039,"enrollment":6311,"conditions":19040,"interventions":19041},"NCT04521478","A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression",[91],"2024-01-10","2024-02-02","2020-11-20",[7303],[4176,19042],"Quetiapine",{"nctId":19044,"briefTitle":19045,"status":162,"phases":19046,"primaryCompletion":19047,"completion":19048,"start":19049,"enrollment":1535,"conditions":19050,"interventions":19051},"NCT04423757","A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression",[91],"2022-04-19","2022-05-08","2020-06-22",[7303],[4176],{"trials":19053,"activeCount":101},[],{"trials":19055,"activeCount":101},[],{"trials":19057,"activeCount":101},[],{"intervention":19059,"totalTrials":188,"cells":19060},"BI 1744 CL",{"EARLY_PHASE1":19061,"PHASE1":19063,"PHASE2":19130,"PHASE3":19145,"PHASE4":19147,"NA":19149},{"trials":19062,"activeCount":101},[],{"trials":19064,"activeCount":101},[19065,19073,19079,19085,19092,19098,19104,19110,19117,19123],{"nctId":19066,"briefTitle":19067,"status":107,"phases":19068,"primaryCompletion":5905,"start":2003,"enrollment":132,"conditions":19069,"interventions":19070},"NCT02220660","Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers",[90],[15],[19059,19071,19072],"BI 54903 XX","BI 1744 CL + BI 54903 XX FDC",{"nctId":19074,"briefTitle":19075,"status":162,"phases":19076,"primaryCompletion":9902,"start":1990,"enrollment":1208,"conditions":19077,"interventions":19078},"NCT02172131","Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects",[90],[15],[19059],{"nctId":19080,"briefTitle":19081,"status":107,"phases":19082,"primaryCompletion":8911,"start":4517,"enrollment":380,"conditions":19083,"interventions":19084},"NCT02171793","Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers",[90],[15],[19059],{"nctId":19086,"briefTitle":19087,"status":107,"phases":19088,"primaryCompletion":3991,"start":9404,"enrollment":448,"conditions":19089,"interventions":19090},"NCT02222428","Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers",[90],[15],[19091,19071,19059],"BI 1744 CL\u002FBI 54903 XX FDC",{"nctId":19093,"briefTitle":19094,"status":107,"phases":19095,"primaryCompletion":2145,"start":6156,"enrollment":410,"conditions":19096,"interventions":19097},"NCT02259946","Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers",[90],[15],[19059,5978],{"nctId":19099,"briefTitle":19100,"status":107,"phases":19101,"primaryCompletion":6911,"start":4005,"enrollment":4433,"conditions":19102,"interventions":19103},"NCT02171806","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers",[90],[15],[19059],{"nctId":19105,"briefTitle":19106,"status":107,"phases":19107,"primaryCompletion":11642,"start":17247,"enrollment":25,"conditions":19108,"interventions":19109},"NCT02171780","A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers",[90],[15],[19059],{"nctId":19111,"briefTitle":19112,"status":107,"phases":19113,"primaryCompletion":6471,"start":4129,"enrollment":281,"conditions":19114,"interventions":19115},"NCT02172157","Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects",[90],[15],[19116,19059],"BI 1744 CL i.v.",{"nctId":19118,"briefTitle":19119,"status":107,"phases":19120,"primaryCompletion":5906,"start":4507,"enrollment":448,"conditions":19121,"interventions":19122},"NCT02172105","Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers",[90],[15],[19059],{"nctId":19124,"briefTitle":19125,"status":107,"phases":19126,"primaryCompletion":10775,"start":4413,"enrollment":4433,"conditions":19127,"interventions":19128},"NCT02231177","Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)",[90],[18],[19059,19129,5860],"BI 1744 CL\u002FTiotropium FDC",{"trials":19131,"activeCount":101},[19132,19139],{"nctId":19133,"briefTitle":19134,"status":107,"phases":19135,"primaryCompletion":4412,"start":1114,"enrollment":19136,"conditions":19137,"interventions":19138},"NCT00467740","Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma",[91],296,[30],[19059],{"nctId":19140,"briefTitle":19141,"status":107,"phases":19142,"primaryCompletion":3991,"start":1989,"enrollment":4433,"conditions":19143,"interventions":19144},"NCT00846768","BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD",[91],[18],[19059],{"trials":19146,"activeCount":101},[],{"trials":19148,"activeCount":101},[],{"trials":19150,"activeCount":101},[],{"intervention":4109,"totalTrials":281,"cells":19152},{"EARLY_PHASE1":19153,"PHASE1":19155,"PHASE2":19232,"PHASE3":19253,"PHASE4":19255,"NA":19257},{"trials":19154,"activeCount":101},[],{"trials":19156,"activeCount":101},[19157,19165,19173,19181,19189,19200,19204,19213,19221],{"nctId":19158,"briefTitle":19159,"status":107,"phases":19160,"primaryCompletion":19161,"completion":19161,"start":19162,"enrollment":177,"conditions":19163,"interventions":19164},"NCT03782987","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 730357 in the Blood",[90],"2019-03-11","2019-01-10",[15],[4109,949],{"nctId":19166,"briefTitle":19167,"status":107,"phases":19168,"primaryCompletion":19169,"completion":19169,"start":19170,"enrollment":380,"conditions":19171,"interventions":19172},"NCT03793621","This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated",[90],"2019-04-26","2019-01-21",[15],[4109],{"nctId":19174,"briefTitle":19175,"status":107,"phases":19176,"primaryCompletion":19177,"completion":19177,"start":19178,"enrollment":6117,"conditions":19179,"interventions":19180},"NCT03004404","To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers",[90],"2017-08-15","2017-01-12",[10409],[4109,4109],{"nctId":19182,"briefTitle":19183,"status":107,"phases":19184,"primaryCompletion":19185,"completion":19185,"start":19186,"enrollment":2789,"conditions":19187,"interventions":19188},"NCT03886272","A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood",[90],"2019-06-21","2019-04-11",[15],[4109,4109],{"nctId":19190,"briefTitle":19191,"status":107,"phases":19192,"primaryCompletion":784,"completion":784,"start":19193,"enrollment":956,"conditions":19194,"interventions":19195},"NCT04590937","A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body",[90],"2020-10-20",[15],[4109,19196,19197,19198,19199],"CRESTOR®","Lenoxin®","MetfoLiquid GeriaSan®","Lasix®",{"nctId":4101,"briefTitle":4102,"status":107,"phases":19201,"primaryCompletion":4104,"completion":4105,"start":4106,"enrollment":1126,"conditions":19202,"interventions":19203},[90],[15,114],[4109,1242],{"nctId":19205,"briefTitle":19206,"status":107,"phases":19207,"primaryCompletion":19208,"completion":19208,"start":19209,"enrollment":1468,"conditions":19210,"interventions":19211},"NCT04147260","Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin",[90],"2020-09-09","2019-11-06",[15],[4109,19212],"Ciprofloxacin",{"nctId":19214,"briefTitle":19215,"status":107,"phases":19216,"primaryCompletion":19217,"completion":19217,"start":230,"enrollment":1512,"conditions":19218,"interventions":19219},"NCT03804671","A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet",[90],"2019-03-26",[15],[4109,19220],"BI 730357 mixed with [C-14] BI 730357 BS",{"nctId":19222,"briefTitle":19223,"status":107,"phases":19224,"primaryCompletion":18773,"completion":18773,"start":19225,"enrollment":401,"conditions":19226,"interventions":19227},"NCT04679948","A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood",[90],"2020-12-21",[15],[19228,19229,19230,19231,4109],"Percoffedrinol®","Coumadin®","Antra MUPS®","Midazolam-ratiopharm®",{"trials":19233,"activeCount":101},[19234,19244],{"nctId":19235,"briefTitle":19236,"status":600,"phases":19237,"primaryCompletion":19238,"completion":19239,"start":19240,"enrollment":101,"conditions":19241,"interventions":19243},"NCT04680676","A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis",[91],"2023-06-26","2023-09-25","2022-05-02",[19242],"Arthritis, Psoriatic",[4109],{"nctId":19245,"briefTitle":19246,"status":162,"phases":19247,"primaryCompletion":2089,"completion":19248,"start":19249,"enrollment":19250,"conditions":19251,"interventions":19252},"NCT03835481","A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is",[91],"2021-07-27","2019-03-18",165,[114],[4109],{"trials":19254,"activeCount":101},[],{"trials":19256,"activeCount":101},[],{"trials":19258,"activeCount":101},[],{"intervention":19260,"totalTrials":1081,"cells":19261},"BI 1467335",{"EARLY_PHASE1":19262,"PHASE1":19264,"PHASE2":19333,"PHASE3":19353,"PHASE4":19355,"NA":19357},{"trials":19263,"activeCount":101},[],{"trials":19265,"activeCount":101},[19266,19273,19281,19290,19299,19307,19316,19325],{"nctId":19267,"briefTitle":19268,"status":107,"phases":19269,"primaryCompletion":19270,"completion":19270,"start":209,"enrollment":410,"conditions":19271,"interventions":19272},"NCT03159455","This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated",[90],"2017-12-16",[15],[19260],{"nctId":19274,"briefTitle":19275,"status":107,"phases":19276,"primaryCompletion":19277,"completion":19277,"start":19278,"enrollment":448,"conditions":19279,"interventions":19280},"NCT02733627","To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days",[90],"2017-07-12","2016-07-07",[15],[19260],{"nctId":19282,"briefTitle":19283,"status":162,"phases":19284,"primaryCompletion":19285,"completion":19285,"start":198,"enrollment":231,"conditions":19286,"interventions":19287},"NCT03979820","A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure",[90],"2020-04-08",[15],[19260,19288,19289],"Phenelzine sulfate","Tyramine",{"nctId":19291,"briefTitle":19292,"status":107,"phases":19293,"primaryCompletion":19294,"completion":19294,"start":19295,"enrollment":188,"conditions":19296,"interventions":19297},"NCT03483506","This Study in Healthy Men Tests How the Body Takes up BI 1467335",[90],"2018-06-27","2018-04-10",[15],[19260,19298],"BI 1467335 (C-14) intravenous solution",{"nctId":19300,"briefTitle":19301,"status":107,"phases":19302,"primaryCompletion":19303,"completion":19303,"start":19304,"enrollment":1081,"conditions":19305,"interventions":19306},"NCT03927209","A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.",[90],"2019-11-22","2019-06-06",[15],[19260],{"nctId":19308,"briefTitle":19309,"status":107,"phases":19310,"primaryCompletion":19311,"completion":19311,"start":19312,"enrollment":401,"conditions":19313,"interventions":19314},"NCT03382509","This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body",[90],"2018-04-19","2018-01-12",[15],[19315,19260],"[14C]BI 1467335",{"nctId":19317,"briefTitle":19318,"status":107,"phases":19319,"primaryCompletion":19320,"completion":19321,"start":19322,"enrollment":392,"conditions":19323,"interventions":19324},"NCT02999191","Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects",[90],"2017-03-15","2017-04-10","2017-01-10",[10409],[19260,19260,19260],{"nctId":19326,"briefTitle":19327,"status":107,"phases":19328,"primaryCompletion":19329,"completion":19329,"start":19330,"enrollment":1672,"conditions":19331,"interventions":19332},"NCT03302091","A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body",[90],"2018-08-16","2017-10-17",[2550,15],[19260],{"trials":19334,"activeCount":101},[19335,19343],{"nctId":19336,"briefTitle":19337,"status":107,"phases":19338,"primaryCompletion":19339,"completion":19339,"start":19340,"enrollment":269,"conditions":19341,"interventions":19342},"NCT03238963","A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.",[91],"2020-05-14","2017-09-19",[2925],[19260],{"nctId":19344,"briefTitle":19345,"status":107,"phases":19346,"primaryCompletion":19347,"completion":19347,"start":19348,"enrollment":19349,"conditions":19350,"interventions":19352},"NCT03166735","Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH",[91],"2019-06-14","2017-06-06",114,[19351],"Non-alcoholic Fatty Liver Disease",[19260],{"trials":19354,"activeCount":101},[],{"trials":19356,"activeCount":101},[],{"trials":19358,"activeCount":101},[],{"intervention":19360,"totalTrials":1340,"cells":19361},"BI 1026706",{"EARLY_PHASE1":19362,"PHASE1":19364,"PHASE2":19435,"PHASE3":19445,"PHASE4":19447,"NA":19449},{"trials":19363,"activeCount":101},[],{"trials":19365,"activeCount":101},[19366,19375,19384,19391,19401,19410,19419,19427],{"nctId":19367,"briefTitle":19368,"status":107,"phases":19369,"primaryCompletion":19370,"completion":19371,"start":19372,"enrollment":401,"conditions":19373,"interventions":19374},"NCT02513446","Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects",[90],"2015-11-14","2015-11-20","2015-09-29",[15],[19360,949],{"nctId":19376,"briefTitle":19377,"status":107,"phases":19378,"primaryCompletion":19379,"completion":19380,"start":19381,"enrollment":3551,"conditions":19382,"interventions":19383},"NCT02126826","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee",[90],"2014-10-01","2014-10-21","2014-05-28",[6609],[19360],{"nctId":19385,"briefTitle":19386,"status":107,"phases":19387,"primaryCompletion":419,"completion":419,"start":9824,"enrollment":1429,"conditions":19388,"interventions":19389},"NCT02084511","Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain",[90],[10445],[19360,19390],"Celecoxib",{"nctId":19392,"briefTitle":19393,"status":107,"phases":19394,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":439,"conditions":19398,"interventions":19399},"NCT02037165","Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2\u002FP2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers",[90],"2014-04-09","2014-04-15","2014-01-21",[15],[19400,19360,19390],"Pregabalin",{"nctId":19402,"briefTitle":19403,"status":107,"phases":19404,"primaryCompletion":19405,"completion":19405,"start":19406,"enrollment":1429,"conditions":19407,"interventions":19408},"NCT01763333","To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706",[90],"2013-09-04","2013-01-08",[15],[19409,19360],"BI 1026706 Placebo",{"nctId":19411,"briefTitle":19412,"status":107,"phases":19413,"primaryCompletion":19414,"completion":19415,"start":19416,"enrollment":34,"conditions":19417,"interventions":19418},"NCT02657408","Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo",[90],"2017-02-14","2017-03-13","2016-03-11",[15],[19360],{"nctId":19420,"briefTitle":19421,"status":107,"phases":19422,"primaryCompletion":19423,"completion":19423,"start":19424,"enrollment":716,"conditions":19425,"interventions":19426},"NCT02652416","Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers",[90],"2016-12-09","2016-09-16",[15],[19360],{"nctId":19428,"briefTitle":19429,"status":107,"phases":19430,"primaryCompletion":19431,"completion":19431,"start":19432,"enrollment":641,"conditions":19433,"interventions":19434},"NCT02642614","Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD",[90],"2016-06-14","2016-01-25",[18],[19360],{"trials":19436,"activeCount":101},[19437],{"nctId":19438,"briefTitle":19439,"status":107,"phases":19440,"primaryCompletion":619,"completion":19441,"start":19442,"enrollment":3389,"conditions":19443,"interventions":19444},"NCT02732951","Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema",[91],"2017-10-24","2016-04-14",[2860],[19360],{"trials":19446,"activeCount":101},[],{"trials":19448,"activeCount":101},[],{"trials":19450,"activeCount":101},[],{"intervention":1994,"totalTrials":155,"cells":19452},{"EARLY_PHASE1":19453,"PHASE1":19455,"PHASE2":19475,"PHASE3":19515,"PHASE4":19517,"NA":19519},{"trials":19454,"activeCount":101},[],{"trials":19456,"activeCount":101},[19457,19464,19471],{"nctId":19458,"briefTitle":19459,"status":107,"phases":19460,"primaryCompletion":19461,"start":8479,"enrollment":2507,"conditions":19462,"interventions":19463},"NCT02211859","Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit",[90],"2007-12",[33],[1994],{"nctId":19465,"briefTitle":19466,"status":107,"phases":19467,"primaryCompletion":6223,"start":11642,"enrollment":1991,"conditions":19468,"interventions":19470},"NCT00243087","Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)",[90],[19469],"Lymphoma",[1994],{"nctId":1986,"briefTitle":1987,"status":107,"phases":19472,"primaryCompletion":1989,"start":1990,"enrollment":1991,"conditions":19473,"interventions":19474},[90],[36],[1994,1011],{"trials":19476,"activeCount":101},[19477,19486,19495,19503,19509],{"nctId":19478,"briefTitle":19479,"status":107,"phases":19480,"primaryCompletion":19481,"completion":19481,"start":19482,"enrollment":97,"conditions":19483,"interventions":19485},"NCT00412880","BI 2536 Second Line Monotherapy in SCLC",[91],"2008-06-30","2007-02-14",[19484],"Carcinoma, Small Cell",[1994],{"nctId":19487,"briefTitle":19488,"status":107,"phases":19489,"primaryCompletion":19490,"completion":19490,"start":19491,"enrollment":19492,"conditions":19493,"interventions":19494},"NCT00710710","Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer",[91],"2008-10-14","2006-08-01",89,[2691],[1994],{"nctId":19496,"briefTitle":19497,"status":107,"phases":19498,"primaryCompletion":19499,"completion":19499,"start":19500,"enrollment":8,"conditions":19501,"interventions":19502},"NCT00376623","Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer",[91],"2008-04-01","2006-07-25",[36],[1994],{"nctId":19504,"briefTitle":19505,"status":107,"phases":19506,"primaryCompletion":9443,"start":1990,"enrollment":2898,"conditions":19507,"interventions":19508},"NCT00701766","BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia",[91],[10147],[1994],{"nctId":19510,"briefTitle":19511,"status":107,"phases":19512,"primaryCompletion":4129,"start":6911,"enrollment":1672,"conditions":19513,"interventions":19514},"NCT00706498","Phase II Study of BI 2536 in Prostate Cancer",[91],[9651],[1994],{"trials":19516,"activeCount":101},[],{"trials":19518,"activeCount":101},[],{"trials":19520,"activeCount":101},[],{"intervention":2007,"totalTrials":112,"cells":19522},{"EARLY_PHASE1":19523,"PHASE1":19525,"PHASE2":19558,"PHASE3":19568,"PHASE4":19570,"NA":19572},{"trials":19524,"activeCount":101},[],{"trials":19526,"activeCount":101},[19527,19533,19541,19545,19552],{"nctId":19528,"briefTitle":19529,"status":107,"phases":19530,"primaryCompletion":4441,"completion":4441,"start":3754,"enrollment":112,"conditions":19531,"interventions":19532},"NCT01145885","BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours",[90],[33],[2007],{"nctId":19534,"briefTitle":19535,"status":107,"phases":19536,"primaryCompletion":19537,"completion":13218,"start":19538,"enrollment":7524,"conditions":19539,"interventions":19540},"NCT02273388","BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours",[90],"2009-01-19","2005-11-04",[33],[2007],{"nctId":9611,"briefTitle":9612,"status":107,"phases":19542,"primaryCompletion":9614,"completion":9614,"start":9381,"enrollment":357,"conditions":19543,"interventions":19544},[90],[33],[2007,1119],{"nctId":19546,"briefTitle":19547,"status":107,"phases":19548,"primaryCompletion":390,"completion":9538,"start":3990,"enrollment":9606,"conditions":19549,"interventions":19550},"NCT00969761","BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour",[90],[33],[19551,2007],"BI-6727",{"nctId":19553,"briefTitle":19554,"status":107,"phases":19555,"primaryCompletion":5296,"completion":5296,"start":3990,"enrollment":241,"conditions":19556,"interventions":19557},"NCT00969553","Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers",[90],[33],[2007],{"trials":19559,"activeCount":101},[19560,19564],{"nctId":1998,"briefTitle":1999,"status":107,"phases":19561,"primaryCompletion":2001,"completion":2002,"start":2003,"enrollment":2004,"conditions":19562,"interventions":19563},[91],[36],[1074,1074,2007],{"nctId":4388,"briefTitle":4389,"status":107,"phases":19565,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":4219,"conditions":19566,"interventions":19567},[91],[1187],[1120,2730,3662,4395,2007],{"trials":19569,"activeCount":101},[],{"trials":19571,"activeCount":101},[],{"trials":19573,"activeCount":101},[],{"intervention":11653,"totalTrials":112,"cells":19575},{"EARLY_PHASE1":19576,"PHASE1":19578,"PHASE2":19620,"PHASE3":19628,"PHASE4":19630,"NA":19632},{"trials":19577,"activeCount":101},[],{"trials":19579,"activeCount":101},[19580,19587,19594,19601,19609,19613],{"nctId":19581,"briefTitle":19582,"status":107,"phases":19583,"primaryCompletion":6081,"start":5887,"enrollment":1631,"conditions":19584,"interventions":19585},"NCT02254538","A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers",[90],[15],[11653,19586],"PEG 400",{"nctId":19588,"briefTitle":19589,"status":107,"phases":19590,"primaryCompletion":7300,"start":7618,"enrollment":5205,"conditions":19591,"interventions":19592},"NCT02256774","Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects",[90],[15],[11653,19593,4010],"Combivir®",{"nctId":19595,"briefTitle":19596,"status":107,"phases":19597,"primaryCompletion":1115,"start":11581,"enrollment":1237,"conditions":19598,"interventions":19599},"NCT02256826","Study of Pharmacokinetic Interaction Between Kaletra® (LPV\u002Fr) and BILR 355 BS Plus Ritonavir in Healthy Subjects",[90],[15],[11653,4010,19600],"Kaletra®",{"nctId":19602,"briefTitle":19603,"status":107,"phases":19604,"primaryCompletion":7300,"start":17247,"enrollment":1237,"conditions":19605,"interventions":19606},"NCT02257021","Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers",[90],[15],[11653,4008,19607,19608],"Low dose of ritonavir","High dose of ritonavir",{"nctId":11646,"briefTitle":11647,"status":107,"phases":19610,"primaryCompletion":11649,"start":11650,"enrollment":1891,"conditions":19611,"interventions":19612},[90],[15],[11653,11654,11632,4010],{"nctId":19614,"briefTitle":19615,"status":107,"phases":19616,"primaryCompletion":7300,"start":15139,"enrollment":1116,"conditions":19617,"interventions":19618},"NCT02253901","Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers",[90],[15],[11653,4010,19619],"TRUVADA",{"trials":19621,"activeCount":101},[19622],{"nctId":19623,"briefTitle":19624,"status":162,"phases":19625,"primaryCompletion":6140,"start":7151,"enrollment":448,"conditions":19626,"interventions":19627},"NCT00294372","Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients",[91],[27],[11653],{"trials":19629,"activeCount":101},[],{"trials":19631,"activeCount":101},[],{"trials":19633,"activeCount":101},[],{"intervention":4149,"totalTrials":112,"cells":19635},{"EARLY_PHASE1":19636,"PHASE1":19638,"PHASE2":19683,"PHASE3":19693,"PHASE4":19695,"NA":19697},{"trials":19637,"activeCount":101},[],{"trials":19639,"activeCount":101},[19640,19648,19656,19663,19667,19675],{"nctId":19641,"briefTitle":19642,"status":107,"phases":19643,"primaryCompletion":19644,"completion":19644,"start":19645,"enrollment":37,"conditions":19646,"interventions":19647},"NCT04958252","A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated",[90],"2023-10-30","2021-08-05",[15],[4149],{"nctId":19649,"briefTitle":19650,"status":107,"phases":19651,"primaryCompletion":19652,"completion":19652,"start":19653,"enrollment":241,"conditions":19654,"interventions":19655},"NCT04937829","A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication",[90],"2023-11-16","2021-07-20",[7303],[4149],{"nctId":19657,"briefTitle":19658,"status":107,"phases":19659,"primaryCompletion":963,"completion":963,"start":19660,"enrollment":155,"conditions":19661,"interventions":19662},"NCT06520553","A Study in Healthy Men to Test How BI 1569912 is Processed in the Body",[90],"2024-08-26",[15],[4149,4149],{"nctId":4144,"briefTitle":4145,"status":107,"phases":19664,"primaryCompletion":965,"completion":965,"start":2922,"enrollment":392,"conditions":19665,"interventions":19666},[90],[15],[4149,4150,1242,1240],{"nctId":19668,"briefTitle":19669,"status":162,"phases":19670,"primaryCompletion":19671,"completion":19671,"start":19672,"enrollment":2400,"conditions":19673,"interventions":19674},"NCT04445090","A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood",[90],"2021-09-10","2020-07-21",[15],[4149],{"nctId":19676,"briefTitle":19677,"status":107,"phases":19678,"primaryCompletion":19679,"completion":19679,"start":19680,"enrollment":1126,"conditions":19681,"interventions":19682},"NCT04978506","A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated",[90],"2024-07-04","2021-09-03",[15],[4149],{"trials":19684,"activeCount":101},[19685],{"nctId":19686,"briefTitle":19687,"status":107,"phases":19688,"primaryCompletion":10544,"completion":4550,"start":19689,"enrollment":19690,"conditions":19691,"interventions":19692},"NCT06280235","A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine",[91],"2024-03-27",243,[7303],[4149],{"trials":19694,"activeCount":101},[],{"trials":19696,"activeCount":101},[],{"trials":19698,"activeCount":101},[],{"intervention":19700,"totalTrials":112,"cells":19701},"BEA 2180 BR",{"EARLY_PHASE1":19702,"PHASE1":19704,"PHASE2":19726,"PHASE3":19756,"PHASE4":19758,"NA":19760},{"trials":19703,"activeCount":101},[],{"trials":19705,"activeCount":101},[19706,19712,19720],{"nctId":19707,"briefTitle":19708,"status":107,"phases":19709,"primaryCompletion":17247,"start":6445,"enrollment":241,"conditions":19710,"interventions":19711},"NCT02254122","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers",[90],[15],[19700],{"nctId":19713,"briefTitle":19714,"status":107,"phases":19715,"primaryCompletion":6235,"start":6472,"enrollment":3436,"conditions":19716,"interventions":19717},"NCT02263976","Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects",[90],[15],[19700,19718,19719],"Methacholine Chloride","Spiriva",{"nctId":19721,"briefTitle":19722,"status":107,"phases":19723,"primaryCompletion":1114,"start":6116,"enrollment":177,"conditions":19724,"interventions":19725},"NCT02258971","Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers",[90],[15],[19700,19700],{"trials":19727,"activeCount":101},[19728,19734,19740,19750],{"nctId":19729,"briefTitle":19730,"status":107,"phases":19731,"primaryCompletion":6911,"start":3978,"enrollment":11163,"conditions":19732,"interventions":19733},"NCT00128440","High Dose Trial in COPD",[91],[18],[19700,5899],{"nctId":19735,"briefTitle":19736,"status":107,"phases":19737,"primaryCompletion":6413,"start":6235,"enrollment":3398,"conditions":19738,"interventions":19739},"NCT02242279","Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients",[91],[18],[19700,5860],{"nctId":19741,"briefTitle":19742,"status":107,"phases":19743,"primaryCompletion":19744,"completion":19744,"start":19745,"enrollment":19746,"conditions":19747,"interventions":19748},"NCT00528996","An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.",[91],"2009-05-05","2007-09-06",2080,[18],[19700,19749],"Tiotropium Bromide",{"nctId":19751,"briefTitle":19752,"status":107,"phases":19753,"primaryCompletion":4498,"start":11642,"enrollment":6311,"conditions":19754,"interventions":19755},"NCT00122434","Dose Finding Study in COPD",[91],[18],[19700,5899],{"trials":19757,"activeCount":101},[],{"trials":19759,"activeCount":101},[],{"trials":19761,"activeCount":101},[],{"intervention":3994,"totalTrials":112,"cells":19763},{"EARLY_PHASE1":19764,"PHASE1":19766,"PHASE2":19805,"PHASE3":19811,"PHASE4":19813,"NA":19815},{"trials":19765,"activeCount":101},[],{"trials":19767,"activeCount":101},[19768,19774,19778,19784,19790,19798],{"nctId":19769,"briefTitle":19770,"status":107,"phases":19771,"primaryCompletion":2030,"start":9348,"enrollment":123,"conditions":19772,"interventions":19773},"NCT01347086","Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers",[90],[15],[3994,3994,3994],{"nctId":3987,"briefTitle":3988,"status":162,"phases":19775,"primaryCompletion":3990,"start":3991,"enrollment":3398,"conditions":19776,"interventions":19777},[90],[15],[3994,3995,1242,3996],{"nctId":19779,"briefTitle":19780,"status":107,"phases":19781,"primaryCompletion":9381,"start":19461,"enrollment":3939,"conditions":19782,"interventions":19783},"NCT02176525","Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients",[90],[4040],[3994],{"nctId":19785,"briefTitle":19786,"status":107,"phases":19787,"primaryCompletion":456,"completion":456,"start":2506,"enrollment":188,"conditions":19788,"interventions":19789},"NCT01605461","Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers",[90],[15],[3994],{"nctId":19791,"briefTitle":19792,"status":107,"phases":19793,"primaryCompletion":400,"start":9411,"enrollment":331,"conditions":19794,"interventions":19795},"NCT02182414","Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers",[90],[15],[3994,3994,19796,19797,19797,19797],"BI 207127 NA delayed release","BI 207127 NA extended release",{"nctId":19799,"briefTitle":19800,"status":107,"phases":19801,"primaryCompletion":1114,"start":7573,"enrollment":4273,"conditions":19802,"interventions":19803},"NCT02182388","Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects",[90],[15],[19804,3994],"BI 207127 NA powder for solution",{"trials":19806,"activeCount":101},[19807],{"nctId":10088,"briefTitle":10089,"status":107,"phases":19808,"primaryCompletion":9515,"completion":9515,"start":9538,"enrollment":439,"conditions":19809,"interventions":19810},[91],[4040],[3994,10093,9801,9801,3994,3995,3995,10093],{"trials":19812,"activeCount":101},[],{"trials":19814,"activeCount":101},[],{"trials":19816,"activeCount":101},[],{"intervention":3845,"totalTrials":112,"cells":19818},{"EARLY_PHASE1":19819,"PHASE1":19821,"PHASE2":19873,"PHASE3":19879,"PHASE4":19881,"NA":19883},{"trials":19820,"activeCount":101},[],{"trials":19822,"activeCount":101},[19823,19833,19837,19850,19854,19864],{"nctId":19824,"briefTitle":19825,"status":162,"phases":19826,"primaryCompletion":19827,"completion":19828,"start":19829,"enrollment":155,"conditions":19830,"interventions":19831},"NCT03780725","This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091",[90],"2020-02-19","2020-12-08","2019-01-22",[36,3766],[3470,19832,3845],"[89Zr]Zr-BI 754111",{"nctId":4333,"briefTitle":4334,"status":107,"phases":19834,"primaryCompletion":4336,"completion":4337,"start":4338,"enrollment":3454,"conditions":19835,"interventions":19836},[90],[33],[3519,3845],{"nctId":19838,"briefTitle":19839,"status":107,"phases":19840,"primaryCompletion":19841,"completion":19842,"start":19843,"enrollment":331,"conditions":19844,"interventions":19845},"NCT04147234","A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)",[90],"2022-11-15","2024-03-21","2020-08-03",[33],[19846,3845,19847,19848,19849],"BI 1387446 50 μg","BI 1387446 100 μg","BI 1387446 200 μg","BI 1387446 400 μg",{"nctId":3838,"briefTitle":3839,"status":107,"phases":19851,"primaryCompletion":3841,"completion":3841,"start":3842,"enrollment":392,"conditions":19852,"interventions":19853},[90],[2057],[43,3845],{"nctId":19855,"briefTitle":19856,"status":162,"phases":19857,"primaryCompletion":19858,"completion":19859,"start":19860,"enrollment":31,"conditions":19861,"interventions":19862},"NCT03166631","A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread",[90],"2020-09-15","2020-10-28","2017-09-08",[33,938,36],[19863,3845],"BI 891065",{"nctId":19865,"briefTitle":19866,"status":107,"phases":19867,"primaryCompletion":19868,"completion":19869,"start":19870,"enrollment":4219,"conditions":19871,"interventions":19872},"NCT02952248","A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours",[90],"2021-04-30","2023-08-01","2016-11-21",[33],[3845],{"trials":19874,"activeCount":101},[19875],{"nctId":4348,"briefTitle":4349,"status":600,"phases":19876,"primaryCompletion":4351,"completion":4351,"start":4352,"enrollment":101,"conditions":19877,"interventions":19878},[91],[4354],[3845,3519],{"trials":19880,"activeCount":101},[],{"trials":19882,"activeCount":101},[],{"trials":19884,"activeCount":101},[],{"intervention":553,"totalTrials":112,"cells":19886},{"EARLY_PHASE1":19887,"PHASE1":19889,"PHASE2":19906,"PHASE3":19942,"PHASE4":19944,"NA":19946},{"trials":19888,"activeCount":101},[],{"trials":19890,"activeCount":101},[19891,19898],{"nctId":19892,"briefTitle":19893,"status":162,"phases":19894,"primaryCompletion":561,"completion":561,"start":19895,"enrollment":1564,"conditions":19896,"interventions":19897},"NCT06272058","A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems",[90],"2024-05-03",[15,550],[553],{"nctId":19899,"briefTitle":19900,"status":107,"phases":19901,"primaryCompletion":19902,"completion":19902,"start":1263,"enrollment":401,"conditions":19903,"interventions":19904},"NCT06193811","A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood",[90],"2024-03-14",[15],[553,553,19905],"esomeprazole",{"trials":19907,"activeCount":101},[19908,19916,19923,19930,19934],{"nctId":19909,"briefTitle":19910,"status":162,"phases":19911,"primaryCompletion":19912,"completion":19913,"start":4272,"enrollment":1429,"conditions":19914,"interventions":19915},"NCT05161481","A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)",[91],"2024-05-02","2024-06-12",[551],[553],{"nctId":19917,"briefTitle":19918,"status":162,"phases":19919,"primaryCompletion":1702,"completion":1702,"start":19920,"enrollment":210,"conditions":19921,"interventions":19922},"NCT06082843","A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly",[91],"2024-01-03",[551,2968],[553],{"nctId":19924,"briefTitle":19925,"status":107,"phases":19926,"primaryCompletion":4217,"completion":19927,"start":2688,"enrollment":5680,"conditions":19928,"interventions":19929},"NCT05559580","A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms",[91],"2026-01-30",[5244],[553],{"nctId":543,"briefTitle":544,"status":162,"phases":19931,"primaryCompletion":546,"completion":547,"start":548,"enrollment":319,"conditions":19932,"interventions":19933},[91],[550,551],[553,73],{"nctId":19935,"briefTitle":19936,"status":107,"phases":19937,"primaryCompletion":2547,"completion":19938,"start":1251,"enrollment":19939,"conditions":19940,"interventions":19941},"NCT04736628","A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease",[91],"2023-09-21",261,[497],[553],{"trials":19943,"activeCount":101},[],{"trials":19945,"activeCount":101},[],{"trials":19947,"activeCount":101},[],{"intervention":2166,"totalTrials":1512,"cells":19949},{"EARLY_PHASE1":19950,"PHASE1":19952,"PHASE2":19977,"PHASE3":19991,"PHASE4":19993,"NA":19995},{"trials":19951,"activeCount":101},[],{"trials":19953,"activeCount":101},[19954,19961,19965,19971],{"nctId":19955,"briefTitle":19956,"status":107,"phases":19957,"primaryCompletion":2162,"start":2122,"enrollment":401,"conditions":19958,"interventions":19959},"NCT02273440","Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers",[90],[15],[2166,19960],"Theophylline",{"nctId":2159,"briefTitle":2160,"status":107,"phases":19962,"primaryCompletion":2162,"start":2163,"enrollment":1672,"conditions":19963,"interventions":19964},[90],[15],[2166,323],{"nctId":19966,"briefTitle":19967,"status":107,"phases":19968,"primaryCompletion":6594,"start":8538,"enrollment":380,"conditions":19969,"interventions":19970},"NCT02273427","Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers",[90],[15],[2166],{"nctId":19972,"briefTitle":19973,"status":107,"phases":19974,"primaryCompletion":6949,"start":6594,"enrollment":132,"conditions":19975,"interventions":19976},"NCT02265627","Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers",[90],[2526],[2166],{"trials":19978,"activeCount":101},[19979,19985],{"nctId":19980,"briefTitle":19981,"status":107,"phases":19982,"primaryCompletion":2163,"start":13117,"enrollment":2887,"conditions":19983,"interventions":19984},"NCT02249312","The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma",[91],[30],[2166],{"nctId":19986,"briefTitle":19987,"status":107,"phases":19988,"primaryCompletion":2163,"start":6207,"enrollment":231,"conditions":19989,"interventions":19990},"NCT02249338","Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[2166],{"trials":19992,"activeCount":101},[],{"trials":19994,"activeCount":101},[],{"trials":19996,"activeCount":101},[],{"intervention":19998,"totalTrials":1512,"cells":19999},"BI 655064",{"EARLY_PHASE1":20000,"PHASE1":20002,"PHASE2":20044,"PHASE3":20054,"PHASE4":20056,"NA":20058},{"trials":20001,"activeCount":101},[],{"trials":20003,"activeCount":101},[20004,20012,20020,20029,20038],{"nctId":20005,"briefTitle":20006,"status":107,"phases":20007,"primaryCompletion":20008,"completion":20008,"start":20009,"enrollment":188,"conditions":20010,"interventions":20011},"NCT02331277","Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers",[90],"2016-05-25","2015-09-01",[15],[19998],{"nctId":20013,"briefTitle":20014,"status":107,"phases":20015,"primaryCompletion":20016,"completion":20016,"start":20017,"enrollment":1208,"conditions":20018,"interventions":20019},"NCT01917916","Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers",[90],"2014-05-14","2013-08-05",[15],[19998],{"nctId":20021,"briefTitle":20022,"status":107,"phases":20023,"primaryCompletion":20024,"completion":20025,"start":20026,"enrollment":8480,"conditions":20027,"interventions":20028},"NCT01751776","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy",[90],"2015-03-02","2015-04-27","2012-12-18",[10667,15],[19998],{"nctId":20030,"briefTitle":20031,"status":162,"phases":20032,"primaryCompletion":20033,"completion":20033,"start":20034,"enrollment":1512,"conditions":20035,"interventions":20037},"NCT02009761","Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).",[90],"2016-04-26","2013-12-18",[20036],"Purpura, Thrombocytopenic, Idiopathic",[19998],{"nctId":20039,"briefTitle":20040,"status":107,"phases":20041,"primaryCompletion":2001,"completion":2001,"start":7338,"enrollment":716,"conditions":20042,"interventions":20043},"NCT01510782","Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers",[90],[15],[19998,19998],{"trials":20045,"activeCount":101},[20046],{"nctId":20047,"briefTitle":20048,"status":107,"phases":20049,"primaryCompletion":20050,"completion":19248,"start":4106,"enrollment":3659,"conditions":20051,"interventions":20053},"NCT03385564","An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis",[91],"2021-05-25",[20052],"Lupus Nephritis",[19998],{"trials":20055,"activeCount":101},[],{"trials":20057,"activeCount":101},[],{"trials":20059,"activeCount":101},[],{"intervention":4166,"totalTrials":1512,"cells":20061},{"EARLY_PHASE1":20062,"PHASE1":20064,"PHASE2":20095,"PHASE3":20103,"PHASE4":20105,"NA":20107},{"trials":20063,"activeCount":101},[],{"trials":20065,"activeCount":101},[20066,20072,20078,20084,20091],{"nctId":20067,"briefTitle":20068,"status":107,"phases":20069,"primaryCompletion":5233,"completion":5233,"start":9842,"enrollment":401,"conditions":20070,"interventions":20071},"NCT02109679","Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects",[90],[15],[384,4166,4166,384],{"nctId":20073,"briefTitle":20074,"status":107,"phases":20075,"primaryCompletion":516,"completion":516,"start":525,"enrollment":2898,"conditions":20076,"interventions":20077},"NCT01874483","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus",[90],[21],[4166,4166,4166,4166,4166,4166,4166],{"nctId":20079,"briefTitle":20080,"status":107,"phases":20081,"primaryCompletion":420,"completion":420,"start":4391,"enrollment":5242,"conditions":20082,"interventions":20083},"NCT02161432","Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers",[90],[15],[4166,4166,4166],{"nctId":20085,"briefTitle":20086,"status":107,"phases":20087,"primaryCompletion":4120,"completion":4120,"start":474,"enrollment":392,"conditions":20088,"interventions":20089},"NCT02305901","The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers",[90],[15],[929,4166,20090],"bupropion extended release",{"nctId":4160,"briefTitle":4161,"status":107,"phases":20092,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":20093,"interventions":20094},[90],[15],[927,4044,4076,4165,928,4166,4167],{"trials":20096,"activeCount":101},[20097],{"nctId":20098,"briefTitle":20099,"status":107,"phases":20100,"primaryCompletion":7092,"completion":2002,"start":5233,"enrollment":5857,"conditions":20101,"interventions":20102},"NCT02150824","Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin",[91],[21],[4166,4166,4166,4166],{"trials":20104,"activeCount":101},[],{"trials":20106,"activeCount":101},[],{"trials":20108,"activeCount":101},[],{"intervention":20110,"totalTrials":1512,"cells":20111},"BI 685509",{"EARLY_PHASE1":20112,"PHASE1":20114,"PHASE2":20152,"PHASE3":20161,"PHASE4":20163,"NA":20165},{"trials":20113,"activeCount":101},[],{"trials":20115,"activeCount":101},[20116,20122,20130,20138,20144],{"nctId":20117,"briefTitle":20118,"status":107,"phases":20119,"primaryCompletion":3744,"completion":3744,"start":5282,"enrollment":401,"conditions":20120,"interventions":20121},"NCT02694354","Investigation of Single Rising Doses of BI 685509",[90],[15],[20110],{"nctId":20123,"briefTitle":20124,"status":107,"phases":20125,"primaryCompletion":20126,"completion":20126,"start":20127,"enrollment":123,"conditions":20128,"interventions":20129},"NCT03116906","Safety and Tolerability of BI 685509 in Healthy Subjects",[90],"2018-06-01","2017-04-24",[15],[20110],{"nctId":20131,"briefTitle":20132,"status":107,"phases":20133,"primaryCompletion":20134,"completion":20134,"start":20135,"enrollment":716,"conditions":20136,"interventions":20137},"NCT03259464","This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated",[90],"2018-05-26","2017-09-04",[15],[20110],{"nctId":20139,"briefTitle":20140,"status":107,"phases":20141,"primaryCompletion":1864,"completion":1864,"start":19330,"enrollment":3939,"conditions":20142,"interventions":20143},"NCT03165227","This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)",[90],[2203],[20110],{"nctId":20145,"briefTitle":20146,"status":107,"phases":20147,"primaryCompletion":20148,"completion":20149,"start":18814,"enrollment":1208,"conditions":20150,"interventions":20151},"NCT03842761","A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems",[90],"2021-04-09","2021-05-20",[15,2526],[20110],{"trials":20153,"activeCount":101},[20154],{"nctId":20155,"briefTitle":20156,"status":107,"phases":20157,"primaryCompletion":5662,"completion":20158,"start":1251,"enrollment":19690,"conditions":20159,"interventions":20160},"NCT04750577","A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease",[91],"2022-12-27",[2203],[20110],{"trials":20162,"activeCount":101},[],{"trials":20164,"activeCount":101},[],{"trials":20166,"activeCount":101},[],{"intervention":3995,"totalTrials":1512,"cells":20168},{"EARLY_PHASE1":20169,"PHASE1":20171,"PHASE2":20204,"PHASE3":20210,"PHASE4":20212,"NA":20214},{"trials":20170,"activeCount":101},[],{"trials":20172,"activeCount":101},[20173,20177,20184,20190,20196],{"nctId":3987,"briefTitle":3988,"status":162,"phases":20174,"primaryCompletion":3990,"start":3991,"enrollment":3398,"conditions":20175,"interventions":20176},[90],[15],[3994,3995,1242,3996],{"nctId":20178,"briefTitle":20179,"status":107,"phases":20180,"primaryCompletion":20181,"start":6911,"enrollment":6702,"conditions":20182,"interventions":20183},"NCT02182323","Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects",[90],"2006-12",[15],[3995],{"nctId":20185,"briefTitle":20186,"status":107,"phases":20187,"primaryCompletion":3732,"start":6811,"enrollment":380,"conditions":20188,"interventions":20189},"NCT02182375","Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers",[90],[15],[3995,10009],{"nctId":20191,"briefTitle":20192,"status":107,"phases":20193,"primaryCompletion":4129,"start":1114,"enrollment":291,"conditions":20194,"interventions":20195},"NCT02182362","Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects",[90],[15],[3995],{"nctId":20197,"briefTitle":20198,"status":107,"phases":20199,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":20200,"interventions":20201},"NCT02182336","Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers",[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],"Midazolam HCl solution","Midazolam HCl oral syrup",{"trials":20205,"activeCount":101},[20206],{"nctId":10088,"briefTitle":10089,"status":107,"phases":20207,"primaryCompletion":9515,"completion":9515,"start":9538,"enrollment":439,"conditions":20208,"interventions":20209},[91],[4040],[3994,10093,9801,9801,3994,3995,3995,10093],{"trials":20211,"activeCount":101},[],{"trials":20213,"activeCount":101},[],{"trials":20215,"activeCount":101},[],{"intervention":20217,"totalTrials":1512,"cells":20218},"BI 1819479",{"EARLY_PHASE1":20219,"PHASE1":20221,"PHASE2":20265,"PHASE3":20274,"PHASE4":20276,"NA":20278},{"trials":20220,"activeCount":101},[],{"trials":20222,"activeCount":101},[20223,20231,20241,20249,20256],{"nctId":20224,"briefTitle":20225,"status":107,"phases":20226,"primaryCompletion":20227,"completion":20158,"start":20228,"enrollment":380,"conditions":20229,"interventions":20230},"NCT05469646","A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated",[90],"2022-12-20","2022-08-03",[15],[20217],{"nctId":20232,"briefTitle":20233,"status":162,"phases":20234,"primaryCompletion":20235,"completion":20236,"start":20237,"enrollment":112,"conditions":20238,"interventions":20239},"NCT07065617","A Study to Test How BI 1819479 is Taken up and Processed by the Body",[90],"2025-10-04","2025-11-04","2025-08-04",[15],[20240,20217,20217],"[14C]BI 1819479",{"nctId":20242,"briefTitle":20243,"status":107,"phases":20244,"primaryCompletion":20245,"completion":20245,"start":20246,"enrollment":3565,"conditions":20247,"interventions":20248},"NCT04801693","A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food",[90],"2022-04-25","2021-05-26",[15],[20217],{"nctId":20250,"briefTitle":20251,"status":107,"phases":20252,"primaryCompletion":2831,"completion":2831,"start":20253,"enrollment":31,"conditions":20254,"interventions":20255},"NCT05440799","A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479",[90],"2022-07-20",[15],[20217],{"nctId":20257,"briefTitle":20258,"status":107,"phases":20259,"primaryCompletion":20260,"completion":20260,"start":20261,"enrollment":956,"conditions":20262,"interventions":20263},"NCT05467475","A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood",[90],"2023-01-23","2022-10-18",[15],[20217,20264],"Esomeprazole",{"trials":20266,"activeCount":101},[20267],{"nctId":20268,"briefTitle":20269,"status":107,"phases":20270,"primaryCompletion":20271,"completion":1053,"start":3573,"enrollment":1704,"conditions":20272,"interventions":20273},"NCT06335303","A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)",[91],"2025-11-25",[1397],[20217],{"trials":20275,"activeCount":101},[],{"trials":20277,"activeCount":101},[],{"trials":20279,"activeCount":101},[],{"intervention":6314,"totalTrials":1512,"cells":20281},{"EARLY_PHASE1":20282,"PHASE1":20284,"PHASE2":20304,"PHASE3":20328,"PHASE4":20330,"NA":20332},{"trials":20283,"activeCount":101},[],{"trials":20285,"activeCount":101},[20286,20292,20298],{"nctId":20287,"briefTitle":20288,"status":107,"phases":20289,"primaryCompletion":12600,"start":7703,"enrollment":155,"conditions":20290,"interventions":20291},"NCT01205373","A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers",[90],[15],[6314],{"nctId":20293,"briefTitle":20294,"status":107,"phases":20295,"primaryCompletion":9396,"start":12600,"enrollment":19006,"conditions":20296,"interventions":20297},"NCT01216384","Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers",[90],[30,11866],[6314],{"nctId":20299,"briefTitle":20300,"status":107,"phases":20301,"primaryCompletion":9396,"start":12600,"enrollment":380,"conditions":20302,"interventions":20303},"NCT01215773","Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.",[90],[15],[6314,6314],{"trials":20305,"activeCount":101},[20306,20310,20319],{"nctId":6306,"briefTitle":6307,"status":107,"phases":20307,"primaryCompletion":6309,"completion":6309,"start":6310,"enrollment":6311,"conditions":20308,"interventions":20309},[91],[30],[6314,6315,5960,6316],{"nctId":20311,"briefTitle":20312,"status":107,"phases":20313,"primaryCompletion":20314,"completion":20315,"start":20316,"enrollment":220,"conditions":20317,"interventions":20318},"NCT01090024","Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids",[91],"2011-02-01","2011-02-18","2010-03-01",[30],[6314],{"nctId":20320,"briefTitle":20321,"status":107,"phases":20322,"primaryCompletion":20323,"completion":20323,"start":20324,"enrollment":19690,"conditions":20325,"interventions":20326},"NCT01103349","BI 671800 in Asthmatic Patients on Inhaled Corticosteroids",[91],"2011-08-09","2010-04-20",[30],[6314,20327],"Montelukast",{"trials":20329,"activeCount":101},[],{"trials":20331,"activeCount":101},[],{"trials":20333,"activeCount":101},[],{"intervention":4075,"totalTrials":166,"cells":20335},{"EARLY_PHASE1":20336,"PHASE1":20338,"PHASE2":20370,"PHASE3":20378,"PHASE4":20380,"NA":20382},{"trials":20337,"activeCount":101},[],{"trials":20339,"activeCount":101},[20340,20350,20358,20366],{"nctId":20341,"briefTitle":20342,"status":162,"phases":20343,"primaryCompletion":10555,"completion":20344,"start":20345,"enrollment":155,"conditions":20346,"interventions":20347},"NCT06572111","A Study in Healthy Men to Test How BI 1839100 is Taken up and Handled by the Body",[90],"2025-09-02","2024-09-30",[15],[20348,4075,20349],"BI 1839100 (C-14) formulation 1","BI 1839100 (C-14) formulation 2",{"nctId":20351,"briefTitle":20352,"status":107,"phases":20353,"primaryCompletion":20354,"completion":20354,"start":12552,"enrollment":13929,"conditions":20355,"interventions":20356},"NCT05354453","A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)",[90],"2023-06-14",[15],[4075,20357],"allyl isothiocyanate",{"nctId":20359,"briefTitle":20360,"status":107,"phases":20361,"primaryCompletion":19239,"completion":20362,"start":20363,"enrollment":380,"conditions":20364,"interventions":20365},"NCT05934955","A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)",[90],"2023-10-02","2023-07-13",[15],[4075],{"nctId":4068,"briefTitle":4069,"status":107,"phases":20367,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":28,"conditions":20368,"interventions":20369},[90],[15],[4075,927,4076,4077],{"trials":20371,"activeCount":101},[20372],{"nctId":20373,"briefTitle":20374,"status":162,"phases":20375,"primaryCompletion":20344,"completion":20344,"start":2498,"enrollment":1468,"conditions":20376,"interventions":20377},"NCT06360094","A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis",[91],[1397,1398],[4075],{"trials":20379,"activeCount":101},[],{"trials":20381,"activeCount":101},[],{"trials":20383,"activeCount":101},[],{"intervention":3981,"totalTrials":166,"cells":20385},{"EARLY_PHASE1":20386,"PHASE1":20388,"PHASE2":20415,"PHASE3":20423,"PHASE4":20425,"NA":20427},{"trials":20387,"activeCount":101},[],{"trials":20389,"activeCount":101},[20390,20394,20400,20408],{"nctId":3975,"briefTitle":3976,"status":107,"phases":20391,"primaryCompletion":3978,"start":1115,"enrollment":1672,"conditions":20392,"interventions":20393},[90],[15],[3981,1242],{"nctId":20395,"briefTitle":20396,"status":107,"phases":20397,"primaryCompletion":6235,"start":6401,"enrollment":1106,"conditions":20398,"interventions":20399},"NCT02259894","Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers",[90],[15],[3981],{"nctId":20401,"briefTitle":20402,"status":107,"phases":20403,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":20404,"interventions":20405},"NCT02256813","Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers",[90],[15],[3981,4011,4013,4014,1241,20406,20407],"Midazolam hydrochloride","Vitamin K1",{"nctId":20409,"briefTitle":20410,"status":107,"phases":20411,"primaryCompletion":6910,"start":8479,"enrollment":380,"conditions":20412,"interventions":20413},"NCT02256878","Study to Evaluate the Effect Single and Multiple Oral Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects",[90],[15],[3981,20414],"Amitriptyline",{"trials":20416,"activeCount":101},[20417],{"nctId":20418,"briefTitle":20419,"status":107,"phases":20420,"primaryCompletion":4413,"start":2111,"enrollment":11419,"conditions":20421,"interventions":20422},"NCT00333411","Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate\u002FSevere Psoriasis",[91],[114],[3981],{"trials":20424,"activeCount":101},[],{"trials":20426,"activeCount":101},[],{"trials":20428,"activeCount":101},[],{"intervention":13488,"totalTrials":166,"cells":20430},{"EARLY_PHASE1":20431,"PHASE1":20433,"PHASE2":20468,"PHASE3":20474,"PHASE4":20476,"NA":20478},{"trials":20432,"activeCount":101},[],{"trials":20434,"activeCount":101},[20435,20444,20452,20459],{"nctId":20436,"briefTitle":20437,"status":107,"phases":20438,"primaryCompletion":18933,"completion":20439,"start":2626,"enrollment":112,"conditions":20440,"interventions":20442},"NCT02759016","Intravenous BI 836826 in Combination With Ibrutinib in Relapsed\u002FRefractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib",[90],"2019-07-09",[20441],"Leukemia, Lymphocytic, Chronic, B-Cell",[13488,20443],"Ibrutinib",{"nctId":20445,"briefTitle":20446,"status":107,"phases":20447,"primaryCompletion":20448,"completion":20449,"start":18669,"enrollment":410,"conditions":20450,"interventions":20451},"NCT01403948","BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)",[90],"2017-11-14","2018-02-28",[10976],[13488],{"nctId":20453,"briefTitle":20454,"status":107,"phases":20455,"primaryCompletion":240,"completion":10692,"start":20456,"enrollment":3398,"conditions":20457,"interventions":20458},"NCT01296932","BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)",[90],"2011-02-11",[20441],[13488],{"nctId":20460,"briefTitle":20461,"status":600,"phases":20462,"primaryCompletion":20463,"completion":20464,"start":10701,"enrollment":101,"conditions":20465,"interventions":20466},"NCT03343678","This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax",[90],"2018-05-25","2020-11-25",[20441],[20467,13488],"Venetoclax",{"trials":20469,"activeCount":101},[20470],{"nctId":13481,"briefTitle":13482,"status":107,"phases":20471,"primaryCompletion":1779,"completion":1779,"start":13484,"enrollment":3454,"conditions":20472,"interventions":20473},[91],[13486],[13488,13489,10978,13489],{"trials":20475,"activeCount":101},[],{"trials":20477,"activeCount":101},[],{"trials":20479,"activeCount":101},[],{"intervention":3470,"totalTrials":166,"cells":20481},{"EARLY_PHASE1":20482,"PHASE1":20488,"PHASE2":20502,"PHASE3":20508,"PHASE4":20510,"NA":20512},{"trials":20483,"activeCount":101},[20484],{"nctId":3462,"briefTitle":3463,"status":107,"phases":20485,"primaryCompletion":3465,"completion":3465,"start":3466,"enrollment":3467,"conditions":20486,"interventions":20487},[89],[33],[1461,3470],{"trials":20489,"activeCount":101},[20490,20494,20498],{"nctId":19824,"briefTitle":19825,"status":162,"phases":20491,"primaryCompletion":19827,"completion":19828,"start":19829,"enrollment":155,"conditions":20492,"interventions":20493},[90],[36,3766],[3470,19832,3845],{"nctId":3503,"briefTitle":3504,"status":107,"phases":20495,"primaryCompletion":3506,"completion":3507,"start":3508,"enrollment":3509,"conditions":20496,"interventions":20497},[90],[33,36],[1461,3470],{"nctId":3570,"briefTitle":3571,"status":107,"phases":20499,"primaryCompletion":3573,"completion":1874,"start":3574,"enrollment":3575,"conditions":20500,"interventions":20501},[90],[33],[3578,3490,3470],{"trials":20503,"activeCount":101},[20504],{"nctId":3613,"briefTitle":3614,"status":107,"phases":20505,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":3618,"conditions":20506,"interventions":20507},[91],[938,3620,3621],[1461,3470,3519],{"trials":20509,"activeCount":101},[],{"trials":20511,"activeCount":101},[],{"trials":20513,"activeCount":101},[],{"intervention":6304,"totalTrials":166,"cells":20515},{"EARLY_PHASE1":20516,"PHASE1":20518,"PHASE2":20526,"PHASE3":20547,"PHASE4":20549,"NA":20551},{"trials":20517,"activeCount":101},[],{"trials":20519,"activeCount":101},[20520],{"nctId":20521,"briefTitle":20522,"status":107,"phases":20523,"primaryCompletion":2030,"start":6132,"enrollment":448,"conditions":20524,"interventions":20525},"NCT01309139","Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers",[90],[15],[5860,5860,6304,6304],{"trials":20527,"activeCount":101},[20528,20532,20539,20543],{"nctId":6297,"briefTitle":6298,"status":162,"phases":20529,"primaryCompletion":6300,"completion":6300,"start":6301,"enrollment":357,"conditions":20530,"interventions":20531},[91],[30],[6304,5960],{"nctId":20533,"briefTitle":20534,"status":600,"phases":20535,"primaryCompletion":408,"start":390,"enrollment":101,"conditions":20536,"interventions":20537},"NCT01458886","Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone",[91],[30],[20538,6304],"BI 54903 MD",{"nctId":6318,"briefTitle":6319,"status":162,"phases":20540,"primaryCompletion":6300,"completion":6300,"start":6321,"enrollment":993,"conditions":20541,"interventions":20542},[91],[30],[5960,6304],{"nctId":6325,"briefTitle":6326,"status":162,"phases":20544,"primaryCompletion":6328,"completion":6329,"start":6301,"enrollment":1340,"conditions":20545,"interventions":20546},[91],[30],[5960,6304],{"trials":20548,"activeCount":101},[],{"trials":20550,"activeCount":101},[],{"trials":20552,"activeCount":101},[],{"intervention":20554,"totalTrials":1564,"cells":20555},"Dabigatran etexilate low dose",{"EARLY_PHASE1":20556,"PHASE1":20558,"PHASE2":20574,"PHASE3":20584,"PHASE4":20586,"NA":20588},{"trials":20557,"activeCount":101},[],{"trials":20559,"activeCount":101},[20560,20568],{"nctId":20561,"briefTitle":20562,"status":107,"phases":20563,"primaryCompletion":4005,"start":4005,"enrollment":1081,"conditions":20564,"interventions":20565},"NCT02171455","Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects",[90],[15],[20554,20566,20567],"Dabigatran etexilate medium dose","Dabigatran etexilate high dose",{"nctId":20569,"briefTitle":20570,"status":107,"phases":20571,"primaryCompletion":4461,"start":11581,"enrollment":1418,"conditions":20572,"interventions":20573},"NCT02182024","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment",[90],[2550],[20567,20554],{"trials":20575,"activeCount":101},[20576,20580],{"nctId":11230,"briefTitle":11231,"status":162,"phases":20577,"primaryCompletion":525,"completion":525,"start":6095,"enrollment":5568,"conditions":20578,"interventions":20579},[91],[10332,11234],[11236,11237,11238,11239,11240,11221],{"nctId":11242,"briefTitle":11243,"status":162,"phases":20581,"primaryCompletion":525,"completion":525,"start":391,"enrollment":11245,"conditions":20582,"interventions":20583},[91],[11247],[11239,11238,11236,11237,11240,11221],{"trials":20585,"activeCount":101},[],{"trials":20587,"activeCount":101},[],{"trials":20589,"activeCount":101},[],{"intervention":20567,"totalTrials":1564,"cells":20591},{"EARLY_PHASE1":20592,"PHASE1":20594,"PHASE2":20604,"PHASE3":20614,"PHASE4":20616,"NA":20618},{"trials":20593,"activeCount":101},[],{"trials":20595,"activeCount":101},[20596,20600],{"nctId":20561,"briefTitle":20562,"status":107,"phases":20597,"primaryCompletion":4005,"start":4005,"enrollment":1081,"conditions":20598,"interventions":20599},[90],[15],[20554,20566,20567],{"nctId":20569,"briefTitle":20570,"status":107,"phases":20601,"primaryCompletion":4461,"start":11581,"enrollment":1418,"conditions":20602,"interventions":20603},[90],[2550],[20567,20554],{"trials":20605,"activeCount":101},[20606,20610],{"nctId":11230,"briefTitle":11231,"status":162,"phases":20607,"primaryCompletion":525,"completion":525,"start":6095,"enrollment":5568,"conditions":20608,"interventions":20609},[91],[10332,11234],[11236,11237,11238,11239,11240,11221],{"nctId":11242,"briefTitle":11243,"status":162,"phases":20611,"primaryCompletion":525,"completion":525,"start":391,"enrollment":11245,"conditions":20612,"interventions":20613},[91],[11247],[11239,11238,11236,11237,11240,11221],{"trials":20615,"activeCount":101},[],{"trials":20617,"activeCount":101},[],{"trials":20619,"activeCount":101},[],{"intervention":20621,"totalTrials":1564,"cells":20622},"BI 144807",{"EARLY_PHASE1":20623,"PHASE1":20625,"PHASE2":20646,"PHASE3":20654,"PHASE4":20656,"NA":20658},{"trials":20624,"activeCount":101},[],{"trials":20626,"activeCount":101},[20627,20633,20640],{"nctId":20628,"briefTitle":20629,"status":107,"phases":20630,"primaryCompletion":9593,"completion":9593,"start":517,"enrollment":380,"conditions":20631,"interventions":20632},"NCT01707940","Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers",[90],[15],[5264,20621,20621],{"nctId":20634,"briefTitle":20635,"status":107,"phases":20636,"primaryCompletion":9538,"start":390,"enrollment":6702,"conditions":20637,"interventions":20638},"NCT01480648","Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers",[90],[15],[20639,20621],"BI 144807 Placebo",{"nctId":20641,"briefTitle":20642,"status":107,"phases":20643,"primaryCompletion":3730,"completion":3730,"start":9491,"enrollment":34,"conditions":20644,"interventions":20645},"NCT01651598","Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients",[90],[15,30],[20621],{"trials":20647,"activeCount":101},[20648],{"nctId":20649,"briefTitle":20650,"status":107,"phases":20651,"primaryCompletion":4120,"completion":4118,"start":4391,"enrollment":177,"conditions":20652,"interventions":20653},"NCT02121522","A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration",[91],[4367],[20621],{"trials":20655,"activeCount":101},[],{"trials":20657,"activeCount":101},[],{"trials":20659,"activeCount":101},[],{"intervention":20661,"totalTrials":1564,"cells":20662},"BI 706321",{"EARLY_PHASE1":20663,"PHASE1":20665,"PHASE2":20689,"PHASE3":20700,"PHASE4":20702,"NA":20704},{"trials":20664,"activeCount":101},[],{"trials":20666,"activeCount":101},[20667,20675,20682],{"nctId":20668,"briefTitle":20669,"status":162,"phases":20670,"primaryCompletion":18701,"completion":20671,"start":20672,"enrollment":410,"conditions":20673,"interventions":20674},"NCT05183360","A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated",[90],"2024-08-08","2022-02-07",[15],[20661],{"nctId":20676,"briefTitle":20677,"status":107,"phases":20678,"primaryCompletion":19868,"completion":19868,"start":20679,"enrollment":177,"conditions":20680,"interventions":20681},"NCT04714073","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood",[90],"2021-02-11",[15],[20661,949],{"nctId":20683,"briefTitle":20684,"status":107,"phases":20685,"primaryCompletion":5725,"completion":5725,"start":20686,"enrollment":19006,"conditions":20687,"interventions":20688},"NCT03971695","A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321",[90],"2019-06-18",[15],[20661],{"trials":20690,"activeCount":101},[20691],{"nctId":20692,"briefTitle":20693,"status":162,"phases":20694,"primaryCompletion":20695,"completion":20671,"start":20696,"enrollment":2123,"conditions":20697,"interventions":20698},"NCT04978493","A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease",[91],"2024-07-08","2021-12-02",[190],[20661,20699],"Ustekinumab",{"trials":20701,"activeCount":101},[],{"trials":20703,"activeCount":101},[],{"trials":20705,"activeCount":101},[],{"intervention":1131,"totalTrials":1564,"cells":20707},{"EARLY_PHASE1":20708,"PHASE1":20710,"PHASE2":20732,"PHASE3":20738,"PHASE4":20740,"NA":20742},{"trials":20709,"activeCount":101},[],{"trials":20711,"activeCount":101},[20712,20716,20728],{"nctId":11530,"briefTitle":11531,"status":107,"phases":20713,"primaryCompletion":11533,"completion":11533,"start":11534,"enrollment":6607,"conditions":20714,"interventions":20715},[90],[15],[11523,9711,9711],{"nctId":20717,"briefTitle":20718,"status":107,"phases":20719,"primaryCompletion":20720,"completion":20721,"start":20722,"enrollment":912,"conditions":20723,"interventions":20725},"NCT05087992","A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers",[90],"2023-10-23","2023-11-14","2021-11-24",[20724],"Gastrointestinal Cancer, Metastatic",[20726,20727,1131],"BI 905711","FOLFIRI",{"nctId":1122,"briefTitle":1123,"status":107,"phases":20729,"primaryCompletion":1125,"completion":1125,"start":1114,"enrollment":1126,"conditions":20730,"interventions":20731},[90],[33],[1120,1010,1129,1120,1130,1120,1010,1131,1129,1129],{"trials":20733,"activeCount":101},[20734],{"nctId":9704,"briefTitle":9705,"status":107,"phases":20735,"primaryCompletion":7338,"completion":7338,"start":9411,"enrollment":6585,"conditions":20736,"interventions":20737},[91],[3060],[1119,1119,9709,1131,9710,9711],{"trials":20739,"activeCount":101},[],{"trials":20741,"activeCount":101},[],{"trials":20743,"activeCount":101},[],{"intervention":20745,"totalTrials":1564,"cells":20746},"Tipranavir low dose",{"EARLY_PHASE1":20747,"PHASE1":20749,"PHASE2":20769,"PHASE3":20786,"PHASE4":20788,"NA":20790},{"trials":20748,"activeCount":101},[],{"trials":20750,"activeCount":101},[20751,20762],{"nctId":20752,"briefTitle":20753,"status":107,"phases":20754,"primaryCompletion":20755,"start":5887,"enrollment":2123,"conditions":20756,"interventions":20757},"NCT02251145","Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers",[90],"2002-06",[15],[20745,20758,20759,20760,20761],"Tipranavir high dose","Ritonavir low dose","Ritonavir high dose","Tenofovir disoproxil fumarate",{"nctId":20763,"briefTitle":20764,"status":162,"phases":20765,"primaryCompletion":20755,"start":5887,"enrollment":342,"conditions":20766,"interventions":20767},"NCT02245438","Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers",[90],[15],[20745,20758,20759,20760,20768],"Norethindrone-Ethinyl Estradiol",{"trials":20770,"activeCount":101},[20771,20778],{"nctId":20772,"briefTitle":20773,"status":107,"phases":20774,"primaryCompletion":6030,"start":7419,"enrollment":12378,"conditions":20775,"interventions":20776},"NCT02251223","Effects of Tipranavir\u002FRitonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects",[90,91],[27],[20745,20777,20758,20759,20760],"Tipranavir medium dose",{"nctId":20779,"briefTitle":20780,"status":107,"phases":20781,"primaryCompletion":6584,"start":6438,"enrollment":1991,"conditions":20782,"interventions":20783},"NCT02238314","Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients",[91],[27],[20745,20758,4010,20784,20785],"Nucleoside Reverse Transcriptase Inhibitor","Non-Nucleoside Reverse Transcriptase Inhibitor",{"trials":20787,"activeCount":101},[],{"trials":20789,"activeCount":101},[],{"trials":20791,"activeCount":101},[],{"intervention":20758,"totalTrials":1564,"cells":20793},{"EARLY_PHASE1":20794,"PHASE1":20796,"PHASE2":20806,"PHASE3":20816,"PHASE4":20818,"NA":20820},{"trials":20795,"activeCount":101},[],{"trials":20797,"activeCount":101},[20798,20802],{"nctId":20752,"briefTitle":20753,"status":107,"phases":20799,"primaryCompletion":20755,"start":5887,"enrollment":2123,"conditions":20800,"interventions":20801},[90],[15],[20745,20758,20759,20760,20761],{"nctId":20763,"briefTitle":20764,"status":162,"phases":20803,"primaryCompletion":20755,"start":5887,"enrollment":342,"conditions":20804,"interventions":20805},[90],[15],[20745,20758,20759,20760,20768],{"trials":20807,"activeCount":101},[20808,20812],{"nctId":20772,"briefTitle":20773,"status":107,"phases":20809,"primaryCompletion":6030,"start":7419,"enrollment":12378,"conditions":20810,"interventions":20811},[90,91],[27],[20745,20777,20758,20759,20760],{"nctId":20779,"briefTitle":20780,"status":107,"phases":20813,"primaryCompletion":6584,"start":6438,"enrollment":1991,"conditions":20814,"interventions":20815},[91],[27],[20745,20758,4010,20784,20785],{"trials":20817,"activeCount":101},[],{"trials":20819,"activeCount":101},[],{"trials":20821,"activeCount":101},[],{"intervention":20759,"totalTrials":1564,"cells":20823},{"EARLY_PHASE1":20824,"PHASE1":20826,"PHASE2":20836,"PHASE3":20851,"PHASE4":20853,"NA":20855},{"trials":20825,"activeCount":101},[],{"trials":20827,"activeCount":101},[20828,20832],{"nctId":20752,"briefTitle":20753,"status":107,"phases":20829,"primaryCompletion":20755,"start":5887,"enrollment":2123,"conditions":20830,"interventions":20831},[90],[15],[20745,20758,20759,20760,20761],{"nctId":20763,"briefTitle":20764,"status":162,"phases":20833,"primaryCompletion":20755,"start":5887,"enrollment":342,"conditions":20834,"interventions":20835},[90],[15],[20745,20758,20759,20760,20768],{"trials":20837,"activeCount":101},[20838,20842],{"nctId":20772,"briefTitle":20773,"status":107,"phases":20839,"primaryCompletion":6030,"start":7419,"enrollment":12378,"conditions":20840,"interventions":20841},[90,91],[27],[20745,20777,20758,20759,20760],{"nctId":20843,"briefTitle":20844,"status":162,"phases":20845,"primaryCompletion":6015,"start":6206,"enrollment":269,"conditions":20846,"interventions":20847},"NCT02239835","Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients",[91],[27],[20848,20849,20759,20760,20850],"Tipranavir (TPV) low dose","Tipranavir (TPV) high dose","Saquinavir",{"trials":20852,"activeCount":101},[],{"trials":20854,"activeCount":101},[],{"trials":20856,"activeCount":101},[],{"intervention":20760,"totalTrials":1564,"cells":20858},{"EARLY_PHASE1":20859,"PHASE1":20861,"PHASE2":20871,"PHASE3":20881,"PHASE4":20883,"NA":20885},{"trials":20860,"activeCount":101},[],{"trials":20862,"activeCount":101},[20863,20867],{"nctId":20752,"briefTitle":20753,"status":107,"phases":20864,"primaryCompletion":20755,"start":5887,"enrollment":2123,"conditions":20865,"interventions":20866},[90],[15],[20745,20758,20759,20760,20761],{"nctId":20763,"briefTitle":20764,"status":162,"phases":20868,"primaryCompletion":20755,"start":5887,"enrollment":342,"conditions":20869,"interventions":20870},[90],[15],[20745,20758,20759,20760,20768],{"trials":20872,"activeCount":101},[20873,20877],{"nctId":20772,"briefTitle":20773,"status":107,"phases":20874,"primaryCompletion":6030,"start":7419,"enrollment":12378,"conditions":20875,"interventions":20876},[90,91],[27],[20745,20777,20758,20759,20760],{"nctId":20843,"briefTitle":20844,"status":162,"phases":20878,"primaryCompletion":6015,"start":6206,"enrollment":269,"conditions":20879,"interventions":20880},[91],[27],[20848,20849,20759,20760,20850],{"trials":20882,"activeCount":101},[],{"trials":20884,"activeCount":101},[],{"trials":20886,"activeCount":101},[],{"intervention":20888,"totalTrials":1564,"cells":20889},"BI 655130",{"EARLY_PHASE1":20890,"PHASE1":20892,"PHASE2":20916,"PHASE3":20927,"PHASE4":20929,"NA":20931},{"trials":20891,"activeCount":101},[],{"trials":20893,"activeCount":101},[20894,20902,20908],{"nctId":20895,"briefTitle":20896,"status":107,"phases":20897,"primaryCompletion":20898,"completion":20898,"start":20899,"enrollment":11163,"conditions":20900,"interventions":20901},"NCT02525679","Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers",[90],"2016-05-27","2015-09-14",[15],[20888],{"nctId":20903,"briefTitle":20904,"status":107,"phases":20905,"primaryCompletion":110,"completion":110,"start":20127,"enrollment":448,"conditions":20906,"interventions":20907},"NCT03100903","Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects",[90],[15],[20888],{"nctId":20909,"briefTitle":20910,"status":107,"phases":20911,"primaryCompletion":20912,"completion":20912,"start":20913,"enrollment":2382,"conditions":20914,"interventions":20915},"NCT02852824","Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers",[90],"2017-08-01","2016-08-10",[15],[20888],{"trials":20917,"activeCount":101},[20918],{"nctId":20919,"briefTitle":20920,"status":107,"phases":20921,"primaryCompletion":20922,"completion":20923,"start":20924,"enrollment":5205,"conditions":20925,"interventions":20926},"NCT03822832","A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated",[91],"2020-01-17","2020-07-22","2019-02-12",[179],[20888],{"trials":20928,"activeCount":101},[],{"trials":20930,"activeCount":101},[],{"trials":20932,"activeCount":101},[],{"intervention":20934,"totalTrials":1564,"cells":20935},"BIBR 796 BS",{"EARLY_PHASE1":20936,"PHASE1":20938,"PHASE2":20958,"PHASE3":20967,"PHASE4":20969,"NA":20971},{"trials":20937,"activeCount":101},[],{"trials":20939,"activeCount":101},[20940,20946,20952],{"nctId":20941,"briefTitle":20942,"status":107,"phases":20943,"primaryCompletion":6206,"start":7022,"enrollment":1208,"conditions":20944,"interventions":20945},"NCT02208856","Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects",[90],[15],[20934],{"nctId":20947,"briefTitle":20948,"status":107,"phases":20949,"primaryCompletion":2162,"start":6594,"enrollment":380,"conditions":20950,"interventions":20951},"NCT02211157","Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects",[90],[15],[20934],{"nctId":20953,"briefTitle":20954,"status":107,"phases":20955,"primaryCompletion":6082,"start":5992,"enrollment":641,"conditions":20956,"interventions":20957},"NCT02211144","Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects",[90],[15],[20934],{"trials":20959,"activeCount":101},[20960],{"nctId":20961,"briefTitle":20962,"status":107,"phases":20963,"primaryCompletion":20755,"start":6701,"enrollment":20964,"conditions":20965,"interventions":20966},"NCT02209779","Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis",[91],167,[10667],[20934],{"trials":20968,"activeCount":101},[],{"trials":20970,"activeCount":101},[],{"trials":20972,"activeCount":101},[],{"intervention":20974,"totalTrials":1564,"cells":20975},"Hyoscine butylbromide",{"EARLY_PHASE1":20976,"PHASE1":20978,"PHASE2":21000,"PHASE3":21009,"PHASE4":21011,"NA":21013},{"trials":20977,"activeCount":101},[],{"trials":20979,"activeCount":101},[20980,20986,20993],{"nctId":20981,"briefTitle":20982,"status":107,"phases":20983,"primaryCompletion":8911,"start":1114,"enrollment":123,"conditions":20984,"interventions":20985},"NCT02261077","Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers",[90],[15],[20974],{"nctId":20987,"briefTitle":20988,"status":107,"phases":20989,"primaryCompletion":2031,"completion":2031,"start":437,"enrollment":37,"conditions":20990,"interventions":20991},"NCT02516098","Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.",[90],[15],[20992],"hyoscine butylbromide",{"nctId":20994,"briefTitle":20995,"status":107,"phases":20996,"primaryCompletion":20997,"completion":20997,"start":11533,"enrollment":357,"conditions":20998,"interventions":20999},"NCT01734902","Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers",[90],"2012-12-01",[15],[20974,20974],{"trials":21001,"activeCount":101},[21002],{"nctId":21003,"briefTitle":21004,"status":107,"phases":21005,"primaryCompletion":7573,"start":6156,"enrollment":7804,"conditions":21006,"interventions":21008},"NCT02242292","Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort",[91],[21007],"Colic",[20974],{"trials":21010,"activeCount":101},[],{"trials":21012,"activeCount":101},[],{"trials":21014,"activeCount":101},[],{"intervention":21016,"totalTrials":1564,"cells":21017},"BI 1265162",{"EARLY_PHASE1":21018,"PHASE1":21020,"PHASE2":21043,"PHASE3":21052,"PHASE4":21054,"NA":21056},{"trials":21019,"activeCount":101},[],{"trials":21021,"activeCount":101},[21022,21029,21035],{"nctId":21023,"briefTitle":21024,"status":107,"phases":21025,"primaryCompletion":21026,"completion":21026,"start":5322,"enrollment":188,"conditions":21027,"interventions":21028},"NCT03907280","A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood",[90],"2019-12-06",[15],[21016,21016,21016,21016],{"nctId":21030,"briefTitle":21031,"status":107,"phases":21032,"primaryCompletion":5953,"completion":5953,"start":17942,"enrollment":34,"conditions":21033,"interventions":21034},"NCT03349723","This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men",[90],[15],[21016],{"nctId":21036,"briefTitle":21037,"status":107,"phases":21038,"primaryCompletion":21039,"completion":21039,"start":21040,"enrollment":2235,"conditions":21041,"interventions":21042},"NCT03576144","This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.",[90],"2018-12-06","2018-07-11",[15],[21016],{"trials":21044,"activeCount":101},[21045],{"nctId":21046,"briefTitle":21047,"status":162,"phases":21048,"primaryCompletion":2199,"completion":21049,"start":776,"enrollment":342,"conditions":21050,"interventions":21051},"NCT04059094","A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1",[91],"2020-04-24",[1724],[21016],{"trials":21053,"activeCount":101},[],{"trials":21055,"activeCount":101},[],{"trials":21057,"activeCount":101},[],{"intervention":21059,"totalTrials":1044,"cells":21060},"BIRB 796 BS, low dose",{"EARLY_PHASE1":21061,"PHASE1":21063,"PHASE2":21072,"PHASE3":21090,"PHASE4":21092,"NA":21094},{"trials":21062,"activeCount":101},[],{"trials":21064,"activeCount":101},[21065],{"nctId":21066,"briefTitle":21067,"status":107,"phases":21068,"primaryCompletion":7381,"start":7003,"enrollment":2123,"conditions":21069,"interventions":21070},"NCT02209805","Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects",[90],[15],[21059,21071],"BIRB 796 BS, high dose",{"trials":21073,"activeCount":101},[21074,21081],{"nctId":21075,"briefTitle":21076,"status":162,"phases":21077,"primaryCompletion":2112,"start":21078,"enrollment":11734,"conditions":21079,"interventions":21080},"NCT02214888","Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis",[91],"2003-05",[10667],[21059,21071],{"nctId":21082,"briefTitle":21083,"status":107,"phases":21084,"primaryCompletion":6375,"start":2121,"enrollment":21085,"conditions":21086,"interventions":21087},"NCT02209753","BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis",[91],182,[114],[21059,21088,21089,21071],"BIRB 796 BS, medium dose 1","BIRB 796 BS, medium dose 2",{"trials":21091,"activeCount":101},[],{"trials":21093,"activeCount":101},[],{"trials":21095,"activeCount":101},[],{"intervention":21071,"totalTrials":1044,"cells":21097},{"EARLY_PHASE1":21098,"PHASE1":21100,"PHASE2":21106,"PHASE3":21116,"PHASE4":21118,"NA":21120},{"trials":21099,"activeCount":101},[],{"trials":21101,"activeCount":101},[21102],{"nctId":21066,"briefTitle":21067,"status":107,"phases":21103,"primaryCompletion":7381,"start":7003,"enrollment":2123,"conditions":21104,"interventions":21105},[90],[15],[21059,21071],{"trials":21107,"activeCount":101},[21108,21112],{"nctId":21075,"briefTitle":21076,"status":162,"phases":21109,"primaryCompletion":2112,"start":21078,"enrollment":11734,"conditions":21110,"interventions":21111},[91],[10667],[21059,21071],{"nctId":21082,"briefTitle":21083,"status":107,"phases":21113,"primaryCompletion":6375,"start":2121,"enrollment":21085,"conditions":21114,"interventions":21115},[91],[114],[21059,21088,21089,21071],{"trials":21117,"activeCount":101},[],{"trials":21119,"activeCount":101},[],{"trials":21121,"activeCount":101},[],{"intervention":21123,"totalTrials":1044,"cells":21124},"Exemestane",{"EARLY_PHASE1":21125,"PHASE1":21127,"PHASE2":21145,"PHASE3":21156,"PHASE4":21158,"NA":21160},{"trials":21126,"activeCount":101},[],{"trials":21128,"activeCount":101},[21129,21133],{"nctId":10590,"briefTitle":10591,"status":107,"phases":21130,"primaryCompletion":10593,"completion":10594,"start":10595,"enrollment":319,"conditions":21131,"interventions":21132},[90],[33],[10598,10599,10598,10598,10600],{"nctId":21134,"briefTitle":21135,"status":107,"phases":21136,"primaryCompletion":21137,"completion":21138,"start":21139,"enrollment":21140,"conditions":21141,"interventions":21142},"NCT02123823","BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer",[90],"2016-11-25","2021-12-14","2014-05-15",164,[33],[21143,21123,21144],"Everolimus","BI 836845",{"trials":21146,"activeCount":101},[21147],{"nctId":21148,"briefTitle":21149,"status":107,"phases":21150,"primaryCompletion":21151,"completion":21152,"start":5388,"enrollment":5857,"conditions":21153,"interventions":21154},"NCT03659136","The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread",[91],"2021-08-30","2022-05-11",[2629],[21155,21143,21123],"Xentuzumab",{"trials":21157,"activeCount":101},[],{"trials":21159,"activeCount":101},[],{"trials":21161,"activeCount":101},[],{"intervention":21163,"totalTrials":1044,"cells":21164},"BI 765845",{"EARLY_PHASE1":21165,"PHASE1":21167,"PHASE2":21186,"PHASE3":21195,"PHASE4":21197,"NA":21199},{"trials":21166,"activeCount":101},[],{"trials":21168,"activeCount":101},[21169,21177],{"nctId":21170,"briefTitle":21171,"status":107,"phases":21172,"primaryCompletion":21173,"completion":21173,"start":21174,"enrollment":132,"conditions":21175,"interventions":21176},"NCT06139341","A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated",[90],"2023-12-17","2023-07-21",[15],[21163],{"nctId":21178,"briefTitle":21179,"status":107,"phases":21180,"primaryCompletion":21181,"completion":21181,"start":21182,"enrollment":21183,"conditions":21184,"interventions":21185},"NCT06139315","A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People",[90],"2023-06-07","2022-06-02",92,[15],[21163],{"trials":21187,"activeCount":101},[21188],{"nctId":21189,"briefTitle":21190,"status":162,"phases":21191,"primaryCompletion":20344,"completion":1272,"start":21192,"enrollment":9807,"conditions":21193,"interventions":21194},"NCT06139328","IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack",[91],"2023-12-05",[632],[21163],{"trials":21196,"activeCount":101},[],{"trials":21198,"activeCount":101},[],{"trials":21200,"activeCount":101},[],{"intervention":1130,"totalTrials":1044,"cells":21202},{"EARLY_PHASE1":21203,"PHASE1":21205,"PHASE2":21220,"PHASE3":21229,"PHASE4":21231,"NA":21233},{"trials":21204,"activeCount":101},[],{"trials":21206,"activeCount":101},[21207,21216],{"nctId":21208,"briefTitle":21209,"status":107,"phases":21210,"primaryCompletion":723,"completion":723,"start":21211,"enrollment":448,"conditions":21212,"interventions":21214},"NCT00977431","Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform",[90],"2009-09-17",[21213],"Glioblastoma",[21215,1130,1130],"Temozolomide",{"nctId":1122,"briefTitle":1123,"status":107,"phases":21217,"primaryCompletion":1125,"completion":1125,"start":1114,"enrollment":1126,"conditions":21218,"interventions":21219},[90],[33],[1120,1010,1129,1120,1130,1120,1010,1131,1129,1129],{"trials":21221,"activeCount":101},[21222],{"nctId":21223,"briefTitle":21224,"status":107,"phases":21225,"primaryCompletion":7338,"start":4413,"enrollment":1991,"conditions":21226,"interventions":21227},"NCT00730925","Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients",[91],[36],[1130,21228],"BIBW2992 + paclitaxel",{"trials":21230,"activeCount":101},[],{"trials":21232,"activeCount":101},[],{"trials":21234,"activeCount":101},[],{"intervention":21236,"totalTrials":1044,"cells":21237},"BIBR 277",{"EARLY_PHASE1":21238,"PHASE1":21240,"PHASE2":21254,"PHASE3":21262,"PHASE4":21264,"NA":21266},{"trials":21239,"activeCount":101},[],{"trials":21241,"activeCount":101},[21242,21248],{"nctId":21243,"briefTitle":21244,"status":107,"phases":21245,"primaryCompletion":6494,"start":6495,"enrollment":357,"conditions":21246,"interventions":21247},"NCT02262585","Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers",[90],[15],[21236,21236],{"nctId":21249,"briefTitle":21250,"status":107,"phases":21251,"primaryCompletion":6494,"start":6495,"enrollment":357,"conditions":21252,"interventions":21253},"NCT02262559","Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers",[90],[15],[21236,21236],{"trials":21255,"activeCount":101},[21256],{"nctId":21257,"briefTitle":21258,"status":107,"phases":21259,"primaryCompletion":6738,"start":7395,"enrollment":97,"conditions":21260,"interventions":21261},"NCT02187484","BIBR 277 Capsules in Hypertensive Patients With Nephropathy",[91],[24],[21236],{"trials":21263,"activeCount":101},[],{"trials":21265,"activeCount":101},[],{"trials":21267,"activeCount":101},[],{"intervention":21269,"totalTrials":1044,"cells":21270},"BI 836858",{"EARLY_PHASE1":21271,"PHASE1":21273,"PHASE2":21283,"PHASE3":21300,"PHASE4":21302,"NA":21304},{"trials":21272,"activeCount":101},[],{"trials":21274,"activeCount":101},[21275],{"nctId":21276,"briefTitle":21277,"status":107,"phases":21278,"primaryCompletion":21279,"completion":21279,"start":21280,"enrollment":357,"conditions":21281,"interventions":21282},"NCT01690624","BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse",[90],"2018-05-21","2012-09-13",[10147],[21269],{"trials":21284,"activeCount":101},[21285,21293],{"nctId":21286,"briefTitle":21287,"status":107,"phases":21288,"primaryCompletion":217,"completion":217,"start":21289,"enrollment":2123,"conditions":21290,"interventions":21291},"NCT02632721","A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)",[90,91],"2016-06-16",[10147],[21292,21269],"Decitabine",{"nctId":21294,"briefTitle":21295,"status":162,"phases":21296,"primaryCompletion":1629,"completion":1629,"start":21297,"enrollment":251,"conditions":21298,"interventions":21299},"NCT02240706","Phase I\u002FII Trial to Investigate BI 836858 in Myelodysplastic Syndromes",[91],"2015-01-22",[10156],[21269],{"trials":21301,"activeCount":101},[],{"trials":21303,"activeCount":101},[],{"trials":21305,"activeCount":101},[],{"intervention":7155,"totalTrials":1044,"cells":21307},{"EARLY_PHASE1":21308,"PHASE1":21310,"PHASE2":21316,"PHASE3":21331,"PHASE4":21333,"NA":21335},{"trials":21309,"activeCount":101},[],{"trials":21311,"activeCount":101},[21312],{"nctId":11318,"briefTitle":11319,"status":107,"phases":21313,"primaryCompletion":2145,"start":4461,"enrollment":448,"conditions":21314,"interventions":21315},[90],[15],[5945,7155,11323],{"trials":21317,"activeCount":101},[21318,21322],{"nctId":7148,"briefTitle":7149,"status":107,"phases":21319,"primaryCompletion":7151,"start":1981,"enrollment":7152,"conditions":21320,"interventions":21321},[91],[18],[7139,7155],{"nctId":21323,"briefTitle":21324,"status":107,"phases":21325,"primaryCompletion":7151,"start":1981,"enrollment":5086,"conditions":21326,"interventions":21327},"NCT02238106","Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[21328,21329,21330,7155],"Salmeterol medium dose","Salmeterol low dose","Salmeterol high dose",{"trials":21332,"activeCount":101},[],{"trials":21334,"activeCount":101},[],{"trials":21336,"activeCount":101},[],{"intervention":21338,"totalTrials":1044,"cells":21339},"BIII 890 CL",{"EARLY_PHASE1":21340,"PHASE1":21342,"PHASE2":21356,"PHASE3":21364,"PHASE4":21366,"NA":21368},{"trials":21341,"activeCount":101},[],{"trials":21343,"activeCount":101},[21344,21350],{"nctId":21345,"briefTitle":21346,"status":107,"phases":21347,"primaryCompletion":6949,"start":2181,"enrollment":19006,"conditions":21348,"interventions":21349},"NCT02269215","Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers",[90],[15],[21338],{"nctId":21351,"briefTitle":21352,"status":162,"phases":21353,"primaryCompletion":6206,"start":2182,"enrollment":5956,"conditions":21354,"interventions":21355},"NCT02268136","Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL",[90],[15],[21338],{"trials":21357,"activeCount":101},[21358],{"nctId":21359,"briefTitle":21360,"status":107,"phases":21361,"primaryCompletion":6189,"start":6884,"enrollment":5870,"conditions":21362,"interventions":21363},"NCT02251197","Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke",[91],[2092],[21338],{"trials":21365,"activeCount":101},[],{"trials":21367,"activeCount":101},[],{"trials":21369,"activeCount":101},[],{"intervention":18681,"totalTrials":1044,"cells":21371},{"EARLY_PHASE1":21372,"PHASE1":21374,"PHASE2":21384,"PHASE3":21390,"PHASE4":21392,"NA":21394},{"trials":21373,"activeCount":101},[],{"trials":21375,"activeCount":101},[21376,21380],{"nctId":18860,"briefTitle":18861,"status":107,"phases":21377,"primaryCompletion":18863,"completion":18863,"start":1663,"enrollment":132,"conditions":21378,"interventions":21379},[90],[15],[4095,18681],{"nctId":18675,"briefTitle":18676,"status":107,"phases":21381,"primaryCompletion":18678,"completion":4325,"start":5215,"enrollment":132,"conditions":21382,"interventions":21383},[90],[15],[4436,18681],{"trials":21385,"activeCount":101},[21386],{"nctId":18780,"briefTitle":18781,"status":107,"phases":21387,"primaryCompletion":18783,"completion":18784,"start":18785,"enrollment":18786,"conditions":21388,"interventions":21389},[91],[11139],[4436,18681],{"trials":21391,"activeCount":101},[],{"trials":21393,"activeCount":101},[],{"trials":21395,"activeCount":101},[],{"intervention":21397,"totalTrials":1044,"cells":21398},"Seresis®",{"EARLY_PHASE1":21399,"PHASE1":21401,"PHASE2":21416,"PHASE3":21424,"PHASE4":21426,"NA":21428},{"trials":21400,"activeCount":101},[],{"trials":21402,"activeCount":101},[21403,21410],{"nctId":21404,"briefTitle":21405,"status":107,"phases":21406,"primaryCompletion":7250,"start":21407,"enrollment":1081,"conditions":21408,"interventions":21409},"NCT02191787","Pharmacokinetic-pharmacodynamic Assessment of Seresis® in Healthy Volunteers",[90],"1998-03",[15],[21397],{"nctId":21411,"briefTitle":21412,"status":107,"phases":21413,"primaryCompletion":6207,"start":6391,"enrollment":155,"conditions":21414,"interventions":21415},"NCT02191852","Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers",[90],[15],[21397],{"trials":21417,"activeCount":101},[21418],{"nctId":21419,"briefTitle":21420,"status":107,"phases":21421,"primaryCompletion":2162,"start":6594,"enrollment":410,"conditions":21422,"interventions":21423},"NCT02191813","Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers",[91],[15],[21397],{"trials":21425,"activeCount":101},[],{"trials":21427,"activeCount":101},[],{"trials":21429,"activeCount":101},[],{"intervention":21155,"totalTrials":1044,"cells":21431},{"EARLY_PHASE1":21432,"PHASE1":21434,"PHASE2":21455,"PHASE3":21461,"PHASE4":21463,"NA":21465},{"trials":21433,"activeCount":101},[],{"trials":21435,"activeCount":101},[21436,21443],{"nctId":21437,"briefTitle":21438,"status":107,"phases":21439,"primaryCompletion":21440,"completion":21440,"start":19380,"enrollment":132,"conditions":21441,"interventions":21442},"NCT02191891","Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)",[90],"2018-04-18",[36],[21155,1492],{"nctId":21444,"briefTitle":21445,"status":107,"phases":21446,"primaryCompletion":581,"completion":21447,"start":21448,"enrollment":1918,"conditions":21449,"interventions":21450},"NCT03099174","This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer",[90],"2024-05-16","2017-05-04",[33,2629],[21155,21451,21452,21453,21454,21451],"Abemaciclib","Letrozole","Anastrozole","Fulvestrant",{"trials":21456,"activeCount":101},[21457],{"nctId":21148,"briefTitle":21149,"status":107,"phases":21458,"primaryCompletion":21151,"completion":21152,"start":5388,"enrollment":5857,"conditions":21459,"interventions":21460},[91],[2629],[21155,21143,21123],{"trials":21462,"activeCount":101},[],{"trials":21464,"activeCount":101},[],{"trials":21466,"activeCount":101},[],{"intervention":10301,"totalTrials":1044,"cells":21468},{"EARLY_PHASE1":21469,"PHASE1":21471,"PHASE2":21473,"PHASE3":21492,"PHASE4":21494,"NA":21496},{"trials":21470,"activeCount":101},[],{"trials":21472,"activeCount":101},[],{"trials":21474,"activeCount":101},[21475,21481,21488],{"nctId":21476,"briefTitle":21477,"status":107,"phases":21478,"primaryCompletion":20755,"start":6029,"enrollment":31,"conditions":21479,"interventions":21480},"NCT02170935","Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery",[91],[10299],[10301],{"nctId":21482,"briefTitle":21483,"status":107,"phases":21484,"primaryCompletion":2121,"start":6053,"enrollment":21485,"conditions":21486,"interventions":21487},"NCT02170701","BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery",[91],289,[10299],[10301],{"nctId":10294,"briefTitle":10295,"status":107,"phases":21489,"primaryCompletion":6472,"start":6082,"enrollment":10297,"conditions":21490,"interventions":21491},[91],[10299],[10285,10301,10301,10301,10301],{"trials":21493,"activeCount":101},[],{"trials":21495,"activeCount":101},[],{"trials":21497,"activeCount":101},[],{"intervention":6914,"totalTrials":1044,"cells":21499},{"EARLY_PHASE1":21500,"PHASE1":21502,"PHASE2":21512,"PHASE3":21522,"PHASE4":21524,"NA":21526},{"trials":21501,"activeCount":101},[],{"trials":21503,"activeCount":101},[21504,21508],{"nctId":6907,"briefTitle":6908,"status":107,"phases":21505,"primaryCompletion":6910,"start":6911,"enrollment":380,"conditions":21506,"interventions":21507},[90],[15],[6914,6890],{"nctId":6916,"briefTitle":6917,"status":107,"phases":21509,"primaryCompletion":2145,"start":6156,"enrollment":291,"conditions":21510,"interventions":21511},[90],[15],[6914,6890],{"trials":21513,"activeCount":101},[21514],{"nctId":21515,"briefTitle":21516,"status":162,"phases":21517,"primaryCompletion":10775,"start":6224,"enrollment":9606,"conditions":21518,"interventions":21520},"NCT00689052","Pramipexole ER vs. Placebo in Fibromyalgia",[91],[21519],"Fibromyalgia",[21521],"pramipexole ER",{"trials":21523,"activeCount":101},[],{"trials":21525,"activeCount":101},[],{"trials":21527,"activeCount":101},[],{"intervention":21529,"totalTrials":1075,"cells":21530},"olodaterol (BI 1744) low",{"EARLY_PHASE1":21531,"PHASE1":21533,"PHASE2":21535,"PHASE3":21559,"PHASE4":21561,"NA":21563},{"trials":21532,"activeCount":101},[],{"trials":21534,"activeCount":101},[],{"trials":21536,"activeCount":101},[21537,21548],{"nctId":21538,"briefTitle":21539,"status":107,"phases":21540,"primaryCompletion":9332,"start":6811,"enrollment":21541,"conditions":21542,"interventions":21543},"NCT01040403","Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)",[91],233,[18],[21529,21544,21545,21546,21547],"low tiotropium bromide","olodaterol (BI 1744) high","medium tiotropium bromide","high tiotropium bromide",{"nctId":21549,"briefTitle":21550,"status":107,"phases":21551,"primaryCompletion":6133,"completion":6133,"start":17427,"enrollment":6392,"conditions":21552,"interventions":21553},"NCT01013753","A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.",[91],[30],[21554,21555,21556,21557,21558],"Olodaterol (BI 1744) high","Olodaterol (BI 1744) medium","Olodaterol (BI 1744) very low","Formoterol 12 mcg","Olodaterol (BI 1744) low",{"trials":21560,"activeCount":101},[],{"trials":21562,"activeCount":101},[],{"trials":21564,"activeCount":101},[],{"intervention":21545,"totalTrials":1075,"cells":21566},{"EARLY_PHASE1":21567,"PHASE1":21569,"PHASE2":21571,"PHASE3":21581,"PHASE4":21583,"NA":21585},{"trials":21568,"activeCount":101},[],{"trials":21570,"activeCount":101},[],{"trials":21572,"activeCount":101},[21573,21577],{"nctId":21538,"briefTitle":21539,"status":107,"phases":21574,"primaryCompletion":9332,"start":6811,"enrollment":21541,"conditions":21575,"interventions":21576},[91],[18],[21529,21544,21545,21546,21547],{"nctId":21549,"briefTitle":21550,"status":107,"phases":21578,"primaryCompletion":6133,"completion":6133,"start":17427,"enrollment":6392,"conditions":21579,"interventions":21580},[91],[30],[21554,21555,21556,21557,21558],{"trials":21582,"activeCount":101},[],{"trials":21584,"activeCount":101},[],{"trials":21586,"activeCount":101},[],{"intervention":11439,"totalTrials":1075,"cells":21588},{"EARLY_PHASE1":21589,"PHASE1":21591,"PHASE2":21597,"PHASE3":21603,"PHASE4":21605,"NA":21607},{"trials":21590,"activeCount":101},[],{"trials":21592,"activeCount":101},[21593],{"nctId":11434,"briefTitle":11435,"status":107,"phases":21594,"primaryCompletion":5283,"completion":5283,"start":4391,"enrollment":251,"conditions":21595,"interventions":21596},[90],[21],[11439,11427,11440],{"trials":21598,"activeCount":101},[21599],{"nctId":11444,"briefTitle":11445,"status":107,"phases":21600,"primaryCompletion":11447,"completion":11448,"start":11449,"enrollment":410,"conditions":21601,"interventions":21602},[91],[538],[11439,11440,11427],{"trials":21604,"activeCount":101},[],{"trials":21606,"activeCount":101},[],{"trials":21608,"activeCount":101},[],{"intervention":20538,"totalTrials":1075,"cells":21610},{"EARLY_PHASE1":21611,"PHASE1":21613,"PHASE2":21615,"PHASE3":21628,"PHASE4":21630,"NA":21632},{"trials":21612,"activeCount":101},[],{"trials":21614,"activeCount":101},[],{"trials":21616,"activeCount":101},[21617,21624],{"nctId":21618,"briefTitle":21619,"status":600,"phases":21620,"primaryCompletion":408,"start":390,"enrollment":101,"conditions":21621,"interventions":21622},"NCT01458912","Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids",[91],[30],[20538,21623],"BI 54903 HD",{"nctId":20533,"briefTitle":20534,"status":600,"phases":21625,"primaryCompletion":408,"start":390,"enrollment":101,"conditions":21626,"interventions":21627},[91],[30],[20538,6304],{"trials":21629,"activeCount":101},[],{"trials":21631,"activeCount":101},[],{"trials":21633,"activeCount":101},[],{"intervention":21635,"totalTrials":1075,"cells":21636},"BIBW 2948 BS",{"EARLY_PHASE1":21637,"PHASE1":21639,"PHASE2":21641,"PHASE3":21658,"PHASE4":21660,"NA":21662},{"trials":21638,"activeCount":101},[],{"trials":21640,"activeCount":101},[],{"trials":21642,"activeCount":101},[21643,21652],{"nctId":21644,"briefTitle":21645,"status":107,"phases":21646,"primaryCompletion":21647,"completion":21647,"start":21648,"enrollment":410,"conditions":21649,"interventions":21651},"NCT00423137","Effect of BIBW 2948 BS in COPD",[91],"2008-07-09","2007-01-17",[18,21650],"Bronchitis, Chronic",[21635],{"nctId":21653,"briefTitle":21654,"status":600,"phases":21655,"primaryCompletion":5856,"start":6223,"enrollment":101,"conditions":21656,"interventions":21657},"NCT00726479","Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis",[91],[18,21650],[21635],{"trials":21659,"activeCount":101},[],{"trials":21661,"activeCount":101},[],{"trials":21663,"activeCount":101},[],{"intervention":21665,"totalTrials":1075,"cells":21666},"NS 2330",{"EARLY_PHASE1":21667,"PHASE1":21669,"PHASE2":21671,"PHASE3":21685,"PHASE4":21687,"NA":21689},{"trials":21668,"activeCount":101},[],{"trials":21670,"activeCount":101},[],{"trials":21672,"activeCount":101},[21673,21679],{"nctId":21674,"briefTitle":21675,"status":107,"phases":21676,"primaryCompletion":15139,"start":6871,"enrollment":19939,"conditions":21677,"interventions":21678},"NCT00148486","A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 \u002F SCEPTRE)",[91],[6934],[21665],{"nctId":21680,"briefTitle":21681,"status":107,"phases":21682,"primaryCompletion":15139,"start":6081,"enrollment":1020,"conditions":21683,"interventions":21684},"NCT00153010","An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type",[91],[11139],[21665],{"trials":21686,"activeCount":101},[],{"trials":21688,"activeCount":101},[],{"trials":21690,"activeCount":101},[],{"intervention":20699,"totalTrials":1075,"cells":21692},{"EARLY_PHASE1":21693,"PHASE1":21695,"PHASE2":21697,"PHASE3":21710,"PHASE4":21712,"NA":21714},{"trials":21694,"activeCount":101},[],{"trials":21696,"activeCount":101},[],{"trials":21698,"activeCount":101},[21699,21703],{"nctId":20692,"briefTitle":20693,"status":162,"phases":21700,"primaryCompletion":20695,"completion":20671,"start":20696,"enrollment":2123,"conditions":21701,"interventions":21702},[91],[190],[20661,20699],{"nctId":21704,"briefTitle":21705,"status":107,"phases":21706,"primaryCompletion":475,"completion":7092,"start":12159,"enrollment":7681,"conditions":21707,"interventions":21708},"NCT02054481","BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab",[91],[114],[21709,21709,20699,21709],"BI 655066",{"trials":21711,"activeCount":101},[],{"trials":21713,"activeCount":101},[],{"trials":21715,"activeCount":101},[],{"intervention":21717,"totalTrials":1075,"cells":21718},"Albuterol HFA MDI",{"EARLY_PHASE1":21719,"PHASE1":21721,"PHASE2":21723,"PHASE3":21740,"PHASE4":21742,"NA":21744},{"trials":21720,"activeCount":101},[],{"trials":21722,"activeCount":101},[],{"trials":21724,"activeCount":101},[21725,21733],{"nctId":21726,"briefTitle":21727,"status":107,"phases":21728,"primaryCompletion":400,"start":2032,"enrollment":15618,"conditions":21729,"interventions":21730},"NCT00818454","4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma",[91],[30],[21731,21717,21732],"Combivent CFC MDI","Respimat Combivent",{"nctId":21734,"briefTitle":21735,"status":107,"phases":21736,"primaryCompletion":4461,"start":8086,"enrollment":5407,"conditions":21737,"interventions":21738},"NCT00096616","Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma",[91],[30],[21739,21717],"Combivent® CFC MDI",{"trials":21741,"activeCount":101},[],{"trials":21743,"activeCount":101},[],{"trials":21745,"activeCount":101},[],{"intervention":21747,"totalTrials":1075,"cells":21748},"Anthocyan",{"EARLY_PHASE1":21749,"PHASE1":21751,"PHASE2":21753,"PHASE3":21768,"PHASE4":21770,"NA":21772},{"trials":21750,"activeCount":101},[],{"trials":21752,"activeCount":101},[],{"trials":21754,"activeCount":101},[21755,21761],{"nctId":21756,"briefTitle":21757,"status":107,"phases":21758,"primaryCompletion":2162,"start":6206,"enrollment":3575,"conditions":21759,"interventions":21760},"NCT02194361","Efficacy of a Standardised Bilberry Extract in Improving the Night Vision of Healthy Volunteers",[91],[15],[21747],{"nctId":21762,"briefTitle":21763,"status":107,"phases":21764,"primaryCompletion":6391,"start":11123,"enrollment":21765,"conditions":21766,"interventions":21767},"NCT02194127","Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision",[91],195,[15],[21747],{"trials":21769,"activeCount":101},[],{"trials":21771,"activeCount":101},[],{"trials":21773,"activeCount":101},[],{"intervention":10869,"totalTrials":1075,"cells":21775},{"EARLY_PHASE1":21776,"PHASE1":21778,"PHASE2":21787,"PHASE3":21793,"PHASE4":21795,"NA":21797},{"trials":21777,"activeCount":101},[],{"trials":21779,"activeCount":101},[21780],{"nctId":21781,"briefTitle":21782,"status":107,"phases":21783,"enrollment":380,"conditions":21784,"interventions":21785},"NCT00002381","The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine",[90],[27],[21786,2186,10869],"Nelfinavir mesylate",{"trials":21788,"activeCount":101},[21789],{"nctId":10863,"briefTitle":10864,"status":107,"phases":21790,"primaryCompletion":2163,"start":6453,"enrollment":392,"conditions":21791,"interventions":21792},[91],[27],[4008,4010,10868,7579,10854,10869],{"trials":21794,"activeCount":101},[],{"trials":21796,"activeCount":101},[],{"trials":21798,"activeCount":101},[],{"intervention":21800,"totalTrials":1075,"cells":21801},"Low dose of BIIL 284 BS",{"EARLY_PHASE1":21802,"PHASE1":21804,"PHASE2":21813,"PHASE3":21823,"PHASE4":21825,"NA":21827},{"trials":21803,"activeCount":101},[],{"trials":21805,"activeCount":101},[21806],{"nctId":21807,"briefTitle":21808,"status":107,"phases":21809,"primaryCompletion":2122,"start":2181,"enrollment":1982,"conditions":21810,"interventions":21811},"NCT02247375","Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)",[90],[10667],[21800,21812],"High dose of BIIL 284 BS",{"trials":21814,"activeCount":101},[21815],{"nctId":21816,"briefTitle":21817,"status":107,"phases":21818,"primaryCompletion":6494,"start":6005,"enrollment":21819,"conditions":21820,"interventions":21821},"NCT02249247","Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease",[91],577,[18],[21800,21822,21812],"Medium dose of BIIL 284 BS",{"trials":21824,"activeCount":101},[],{"trials":21826,"activeCount":101},[],{"trials":21828,"activeCount":101},[],{"intervention":21812,"totalTrials":1075,"cells":21830},{"EARLY_PHASE1":21831,"PHASE1":21833,"PHASE2":21839,"PHASE3":21845,"PHASE4":21847,"NA":21849},{"trials":21832,"activeCount":101},[],{"trials":21834,"activeCount":101},[21835],{"nctId":21807,"briefTitle":21808,"status":107,"phases":21836,"primaryCompletion":2122,"start":2181,"enrollment":1982,"conditions":21837,"interventions":21838},[90],[10667],[21800,21812],{"trials":21840,"activeCount":101},[21841],{"nctId":21816,"briefTitle":21817,"status":107,"phases":21842,"primaryCompletion":6494,"start":6005,"enrollment":21819,"conditions":21843,"interventions":21844},[91],[18],[21800,21822,21812],{"trials":21846,"activeCount":101},[],{"trials":21848,"activeCount":101},[],{"trials":21850,"activeCount":101},[],{"intervention":21852,"totalTrials":1075,"cells":21853},"Ipratropium bromide HFA-134a inhalation aerosol",{"EARLY_PHASE1":21854,"PHASE1":21856,"PHASE2":21858,"PHASE3":21874,"PHASE4":21876,"NA":21878},{"trials":21855,"activeCount":101},[],{"trials":21857,"activeCount":101},[],{"trials":21859,"activeCount":101},[21860,21867],{"nctId":21861,"briefTitle":21862,"status":107,"phases":21863,"primaryCompletion":7419,"start":6053,"enrollment":1991,"conditions":21864,"interventions":21865},"NCT02260011","Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease",[91],[18],[21852,21866],"Atrovent® CFC inhalation aerosol",{"nctId":21868,"briefTitle":21869,"status":107,"phases":21870,"primaryCompletion":6005,"start":6053,"enrollment":357,"conditions":21871,"interventions":21872},"NCT02236169","Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[21852,21873],"Atrovent CFC inhalation aerosol",{"trials":21875,"activeCount":101},[],{"trials":21877,"activeCount":101},[],{"trials":21879,"activeCount":101},[],{"intervention":21881,"totalTrials":1075,"cells":21882},"saquinavir",{"EARLY_PHASE1":21883,"PHASE1":21885,"PHASE2":21887,"PHASE3":21903,"PHASE4":21905,"NA":21907},{"trials":21884,"activeCount":101},[],{"trials":21886,"activeCount":101},[],{"trials":21888,"activeCount":101},[21889,21899],{"nctId":21890,"briefTitle":21891,"status":107,"phases":21892,"primaryCompletion":21893,"start":21894,"enrollment":11245,"conditions":21895,"interventions":21896},"NCT00056641","Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir \u002F Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients",[91],"2004-01-27","2003-02-18",[27],[18356,18357,21881,21897,21898],"amprenavir","lopinavir",{"nctId":20843,"briefTitle":20844,"status":162,"phases":21900,"primaryCompletion":6015,"start":6206,"enrollment":269,"conditions":21901,"interventions":21902},[91],[27],[20848,20849,20759,20760,20850],{"trials":21904,"activeCount":101},[],{"trials":21906,"activeCount":101},[],{"trials":21908,"activeCount":101},[],{"intervention":21897,"totalTrials":1075,"cells":21910},{"EARLY_PHASE1":21911,"PHASE1":21913,"PHASE2":21923,"PHASE3":21929,"PHASE4":21931,"NA":21933},{"trials":21912,"activeCount":101},[],{"trials":21914,"activeCount":101},[21915],{"nctId":21916,"briefTitle":21917,"status":162,"phases":21918,"primaryCompletion":6884,"start":2182,"enrollment":155,"conditions":21919,"interventions":21920},"NCT02182765","Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults",[90],[27],[2186,21921,21922],"Amprenavir","Abacavir",{"trials":21924,"activeCount":101},[21925],{"nctId":21890,"briefTitle":21891,"status":107,"phases":21926,"primaryCompletion":21893,"start":21894,"enrollment":11245,"conditions":21927,"interventions":21928},[91],[27],[18356,18357,21881,21897,21898],{"trials":21930,"activeCount":101},[],{"trials":21932,"activeCount":101},[],{"trials":21934,"activeCount":101},[],{"intervention":11238,"totalTrials":1075,"cells":21936},{"EARLY_PHASE1":21937,"PHASE1":21939,"PHASE2":21941,"PHASE3":21951,"PHASE4":21953,"NA":21955},{"trials":21938,"activeCount":101},[],{"trials":21940,"activeCount":101},[],{"trials":21942,"activeCount":101},[21943,21947],{"nctId":11230,"briefTitle":11231,"status":162,"phases":21944,"primaryCompletion":525,"completion":525,"start":6095,"enrollment":5568,"conditions":21945,"interventions":21946},[91],[10332,11234],[11236,11237,11238,11239,11240,11221],{"nctId":11242,"briefTitle":11243,"status":162,"phases":21948,"primaryCompletion":525,"completion":525,"start":391,"enrollment":11245,"conditions":21949,"interventions":21950},[91],[11247],[11239,11238,11236,11237,11240,11221],{"trials":21952,"activeCount":101},[],{"trials":21954,"activeCount":101},[],{"trials":21956,"activeCount":101},[],{"intervention":11767,"totalTrials":1075,"cells":21958},{"EARLY_PHASE1":21959,"PHASE1":21961,"PHASE2":21969,"PHASE3":21975,"PHASE4":21977,"NA":21979},{"trials":21960,"activeCount":101},[],{"trials":21962,"activeCount":101},[21963],{"nctId":21964,"briefTitle":21965,"status":107,"phases":21966,"primaryCompletion":9348,"completion":9348,"start":4517,"enrollment":3764,"conditions":21967,"interventions":21968},"NCT00701324","BI 811283 in Various Solid Tumours",[90],[33],[11767,11767,11767],{"trials":21970,"activeCount":101},[21971],{"nctId":11762,"briefTitle":11763,"status":107,"phases":21972,"primaryCompletion":9824,"completion":9824,"start":5906,"enrollment":2400,"conditions":21973,"interventions":21974},[91],[10147],[11767,10211,11767,10211],{"trials":21976,"activeCount":101},[],{"trials":21978,"activeCount":101},[],{"trials":21980,"activeCount":101},[],{"intervention":21982,"totalTrials":1075,"cells":21983},"BIBH 1",{"EARLY_PHASE1":21984,"PHASE1":21986,"PHASE2":21994,"PHASE3":22002,"PHASE4":22004,"NA":22006},{"trials":21985,"activeCount":101},[],{"trials":21987,"activeCount":101},[21988],{"nctId":21989,"briefTitle":21990,"status":162,"phases":21991,"primaryCompletion":6040,"start":6074,"enrollment":1512,"conditions":21992,"interventions":21993},"NCT02199886","Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection",[90],[2693],[21982],{"trials":21995,"activeCount":101},[21996],{"nctId":21997,"briefTitle":21998,"status":107,"phases":21999,"primaryCompletion":6053,"start":8538,"enrollment":439,"conditions":22000,"interventions":22001},"NCT02198274","Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer",[91],[3060],[21982],{"trials":22003,"activeCount":101},[],{"trials":22005,"activeCount":101},[],{"trials":22007,"activeCount":101},[],{"intervention":21143,"totalTrials":1075,"cells":22009},{"EARLY_PHASE1":22010,"PHASE1":22012,"PHASE2":22018,"PHASE3":22024,"PHASE4":22026,"NA":22028},{"trials":22011,"activeCount":101},[],{"trials":22013,"activeCount":101},[22014],{"nctId":21134,"briefTitle":21135,"status":107,"phases":22015,"primaryCompletion":21137,"completion":21138,"start":21139,"enrollment":21140,"conditions":22016,"interventions":22017},[90],[33],[21143,21123,21144],{"trials":22019,"activeCount":101},[22020],{"nctId":21148,"briefTitle":21149,"status":107,"phases":22021,"primaryCompletion":21151,"completion":21152,"start":5388,"enrollment":5857,"conditions":22022,"interventions":22023},[91],[2629],[21155,21143,21123],{"trials":22025,"activeCount":101},[],{"trials":22027,"activeCount":101},[],{"trials":22029,"activeCount":101},[],{"intervention":9692,"totalTrials":1075,"cells":22031},{"EARLY_PHASE1":22032,"PHASE1":22034,"PHASE2":22036,"PHASE3":22046,"PHASE4":22048,"NA":22050},{"trials":22033,"activeCount":101},[],{"trials":22035,"activeCount":101},[],{"trials":22037,"activeCount":101},[22038,22042],{"nctId":9685,"briefTitle":9686,"status":107,"phases":22039,"primaryCompletion":5233,"completion":9688,"start":9443,"enrollment":7015,"conditions":22040,"interventions":22041},[91],[9690],[9692,1119],{"nctId":9694,"briefTitle":9695,"status":107,"phases":22043,"primaryCompletion":9697,"completion":9698,"start":9699,"enrollment":9700,"conditions":22044,"interventions":22045},[91],[9690],[9692,1119],{"trials":22047,"activeCount":101},[],{"trials":22049,"activeCount":101},[],{"trials":22051,"activeCount":101},[],{"intervention":22053,"totalTrials":1075,"cells":22054},"Meloxicam 7.5 mg",{"EARLY_PHASE1":22055,"PHASE1":22057,"PHASE2":22059,"PHASE3":22082,"PHASE4":22084,"NA":22086},{"trials":22056,"activeCount":101},[],{"trials":22058,"activeCount":101},[],{"trials":22060,"activeCount":101},[22061,22073],{"nctId":22062,"briefTitle":22063,"status":107,"phases":22064,"primaryCompletion":7553,"start":6065,"enrollment":22065,"conditions":22066,"interventions":22067},"NCT02183051","Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar",[91],381,[6596],[22053,22068,22069,22070,22071,22072],"Meloxicam 3.75 mg","Meloxicam 1.875 mg","Ibuprofen 200 mg","Meloxicam 15 mg","Ibuprofen 400 mg",{"nctId":22074,"briefTitle":22075,"status":107,"phases":22076,"primaryCompletion":2182,"start":17270,"enrollment":22077,"conditions":22078,"interventions":22080},"NCT02183025","Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea",[91],337,[22079],"Dysmenorrhea",[22053,22071,22081],"Mefenamic acid 500 mg",{"trials":22083,"activeCount":101},[],{"trials":22085,"activeCount":101},[],{"trials":22087,"activeCount":101},[],{"intervention":22071,"totalTrials":1075,"cells":22089},{"EARLY_PHASE1":22090,"PHASE1":22092,"PHASE2":22094,"PHASE3":22104,"PHASE4":22106,"NA":22108},{"trials":22091,"activeCount":101},[],{"trials":22093,"activeCount":101},[],{"trials":22095,"activeCount":101},[22096,22100],{"nctId":22062,"briefTitle":22063,"status":107,"phases":22097,"primaryCompletion":7553,"start":6065,"enrollment":22065,"conditions":22098,"interventions":22099},[91],[6596],[22053,22068,22069,22070,22071,22072],{"nctId":22074,"briefTitle":22075,"status":107,"phases":22101,"primaryCompletion":2182,"start":17270,"enrollment":22077,"conditions":22102,"interventions":22103},[91],[22079],[22053,22071,22081],{"trials":22105,"activeCount":101},[],{"trials":22107,"activeCount":101},[],{"trials":22109,"activeCount":101},[],{"intervention":22111,"totalTrials":1075,"cells":22112},"BI 425809 dose 1",{"EARLY_PHASE1":22113,"PHASE1":22115,"PHASE2":22117,"PHASE3":22141,"PHASE4":22143,"NA":22145},{"trials":22114,"activeCount":101},[],{"trials":22116,"activeCount":101},[],{"trials":22118,"activeCount":101},[22119,22132],{"nctId":22120,"briefTitle":22121,"status":107,"phases":22122,"primaryCompletion":22123,"completion":22124,"start":22125,"enrollment":22126,"conditions":22127,"interventions":22128},"NCT02832037","Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia",[91],"2019-12-27","2020-01-29","2016-07-25",509,[10549],[22111,22129,22130,22131],"BI 425809 dose 2","BI 425809 dose 3","BI 425809 dose 4",{"nctId":22133,"briefTitle":22134,"status":107,"phases":22135,"primaryCompletion":22136,"completion":22137,"start":22138,"enrollment":10576,"conditions":22139,"interventions":22140},"NCT02788513","BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.",[91],"2019-09-12","2019-10-11","2016-08-11",[11139],[22111,22129,22130,22131],{"trials":22142,"activeCount":101},[],{"trials":22144,"activeCount":101},[],{"trials":22146,"activeCount":101},[],{"intervention":22129,"totalTrials":1075,"cells":22148},{"EARLY_PHASE1":22149,"PHASE1":22151,"PHASE2":22153,"PHASE3":22163,"PHASE4":22165,"NA":22167},{"trials":22150,"activeCount":101},[],{"trials":22152,"activeCount":101},[],{"trials":22154,"activeCount":101},[22155,22159],{"nctId":22120,"briefTitle":22121,"status":107,"phases":22156,"primaryCompletion":22123,"completion":22124,"start":22125,"enrollment":22126,"conditions":22157,"interventions":22158},[91],[10549],[22111,22129,22130,22131],{"nctId":22133,"briefTitle":22134,"status":107,"phases":22160,"primaryCompletion":22136,"completion":22137,"start":22138,"enrollment":10576,"conditions":22161,"interventions":22162},[91],[11139],[22111,22129,22130,22131],{"trials":22164,"activeCount":101},[],{"trials":22166,"activeCount":101},[],{"trials":22168,"activeCount":101},[],{"intervention":22130,"totalTrials":1075,"cells":22170},{"EARLY_PHASE1":22171,"PHASE1":22173,"PHASE2":22175,"PHASE3":22185,"PHASE4":22187,"NA":22189},{"trials":22172,"activeCount":101},[],{"trials":22174,"activeCount":101},[],{"trials":22176,"activeCount":101},[22177,22181],{"nctId":22120,"briefTitle":22121,"status":107,"phases":22178,"primaryCompletion":22123,"completion":22124,"start":22125,"enrollment":22126,"conditions":22179,"interventions":22180},[91],[10549],[22111,22129,22130,22131],{"nctId":22133,"briefTitle":22134,"status":107,"phases":22182,"primaryCompletion":22136,"completion":22137,"start":22138,"enrollment":10576,"conditions":22183,"interventions":22184},[91],[11139],[22111,22129,22130,22131],{"trials":22186,"activeCount":101},[],{"trials":22188,"activeCount":101},[],{"trials":22190,"activeCount":101},[],{"intervention":22131,"totalTrials":1075,"cells":22192},{"EARLY_PHASE1":22193,"PHASE1":22195,"PHASE2":22197,"PHASE3":22207,"PHASE4":22209,"NA":22211},{"trials":22194,"activeCount":101},[],{"trials":22196,"activeCount":101},[],{"trials":22198,"activeCount":101},[22199,22203],{"nctId":22120,"briefTitle":22121,"status":107,"phases":22200,"primaryCompletion":22123,"completion":22124,"start":22125,"enrollment":22126,"conditions":22201,"interventions":22202},[91],[10549],[22111,22129,22130,22131],{"nctId":22133,"briefTitle":22134,"status":107,"phases":22204,"primaryCompletion":22136,"completion":22137,"start":22138,"enrollment":10576,"conditions":22205,"interventions":22206},[91],[11139],[22111,22129,22130,22131],{"trials":22208,"activeCount":101},[],{"trials":22210,"activeCount":101},[],{"trials":22212,"activeCount":101},[],{"intervention":22214,"totalTrials":1075,"cells":22215},"BI 695501 prefilled syringe",{"EARLY_PHASE1":22216,"PHASE1":22218,"PHASE2":22229,"PHASE3":22241,"PHASE4":22243,"NA":22245},{"trials":22217,"activeCount":101},[],{"trials":22219,"activeCount":101},[22220],{"nctId":22221,"briefTitle":22222,"status":107,"phases":22223,"primaryCompletion":22224,"completion":22225,"start":756,"enrollment":2898,"conditions":22226,"interventions":22227},"NCT02606903","Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector",[90],"2016-09-07","2016-10-04",[15],[22214,22228],"BI 695501 autoinjector",{"trials":22230,"activeCount":101},[22231],{"nctId":22232,"briefTitle":22233,"status":107,"phases":22234,"primaryCompletion":22235,"completion":18653,"start":22236,"enrollment":2772,"conditions":22237,"interventions":22238},"NCT02636907","Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe",[91],"2016-06-21","2016-01-06",[10667],[22239,22240],"BI 695501 Autoinjector","BI 695501 Prefilled syringe",{"trials":22242,"activeCount":101},[],{"trials":22244,"activeCount":101},[],{"trials":22246,"activeCount":101},[],{"intervention":22228,"totalTrials":1075,"cells":22248},{"EARLY_PHASE1":22249,"PHASE1":22251,"PHASE2":22257,"PHASE3":22263,"PHASE4":22265,"NA":22267},{"trials":22250,"activeCount":101},[],{"trials":22252,"activeCount":101},[22253],{"nctId":22221,"briefTitle":22222,"status":107,"phases":22254,"primaryCompletion":22224,"completion":22225,"start":756,"enrollment":2898,"conditions":22255,"interventions":22256},[90],[15],[22214,22228],{"trials":22258,"activeCount":101},[22259],{"nctId":22232,"briefTitle":22233,"status":107,"phases":22260,"primaryCompletion":22235,"completion":18653,"start":22236,"enrollment":2772,"conditions":22261,"interventions":22262},[91],[10667],[22239,22240],{"trials":22264,"activeCount":101},[],{"trials":22266,"activeCount":101},[],{"trials":22268,"activeCount":101},[],{"intervention":21452,"totalTrials":1075,"cells":22270},{"EARLY_PHASE1":22271,"PHASE1":22273,"PHASE2":22279,"PHASE3":22287,"PHASE4":22289,"NA":22291},{"trials":22272,"activeCount":101},[],{"trials":22274,"activeCount":101},[22275],{"nctId":21444,"briefTitle":21445,"status":107,"phases":22276,"primaryCompletion":581,"completion":21447,"start":21448,"enrollment":1918,"conditions":22277,"interventions":22278},[90],[33,2629],[21155,21451,21452,21453,21454,21451],{"trials":22280,"activeCount":101},[22281],{"nctId":22282,"briefTitle":22283,"status":107,"phases":22284,"primaryCompletion":17427,"start":7573,"enrollment":1865,"conditions":22285,"interventions":22286},"NCT00708214","BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer",[91],[2629],[1129,1129,21452,21452],{"trials":22288,"activeCount":101},[],{"trials":22290,"activeCount":101},[],{"trials":22292,"activeCount":101},[],{"intervention":22294,"totalTrials":1075,"cells":22295},"GINSANA",{"EARLY_PHASE1":22296,"PHASE1":22298,"PHASE2":22300,"PHASE3":22315,"PHASE4":22317,"NA":22319},{"trials":22297,"activeCount":101},[],{"trials":22299,"activeCount":101},[],{"trials":22301,"activeCount":101},[22302,22308],{"nctId":22303,"briefTitle":22304,"status":107,"phases":22305,"primaryCompletion":6207,"start":6453,"enrollment":993,"conditions":22306,"interventions":22307},"NCT02182882","Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People",[91],[15],[22294],{"nctId":22309,"briefTitle":22310,"status":107,"phases":22311,"primaryCompletion":2163,"start":6246,"enrollment":1982,"conditions":22312,"interventions":22313},"NCT02182934","Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy Recreational Sports People",[91],[15],[22314],"Ginsana",{"trials":22316,"activeCount":101},[],{"trials":22318,"activeCount":101},[],{"trials":22320,"activeCount":101},[],{"intervention":6456,"totalTrials":1075,"cells":22322},{"EARLY_PHASE1":22323,"PHASE1":22325,"PHASE2":22331,"PHASE3":22340,"PHASE4":22342,"NA":22344},{"trials":22324,"activeCount":101},[],{"trials":22326,"activeCount":101},[22327],{"nctId":6450,"briefTitle":6451,"status":107,"phases":22328,"primaryCompletion":6453,"start":5923,"enrollment":177,"conditions":22329,"interventions":22330},[90],[15],[6456,6420],{"trials":22332,"activeCount":101},[22333],{"nctId":22334,"briefTitle":22335,"status":162,"phases":22336,"primaryCompletion":6594,"start":7553,"enrollment":1116,"conditions":22337,"interventions":22339},"NCT02223494","Safety of Terbogrel in Patients With Primary Pulmonary Hypertension",[91],[22338],"Hypertension, Pulmonary",[6456],{"trials":22341,"activeCount":101},[],{"trials":22343,"activeCount":101},[],{"trials":22345,"activeCount":101},[],{"intervention":22347,"totalTrials":272,"cells":22348},"Tiotropium 5 mcg qd",{"EARLY_PHASE1":22349,"PHASE1":22351,"PHASE2":22353,"PHASE3":22362,"PHASE4":22364,"NA":22366},{"trials":22350,"activeCount":101},[],{"trials":22352,"activeCount":101},[],{"trials":22354,"activeCount":101},[22355],{"nctId":22356,"briefTitle":22357,"status":107,"phases":22358,"primaryCompletion":525,"completion":525,"start":2001,"enrollment":300,"conditions":22359,"interventions":22360},"NCT01696071","Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication",[91],[30],[22347,22361],"Tiotropium 2.5 mcg bid",{"trials":22363,"activeCount":101},[],{"trials":22365,"activeCount":101},[],{"trials":22367,"activeCount":101},[],{"intervention":22361,"totalTrials":272,"cells":22369},{"EARLY_PHASE1":22370,"PHASE1":22372,"PHASE2":22374,"PHASE3":22380,"PHASE4":22382,"NA":22384},{"trials":22371,"activeCount":101},[],{"trials":22373,"activeCount":101},[],{"trials":22375,"activeCount":101},[22376],{"nctId":22356,"briefTitle":22357,"status":107,"phases":22377,"primaryCompletion":525,"completion":525,"start":2001,"enrollment":300,"conditions":22378,"interventions":22379},[91],[30],[22347,22361],{"trials":22381,"activeCount":101},[],{"trials":22383,"activeCount":101},[],{"trials":22385,"activeCount":101},[],{"intervention":10726,"totalTrials":272,"cells":22387},{"EARLY_PHASE1":22388,"PHASE1":22390,"PHASE2":22392,"PHASE3":22398,"PHASE4":22400,"NA":22402},{"trials":22389,"activeCount":101},[],{"trials":22391,"activeCount":101},[],{"trials":22393,"activeCount":101},[22394],{"nctId":10720,"briefTitle":10721,"status":107,"phases":22395,"primaryCompletion":390,"start":4412,"enrollment":10723,"conditions":22396,"interventions":22397},[91],[4040],[10726,9828,10727,9828,10728,9828,10728,9828,10729,9828,9828,10728,9828],{"trials":22399,"activeCount":101},[],{"trials":22401,"activeCount":101},[],{"trials":22403,"activeCount":101},[],{"intervention":10727,"totalTrials":272,"cells":22405},{"EARLY_PHASE1":22406,"PHASE1":22408,"PHASE2":22410,"PHASE3":22416,"PHASE4":22418,"NA":22420},{"trials":22407,"activeCount":101},[],{"trials":22409,"activeCount":101},[],{"trials":22411,"activeCount":101},[22412],{"nctId":10720,"briefTitle":10721,"status":107,"phases":22413,"primaryCompletion":390,"start":4412,"enrollment":10723,"conditions":22414,"interventions":22415},[91],[4040],[10726,9828,10727,9828,10728,9828,10728,9828,10729,9828,9828,10728,9828],{"trials":22417,"activeCount":101},[],{"trials":22419,"activeCount":101},[],{"trials":22421,"activeCount":101},[],{"intervention":10728,"totalTrials":272,"cells":22423},{"EARLY_PHASE1":22424,"PHASE1":22426,"PHASE2":22428,"PHASE3":22434,"PHASE4":22436,"NA":22438},{"trials":22425,"activeCount":101},[],{"trials":22427,"activeCount":101},[],{"trials":22429,"activeCount":101},[22430],{"nctId":10720,"briefTitle":10721,"status":107,"phases":22431,"primaryCompletion":390,"start":4412,"enrollment":10723,"conditions":22432,"interventions":22433},[91],[4040],[10726,9828,10727,9828,10728,9828,10728,9828,10729,9828,9828,10728,9828],{"trials":22435,"activeCount":101},[],{"trials":22437,"activeCount":101},[],{"trials":22439,"activeCount":101},[],{"intervention":10729,"totalTrials":272,"cells":22441},{"EARLY_PHASE1":22442,"PHASE1":22444,"PHASE2":22446,"PHASE3":22452,"PHASE4":22454,"NA":22456},{"trials":22443,"activeCount":101},[],{"trials":22445,"activeCount":101},[],{"trials":22447,"activeCount":101},[22448],{"nctId":10720,"briefTitle":10721,"status":107,"phases":22449,"primaryCompletion":390,"start":4412,"enrollment":10723,"conditions":22450,"interventions":22451},[91],[4040],[10726,9828,10727,9828,10728,9828,10728,9828,10729,9828,9828,10728,9828],{"trials":22453,"activeCount":101},[],{"trials":22455,"activeCount":101},[],{"trials":22457,"activeCount":101},[],{"intervention":21544,"totalTrials":272,"cells":22459},{"EARLY_PHASE1":22460,"PHASE1":22462,"PHASE2":22464,"PHASE3":22470,"PHASE4":22472,"NA":22474},{"trials":22461,"activeCount":101},[],{"trials":22463,"activeCount":101},[],{"trials":22465,"activeCount":101},[22466],{"nctId":21538,"briefTitle":21539,"status":107,"phases":22467,"primaryCompletion":9332,"start":6811,"enrollment":21541,"conditions":22468,"interventions":22469},[91],[18],[21529,21544,21545,21546,21547],{"trials":22471,"activeCount":101},[],{"trials":22473,"activeCount":101},[],{"trials":22475,"activeCount":101},[],{"intervention":21546,"totalTrials":272,"cells":22477},{"EARLY_PHASE1":22478,"PHASE1":22480,"PHASE2":22482,"PHASE3":22488,"PHASE4":22490,"NA":22492},{"trials":22479,"activeCount":101},[],{"trials":22481,"activeCount":101},[],{"trials":22483,"activeCount":101},[22484],{"nctId":21538,"briefTitle":21539,"status":107,"phases":22485,"primaryCompletion":9332,"start":6811,"enrollment":21541,"conditions":22486,"interventions":22487},[91],[18],[21529,21544,21545,21546,21547],{"trials":22489,"activeCount":101},[],{"trials":22491,"activeCount":101},[],{"trials":22493,"activeCount":101},[],{"intervention":21547,"totalTrials":272,"cells":22495},{"EARLY_PHASE1":22496,"PHASE1":22498,"PHASE2":22500,"PHASE3":22506,"PHASE4":22508,"NA":22510},{"trials":22497,"activeCount":101},[],{"trials":22499,"activeCount":101},[],{"trials":22501,"activeCount":101},[22502],{"nctId":21538,"briefTitle":21539,"status":107,"phases":22503,"primaryCompletion":9332,"start":6811,"enrollment":21541,"conditions":22504,"interventions":22505},[91],[18],[21529,21544,21545,21546,21547],{"trials":22507,"activeCount":101},[],{"trials":22509,"activeCount":101},[],{"trials":22511,"activeCount":101},[],{"intervention":22513,"totalTrials":272,"cells":22514},"Antistax®, low dose",{"EARLY_PHASE1":22515,"PHASE1":22517,"PHASE2":22519,"PHASE3":22529,"PHASE4":22531,"NA":22533},{"trials":22516,"activeCount":101},[],{"trials":22518,"activeCount":101},[],{"trials":22520,"activeCount":101},[22521],{"nctId":22522,"briefTitle":22523,"status":107,"phases":22524,"primaryCompletion":7084,"start":6065,"enrollment":22525,"conditions":22526,"interventions":22527},"NCT02191280","Antistax® in Patients With Chronic Venous Insufficiency",[91],260,[8458],[22513,22528],"Antistax®, high dose",{"trials":22530,"activeCount":101},[],{"trials":22532,"activeCount":101},[],{"trials":22534,"activeCount":101},[],{"intervention":22528,"totalTrials":272,"cells":22536},{"EARLY_PHASE1":22537,"PHASE1":22539,"PHASE2":22541,"PHASE3":22547,"PHASE4":22549,"NA":22551},{"trials":22538,"activeCount":101},[],{"trials":22540,"activeCount":101},[],{"trials":22542,"activeCount":101},[22543],{"nctId":22522,"briefTitle":22523,"status":107,"phases":22544,"primaryCompletion":7084,"start":6065,"enrollment":22525,"conditions":22545,"interventions":22546},[91],[8458],[22513,22528],{"trials":22548,"activeCount":101},[],{"trials":22550,"activeCount":101},[],{"trials":22552,"activeCount":101},[],{"intervention":22554,"totalTrials":272,"cells":22555},"Ambroxol Spray",{"EARLY_PHASE1":22556,"PHASE1":22558,"PHASE2":22560,"PHASE3":22568,"PHASE4":22570,"NA":22572},{"trials":22557,"activeCount":101},[],{"trials":22559,"activeCount":101},[],{"trials":22561,"activeCount":101},[22562],{"nctId":22563,"briefTitle":22564,"status":107,"phases":22565,"primaryCompletion":2648,"start":9348,"enrollment":11098,"conditions":22566,"interventions":22567},"NCT01361802","Ambroxol Spray Sore Throat Study",[91],[6587,6596],[22554,22554,22554],{"trials":22569,"activeCount":101},[],{"trials":22571,"activeCount":101},[],{"trials":22573,"activeCount":101},[],{"intervention":21623,"totalTrials":272,"cells":22575},{"EARLY_PHASE1":22576,"PHASE1":22578,"PHASE2":22580,"PHASE3":22586,"PHASE4":22588,"NA":22590},{"trials":22577,"activeCount":101},[],{"trials":22579,"activeCount":101},[],{"trials":22581,"activeCount":101},[22582],{"nctId":21618,"briefTitle":21619,"status":600,"phases":22583,"primaryCompletion":408,"start":390,"enrollment":101,"conditions":22584,"interventions":22585},[91],[30],[20538,21623],{"trials":22587,"activeCount":101},[],{"trials":22589,"activeCount":101},[],{"trials":22591,"activeCount":101},[],{"intervention":22593,"totalTrials":272,"cells":22594},"BIBF 1120 low dose",{"EARLY_PHASE1":22595,"PHASE1":22597,"PHASE2":22599,"PHASE3":22608,"PHASE4":22610,"NA":22612},{"trials":22596,"activeCount":101},[],{"trials":22598,"activeCount":101},[],{"trials":22600,"activeCount":101},[22601],{"nctId":22602,"briefTitle":22603,"status":107,"phases":22604,"primaryCompletion":7573,"start":5842,"enrollment":4463,"conditions":22605,"interventions":22606},"NCT02182063","A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer",[91],[9651],[22593,22607],"BIBF 1120 high dose",{"trials":22609,"activeCount":101},[],{"trials":22611,"activeCount":101},[],{"trials":22613,"activeCount":101},[],{"intervention":22607,"totalTrials":272,"cells":22615},{"EARLY_PHASE1":22616,"PHASE1":22618,"PHASE2":22620,"PHASE3":22626,"PHASE4":22628,"NA":22630},{"trials":22617,"activeCount":101},[],{"trials":22619,"activeCount":101},[],{"trials":22621,"activeCount":101},[22622],{"nctId":22602,"briefTitle":22603,"status":107,"phases":22623,"primaryCompletion":7573,"start":5842,"enrollment":4463,"conditions":22624,"interventions":22625},[91],[9651],[22593,22607],{"trials":22627,"activeCount":101},[],{"trials":22629,"activeCount":101},[],{"trials":22631,"activeCount":101},[],{"intervention":22633,"totalTrials":272,"cells":22634},"BIIL 283 BS",{"EARLY_PHASE1":22635,"PHASE1":22637,"PHASE2":22639,"PHASE3":22648,"PHASE4":22650,"NA":22652},{"trials":22636,"activeCount":101},[],{"trials":22638,"activeCount":101},[],{"trials":22640,"activeCount":101},[22641],{"nctId":22642,"briefTitle":22643,"status":162,"phases":22644,"primaryCompletion":5868,"start":21078,"enrollment":22645,"conditions":22646,"interventions":22647},"NCT00060801","Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients",[91],420,[1724],[22633],{"trials":22649,"activeCount":101},[],{"trials":22651,"activeCount":101},[],{"trials":22653,"activeCount":101},[],{"intervention":21731,"totalTrials":272,"cells":22655},{"EARLY_PHASE1":22656,"PHASE1":22658,"PHASE2":22660,"PHASE3":22666,"PHASE4":22668,"NA":22670},{"trials":22657,"activeCount":101},[],{"trials":22659,"activeCount":101},[],{"trials":22661,"activeCount":101},[22662],{"nctId":21726,"briefTitle":21727,"status":107,"phases":22663,"primaryCompletion":400,"start":2032,"enrollment":15618,"conditions":22664,"interventions":22665},[91],[30],[21731,21717,21732],{"trials":22667,"activeCount":101},[],{"trials":22669,"activeCount":101},[],{"trials":22671,"activeCount":101},[],{"intervention":21732,"totalTrials":272,"cells":22673},{"EARLY_PHASE1":22674,"PHASE1":22676,"PHASE2":22678,"PHASE3":22684,"PHASE4":22686,"NA":22688},{"trials":22675,"activeCount":101},[],{"trials":22677,"activeCount":101},[],{"trials":22679,"activeCount":101},[22680],{"nctId":21726,"briefTitle":21727,"status":107,"phases":22681,"primaryCompletion":400,"start":2032,"enrollment":15618,"conditions":22682,"interventions":22683},[91],[30],[21731,21717,21732],{"trials":22685,"activeCount":101},[],{"trials":22687,"activeCount":101},[],{"trials":22689,"activeCount":101},[],{"intervention":22691,"totalTrials":272,"cells":22692},"BI 1744 CL plus tiotropium bromide",{"EARLY_PHASE1":22693,"PHASE1":22695,"PHASE2":22697,"PHASE3":22705,"PHASE4":22707,"NA":22709},{"trials":22694,"activeCount":101},[],{"trials":22696,"activeCount":101},[],{"trials":22698,"activeCount":101},[22699],{"nctId":22700,"briefTitle":22701,"status":107,"phases":22702,"primaryCompletion":1989,"start":6224,"enrollment":15678,"conditions":22703,"interventions":22704},"NCT00720499","Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744\u002FTiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[22691],{"trials":22706,"activeCount":101},[],{"trials":22708,"activeCount":101},[],{"trials":22710,"activeCount":101},[],{"intervention":2652,"totalTrials":272,"cells":22712},{"EARLY_PHASE1":22713,"PHASE1":22715,"PHASE2":22717,"PHASE3":22723,"PHASE4":22725,"NA":22727},{"trials":22714,"activeCount":101},[],{"trials":22716,"activeCount":101},[],{"trials":22718,"activeCount":101},[22719],{"nctId":2645,"briefTitle":2646,"status":107,"phases":22720,"primaryCompletion":2648,"start":2649,"enrollment":993,"conditions":22721,"interventions":22722},[91],[2629],[2652,1129,2616],{"trials":22724,"activeCount":101},[],{"trials":22726,"activeCount":101},[],{"trials":22728,"activeCount":101},[],{"intervention":21555,"totalTrials":272,"cells":22730},{"EARLY_PHASE1":22731,"PHASE1":22733,"PHASE2":22735,"PHASE3":22741,"PHASE4":22743,"NA":22745},{"trials":22732,"activeCount":101},[],{"trials":22734,"activeCount":101},[],{"trials":22736,"activeCount":101},[22737],{"nctId":21549,"briefTitle":21550,"status":107,"phases":22738,"primaryCompletion":6133,"completion":6133,"start":17427,"enrollment":6392,"conditions":22739,"interventions":22740},[91],[30],[21554,21555,21556,21557,21558],{"trials":22742,"activeCount":101},[],{"trials":22744,"activeCount":101},[],{"trials":22746,"activeCount":101},[],{"intervention":21556,"totalTrials":272,"cells":22748},{"EARLY_PHASE1":22749,"PHASE1":22751,"PHASE2":22753,"PHASE3":22759,"PHASE4":22761,"NA":22763},{"trials":22750,"activeCount":101},[],{"trials":22752,"activeCount":101},[],{"trials":22754,"activeCount":101},[22755],{"nctId":21549,"briefTitle":21550,"status":107,"phases":22756,"primaryCompletion":6133,"completion":6133,"start":17427,"enrollment":6392,"conditions":22757,"interventions":22758},[91],[30],[21554,21555,21556,21557,21558],{"trials":22760,"activeCount":101},[],{"trials":22762,"activeCount":101},[],{"trials":22764,"activeCount":101},[],{"intervention":21557,"totalTrials":272,"cells":22766},{"EARLY_PHASE1":22767,"PHASE1":22769,"PHASE2":22771,"PHASE3":22777,"PHASE4":22779,"NA":22781},{"trials":22768,"activeCount":101},[],{"trials":22770,"activeCount":101},[],{"trials":22772,"activeCount":101},[22773],{"nctId":21549,"briefTitle":21550,"status":107,"phases":22774,"primaryCompletion":6133,"completion":6133,"start":17427,"enrollment":6392,"conditions":22775,"interventions":22776},[91],[30],[21554,21555,21556,21557,21558],{"trials":22778,"activeCount":101},[],{"trials":22780,"activeCount":101},[],{"trials":22782,"activeCount":101},[],{"intervention":20777,"totalTrials":272,"cells":22784},{"EARLY_PHASE1":22785,"PHASE1":22787,"PHASE2":22789,"PHASE3":22795,"PHASE4":22797,"NA":22799},{"trials":22786,"activeCount":101},[],{"trials":22788,"activeCount":101},[],{"trials":22790,"activeCount":101},[22791],{"nctId":20772,"briefTitle":20773,"status":107,"phases":22792,"primaryCompletion":6030,"start":7419,"enrollment":12378,"conditions":22793,"interventions":22794},[90,91],[27],[20745,20777,20758,20759,20760],{"trials":22796,"activeCount":101},[],{"trials":22798,"activeCount":101},[],{"trials":22800,"activeCount":101},[],{"intervention":12315,"totalTrials":272,"cells":22802},{"EARLY_PHASE1":22803,"PHASE1":22805,"PHASE2":22807,"PHASE3":22813,"PHASE4":22815,"NA":22817},{"trials":22804,"activeCount":101},[],{"trials":22806,"activeCount":101},[],{"trials":22808,"activeCount":101},[22809],{"nctId":12308,"briefTitle":12309,"status":107,"phases":22810,"primaryCompletion":6207,"start":7924,"enrollment":12311,"conditions":22811,"interventions":22812},[91],[12313],[12315,12299,12316],{"trials":22814,"activeCount":101},[],{"trials":22816,"activeCount":101},[],{"trials":22818,"activeCount":101},[],{"intervention":10420,"totalTrials":272,"cells":22820},{"EARLY_PHASE1":22821,"PHASE1":22823,"PHASE2":22825,"PHASE3":22831,"PHASE4":22833,"NA":22835},{"trials":22822,"activeCount":101},[],{"trials":22824,"activeCount":101},[],{"trials":22826,"activeCount":101},[22827],{"nctId":10414,"briefTitle":10415,"status":107,"phases":22828,"primaryCompletion":9235,"start":7924,"enrollment":10417,"conditions":22829,"interventions":22830},[91],[6596],[10420,10421,10368,10422,10423,10424],{"trials":22832,"activeCount":101},[],{"trials":22834,"activeCount":101},[],{"trials":22836,"activeCount":101},[],{"intervention":10421,"totalTrials":272,"cells":22838},{"EARLY_PHASE1":22839,"PHASE1":22841,"PHASE2":22843,"PHASE3":22849,"PHASE4":22851,"NA":22853},{"trials":22840,"activeCount":101},[],{"trials":22842,"activeCount":101},[],{"trials":22844,"activeCount":101},[22845],{"nctId":10414,"briefTitle":10415,"status":107,"phases":22846,"primaryCompletion":9235,"start":7924,"enrollment":10417,"conditions":22847,"interventions":22848},[91],[6596],[10420,10421,10368,10422,10423,10424],{"trials":22850,"activeCount":101},[],{"trials":22852,"activeCount":101},[],{"trials":22854,"activeCount":101},[],{"intervention":10422,"totalTrials":272,"cells":22856},{"EARLY_PHASE1":22857,"PHASE1":22859,"PHASE2":22861,"PHASE3":22867,"PHASE4":22869,"NA":22871},{"trials":22858,"activeCount":101},[],{"trials":22860,"activeCount":101},[],{"trials":22862,"activeCount":101},[22863],{"nctId":10414,"briefTitle":10415,"status":107,"phases":22864,"primaryCompletion":9235,"start":7924,"enrollment":10417,"conditions":22865,"interventions":22866},[91],[6596],[10420,10421,10368,10422,10423,10424],{"trials":22868,"activeCount":101},[],{"trials":22870,"activeCount":101},[],{"trials":22872,"activeCount":101},[],{"intervention":10423,"totalTrials":272,"cells":22874},{"EARLY_PHASE1":22875,"PHASE1":22877,"PHASE2":22879,"PHASE3":22885,"PHASE4":22887,"NA":22889},{"trials":22876,"activeCount":101},[],{"trials":22878,"activeCount":101},[],{"trials":22880,"activeCount":101},[22881],{"nctId":10414,"briefTitle":10415,"status":107,"phases":22882,"primaryCompletion":9235,"start":7924,"enrollment":10417,"conditions":22883,"interventions":22884},[91],[6596],[10420,10421,10368,10422,10423,10424],{"trials":22886,"activeCount":101},[],{"trials":22888,"activeCount":101},[],{"trials":22890,"activeCount":101},[],{"intervention":10424,"totalTrials":272,"cells":22892},{"EARLY_PHASE1":22893,"PHASE1":22895,"PHASE2":22897,"PHASE3":22903,"PHASE4":22905,"NA":22907},{"trials":22894,"activeCount":101},[],{"trials":22896,"activeCount":101},[],{"trials":22898,"activeCount":101},[22899],{"nctId":10414,"briefTitle":10415,"status":107,"phases":22900,"primaryCompletion":9235,"start":7924,"enrollment":10417,"conditions":22901,"interventions":22902},[91],[6596],[10420,10421,10368,10422,10423,10424],{"trials":22904,"activeCount":101},[],{"trials":22906,"activeCount":101},[],{"trials":22908,"activeCount":101},[],{"intervention":22910,"totalTrials":272,"cells":22911},"HBB 20 mg",{"EARLY_PHASE1":22912,"PHASE1":22914,"PHASE2":22916,"PHASE3":22927,"PHASE4":22929,"NA":22931},{"trials":22913,"activeCount":101},[],{"trials":22915,"activeCount":101},[],{"trials":22917,"activeCount":101},[22918],{"nctId":22919,"briefTitle":22920,"status":107,"phases":22921,"primaryCompletion":22922,"completion":22922,"start":22923,"enrollment":22924,"conditions":22925,"interventions":22926},"NCT00932737","(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis",[91],"2010-02-08","2009-06-09",197,[17777],[22910],{"trials":22928,"activeCount":101},[],{"trials":22930,"activeCount":101},[],{"trials":22932,"activeCount":101},[],{"intervention":9683,"totalTrials":272,"cells":22934},{"EARLY_PHASE1":22935,"PHASE1":22937,"PHASE2":22939,"PHASE3":22945,"PHASE4":22947,"NA":22949},{"trials":22936,"activeCount":101},[],{"trials":22938,"activeCount":101},[],{"trials":22940,"activeCount":101},[22941],{"nctId":9674,"briefTitle":9675,"status":107,"phases":22942,"primaryCompletion":9677,"completion":9678,"start":9679,"enrollment":2689,"conditions":22943,"interventions":22944},[91],[9681],[1119,9683],{"trials":22946,"activeCount":101},[],{"trials":22948,"activeCount":101},[],{"trials":22950,"activeCount":101},[],{"intervention":22952,"totalTrials":272,"cells":22953},"Tiotropium 0.625 mcg\u002Fpuff",{"EARLY_PHASE1":22954,"PHASE1":22956,"PHASE2":22958,"PHASE3":22972,"PHASE4":22974,"NA":22976},{"trials":22955,"activeCount":101},[],{"trials":22957,"activeCount":101},[],{"trials":22959,"activeCount":101},[22960],{"nctId":22961,"briefTitle":22962,"status":107,"phases":22963,"primaryCompletion":6606,"start":22964,"enrollment":3029,"conditions":22965,"interventions":22966},"NCT02175342","Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],"1998-03-01",[18],[22952,22967,22968,22969,22970,22971],"Tiotropium 1.25 mcg\u002Fpuff","Tiotropium 2.5 mcg\u002Fpuff","Tiotropium 5 mcg\u002Fpuff","Tiotropium-18 lactose powder","Tiotropium 10 mcg\u002Fpuff",{"trials":22973,"activeCount":101},[],{"trials":22975,"activeCount":101},[],{"trials":22977,"activeCount":101},[],{"intervention":22967,"totalTrials":272,"cells":22979},{"EARLY_PHASE1":22980,"PHASE1":22982,"PHASE2":22984,"PHASE3":22990,"PHASE4":22992,"NA":22994},{"trials":22981,"activeCount":101},[],{"trials":22983,"activeCount":101},[],{"trials":22985,"activeCount":101},[22986],{"nctId":22961,"briefTitle":22962,"status":107,"phases":22987,"primaryCompletion":6606,"start":22964,"enrollment":3029,"conditions":22988,"interventions":22989},[91],[18],[22952,22967,22968,22969,22970,22971],{"trials":22991,"activeCount":101},[],{"trials":22993,"activeCount":101},[],{"trials":22995,"activeCount":101},[],{"intervention":22968,"totalTrials":272,"cells":22997},{"EARLY_PHASE1":22998,"PHASE1":23000,"PHASE2":23002,"PHASE3":23008,"PHASE4":23010,"NA":23012},{"trials":22999,"activeCount":101},[],{"trials":23001,"activeCount":101},[],{"trials":23003,"activeCount":101},[23004],{"nctId":22961,"briefTitle":22962,"status":107,"phases":23005,"primaryCompletion":6606,"start":22964,"enrollment":3029,"conditions":23006,"interventions":23007},[91],[18],[22952,22967,22968,22969,22970,22971],{"trials":23009,"activeCount":101},[],{"trials":23011,"activeCount":101},[],{"trials":23013,"activeCount":101},[],{"intervention":22969,"totalTrials":272,"cells":23015},{"EARLY_PHASE1":23016,"PHASE1":23018,"PHASE2":23020,"PHASE3":23026,"PHASE4":23028,"NA":23030},{"trials":23017,"activeCount":101},[],{"trials":23019,"activeCount":101},[],{"trials":23021,"activeCount":101},[23022],{"nctId":22961,"briefTitle":22962,"status":107,"phases":23023,"primaryCompletion":6606,"start":22964,"enrollment":3029,"conditions":23024,"interventions":23025},[91],[18],[22952,22967,22968,22969,22970,22971],{"trials":23027,"activeCount":101},[],{"trials":23029,"activeCount":101},[],{"trials":23031,"activeCount":101},[],{"intervention":22970,"totalTrials":272,"cells":23033},{"EARLY_PHASE1":23034,"PHASE1":23036,"PHASE2":23038,"PHASE3":23044,"PHASE4":23046,"NA":23048},{"trials":23035,"activeCount":101},[],{"trials":23037,"activeCount":101},[],{"trials":23039,"activeCount":101},[23040],{"nctId":22961,"briefTitle":22962,"status":107,"phases":23041,"primaryCompletion":6606,"start":22964,"enrollment":3029,"conditions":23042,"interventions":23043},[91],[18],[22952,22967,22968,22969,22970,22971],{"trials":23045,"activeCount":101},[],{"trials":23047,"activeCount":101},[],{"trials":23049,"activeCount":101},[],{"intervention":22971,"totalTrials":272,"cells":23051},{"EARLY_PHASE1":23052,"PHASE1":23054,"PHASE2":23056,"PHASE3":23062,"PHASE4":23064,"NA":23066},{"trials":23053,"activeCount":101},[],{"trials":23055,"activeCount":101},[],{"trials":23057,"activeCount":101},[23058],{"nctId":22961,"briefTitle":22962,"status":107,"phases":23059,"primaryCompletion":6606,"start":22964,"enrollment":3029,"conditions":23060,"interventions":23061},[91],[18],[22952,22967,22968,22969,22970,22971],{"trials":23063,"activeCount":101},[],{"trials":23065,"activeCount":101},[],{"trials":23067,"activeCount":101},[],{"intervention":21822,"totalTrials":272,"cells":23069},{"EARLY_PHASE1":23070,"PHASE1":23072,"PHASE2":23074,"PHASE3":23080,"PHASE4":23082,"NA":23084},{"trials":23071,"activeCount":101},[],{"trials":23073,"activeCount":101},[],{"trials":23075,"activeCount":101},[23076],{"nctId":21816,"briefTitle":21817,"status":107,"phases":23077,"primaryCompletion":6494,"start":6005,"enrollment":21819,"conditions":23078,"interventions":23079},[91],[18],[21800,21822,21812],{"trials":23081,"activeCount":101},[],{"trials":23083,"activeCount":101},[],{"trials":23085,"activeCount":101},[],{"intervention":23087,"totalTrials":272,"cells":23088},"Meloxicam low",{"EARLY_PHASE1":23089,"PHASE1":23091,"PHASE2":23093,"PHASE3":23106,"PHASE4":23108,"NA":23110},{"trials":23090,"activeCount":101},[],{"trials":23092,"activeCount":101},[],{"trials":23094,"activeCount":101},[23095],{"nctId":23096,"briefTitle":23097,"status":107,"phases":23098,"primaryCompletion":5923,"start":6074,"enrollment":1155,"conditions":23099,"interventions":23100},"NCT02183038","Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis",[91],[6587],[23087,23101,23102,23103,23104,23105],"Meloxicam high","Naproxen sodium","Meloxicam placebo low","Meloxicam placebo high","Naproxen sodium placebo",{"trials":23107,"activeCount":101},[],{"trials":23109,"activeCount":101},[],{"trials":23111,"activeCount":101},[],{"intervention":23101,"totalTrials":272,"cells":23113},{"EARLY_PHASE1":23114,"PHASE1":23116,"PHASE2":23118,"PHASE3":23124,"PHASE4":23126,"NA":23128},{"trials":23115,"activeCount":101},[],{"trials":23117,"activeCount":101},[],{"trials":23119,"activeCount":101},[23120],{"nctId":23096,"briefTitle":23097,"status":107,"phases":23121,"primaryCompletion":5923,"start":6074,"enrollment":1155,"conditions":23122,"interventions":23123},[91],[6587],[23087,23101,23102,23103,23104,23105],{"trials":23125,"activeCount":101},[],{"trials":23127,"activeCount":101},[],{"trials":23129,"activeCount":101},[],{"intervention":23102,"totalTrials":272,"cells":23131},{"EARLY_PHASE1":23132,"PHASE1":23134,"PHASE2":23136,"PHASE3":23142,"PHASE4":23144,"NA":23146},{"trials":23133,"activeCount":101},[],{"trials":23135,"activeCount":101},[],{"trials":23137,"activeCount":101},[23138],{"nctId":23096,"briefTitle":23097,"status":107,"phases":23139,"primaryCompletion":5923,"start":6074,"enrollment":1155,"conditions":23140,"interventions":23141},[91],[6587],[23087,23101,23102,23103,23104,23105],{"trials":23143,"activeCount":101},[],{"trials":23145,"activeCount":101},[],{"trials":23147,"activeCount":101},[],{"intervention":23103,"totalTrials":272,"cells":23149},{"EARLY_PHASE1":23150,"PHASE1":23152,"PHASE2":23154,"PHASE3":23160,"PHASE4":23162,"NA":23164},{"trials":23151,"activeCount":101},[],{"trials":23153,"activeCount":101},[],{"trials":23155,"activeCount":101},[23156],{"nctId":23096,"briefTitle":23097,"status":107,"phases":23157,"primaryCompletion":5923,"start":6074,"enrollment":1155,"conditions":23158,"interventions":23159},[91],[6587],[23087,23101,23102,23103,23104,23105],{"trials":23161,"activeCount":101},[],{"trials":23163,"activeCount":101},[],{"trials":23165,"activeCount":101},[],{"intervention":23104,"totalTrials":272,"cells":23167},{"EARLY_PHASE1":23168,"PHASE1":23170,"PHASE2":23172,"PHASE3":23178,"PHASE4":23180,"NA":23182},{"trials":23169,"activeCount":101},[],{"trials":23171,"activeCount":101},[],{"trials":23173,"activeCount":101},[23174],{"nctId":23096,"briefTitle":23097,"status":107,"phases":23175,"primaryCompletion":5923,"start":6074,"enrollment":1155,"conditions":23176,"interventions":23177},[91],[6587],[23087,23101,23102,23103,23104,23105],{"trials":23179,"activeCount":101},[],{"trials":23181,"activeCount":101},[],{"trials":23183,"activeCount":101},[],{"intervention":23105,"totalTrials":272,"cells":23185},{"EARLY_PHASE1":23186,"PHASE1":23188,"PHASE2":23190,"PHASE3":23196,"PHASE4":23198,"NA":23200},{"trials":23187,"activeCount":101},[],{"trials":23189,"activeCount":101},[],{"trials":23191,"activeCount":101},[23192],{"nctId":23096,"briefTitle":23097,"status":107,"phases":23193,"primaryCompletion":5923,"start":6074,"enrollment":1155,"conditions":23194,"interventions":23195},[91],[6587],[23087,23101,23102,23103,23104,23105],{"trials":23197,"activeCount":101},[],{"trials":23199,"activeCount":101},[],{"trials":23201,"activeCount":101},[],{"intervention":23203,"totalTrials":272,"cells":23204},"BIBN 4096 BS",{"EARLY_PHASE1":23205,"PHASE1":23207,"PHASE2":23209,"PHASE3":23217,"PHASE4":23219,"NA":23221},{"trials":23206,"activeCount":101},[],{"trials":23208,"activeCount":101},[],{"trials":23210,"activeCount":101},[23211],{"nctId":23212,"briefTitle":23213,"status":107,"phases":23214,"primaryCompletion":6206,"start":5923,"enrollment":22,"conditions":23215,"interventions":23216},"NCT02198339","Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache",[91],[13290],[23203],{"trials":23218,"activeCount":101},[],{"trials":23220,"activeCount":101},[],{"trials":23222,"activeCount":101},[],{"intervention":23224,"totalTrials":272,"cells":23225},"BI 1356 dose 3 once daily",{"EARLY_PHASE1":23226,"PHASE1":23228,"PHASE2":23230,"PHASE3":23240,"PHASE4":23242,"NA":23244},{"trials":23227,"activeCount":101},[],{"trials":23229,"activeCount":101},[],{"trials":23231,"activeCount":101},[23232],{"nctId":23233,"briefTitle":23234,"status":107,"phases":23235,"primaryCompletion":3763,"start":4498,"enrollment":5968,"conditions":23236,"interventions":23237},"NCT00328172","Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients",[91],[21],[23224,23238,23239,413],"BI 1356 dose 2 once daily","BI 1356 dose 1 once daily",{"trials":23241,"activeCount":101},[],{"trials":23243,"activeCount":101},[],{"trials":23245,"activeCount":101},[],{"intervention":23238,"totalTrials":272,"cells":23247},{"EARLY_PHASE1":23248,"PHASE1":23250,"PHASE2":23252,"PHASE3":23258,"PHASE4":23260,"NA":23262},{"trials":23249,"activeCount":101},[],{"trials":23251,"activeCount":101},[],{"trials":23253,"activeCount":101},[23254],{"nctId":23233,"briefTitle":23234,"status":107,"phases":23255,"primaryCompletion":3763,"start":4498,"enrollment":5968,"conditions":23256,"interventions":23257},[91],[21],[23224,23238,23239,413],{"trials":23259,"activeCount":101},[],{"trials":23261,"activeCount":101},[],{"trials":23263,"activeCount":101},[],{"intervention":23239,"totalTrials":272,"cells":23265},{"EARLY_PHASE1":23266,"PHASE1":23268,"PHASE2":23270,"PHASE3":23276,"PHASE4":23278,"NA":23280},{"trials":23267,"activeCount":101},[],{"trials":23269,"activeCount":101},[],{"trials":23271,"activeCount":101},[23272],{"nctId":23233,"briefTitle":23234,"status":107,"phases":23273,"primaryCompletion":3763,"start":4498,"enrollment":5968,"conditions":23274,"interventions":23275},[91],[21],[23224,23238,23239,413],{"trials":23277,"activeCount":101},[],{"trials":23279,"activeCount":101},[],{"trials":23281,"activeCount":101},[],{"intervention":11610,"totalTrials":272,"cells":23283},{"EARLY_PHASE1":23284,"PHASE1":23286,"PHASE2":23288,"PHASE3":23294,"PHASE4":23296,"NA":23298},{"trials":23285,"activeCount":101},[],{"trials":23287,"activeCount":101},[],{"trials":23289,"activeCount":101},[23290],{"nctId":11605,"briefTitle":11606,"status":107,"phases":23291,"primaryCompletion":6494,"start":6030,"enrollment":6702,"conditions":23292,"interventions":23293},[91],[18],[11610,5860,11596],{"trials":23295,"activeCount":101},[],{"trials":23297,"activeCount":101},[],{"trials":23299,"activeCount":101},[],{"intervention":21228,"totalTrials":272,"cells":23301},{"EARLY_PHASE1":23302,"PHASE1":23304,"PHASE2":23306,"PHASE3":23312,"PHASE4":23314,"NA":23316},{"trials":23303,"activeCount":101},[],{"trials":23305,"activeCount":101},[],{"trials":23307,"activeCount":101},[23308],{"nctId":21223,"briefTitle":21224,"status":107,"phases":23309,"primaryCompletion":7338,"start":4413,"enrollment":1991,"conditions":23310,"interventions":23311},[91],[36],[1130,21228],{"trials":23313,"activeCount":101},[],{"trials":23315,"activeCount":101},[],{"trials":23317,"activeCount":101},[],{"intervention":23319,"totalTrials":272,"cells":23320},"Low dose of BIBR 277",{"EARLY_PHASE1":23321,"PHASE1":23323,"PHASE2":23325,"PHASE3":23336,"PHASE4":23338,"NA":23340},{"trials":23322,"activeCount":101},[],{"trials":23324,"activeCount":101},[],{"trials":23326,"activeCount":101},[23327],{"nctId":23328,"briefTitle":23329,"status":107,"phases":23330,"primaryCompletion":7084,"start":6064,"enrollment":23331,"conditions":23332,"interventions":23333},"NCT02187497","Pharmacokinetics of BIBR 277 in Hypertensive Patients",[91],93,[24],[23319,23334,23335],"Medium dose of BIBR 277","High dose of BIBR 277",{"trials":23337,"activeCount":101},[],{"trials":23339,"activeCount":101},[],{"trials":23341,"activeCount":101},[],{"intervention":23334,"totalTrials":272,"cells":23343},{"EARLY_PHASE1":23344,"PHASE1":23346,"PHASE2":23348,"PHASE3":23354,"PHASE4":23356,"NA":23358},{"trials":23345,"activeCount":101},[],{"trials":23347,"activeCount":101},[],{"trials":23349,"activeCount":101},[23350],{"nctId":23328,"briefTitle":23329,"status":107,"phases":23351,"primaryCompletion":7084,"start":6064,"enrollment":23331,"conditions":23352,"interventions":23353},[91],[24],[23319,23334,23335],{"trials":23355,"activeCount":101},[],{"trials":23357,"activeCount":101},[],{"trials":23359,"activeCount":101},[],{"intervention":23335,"totalTrials":272,"cells":23361},{"EARLY_PHASE1":23362,"PHASE1":23364,"PHASE2":23366,"PHASE3":23372,"PHASE4":23374,"NA":23376},{"trials":23363,"activeCount":101},[],{"trials":23365,"activeCount":101},[],{"trials":23367,"activeCount":101},[23368],{"nctId":23328,"briefTitle":23329,"status":107,"phases":23369,"primaryCompletion":7084,"start":6064,"enrollment":23331,"conditions":23370,"interventions":23371},[91],[24],[23319,23334,23335],{"trials":23373,"activeCount":101},[],{"trials":23375,"activeCount":101},[],{"trials":23377,"activeCount":101},[],{"intervention":10868,"totalTrials":272,"cells":23379},{"EARLY_PHASE1":23380,"PHASE1":23382,"PHASE2":23384,"PHASE3":23390,"PHASE4":23392,"NA":23394},{"trials":23381,"activeCount":101},[],{"trials":23383,"activeCount":101},[],{"trials":23385,"activeCount":101},[23386],{"nctId":10863,"briefTitle":10864,"status":107,"phases":23387,"primaryCompletion":2163,"start":6453,"enrollment":392,"conditions":23388,"interventions":23389},[91],[27],[4008,4010,10868,7579,10854,10869],{"trials":23391,"activeCount":101},[],{"trials":23393,"activeCount":101},[],{"trials":23395,"activeCount":101},[],{"intervention":23397,"totalTrials":272,"cells":23398},"Ba 679 BR low dose",{"EARLY_PHASE1":23399,"PHASE1":23401,"PHASE2":23403,"PHASE3":23413,"PHASE4":23415,"NA":23417},{"trials":23400,"activeCount":101},[],{"trials":23402,"activeCount":101},[],{"trials":23404,"activeCount":101},[23405],{"nctId":23406,"briefTitle":23407,"status":107,"phases":23408,"primaryCompletion":9235,"start":6074,"enrollment":1865,"conditions":23409,"interventions":23410},"NCT02172352","Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients",[91],[18],[23397,23411,23412],"Ba 679 BR middle dose","Ba 679 BR high dose",{"trials":23414,"activeCount":101},[],{"trials":23416,"activeCount":101},[],{"trials":23418,"activeCount":101},[],{"intervention":23411,"totalTrials":272,"cells":23420},{"EARLY_PHASE1":23421,"PHASE1":23423,"PHASE2":23425,"PHASE3":23431,"PHASE4":23433,"NA":23435},{"trials":23422,"activeCount":101},[],{"trials":23424,"activeCount":101},[],{"trials":23426,"activeCount":101},[23427],{"nctId":23406,"briefTitle":23407,"status":107,"phases":23428,"primaryCompletion":9235,"start":6074,"enrollment":1865,"conditions":23429,"interventions":23430},[91],[18],[23397,23411,23412],{"trials":23432,"activeCount":101},[],{"trials":23434,"activeCount":101},[],{"trials":23436,"activeCount":101},[],{"intervention":23412,"totalTrials":272,"cells":23438},{"EARLY_PHASE1":23439,"PHASE1":23441,"PHASE2":23443,"PHASE3":23449,"PHASE4":23451,"NA":23453},{"trials":23440,"activeCount":101},[],{"trials":23442,"activeCount":101},[],{"trials":23444,"activeCount":101},[23445],{"nctId":23406,"briefTitle":23407,"status":107,"phases":23446,"primaryCompletion":9235,"start":6074,"enrollment":1865,"conditions":23447,"interventions":23448},[91],[18],[23397,23411,23412],{"trials":23450,"activeCount":101},[],{"trials":23452,"activeCount":101},[],{"trials":23454,"activeCount":101},[],{"intervention":23456,"totalTrials":272,"cells":23457},"BIBW 2992 MA2 40mg\u002Fday",{"EARLY_PHASE1":23458,"PHASE1":23460,"PHASE2":23462,"PHASE3":23473,"PHASE4":23475,"NA":23477},{"trials":23459,"activeCount":101},[],{"trials":23461,"activeCount":101},[],{"trials":23463,"activeCount":101},[23464],{"nctId":23465,"briefTitle":23466,"status":107,"phases":23467,"primaryCompletion":378,"completion":378,"start":6471,"enrollment":6702,"conditions":23468,"interventions":23469},"NCT00711594","LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib",[91],[36],[23456,23470,23471,23472],"BIBW 2992 MA2 50mg\u002Fday","BIBW 2992 MA2 20mg\u002Fday","BIBW 2992 QD",{"trials":23474,"activeCount":101},[],{"trials":23476,"activeCount":101},[],{"trials":23478,"activeCount":101},[],{"intervention":23470,"totalTrials":272,"cells":23480},{"EARLY_PHASE1":23481,"PHASE1":23483,"PHASE2":23485,"PHASE3":23491,"PHASE4":23493,"NA":23495},{"trials":23482,"activeCount":101},[],{"trials":23484,"activeCount":101},[],{"trials":23486,"activeCount":101},[23487],{"nctId":23465,"briefTitle":23466,"status":107,"phases":23488,"primaryCompletion":378,"completion":378,"start":6471,"enrollment":6702,"conditions":23489,"interventions":23490},[91],[36],[23456,23470,23471,23472],{"trials":23492,"activeCount":101},[],{"trials":23494,"activeCount":101},[],{"trials":23496,"activeCount":101},[],{"intervention":23471,"totalTrials":272,"cells":23498},{"EARLY_PHASE1":23499,"PHASE1":23501,"PHASE2":23503,"PHASE3":23509,"PHASE4":23511,"NA":23513},{"trials":23500,"activeCount":101},[],{"trials":23502,"activeCount":101},[],{"trials":23504,"activeCount":101},[23505],{"nctId":23465,"briefTitle":23466,"status":107,"phases":23506,"primaryCompletion":378,"completion":378,"start":6471,"enrollment":6702,"conditions":23507,"interventions":23508},[91],[36],[23456,23470,23471,23472],{"trials":23510,"activeCount":101},[],{"trials":23512,"activeCount":101},[],{"trials":23514,"activeCount":101},[],{"intervention":23472,"totalTrials":272,"cells":23516},{"EARLY_PHASE1":23517,"PHASE1":23519,"PHASE2":23521,"PHASE3":23527,"PHASE4":23529,"NA":23531},{"trials":23518,"activeCount":101},[],{"trials":23520,"activeCount":101},[],{"trials":23522,"activeCount":101},[23523],{"nctId":23465,"briefTitle":23466,"status":107,"phases":23524,"primaryCompletion":378,"completion":378,"start":6471,"enrollment":6702,"conditions":23525,"interventions":23526},[91],[36],[23456,23470,23471,23472],{"trials":23528,"activeCount":101},[],{"trials":23530,"activeCount":101},[],{"trials":23532,"activeCount":101},[],{"intervention":23534,"totalTrials":272,"cells":23535},"Afatinib once daily",{"EARLY_PHASE1":23536,"PHASE1":23538,"PHASE2":23540,"PHASE3":23549,"PHASE4":23551,"NA":23553},{"trials":23537,"activeCount":101},[],{"trials":23539,"activeCount":101},[],{"trials":23541,"activeCount":101},[23542],{"nctId":23543,"briefTitle":23544,"status":107,"phases":23545,"primaryCompletion":475,"completion":475,"start":2648,"enrollment":1982,"conditions":23546,"interventions":23547},"NCT01325428","Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer",[91],[2629],[23534,23548],"Vinorelbine Weekly",{"trials":23550,"activeCount":101},[],{"trials":23552,"activeCount":101},[],{"trials":23554,"activeCount":101},[],{"intervention":23548,"totalTrials":272,"cells":23556},{"EARLY_PHASE1":23557,"PHASE1":23559,"PHASE2":23561,"PHASE3":23567,"PHASE4":23569,"NA":23571},{"trials":23558,"activeCount":101},[],{"trials":23560,"activeCount":101},[],{"trials":23562,"activeCount":101},[23563],{"nctId":23543,"briefTitle":23544,"status":107,"phases":23564,"primaryCompletion":475,"completion":475,"start":2648,"enrollment":1982,"conditions":23565,"interventions":23566},[91],[2629],[23534,23548],{"trials":23568,"activeCount":101},[],{"trials":23570,"activeCount":101},[],{"trials":23572,"activeCount":101},[],{"intervention":11726,"totalTrials":272,"cells":23574},{"EARLY_PHASE1":23575,"PHASE1":23577,"PHASE2":23579,"PHASE3":23585,"PHASE4":23587,"NA":23589},{"trials":23576,"activeCount":101},[],{"trials":23578,"activeCount":101},[],{"trials":23580,"activeCount":101},[23581],{"nctId":11720,"briefTitle":11721,"status":107,"phases":23582,"primaryCompletion":4462,"start":8479,"enrollment":1991,"conditions":23583,"interventions":23584},[91],[11724],[11711,11726],{"trials":23586,"activeCount":101},[],{"trials":23588,"activeCount":101},[],{"trials":23590,"activeCount":101},[],{"intervention":21088,"totalTrials":272,"cells":23592},{"EARLY_PHASE1":23593,"PHASE1":23595,"PHASE2":23597,"PHASE3":23603,"PHASE4":23605,"NA":23607},{"trials":23594,"activeCount":101},[],{"trials":23596,"activeCount":101},[],{"trials":23598,"activeCount":101},[23599],{"nctId":21082,"briefTitle":21083,"status":107,"phases":23600,"primaryCompletion":6375,"start":2121,"enrollment":21085,"conditions":23601,"interventions":23602},[91],[114],[21059,21088,21089,21071],{"trials":23604,"activeCount":101},[],{"trials":23606,"activeCount":101},[],{"trials":23608,"activeCount":101},[],{"intervention":21089,"totalTrials":272,"cells":23610},{"EARLY_PHASE1":23611,"PHASE1":23613,"PHASE2":23615,"PHASE3":23621,"PHASE4":23623,"NA":23625},{"trials":23612,"activeCount":101},[],{"trials":23614,"activeCount":101},[],{"trials":23616,"activeCount":101},[23617],{"nctId":21082,"briefTitle":21083,"status":107,"phases":23618,"primaryCompletion":6375,"start":2121,"enrollment":21085,"conditions":23619,"interventions":23620},[91],[114],[21059,21088,21089,21071],{"trials":23622,"activeCount":101},[],{"trials":23624,"activeCount":101},[],{"trials":23626,"activeCount":101},[],{"intervention":23628,"totalTrials":272,"cells":23629},"BIBF 1120 and BIBW 2992",{"EARLY_PHASE1":23630,"PHASE1":23632,"PHASE2":23634,"PHASE3":23644,"PHASE4":23646,"NA":23648},{"trials":23631,"activeCount":101},[],{"trials":23633,"activeCount":101},[],{"trials":23635,"activeCount":101},[23636],{"nctId":23637,"briefTitle":23638,"status":107,"phases":23639,"primaryCompletion":23640,"start":23641,"enrollment":1094,"conditions":23642,"interventions":23643},"NCT00801294","A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer",[91],"2007-11-01","2006-07-01",[3060],[23628],{"trials":23645,"activeCount":101},[],{"trials":23647,"activeCount":101},[],{"trials":23649,"activeCount":101},[],{"intervention":23651,"totalTrials":272,"cells":23652},"tiotropium bromide 2.5µg once daily",{"EARLY_PHASE1":23653,"PHASE1":23655,"PHASE2":23657,"PHASE3":23668,"PHASE4":23670,"NA":23672},{"trials":23654,"activeCount":101},[],{"trials":23656,"activeCount":101},[],{"trials":23658,"activeCount":101},[23659],{"nctId":23660,"briefTitle":23661,"status":107,"phases":23662,"primaryCompletion":7338,"start":4441,"enrollment":23663,"conditions":23664,"interventions":23665},"NCT01233284","Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.",[91],149,[30],[23651,23666,23667],"tiotropium bromide high dose once daily","tiotropium bromide 1.25µg once daily",{"trials":23669,"activeCount":101},[],{"trials":23671,"activeCount":101},[],{"trials":23673,"activeCount":101},[],{"intervention":23666,"totalTrials":272,"cells":23675},{"EARLY_PHASE1":23676,"PHASE1":23678,"PHASE2":23680,"PHASE3":23686,"PHASE4":23688,"NA":23690},{"trials":23677,"activeCount":101},[],{"trials":23679,"activeCount":101},[],{"trials":23681,"activeCount":101},[23682],{"nctId":23660,"briefTitle":23661,"status":107,"phases":23683,"primaryCompletion":7338,"start":4441,"enrollment":23663,"conditions":23684,"interventions":23685},[91],[30],[23651,23666,23667],{"trials":23687,"activeCount":101},[],{"trials":23689,"activeCount":101},[],{"trials":23691,"activeCount":101},[],{"intervention":23667,"totalTrials":272,"cells":23693},{"EARLY_PHASE1":23694,"PHASE1":23696,"PHASE2":23698,"PHASE3":23704,"PHASE4":23706,"NA":23708},{"trials":23695,"activeCount":101},[],{"trials":23697,"activeCount":101},[],{"trials":23699,"activeCount":101},[23700],{"nctId":23660,"briefTitle":23661,"status":107,"phases":23701,"primaryCompletion":7338,"start":4441,"enrollment":23663,"conditions":23702,"interventions":23703},[91],[30],[23651,23666,23667],{"trials":23705,"activeCount":101},[],{"trials":23707,"activeCount":101},[],{"trials":23709,"activeCount":101},[],{"intervention":23711,"totalTrials":272,"cells":23712},"TMZ",{"EARLY_PHASE1":23713,"PHASE1":23715,"PHASE2":23717,"PHASE3":23728,"PHASE4":23730,"NA":23732},{"trials":23714,"activeCount":101},[],{"trials":23716,"activeCount":101},[],{"trials":23718,"activeCount":101},[23719],{"nctId":23720,"briefTitle":23721,"status":107,"phases":23722,"primaryCompletion":23723,"completion":20008,"start":23724,"enrollment":1458,"conditions":23725,"interventions":23726},"NCT00727506","BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma",[91],"2011-05-12","2008-07-14",[3671],[1129,23711,23727],"BIBW 2992 plus TMZ",{"trials":23729,"activeCount":101},[],{"trials":23731,"activeCount":101},[],{"trials":23733,"activeCount":101},[],{"intervention":23727,"totalTrials":272,"cells":23735},{"EARLY_PHASE1":23736,"PHASE1":23738,"PHASE2":23740,"PHASE3":23746,"PHASE4":23748,"NA":23750},{"trials":23737,"activeCount":101},[],{"trials":23739,"activeCount":101},[],{"trials":23741,"activeCount":101},[23742],{"nctId":23720,"briefTitle":23721,"status":107,"phases":23743,"primaryCompletion":23723,"completion":20008,"start":23724,"enrollment":1458,"conditions":23744,"interventions":23745},[91],[3671],[1129,23711,23727],{"trials":23747,"activeCount":101},[],{"trials":23749,"activeCount":101},[],{"trials":23751,"activeCount":101},[],{"intervention":23753,"totalTrials":272,"cells":23754},"1. Tesofensine",{"EARLY_PHASE1":23755,"PHASE1":23757,"PHASE2":23759,"PHASE3":23768,"PHASE4":23770,"NA":23772},{"trials":23756,"activeCount":101},[],{"trials":23758,"activeCount":101},[],{"trials":23760,"activeCount":101},[23761],{"nctId":23762,"briefTitle":23763,"status":107,"phases":23764,"primaryCompletion":17247,"completion":17247,"start":11650,"enrollment":23765,"conditions":23766,"interventions":23767},"NCT00148512","A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations",[91],254,[6934],[23753],{"trials":23769,"activeCount":101},[],{"trials":23771,"activeCount":101},[],{"trials":23773,"activeCount":101},[],{"intervention":21866,"totalTrials":272,"cells":23775},{"EARLY_PHASE1":23776,"PHASE1":23778,"PHASE2":23780,"PHASE3":23786,"PHASE4":23788,"NA":23790},{"trials":23777,"activeCount":101},[],{"trials":23779,"activeCount":101},[],{"trials":23781,"activeCount":101},[23782],{"nctId":21861,"briefTitle":21862,"status":107,"phases":23783,"primaryCompletion":7419,"start":6053,"enrollment":1991,"conditions":23784,"interventions":23785},[91],[18],[21852,21866],{"trials":23787,"activeCount":101},[],{"trials":23789,"activeCount":101},[],{"trials":23791,"activeCount":101},[],{"intervention":20784,"totalTrials":272,"cells":23793},{"EARLY_PHASE1":23794,"PHASE1":23796,"PHASE2":23798,"PHASE3":23804,"PHASE4":23806,"NA":23808},{"trials":23795,"activeCount":101},[],{"trials":23797,"activeCount":101},[],{"trials":23799,"activeCount":101},[23800],{"nctId":20779,"briefTitle":20780,"status":107,"phases":23801,"primaryCompletion":6584,"start":6438,"enrollment":1991,"conditions":23802,"interventions":23803},[91],[27],[20745,20758,4010,20784,20785],{"trials":23805,"activeCount":101},[],{"trials":23807,"activeCount":101},[],{"trials":23809,"activeCount":101},[],{"intervention":20785,"totalTrials":272,"cells":23811},{"EARLY_PHASE1":23812,"PHASE1":23814,"PHASE2":23816,"PHASE3":23822,"PHASE4":23824,"NA":23826},{"trials":23813,"activeCount":101},[],{"trials":23815,"activeCount":101},[],{"trials":23817,"activeCount":101},[23818],{"nctId":20779,"briefTitle":20780,"status":107,"phases":23819,"primaryCompletion":6584,"start":6438,"enrollment":1991,"conditions":23820,"interventions":23821},[91],[27],[20745,20758,4010,20784,20785],{"trials":23823,"activeCount":101},[],{"trials":23825,"activeCount":101},[],{"trials":23827,"activeCount":101},[],{"intervention":9802,"totalTrials":272,"cells":23829},{"EARLY_PHASE1":23830,"PHASE1":23832,"PHASE2":23834,"PHASE3":23840,"PHASE4":23842,"NA":23844},{"trials":23831,"activeCount":101},[],{"trials":23833,"activeCount":101},[],{"trials":23835,"activeCount":101},[23836],{"nctId":9795,"briefTitle":9796,"status":107,"phases":23837,"primaryCompletion":419,"completion":419,"start":1980,"enrollment":9798,"conditions":23838,"interventions":23839},[91],[4040],[4047,4042,4047,4042,9801,9801,9801,4047,4047,4047,4042,9801,9801,4047,4047,4042,4042,9801,4042,4042,4047,4042,4042,4047,4042,9801,9801,9802,4042,4047,9801,4047,4042,9801,9801],{"trials":23841,"activeCount":101},[],{"trials":23843,"activeCount":101},[],{"trials":23845,"activeCount":101},[],{"intervention":10093,"totalTrials":272,"cells":23847},{"EARLY_PHASE1":23848,"PHASE1":23850,"PHASE2":23852,"PHASE3":23858,"PHASE4":23860,"NA":23862},{"trials":23849,"activeCount":101},[],{"trials":23851,"activeCount":101},[],{"trials":23853,"activeCount":101},[23854],{"nctId":10088,"briefTitle":10089,"status":107,"phases":23855,"primaryCompletion":9515,"completion":9515,"start":9538,"enrollment":439,"conditions":23856,"interventions":23857},[91],[4040],[3994,10093,9801,9801,3994,3995,3995,10093],{"trials":23859,"activeCount":101},[],{"trials":23861,"activeCount":101},[],{"trials":23863,"activeCount":101},[],{"intervention":23865,"totalTrials":272,"cells":23866},"Pharmaton® Caplets",{"EARLY_PHASE1":23867,"PHASE1":23869,"PHASE2":23871,"PHASE3":23880,"PHASE4":23882,"NA":23884},{"trials":23868,"activeCount":101},[],{"trials":23870,"activeCount":101},[],{"trials":23872,"activeCount":101},[23873],{"nctId":23874,"briefTitle":23875,"status":107,"phases":23876,"primaryCompletion":7003,"start":7394,"enrollment":132,"conditions":23877,"interventions":23879},"NCT02199847","Evaluation of the Effects of Pharmaton Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shift",[91],[23878],"Sleep Disorders, Circadian Rhythm",[23865],{"trials":23881,"activeCount":101},[],{"trials":23883,"activeCount":101},[],{"trials":23885,"activeCount":101},[],{"intervention":23887,"totalTrials":272,"cells":23888},"BIBF 1120 ES low dose",{"EARLY_PHASE1":23889,"PHASE1":23891,"PHASE2":23893,"PHASE3":23902,"PHASE4":23904,"NA":23906},{"trials":23890,"activeCount":101},[],{"trials":23892,"activeCount":101},[],{"trials":23894,"activeCount":101},[23895],{"nctId":23896,"briefTitle":23897,"status":107,"phases":23898,"primaryCompletion":7573,"start":3978,"enrollment":19006,"conditions":23899,"interventions":23900},"NCT02182050","Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer",[91],[36],[23887,23901],"BIBF 1120 ES high dose",{"trials":23903,"activeCount":101},[],{"trials":23905,"activeCount":101},[],{"trials":23907,"activeCount":101},[],{"intervention":23901,"totalTrials":272,"cells":23909},{"EARLY_PHASE1":23910,"PHASE1":23912,"PHASE2":23914,"PHASE3":23920,"PHASE4":23922,"NA":23924},{"trials":23911,"activeCount":101},[],{"trials":23913,"activeCount":101},[],{"trials":23915,"activeCount":101},[23916],{"nctId":23896,"briefTitle":23897,"status":107,"phases":23917,"primaryCompletion":7573,"start":3978,"enrollment":19006,"conditions":23918,"interventions":23919},[91],[36],[23887,23901],{"trials":23921,"activeCount":101},[],{"trials":23923,"activeCount":101},[],{"trials":23925,"activeCount":101},[],{"intervention":23927,"totalTrials":272,"cells":23928},"Tiotropium bromide 5 mcg",{"EARLY_PHASE1":23929,"PHASE1":23931,"PHASE2":23933,"PHASE3":23943,"PHASE4":23945,"NA":23947},{"trials":23930,"activeCount":101},[],{"trials":23932,"activeCount":101},[],{"trials":23934,"activeCount":101},[23935],{"nctId":23936,"briefTitle":23937,"status":107,"phases":23938,"primaryCompletion":4392,"start":5856,"enrollment":23939,"conditions":23940,"interventions":23941},"NCT00737100","Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis",[91],510,[1724],[23927,23942],"tiotropium bromide-low dose-2.5mcg",{"trials":23944,"activeCount":101},[],{"trials":23946,"activeCount":101},[],{"trials":23948,"activeCount":101},[],{"intervention":23942,"totalTrials":272,"cells":23950},{"EARLY_PHASE1":23951,"PHASE1":23953,"PHASE2":23955,"PHASE3":23961,"PHASE4":23963,"NA":23965},{"trials":23952,"activeCount":101},[],{"trials":23954,"activeCount":101},[],{"trials":23956,"activeCount":101},[23957],{"nctId":23936,"briefTitle":23937,"status":107,"phases":23958,"primaryCompletion":4392,"start":5856,"enrollment":23939,"conditions":23959,"interventions":23960},[91],[1724],[23927,23942],{"trials":23962,"activeCount":101},[],{"trials":23964,"activeCount":101},[],{"trials":23966,"activeCount":101},[],{"intervention":21898,"totalTrials":272,"cells":23968},{"EARLY_PHASE1":23969,"PHASE1":23971,"PHASE2":23973,"PHASE3":23979,"PHASE4":23981,"NA":23983},{"trials":23970,"activeCount":101},[],{"trials":23972,"activeCount":101},[],{"trials":23974,"activeCount":101},[23975],{"nctId":21890,"briefTitle":21891,"status":107,"phases":23976,"primaryCompletion":21893,"start":21894,"enrollment":11245,"conditions":23977,"interventions":23978},[91],[27],[18356,18357,21881,21897,21898],{"trials":23980,"activeCount":101},[],{"trials":23982,"activeCount":101},[],{"trials":23984,"activeCount":101},[],{"intervention":23986,"totalTrials":272,"cells":23987},"BI1356 low dose",{"EARLY_PHASE1":23988,"PHASE1":23990,"PHASE2":23992,"PHASE3":24001,"PHASE4":24003,"NA":24005},{"trials":23989,"activeCount":101},[],{"trials":23991,"activeCount":101},[],{"trials":23993,"activeCount":101},[23994],{"nctId":23995,"briefTitle":23996,"status":107,"phases":23997,"primaryCompletion":5283,"completion":5283,"start":9340,"enrollment":2382,"conditions":23998,"interventions":23999},"NCT01342484","Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes",[91],[21],[23986,24000],"BI1356 high dose",{"trials":24002,"activeCount":101},[],{"trials":24004,"activeCount":101},[],{"trials":24006,"activeCount":101},[],{"intervention":24000,"totalTrials":272,"cells":24008},{"EARLY_PHASE1":24009,"PHASE1":24011,"PHASE2":24013,"PHASE3":24019,"PHASE4":24021,"NA":24023},{"trials":24010,"activeCount":101},[],{"trials":24012,"activeCount":101},[],{"trials":24014,"activeCount":101},[24015],{"nctId":23995,"briefTitle":23996,"status":107,"phases":24016,"primaryCompletion":5283,"completion":5283,"start":9340,"enrollment":2382,"conditions":24017,"interventions":24018},[91],[21],[23986,24000],{"trials":24020,"activeCount":101},[],{"trials":24022,"activeCount":101},[],{"trials":24024,"activeCount":101},[],{"intervention":6315,"totalTrials":272,"cells":24026},{"EARLY_PHASE1":24027,"PHASE1":24029,"PHASE2":24031,"PHASE3":24037,"PHASE4":24039,"NA":24041},{"trials":24028,"activeCount":101},[],{"trials":24030,"activeCount":101},[],{"trials":24032,"activeCount":101},[24033],{"nctId":6306,"briefTitle":6307,"status":107,"phases":24034,"primaryCompletion":6309,"completion":6309,"start":6310,"enrollment":6311,"conditions":24035,"interventions":24036},[91],[30],[6314,6315,5960,6316],{"trials":24038,"activeCount":101},[],{"trials":24040,"activeCount":101},[],{"trials":24042,"activeCount":101},[],{"intervention":6316,"totalTrials":272,"cells":24044},{"EARLY_PHASE1":24045,"PHASE1":24047,"PHASE2":24049,"PHASE3":24055,"PHASE4":24057,"NA":24059},{"trials":24046,"activeCount":101},[],{"trials":24048,"activeCount":101},[],{"trials":24050,"activeCount":101},[24051],{"nctId":6306,"briefTitle":6307,"status":107,"phases":24052,"primaryCompletion":6309,"completion":6309,"start":6310,"enrollment":6311,"conditions":24053,"interventions":24054},[91],[30],[6314,6315,5960,6316],{"trials":24056,"activeCount":101},[],{"trials":24058,"activeCount":101},[],{"trials":24060,"activeCount":101},[],{"intervention":5861,"totalTrials":272,"cells":24062},{"EARLY_PHASE1":24063,"PHASE1":24065,"PHASE2":24067,"PHASE3":24073,"PHASE4":24075,"NA":24077},{"trials":24064,"activeCount":101},[],{"trials":24066,"activeCount":101},[],{"trials":24068,"activeCount":101},[24069],{"nctId":5853,"briefTitle":5854,"status":107,"phases":24070,"primaryCompletion":5856,"start":4516,"enrollment":5857,"conditions":24071,"interventions":24072},[91],[18],[5860,5832,5861,5862,5863],{"trials":24074,"activeCount":101},[],{"trials":24076,"activeCount":101},[],{"trials":24078,"activeCount":101},[],{"intervention":5862,"totalTrials":272,"cells":24080},{"EARLY_PHASE1":24081,"PHASE1":24083,"PHASE2":24085,"PHASE3":24091,"PHASE4":24093,"NA":24095},{"trials":24082,"activeCount":101},[],{"trials":24084,"activeCount":101},[],{"trials":24086,"activeCount":101},[24087],{"nctId":5853,"briefTitle":5854,"status":107,"phases":24088,"primaryCompletion":5856,"start":4516,"enrollment":5857,"conditions":24089,"interventions":24090},[91],[18],[5860,5832,5861,5862,5863],{"trials":24092,"activeCount":101},[],{"trials":24094,"activeCount":101},[],{"trials":24096,"activeCount":101},[],{"intervention":5863,"totalTrials":272,"cells":24098},{"EARLY_PHASE1":24099,"PHASE1":24101,"PHASE2":24103,"PHASE3":24109,"PHASE4":24111,"NA":24113},{"trials":24100,"activeCount":101},[],{"trials":24102,"activeCount":101},[],{"trials":24104,"activeCount":101},[24105],{"nctId":5853,"briefTitle":5854,"status":107,"phases":24106,"primaryCompletion":5856,"start":4516,"enrollment":5857,"conditions":24107,"interventions":24108},[91],[18],[5860,5832,5861,5862,5863],{"trials":24110,"activeCount":101},[],{"trials":24112,"activeCount":101},[],{"trials":24114,"activeCount":101},[],{"intervention":24116,"totalTrials":272,"cells":24117},"Talsaclidine 6 mg",{"EARLY_PHASE1":24118,"PHASE1":24120,"PHASE2":24122,"PHASE3":24134,"PHASE4":24136,"NA":24138},{"trials":24119,"activeCount":101},[],{"trials":24121,"activeCount":101},[],{"trials":24123,"activeCount":101},[24124],{"nctId":24125,"briefTitle":24126,"status":107,"phases":24127,"primaryCompletion":2181,"start":6438,"enrollment":24128,"conditions":24129,"interventions":24130},"NCT02249403","Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type",[91],362,[11139],[24116,24131,24132,24133],"Talsaclidine 12 mg","Talsaclidine 24 mg","Talsaclidine 36 mg",{"trials":24135,"activeCount":101},[],{"trials":24137,"activeCount":101},[],{"trials":24139,"activeCount":101},[],{"intervention":24131,"totalTrials":272,"cells":24141},{"EARLY_PHASE1":24142,"PHASE1":24144,"PHASE2":24146,"PHASE3":24152,"PHASE4":24154,"NA":24156},{"trials":24143,"activeCount":101},[],{"trials":24145,"activeCount":101},[],{"trials":24147,"activeCount":101},[24148],{"nctId":24125,"briefTitle":24126,"status":107,"phases":24149,"primaryCompletion":2181,"start":6438,"enrollment":24128,"conditions":24150,"interventions":24151},[91],[11139],[24116,24131,24132,24133],{"trials":24153,"activeCount":101},[],{"trials":24155,"activeCount":101},[],{"trials":24157,"activeCount":101},[],{"intervention":24132,"totalTrials":272,"cells":24159},{"EARLY_PHASE1":24160,"PHASE1":24162,"PHASE2":24164,"PHASE3":24170,"PHASE4":24172,"NA":24174},{"trials":24161,"activeCount":101},[],{"trials":24163,"activeCount":101},[],{"trials":24165,"activeCount":101},[24166],{"nctId":24125,"briefTitle":24126,"status":107,"phases":24167,"primaryCompletion":2181,"start":6438,"enrollment":24128,"conditions":24168,"interventions":24169},[91],[11139],[24116,24131,24132,24133],{"trials":24171,"activeCount":101},[],{"trials":24173,"activeCount":101},[],{"trials":24175,"activeCount":101},[],{"intervention":24133,"totalTrials":272,"cells":24177},{"EARLY_PHASE1":24178,"PHASE1":24180,"PHASE2":24182,"PHASE3":24188,"PHASE4":24190,"NA":24192},{"trials":24179,"activeCount":101},[],{"trials":24181,"activeCount":101},[],{"trials":24183,"activeCount":101},[24184],{"nctId":24125,"briefTitle":24126,"status":107,"phases":24185,"primaryCompletion":2181,"start":6438,"enrollment":24128,"conditions":24186,"interventions":24187},[91],[11139],[24116,24131,24132,24133],{"trials":24189,"activeCount":101},[],{"trials":24191,"activeCount":101},[],{"trials":24193,"activeCount":101},[],{"intervention":24195,"totalTrials":272,"cells":24196},"BILN 2061 ZW",{"EARLY_PHASE1":24197,"PHASE1":24199,"PHASE2":24201,"PHASE3":24209,"PHASE4":24211,"NA":24213},{"trials":24198,"activeCount":101},[],{"trials":24200,"activeCount":101},[],{"trials":24202,"activeCount":101},[24203],{"nctId":24204,"briefTitle":24205,"status":107,"phases":24206,"primaryCompletion":6082,"start":6375,"enrollment":1081,"conditions":24207,"interventions":24208},"NCT02226939","Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C",[91],[2968,4040],[24195],{"trials":24210,"activeCount":101},[],{"trials":24212,"activeCount":101},[],{"trials":24214,"activeCount":101},[],{"intervention":24216,"totalTrials":272,"cells":24217},"BI 67100 ED 25 mg",{"EARLY_PHASE1":24218,"PHASE1":24220,"PHASE2":24222,"PHASE3":24239,"PHASE4":24241,"NA":24243},{"trials":24219,"activeCount":101},[],{"trials":24221,"activeCount":101},[],{"trials":24223,"activeCount":101},[24224],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24227,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24228,"interventions":24230},"NCT01007721","Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season",[91],[24229,30],"Rhinitis, Allergic, Seasonal",[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],"BI 671800 ED placebo","montelukast placebo","fluticasone propionate placebo nasal spray","BI 671800 ED 100 mg","671800 ED placebo","montelukast 10 mg","fluticasone propionate nasal spray placebo","Fluticasonepropionate nasal spray 200 mcg",{"trials":24240,"activeCount":101},[],{"trials":24242,"activeCount":101},[],{"trials":24244,"activeCount":101},[],{"intervention":24231,"totalTrials":272,"cells":24246},{"EARLY_PHASE1":24247,"PHASE1":24249,"PHASE2":24251,"PHASE3":24257,"PHASE4":24259,"NA":24261},{"trials":24248,"activeCount":101},[],{"trials":24250,"activeCount":101},[],{"trials":24252,"activeCount":101},[24253],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24254,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24255,"interventions":24256},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24258,"activeCount":101},[],{"trials":24260,"activeCount":101},[],{"trials":24262,"activeCount":101},[],{"intervention":24232,"totalTrials":272,"cells":24264},{"EARLY_PHASE1":24265,"PHASE1":24267,"PHASE2":24269,"PHASE3":24275,"PHASE4":24277,"NA":24279},{"trials":24266,"activeCount":101},[],{"trials":24268,"activeCount":101},[],{"trials":24270,"activeCount":101},[24271],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24272,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24273,"interventions":24274},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24276,"activeCount":101},[],{"trials":24278,"activeCount":101},[],{"trials":24280,"activeCount":101},[],{"intervention":24233,"totalTrials":272,"cells":24282},{"EARLY_PHASE1":24283,"PHASE1":24285,"PHASE2":24287,"PHASE3":24293,"PHASE4":24295,"NA":24297},{"trials":24284,"activeCount":101},[],{"trials":24286,"activeCount":101},[],{"trials":24288,"activeCount":101},[24289],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24290,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24291,"interventions":24292},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24294,"activeCount":101},[],{"trials":24296,"activeCount":101},[],{"trials":24298,"activeCount":101},[],{"intervention":24234,"totalTrials":272,"cells":24300},{"EARLY_PHASE1":24301,"PHASE1":24303,"PHASE2":24305,"PHASE3":24311,"PHASE4":24313,"NA":24315},{"trials":24302,"activeCount":101},[],{"trials":24304,"activeCount":101},[],{"trials":24306,"activeCount":101},[24307],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24308,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24309,"interventions":24310},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24312,"activeCount":101},[],{"trials":24314,"activeCount":101},[],{"trials":24316,"activeCount":101},[],{"intervention":24235,"totalTrials":272,"cells":24318},{"EARLY_PHASE1":24319,"PHASE1":24321,"PHASE2":24323,"PHASE3":24329,"PHASE4":24331,"NA":24333},{"trials":24320,"activeCount":101},[],{"trials":24322,"activeCount":101},[],{"trials":24324,"activeCount":101},[24325],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24326,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24327,"interventions":24328},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24330,"activeCount":101},[],{"trials":24332,"activeCount":101},[],{"trials":24334,"activeCount":101},[],{"intervention":24236,"totalTrials":272,"cells":24336},{"EARLY_PHASE1":24337,"PHASE1":24339,"PHASE2":24341,"PHASE3":24347,"PHASE4":24349,"NA":24351},{"trials":24338,"activeCount":101},[],{"trials":24340,"activeCount":101},[],{"trials":24342,"activeCount":101},[24343],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24344,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24345,"interventions":24346},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24348,"activeCount":101},[],{"trials":24350,"activeCount":101},[],{"trials":24352,"activeCount":101},[],{"intervention":24237,"totalTrials":272,"cells":24354},{"EARLY_PHASE1":24355,"PHASE1":24357,"PHASE2":24359,"PHASE3":24365,"PHASE4":24367,"NA":24369},{"trials":24356,"activeCount":101},[],{"trials":24358,"activeCount":101},[],{"trials":24360,"activeCount":101},[24361],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24362,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24363,"interventions":24364},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24366,"activeCount":101},[],{"trials":24368,"activeCount":101},[],{"trials":24370,"activeCount":101},[],{"intervention":24238,"totalTrials":272,"cells":24372},{"EARLY_PHASE1":24373,"PHASE1":24375,"PHASE2":24377,"PHASE3":24383,"PHASE4":24385,"NA":24387},{"trials":24374,"activeCount":101},[],{"trials":24376,"activeCount":101},[],{"trials":24378,"activeCount":101},[24379],{"nctId":24225,"briefTitle":24226,"status":107,"phases":24380,"primaryCompletion":4392,"start":9443,"enrollment":3467,"conditions":24381,"interventions":24382},[91],[24229,30],[24216,24231,24232,24232,24233,24233,24233,24234,24231,24231,24231,24234,24235,24232,24232,24232,24236,24233,24237,24238],{"trials":24384,"activeCount":101},[],{"trials":24386,"activeCount":101},[],{"trials":24388,"activeCount":101},[],{"intervention":19042,"totalTrials":272,"cells":24390},{"EARLY_PHASE1":24391,"PHASE1":24393,"PHASE2":24395,"PHASE3":24401,"PHASE4":24403,"NA":24405},{"trials":24392,"activeCount":101},[],{"trials":24394,"activeCount":101},[],{"trials":24396,"activeCount":101},[24397],{"nctId":19034,"briefTitle":19035,"status":107,"phases":24398,"primaryCompletion":19037,"completion":19038,"start":19039,"enrollment":6311,"conditions":24399,"interventions":24400},[91],[7303],[4176,19042],{"trials":24402,"activeCount":101},[],{"trials":24404,"activeCount":101},[],{"trials":24406,"activeCount":101},[],{"intervention":24408,"totalTrials":272,"cells":24409},"Ba 679 BR Respimat",{"EARLY_PHASE1":24410,"PHASE1":24412,"PHASE2":24414,"PHASE3":24423,"PHASE4":24425,"NA":24427},{"trials":24411,"activeCount":101},[],{"trials":24413,"activeCount":101},[],{"trials":24415,"activeCount":101},[24416],{"nctId":24417,"briefTitle":24418,"status":107,"phases":24419,"completion":6116,"start":7151,"enrollment":13515,"conditions":24420,"interventions":24421},"NCT00292448","A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[24408,24422],"Tiotropium (Spiriva) inhalation capsule 18 ug",{"trials":24424,"activeCount":101},[],{"trials":24426,"activeCount":101},[],{"trials":24428,"activeCount":101},[],{"intervention":24422,"totalTrials":272,"cells":24430},{"EARLY_PHASE1":24431,"PHASE1":24433,"PHASE2":24435,"PHASE3":24441,"PHASE4":24443,"NA":24445},{"trials":24432,"activeCount":101},[],{"trials":24434,"activeCount":101},[],{"trials":24436,"activeCount":101},[24437],{"nctId":24417,"briefTitle":24418,"status":107,"phases":24438,"completion":6116,"start":7151,"enrollment":13515,"conditions":24439,"interventions":24440},[91],[18],[24408,24422],{"trials":24442,"activeCount":101},[],{"trials":24444,"activeCount":101},[],{"trials":24446,"activeCount":101},[],{"intervention":24448,"totalTrials":272,"cells":24449},"Vinorelbine 25 mg\u002Fm2 weekly",{"EARLY_PHASE1":24450,"PHASE1":24452,"PHASE2":24454,"PHASE3":24465,"PHASE4":24467,"NA":24469},{"trials":24451,"activeCount":101},[],{"trials":24453,"activeCount":101},[],{"trials":24455,"activeCount":101},[24456],{"nctId":24457,"briefTitle":24458,"status":107,"phases":24459,"primaryCompletion":19415,"completion":19415,"start":24460,"enrollment":6702,"conditions":24461,"interventions":24462},"NCT01271725","LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures",[91],"2011-05-24",[2629],[24448,24463,24464],"Afatinib 40mg once daily","Paclitaxel 80 mg\u002Fm2 weekly",{"trials":24466,"activeCount":101},[],{"trials":24468,"activeCount":101},[],{"trials":24470,"activeCount":101},[],{"intervention":24463,"totalTrials":272,"cells":24472},{"EARLY_PHASE1":24473,"PHASE1":24475,"PHASE2":24477,"PHASE3":24483,"PHASE4":24485,"NA":24487},{"trials":24474,"activeCount":101},[],{"trials":24476,"activeCount":101},[],{"trials":24478,"activeCount":101},[24479],{"nctId":24457,"briefTitle":24458,"status":107,"phases":24480,"primaryCompletion":19415,"completion":19415,"start":24460,"enrollment":6702,"conditions":24481,"interventions":24482},[91],[2629],[24448,24463,24464],{"trials":24484,"activeCount":101},[],{"trials":24486,"activeCount":101},[],{"trials":24488,"activeCount":101},[],{"intervention":24464,"totalTrials":272,"cells":24490},{"EARLY_PHASE1":24491,"PHASE1":24493,"PHASE2":24495,"PHASE3":24501,"PHASE4":24503,"NA":24505},{"trials":24492,"activeCount":101},[],{"trials":24494,"activeCount":101},[],{"trials":24496,"activeCount":101},[24497],{"nctId":24457,"briefTitle":24458,"status":107,"phases":24498,"primaryCompletion":19415,"completion":19415,"start":24460,"enrollment":6702,"conditions":24499,"interventions":24500},[91],[2629],[24448,24463,24464],{"trials":24502,"activeCount":101},[],{"trials":24504,"activeCount":101},[],{"trials":24506,"activeCount":101},[],{"intervention":24508,"totalTrials":272,"cells":24509},"BI 6727, IV",{"EARLY_PHASE1":24510,"PHASE1":24512,"PHASE2":24514,"PHASE3":24524,"PHASE4":24526,"NA":24528},{"trials":24511,"activeCount":101},[],{"trials":24513,"activeCount":101},[],{"trials":24515,"activeCount":101},[24516],{"nctId":24517,"briefTitle":24518,"status":107,"phases":24519,"primaryCompletion":24520,"completion":24520,"start":24521,"enrollment":2235,"conditions":24522,"interventions":24523},"NCT01023958","Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer",[91],"2011-09-19","2009-11-19",[33],[24508],{"trials":24525,"activeCount":101},[],{"trials":24527,"activeCount":101},[],{"trials":24529,"activeCount":101},[],{"intervention":24531,"totalTrials":272,"cells":24532},"single dose of 5 mcg",{"EARLY_PHASE1":24533,"PHASE1":24535,"PHASE2":24537,"PHASE3":24550,"PHASE4":24552,"NA":24554},{"trials":24534,"activeCount":101},[],{"trials":24536,"activeCount":101},[],{"trials":24538,"activeCount":101},[24539],{"nctId":24540,"briefTitle":24541,"status":107,"phases":24542,"primaryCompletion":6910,"completion":6910,"start":4462,"enrollment":448,"conditions":24543,"interventions":24544},"NCT01809262","Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease",[91],[18],[24531,24545,24546,24547,24548,24549],"single dose of placebo","single dose of 40 mcg","single dose of 20 mcg","single dose of 2 mcg","single dose of 10 mcg",{"trials":24551,"activeCount":101},[],{"trials":24553,"activeCount":101},[],{"trials":24555,"activeCount":101},[],{"intervention":24545,"totalTrials":272,"cells":24557},{"EARLY_PHASE1":24558,"PHASE1":24560,"PHASE2":24562,"PHASE3":24568,"PHASE4":24570,"NA":24572},{"trials":24559,"activeCount":101},[],{"trials":24561,"activeCount":101},[],{"trials":24563,"activeCount":101},[24564],{"nctId":24540,"briefTitle":24541,"status":107,"phases":24565,"primaryCompletion":6910,"completion":6910,"start":4462,"enrollment":448,"conditions":24566,"interventions":24567},[91],[18],[24531,24545,24546,24547,24548,24549],{"trials":24569,"activeCount":101},[],{"trials":24571,"activeCount":101},[],{"trials":24573,"activeCount":101},[],{"intervention":24546,"totalTrials":272,"cells":24575},{"EARLY_PHASE1":24576,"PHASE1":24578,"PHASE2":24580,"PHASE3":24586,"PHASE4":24588,"NA":24590},{"trials":24577,"activeCount":101},[],{"trials":24579,"activeCount":101},[],{"trials":24581,"activeCount":101},[24582],{"nctId":24540,"briefTitle":24541,"status":107,"phases":24583,"primaryCompletion":6910,"completion":6910,"start":4462,"enrollment":448,"conditions":24584,"interventions":24585},[91],[18],[24531,24545,24546,24547,24548,24549],{"trials":24587,"activeCount":101},[],{"trials":24589,"activeCount":101},[],{"trials":24591,"activeCount":101},[],{"intervention":24547,"totalTrials":272,"cells":24593},{"EARLY_PHASE1":24594,"PHASE1":24596,"PHASE2":24598,"PHASE3":24604,"PHASE4":24606,"NA":24608},{"trials":24595,"activeCount":101},[],{"trials":24597,"activeCount":101},[],{"trials":24599,"activeCount":101},[24600],{"nctId":24540,"briefTitle":24541,"status":107,"phases":24601,"primaryCompletion":6910,"completion":6910,"start":4462,"enrollment":448,"conditions":24602,"interventions":24603},[91],[18],[24531,24545,24546,24547,24548,24549],{"trials":24605,"activeCount":101},[],{"trials":24607,"activeCount":101},[],{"trials":24609,"activeCount":101},[],{"intervention":24548,"totalTrials":272,"cells":24611},{"EARLY_PHASE1":24612,"PHASE1":24614,"PHASE2":24616,"PHASE3":24622,"PHASE4":24624,"NA":24626},{"trials":24613,"activeCount":101},[],{"trials":24615,"activeCount":101},[],{"trials":24617,"activeCount":101},[24618],{"nctId":24540,"briefTitle":24541,"status":107,"phases":24619,"primaryCompletion":6910,"completion":6910,"start":4462,"enrollment":448,"conditions":24620,"interventions":24621},[91],[18],[24531,24545,24546,24547,24548,24549],{"trials":24623,"activeCount":101},[],{"trials":24625,"activeCount":101},[],{"trials":24627,"activeCount":101},[],{"intervention":24549,"totalTrials":272,"cells":24629},{"EARLY_PHASE1":24630,"PHASE1":24632,"PHASE2":24634,"PHASE3":24640,"PHASE4":24642,"NA":24644},{"trials":24631,"activeCount":101},[],{"trials":24633,"activeCount":101},[],{"trials":24635,"activeCount":101},[24636],{"nctId":24540,"briefTitle":24541,"status":107,"phases":24637,"primaryCompletion":6910,"completion":6910,"start":4462,"enrollment":448,"conditions":24638,"interventions":24639},[91],[18],[24531,24545,24546,24547,24548,24549],{"trials":24641,"activeCount":101},[],{"trials":24643,"activeCount":101},[],{"trials":24645,"activeCount":101},[],{"intervention":10101,"totalTrials":272,"cells":24647},{"EARLY_PHASE1":24648,"PHASE1":24650,"PHASE2":24652,"PHASE3":24658,"PHASE4":24660,"NA":24662},{"trials":24649,"activeCount":101},[],{"trials":24651,"activeCount":101},[],{"trials":24653,"activeCount":101},[24654],{"nctId":10095,"briefTitle":10096,"status":107,"phases":24655,"primaryCompletion":2648,"completion":2648,"start":3991,"enrollment":210,"conditions":24656,"interventions":24657},[91],[9764,10099],[4048,10101,10101,4048,10102,10101,4048,10103,10104,10105,10103],{"trials":24659,"activeCount":101},[],{"trials":24661,"activeCount":101},[],{"trials":24663,"activeCount":101},[],{"intervention":10102,"totalTrials":272,"cells":24665},{"EARLY_PHASE1":24666,"PHASE1":24668,"PHASE2":24670,"PHASE3":24676,"PHASE4":24678,"NA":24680},{"trials":24667,"activeCount":101},[],{"trials":24669,"activeCount":101},[],{"trials":24671,"activeCount":101},[24672],{"nctId":10095,"briefTitle":10096,"status":107,"phases":24673,"primaryCompletion":2648,"completion":2648,"start":3991,"enrollment":210,"conditions":24674,"interventions":24675},[91],[9764,10099],[4048,10101,10101,4048,10102,10101,4048,10103,10104,10105,10103],{"trials":24677,"activeCount":101},[],{"trials":24679,"activeCount":101},[],{"trials":24681,"activeCount":101},[],{"intervention":10103,"totalTrials":272,"cells":24683},{"EARLY_PHASE1":24684,"PHASE1":24686,"PHASE2":24688,"PHASE3":24694,"PHASE4":24696,"NA":24698},{"trials":24685,"activeCount":101},[],{"trials":24687,"activeCount":101},[],{"trials":24689,"activeCount":101},[24690],{"nctId":10095,"briefTitle":10096,"status":107,"phases":24691,"primaryCompletion":2648,"completion":2648,"start":3991,"enrollment":210,"conditions":24692,"interventions":24693},[91],[9764,10099],[4048,10101,10101,4048,10102,10101,4048,10103,10104,10105,10103],{"trials":24695,"activeCount":101},[],{"trials":24697,"activeCount":101},[],{"trials":24699,"activeCount":101},[],{"intervention":10104,"totalTrials":272,"cells":24701},{"EARLY_PHASE1":24702,"PHASE1":24704,"PHASE2":24706,"PHASE3":24712,"PHASE4":24714,"NA":24716},{"trials":24703,"activeCount":101},[],{"trials":24705,"activeCount":101},[],{"trials":24707,"activeCount":101},[24708],{"nctId":10095,"briefTitle":10096,"status":107,"phases":24709,"primaryCompletion":2648,"completion":2648,"start":3991,"enrollment":210,"conditions":24710,"interventions":24711},[91],[9764,10099],[4048,10101,10101,4048,10102,10101,4048,10103,10104,10105,10103],{"trials":24713,"activeCount":101},[],{"trials":24715,"activeCount":101},[],{"trials":24717,"activeCount":101},[],{"intervention":10105,"totalTrials":272,"cells":24719},{"EARLY_PHASE1":24720,"PHASE1":24722,"PHASE2":24724,"PHASE3":24730,"PHASE4":24732,"NA":24734},{"trials":24721,"activeCount":101},[],{"trials":24723,"activeCount":101},[],{"trials":24725,"activeCount":101},[24726],{"nctId":10095,"briefTitle":10096,"status":107,"phases":24727,"primaryCompletion":2648,"completion":2648,"start":3991,"enrollment":210,"conditions":24728,"interventions":24729},[91],[9764,10099],[4048,10101,10101,4048,10102,10101,4048,10103,10104,10105,10103],{"trials":24731,"activeCount":101},[],{"trials":24733,"activeCount":101},[],{"trials":24735,"activeCount":101},[],{"intervention":24737,"totalTrials":272,"cells":24738},"Lacidipine, low dose",{"EARLY_PHASE1":24739,"PHASE1":24741,"PHASE2":24743,"PHASE3":24755,"PHASE4":24757,"NA":24759},{"trials":24740,"activeCount":101},[],{"trials":24742,"activeCount":101},[],{"trials":24744,"activeCount":101},[24745],{"nctId":24746,"briefTitle":24747,"status":107,"phases":24748,"primaryCompletion":6391,"start":6065,"enrollment":24749,"conditions":24750,"interventions":24752},"NCT02232607","Efficacy and Safety of Lacidipine in Chronic Stable Angina",[91],283,[24751],"Angina Pectoris",[24737,24753,24754],"Lacidipine, medium dose","Lacidipine, high dose",{"trials":24756,"activeCount":101},[],{"trials":24758,"activeCount":101},[],{"trials":24760,"activeCount":101},[],{"intervention":24753,"totalTrials":272,"cells":24762},{"EARLY_PHASE1":24763,"PHASE1":24765,"PHASE2":24767,"PHASE3":24773,"PHASE4":24775,"NA":24777},{"trials":24764,"activeCount":101},[],{"trials":24766,"activeCount":101},[],{"trials":24768,"activeCount":101},[24769],{"nctId":24746,"briefTitle":24747,"status":107,"phases":24770,"primaryCompletion":6391,"start":6065,"enrollment":24749,"conditions":24771,"interventions":24772},[91],[24751],[24737,24753,24754],{"trials":24774,"activeCount":101},[],{"trials":24776,"activeCount":101},[],{"trials":24778,"activeCount":101},[],{"intervention":24754,"totalTrials":272,"cells":24780},{"EARLY_PHASE1":24781,"PHASE1":24783,"PHASE2":24785,"PHASE3":24791,"PHASE4":24793,"NA":24795},{"trials":24782,"activeCount":101},[],{"trials":24784,"activeCount":101},[],{"trials":24786,"activeCount":101},[24787],{"nctId":24746,"briefTitle":24747,"status":107,"phases":24788,"primaryCompletion":6391,"start":6065,"enrollment":24749,"conditions":24789,"interventions":24790},[91],[24751],[24737,24753,24754],{"trials":24792,"activeCount":101},[],{"trials":24794,"activeCount":101},[],{"trials":24796,"activeCount":101},[],{"intervention":24798,"totalTrials":272,"cells":24799},"BI 1744 CL 2 µg",{"EARLY_PHASE1":24800,"PHASE1":24802,"PHASE2":24804,"PHASE3":24814,"PHASE4":24816,"NA":24818},{"trials":24801,"activeCount":101},[],{"trials":24803,"activeCount":101},[],{"trials":24805,"activeCount":101},[24806],{"nctId":24807,"briefTitle":24808,"status":107,"phases":24809,"primaryCompletion":3732,"start":2649,"enrollment":11245,"conditions":24810,"interventions":24811},"NCT00824382","Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD",[91],[18],[24798,24812,24813],"BI 1744 CL 5 µg","BI 1744 CL 10 µg",{"trials":24815,"activeCount":101},[],{"trials":24817,"activeCount":101},[],{"trials":24819,"activeCount":101},[],{"intervention":24812,"totalTrials":272,"cells":24821},{"EARLY_PHASE1":24822,"PHASE1":24824,"PHASE2":24826,"PHASE3":24832,"PHASE4":24834,"NA":24836},{"trials":24823,"activeCount":101},[],{"trials":24825,"activeCount":101},[],{"trials":24827,"activeCount":101},[24828],{"nctId":24807,"briefTitle":24808,"status":107,"phases":24829,"primaryCompletion":3732,"start":2649,"enrollment":11245,"conditions":24830,"interventions":24831},[91],[18],[24798,24812,24813],{"trials":24833,"activeCount":101},[],{"trials":24835,"activeCount":101},[],{"trials":24837,"activeCount":101},[],{"intervention":24813,"totalTrials":272,"cells":24839},{"EARLY_PHASE1":24840,"PHASE1":24842,"PHASE2":24844,"PHASE3":24850,"PHASE4":24852,"NA":24854},{"trials":24841,"activeCount":101},[],{"trials":24843,"activeCount":101},[],{"trials":24845,"activeCount":101},[24846],{"nctId":24807,"briefTitle":24808,"status":107,"phases":24847,"primaryCompletion":3732,"start":2649,"enrollment":11245,"conditions":24848,"interventions":24849},[91],[18],[24798,24812,24813],{"trials":24851,"activeCount":101},[],{"trials":24853,"activeCount":101},[],{"trials":24855,"activeCount":101},[],{"intervention":12163,"totalTrials":272,"cells":24857},{"EARLY_PHASE1":24858,"PHASE1":24860,"PHASE2":24862,"PHASE3":24868,"PHASE4":24870,"NA":24872},{"trials":24859,"activeCount":101},[],{"trials":24861,"activeCount":101},[],{"trials":24863,"activeCount":101},[24864],{"nctId":12156,"briefTitle":12157,"status":107,"phases":24865,"primaryCompletion":12159,"completion":3731,"start":391,"enrollment":10776,"conditions":24866,"interventions":24867},[91],[2629,938],[12162,12163,2633,2633],{"trials":24869,"activeCount":101},[],{"trials":24871,"activeCount":101},[],{"trials":24873,"activeCount":101},[],{"intervention":24875,"totalTrials":272,"cells":24876},"Low dose of BI 1356 BS",{"EARLY_PHASE1":24877,"PHASE1":24879,"PHASE2":24881,"PHASE3":24891,"PHASE4":24893,"NA":24895},{"trials":24878,"activeCount":101},[],{"trials":24880,"activeCount":101},[],{"trials":24882,"activeCount":101},[24883],{"nctId":24884,"briefTitle":24885,"status":107,"phases":24886,"primaryCompletion":4517,"start":9902,"enrollment":716,"conditions":24887,"interventions":24888},"NCT02183324","BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus",[91],[21],[24875,24889,24890],"Medium dose of BI 1356 BS","High dose of BI 1356 BS",{"trials":24892,"activeCount":101},[],{"trials":24894,"activeCount":101},[],{"trials":24896,"activeCount":101},[],{"intervention":24889,"totalTrials":272,"cells":24898},{"EARLY_PHASE1":24899,"PHASE1":24901,"PHASE2":24903,"PHASE3":24909,"PHASE4":24911,"NA":24913},{"trials":24900,"activeCount":101},[],{"trials":24902,"activeCount":101},[],{"trials":24904,"activeCount":101},[24905],{"nctId":24884,"briefTitle":24885,"status":107,"phases":24906,"primaryCompletion":4517,"start":9902,"enrollment":716,"conditions":24907,"interventions":24908},[91],[21],[24875,24889,24890],{"trials":24910,"activeCount":101},[],{"trials":24912,"activeCount":101},[],{"trials":24914,"activeCount":101},[],{"intervention":24890,"totalTrials":272,"cells":24916},{"EARLY_PHASE1":24917,"PHASE1":24919,"PHASE2":24921,"PHASE3":24927,"PHASE4":24929,"NA":24931},{"trials":24918,"activeCount":101},[],{"trials":24920,"activeCount":101},[],{"trials":24922,"activeCount":101},[24923],{"nctId":24884,"briefTitle":24885,"status":107,"phases":24924,"primaryCompletion":4517,"start":9902,"enrollment":716,"conditions":24925,"interventions":24926},[91],[21],[24875,24889,24890],{"trials":24928,"activeCount":101},[],{"trials":24930,"activeCount":101},[],{"trials":24932,"activeCount":101},[],{"intervention":20848,"totalTrials":272,"cells":24934},{"EARLY_PHASE1":24935,"PHASE1":24937,"PHASE2":24939,"PHASE3":24945,"PHASE4":24947,"NA":24949},{"trials":24936,"activeCount":101},[],{"trials":24938,"activeCount":101},[],{"trials":24940,"activeCount":101},[24941],{"nctId":20843,"briefTitle":20844,"status":162,"phases":24942,"primaryCompletion":6015,"start":6206,"enrollment":269,"conditions":24943,"interventions":24944},[91],[27],[20848,20849,20759,20760,20850],{"trials":24946,"activeCount":101},[],{"trials":24948,"activeCount":101},[],{"trials":24950,"activeCount":101},[],{"intervention":20849,"totalTrials":272,"cells":24952},{"EARLY_PHASE1":24953,"PHASE1":24955,"PHASE2":24957,"PHASE3":24963,"PHASE4":24965,"NA":24967},{"trials":24954,"activeCount":101},[],{"trials":24956,"activeCount":101},[],{"trials":24958,"activeCount":101},[24959],{"nctId":20843,"briefTitle":20844,"status":162,"phases":24960,"primaryCompletion":6015,"start":6206,"enrollment":269,"conditions":24961,"interventions":24962},[91],[27],[20848,20849,20759,20760,20850],{"trials":24964,"activeCount":101},[],{"trials":24966,"activeCount":101},[],{"trials":24968,"activeCount":101},[],{"intervention":20327,"totalTrials":272,"cells":24970},{"EARLY_PHASE1":24971,"PHASE1":24973,"PHASE2":24975,"PHASE3":24981,"PHASE4":24983,"NA":24985},{"trials":24972,"activeCount":101},[],{"trials":24974,"activeCount":101},[],{"trials":24976,"activeCount":101},[24977],{"nctId":20320,"briefTitle":20321,"status":107,"phases":24978,"primaryCompletion":20323,"completion":20323,"start":20324,"enrollment":19690,"conditions":24979,"interventions":24980},[91],[30],[6314,20327],{"trials":24982,"activeCount":101},[],{"trials":24984,"activeCount":101},[],{"trials":24986,"activeCount":101},[],{"intervention":24988,"totalTrials":272,"cells":24989},"Formoterol twice daily",{"EARLY_PHASE1":24990,"PHASE1":24992,"PHASE2":24994,"PHASE3":25004,"PHASE4":25006,"NA":25008},{"trials":24991,"activeCount":101},[],{"trials":24993,"activeCount":101},[],{"trials":24995,"activeCount":101},[24996],{"nctId":24997,"briefTitle":24998,"status":107,"phases":24999,"primaryCompletion":6040,"start":7381,"enrollment":10951,"conditions":25000,"interventions":25001},"NCT02242240","Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[24988,25002,25003],"Formoterol once daily","Tiotropium once daily",{"trials":25005,"activeCount":101},[],{"trials":25007,"activeCount":101},[],{"trials":25009,"activeCount":101},[],{"intervention":25002,"totalTrials":272,"cells":25011},{"EARLY_PHASE1":25012,"PHASE1":25014,"PHASE2":25016,"PHASE3":25022,"PHASE4":25024,"NA":25026},{"trials":25013,"activeCount":101},[],{"trials":25015,"activeCount":101},[],{"trials":25017,"activeCount":101},[25018],{"nctId":24997,"briefTitle":24998,"status":107,"phases":25019,"primaryCompletion":6040,"start":7381,"enrollment":10951,"conditions":25020,"interventions":25021},[91],[18],[24988,25002,25003],{"trials":25023,"activeCount":101},[],{"trials":25025,"activeCount":101},[],{"trials":25027,"activeCount":101},[],{"intervention":25003,"totalTrials":272,"cells":25029},{"EARLY_PHASE1":25030,"PHASE1":25032,"PHASE2":25034,"PHASE3":25040,"PHASE4":25042,"NA":25044},{"trials":25031,"activeCount":101},[],{"trials":25033,"activeCount":101},[],{"trials":25035,"activeCount":101},[25036],{"nctId":24997,"briefTitle":24998,"status":107,"phases":25037,"primaryCompletion":6040,"start":7381,"enrollment":10951,"conditions":25038,"interventions":25039},[91],[18],[24988,25002,25003],{"trials":25041,"activeCount":101},[],{"trials":25043,"activeCount":101},[],{"trials":25045,"activeCount":101},[],{"intervention":22068,"totalTrials":272,"cells":25047},{"EARLY_PHASE1":25048,"PHASE1":25050,"PHASE2":25052,"PHASE3":25058,"PHASE4":25060,"NA":25062},{"trials":25049,"activeCount":101},[],{"trials":25051,"activeCount":101},[],{"trials":25053,"activeCount":101},[25054],{"nctId":22062,"briefTitle":22063,"status":107,"phases":25055,"primaryCompletion":7553,"start":6065,"enrollment":22065,"conditions":25056,"interventions":25057},[91],[6596],[22053,22068,22069,22070,22071,22072],{"trials":25059,"activeCount":101},[],{"trials":25061,"activeCount":101},[],{"trials":25063,"activeCount":101},[],{"intervention":22069,"totalTrials":272,"cells":25065},{"EARLY_PHASE1":25066,"PHASE1":25068,"PHASE2":25070,"PHASE3":25076,"PHASE4":25078,"NA":25080},{"trials":25067,"activeCount":101},[],{"trials":25069,"activeCount":101},[],{"trials":25071,"activeCount":101},[25072],{"nctId":22062,"briefTitle":22063,"status":107,"phases":25073,"primaryCompletion":7553,"start":6065,"enrollment":22065,"conditions":25074,"interventions":25075},[91],[6596],[22053,22068,22069,22070,22071,22072],{"trials":25077,"activeCount":101},[],{"trials":25079,"activeCount":101},[],{"trials":25081,"activeCount":101},[],{"intervention":22070,"totalTrials":272,"cells":25083},{"EARLY_PHASE1":25084,"PHASE1":25086,"PHASE2":25088,"PHASE3":25094,"PHASE4":25096,"NA":25098},{"trials":25085,"activeCount":101},[],{"trials":25087,"activeCount":101},[],{"trials":25089,"activeCount":101},[25090],{"nctId":22062,"briefTitle":22063,"status":107,"phases":25091,"primaryCompletion":7553,"start":6065,"enrollment":22065,"conditions":25092,"interventions":25093},[91],[6596],[22053,22068,22069,22070,22071,22072],{"trials":25095,"activeCount":101},[],{"trials":25097,"activeCount":101},[],{"trials":25099,"activeCount":101},[],{"intervention":22072,"totalTrials":272,"cells":25101},{"EARLY_PHASE1":25102,"PHASE1":25104,"PHASE2":25106,"PHASE3":25112,"PHASE4":25114,"NA":25116},{"trials":25103,"activeCount":101},[],{"trials":25105,"activeCount":101},[],{"trials":25107,"activeCount":101},[25108],{"nctId":22062,"briefTitle":22063,"status":107,"phases":25109,"primaryCompletion":7553,"start":6065,"enrollment":22065,"conditions":25110,"interventions":25111},[91],[6596],[22053,22068,22069,22070,22071,22072],{"trials":25113,"activeCount":101},[],{"trials":25115,"activeCount":101},[],{"trials":25117,"activeCount":101},[],{"intervention":13222,"totalTrials":272,"cells":25119},{"EARLY_PHASE1":25120,"PHASE1":25122,"PHASE2":25124,"PHASE3":25130,"PHASE4":25132,"NA":25134},{"trials":25121,"activeCount":101},[],{"trials":25123,"activeCount":101},[],{"trials":25125,"activeCount":101},[25126],{"nctId":13213,"briefTitle":13214,"status":107,"phases":25127,"primaryCompletion":13216,"completion":13217,"start":13218,"enrollment":342,"conditions":25128,"interventions":25129},[91],[13220],[13204,13222],{"trials":25131,"activeCount":101},[],{"trials":25133,"activeCount":101},[],{"trials":25135,"activeCount":101},[],{"intervention":25137,"totalTrials":272,"cells":25138},"Olodaterol low daily dose twice daily",{"EARLY_PHASE1":25139,"PHASE1":25141,"PHASE2":25143,"PHASE3":25154,"PHASE4":25156,"NA":25158},{"trials":25140,"activeCount":101},[],{"trials":25142,"activeCount":101},[],{"trials":25144,"activeCount":101},[25145],{"nctId":25146,"briefTitle":25147,"status":107,"phases":25148,"primaryCompletion":6095,"start":6132,"enrollment":18380,"conditions":25149,"interventions":25150},"NCT01311661","A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma",[91],[30],[25137,25151,25152,25153],"Olodaterol medium daily dose twice daily","Olodaterol high daily dose once daily and placebo","Olodaterol medium daily dose once daily and placebo",{"trials":25155,"activeCount":101},[],{"trials":25157,"activeCount":101},[],{"trials":25159,"activeCount":101},[],{"intervention":25151,"totalTrials":272,"cells":25161},{"EARLY_PHASE1":25162,"PHASE1":25164,"PHASE2":25166,"PHASE3":25172,"PHASE4":25174,"NA":25176},{"trials":25163,"activeCount":101},[],{"trials":25165,"activeCount":101},[],{"trials":25167,"activeCount":101},[25168],{"nctId":25146,"briefTitle":25147,"status":107,"phases":25169,"primaryCompletion":6095,"start":6132,"enrollment":18380,"conditions":25170,"interventions":25171},[91],[30],[25137,25151,25152,25153],{"trials":25173,"activeCount":101},[],{"trials":25175,"activeCount":101},[],{"trials":25177,"activeCount":101},[],{"intervention":25152,"totalTrials":272,"cells":25179},{"EARLY_PHASE1":25180,"PHASE1":25182,"PHASE2":25184,"PHASE3":25190,"PHASE4":25192,"NA":25194},{"trials":25181,"activeCount":101},[],{"trials":25183,"activeCount":101},[],{"trials":25185,"activeCount":101},[25186],{"nctId":25146,"briefTitle":25147,"status":107,"phases":25187,"primaryCompletion":6095,"start":6132,"enrollment":18380,"conditions":25188,"interventions":25189},[91],[30],[25137,25151,25152,25153],{"trials":25191,"activeCount":101},[],{"trials":25193,"activeCount":101},[],{"trials":25195,"activeCount":101},[],{"intervention":25153,"totalTrials":272,"cells":25197},{"EARLY_PHASE1":25198,"PHASE1":25200,"PHASE2":25202,"PHASE3":25208,"PHASE4":25210,"NA":25212},{"trials":25199,"activeCount":101},[],{"trials":25201,"activeCount":101},[],{"trials":25203,"activeCount":101},[25204],{"nctId":25146,"briefTitle":25147,"status":107,"phases":25205,"primaryCompletion":6095,"start":6132,"enrollment":18380,"conditions":25206,"interventions":25207},[91],[30],[25137,25151,25152,25153],{"trials":25209,"activeCount":101},[],{"trials":25211,"activeCount":101},[],{"trials":25213,"activeCount":101},[],{"intervention":25215,"totalTrials":272,"cells":25216},"Tiotropium 2.5 µg b.i.d",{"EARLY_PHASE1":25217,"PHASE1":25219,"PHASE2":25221,"PHASE3":25230,"PHASE4":25232,"NA":25234},{"trials":25218,"activeCount":101},[],{"trials":25220,"activeCount":101},[],{"trials":25222,"activeCount":101},[25223],{"nctId":25224,"briefTitle":25225,"status":107,"phases":25226,"primaryCompletion":2648,"start":1967,"enrollment":3755,"conditions":25227,"interventions":25228},"NCT01152450","A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma",[91],[30],[25215,25229],"Tiotropium 5 µg q.d.",{"trials":25231,"activeCount":101},[],{"trials":25233,"activeCount":101},[],{"trials":25235,"activeCount":101},[],{"intervention":25229,"totalTrials":272,"cells":25237},{"EARLY_PHASE1":25238,"PHASE1":25240,"PHASE2":25242,"PHASE3":25248,"PHASE4":25250,"NA":25252},{"trials":25239,"activeCount":101},[],{"trials":25241,"activeCount":101},[],{"trials":25243,"activeCount":101},[25244],{"nctId":25224,"briefTitle":25225,"status":107,"phases":25245,"primaryCompletion":2648,"start":1967,"enrollment":3755,"conditions":25246,"interventions":25247},[91],[30],[25215,25229],{"trials":25249,"activeCount":101},[],{"trials":25251,"activeCount":101},[],{"trials":25253,"activeCount":101},[],{"intervention":25255,"totalTrials":272,"cells":25256},"BILB 1941 ZW",{"EARLY_PHASE1":25257,"PHASE1":25259,"PHASE2":25261,"PHASE3":25269,"PHASE4":25271,"NA":25273},{"trials":25258,"activeCount":101},[],{"trials":25260,"activeCount":101},[],{"trials":25262,"activeCount":101},[25263],{"nctId":25264,"briefTitle":25265,"status":107,"phases":25266,"primaryCompletion":6156,"start":5868,"enrollment":8,"conditions":25267,"interventions":25268},"NCT02254707","Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection",[90,91],[4040],[25255],{"trials":25270,"activeCount":101},[],{"trials":25272,"activeCount":101},[],{"trials":25274,"activeCount":101},[],{"intervention":2937,"totalTrials":272,"cells":25276},{"EARLY_PHASE1":25277,"PHASE1":25279,"PHASE2":25281,"PHASE3":25287,"PHASE4":25289,"NA":25291},{"trials":25278,"activeCount":101},[],{"trials":25280,"activeCount":101},[],{"trials":25282,"activeCount":101},[25283],{"nctId":2930,"briefTitle":2931,"status":107,"phases":25284,"primaryCompletion":2933,"completion":2933,"start":2934,"enrollment":1535,"conditions":25285,"interventions":25286},[90,91],[2925],[2908,2937],{"trials":25288,"activeCount":101},[],{"trials":25290,"activeCount":101},[],{"trials":25292,"activeCount":101},[],{"intervention":25294,"totalTrials":272,"cells":25295},"BIBF1120",{"EARLY_PHASE1":25296,"PHASE1":25298,"PHASE2":25300,"PHASE3":25308,"PHASE4":25310,"NA":25312},{"trials":25297,"activeCount":101},[],{"trials":25299,"activeCount":101},[],{"trials":25301,"activeCount":101},[25302],{"nctId":25303,"briefTitle":25304,"status":107,"phases":25305,"primaryCompletion":5856,"completion":9824,"start":4461,"enrollment":19492,"conditions":25306,"interventions":25307},"NCT00710762","A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer",[91],[1187],[25294],{"trials":25309,"activeCount":101},[],{"trials":25311,"activeCount":101},[],{"trials":25313,"activeCount":101},[],{"intervention":25315,"totalTrials":272,"cells":25316},"BI 655064 dose 1",{"EARLY_PHASE1":25317,"PHASE1":25319,"PHASE2":25321,"PHASE3":25334,"PHASE4":25336,"NA":25338},{"trials":25318,"activeCount":101},[],{"trials":25320,"activeCount":101},[],{"trials":25322,"activeCount":101},[25323],{"nctId":25324,"briefTitle":25325,"status":107,"phases":25326,"primaryCompletion":25327,"completion":25328,"start":25329,"enrollment":10776,"conditions":25330,"interventions":25331},"NCT02770170","Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis",[91],"2020-06-23","2020-08-18","2016-05-16",[20052],[25315,25332,25333],"BI 655064 dose 2","BI 655064 dose 3",{"trials":25335,"activeCount":101},[],{"trials":25337,"activeCount":101},[],{"trials":25339,"activeCount":101},[],{"intervention":25332,"totalTrials":272,"cells":25341},{"EARLY_PHASE1":25342,"PHASE1":25344,"PHASE2":25346,"PHASE3":25352,"PHASE4":25354,"NA":25356},{"trials":25343,"activeCount":101},[],{"trials":25345,"activeCount":101},[],{"trials":25347,"activeCount":101},[25348],{"nctId":25324,"briefTitle":25325,"status":107,"phases":25349,"primaryCompletion":25327,"completion":25328,"start":25329,"enrollment":10776,"conditions":25350,"interventions":25351},[91],[20052],[25315,25332,25333],{"trials":25353,"activeCount":101},[],{"trials":25355,"activeCount":101},[],{"trials":25357,"activeCount":101},[],{"intervention":25333,"totalTrials":272,"cells":25359},{"EARLY_PHASE1":25360,"PHASE1":25362,"PHASE2":25364,"PHASE3":25370,"PHASE4":25372,"NA":25374},{"trials":25361,"activeCount":101},[],{"trials":25363,"activeCount":101},[],{"trials":25365,"activeCount":101},[25366],{"nctId":25324,"briefTitle":25325,"status":107,"phases":25367,"primaryCompletion":25327,"completion":25328,"start":25329,"enrollment":10776,"conditions":25368,"interventions":25369},[91],[20052],[25315,25332,25333],{"trials":25371,"activeCount":101},[],{"trials":25373,"activeCount":101},[],{"trials":25375,"activeCount":101},[],{"intervention":25377,"totalTrials":272,"cells":25378},"BILN 2061 W, low dose",{"EARLY_PHASE1":25379,"PHASE1":25381,"PHASE2":25383,"PHASE3":25393,"PHASE4":25395,"NA":25397},{"trials":25380,"activeCount":101},[],{"trials":25382,"activeCount":101},[],{"trials":25384,"activeCount":101},[25385],{"nctId":25386,"briefTitle":25387,"status":107,"phases":25388,"primaryCompletion":6029,"start":6015,"enrollment":5205,"conditions":25389,"interventions":25390},"NCT02226952","Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection",[90,91],[4040],[25377,25391,25392],"BILN 2061 W, medium dose","BILN 2061 W, high dose",{"trials":25394,"activeCount":101},[],{"trials":25396,"activeCount":101},[],{"trials":25398,"activeCount":101},[],{"intervention":25391,"totalTrials":272,"cells":25400},{"EARLY_PHASE1":25401,"PHASE1":25403,"PHASE2":25405,"PHASE3":25411,"PHASE4":25413,"NA":25415},{"trials":25402,"activeCount":101},[],{"trials":25404,"activeCount":101},[],{"trials":25406,"activeCount":101},[25407],{"nctId":25386,"briefTitle":25387,"status":107,"phases":25408,"primaryCompletion":6029,"start":6015,"enrollment":5205,"conditions":25409,"interventions":25410},[90,91],[4040],[25377,25391,25392],{"trials":25412,"activeCount":101},[],{"trials":25414,"activeCount":101},[],{"trials":25416,"activeCount":101},[],{"intervention":25392,"totalTrials":272,"cells":25418},{"EARLY_PHASE1":25419,"PHASE1":25421,"PHASE2":25423,"PHASE3":25429,"PHASE4":25431,"NA":25433},{"trials":25420,"activeCount":101},[],{"trials":25422,"activeCount":101},[],{"trials":25424,"activeCount":101},[25425],{"nctId":25386,"briefTitle":25387,"status":107,"phases":25426,"primaryCompletion":6029,"start":6015,"enrollment":5205,"conditions":25427,"interventions":25428},[90,91],[4040],[25377,25391,25392],{"trials":25430,"activeCount":101},[],{"trials":25432,"activeCount":101},[],{"trials":25434,"activeCount":101},[],{"intervention":12855,"totalTrials":272,"cells":25436},{"EARLY_PHASE1":25437,"PHASE1":25439,"PHASE2":25441,"PHASE3":25447,"PHASE4":25449,"NA":25451},{"trials":25438,"activeCount":101},[],{"trials":25440,"activeCount":101},[],{"trials":25442,"activeCount":101},[25443],{"nctId":12847,"briefTitle":12848,"status":107,"phases":25444,"primaryCompletion":12850,"start":12851,"enrollment":10776,"conditions":25445,"interventions":25446},[91],[18],[12854,12855,12856],{"trials":25448,"activeCount":101},[],{"trials":25450,"activeCount":101},[],{"trials":25452,"activeCount":101},[],{"intervention":12856,"totalTrials":272,"cells":25454},{"EARLY_PHASE1":25455,"PHASE1":25457,"PHASE2":25459,"PHASE3":25465,"PHASE4":25467,"NA":25469},{"trials":25456,"activeCount":101},[],{"trials":25458,"activeCount":101},[],{"trials":25460,"activeCount":101},[25461],{"nctId":12847,"briefTitle":12848,"status":107,"phases":25462,"primaryCompletion":12850,"start":12851,"enrollment":10776,"conditions":25463,"interventions":25464},[91],[18],[12854,12855,12856],{"trials":25466,"activeCount":101},[],{"trials":25468,"activeCount":101},[],{"trials":25470,"activeCount":101},[],{"intervention":21292,"totalTrials":272,"cells":25472},{"EARLY_PHASE1":25473,"PHASE1":25475,"PHASE2":25477,"PHASE3":25483,"PHASE4":25485,"NA":25487},{"trials":25474,"activeCount":101},[],{"trials":25476,"activeCount":101},[],{"trials":25478,"activeCount":101},[25479],{"nctId":21286,"briefTitle":21287,"status":107,"phases":25480,"primaryCompletion":217,"completion":217,"start":21289,"enrollment":2123,"conditions":25481,"interventions":25482},[90,91],[10147],[21292,21269],{"trials":25484,"activeCount":101},[],{"trials":25486,"activeCount":101},[],{"trials":25488,"activeCount":101},[],{"intervention":10050,"totalTrials":272,"cells":25490},{"EARLY_PHASE1":25491,"PHASE1":25493,"PHASE2":25495,"PHASE3":25501,"PHASE4":25503,"NA":25505},{"trials":25492,"activeCount":101},[],{"trials":25494,"activeCount":101},[],{"trials":25496,"activeCount":101},[25497],{"nctId":10045,"briefTitle":10046,"status":107,"phases":25498,"primaryCompletion":419,"completion":419,"start":379,"enrollment":1418,"conditions":25499,"interventions":25500},[91],[4040],[9801,10050,4479,9801,10051,4479],{"trials":25502,"activeCount":101},[],{"trials":25504,"activeCount":101},[],{"trials":25506,"activeCount":101},[],{"intervention":10051,"totalTrials":272,"cells":25508},{"EARLY_PHASE1":25509,"PHASE1":25511,"PHASE2":25513,"PHASE3":25519,"PHASE4":25521,"NA":25523},{"trials":25510,"activeCount":101},[],{"trials":25512,"activeCount":101},[],{"trials":25514,"activeCount":101},[25515],{"nctId":10045,"briefTitle":10046,"status":107,"phases":25516,"primaryCompletion":419,"completion":419,"start":379,"enrollment":1418,"conditions":25517,"interventions":25518},[91],[4040],[9801,10050,4479,9801,10051,4479],{"trials":25520,"activeCount":101},[],{"trials":25522,"activeCount":101},[],{"trials":25524,"activeCount":101},[],{"intervention":25526,"totalTrials":272,"cells":25527},"Pharmaton® with DMAE",{"EARLY_PHASE1":25528,"PHASE1":25530,"PHASE2":25532,"PHASE3":25541,"PHASE4":25543,"NA":25545},{"trials":25529,"activeCount":101},[],{"trials":25531,"activeCount":101},[],{"trials":25533,"activeCount":101},[25534],{"nctId":25535,"briefTitle":25536,"status":107,"phases":25537,"primaryCompletion":2182,"start":7114,"enrollment":2183,"conditions":25538,"interventions":25539},"NCT02181959","Safety and Tolerability of Pharmaton Capsules in Healthy Volunteers",[91],[15],[25526,25540],"Pharmaton® without DMAE",{"trials":25542,"activeCount":101},[],{"trials":25544,"activeCount":101},[],{"trials":25546,"activeCount":101},[],{"intervention":25540,"totalTrials":272,"cells":25548},{"EARLY_PHASE1":25549,"PHASE1":25551,"PHASE2":25553,"PHASE3":25559,"PHASE4":25561,"NA":25563},{"trials":25550,"activeCount":101},[],{"trials":25552,"activeCount":101},[],{"trials":25554,"activeCount":101},[25555],{"nctId":25535,"briefTitle":25536,"status":107,"phases":25556,"primaryCompletion":2182,"start":7114,"enrollment":2183,"conditions":25557,"interventions":25558},[91],[15],[25526,25540],{"trials":25560,"activeCount":101},[],{"trials":25562,"activeCount":101},[],{"trials":25564,"activeCount":101},[],{"intervention":25566,"totalTrials":272,"cells":25567},"dabigatran with ASA",{"EARLY_PHASE1":25568,"PHASE1":25570,"PHASE2":25572,"PHASE3":25581,"PHASE4":25583,"NA":25585},{"trials":25569,"activeCount":101},[],{"trials":25571,"activeCount":101},[],{"trials":25573,"activeCount":101},[25574],{"nctId":25575,"briefTitle":25576,"status":107,"phases":25577,"primaryCompletion":8086,"start":5869,"enrollment":10931,"conditions":25578,"interventions":25579},"NCT01227629","PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin",[91],[6098],[25566,25566,25566,25566,25566,25566,4165,25580,25580,25580],"dabigatran without ASA",{"trials":25582,"activeCount":101},[],{"trials":25584,"activeCount":101},[],{"trials":25586,"activeCount":101},[],{"intervention":25580,"totalTrials":272,"cells":25588},{"EARLY_PHASE1":25589,"PHASE1":25591,"PHASE2":25593,"PHASE3":25599,"PHASE4":25601,"NA":25603},{"trials":25590,"activeCount":101},[],{"trials":25592,"activeCount":101},[],{"trials":25594,"activeCount":101},[25595],{"nctId":25575,"briefTitle":25576,"status":107,"phases":25596,"primaryCompletion":8086,"start":5869,"enrollment":10931,"conditions":25597,"interventions":25598},[91],[6098],[25566,25566,25566,25566,25566,25566,4165,25580,25580,25580],{"trials":25600,"activeCount":101},[],{"trials":25602,"activeCount":101},[],{"trials":25604,"activeCount":101},[],{"intervention":25606,"totalTrials":272,"cells":25607},"BIIL 284 BS low dose",{"EARLY_PHASE1":25608,"PHASE1":25610,"PHASE2":25612,"PHASE3":25623,"PHASE4":25625,"NA":25627},{"trials":25609,"activeCount":101},[],{"trials":25611,"activeCount":101},[],{"trials":25613,"activeCount":101},[25614],{"nctId":25615,"briefTitle":25616,"status":107,"phases":25617,"primaryCompletion":6082,"start":6701,"enrollment":25618,"conditions":25619,"interventions":25620},"NCT02251210","Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis",[91],404,[10667],[25606,25621,25622],"BIIL 284 BS medium dose","BIIL 284 BS high dose",{"trials":25624,"activeCount":101},[],{"trials":25626,"activeCount":101},[],{"trials":25628,"activeCount":101},[],{"intervention":25621,"totalTrials":272,"cells":25630},{"EARLY_PHASE1":25631,"PHASE1":25633,"PHASE2":25635,"PHASE3":25641,"PHASE4":25643,"NA":25645},{"trials":25632,"activeCount":101},[],{"trials":25634,"activeCount":101},[],{"trials":25636,"activeCount":101},[25637],{"nctId":25615,"briefTitle":25616,"status":107,"phases":25638,"primaryCompletion":6082,"start":6701,"enrollment":25618,"conditions":25639,"interventions":25640},[91],[10667],[25606,25621,25622],{"trials":25642,"activeCount":101},[],{"trials":25644,"activeCount":101},[],{"trials":25646,"activeCount":101},[],{"intervention":25622,"totalTrials":272,"cells":25648},{"EARLY_PHASE1":25649,"PHASE1":25651,"PHASE2":25653,"PHASE3":25659,"PHASE4":25661,"NA":25663},{"trials":25650,"activeCount":101},[],{"trials":25652,"activeCount":101},[],{"trials":25654,"activeCount":101},[25655],{"nctId":25615,"briefTitle":25616,"status":107,"phases":25656,"primaryCompletion":6082,"start":6701,"enrollment":25618,"conditions":25657,"interventions":25658},[91],[10667],[25606,25621,25622],{"trials":25660,"activeCount":101},[],{"trials":25662,"activeCount":101},[],{"trials":25664,"activeCount":101},[],{"intervention":25666,"totalTrials":272,"cells":25667},"5 mg BI 1569912",{"EARLY_PHASE1":25668,"PHASE1":25670,"PHASE2":25672,"PHASE3":25684,"PHASE4":25686,"NA":25688},{"trials":25669,"activeCount":101},[],{"trials":25671,"activeCount":101},[],{"trials":25673,"activeCount":101},[25674],{"nctId":25675,"briefTitle":25676,"status":107,"phases":25677,"primaryCompletion":25678,"completion":25679,"start":1236,"enrollment":15558,"conditions":25680,"interventions":25681},"NCT06558344","A Study to Test Different Doses of BI 1569912 in People With Depression",[91],"2025-05-02","2025-05-12",[7303],[25666,25682,25683],"10 mg BI 1569912","20 mg of BI 1569912",{"trials":25685,"activeCount":101},[],{"trials":25687,"activeCount":101},[],{"trials":25689,"activeCount":101},[],{"intervention":25682,"totalTrials":272,"cells":25691},{"EARLY_PHASE1":25692,"PHASE1":25694,"PHASE2":25696,"PHASE3":25702,"PHASE4":25704,"NA":25706},{"trials":25693,"activeCount":101},[],{"trials":25695,"activeCount":101},[],{"trials":25697,"activeCount":101},[25698],{"nctId":25675,"briefTitle":25676,"status":107,"phases":25699,"primaryCompletion":25678,"completion":25679,"start":1236,"enrollment":15558,"conditions":25700,"interventions":25701},[91],[7303],[25666,25682,25683],{"trials":25703,"activeCount":101},[],{"trials":25705,"activeCount":101},[],{"trials":25707,"activeCount":101},[],{"intervention":25683,"totalTrials":272,"cells":25709},{"EARLY_PHASE1":25710,"PHASE1":25712,"PHASE2":25714,"PHASE3":25720,"PHASE4":25722,"NA":25724},{"trials":25711,"activeCount":101},[],{"trials":25713,"activeCount":101},[],{"trials":25715,"activeCount":101},[25716],{"nctId":25675,"briefTitle":25676,"status":107,"phases":25717,"primaryCompletion":25678,"completion":25679,"start":1236,"enrollment":15558,"conditions":25718,"interventions":25719},[91],[7303],[25666,25682,25683],{"trials":25721,"activeCount":101},[],{"trials":25723,"activeCount":101},[],{"trials":25725,"activeCount":101},[],{"intervention":25727,"totalTrials":272,"cells":25728},"BI 765128",{"EARLY_PHASE1":25729,"PHASE1":25731,"PHASE2":25733,"PHASE3":25743,"PHASE4":25745,"NA":25747},{"trials":25730,"activeCount":101},[],{"trials":25732,"activeCount":101},[],{"trials":25734,"activeCount":101},[25735],{"nctId":25736,"briefTitle":25737,"status":107,"phases":25738,"primaryCompletion":25739,"completion":25739,"start":25740,"enrollment":1094,"conditions":25741,"interventions":25742},"NCT04919499","A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment",[90,91],"2023-08-07","2021-07-30",[2925],[25727],{"trials":25744,"activeCount":101},[],{"trials":25746,"activeCount":101},[],{"trials":25748,"activeCount":101},[],{"intervention":25750,"totalTrials":272,"cells":25751},"linagliptin low dose",{"EARLY_PHASE1":25752,"PHASE1":25754,"PHASE2":25756,"PHASE3":25765,"PHASE4":25767,"NA":25769},{"trials":25753,"activeCount":101},[],{"trials":25755,"activeCount":101},[],{"trials":25757,"activeCount":101},[25758],{"nctId":25759,"briefTitle":25760,"status":107,"phases":25761,"primaryCompletion":7703,"start":399,"enrollment":11989,"conditions":25762,"interventions":25763},"NCT01012037","Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes",[91],[21],[25750,25764],"linagliptin medium dose",{"trials":25766,"activeCount":101},[],{"trials":25768,"activeCount":101},[],{"trials":25770,"activeCount":101},[],{"intervention":25764,"totalTrials":272,"cells":25772},{"EARLY_PHASE1":25773,"PHASE1":25775,"PHASE2":25777,"PHASE3":25783,"PHASE4":25785,"NA":25787},{"trials":25774,"activeCount":101},[],{"trials":25776,"activeCount":101},[],{"trials":25778,"activeCount":101},[25779],{"nctId":25759,"briefTitle":25760,"status":107,"phases":25780,"primaryCompletion":7703,"start":399,"enrollment":11989,"conditions":25781,"interventions":25782},[91],[21],[25750,25764],{"trials":25784,"activeCount":101},[],{"trials":25786,"activeCount":101},[],{"trials":25788,"activeCount":101},[],{"intervention":21709,"totalTrials":272,"cells":25790},{"EARLY_PHASE1":25791,"PHASE1":25793,"PHASE2":25795,"PHASE3":25801,"PHASE4":25803,"NA":25805},{"trials":25792,"activeCount":101},[],{"trials":25794,"activeCount":101},[],{"trials":25796,"activeCount":101},[25797],{"nctId":21704,"briefTitle":21705,"status":107,"phases":25798,"primaryCompletion":475,"completion":7092,"start":12159,"enrollment":7681,"conditions":25799,"interventions":25800},[91],[114],[21709,21709,20699,21709],{"trials":25802,"activeCount":101},[],{"trials":25804,"activeCount":101},[],{"trials":25806,"activeCount":101},[],{"intervention":25808,"totalTrials":272,"cells":25809},"Spesolimab 1200 mg",{"EARLY_PHASE1":25810,"PHASE1":25812,"PHASE2":25814,"PHASE3":25824,"PHASE4":25826,"NA":25828},{"trials":25811,"activeCount":101},[],{"trials":25813,"activeCount":101},[],{"trials":25815,"activeCount":101},[25816],{"nctId":25817,"briefTitle":25818,"status":107,"phases":25819,"primaryCompletion":25820,"completion":25820,"start":10575,"enrollment":1535,"conditions":25821,"interventions":25822},"NCT04876391","A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial",[91],"2024-04-26",[13220],[25808,25823],"Spesolimab 600 mg",{"trials":25825,"activeCount":101},[],{"trials":25827,"activeCount":101},[],{"trials":25829,"activeCount":101},[],{"intervention":25823,"totalTrials":272,"cells":25831},{"EARLY_PHASE1":25832,"PHASE1":25834,"PHASE2":25836,"PHASE3":25842,"PHASE4":25844,"NA":25846},{"trials":25833,"activeCount":101},[],{"trials":25835,"activeCount":101},[],{"trials":25837,"activeCount":101},[25838],{"nctId":25817,"briefTitle":25818,"status":107,"phases":25839,"primaryCompletion":25820,"completion":25820,"start":10575,"enrollment":1535,"conditions":25840,"interventions":25841},[91],[13220],[25808,25823],{"trials":25843,"activeCount":101},[],{"trials":25845,"activeCount":101},[],{"trials":25847,"activeCount":101},[],{"intervention":25849,"totalTrials":272,"cells":25850},"MIRAPEX® - low",{"EARLY_PHASE1":25851,"PHASE1":25853,"PHASE2":25855,"PHASE3":25865,"PHASE4":25867,"NA":25869},{"trials":25852,"activeCount":101},[],{"trials":25854,"activeCount":101},[],{"trials":25856,"activeCount":101},[25857],{"nctId":25858,"briefTitle":25859,"status":107,"phases":25860,"primaryCompletion":8911,"start":4498,"enrollment":1982,"conditions":25861,"interventions":25862},"NCT02231918","Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)",[91],[11724],[25849,25863,25864],"MIRAPEX® - medium","MIRAPEX® - high",{"trials":25866,"activeCount":101},[],{"trials":25868,"activeCount":101},[],{"trials":25870,"activeCount":101},[],{"intervention":25863,"totalTrials":272,"cells":25872},{"EARLY_PHASE1":25873,"PHASE1":25875,"PHASE2":25877,"PHASE3":25883,"PHASE4":25885,"NA":25887},{"trials":25874,"activeCount":101},[],{"trials":25876,"activeCount":101},[],{"trials":25878,"activeCount":101},[25879],{"nctId":25858,"briefTitle":25859,"status":107,"phases":25880,"primaryCompletion":8911,"start":4498,"enrollment":1982,"conditions":25881,"interventions":25882},[91],[11724],[25849,25863,25864],{"trials":25884,"activeCount":101},[],{"trials":25886,"activeCount":101},[],{"trials":25888,"activeCount":101},[],{"intervention":25864,"totalTrials":272,"cells":25890},{"EARLY_PHASE1":25891,"PHASE1":25893,"PHASE2":25895,"PHASE3":25901,"PHASE4":25903,"NA":25905},{"trials":25892,"activeCount":101},[],{"trials":25894,"activeCount":101},[],{"trials":25896,"activeCount":101},[25897],{"nctId":25858,"briefTitle":25859,"status":107,"phases":25898,"primaryCompletion":8911,"start":4498,"enrollment":1982,"conditions":25899,"interventions":25900},[91],[11724],[25849,25863,25864],{"trials":25902,"activeCount":101},[],{"trials":25904,"activeCount":101},[],{"trials":25906,"activeCount":101},[],{"intervention":25908,"totalTrials":272,"cells":25909},"dabigatran 110 mg",{"EARLY_PHASE1":25910,"PHASE1":25912,"PHASE2":25914,"PHASE3":25925,"PHASE4":25927,"NA":25929},{"trials":25911,"activeCount":101},[],{"trials":25913,"activeCount":101},[],{"trials":25915,"activeCount":101},[25916],{"nctId":25917,"briefTitle":25918,"status":107,"phases":25919,"primaryCompletion":4442,"start":2649,"enrollment":231,"conditions":25920,"interventions":25922},"NCT00818753","Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention",[91],[25921],"Heart Catheterization",[25908,25923,25924],"dabigatran 150 mg","unfractionated heparin",{"trials":25926,"activeCount":101},[],{"trials":25928,"activeCount":101},[],{"trials":25930,"activeCount":101},[],{"intervention":25924,"totalTrials":272,"cells":25932},{"EARLY_PHASE1":25933,"PHASE1":25935,"PHASE2":25937,"PHASE3":25943,"PHASE4":25945,"NA":25947},{"trials":25934,"activeCount":101},[],{"trials":25936,"activeCount":101},[],{"trials":25938,"activeCount":101},[25939],{"nctId":25917,"briefTitle":25918,"status":107,"phases":25940,"primaryCompletion":4442,"start":2649,"enrollment":231,"conditions":25941,"interventions":25942},[91],[25921],[25908,25923,25924],{"trials":25944,"activeCount":101},[],{"trials":25946,"activeCount":101},[],{"trials":25948,"activeCount":101},[],{"intervention":25950,"totalTrials":272,"cells":25951},"BI 25 mg",{"EARLY_PHASE1":25952,"PHASE1":25954,"PHASE2":25956,"PHASE3":25971,"PHASE4":25973,"NA":25975},{"trials":25953,"activeCount":101},[],{"trials":25955,"activeCount":101},[],{"trials":25957,"activeCount":101},[25958],{"nctId":25959,"briefTitle":25960,"status":107,"phases":25961,"primaryCompletion":25962,"completion":20246,"start":25963,"enrollment":1264,"conditions":25964,"interventions":25965},"NCT03635099","This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is",[91],"2021-05-06","2018-09-17",[114],[25950,25966,25967,25968,25969,25970],"BI 50 mg","BI 100 mg","BI 200 mg","BI 400 mg once daily","BI 200 mg twice daily, 400 mg total",{"trials":25972,"activeCount":101},[],{"trials":25974,"activeCount":101},[],{"trials":25976,"activeCount":101},[],{"intervention":25966,"totalTrials":272,"cells":25978},{"EARLY_PHASE1":25979,"PHASE1":25981,"PHASE2":25983,"PHASE3":25989,"PHASE4":25991,"NA":25993},{"trials":25980,"activeCount":101},[],{"trials":25982,"activeCount":101},[],{"trials":25984,"activeCount":101},[25985],{"nctId":25959,"briefTitle":25960,"status":107,"phases":25986,"primaryCompletion":25962,"completion":20246,"start":25963,"enrollment":1264,"conditions":25987,"interventions":25988},[91],[114],[25950,25966,25967,25968,25969,25970],{"trials":25990,"activeCount":101},[],{"trials":25992,"activeCount":101},[],{"trials":25994,"activeCount":101},[],{"intervention":25967,"totalTrials":272,"cells":25996},{"EARLY_PHASE1":25997,"PHASE1":25999,"PHASE2":26001,"PHASE3":26007,"PHASE4":26009,"NA":26011},{"trials":25998,"activeCount":101},[],{"trials":26000,"activeCount":101},[],{"trials":26002,"activeCount":101},[26003],{"nctId":25959,"briefTitle":25960,"status":107,"phases":26004,"primaryCompletion":25962,"completion":20246,"start":25963,"enrollment":1264,"conditions":26005,"interventions":26006},[91],[114],[25950,25966,25967,25968,25969,25970],{"trials":26008,"activeCount":101},[],{"trials":26010,"activeCount":101},[],{"trials":26012,"activeCount":101},[],{"intervention":25968,"totalTrials":272,"cells":26014},{"EARLY_PHASE1":26015,"PHASE1":26017,"PHASE2":26019,"PHASE3":26025,"PHASE4":26027,"NA":26029},{"trials":26016,"activeCount":101},[],{"trials":26018,"activeCount":101},[],{"trials":26020,"activeCount":101},[26021],{"nctId":25959,"briefTitle":25960,"status":107,"phases":26022,"primaryCompletion":25962,"completion":20246,"start":25963,"enrollment":1264,"conditions":26023,"interventions":26024},[91],[114],[25950,25966,25967,25968,25969,25970],{"trials":26026,"activeCount":101},[],{"trials":26028,"activeCount":101},[],{"trials":26030,"activeCount":101},[],{"intervention":25969,"totalTrials":272,"cells":26032},{"EARLY_PHASE1":26033,"PHASE1":26035,"PHASE2":26037,"PHASE3":26043,"PHASE4":26045,"NA":26047},{"trials":26034,"activeCount":101},[],{"trials":26036,"activeCount":101},[],{"trials":26038,"activeCount":101},[26039],{"nctId":25959,"briefTitle":25960,"status":107,"phases":26040,"primaryCompletion":25962,"completion":20246,"start":25963,"enrollment":1264,"conditions":26041,"interventions":26042},[91],[114],[25950,25966,25967,25968,25969,25970],{"trials":26044,"activeCount":101},[],{"trials":26046,"activeCount":101},[],{"trials":26048,"activeCount":101},[],{"intervention":25970,"totalTrials":272,"cells":26050},{"EARLY_PHASE1":26051,"PHASE1":26053,"PHASE2":26055,"PHASE3":26061,"PHASE4":26063,"NA":26065},{"trials":26052,"activeCount":101},[],{"trials":26054,"activeCount":101},[],{"trials":26056,"activeCount":101},[26057],{"nctId":25959,"briefTitle":25960,"status":107,"phases":26058,"primaryCompletion":25962,"completion":20246,"start":25963,"enrollment":1264,"conditions":26059,"interventions":26060},[91],[114],[25950,25966,25967,25968,25969,25970],{"trials":26062,"activeCount":101},[],{"trials":26064,"activeCount":101},[],{"trials":26066,"activeCount":101},[],{"intervention":12603,"totalTrials":272,"cells":26068},{"EARLY_PHASE1":26069,"PHASE1":26071,"PHASE2":26073,"PHASE3":26079,"PHASE4":26081,"NA":26083},{"trials":26070,"activeCount":101},[],{"trials":26072,"activeCount":101},[],{"trials":26074,"activeCount":101},[26075],{"nctId":12597,"briefTitle":12598,"status":107,"phases":26076,"primaryCompletion":390,"start":12600,"enrollment":9115,"conditions":26077,"interventions":26078},[91],[18],[12603,12588,12604,12605,12606],{"trials":26080,"activeCount":101},[],{"trials":26082,"activeCount":101},[],{"trials":26084,"activeCount":101},[],{"intervention":12605,"totalTrials":272,"cells":26086},{"EARLY_PHASE1":26087,"PHASE1":26089,"PHASE2":26091,"PHASE3":26097,"PHASE4":26099,"NA":26101},{"trials":26088,"activeCount":101},[],{"trials":26090,"activeCount":101},[],{"trials":26092,"activeCount":101},[26093],{"nctId":12597,"briefTitle":12598,"status":107,"phases":26094,"primaryCompletion":390,"start":12600,"enrollment":9115,"conditions":26095,"interventions":26096},[91],[18],[12603,12588,12604,12605,12606],{"trials":26098,"activeCount":101},[],{"trials":26100,"activeCount":101},[],{"trials":26102,"activeCount":101},[],{"intervention":12606,"totalTrials":272,"cells":26104},{"EARLY_PHASE1":26105,"PHASE1":26107,"PHASE2":26109,"PHASE3":26115,"PHASE4":26117,"NA":26119},{"trials":26106,"activeCount":101},[],{"trials":26108,"activeCount":101},[],{"trials":26110,"activeCount":101},[26111],{"nctId":12597,"briefTitle":12598,"status":107,"phases":26112,"primaryCompletion":390,"start":12600,"enrollment":9115,"conditions":26113,"interventions":26114},[91],[18],[12603,12588,12604,12605,12606],{"trials":26116,"activeCount":101},[],{"trials":26118,"activeCount":101},[],{"trials":26120,"activeCount":101},[],{"intervention":26122,"totalTrials":272,"cells":26123},"low dose BIBF1120 once daily",{"EARLY_PHASE1":26124,"PHASE1":26126,"PHASE2":26128,"PHASE3":26140,"PHASE4":26142,"NA":26144},{"trials":26125,"activeCount":101},[],{"trials":26127,"activeCount":101},[],{"trials":26129,"activeCount":101},[26130],{"nctId":26131,"briefTitle":26132,"status":107,"phases":26133,"primaryCompletion":3754,"start":3763,"enrollment":26134,"conditions":26135,"interventions":26136},"NCT00514683","Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis",[91],432,[3428],[26122,26137,26138,26139],"low dose BIBF 1120 twice daily","intermediate dose BIBF 1120 twice daily","high dose BIBF 1120 twice daily",{"trials":26141,"activeCount":101},[],{"trials":26143,"activeCount":101},[],{"trials":26145,"activeCount":101},[],{"intervention":26137,"totalTrials":272,"cells":26147},{"EARLY_PHASE1":26148,"PHASE1":26150,"PHASE2":26152,"PHASE3":26158,"PHASE4":26160,"NA":26162},{"trials":26149,"activeCount":101},[],{"trials":26151,"activeCount":101},[],{"trials":26153,"activeCount":101},[26154],{"nctId":26131,"briefTitle":26132,"status":107,"phases":26155,"primaryCompletion":3754,"start":3763,"enrollment":26134,"conditions":26156,"interventions":26157},[91],[3428],[26122,26137,26138,26139],{"trials":26159,"activeCount":101},[],{"trials":26161,"activeCount":101},[],{"trials":26163,"activeCount":101},[],{"intervention":26138,"totalTrials":272,"cells":26165},{"EARLY_PHASE1":26166,"PHASE1":26168,"PHASE2":26170,"PHASE3":26176,"PHASE4":26178,"NA":26180},{"trials":26167,"activeCount":101},[],{"trials":26169,"activeCount":101},[],{"trials":26171,"activeCount":101},[26172],{"nctId":26131,"briefTitle":26132,"status":107,"phases":26173,"primaryCompletion":3754,"start":3763,"enrollment":26134,"conditions":26174,"interventions":26175},[91],[3428],[26122,26137,26138,26139],{"trials":26177,"activeCount":101},[],{"trials":26179,"activeCount":101},[],{"trials":26181,"activeCount":101},[],{"intervention":26139,"totalTrials":272,"cells":26183},{"EARLY_PHASE1":26184,"PHASE1":26186,"PHASE2":26188,"PHASE3":26194,"PHASE4":26196,"NA":26198},{"trials":26185,"activeCount":101},[],{"trials":26187,"activeCount":101},[],{"trials":26189,"activeCount":101},[26190],{"nctId":26131,"briefTitle":26132,"status":107,"phases":26191,"primaryCompletion":3754,"start":3763,"enrollment":26134,"conditions":26192,"interventions":26193},[91],[3428],[26122,26137,26138,26139],{"trials":26195,"activeCount":101},[],{"trials":26197,"activeCount":101},[],{"trials":26199,"activeCount":101},[],{"intervention":9709,"totalTrials":272,"cells":26201},{"EARLY_PHASE1":26202,"PHASE1":26204,"PHASE2":26206,"PHASE3":26212,"PHASE4":26214,"NA":26216},{"trials":26203,"activeCount":101},[],{"trials":26205,"activeCount":101},[],{"trials":26207,"activeCount":101},[26208],{"nctId":9704,"briefTitle":9705,"status":107,"phases":26209,"primaryCompletion":7338,"completion":7338,"start":9411,"enrollment":6585,"conditions":26210,"interventions":26211},[91],[3060],[1119,1119,9709,1131,9710,9711],{"trials":26213,"activeCount":101},[],{"trials":26215,"activeCount":101},[],{"trials":26217,"activeCount":101},[],{"intervention":9710,"totalTrials":272,"cells":26219},{"EARLY_PHASE1":26220,"PHASE1":26222,"PHASE2":26224,"PHASE3":26230,"PHASE4":26232,"NA":26234},{"trials":26221,"activeCount":101},[],{"trials":26223,"activeCount":101},[],{"trials":26225,"activeCount":101},[26226],{"nctId":9704,"briefTitle":9705,"status":107,"phases":26227,"primaryCompletion":7338,"completion":7338,"start":9411,"enrollment":6585,"conditions":26228,"interventions":26229},[91],[3060],[1119,1119,9709,1131,9710,9711],{"trials":26231,"activeCount":101},[],{"trials":26233,"activeCount":101},[],{"trials":26235,"activeCount":101},[],{"intervention":13489,"totalTrials":272,"cells":26237},{"EARLY_PHASE1":26238,"PHASE1":26240,"PHASE2":26242,"PHASE3":26248,"PHASE4":26250,"NA":26252},{"trials":26239,"activeCount":101},[],{"trials":26241,"activeCount":101},[],{"trials":26243,"activeCount":101},[26244],{"nctId":13481,"briefTitle":13482,"status":107,"phases":26245,"primaryCompletion":1779,"completion":1779,"start":13484,"enrollment":3454,"conditions":26246,"interventions":26247},[91],[13486],[13488,13489,10978,13489],{"trials":26249,"activeCount":101},[],{"trials":26251,"activeCount":101},[],{"trials":26253,"activeCount":101},[],{"intervention":26255,"totalTrials":272,"cells":26256},"Ipratropium Bromide low dose",{"EARLY_PHASE1":26257,"PHASE1":26259,"PHASE2":26261,"PHASE3":26270,"PHASE4":26272,"NA":26274},{"trials":26258,"activeCount":101},[],{"trials":26260,"activeCount":101},[],{"trials":26262,"activeCount":101},[26263],{"nctId":26264,"briefTitle":26265,"status":107,"phases":26266,"primaryCompletion":5923,"start":6074,"enrollment":34,"conditions":26267,"interventions":26268},"NCT02236182","Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[91],[18],[26255,26269],"Ipratropium Bromide high dose",{"trials":26271,"activeCount":101},[],{"trials":26273,"activeCount":101},[],{"trials":26275,"activeCount":101},[],{"intervention":26269,"totalTrials":272,"cells":26277},{"EARLY_PHASE1":26278,"PHASE1":26280,"PHASE2":26282,"PHASE3":26288,"PHASE4":26290,"NA":26292},{"trials":26279,"activeCount":101},[],{"trials":26281,"activeCount":101},[],{"trials":26283,"activeCount":101},[26284],{"nctId":26264,"briefTitle":26265,"status":107,"phases":26285,"primaryCompletion":5923,"start":6074,"enrollment":34,"conditions":26286,"interventions":26287},[91],[18],[26255,26269],{"trials":26289,"activeCount":101},[],{"trials":26291,"activeCount":101},[],{"trials":26293,"activeCount":101},[],{"intervention":26295,"totalTrials":272,"cells":26296},"Combivent® HFA inhalation aerosol",{"EARLY_PHASE1":26297,"PHASE1":26299,"PHASE2":26301,"PHASE3":26310,"PHASE4":26312,"NA":26314},{"trials":26298,"activeCount":101},[],{"trials":26300,"activeCount":101},[],{"trials":26302,"activeCount":101},[26303],{"nctId":26304,"briefTitle":26305,"status":162,"phases":26306,"primaryCompletion":6584,"start":6005,"enrollment":112,"conditions":26307,"interventions":26308},"NCT02182869","Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)",[91],[18],[26295,26309],"Combivent® CFC inhalation aerosol",{"trials":26311,"activeCount":101},[],{"trials":26313,"activeCount":101},[],{"trials":26315,"activeCount":101},[],{"intervention":26309,"totalTrials":272,"cells":26317},{"EARLY_PHASE1":26318,"PHASE1":26320,"PHASE2":26322,"PHASE3":26328,"PHASE4":26330,"NA":26332},{"trials":26319,"activeCount":101},[],{"trials":26321,"activeCount":101},[],{"trials":26323,"activeCount":101},[26324],{"nctId":26304,"briefTitle":26305,"status":162,"phases":26325,"primaryCompletion":6584,"start":6005,"enrollment":112,"conditions":26326,"interventions":26327},[91],[18],[26295,26309],{"trials":26329,"activeCount":101},[],{"trials":26331,"activeCount":101},[],{"trials":26333,"activeCount":101},[],{"intervention":26335,"totalTrials":272,"cells":26336},"TPV500mg\u002FRTV200mgBID",{"EARLY_PHASE1":26337,"PHASE1":26339,"PHASE2":26341,"PHASE3":26351,"PHASE4":26353,"NA":26355},{"trials":26338,"activeCount":101},[],{"trials":26340,"activeCount":101},[],{"trials":26342,"activeCount":101},[26343],{"nctId":26344,"briefTitle":26345,"status":162,"phases":26346,"primaryCompletion":6910,"start":11733,"enrollment":10443,"conditions":26347,"interventions":26348},"NCT00144105","A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.",[91],[27],[26335,26349,26350],"TPV500mg\u002FRTV100mgBID","LPV400mg\u002FRTV100mgBID",{"trials":26352,"activeCount":101},[],{"trials":26354,"activeCount":101},[],{"trials":26356,"activeCount":101},[],{"intervention":26349,"totalTrials":272,"cells":26358},{"EARLY_PHASE1":26359,"PHASE1":26361,"PHASE2":26363,"PHASE3":26369,"PHASE4":26371,"NA":26373},{"trials":26360,"activeCount":101},[],{"trials":26362,"activeCount":101},[],{"trials":26364,"activeCount":101},[26365],{"nctId":26344,"briefTitle":26345,"status":162,"phases":26366,"primaryCompletion":6910,"start":11733,"enrollment":10443,"conditions":26367,"interventions":26368},[91],[27],[26335,26349,26350],{"trials":26370,"activeCount":101},[],{"trials":26372,"activeCount":101},[],{"trials":26374,"activeCount":101},[],{"intervention":26350,"totalTrials":272,"cells":26376},{"EARLY_PHASE1":26377,"PHASE1":26379,"PHASE2":26381,"PHASE3":26387,"PHASE4":26389,"NA":26391},{"trials":26378,"activeCount":101},[],{"trials":26380,"activeCount":101},[],{"trials":26382,"activeCount":101},[26383],{"nctId":26344,"briefTitle":26345,"status":162,"phases":26384,"primaryCompletion":6910,"start":11733,"enrollment":10443,"conditions":26385,"interventions":26386},[91],[27],[26335,26349,26350],{"trials":26388,"activeCount":101},[],{"trials":26390,"activeCount":101},[],{"trials":26392,"activeCount":101},[],{"intervention":21873,"totalTrials":272,"cells":26394},{"EARLY_PHASE1":26395,"PHASE1":26397,"PHASE2":26399,"PHASE3":26405,"PHASE4":26407,"NA":26409},{"trials":26396,"activeCount":101},[],{"trials":26398,"activeCount":101},[],{"trials":26400,"activeCount":101},[26401],{"nctId":21868,"briefTitle":21869,"status":107,"phases":26402,"primaryCompletion":6005,"start":6053,"enrollment":357,"conditions":26403,"interventions":26404},[91],[18],[21852,21873],{"trials":26406,"activeCount":101},[],{"trials":26408,"activeCount":101},[],{"trials":26410,"activeCount":101},[],{"intervention":26412,"totalTrials":272,"cells":26413},"BI 409306 100 mg QD",{"EARLY_PHASE1":26414,"PHASE1":26416,"PHASE2":26418,"PHASE3":26432,"PHASE4":26434,"NA":26436},{"trials":26415,"activeCount":101},[],{"trials":26417,"activeCount":101},[],{"trials":26419,"activeCount":101},[26420],{"nctId":26421,"briefTitle":26422,"status":107,"phases":26423,"primaryCompletion":26424,"completion":26425,"start":26426,"enrollment":8539,"conditions":26427,"interventions":26428},"NCT02281773","A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.",[91],"2016-05-26","2016-06-13","2014-11-10",[10549],[26412,26429,26430,26431],"BI 498306 50 mg QD","BI 498306 25 mg QD","BI 409306 10 mg QD",{"trials":26433,"activeCount":101},[],{"trials":26435,"activeCount":101},[],{"trials":26437,"activeCount":101},[],{"intervention":26429,"totalTrials":272,"cells":26439},{"EARLY_PHASE1":26440,"PHASE1":26442,"PHASE2":26444,"PHASE3":26450,"PHASE4":26452,"NA":26454},{"trials":26441,"activeCount":101},[],{"trials":26443,"activeCount":101},[],{"trials":26445,"activeCount":101},[26446],{"nctId":26421,"briefTitle":26422,"status":107,"phases":26447,"primaryCompletion":26424,"completion":26425,"start":26426,"enrollment":8539,"conditions":26448,"interventions":26449},[91],[10549],[26412,26429,26430,26431],{"trials":26451,"activeCount":101},[],{"trials":26453,"activeCount":101},[],{"trials":26455,"activeCount":101},[],{"intervention":26430,"totalTrials":272,"cells":26457},{"EARLY_PHASE1":26458,"PHASE1":26460,"PHASE2":26462,"PHASE3":26468,"PHASE4":26470,"NA":26472},{"trials":26459,"activeCount":101},[],{"trials":26461,"activeCount":101},[],{"trials":26463,"activeCount":101},[26464],{"nctId":26421,"briefTitle":26422,"status":107,"phases":26465,"primaryCompletion":26424,"completion":26425,"start":26426,"enrollment":8539,"conditions":26466,"interventions":26467},[91],[10549],[26412,26429,26430,26431],{"trials":26469,"activeCount":101},[],{"trials":26471,"activeCount":101},[],{"trials":26473,"activeCount":101},[],{"intervention":26431,"totalTrials":272,"cells":26475},{"EARLY_PHASE1":26476,"PHASE1":26478,"PHASE2":26480,"PHASE3":26486,"PHASE4":26488,"NA":26490},{"trials":26477,"activeCount":101},[],{"trials":26479,"activeCount":101},[],{"trials":26481,"activeCount":101},[26482],{"nctId":26421,"briefTitle":26422,"status":107,"phases":26483,"primaryCompletion":26424,"completion":26425,"start":26426,"enrollment":8539,"conditions":26484,"interventions":26485},[91],[10549],[26412,26429,26430,26431],{"trials":26487,"activeCount":101},[],{"trials":26489,"activeCount":101},[],{"trials":26491,"activeCount":101},[],{"intervention":26493,"totalTrials":272,"cells":26494},"Olodaterol & BI54903",{"EARLY_PHASE1":26495,"PHASE1":26497,"PHASE2":26499,"PHASE3":26508,"PHASE4":26510,"NA":26512},{"trials":26496,"activeCount":101},[],{"trials":26498,"activeCount":101},[],{"trials":26500,"activeCount":101},[26501],{"nctId":26502,"briefTitle":26503,"status":600,"phases":26504,"start":391,"enrollment":101,"conditions":26505,"interventions":26506},"NCT01428622","Olodaterol Bridging Study in Asthma",[91],[30],[5959,5959,5959,5959,5959,5959,5959,26493,26493,26493,26493,26493,26493,26493,26507,26507,26507,26507,26507,26507,26507],"BI54903",{"trials":26509,"activeCount":101},[],{"trials":26511,"activeCount":101},[],{"trials":26513,"activeCount":101},[],{"intervention":26507,"totalTrials":272,"cells":26515},{"EARLY_PHASE1":26516,"PHASE1":26518,"PHASE2":26520,"PHASE3":26526,"PHASE4":26528,"NA":26530},{"trials":26517,"activeCount":101},[],{"trials":26519,"activeCount":101},[],{"trials":26521,"activeCount":101},[26522],{"nctId":26502,"briefTitle":26503,"status":600,"phases":26523,"start":391,"enrollment":101,"conditions":26524,"interventions":26525},[91],[30],[5959,5959,5959,5959,5959,5959,5959,26493,26493,26493,26493,26493,26493,26493,26507,26507,26507,26507,26507,26507,26507],{"trials":26527,"activeCount":101},[],{"trials":26529,"activeCount":101},[],{"trials":26531,"activeCount":101},[],{"intervention":26533,"totalTrials":272,"cells":26534},"BI 1744 CL\u002Ftiotropium bromide fixed dose combination",{"EARLY_PHASE1":26535,"PHASE1":26537,"PHASE2":26539,"PHASE3":26548,"PHASE4":26550,"NA":26552},{"trials":26536,"activeCount":101},[],{"trials":26538,"activeCount":101},[],{"trials":26540,"activeCount":101},[26541],{"nctId":26542,"briefTitle":26543,"status":107,"phases":26544,"primaryCompletion":1989,"start":4413,"enrollment":11419,"conditions":26545,"interventions":26546},"NCT00696020","Combination of Orally Inhaled BI1744CL\u002FTiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)",[91],[18],[26533,26547],"tiotropium bromide",{"trials":26549,"activeCount":101},[],{"trials":26551,"activeCount":101},[],{"trials":26553,"activeCount":101},[],{"intervention":26555,"totalTrials":272,"cells":26556},"Terbogrel low dose",{"EARLY_PHASE1":26557,"PHASE1":26559,"PHASE2":26561,"PHASE3":26570,"PHASE4":26572,"NA":26574},{"trials":26558,"activeCount":101},[],{"trials":26560,"activeCount":101},[],{"trials":26562,"activeCount":101},[26563],{"nctId":26564,"briefTitle":26565,"status":107,"phases":26566,"primaryCompletion":7022,"start":7250,"enrollment":2898,"conditions":26567,"interventions":26568},"NCT02223481","Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension",[91],[22338],[26555,26569],"Terbogrel high dose",{"trials":26571,"activeCount":101},[],{"trials":26573,"activeCount":101},[],{"trials":26575,"activeCount":101},[],{"intervention":26569,"totalTrials":272,"cells":26577},{"EARLY_PHASE1":26578,"PHASE1":26580,"PHASE2":26582,"PHASE3":26588,"PHASE4":26590,"NA":26592},{"trials":26579,"activeCount":101},[],{"trials":26581,"activeCount":101},[],{"trials":26583,"activeCount":101},[26584],{"nctId":26564,"briefTitle":26565,"status":107,"phases":26585,"primaryCompletion":7022,"start":7250,"enrollment":2898,"conditions":26586,"interventions":26587},[91],[22338],[26555,26569],{"trials":26589,"activeCount":101},[],{"trials":26591,"activeCount":101},[],{"trials":26593,"activeCount":101},[],{"intervention":21328,"totalTrials":272,"cells":26595},{"EARLY_PHASE1":26596,"PHASE1":26598,"PHASE2":26600,"PHASE3":26606,"PHASE4":26608,"NA":26610},{"trials":26597,"activeCount":101},[],{"trials":26599,"activeCount":101},[],{"trials":26601,"activeCount":101},[26602],{"nctId":21323,"briefTitle":21324,"status":107,"phases":26603,"primaryCompletion":7151,"start":1981,"enrollment":5086,"conditions":26604,"interventions":26605},[91],[18],[21328,21329,21330,7155],{"trials":26607,"activeCount":101},[],{"trials":26609,"activeCount":101},[],{"trials":26611,"activeCount":101},[],{"intervention":21329,"totalTrials":272,"cells":26613},{"EARLY_PHASE1":26614,"PHASE1":26616,"PHASE2":26618,"PHASE3":26624,"PHASE4":26626,"NA":26628},{"trials":26615,"activeCount":101},[],{"trials":26617,"activeCount":101},[],{"trials":26619,"activeCount":101},[26620],{"nctId":21323,"briefTitle":21324,"status":107,"phases":26621,"primaryCompletion":7151,"start":1981,"enrollment":5086,"conditions":26622,"interventions":26623},[91],[18],[21328,21329,21330,7155],{"trials":26625,"activeCount":101},[],{"trials":26627,"activeCount":101},[],{"trials":26629,"activeCount":101},[],{"intervention":21330,"totalTrials":272,"cells":26631},{"EARLY_PHASE1":26632,"PHASE1":26634,"PHASE2":26636,"PHASE3":26642,"PHASE4":26644,"NA":26646},{"trials":26633,"activeCount":101},[],{"trials":26635,"activeCount":101},[],{"trials":26637,"activeCount":101},[26638],{"nctId":21323,"briefTitle":21324,"status":107,"phases":26639,"primaryCompletion":7151,"start":1981,"enrollment":5086,"conditions":26640,"interventions":26641},[91],[18],[21328,21329,21330,7155],{"trials":26643,"activeCount":101},[],{"trials":26645,"activeCount":101},[],{"trials":26647,"activeCount":101},[],{"intervention":22081,"totalTrials":272,"cells":26649},{"EARLY_PHASE1":26650,"PHASE1":26652,"PHASE2":26654,"PHASE3":26660,"PHASE4":26662,"NA":26664},{"trials":26651,"activeCount":101},[],{"trials":26653,"activeCount":101},[],{"trials":26655,"activeCount":101},[26656],{"nctId":22074,"briefTitle":22075,"status":107,"phases":26657,"primaryCompletion":2182,"start":17270,"enrollment":22077,"conditions":26658,"interventions":26659},[91],[22079],[22053,22071,22081],{"trials":26661,"activeCount":101},[],{"trials":26663,"activeCount":101},[],{"trials":26665,"activeCount":101},[],{"intervention":4395,"totalTrials":272,"cells":26667},{"EARLY_PHASE1":26668,"PHASE1":26670,"PHASE2":26672,"PHASE3":26678,"PHASE4":26680,"NA":26682},{"trials":26669,"activeCount":101},[],{"trials":26671,"activeCount":101},[],{"trials":26673,"activeCount":101},[26674],{"nctId":4388,"briefTitle":4389,"status":107,"phases":26675,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":4219,"conditions":26676,"interventions":26677},[91],[1187],[1120,2730,3662,4395,2007],{"trials":26679,"activeCount":101},[],{"trials":26681,"activeCount":101},[],{"trials":26683,"activeCount":101},[],{"intervention":26685,"totalTrials":272,"cells":26686},"Alovudine - low",{"EARLY_PHASE1":26687,"PHASE1":26689,"PHASE2":26691,"PHASE3":26701,"PHASE4":26703,"NA":26705},{"trials":26688,"activeCount":101},[],{"trials":26690,"activeCount":101},[],{"trials":26692,"activeCount":101},[26693],{"nctId":26694,"briefTitle":26695,"status":107,"phases":26696,"primaryCompletion":6413,"start":6446,"enrollment":716,"conditions":26697,"interventions":26698},"NCT02232581","Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure",[91],[27],[26685,26699,26700],"Alovudine - medium","Alovudine - high",{"trials":26702,"activeCount":101},[],{"trials":26704,"activeCount":101},[],{"trials":26706,"activeCount":101},[],{"intervention":26699,"totalTrials":272,"cells":26708},{"EARLY_PHASE1":26709,"PHASE1":26711,"PHASE2":26713,"PHASE3":26719,"PHASE4":26721,"NA":26723},{"trials":26710,"activeCount":101},[],{"trials":26712,"activeCount":101},[],{"trials":26714,"activeCount":101},[26715],{"nctId":26694,"briefTitle":26695,"status":107,"phases":26716,"primaryCompletion":6413,"start":6446,"enrollment":716,"conditions":26717,"interventions":26718},[91],[27],[26685,26699,26700],{"trials":26720,"activeCount":101},[],{"trials":26722,"activeCount":101},[],{"trials":26724,"activeCount":101},[],{"intervention":26700,"totalTrials":272,"cells":26726},{"EARLY_PHASE1":26727,"PHASE1":26729,"PHASE2":26731,"PHASE3":26737,"PHASE4":26739,"NA":26741},{"trials":26728,"activeCount":101},[],{"trials":26730,"activeCount":101},[],{"trials":26732,"activeCount":101},[26733],{"nctId":26694,"briefTitle":26695,"status":107,"phases":26734,"primaryCompletion":6413,"start":6446,"enrollment":716,"conditions":26735,"interventions":26736},[91],[27],[26685,26699,26700],{"trials":26738,"activeCount":101},[],{"trials":26740,"activeCount":101},[],{"trials":26742,"activeCount":101},[],{"intervention":26744,"totalTrials":272,"cells":26745},"BIBR 796 BS, 5 mg",{"EARLY_PHASE1":26746,"PHASE1":26748,"PHASE2":26750,"PHASE3":26760,"PHASE4":26762,"NA":26764},{"trials":26747,"activeCount":101},[],{"trials":26749,"activeCount":101},[],{"trials":26751,"activeCount":101},[26752],{"nctId":26753,"briefTitle":26754,"status":162,"phases":26755,"primaryCompletion":2112,"start":6041,"enrollment":26756,"conditions":26757,"interventions":26758},"NCT02209792","Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease",[91],284,[190],[26744,26759],"BIBR 796 BS, 20 mg",{"trials":26761,"activeCount":101},[],{"trials":26763,"activeCount":101},[],{"trials":26765,"activeCount":101},[],{"intervention":26759,"totalTrials":272,"cells":26767},{"EARLY_PHASE1":26768,"PHASE1":26770,"PHASE2":26772,"PHASE3":26778,"PHASE4":26780,"NA":26782},{"trials":26769,"activeCount":101},[],{"trials":26771,"activeCount":101},[],{"trials":26773,"activeCount":101},[26774],{"nctId":26753,"briefTitle":26754,"status":162,"phases":26775,"primaryCompletion":2112,"start":6041,"enrollment":26756,"conditions":26776,"interventions":26777},[91],[190],[26744,26759],{"trials":26779,"activeCount":101},[],{"trials":26781,"activeCount":101},[],{"trials":26783,"activeCount":101},[],{"intervention":26785,"totalTrials":272,"cells":26786},"Kiddi® Pharmaton Fizz, effervescent",{"EARLY_PHASE1":26787,"PHASE1":26789,"PHASE2":26791,"PHASE3":26801,"PHASE4":26803,"NA":26805},{"trials":26788,"activeCount":101},[],{"trials":26790,"activeCount":101},[],{"trials":26792,"activeCount":101},[26793],{"nctId":26794,"briefTitle":26795,"status":107,"phases":26796,"primaryCompletion":8538,"start":6246,"enrollment":8,"conditions":26797,"interventions":26798},"NCT02184325","Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children",[91],[15],[26785,26799,26800],"Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula","Comparator product",{"trials":26802,"activeCount":101},[],{"trials":26804,"activeCount":101},[],{"trials":26806,"activeCount":101},[],{"intervention":26799,"totalTrials":272,"cells":26808},{"EARLY_PHASE1":26809,"PHASE1":26811,"PHASE2":26813,"PHASE3":26819,"PHASE4":26821,"NA":26823},{"trials":26810,"activeCount":101},[],{"trials":26812,"activeCount":101},[],{"trials":26814,"activeCount":101},[26815],{"nctId":26794,"briefTitle":26795,"status":107,"phases":26816,"primaryCompletion":8538,"start":6246,"enrollment":8,"conditions":26817,"interventions":26818},[91],[15],[26785,26799,26800],{"trials":26820,"activeCount":101},[],{"trials":26822,"activeCount":101},[],{"trials":26824,"activeCount":101},[],{"intervention":26800,"totalTrials":272,"cells":26826},{"EARLY_PHASE1":26827,"PHASE1":26829,"PHASE2":26831,"PHASE3":26837,"PHASE4":26839,"NA":26841},{"trials":26828,"activeCount":101},[],{"trials":26830,"activeCount":101},[],{"trials":26832,"activeCount":101},[26833],{"nctId":26794,"briefTitle":26795,"status":107,"phases":26834,"primaryCompletion":8538,"start":6246,"enrollment":8,"conditions":26835,"interventions":26836},[91],[15],[26785,26799,26800],{"trials":26838,"activeCount":101},[],{"trials":26840,"activeCount":101},[],{"trials":26842,"activeCount":101},[],{"intervention":21739,"totalTrials":272,"cells":26844},{"EARLY_PHASE1":26845,"PHASE1":26847,"PHASE2":26849,"PHASE3":26855,"PHASE4":26857,"NA":26859},{"trials":26846,"activeCount":101},[],{"trials":26848,"activeCount":101},[],{"trials":26850,"activeCount":101},[26851],{"nctId":21734,"briefTitle":21735,"status":107,"phases":26852,"primaryCompletion":4461,"start":8086,"enrollment":5407,"conditions":26853,"interventions":26854},[91],[30],[21739,21717],{"trials":26856,"activeCount":101},[],{"trials":26858,"activeCount":101},[],{"trials":26860,"activeCount":101},[],{"intervention":9718,"totalTrials":272,"cells":26862},{"EARLY_PHASE1":26863,"PHASE1":26865,"PHASE2":26867,"PHASE3":26873,"PHASE4":26875,"NA":26877},{"trials":26864,"activeCount":101},[],{"trials":26866,"activeCount":101},[],{"trials":26868,"activeCount":101},[26869],{"nctId":9713,"briefTitle":9714,"status":107,"phases":26870,"primaryCompletion":2032,"start":4461,"enrollment":3970,"conditions":26871,"interventions":26872},[91],[9651],[1119,1129,9718],{"trials":26874,"activeCount":101},[],{"trials":26876,"activeCount":101},[],{"trials":26878,"activeCount":101},[],{"intervention":26880,"totalTrials":272,"cells":26881},"BI 44370 TA Low Dose",{"EARLY_PHASE1":26882,"PHASE1":26884,"PHASE2":26886,"PHASE3":26897,"PHASE4":26899,"NA":26901},{"trials":26883,"activeCount":101},[],{"trials":26885,"activeCount":101},[],{"trials":26887,"activeCount":101},[26888],{"nctId":26889,"briefTitle":26890,"status":107,"phases":26891,"primaryCompletion":9411,"start":6223,"enrollment":26892,"conditions":26893,"interventions":26894},"NCT00751803","BI 44370 TA in Acute Migraine Attack",[91],416,[13290],[26880,26895,26896],"Eletriptan","BI 44370 TA Medium Dose",{"trials":26898,"activeCount":101},[],{"trials":26900,"activeCount":101},[],{"trials":26902,"activeCount":101},[],{"intervention":26895,"totalTrials":272,"cells":26904},{"EARLY_PHASE1":26905,"PHASE1":26907,"PHASE2":26909,"PHASE3":26915,"PHASE4":26917,"NA":26919},{"trials":26906,"activeCount":101},[],{"trials":26908,"activeCount":101},[],{"trials":26910,"activeCount":101},[26911],{"nctId":26889,"briefTitle":26890,"status":107,"phases":26912,"primaryCompletion":9411,"start":6223,"enrollment":26892,"conditions":26913,"interventions":26914},[91],[13290],[26880,26895,26896],{"trials":26916,"activeCount":101},[],{"trials":26918,"activeCount":101},[],{"trials":26920,"activeCount":101},[],{"intervention":26896,"totalTrials":272,"cells":26922},{"EARLY_PHASE1":26923,"PHASE1":26925,"PHASE2":26927,"PHASE3":26933,"PHASE4":26935,"NA":26937},{"trials":26924,"activeCount":101},[],{"trials":26926,"activeCount":101},[],{"trials":26928,"activeCount":101},[26929],{"nctId":26889,"briefTitle":26890,"status":107,"phases":26930,"primaryCompletion":9411,"start":6223,"enrollment":26892,"conditions":26931,"interventions":26932},[91],[13290],[26880,26895,26896],{"trials":26934,"activeCount":101},[],{"trials":26936,"activeCount":101},[],{"trials":26938,"activeCount":101},[],{"intervention":26940,"totalTrials":272,"cells":26941},"BI 1744CL",{"EARLY_PHASE1":26942,"PHASE1":26944,"PHASE2":26946,"PHASE3":26955,"PHASE4":26957,"NA":26959},{"trials":26943,"activeCount":101},[],{"trials":26945,"activeCount":101},[],{"trials":26947,"activeCount":101},[26948],{"nctId":26949,"briefTitle":26950,"status":107,"phases":26951,"primaryCompletion":4507,"start":6116,"enrollment":26952,"conditions":26953,"interventions":26954},"NCT00452400","Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.",[91],409,[18,30],[26940],{"trials":26956,"activeCount":101},[],{"trials":26958,"activeCount":101},[],{"trials":26960,"activeCount":101},[],{"intervention":26962,"totalTrials":272,"cells":26963},"Empagliflozin medium placebo",{"EARLY_PHASE1":26964,"PHASE1":26966,"PHASE2":26968,"PHASE3":26981,"PHASE4":26983,"NA":26985},{"trials":26965,"activeCount":101},[],{"trials":26967,"activeCount":101},[],{"trials":26969,"activeCount":101},[26970],{"nctId":26971,"briefTitle":26972,"status":107,"phases":26973,"primaryCompletion":10024,"completion":10024,"start":378,"enrollment":3939,"conditions":26974,"interventions":26975},"NCT01969747","Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days",[91],[538],[26962,26976,26976,26977,26978,26962,26977,26977,26962,26976,26979,26980],"Empagliflozin low placebo","Empagliflozin high placebo","Empagliflozin medium","Empagliflozin low","Empagliflozin high",{"trials":26982,"activeCount":101},[],{"trials":26984,"activeCount":101},[],{"trials":26986,"activeCount":101},[],{"intervention":26976,"totalTrials":272,"cells":26988},{"EARLY_PHASE1":26989,"PHASE1":26991,"PHASE2":26993,"PHASE3":26999,"PHASE4":27001,"NA":27003},{"trials":26990,"activeCount":101},[],{"trials":26992,"activeCount":101},[],{"trials":26994,"activeCount":101},[26995],{"nctId":26971,"briefTitle":26972,"status":107,"phases":26996,"primaryCompletion":10024,"completion":10024,"start":378,"enrollment":3939,"conditions":26997,"interventions":26998},[91],[538],[26962,26976,26976,26977,26978,26962,26977,26977,26962,26976,26979,26980],{"trials":27000,"activeCount":101},[],{"trials":27002,"activeCount":101},[],{"trials":27004,"activeCount":101},[],{"intervention":26977,"totalTrials":272,"cells":27006},{"EARLY_PHASE1":27007,"PHASE1":27009,"PHASE2":27011,"PHASE3":27017,"PHASE4":27019,"NA":27021},{"trials":27008,"activeCount":101},[],{"trials":27010,"activeCount":101},[],{"trials":27012,"activeCount":101},[27013],{"nctId":26971,"briefTitle":26972,"status":107,"phases":27014,"primaryCompletion":10024,"completion":10024,"start":378,"enrollment":3939,"conditions":27015,"interventions":27016},[91],[538],[26962,26976,26976,26977,26978,26962,26977,26977,26962,26976,26979,26980],{"trials":27018,"activeCount":101},[],{"trials":27020,"activeCount":101},[],{"trials":27022,"activeCount":101},[],{"intervention":26978,"totalTrials":272,"cells":27024},{"EARLY_PHASE1":27025,"PHASE1":27027,"PHASE2":27029,"PHASE3":27035,"PHASE4":27037,"NA":27039},{"trials":27026,"activeCount":101},[],{"trials":27028,"activeCount":101},[],{"trials":27030,"activeCount":101},[27031],{"nctId":26971,"briefTitle":26972,"status":107,"phases":27032,"primaryCompletion":10024,"completion":10024,"start":378,"enrollment":3939,"conditions":27033,"interventions":27034},[91],[538],[26962,26976,26976,26977,26978,26962,26977,26977,26962,26976,26979,26980],{"trials":27036,"activeCount":101},[],{"trials":27038,"activeCount":101},[],{"trials":27040,"activeCount":101},[],{"intervention":26979,"totalTrials":272,"cells":27042},{"EARLY_PHASE1":27043,"PHASE1":27045,"PHASE2":27047,"PHASE3":27053,"PHASE4":27055,"NA":27057},{"trials":27044,"activeCount":101},[],{"trials":27046,"activeCount":101},[],{"trials":27048,"activeCount":101},[27049],{"nctId":26971,"briefTitle":26972,"status":107,"phases":27050,"primaryCompletion":10024,"completion":10024,"start":378,"enrollment":3939,"conditions":27051,"interventions":27052},[91],[538],[26962,26976,26976,26977,26978,26962,26977,26977,26962,26976,26979,26980],{"trials":27054,"activeCount":101},[],{"trials":27056,"activeCount":101},[],{"trials":27058,"activeCount":101},[],{"intervention":26980,"totalTrials":272,"cells":27060},{"EARLY_PHASE1":27061,"PHASE1":27063,"PHASE2":27065,"PHASE3":27071,"PHASE4":27073,"NA":27075},{"trials":27062,"activeCount":101},[],{"trials":27064,"activeCount":101},[],{"trials":27066,"activeCount":101},[27067],{"nctId":26971,"briefTitle":26972,"status":107,"phases":27068,"primaryCompletion":10024,"completion":10024,"start":378,"enrollment":3939,"conditions":27069,"interventions":27070},[91],[538],[26962,26976,26976,26977,26978,26962,26977,26977,26962,26976,26979,26980],{"trials":27072,"activeCount":101},[],{"trials":27074,"activeCount":101},[],{"trials":27076,"activeCount":101},[],{"intervention":27078,"totalTrials":272,"cells":27079},"Protease inhibitor tipranavir",{"EARLY_PHASE1":27080,"PHASE1":27082,"PHASE2":27084,"PHASE3":27092,"PHASE4":27094,"NA":27096},{"trials":27081,"activeCount":101},[],{"trials":27083,"activeCount":101},[],{"trials":27085,"activeCount":101},[27086],{"nctId":27087,"briefTitle":27088,"status":107,"phases":27089,"completion":6189,"start":6029,"enrollment":19250,"conditions":27090,"interventions":27091},"NCT00034866","Dose Ranging Trial of Tipranavir\u002FRitonavir in Treatment-Experienced HIV Infected Individuals",[91],[27],[27078],{"trials":27093,"activeCount":101},[],{"trials":27095,"activeCount":101},[],{"trials":27097,"activeCount":101},[],{"intervention":5299,"totalTrials":272,"cells":27099},{"EARLY_PHASE1":27100,"PHASE1":27102,"PHASE2":27104,"PHASE3":27110,"PHASE4":27112,"NA":27114},{"trials":27101,"activeCount":101},[],{"trials":27103,"activeCount":101},[],{"trials":27105,"activeCount":101},[27106],{"nctId":5293,"briefTitle":5294,"status":107,"phases":27107,"primaryCompletion":437,"completion":437,"start":5296,"enrollment":1672,"conditions":27108,"interventions":27109},[91],[3428],[78,5299],{"trials":27111,"activeCount":101},[],{"trials":27113,"activeCount":101},[],{"trials":27115,"activeCount":101},[],{"intervention":949,"totalTrials":97,"cells":27117},{"EARLY_PHASE1":27118,"PHASE1":27120,"PHASE2":27245,"PHASE3":27247,"PHASE4":27249,"NA":27251},{"trials":27119,"activeCount":101},[],{"trials":27121,"activeCount":101},[27122,27126,27134,27138,27144,27148,27155,27159,27167,27171,27175,27179,27183,27187,27194,27198,27205,27209,27213,27222,27226,27237,27241],{"nctId":19158,"briefTitle":19159,"status":107,"phases":27123,"primaryCompletion":19161,"completion":19161,"start":19162,"enrollment":177,"conditions":27124,"interventions":27125},[90],[15],[4109,949],{"nctId":27127,"briefTitle":27128,"status":107,"phases":27129,"primaryCompletion":6446,"start":2112,"enrollment":439,"conditions":27130,"interventions":27131},"NCT02264041","Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine",[90],[15],[27132,27133,949],"Cilobradine, low dose","Cilobradine, high dose",{"nctId":18930,"briefTitle":18931,"status":107,"phases":27135,"primaryCompletion":18933,"completion":18933,"start":3617,"enrollment":401,"conditions":27136,"interventions":27137},[90],[15],[4176,949],{"nctId":27139,"briefTitle":27140,"status":107,"phases":27141,"primaryCompletion":4021,"completion":4021,"start":5333,"enrollment":177,"conditions":27142,"interventions":27143},"NCT04716894","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the Blood",[90],[15],[4066,949],{"nctId":2751,"briefTitle":2752,"status":107,"phases":27145,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":177,"conditions":27146,"interventions":27147},[90],[15],[2744,2560],{"nctId":27149,"briefTitle":27150,"status":107,"phases":27151,"primaryCompletion":25740,"completion":27152,"start":19030,"enrollment":6702,"conditions":27153,"interventions":27154},"NCT04619251","A Study in Healthy Japanese Men to Test How Different Doses of BI 1323495 Are Tolerated and How Itraconazole Influences the Amount of BI 1323495 in the Blood",[90],"2021-08-03",[15],[3973,949],{"nctId":2827,"briefTitle":2828,"status":107,"phases":27156,"primaryCompletion":2830,"completion":2830,"start":2831,"enrollment":177,"conditions":27157,"interventions":27158},[90],[15],[2811,949],{"nctId":27160,"briefTitle":27161,"status":107,"phases":27162,"primaryCompletion":27163,"completion":1671,"start":27164,"enrollment":1116,"conditions":27165,"interventions":27166},"NCT05372367","A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor",[90],"2024-07-17","2022-08-11",[2057],[3578,460,949],{"nctId":19367,"briefTitle":19368,"status":107,"phases":27168,"primaryCompletion":19370,"completion":19371,"start":19372,"enrollment":401,"conditions":27169,"interventions":27170},[90],[15],[19360,949],{"nctId":942,"briefTitle":943,"status":107,"phases":27172,"primaryCompletion":945,"completion":945,"start":946,"enrollment":401,"conditions":27173,"interventions":27174},[90],[15],[911,949],{"nctId":18831,"briefTitle":18832,"status":107,"phases":27176,"primaryCompletion":4120,"completion":4120,"start":603,"enrollment":401,"conditions":27177,"interventions":27178},[90],[15],[4095,949,4095],{"nctId":1659,"briefTitle":1660,"status":107,"phases":27180,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":177,"conditions":27181,"interventions":27182},[90],[15],[1595,949],{"nctId":20676,"briefTitle":20677,"status":107,"phases":27184,"primaryCompletion":19868,"completion":19868,"start":20679,"enrollment":177,"conditions":27185,"interventions":27186},[90],[15],[20661,949],{"nctId":27188,"briefTitle":27189,"status":107,"phases":27190,"primaryCompletion":9842,"completion":9842,"start":4473,"enrollment":1672,"conditions":27191,"interventions":27192},"NCT02044393","Interaction of BI 691751 With Itraconazole",[90],[15],[2560,27193,27193],"BI 691751",{"nctId":10186,"briefTitle":10187,"status":107,"phases":27195,"primaryCompletion":10189,"completion":10190,"start":10191,"enrollment":1865,"conditions":27196,"interventions":27197},[90],[33],[10176,2560],{"nctId":27199,"briefTitle":27200,"status":107,"phases":27201,"primaryCompletion":4431,"completion":4431,"start":27202,"enrollment":177,"conditions":27203,"interventions":27204},"NCT04011241","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood",[90],"2019-07-24",[15],[3973,949],{"nctId":18715,"briefTitle":18716,"status":107,"phases":27206,"primaryCompletion":18718,"completion":18719,"start":18720,"enrollment":439,"conditions":27207,"interventions":27208},[90],[15],[4436,949],{"nctId":1895,"briefTitle":1896,"status":107,"phases":27210,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":177,"conditions":27211,"interventions":27212},[90],[15],[1845,949],{"nctId":27214,"briefTitle":27215,"status":107,"phases":27216,"primaryCompletion":27217,"completion":4173,"start":27218,"enrollment":177,"conditions":27219,"interventions":27220},"NCT03722173","A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 894416 in the Blood",[90],"2018-12-14","2018-11-13",[15],[949,27221],"BI 894416",{"nctId":2553,"briefTitle":2554,"status":107,"phases":27223,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":401,"conditions":27224,"interventions":27225},[90],[15],[2441,2560],{"nctId":27227,"briefTitle":27228,"status":107,"phases":27229,"primaryCompletion":27230,"completion":27230,"start":27231,"enrollment":956,"conditions":27232,"interventions":27233},"NCT03116893","Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect",[90],"2017-05-31","2017-04-19",[15],[27234,949,27235,27236],"BI 685509 After Standardised Breakfast","Rifampin","BI 685509 Fasted Conditions",{"nctId":3929,"briefTitle":3930,"status":107,"phases":27238,"primaryCompletion":3932,"completion":3932,"start":1379,"enrollment":177,"conditions":27239,"interventions":27240},[90],[15],[3911,949],{"nctId":10036,"briefTitle":10037,"status":107,"phases":27242,"primaryCompletion":409,"completion":409,"start":9614,"enrollment":5205,"conditions":27243,"interventions":27244},[90],[15],[949,10041,4479,969,4479],{"trials":27246,"activeCount":101},[],{"trials":27248,"activeCount":101},[],{"trials":27250,"activeCount":101},[],{"trials":27252,"activeCount":101},[],{"intervention":460,"totalTrials":1340,"cells":27254},{"EARLY_PHASE1":27255,"PHASE1":27257,"PHASE2":27305,"PHASE3":27307,"PHASE4":27309,"NA":27311},{"trials":27256,"activeCount":101},[],{"trials":27258,"activeCount":101},[27259,27265,27269,27275,27281,27285,27293,27297,27301],{"nctId":27260,"briefTitle":27261,"status":107,"phases":27262,"primaryCompletion":9443,"start":400,"enrollment":401,"conditions":27263,"interventions":27264},"NCT02183584","Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers",[90],[15],[460,361],{"nctId":27160,"briefTitle":27161,"status":107,"phases":27266,"primaryCompletion":27163,"completion":1671,"start":27164,"enrollment":1116,"conditions":27267,"interventions":27268},[90],[2057],[3578,460,949],{"nctId":27270,"briefTitle":27271,"status":107,"phases":27272,"primaryCompletion":3991,"start":5905,"enrollment":380,"conditions":27273,"interventions":27274},"NCT02173717","Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers",[90],[15],[6561,460],{"nctId":27276,"briefTitle":27277,"status":107,"phases":27278,"primaryCompletion":2648,"start":9752,"enrollment":210,"conditions":27279,"interventions":27280},"NCT01396265","Drug Interaction Study With Rifampicin and Afatinib",[90],[15],[1492,1492,460],{"nctId":18683,"briefTitle":18684,"status":107,"phases":27282,"primaryCompletion":18686,"completion":18686,"start":240,"enrollment":956,"conditions":27283,"interventions":27284},[90],[15],[4436,460],{"nctId":27286,"briefTitle":27287,"status":107,"phases":27288,"primaryCompletion":27289,"completion":27289,"start":27290,"enrollment":401,"conditions":27291,"interventions":27292},"NCT04060719","A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood",[90],"2019-10-17","2019-09-04",[15],[27221,460],{"nctId":453,"briefTitle":454,"status":107,"phases":27294,"primaryCompletion":447,"completion":447,"start":456,"enrollment":392,"conditions":27295,"interventions":27296},[90],[15],[459,460,73,73,460,459,73],{"nctId":5266,"briefTitle":5267,"status":107,"phases":27298,"primaryCompletion":409,"completion":409,"start":3730,"enrollment":1982,"conditions":27299,"interventions":27300},[90],[15],[78,460,78],{"nctId":18899,"briefTitle":18900,"status":107,"phases":27302,"primaryCompletion":18902,"completion":18902,"start":18903,"enrollment":401,"conditions":27303,"interventions":27304},[90],[15],[460,4095],{"trials":27306,"activeCount":101},[],{"trials":27308,"activeCount":101},[],{"trials":27310,"activeCount":101},[],{"trials":27312,"activeCount":101},[],{"intervention":6024,"totalTrials":112,"cells":27314},{"EARLY_PHASE1":27315,"PHASE1":27317,"PHASE2":27362,"PHASE3":27364,"PHASE4":27366,"NA":27368},{"trials":27316,"activeCount":101},[],{"trials":27318,"activeCount":101},[27319,27328,27334,27341,27345,27351,27358],{"nctId":27320,"briefTitle":27321,"status":107,"phases":27322,"primaryCompletion":7381,"start":7003,"enrollment":357,"conditions":27323,"interventions":27324},"NCT02170584","Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males",[90],[15],[27325,6024,27326,27327],"BIBR 953 ZW IV","BIBR 1048 MS oral solution","BIBR 953 ZW IV Placebo",{"nctId":27329,"briefTitle":27330,"status":107,"phases":27331,"primaryCompletion":8479,"start":6235,"enrollment":2382,"conditions":27332,"interventions":27333},"NCT02170844","Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin",[90],[15],[6024],{"nctId":27335,"briefTitle":27336,"status":107,"phases":27337,"primaryCompletion":7381,"start":7419,"enrollment":357,"conditions":27338,"interventions":27339},"NCT02170792","Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS",[90],[15],[6024,27340],"Ranitidine",{"nctId":6019,"briefTitle":6020,"status":107,"phases":27342,"primaryCompletion":5887,"start":5992,"enrollment":392,"conditions":27343,"interventions":27344},[90],[15],[6024,5982],{"nctId":27346,"briefTitle":27347,"status":107,"phases":27348,"primaryCompletion":7300,"start":11581,"enrollment":112,"conditions":27349,"interventions":27350},"NCT02171000","Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects",[90],[15],[6024],{"nctId":27352,"briefTitle":27353,"status":107,"phases":27354,"primaryCompletion":6738,"start":13117,"enrollment":1512,"conditions":27355,"interventions":27356},"NCT02170922","Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food",[90],[15],[6024,27357],"BIBR 1048 MS solution",{"nctId":6078,"briefTitle":6079,"status":107,"phases":27359,"primaryCompletion":6081,"start":6082,"enrollment":448,"conditions":27360,"interventions":27361},[90],[15],[6024,5982],{"trials":27363,"activeCount":101},[],{"trials":27365,"activeCount":101},[],{"trials":27367,"activeCount":101},[],{"trials":27369,"activeCount":101},[],{"intervention":5264,"totalTrials":1512,"cells":27371},{"EARLY_PHASE1":27372,"PHASE1":27374,"PHASE2":27409,"PHASE3":27411,"PHASE4":27413,"NA":27415},{"trials":27373,"activeCount":101},[],{"trials":27375,"activeCount":101},[27376,27380,27387,27393,27397,27405],{"nctId":20628,"briefTitle":20629,"status":107,"phases":27377,"primaryCompletion":9593,"completion":9593,"start":517,"enrollment":380,"conditions":27378,"interventions":27379},[90],[15],[5264,20621,20621],{"nctId":27381,"briefTitle":27382,"status":107,"phases":27383,"primaryCompletion":4413,"start":6471,"enrollment":380,"conditions":27384,"interventions":27385},"NCT02264171","Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers",[90],[15],[27386,5264],"Tamsulosin HCl",{"nctId":27388,"briefTitle":27389,"status":107,"phases":27390,"primaryCompletion":3991,"start":5905,"enrollment":380,"conditions":27391,"interventions":27392},"NCT02170675","Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers",[90],[15],[6561,5264],{"nctId":5259,"briefTitle":5260,"status":107,"phases":27394,"primaryCompletion":446,"completion":446,"start":2001,"enrollment":1237,"conditions":27395,"interventions":27396},[90],[15],[78,78,5264,78,78,5264],{"nctId":27398,"briefTitle":27399,"status":107,"phases":27400,"primaryCompletion":379,"completion":379,"start":3730,"enrollment":1672,"conditions":27401,"interventions":27402},"NCT01787032","Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects",[90],[15],[27403,27403,27403,5264,27404],"BI 113608","Voriconazole",{"nctId":11947,"briefTitle":11948,"status":107,"phases":27406,"primaryCompletion":4442,"start":1980,"enrollment":132,"conditions":27407,"interventions":27408},[90],[15,18],[6866,6866,5264,5264],{"trials":27410,"activeCount":101},[],{"trials":27412,"activeCount":101},[],{"trials":27414,"activeCount":101},[],{"trials":27416,"activeCount":101},[],{"intervention":27221,"totalTrials":1512,"cells":27418},{"EARLY_PHASE1":27419,"PHASE1":27421,"PHASE2":27460,"PHASE3":27462,"PHASE4":27464,"NA":27466},{"trials":27420,"activeCount":101},[],{"trials":27422,"activeCount":101},[27423,27430,27437,27444,27448,27456],{"nctId":27424,"briefTitle":27425,"status":107,"phases":27426,"primaryCompletion":1613,"completion":1613,"start":27427,"enrollment":177,"conditions":27428,"interventions":27429},"NCT03871595","A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood",[90],"2019-03-20",[15],[27221],{"nctId":27431,"briefTitle":27432,"status":107,"phases":27433,"primaryCompletion":27434,"completion":27434,"start":1489,"enrollment":2400,"conditions":27435,"interventions":27436},"NCT03315936","This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated",[90],"2018-09-10",[15],[27221,27221],{"nctId":27438,"briefTitle":27439,"status":162,"phases":27440,"primaryCompletion":27441,"completion":27441,"start":746,"enrollment":155,"conditions":27442,"interventions":27443},"NCT04540874","A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated",[90],"2020-11-12",[15],[27221],{"nctId":27286,"briefTitle":27287,"status":107,"phases":27445,"primaryCompletion":27289,"completion":27289,"start":27290,"enrollment":401,"conditions":27446,"interventions":27447},[90],[15],[27221,460],{"nctId":27449,"briefTitle":27450,"status":107,"phases":27451,"primaryCompletion":27452,"completion":27452,"start":27453,"enrollment":2400,"conditions":27454,"interventions":27455},"NCT03971539","Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma",[90],"2020-10-26","2019-07-15",[30],[27221],{"nctId":27214,"briefTitle":27215,"status":107,"phases":27457,"primaryCompletion":27217,"completion":4173,"start":27218,"enrollment":177,"conditions":27458,"interventions":27459},[90],[15],[949,27221],{"trials":27461,"activeCount":101},[],{"trials":27463,"activeCount":101},[],{"trials":27465,"activeCount":101},[],{"trials":27467,"activeCount":101},[],{"intervention":27469,"totalTrials":166,"cells":27470},"Linagliptin\u002FMetformin FDC",{"EARLY_PHASE1":27471,"PHASE1":27473,"PHASE2":27506,"PHASE3":27508,"PHASE4":27510,"NA":27512},{"trials":27472,"activeCount":101},[],{"trials":27474,"activeCount":101},[27475,27481,27488,27494,27500],{"nctId":27476,"briefTitle":27477,"status":107,"phases":27478,"primaryCompletion":4392,"start":6811,"enrollment":8,"conditions":27479,"interventions":27480},"NCT02221401","Bioequivalence of a Linagliptin \u002F Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers",[90],[15],[27469,361,413],{"nctId":27482,"briefTitle":27483,"status":107,"phases":27484,"primaryCompletion":3732,"start":6811,"enrollment":132,"conditions":27485,"interventions":27486},"NCT02223026","Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects",[90],[15],[27487],"Linagliptin\u002Fmetformin FDC",{"nctId":27489,"briefTitle":27490,"status":107,"phases":27491,"primaryCompletion":4392,"start":6811,"enrollment":8,"conditions":27492,"interventions":27493},"NCT02220647","Bioequivalence of a 2.5 mg Linagliptin \u002F 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers",[90],[15],[27469,361,413],{"nctId":27495,"briefTitle":27496,"status":107,"phases":27497,"primaryCompletion":5233,"completion":5233,"start":10024,"enrollment":6702,"conditions":27498,"interventions":27499},"NCT02084056","Bioequivalence of a FDC Tablet of Linagliptin\u002FMetformin (2.5mg\u002F1000mg) Extended Release in Healthy Subjects.",[90],[15],[361,413,27469],{"nctId":27501,"briefTitle":27502,"status":107,"phases":27503,"primaryCompletion":3732,"start":6811,"enrollment":10951,"conditions":27504,"interventions":27505},"NCT02221414","Bioequivalence of a 2.5 mg Linagliptin \u002F 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers",[90],[15],[27469,361,413],{"trials":27507,"activeCount":101},[],{"trials":27509,"activeCount":101},[],{"trials":27511,"activeCount":101},[],{"trials":27513,"activeCount":101},[],{"intervention":970,"totalTrials":166,"cells":27515},{"EARLY_PHASE1":27516,"PHASE1":27518,"PHASE2":27549,"PHASE3":27551,"PHASE4":27553,"NA":27555},{"trials":27517,"activeCount":101},[],{"trials":27519,"activeCount":101},[27520,27528,27532,27536,27540],{"nctId":27521,"briefTitle":27522,"status":107,"phases":27523,"primaryCompletion":7193,"completion":27524,"start":27525,"enrollment":357,"conditions":27526,"interventions":27527},"NCT02854527","Transporter Cocktail Mutual Interaction",[90],"2016-11-19","2016-08-22",[15],[2393,971,413,969,2393,971,970,969],{"nctId":2818,"briefTitle":2819,"status":107,"phases":27529,"primaryCompletion":2821,"completion":2822,"start":2823,"enrollment":177,"conditions":27530,"interventions":27531},[90],[15],[970,2811],{"nctId":960,"briefTitle":961,"status":107,"phases":27533,"primaryCompletion":963,"completion":964,"start":965,"enrollment":132,"conditions":27534,"interventions":27535},[90],[15],[911,968,969,970,971],{"nctId":1869,"briefTitle":1870,"status":107,"phases":27537,"primaryCompletion":1872,"completion":1873,"start":1874,"enrollment":177,"conditions":27538,"interventions":27539},[90],[15],[970,1845],{"nctId":27541,"briefTitle":27542,"status":107,"phases":27543,"primaryCompletion":27544,"completion":27544,"start":27545,"enrollment":380,"conditions":27546,"interventions":27547},"NCT02231931","Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin",[90],"2015-01-01","2014-09-01",[15],[2393,969,27548,27548,970,27548,971],"Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin",{"trials":27550,"activeCount":101},[],{"trials":27552,"activeCount":101},[],{"trials":27554,"activeCount":101},[],{"trials":27556,"activeCount":101},[],{"intervention":3973,"totalTrials":166,"cells":27558},{"EARLY_PHASE1":27559,"PHASE1":27561,"PHASE2":27590,"PHASE3":27592,"PHASE4":27594,"NA":27596},{"trials":27560,"activeCount":101},[],{"trials":27562,"activeCount":101},[27563,27567,27575,27579,27586],{"nctId":3965,"briefTitle":3966,"status":107,"phases":27564,"primaryCompletion":3968,"completion":3969,"start":3879,"enrollment":3970,"conditions":27565,"interventions":27566},[90],[15],[3973,1242],{"nctId":27568,"briefTitle":27569,"status":162,"phases":27570,"primaryCompletion":887,"completion":13216,"start":27571,"enrollment":112,"conditions":27572,"interventions":27574},"NCT04656275","A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation",[90],"2021-03-04",[27573],"Non-cystic Fibrosis Bronchiectasis",[3973],{"nctId":27149,"briefTitle":27150,"status":107,"phases":27576,"primaryCompletion":25740,"completion":27152,"start":19030,"enrollment":6702,"conditions":27577,"interventions":27578},[90],[15],[3973,949],{"nctId":27580,"briefTitle":27581,"status":107,"phases":27582,"primaryCompletion":239,"completion":239,"start":27583,"enrollment":8304,"conditions":27584,"interventions":27585},"NCT03588390","This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.",[90],"2018-07-31",[15],[3973,3973,3973],{"nctId":27199,"briefTitle":27200,"status":107,"phases":27587,"primaryCompletion":4431,"completion":4431,"start":27202,"enrollment":177,"conditions":27588,"interventions":27589},[90],[15],[3973,949],{"trials":27591,"activeCount":101},[],{"trials":27593,"activeCount":101},[],{"trials":27595,"activeCount":101},[],{"trials":27597,"activeCount":101},[],{"intervention":4066,"totalTrials":166,"cells":27599},{"EARLY_PHASE1":27600,"PHASE1":27602,"PHASE2":27638,"PHASE3":27640,"PHASE4":27642,"NA":27644},{"trials":27601,"activeCount":101},[],{"trials":27603,"activeCount":101},[27604,27608,27612,27620,27630],{"nctId":27139,"briefTitle":27140,"status":107,"phases":27605,"primaryCompletion":4021,"completion":4021,"start":5333,"enrollment":177,"conditions":27606,"interventions":27607},[90],[15],[4066,949],{"nctId":4059,"briefTitle":4060,"status":107,"phases":27609,"primaryCompletion":4062,"completion":4062,"start":4063,"enrollment":2507,"conditions":27610,"interventions":27611},[90],[15],[4066,1242],{"nctId":27613,"briefTitle":27614,"status":107,"phases":27615,"primaryCompletion":27616,"completion":8803,"start":27617,"enrollment":132,"conditions":27618,"interventions":27619},"NCT04964453","A Study in Healthy Men to Test How BI 474121 is Tolerated",[90],"2021-11-11","2021-07-21",[15],[4066],{"nctId":27621,"briefTitle":27622,"status":600,"phases":27623,"primaryCompletion":27624,"completion":27625,"start":27626,"enrollment":101,"conditions":27627,"interventions":27628},"NCT05451095","A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine",[90],"2023-06-05","2023-06-20","2022-11-07",[15],[4066,27629],"Ketamine hydrochloride",{"nctId":27631,"briefTitle":27632,"status":107,"phases":27633,"primaryCompletion":2540,"completion":2540,"start":27634,"enrollment":3565,"conditions":27635,"interventions":27636},"NCT04194645","A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.",[90],"2020-01-09",[15],[4066,27637],"BI 474121 oral solution",{"trials":27639,"activeCount":101},[],{"trials":27641,"activeCount":101},[],{"trials":27643,"activeCount":101},[],{"trials":27645,"activeCount":101},[],{"intervention":27647,"totalTrials":166,"cells":27648},"BIBN 4096 BS - in single rising doses",{"EARLY_PHASE1":27649,"PHASE1":27651,"PHASE2":27683,"PHASE3":27685,"PHASE4":27687,"NA":27689},{"trials":27650,"activeCount":101},[],{"trials":27652,"activeCount":101},[27653,27659,27665,27671,27677],{"nctId":27654,"briefTitle":27655,"status":107,"phases":27656,"primaryCompletion":5993,"start":6015,"enrollment":2887,"conditions":27657,"interventions":27658},"NCT02194322","Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers",[90],[15],[27647],{"nctId":27660,"briefTitle":27661,"status":107,"phases":27662,"primaryCompletion":5880,"start":6053,"enrollment":132,"conditions":27663,"interventions":27664},"NCT02194335","Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers",[90],[15],[27647],{"nctId":27666,"briefTitle":27667,"status":107,"phases":27668,"primaryCompletion":6594,"start":8538,"enrollment":188,"conditions":27669,"interventions":27670},"NCT02194348","Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers",[90],[15],[27647],{"nctId":27672,"briefTitle":27673,"status":107,"phases":27674,"primaryCompletion":7395,"start":6064,"enrollment":1106,"conditions":27675,"interventions":27676},"NCT02198352","Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers",[90],[15],[27647],{"nctId":27678,"briefTitle":27679,"status":107,"phases":27680,"primaryCompletion":6584,"start":2121,"enrollment":410,"conditions":27681,"interventions":27682},"NCT02194777","Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers",[90],[15],[27647],{"trials":27684,"activeCount":101},[],{"trials":27686,"activeCount":101},[],{"trials":27688,"activeCount":101},[],{"trials":27690,"activeCount":101},[],{"intervention":3578,"totalTrials":166,"cells":27692},{"EARLY_PHASE1":27693,"PHASE1":27695,"PHASE2":27728,"PHASE3":27730,"PHASE4":27732,"NA":27734},{"trials":27694,"activeCount":101},[],{"trials":27696,"activeCount":101},[27697,27701,27710,27714,27720],{"nctId":27160,"briefTitle":27161,"status":107,"phases":27698,"primaryCompletion":27163,"completion":1671,"start":27164,"enrollment":1116,"conditions":27699,"interventions":27700},[90],[2057],[3578,460,949],{"nctId":27702,"briefTitle":27703,"status":107,"phases":27704,"primaryCompletion":27705,"completion":2822,"start":27706,"enrollment":912,"conditions":27707,"interventions":27708},"NCT05613036","A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body",[90],"2024-04-25","2023-01-03",[2057],[27709,27709,3578],"[¹⁴C]-BI 907828 mixed with BI 907828",{"nctId":3570,"briefTitle":3571,"status":107,"phases":27711,"primaryCompletion":3573,"completion":1874,"start":3574,"enrollment":3575,"conditions":27712,"interventions":27713},[90],[33],[3578,3490,3470],{"nctId":27715,"briefTitle":27716,"status":107,"phases":27717,"primaryCompletion":13229,"completion":13229,"start":5662,"enrollment":380,"conditions":27718,"interventions":27719},"NCT05376800","A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma",[90],[21213],[3578],{"nctId":27721,"briefTitle":27722,"status":107,"phases":27723,"primaryCompletion":2897,"completion":2897,"start":27724,"enrollment":27725,"conditions":27726,"interventions":27727},"NCT03449381","This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)",[90],"2018-06-20",266,[33],[3578],{"trials":27729,"activeCount":101},[],{"trials":27731,"activeCount":101},[],{"trials":27733,"activeCount":101},[],{"trials":27735,"activeCount":101},[],{"intervention":27737,"totalTrials":166,"cells":27738},"BI 44847",{"EARLY_PHASE1":27739,"PHASE1":27741,"PHASE2":27774,"PHASE3":27776,"PHASE4":27778,"NA":27780},{"trials":27740,"activeCount":101},[],{"trials":27742,"activeCount":101},[27743,27749,27755,27761,27767],{"nctId":27744,"briefTitle":27745,"status":107,"phases":27746,"primaryCompletion":9418,"start":4517,"enrollment":1429,"conditions":27747,"interventions":27748},"NCT00558909","4 Weeks Treatment of Type II Diabetic Patients With BI 44847",[90],[21],[27737],{"nctId":27750,"briefTitle":27751,"status":107,"phases":27752,"primaryCompletion":6140,"start":3763,"enrollment":410,"conditions":27753,"interventions":27754},"NCT02211924","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects",[90],[15],[27737],{"nctId":27756,"briefTitle":27757,"status":107,"phases":27758,"primaryCompletion":7573,"start":11588,"enrollment":716,"conditions":27759,"interventions":27760},"NCT02209844","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects",[90],[15],[27737],{"nctId":27762,"briefTitle":27763,"status":107,"phases":27764,"primaryCompletion":4517,"start":9902,"enrollment":410,"conditions":27765,"interventions":27766},"NCT02211963","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes",[90],[21],[27737],{"nctId":27768,"briefTitle":27769,"status":107,"phases":27770,"primaryCompletion":2032,"start":4412,"enrollment":3398,"conditions":27771,"interventions":27772},"NCT02211950","Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers",[90],[15],[27737,27773],"Acarbose",{"trials":27775,"activeCount":101},[],{"trials":27777,"activeCount":101},[],{"trials":27779,"activeCount":101},[],{"trials":27781,"activeCount":101},[],{"intervention":5846,"totalTrials":1564,"cells":27783},{"EARLY_PHASE1":27784,"PHASE1":27786,"PHASE2":27811,"PHASE3":27813,"PHASE4":27815,"NA":27817},{"trials":27785,"activeCount":101},[],{"trials":27787,"activeCount":101},[27788,27794,27798,27804],{"nctId":27789,"briefTitle":27790,"status":107,"phases":27791,"primaryCompletion":11733,"start":21078,"enrollment":2235,"conditions":27792,"interventions":27793},"NCT02259907","Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers",[90],[15],[5846],{"nctId":5839,"briefTitle":5840,"status":107,"phases":27795,"primaryCompletion":5842,"start":5843,"enrollment":188,"conditions":27796,"interventions":27797},[90],[15],[5846,5847,5848,5849,5832],{"nctId":27799,"briefTitle":27800,"status":107,"phases":27801,"primaryCompletion":6445,"start":11733,"enrollment":1418,"conditions":27802,"interventions":27803},"NCT02259933","Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers",[90],[15],[5846],{"nctId":27805,"briefTitle":27806,"status":107,"phases":27807,"primaryCompletion":17247,"start":11733,"enrollment":1982,"conditions":27808,"interventions":27810},"NCT02259751","Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity",[90],[27809],"Spinal Cord Injuries",[5846],{"trials":27812,"activeCount":101},[],{"trials":27814,"activeCount":101},[],{"trials":27816,"activeCount":101},[],{"trials":27818,"activeCount":101},[],{"intervention":21144,"totalTrials":1564,"cells":27820},{"EARLY_PHASE1":27821,"PHASE1":27823,"PHASE2":27856,"PHASE3":27858,"PHASE4":27860,"NA":27862},{"trials":27822,"activeCount":101},[],{"trials":27824,"activeCount":101},[27825,27836,27844,27848],{"nctId":27826,"briefTitle":27827,"status":107,"phases":27828,"primaryCompletion":27829,"completion":27830,"start":27831,"enrollment":641,"conditions":27832,"interventions":27834},"NCT02204072","BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)",[90],"2019-10-18","2023-06-01","2014-11-11",[27833],"Prostatic Neoplasms, Castration-Resistant",[21144,27835,27835],"Enzalutamide",{"nctId":27837,"briefTitle":27838,"status":107,"phases":27839,"primaryCompletion":27840,"completion":27840,"start":27841,"enrollment":1208,"conditions":27842,"interventions":27843},"NCT01317420","Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types",[90],"2016-02-15","2011-04-13",[33],[21144],{"nctId":21134,"briefTitle":21135,"status":107,"phases":27845,"primaryCompletion":21137,"completion":21138,"start":21139,"enrollment":21140,"conditions":27846,"interventions":27847},[90],[33],[21143,21123,21144],{"nctId":27849,"briefTitle":27850,"status":107,"phases":27851,"primaryCompletion":11546,"completion":27852,"start":27853,"enrollment":9606,"conditions":27854,"interventions":27855},"NCT01403974","Phase I Trial of BI 836845 for Various Solid Cancer",[90],"2015-12-23","2011-07-19",[33],[21144],{"trials":27857,"activeCount":101},[],{"trials":27859,"activeCount":101},[],{"trials":27861,"activeCount":101},[],{"trials":27863,"activeCount":101},[],{"intervention":4283,"totalTrials":1564,"cells":27865},{"EARLY_PHASE1":27866,"PHASE1":27868,"PHASE2":27886,"PHASE3":27888,"PHASE4":27890,"NA":27892},{"trials":27867,"activeCount":101},[],{"trials":27869,"activeCount":101},[27870,27874,27878,27882],{"nctId":10513,"briefTitle":10514,"status":107,"phases":27871,"primaryCompletion":10516,"completion":10516,"start":10517,"enrollment":2442,"conditions":27872,"interventions":27873},[90],[15],[4283,4454],{"nctId":9913,"briefTitle":9914,"status":107,"phases":27875,"primaryCompletion":4412,"start":6224,"enrollment":392,"conditions":27876,"interventions":27877},[90],[15],[4283,9872],{"nctId":10030,"briefTitle":10031,"status":162,"phases":27879,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":392,"conditions":27880,"interventions":27881},[90],[15],[9996,4283,4047],{"nctId":4277,"briefTitle":4278,"status":107,"phases":27883,"primaryCompletion":4280,"completion":1207,"start":1250,"enrollment":132,"conditions":27884,"interventions":27885},[90],[15],[3796,4283],{"trials":27887,"activeCount":101},[],{"trials":27889,"activeCount":101},[],{"trials":27891,"activeCount":101},[],{"trials":27893,"activeCount":101},[],{"intervention":9370,"totalTrials":1564,"cells":27895},{"EARLY_PHASE1":27896,"PHASE1":27898,"PHASE2":27927,"PHASE3":27929,"PHASE4":27931,"NA":27933},{"trials":27897,"activeCount":101},[],{"trials":27899,"activeCount":101},[27900,27904,27914,27918],{"nctId":9365,"briefTitle":9366,"status":107,"phases":27901,"primaryCompletion":3991,"start":5905,"enrollment":1672,"conditions":27902,"interventions":27903},[90],[15],[528,9370],{"nctId":27905,"briefTitle":27906,"status":107,"phases":27907,"primaryCompletion":1967,"start":4392,"enrollment":1672,"conditions":27908,"interventions":27909},"NCT02172235","Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers",[90],[15],[9370,27910,27911,27912,27913],"Pioglitazone - low dose","BI 10773 - low dose","BI 10773 - medium dose","BI 10773 - high dose",{"nctId":9899,"briefTitle":9900,"status":107,"phases":27915,"primaryCompletion":6155,"start":9902,"enrollment":1672,"conditions":27916,"interventions":27917},[90],[15],[9872,9905,9370],{"nctId":27919,"briefTitle":27920,"status":107,"phases":27921,"primaryCompletion":9381,"start":3990,"enrollment":291,"conditions":27922,"interventions":27923},"NCT02183636","Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin\u002FPioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects",[90],[15],[27924,27925,361,27926],"Linagliptin\u002Fpioglitazone, FDC formulation C5","Linagliptin\u002Fpioglitazone, FDC formulation C8","pioglitazone",{"trials":27928,"activeCount":101},[],{"trials":27930,"activeCount":101},[],{"trials":27932,"activeCount":101},[],{"trials":27934,"activeCount":101},[],{"intervention":4057,"totalTrials":1564,"cells":27936},{"EARLY_PHASE1":27937,"PHASE1":27939,"PHASE2":27969,"PHASE3":27971,"PHASE4":27973,"NA":27975},{"trials":27938,"activeCount":101},[],{"trials":27940,"activeCount":101},[27941,27949,27958,27962],{"nctId":27942,"briefTitle":27943,"status":600,"phases":27944,"primaryCompletion":5323,"completion":27945,"start":27946,"enrollment":101,"conditions":27947,"interventions":27948},"NCT03747926","This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated",[90],"2019-09-02","2019-04-05",[15],[4057],{"nctId":27950,"briefTitle":27951,"status":600,"phases":27952,"primaryCompletion":27953,"completion":6931,"start":27954,"enrollment":101,"conditions":27955,"interventions":27957},"NCT03771885","BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)",[90],"2019-12-21","2019-03-16",[27956],"Lupus Erythematosus, Systemic",[4057],{"nctId":4050,"briefTitle":4051,"status":107,"phases":27959,"primaryCompletion":4053,"completion":4053,"start":4054,"enrollment":123,"conditions":27960,"interventions":27961},[90],[15],[4057,1242],{"nctId":27963,"briefTitle":27964,"status":107,"phases":27965,"primaryCompletion":4209,"completion":4209,"start":27966,"enrollment":6607,"conditions":27967,"interventions":27968},"NCT03123185","Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects",[90],"2017-04-27",[15],[4057,4057],{"trials":27970,"activeCount":101},[],{"trials":27972,"activeCount":101},[],{"trials":27974,"activeCount":101},[],{"trials":27976,"activeCount":101},[],{"intervention":27978,"totalTrials":1564,"cells":27979},"Asasantin ER",{"EARLY_PHASE1":27980,"PHASE1":27982,"PHASE2":28009,"PHASE3":28011,"PHASE4":28013,"NA":28015},{"trials":27981,"activeCount":101},[],{"trials":27983,"activeCount":101},[27984,27990,27996,28003],{"nctId":27985,"briefTitle":27986,"status":107,"phases":27987,"primaryCompletion":2163,"start":8538,"enrollment":1218,"conditions":27988,"interventions":27989},"NCT02269228","Tolerability of Asasantin in Healthy Female and Male Subjects",[90],[15],[27978],{"nctId":27991,"briefTitle":27992,"status":107,"phases":27993,"primaryCompletion":6081,"start":7574,"enrollment":2442,"conditions":27994,"interventions":27995},"NCT02273557","Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects",[90],[15],[27978,27978,27978,27978],{"nctId":27997,"briefTitle":27998,"status":162,"phases":27999,"primaryCompletion":6189,"start":6375,"enrollment":401,"conditions":28000,"interventions":28001},"NCT02273544","Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects",[90],[15],[27978,27978,27978,28002],"Asasantin ER - commercial formulation",{"nctId":28004,"briefTitle":28005,"status":107,"phases":28006,"primaryCompletion":6207,"start":6738,"enrollment":1865,"conditions":28007,"interventions":28008},"NCT02273492","Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects",[90],[15],[27978],{"trials":28010,"activeCount":101},[],{"trials":28012,"activeCount":101},[],{"trials":28014,"activeCount":101},[],{"trials":28016,"activeCount":101},[],{"intervention":28018,"totalTrials":1564,"cells":28019},"bivatuzumab mertansine",{"EARLY_PHASE1":28020,"PHASE1":28022,"PHASE2":28053,"PHASE3":28055,"PHASE4":28057,"NA":28059},{"trials":28021,"activeCount":101},[],{"trials":28023,"activeCount":101},[28024,28030,28037,28045],{"nctId":28025,"briefTitle":28026,"status":162,"phases":28027,"primaryCompletion":8086,"start":6374,"enrollment":112,"conditions":28028,"interventions":28029},"NCT02254044","Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus",[90],[3767],[28018],{"nctId":28031,"briefTitle":28032,"status":107,"phases":28033,"primaryCompletion":11701,"start":28034,"enrollment":380,"conditions":28035,"interventions":28036},"NCT02254005","Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer",[90],"2002-10-01",[2629],[28018],{"nctId":28038,"briefTitle":28039,"status":107,"phases":28040,"primaryCompletion":28041,"start":28042,"enrollment":536,"conditions":28043,"interventions":28044},"NCT02254018","Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck",[90],"2005-02-01","2002-09-01",[3766],[28018],{"nctId":28046,"briefTitle":28047,"status":162,"phases":28048,"primaryCompletion":28049,"start":28050,"enrollment":155,"conditions":28051,"interventions":28052},"NCT02254031","Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer",[90],"2005-01-01","2003-07-01",[2629],[28018],{"trials":28054,"activeCount":101},[],{"trials":28056,"activeCount":101},[],{"trials":28058,"activeCount":101},[],{"trials":28060,"activeCount":101},[],{"intervention":27403,"totalTrials":1564,"cells":28062},{"EARLY_PHASE1":28063,"PHASE1":28065,"PHASE2":28091,"PHASE3":28093,"PHASE4":28095,"NA":28097},{"trials":28064,"activeCount":101},[],{"trials":28066,"activeCount":101},[28067,28073,28081,28087],{"nctId":28068,"briefTitle":28069,"status":107,"phases":28070,"primaryCompletion":9842,"completion":9842,"start":9515,"enrollment":300,"conditions":28071,"interventions":28072},"NCT01922349","Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers",[90],[15],[27403,27403,27403,27403,27403,27403],{"nctId":28074,"briefTitle":28075,"status":107,"phases":28076,"primaryCompletion":3730,"completion":3730,"start":2001,"enrollment":956,"conditions":28077,"interventions":28078},"NCT01703858","Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608",[90],[15],[28079,27403,27403,27403,28080,27403],"BI 113608 PIB","pantoprazole 40 mg STADA",{"nctId":28082,"briefTitle":28083,"status":107,"phases":28084,"primaryCompletion":2506,"completion":2506,"start":9538,"enrollment":1429,"conditions":28085,"interventions":28086},"NCT01540825","First in Man Trial of BI 113608",[90],[15],[27403,27403,27403,27403,27403,27403,27403,27403,27403,27403],{"nctId":27398,"briefTitle":27399,"status":107,"phases":28088,"primaryCompletion":379,"completion":379,"start":3730,"enrollment":1672,"conditions":28089,"interventions":28090},[90],[15],[27403,27403,27403,5264,27404],{"trials":28092,"activeCount":101},[],{"trials":28094,"activeCount":101},[],{"trials":28096,"activeCount":101},[],{"trials":28098,"activeCount":101},[],{"intervention":28100,"totalTrials":1044,"cells":28101},"Tamsulosin HCL",{"EARLY_PHASE1":28102,"PHASE1":28104,"PHASE2":28126,"PHASE3":28128,"PHASE4":28130,"NA":28132},{"trials":28103,"activeCount":101},[],{"trials":28105,"activeCount":101},[28106,28113,28117],{"nctId":28107,"briefTitle":28108,"status":107,"phases":28109,"primaryCompletion":4119,"completion":4119,"start":4118,"enrollment":1237,"conditions":28110,"interventions":28111},"NCT02417844","Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.",[90],[6741],[28112,28100],"tamsulosin",{"nctId":27381,"briefTitle":27382,"status":107,"phases":28114,"primaryCompletion":4413,"start":6471,"enrollment":380,"conditions":28115,"interventions":28116},[90],[15],[27386,5264],{"nctId":28118,"briefTitle":28119,"status":107,"phases":28120,"primaryCompletion":28121,"completion":28121,"start":28122,"enrollment":1237,"conditions":28123,"interventions":28124},"NCT02417831","Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.",[90],"2015-05-31","2015-04-30",[6741],[28112,28125],"tamsulosin HCl",{"trials":28127,"activeCount":101},[],{"trials":28129,"activeCount":101},[],{"trials":28131,"activeCount":101},[],{"trials":28133,"activeCount":101},[],{"intervention":27193,"totalTrials":1044,"cells":28135},{"EARLY_PHASE1":28136,"PHASE1":28138,"PHASE2":28156,"PHASE3":28158,"PHASE4":28160,"NA":28162},{"trials":28137,"activeCount":101},[],{"trials":28139,"activeCount":101},[28140,28146,28150],{"nctId":28141,"briefTitle":28142,"status":162,"phases":28143,"primaryCompletion":5233,"completion":3731,"start":9842,"enrollment":392,"conditions":28144,"interventions":28145},"NCT02148107","Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects",[90],[15],[27193,27193,27193,27193,27193,27193],{"nctId":27188,"briefTitle":27189,"status":107,"phases":28147,"primaryCompletion":9842,"completion":9842,"start":4473,"enrollment":1672,"conditions":28148,"interventions":28149},[90],[15],[2560,27193,27193],{"nctId":28151,"briefTitle":28152,"status":107,"phases":28153,"primaryCompletion":378,"completion":378,"start":379,"enrollment":4463,"conditions":28154,"interventions":28155},"NCT01843972","Safety of Single Rising Doses and Relative Bioavailability of BI 691751",[90],[15],[27193,27193,27193,27193,27193,27193,27193,27193,27193],{"trials":28157,"activeCount":101},[],{"trials":28159,"activeCount":101},[],{"trials":28161,"activeCount":101},[],{"trials":28163,"activeCount":101},[],{"intervention":28165,"totalTrials":1044,"cells":28166},"Linagliptin\u002Fmetformin",{"EARLY_PHASE1":28167,"PHASE1":28169,"PHASE2":28191,"PHASE3":28193,"PHASE4":28195,"NA":28197},{"trials":28168,"activeCount":101},[],{"trials":28170,"activeCount":101},[28171,28177,28184],{"nctId":28172,"briefTitle":28173,"status":107,"phases":28174,"primaryCompletion":456,"completion":456,"start":4038,"enrollment":132,"conditions":28175,"interventions":28176},"NCT01581931","Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin \u002F Metformin Fixed Dose Combination Tablet and Single Tablets",[90],[15],[28165,413,361],{"nctId":28178,"briefTitle":28179,"status":107,"phases":28180,"primaryCompletion":9396,"start":7703,"enrollment":2382,"conditions":28181,"interventions":28182},"NCT01216397","Relative Bioavailability of Two Different Batches of a Linagliptin \u002F Metformin Combination Tablet in Healthy Volunteers",[90],[15],[28183,28183],"Linagliptin\u002FMetformin",{"nctId":28185,"briefTitle":28186,"status":107,"phases":28187,"primaryCompletion":456,"completion":456,"start":9538,"enrollment":410,"conditions":28188,"interventions":28189},"NCT01540487","Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin \u002FMetformin",[90],[15],[28190,28165],"linagliptin\u002Fmetformin",{"trials":28192,"activeCount":101},[],{"trials":28194,"activeCount":101},[],{"trials":28196,"activeCount":101},[],{"trials":28198,"activeCount":101},[],{"intervention":28200,"totalTrials":1044,"cells":28201},"BIIL 284 BS tablet C",{"EARLY_PHASE1":28202,"PHASE1":28204,"PHASE2":28227,"PHASE3":28229,"PHASE4":28231,"NA":28233},{"trials":28203,"activeCount":101},[],{"trials":28205,"activeCount":101},[28206,28213,28221],{"nctId":28207,"briefTitle":28208,"status":107,"phases":28209,"primaryCompletion":6015,"start":6041,"enrollment":401,"conditions":28210,"interventions":28211},"NCT02265666","Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS",[90],[15],[28212,28200],"BIIL 284 BS Tablet FF",{"nctId":28214,"briefTitle":28215,"status":107,"phases":28216,"primaryCompletion":6206,"start":6246,"enrollment":188,"conditions":28217,"interventions":28218},"NCT02265653","Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers",[90],[15],[28200,28219,28220],"BIIL 284 BS tablet D","BIIL 284 BS WIF",{"nctId":28222,"briefTitle":28215,"status":107,"phases":28223,"primaryCompletion":5880,"start":6053,"enrollment":401,"conditions":28224,"interventions":28225},"NCT02265640",[90],[15],[28226,28200],"BIIL 284 BS boli",{"trials":28228,"activeCount":101},[],{"trials":28230,"activeCount":101},[],{"trials":28232,"activeCount":101},[],{"trials":28234,"activeCount":101},[],{"intervention":362,"totalTrials":1044,"cells":28236},{"EARLY_PHASE1":28237,"PHASE1":28239,"PHASE2":28258,"PHASE3":28260,"PHASE4":28262,"NA":28264},{"trials":28238,"activeCount":101},[],{"trials":28240,"activeCount":101},[28241,28245,28254],{"nctId":352,"briefTitle":353,"status":107,"phases":28242,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":28243,"interventions":28244},[90],[15],[360,73,361,362],{"nctId":28246,"briefTitle":28247,"status":107,"phases":28248,"primaryCompletion":28249,"completion":28250,"start":28251,"enrollment":392,"conditions":28252,"interventions":28253},"NCT02574845","DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)",[90],"2015-12-09","2015-12-14","2015-10-12",[15],[969,362,971],{"nctId":425,"briefTitle":426,"status":107,"phases":28255,"primaryCompletion":428,"completion":428,"start":429,"enrollment":357,"conditions":28256,"interventions":28257},[90],[15],[432,73,361,362],{"trials":28259,"activeCount":101},[],{"trials":28261,"activeCount":101},[],{"trials":28263,"activeCount":101},[],{"trials":28265,"activeCount":101},[],{"intervention":28267,"totalTrials":1044,"cells":28268},"BI 443651",{"EARLY_PHASE1":28269,"PHASE1":28271,"PHASE2":28297,"PHASE3":28299,"PHASE4":28301,"NA":28303},{"trials":28270,"activeCount":101},[],{"trials":28272,"activeCount":101},[28273,28281,28289],{"nctId":28274,"briefTitle":28275,"status":107,"phases":28276,"primaryCompletion":28277,"completion":28277,"start":28278,"enrollment":1208,"conditions":28279,"interventions":28280},"NCT02976519","BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects",[90],"2018-08-29","2017-02-15",[1724],[28267],{"nctId":28282,"briefTitle":28283,"status":107,"phases":28284,"primaryCompletion":28285,"completion":28286,"start":11458,"enrollment":3398,"conditions":28287,"interventions":28288},"NCT03135899","BI 443651 Methacholine Challenge",[90],"2018-02-07","2018-02-21",[30],[28267],{"nctId":28290,"briefTitle":28291,"status":107,"phases":28292,"primaryCompletion":28293,"completion":26425,"start":28294,"enrollment":8304,"conditions":28295,"interventions":28296},"NCT02706925","To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers",[90],"2016-06-12","2016-03-22",[15],[28267],{"trials":28298,"activeCount":101},[],{"trials":28300,"activeCount":101},[],{"trials":28302,"activeCount":101},[],{"trials":28304,"activeCount":101},[],{"intervention":9335,"totalTrials":1044,"cells":28306},{"EARLY_PHASE1":28307,"PHASE1":28309,"PHASE2":28332,"PHASE3":28334,"PHASE4":28336,"NA":28338},{"trials":28308,"activeCount":101},[],{"trials":28310,"activeCount":101},[28311,28315,28324],{"nctId":9329,"briefTitle":9330,"status":107,"phases":28312,"primaryCompletion":9332,"start":6133,"enrollment":401,"conditions":28313,"interventions":28314},[90],[15],[9335,528,528],{"nctId":28316,"briefTitle":28317,"status":107,"phases":28318,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":28321,"interventions":28322},"NCT03307252","This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men",[90],"2018-05-02","2017-10-25",[15],[2393,971,413,969,9335,27235,28323,459],"Cimetidine",{"nctId":28325,"briefTitle":28326,"status":107,"phases":28327,"primaryCompletion":6223,"start":4413,"enrollment":2382,"conditions":28328,"interventions":28329},"NCT02171533","Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers",[90],[15],[28330,9335,28331],"dabigatran","Verapamil ER",{"trials":28333,"activeCount":101},[],{"trials":28335,"activeCount":101},[],{"trials":28337,"activeCount":101},[],{"trials":28339,"activeCount":101},[],{"intervention":28341,"totalTrials":1044,"cells":28342},"BI 3006337",{"EARLY_PHASE1":28343,"PHASE1":28345,"PHASE2":28369,"PHASE3":28371,"PHASE4":28373,"NA":28375},{"trials":28344,"activeCount":101},[],{"trials":28346,"activeCount":101},[28347,28355,28362],{"nctId":28348,"briefTitle":28349,"status":107,"phases":28350,"primaryCompletion":28351,"completion":1304,"start":28352,"enrollment":1208,"conditions":28353,"interventions":28354},"NCT05970640","A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease",[90],"2024-10-31","2023-08-14",[19351,539],[28341],{"nctId":28356,"briefTitle":28357,"status":107,"phases":28358,"primaryCompletion":28351,"completion":28351,"start":28359,"enrollment":448,"conditions":28360,"interventions":28361},"NCT06310005","A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated",[90],"2024-04-19",[15],[28341],{"nctId":28363,"briefTitle":28364,"status":107,"phases":28365,"primaryCompletion":28366,"completion":28366,"start":1457,"enrollment":1429,"conditions":28367,"interventions":28368},"NCT05076422","A Study to Test How Well Men Tolerate Different Doses of BI 3006337",[90],"2023-03-03",[15],[28341],{"trials":28370,"activeCount":101},[],{"trials":28372,"activeCount":101},[],{"trials":28374,"activeCount":101},[],{"trials":28376,"activeCount":101},[],{"intervention":10159,"totalTrials":1044,"cells":28378},{"EARLY_PHASE1":28379,"PHASE1":28381,"PHASE2":28395,"PHASE3":28397,"PHASE4":28399,"NA":28401},{"trials":28380,"activeCount":101},[],{"trials":28382,"activeCount":101},[28383,28387,28391],{"nctId":10150,"briefTitle":10151,"status":162,"phases":28384,"primaryCompletion":10153,"completion":10153,"start":10154,"enrollment":401,"conditions":28385,"interventions":28386},[90],[10156,10157],[10159,10133],{"nctId":10178,"briefTitle":10179,"status":162,"phases":28388,"primaryCompletion":10181,"completion":482,"start":10182,"enrollment":272,"conditions":28389,"interventions":28390},[90],[10156],[10133,10133,10159],{"nctId":10195,"briefTitle":10196,"status":107,"phases":28392,"primaryCompletion":603,"completion":438,"start":3731,"enrollment":166,"conditions":28393,"interventions":28394},[90],[10156,10157],[10159,10133],{"trials":28396,"activeCount":101},[],{"trials":28398,"activeCount":101},[],{"trials":28400,"activeCount":101},[],{"trials":28402,"activeCount":101},[],{"intervention":28404,"totalTrials":1044,"cells":28405},"BI 11634",{"EARLY_PHASE1":28406,"PHASE1":28408,"PHASE2":28429,"PHASE3":28431,"PHASE4":28433,"NA":28435},{"trials":28407,"activeCount":101},[],{"trials":28409,"activeCount":101},[28410,28417,28423],{"nctId":28411,"briefTitle":28412,"status":107,"phases":28413,"primaryCompletion":8911,"start":1114,"enrollment":380,"conditions":28414,"interventions":28415},"NCT02214927","Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers",[90],[15],[28404,28416],"BI 11634 drinking solution",{"nctId":28418,"briefTitle":28419,"status":107,"phases":28420,"primaryCompletion":6140,"start":4517,"enrollment":410,"conditions":28421,"interventions":28422},"NCT02214940","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers",[90],[15],[28404],{"nctId":28424,"briefTitle":28425,"status":107,"phases":28426,"primaryCompletion":6116,"start":6910,"enrollment":37,"conditions":28427,"interventions":28428},"NCT02214914","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers",[90],[15],[28416,28404],{"trials":28430,"activeCount":101},[],{"trials":28432,"activeCount":101},[],{"trials":28434,"activeCount":101},[],{"trials":28436,"activeCount":101},[],{"intervention":459,"totalTrials":1044,"cells":28438},{"EARLY_PHASE1":28439,"PHASE1":28441,"PHASE2":28461,"PHASE3":28463,"PHASE4":28465,"NA":28467},{"trials":28440,"activeCount":101},[],{"trials":28442,"activeCount":101},[28443,28453,28457],{"nctId":28444,"briefTitle":28445,"status":107,"phases":28446,"primaryCompletion":28447,"completion":28448,"start":2838,"enrollment":956,"conditions":28449,"interventions":28450},"NCT06647810","A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood",[90],"2024-12-12","2025-01-07",[15],[28451,28452,459],"BI 690517 formulation 1","BI 690517 formulation 2",{"nctId":28316,"briefTitle":28317,"status":107,"phases":28454,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":28455,"interventions":28456},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":453,"briefTitle":454,"status":107,"phases":28458,"primaryCompletion":447,"completion":447,"start":456,"enrollment":392,"conditions":28459,"interventions":28460},[90],[15],[459,460,73,73,460,459,73],{"trials":28462,"activeCount":101},[],{"trials":28464,"activeCount":101},[],{"trials":28466,"activeCount":101},[],{"trials":28468,"activeCount":101},[],{"intervention":28470,"totalTrials":1044,"cells":28471},"BI 113823",{"EARLY_PHASE1":28472,"PHASE1":28474,"PHASE2":28496,"PHASE3":28498,"PHASE4":28500,"NA":28502},{"trials":28473,"activeCount":101},[],{"trials":28475,"activeCount":101},[28476,28483,28490],{"nctId":28477,"briefTitle":28478,"status":107,"phases":28479,"primaryCompletion":7703,"start":4442,"enrollment":401,"conditions":28480,"interventions":28481},"NCT01189175","Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823",[90],[15],[28482,28470],"BI 113823 + Ketokonazole",{"nctId":28484,"briefTitle":28485,"status":107,"phases":28486,"primaryCompletion":3754,"start":6811,"enrollment":8304,"conditions":28487,"interventions":28488},"NCT02259972","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers",[90],[15],[28489,28470],"BI 113823 solution",{"nctId":28491,"briefTitle":28492,"status":162,"phases":28493,"primaryCompletion":6133,"start":7703,"enrollment":448,"conditions":28494,"interventions":28495},"NCT01207973","Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee",[90],[6609],[28470],{"trials":28497,"activeCount":101},[],{"trials":28499,"activeCount":101},[],{"trials":28501,"activeCount":101},[],{"trials":28503,"activeCount":101},[],{"intervention":28505,"totalTrials":1044,"cells":28506},"BI 1356225",{"EARLY_PHASE1":28507,"PHASE1":28509,"PHASE2":28537,"PHASE3":28539,"PHASE4":28541,"NA":28543},{"trials":28508,"activeCount":101},[],{"trials":28510,"activeCount":101},[28511,28521,28529],{"nctId":28512,"briefTitle":28513,"status":4581,"phases":28514,"primaryCompletion":28515,"completion":28516,"start":28517,"enrollment":123,"conditions":28518,"interventions":28520},"NCT06628622","A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine",[90],"2027-02-04","2027-02-14","2025-01-27",[28519],"Opioid Use Disorder",[28505],{"nctId":28522,"briefTitle":28523,"status":107,"phases":28524,"primaryCompletion":28525,"completion":28525,"start":28526,"enrollment":3970,"conditions":28527,"interventions":28528},"NCT04447261","A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight",[90],"2021-04-25","2020-06-30",[539],[28505],{"nctId":28530,"briefTitle":28531,"status":107,"phases":28532,"primaryCompletion":28533,"completion":28533,"start":28534,"enrollment":7524,"conditions":28535,"interventions":28536},"NCT04065295","A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225",[90],"2019-12-23","2019-09-09",[15],[28505],{"trials":28538,"activeCount":101},[],{"trials":28540,"activeCount":101},[],{"trials":28542,"activeCount":101},[],{"trials":28544,"activeCount":101},[],{"intervention":6994,"totalTrials":1044,"cells":28546},{"EARLY_PHASE1":28547,"PHASE1":28549,"PHASE2":28570,"PHASE3":28572,"PHASE4":28574,"NA":28576},{"trials":28548,"activeCount":101},[],{"trials":28550,"activeCount":101},[28551,28558,28566],{"nctId":28552,"briefTitle":28553,"status":107,"phases":28554,"primaryCompletion":5843,"start":3978,"enrollment":2400,"conditions":28555,"interventions":28556},"NCT02262858","Bioequivalence of Telmisartan\u002F HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II",[90],[15],[28557,6121,6994],"Telmisartan and HCTZ",{"nctId":28559,"briefTitle":28560,"status":107,"phases":28561,"primaryCompletion":7553,"start":7084,"enrollment":1672,"conditions":28562,"interventions":28563},"NCT02176512","Telmisartan\u002FHydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects",[90],[15],[28564,28565,6994],"BIBR 277 SE and HCTZ","BIBR 277 SE",{"nctId":6986,"briefTitle":6987,"status":107,"phases":28567,"primaryCompletion":6989,"start":6990,"enrollment":1672,"conditions":28568,"interventions":28569},[90],[15],[6979,6993,6994],{"trials":28571,"activeCount":101},[],{"trials":28573,"activeCount":101},[],{"trials":28575,"activeCount":101},[],{"trials":28577,"activeCount":101},[],{"intervention":929,"totalTrials":1044,"cells":28579},{"EARLY_PHASE1":28580,"PHASE1":28582,"PHASE2":28596,"PHASE3":28598,"PHASE4":28600,"NA":28602},{"trials":28581,"activeCount":101},[],{"trials":28583,"activeCount":101},[28584,28588,28592],{"nctId":919,"briefTitle":920,"status":107,"phases":28585,"primaryCompletion":922,"completion":922,"start":923,"enrollment":401,"conditions":28586,"interventions":28587},[90],[15],[926,927,928,929],{"nctId":20085,"briefTitle":20086,"status":107,"phases":28589,"primaryCompletion":4120,"completion":4120,"start":474,"enrollment":392,"conditions":28590,"interventions":28591},[90],[15],[929,4166,20090],{"nctId":4144,"briefTitle":4145,"status":107,"phases":28593,"primaryCompletion":965,"completion":965,"start":2922,"enrollment":392,"conditions":28594,"interventions":28595},[90],[15],[4149,4150,1242,1240],{"trials":28597,"activeCount":101},[],{"trials":28599,"activeCount":101},[],{"trials":28601,"activeCount":101},[],{"trials":28603,"activeCount":101},[],{"intervention":28605,"totalTrials":1044,"cells":28606},"BI 44370 TA",{"EARLY_PHASE1":28607,"PHASE1":28609,"PHASE2":28630,"PHASE3":28632,"PHASE4":28634,"NA":28636},{"trials":28608,"activeCount":101},[],{"trials":28610,"activeCount":101},[28611,28617,28624],{"nctId":28612,"briefTitle":28613,"status":107,"phases":28614,"primaryCompletion":2003,"start":5856,"enrollment":2442,"conditions":28615,"interventions":28616},"NCT00743015","Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks",[90],[13290],[28605],{"nctId":28618,"briefTitle":28619,"status":107,"phases":28620,"primaryCompletion":3763,"start":6155,"enrollment":37,"conditions":28621,"interventions":28622},"NCT02215018","Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers",[90],[15],[28623,28605],"BI 44370 TA solution",{"nctId":28625,"briefTitle":28626,"status":107,"phases":28627,"primaryCompletion":5905,"start":2649,"enrollment":1237,"conditions":28628,"interventions":28629},"NCT02215759","Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers",[90],[15],[28605],{"trials":28631,"activeCount":101},[],{"trials":28633,"activeCount":101},[],{"trials":28635,"activeCount":101},[],{"trials":28637,"activeCount":101},[],{"intervention":1383,"totalTrials":1044,"cells":28639},{"EARLY_PHASE1":28640,"PHASE1":28642,"PHASE2":28656,"PHASE3":28658,"PHASE4":28660,"NA":28662},{"trials":28641,"activeCount":101},[],{"trials":28643,"activeCount":101},[28644,28648,28652],{"nctId":18824,"briefTitle":18825,"status":107,"phases":28645,"primaryCompletion":18827,"completion":18827,"start":2770,"enrollment":177,"conditions":28646,"interventions":28647},[90],[15],[4095,1383],{"nctId":1375,"briefTitle":1376,"status":107,"phases":28649,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":401,"conditions":28650,"interventions":28651},[90],[15],[1339,1383],{"nctId":5279,"briefTitle":5280,"status":107,"phases":28653,"primaryCompletion":5282,"completion":5282,"start":5283,"enrollment":912,"conditions":28654,"interventions":28655},[90],[15],[1383,78],{"trials":28657,"activeCount":101},[],{"trials":28659,"activeCount":101},[],{"trials":28661,"activeCount":101},[],{"trials":28663,"activeCount":101},[],{"intervention":987,"totalTrials":1044,"cells":28665},{"EARLY_PHASE1":28666,"PHASE1":28668,"PHASE2":28684,"PHASE3":28686,"PHASE4":28688,"NA":28690},{"trials":28667,"activeCount":101},[],{"trials":28669,"activeCount":101},[28670,28676,28680],{"nctId":28671,"briefTitle":28672,"status":107,"phases":28673,"primaryCompletion":2111,"start":5842,"enrollment":1865,"conditions":28674,"interventions":28675},"NCT02253849","Effects of TPV\u002Fr on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers",[90],[15],[987,4008,4010],{"nctId":1364,"briefTitle":1365,"status":107,"phases":28677,"primaryCompletion":1367,"completion":1368,"start":1369,"enrollment":401,"conditions":28678,"interventions":28679},[90],[15],[1372,1373],{"nctId":980,"briefTitle":981,"status":107,"phases":28681,"primaryCompletion":983,"completion":983,"start":984,"enrollment":401,"conditions":28682,"interventions":28683},[90],[15],[911,987],{"trials":28685,"activeCount":101},[],{"trials":28687,"activeCount":101},[],{"trials":28689,"activeCount":101},[],{"trials":28691,"activeCount":101},[],{"intervention":4014,"totalTrials":1044,"cells":28693},{"EARLY_PHASE1":28694,"PHASE1":28696,"PHASE2":28710,"PHASE3":28712,"PHASE4":28714,"NA":28716},{"trials":28695,"activeCount":101},[],{"trials":28697,"activeCount":101},[28698,28702,28706],{"nctId":4002,"briefTitle":4003,"status":107,"phases":28699,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":28700,"interventions":28701},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":20401,"briefTitle":20402,"status":107,"phases":28703,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":28704,"interventions":28705},[90],[15],[3981,4011,4013,4014,1241,20406,20407],{"nctId":20197,"briefTitle":20198,"status":107,"phases":28707,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":28708,"interventions":28709},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":28711,"activeCount":101},[],{"trials":28713,"activeCount":101},[],{"trials":28715,"activeCount":101},[],{"trials":28717,"activeCount":101},[],{"intervention":4024,"totalTrials":1044,"cells":28719},{"EARLY_PHASE1":28720,"PHASE1":28722,"PHASE2":28743,"PHASE3":28745,"PHASE4":28747,"NA":28749},{"trials":28721,"activeCount":101},[],{"trials":28723,"activeCount":101},[28724,28728,28735],{"nctId":4017,"briefTitle":4018,"status":107,"phases":28725,"primaryCompletion":4020,"completion":4020,"start":4021,"enrollment":357,"conditions":28726,"interventions":28727},[90],[15],[4024,1242],{"nctId":28729,"briefTitle":28730,"status":107,"phases":28731,"primaryCompletion":28732,"completion":28732,"start":3540,"enrollment":912,"conditions":28733,"interventions":28734},"NCT04789291","A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food",[90],"2021-08-07",[15],[4024],{"nctId":28736,"briefTitle":28737,"status":107,"phases":28738,"primaryCompletion":28739,"completion":28739,"start":28740,"enrollment":1208,"conditions":28741,"interventions":28742},"NCT04439838","A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated",[90],"2021-03-19","2020-08-13",[15],[4024],{"trials":28744,"activeCount":101},[],{"trials":28746,"activeCount":101},[],{"trials":28748,"activeCount":101},[],{"trials":28750,"activeCount":101},[],{"intervention":3794,"totalTrials":1044,"cells":28752},{"EARLY_PHASE1":28753,"PHASE1":28755,"PHASE2":28774,"PHASE3":28776,"PHASE4":28778,"NA":28780},{"trials":28754,"activeCount":101},[],{"trials":28756,"activeCount":101},[28757,28761,28765],{"nctId":3786,"briefTitle":3787,"status":107,"phases":28758,"primaryCompletion":3789,"completion":3789,"start":3790,"enrollment":3791,"conditions":28759,"interventions":28760},[90],[15,539],[3794,3795,3796],{"nctId":4241,"briefTitle":4242,"status":107,"phases":28762,"primaryCompletion":4244,"completion":4244,"start":4245,"enrollment":97,"conditions":28763,"interventions":28764},[90],[539],[3796,3794],{"nctId":28766,"briefTitle":28767,"status":107,"phases":28768,"primaryCompletion":745,"completion":745,"start":28769,"enrollment":10951,"conditions":28770,"interventions":28771},"NCT04903509","A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide",[90],"2021-06-08",[15],[3794,28772,28773],"Saxenda®","Paracetamol-ratiopharm®",{"trials":28775,"activeCount":101},[],{"trials":28777,"activeCount":101},[],{"trials":28779,"activeCount":101},[],{"trials":28781,"activeCount":101},[],{"intervention":28783,"totalTrials":1044,"cells":28784},"BI 1060469",{"EARLY_PHASE1":28785,"PHASE1":28787,"PHASE2":28808,"PHASE3":28810,"PHASE4":28812,"NA":28814},{"trials":28786,"activeCount":101},[],{"trials":28788,"activeCount":101},[28789,28796,28802],{"nctId":28790,"briefTitle":28791,"status":107,"phases":28792,"primaryCompletion":475,"completion":474,"start":420,"enrollment":401,"conditions":28793,"interventions":28794},"NCT02225626","Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects",[90],[15],[28783,28783,28795],"Other: standard breakfast",{"nctId":28797,"briefTitle":28798,"status":107,"phases":28799,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":1429,"conditions":28800,"interventions":28801},"NCT02183545","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers",[90],[15],[28783],{"nctId":28803,"briefTitle":28804,"status":107,"phases":28805,"primaryCompletion":12159,"completion":12159,"start":4474,"enrollment":2400,"conditions":28806,"interventions":28807},"NCT01971502","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469",[90],[15],[28783,28783],{"trials":28809,"activeCount":101},[],{"trials":28811,"activeCount":101},[],{"trials":28813,"activeCount":101},[],{"trials":28815,"activeCount":101},[],{"intervention":4142,"totalTrials":1044,"cells":28817},{"EARLY_PHASE1":28818,"PHASE1":28820,"PHASE2":28841,"PHASE3":28843,"PHASE4":28845,"NA":28847},{"trials":28819,"activeCount":101},[],{"trials":28821,"activeCount":101},[28822,28828,28837],{"nctId":28823,"briefTitle":28824,"status":107,"phases":28825,"primaryCompletion":4139,"completion":467,"start":20695,"enrollment":8304,"conditions":28826,"interventions":28827},"NCT06429137","A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated",[90],[15],[4142],{"nctId":28829,"briefTitle":28830,"status":107,"phases":28831,"primaryCompletion":28832,"completion":28833,"start":28834,"enrollment":188,"conditions":28835,"interventions":28836},"NCT06861829","A Study in Healthy Men to Test Whether Food Influences the Amount of BI 3731579 in the Blood",[90],"2025-04-17","2025-04-23","2025-03-19",[15],[4142],{"nctId":4136,"briefTitle":4137,"status":162,"phases":28838,"primaryCompletion":4139,"completion":2857,"start":964,"enrollment":357,"conditions":28839,"interventions":28840},[90],[15],[4142,1242],{"trials":28842,"activeCount":101},[],{"trials":28844,"activeCount":101},[],{"trials":28846,"activeCount":101},[],{"trials":28848,"activeCount":101},[],{"intervention":28850,"totalTrials":1044,"cells":28851},"BI 135585",{"EARLY_PHASE1":28852,"PHASE1":28854,"PHASE2":28874,"PHASE3":28876,"PHASE4":28878,"NA":28880},{"trials":28853,"activeCount":101},[],{"trials":28855,"activeCount":101},[28856,28862,28868],{"nctId":28857,"briefTitle":28858,"status":107,"phases":28859,"primaryCompletion":7703,"start":3754,"enrollment":123,"conditions":28860,"interventions":28861},"NCT01146886","Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers",[90],[21],[28850],{"nctId":28863,"briefTitle":28864,"status":107,"phases":28865,"primaryCompletion":9752,"start":9332,"enrollment":716,"conditions":28866,"interventions":28867},"NCT01282970","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes",[90],[21],[28850],{"nctId":28869,"briefTitle":28870,"status":107,"phases":28871,"primaryCompletion":6132,"start":6133,"enrollment":177,"conditions":28872,"interventions":28873},"NCT01286571","Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food",[90],[15],[28850,28850],{"trials":28875,"activeCount":101},[],{"trials":28877,"activeCount":101},[],{"trials":28879,"activeCount":101},[],{"trials":28881,"activeCount":101},[],{"intervention":6227,"totalTrials":1044,"cells":28883},{"EARLY_PHASE1":28884,"PHASE1":28886,"PHASE2":28906,"PHASE3":28908,"PHASE4":28910,"NA":28912},{"trials":28885,"activeCount":101},[],{"trials":28887,"activeCount":101},[28888,28894,28902],{"nctId":28889,"briefTitle":28890,"status":107,"phases":28891,"primaryCompletion":20181,"start":6911,"enrollment":380,"conditions":28892,"interventions":28893},"NCT02194309","Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan\u002F5 mg Amlodipine and 80 mg Telmisartan\u002F5 mg Amlodipine in Healthy Male Volunteers",[90],[15],[6227,6228,12224],{"nctId":28895,"briefTitle":28896,"status":107,"phases":28897,"primaryCompletion":5992,"start":7132,"enrollment":23663,"conditions":28898,"interventions":28899},"NCT02264158","Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers",[90],[15],[6228,6227,28900,28901],"Lacidipine high","Lacidipine low",{"nctId":6220,"briefTitle":6221,"status":107,"phases":28903,"primaryCompletion":6223,"start":6224,"enrollment":132,"conditions":28904,"interventions":28905},[90],[15],[6227,6228,6196],{"trials":28907,"activeCount":101},[],{"trials":28909,"activeCount":101},[],{"trials":28911,"activeCount":101},[],{"trials":28913,"activeCount":101},[],{"intervention":6228,"totalTrials":1044,"cells":28915},{"EARLY_PHASE1":28916,"PHASE1":28918,"PHASE2":28932,"PHASE3":28934,"PHASE4":28936,"NA":28938},{"trials":28917,"activeCount":101},[],{"trials":28919,"activeCount":101},[28920,28924,28928],{"nctId":28889,"briefTitle":28890,"status":107,"phases":28921,"primaryCompletion":20181,"start":6911,"enrollment":380,"conditions":28922,"interventions":28923},[90],[15],[6227,6228,12224],{"nctId":28895,"briefTitle":28896,"status":107,"phases":28925,"primaryCompletion":5992,"start":7132,"enrollment":23663,"conditions":28926,"interventions":28927},[90],[15],[6228,6227,28900,28901],{"nctId":6220,"briefTitle":6221,"status":107,"phases":28929,"primaryCompletion":6223,"start":6224,"enrollment":132,"conditions":28930,"interventions":28931},[90],[15],[6227,6228,6196],{"trials":28933,"activeCount":101},[],{"trials":28935,"activeCount":101},[],{"trials":28937,"activeCount":101},[],{"trials":28939,"activeCount":101},[],{"intervention":28941,"totalTrials":1044,"cells":28942},"BIIB 722 CL",{"EARLY_PHASE1":28943,"PHASE1":28945,"PHASE2":28966,"PHASE3":28968,"PHASE4":28970,"NA":28972},{"trials":28944,"activeCount":101},[],{"trials":28946,"activeCount":101},[28947,28953,28960],{"nctId":28948,"briefTitle":28949,"status":107,"phases":28950,"primaryCompletion":20755,"start":6029,"enrollment":1218,"conditions":28951,"interventions":28952},"NCT02224079","Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers",[90],[15],[28941],{"nctId":28954,"briefTitle":28955,"status":107,"phases":28956,"primaryCompletion":6949,"start":2163,"enrollment":2898,"conditions":28957,"interventions":28958},"NCT02227030","Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects",[90],[15],[28959,28941],"BIIB 722 CL solution",{"nctId":28961,"briefTitle":28962,"status":162,"phases":28963,"primaryCompletion":12600,"start":12600,"enrollment":1081,"conditions":28964,"interventions":28965},"NCT02268604","Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers",[90],[15],[28941],{"trials":28967,"activeCount":101},[],{"trials":28969,"activeCount":101},[],{"trials":28971,"activeCount":101},[],{"trials":28973,"activeCount":101},[],{"intervention":423,"totalTrials":1044,"cells":28975},{"EARLY_PHASE1":28976,"PHASE1":28978,"PHASE2":28992,"PHASE3":28994,"PHASE4":28996,"NA":28998},{"trials":28977,"activeCount":101},[],{"trials":28979,"activeCount":101},[28980,28984,28988],{"nctId":405,"briefTitle":406,"status":107,"phases":28981,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":28982,"interventions":28983},[90],[15],[73,413,73,414,413,414,73,413,414],{"nctId":416,"briefTitle":417,"status":107,"phases":28985,"primaryCompletion":419,"completion":419,"start":420,"enrollment":357,"conditions":28986,"interventions":28987},[90],[15],[384,423,383],{"nctId":471,"briefTitle":472,"status":107,"phases":28989,"primaryCompletion":474,"completion":474,"start":475,"enrollment":357,"conditions":28990,"interventions":28991},[90],[15],[384,423,383],{"trials":28993,"activeCount":101},[],{"trials":28995,"activeCount":101},[],{"trials":28997,"activeCount":101},[],{"trials":28999,"activeCount":101},[],{"intervention":19905,"totalTrials":1044,"cells":29001},{"EARLY_PHASE1":29002,"PHASE1":29004,"PHASE2":29022,"PHASE3":29024,"PHASE4":29026,"NA":29028},{"trials":29003,"activeCount":101},[],{"trials":29005,"activeCount":101},[29006,29010,29014],{"nctId":19899,"briefTitle":19900,"status":107,"phases":29007,"primaryCompletion":19902,"completion":19902,"start":1263,"enrollment":401,"conditions":29008,"interventions":29009},[90],[15],[553,553,19905],{"nctId":20257,"briefTitle":20258,"status":107,"phases":29011,"primaryCompletion":20260,"completion":20260,"start":20261,"enrollment":956,"conditions":29012,"interventions":29013},[90],[15],[20217,20264],{"nctId":29015,"briefTitle":29016,"status":107,"phases":29017,"primaryCompletion":20695,"completion":20695,"start":29018,"enrollment":956,"conditions":29019,"interventions":29020},"NCT06419660","A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood",[90],"2024-05-22",[15],[29021,19905],"BI 300202",{"trials":29023,"activeCount":101},[],{"trials":29025,"activeCount":101},[],{"trials":29027,"activeCount":101},[],{"trials":29029,"activeCount":101},[],{"intervention":29031,"totalTrials":1044,"cells":29032},"Clarithromycin",{"EARLY_PHASE1":29033,"PHASE1":29035,"PHASE2":29056,"PHASE3":29058,"PHASE4":29060,"NA":29062},{"trials":29034,"activeCount":101},[],{"trials":29036,"activeCount":101},[29037,29043,29049],{"nctId":29038,"briefTitle":29039,"status":107,"phases":29040,"primaryCompletion":6223,"start":4413,"enrollment":1672,"conditions":29041,"interventions":29042},"NCT02171585","Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers",[90],[15],[6561,29031],{"nctId":29044,"briefTitle":29045,"status":107,"phases":29046,"primaryCompletion":5869,"start":6472,"enrollment":380,"conditions":29047,"interventions":29048},"NCT02251769","Effects of Single-dose and Steady-state TPV\u002Fr on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir",[90],[15],[4008,4010,29031],{"nctId":29050,"briefTitle":29051,"status":107,"phases":29052,"enrollment":448,"conditions":29053,"interventions":29054},"NCT00002194","An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.",[90],[27],[29055,2186,29031],"Erythromycin",{"trials":29057,"activeCount":101},[],{"trials":29059,"activeCount":101},[],{"trials":29061,"activeCount":101},[],{"trials":29063,"activeCount":101},[],{"intervention":29065,"totalTrials":1044,"cells":29066},"BIIR 561 CL",{"EARLY_PHASE1":29067,"PHASE1":29069,"PHASE2":29089,"PHASE3":29091,"PHASE4":29093,"NA":29095},{"trials":29068,"activeCount":101},[],{"trials":29070,"activeCount":101},[29071,29077,29083],{"nctId":29072,"briefTitle":29073,"status":107,"phases":29074,"primaryCompletion":7394,"start":6246,"enrollment":123,"conditions":29075,"interventions":29076},"NCT02222961","Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers",[90],[15],[29065],{"nctId":29078,"briefTitle":29079,"status":107,"phases":29080,"primaryCompletion":6738,"start":6438,"enrollment":6117,"conditions":29081,"interventions":29082},"NCT02222974","Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL",[90],[15],[29065],{"nctId":29084,"briefTitle":29085,"status":107,"phases":29086,"primaryCompletion":6949,"start":6262,"enrollment":912,"conditions":29087,"interventions":29088},"NCT02223507","Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers",[90],[15],[29065],{"trials":29090,"activeCount":101},[],{"trials":29092,"activeCount":101},[],{"trials":29094,"activeCount":101},[],{"trials":29096,"activeCount":101},[],{"intervention":6068,"totalTrials":1044,"cells":29098},{"EARLY_PHASE1":29099,"PHASE1":29101,"PHASE2":29115,"PHASE3":29117,"PHASE4":29119,"NA":29121},{"trials":29100,"activeCount":101},[],{"trials":29102,"activeCount":101},[29103,29107,29111],{"nctId":6061,"briefTitle":6062,"status":107,"phases":29104,"primaryCompletion":6064,"start":6065,"enrollment":188,"conditions":29105,"interventions":29106},[90],[15],[6068,6069,5982],{"nctId":6071,"briefTitle":6072,"status":107,"phases":29108,"primaryCompletion":6074,"start":6065,"enrollment":188,"conditions":29109,"interventions":29110},[90],[15],[6068,5982],{"nctId":6435,"briefTitle":6436,"status":107,"phases":29112,"primaryCompletion":5923,"start":6438,"enrollment":177,"conditions":29113,"interventions":29114},[90],[15],[6068,6420],{"trials":29116,"activeCount":101},[],{"trials":29118,"activeCount":101},[],{"trials":29120,"activeCount":101},[],{"trials":29122,"activeCount":101},[],{"intervention":10041,"totalTrials":1044,"cells":29124},{"EARLY_PHASE1":29125,"PHASE1":29127,"PHASE2":29147,"PHASE3":29149,"PHASE4":29151,"NA":29153},{"trials":29126,"activeCount":101},[],{"trials":29128,"activeCount":101},[29129,29136,29143],{"nctId":29130,"briefTitle":29131,"status":107,"phases":29132,"primaryCompletion":6374,"start":5879,"enrollment":97,"conditions":29133,"interventions":29134},"NCT02245269","Pharmacokinetics of Atorvastatin With Tipranavir\u002FRitonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir\u002FRitonavir in Healthy Volunteers",[90],[15],[4008,4010,10041,29135],"Maalox",{"nctId":29137,"briefTitle":29138,"status":107,"phases":29139,"primaryCompletion":11588,"start":2111,"enrollment":380,"conditions":29140,"interventions":29141},"NCT02171039","Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers",[90],[15],[29142,10041],"Dabigatran",{"nctId":10036,"briefTitle":10037,"status":107,"phases":29144,"primaryCompletion":409,"completion":409,"start":9614,"enrollment":5205,"conditions":29145,"interventions":29146},[90],[15],[949,10041,4479,969,4479],{"trials":29148,"activeCount":101},[],{"trials":29150,"activeCount":101},[],{"trials":29152,"activeCount":101},[],{"trials":29154,"activeCount":101},[],{"intervention":29156,"totalTrials":1044,"cells":29157},"BI 14332 CL",{"EARLY_PHASE1":29158,"PHASE1":29160,"PHASE2":29180,"PHASE3":29182,"PHASE4":29184,"NA":29186},{"trials":29159,"activeCount":101},[],{"trials":29161,"activeCount":101},[29162,29168,29174],{"nctId":29163,"briefTitle":29164,"status":162,"phases":29165,"primaryCompletion":6116,"start":6910,"enrollment":2887,"conditions":29166,"interventions":29167},"NCT02212925","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes",[90],[21],[29156],{"nctId":29169,"briefTitle":29170,"status":107,"phases":29171,"primaryCompletion":6156,"start":7151,"enrollment":231,"conditions":29172,"interventions":29173},"NCT02211989","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects",[90],[15],[29156],{"nctId":29175,"briefTitle":29176,"status":107,"phases":29177,"primaryCompletion":6910,"start":6911,"enrollment":188,"conditions":29178,"interventions":29179},"NCT02212938","Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers",[90],[15],[29156],{"trials":29181,"activeCount":101},[],{"trials":29183,"activeCount":101},[],{"trials":29185,"activeCount":101},[],{"trials":29187,"activeCount":101},[],{"intervention":19586,"totalTrials":1075,"cells":29189},{"EARLY_PHASE1":29190,"PHASE1":29192,"PHASE2":29204,"PHASE3":29206,"PHASE4":29208,"NA":29210},{"trials":29191,"activeCount":101},[],{"trials":29193,"activeCount":101},[29194,29198],{"nctId":19581,"briefTitle":19582,"status":107,"phases":29195,"primaryCompletion":6081,"start":5887,"enrollment":1631,"conditions":29196,"interventions":29197},[90],[15],[11653,19586],{"nctId":29199,"briefTitle":29200,"status":107,"phases":29201,"primaryCompletion":5992,"start":7132,"enrollment":1208,"conditions":29202,"interventions":29203},"NCT02260076","Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects",[90],[15],[19586],{"trials":29205,"activeCount":101},[],{"trials":29207,"activeCount":101},[],{"trials":29209,"activeCount":101},[],{"trials":29211,"activeCount":101},[],{"intervention":4511,"totalTrials":1075,"cells":29213},{"EARLY_PHASE1":29214,"PHASE1":29216,"PHASE2":29228,"PHASE3":29230,"PHASE4":29232,"NA":29234},{"trials":29215,"activeCount":101},[],{"trials":29217,"activeCount":101},[29218,29224],{"nctId":29219,"briefTitle":29220,"status":107,"phases":29221,"primaryCompletion":6471,"start":4128,"enrollment":401,"conditions":29222,"interventions":29223},"NCT02173652","Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers",[90],[15],[4511,4510],{"nctId":4504,"briefTitle":4505,"status":107,"phases":29225,"primaryCompletion":4413,"start":4507,"enrollment":1891,"conditions":29226,"interventions":29227},[90],[15],[4510,4511,1538],{"trials":29229,"activeCount":101},[],{"trials":29231,"activeCount":101},[],{"trials":29233,"activeCount":101},[],{"trials":29235,"activeCount":101},[],{"intervention":4510,"totalTrials":1075,"cells":29237},{"EARLY_PHASE1":29238,"PHASE1":29240,"PHASE2":29250,"PHASE3":29252,"PHASE4":29254,"NA":29256},{"trials":29239,"activeCount":101},[],{"trials":29241,"activeCount":101},[29242,29246],{"nctId":29219,"briefTitle":29220,"status":107,"phases":29243,"primaryCompletion":6471,"start":4128,"enrollment":401,"conditions":29244,"interventions":29245},[90],[15],[4511,4510],{"nctId":4504,"briefTitle":4505,"status":107,"phases":29247,"primaryCompletion":4413,"start":4507,"enrollment":1891,"conditions":29248,"interventions":29249},[90],[15],[4510,4511,1538],{"trials":29251,"activeCount":101},[],{"trials":29253,"activeCount":101},[],{"trials":29255,"activeCount":101},[],{"trials":29257,"activeCount":101},[],{"intervention":19071,"totalTrials":1075,"cells":29259},{"EARLY_PHASE1":29260,"PHASE1":29262,"PHASE2":29272,"PHASE3":29274,"PHASE4":29276,"NA":29278},{"trials":29261,"activeCount":101},[],{"trials":29263,"activeCount":101},[29264,29268],{"nctId":19066,"briefTitle":19067,"status":107,"phases":29265,"primaryCompletion":5905,"start":2003,"enrollment":132,"conditions":29266,"interventions":29267},[90],[15],[19059,19071,19072],{"nctId":19086,"briefTitle":19087,"status":107,"phases":29269,"primaryCompletion":3991,"start":9404,"enrollment":448,"conditions":29270,"interventions":29271},[90],[15],[19091,19071,19059],{"trials":29273,"activeCount":101},[],{"trials":29275,"activeCount":101},[],{"trials":29277,"activeCount":101},[],{"trials":29279,"activeCount":101},[],{"intervention":29281,"totalTrials":1075,"cells":29282},"Telmisartan\u002Famlodipine fixed-dose combination (FDC)",{"EARLY_PHASE1":29283,"PHASE1":29285,"PHASE2":29300,"PHASE3":29302,"PHASE4":29304,"NA":29306},{"trials":29284,"activeCount":101},[],{"trials":29286,"activeCount":101},[29287,29293],{"nctId":29288,"briefTitle":29289,"status":107,"phases":29290,"primaryCompletion":9418,"start":4516,"enrollment":357,"conditions":29291,"interventions":29292},"NCT02259803","Relative Bioavailability of Telmisartan\u002FAmlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers",[90],[15],[29281,6121,10908],{"nctId":29294,"briefTitle":29295,"status":107,"phases":29296,"primaryCompletion":3763,"start":8911,"enrollment":357,"conditions":29297,"interventions":29298},"NCT02259790","Bioavailability of Telmisartan\u002FAmlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers",[90],[15],[29299,6121,10908],"Telmisartan\u002Famlodipine fixed-dose combination",{"trials":29301,"activeCount":101},[],{"trials":29303,"activeCount":101},[],{"trials":29305,"activeCount":101},[],{"trials":29307,"activeCount":101},[],{"intervention":29309,"totalTrials":1075,"cells":29310},"Ticagrelor",{"EARLY_PHASE1":29311,"PHASE1":29313,"PHASE2":29328,"PHASE3":29330,"PHASE4":29332,"NA":29334},{"trials":29312,"activeCount":101},[],{"trials":29314,"activeCount":101},[29315,29321],{"nctId":29316,"briefTitle":29317,"status":107,"phases":29318,"primaryCompletion":456,"completion":456,"start":2506,"enrollment":448,"conditions":29319,"interventions":29320},"NCT01595854","Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran",[90],[15],[1685,29309,29309,1685,1685],{"nctId":29322,"briefTitle":29323,"status":107,"phases":29324,"primaryCompletion":525,"completion":525,"start":446,"enrollment":410,"conditions":29325,"interventions":29326},"NCT01734772","Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor",[90],[15],[1685,1685,29327,29327,29327,1685],"ticagrelor",{"trials":29329,"activeCount":101},[],{"trials":29331,"activeCount":101},[],{"trials":29333,"activeCount":101},[],{"trials":29335,"activeCount":101},[],{"intervention":29337,"totalTrials":1075,"cells":29338},"BI 1356 BS",{"EARLY_PHASE1":29339,"PHASE1":29341,"PHASE2":29355,"PHASE3":29357,"PHASE4":29359,"NA":29361},{"trials":29340,"activeCount":101},[],{"trials":29342,"activeCount":101},[29343,29349],{"nctId":29344,"briefTitle":29345,"status":107,"phases":29346,"primaryCompletion":3991,"start":3991,"enrollment":188,"conditions":29347,"interventions":29348},"NCT02183532","Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers",[90],[15],[29337,29337],{"nctId":29350,"briefTitle":29351,"status":107,"phases":29352,"primaryCompletion":4462,"start":1981,"enrollment":401,"conditions":29353,"interventions":29354},"NCT02183506","Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers",[90],[15],[413,29337],{"trials":29356,"activeCount":101},[],{"trials":29358,"activeCount":101},[],{"trials":29360,"activeCount":101},[],{"trials":29362,"activeCount":101},[],{"intervention":4501,"totalTrials":1075,"cells":29364},{"EARLY_PHASE1":29365,"PHASE1":29367,"PHASE2":29379,"PHASE3":29381,"PHASE4":29383,"NA":29385},{"trials":29366,"activeCount":101},[],{"trials":29368,"activeCount":101},[29369,29375],{"nctId":29370,"briefTitle":29371,"status":107,"phases":29372,"primaryCompletion":399,"start":9443,"enrollment":1865,"conditions":29373,"interventions":29374},"NCT02171572","Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects",[90],[15],[4501,4502],{"nctId":4495,"briefTitle":4496,"status":107,"phases":29376,"primaryCompletion":4498,"start":4461,"enrollment":2382,"conditions":29377,"interventions":29378},[90],[15],[4501,4502,1538],{"trials":29380,"activeCount":101},[],{"trials":29382,"activeCount":101},[],{"trials":29384,"activeCount":101},[],{"trials":29386,"activeCount":101},[],{"intervention":4502,"totalTrials":1075,"cells":29388},{"EARLY_PHASE1":29389,"PHASE1":29391,"PHASE2":29401,"PHASE3":29403,"PHASE4":29405,"NA":29407},{"trials":29390,"activeCount":101},[],{"trials":29392,"activeCount":101},[29393,29397],{"nctId":29370,"briefTitle":29371,"status":107,"phases":29394,"primaryCompletion":399,"start":9443,"enrollment":1865,"conditions":29395,"interventions":29396},[90],[15],[4501,4502],{"nctId":4495,"briefTitle":4496,"status":107,"phases":29398,"primaryCompletion":4498,"start":4461,"enrollment":2382,"conditions":29399,"interventions":29400},[90],[15],[4501,4502,1538],{"trials":29402,"activeCount":101},[],{"trials":29404,"activeCount":101},[],{"trials":29406,"activeCount":101},[],{"trials":29408,"activeCount":101},[],{"intervention":29410,"totalTrials":1075,"cells":29411},"Hydrochlorthiazide",{"EARLY_PHASE1":29412,"PHASE1":29414,"PHASE2":29430,"PHASE3":29432,"PHASE4":29434,"NA":29436},{"trials":29413,"activeCount":101},[],{"trials":29415,"activeCount":101},[29416,29423],{"nctId":29417,"briefTitle":29418,"status":107,"phases":29419,"primaryCompletion":7618,"start":9276,"enrollment":357,"conditions":29420,"interventions":29421},"NCT02262598","Bioequivalence of Telmisartan \u002F HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers",[90],[15],[6121,29410,29422],"Telmisartan\u002FHCTZ fixed dose",{"nctId":29424,"briefTitle":29425,"status":107,"phases":29426,"primaryCompletion":17247,"start":17247,"enrollment":448,"conditions":29427,"interventions":29428},"NCT02262624","Bioequivalence of Telmisartan \u002F HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers",[90],[15],[6121,29410,29429],"Telmisartan\u002FHCTZ fixed combination",{"trials":29431,"activeCount":101},[],{"trials":29433,"activeCount":101},[],{"trials":29435,"activeCount":101},[],{"trials":29437,"activeCount":101},[],{"intervention":29439,"totalTrials":1075,"cells":29440},"BI 44370",{"EARLY_PHASE1":29441,"PHASE1":29443,"PHASE2":29458,"PHASE3":29460,"PHASE4":29462,"NA":29464},{"trials":29442,"activeCount":101},[],{"trials":29444,"activeCount":101},[29445,29452],{"nctId":29446,"briefTitle":29447,"status":107,"phases":29448,"primaryCompletion":6471,"start":4507,"enrollment":188,"conditions":29449,"interventions":29450},"NCT02215746","Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers",[90],[15],[29451,29439],"BI 44370 powder for oral solution",{"nctId":29453,"briefTitle":29454,"status":107,"phases":29455,"primaryCompletion":10775,"start":5856,"enrollment":97,"conditions":29456,"interventions":29457},"NCT02215031","Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers",[90],[15],[29439],{"trials":29459,"activeCount":101},[],{"trials":29461,"activeCount":101},[],{"trials":29463,"activeCount":101},[],{"trials":29465,"activeCount":101},[],{"intervention":29467,"totalTrials":1075,"cells":29468},"BEA 2180 BR - rising dose",{"EARLY_PHASE1":29469,"PHASE1":29471,"PHASE2":29485,"PHASE3":29487,"PHASE4":29489,"NA":29491},{"trials":29470,"activeCount":101},[],{"trials":29472,"activeCount":101},[29473,29479],{"nctId":29474,"briefTitle":29475,"status":107,"phases":29476,"primaryCompletion":4412,"start":6471,"enrollment":448,"conditions":29477,"interventions":29478},"NCT02254109","Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers",[90],[15],[29467],{"nctId":29480,"briefTitle":29481,"status":107,"phases":29482,"primaryCompletion":7573,"start":20181,"enrollment":380,"conditions":29483,"interventions":29484},"NCT02254135","Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers",[90],[15],[29467],{"trials":29486,"activeCount":101},[],{"trials":29488,"activeCount":101},[],{"trials":29490,"activeCount":101},[],{"trials":29492,"activeCount":101},[],{"intervention":3996,"totalTrials":1075,"cells":29494},{"EARLY_PHASE1":29495,"PHASE1":29497,"PHASE2":29507,"PHASE3":29509,"PHASE4":29511,"NA":29513},{"trials":29496,"activeCount":101},[],{"trials":29498,"activeCount":101},[29499,29503],{"nctId":3987,"briefTitle":3988,"status":162,"phases":29500,"primaryCompletion":3990,"start":3991,"enrollment":3398,"conditions":29501,"interventions":29502},[90],[15],[3994,3995,1242,3996],{"nctId":4035,"briefTitle":4036,"status":107,"phases":29504,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":29505,"interventions":29506},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"trials":29508,"activeCount":101},[],{"trials":29510,"activeCount":101},[],{"trials":29512,"activeCount":101},[],{"trials":29514,"activeCount":101},[],{"intervention":29516,"totalTrials":1075,"cells":29517},"BI 1356 BS -",{"EARLY_PHASE1":29518,"PHASE1":29520,"PHASE2":29536,"PHASE3":29538,"PHASE4":29540,"NA":29542},{"trials":29519,"activeCount":101},[],{"trials":29521,"activeCount":101},[29522,29529],{"nctId":29523,"briefTitle":29524,"status":107,"phases":29525,"primaryCompletion":6413,"start":7618,"enrollment":1208,"conditions":29526,"interventions":29527},"NCT02173665","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects",[90],[15],[29528,29516],"BI 1356 BS - Powder in bottle",{"nctId":29530,"briefTitle":29531,"status":107,"phases":29532,"primaryCompletion":2145,"start":4498,"enrollment":448,"conditions":29533,"interventions":29534},"NCT02183298","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers",[90],[15],[29535,29516],"BI 1356 BS - intravenous",{"trials":29537,"activeCount":101},[],{"trials":29539,"activeCount":101},[],{"trials":29541,"activeCount":101},[],{"trials":29543,"activeCount":101},[],{"intervention":28416,"totalTrials":1075,"cells":29545},{"EARLY_PHASE1":29546,"PHASE1":29548,"PHASE2":29558,"PHASE3":29560,"PHASE4":29562,"NA":29564},{"trials":29547,"activeCount":101},[],{"trials":29549,"activeCount":101},[29550,29554],{"nctId":28411,"briefTitle":28412,"status":107,"phases":29551,"primaryCompletion":8911,"start":1114,"enrollment":380,"conditions":29552,"interventions":29553},[90],[15],[28404,28416],{"nctId":28424,"briefTitle":28425,"status":107,"phases":29555,"primaryCompletion":6116,"start":6910,"enrollment":37,"conditions":29556,"interventions":29557},[90],[15],[28416,28404],{"trials":29559,"activeCount":101},[],{"trials":29561,"activeCount":101},[],{"trials":29563,"activeCount":101},[],{"trials":29565,"activeCount":101},[],{"intervention":29567,"totalTrials":1075,"cells":29568},"BIBV 308 SE solution",{"EARLY_PHASE1":29569,"PHASE1":29571,"PHASE2":29589,"PHASE3":29591,"PHASE4":29593,"NA":29595},{"trials":29570,"activeCount":101},[],{"trials":29572,"activeCount":101},[29573,29581],{"nctId":29574,"briefTitle":29575,"status":107,"phases":29576,"primaryCompletion":9235,"start":2182,"enrollment":1340,"conditions":29577,"interventions":29578},"NCT02223013","Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects",[90],[15],[29567,29579,29580],"BIBV 308 SE capsule L","BIBV 308 SE capsule S",{"nctId":29582,"briefTitle":29583,"status":107,"phases":29584,"primaryCompletion":6074,"start":21407,"enrollment":1340,"conditions":29585,"interventions":29586},"NCT02223000","Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects",[90],[15],[29567,29587,29588],"BIBV 308 SE capsule 1","BIBV 308 SE capsule 2",{"trials":29590,"activeCount":101},[],{"trials":29592,"activeCount":101},[],{"trials":29594,"activeCount":101},[],{"trials":29596,"activeCount":101},[],{"intervention":5848,"totalTrials":1075,"cells":29598},{"EARLY_PHASE1":29599,"PHASE1":29601,"PHASE2":29611,"PHASE3":29613,"PHASE4":29615,"NA":29617},{"trials":29600,"activeCount":101},[],{"trials":29602,"activeCount":101},[29603,29607],{"nctId":5839,"briefTitle":5840,"status":107,"phases":29604,"primaryCompletion":5842,"start":5843,"enrollment":188,"conditions":29605,"interventions":29606},[90],[15],[5846,5847,5848,5849,5832],{"nctId":11127,"briefTitle":11128,"status":107,"phases":29608,"primaryCompletion":8538,"start":6246,"enrollment":188,"conditions":29609,"interventions":29610},[90],[15],[5848,11113],{"trials":29612,"activeCount":101},[],{"trials":29614,"activeCount":101},[],{"trials":29616,"activeCount":101},[],{"trials":29618,"activeCount":101},[],{"intervention":6120,"totalTrials":1075,"cells":29620},{"EARLY_PHASE1":29621,"PHASE1":29623,"PHASE2":29633,"PHASE3":29635,"PHASE4":29637,"NA":29639},{"trials":29622,"activeCount":101},[],{"trials":29624,"activeCount":101},[29625,29629],{"nctId":6113,"briefTitle":6114,"status":107,"phases":29626,"primaryCompletion":4517,"start":6116,"enrollment":6117,"conditions":29627,"interventions":29628},[90],[15],[6120,6121,6106,6106],{"nctId":6123,"briefTitle":6124,"status":107,"phases":29630,"primaryCompletion":4517,"start":6116,"enrollment":6117,"conditions":29631,"interventions":29632},[90],[15],[6120,6121,6106,6106],{"trials":29634,"activeCount":101},[],{"trials":29636,"activeCount":101},[],{"trials":29638,"activeCount":101},[],{"trials":29640,"activeCount":101},[],{"intervention":6000,"totalTrials":1075,"cells":29642},{"EARLY_PHASE1":29643,"PHASE1":29645,"PHASE2":29655,"PHASE3":29657,"PHASE4":29659,"NA":29661},{"trials":29644,"activeCount":101},[],{"trials":29646,"activeCount":101},[29647,29651],{"nctId":5989,"briefTitle":5990,"status":107,"phases":29648,"primaryCompletion":5992,"start":5993,"enrollment":956,"conditions":29649,"interventions":29650},[90],[15],[5996,5997,5998,5999,6000,5982],{"nctId":6026,"briefTitle":6027,"status":107,"phases":29652,"primaryCompletion":6029,"start":6030,"enrollment":188,"conditions":29653,"interventions":29654},[90],[15],[6033,6034,5982,6035],{"trials":29656,"activeCount":101},[],{"trials":29658,"activeCount":101},[],{"trials":29660,"activeCount":101},[],{"trials":29662,"activeCount":101},[],{"intervention":11046,"totalTrials":1075,"cells":29664},{"EARLY_PHASE1":29665,"PHASE1":29667,"PHASE2":29679,"PHASE3":29681,"PHASE4":29683,"NA":29685},{"trials":29666,"activeCount":101},[],{"trials":29668,"activeCount":101},[29669,29673],{"nctId":11041,"briefTitle":11042,"status":107,"phases":29670,"primaryCompletion":6949,"start":6262,"enrollment":357,"conditions":29671,"interventions":29672},[90],[15],[11046,11034],{"nctId":29674,"briefTitle":29675,"status":107,"phases":29676,"primaryCompletion":6594,"start":6594,"enrollment":1081,"conditions":29677,"interventions":29678},"NCT02218671","Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers",[90],[15],[11046],{"trials":29680,"activeCount":101},[],{"trials":29682,"activeCount":101},[],{"trials":29684,"activeCount":101},[],{"trials":29686,"activeCount":101},[],{"intervention":29688,"totalTrials":1075,"cells":29689},"UHAC 62 XX",{"EARLY_PHASE1":29690,"PHASE1":29692,"PHASE2":29706,"PHASE3":29708,"PHASE4":29710,"NA":29712},{"trials":29691,"activeCount":101},[],{"trials":29693,"activeCount":101},[29694,29700],{"nctId":29695,"briefTitle":29696,"status":107,"phases":29697,"primaryCompletion":6375,"start":6495,"enrollment":1982,"conditions":29698,"interventions":29699},"NCT02187575","Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers",[90],[15],[29688,29688],{"nctId":29701,"briefTitle":29702,"status":107,"phases":29703,"primaryCompletion":6495,"start":5887,"enrollment":123,"conditions":29704,"interventions":29705},"NCT02180490","Bioequivalence Study of UHAC 62 XX Tablets Compared With Capsules in Healthy Volunteers",[90],[15],[29688,29688],{"trials":29707,"activeCount":101},[],{"trials":29709,"activeCount":101},[],{"trials":29711,"activeCount":101},[],{"trials":29713,"activeCount":101},[],{"intervention":29715,"totalTrials":1075,"cells":29716},"BI 765080",{"EARLY_PHASE1":29717,"PHASE1":29719,"PHASE2":29737,"PHASE3":29739,"PHASE4":29741,"NA":29743},{"trials":29718,"activeCount":101},[],{"trials":29720,"activeCount":101},[29721,29729],{"nctId":29722,"briefTitle":29723,"status":107,"phases":29724,"primaryCompletion":29725,"completion":29725,"start":29726,"enrollment":1865,"conditions":29727,"interventions":29728},"NCT05075772","A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein",[90],"2022-03-11","2021-10-25",[15],[29715],{"nctId":29730,"briefTitle":29731,"status":107,"phases":29732,"primaryCompletion":29733,"completion":29733,"start":29734,"enrollment":410,"conditions":29735,"interventions":29736},"NCT04666922","A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080",[90],"2021-08-25","2021-01-14",[15],[29715],{"trials":29738,"activeCount":101},[],{"trials":29740,"activeCount":101},[],{"trials":29742,"activeCount":101},[],{"trials":29744,"activeCount":101},[],{"intervention":4012,"totalTrials":1075,"cells":29746},{"EARLY_PHASE1":29747,"PHASE1":29749,"PHASE2":29759,"PHASE3":29761,"PHASE4":29763,"NA":29765},{"trials":29748,"activeCount":101},[],{"trials":29750,"activeCount":101},[29751,29755],{"nctId":4002,"briefTitle":4003,"status":107,"phases":29752,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":29753,"interventions":29754},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":20197,"briefTitle":20198,"status":107,"phases":29756,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":29757,"interventions":29758},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":29760,"activeCount":101},[],{"trials":29762,"activeCount":101},[],{"trials":29764,"activeCount":101},[],{"trials":29766,"activeCount":101},[],{"intervention":29768,"totalTrials":1075,"cells":29769},"Asasantin®",{"EARLY_PHASE1":29770,"PHASE1":29772,"PHASE2":29788,"PHASE3":29790,"PHASE4":29792,"NA":29794},{"trials":29771,"activeCount":101},[],{"trials":29773,"activeCount":101},[29774,29782],{"nctId":29775,"briefTitle":29776,"status":107,"phases":29777,"primaryCompletion":2122,"start":2181,"enrollment":251,"conditions":29778,"interventions":29779},"NCT02268773","Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers",[90],[15],[29768,29780,29781],"Acetylsalicylic acid low dose","Acetylsalicylic acid high dose",{"nctId":29783,"briefTitle":29784,"status":107,"phases":29785,"primaryCompletion":7022,"start":13117,"enrollment":132,"conditions":29786,"interventions":29787},"NCT02273479","Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers",[90],[15],[29768],{"trials":29789,"activeCount":101},[],{"trials":29791,"activeCount":101},[],{"trials":29793,"activeCount":101},[],{"trials":29795,"activeCount":101},[],{"intervention":29797,"totalTrials":1075,"cells":29798},"BI 3032950",{"EARLY_PHASE1":29799,"PHASE1":29801,"PHASE2":29816,"PHASE3":29818,"PHASE4":29820,"NA":29822},{"trials":29800,"activeCount":101},[],{"trials":29802,"activeCount":101},[29803,29810],{"nctId":29804,"briefTitle":29805,"status":107,"phases":29806,"primaryCompletion":2839,"completion":2839,"start":29807,"enrollment":2382,"conditions":29808,"interventions":29809},"NCT05985200","A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated",[90],"2023-09-15",[15],[29797],{"nctId":29811,"briefTitle":29812,"status":107,"phases":29813,"primaryCompletion":19938,"completion":19938,"start":1479,"enrollment":3755,"conditions":29814,"interventions":29815},"NCT05518708","A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated",[90],[15],[29797],{"trials":29817,"activeCount":101},[],{"trials":29819,"activeCount":101},[],{"trials":29821,"activeCount":101},[],{"trials":29823,"activeCount":101},[],{"intervention":20726,"totalTrials":1075,"cells":29825},{"EARLY_PHASE1":29826,"PHASE1":29828,"PHASE2":29844,"PHASE3":29846,"PHASE4":29848,"NA":29850},{"trials":29827,"activeCount":101},[],{"trials":29829,"activeCount":101},[29830,29834],{"nctId":20717,"briefTitle":20718,"status":107,"phases":29831,"primaryCompletion":20720,"completion":20721,"start":20722,"enrollment":912,"conditions":29832,"interventions":29833},[90],[20724],[20726,20727,1131],{"nctId":29835,"briefTitle":29836,"status":107,"phases":29837,"primaryCompletion":29838,"completion":1315,"start":29839,"enrollment":4219,"conditions":29840,"interventions":29843},"NCT04137289","A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer",[90],"2023-07-26","2020-03-11",[29841,29842,2691],"Gastrointestinal Neoplasms","Cholangiocarcinoma",[20726],{"trials":29845,"activeCount":101},[],{"trials":29847,"activeCount":101},[],{"trials":29849,"activeCount":101},[],{"trials":29851,"activeCount":101},[],{"intervention":27235,"totalTrials":1075,"cells":29853},{"EARLY_PHASE1":29854,"PHASE1":29856,"PHASE2":29866,"PHASE3":29868,"PHASE4":29870,"NA":29872},{"trials":29855,"activeCount":101},[],{"trials":29857,"activeCount":101},[29858,29862],{"nctId":28316,"briefTitle":28317,"status":107,"phases":29859,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":29860,"interventions":29861},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":27227,"briefTitle":27228,"status":107,"phases":29863,"primaryCompletion":27230,"completion":27230,"start":27231,"enrollment":956,"conditions":29864,"interventions":29865},[90],[15],[27234,949,27235,27236],{"trials":29867,"activeCount":101},[],{"trials":29869,"activeCount":101},[],{"trials":29871,"activeCount":101},[],{"trials":29873,"activeCount":101},[],{"intervention":28323,"totalTrials":1075,"cells":29875},{"EARLY_PHASE1":29876,"PHASE1":29878,"PHASE2":29894,"PHASE3":29896,"PHASE4":29898,"NA":29900},{"trials":29877,"activeCount":101},[],{"trials":29879,"activeCount":101},[29880,29884],{"nctId":28316,"briefTitle":28317,"status":107,"phases":29881,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":29882,"interventions":29883},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":29885,"briefTitle":29886,"status":107,"phases":29887,"primaryCompletion":474,"completion":474,"start":420,"enrollment":231,"conditions":29888,"interventions":29889},"NCT02202512","Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers",[90],[15],[28323,29890,29891,29892,29893],"BI 1060469 high dose","BI 1060469 low dose","Naproxen","BI 1021958",{"trials":29895,"activeCount":101},[],{"trials":29897,"activeCount":101},[],{"trials":29899,"activeCount":101},[],{"trials":29901,"activeCount":101},[],{"intervention":5228,"totalTrials":1075,"cells":29903},{"EARLY_PHASE1":29904,"PHASE1":29906,"PHASE2":29916,"PHASE3":29918,"PHASE4":29920,"NA":29922},{"trials":29905,"activeCount":101},[],{"trials":29907,"activeCount":101},[29908,29912],{"nctId":5221,"briefTitle":5222,"status":162,"phases":29909,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":1075,"conditions":29910,"interventions":29911},[90],[36],[5228,78],{"nctId":5237,"briefTitle":5238,"status":107,"phases":29913,"primaryCompletion":649,"completion":5240,"start":5241,"enrollment":5242,"conditions":29914,"interventions":29915},[90],[5244],[5228,78],{"trials":29917,"activeCount":101},[],{"trials":29919,"activeCount":101},[],{"trials":29921,"activeCount":101},[],{"trials":29923,"activeCount":101},[],{"intervention":10009,"totalTrials":1075,"cells":29925},{"EARLY_PHASE1":29926,"PHASE1":29928,"PHASE2":29938,"PHASE3":29940,"PHASE4":29942,"NA":29944},{"trials":29927,"activeCount":101},[],{"trials":29929,"activeCount":101},[29930,29934],{"nctId":20185,"briefTitle":20186,"status":107,"phases":29931,"primaryCompletion":3732,"start":6811,"enrollment":380,"conditions":29932,"interventions":29933},[90],[15],[3995,10009],{"nctId":10004,"briefTitle":10005,"status":107,"phases":29935,"primaryCompletion":409,"completion":409,"start":9614,"enrollment":439,"conditions":29936,"interventions":29937},[90],[15],[10009,10009,4479],{"trials":29939,"activeCount":101},[],{"trials":29941,"activeCount":101},[],{"trials":29943,"activeCount":101},[],{"trials":29945,"activeCount":101},[],{"intervention":4456,"totalTrials":1075,"cells":29947},{"EARLY_PHASE1":29948,"PHASE1":29950,"PHASE2":29960,"PHASE3":29962,"PHASE4":29964,"NA":29966},{"trials":29949,"activeCount":101},[],{"trials":29951,"activeCount":101},[29952,29956],{"nctId":4447,"briefTitle":4448,"status":107,"phases":29953,"primaryCompletion":4450,"completion":4450,"start":4451,"enrollment":37,"conditions":29954,"interventions":29955},[90],[15],[4454,4455,1538,4456],{"nctId":4522,"briefTitle":4523,"status":107,"phases":29957,"primaryCompletion":4516,"start":1114,"enrollment":123,"conditions":29958,"interventions":29959},[90],[15],[4527,4528,1538,4529,4456],{"trials":29961,"activeCount":101},[],{"trials":29963,"activeCount":101},[],{"trials":29965,"activeCount":101},[],{"trials":29967,"activeCount":101},[],{"intervention":4468,"totalTrials":1075,"cells":29969},{"EARLY_PHASE1":29970,"PHASE1":29972,"PHASE2":29987,"PHASE3":29989,"PHASE4":29991,"NA":29993},{"trials":29971,"activeCount":101},[],{"trials":29973,"activeCount":101},[29974,29978],{"nctId":4458,"briefTitle":4459,"status":107,"phases":29975,"primaryCompletion":4461,"start":4462,"enrollment":4463,"conditions":29976,"interventions":29977},[90],[15],[4466,1538,4467,4468],{"nctId":29979,"briefTitle":29980,"status":107,"phases":29981,"primaryCompletion":6156,"start":7151,"enrollment":1418,"conditions":29982,"interventions":29983},"NCT02227017","Relative Bioavailability of Tipranavir (TPV)\u002FRitonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers",[90],[15],[29984,29985,4468,29986],"TPV","TPV solution","RTV solution",{"trials":29988,"activeCount":101},[],{"trials":29990,"activeCount":101},[],{"trials":29992,"activeCount":101},[],{"trials":29994,"activeCount":101},[],{"intervention":29996,"totalTrials":1075,"cells":29997},"BIWH 3",{"EARLY_PHASE1":29998,"PHASE1":30000,"PHASE2":30015,"PHASE3":30017,"PHASE4":30019,"NA":30021},{"trials":29999,"activeCount":101},[],{"trials":30001,"activeCount":101},[30002,30008],{"nctId":30003,"briefTitle":30004,"status":107,"phases":30005,"primaryCompletion":6472,"start":6871,"enrollment":448,"conditions":30006,"interventions":30007},"NCT02249117","Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers",[90],[15],[29996],{"nctId":30009,"briefTitle":30010,"status":162,"phases":30011,"primaryCompletion":6374,"start":6189,"enrollment":112,"conditions":30012,"interventions":30014},"NCT02215824","Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia",[90],[30013],"Peripheral Arterial Disease",[29996],{"trials":30016,"activeCount":101},[],{"trials":30018,"activeCount":101},[],{"trials":30020,"activeCount":101},[],{"trials":30022,"activeCount":101},[],{"intervention":9784,"totalTrials":1075,"cells":30024},{"EARLY_PHASE1":30025,"PHASE1":30027,"PHASE2":30040,"PHASE3":30042,"PHASE4":30044,"NA":30046},{"trials":30026,"activeCount":101},[],{"trials":30028,"activeCount":101},[30029,30036],{"nctId":30030,"briefTitle":30031,"status":107,"phases":30032,"primaryCompletion":9752,"start":9340,"enrollment":392,"conditions":30033,"interventions":30034},"NCT01328184","Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon",[90],[15],[9784,9784,9785,30035,9785],"Microgynon + BI 10773",{"nctId":9779,"briefTitle":9780,"status":107,"phases":30037,"primaryCompletion":447,"completion":447,"start":4038,"enrollment":401,"conditions":30038,"interventions":30039},[90],[4040],[9784,9785,9784,4042,9785],{"trials":30041,"activeCount":101},[],{"trials":30043,"activeCount":101},[],{"trials":30045,"activeCount":101},[],{"trials":30047,"activeCount":101},[],{"intervention":9785,"totalTrials":1075,"cells":30049},{"EARLY_PHASE1":30050,"PHASE1":30052,"PHASE2":30062,"PHASE3":30064,"PHASE4":30066,"NA":30068},{"trials":30051,"activeCount":101},[],{"trials":30053,"activeCount":101},[30054,30058],{"nctId":30030,"briefTitle":30031,"status":107,"phases":30055,"primaryCompletion":9752,"start":9340,"enrollment":392,"conditions":30056,"interventions":30057},[90],[15],[9784,9784,9785,30035,9785],{"nctId":9779,"briefTitle":9780,"status":107,"phases":30059,"primaryCompletion":447,"completion":447,"start":4038,"enrollment":401,"conditions":30060,"interventions":30061},[90],[4040],[9784,9785,9784,4042,9785],{"trials":30063,"activeCount":101},[],{"trials":30065,"activeCount":101},[],{"trials":30067,"activeCount":101},[],{"trials":30069,"activeCount":101},[],{"intervention":30071,"totalTrials":1075,"cells":30072},"BI 1356 BS - single rising dose",{"EARLY_PHASE1":30073,"PHASE1":30075,"PHASE2":30090,"PHASE3":30092,"PHASE4":30094,"NA":30096},{"trials":30074,"activeCount":101},[],{"trials":30076,"activeCount":101},[30077,30084],{"nctId":30078,"briefTitle":30079,"status":107,"phases":30080,"primaryCompletion":1990,"start":2111,"enrollment":37,"conditions":30081,"interventions":30082},"NCT02183311","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers",[90],[15],[30071,30083],"BI 1356 BS - multiple rising dose",{"nctId":30085,"briefTitle":30086,"status":107,"phases":30087,"primaryCompletion":3978,"start":11581,"enrollment":4433,"conditions":30088,"interventions":30089},"NCT02183350","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes",[90],[21],[30071],{"trials":30091,"activeCount":101},[],{"trials":30093,"activeCount":101},[],{"trials":30095,"activeCount":101},[],{"trials":30097,"activeCount":101},[],{"intervention":30099,"totalTrials":1075,"cells":30100},"BI 135585 XX",{"EARLY_PHASE1":30101,"PHASE1":30103,"PHASE2":30117,"PHASE3":30119,"PHASE4":30121,"NA":30123},{"trials":30102,"activeCount":101},[],{"trials":30104,"activeCount":101},[30105,30111],{"nctId":30106,"briefTitle":30107,"status":107,"phases":30108,"primaryCompletion":9340,"start":9332,"enrollment":410,"conditions":30109,"interventions":30110},"NCT01291732","Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.",[90],[15],[30099],{"nctId":30112,"briefTitle":30113,"status":107,"phases":30114,"primaryCompletion":2001,"completion":2001,"start":9491,"enrollment":1340,"conditions":30115,"interventions":30116},"NCT01652742","Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX",[90],[15],[30099],{"trials":30118,"activeCount":101},[],{"trials":30120,"activeCount":101},[],{"trials":30122,"activeCount":101},[],{"trials":30124,"activeCount":101},[],{"intervention":3874,"totalTrials":1075,"cells":30126},{"EARLY_PHASE1":30127,"PHASE1":30129,"PHASE2":30144,"PHASE3":30146,"PHASE4":30148,"NA":30150},{"trials":30128,"activeCount":101},[],{"trials":30130,"activeCount":101},[30131,30135],{"nctId":3866,"briefTitle":3867,"status":162,"phases":30132,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":155,"conditions":30133,"interventions":30134},[90],[3872],[3859,3874],{"nctId":30136,"briefTitle":30137,"status":107,"phases":30138,"primaryCompletion":30139,"completion":30140,"start":30141,"enrollment":956,"conditions":30142,"interventions":30143},"NCT04742556","A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS\u002FKRAS Mutation Positive)",[90],"2022-10-13","2022-10-20","2021-03-15",[3872],[3874],{"trials":30145,"activeCount":101},[],{"trials":30147,"activeCount":101},[],{"trials":30149,"activeCount":101},[],{"trials":30151,"activeCount":101},[],{"intervention":30153,"totalTrials":1075,"cells":30154},"BI 853520",{"EARLY_PHASE1":30155,"PHASE1":30157,"PHASE2":30171,"PHASE3":30173,"PHASE4":30175,"NA":30177},{"trials":30156,"activeCount":101},[],{"trials":30158,"activeCount":101},[30159,30165],{"nctId":30160,"briefTitle":30161,"status":107,"phases":30162,"primaryCompletion":438,"completion":2031,"start":9752,"enrollment":8,"conditions":30163,"interventions":30164},"NCT01335269","A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer",[90],[33],[30153],{"nctId":30166,"briefTitle":30167,"status":107,"phases":30168,"primaryCompletion":3731,"completion":3731,"start":3762,"enrollment":3454,"conditions":30169,"interventions":30170},"NCT01905111","A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer",[90],[33],[30153],{"trials":30172,"activeCount":101},[],{"trials":30174,"activeCount":101},[],{"trials":30176,"activeCount":101},[],{"trials":30178,"activeCount":101},[],{"intervention":29893,"totalTrials":1075,"cells":30180},{"EARLY_PHASE1":30181,"PHASE1":30183,"PHASE2":30195,"PHASE3":30197,"PHASE4":30199,"NA":30201},{"trials":30182,"activeCount":101},[],{"trials":30184,"activeCount":101},[30185,30189],{"nctId":29885,"briefTitle":29886,"status":107,"phases":30186,"primaryCompletion":474,"completion":474,"start":420,"enrollment":231,"conditions":30187,"interventions":30188},[90],[15],[28323,29890,29891,29892,29893],{"nctId":30190,"briefTitle":30191,"status":107,"phases":30192,"primaryCompletion":2506,"start":9538,"enrollment":3565,"conditions":30193,"interventions":30194},"NCT01541488","Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers",[90],[15],[29893,29893],{"trials":30196,"activeCount":101},[],{"trials":30198,"activeCount":101},[],{"trials":30200,"activeCount":101},[],{"trials":30202,"activeCount":101},[],{"intervention":30204,"totalTrials":1075,"cells":30205},"Linagliptin\u002FMetformin ER FDC",{"EARLY_PHASE1":30206,"PHASE1":30208,"PHASE2":30223,"PHASE3":30225,"PHASE4":30227,"NA":30229},{"trials":30207,"activeCount":101},[],{"trials":30209,"activeCount":101},[30210,30217],{"nctId":30211,"briefTitle":30212,"status":107,"phases":30213,"primaryCompletion":5233,"completion":5233,"start":10024,"enrollment":2400,"conditions":30214,"interventions":30215},"NCT02084082","Bioequivalence of a FDC Tablet of Linagliptin\u002FMetformin (5mg\u002F1000mg) Extended Release in Healthy Subjects",[90],[15],[30204,361,30216],"Metformin ER",{"nctId":30218,"briefTitle":30219,"status":107,"phases":30220,"primaryCompletion":5233,"completion":5233,"start":9842,"enrollment":6702,"conditions":30221,"interventions":30222},"NCT02121509","Bioequivalence of a FDC Tablet of Linagliptin\u002FMetformin (2.5mg\u002F750mg) Extended Release in Healthy Subjects",[90],[15],[361,30204,30216],{"trials":30224,"activeCount":101},[],{"trials":30226,"activeCount":101},[],{"trials":30228,"activeCount":101},[],{"trials":30230,"activeCount":101},[],{"intervention":30216,"totalTrials":1075,"cells":30232},{"EARLY_PHASE1":30233,"PHASE1":30235,"PHASE2":30245,"PHASE3":30247,"PHASE4":30249,"NA":30251},{"trials":30234,"activeCount":101},[],{"trials":30236,"activeCount":101},[30237,30241],{"nctId":30211,"briefTitle":30212,"status":107,"phases":30238,"primaryCompletion":5233,"completion":5233,"start":10024,"enrollment":2400,"conditions":30239,"interventions":30240},[90],[15],[30204,361,30216],{"nctId":30218,"briefTitle":30219,"status":107,"phases":30242,"primaryCompletion":5233,"completion":5233,"start":9842,"enrollment":6702,"conditions":30243,"interventions":30244},[90],[15],[361,30204,30216],{"trials":30246,"activeCount":101},[],{"trials":30248,"activeCount":101},[],{"trials":30250,"activeCount":101},[],{"trials":30252,"activeCount":101},[],{"intervention":30254,"totalTrials":1075,"cells":30255},"BI 224436",{"EARLY_PHASE1":30256,"PHASE1":30258,"PHASE2":30272,"PHASE3":30274,"PHASE4":30276,"NA":30278},{"trials":30257,"activeCount":101},[],{"trials":30259,"activeCount":101},[30260,30266],{"nctId":30261,"briefTitle":30262,"status":107,"phases":30263,"primaryCompletion":3732,"start":399,"enrollment":3389,"conditions":30264,"interventions":30265},"NCT02183662","Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.",[90],[15],[30254],{"nctId":30267,"briefTitle":30268,"status":600,"phases":30269,"primaryCompletion":2001,"start":6133,"enrollment":101,"conditions":30270,"interventions":30271},"NCT01276990","Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.",[90],[27,15],[30254,30254,30254,30254,30254,30254,30254,30254,30254],{"trials":30273,"activeCount":101},[],{"trials":30275,"activeCount":101},[],{"trials":30277,"activeCount":101},[],{"trials":30279,"activeCount":101},[],{"intervention":19390,"totalTrials":1075,"cells":30281},{"EARLY_PHASE1":30282,"PHASE1":30284,"PHASE2":30294,"PHASE3":30296,"PHASE4":30298,"NA":30300},{"trials":30283,"activeCount":101},[],{"trials":30285,"activeCount":101},[30286,30290],{"nctId":19385,"briefTitle":19386,"status":107,"phases":30287,"primaryCompletion":419,"completion":419,"start":9824,"enrollment":1429,"conditions":30288,"interventions":30289},[90],[10445],[19360,19390],{"nctId":19392,"briefTitle":19393,"status":107,"phases":30291,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":439,"conditions":30292,"interventions":30293},[90],[15],[19400,19360,19390],{"trials":30295,"activeCount":101},[],{"trials":30297,"activeCount":101},[],{"trials":30299,"activeCount":101},[],{"trials":30301,"activeCount":101},[],{"intervention":19212,"totalTrials":1075,"cells":30303},{"EARLY_PHASE1":30304,"PHASE1":30306,"PHASE2":30320,"PHASE3":30322,"PHASE4":30324,"NA":30326},{"trials":30305,"activeCount":101},[],{"trials":30307,"activeCount":101},[30308,30316],{"nctId":30309,"briefTitle":30310,"status":600,"phases":30311,"primaryCompletion":419,"completion":419,"start":10024,"enrollment":101,"conditions":30312,"interventions":30313},"NCT02114671","A Study to Investigate the Phototoxic Potential of Faldaprevir",[90],[15],[30314,19212,30315],"Faldaprevir high dose","Faldaprevir low dose",{"nctId":19205,"briefTitle":19206,"status":107,"phases":30317,"primaryCompletion":19208,"completion":19208,"start":19209,"enrollment":1468,"conditions":30318,"interventions":30319},[90],[15],[4109,19212],{"trials":30321,"activeCount":101},[],{"trials":30323,"activeCount":101},[],{"trials":30325,"activeCount":101},[],{"trials":30327,"activeCount":101},[],{"intervention":13251,"totalTrials":1075,"cells":30329},{"EARLY_PHASE1":30330,"PHASE1":30332,"PHASE2":30348,"PHASE3":30350,"PHASE4":30352,"NA":30354},{"trials":30331,"activeCount":101},[],{"trials":30333,"activeCount":101},[30334,30338],{"nctId":13245,"briefTitle":13246,"status":107,"phases":30335,"primaryCompletion":3731,"completion":420,"start":9842,"enrollment":716,"conditions":30336,"interventions":30337},[90],[15],[13238,13250,13251],{"nctId":30339,"briefTitle":30340,"status":107,"phases":30341,"primaryCompletion":3731,"completion":3731,"start":10024,"enrollment":716,"conditions":30342,"interventions":30343},"NCT02121535","Bioequivalence Study of Telmisartan Between T80\u002FA5\u002FH12.5 mg FDC Tablet and T80\u002FA5 mg Tab and H12.5 mg Tab Concomitant Use",[90],[15],[30344,30344,30345,30346,30347,13251],"T80\u002FA5 mg FDC","H12.5 mg","T80\u002FA5\u002FH12.5 ng FDC","H12.5 mf",{"trials":30349,"activeCount":101},[],{"trials":30351,"activeCount":101},[],{"trials":30353,"activeCount":101},[],{"trials":30355,"activeCount":101},[],{"intervention":30357,"totalTrials":1075,"cells":30358},"BI 655075",{"EARLY_PHASE1":30359,"PHASE1":30361,"PHASE2":30376,"PHASE3":30378,"PHASE4":30380,"NA":30382},{"trials":30360,"activeCount":101},[],{"trials":30362,"activeCount":101},[30363,30370],{"nctId":30364,"briefTitle":30365,"status":107,"phases":30366,"primaryCompletion":9842,"completion":3731,"start":611,"enrollment":1094,"conditions":30367,"interventions":30369},"NCT01955720","Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran",[90],[30368],"Hemorrhage",[30357,30357,30357,30357],{"nctId":30371,"briefTitle":30372,"status":107,"phases":30373,"primaryCompletion":378,"completion":378,"start":2001,"enrollment":13515,"conditions":30374,"interventions":30375},"NCT01688830","Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate",[90],[15],[29142,30357],{"trials":30377,"activeCount":101},[],{"trials":30379,"activeCount":101},[],{"trials":30381,"activeCount":101},[],{"trials":30383,"activeCount":101},[],{"intervention":30385,"totalTrials":1075,"cells":30386},"BI 3810477",{"EARLY_PHASE1":30387,"PHASE1":30389,"PHASE2":30407,"PHASE3":30409,"PHASE4":30411,"NA":30413},{"trials":30388,"activeCount":101},[],{"trials":30390,"activeCount":101},[30391,30399],{"nctId":30392,"briefTitle":30393,"status":107,"phases":30394,"primaryCompletion":30395,"completion":30395,"start":30396,"enrollment":4433,"conditions":30397,"interventions":30398},"NCT06984926","A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults",[90],"2026-03-09","2025-06-06",[15],[30385],{"nctId":30400,"briefTitle":30401,"status":107,"phases":30402,"primaryCompletion":30403,"completion":30403,"start":30404,"enrollment":380,"conditions":30405,"interventions":30406},"NCT06631430","A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men",[90],"2025-06-12","2024-10-30",[15],[30385,30385],{"trials":30408,"activeCount":101},[],{"trials":30410,"activeCount":101},[],{"trials":30412,"activeCount":101},[],{"trials":30414,"activeCount":101},[],{"intervention":1240,"totalTrials":1075,"cells":30416},{"EARLY_PHASE1":30417,"PHASE1":30419,"PHASE2":30429,"PHASE3":30431,"PHASE4":30433,"NA":30435},{"trials":30418,"activeCount":101},[],{"trials":30420,"activeCount":101},[30421,30425],{"nctId":1231,"briefTitle":1232,"status":107,"phases":30422,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":30423,"interventions":30424},[90],[1228,539],[1195,1240,1241,1242],{"nctId":4144,"briefTitle":4145,"status":107,"phases":30426,"primaryCompletion":965,"completion":965,"start":2922,"enrollment":392,"conditions":30427,"interventions":30428},[90],[15],[4149,4150,1242,1240],{"trials":30430,"activeCount":101},[],{"trials":30432,"activeCount":101},[],{"trials":30434,"activeCount":101},[],{"trials":30436,"activeCount":101},[],{"intervention":30438,"totalTrials":1075,"cells":30439},"1 tablet Empagliflozin\u002F2 tablets Metformin XR",{"EARLY_PHASE1":30440,"PHASE1":30442,"PHASE2":30463,"PHASE3":30465,"PHASE4":30467,"NA":30469},{"trials":30441,"activeCount":101},[],{"trials":30443,"activeCount":101},[30444,30454],{"nctId":30445,"briefTitle":30446,"status":107,"phases":30447,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":716,"conditions":30448,"interventions":30449},"NCT01975220","Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin\u002FMetformin Compared With Single Tablets",[90],[15],[30450,30451,30452,30438,30453,30438],"Empagliflozin\u002FMetformin XR, FDC","Empagliflozin\u002FMetformin XR FDC","25 mg Empagliflozin\u002F1000 mg Metformin XR, FDC","1 tablet Empagliflozin\u002F3 tablets Metformin XR",{"nctId":30455,"briefTitle":30456,"status":107,"phases":30457,"primaryCompletion":4391,"completion":5233,"start":10024,"enrollment":716,"conditions":30458,"interventions":30459},"NCT02106923","Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin\u002FMetformin Extended Release (XR) Compared With Single Tablets",[90],[15],[30438,30460,30461,30462,30438,30460],"10 mg Empagliflozin\u002F1000 mg Metformin XR","1 tablet 10 mg Empagliflozin\u002F3 tablets Metformin XR","2 tablets 5 mg Empagliflozin\u002F750 Metformin XR",{"trials":30464,"activeCount":101},[],{"trials":30466,"activeCount":101},[],{"trials":30468,"activeCount":101},[],{"trials":30470,"activeCount":101},[],{"intervention":30472,"totalTrials":1075,"cells":30473},"Asasantin ER, present commercial formulation",{"EARLY_PHASE1":30474,"PHASE1":30476,"PHASE2":30493,"PHASE3":30495,"PHASE4":30497,"NA":30499},{"trials":30475,"activeCount":101},[],{"trials":30477,"activeCount":101},[30478,30485],{"nctId":30479,"briefTitle":30480,"status":107,"phases":30481,"primaryCompletion":6401,"start":2112,"enrollment":380,"conditions":30482,"interventions":30483},"NCT02273531","Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers",[90],[15],[30484,30472],"Asasantin ER, new formulation",{"nctId":30486,"briefTitle":30487,"status":107,"phases":30488,"primaryCompletion":6701,"start":6005,"enrollment":392,"conditions":30489,"interventions":30490},"NCT02273518","Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers",[90],[15],[30491,30492,30472],"Asasantin ER, new formulation I","Asasantin ER, new formulation II",{"trials":30494,"activeCount":101},[],{"trials":30496,"activeCount":101},[],{"trials":30498,"activeCount":101},[],{"trials":30500,"activeCount":101},[],{"intervention":10393,"totalTrials":1075,"cells":30502},{"EARLY_PHASE1":30503,"PHASE1":30505,"PHASE2":30515,"PHASE3":30517,"PHASE4":30519,"NA":30521},{"trials":30504,"activeCount":101},[],{"trials":30506,"activeCount":101},[30507,30511],{"nctId":10388,"briefTitle":10389,"status":107,"phases":30508,"primaryCompletion":7703,"start":1967,"enrollment":4433,"conditions":30509,"interventions":30510},[90],[15],[10368,10368,10393,10393],{"nctId":10403,"briefTitle":10404,"status":107,"phases":30512,"primaryCompletion":3387,"completion":10406,"start":10407,"enrollment":37,"conditions":30513,"interventions":30514},[90],[10409],[10368,10393],{"trials":30516,"activeCount":101},[],{"trials":30518,"activeCount":101},[],{"trials":30520,"activeCount":101},[],{"trials":30522,"activeCount":101},[],{"intervention":30524,"totalTrials":1075,"cells":30525},"BIBB 515 BS",{"EARLY_PHASE1":30526,"PHASE1":30528,"PHASE2":30543,"PHASE3":30545,"PHASE4":30547,"NA":30549},{"trials":30527,"activeCount":101},[],{"trials":30529,"activeCount":101},[30530,30537],{"nctId":30531,"briefTitle":30532,"status":107,"phases":30533,"primaryCompletion":7084,"start":6074,"enrollment":123,"conditions":30534,"interventions":30535},"NCT02266485","Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects",[90],[15],[30524,30536],"Pravastatin",{"nctId":30538,"briefTitle":30539,"status":107,"phases":30540,"primaryCompletion":6074,"start":6064,"enrollment":155,"conditions":30541,"interventions":30542},"NCT02266498","Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects",[90],[15],[30524],{"trials":30544,"activeCount":101},[],{"trials":30546,"activeCount":101},[],{"trials":30548,"activeCount":101},[],{"trials":30550,"activeCount":101},[],{"intervention":30536,"totalTrials":1075,"cells":30552},{"EARLY_PHASE1":30553,"PHASE1":30555,"PHASE2":30570,"PHASE3":30572,"PHASE4":30574,"NA":30576},{"trials":30554,"activeCount":101},[],{"trials":30556,"activeCount":101},[30557,30561],{"nctId":30531,"briefTitle":30532,"status":107,"phases":30558,"primaryCompletion":7084,"start":6074,"enrollment":123,"conditions":30559,"interventions":30560},[90],[15],[30524,30536],{"nctId":30562,"briefTitle":30563,"status":107,"phases":30564,"primaryCompletion":2122,"start":2181,"enrollment":1218,"conditions":30565,"interventions":30566},"NCT02229773","Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects",[90],[15],[30567,30536,30568,30569],"BIBB 1464 MS low dose","BIBB 1464 MS medium dose","BIBB 1464 MS high dose",{"trials":30571,"activeCount":101},[],{"trials":30573,"activeCount":101},[],{"trials":30575,"activeCount":101},[],{"trials":30577,"activeCount":101},[],{"intervention":1675,"totalTrials":1075,"cells":30579},{"EARLY_PHASE1":30580,"PHASE1":30582,"PHASE2":30592,"PHASE3":30594,"PHASE4":30596,"NA":30598},{"trials":30581,"activeCount":101},[],{"trials":30583,"activeCount":101},[30584,30588],{"nctId":1667,"briefTitle":1668,"status":107,"phases":30585,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":30586,"interventions":30587},[90],[15],[1595,1675],{"nctId":29050,"briefTitle":29051,"status":107,"phases":30589,"enrollment":448,"conditions":30590,"interventions":30591},[90],[27],[29055,2186,29031],{"trials":30593,"activeCount":101},[],{"trials":30595,"activeCount":101},[],{"trials":30597,"activeCount":101},[],{"trials":30599,"activeCount":101},[],{"intervention":19863,"totalTrials":1075,"cells":30601},{"EARLY_PHASE1":30602,"PHASE1":30604,"PHASE2":30619,"PHASE3":30621,"PHASE4":30623,"NA":30625},{"trials":30603,"activeCount":101},[],{"trials":30605,"activeCount":101},[30606,30615],{"nctId":30607,"briefTitle":30608,"status":107,"phases":30609,"primaryCompletion":30610,"completion":30610,"start":30611,"enrollment":188,"conditions":30612,"interventions":30614},"NCT04138823","A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)",[90],"2023-05-17","2019-11-26",[30613],"Neoplasm",[19863],{"nctId":19855,"briefTitle":19856,"status":162,"phases":30616,"primaryCompletion":19858,"completion":19859,"start":19860,"enrollment":31,"conditions":30617,"interventions":30618},[90],[33,938,36],[19863,3845],{"trials":30620,"activeCount":101},[],{"trials":30622,"activeCount":101},[],{"trials":30624,"activeCount":101},[],{"trials":30626,"activeCount":101},[],{"intervention":4123,"totalTrials":1075,"cells":30628},{"EARLY_PHASE1":30629,"PHASE1":30631,"PHASE2":30646,"PHASE3":30648,"PHASE4":30650,"NA":30652},{"trials":30630,"activeCount":101},[],{"trials":30632,"activeCount":101},[30633,30637],{"nctId":4115,"briefTitle":4116,"status":600,"phases":30634,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":101,"conditions":30635,"interventions":30636},[90],[15],[4013,4094,4123,1242,4013,4123,1242,1242,4094,4123,2393,2393],{"nctId":30638,"briefTitle":30639,"status":107,"phases":30640,"primaryCompletion":420,"completion":420,"start":4473,"enrollment":7524,"conditions":30641,"interventions":30642},"NCT02044406","Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181",[90],[15],[4123,30643,30644,30645],"BI 1181181, R","BI 1181181, T2","BI 1181181, T1",{"trials":30647,"activeCount":101},[],{"trials":30649,"activeCount":101},[],{"trials":30651,"activeCount":101},[],{"trials":30653,"activeCount":101},[],{"intervention":6432,"totalTrials":1075,"cells":30655},{"EARLY_PHASE1":30656,"PHASE1":30658,"PHASE2":30670,"PHASE3":30672,"PHASE4":30674,"NA":30676},{"trials":30657,"activeCount":101},[],{"trials":30659,"activeCount":101},[30660,30664],{"nctId":6427,"briefTitle":6428,"status":107,"phases":30661,"primaryCompletion":3991,"start":1989,"enrollment":1891,"conditions":30662,"interventions":30663},[90],[15],[6420,6432,6433],{"nctId":30665,"briefTitle":30666,"status":107,"phases":30667,"primaryCompletion":2145,"start":4498,"enrollment":410,"conditions":30668,"interventions":30669},"NCT02171468","Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects",[90],[15],[6432,6433],{"trials":30671,"activeCount":101},[],{"trials":30673,"activeCount":101},[],{"trials":30675,"activeCount":101},[],{"trials":30677,"activeCount":101},[],{"intervention":6433,"totalTrials":1075,"cells":30679},{"EARLY_PHASE1":30680,"PHASE1":30682,"PHASE2":30692,"PHASE3":30694,"PHASE4":30696,"NA":30698},{"trials":30681,"activeCount":101},[],{"trials":30683,"activeCount":101},[30684,30688],{"nctId":6427,"briefTitle":6428,"status":107,"phases":30685,"primaryCompletion":3991,"start":1989,"enrollment":1891,"conditions":30686,"interventions":30687},[90],[15],[6420,6432,6433],{"nctId":30665,"briefTitle":30666,"status":107,"phases":30689,"primaryCompletion":2145,"start":4498,"enrollment":410,"conditions":30690,"interventions":30691},[90],[15],[6432,6433],{"trials":30693,"activeCount":101},[],{"trials":30695,"activeCount":101},[],{"trials":30697,"activeCount":101},[],{"trials":30699,"activeCount":101},[],{"intervention":30701,"totalTrials":1075,"cells":30702},"BI 765250",{"EARLY_PHASE1":30703,"PHASE1":30705,"PHASE2":30723,"PHASE3":30725,"PHASE4":30727,"NA":30729},{"trials":30704,"activeCount":101},[],{"trials":30706,"activeCount":101},[30707,30714],{"nctId":30708,"briefTitle":30709,"status":107,"phases":30710,"primaryCompletion":4244,"completion":4244,"start":30711,"enrollment":1208,"conditions":30712,"interventions":30713},"NCT05728489","A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis",[90],"2023-04-27",[114],[30701],{"nctId":30715,"briefTitle":30716,"status":107,"phases":30717,"primaryCompletion":30718,"completion":30718,"start":30719,"enrollment":30720,"conditions":30721,"interventions":30722},"NCT05151653","A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin",[90],"2024-09-13","2022-01-26",139,[15],[30701],{"trials":30724,"activeCount":101},[],{"trials":30726,"activeCount":101},[],{"trials":30728,"activeCount":101},[],{"trials":30730,"activeCount":101},[],{"intervention":30732,"totalTrials":1075,"cells":30733},"BIBF 1120 ES",{"EARLY_PHASE1":30734,"PHASE1":30736,"PHASE2":30751,"PHASE3":30753,"PHASE4":30755,"NA":30757},{"trials":30735,"activeCount":101},[],{"trials":30737,"activeCount":101},[30738,30745],{"nctId":30739,"briefTitle":30740,"status":107,"phases":30741,"primaryCompletion":15139,"start":7124,"enrollment":5242,"conditions":30742,"interventions":30744},"NCT02182141","An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma",[90],[30743],"Multiple Myeloma",[30732],{"nctId":30746,"briefTitle":30747,"status":107,"phases":30748,"primaryCompletion":5842,"start":5843,"enrollment":155,"conditions":30749,"interventions":30750},"NCT02182154","Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers",[90],[15],[30732],{"trials":30752,"activeCount":101},[],{"trials":30754,"activeCount":101},[],{"trials":30756,"activeCount":101},[],{"trials":30758,"activeCount":101},[],{"intervention":30760,"totalTrials":272,"cells":30761},"BI 409306 25 mg",{"EARLY_PHASE1":30762,"PHASE1":30764,"PHASE2":30776,"PHASE3":30778,"PHASE4":30780,"NA":30782},{"trials":30763,"activeCount":101},[],{"trials":30765,"activeCount":101},[30766],{"nctId":30767,"briefTitle":30768,"status":107,"phases":30769,"primaryCompletion":30770,"completion":30771,"start":30772,"enrollment":9606,"conditions":30773,"interventions":30774},"NCT02392468","Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers",[90],"2017-08-03","2017-08-10","2015-04-15",[10549,11139],[30760,30775],"BI 409306 50 mg",{"trials":30777,"activeCount":101},[],{"trials":30779,"activeCount":101},[],{"trials":30781,"activeCount":101},[],{"trials":30783,"activeCount":101},[],{"intervention":30775,"totalTrials":272,"cells":30785},{"EARLY_PHASE1":30786,"PHASE1":30788,"PHASE2":30794,"PHASE3":30796,"PHASE4":30798,"NA":30800},{"trials":30787,"activeCount":101},[],{"trials":30789,"activeCount":101},[30790],{"nctId":30767,"briefTitle":30768,"status":107,"phases":30791,"primaryCompletion":30770,"completion":30771,"start":30772,"enrollment":9606,"conditions":30792,"interventions":30793},[90],[10549,11139],[30760,30775],{"trials":30795,"activeCount":101},[],{"trials":30797,"activeCount":101},[],{"trials":30799,"activeCount":101},[],{"trials":30801,"activeCount":101},[],{"intervention":2454,"totalTrials":272,"cells":30803},{"EARLY_PHASE1":30804,"PHASE1":30806,"PHASE2":30812,"PHASE3":30814,"PHASE4":30816,"NA":30818},{"trials":30805,"activeCount":101},[],{"trials":30807,"activeCount":101},[30808],{"nctId":2449,"briefTitle":2450,"status":107,"phases":30809,"primaryCompletion":525,"completion":525,"start":379,"enrollment":380,"conditions":30810,"interventions":30811},[90],[15],[2441,2441,2454,2441],{"trials":30813,"activeCount":101},[],{"trials":30815,"activeCount":101},[],{"trials":30817,"activeCount":101},[],{"trials":30819,"activeCount":101},[],{"intervention":30821,"totalTrials":272,"cells":30822},"AbGn-168H",{"EARLY_PHASE1":30823,"PHASE1":30825,"PHASE2":30833,"PHASE3":30835,"PHASE4":30837,"NA":30839},{"trials":30824,"activeCount":101},[],{"trials":30826,"activeCount":101},[30827],{"nctId":30828,"briefTitle":30829,"status":107,"phases":30830,"primaryCompletion":390,"start":2030,"enrollment":410,"conditions":30831,"interventions":30832},"NCT01378364","Phase I Study of AbGn-168H in Healthy Male Volunteers",[90],[15],[30821,30821,30821,30821,30821,30821],{"trials":30834,"activeCount":101},[],{"trials":30836,"activeCount":101},[],{"trials":30838,"activeCount":101},[],{"trials":30840,"activeCount":101},[],{"intervention":20566,"totalTrials":272,"cells":30842},{"EARLY_PHASE1":30843,"PHASE1":30845,"PHASE2":30851,"PHASE3":30853,"PHASE4":30855,"NA":30857},{"trials":30844,"activeCount":101},[],{"trials":30846,"activeCount":101},[30847],{"nctId":20561,"briefTitle":20562,"status":107,"phases":30848,"primaryCompletion":4005,"start":4005,"enrollment":1081,"conditions":30849,"interventions":30850},[90],[15],[20554,20566,20567],{"trials":30852,"activeCount":101},[],{"trials":30854,"activeCount":101},[],{"trials":30856,"activeCount":101},[],{"trials":30858,"activeCount":101},[],{"intervention":30860,"totalTrials":272,"cells":30861},"BI 201335 ZW - single rising dose",{"EARLY_PHASE1":30862,"PHASE1":30864,"PHASE2":30872,"PHASE3":30874,"PHASE4":30876,"NA":30878},{"trials":30863,"activeCount":101},[],{"trials":30865,"activeCount":101},[30866],{"nctId":30867,"briefTitle":30868,"status":162,"phases":30869,"primaryCompletion":7618,"start":7618,"enrollment":155,"conditions":30870,"interventions":30871},"NCT02182271","Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects",[90],[15],[30860],{"trials":30873,"activeCount":101},[],{"trials":30875,"activeCount":101},[],{"trials":30877,"activeCount":101},[],{"trials":30879,"activeCount":101},[],{"intervention":30881,"totalTrials":272,"cells":30882},"BI 3034701",{"EARLY_PHASE1":30883,"PHASE1":30885,"PHASE2":30895,"PHASE3":30897,"PHASE4":30899,"NA":30901},{"trials":30884,"activeCount":101},[],{"trials":30886,"activeCount":101},[30887],{"nctId":30888,"briefTitle":30889,"status":107,"phases":30890,"primaryCompletion":30891,"completion":30891,"start":30892,"enrollment":9700,"conditions":30893,"interventions":30894},"NCT06352437","A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity",[90],"2025-10-07","2024-06-10",[15],[30881],{"trials":30896,"activeCount":101},[],{"trials":30898,"activeCount":101},[],{"trials":30900,"activeCount":101},[],{"trials":30902,"activeCount":101},[],{"intervention":1970,"totalTrials":272,"cells":30904},{"EARLY_PHASE1":30905,"PHASE1":30907,"PHASE2":30913,"PHASE3":30915,"PHASE4":30917,"NA":30919},{"trials":30906,"activeCount":101},[],{"trials":30908,"activeCount":101},[30909],{"nctId":1964,"briefTitle":1965,"status":107,"phases":30910,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":30911,"interventions":30912},[90],[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],{"trials":30914,"activeCount":101},[],{"trials":30916,"activeCount":101},[],{"trials":30918,"activeCount":101},[],{"trials":30920,"activeCount":101},[],{"intervention":1971,"totalTrials":272,"cells":30922},{"EARLY_PHASE1":30923,"PHASE1":30925,"PHASE2":30931,"PHASE3":30933,"PHASE4":30935,"NA":30937},{"trials":30924,"activeCount":101},[],{"trials":30926,"activeCount":101},[30927],{"nctId":1964,"briefTitle":1965,"status":107,"phases":30928,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":30929,"interventions":30930},[90],[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],{"trials":30932,"activeCount":101},[],{"trials":30934,"activeCount":101},[],{"trials":30936,"activeCount":101},[],{"trials":30938,"activeCount":101},[],{"intervention":1972,"totalTrials":272,"cells":30940},{"EARLY_PHASE1":30941,"PHASE1":30943,"PHASE2":30949,"PHASE3":30951,"PHASE4":30953,"NA":30955},{"trials":30942,"activeCount":101},[],{"trials":30944,"activeCount":101},[30945],{"nctId":1964,"briefTitle":1965,"status":107,"phases":30946,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":30947,"interventions":30948},[90],[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],{"trials":30950,"activeCount":101},[],{"trials":30952,"activeCount":101},[],{"trials":30954,"activeCount":101},[],{"trials":30956,"activeCount":101},[],{"intervention":1973,"totalTrials":272,"cells":30958},{"EARLY_PHASE1":30959,"PHASE1":30961,"PHASE2":30967,"PHASE3":30969,"PHASE4":30971,"NA":30973},{"trials":30960,"activeCount":101},[],{"trials":30962,"activeCount":101},[30963],{"nctId":1964,"briefTitle":1965,"status":107,"phases":30964,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":30965,"interventions":30966},[90],[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],{"trials":30968,"activeCount":101},[],{"trials":30970,"activeCount":101},[],{"trials":30972,"activeCount":101},[],{"trials":30974,"activeCount":101},[],{"intervention":1974,"totalTrials":272,"cells":30976},{"EARLY_PHASE1":30977,"PHASE1":30979,"PHASE2":30985,"PHASE3":30987,"PHASE4":30989,"NA":30991},{"trials":30978,"activeCount":101},[],{"trials":30980,"activeCount":101},[30981],{"nctId":1964,"briefTitle":1965,"status":107,"phases":30982,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":30983,"interventions":30984},[90],[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],{"trials":30986,"activeCount":101},[],{"trials":30988,"activeCount":101},[],{"trials":30990,"activeCount":101},[],{"trials":30992,"activeCount":101},[],{"intervention":1975,"totalTrials":272,"cells":30994},{"EARLY_PHASE1":30995,"PHASE1":30997,"PHASE2":31003,"PHASE3":31005,"PHASE4":31007,"NA":31009},{"trials":30996,"activeCount":101},[],{"trials":30998,"activeCount":101},[30999],{"nctId":1964,"briefTitle":1965,"status":107,"phases":31000,"primaryCompletion":446,"completion":446,"start":1967,"enrollment":231,"conditions":31001,"interventions":31002},[90],[33],[1970,1971,1074,1074,1972,1074,1074,1074,1074,1973,1974,1975],{"trials":31004,"activeCount":101},[],{"trials":31006,"activeCount":101},[],{"trials":31008,"activeCount":101},[],{"trials":31010,"activeCount":101},[],{"intervention":31012,"totalTrials":272,"cells":31013},"day 1 to day 5",{"EARLY_PHASE1":31014,"PHASE1":31016,"PHASE2":31028,"PHASE3":31030,"PHASE4":31032,"NA":31034},{"trials":31015,"activeCount":101},[],{"trials":31017,"activeCount":101},[31018],{"nctId":31019,"briefTitle":31020,"status":107,"phases":31021,"primaryCompletion":31022,"completion":31023,"start":31024,"enrollment":3659,"conditions":31025,"interventions":31026},"NCT01324830","Monotherapy Dose Finding With BI 847325 in Solid Tumours",[90],"2013-06-06","2013-10-10","2011-04-15",[33],[31012,31027],"day 1 to day 14",{"trials":31029,"activeCount":101},[],{"trials":31031,"activeCount":101},[],{"trials":31033,"activeCount":101},[],{"trials":31035,"activeCount":101},[],{"intervention":31027,"totalTrials":272,"cells":31037},{"EARLY_PHASE1":31038,"PHASE1":31040,"PHASE2":31046,"PHASE3":31048,"PHASE4":31050,"NA":31052},{"trials":31039,"activeCount":101},[],{"trials":31041,"activeCount":101},[31042],{"nctId":31019,"briefTitle":31020,"status":107,"phases":31043,"primaryCompletion":31022,"completion":31023,"start":31024,"enrollment":3659,"conditions":31044,"interventions":31045},[90],[33],[31012,31027],{"trials":31047,"activeCount":101},[],{"trials":31049,"activeCount":101},[],{"trials":31051,"activeCount":101},[],{"trials":31053,"activeCount":101},[],{"intervention":31055,"totalTrials":272,"cells":31056},"BI 2536, intravenous",{"EARLY_PHASE1":31057,"PHASE1":31059,"PHASE2":31068,"PHASE3":31070,"PHASE4":31072,"NA":31074},{"trials":31058,"activeCount":101},[],{"trials":31060,"activeCount":101},[31061],{"nctId":31062,"briefTitle":31063,"status":162,"phases":31064,"primaryCompletion":2032,"start":4517,"enrollment":188,"conditions":31065,"interventions":31066},"NCT02215044","Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer",[90],[2691],[31055,31067],"Gemcitabine, intravenous",{"trials":31069,"activeCount":101},[],{"trials":31071,"activeCount":101},[],{"trials":31073,"activeCount":101},[],{"trials":31075,"activeCount":101},[],{"intervention":31067,"totalTrials":272,"cells":31077},{"EARLY_PHASE1":31078,"PHASE1":31080,"PHASE2":31086,"PHASE3":31088,"PHASE4":31090,"NA":31092},{"trials":31079,"activeCount":101},[],{"trials":31081,"activeCount":101},[31082],{"nctId":31062,"briefTitle":31063,"status":162,"phases":31083,"primaryCompletion":2032,"start":4517,"enrollment":188,"conditions":31084,"interventions":31085},[90],[2691],[31055,31067],{"trials":31087,"activeCount":101},[],{"trials":31089,"activeCount":101},[],{"trials":31091,"activeCount":101},[],{"trials":31093,"activeCount":101},[],{"intervention":31095,"totalTrials":272,"cells":31096},"Telmisartan \u002FHCTZ - compression",{"EARLY_PHASE1":31097,"PHASE1":31099,"PHASE2":31109,"PHASE3":31111,"PHASE4":31113,"NA":31115},{"trials":31098,"activeCount":101},[],{"trials":31100,"activeCount":101},[31101],{"nctId":31102,"briefTitle":31103,"status":107,"phases":31104,"primaryCompletion":6472,"start":7124,"enrollment":380,"conditions":31105,"interventions":31106},"NCT02262572","Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects",[90],[15],[31095,31107,31108],"Telmisartan \u002FHCTZ - dry granulation","Telmisartan \u002FHCTZ - present commercial formulation",{"trials":31110,"activeCount":101},[],{"trials":31112,"activeCount":101},[],{"trials":31114,"activeCount":101},[],{"trials":31116,"activeCount":101},[],{"intervention":31107,"totalTrials":272,"cells":31118},{"EARLY_PHASE1":31119,"PHASE1":31121,"PHASE2":31127,"PHASE3":31129,"PHASE4":31131,"NA":31133},{"trials":31120,"activeCount":101},[],{"trials":31122,"activeCount":101},[31123],{"nctId":31102,"briefTitle":31103,"status":107,"phases":31124,"primaryCompletion":6472,"start":7124,"enrollment":380,"conditions":31125,"interventions":31126},[90],[15],[31095,31107,31108],{"trials":31128,"activeCount":101},[],{"trials":31130,"activeCount":101},[],{"trials":31132,"activeCount":101},[],{"trials":31134,"activeCount":101},[],{"intervention":31108,"totalTrials":272,"cells":31136},{"EARLY_PHASE1":31137,"PHASE1":31139,"PHASE2":31145,"PHASE3":31147,"PHASE4":31149,"NA":31151},{"trials":31138,"activeCount":101},[],{"trials":31140,"activeCount":101},[31141],{"nctId":31102,"briefTitle":31103,"status":107,"phases":31142,"primaryCompletion":6472,"start":7124,"enrollment":380,"conditions":31143,"interventions":31144},[90],[15],[31095,31107,31108],{"trials":31146,"activeCount":101},[],{"trials":31148,"activeCount":101},[],{"trials":31150,"activeCount":101},[],{"trials":31152,"activeCount":101},[],{"intervention":31154,"totalTrials":272,"cells":31155},"Dextromethorphan syrup",{"EARLY_PHASE1":31156,"PHASE1":31158,"PHASE2":31167,"PHASE3":31169,"PHASE4":31171,"NA":31173},{"trials":31157,"activeCount":101},[],{"trials":31159,"activeCount":101},[31160],{"nctId":31161,"briefTitle":31162,"status":107,"phases":31163,"primaryCompletion":1989,"start":2649,"enrollment":392,"conditions":31164,"interventions":31165},"NCT02191709","Relative Bioavailability of Dextromethorphan Syrup in Comparison to Dextromethorphan Soft Pastilles in Healthy Male and Female Subjects",[90],[15],[31154,31166],"Dextromethorphan soft pastilles",{"trials":31168,"activeCount":101},[],{"trials":31170,"activeCount":101},[],{"trials":31172,"activeCount":101},[],{"trials":31174,"activeCount":101},[],{"intervention":31166,"totalTrials":272,"cells":31176},{"EARLY_PHASE1":31177,"PHASE1":31179,"PHASE2":31185,"PHASE3":31187,"PHASE4":31189,"NA":31191},{"trials":31178,"activeCount":101},[],{"trials":31180,"activeCount":101},[31181],{"nctId":31161,"briefTitle":31162,"status":107,"phases":31182,"primaryCompletion":1989,"start":2649,"enrollment":392,"conditions":31183,"interventions":31184},[90],[15],[31154,31166],{"trials":31186,"activeCount":101},[],{"trials":31188,"activeCount":101},[],{"trials":31190,"activeCount":101},[],{"trials":31192,"activeCount":101},[],{"intervention":31194,"totalTrials":272,"cells":31195},"BIBF 1120 capsules charge 1",{"EARLY_PHASE1":31196,"PHASE1":31198,"PHASE2":31208,"PHASE3":31210,"PHASE4":31212,"NA":31214},{"trials":31197,"activeCount":101},[],{"trials":31199,"activeCount":101},[31200],{"nctId":31201,"briefTitle":31202,"status":107,"phases":31203,"primaryCompletion":6910,"start":6911,"enrollment":1631,"conditions":31204,"interventions":31205},"NCT02182193","Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers",[90],[15],[31194,31206,31207],"BIBF 1120 capsules charge 2","BIBF 1120 drinking solution",{"trials":31209,"activeCount":101},[],{"trials":31211,"activeCount":101},[],{"trials":31213,"activeCount":101},[],{"trials":31215,"activeCount":101},[],{"intervention":31206,"totalTrials":272,"cells":31217},{"EARLY_PHASE1":31218,"PHASE1":31220,"PHASE2":31226,"PHASE3":31228,"PHASE4":31230,"NA":31232},{"trials":31219,"activeCount":101},[],{"trials":31221,"activeCount":101},[31222],{"nctId":31201,"briefTitle":31202,"status":107,"phases":31223,"primaryCompletion":6910,"start":6911,"enrollment":1631,"conditions":31224,"interventions":31225},[90],[15],[31194,31206,31207],{"trials":31227,"activeCount":101},[],{"trials":31229,"activeCount":101},[],{"trials":31231,"activeCount":101},[],{"trials":31233,"activeCount":101},[],{"intervention":31207,"totalTrials":272,"cells":31235},{"EARLY_PHASE1":31236,"PHASE1":31238,"PHASE2":31244,"PHASE3":31246,"PHASE4":31248,"NA":31250},{"trials":31237,"activeCount":101},[],{"trials":31239,"activeCount":101},[31240],{"nctId":31201,"briefTitle":31202,"status":107,"phases":31241,"primaryCompletion":6910,"start":6911,"enrollment":1631,"conditions":31242,"interventions":31243},[90],[15],[31194,31206,31207],{"trials":31245,"activeCount":101},[],{"trials":31247,"activeCount":101},[],{"trials":31249,"activeCount":101},[],{"trials":31251,"activeCount":101},[],{"intervention":10380,"totalTrials":272,"cells":31253},{"EARLY_PHASE1":31254,"PHASE1":31256,"PHASE2":31262,"PHASE3":31264,"PHASE4":31266,"NA":31268},{"trials":31255,"activeCount":101},[],{"trials":31257,"activeCount":101},[31258],{"nctId":10375,"briefTitle":10376,"status":107,"phases":31259,"primaryCompletion":3762,"completion":3762,"start":525,"enrollment":448,"conditions":31260,"interventions":31261},[90],[15],[10380,10368,10368],{"trials":31263,"activeCount":101},[],{"trials":31265,"activeCount":101},[],{"trials":31267,"activeCount":101},[],{"trials":31269,"activeCount":101},[],{"intervention":31271,"totalTrials":272,"cells":31272},"[13C]-labeled BI 1584862",{"EARLY_PHASE1":31273,"PHASE1":31275,"PHASE2":31286,"PHASE3":31288,"PHASE4":31290,"NA":31292},{"trials":31274,"activeCount":101},[],{"trials":31276,"activeCount":101},[31277],{"nctId":31278,"briefTitle":31279,"status":107,"phases":31280,"primaryCompletion":31281,"completion":31281,"start":31282,"enrollment":155,"conditions":31283,"interventions":31284},"NCT07336758","A Study in Healthy Men to Test How BI 1584862 is Processed in the Body",[90],"2026-03-04","2026-01-22",[15],[31271,31285],"Unlabeled BI 1584862 mixed with [14C]-labeled BI 1584862",{"trials":31287,"activeCount":101},[],{"trials":31289,"activeCount":101},[],{"trials":31291,"activeCount":101},[],{"trials":31293,"activeCount":101},[],{"intervention":31285,"totalTrials":272,"cells":31295},{"EARLY_PHASE1":31296,"PHASE1":31298,"PHASE2":31304,"PHASE3":31306,"PHASE4":31308,"NA":31310},{"trials":31297,"activeCount":101},[],{"trials":31299,"activeCount":101},[31300],{"nctId":31278,"briefTitle":31279,"status":107,"phases":31301,"primaryCompletion":31281,"completion":31281,"start":31282,"enrollment":155,"conditions":31302,"interventions":31303},[90],[15],[31271,31285],{"trials":31305,"activeCount":101},[],{"trials":31307,"activeCount":101},[],{"trials":31309,"activeCount":101},[],{"trials":31311,"activeCount":101},[],{"intervention":31313,"totalTrials":272,"cells":31314},"BIBW 2992 MA2 - single rising dose",{"EARLY_PHASE1":31315,"PHASE1":31317,"PHASE2":31325,"PHASE3":31327,"PHASE4":31329,"NA":31331},{"trials":31316,"activeCount":101},[],{"trials":31318,"activeCount":101},[31319],{"nctId":31320,"briefTitle":31321,"status":107,"phases":31322,"primaryCompletion":9443,"start":3990,"enrollment":410,"conditions":31323,"interventions":31324},"NCT02171767","Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers",[90],[15],[31313],{"trials":31326,"activeCount":101},[],{"trials":31328,"activeCount":101},[],{"trials":31330,"activeCount":101},[],{"trials":31332,"activeCount":101},[],{"intervention":31334,"totalTrials":272,"cells":31335},"EFV",{"EARLY_PHASE1":31336,"PHASE1":31338,"PHASE2":31348,"PHASE3":31350,"PHASE4":31352,"NA":31354},{"trials":31337,"activeCount":101},[],{"trials":31339,"activeCount":101},[31340],{"nctId":31341,"briefTitle":31342,"status":107,"phases":31343,"primaryCompletion":5992,"start":6040,"enrollment":2400,"conditions":31344,"interventions":31345},"NCT02253823","Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir\u002FRitonavir (TPV\u002FRTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers",[90],[15],[31334,31346,31347],"TPV\u002FRTV - low dose","TPV\u002FRTV - high dose",{"trials":31349,"activeCount":101},[],{"trials":31351,"activeCount":101},[],{"trials":31353,"activeCount":101},[],{"trials":31355,"activeCount":101},[],{"intervention":31346,"totalTrials":272,"cells":31357},{"EARLY_PHASE1":31358,"PHASE1":31360,"PHASE2":31366,"PHASE3":31368,"PHASE4":31370,"NA":31372},{"trials":31359,"activeCount":101},[],{"trials":31361,"activeCount":101},[31362],{"nctId":31341,"briefTitle":31342,"status":107,"phases":31363,"primaryCompletion":5992,"start":6040,"enrollment":2400,"conditions":31364,"interventions":31365},[90],[15],[31334,31346,31347],{"trials":31367,"activeCount":101},[],{"trials":31369,"activeCount":101},[],{"trials":31371,"activeCount":101},[],{"trials":31373,"activeCount":101},[],{"intervention":31347,"totalTrials":272,"cells":31375},{"EARLY_PHASE1":31376,"PHASE1":31378,"PHASE2":31384,"PHASE3":31386,"PHASE4":31388,"NA":31390},{"trials":31377,"activeCount":101},[],{"trials":31379,"activeCount":101},[31380],{"nctId":31341,"briefTitle":31342,"status":107,"phases":31381,"primaryCompletion":5992,"start":6040,"enrollment":2400,"conditions":31382,"interventions":31383},[90],[15],[31334,31346,31347],{"trials":31385,"activeCount":101},[],{"trials":31387,"activeCount":101},[],{"trials":31389,"activeCount":101},[],{"trials":31391,"activeCount":101},[],{"intervention":31393,"totalTrials":272,"cells":31394},"BI 1821736",{"EARLY_PHASE1":31395,"PHASE1":31397,"PHASE2":31406,"PHASE3":31408,"PHASE4":31410,"NA":31412},{"trials":31396,"activeCount":101},[],{"trials":31398,"activeCount":101},[31399],{"nctId":31400,"briefTitle":31401,"status":162,"phases":31402,"primaryCompletion":31403,"completion":31403,"start":21181,"enrollment":1081,"conditions":31404,"interventions":31405},"NCT05839600","A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer",[90],"2025-04-10",[2057],[31393],{"trials":31407,"activeCount":101},[],{"trials":31409,"activeCount":101},[],{"trials":31411,"activeCount":101},[],{"trials":31413,"activeCount":101},[],{"intervention":31415,"totalTrials":272,"cells":31416},"Flomax®, Norman II facility",{"EARLY_PHASE1":31417,"PHASE1":31419,"PHASE2":31428,"PHASE3":31430,"PHASE4":31432,"NA":31434},{"trials":31418,"activeCount":101},[],{"trials":31420,"activeCount":101},[31421],{"nctId":31422,"briefTitle":31423,"status":107,"phases":31424,"primaryCompletion":7022,"start":6738,"enrollment":357,"conditions":31425,"interventions":31426},"NCT02266511","Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects",[90],[15],[31415,31427],"Flomax®, Nishine facility",{"trials":31429,"activeCount":101},[],{"trials":31431,"activeCount":101},[],{"trials":31433,"activeCount":101},[],{"trials":31435,"activeCount":101},[],{"intervention":31427,"totalTrials":272,"cells":31437},{"EARLY_PHASE1":31438,"PHASE1":31440,"PHASE2":31446,"PHASE3":31448,"PHASE4":31450,"NA":31452},{"trials":31439,"activeCount":101},[],{"trials":31441,"activeCount":101},[31442],{"nctId":31422,"briefTitle":31423,"status":107,"phases":31443,"primaryCompletion":7022,"start":6738,"enrollment":357,"conditions":31444,"interventions":31445},[90],[15],[31415,31427],{"trials":31447,"activeCount":101},[],{"trials":31449,"activeCount":101},[],{"trials":31451,"activeCount":101},[],{"trials":31453,"activeCount":101},[],{"intervention":4417,"totalTrials":272,"cells":31455},{"EARLY_PHASE1":31456,"PHASE1":31458,"PHASE2":31464,"PHASE3":31466,"PHASE4":31468,"NA":31470},{"trials":31457,"activeCount":101},[],{"trials":31459,"activeCount":101},[31460],{"nctId":4409,"briefTitle":4410,"status":107,"phases":31461,"primaryCompletion":4412,"start":4413,"enrollment":37,"conditions":31462,"interventions":31463},[90],[15],[4416,4417,1538,4418],{"trials":31465,"activeCount":101},[],{"trials":31467,"activeCount":101},[],{"trials":31469,"activeCount":101},[],{"trials":31471,"activeCount":101},[],{"intervention":31473,"totalTrials":272,"cells":31474},"Telmisartan\u002FAmlodipin FDC",{"EARLY_PHASE1":31475,"PHASE1":31477,"PHASE2":31486,"PHASE3":31488,"PHASE4":31490,"NA":31492},{"trials":31476,"activeCount":101},[],{"trials":31478,"activeCount":101},[31479],{"nctId":31480,"briefTitle":31481,"status":107,"phases":31482,"primaryCompletion":9752,"start":9340,"enrollment":1208,"conditions":31483,"interventions":31484},"NCT01344629","Bioequivalence Study of Telmisartan Between Telmisartan 80 mg\u002FAmlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use",[90],[15],[31473,6121,31485],"Amlodipin",{"trials":31487,"activeCount":101},[],{"trials":31489,"activeCount":101},[],{"trials":31491,"activeCount":101},[],{"trials":31493,"activeCount":101},[],{"intervention":31485,"totalTrials":272,"cells":31495},{"EARLY_PHASE1":31496,"PHASE1":31498,"PHASE2":31504,"PHASE3":31506,"PHASE4":31508,"NA":31510},{"trials":31497,"activeCount":101},[],{"trials":31499,"activeCount":101},[31500],{"nctId":31480,"briefTitle":31481,"status":107,"phases":31501,"primaryCompletion":9752,"start":9340,"enrollment":1208,"conditions":31502,"interventions":31503},[90],[15],[31473,6121,31485],{"trials":31505,"activeCount":101},[],{"trials":31507,"activeCount":101},[],{"trials":31509,"activeCount":101},[],{"trials":31511,"activeCount":101},[],{"intervention":31513,"totalTrials":272,"cells":31514},"TPV + RTV",{"EARLY_PHASE1":31515,"PHASE1":31517,"PHASE2":31526,"PHASE3":31528,"PHASE4":31530,"NA":31532},{"trials":31516,"activeCount":101},[],{"trials":31518,"activeCount":101},[31519],{"nctId":31520,"briefTitle":31521,"status":107,"phases":31522,"primaryCompletion":5992,"start":7132,"enrollment":2235,"conditions":31523,"interventions":31524},"NCT02251873","Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers",[90],[15],[31513,31513,31525],"ddl",{"trials":31527,"activeCount":101},[],{"trials":31529,"activeCount":101},[],{"trials":31531,"activeCount":101},[],{"trials":31533,"activeCount":101},[],{"intervention":31525,"totalTrials":272,"cells":31535},{"EARLY_PHASE1":31536,"PHASE1":31538,"PHASE2":31544,"PHASE3":31546,"PHASE4":31548,"NA":31550},{"trials":31537,"activeCount":101},[],{"trials":31539,"activeCount":101},[31540],{"nctId":31520,"briefTitle":31521,"status":107,"phases":31541,"primaryCompletion":5992,"start":7132,"enrollment":2235,"conditions":31542,"interventions":31543},[90],[15],[31513,31513,31525],{"trials":31545,"activeCount":101},[],{"trials":31547,"activeCount":101},[],{"trials":31549,"activeCount":101},[],{"trials":31551,"activeCount":101},[],{"intervention":28212,"totalTrials":272,"cells":31553},{"EARLY_PHASE1":31554,"PHASE1":31556,"PHASE2":31562,"PHASE3":31564,"PHASE4":31566,"NA":31568},{"trials":31555,"activeCount":101},[],{"trials":31557,"activeCount":101},[31558],{"nctId":28207,"briefTitle":28208,"status":107,"phases":31559,"primaryCompletion":6015,"start":6041,"enrollment":401,"conditions":31560,"interventions":31561},[90],[15],[28212,28200],{"trials":31563,"activeCount":101},[],{"trials":31565,"activeCount":101},[],{"trials":31567,"activeCount":101},[],{"trials":31569,"activeCount":101},[],{"intervention":31571,"totalTrials":272,"cells":31572},"BI 1358894, intended Commercial Formulation",{"EARLY_PHASE1":31573,"PHASE1":31575,"PHASE2":31585,"PHASE3":31587,"PHASE4":31589,"NA":31591},{"trials":31574,"activeCount":101},[],{"trials":31576,"activeCount":101},[31577],{"nctId":31578,"briefTitle":31579,"status":107,"phases":31580,"primaryCompletion":31581,"completion":31581,"start":4020,"enrollment":380,"conditions":31582,"interventions":31583},"NCT05155306","A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food",[90],"2022-05-16",[15],[31571,31584],"BI 1358894, Trial Formulation 2",{"trials":31586,"activeCount":101},[],{"trials":31588,"activeCount":101},[],{"trials":31590,"activeCount":101},[],{"trials":31592,"activeCount":101},[],{"intervention":31584,"totalTrials":272,"cells":31594},{"EARLY_PHASE1":31595,"PHASE1":31597,"PHASE2":31603,"PHASE3":31605,"PHASE4":31607,"NA":31609},{"trials":31596,"activeCount":101},[],{"trials":31598,"activeCount":101},[31599],{"nctId":31578,"briefTitle":31579,"status":107,"phases":31600,"primaryCompletion":31581,"completion":31581,"start":4020,"enrollment":380,"conditions":31601,"interventions":31602},[90],[15],[31571,31584],{"trials":31604,"activeCount":101},[],{"trials":31606,"activeCount":101},[],{"trials":31608,"activeCount":101},[],{"trials":31610,"activeCount":101},[],{"intervention":31612,"totalTrials":272,"cells":31613},"BI 187004 CL",{"EARLY_PHASE1":31614,"PHASE1":31616,"PHASE2":31624,"PHASE3":31626,"PHASE4":31628,"NA":31630},{"trials":31615,"activeCount":101},[],{"trials":31617,"activeCount":101},[31618],{"nctId":31619,"briefTitle":31620,"status":107,"phases":31621,"primaryCompletion":517,"completion":517,"start":4038,"enrollment":716,"conditions":31622,"interventions":31623},"NCT01587417","Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL",[90],[15],[31612],{"trials":31625,"activeCount":101},[],{"trials":31627,"activeCount":101},[],{"trials":31629,"activeCount":101},[],{"trials":31631,"activeCount":101},[],{"intervention":19072,"totalTrials":272,"cells":31633},{"EARLY_PHASE1":31634,"PHASE1":31636,"PHASE2":31642,"PHASE3":31644,"PHASE4":31646,"NA":31648},{"trials":31635,"activeCount":101},[],{"trials":31637,"activeCount":101},[31638],{"nctId":19066,"briefTitle":19067,"status":107,"phases":31639,"primaryCompletion":5905,"start":2003,"enrollment":132,"conditions":31640,"interventions":31641},[90],[15],[19059,19071,19072],{"trials":31643,"activeCount":101},[],{"trials":31645,"activeCount":101},[],{"trials":31647,"activeCount":101},[],{"trials":31649,"activeCount":101},[],{"intervention":31651,"totalTrials":272,"cells":31652},"NVP XR 400 mg",{"EARLY_PHASE1":31653,"PHASE1":31655,"PHASE2":31665,"PHASE3":31667,"PHASE4":31669,"NA":31671},{"trials":31654,"activeCount":101},[],{"trials":31656,"activeCount":101},[31657],{"nctId":31658,"briefTitle":31659,"status":107,"phases":31660,"primaryCompletion":1114,"start":20181,"enrollment":21183,"conditions":31661,"interventions":31662},"NCT02194179","Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects",[90],[27],[31651,31651,31663,31663,31664],"NVP XR 300 mg","NVP IR 200 mg",{"trials":31666,"activeCount":101},[],{"trials":31668,"activeCount":101},[],{"trials":31670,"activeCount":101},[],{"trials":31672,"activeCount":101},[],{"intervention":31663,"totalTrials":272,"cells":31674},{"EARLY_PHASE1":31675,"PHASE1":31677,"PHASE2":31683,"PHASE3":31685,"PHASE4":31687,"NA":31689},{"trials":31676,"activeCount":101},[],{"trials":31678,"activeCount":101},[31679],{"nctId":31658,"briefTitle":31659,"status":107,"phases":31680,"primaryCompletion":1114,"start":20181,"enrollment":21183,"conditions":31681,"interventions":31682},[90],[27],[31651,31651,31663,31663,31664],{"trials":31684,"activeCount":101},[],{"trials":31686,"activeCount":101},[],{"trials":31688,"activeCount":101},[],{"trials":31690,"activeCount":101},[],{"intervention":31664,"totalTrials":272,"cells":31692},{"EARLY_PHASE1":31693,"PHASE1":31695,"PHASE2":31701,"PHASE3":31703,"PHASE4":31705,"NA":31707},{"trials":31694,"activeCount":101},[],{"trials":31696,"activeCount":101},[31697],{"nctId":31658,"briefTitle":31659,"status":107,"phases":31698,"primaryCompletion":1114,"start":20181,"enrollment":21183,"conditions":31699,"interventions":31700},[90],[27],[31651,31651,31663,31663,31664],{"trials":31702,"activeCount":101},[],{"trials":31704,"activeCount":101},[],{"trials":31706,"activeCount":101},[],{"trials":31708,"activeCount":101},[],{"intervention":18809,"totalTrials":272,"cells":31710},{"EARLY_PHASE1":31711,"PHASE1":31713,"PHASE2":31719,"PHASE3":31721,"PHASE4":31723,"NA":31725},{"trials":31712,"activeCount":101},[],{"trials":31714,"activeCount":101},[31715],{"nctId":18802,"briefTitle":18803,"status":107,"phases":31716,"primaryCompletion":18805,"completion":18805,"start":18806,"enrollment":401,"conditions":31717,"interventions":31718},[90],[15],[4095,18809],{"trials":31720,"activeCount":101},[],{"trials":31722,"activeCount":101},[],{"trials":31724,"activeCount":101},[],{"trials":31726,"activeCount":101},[],{"intervention":31728,"totalTrials":272,"cells":31729},"BI 695501 - higher concentration",{"EARLY_PHASE1":31730,"PHASE1":31732,"PHASE2":31743,"PHASE3":31745,"PHASE4":31747,"NA":31749},{"trials":31731,"activeCount":101},[],{"trials":31733,"activeCount":101},[31734],{"nctId":31735,"briefTitle":31736,"status":107,"phases":31737,"primaryCompletion":31738,"completion":31738,"start":31739,"enrollment":10417,"conditions":31740,"interventions":31741},"NCT05203289","A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection",[90],"2022-08-29","2022-02-18",[15],[31728,31742],"BI 695501 - lower concentration",{"trials":31744,"activeCount":101},[],{"trials":31746,"activeCount":101},[],{"trials":31748,"activeCount":101},[],{"trials":31750,"activeCount":101},[],{"intervention":31742,"totalTrials":272,"cells":31752},{"EARLY_PHASE1":31753,"PHASE1":31755,"PHASE2":31761,"PHASE3":31763,"PHASE4":31765,"NA":31767},{"trials":31754,"activeCount":101},[],{"trials":31756,"activeCount":101},[31757],{"nctId":31735,"briefTitle":31736,"status":107,"phases":31758,"primaryCompletion":31738,"completion":31738,"start":31739,"enrollment":10417,"conditions":31759,"interventions":31760},[90],[15],[31728,31742],{"trials":31762,"activeCount":101},[],{"trials":31764,"activeCount":101},[],{"trials":31766,"activeCount":101},[],{"trials":31768,"activeCount":101},[],{"intervention":31770,"totalTrials":272,"cells":31771},"BI 639667",{"EARLY_PHASE1":31772,"PHASE1":31774,"PHASE2":31782,"PHASE3":31784,"PHASE4":31786,"NA":31788},{"trials":31773,"activeCount":101},[],{"trials":31775,"activeCount":101},[31776],{"nctId":31777,"briefTitle":31778,"status":600,"phases":31779,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":101,"conditions":31780,"interventions":31781},"NCT02133482","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667",[90],[15],[31770],{"trials":31783,"activeCount":101},[],{"trials":31785,"activeCount":101},[],{"trials":31787,"activeCount":101},[],{"trials":31789,"activeCount":101},[],{"intervention":20348,"totalTrials":272,"cells":31791},{"EARLY_PHASE1":31792,"PHASE1":31794,"PHASE2":31800,"PHASE3":31802,"PHASE4":31804,"NA":31806},{"trials":31793,"activeCount":101},[],{"trials":31795,"activeCount":101},[31796],{"nctId":20341,"briefTitle":20342,"status":162,"phases":31797,"primaryCompletion":10555,"completion":20344,"start":20345,"enrollment":155,"conditions":31798,"interventions":31799},[90],[15],[20348,4075,20349],{"trials":31801,"activeCount":101},[],{"trials":31803,"activeCount":101},[],{"trials":31805,"activeCount":101},[],{"trials":31807,"activeCount":101},[],{"intervention":20349,"totalTrials":272,"cells":31809},{"EARLY_PHASE1":31810,"PHASE1":31812,"PHASE2":31818,"PHASE3":31820,"PHASE4":31822,"NA":31824},{"trials":31811,"activeCount":101},[],{"trials":31813,"activeCount":101},[31814],{"nctId":20341,"briefTitle":20342,"status":162,"phases":31815,"primaryCompletion":10555,"completion":20344,"start":20345,"enrollment":155,"conditions":31816,"interventions":31817},[90],[15],[20348,4075,20349],{"trials":31819,"activeCount":101},[],{"trials":31821,"activeCount":101},[],{"trials":31823,"activeCount":101},[],{"trials":31825,"activeCount":101},[],{"intervention":31827,"totalTrials":272,"cells":31828},"Bromihexine hydrochloride syrup",{"EARLY_PHASE1":31829,"PHASE1":31831,"PHASE2":31840,"PHASE3":31842,"PHASE4":31844,"NA":31846},{"trials":31830,"activeCount":101},[],{"trials":31832,"activeCount":101},[31833],{"nctId":31834,"briefTitle":31835,"status":107,"phases":31836,"primaryCompletion":391,"start":2648,"enrollment":291,"conditions":31837,"interventions":31838},"NCT01423721","Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)",[90],[15],[31827,31839],"Bromihexine hydrochloride granules",{"trials":31841,"activeCount":101},[],{"trials":31843,"activeCount":101},[],{"trials":31845,"activeCount":101},[],{"trials":31847,"activeCount":101},[],{"intervention":31839,"totalTrials":272,"cells":31849},{"EARLY_PHASE1":31850,"PHASE1":31852,"PHASE2":31858,"PHASE3":31860,"PHASE4":31862,"NA":31864},{"trials":31851,"activeCount":101},[],{"trials":31853,"activeCount":101},[31854],{"nctId":31834,"briefTitle":31835,"status":107,"phases":31855,"primaryCompletion":391,"start":2648,"enrollment":291,"conditions":31856,"interventions":31857},[90],[15],[31827,31839],{"trials":31859,"activeCount":101},[],{"trials":31861,"activeCount":101},[],{"trials":31863,"activeCount":101},[],{"trials":31865,"activeCount":101},[],{"intervention":27325,"totalTrials":272,"cells":31867},{"EARLY_PHASE1":31868,"PHASE1":31870,"PHASE2":31876,"PHASE3":31878,"PHASE4":31880,"NA":31882},{"trials":31869,"activeCount":101},[],{"trials":31871,"activeCount":101},[31872],{"nctId":27320,"briefTitle":27321,"status":107,"phases":31873,"primaryCompletion":7381,"start":7003,"enrollment":357,"conditions":31874,"interventions":31875},[90],[15],[27325,6024,27326,27327],{"trials":31877,"activeCount":101},[],{"trials":31879,"activeCount":101},[],{"trials":31881,"activeCount":101},[],{"trials":31883,"activeCount":101},[],{"intervention":27326,"totalTrials":272,"cells":31885},{"EARLY_PHASE1":31886,"PHASE1":31888,"PHASE2":31894,"PHASE3":31896,"PHASE4":31898,"NA":31900},{"trials":31887,"activeCount":101},[],{"trials":31889,"activeCount":101},[31890],{"nctId":27320,"briefTitle":27321,"status":107,"phases":31891,"primaryCompletion":7381,"start":7003,"enrollment":357,"conditions":31892,"interventions":31893},[90],[15],[27325,6024,27326,27327],{"trials":31895,"activeCount":101},[],{"trials":31897,"activeCount":101},[],{"trials":31899,"activeCount":101},[],{"trials":31901,"activeCount":101},[],{"intervention":27327,"totalTrials":272,"cells":31903},{"EARLY_PHASE1":31904,"PHASE1":31906,"PHASE2":31912,"PHASE3":31914,"PHASE4":31916,"NA":31918},{"trials":31905,"activeCount":101},[],{"trials":31907,"activeCount":101},[31908],{"nctId":27320,"briefTitle":27321,"status":107,"phases":31909,"primaryCompletion":7381,"start":7003,"enrollment":357,"conditions":31910,"interventions":31911},[90],[15],[27325,6024,27326,27327],{"trials":31913,"activeCount":101},[],{"trials":31915,"activeCount":101},[],{"trials":31917,"activeCount":101},[],{"trials":31919,"activeCount":101},[],{"intervention":360,"totalTrials":272,"cells":31921},{"EARLY_PHASE1":31922,"PHASE1":31924,"PHASE2":31930,"PHASE3":31932,"PHASE4":31934,"NA":31936},{"trials":31923,"activeCount":101},[],{"trials":31925,"activeCount":101},[31926],{"nctId":352,"briefTitle":353,"status":107,"phases":31927,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":31928,"interventions":31929},[90],[15],[360,73,361,362],{"trials":31931,"activeCount":101},[],{"trials":31933,"activeCount":101},[],{"trials":31935,"activeCount":101},[],{"trials":31937,"activeCount":101},[],{"intervention":9884,"totalTrials":272,"cells":31939},{"EARLY_PHASE1":31940,"PHASE1":31942,"PHASE2":31948,"PHASE3":31950,"PHASE4":31952,"NA":31954},{"trials":31941,"activeCount":101},[],{"trials":31943,"activeCount":101},[31944],{"nctId":9879,"briefTitle":9880,"status":107,"phases":31945,"primaryCompletion":6224,"start":5906,"enrollment":1672,"conditions":31946,"interventions":31947},[90],[15],[9872,9884,9885],{"trials":31949,"activeCount":101},[],{"trials":31951,"activeCount":101},[],{"trials":31953,"activeCount":101},[],{"trials":31955,"activeCount":101},[],{"intervention":9885,"totalTrials":272,"cells":31957},{"EARLY_PHASE1":31958,"PHASE1":31960,"PHASE2":31966,"PHASE3":31968,"PHASE4":31970,"NA":31972},{"trials":31959,"activeCount":101},[],{"trials":31961,"activeCount":101},[31962],{"nctId":9879,"briefTitle":9880,"status":107,"phases":31963,"primaryCompletion":6224,"start":5906,"enrollment":1672,"conditions":31964,"interventions":31965},[90],[15],[9872,9884,9885],{"trials":31967,"activeCount":101},[],{"trials":31969,"activeCount":101},[],{"trials":31971,"activeCount":101},[],{"trials":31973,"activeCount":101},[],{"intervention":31975,"totalTrials":272,"cells":31976},"[14C]talsaclidine,",{"EARLY_PHASE1":31977,"PHASE1":31979,"PHASE2":31988,"PHASE3":31990,"PHASE4":31992,"NA":31994},{"trials":31978,"activeCount":101},[],{"trials":31980,"activeCount":101},[31981],{"nctId":31982,"briefTitle":31983,"status":107,"phases":31984,"primaryCompletion":6453,"start":5923,"enrollment":1512,"conditions":31985,"interventions":31986},"NCT02264054","Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects",[90],[15],[31975,31987],"[14C]talsaclidine, iv",{"trials":31989,"activeCount":101},[],{"trials":31991,"activeCount":101},[],{"trials":31993,"activeCount":101},[],{"trials":31995,"activeCount":101},[],{"intervention":31987,"totalTrials":272,"cells":31997},{"EARLY_PHASE1":31998,"PHASE1":32000,"PHASE2":32006,"PHASE3":32008,"PHASE4":32010,"NA":32012},{"trials":31999,"activeCount":101},[],{"trials":32001,"activeCount":101},[32002],{"nctId":31982,"briefTitle":31983,"status":107,"phases":32003,"primaryCompletion":6453,"start":5923,"enrollment":1512,"conditions":32004,"interventions":32005},[90],[15],[31975,31987],{"trials":32007,"activeCount":101},[],{"trials":32009,"activeCount":101},[],{"trials":32011,"activeCount":101},[],{"trials":32013,"activeCount":101},[],{"intervention":32015,"totalTrials":272,"cells":32016},"BI 10773 single rising dose",{"EARLY_PHASE1":32017,"PHASE1":32019,"PHASE2":32027,"PHASE3":32029,"PHASE4":32031,"NA":32033},{"trials":32018,"activeCount":101},[],{"trials":32020,"activeCount":101},[32021],{"nctId":32022,"briefTitle":32023,"status":107,"phases":32024,"primaryCompletion":6116,"start":7573,"enrollment":716,"conditions":32025,"interventions":32026},"NCT02172170","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects",[90],[15],[32015],{"trials":32028,"activeCount":101},[],{"trials":32030,"activeCount":101},[],{"trials":32032,"activeCount":101},[],{"trials":32034,"activeCount":101},[],{"intervention":28219,"totalTrials":272,"cells":32036},{"EARLY_PHASE1":32037,"PHASE1":32039,"PHASE2":32045,"PHASE3":32047,"PHASE4":32049,"NA":32051},{"trials":32038,"activeCount":101},[],{"trials":32040,"activeCount":101},[32041],{"nctId":28214,"briefTitle":28215,"status":107,"phases":32042,"primaryCompletion":6206,"start":6246,"enrollment":188,"conditions":32043,"interventions":32044},[90],[15],[28200,28219,28220],{"trials":32046,"activeCount":101},[],{"trials":32048,"activeCount":101},[],{"trials":32050,"activeCount":101},[],{"trials":32052,"activeCount":101},[],{"intervention":28220,"totalTrials":272,"cells":32054},{"EARLY_PHASE1":32055,"PHASE1":32057,"PHASE2":32063,"PHASE3":32065,"PHASE4":32067,"NA":32069},{"trials":32056,"activeCount":101},[],{"trials":32058,"activeCount":101},[32059],{"nctId":28214,"briefTitle":28215,"status":107,"phases":32060,"primaryCompletion":6206,"start":6246,"enrollment":188,"conditions":32061,"interventions":32062},[90],[15],[28200,28219,28220],{"trials":32064,"activeCount":101},[],{"trials":32066,"activeCount":101},[],{"trials":32068,"activeCount":101},[],{"trials":32070,"activeCount":101},[],{"intervention":32072,"totalTrials":272,"cells":32073},"BI 10773\u002Flinagliptin",{"EARLY_PHASE1":32074,"PHASE1":32076,"PHASE2":32086,"PHASE3":32088,"PHASE4":32090,"NA":32092},{"trials":32075,"activeCount":101},[],{"trials":32077,"activeCount":101},[32078],{"nctId":32079,"briefTitle":32080,"status":107,"phases":32081,"primaryCompletion":4441,"start":4442,"enrollment":331,"conditions":32082,"interventions":32083},"NCT01189201","Rel. BA of Empagliflozin (BI 10773)\u002FLinagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food",[90],[15],[32072,32072,32084,32085],"BI 10773\u002Flinagliptin SID","BI 10773\u002Flinagliptin FDC",{"trials":32087,"activeCount":101},[],{"trials":32089,"activeCount":101},[],{"trials":32091,"activeCount":101},[],{"trials":32093,"activeCount":101},[],{"intervention":32084,"totalTrials":272,"cells":32095},{"EARLY_PHASE1":32096,"PHASE1":32098,"PHASE2":32104,"PHASE3":32106,"PHASE4":32108,"NA":32110},{"trials":32097,"activeCount":101},[],{"trials":32099,"activeCount":101},[32100],{"nctId":32079,"briefTitle":32080,"status":107,"phases":32101,"primaryCompletion":4441,"start":4442,"enrollment":331,"conditions":32102,"interventions":32103},[90],[15],[32072,32072,32084,32085],{"trials":32105,"activeCount":101},[],{"trials":32107,"activeCount":101},[],{"trials":32109,"activeCount":101},[],{"trials":32111,"activeCount":101},[],{"intervention":32085,"totalTrials":272,"cells":32113},{"EARLY_PHASE1":32114,"PHASE1":32116,"PHASE2":32122,"PHASE3":32124,"PHASE4":32126,"NA":32128},{"trials":32115,"activeCount":101},[],{"trials":32117,"activeCount":101},[32118],{"nctId":32079,"briefTitle":32080,"status":107,"phases":32119,"primaryCompletion":4441,"start":4442,"enrollment":331,"conditions":32120,"interventions":32121},[90],[15],[32072,32072,32084,32085],{"trials":32123,"activeCount":101},[],{"trials":32125,"activeCount":101},[],{"trials":32127,"activeCount":101},[],{"trials":32129,"activeCount":101},[],{"intervention":32131,"totalTrials":272,"cells":32132},"BIIL 284 BS, high dose",{"EARLY_PHASE1":32133,"PHASE1":32135,"PHASE2":32144,"PHASE3":32146,"PHASE4":32148,"NA":32150},{"trials":32134,"activeCount":101},[],{"trials":32136,"activeCount":101},[32137],{"nctId":32138,"briefTitle":32139,"status":107,"phases":32140,"primaryCompletion":6082,"start":6029,"enrollment":448,"conditions":32141,"interventions":32142},"NCT02269189","Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients",[90],[1724],[32131,32143],"BIIL 284 BS, low dose",{"trials":32145,"activeCount":101},[],{"trials":32147,"activeCount":101},[],{"trials":32149,"activeCount":101},[],{"trials":32151,"activeCount":101},[],{"intervention":32143,"totalTrials":272,"cells":32153},{"EARLY_PHASE1":32154,"PHASE1":32156,"PHASE2":32162,"PHASE3":32164,"PHASE4":32166,"NA":32168},{"trials":32155,"activeCount":101},[],{"trials":32157,"activeCount":101},[32158],{"nctId":32138,"briefTitle":32139,"status":107,"phases":32159,"primaryCompletion":6082,"start":6029,"enrollment":448,"conditions":32160,"interventions":32161},[90],[1724],[32131,32143],{"trials":32163,"activeCount":101},[],{"trials":32165,"activeCount":101},[],{"trials":32167,"activeCount":101},[],{"trials":32169,"activeCount":101},[],{"intervention":32171,"totalTrials":272,"cells":32172},"adalimumab",{"EARLY_PHASE1":32173,"PHASE1":32175,"PHASE2":32185,"PHASE3":32187,"PHASE4":32189,"NA":32191},{"trials":32174,"activeCount":101},[],{"trials":32176,"activeCount":101},[32177],{"nctId":32178,"briefTitle":32179,"status":107,"phases":32180,"primaryCompletion":18727,"completion":18727,"start":6328,"enrollment":32181,"conditions":32182,"interventions":32183},"NCT01505491","Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects",[90],193,[15],[32171,32184,32171],"BI695501",{"trials":32186,"activeCount":101},[],{"trials":32188,"activeCount":101},[],{"trials":32190,"activeCount":101},[],{"trials":32192,"activeCount":101},[],{"intervention":32184,"totalTrials":272,"cells":32194},{"EARLY_PHASE1":32195,"PHASE1":32197,"PHASE2":32203,"PHASE3":32205,"PHASE4":32207,"NA":32209},{"trials":32196,"activeCount":101},[],{"trials":32198,"activeCount":101},[32199],{"nctId":32178,"briefTitle":32179,"status":107,"phases":32200,"primaryCompletion":18727,"completion":18727,"start":6328,"enrollment":32181,"conditions":32201,"interventions":32202},[90],[15],[32171,32184,32171],{"trials":32204,"activeCount":101},[],{"trials":32206,"activeCount":101},[],{"trials":32208,"activeCount":101},[],{"trials":32210,"activeCount":101},[],{"intervention":32212,"totalTrials":272,"cells":32213},"Dabigatran polymorph I",{"EARLY_PHASE1":32214,"PHASE1":32216,"PHASE2":32224,"PHASE3":32226,"PHASE4":32228,"NA":32230},{"trials":32215,"activeCount":101},[],{"trials":32217,"activeCount":101},[32218],{"nctId":32219,"briefTitle":32220,"status":107,"phases":32221,"primaryCompletion":2145,"start":6156,"enrollment":3565,"conditions":32222,"interventions":32223},"NCT02171013","Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers",[90],[15],[32212,32212],{"trials":32225,"activeCount":101},[],{"trials":32227,"activeCount":101},[],{"trials":32229,"activeCount":101},[],{"trials":32231,"activeCount":101},[],{"intervention":19960,"totalTrials":272,"cells":32233},{"EARLY_PHASE1":32234,"PHASE1":32236,"PHASE2":32242,"PHASE3":32244,"PHASE4":32246,"NA":32248},{"trials":32235,"activeCount":101},[],{"trials":32237,"activeCount":101},[32238],{"nctId":19955,"briefTitle":19956,"status":107,"phases":32239,"primaryCompletion":2162,"start":2122,"enrollment":401,"conditions":32240,"interventions":32241},[90],[15],[2166,19960],{"trials":32243,"activeCount":101},[],{"trials":32245,"activeCount":101},[],{"trials":32247,"activeCount":101},[],{"trials":32249,"activeCount":101},[],{"intervention":27132,"totalTrials":272,"cells":32251},{"EARLY_PHASE1":32252,"PHASE1":32254,"PHASE2":32260,"PHASE3":32262,"PHASE4":32264,"NA":32266},{"trials":32253,"activeCount":101},[],{"trials":32255,"activeCount":101},[32256],{"nctId":27127,"briefTitle":27128,"status":107,"phases":32257,"primaryCompletion":6446,"start":2112,"enrollment":439,"conditions":32258,"interventions":32259},[90],[15],[27132,27133,949],{"trials":32261,"activeCount":101},[],{"trials":32263,"activeCount":101},[],{"trials":32265,"activeCount":101},[],{"trials":32267,"activeCount":101},[],{"intervention":27133,"totalTrials":272,"cells":32269},{"EARLY_PHASE1":32270,"PHASE1":32272,"PHASE2":32278,"PHASE3":32280,"PHASE4":32282,"NA":32284},{"trials":32271,"activeCount":101},[],{"trials":32273,"activeCount":101},[32274],{"nctId":27127,"briefTitle":27128,"status":107,"phases":32275,"primaryCompletion":6446,"start":2112,"enrollment":439,"conditions":32276,"interventions":32277},[90],[15],[27132,27133,949],{"trials":32279,"activeCount":101},[],{"trials":32281,"activeCount":101},[],{"trials":32283,"activeCount":101},[],{"trials":32285,"activeCount":101},[],{"intervention":10955,"totalTrials":272,"cells":32287},{"EARLY_PHASE1":32288,"PHASE1":32290,"PHASE2":32296,"PHASE3":32298,"PHASE4":32300,"NA":32302},{"trials":32289,"activeCount":101},[],{"trials":32291,"activeCount":101},[32292],{"nctId":10947,"briefTitle":10948,"status":107,"phases":32293,"primaryCompletion":724,"completion":724,"start":10950,"enrollment":10951,"conditions":32294,"interventions":32295},[90],[10953],[10940,10955],{"trials":32297,"activeCount":101},[],{"trials":32299,"activeCount":101},[],{"trials":32301,"activeCount":101},[],{"trials":32303,"activeCount":101},[],{"intervention":32305,"totalTrials":272,"cells":32306},"Ambroxol - in single rising doses",{"EARLY_PHASE1":32307,"PHASE1":32309,"PHASE2":32317,"PHASE3":32319,"PHASE4":32321,"NA":32323},{"trials":32308,"activeCount":101},[],{"trials":32310,"activeCount":101},[32311],{"nctId":32312,"briefTitle":32313,"status":107,"phases":32314,"primaryCompletion":399,"start":9443,"enrollment":1237,"conditions":32315,"interventions":32316},"NCT02194283","Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers",[90],[15],[32305],{"trials":32318,"activeCount":101},[],{"trials":32320,"activeCount":101},[],{"trials":32322,"activeCount":101},[],{"trials":32324,"activeCount":101},[],{"intervention":32326,"totalTrials":272,"cells":32327},"Nevirapine XR low dose",{"EARLY_PHASE1":32328,"PHASE1":32330,"PHASE2":32340,"PHASE3":32342,"PHASE4":32344,"NA":32346},{"trials":32329,"activeCount":101},[],{"trials":32331,"activeCount":101},[32332],{"nctId":32333,"briefTitle":32334,"status":107,"phases":32335,"primaryCompletion":6224,"start":6471,"enrollment":8,"conditions":32336,"interventions":32337},"NCT02184312","Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers",[90],[15],[32326,32338,32339,2186],"Nevirapine XR medium dose","Nevirapine XR high dose",{"trials":32341,"activeCount":101},[],{"trials":32343,"activeCount":101},[],{"trials":32345,"activeCount":101},[],{"trials":32347,"activeCount":101},[],{"intervention":32338,"totalTrials":272,"cells":32349},{"EARLY_PHASE1":32350,"PHASE1":32352,"PHASE2":32358,"PHASE3":32360,"PHASE4":32362,"NA":32364},{"trials":32351,"activeCount":101},[],{"trials":32353,"activeCount":101},[32354],{"nctId":32333,"briefTitle":32334,"status":107,"phases":32355,"primaryCompletion":6224,"start":6471,"enrollment":8,"conditions":32356,"interventions":32357},[90],[15],[32326,32338,32339,2186],{"trials":32359,"activeCount":101},[],{"trials":32361,"activeCount":101},[],{"trials":32363,"activeCount":101},[],{"trials":32365,"activeCount":101},[],{"intervention":32339,"totalTrials":272,"cells":32367},{"EARLY_PHASE1":32368,"PHASE1":32370,"PHASE2":32376,"PHASE3":32378,"PHASE4":32380,"NA":32382},{"trials":32369,"activeCount":101},[],{"trials":32371,"activeCount":101},[32372],{"nctId":32333,"briefTitle":32334,"status":107,"phases":32373,"primaryCompletion":6224,"start":6471,"enrollment":8,"conditions":32374,"interventions":32375},[90],[15],[32326,32338,32339,2186],{"trials":32377,"activeCount":101},[],{"trials":32379,"activeCount":101},[],{"trials":32381,"activeCount":101},[],{"trials":32383,"activeCount":101},[],{"intervention":1624,"totalTrials":272,"cells":32385},{"EARLY_PHASE1":32386,"PHASE1":32388,"PHASE2":32394,"PHASE3":32396,"PHASE4":32398,"NA":32400},{"trials":32387,"activeCount":101},[],{"trials":32389,"activeCount":101},[32390],{"nctId":1618,"briefTitle":1619,"status":107,"phases":32391,"primaryCompletion":1358,"completion":1358,"start":1621,"enrollment":177,"conditions":32392,"interventions":32393},[90],[15],[1595,1624],{"trials":32395,"activeCount":101},[],{"trials":32397,"activeCount":101},[],{"trials":32399,"activeCount":101},[],{"trials":32401,"activeCount":101},[],{"intervention":32403,"totalTrials":272,"cells":32404},"Salmeterol capsule - low",{"EARLY_PHASE1":32405,"PHASE1":32407,"PHASE2":32417,"PHASE3":32419,"PHASE4":32421,"NA":32423},{"trials":32406,"activeCount":101},[],{"trials":32408,"activeCount":101},[32409],{"nctId":32410,"briefTitle":32411,"status":107,"phases":32412,"primaryCompletion":5843,"start":1981,"enrollment":357,"conditions":32413,"interventions":32414},"NCT02254187","Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers",[90],[15],[32403,32415,32416],"Salmeterol capsule - high","Salmeterol via Serevent® Diskus®",{"trials":32418,"activeCount":101},[],{"trials":32420,"activeCount":101},[],{"trials":32422,"activeCount":101},[],{"trials":32424,"activeCount":101},[],{"intervention":32415,"totalTrials":272,"cells":32426},{"EARLY_PHASE1":32427,"PHASE1":32429,"PHASE2":32435,"PHASE3":32437,"PHASE4":32439,"NA":32441},{"trials":32428,"activeCount":101},[],{"trials":32430,"activeCount":101},[32431],{"nctId":32410,"briefTitle":32411,"status":107,"phases":32432,"primaryCompletion":5843,"start":1981,"enrollment":357,"conditions":32433,"interventions":32434},[90],[15],[32403,32415,32416],{"trials":32436,"activeCount":101},[],{"trials":32438,"activeCount":101},[],{"trials":32440,"activeCount":101},[],{"trials":32442,"activeCount":101},[],{"intervention":32416,"totalTrials":272,"cells":32444},{"EARLY_PHASE1":32445,"PHASE1":32447,"PHASE2":32453,"PHASE3":32455,"PHASE4":32457,"NA":32459},{"trials":32446,"activeCount":101},[],{"trials":32448,"activeCount":101},[32449],{"nctId":32410,"briefTitle":32411,"status":107,"phases":32450,"primaryCompletion":5843,"start":1981,"enrollment":357,"conditions":32451,"interventions":32452},[90],[15],[32403,32415,32416],{"trials":32454,"activeCount":101},[],{"trials":32456,"activeCount":101},[],{"trials":32458,"activeCount":101},[],{"trials":32460,"activeCount":101},[],{"intervention":29422,"totalTrials":272,"cells":32462},{"EARLY_PHASE1":32463,"PHASE1":32465,"PHASE2":32471,"PHASE3":32473,"PHASE4":32475,"NA":32477},{"trials":32464,"activeCount":101},[],{"trials":32466,"activeCount":101},[32467],{"nctId":29417,"briefTitle":29418,"status":107,"phases":32468,"primaryCompletion":7618,"start":9276,"enrollment":357,"conditions":32469,"interventions":32470},[90],[15],[6121,29410,29422],{"trials":32472,"activeCount":101},[],{"trials":32474,"activeCount":101},[],{"trials":32476,"activeCount":101},[],{"trials":32478,"activeCount":101},[],{"intervention":32480,"totalTrials":272,"cells":32481},"Pramipexole manufactured in Ingelheim",{"EARLY_PHASE1":32482,"PHASE1":32484,"PHASE2":32493,"PHASE3":32495,"PHASE4":32497,"NA":32499},{"trials":32483,"activeCount":101},[],{"trials":32485,"activeCount":101},[32486],{"nctId":32487,"briefTitle":32488,"status":107,"phases":32489,"primaryCompletion":1226,"completion":1226,"start":561,"enrollment":1865,"conditions":32490,"interventions":32491},"NCT06457204","A Study in Healthy People to Compare Two Different Sifrol® Tablets",[90],[15],[32480,32492],"Pramipexole manufactured in Ennigerloh",{"trials":32494,"activeCount":101},[],{"trials":32496,"activeCount":101},[],{"trials":32498,"activeCount":101},[],{"trials":32500,"activeCount":101},[],{"intervention":32492,"totalTrials":272,"cells":32502},{"EARLY_PHASE1":32503,"PHASE1":32505,"PHASE2":32511,"PHASE3":32513,"PHASE4":32515,"NA":32517},{"trials":32504,"activeCount":101},[],{"trials":32506,"activeCount":101},[32507],{"nctId":32487,"briefTitle":32488,"status":107,"phases":32508,"primaryCompletion":1226,"completion":1226,"start":561,"enrollment":1865,"conditions":32509,"interventions":32510},[90],[15],[32480,32492],{"trials":32512,"activeCount":101},[],{"trials":32514,"activeCount":101},[],{"trials":32516,"activeCount":101},[],{"trials":32518,"activeCount":101},[],{"intervention":2632,"totalTrials":272,"cells":32520},{"EARLY_PHASE1":32521,"PHASE1":32523,"PHASE2":32529,"PHASE3":32531,"PHASE4":32533,"NA":32535},{"trials":32522,"activeCount":101},[],{"trials":32524,"activeCount":101},[32525],{"nctId":2623,"briefTitle":2624,"status":107,"phases":32526,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":912,"conditions":32527,"interventions":32528},[90],[2629,2630],[2632,2633,2616,2632,2633,2633],{"trials":32530,"activeCount":101},[],{"trials":32532,"activeCount":101},[],{"trials":32534,"activeCount":101},[],{"trials":32536,"activeCount":101},[],{"intervention":32538,"totalTrials":272,"cells":32539},"Tiotropium bromide low",{"EARLY_PHASE1":32540,"PHASE1":32542,"PHASE2":32552,"PHASE3":32554,"PHASE4":32556,"NA":32558},{"trials":32541,"activeCount":101},[],{"trials":32543,"activeCount":101},[32544],{"nctId":32545,"briefTitle":32546,"status":107,"phases":32547,"primaryCompletion":5856,"start":6911,"enrollment":5407,"conditions":32548,"interventions":32549},"NCT02172534","Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients",[90],[1724],[32538,32550,32551],"Tiotropium bromide medium","Tiotropium bromide high",{"trials":32553,"activeCount":101},[],{"trials":32555,"activeCount":101},[],{"trials":32557,"activeCount":101},[],{"trials":32559,"activeCount":101},[],{"intervention":32550,"totalTrials":272,"cells":32561},{"EARLY_PHASE1":32562,"PHASE1":32564,"PHASE2":32570,"PHASE3":32572,"PHASE4":32574,"NA":32576},{"trials":32563,"activeCount":101},[],{"trials":32565,"activeCount":101},[32566],{"nctId":32545,"briefTitle":32546,"status":107,"phases":32567,"primaryCompletion":5856,"start":6911,"enrollment":5407,"conditions":32568,"interventions":32569},[90],[1724],[32538,32550,32551],{"trials":32571,"activeCount":101},[],{"trials":32573,"activeCount":101},[],{"trials":32575,"activeCount":101},[],{"trials":32577,"activeCount":101},[],{"intervention":32551,"totalTrials":272,"cells":32579},{"EARLY_PHASE1":32580,"PHASE1":32582,"PHASE2":32588,"PHASE3":32590,"PHASE4":32592,"NA":32594},{"trials":32581,"activeCount":101},[],{"trials":32583,"activeCount":101},[32584],{"nctId":32545,"briefTitle":32546,"status":107,"phases":32585,"primaryCompletion":5856,"start":6911,"enrollment":5407,"conditions":32586,"interventions":32587},[90],[1724],[32538,32550,32551],{"trials":32589,"activeCount":101},[],{"trials":32591,"activeCount":101},[],{"trials":32593,"activeCount":101},[],{"trials":32595,"activeCount":101},[],{"intervention":32597,"totalTrials":272,"cells":32598},"Linagliptin - single dose",{"EARLY_PHASE1":32599,"PHASE1":32601,"PHASE2":32610,"PHASE3":32612,"PHASE4":32614,"NA":32616},{"trials":32600,"activeCount":101},[],{"trials":32602,"activeCount":101},[32603],{"nctId":32604,"briefTitle":32605,"status":107,"phases":32606,"primaryCompletion":17427,"start":6471,"enrollment":5205,"conditions":32607,"interventions":32608},"NCT02191228","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function",[90],[2550],[32597,32609],"Linagliptin - Multiple dose",{"trials":32611,"activeCount":101},[],{"trials":32613,"activeCount":101},[],{"trials":32615,"activeCount":101},[],{"trials":32617,"activeCount":101},[],{"intervention":32609,"totalTrials":272,"cells":32619},{"EARLY_PHASE1":32620,"PHASE1":32622,"PHASE2":32628,"PHASE3":32630,"PHASE4":32632,"NA":32634},{"trials":32621,"activeCount":101},[],{"trials":32623,"activeCount":101},[32624],{"nctId":32604,"briefTitle":32605,"status":107,"phases":32625,"primaryCompletion":17427,"start":6471,"enrollment":5205,"conditions":32626,"interventions":32627},[90],[2550],[32597,32609],{"trials":32629,"activeCount":101},[],{"trials":32631,"activeCount":101},[],{"trials":32633,"activeCount":101},[],{"trials":32635,"activeCount":101},[],{"intervention":32637,"totalTrials":272,"cells":32638},"UH-AC 62 XX",{"EARLY_PHASE1":32639,"PHASE1":32641,"PHASE2":32649,"PHASE3":32651,"PHASE4":32653,"NA":32655},{"trials":32640,"activeCount":101},[],{"trials":32642,"activeCount":101},[32643],{"nctId":32644,"briefTitle":32645,"status":107,"phases":32646,"primaryCompletion":7124,"start":11650,"enrollment":210,"conditions":32647,"interventions":32648},"NCT02181907","Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers",[90],[15],[32637,32637],{"trials":32650,"activeCount":101},[],{"trials":32652,"activeCount":101},[],{"trials":32654,"activeCount":101},[],{"trials":32656,"activeCount":101},[],{"intervention":32658,"totalTrials":272,"cells":32659},"low dose",{"EARLY_PHASE1":32660,"PHASE1":32662,"PHASE2":32671,"PHASE3":32673,"PHASE4":32675,"NA":32677},{"trials":32661,"activeCount":101},[],{"trials":32663,"activeCount":101},[32664],{"nctId":32665,"briefTitle":32666,"status":107,"phases":32667,"primaryCompletion":5296,"start":2030,"enrollment":993,"conditions":32668,"interventions":32669},"NCT01371006","Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4\u002F5 Metabolism in Healthy Volunteers",[90],[15],[32658,32670,32658],"normal dose",{"trials":32672,"activeCount":101},[],{"trials":32674,"activeCount":101},[],{"trials":32676,"activeCount":101},[],{"trials":32678,"activeCount":101},[],{"intervention":32670,"totalTrials":272,"cells":32680},{"EARLY_PHASE1":32681,"PHASE1":32683,"PHASE2":32689,"PHASE3":32691,"PHASE4":32693,"NA":32695},{"trials":32682,"activeCount":101},[],{"trials":32684,"activeCount":101},[32685],{"nctId":32665,"briefTitle":32666,"status":107,"phases":32686,"primaryCompletion":5296,"start":2030,"enrollment":993,"conditions":32687,"interventions":32688},[90],[15],[32658,32670,32658],{"trials":32690,"activeCount":101},[],{"trials":32692,"activeCount":101},[],{"trials":32694,"activeCount":101},[],{"trials":32696,"activeCount":101},[],{"intervention":32698,"totalTrials":272,"cells":32699},"Dose escalation followed by treatment with MTD",{"EARLY_PHASE1":32700,"PHASE1":32702,"PHASE2":32710,"PHASE3":32712,"PHASE4":32714,"NA":32716},{"trials":32701,"activeCount":101},[],{"trials":32703,"activeCount":101},[32704],{"nctId":32705,"briefTitle":32706,"status":107,"phases":32707,"primaryCompletion":438,"completion":438,"start":9491,"enrollment":1418,"conditions":32708,"interventions":32709},"NCT01647711","A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",[90],[36],[32698],{"trials":32711,"activeCount":101},[],{"trials":32713,"activeCount":101},[],{"trials":32715,"activeCount":101},[],{"trials":32717,"activeCount":101},[],{"intervention":20443,"totalTrials":272,"cells":32719},{"EARLY_PHASE1":32720,"PHASE1":32722,"PHASE2":32728,"PHASE3":32730,"PHASE4":32732,"NA":32734},{"trials":32721,"activeCount":101},[],{"trials":32723,"activeCount":101},[32724],{"nctId":20436,"briefTitle":20437,"status":107,"phases":32725,"primaryCompletion":18933,"completion":20439,"start":2626,"enrollment":112,"conditions":32726,"interventions":32727},[90],[20441],[13488,20443],{"trials":32729,"activeCount":101},[],{"trials":32731,"activeCount":101},[],{"trials":32733,"activeCount":101},[],{"trials":32735,"activeCount":101},[],{"intervention":32737,"totalTrials":272,"cells":32738},"BIBF 1120 (high) + PLD 30 mg\u002Fm2 + CBDCA AUC5 mg\u002FmL*min",{"EARLY_PHASE1":32739,"PHASE1":32741,"PHASE2":32751,"PHASE3":32753,"PHASE4":32755,"NA":32757},{"trials":32740,"activeCount":101},[],{"trials":32742,"activeCount":101},[32743],{"nctId":32744,"briefTitle":32745,"status":162,"phases":32746,"primaryCompletion":517,"completion":517,"start":9340,"enrollment":1075,"conditions":32747,"interventions":32748},"NCT01329549","Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)",[90],[1187],[32737,32749,32750],"BIBF 1120 (medium) + PLD 30 mg\u002Fm2 + CBDCA AUC5 mg\u002FmL*min","BIBF 1120 (low) + PLD 30 mg\u002Fm2 + CBDCA AUC5 mg\u002FmL*min",{"trials":32752,"activeCount":101},[],{"trials":32754,"activeCount":101},[],{"trials":32756,"activeCount":101},[],{"trials":32758,"activeCount":101},[],{"intervention":32749,"totalTrials":272,"cells":32760},{"EARLY_PHASE1":32761,"PHASE1":32763,"PHASE2":32769,"PHASE3":32771,"PHASE4":32773,"NA":32775},{"trials":32762,"activeCount":101},[],{"trials":32764,"activeCount":101},[32765],{"nctId":32744,"briefTitle":32745,"status":162,"phases":32766,"primaryCompletion":517,"completion":517,"start":9340,"enrollment":1075,"conditions":32767,"interventions":32768},[90],[1187],[32737,32749,32750],{"trials":32770,"activeCount":101},[],{"trials":32772,"activeCount":101},[],{"trials":32774,"activeCount":101},[],{"trials":32776,"activeCount":101},[],{"intervention":32750,"totalTrials":272,"cells":32778},{"EARLY_PHASE1":32779,"PHASE1":32781,"PHASE2":32787,"PHASE3":32789,"PHASE4":32791,"NA":32793},{"trials":32780,"activeCount":101},[],{"trials":32782,"activeCount":101},[32783],{"nctId":32744,"briefTitle":32745,"status":162,"phases":32784,"primaryCompletion":517,"completion":517,"start":9340,"enrollment":1075,"conditions":32785,"interventions":32786},[90],[1187],[32737,32749,32750],{"trials":32788,"activeCount":101},[],{"trials":32790,"activeCount":101},[],{"trials":32792,"activeCount":101},[],{"trials":32794,"activeCount":101},[],{"intervention":32796,"totalTrials":272,"cells":32797},"BIBP 5371 CL",{"EARLY_PHASE1":32798,"PHASE1":32800,"PHASE2":32811,"PHASE3":32813,"PHASE4":32815,"NA":32817},{"trials":32799,"activeCount":101},[],{"trials":32801,"activeCount":101},[32802],{"nctId":32803,"briefTitle":32804,"status":107,"phases":32805,"primaryCompletion":8479,"start":6446,"enrollment":2507,"conditions":32806,"interventions":32807},"NCT02256709","Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers",[90],[15],[32796,32808,32809,32810],"BIBP 5371 CL solution","BIBP 5371 CL tablet high dose","BIBP 5371 CL tablet low dose",{"trials":32812,"activeCount":101},[],{"trials":32814,"activeCount":101},[],{"trials":32816,"activeCount":101},[],{"trials":32818,"activeCount":101},[],{"intervention":32808,"totalTrials":272,"cells":32820},{"EARLY_PHASE1":32821,"PHASE1":32823,"PHASE2":32829,"PHASE3":32831,"PHASE4":32833,"NA":32835},{"trials":32822,"activeCount":101},[],{"trials":32824,"activeCount":101},[32825],{"nctId":32803,"briefTitle":32804,"status":107,"phases":32826,"primaryCompletion":8479,"start":6446,"enrollment":2507,"conditions":32827,"interventions":32828},[90],[15],[32796,32808,32809,32810],{"trials":32830,"activeCount":101},[],{"trials":32832,"activeCount":101},[],{"trials":32834,"activeCount":101},[],{"trials":32836,"activeCount":101},[],{"intervention":32809,"totalTrials":272,"cells":32838},{"EARLY_PHASE1":32839,"PHASE1":32841,"PHASE2":32847,"PHASE3":32849,"PHASE4":32851,"NA":32853},{"trials":32840,"activeCount":101},[],{"trials":32842,"activeCount":101},[32843],{"nctId":32803,"briefTitle":32804,"status":107,"phases":32844,"primaryCompletion":8479,"start":6446,"enrollment":2507,"conditions":32845,"interventions":32846},[90],[15],[32796,32808,32809,32810],{"trials":32848,"activeCount":101},[],{"trials":32850,"activeCount":101},[],{"trials":32852,"activeCount":101},[],{"trials":32854,"activeCount":101},[],{"intervention":32810,"totalTrials":272,"cells":32856},{"EARLY_PHASE1":32857,"PHASE1":32859,"PHASE2":32865,"PHASE3":32867,"PHASE4":32869,"NA":32871},{"trials":32858,"activeCount":101},[],{"trials":32860,"activeCount":101},[32861],{"nctId":32803,"briefTitle":32804,"status":107,"phases":32862,"primaryCompletion":8479,"start":6446,"enrollment":2507,"conditions":32863,"interventions":32864},[90],[15],[32796,32808,32809,32810],{"trials":32866,"activeCount":101},[],{"trials":32868,"activeCount":101},[],{"trials":32870,"activeCount":101},[],{"trials":32872,"activeCount":101},[],{"intervention":32874,"totalTrials":272,"cells":32875},"BI 894999",{"EARLY_PHASE1":32876,"PHASE1":32878,"PHASE2":32888,"PHASE3":32890,"PHASE4":32892,"NA":32894},{"trials":32877,"activeCount":101},[],{"trials":32879,"activeCount":101},[32880],{"nctId":32881,"briefTitle":32882,"status":107,"phases":32883,"primaryCompletion":32884,"completion":32884,"start":11546,"enrollment":12724,"conditions":32885,"interventions":32887},"NCT02516553","BI 894999 First in Human Dose Finding Study in Advanced Malignancies",[90],"2021-11-23",[33,32886],"NUT Carcinoma",[32874],{"trials":32889,"activeCount":101},[],{"trials":32891,"activeCount":101},[],{"trials":32893,"activeCount":101},[],{"trials":32895,"activeCount":101},[],{"intervention":372,"totalTrials":272,"cells":32897},{"EARLY_PHASE1":32898,"PHASE1":32900,"PHASE2":32906,"PHASE3":32908,"PHASE4":32910,"NA":32912},{"trials":32899,"activeCount":101},[],{"trials":32901,"activeCount":101},[32902],{"nctId":364,"briefTitle":365,"status":107,"phases":32903,"primaryCompletion":367,"completion":368,"start":369,"enrollment":132,"conditions":32904,"interventions":32905},[90],[15],[372,73,373],{"trials":32907,"activeCount":101},[],{"trials":32909,"activeCount":101},[],{"trials":32911,"activeCount":101},[],{"trials":32913,"activeCount":101},[],{"intervention":373,"totalTrials":272,"cells":32915},{"EARLY_PHASE1":32916,"PHASE1":32918,"PHASE2":32924,"PHASE3":32926,"PHASE4":32928,"NA":32930},{"trials":32917,"activeCount":101},[],{"trials":32919,"activeCount":101},[32920],{"nctId":364,"briefTitle":365,"status":107,"phases":32921,"primaryCompletion":367,"completion":368,"start":369,"enrollment":132,"conditions":32922,"interventions":32923},[90],[15],[372,73,373],{"trials":32925,"activeCount":101},[],{"trials":32927,"activeCount":101},[],{"trials":32929,"activeCount":101},[],{"trials":32931,"activeCount":101},[],{"intervention":32933,"totalTrials":272,"cells":32934},"Telmisartan\u002FAmlodipine FDC",{"EARLY_PHASE1":32935,"PHASE1":32937,"PHASE2":32945,"PHASE3":32947,"PHASE4":32949,"NA":32951},{"trials":32936,"activeCount":101},[],{"trials":32938,"activeCount":101},[32939],{"nctId":32940,"briefTitle":32941,"status":107,"phases":32942,"primaryCompletion":9418,"start":6140,"enrollment":6117,"conditions":32943,"interventions":32944},"NCT02193308","Bioequivalence of Telmisartan\u002FAmlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers",[90],[15],[32933,6121,10908],{"trials":32946,"activeCount":101},[],{"trials":32948,"activeCount":101},[],{"trials":32950,"activeCount":101},[],{"trials":32952,"activeCount":101},[],{"intervention":32954,"totalTrials":272,"cells":32955},"BIBF 1120 M + Pemetrexed",{"EARLY_PHASE1":32956,"PHASE1":32958,"PHASE2":32972,"PHASE3":32974,"PHASE4":32976,"NA":32978},{"trials":32957,"activeCount":101},[],{"trials":32959,"activeCount":101},[32960],{"nctId":32961,"briefTitle":32962,"status":162,"phases":32963,"primaryCompletion":32964,"completion":32964,"start":32965,"enrollment":2442,"conditions":32966,"interventions":32967},"NCT00979576","BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)",[90],"2015-02-16","2009-10-16",[36],[32954,32968,32969,32970,32971],"BIBF 1120 H + Pemetrexed","BIBF 1120 RD + Pemetrexed","BIBF 1120 L + Pemetrexed","BIBF 1120 Placebo + Pemetrexed",{"trials":32973,"activeCount":101},[],{"trials":32975,"activeCount":101},[],{"trials":32977,"activeCount":101},[],{"trials":32979,"activeCount":101},[],{"intervention":32968,"totalTrials":272,"cells":32981},{"EARLY_PHASE1":32982,"PHASE1":32984,"PHASE2":32990,"PHASE3":32992,"PHASE4":32994,"NA":32996},{"trials":32983,"activeCount":101},[],{"trials":32985,"activeCount":101},[32986],{"nctId":32961,"briefTitle":32962,"status":162,"phases":32987,"primaryCompletion":32964,"completion":32964,"start":32965,"enrollment":2442,"conditions":32988,"interventions":32989},[90],[36],[32954,32968,32969,32970,32971],{"trials":32991,"activeCount":101},[],{"trials":32993,"activeCount":101},[],{"trials":32995,"activeCount":101},[],{"trials":32997,"activeCount":101},[],{"intervention":32969,"totalTrials":272,"cells":32999},{"EARLY_PHASE1":33000,"PHASE1":33002,"PHASE2":33008,"PHASE3":33010,"PHASE4":33012,"NA":33014},{"trials":33001,"activeCount":101},[],{"trials":33003,"activeCount":101},[33004],{"nctId":32961,"briefTitle":32962,"status":162,"phases":33005,"primaryCompletion":32964,"completion":32964,"start":32965,"enrollment":2442,"conditions":33006,"interventions":33007},[90],[36],[32954,32968,32969,32970,32971],{"trials":33009,"activeCount":101},[],{"trials":33011,"activeCount":101},[],{"trials":33013,"activeCount":101},[],{"trials":33015,"activeCount":101},[],{"intervention":32970,"totalTrials":272,"cells":33017},{"EARLY_PHASE1":33018,"PHASE1":33020,"PHASE2":33026,"PHASE3":33028,"PHASE4":33030,"NA":33032},{"trials":33019,"activeCount":101},[],{"trials":33021,"activeCount":101},[33022],{"nctId":32961,"briefTitle":32962,"status":162,"phases":33023,"primaryCompletion":32964,"completion":32964,"start":32965,"enrollment":2442,"conditions":33024,"interventions":33025},[90],[36],[32954,32968,32969,32970,32971],{"trials":33027,"activeCount":101},[],{"trials":33029,"activeCount":101},[],{"trials":33031,"activeCount":101},[],{"trials":33033,"activeCount":101},[],{"intervention":32971,"totalTrials":272,"cells":33035},{"EARLY_PHASE1":33036,"PHASE1":33038,"PHASE2":33044,"PHASE3":33046,"PHASE4":33048,"NA":33050},{"trials":33037,"activeCount":101},[],{"trials":33039,"activeCount":101},[33040],{"nctId":32961,"briefTitle":32962,"status":162,"phases":33041,"primaryCompletion":32964,"completion":32964,"start":32965,"enrollment":2442,"conditions":33042,"interventions":33043},[90],[36],[32954,32968,32969,32970,32971],{"trials":33045,"activeCount":101},[],{"trials":33047,"activeCount":101},[],{"trials":33049,"activeCount":101},[],{"trials":33051,"activeCount":101},[],{"intervention":19832,"totalTrials":272,"cells":33053},{"EARLY_PHASE1":33054,"PHASE1":33056,"PHASE2":33062,"PHASE3":33064,"PHASE4":33066,"NA":33068},{"trials":33055,"activeCount":101},[],{"trials":33057,"activeCount":101},[33058],{"nctId":19824,"briefTitle":19825,"status":162,"phases":33059,"primaryCompletion":19827,"completion":19828,"start":19829,"enrollment":155,"conditions":33060,"interventions":33061},[90],[36,3766],[3470,19832,3845],{"trials":33063,"activeCount":101},[],{"trials":33065,"activeCount":101},[],{"trials":33067,"activeCount":101},[],{"trials":33069,"activeCount":101},[],{"intervention":29451,"totalTrials":272,"cells":33071},{"EARLY_PHASE1":33072,"PHASE1":33074,"PHASE2":33080,"PHASE3":33082,"PHASE4":33084,"NA":33086},{"trials":33073,"activeCount":101},[],{"trials":33075,"activeCount":101},[33076],{"nctId":29446,"briefTitle":29447,"status":107,"phases":33077,"primaryCompletion":6471,"start":4507,"enrollment":188,"conditions":33078,"interventions":33079},[90],[15],[29451,29439],{"trials":33081,"activeCount":101},[],{"trials":33083,"activeCount":101},[],{"trials":33085,"activeCount":101},[],{"trials":33087,"activeCount":101},[],{"intervention":33089,"totalTrials":272,"cells":33090},"Asasantin",{"EARLY_PHASE1":33091,"PHASE1":33093,"PHASE2":33103,"PHASE3":33105,"PHASE4":33107,"NA":33109},{"trials":33092,"activeCount":101},[],{"trials":33094,"activeCount":101},[33095],{"nctId":33096,"briefTitle":33097,"status":107,"phases":33098,"primaryCompletion":2122,"start":2163,"enrollment":1672,"conditions":33099,"interventions":33100},"NCT02273505","Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects",[90],[15],[33089,33101,33102],"Persantin","Acetyl salicylic acid",{"trials":33104,"activeCount":101},[],{"trials":33106,"activeCount":101},[],{"trials":33108,"activeCount":101},[],{"trials":33110,"activeCount":101},[],{"intervention":33101,"totalTrials":272,"cells":33112},{"EARLY_PHASE1":33113,"PHASE1":33115,"PHASE2":33121,"PHASE3":33123,"PHASE4":33125,"NA":33127},{"trials":33114,"activeCount":101},[],{"trials":33116,"activeCount":101},[33117],{"nctId":33096,"briefTitle":33097,"status":107,"phases":33118,"primaryCompletion":2122,"start":2163,"enrollment":1672,"conditions":33119,"interventions":33120},[90],[15],[33089,33101,33102],{"trials":33122,"activeCount":101},[],{"trials":33124,"activeCount":101},[],{"trials":33126,"activeCount":101},[],{"trials":33128,"activeCount":101},[],{"intervention":33102,"totalTrials":272,"cells":33130},{"EARLY_PHASE1":33131,"PHASE1":33133,"PHASE2":33139,"PHASE3":33141,"PHASE4":33143,"NA":33145},{"trials":33132,"activeCount":101},[],{"trials":33134,"activeCount":101},[33135],{"nctId":33096,"briefTitle":33097,"status":107,"phases":33136,"primaryCompletion":2122,"start":2163,"enrollment":1672,"conditions":33137,"interventions":33138},[90],[15],[33089,33101,33102],{"trials":33140,"activeCount":101},[],{"trials":33142,"activeCount":101},[],{"trials":33144,"activeCount":101},[],{"trials":33146,"activeCount":101},[],{"intervention":18818,"totalTrials":272,"cells":33148},{"EARLY_PHASE1":33149,"PHASE1":33151,"PHASE2":33157,"PHASE3":33159,"PHASE4":33161,"NA":33163},{"trials":33150,"activeCount":101},[],{"trials":33152,"activeCount":101},[33153],{"nctId":18811,"briefTitle":18812,"status":107,"phases":33154,"primaryCompletion":18814,"completion":18814,"start":18815,"enrollment":1512,"conditions":33155,"interventions":33156},[90],[15],[4095,18818],{"trials":33158,"activeCount":101},[],{"trials":33160,"activeCount":101},[],{"trials":33162,"activeCount":101},[],{"trials":33164,"activeCount":101},[],{"intervention":29528,"totalTrials":272,"cells":33166},{"EARLY_PHASE1":33167,"PHASE1":33169,"PHASE2":33175,"PHASE3":33177,"PHASE4":33179,"NA":33181},{"trials":33168,"activeCount":101},[],{"trials":33170,"activeCount":101},[33171],{"nctId":29523,"briefTitle":29524,"status":107,"phases":33172,"primaryCompletion":6413,"start":7618,"enrollment":1208,"conditions":33173,"interventions":33174},[90],[15],[29528,29516],{"trials":33176,"activeCount":101},[],{"trials":33178,"activeCount":101},[],{"trials":33180,"activeCount":101},[],{"trials":33182,"activeCount":101},[],{"intervention":33184,"totalTrials":272,"cells":33185},"BI 3706674",{"EARLY_PHASE1":33186,"PHASE1":33188,"PHASE2":33199,"PHASE3":33201,"PHASE4":33203,"NA":33205},{"trials":33187,"activeCount":101},[],{"trials":33189,"activeCount":101},[33190],{"nctId":33191,"briefTitle":33192,"status":107,"phases":33193,"primaryCompletion":33194,"completion":33194,"start":33195,"enrollment":4433,"conditions":33196,"interventions":33198},"NCT06056024","A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus",[90],"2025-12-17","2023-12-06",[33197],"Solid Tumor, KRAS Mutation",[33184],{"trials":33200,"activeCount":101},[],{"trials":33202,"activeCount":101},[],{"trials":33204,"activeCount":101},[],{"trials":33206,"activeCount":101},[],{"intervention":33208,"totalTrials":272,"cells":33209},"BI 653048 BS",{"EARLY_PHASE1":33210,"PHASE1":33212,"PHASE2":33224,"PHASE3":33226,"PHASE4":33228,"NA":33230},{"trials":33211,"activeCount":101},[],{"trials":33213,"activeCount":101},[33214],{"nctId":33215,"briefTitle":33216,"status":107,"phases":33217,"primaryCompletion":1980,"start":3732,"enrollment":37,"conditions":33218,"interventions":33219},"NCT02224105","Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects",[90],[15],[33208,33220,33221,33222,33223],"Prednisolone low","Prednisolone high","sodium chloride","endotoxin escherichia coli",{"trials":33225,"activeCount":101},[],{"trials":33227,"activeCount":101},[],{"trials":33229,"activeCount":101},[],{"trials":33231,"activeCount":101},[],{"intervention":33220,"totalTrials":272,"cells":33233},{"EARLY_PHASE1":33234,"PHASE1":33236,"PHASE2":33242,"PHASE3":33244,"PHASE4":33246,"NA":33248},{"trials":33235,"activeCount":101},[],{"trials":33237,"activeCount":101},[33238],{"nctId":33215,"briefTitle":33216,"status":107,"phases":33239,"primaryCompletion":1980,"start":3732,"enrollment":37,"conditions":33240,"interventions":33241},[90],[15],[33208,33220,33221,33222,33223],{"trials":33243,"activeCount":101},[],{"trials":33245,"activeCount":101},[],{"trials":33247,"activeCount":101},[],{"trials":33249,"activeCount":101},[],{"intervention":33221,"totalTrials":272,"cells":33251},{"EARLY_PHASE1":33252,"PHASE1":33254,"PHASE2":33260,"PHASE3":33262,"PHASE4":33264,"NA":33266},{"trials":33253,"activeCount":101},[],{"trials":33255,"activeCount":101},[33256],{"nctId":33215,"briefTitle":33216,"status":107,"phases":33257,"primaryCompletion":1980,"start":3732,"enrollment":37,"conditions":33258,"interventions":33259},[90],[15],[33208,33220,33221,33222,33223],{"trials":33261,"activeCount":101},[],{"trials":33263,"activeCount":101},[],{"trials":33265,"activeCount":101},[],{"trials":33267,"activeCount":101},[],{"intervention":33222,"totalTrials":272,"cells":33269},{"EARLY_PHASE1":33270,"PHASE1":33272,"PHASE2":33278,"PHASE3":33280,"PHASE4":33282,"NA":33284},{"trials":33271,"activeCount":101},[],{"trials":33273,"activeCount":101},[33274],{"nctId":33215,"briefTitle":33216,"status":107,"phases":33275,"primaryCompletion":1980,"start":3732,"enrollment":37,"conditions":33276,"interventions":33277},[90],[15],[33208,33220,33221,33222,33223],{"trials":33279,"activeCount":101},[],{"trials":33281,"activeCount":101},[],{"trials":33283,"activeCount":101},[],{"trials":33285,"activeCount":101},[],{"intervention":33223,"totalTrials":272,"cells":33287},{"EARLY_PHASE1":33288,"PHASE1":33290,"PHASE2":33296,"PHASE3":33298,"PHASE4":33300,"NA":33302},{"trials":33289,"activeCount":101},[],{"trials":33291,"activeCount":101},[33292],{"nctId":33215,"briefTitle":33216,"status":107,"phases":33293,"primaryCompletion":1980,"start":3732,"enrollment":37,"conditions":33294,"interventions":33295},[90],[15],[33208,33220,33221,33222,33223],{"trials":33297,"activeCount":101},[],{"trials":33299,"activeCount":101},[],{"trials":33301,"activeCount":101},[],{"trials":33303,"activeCount":101},[],{"intervention":10598,"totalTrials":272,"cells":33305},{"EARLY_PHASE1":33306,"PHASE1":33308,"PHASE2":33314,"PHASE3":33316,"PHASE4":33318,"NA":33320},{"trials":33307,"activeCount":101},[],{"trials":33309,"activeCount":101},[33310],{"nctId":10590,"briefTitle":10591,"status":107,"phases":33311,"primaryCompletion":10593,"completion":10594,"start":10595,"enrollment":319,"conditions":33312,"interventions":33313},[90],[33],[10598,10599,10598,10598,10600],{"trials":33315,"activeCount":101},[],{"trials":33317,"activeCount":101},[],{"trials":33319,"activeCount":101},[],{"trials":33321,"activeCount":101},[],{"intervention":33323,"totalTrials":272,"cells":33324},"2x500 mg Metformin",{"EARLY_PHASE1":33325,"PHASE1":33327,"PHASE2":33341,"PHASE3":33343,"PHASE4":33345,"NA":33347},{"trials":33326,"activeCount":101},[],{"trials":33328,"activeCount":101},[33329],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33332,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33333,"interventions":33334},"NCT01845077","Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin\u002FMetformin Compared With Single Tablets",[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],"5 mg Linagliptin\u002F1000 mg Metformin FDC","5 mg Linagliptin","3x500 mg Metformin","2 x 500 mg Metformin","5 mg Linagliptin\u002F1000mg Metformin FDC","2 x 2.5 mg Linagliptin\u002F750 mg Metformin FDC",{"trials":33342,"activeCount":101},[],{"trials":33344,"activeCount":101},[],{"trials":33346,"activeCount":101},[],{"trials":33348,"activeCount":101},[],{"intervention":33335,"totalTrials":272,"cells":33350},{"EARLY_PHASE1":33351,"PHASE1":33353,"PHASE2":33359,"PHASE3":33361,"PHASE4":33363,"NA":33365},{"trials":33352,"activeCount":101},[],{"trials":33354,"activeCount":101},[33355],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33356,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33357,"interventions":33358},[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],{"trials":33360,"activeCount":101},[],{"trials":33362,"activeCount":101},[],{"trials":33364,"activeCount":101},[],{"trials":33366,"activeCount":101},[],{"intervention":33336,"totalTrials":272,"cells":33368},{"EARLY_PHASE1":33369,"PHASE1":33371,"PHASE2":33377,"PHASE3":33379,"PHASE4":33381,"NA":33383},{"trials":33370,"activeCount":101},[],{"trials":33372,"activeCount":101},[33373],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33374,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33375,"interventions":33376},[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],{"trials":33378,"activeCount":101},[],{"trials":33380,"activeCount":101},[],{"trials":33382,"activeCount":101},[],{"trials":33384,"activeCount":101},[],{"intervention":33337,"totalTrials":272,"cells":33386},{"EARLY_PHASE1":33387,"PHASE1":33389,"PHASE2":33395,"PHASE3":33397,"PHASE4":33399,"NA":33401},{"trials":33388,"activeCount":101},[],{"trials":33390,"activeCount":101},[33391],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33392,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33393,"interventions":33394},[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],{"trials":33396,"activeCount":101},[],{"trials":33398,"activeCount":101},[],{"trials":33400,"activeCount":101},[],{"trials":33402,"activeCount":101},[],{"intervention":33338,"totalTrials":272,"cells":33404},{"EARLY_PHASE1":33405,"PHASE1":33407,"PHASE2":33413,"PHASE3":33415,"PHASE4":33417,"NA":33419},{"trials":33406,"activeCount":101},[],{"trials":33408,"activeCount":101},[33409],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33410,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33411,"interventions":33412},[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],{"trials":33414,"activeCount":101},[],{"trials":33416,"activeCount":101},[],{"trials":33418,"activeCount":101},[],{"trials":33420,"activeCount":101},[],{"intervention":33339,"totalTrials":272,"cells":33422},{"EARLY_PHASE1":33423,"PHASE1":33425,"PHASE2":33431,"PHASE3":33433,"PHASE4":33435,"NA":33437},{"trials":33424,"activeCount":101},[],{"trials":33426,"activeCount":101},[33427],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33428,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33429,"interventions":33430},[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],{"trials":33432,"activeCount":101},[],{"trials":33434,"activeCount":101},[],{"trials":33436,"activeCount":101},[],{"trials":33438,"activeCount":101},[],{"intervention":33340,"totalTrials":272,"cells":33440},{"EARLY_PHASE1":33441,"PHASE1":33443,"PHASE2":33449,"PHASE3":33451,"PHASE4":33453,"NA":33455},{"trials":33442,"activeCount":101},[],{"trials":33444,"activeCount":101},[33445],{"nctId":33330,"briefTitle":33331,"status":107,"phases":33446,"primaryCompletion":9515,"completion":9515,"start":408,"enrollment":716,"conditions":33447,"interventions":33448},[90],[15],[33323,33335,33336,33336,33337,33336,33338,33339,33340],{"trials":33450,"activeCount":101},[],{"trials":33452,"activeCount":101},[],{"trials":33454,"activeCount":101},[],{"trials":33456,"activeCount":101},[],{"intervention":9351,"totalTrials":272,"cells":33458},{"EARLY_PHASE1":33459,"PHASE1":33461,"PHASE2":33467,"PHASE3":33469,"PHASE4":33471,"NA":33473},{"trials":33460,"activeCount":101},[],{"trials":33462,"activeCount":101},[33463],{"nctId":9345,"briefTitle":9346,"status":107,"phases":33464,"primaryCompletion":9348,"start":9332,"enrollment":392,"conditions":33465,"interventions":33466},[90],[15],[528,9351,528],{"trials":33468,"activeCount":101},[],{"trials":33470,"activeCount":101},[],{"trials":33472,"activeCount":101},[],{"trials":33474,"activeCount":101},[],{"intervention":33476,"totalTrials":272,"cells":33477},"[14C]-BI 10773 - oral solution",{"EARLY_PHASE1":33478,"PHASE1":33480,"PHASE2":33488,"PHASE3":33490,"PHASE4":33492,"NA":33494},{"trials":33479,"activeCount":101},[],{"trials":33481,"activeCount":101},[33482],{"nctId":33483,"briefTitle":33484,"status":107,"phases":33485,"primaryCompletion":6224,"start":4413,"enrollment":155,"conditions":33486,"interventions":33487},"NCT02172274","BI 10773 Administered as Oral Solution to Healthy Male Volunteers",[90],[15],[33476],{"trials":33489,"activeCount":101},[],{"trials":33491,"activeCount":101},[],{"trials":33493,"activeCount":101},[],{"trials":33495,"activeCount":101},[],{"intervention":33497,"totalTrials":272,"cells":33498},"Duloxetine - low dose",{"EARLY_PHASE1":33499,"PHASE1":33501,"PHASE2":33510,"PHASE3":33512,"PHASE4":33514,"NA":33516},{"trials":33500,"activeCount":101},[],{"trials":33502,"activeCount":101},[33503],{"nctId":33504,"briefTitle":33505,"status":107,"phases":33506,"primaryCompletion":6472,"start":6871,"enrollment":132,"conditions":33507,"interventions":33508},"NCT02232542","Tolerability and Safety of Duloxetine BID in Healthy Female Subjects",[90],[15],[33497,33509],"Duloxetine - high dose",{"trials":33511,"activeCount":101},[],{"trials":33513,"activeCount":101},[],{"trials":33515,"activeCount":101},[],{"trials":33517,"activeCount":101},[],{"intervention":33509,"totalTrials":272,"cells":33519},{"EARLY_PHASE1":33520,"PHASE1":33522,"PHASE2":33528,"PHASE3":33530,"PHASE4":33532,"NA":33534},{"trials":33521,"activeCount":101},[],{"trials":33523,"activeCount":101},[33524],{"nctId":33504,"briefTitle":33505,"status":107,"phases":33525,"primaryCompletion":6472,"start":6871,"enrollment":132,"conditions":33526,"interventions":33527},[90],[15],[33497,33509],{"trials":33529,"activeCount":101},[],{"trials":33531,"activeCount":101},[],{"trials":33533,"activeCount":101},[],{"trials":33535,"activeCount":101},[],{"intervention":28451,"totalTrials":272,"cells":33537},{"EARLY_PHASE1":33538,"PHASE1":33540,"PHASE2":33546,"PHASE3":33548,"PHASE4":33550,"NA":33552},{"trials":33539,"activeCount":101},[],{"trials":33541,"activeCount":101},[33542],{"nctId":28444,"briefTitle":28445,"status":107,"phases":33543,"primaryCompletion":28447,"completion":28448,"start":2838,"enrollment":956,"conditions":33544,"interventions":33545},[90],[15],[28451,28452,459],{"trials":33547,"activeCount":101},[],{"trials":33549,"activeCount":101},[],{"trials":33551,"activeCount":101},[],{"trials":33553,"activeCount":101},[],{"intervention":28452,"totalTrials":272,"cells":33555},{"EARLY_PHASE1":33556,"PHASE1":33558,"PHASE2":33564,"PHASE3":33566,"PHASE4":33568,"NA":33570},{"trials":33557,"activeCount":101},[],{"trials":33559,"activeCount":101},[33560],{"nctId":28444,"briefTitle":28445,"status":107,"phases":33561,"primaryCompletion":28447,"completion":28448,"start":2838,"enrollment":956,"conditions":33562,"interventions":33563},[90],[15],[28451,28452,459],{"trials":33565,"activeCount":101},[],{"trials":33567,"activeCount":101},[],{"trials":33569,"activeCount":101},[],{"trials":33571,"activeCount":101},[],{"intervention":29579,"totalTrials":272,"cells":33573},{"EARLY_PHASE1":33574,"PHASE1":33576,"PHASE2":33582,"PHASE3":33584,"PHASE4":33586,"NA":33588},{"trials":33575,"activeCount":101},[],{"trials":33577,"activeCount":101},[33578],{"nctId":29574,"briefTitle":29575,"status":107,"phases":33579,"primaryCompletion":9235,"start":2182,"enrollment":1340,"conditions":33580,"interventions":33581},[90],[15],[29567,29579,29580],{"trials":33583,"activeCount":101},[],{"trials":33585,"activeCount":101},[],{"trials":33587,"activeCount":101},[],{"trials":33589,"activeCount":101},[],{"intervention":29580,"totalTrials":272,"cells":33591},{"EARLY_PHASE1":33592,"PHASE1":33594,"PHASE2":33600,"PHASE3":33602,"PHASE4":33604,"NA":33606},{"trials":33593,"activeCount":101},[],{"trials":33595,"activeCount":101},[33596],{"nctId":29574,"briefTitle":29575,"status":107,"phases":33597,"primaryCompletion":9235,"start":2182,"enrollment":1340,"conditions":33598,"interventions":33599},[90],[15],[29567,29579,29580],{"trials":33601,"activeCount":101},[],{"trials":33603,"activeCount":101},[],{"trials":33605,"activeCount":101},[],{"trials":33607,"activeCount":101},[],{"intervention":33609,"totalTrials":272,"cells":33610},"Low dose of BIBW 2948 BS for oral inhalation",{"EARLY_PHASE1":33611,"PHASE1":33613,"PHASE2":33623,"PHASE3":33625,"PHASE4":33627,"NA":33629},{"trials":33612,"activeCount":101},[],{"trials":33614,"activeCount":101},[33615],{"nctId":33616,"briefTitle":33617,"status":107,"phases":33618,"primaryCompletion":6156,"start":4005,"enrollment":448,"conditions":33619,"interventions":33620},"NCT02216461","Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers",[90],[15],[33609,33621,33622],"Medium dose of BIBW 2948 BS for oral inhalation","High dose of BIBW 2948 BS for oral inhalation",{"trials":33624,"activeCount":101},[],{"trials":33626,"activeCount":101},[],{"trials":33628,"activeCount":101},[],{"trials":33630,"activeCount":101},[],{"intervention":33621,"totalTrials":272,"cells":33632},{"EARLY_PHASE1":33633,"PHASE1":33635,"PHASE2":33641,"PHASE3":33643,"PHASE4":33645,"NA":33647},{"trials":33634,"activeCount":101},[],{"trials":33636,"activeCount":101},[33637],{"nctId":33616,"briefTitle":33617,"status":107,"phases":33638,"primaryCompletion":6156,"start":4005,"enrollment":448,"conditions":33639,"interventions":33640},[90],[15],[33609,33621,33622],{"trials":33642,"activeCount":101},[],{"trials":33644,"activeCount":101},[],{"trials":33646,"activeCount":101},[],{"trials":33648,"activeCount":101},[],{"intervention":33622,"totalTrials":272,"cells":33650},{"EARLY_PHASE1":33651,"PHASE1":33653,"PHASE2":33659,"PHASE3":33661,"PHASE4":33663,"NA":33665},{"trials":33652,"activeCount":101},[],{"trials":33654,"activeCount":101},[33655],{"nctId":33616,"briefTitle":33617,"status":107,"phases":33656,"primaryCompletion":6156,"start":4005,"enrollment":448,"conditions":33657,"interventions":33658},[90],[15],[33609,33621,33622],{"trials":33660,"activeCount":101},[],{"trials":33662,"activeCount":101},[],{"trials":33664,"activeCount":101},[],{"trials":33666,"activeCount":101},[],{"intervention":27835,"totalTrials":272,"cells":33668},{"EARLY_PHASE1":33669,"PHASE1":33671,"PHASE2":33677,"PHASE3":33679,"PHASE4":33681,"NA":33683},{"trials":33670,"activeCount":101},[],{"trials":33672,"activeCount":101},[33673],{"nctId":27826,"briefTitle":27827,"status":107,"phases":33674,"primaryCompletion":27829,"completion":27830,"start":27831,"enrollment":641,"conditions":33675,"interventions":33676},[90],[27833],[21144,27835,27835],{"trials":33678,"activeCount":101},[],{"trials":33680,"activeCount":101},[],{"trials":33682,"activeCount":101},[],{"trials":33684,"activeCount":101},[],{"intervention":28482,"totalTrials":272,"cells":33686},{"EARLY_PHASE1":33687,"PHASE1":33689,"PHASE2":33695,"PHASE3":33697,"PHASE4":33699,"NA":33701},{"trials":33688,"activeCount":101},[],{"trials":33690,"activeCount":101},[33691],{"nctId":28477,"briefTitle":28478,"status":107,"phases":33692,"primaryCompletion":7703,"start":4442,"enrollment":401,"conditions":33693,"interventions":33694},[90],[15],[28482,28470],{"trials":33696,"activeCount":101},[],{"trials":33698,"activeCount":101},[],{"trials":33700,"activeCount":101},[],{"trials":33702,"activeCount":101},[],{"intervention":5847,"totalTrials":272,"cells":33704},{"EARLY_PHASE1":33705,"PHASE1":33707,"PHASE2":33713,"PHASE3":33715,"PHASE4":33717,"NA":33719},{"trials":33706,"activeCount":101},[],{"trials":33708,"activeCount":101},[33709],{"nctId":5839,"briefTitle":5840,"status":107,"phases":33710,"primaryCompletion":5842,"start":5843,"enrollment":188,"conditions":33711,"interventions":33712},[90],[15],[5846,5847,5848,5849,5832],{"trials":33714,"activeCount":101},[],{"trials":33716,"activeCount":101},[],{"trials":33718,"activeCount":101},[],{"trials":33720,"activeCount":101},[],{"intervention":5849,"totalTrials":272,"cells":33722},{"EARLY_PHASE1":33723,"PHASE1":33725,"PHASE2":33731,"PHASE3":33733,"PHASE4":33735,"NA":33737},{"trials":33724,"activeCount":101},[],{"trials":33726,"activeCount":101},[33727],{"nctId":5839,"briefTitle":5840,"status":107,"phases":33728,"primaryCompletion":5842,"start":5843,"enrollment":188,"conditions":33729,"interventions":33730},[90],[15],[5846,5847,5848,5849,5832],{"trials":33732,"activeCount":101},[],{"trials":33734,"activeCount":101},[],{"trials":33736,"activeCount":101},[],{"trials":33738,"activeCount":101},[],{"intervention":21786,"totalTrials":272,"cells":33740},{"EARLY_PHASE1":33741,"PHASE1":33743,"PHASE2":33749,"PHASE3":33751,"PHASE4":33753,"NA":33755},{"trials":33742,"activeCount":101},[],{"trials":33744,"activeCount":101},[33745],{"nctId":21781,"briefTitle":21782,"status":107,"phases":33746,"enrollment":380,"conditions":33747,"interventions":33748},[90],[27],[21786,2186,10869],{"trials":33750,"activeCount":101},[],{"trials":33752,"activeCount":101},[],{"trials":33754,"activeCount":101},[],{"trials":33756,"activeCount":101},[],{"intervention":33758,"totalTrials":272,"cells":33759},"BIIX 1 XX - D1",{"EARLY_PHASE1":33760,"PHASE1":33762,"PHASE2":33772,"PHASE3":33774,"PHASE4":33776,"NA":33778},{"trials":33761,"activeCount":101},[],{"trials":33763,"activeCount":101},[33764],{"nctId":33765,"briefTitle":33766,"status":162,"phases":33767,"primaryCompletion":2182,"start":2182,"enrollment":155,"conditions":33768,"interventions":33769},"NCT02198313","A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers",[90],[15],[33758,33770,33771],"BIIX 1 XX - D2","BIIX 1 XX - D3",{"trials":33773,"activeCount":101},[],{"trials":33775,"activeCount":101},[],{"trials":33777,"activeCount":101},[],{"trials":33779,"activeCount":101},[],{"intervention":33770,"totalTrials":272,"cells":33781},{"EARLY_PHASE1":33782,"PHASE1":33784,"PHASE2":33790,"PHASE3":33792,"PHASE4":33794,"NA":33796},{"trials":33783,"activeCount":101},[],{"trials":33785,"activeCount":101},[33786],{"nctId":33765,"briefTitle":33766,"status":162,"phases":33787,"primaryCompletion":2182,"start":2182,"enrollment":155,"conditions":33788,"interventions":33789},[90],[15],[33758,33770,33771],{"trials":33791,"activeCount":101},[],{"trials":33793,"activeCount":101},[],{"trials":33795,"activeCount":101},[],{"trials":33797,"activeCount":101},[],{"intervention":33771,"totalTrials":272,"cells":33799},{"EARLY_PHASE1":33800,"PHASE1":33802,"PHASE2":33808,"PHASE3":33810,"PHASE4":33812,"NA":33814},{"trials":33801,"activeCount":101},[],{"trials":33803,"activeCount":101},[33804],{"nctId":33765,"briefTitle":33766,"status":162,"phases":33805,"primaryCompletion":2182,"start":2182,"enrollment":155,"conditions":33806,"interventions":33807},[90],[15],[33758,33770,33771],{"trials":33809,"activeCount":101},[],{"trials":33811,"activeCount":101},[],{"trials":33813,"activeCount":101},[],{"trials":33815,"activeCount":101},[],{"intervention":33817,"totalTrials":272,"cells":33818},"BI 10773 25 mg",{"EARLY_PHASE1":33819,"PHASE1":33821,"PHASE2":33830,"PHASE3":33832,"PHASE4":33834,"NA":33836},{"trials":33820,"activeCount":101},[],{"trials":33822,"activeCount":101},[33823],{"nctId":33824,"briefTitle":33825,"status":107,"phases":33826,"primaryCompletion":1967,"start":1980,"enrollment":392,"conditions":33827,"interventions":33828},"NCT01111331","Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers",[90],[15],[33817,33829,33817,4094],"Warfarin 25 mg",{"trials":33831,"activeCount":101},[],{"trials":33833,"activeCount":101},[],{"trials":33835,"activeCount":101},[],{"trials":33837,"activeCount":101},[],{"intervention":33829,"totalTrials":272,"cells":33839},{"EARLY_PHASE1":33840,"PHASE1":33842,"PHASE2":33848,"PHASE3":33850,"PHASE4":33852,"NA":33854},{"trials":33841,"activeCount":101},[],{"trials":33843,"activeCount":101},[33844],{"nctId":33824,"briefTitle":33825,"status":107,"phases":33845,"primaryCompletion":1967,"start":1980,"enrollment":392,"conditions":33846,"interventions":33847},[90],[15],[33817,33829,33817,4094],{"trials":33849,"activeCount":101},[],{"trials":33851,"activeCount":101},[],{"trials":33853,"activeCount":101},[],{"trials":33855,"activeCount":101},[],{"intervention":33857,"totalTrials":272,"cells":33858},"Midazolam,",{"EARLY_PHASE1":33859,"PHASE1":33861,"PHASE2":33870,"PHASE3":33872,"PHASE4":33874,"NA":33876},{"trials":33860,"activeCount":101},[],{"trials":33862,"activeCount":101},[33863],{"nctId":33864,"briefTitle":33865,"status":107,"phases":33866,"primaryCompletion":6029,"start":6030,"enrollment":1672,"conditions":33867,"interventions":33868},"NCT02269202","Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects",[90],[15],[33857,33869],"Crobenetine, i.v.",{"trials":33871,"activeCount":101},[],{"trials":33873,"activeCount":101},[],{"trials":33875,"activeCount":101},[],{"trials":33877,"activeCount":101},[],{"intervention":33869,"totalTrials":272,"cells":33879},{"EARLY_PHASE1":33880,"PHASE1":33882,"PHASE2":33888,"PHASE3":33890,"PHASE4":33892,"NA":33894},{"trials":33881,"activeCount":101},[],{"trials":33883,"activeCount":101},[33884],{"nctId":33864,"briefTitle":33865,"status":107,"phases":33885,"primaryCompletion":6029,"start":6030,"enrollment":1672,"conditions":33886,"interventions":33887},[90],[15],[33857,33869],{"trials":33889,"activeCount":101},[],{"trials":33891,"activeCount":101},[],{"trials":33893,"activeCount":101},[],{"trials":33895,"activeCount":101},[],{"intervention":33897,"totalTrials":272,"cells":33898},"BI 671800 HEA, 200 mg",{"EARLY_PHASE1":33899,"PHASE1":33901,"PHASE2":33912,"PHASE3":33914,"PHASE4":33916,"NA":33918},{"trials":33900,"activeCount":101},[],{"trials":33902,"activeCount":101},[33903],{"nctId":33904,"briefTitle":33905,"status":107,"phases":33906,"primaryCompletion":1967,"start":17427,"enrollment":380,"conditions":33907,"interventions":33908},"NCT02221388","Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers",[90],[15],[33897,33909,33910,33911],"BI 671800 HEA EC, 200 mg","BI 671800 HEA, 50 mg","BI 671800 ED, 100 mg",{"trials":33913,"activeCount":101},[],{"trials":33915,"activeCount":101},[],{"trials":33917,"activeCount":101},[],{"trials":33919,"activeCount":101},[],{"intervention":33909,"totalTrials":272,"cells":33921},{"EARLY_PHASE1":33922,"PHASE1":33924,"PHASE2":33930,"PHASE3":33932,"PHASE4":33934,"NA":33936},{"trials":33923,"activeCount":101},[],{"trials":33925,"activeCount":101},[33926],{"nctId":33904,"briefTitle":33905,"status":107,"phases":33927,"primaryCompletion":1967,"start":17427,"enrollment":380,"conditions":33928,"interventions":33929},[90],[15],[33897,33909,33910,33911],{"trials":33931,"activeCount":101},[],{"trials":33933,"activeCount":101},[],{"trials":33935,"activeCount":101},[],{"trials":33937,"activeCount":101},[],{"intervention":33910,"totalTrials":272,"cells":33939},{"EARLY_PHASE1":33940,"PHASE1":33942,"PHASE2":33948,"PHASE3":33950,"PHASE4":33952,"NA":33954},{"trials":33941,"activeCount":101},[],{"trials":33943,"activeCount":101},[33944],{"nctId":33904,"briefTitle":33905,"status":107,"phases":33945,"primaryCompletion":1967,"start":17427,"enrollment":380,"conditions":33946,"interventions":33947},[90],[15],[33897,33909,33910,33911],{"trials":33949,"activeCount":101},[],{"trials":33951,"activeCount":101},[],{"trials":33953,"activeCount":101},[],{"trials":33955,"activeCount":101},[],{"intervention":33911,"totalTrials":272,"cells":33957},{"EARLY_PHASE1":33958,"PHASE1":33960,"PHASE2":33966,"PHASE3":33968,"PHASE4":33970,"NA":33972},{"trials":33959,"activeCount":101},[],{"trials":33961,"activeCount":101},[33962],{"nctId":33904,"briefTitle":33905,"status":107,"phases":33963,"primaryCompletion":1967,"start":17427,"enrollment":380,"conditions":33964,"interventions":33965},[90],[15],[33897,33909,33910,33911],{"trials":33967,"activeCount":101},[],{"trials":33969,"activeCount":101},[],{"trials":33971,"activeCount":101},[],{"trials":33973,"activeCount":101},[],{"intervention":33975,"totalTrials":272,"cells":33976},"High dose FDC Empagliflozin\u002FLinagliptin\u002FMetformin XR, fed",{"EARLY_PHASE1":33977,"PHASE1":33979,"PHASE2":33993,"PHASE3":33995,"PHASE4":33997,"NA":33999},{"trials":33978,"activeCount":101},[],{"trials":33980,"activeCount":101},[33981],{"nctId":33982,"briefTitle":33983,"status":107,"phases":33984,"primaryCompletion":33985,"completion":33986,"start":33987,"enrollment":2235,"conditions":33988,"interventions":33989},"NCT02821910","Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin\u002FLinagliptin\u002FMetformin Extended Release Compared With Single Tablets",[90],"2016-10-01","2016-10-31","2016-07-20",[15],[33975,33990,33991,33990,33992,33990],"1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR","High dose FDC Empagliflozin\u002FLinagliptin\u002FMetformin XR, fasted","Low dose FDC Empagliflozin\u002FLinagliptin\u002FMetformin XR, fed",{"trials":33994,"activeCount":101},[],{"trials":33996,"activeCount":101},[],{"trials":33998,"activeCount":101},[],{"trials":34000,"activeCount":101},[],{"intervention":33990,"totalTrials":272,"cells":34002},{"EARLY_PHASE1":34003,"PHASE1":34005,"PHASE2":34011,"PHASE3":34013,"PHASE4":34015,"NA":34017},{"trials":34004,"activeCount":101},[],{"trials":34006,"activeCount":101},[34007],{"nctId":33982,"briefTitle":33983,"status":107,"phases":34008,"primaryCompletion":33985,"completion":33986,"start":33987,"enrollment":2235,"conditions":34009,"interventions":34010},[90],[15],[33975,33990,33991,33990,33992,33990],{"trials":34012,"activeCount":101},[],{"trials":34014,"activeCount":101},[],{"trials":34016,"activeCount":101},[],{"trials":34018,"activeCount":101},[],{"intervention":33991,"totalTrials":272,"cells":34020},{"EARLY_PHASE1":34021,"PHASE1":34023,"PHASE2":34029,"PHASE3":34031,"PHASE4":34033,"NA":34035},{"trials":34022,"activeCount":101},[],{"trials":34024,"activeCount":101},[34025],{"nctId":33982,"briefTitle":33983,"status":107,"phases":34026,"primaryCompletion":33985,"completion":33986,"start":33987,"enrollment":2235,"conditions":34027,"interventions":34028},[90],[15],[33975,33990,33991,33990,33992,33990],{"trials":34030,"activeCount":101},[],{"trials":34032,"activeCount":101},[],{"trials":34034,"activeCount":101},[],{"trials":34036,"activeCount":101},[],{"intervention":33992,"totalTrials":272,"cells":34038},{"EARLY_PHASE1":34039,"PHASE1":34041,"PHASE2":34047,"PHASE3":34049,"PHASE4":34051,"NA":34053},{"trials":34040,"activeCount":101},[],{"trials":34042,"activeCount":101},[34043],{"nctId":33982,"briefTitle":33983,"status":107,"phases":34044,"primaryCompletion":33985,"completion":33986,"start":33987,"enrollment":2235,"conditions":34045,"interventions":34046},[90],[15],[33975,33990,33991,33990,33992,33990],{"trials":34048,"activeCount":101},[],{"trials":34050,"activeCount":101},[],{"trials":34052,"activeCount":101},[],{"trials":34054,"activeCount":101},[],{"intervention":34056,"totalTrials":272,"cells":34057},"BIRT 2584 XX - multiple escalating dose",{"EARLY_PHASE1":34058,"PHASE1":34060,"PHASE2":34069,"PHASE3":34071,"PHASE4":34073,"NA":34075},{"trials":34059,"activeCount":101},[],{"trials":34061,"activeCount":101},[34062],{"nctId":34063,"briefTitle":34064,"status":107,"phases":34065,"primaryCompletion":11642,"start":6782,"enrollment":6702,"conditions":34066,"interventions":34067},"NCT02256761","Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male Volunteers",[90],[15],[34056,34068],"BIRT 2584 XX - single dose",{"trials":34070,"activeCount":101},[],{"trials":34072,"activeCount":101},[],{"trials":34074,"activeCount":101},[],{"trials":34076,"activeCount":101},[],{"intervention":34068,"totalTrials":272,"cells":34078},{"EARLY_PHASE1":34079,"PHASE1":34081,"PHASE2":34087,"PHASE3":34089,"PHASE4":34091,"NA":34093},{"trials":34080,"activeCount":101},[],{"trials":34082,"activeCount":101},[34083],{"nctId":34063,"briefTitle":34064,"status":107,"phases":34084,"primaryCompletion":11642,"start":6782,"enrollment":6702,"conditions":34085,"interventions":34086},[90],[15],[34056,34068],{"trials":34088,"activeCount":101},[],{"trials":34090,"activeCount":101},[],{"trials":34092,"activeCount":101},[],{"trials":34094,"activeCount":101},[],{"intervention":34096,"totalTrials":272,"cells":34097},"Ipratropium - unit dose vial",{"EARLY_PHASE1":34098,"PHASE1":34100,"PHASE2":34109,"PHASE3":34111,"PHASE4":34113,"NA":34115},{"trials":34099,"activeCount":101},[],{"trials":34101,"activeCount":101},[34102],{"nctId":34103,"briefTitle":34104,"status":107,"phases":34105,"primaryCompletion":6005,"start":7003,"enrollment":448,"conditions":34106,"interventions":34107},"NCT02172781","Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment",[90],[15],[34096,34108],"Tiotropium - inhalation",{"trials":34110,"activeCount":101},[],{"trials":34112,"activeCount":101},[],{"trials":34114,"activeCount":101},[],{"trials":34116,"activeCount":101},[],{"intervention":34108,"totalTrials":272,"cells":34118},{"EARLY_PHASE1":34119,"PHASE1":34121,"PHASE2":34127,"PHASE3":34129,"PHASE4":34131,"NA":34133},{"trials":34120,"activeCount":101},[],{"trials":34122,"activeCount":101},[34123],{"nctId":34103,"briefTitle":34104,"status":107,"phases":34124,"primaryCompletion":6005,"start":7003,"enrollment":448,"conditions":34125,"interventions":34126},[90],[15],[34096,34108],{"trials":34128,"activeCount":101},[],{"trials":34130,"activeCount":101},[],{"trials":34132,"activeCount":101},[],{"trials":34134,"activeCount":101},[],{"intervention":6210,"totalTrials":272,"cells":34136},{"EARLY_PHASE1":34137,"PHASE1":34139,"PHASE2":34145,"PHASE3":34147,"PHASE4":34149,"NA":34151},{"trials":34138,"activeCount":101},[],{"trials":34140,"activeCount":101},[34141],{"nctId":6203,"briefTitle":6204,"status":107,"phases":34142,"primaryCompletion":6206,"start":6207,"enrollment":132,"conditions":34143,"interventions":34144},[90],[15],[6196,6121,6210],{"trials":34146,"activeCount":101},[],{"trials":34148,"activeCount":101},[],{"trials":34150,"activeCount":101},[],{"trials":34152,"activeCount":101},[],{"intervention":28557,"totalTrials":272,"cells":34154},{"EARLY_PHASE1":34155,"PHASE1":34157,"PHASE2":34163,"PHASE3":34165,"PHASE4":34167,"NA":34169},{"trials":34156,"activeCount":101},[],{"trials":34158,"activeCount":101},[34159],{"nctId":28552,"briefTitle":28553,"status":107,"phases":34160,"primaryCompletion":5843,"start":3978,"enrollment":2400,"conditions":34161,"interventions":34162},[90],[15],[28557,6121,6994],{"trials":34164,"activeCount":101},[],{"trials":34166,"activeCount":101},[],{"trials":34168,"activeCount":101},[],{"trials":34170,"activeCount":101},[],{"intervention":34172,"totalTrials":272,"cells":34173},"BI 201335 NA in single rising doses",{"EARLY_PHASE1":34174,"PHASE1":34176,"PHASE2":34184,"PHASE3":34186,"PHASE4":34188,"NA":34190},{"trials":34175,"activeCount":101},[],{"trials":34177,"activeCount":101},[34178],{"nctId":34179,"briefTitle":34180,"status":107,"phases":34181,"primaryCompletion":2032,"start":6471,"enrollment":2235,"conditions":34182,"interventions":34183},"NCT02182297","Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects",[90],[15],[34172],{"trials":34185,"activeCount":101},[],{"trials":34187,"activeCount":101},[],{"trials":34189,"activeCount":101},[],{"trials":34191,"activeCount":101},[],{"intervention":34193,"totalTrials":272,"cells":34194},"BIBR 953 ZW Intravenously",{"EARLY_PHASE1":34195,"PHASE1":34197,"PHASE2":34206,"PHASE3":34208,"PHASE4":34210,"NA":34212},{"trials":34196,"activeCount":101},[],{"trials":34198,"activeCount":101},[34199],{"nctId":34200,"briefTitle":34201,"status":107,"phases":34202,"primaryCompletion":5887,"start":6029,"enrollment":1081,"conditions":34203,"interventions":34204},"NCT02171442","Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers",[90],[15],[34193,34205],"BIBR 1048 Oral Solution",{"trials":34207,"activeCount":101},[],{"trials":34209,"activeCount":101},[],{"trials":34211,"activeCount":101},[],{"trials":34213,"activeCount":101},[],{"intervention":34205,"totalTrials":272,"cells":34215},{"EARLY_PHASE1":34216,"PHASE1":34218,"PHASE2":34224,"PHASE3":34226,"PHASE4":34228,"NA":34230},{"trials":34217,"activeCount":101},[],{"trials":34219,"activeCount":101},[34220],{"nctId":34200,"briefTitle":34201,"status":107,"phases":34221,"primaryCompletion":5887,"start":6029,"enrollment":1081,"conditions":34222,"interventions":34223},[90],[15],[34193,34205],{"trials":34225,"activeCount":101},[],{"trials":34227,"activeCount":101},[],{"trials":34229,"activeCount":101},[],{"trials":34231,"activeCount":101},[],{"intervention":34233,"totalTrials":272,"cells":34234},"Rabeprazol sodium",{"EARLY_PHASE1":34235,"PHASE1":34237,"PHASE2":34248,"PHASE3":34250,"PHASE4":34252,"NA":34254},{"trials":34236,"activeCount":101},[],{"trials":34238,"activeCount":101},[34239],{"nctId":34240,"briefTitle":34241,"status":107,"phases":34242,"primaryCompletion":34243,"completion":34244,"start":154,"enrollment":448,"conditions":34245,"interventions":34246},"NCT03143166","Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan",[90],"2017-07-27","2017-08-02",[19351],[34247,34233],"Dabigatran Etexilate",{"trials":34249,"activeCount":101},[],{"trials":34251,"activeCount":101},[],{"trials":34253,"activeCount":101},[],{"trials":34255,"activeCount":101},[],{"intervention":34257,"totalTrials":272,"cells":34258},"WAL2014",{"EARLY_PHASE1":34259,"PHASE1":34261,"PHASE2":34269,"PHASE3":34271,"PHASE4":34273,"NA":34275},{"trials":34260,"activeCount":101},[],{"trials":34262,"activeCount":101},[34263],{"nctId":34264,"briefTitle":34265,"status":107,"phases":34266,"primaryCompletion":6453,"start":6453,"enrollment":188,"conditions":34267,"interventions":34268},"NCT02264080","Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers",[90],[15],[34257],{"trials":34270,"activeCount":101},[],{"trials":34272,"activeCount":101},[],{"trials":34274,"activeCount":101},[],{"trials":34276,"activeCount":101},[],{"intervention":34278,"totalTrials":272,"cells":34279},"Songha® Night",{"EARLY_PHASE1":34280,"PHASE1":34282,"PHASE2":34291,"PHASE3":34293,"PHASE4":34295,"NA":34297},{"trials":34281,"activeCount":101},[],{"trials":34283,"activeCount":101},[34284],{"nctId":34285,"briefTitle":34286,"status":107,"phases":34287,"primaryCompletion":6871,"start":6081,"enrollment":1631,"conditions":34288,"interventions":34289},"NCT02273453","Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets",[90],[15],[34278,34290],"Oxazepam",{"trials":34292,"activeCount":101},[],{"trials":34294,"activeCount":101},[],{"trials":34296,"activeCount":101},[],{"trials":34298,"activeCount":101},[],{"intervention":34290,"totalTrials":272,"cells":34300},{"EARLY_PHASE1":34301,"PHASE1":34303,"PHASE2":34309,"PHASE3":34311,"PHASE4":34313,"NA":34315},{"trials":34302,"activeCount":101},[],{"trials":34304,"activeCount":101},[34305],{"nctId":34285,"briefTitle":34286,"status":107,"phases":34306,"primaryCompletion":6871,"start":6081,"enrollment":1631,"conditions":34307,"interventions":34308},[90],[15],[34278,34290],{"trials":34310,"activeCount":101},[],{"trials":34312,"activeCount":101},[],{"trials":34314,"activeCount":101},[],{"trials":34316,"activeCount":101},[],{"intervention":34318,"totalTrials":272,"cells":34319},"Telmisartan\u002FAmlodipine low dose",{"EARLY_PHASE1":34320,"PHASE1":34322,"PHASE2":34331,"PHASE3":34333,"PHASE4":34335,"NA":34337},{"trials":34321,"activeCount":101},[],{"trials":34323,"activeCount":101},[34324],{"nctId":34325,"briefTitle":34326,"status":107,"phases":34327,"primaryCompletion":1989,"start":2032,"enrollment":132,"conditions":34328,"interventions":34329},"NCT02261064","Influence of Food on the Bioavailability of Telmisartan\u002FAmlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers",[90],[15],[34318,34330],"Telmisartan\u002FAmlodipine high dose",{"trials":34332,"activeCount":101},[],{"trials":34334,"activeCount":101},[],{"trials":34336,"activeCount":101},[],{"trials":34338,"activeCount":101},[],{"intervention":34330,"totalTrials":272,"cells":34340},{"EARLY_PHASE1":34341,"PHASE1":34343,"PHASE2":34349,"PHASE3":34351,"PHASE4":34353,"NA":34355},{"trials":34342,"activeCount":101},[],{"trials":34344,"activeCount":101},[34345],{"nctId":34325,"briefTitle":34326,"status":107,"phases":34346,"primaryCompletion":1989,"start":2032,"enrollment":132,"conditions":34347,"interventions":34348},[90],[15],[34318,34330],{"trials":34350,"activeCount":101},[],{"trials":34352,"activeCount":101},[],{"trials":34354,"activeCount":101},[],{"trials":34356,"activeCount":101},[],{"intervention":34358,"totalTrials":272,"cells":34359},"[¹⁴C] BI 685509 formulation 1",{"EARLY_PHASE1":34360,"PHASE1":34362,"PHASE2":34373,"PHASE3":34375,"PHASE4":34377,"NA":34379},{"trials":34361,"activeCount":101},[],{"trials":34363,"activeCount":101},[34364],{"nctId":34365,"briefTitle":34366,"status":107,"phases":34367,"primaryCompletion":2250,"completion":2250,"start":34368,"enrollment":188,"conditions":34369,"interventions":34370},"NCT05515328","A Study in Healthy Men to Test How BI 685509 is Processed in the Body",[90],"2022-09-08",[15],[34358,34371,34372],"[¹⁴C] BI 685509 formulation 2","BI 685509 formulation 3",{"trials":34374,"activeCount":101},[],{"trials":34376,"activeCount":101},[],{"trials":34378,"activeCount":101},[],{"trials":34380,"activeCount":101},[],{"intervention":34371,"totalTrials":272,"cells":34382},{"EARLY_PHASE1":34383,"PHASE1":34385,"PHASE2":34391,"PHASE3":34393,"PHASE4":34395,"NA":34397},{"trials":34384,"activeCount":101},[],{"trials":34386,"activeCount":101},[34387],{"nctId":34365,"briefTitle":34366,"status":107,"phases":34388,"primaryCompletion":2250,"completion":2250,"start":34368,"enrollment":188,"conditions":34389,"interventions":34390},[90],[15],[34358,34371,34372],{"trials":34392,"activeCount":101},[],{"trials":34394,"activeCount":101},[],{"trials":34396,"activeCount":101},[],{"trials":34398,"activeCount":101},[],{"intervention":34372,"totalTrials":272,"cells":34400},{"EARLY_PHASE1":34401,"PHASE1":34403,"PHASE2":34409,"PHASE3":34411,"PHASE4":34413,"NA":34415},{"trials":34402,"activeCount":101},[],{"trials":34404,"activeCount":101},[34405],{"nctId":34365,"briefTitle":34366,"status":107,"phases":34406,"primaryCompletion":2250,"completion":2250,"start":34368,"enrollment":188,"conditions":34407,"interventions":34408},[90],[15],[34358,34371,34372],{"trials":34410,"activeCount":101},[],{"trials":34412,"activeCount":101},[],{"trials":34414,"activeCount":101},[],{"trials":34416,"activeCount":101},[],{"intervention":5996,"totalTrials":272,"cells":34418},{"EARLY_PHASE1":34419,"PHASE1":34421,"PHASE2":34427,"PHASE3":34429,"PHASE4":34431,"NA":34433},{"trials":34420,"activeCount":101},[],{"trials":34422,"activeCount":101},[34423],{"nctId":5989,"briefTitle":5990,"status":107,"phases":34424,"primaryCompletion":5992,"start":5993,"enrollment":956,"conditions":34425,"interventions":34426},[90],[15],[5996,5997,5998,5999,6000,5982],{"trials":34428,"activeCount":101},[],{"trials":34430,"activeCount":101},[],{"trials":34432,"activeCount":101},[],{"trials":34434,"activeCount":101},[],{"intervention":5997,"totalTrials":272,"cells":34436},{"EARLY_PHASE1":34437,"PHASE1":34439,"PHASE2":34445,"PHASE3":34447,"PHASE4":34449,"NA":34451},{"trials":34438,"activeCount":101},[],{"trials":34440,"activeCount":101},[34441],{"nctId":5989,"briefTitle":5990,"status":107,"phases":34442,"primaryCompletion":5992,"start":5993,"enrollment":956,"conditions":34443,"interventions":34444},[90],[15],[5996,5997,5998,5999,6000,5982],{"trials":34446,"activeCount":101},[],{"trials":34448,"activeCount":101},[],{"trials":34450,"activeCount":101},[],{"trials":34452,"activeCount":101},[],{"intervention":5998,"totalTrials":272,"cells":34454},{"EARLY_PHASE1":34455,"PHASE1":34457,"PHASE2":34463,"PHASE3":34465,"PHASE4":34467,"NA":34469},{"trials":34456,"activeCount":101},[],{"trials":34458,"activeCount":101},[34459],{"nctId":5989,"briefTitle":5990,"status":107,"phases":34460,"primaryCompletion":5992,"start":5993,"enrollment":956,"conditions":34461,"interventions":34462},[90],[15],[5996,5997,5998,5999,6000,5982],{"trials":34464,"activeCount":101},[],{"trials":34466,"activeCount":101},[],{"trials":34468,"activeCount":101},[],{"trials":34470,"activeCount":101},[],{"intervention":5999,"totalTrials":272,"cells":34472},{"EARLY_PHASE1":34473,"PHASE1":34475,"PHASE2":34481,"PHASE3":34483,"PHASE4":34485,"NA":34487},{"trials":34474,"activeCount":101},[],{"trials":34476,"activeCount":101},[34477],{"nctId":5989,"briefTitle":5990,"status":107,"phases":34478,"primaryCompletion":5992,"start":5993,"enrollment":956,"conditions":34479,"interventions":34480},[90],[15],[5996,5997,5998,5999,6000,5982],{"trials":34482,"activeCount":101},[],{"trials":34484,"activeCount":101},[],{"trials":34486,"activeCount":101},[],{"trials":34488,"activeCount":101},[],{"intervention":2205,"totalTrials":272,"cells":34490},{"EARLY_PHASE1":34491,"PHASE1":34493,"PHASE2":34499,"PHASE3":34501,"PHASE4":34503,"NA":34505},{"trials":34492,"activeCount":101},[],{"trials":34494,"activeCount":101},[34495],{"nctId":2196,"briefTitle":2197,"status":107,"phases":34496,"primaryCompletion":2199,"completion":2200,"start":2201,"enrollment":31,"conditions":34497,"interventions":34498},[90],[2203],[511,2205],{"trials":34500,"activeCount":101},[],{"trials":34502,"activeCount":101},[],{"trials":34504,"activeCount":101},[],{"trials":34506,"activeCount":101},[],{"intervention":34508,"totalTrials":272,"cells":34509},"Cimetidine + Tiotropium",{"EARLY_PHASE1":34510,"PHASE1":34512,"PHASE2":34521,"PHASE3":34523,"PHASE4":34525,"NA":34527},{"trials":34511,"activeCount":101},[],{"trials":34513,"activeCount":101},[34514],{"nctId":34515,"briefTitle":34516,"status":107,"phases":34517,"primaryCompletion":6390,"start":2162,"enrollment":392,"conditions":34518,"interventions":34519},"NCT02172417","Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects",[90],[15],[34508,34520,5860],"Ranitidine + Tiotropium",{"trials":34522,"activeCount":101},[],{"trials":34524,"activeCount":101},[],{"trials":34526,"activeCount":101},[],{"trials":34528,"activeCount":101},[],{"intervention":34520,"totalTrials":272,"cells":34530},{"EARLY_PHASE1":34531,"PHASE1":34533,"PHASE2":34539,"PHASE3":34541,"PHASE4":34543,"NA":34545},{"trials":34532,"activeCount":101},[],{"trials":34534,"activeCount":101},[34535],{"nctId":34515,"briefTitle":34516,"status":107,"phases":34536,"primaryCompletion":6390,"start":2162,"enrollment":392,"conditions":34537,"interventions":34538},[90],[15],[34508,34520,5860],{"trials":34540,"activeCount":101},[],{"trials":34542,"activeCount":101},[],{"trials":34544,"activeCount":101},[],{"trials":34546,"activeCount":101},[],{"intervention":28226,"totalTrials":272,"cells":34548},{"EARLY_PHASE1":34549,"PHASE1":34551,"PHASE2":34557,"PHASE3":34559,"PHASE4":34561,"NA":34563},{"trials":34550,"activeCount":101},[],{"trials":34552,"activeCount":101},[34553],{"nctId":28222,"briefTitle":28215,"status":107,"phases":34554,"primaryCompletion":5880,"start":6053,"enrollment":401,"conditions":34555,"interventions":34556},[90],[15],[28226,28200],{"trials":34558,"activeCount":101},[],{"trials":34560,"activeCount":101},[],{"trials":34562,"activeCount":101},[],{"trials":34564,"activeCount":101},[],{"intervention":28623,"totalTrials":272,"cells":34566},{"EARLY_PHASE1":34567,"PHASE1":34569,"PHASE2":34575,"PHASE3":34577,"PHASE4":34579,"NA":34581},{"trials":34568,"activeCount":101},[],{"trials":34570,"activeCount":101},[34571],{"nctId":28618,"briefTitle":28619,"status":107,"phases":34572,"primaryCompletion":3763,"start":6155,"enrollment":37,"conditions":34573,"interventions":34574},[90],[15],[28623,28605],{"trials":34576,"activeCount":101},[],{"trials":34578,"activeCount":101},[],{"trials":34580,"activeCount":101},[],{"trials":34582,"activeCount":101},[],{"intervention":6008,"totalTrials":272,"cells":34584},{"EARLY_PHASE1":34585,"PHASE1":34587,"PHASE2":34593,"PHASE3":34595,"PHASE4":34597,"NA":34599},{"trials":34586,"activeCount":101},[],{"trials":34588,"activeCount":101},[34589],{"nctId":6002,"briefTitle":6003,"status":107,"phases":34590,"primaryCompletion":2121,"start":6005,"enrollment":380,"conditions":34591,"interventions":34592},[90],[15],[6008,6009,6010,5982],{"trials":34594,"activeCount":101},[],{"trials":34596,"activeCount":101},[],{"trials":34598,"activeCount":101},[],{"trials":34600,"activeCount":101},[],{"intervention":6009,"totalTrials":272,"cells":34602},{"EARLY_PHASE1":34603,"PHASE1":34605,"PHASE2":34611,"PHASE3":34613,"PHASE4":34615,"NA":34617},{"trials":34604,"activeCount":101},[],{"trials":34606,"activeCount":101},[34607],{"nctId":6002,"briefTitle":6003,"status":107,"phases":34608,"primaryCompletion":2121,"start":6005,"enrollment":380,"conditions":34609,"interventions":34610},[90],[15],[6008,6009,6010,5982],{"trials":34612,"activeCount":101},[],{"trials":34614,"activeCount":101},[],{"trials":34616,"activeCount":101},[],{"trials":34618,"activeCount":101},[],{"intervention":6010,"totalTrials":272,"cells":34620},{"EARLY_PHASE1":34621,"PHASE1":34623,"PHASE2":34629,"PHASE3":34631,"PHASE4":34633,"NA":34635},{"trials":34622,"activeCount":101},[],{"trials":34624,"activeCount":101},[34625],{"nctId":6002,"briefTitle":6003,"status":107,"phases":34626,"primaryCompletion":2121,"start":6005,"enrollment":380,"conditions":34627,"interventions":34628},[90],[15],[6008,6009,6010,5982],{"trials":34630,"activeCount":101},[],{"trials":34632,"activeCount":101},[],{"trials":34634,"activeCount":101},[],{"trials":34636,"activeCount":101},[],{"intervention":34638,"totalTrials":272,"cells":34639},"2.5 milligram (mg) BI 474121",{"EARLY_PHASE1":34640,"PHASE1":34642,"PHASE2":34655,"PHASE3":34657,"PHASE4":34659,"NA":34661},{"trials":34641,"activeCount":101},[],{"trials":34643,"activeCount":101},[34644],{"nctId":34645,"briefTitle":34646,"status":107,"phases":34647,"primaryCompletion":34648,"completion":34648,"start":34649,"enrollment":380,"conditions":34650,"interventions":34651},"NCT04672954","A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid",[90],"2021-07-01","2021-01-07",[15],[34638,34652,34653,34654],"10 milligram (mg) BI 474121","20 milligram (mg) BI 474121","40 milligram (mg) BI 474121",{"trials":34656,"activeCount":101},[],{"trials":34658,"activeCount":101},[],{"trials":34660,"activeCount":101},[],{"trials":34662,"activeCount":101},[],{"intervention":34652,"totalTrials":272,"cells":34664},{"EARLY_PHASE1":34665,"PHASE1":34667,"PHASE2":34673,"PHASE3":34675,"PHASE4":34677,"NA":34679},{"trials":34666,"activeCount":101},[],{"trials":34668,"activeCount":101},[34669],{"nctId":34645,"briefTitle":34646,"status":107,"phases":34670,"primaryCompletion":34648,"completion":34648,"start":34649,"enrollment":380,"conditions":34671,"interventions":34672},[90],[15],[34638,34652,34653,34654],{"trials":34674,"activeCount":101},[],{"trials":34676,"activeCount":101},[],{"trials":34678,"activeCount":101},[],{"trials":34680,"activeCount":101},[],{"intervention":34653,"totalTrials":272,"cells":34682},{"EARLY_PHASE1":34683,"PHASE1":34685,"PHASE2":34691,"PHASE3":34693,"PHASE4":34695,"NA":34697},{"trials":34684,"activeCount":101},[],{"trials":34686,"activeCount":101},[34687],{"nctId":34645,"briefTitle":34646,"status":107,"phases":34688,"primaryCompletion":34648,"completion":34648,"start":34649,"enrollment":380,"conditions":34689,"interventions":34690},[90],[15],[34638,34652,34653,34654],{"trials":34692,"activeCount":101},[],{"trials":34694,"activeCount":101},[],{"trials":34696,"activeCount":101},[],{"trials":34698,"activeCount":101},[],{"intervention":34654,"totalTrials":272,"cells":34700},{"EARLY_PHASE1":34701,"PHASE1":34703,"PHASE2":34709,"PHASE3":34711,"PHASE4":34713,"NA":34715},{"trials":34702,"activeCount":101},[],{"trials":34704,"activeCount":101},[34705],{"nctId":34645,"briefTitle":34646,"status":107,"phases":34706,"primaryCompletion":34648,"completion":34648,"start":34649,"enrollment":380,"conditions":34707,"interventions":34708},[90],[15],[34638,34652,34653,34654],{"trials":34710,"activeCount":101},[],{"trials":34712,"activeCount":101},[],{"trials":34714,"activeCount":101},[],{"trials":34716,"activeCount":101},[],{"intervention":34718,"totalTrials":272,"cells":34719},"BIBF 1120 M + docetaxel M",{"EARLY_PHASE1":34720,"PHASE1":34722,"PHASE2":34734,"PHASE3":34736,"PHASE4":34738,"NA":34740},{"trials":34721,"activeCount":101},[],{"trials":34723,"activeCount":101},[34724],{"nctId":34725,"briefTitle":34726,"status":107,"phases":34727,"primaryCompletion":2001,"completion":7092,"start":2003,"enrollment":2789,"conditions":34728,"interventions":34729},"NCT00876460","BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I",[90],[36],[34718,34730,34731,34732,34733],"BIBF 1120 M + docetaxel H","BIBF 1120 H + docetaxel H","BIBF 1120 L + docetaxel M","BIBF 1120 H + docetaxel M",{"trials":34735,"activeCount":101},[],{"trials":34737,"activeCount":101},[],{"trials":34739,"activeCount":101},[],{"trials":34741,"activeCount":101},[],{"intervention":34730,"totalTrials":272,"cells":34743},{"EARLY_PHASE1":34744,"PHASE1":34746,"PHASE2":34752,"PHASE3":34754,"PHASE4":34756,"NA":34758},{"trials":34745,"activeCount":101},[],{"trials":34747,"activeCount":101},[34748],{"nctId":34725,"briefTitle":34726,"status":107,"phases":34749,"primaryCompletion":2001,"completion":7092,"start":2003,"enrollment":2789,"conditions":34750,"interventions":34751},[90],[36],[34718,34730,34731,34732,34733],{"trials":34753,"activeCount":101},[],{"trials":34755,"activeCount":101},[],{"trials":34757,"activeCount":101},[],{"trials":34759,"activeCount":101},[],{"intervention":34731,"totalTrials":272,"cells":34761},{"EARLY_PHASE1":34762,"PHASE1":34764,"PHASE2":34770,"PHASE3":34772,"PHASE4":34774,"NA":34776},{"trials":34763,"activeCount":101},[],{"trials":34765,"activeCount":101},[34766],{"nctId":34725,"briefTitle":34726,"status":107,"phases":34767,"primaryCompletion":2001,"completion":7092,"start":2003,"enrollment":2789,"conditions":34768,"interventions":34769},[90],[36],[34718,34730,34731,34732,34733],{"trials":34771,"activeCount":101},[],{"trials":34773,"activeCount":101},[],{"trials":34775,"activeCount":101},[],{"trials":34777,"activeCount":101},[],{"intervention":34732,"totalTrials":272,"cells":34779},{"EARLY_PHASE1":34780,"PHASE1":34782,"PHASE2":34788,"PHASE3":34790,"PHASE4":34792,"NA":34794},{"trials":34781,"activeCount":101},[],{"trials":34783,"activeCount":101},[34784],{"nctId":34725,"briefTitle":34726,"status":107,"phases":34785,"primaryCompletion":2001,"completion":7092,"start":2003,"enrollment":2789,"conditions":34786,"interventions":34787},[90],[36],[34718,34730,34731,34732,34733],{"trials":34789,"activeCount":101},[],{"trials":34791,"activeCount":101},[],{"trials":34793,"activeCount":101},[],{"trials":34795,"activeCount":101},[],{"intervention":34733,"totalTrials":272,"cells":34797},{"EARLY_PHASE1":34798,"PHASE1":34800,"PHASE2":34806,"PHASE3":34808,"PHASE4":34810,"NA":34812},{"trials":34799,"activeCount":101},[],{"trials":34801,"activeCount":101},[34802],{"nctId":34725,"briefTitle":34726,"status":107,"phases":34803,"primaryCompletion":2001,"completion":7092,"start":2003,"enrollment":2789,"conditions":34804,"interventions":34805},[90],[36],[34718,34730,34731,34732,34733],{"trials":34807,"activeCount":101},[],{"trials":34809,"activeCount":101},[],{"trials":34811,"activeCount":101},[],{"trials":34813,"activeCount":101},[],{"intervention":34815,"totalTrials":272,"cells":34816},"14C-BIRB 796 BS",{"EARLY_PHASE1":34817,"PHASE1":34819,"PHASE2":34827,"PHASE3":34829,"PHASE4":34831,"NA":34833},{"trials":34818,"activeCount":101},[],{"trials":34820,"activeCount":101},[34821],{"nctId":34822,"briefTitle":34823,"status":107,"phases":34824,"primaryCompletion":6082,"start":6189,"enrollment":1512,"conditions":34825,"interventions":34826},"NCT02211885","Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects",[90],[15],[34815],{"trials":34828,"activeCount":101},[],{"trials":34830,"activeCount":101},[],{"trials":34832,"activeCount":101},[],{"trials":34834,"activeCount":101},[],{"intervention":34836,"totalTrials":272,"cells":34837},"Amiodarone",{"EARLY_PHASE1":34838,"PHASE1":34840,"PHASE2":34848,"PHASE3":34850,"PHASE4":34852,"NA":34854},{"trials":34839,"activeCount":101},[],{"trials":34841,"activeCount":101},[34842],{"nctId":34843,"briefTitle":34844,"status":107,"phases":34845,"primaryCompletion":2111,"start":6156,"enrollment":380,"conditions":34846,"interventions":34847},"NCT02171026","Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers",[90],[15],[6561,34836],{"trials":34849,"activeCount":101},[],{"trials":34851,"activeCount":101},[],{"trials":34853,"activeCount":101},[],{"trials":34855,"activeCount":101},[],{"intervention":20240,"totalTrials":272,"cells":34857},{"EARLY_PHASE1":34858,"PHASE1":34860,"PHASE2":34866,"PHASE3":34868,"PHASE4":34870,"NA":34872},{"trials":34859,"activeCount":101},[],{"trials":34861,"activeCount":101},[34862],{"nctId":20232,"briefTitle":20233,"status":162,"phases":34863,"primaryCompletion":20235,"completion":20236,"start":20237,"enrollment":112,"conditions":34864,"interventions":34865},[90],[15],[20240,20217,20217],{"trials":34867,"activeCount":101},[],{"trials":34869,"activeCount":101},[],{"trials":34871,"activeCount":101},[],{"trials":34873,"activeCount":101},[],{"intervention":4009,"totalTrials":272,"cells":34875},{"EARLY_PHASE1":34876,"PHASE1":34878,"PHASE2":34884,"PHASE3":34886,"PHASE4":34888,"NA":34890},{"trials":34877,"activeCount":101},[],{"trials":34879,"activeCount":101},[34880],{"nctId":4002,"briefTitle":4003,"status":107,"phases":34881,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":34882,"interventions":34883},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"trials":34885,"activeCount":101},[],{"trials":34887,"activeCount":101},[],{"trials":34889,"activeCount":101},[],{"trials":34891,"activeCount":101},[],{"intervention":4015,"totalTrials":272,"cells":34893},{"EARLY_PHASE1":34894,"PHASE1":34896,"PHASE2":34902,"PHASE3":34904,"PHASE4":34906,"NA":34908},{"trials":34895,"activeCount":101},[],{"trials":34897,"activeCount":101},[34898],{"nctId":4002,"briefTitle":4003,"status":107,"phases":34899,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":34900,"interventions":34901},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"trials":34903,"activeCount":101},[],{"trials":34905,"activeCount":101},[],{"trials":34907,"activeCount":101},[],{"trials":34909,"activeCount":101},[],{"intervention":34911,"totalTrials":272,"cells":34912},"BI 11054 CL",{"EARLY_PHASE1":34913,"PHASE1":34915,"PHASE2":34923,"PHASE3":34925,"PHASE4":34927,"NA":34929},{"trials":34914,"activeCount":101},[],{"trials":34916,"activeCount":101},[34917],{"nctId":34918,"briefTitle":34919,"status":107,"phases":34920,"primaryCompletion":6223,"start":4507,"enrollment":8,"conditions":34921,"interventions":34922},"NCT02273401","Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers",[90],[15],[34911],{"trials":34924,"activeCount":101},[],{"trials":34926,"activeCount":101},[],{"trials":34928,"activeCount":101},[],{"trials":34930,"activeCount":101},[],{"intervention":34932,"totalTrials":272,"cells":34933},"Dabigatran etexilate polymorph II",{"EARLY_PHASE1":34934,"PHASE1":34936,"PHASE2":34945,"PHASE3":34947,"PHASE4":34949,"NA":34951},{"trials":34935,"activeCount":101},[],{"trials":34937,"activeCount":101},[34938],{"nctId":34939,"briefTitle":34940,"status":107,"phases":34941,"primaryCompletion":6223,"start":5906,"enrollment":3565,"conditions":34942,"interventions":34943},"NCT02171481","Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers",[90],[15],[34932,34944],"Dabigatran etexilate polymorph I",{"trials":34946,"activeCount":101},[],{"trials":34948,"activeCount":101},[],{"trials":34950,"activeCount":101},[],{"trials":34952,"activeCount":101},[],{"intervention":34944,"totalTrials":272,"cells":34954},{"EARLY_PHASE1":34955,"PHASE1":34957,"PHASE2":34963,"PHASE3":34965,"PHASE4":34967,"NA":34969},{"trials":34956,"activeCount":101},[],{"trials":34958,"activeCount":101},[34959],{"nctId":34939,"briefTitle":34940,"status":107,"phases":34960,"primaryCompletion":6223,"start":5906,"enrollment":3565,"conditions":34961,"interventions":34962},[90],[15],[34932,34944],{"trials":34964,"activeCount":101},[],{"trials":34966,"activeCount":101},[],{"trials":34968,"activeCount":101},[],{"trials":34970,"activeCount":101},[],{"intervention":385,"totalTrials":272,"cells":34972},{"EARLY_PHASE1":34973,"PHASE1":34975,"PHASE2":34981,"PHASE3":34983,"PHASE4":34985,"NA":34987},{"trials":34974,"activeCount":101},[],{"trials":34976,"activeCount":101},[34977],{"nctId":375,"briefTitle":376,"status":107,"phases":34978,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":34979,"interventions":34980},[90],[15],[383,384,384,383,385,385],{"trials":34982,"activeCount":101},[],{"trials":34984,"activeCount":101},[],{"trials":34986,"activeCount":101},[],{"trials":34988,"activeCount":101},[],{"intervention":34990,"totalTrials":272,"cells":34991},"Alfuzosin",{"EARLY_PHASE1":34992,"PHASE1":34994,"PHASE2":35003,"PHASE3":35005,"PHASE4":35007,"NA":35009},{"trials":34993,"activeCount":101},[],{"trials":34995,"activeCount":101},[34996],{"nctId":34997,"briefTitle":34998,"status":107,"phases":34999,"primaryCompletion":7151,"start":5842,"enrollment":5870,"conditions":35000,"interventions":35001},"NCT02266537","Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers",[90],[15],[9095,34990,35002],"Doxazosin",{"trials":35004,"activeCount":101},[],{"trials":35006,"activeCount":101},[],{"trials":35008,"activeCount":101},[],{"trials":35010,"activeCount":101},[],{"intervention":35002,"totalTrials":272,"cells":35012},{"EARLY_PHASE1":35013,"PHASE1":35015,"PHASE2":35021,"PHASE3":35023,"PHASE4":35025,"NA":35027},{"trials":35014,"activeCount":101},[],{"trials":35016,"activeCount":101},[35017],{"nctId":34997,"briefTitle":34998,"status":107,"phases":35018,"primaryCompletion":7151,"start":5842,"enrollment":5870,"conditions":35019,"interventions":35020},[90],[15],[9095,34990,35002],{"trials":35022,"activeCount":101},[],{"trials":35024,"activeCount":101},[],{"trials":35026,"activeCount":101},[],{"trials":35028,"activeCount":101},[],{"intervention":28489,"totalTrials":272,"cells":35030},{"EARLY_PHASE1":35031,"PHASE1":35033,"PHASE2":35039,"PHASE3":35041,"PHASE4":35043,"NA":35045},{"trials":35032,"activeCount":101},[],{"trials":35034,"activeCount":101},[35035],{"nctId":28484,"briefTitle":28485,"status":107,"phases":35036,"primaryCompletion":3754,"start":6811,"enrollment":8304,"conditions":35037,"interventions":35038},[90],[15],[28489,28470],{"trials":35040,"activeCount":101},[],{"trials":35042,"activeCount":101},[],{"trials":35044,"activeCount":101},[],{"trials":35046,"activeCount":101},[],{"intervention":29780,"totalTrials":272,"cells":35048},{"EARLY_PHASE1":35049,"PHASE1":35051,"PHASE2":35057,"PHASE3":35059,"PHASE4":35061,"NA":35063},{"trials":35050,"activeCount":101},[],{"trials":35052,"activeCount":101},[35053],{"nctId":29775,"briefTitle":29776,"status":107,"phases":35054,"primaryCompletion":2122,"start":2181,"enrollment":251,"conditions":35055,"interventions":35056},[90],[15],[29768,29780,29781],{"trials":35058,"activeCount":101},[],{"trials":35060,"activeCount":101},[],{"trials":35062,"activeCount":101},[],{"trials":35064,"activeCount":101},[],{"intervention":29781,"totalTrials":272,"cells":35066},{"EARLY_PHASE1":35067,"PHASE1":35069,"PHASE2":35075,"PHASE3":35077,"PHASE4":35079,"NA":35081},{"trials":35068,"activeCount":101},[],{"trials":35070,"activeCount":101},[35071],{"nctId":29775,"briefTitle":29776,"status":107,"phases":35072,"primaryCompletion":2122,"start":2181,"enrollment":251,"conditions":35073,"interventions":35074},[90],[15],[29768,29780,29781],{"trials":35076,"activeCount":101},[],{"trials":35078,"activeCount":101},[],{"trials":35080,"activeCount":101},[],{"trials":35082,"activeCount":101},[],{"intervention":35084,"totalTrials":272,"cells":35085},"BIBW 2948 BS for oral inhalation",{"EARLY_PHASE1":35086,"PHASE1":35088,"PHASE2":35096,"PHASE3":35098,"PHASE4":35100,"NA":35102},{"trials":35087,"activeCount":101},[],{"trials":35089,"activeCount":101},[35090],{"nctId":35091,"briefTitle":35092,"status":107,"phases":35093,"primaryCompletion":11642,"start":15139,"enrollment":6607,"conditions":35094,"interventions":35095},"NCT02214901","Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers",[90],[15],[35084],{"trials":35097,"activeCount":101},[],{"trials":35099,"activeCount":101},[],{"trials":35101,"activeCount":101},[],{"trials":35103,"activeCount":101},[],{"intervention":35105,"totalTrials":272,"cells":35106},"BIBF 1120 soft gelatine",{"EARLY_PHASE1":35107,"PHASE1":35109,"PHASE2":35118,"PHASE3":35120,"PHASE4":35122,"NA":35124},{"trials":35108,"activeCount":101},[],{"trials":35110,"activeCount":101},[35111],{"nctId":35112,"briefTitle":35113,"status":107,"phases":35114,"primaryCompletion":3990,"start":5905,"enrollment":357,"conditions":35115,"interventions":35116},"NCT02182258","Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects",[90],[15],[35105,35117],"BIBF 1120 intravenous solution",{"trials":35119,"activeCount":101},[],{"trials":35121,"activeCount":101},[],{"trials":35123,"activeCount":101},[],{"trials":35125,"activeCount":101},[],{"intervention":35117,"totalTrials":272,"cells":35127},{"EARLY_PHASE1":35128,"PHASE1":35130,"PHASE2":35136,"PHASE3":35138,"PHASE4":35140,"NA":35142},{"trials":35129,"activeCount":101},[],{"trials":35131,"activeCount":101},[35132],{"nctId":35112,"briefTitle":35113,"status":107,"phases":35133,"primaryCompletion":3990,"start":5905,"enrollment":357,"conditions":35134,"interventions":35135},[90],[15],[35105,35117],{"trials":35137,"activeCount":101},[],{"trials":35139,"activeCount":101},[],{"trials":35141,"activeCount":101},[],{"trials":35143,"activeCount":101},[],{"intervention":19593,"totalTrials":272,"cells":35145},{"EARLY_PHASE1":35146,"PHASE1":35148,"PHASE2":35154,"PHASE3":35156,"PHASE4":35158,"NA":35160},{"trials":35147,"activeCount":101},[],{"trials":35149,"activeCount":101},[35150],{"nctId":19588,"briefTitle":19589,"status":107,"phases":35151,"primaryCompletion":7300,"start":7618,"enrollment":5205,"conditions":35152,"interventions":35153},[90],[15],[11653,19593,4010],{"trials":35155,"activeCount":101},[],{"trials":35157,"activeCount":101},[],{"trials":35159,"activeCount":101},[],{"trials":35161,"activeCount":101},[],{"intervention":18656,"totalTrials":272,"cells":35163},{"EARLY_PHASE1":35164,"PHASE1":35166,"PHASE2":35172,"PHASE3":35174,"PHASE4":35176,"NA":35178},{"trials":35165,"activeCount":101},[],{"trials":35167,"activeCount":101},[35168],{"nctId":18649,"briefTitle":18650,"status":107,"phases":35169,"primaryCompletion":18652,"completion":18652,"start":18653,"enrollment":401,"conditions":35170,"interventions":35171},[90],[15],[18656,4436],{"trials":35173,"activeCount":101},[],{"trials":35175,"activeCount":101},[],{"trials":35177,"activeCount":101},[],{"trials":35179,"activeCount":101},[],{"intervention":35181,"totalTrials":272,"cells":35182},"Tiotropium (high dose) + Olodaterol",{"EARLY_PHASE1":35183,"PHASE1":35185,"PHASE2":35194,"PHASE3":35196,"PHASE4":35198,"NA":35200},{"trials":35184,"activeCount":101},[],{"trials":35186,"activeCount":101},[35187],{"nctId":35188,"briefTitle":35189,"status":107,"phases":35190,"primaryCompletion":409,"completion":409,"start":517,"enrollment":132,"conditions":35191,"interventions":35192},"NCT01703845","A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.",[90],[18],[35181,35193],"Tiotropium (low dose) + Olodaterol",{"trials":35195,"activeCount":101},[],{"trials":35197,"activeCount":101},[],{"trials":35199,"activeCount":101},[],{"trials":35201,"activeCount":101},[],{"intervention":35193,"totalTrials":272,"cells":35203},{"EARLY_PHASE1":35204,"PHASE1":35206,"PHASE2":35212,"PHASE3":35214,"PHASE4":35216,"NA":35218},{"trials":35205,"activeCount":101},[],{"trials":35207,"activeCount":101},[35208],{"nctId":35188,"briefTitle":35189,"status":107,"phases":35209,"primaryCompletion":409,"completion":409,"start":517,"enrollment":132,"conditions":35210,"interventions":35211},[90],[18],[35181,35193],{"trials":35213,"activeCount":101},[],{"trials":35215,"activeCount":101},[],{"trials":35217,"activeCount":101},[],{"trials":35219,"activeCount":101},[],{"intervention":35221,"totalTrials":272,"cells":35222},"BI 3009947",{"EARLY_PHASE1":35223,"PHASE1":35225,"PHASE2":35235,"PHASE3":35237,"PHASE4":35239,"NA":35241},{"trials":35224,"activeCount":101},[],{"trials":35226,"activeCount":101},[35227],{"nctId":35228,"briefTitle":35229,"status":162,"phases":35230,"primaryCompletion":35231,"completion":35231,"start":35232,"enrollment":2382,"conditions":35233,"interventions":35234},"NCT07250048","A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood",[90],"2026-03-02","2025-11-21",[15],[35221,35221],{"trials":35236,"activeCount":101},[],{"trials":35238,"activeCount":101},[],{"trials":35240,"activeCount":101},[],{"trials":35242,"activeCount":101},[],{"intervention":35244,"totalTrials":272,"cells":35245},"BI 691751 high dose",{"EARLY_PHASE1":35246,"PHASE1":35248,"PHASE2":35259,"PHASE3":35261,"PHASE4":35263,"NA":35265},{"trials":35247,"activeCount":101},[],{"trials":35249,"activeCount":101},[35250],{"nctId":35251,"briefTitle":35252,"status":107,"phases":35253,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":1208,"conditions":35254,"interventions":35255},"NCT02057835","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers",[90],[15],[35244,35256,35257,35258],"BI 691751 middle dose","BI 691751 low dose 1","BI 691751 low dose 2",{"trials":35260,"activeCount":101},[],{"trials":35262,"activeCount":101},[],{"trials":35264,"activeCount":101},[],{"trials":35266,"activeCount":101},[],{"intervention":35256,"totalTrials":272,"cells":35268},{"EARLY_PHASE1":35269,"PHASE1":35271,"PHASE2":35277,"PHASE3":35279,"PHASE4":35281,"NA":35283},{"trials":35270,"activeCount":101},[],{"trials":35272,"activeCount":101},[35273],{"nctId":35251,"briefTitle":35252,"status":107,"phases":35274,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":1208,"conditions":35275,"interventions":35276},[90],[15],[35244,35256,35257,35258],{"trials":35278,"activeCount":101},[],{"trials":35280,"activeCount":101},[],{"trials":35282,"activeCount":101},[],{"trials":35284,"activeCount":101},[],{"intervention":35257,"totalTrials":272,"cells":35286},{"EARLY_PHASE1":35287,"PHASE1":35289,"PHASE2":35295,"PHASE3":35297,"PHASE4":35299,"NA":35301},{"trials":35288,"activeCount":101},[],{"trials":35290,"activeCount":101},[35291],{"nctId":35251,"briefTitle":35252,"status":107,"phases":35292,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":1208,"conditions":35293,"interventions":35294},[90],[15],[35244,35256,35257,35258],{"trials":35296,"activeCount":101},[],{"trials":35298,"activeCount":101},[],{"trials":35300,"activeCount":101},[],{"trials":35302,"activeCount":101},[],{"intervention":35258,"totalTrials":272,"cells":35304},{"EARLY_PHASE1":35305,"PHASE1":35307,"PHASE2":35313,"PHASE3":35315,"PHASE4":35317,"NA":35319},{"trials":35306,"activeCount":101},[],{"trials":35308,"activeCount":101},[35309],{"nctId":35251,"briefTitle":35252,"status":107,"phases":35310,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":1208,"conditions":35311,"interventions":35312},[90],[15],[35244,35256,35257,35258],{"trials":35314,"activeCount":101},[],{"trials":35316,"activeCount":101},[],{"trials":35318,"activeCount":101},[],{"trials":35320,"activeCount":101},[],{"intervention":28564,"totalTrials":272,"cells":35322},{"EARLY_PHASE1":35323,"PHASE1":35325,"PHASE2":35331,"PHASE3":35333,"PHASE4":35335,"NA":35337},{"trials":35324,"activeCount":101},[],{"trials":35326,"activeCount":101},[35327],{"nctId":28559,"briefTitle":28560,"status":107,"phases":35328,"primaryCompletion":7553,"start":7084,"enrollment":1672,"conditions":35329,"interventions":35330},[90],[15],[28564,28565,6994],{"trials":35332,"activeCount":101},[],{"trials":35334,"activeCount":101},[],{"trials":35336,"activeCount":101},[],{"trials":35338,"activeCount":101},[],{"intervention":28565,"totalTrials":272,"cells":35340},{"EARLY_PHASE1":35341,"PHASE1":35343,"PHASE2":35349,"PHASE3":35351,"PHASE4":35353,"NA":35355},{"trials":35342,"activeCount":101},[],{"trials":35344,"activeCount":101},[35345],{"nctId":28559,"briefTitle":28560,"status":107,"phases":35346,"primaryCompletion":7553,"start":7084,"enrollment":1672,"conditions":35347,"interventions":35348},[90],[15],[28564,28565,6994],{"trials":35350,"activeCount":101},[],{"trials":35352,"activeCount":101},[],{"trials":35354,"activeCount":101},[],{"trials":35356,"activeCount":101},[],{"intervention":20727,"totalTrials":272,"cells":35358},{"EARLY_PHASE1":35359,"PHASE1":35361,"PHASE2":35367,"PHASE3":35369,"PHASE4":35371,"NA":35373},{"trials":35360,"activeCount":101},[],{"trials":35362,"activeCount":101},[35363],{"nctId":20717,"briefTitle":20718,"status":107,"phases":35364,"primaryCompletion":20720,"completion":20721,"start":20722,"enrollment":912,"conditions":35365,"interventions":35366},[90],[20724],[20726,20727,1131],{"trials":35368,"activeCount":101},[],{"trials":35370,"activeCount":101},[],{"trials":35372,"activeCount":101},[],{"trials":35374,"activeCount":101},[],{"intervention":35376,"totalTrials":272,"cells":35377},"BIBN 4096 BS- in single rising doses",{"EARLY_PHASE1":35378,"PHASE1":35380,"PHASE2":35388,"PHASE3":35390,"PHASE4":35392,"NA":35394},{"trials":35379,"activeCount":101},[],{"trials":35381,"activeCount":101},[35382],{"nctId":35383,"briefTitle":35384,"status":107,"phases":35385,"primaryCompletion":6738,"start":13117,"enrollment":132,"conditions":35386,"interventions":35387},"NCT02198326","Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers",[90],[15],[35376],{"trials":35389,"activeCount":101},[],{"trials":35391,"activeCount":101},[],{"trials":35393,"activeCount":101},[],{"trials":35395,"activeCount":101},[],{"intervention":35397,"totalTrials":272,"cells":35398},"Telmisartan\u002FAmlodipine Combination",{"EARLY_PHASE1":35399,"PHASE1":35401,"PHASE2":35410,"PHASE3":35412,"PHASE4":35414,"NA":35416},{"trials":35400,"activeCount":101},[],{"trials":35402,"activeCount":101},[35403],{"nctId":35404,"briefTitle":35405,"status":107,"phases":35406,"primaryCompletion":9332,"start":6133,"enrollment":1865,"conditions":35407,"interventions":35408},"NCT01278797","Telmisartan and Amlodipine Versus Monocomponent Tablets",[90],[24],[35397,35409],"Amlodipine Monocomponent",{"trials":35411,"activeCount":101},[],{"trials":35413,"activeCount":101},[],{"trials":35415,"activeCount":101},[],{"trials":35417,"activeCount":101},[],{"intervention":35409,"totalTrials":272,"cells":35419},{"EARLY_PHASE1":35420,"PHASE1":35422,"PHASE2":35428,"PHASE3":35430,"PHASE4":35432,"NA":35434},{"trials":35421,"activeCount":101},[],{"trials":35423,"activeCount":101},[35424],{"nctId":35404,"briefTitle":35405,"status":107,"phases":35425,"primaryCompletion":9332,"start":6133,"enrollment":1865,"conditions":35426,"interventions":35427},[90],[24],[35397,35409],{"trials":35429,"activeCount":101},[],{"trials":35431,"activeCount":101},[],{"trials":35433,"activeCount":101},[],{"trials":35435,"activeCount":101},[],{"intervention":35437,"totalTrials":272,"cells":35438},"Dextromethorphan syrup - low dose",{"EARLY_PHASE1":35439,"PHASE1":35441,"PHASE2":35450,"PHASE3":35452,"PHASE4":35454,"NA":35456},{"trials":35440,"activeCount":101},[],{"trials":35442,"activeCount":101},[35443],{"nctId":35444,"briefTitle":35445,"status":107,"phases":35446,"primaryCompletion":3991,"start":5905,"enrollment":410,"conditions":35447,"interventions":35448},"NCT02191176","Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects",[90],[15],[35437,35449],"Dextromethorphan syrup - high dose",{"trials":35451,"activeCount":101},[],{"trials":35453,"activeCount":101},[],{"trials":35455,"activeCount":101},[],{"trials":35457,"activeCount":101},[],{"intervention":35449,"totalTrials":272,"cells":35459},{"EARLY_PHASE1":35460,"PHASE1":35462,"PHASE2":35468,"PHASE3":35470,"PHASE4":35472,"NA":35474},{"trials":35461,"activeCount":101},[],{"trials":35463,"activeCount":101},[35464],{"nctId":35444,"briefTitle":35445,"status":107,"phases":35465,"primaryCompletion":3991,"start":5905,"enrollment":410,"conditions":35466,"interventions":35467},[90],[15],[35437,35449],{"trials":35469,"activeCount":101},[],{"trials":35471,"activeCount":101},[],{"trials":35473,"activeCount":101},[],{"trials":35475,"activeCount":101},[],{"intervention":35477,"totalTrials":272,"cells":35478},"R - Low dose of BI 655130",{"EARLY_PHASE1":35479,"PHASE1":35481,"PHASE2":35492,"PHASE3":35494,"PHASE4":35496,"NA":35498},{"trials":35480,"activeCount":101},[],{"trials":35482,"activeCount":101},[35483],{"nctId":35484,"briefTitle":35485,"status":107,"phases":35486,"primaryCompletion":18933,"completion":18933,"start":19329,"enrollment":410,"conditions":35487,"interventions":35488},"NCT03617835","A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body",[90],[15],[35477,35489,35490,35491],"T1 - Low dose of BI 655130","T2 - Low dose of BI 655130","T3 - High dose of BI 655130",{"trials":35493,"activeCount":101},[],{"trials":35495,"activeCount":101},[],{"trials":35497,"activeCount":101},[],{"trials":35499,"activeCount":101},[],{"intervention":35489,"totalTrials":272,"cells":35501},{"EARLY_PHASE1":35502,"PHASE1":35504,"PHASE2":35510,"PHASE3":35512,"PHASE4":35514,"NA":35516},{"trials":35503,"activeCount":101},[],{"trials":35505,"activeCount":101},[35506],{"nctId":35484,"briefTitle":35485,"status":107,"phases":35507,"primaryCompletion":18933,"completion":18933,"start":19329,"enrollment":410,"conditions":35508,"interventions":35509},[90],[15],[35477,35489,35490,35491],{"trials":35511,"activeCount":101},[],{"trials":35513,"activeCount":101},[],{"trials":35515,"activeCount":101},[],{"trials":35517,"activeCount":101},[],{"intervention":35490,"totalTrials":272,"cells":35519},{"EARLY_PHASE1":35520,"PHASE1":35522,"PHASE2":35528,"PHASE3":35530,"PHASE4":35532,"NA":35534},{"trials":35521,"activeCount":101},[],{"trials":35523,"activeCount":101},[35524],{"nctId":35484,"briefTitle":35485,"status":107,"phases":35525,"primaryCompletion":18933,"completion":18933,"start":19329,"enrollment":410,"conditions":35526,"interventions":35527},[90],[15],[35477,35489,35490,35491],{"trials":35529,"activeCount":101},[],{"trials":35531,"activeCount":101},[],{"trials":35533,"activeCount":101},[],{"trials":35535,"activeCount":101},[],{"intervention":35491,"totalTrials":272,"cells":35537},{"EARLY_PHASE1":35538,"PHASE1":35540,"PHASE2":35546,"PHASE3":35548,"PHASE4":35550,"NA":35552},{"trials":35539,"activeCount":101},[],{"trials":35541,"activeCount":101},[35542],{"nctId":35484,"briefTitle":35485,"status":107,"phases":35543,"primaryCompletion":18933,"completion":18933,"start":19329,"enrollment":410,"conditions":35544,"interventions":35545},[90],[15],[35477,35489,35490,35491],{"trials":35547,"activeCount":101},[],{"trials":35549,"activeCount":101},[],{"trials":35551,"activeCount":101},[],{"trials":35553,"activeCount":101},[],{"intervention":35555,"totalTrials":272,"cells":35556},"BHT low",{"EARLY_PHASE1":35557,"PHASE1":35559,"PHASE2":35574,"PHASE3":35576,"PHASE4":35578,"NA":35580},{"trials":35558,"activeCount":101},[],{"trials":35560,"activeCount":101},[35561],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35564,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35565,"interventions":35566},"NCT02221375","Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers",[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],"BHT medium","BHT high","BI 54903 XX low","BI 54903 XX medium 1","BI 54903 XX medium 2","BI 54903 XX high","Ciclesonide",{"trials":35575,"activeCount":101},[],{"trials":35577,"activeCount":101},[],{"trials":35579,"activeCount":101},[],{"trials":35581,"activeCount":101},[],{"intervention":35567,"totalTrials":272,"cells":35583},{"EARLY_PHASE1":35584,"PHASE1":35586,"PHASE2":35592,"PHASE3":35594,"PHASE4":35596,"NA":35598},{"trials":35585,"activeCount":101},[],{"trials":35587,"activeCount":101},[35588],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35589,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35590,"interventions":35591},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35593,"activeCount":101},[],{"trials":35595,"activeCount":101},[],{"trials":35597,"activeCount":101},[],{"trials":35599,"activeCount":101},[],{"intervention":35568,"totalTrials":272,"cells":35601},{"EARLY_PHASE1":35602,"PHASE1":35604,"PHASE2":35610,"PHASE3":35612,"PHASE4":35614,"NA":35616},{"trials":35603,"activeCount":101},[],{"trials":35605,"activeCount":101},[35606],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35607,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35608,"interventions":35609},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35611,"activeCount":101},[],{"trials":35613,"activeCount":101},[],{"trials":35615,"activeCount":101},[],{"trials":35617,"activeCount":101},[],{"intervention":35569,"totalTrials":272,"cells":35619},{"EARLY_PHASE1":35620,"PHASE1":35622,"PHASE2":35628,"PHASE3":35630,"PHASE4":35632,"NA":35634},{"trials":35621,"activeCount":101},[],{"trials":35623,"activeCount":101},[35624],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35625,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35626,"interventions":35627},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35629,"activeCount":101},[],{"trials":35631,"activeCount":101},[],{"trials":35633,"activeCount":101},[],{"trials":35635,"activeCount":101},[],{"intervention":35570,"totalTrials":272,"cells":35637},{"EARLY_PHASE1":35638,"PHASE1":35640,"PHASE2":35646,"PHASE3":35648,"PHASE4":35650,"NA":35652},{"trials":35639,"activeCount":101},[],{"trials":35641,"activeCount":101},[35642],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35643,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35644,"interventions":35645},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35647,"activeCount":101},[],{"trials":35649,"activeCount":101},[],{"trials":35651,"activeCount":101},[],{"trials":35653,"activeCount":101},[],{"intervention":35571,"totalTrials":272,"cells":35655},{"EARLY_PHASE1":35656,"PHASE1":35658,"PHASE2":35664,"PHASE3":35666,"PHASE4":35668,"NA":35670},{"trials":35657,"activeCount":101},[],{"trials":35659,"activeCount":101},[35660],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35661,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35662,"interventions":35663},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35665,"activeCount":101},[],{"trials":35667,"activeCount":101},[],{"trials":35669,"activeCount":101},[],{"trials":35671,"activeCount":101},[],{"intervention":35572,"totalTrials":272,"cells":35673},{"EARLY_PHASE1":35674,"PHASE1":35676,"PHASE2":35682,"PHASE3":35684,"PHASE4":35686,"NA":35688},{"trials":35675,"activeCount":101},[],{"trials":35677,"activeCount":101},[35678],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35679,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35680,"interventions":35681},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35683,"activeCount":101},[],{"trials":35685,"activeCount":101},[],{"trials":35687,"activeCount":101},[],{"trials":35689,"activeCount":101},[],{"intervention":35573,"totalTrials":272,"cells":35691},{"EARLY_PHASE1":35692,"PHASE1":35694,"PHASE2":35700,"PHASE3":35702,"PHASE4":35704,"NA":35706},{"trials":35693,"activeCount":101},[],{"trials":35695,"activeCount":101},[35696],{"nctId":35562,"briefTitle":35563,"status":107,"phases":35697,"primaryCompletion":5856,"start":4413,"enrollment":37,"conditions":35698,"interventions":35699},[90],[15],[35555,35567,35568,35569,35570,35571,35572,35573],{"trials":35701,"activeCount":101},[],{"trials":35703,"activeCount":101},[],{"trials":35705,"activeCount":101},[],{"trials":35707,"activeCount":101},[],{"intervention":35709,"totalTrials":272,"cells":35710},"Single rising doses of BIBT 1011 BS",{"EARLY_PHASE1":35711,"PHASE1":35713,"PHASE2":35722,"PHASE3":35724,"PHASE4":35726,"NA":35728},{"trials":35712,"activeCount":101},[],{"trials":35714,"activeCount":101},[35715],{"nctId":35716,"briefTitle":35717,"status":107,"phases":35718,"primaryCompletion":7132,"start":6584,"enrollment":37,"conditions":35719,"interventions":35720},"NCT02182037","Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects",[90],[15],[35709,35721],"BIBT 1011 BS placebo",{"trials":35723,"activeCount":101},[],{"trials":35725,"activeCount":101},[],{"trials":35727,"activeCount":101},[],{"trials":35729,"activeCount":101},[],{"intervention":35721,"totalTrials":272,"cells":35731},{"EARLY_PHASE1":35732,"PHASE1":35734,"PHASE2":35740,"PHASE3":35742,"PHASE4":35744,"NA":35746},{"trials":35733,"activeCount":101},[],{"trials":35735,"activeCount":101},[35736],{"nctId":35716,"briefTitle":35717,"status":107,"phases":35737,"primaryCompletion":7132,"start":6584,"enrollment":37,"conditions":35738,"interventions":35739},[90],[15],[35709,35721],{"trials":35741,"activeCount":101},[],{"trials":35743,"activeCount":101},[],{"trials":35745,"activeCount":101},[],{"trials":35747,"activeCount":101},[],{"intervention":35749,"totalTrials":272,"cells":35750},"BILR 355 - D1",{"EARLY_PHASE1":35751,"PHASE1":35753,"PHASE2":35764,"PHASE3":35766,"PHASE4":35768,"NA":35770},{"trials":35752,"activeCount":101},[],{"trials":35754,"activeCount":101},[35755],{"nctId":35756,"briefTitle":35757,"status":107,"phases":35758,"primaryCompletion":11588,"start":4498,"enrollment":410,"conditions":35759,"interventions":35760},"NCT02253927","Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers",[90],[15],[35749,35761,35762,35763,4010],"BILR 355 - D2","BILR 355 - D3","BILR 355 - D4",{"trials":35765,"activeCount":101},[],{"trials":35767,"activeCount":101},[],{"trials":35769,"activeCount":101},[],{"trials":35771,"activeCount":101},[],{"intervention":35761,"totalTrials":272,"cells":35773},{"EARLY_PHASE1":35774,"PHASE1":35776,"PHASE2":35782,"PHASE3":35784,"PHASE4":35786,"NA":35788},{"trials":35775,"activeCount":101},[],{"trials":35777,"activeCount":101},[35778],{"nctId":35756,"briefTitle":35757,"status":107,"phases":35779,"primaryCompletion":11588,"start":4498,"enrollment":410,"conditions":35780,"interventions":35781},[90],[15],[35749,35761,35762,35763,4010],{"trials":35783,"activeCount":101},[],{"trials":35785,"activeCount":101},[],{"trials":35787,"activeCount":101},[],{"trials":35789,"activeCount":101},[],{"intervention":35762,"totalTrials":272,"cells":35791},{"EARLY_PHASE1":35792,"PHASE1":35794,"PHASE2":35800,"PHASE3":35802,"PHASE4":35804,"NA":35806},{"trials":35793,"activeCount":101},[],{"trials":35795,"activeCount":101},[35796],{"nctId":35756,"briefTitle":35757,"status":107,"phases":35797,"primaryCompletion":11588,"start":4498,"enrollment":410,"conditions":35798,"interventions":35799},[90],[15],[35749,35761,35762,35763,4010],{"trials":35801,"activeCount":101},[],{"trials":35803,"activeCount":101},[],{"trials":35805,"activeCount":101},[],{"trials":35807,"activeCount":101},[],{"intervention":35763,"totalTrials":272,"cells":35809},{"EARLY_PHASE1":35810,"PHASE1":35812,"PHASE2":35818,"PHASE3":35820,"PHASE4":35822,"NA":35824},{"trials":35811,"activeCount":101},[],{"trials":35813,"activeCount":101},[35814],{"nctId":35756,"briefTitle":35757,"status":107,"phases":35815,"primaryCompletion":11588,"start":4498,"enrollment":410,"conditions":35816,"interventions":35817},[90],[15],[35749,35761,35762,35763,4010],{"trials":35819,"activeCount":101},[],{"trials":35821,"activeCount":101},[],{"trials":35823,"activeCount":101},[],{"trials":35825,"activeCount":101},[],{"intervention":35827,"totalTrials":272,"cells":35828},"BIWA 4",{"EARLY_PHASE1":35829,"PHASE1":35831,"PHASE2":35839,"PHASE3":35841,"PHASE4":35843,"NA":35845},{"trials":35830,"activeCount":101},[],{"trials":35832,"activeCount":101},[35833],{"nctId":35834,"briefTitle":35835,"status":107,"phases":35836,"primaryCompletion":7419,"start":2181,"enrollment":1340,"conditions":35837,"interventions":35838},"NCT02204046","Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast",[90],[1773],[35827],{"trials":35840,"activeCount":101},[],{"trials":35842,"activeCount":101},[],{"trials":35844,"activeCount":101},[],{"trials":35846,"activeCount":101},[],{"intervention":12745,"totalTrials":272,"cells":35848},{"EARLY_PHASE1":35849,"PHASE1":35851,"PHASE2":35857,"PHASE3":35859,"PHASE4":35861,"NA":35863},{"trials":35850,"activeCount":101},[],{"trials":35852,"activeCount":101},[35853],{"nctId":12740,"briefTitle":12741,"status":107,"phases":35854,"primaryCompletion":5906,"start":4129,"enrollment":401,"conditions":35855,"interventions":35856},[90],[15],[12733,12745],{"trials":35858,"activeCount":101},[],{"trials":35860,"activeCount":101},[],{"trials":35862,"activeCount":101},[],{"trials":35864,"activeCount":101},[],{"intervention":35866,"totalTrials":272,"cells":35867},"tiotropium 18 mcg or 54 mcg qd",{"EARLY_PHASE1":35868,"PHASE1":35870,"PHASE2":35879,"PHASE3":35881,"PHASE4":35883,"NA":35885},{"trials":35869,"activeCount":101},[],{"trials":35871,"activeCount":101},[35872],{"nctId":35873,"briefTitle":35874,"status":107,"phases":35875,"primaryCompletion":11642,"completion":11642,"start":7618,"enrollment":37,"conditions":35876,"interventions":35877},"NCT00257452","A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)",[90],[15],[35866,35878],"moxifloxacin 200 mg",{"trials":35880,"activeCount":101},[],{"trials":35882,"activeCount":101},[],{"trials":35884,"activeCount":101},[],{"trials":35886,"activeCount":101},[],{"intervention":35878,"totalTrials":272,"cells":35888},{"EARLY_PHASE1":35889,"PHASE1":35891,"PHASE2":35897,"PHASE3":35899,"PHASE4":35901,"NA":35903},{"trials":35890,"activeCount":101},[],{"trials":35892,"activeCount":101},[35893],{"nctId":35873,"briefTitle":35874,"status":107,"phases":35894,"primaryCompletion":11642,"completion":11642,"start":7618,"enrollment":37,"conditions":35895,"interventions":35896},[90],[15],[35866,35878],{"trials":35898,"activeCount":101},[],{"trials":35900,"activeCount":101},[],{"trials":35902,"activeCount":101},[],{"trials":35904,"activeCount":101},[],{"intervention":35906,"totalTrials":272,"cells":35907},"empagliflozin\u002Flinagliptin FDC",{"EARLY_PHASE1":35908,"PHASE1":35910,"PHASE2":35920,"PHASE3":35922,"PHASE4":35924,"NA":35926},{"trials":35909,"activeCount":101},[],{"trials":35911,"activeCount":101},[35912],{"nctId":35913,"briefTitle":35914,"status":107,"phases":35915,"primaryCompletion":35916,"completion":35916,"start":35917,"enrollment":210,"conditions":35918,"interventions":35919},"NCT02815644","Empa\u002FLina FDC Food Effect Study (Japan)",[90],"2016-10-05","2016-07-15",[15],[35906],{"trials":35921,"activeCount":101},[],{"trials":35923,"activeCount":101},[],{"trials":35925,"activeCount":101},[],{"trials":35927,"activeCount":101},[],{"intervention":35929,"totalTrials":272,"cells":35930},"Volasertib, low dose, d1q3w",{"EARLY_PHASE1":35931,"PHASE1":35933,"PHASE2":35945,"PHASE3":35947,"PHASE4":35949,"NA":35951},{"trials":35932,"activeCount":101},[],{"trials":35934,"activeCount":101},[35935],{"nctId":35936,"briefTitle":35937,"status":107,"phases":35938,"primaryCompletion":35939,"completion":21139,"start":35940,"enrollment":956,"conditions":35941,"interventions":35942},"NCT01348347","BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours",[90],"2012-08-27","2011-04-25",[33],[35929,35943,35944],"Volasertib, middle dose, d1q3w","Volasertib, high dose, d1q3w",{"trials":35946,"activeCount":101},[],{"trials":35948,"activeCount":101},[],{"trials":35950,"activeCount":101},[],{"trials":35952,"activeCount":101},[],{"intervention":35943,"totalTrials":272,"cells":35954},{"EARLY_PHASE1":35955,"PHASE1":35957,"PHASE2":35963,"PHASE3":35965,"PHASE4":35967,"NA":35969},{"trials":35956,"activeCount":101},[],{"trials":35958,"activeCount":101},[35959],{"nctId":35936,"briefTitle":35937,"status":107,"phases":35960,"primaryCompletion":35939,"completion":21139,"start":35940,"enrollment":956,"conditions":35961,"interventions":35962},[90],[33],[35929,35943,35944],{"trials":35964,"activeCount":101},[],{"trials":35966,"activeCount":101},[],{"trials":35968,"activeCount":101},[],{"trials":35970,"activeCount":101},[],{"intervention":35944,"totalTrials":272,"cells":35972},{"EARLY_PHASE1":35973,"PHASE1":35975,"PHASE2":35981,"PHASE3":35983,"PHASE4":35985,"NA":35987},{"trials":35974,"activeCount":101},[],{"trials":35976,"activeCount":101},[35977],{"nctId":35936,"briefTitle":35937,"status":107,"phases":35978,"primaryCompletion":35939,"completion":21139,"start":35940,"enrollment":956,"conditions":35979,"interventions":35980},[90],[33],[35929,35943,35944],{"trials":35982,"activeCount":101},[],{"trials":35984,"activeCount":101},[],{"trials":35986,"activeCount":101},[],{"trials":35988,"activeCount":101},[],{"intervention":4033,"totalTrials":272,"cells":35990},{"EARLY_PHASE1":35991,"PHASE1":35993,"PHASE2":35999,"PHASE3":36001,"PHASE4":36003,"NA":36005},{"trials":35992,"activeCount":101},[],{"trials":35994,"activeCount":101},[35995],{"nctId":4026,"briefTitle":4027,"status":107,"phases":35996,"primaryCompletion":4029,"completion":4029,"start":4030,"enrollment":291,"conditions":35997,"interventions":35998},[90],[15],[4033,1242],{"trials":36000,"activeCount":101},[],{"trials":36002,"activeCount":101},[],{"trials":36004,"activeCount":101},[],{"trials":36006,"activeCount":101},[],{"intervention":36008,"totalTrials":272,"cells":36009},"Paroxetine",{"EARLY_PHASE1":36010,"PHASE1":36012,"PHASE2":36020,"PHASE3":36022,"PHASE4":36024,"NA":36026},{"trials":36011,"activeCount":101},[],{"trials":36013,"activeCount":101},[36014],{"nctId":36015,"briefTitle":36016,"status":107,"phases":36017,"primaryCompletion":2032,"start":5856,"enrollment":380,"conditions":36018,"interventions":36019},"NCT02264184","Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers",[90],[15],[9095,36008],{"trials":36021,"activeCount":101},[],{"trials":36023,"activeCount":101},[],{"trials":36025,"activeCount":101},[],{"trials":36027,"activeCount":101},[],{"intervention":11009,"totalTrials":272,"cells":36029},{"EARLY_PHASE1":36030,"PHASE1":36032,"PHASE2":36038,"PHASE3":36040,"PHASE4":36042,"NA":36044},{"trials":36031,"activeCount":101},[],{"trials":36033,"activeCount":101},[36034],{"nctId":11003,"briefTitle":11004,"status":107,"phases":36035,"primaryCompletion":5843,"start":1981,"enrollment":1672,"conditions":36036,"interventions":36037},[90],[15],[11008,11009],{"trials":36039,"activeCount":101},[],{"trials":36041,"activeCount":101},[],{"trials":36043,"activeCount":101},[],{"trials":36045,"activeCount":101},[],{"intervention":4455,"totalTrials":272,"cells":36047},{"EARLY_PHASE1":36048,"PHASE1":36050,"PHASE2":36056,"PHASE3":36058,"PHASE4":36060,"NA":36062},{"trials":36049,"activeCount":101},[],{"trials":36051,"activeCount":101},[36052],{"nctId":4447,"briefTitle":4448,"status":107,"phases":36053,"primaryCompletion":4450,"completion":4450,"start":4451,"enrollment":37,"conditions":36054,"interventions":36055},[90],[15],[4454,4455,1538,4456],{"trials":36057,"activeCount":101},[],{"trials":36059,"activeCount":101},[],{"trials":36061,"activeCount":101},[],{"trials":36063,"activeCount":101},[],{"intervention":36065,"totalTrials":272,"cells":36066},"BIRT 1696 BS",{"EARLY_PHASE1":36067,"PHASE1":36069,"PHASE2":36077,"PHASE3":36079,"PHASE4":36081,"NA":36083},{"trials":36068,"activeCount":101},[],{"trials":36070,"activeCount":101},[36071],{"nctId":36072,"briefTitle":36073,"status":107,"phases":36074,"primaryCompletion":6495,"start":5887,"enrollment":1094,"conditions":36075,"interventions":36076},"NCT02254096","Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human Subjects",[90],[15],[36065],{"trials":36078,"activeCount":101},[],{"trials":36080,"activeCount":101},[],{"trials":36082,"activeCount":101},[],{"trials":36084,"activeCount":101},[],{"intervention":36086,"totalTrials":272,"cells":36087},"BIBR 1048 MS HPMC",{"EARLY_PHASE1":36088,"PHASE1":36090,"PHASE2":36099,"PHASE3":36101,"PHASE4":36103,"NA":36105},{"trials":36089,"activeCount":101},[],{"trials":36091,"activeCount":101},[36092],{"nctId":36093,"briefTitle":36094,"status":107,"phases":36095,"primaryCompletion":5869,"start":6472,"enrollment":188,"conditions":36096,"interventions":36097},"NCT02170597","Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects",[90],[15],[36086,36098],"BIBR 1048 MS gelatine",{"trials":36100,"activeCount":101},[],{"trials":36102,"activeCount":101},[],{"trials":36104,"activeCount":101},[],{"trials":36106,"activeCount":101},[],{"intervention":36098,"totalTrials":272,"cells":36108},{"EARLY_PHASE1":36109,"PHASE1":36111,"PHASE2":36117,"PHASE3":36119,"PHASE4":36121,"NA":36123},{"trials":36110,"activeCount":101},[],{"trials":36112,"activeCount":101},[36113],{"nctId":36093,"briefTitle":36094,"status":107,"phases":36114,"primaryCompletion":5869,"start":6472,"enrollment":188,"conditions":36115,"interventions":36116},[90],[15],[36086,36098],{"trials":36118,"activeCount":101},[],{"trials":36120,"activeCount":101},[],{"trials":36122,"activeCount":101},[],{"trials":36124,"activeCount":101},[],{"intervention":36126,"totalTrials":272,"cells":36127},"WAL 801 CL dry syrup new formulation",{"EARLY_PHASE1":36128,"PHASE1":36130,"PHASE2":36139,"PHASE3":36141,"PHASE4":36143,"NA":36145},{"trials":36129,"activeCount":101},[],{"trials":36131,"activeCount":101},[36132],{"nctId":36133,"briefTitle":36134,"status":107,"phases":36135,"primaryCompletion":5868,"start":6235,"enrollment":1237,"conditions":36136,"interventions":36137},"NCT02260050","Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers",[90],[15],[36126,36138],"WAL 801 CL dry syrup conventional formulation",{"trials":36140,"activeCount":101},[],{"trials":36142,"activeCount":101},[],{"trials":36144,"activeCount":101},[],{"trials":36146,"activeCount":101},[],{"intervention":36138,"totalTrials":272,"cells":36148},{"EARLY_PHASE1":36149,"PHASE1":36151,"PHASE2":36157,"PHASE3":36159,"PHASE4":36161,"NA":36163},{"trials":36150,"activeCount":101},[],{"trials":36152,"activeCount":101},[36153],{"nctId":36133,"briefTitle":36134,"status":107,"phases":36154,"primaryCompletion":5868,"start":6235,"enrollment":1237,"conditions":36155,"interventions":36156},[90],[15],[36126,36138],{"trials":36158,"activeCount":101},[],{"trials":36160,"activeCount":101},[],{"trials":36162,"activeCount":101},[],{"trials":36164,"activeCount":101},[],{"intervention":36166,"totalTrials":272,"cells":36167},"BI 34021 FU2 solution",{"EARLY_PHASE1":36168,"PHASE1":36170,"PHASE2":36179,"PHASE3":36181,"PHASE4":36183,"NA":36185},{"trials":36169,"activeCount":101},[],{"trials":36171,"activeCount":101},[36172],{"nctId":36173,"briefTitle":36174,"status":107,"phases":36175,"primaryCompletion":4413,"start":4128,"enrollment":8304,"conditions":36176,"interventions":36177},"NCT02259842","Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers",[90],[15],[36166,36178],"BI 34021 FU2",{"trials":36180,"activeCount":101},[],{"trials":36182,"activeCount":101},[],{"trials":36184,"activeCount":101},[],{"trials":36186,"activeCount":101},[],{"intervention":36178,"totalTrials":272,"cells":36188},{"EARLY_PHASE1":36189,"PHASE1":36191,"PHASE2":36197,"PHASE3":36199,"PHASE4":36201,"NA":36203},{"trials":36190,"activeCount":101},[],{"trials":36192,"activeCount":101},[36193],{"nctId":36173,"briefTitle":36174,"status":107,"phases":36194,"primaryCompletion":4413,"start":4128,"enrollment":8304,"conditions":36195,"interventions":36196},[90],[15],[36166,36178],{"trials":36198,"activeCount":101},[],{"trials":36200,"activeCount":101},[],{"trials":36202,"activeCount":101},[],{"trials":36204,"activeCount":101},[],{"intervention":4466,"totalTrials":272,"cells":36206},{"EARLY_PHASE1":36207,"PHASE1":36209,"PHASE2":36215,"PHASE3":36217,"PHASE4":36219,"NA":36221},{"trials":36208,"activeCount":101},[],{"trials":36210,"activeCount":101},[36211],{"nctId":4458,"briefTitle":4459,"status":107,"phases":36212,"primaryCompletion":4461,"start":4462,"enrollment":4463,"conditions":36213,"interventions":36214},[90],[15],[4466,1538,4467,4468],{"trials":36216,"activeCount":101},[],{"trials":36218,"activeCount":101},[],{"trials":36220,"activeCount":101},[],{"trials":36222,"activeCount":101},[],{"intervention":4467,"totalTrials":272,"cells":36224},{"EARLY_PHASE1":36225,"PHASE1":36227,"PHASE2":36233,"PHASE3":36235,"PHASE4":36237,"NA":36239},{"trials":36226,"activeCount":101},[],{"trials":36228,"activeCount":101},[36229],{"nctId":4458,"briefTitle":4459,"status":107,"phases":36230,"primaryCompletion":4461,"start":4462,"enrollment":4463,"conditions":36231,"interventions":36232},[90],[15],[4466,1538,4467,4468],{"trials":36234,"activeCount":101},[],{"trials":36236,"activeCount":101},[],{"trials":36238,"activeCount":101},[],{"trials":36240,"activeCount":101},[],{"intervention":19600,"totalTrials":272,"cells":36242},{"EARLY_PHASE1":36243,"PHASE1":36245,"PHASE2":36251,"PHASE3":36253,"PHASE4":36255,"NA":36257},{"trials":36244,"activeCount":101},[],{"trials":36246,"activeCount":101},[36247],{"nctId":19595,"briefTitle":19596,"status":107,"phases":36248,"primaryCompletion":1115,"start":11581,"enrollment":1237,"conditions":36249,"interventions":36250},[90],[15],[11653,4010,19600],{"trials":36252,"activeCount":101},[],{"trials":36254,"activeCount":101},[],{"trials":36256,"activeCount":101},[],{"trials":36258,"activeCount":101},[],{"intervention":36260,"totalTrials":272,"cells":36261},"Telmisartan\u002FHCTZ combination",{"EARLY_PHASE1":36262,"PHASE1":36264,"PHASE2":36272,"PHASE3":36274,"PHASE4":36276,"NA":36278},{"trials":36263,"activeCount":101},[],{"trials":36265,"activeCount":101},[36266],{"nctId":36267,"briefTitle":36268,"status":107,"phases":36269,"primaryCompletion":4412,"start":6224,"enrollment":1208,"conditions":36270,"interventions":36271},"NCT02276391","Bioequivalence of Telmisartan as Telmisartan 80 mg\u002FHCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers",[90],[15],[36260,6121],{"trials":36273,"activeCount":101},[],{"trials":36275,"activeCount":101},[],{"trials":36277,"activeCount":101},[],{"trials":36279,"activeCount":101},[],{"intervention":36281,"totalTrials":272,"cells":36282},"BI 113608 high dose b.i.d.",{"EARLY_PHASE1":36283,"PHASE1":36285,"PHASE2":36295,"PHASE3":36297,"PHASE4":36299,"NA":36301},{"trials":36284,"activeCount":101},[],{"trials":36286,"activeCount":101},[36287],{"nctId":36288,"briefTitle":36289,"status":107,"phases":36290,"primaryCompletion":9842,"completion":9842,"start":611,"enrollment":6117,"conditions":36291,"interventions":36292},"NCT01958008","BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis",[90],[18],[36281,36293,36294],"BI 113608 low dose b.i.d.","BI 113608 medium dose b.i.d.",{"trials":36296,"activeCount":101},[],{"trials":36298,"activeCount":101},[],{"trials":36300,"activeCount":101},[],{"trials":36302,"activeCount":101},[],{"intervention":36293,"totalTrials":272,"cells":36304},{"EARLY_PHASE1":36305,"PHASE1":36307,"PHASE2":36313,"PHASE3":36315,"PHASE4":36317,"NA":36319},{"trials":36306,"activeCount":101},[],{"trials":36308,"activeCount":101},[36309],{"nctId":36288,"briefTitle":36289,"status":107,"phases":36310,"primaryCompletion":9842,"completion":9842,"start":611,"enrollment":6117,"conditions":36311,"interventions":36312},[90],[18],[36281,36293,36294],{"trials":36314,"activeCount":101},[],{"trials":36316,"activeCount":101},[],{"trials":36318,"activeCount":101},[],{"trials":36320,"activeCount":101},[],{"intervention":36294,"totalTrials":272,"cells":36322},{"EARLY_PHASE1":36323,"PHASE1":36325,"PHASE2":36331,"PHASE3":36333,"PHASE4":36335,"NA":36337},{"trials":36324,"activeCount":101},[],{"trials":36326,"activeCount":101},[36327],{"nctId":36288,"briefTitle":36289,"status":107,"phases":36328,"primaryCompletion":9842,"completion":9842,"start":611,"enrollment":6117,"conditions":36329,"interventions":36330},[90],[18],[36281,36293,36294],{"trials":36332,"activeCount":101},[],{"trials":36334,"activeCount":101},[],{"trials":36336,"activeCount":101},[],{"trials":36338,"activeCount":101},[],{"intervention":36340,"totalTrials":272,"cells":36341},"BI 416970",{"EARLY_PHASE1":36342,"PHASE1":36344,"PHASE2":36352,"PHASE3":36354,"PHASE4":36356,"NA":36358},{"trials":36343,"activeCount":101},[],{"trials":36345,"activeCount":101},[36346],{"nctId":36347,"briefTitle":36348,"status":107,"phases":36349,"primaryCompletion":4391,"completion":4391,"start":10024,"enrollment":123,"conditions":36350,"interventions":36351},"NCT02093819","To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers",[90],[15],[36340],{"trials":36353,"activeCount":101},[],{"trials":36355,"activeCount":101},[],{"trials":36357,"activeCount":101},[],{"trials":36359,"activeCount":101},[],{"intervention":36361,"totalTrials":272,"cells":36362},"5 mg empagliflozin\u002F850 mg metformin FDC",{"EARLY_PHASE1":36363,"PHASE1":36365,"PHASE2":36380,"PHASE3":36382,"PHASE4":36384,"NA":36386},{"trials":36364,"activeCount":101},[],{"trials":36366,"activeCount":101},[36367],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36370,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36371,"interventions":36372},"NCT02102932","Bioavailability of Empagliflozin\u002FMetformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers",[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],"12.5 mg empagliflozin","850 mg metformin","5 mg empagliflozin","12.5 mg empagliflozin\u002F850 mg metformin FDC","12.5 mg empagliflozin\u002F500 mg metformin FDC","5 mg empagliflozin\u002F500 mg metformin FDC","500 mg metformin",{"trials":36381,"activeCount":101},[],{"trials":36383,"activeCount":101},[],{"trials":36385,"activeCount":101},[],{"trials":36387,"activeCount":101},[],{"intervention":36373,"totalTrials":272,"cells":36389},{"EARLY_PHASE1":36390,"PHASE1":36392,"PHASE2":36398,"PHASE3":36400,"PHASE4":36402,"NA":36404},{"trials":36391,"activeCount":101},[],{"trials":36393,"activeCount":101},[36394],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36395,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36396,"interventions":36397},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36399,"activeCount":101},[],{"trials":36401,"activeCount":101},[],{"trials":36403,"activeCount":101},[],{"trials":36405,"activeCount":101},[],{"intervention":36374,"totalTrials":272,"cells":36407},{"EARLY_PHASE1":36408,"PHASE1":36410,"PHASE2":36416,"PHASE3":36418,"PHASE4":36420,"NA":36422},{"trials":36409,"activeCount":101},[],{"trials":36411,"activeCount":101},[36412],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36413,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36414,"interventions":36415},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36417,"activeCount":101},[],{"trials":36419,"activeCount":101},[],{"trials":36421,"activeCount":101},[],{"trials":36423,"activeCount":101},[],{"intervention":36375,"totalTrials":272,"cells":36425},{"EARLY_PHASE1":36426,"PHASE1":36428,"PHASE2":36434,"PHASE3":36436,"PHASE4":36438,"NA":36440},{"trials":36427,"activeCount":101},[],{"trials":36429,"activeCount":101},[36430],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36431,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36432,"interventions":36433},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36435,"activeCount":101},[],{"trials":36437,"activeCount":101},[],{"trials":36439,"activeCount":101},[],{"trials":36441,"activeCount":101},[],{"intervention":36376,"totalTrials":272,"cells":36443},{"EARLY_PHASE1":36444,"PHASE1":36446,"PHASE2":36452,"PHASE3":36454,"PHASE4":36456,"NA":36458},{"trials":36445,"activeCount":101},[],{"trials":36447,"activeCount":101},[36448],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36449,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36450,"interventions":36451},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36453,"activeCount":101},[],{"trials":36455,"activeCount":101},[],{"trials":36457,"activeCount":101},[],{"trials":36459,"activeCount":101},[],{"intervention":36377,"totalTrials":272,"cells":36461},{"EARLY_PHASE1":36462,"PHASE1":36464,"PHASE2":36470,"PHASE3":36472,"PHASE4":36474,"NA":36476},{"trials":36463,"activeCount":101},[],{"trials":36465,"activeCount":101},[36466],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36467,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36468,"interventions":36469},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36471,"activeCount":101},[],{"trials":36473,"activeCount":101},[],{"trials":36475,"activeCount":101},[],{"trials":36477,"activeCount":101},[],{"intervention":36378,"totalTrials":272,"cells":36479},{"EARLY_PHASE1":36480,"PHASE1":36482,"PHASE2":36488,"PHASE3":36490,"PHASE4":36492,"NA":36494},{"trials":36481,"activeCount":101},[],{"trials":36483,"activeCount":101},[36484],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36485,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36486,"interventions":36487},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36489,"activeCount":101},[],{"trials":36491,"activeCount":101},[],{"trials":36493,"activeCount":101},[],{"trials":36495,"activeCount":101},[],{"intervention":36379,"totalTrials":272,"cells":36497},{"EARLY_PHASE1":36498,"PHASE1":36500,"PHASE2":36506,"PHASE3":36508,"PHASE4":36510,"NA":36512},{"trials":36499,"activeCount":101},[],{"trials":36501,"activeCount":101},[36502],{"nctId":36368,"briefTitle":36369,"status":107,"phases":36503,"primaryCompletion":3731,"completion":3731,"start":9842,"enrollment":8,"conditions":36504,"interventions":36505},[90],[15],[36361,36373,36373,36374,36375,36375,36374,36376,36377,36378,36379,36379],{"trials":36507,"activeCount":101},[],{"trials":36509,"activeCount":101},[],{"trials":36511,"activeCount":101},[],{"trials":36513,"activeCount":101},[],{"intervention":36515,"totalTrials":272,"cells":36516},"COMBIVENT® HFA-MDI",{"EARLY_PHASE1":36517,"PHASE1":36519,"PHASE2":36528,"PHASE3":36530,"PHASE4":36532,"NA":36534},{"trials":36518,"activeCount":101},[],{"trials":36520,"activeCount":101},[36521],{"nctId":36522,"briefTitle":36523,"status":107,"phases":36524,"primaryCompletion":6246,"start":6207,"enrollment":188,"conditions":36525,"interventions":36526},"NCT02173678","Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects",[90],[15],[36515,36527],"COMBIVENT® CFC-MDI",{"trials":36529,"activeCount":101},[],{"trials":36531,"activeCount":101},[],{"trials":36533,"activeCount":101},[],{"trials":36535,"activeCount":101},[],{"intervention":36527,"totalTrials":272,"cells":36537},{"EARLY_PHASE1":36538,"PHASE1":36540,"PHASE2":36546,"PHASE3":36548,"PHASE4":36550,"NA":36552},{"trials":36539,"activeCount":101},[],{"trials":36541,"activeCount":101},[36542],{"nctId":36522,"briefTitle":36523,"status":107,"phases":36543,"primaryCompletion":6246,"start":6207,"enrollment":188,"conditions":36544,"interventions":36545},[90],[15],[36515,36527],{"trials":36547,"activeCount":101},[],{"trials":36549,"activeCount":101},[],{"trials":36551,"activeCount":101},[],{"trials":36553,"activeCount":101},[],{"intervention":36555,"totalTrials":272,"cells":36556},"BI 6727 + BIBW 2992",{"EARLY_PHASE1":36557,"PHASE1":36559,"PHASE2":36569,"PHASE3":36571,"PHASE4":36573,"NA":36575},{"trials":36558,"activeCount":101},[],{"trials":36560,"activeCount":101},[36561],{"nctId":36562,"briefTitle":36563,"status":107,"phases":36564,"primaryCompletion":36565,"completion":36565,"start":36566,"enrollment":34,"conditions":36567,"interventions":36568},"NCT01206816","An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours",[90],"2012-11-15","2010-10-04",[33],[36555],{"trials":36570,"activeCount":101},[],{"trials":36572,"activeCount":101},[],{"trials":36574,"activeCount":101},[],{"trials":36576,"activeCount":101},[],{"intervention":6218,"totalTrials":272,"cells":36578},{"EARLY_PHASE1":36579,"PHASE1":36581,"PHASE2":36587,"PHASE3":36589,"PHASE4":36591,"NA":36593},{"trials":36580,"activeCount":101},[],{"trials":36582,"activeCount":101},[36583],{"nctId":6212,"briefTitle":6213,"status":107,"phases":36584,"primaryCompletion":2030,"start":6133,"enrollment":97,"conditions":36585,"interventions":36586},[90],[21],[528,6217,6218,528,6218,528,6217],{"trials":36588,"activeCount":101},[],{"trials":36590,"activeCount":101},[],{"trials":36592,"activeCount":101},[],{"trials":36594,"activeCount":101},[],{"intervention":30035,"totalTrials":272,"cells":36596},{"EARLY_PHASE1":36597,"PHASE1":36599,"PHASE2":36605,"PHASE3":36607,"PHASE4":36609,"NA":36611},{"trials":36598,"activeCount":101},[],{"trials":36600,"activeCount":101},[36601],{"nctId":30030,"briefTitle":30031,"status":107,"phases":36602,"primaryCompletion":9752,"start":9340,"enrollment":392,"conditions":36603,"interventions":36604},[90],[15],[9784,9784,9785,30035,9785],{"trials":36606,"activeCount":101},[],{"trials":36608,"activeCount":101},[],{"trials":36610,"activeCount":101},[],{"trials":36612,"activeCount":101},[],{"intervention":11053,"totalTrials":272,"cells":36614},{"EARLY_PHASE1":36615,"PHASE1":36617,"PHASE2":36623,"PHASE3":36625,"PHASE4":36627,"NA":36629},{"trials":36616,"activeCount":101},[],{"trials":36618,"activeCount":101},[36619],{"nctId":11048,"briefTitle":11049,"status":107,"phases":36620,"primaryCompletion":6262,"start":2162,"enrollment":357,"conditions":36621,"interventions":36622},[90],[15],[11053,11034],{"trials":36624,"activeCount":101},[],{"trials":36626,"activeCount":101},[],{"trials":36628,"activeCount":101},[],{"trials":36630,"activeCount":101},[],{"intervention":36632,"totalTrials":272,"cells":36633},"pentoxyverine citrate",{"EARLY_PHASE1":36634,"PHASE1":36636,"PHASE2":36644,"PHASE3":36646,"PHASE4":36648,"NA":36650},{"trials":36635,"activeCount":101},[],{"trials":36637,"activeCount":101},[36638],{"nctId":36639,"briefTitle":36640,"status":107,"phases":36641,"primaryCompletion":9381,"start":399,"enrollment":392,"conditions":36642,"interventions":36643},"NCT02183649","Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers",[90],[15],[36632],{"trials":36645,"activeCount":101},[],{"trials":36647,"activeCount":101},[],{"trials":36649,"activeCount":101},[],{"trials":36651,"activeCount":101},[],{"intervention":20467,"totalTrials":272,"cells":36653},{"EARLY_PHASE1":36654,"PHASE1":36656,"PHASE2":36662,"PHASE3":36664,"PHASE4":36666,"NA":36668},{"trials":36655,"activeCount":101},[],{"trials":36657,"activeCount":101},[36658],{"nctId":20460,"briefTitle":20461,"status":600,"phases":36659,"primaryCompletion":20463,"completion":20464,"start":10701,"enrollment":101,"conditions":36660,"interventions":36661},[90],[20441],[20467,13488],{"trials":36663,"activeCount":101},[],{"trials":36665,"activeCount":101},[],{"trials":36667,"activeCount":101},[],{"trials":36669,"activeCount":101},[],{"intervention":12452,"totalTrials":272,"cells":36671},{"EARLY_PHASE1":36672,"PHASE1":36674,"PHASE2":36680,"PHASE3":36682,"PHASE4":36684,"NA":36686},{"trials":36673,"activeCount":101},[],{"trials":36675,"activeCount":101},[36676],{"nctId":12447,"briefTitle":12448,"status":107,"phases":36677,"primaryCompletion":2032,"start":4412,"enrollment":188,"conditions":36678,"interventions":36679},[90],[15],[12452,12453,12454],{"trials":36681,"activeCount":101},[],{"trials":36683,"activeCount":101},[],{"trials":36685,"activeCount":101},[],{"trials":36687,"activeCount":101},[],{"intervention":12453,"totalTrials":272,"cells":36689},{"EARLY_PHASE1":36690,"PHASE1":36692,"PHASE2":36698,"PHASE3":36700,"PHASE4":36702,"NA":36704},{"trials":36691,"activeCount":101},[],{"trials":36693,"activeCount":101},[36694],{"nctId":12447,"briefTitle":12448,"status":107,"phases":36695,"primaryCompletion":2032,"start":4412,"enrollment":188,"conditions":36696,"interventions":36697},[90],[15],[12452,12453,12454],{"trials":36699,"activeCount":101},[],{"trials":36701,"activeCount":101},[],{"trials":36703,"activeCount":101},[],{"trials":36705,"activeCount":101},[],{"intervention":36707,"totalTrials":272,"cells":36708},"BI 661051",{"EARLY_PHASE1":36709,"PHASE1":36711,"PHASE2":36719,"PHASE3":36721,"PHASE4":36723,"NA":36725},{"trials":36710,"activeCount":101},[],{"trials":36712,"activeCount":101},[36713],{"nctId":36714,"briefTitle":36715,"status":107,"phases":36716,"primaryCompletion":9752,"start":9340,"enrollment":1208,"conditions":36717,"interventions":36718},"NCT01343719","Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.",[90],[15],[36707,36707,36707,36707,36707,36707,36707,36707,36707,36707],{"trials":36720,"activeCount":101},[],{"trials":36722,"activeCount":101},[],{"trials":36724,"activeCount":101},[],{"trials":36726,"activeCount":101},[],{"intervention":30083,"totalTrials":272,"cells":36728},{"EARLY_PHASE1":36729,"PHASE1":36731,"PHASE2":36737,"PHASE3":36739,"PHASE4":36741,"NA":36743},{"trials":36730,"activeCount":101},[],{"trials":36732,"activeCount":101},[36733],{"nctId":30078,"briefTitle":30079,"status":107,"phases":36734,"primaryCompletion":1990,"start":2111,"enrollment":37,"conditions":36735,"interventions":36736},[90],[15],[30071,30083],{"trials":36738,"activeCount":101},[],{"trials":36740,"activeCount":101},[],{"trials":36742,"activeCount":101},[],{"trials":36744,"activeCount":101},[],{"intervention":36746,"totalTrials":272,"cells":36747},"[14C]-DK-AH 269 CL, solution for",{"EARLY_PHASE1":36748,"PHASE1":36750,"PHASE2":36759,"PHASE3":36761,"PHASE4":36763,"NA":36765},{"trials":36749,"activeCount":101},[],{"trials":36751,"activeCount":101},[36752],{"nctId":36753,"briefTitle":36754,"status":107,"phases":36755,"primaryCompletion":6446,"start":6401,"enrollment":188,"conditions":36756,"interventions":36757},"NCT02264028","Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers",[90],[15],[36746,36758],"[14C]-DK-AH 269 CL, drinking solution",{"trials":36760,"activeCount":101},[],{"trials":36762,"activeCount":101},[],{"trials":36764,"activeCount":101},[],{"trials":36766,"activeCount":101},[],{"intervention":36758,"totalTrials":272,"cells":36768},{"EARLY_PHASE1":36769,"PHASE1":36771,"PHASE2":36777,"PHASE3":36779,"PHASE4":36781,"NA":36783},{"trials":36770,"activeCount":101},[],{"trials":36772,"activeCount":101},[36773],{"nctId":36753,"briefTitle":36754,"status":107,"phases":36774,"primaryCompletion":6446,"start":6401,"enrollment":188,"conditions":36775,"interventions":36776},[90],[15],[36746,36758],{"trials":36778,"activeCount":101},[],{"trials":36780,"activeCount":101},[],{"trials":36782,"activeCount":101},[],{"trials":36784,"activeCount":101},[],{"intervention":36786,"totalTrials":272,"cells":36787},"BIBR 1048 MS low dose",{"EARLY_PHASE1":36788,"PHASE1":36790,"PHASE2":36800,"PHASE3":36802,"PHASE4":36804,"NA":36806},{"trials":36789,"activeCount":101},[],{"trials":36791,"activeCount":101},[36792],{"nctId":36793,"briefTitle":36794,"status":107,"phases":36795,"primaryCompletion":1115,"start":6413,"enrollment":331,"conditions":36796,"interventions":36797},"NCT02170909","Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin",[90],[15],[36786,36798,36799],"BIBR 1048 MS medium dose","BIBR 1048 MS high dose",{"trials":36801,"activeCount":101},[],{"trials":36803,"activeCount":101},[],{"trials":36805,"activeCount":101},[],{"trials":36807,"activeCount":101},[],{"intervention":36798,"totalTrials":272,"cells":36809},{"EARLY_PHASE1":36810,"PHASE1":36812,"PHASE2":36818,"PHASE3":36820,"PHASE4":36822,"NA":36824},{"trials":36811,"activeCount":101},[],{"trials":36813,"activeCount":101},[36814],{"nctId":36793,"briefTitle":36794,"status":107,"phases":36815,"primaryCompletion":1115,"start":6413,"enrollment":331,"conditions":36816,"interventions":36817},[90],[15],[36786,36798,36799],{"trials":36819,"activeCount":101},[],{"trials":36821,"activeCount":101},[],{"trials":36823,"activeCount":101},[],{"trials":36825,"activeCount":101},[],{"intervention":36799,"totalTrials":272,"cells":36827},{"EARLY_PHASE1":36828,"PHASE1":36830,"PHASE2":36836,"PHASE3":36838,"PHASE4":36840,"NA":36842},{"trials":36829,"activeCount":101},[],{"trials":36831,"activeCount":101},[36832],{"nctId":36793,"briefTitle":36794,"status":107,"phases":36833,"primaryCompletion":1115,"start":6413,"enrollment":331,"conditions":36834,"interventions":36835},[90],[15],[36786,36798,36799],{"trials":36837,"activeCount":101},[],{"trials":36839,"activeCount":101},[],{"trials":36841,"activeCount":101},[],{"trials":36843,"activeCount":101},[],{"intervention":36845,"totalTrials":272,"cells":36846},"BI 11634 ER formulation A",{"EARLY_PHASE1":36847,"PHASE1":36849,"PHASE2":36861,"PHASE3":36863,"PHASE4":36865,"NA":36867},{"trials":36848,"activeCount":101},[],{"trials":36850,"activeCount":101},[36851],{"nctId":36852,"briefTitle":36853,"status":107,"phases":36854,"primaryCompletion":19461,"start":4516,"enrollment":5242,"conditions":36855,"interventions":36856},"NCT02214953","Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers",[90],[15],[36845,36857,36858,36859,36860],"BI 11634 ER formulation B","BI 11634 ER formulation M","BI 11634 ER formulation C","BI 11634 IR",{"trials":36862,"activeCount":101},[],{"trials":36864,"activeCount":101},[],{"trials":36866,"activeCount":101},[],{"trials":36868,"activeCount":101},[],{"intervention":36857,"totalTrials":272,"cells":36870},{"EARLY_PHASE1":36871,"PHASE1":36873,"PHASE2":36879,"PHASE3":36881,"PHASE4":36883,"NA":36885},{"trials":36872,"activeCount":101},[],{"trials":36874,"activeCount":101},[36875],{"nctId":36852,"briefTitle":36853,"status":107,"phases":36876,"primaryCompletion":19461,"start":4516,"enrollment":5242,"conditions":36877,"interventions":36878},[90],[15],[36845,36857,36858,36859,36860],{"trials":36880,"activeCount":101},[],{"trials":36882,"activeCount":101},[],{"trials":36884,"activeCount":101},[],{"trials":36886,"activeCount":101},[],{"intervention":36858,"totalTrials":272,"cells":36888},{"EARLY_PHASE1":36889,"PHASE1":36891,"PHASE2":36897,"PHASE3":36899,"PHASE4":36901,"NA":36903},{"trials":36890,"activeCount":101},[],{"trials":36892,"activeCount":101},[36893],{"nctId":36852,"briefTitle":36853,"status":107,"phases":36894,"primaryCompletion":19461,"start":4516,"enrollment":5242,"conditions":36895,"interventions":36896},[90],[15],[36845,36857,36858,36859,36860],{"trials":36898,"activeCount":101},[],{"trials":36900,"activeCount":101},[],{"trials":36902,"activeCount":101},[],{"trials":36904,"activeCount":101},[],{"intervention":36859,"totalTrials":272,"cells":36906},{"EARLY_PHASE1":36907,"PHASE1":36909,"PHASE2":36915,"PHASE3":36917,"PHASE4":36919,"NA":36921},{"trials":36908,"activeCount":101},[],{"trials":36910,"activeCount":101},[36911],{"nctId":36852,"briefTitle":36853,"status":107,"phases":36912,"primaryCompletion":19461,"start":4516,"enrollment":5242,"conditions":36913,"interventions":36914},[90],[15],[36845,36857,36858,36859,36860],{"trials":36916,"activeCount":101},[],{"trials":36918,"activeCount":101},[],{"trials":36920,"activeCount":101},[],{"trials":36922,"activeCount":101},[],{"intervention":36860,"totalTrials":272,"cells":36924},{"EARLY_PHASE1":36925,"PHASE1":36927,"PHASE2":36933,"PHASE3":36935,"PHASE4":36937,"NA":36939},{"trials":36926,"activeCount":101},[],{"trials":36928,"activeCount":101},[36929],{"nctId":36852,"briefTitle":36853,"status":107,"phases":36930,"primaryCompletion":19461,"start":4516,"enrollment":5242,"conditions":36931,"interventions":36932},[90],[15],[36845,36857,36858,36859,36860],{"trials":36934,"activeCount":101},[],{"trials":36936,"activeCount":101},[],{"trials":36938,"activeCount":101},[],{"trials":36940,"activeCount":101},[],{"intervention":20357,"totalTrials":272,"cells":36942},{"EARLY_PHASE1":36943,"PHASE1":36945,"PHASE2":36951,"PHASE3":36953,"PHASE4":36955,"NA":36957},{"trials":36944,"activeCount":101},[],{"trials":36946,"activeCount":101},[36947],{"nctId":20351,"briefTitle":20352,"status":107,"phases":36948,"primaryCompletion":20354,"completion":20354,"start":12552,"enrollment":13929,"conditions":36949,"interventions":36950},[90],[15],[4075,20357],{"trials":36952,"activeCount":101},[],{"trials":36954,"activeCount":101},[],{"trials":36956,"activeCount":101},[],{"trials":36958,"activeCount":101},[],{"intervention":11166,"totalTrials":272,"cells":36960},{"EARLY_PHASE1":36961,"PHASE1":36963,"PHASE2":36969,"PHASE3":36971,"PHASE4":36973,"NA":36975},{"trials":36962,"activeCount":101},[],{"trials":36964,"activeCount":101},[36965],{"nctId":11160,"briefTitle":11161,"status":107,"phases":36966,"primaryCompletion":6471,"start":4507,"enrollment":11163,"conditions":36967,"interventions":36968},[90],[21],[6673,11166,6668],{"trials":36970,"activeCount":101},[],{"trials":36972,"activeCount":101},[],{"trials":36974,"activeCount":101},[],{"trials":36976,"activeCount":101},[],{"intervention":19091,"totalTrials":272,"cells":36978},{"EARLY_PHASE1":36979,"PHASE1":36981,"PHASE2":36987,"PHASE3":36989,"PHASE4":36991,"NA":36993},{"trials":36980,"activeCount":101},[],{"trials":36982,"activeCount":101},[36983],{"nctId":19086,"briefTitle":19087,"status":107,"phases":36984,"primaryCompletion":3991,"start":9404,"enrollment":448,"conditions":36985,"interventions":36986},[90],[15],[19091,19071,19059],{"trials":36988,"activeCount":101},[],{"trials":36990,"activeCount":101},[],{"trials":36992,"activeCount":101},[],{"trials":36994,"activeCount":101},[],{"intervention":28795,"totalTrials":272,"cells":36996},{"EARLY_PHASE1":36997,"PHASE1":36999,"PHASE2":37005,"PHASE3":37007,"PHASE4":37009,"NA":37011},{"trials":36998,"activeCount":101},[],{"trials":37000,"activeCount":101},[37001],{"nctId":28790,"briefTitle":28791,"status":107,"phases":37002,"primaryCompletion":475,"completion":474,"start":420,"enrollment":401,"conditions":37003,"interventions":37004},[90],[15],[28783,28783,28795],{"trials":37006,"activeCount":101},[],{"trials":37008,"activeCount":101},[],{"trials":37010,"activeCount":101},[],{"trials":37012,"activeCount":101},[],{"intervention":27910,"totalTrials":272,"cells":37014},{"EARLY_PHASE1":37015,"PHASE1":37017,"PHASE2":37023,"PHASE3":37025,"PHASE4":37027,"NA":37029},{"trials":37016,"activeCount":101},[],{"trials":37018,"activeCount":101},[37019],{"nctId":27905,"briefTitle":27906,"status":107,"phases":37020,"primaryCompletion":1967,"start":4392,"enrollment":1672,"conditions":37021,"interventions":37022},[90],[15],[9370,27910,27911,27912,27913],{"trials":37024,"activeCount":101},[],{"trials":37026,"activeCount":101},[],{"trials":37028,"activeCount":101},[],{"trials":37030,"activeCount":101},[],{"intervention":27911,"totalTrials":272,"cells":37032},{"EARLY_PHASE1":37033,"PHASE1":37035,"PHASE2":37041,"PHASE3":37043,"PHASE4":37045,"NA":37047},{"trials":37034,"activeCount":101},[],{"trials":37036,"activeCount":101},[37037],{"nctId":27905,"briefTitle":27906,"status":107,"phases":37038,"primaryCompletion":1967,"start":4392,"enrollment":1672,"conditions":37039,"interventions":37040},[90],[15],[9370,27910,27911,27912,27913],{"trials":37042,"activeCount":101},[],{"trials":37044,"activeCount":101},[],{"trials":37046,"activeCount":101},[],{"trials":37048,"activeCount":101},[],{"intervention":27912,"totalTrials":272,"cells":37050},{"EARLY_PHASE1":37051,"PHASE1":37053,"PHASE2":37059,"PHASE3":37061,"PHASE4":37063,"NA":37065},{"trials":37052,"activeCount":101},[],{"trials":37054,"activeCount":101},[37055],{"nctId":27905,"briefTitle":27906,"status":107,"phases":37056,"primaryCompletion":1967,"start":4392,"enrollment":1672,"conditions":37057,"interventions":37058},[90],[15],[9370,27910,27911,27912,27913],{"trials":37060,"activeCount":101},[],{"trials":37062,"activeCount":101},[],{"trials":37064,"activeCount":101},[],{"trials":37066,"activeCount":101},[],{"intervention":27913,"totalTrials":272,"cells":37068},{"EARLY_PHASE1":37069,"PHASE1":37071,"PHASE2":37077,"PHASE3":37079,"PHASE4":37081,"NA":37083},{"trials":37070,"activeCount":101},[],{"trials":37072,"activeCount":101},[37073],{"nctId":27905,"briefTitle":27906,"status":107,"phases":37074,"primaryCompletion":1967,"start":4392,"enrollment":1672,"conditions":37075,"interventions":37076},[90],[15],[9370,27910,27911,27912,27913],{"trials":37078,"activeCount":101},[],{"trials":37080,"activeCount":101},[],{"trials":37082,"activeCount":101},[],{"trials":37084,"activeCount":101},[],{"intervention":4043,"totalTrials":272,"cells":37086},{"EARLY_PHASE1":37087,"PHASE1":37089,"PHASE2":37095,"PHASE3":37097,"PHASE4":37099,"NA":37101},{"trials":37088,"activeCount":101},[],{"trials":37090,"activeCount":101},[37091],{"nctId":4035,"briefTitle":4036,"status":107,"phases":37092,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":37093,"interventions":37094},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"trials":37096,"activeCount":101},[],{"trials":37098,"activeCount":101},[],{"trials":37100,"activeCount":101},[],{"trials":37102,"activeCount":101},[],{"intervention":37104,"totalTrials":272,"cells":37105},"BI 764122",{"EARLY_PHASE1":37106,"PHASE1":37108,"PHASE2":37117,"PHASE3":37119,"PHASE4":37121,"NA":37123},{"trials":37107,"activeCount":101},[],{"trials":37109,"activeCount":101},[37110],{"nctId":37111,"briefTitle":37112,"status":107,"phases":37113,"primaryCompletion":5323,"completion":5323,"start":37114,"enrollment":5956,"conditions":37115,"interventions":37116},"NCT03794323","A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood",[90],"2019-01-30",[15],[37104],{"trials":37118,"activeCount":101},[],{"trials":37120,"activeCount":101},[],{"trials":37122,"activeCount":101},[],{"trials":37124,"activeCount":101},[],{"intervention":37126,"totalTrials":272,"cells":37127},"BILN 2061 ZW single rising doses",{"EARLY_PHASE1":37128,"PHASE1":37130,"PHASE2":37139,"PHASE3":37141,"PHASE4":37143,"NA":37145},{"trials":37129,"activeCount":101},[],{"trials":37131,"activeCount":101},[37132],{"nctId":37133,"briefTitle":37134,"status":107,"phases":37135,"primaryCompletion":7132,"start":2121,"enrollment":5857,"conditions":37136,"interventions":37137},"NCT02268760","Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect",[90],[15],[37126,37138],"BILN 2061 ZW fixed dose",{"trials":37140,"activeCount":101},[],{"trials":37142,"activeCount":101},[],{"trials":37144,"activeCount":101},[],{"trials":37146,"activeCount":101},[],{"intervention":37138,"totalTrials":272,"cells":37148},{"EARLY_PHASE1":37149,"PHASE1":37151,"PHASE2":37157,"PHASE3":37159,"PHASE4":37161,"NA":37163},{"trials":37150,"activeCount":101},[],{"trials":37152,"activeCount":101},[37153],{"nctId":37133,"briefTitle":37134,"status":107,"phases":37154,"primaryCompletion":7132,"start":2121,"enrollment":5857,"conditions":37155,"interventions":37156},[90],[15],[37126,37138],{"trials":37158,"activeCount":101},[],{"trials":37160,"activeCount":101},[],{"trials":37162,"activeCount":101},[],{"trials":37164,"activeCount":101},[],{"intervention":37166,"totalTrials":272,"cells":37167},"decitabine iv",{"EARLY_PHASE1":37168,"PHASE1":37170,"PHASE2":37182,"PHASE3":37184,"PHASE4":37186,"NA":37188},{"trials":37169,"activeCount":101},[],{"trials":37171,"activeCount":101},[37172],{"nctId":37173,"briefTitle":37174,"status":162,"phases":37175,"primaryCompletion":37176,"completion":37177,"start":37178,"enrollment":912,"conditions":37179,"interventions":37180},"NCT02003573","Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)",[90],"2015-01-06","2016-05-15","2014-01-29",[10147],[37166,37181],"volasertib iv",{"trials":37183,"activeCount":101},[],{"trials":37185,"activeCount":101},[],{"trials":37187,"activeCount":101},[],{"trials":37189,"activeCount":101},[],{"intervention":37181,"totalTrials":272,"cells":37191},{"EARLY_PHASE1":37192,"PHASE1":37194,"PHASE2":37200,"PHASE3":37202,"PHASE4":37204,"NA":37206},{"trials":37193,"activeCount":101},[],{"trials":37195,"activeCount":101},[37196],{"nctId":37173,"briefTitle":37174,"status":162,"phases":37197,"primaryCompletion":37176,"completion":37177,"start":37178,"enrollment":912,"conditions":37198,"interventions":37199},[90],[10147],[37166,37181],{"trials":37201,"activeCount":101},[],{"trials":37203,"activeCount":101},[],{"trials":37205,"activeCount":101},[],{"trials":37207,"activeCount":101},[],{"intervention":37209,"totalTrials":272,"cells":37210},"[14C]BI 1482694",{"EARLY_PHASE1":37211,"PHASE1":37213,"PHASE2":37222,"PHASE3":37224,"PHASE4":37226,"NA":37228},{"trials":37212,"activeCount":101},[],{"trials":37214,"activeCount":101},[37215],{"nctId":37216,"briefTitle":37217,"status":107,"phases":37218,"primaryCompletion":37219,"completion":37219,"start":3744,"enrollment":155,"conditions":37220,"interventions":37221},"NCT02722161","Olmutinib (BI 1482694) ADME Study",[90],"2016-06",[15],[37209],{"trials":37223,"activeCount":101},[],{"trials":37225,"activeCount":101},[],{"trials":37227,"activeCount":101},[],{"trials":37229,"activeCount":101},[],{"intervention":37231,"totalTrials":272,"cells":37232},"BI 473494",{"EARLY_PHASE1":37233,"PHASE1":37235,"PHASE2":37243,"PHASE3":37245,"PHASE4":37247,"NA":37249},{"trials":37234,"activeCount":101},[],{"trials":37236,"activeCount":101},[37237],{"nctId":37238,"briefTitle":37239,"status":162,"phases":37240,"primaryCompletion":20448,"completion":20448,"start":34243,"enrollment":401,"conditions":37241,"interventions":37242},"NCT03195088","Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects",[90],[15],[37231],{"trials":37244,"activeCount":101},[],{"trials":37246,"activeCount":101},[],{"trials":37248,"activeCount":101},[],{"trials":37250,"activeCount":101},[],{"intervention":37252,"totalTrials":272,"cells":37253},"Mobic, China, 7.5 mg",{"EARLY_PHASE1":37254,"PHASE1":37256,"PHASE2":37265,"PHASE3":37267,"PHASE4":37269,"NA":37271},{"trials":37255,"activeCount":101},[],{"trials":37257,"activeCount":101},[37258],{"nctId":37259,"briefTitle":37260,"status":107,"phases":37261,"primaryCompletion":6005,"start":7381,"enrollment":1672,"conditions":37262,"interventions":37263},"NCT02183142","Study of Relative Bioavailability of Mobic Manufactured in China in Comparison With Mobic Manufactured in Germany in Chinese Healthy Volunteers",[90],[15],[37252,37264],"Mobic, Germany, 7.5 mg",{"trials":37266,"activeCount":101},[],{"trials":37268,"activeCount":101},[],{"trials":37270,"activeCount":101},[],{"trials":37272,"activeCount":101},[],{"intervention":37264,"totalTrials":272,"cells":37274},{"EARLY_PHASE1":37275,"PHASE1":37277,"PHASE2":37283,"PHASE3":37285,"PHASE4":37287,"NA":37289},{"trials":37276,"activeCount":101},[],{"trials":37278,"activeCount":101},[37279],{"nctId":37259,"briefTitle":37260,"status":107,"phases":37280,"primaryCompletion":6005,"start":7381,"enrollment":1672,"conditions":37281,"interventions":37282},[90],[15],[37252,37264],{"trials":37284,"activeCount":101},[],{"trials":37286,"activeCount":101},[],{"trials":37288,"activeCount":101},[],{"trials":37290,"activeCount":101},[],{"intervention":37292,"totalTrials":272,"cells":37293},"BILR 355 BS, D1",{"EARLY_PHASE1":37294,"PHASE1":37296,"PHASE2":37312,"PHASE3":37314,"PHASE4":37316,"NA":37318},{"trials":37295,"activeCount":101},[],{"trials":37297,"activeCount":101},[37298],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37301,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37302,"interventions":37303},"NCT02253953","Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers",[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],"BILR 355 BS, D2","BILR 355 BS, D3","BILR 355 BS, D4","BILR 355 BS, D5","BILR 355 BS, D6","BILR 355 BS, D7","BILR 355 BS, D8","BILR 355 BS, D10",{"trials":37313,"activeCount":101},[],{"trials":37315,"activeCount":101},[],{"trials":37317,"activeCount":101},[],{"trials":37319,"activeCount":101},[],{"intervention":37304,"totalTrials":272,"cells":37321},{"EARLY_PHASE1":37322,"PHASE1":37324,"PHASE2":37330,"PHASE3":37332,"PHASE4":37334,"NA":37336},{"trials":37323,"activeCount":101},[],{"trials":37325,"activeCount":101},[37326],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37327,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37328,"interventions":37329},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37331,"activeCount":101},[],{"trials":37333,"activeCount":101},[],{"trials":37335,"activeCount":101},[],{"trials":37337,"activeCount":101},[],{"intervention":37305,"totalTrials":272,"cells":37339},{"EARLY_PHASE1":37340,"PHASE1":37342,"PHASE2":37348,"PHASE3":37350,"PHASE4":37352,"NA":37354},{"trials":37341,"activeCount":101},[],{"trials":37343,"activeCount":101},[37344],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37345,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37346,"interventions":37347},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37349,"activeCount":101},[],{"trials":37351,"activeCount":101},[],{"trials":37353,"activeCount":101},[],{"trials":37355,"activeCount":101},[],{"intervention":37306,"totalTrials":272,"cells":37357},{"EARLY_PHASE1":37358,"PHASE1":37360,"PHASE2":37366,"PHASE3":37368,"PHASE4":37370,"NA":37372},{"trials":37359,"activeCount":101},[],{"trials":37361,"activeCount":101},[37362],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37363,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37364,"interventions":37365},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37367,"activeCount":101},[],{"trials":37369,"activeCount":101},[],{"trials":37371,"activeCount":101},[],{"trials":37373,"activeCount":101},[],{"intervention":37307,"totalTrials":272,"cells":37375},{"EARLY_PHASE1":37376,"PHASE1":37378,"PHASE2":37384,"PHASE3":37386,"PHASE4":37388,"NA":37390},{"trials":37377,"activeCount":101},[],{"trials":37379,"activeCount":101},[37380],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37381,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37382,"interventions":37383},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37385,"activeCount":101},[],{"trials":37387,"activeCount":101},[],{"trials":37389,"activeCount":101},[],{"trials":37391,"activeCount":101},[],{"intervention":37308,"totalTrials":272,"cells":37393},{"EARLY_PHASE1":37394,"PHASE1":37396,"PHASE2":37402,"PHASE3":37404,"PHASE4":37406,"NA":37408},{"trials":37395,"activeCount":101},[],{"trials":37397,"activeCount":101},[37398],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37399,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37400,"interventions":37401},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37403,"activeCount":101},[],{"trials":37405,"activeCount":101},[],{"trials":37407,"activeCount":101},[],{"trials":37409,"activeCount":101},[],{"intervention":37309,"totalTrials":272,"cells":37411},{"EARLY_PHASE1":37412,"PHASE1":37414,"PHASE2":37420,"PHASE3":37422,"PHASE4":37424,"NA":37426},{"trials":37413,"activeCount":101},[],{"trials":37415,"activeCount":101},[37416],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37417,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37418,"interventions":37419},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37421,"activeCount":101},[],{"trials":37423,"activeCount":101},[],{"trials":37425,"activeCount":101},[],{"trials":37427,"activeCount":101},[],{"intervention":37310,"totalTrials":272,"cells":37429},{"EARLY_PHASE1":37430,"PHASE1":37432,"PHASE2":37438,"PHASE3":37440,"PHASE4":37442,"NA":37444},{"trials":37431,"activeCount":101},[],{"trials":37433,"activeCount":101},[37434],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37435,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37436,"interventions":37437},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37439,"activeCount":101},[],{"trials":37441,"activeCount":101},[],{"trials":37443,"activeCount":101},[],{"trials":37445,"activeCount":101},[],{"intervention":37311,"totalTrials":272,"cells":37447},{"EARLY_PHASE1":37448,"PHASE1":37450,"PHASE2":37456,"PHASE3":37458,"PHASE4":37460,"NA":37462},{"trials":37449,"activeCount":101},[],{"trials":37451,"activeCount":101},[37452],{"nctId":37299,"briefTitle":37300,"status":107,"phases":37453,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":37454,"interventions":37455},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"trials":37457,"activeCount":101},[],{"trials":37459,"activeCount":101},[],{"trials":37461,"activeCount":101},[],{"trials":37463,"activeCount":101},[],{"intervention":37465,"totalTrials":272,"cells":37466},"Telmisartan\u002FRamipril, fixed dose combination",{"EARLY_PHASE1":37467,"PHASE1":37469,"PHASE2":37477,"PHASE3":37479,"PHASE4":37481,"NA":37483},{"trials":37468,"activeCount":101},[],{"trials":37470,"activeCount":101},[37471],{"nctId":37472,"briefTitle":37473,"status":107,"phases":37474,"primaryCompletion":19461,"start":4516,"enrollment":331,"conditions":37475,"interventions":37476},"NCT02214966","Influence of Food on the Bioavailability of Telmisartan \u002F Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers",[90],[15],[37465],{"trials":37478,"activeCount":101},[],{"trials":37480,"activeCount":101},[],{"trials":37482,"activeCount":101},[],{"trials":37484,"activeCount":101},[],{"intervention":37486,"totalTrials":272,"cells":37487},"anhydrous theophylline, 350 mg",{"EARLY_PHASE1":37488,"PHASE1":37490,"PHASE2":37499,"PHASE3":37501,"PHASE4":37503,"NA":37505},{"trials":37489,"activeCount":101},[],{"trials":37491,"activeCount":101},[37492],{"nctId":37493,"briefTitle":37494,"status":107,"phases":37495,"primaryCompletion":7250,"start":6065,"enrollment":210,"conditions":37496,"interventions":37497},"NCT02184247","Bioavailability of Two Sustained-release Theophylline Products in Healthy Males",[90],[15],[37486,37498],"anhydrous theophylline, 300 mg",{"trials":37500,"activeCount":101},[],{"trials":37502,"activeCount":101},[],{"trials":37504,"activeCount":101},[],{"trials":37506,"activeCount":101},[],{"intervention":37498,"totalTrials":272,"cells":37508},{"EARLY_PHASE1":37509,"PHASE1":37511,"PHASE2":37517,"PHASE3":37519,"PHASE4":37521,"NA":37523},{"trials":37510,"activeCount":101},[],{"trials":37512,"activeCount":101},[37513],{"nctId":37493,"briefTitle":37494,"status":107,"phases":37514,"primaryCompletion":7250,"start":6065,"enrollment":210,"conditions":37515,"interventions":37516},[90],[15],[37486,37498],{"trials":37518,"activeCount":101},[],{"trials":37520,"activeCount":101},[],{"trials":37522,"activeCount":101},[],{"trials":37524,"activeCount":101},[],{"intervention":37526,"totalTrials":272,"cells":37527},"Telmisartan film coated",{"EARLY_PHASE1":37528,"PHASE1":37530,"PHASE2":37539,"PHASE3":37541,"PHASE4":37543,"NA":37545},{"trials":37529,"activeCount":101},[],{"trials":37531,"activeCount":101},[37532],{"nctId":37533,"briefTitle":37534,"status":107,"phases":37535,"primaryCompletion":6155,"start":7573,"enrollment":357,"conditions":37536,"interventions":37537},"NCT02263989","Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers",[90],[15],[37526,37538],"Telmisartan conventional",{"trials":37540,"activeCount":101},[],{"trials":37542,"activeCount":101},[],{"trials":37544,"activeCount":101},[],{"trials":37546,"activeCount":101},[],{"intervention":37538,"totalTrials":272,"cells":37548},{"EARLY_PHASE1":37549,"PHASE1":37551,"PHASE2":37557,"PHASE3":37559,"PHASE4":37561,"NA":37563},{"trials":37550,"activeCount":101},[],{"trials":37552,"activeCount":101},[37553],{"nctId":37533,"briefTitle":37534,"status":107,"phases":37554,"primaryCompletion":6155,"start":7573,"enrollment":357,"conditions":37555,"interventions":37556},[90],[15],[37526,37538],{"trials":37558,"activeCount":101},[],{"trials":37560,"activeCount":101},[],{"trials":37562,"activeCount":101},[],{"trials":37564,"activeCount":101},[],{"intervention":37566,"totalTrials":272,"cells":37567},"BIBW2 component A",{"EARLY_PHASE1":37568,"PHASE1":37570,"PHASE2":37579,"PHASE3":37581,"PHASE4":37583,"NA":37585},{"trials":37569,"activeCount":101},[],{"trials":37571,"activeCount":101},[37572],{"nctId":37573,"briefTitle":37574,"status":107,"phases":37575,"primaryCompletion":7419,"start":7395,"enrollment":2123,"conditions":37576,"interventions":37577},"NCT02203864","Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma",[90],[3480],[37566,37578],"BIBW2 component B",{"trials":37580,"activeCount":101},[],{"trials":37582,"activeCount":101},[],{"trials":37584,"activeCount":101},[],{"trials":37586,"activeCount":101},[],{"intervention":37578,"totalTrials":272,"cells":37588},{"EARLY_PHASE1":37589,"PHASE1":37591,"PHASE2":37597,"PHASE3":37599,"PHASE4":37601,"NA":37603},{"trials":37590,"activeCount":101},[],{"trials":37592,"activeCount":101},[37593],{"nctId":37573,"briefTitle":37574,"status":107,"phases":37594,"primaryCompletion":7419,"start":7395,"enrollment":2123,"conditions":37595,"interventions":37596},[90],[3480],[37566,37578],{"trials":37598,"activeCount":101},[],{"trials":37600,"activeCount":101},[],{"trials":37602,"activeCount":101},[],{"trials":37604,"activeCount":101},[],{"intervention":37606,"totalTrials":272,"cells":37607},"UHAC 62 XX - TF1",{"EARLY_PHASE1":37608,"PHASE1":37610,"PHASE2":37620,"PHASE3":37622,"PHASE4":37624,"NA":37626},{"trials":37609,"activeCount":101},[],{"trials":37611,"activeCount":101},[37612],{"nctId":37613,"briefTitle":37614,"status":107,"phases":37615,"primaryCompletion":6040,"start":6015,"enrollment":1340,"conditions":37616,"interventions":37617},"NCT02180477","Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers",[90],[15],[37606,37618,37619],"UHAC 62 XX - TF2","UHAC 62 XX -",{"trials":37621,"activeCount":101},[],{"trials":37623,"activeCount":101},[],{"trials":37625,"activeCount":101},[],{"trials":37627,"activeCount":101},[],{"intervention":37618,"totalTrials":272,"cells":37629},{"EARLY_PHASE1":37630,"PHASE1":37632,"PHASE2":37638,"PHASE3":37640,"PHASE4":37642,"NA":37644},{"trials":37631,"activeCount":101},[],{"trials":37633,"activeCount":101},[37634],{"nctId":37613,"briefTitle":37614,"status":107,"phases":37635,"primaryCompletion":6040,"start":6015,"enrollment":1340,"conditions":37636,"interventions":37637},[90],[15],[37606,37618,37619],{"trials":37639,"activeCount":101},[],{"trials":37641,"activeCount":101},[],{"trials":37643,"activeCount":101},[],{"trials":37645,"activeCount":101},[],{"intervention":37619,"totalTrials":272,"cells":37647},{"EARLY_PHASE1":37648,"PHASE1":37650,"PHASE2":37656,"PHASE3":37658,"PHASE4":37660,"NA":37662},{"trials":37649,"activeCount":101},[],{"trials":37651,"activeCount":101},[37652],{"nctId":37613,"briefTitle":37614,"status":107,"phases":37653,"primaryCompletion":6040,"start":6015,"enrollment":1340,"conditions":37654,"interventions":37655},[90],[15],[37606,37618,37619],{"trials":37657,"activeCount":101},[],{"trials":37659,"activeCount":101},[],{"trials":37661,"activeCount":101},[],{"trials":37663,"activeCount":101},[],{"intervention":29890,"totalTrials":272,"cells":37665},{"EARLY_PHASE1":37666,"PHASE1":37668,"PHASE2":37674,"PHASE3":37676,"PHASE4":37678,"NA":37680},{"trials":37667,"activeCount":101},[],{"trials":37669,"activeCount":101},[37670],{"nctId":29885,"briefTitle":29886,"status":107,"phases":37671,"primaryCompletion":474,"completion":474,"start":420,"enrollment":231,"conditions":37672,"interventions":37673},[90],[15],[28323,29890,29891,29892,29893],{"trials":37675,"activeCount":101},[],{"trials":37677,"activeCount":101},[],{"trials":37679,"activeCount":101},[],{"trials":37681,"activeCount":101},[],{"intervention":29891,"totalTrials":272,"cells":37683},{"EARLY_PHASE1":37684,"PHASE1":37686,"PHASE2":37692,"PHASE3":37694,"PHASE4":37696,"NA":37698},{"trials":37685,"activeCount":101},[],{"trials":37687,"activeCount":101},[37688],{"nctId":29885,"briefTitle":29886,"status":107,"phases":37689,"primaryCompletion":474,"completion":474,"start":420,"enrollment":231,"conditions":37690,"interventions":37691},[90],[15],[28323,29890,29891,29892,29893],{"trials":37693,"activeCount":101},[],{"trials":37695,"activeCount":101},[],{"trials":37697,"activeCount":101},[],{"trials":37699,"activeCount":101},[],{"intervention":29892,"totalTrials":272,"cells":37701},{"EARLY_PHASE1":37702,"PHASE1":37704,"PHASE2":37710,"PHASE3":37712,"PHASE4":37714,"NA":37716},{"trials":37703,"activeCount":101},[],{"trials":37705,"activeCount":101},[37706],{"nctId":29885,"briefTitle":29886,"status":107,"phases":37707,"primaryCompletion":474,"completion":474,"start":420,"enrollment":231,"conditions":37708,"interventions":37709},[90],[15],[28323,29890,29891,29892,29893],{"trials":37711,"activeCount":101},[],{"trials":37713,"activeCount":101},[],{"trials":37715,"activeCount":101},[],{"trials":37717,"activeCount":101},[],{"intervention":37719,"totalTrials":272,"cells":37720},"Valaciclovir",{"EARLY_PHASE1":37721,"PHASE1":37723,"PHASE2":37731,"PHASE3":37733,"PHASE4":37735,"NA":37737},{"trials":37722,"activeCount":101},[],{"trials":37724,"activeCount":101},[37725],{"nctId":37726,"briefTitle":37727,"status":107,"phases":37728,"primaryCompletion":1114,"start":9902,"enrollment":993,"conditions":37729,"interventions":37730},"NCT02226978","Pharmacokinetic Interaction Study of Steady-state Tipranavir\u002FRitonavir (TPV\u002Fr) With Single-dose Valaciclovir (VAL) in Healthy Volunteers",[90],[15],[4008,4010,37719],{"trials":37732,"activeCount":101},[],{"trials":37734,"activeCount":101},[],{"trials":37736,"activeCount":101},[],{"trials":37738,"activeCount":101},[],{"intervention":37740,"totalTrials":272,"cells":37741},"Test drug",{"EARLY_PHASE1":37742,"PHASE1":37744,"PHASE2":37752,"PHASE3":37754,"PHASE4":37756,"NA":37758},{"trials":37743,"activeCount":101},[],{"trials":37745,"activeCount":101},[37746],{"nctId":37747,"briefTitle":37748,"status":107,"phases":37749,"primaryCompletion":447,"completion":447,"start":9491,"enrollment":1429,"conditions":37750,"interventions":37751},"NCT01638598","Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers",[90],[15],[37740,37740,37740,37740,37740],{"trials":37753,"activeCount":101},[],{"trials":37755,"activeCount":101},[],{"trials":37757,"activeCount":101},[],{"trials":37759,"activeCount":101},[],{"intervention":27340,"totalTrials":272,"cells":37761},{"EARLY_PHASE1":37762,"PHASE1":37764,"PHASE2":37770,"PHASE3":37772,"PHASE4":37774,"NA":37776},{"trials":37763,"activeCount":101},[],{"trials":37765,"activeCount":101},[37766],{"nctId":27335,"briefTitle":27336,"status":107,"phases":37767,"primaryCompletion":7381,"start":7419,"enrollment":357,"conditions":37768,"interventions":37769},[90],[15],[6024,27340],{"trials":37771,"activeCount":101},[],{"trials":37773,"activeCount":101},[],{"trials":37775,"activeCount":101},[],{"trials":37777,"activeCount":101},[],{"intervention":37779,"totalTrials":272,"cells":37780},"Persantin® new formulation",{"EARLY_PHASE1":37781,"PHASE1":37783,"PHASE2":37792,"PHASE3":37794,"PHASE4":37796,"NA":37798},{"trials":37782,"activeCount":101},[],{"trials":37784,"activeCount":101},[37785],{"nctId":37786,"briefTitle":37787,"status":107,"phases":37788,"primaryCompletion":6040,"start":6041,"enrollment":357,"conditions":37789,"interventions":37790},"NCT02259998","Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers",[90],[15],[37779,37791],"Persantin® commercial formulation",{"trials":37793,"activeCount":101},[],{"trials":37795,"activeCount":101},[],{"trials":37797,"activeCount":101},[],{"trials":37799,"activeCount":101},[],{"intervention":37791,"totalTrials":272,"cells":37801},{"EARLY_PHASE1":37802,"PHASE1":37804,"PHASE2":37810,"PHASE3":37812,"PHASE4":37814,"NA":37816},{"trials":37803,"activeCount":101},[],{"trials":37805,"activeCount":101},[37806],{"nctId":37786,"briefTitle":37787,"status":107,"phases":37807,"primaryCompletion":6040,"start":6041,"enrollment":357,"conditions":37808,"interventions":37809},[90],[15],[37779,37791],{"trials":37811,"activeCount":101},[],{"trials":37813,"activeCount":101},[],{"trials":37815,"activeCount":101},[],{"trials":37817,"activeCount":101},[],{"intervention":37819,"totalTrials":272,"cells":37820},"Nevirapine, low dose",{"EARLY_PHASE1":37821,"PHASE1":37823,"PHASE2":37832,"PHASE3":37834,"PHASE4":37836,"NA":37838},{"trials":37822,"activeCount":101},[],{"trials":37824,"activeCount":101},[37825],{"nctId":37826,"briefTitle":37827,"status":107,"phases":37828,"primaryCompletion":399,"start":400,"enrollment":410,"conditions":37829,"interventions":37830},"NCT02194218","Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers",[90],[15],[37819,37831],"Nevirapine, high dose",{"trials":37833,"activeCount":101},[],{"trials":37835,"activeCount":101},[],{"trials":37837,"activeCount":101},[],{"trials":37839,"activeCount":101},[],{"intervention":37831,"totalTrials":272,"cells":37841},{"EARLY_PHASE1":37842,"PHASE1":37844,"PHASE2":37850,"PHASE3":37852,"PHASE4":37854,"NA":37856},{"trials":37843,"activeCount":101},[],{"trials":37845,"activeCount":101},[37846],{"nctId":37826,"briefTitle":37827,"status":107,"phases":37847,"primaryCompletion":399,"start":400,"enrollment":410,"conditions":37848,"interventions":37849},[90],[15],[37819,37831],{"trials":37851,"activeCount":101},[],{"trials":37853,"activeCount":101},[],{"trials":37855,"activeCount":101},[],{"trials":37857,"activeCount":101},[],{"intervention":37859,"totalTrials":272,"cells":37860},"BI 1034020",{"EARLY_PHASE1":37861,"PHASE1":37863,"PHASE2":37871,"PHASE3":37873,"PHASE4":37875,"NA":37877},{"trials":37862,"activeCount":101},[],{"trials":37864,"activeCount":101},[37865],{"nctId":37866,"briefTitle":37867,"status":162,"phases":37868,"primaryCompletion":10024,"completion":10024,"start":4474,"enrollment":1418,"conditions":37869,"interventions":37870},"NCT01958060","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers",[90],[15],[37859],{"trials":37872,"activeCount":101},[],{"trials":37874,"activeCount":101},[],{"trials":37876,"activeCount":101},[],{"trials":37878,"activeCount":101},[],{"intervention":4477,"totalTrials":272,"cells":37880},{"EARLY_PHASE1":37881,"PHASE1":37883,"PHASE2":37889,"PHASE3":37891,"PHASE4":37893,"NA":37895},{"trials":37882,"activeCount":101},[],{"trials":37884,"activeCount":101},[37885],{"nctId":4470,"briefTitle":4471,"status":107,"phases":37886,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":410,"conditions":37887,"interventions":37888},[90],[15],[4047,4477,4478,4479,1538],{"trials":37890,"activeCount":101},[],{"trials":37892,"activeCount":101},[],{"trials":37894,"activeCount":101},[],{"trials":37896,"activeCount":101},[],{"intervention":4478,"totalTrials":272,"cells":37898},{"EARLY_PHASE1":37899,"PHASE1":37901,"PHASE2":37907,"PHASE3":37909,"PHASE4":37911,"NA":37913},{"trials":37900,"activeCount":101},[],{"trials":37902,"activeCount":101},[37903],{"nctId":4470,"briefTitle":4471,"status":107,"phases":37904,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":410,"conditions":37905,"interventions":37906},[90],[15],[4047,4477,4478,4479,1538],{"trials":37908,"activeCount":101},[],{"trials":37910,"activeCount":101},[],{"trials":37912,"activeCount":101},[],{"trials":37914,"activeCount":101},[],{"intervention":37916,"totalTrials":272,"cells":37917},"Itasetron",{"EARLY_PHASE1":37918,"PHASE1":37920,"PHASE2":37928,"PHASE3":37930,"PHASE4":37932,"NA":37934},{"trials":37919,"activeCount":101},[],{"trials":37921,"activeCount":101},[37922],{"nctId":37923,"briefTitle":37924,"status":107,"phases":37925,"primaryCompletion":7250,"start":21407,"enrollment":956,"conditions":37926,"interventions":37927},"NCT02259985","Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects",[90],[15],[37916,37916],{"trials":37929,"activeCount":101},[],{"trials":37931,"activeCount":101},[],{"trials":37933,"activeCount":101},[],{"trials":37935,"activeCount":101},[],{"intervention":37937,"totalTrials":272,"cells":37938},"Efavirenz",{"EARLY_PHASE1":37939,"PHASE1":37941,"PHASE2":37949,"PHASE3":37951,"PHASE4":37953,"NA":37955},{"trials":37940,"activeCount":101},[],{"trials":37942,"activeCount":101},[37943],{"nctId":37944,"briefTitle":37945,"status":107,"phases":37946,"primaryCompletion":2145,"start":6156,"enrollment":1237,"conditions":37947,"interventions":37948},"NCT02226991","Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers",[90],[15],[4008,4010,37937],{"trials":37950,"activeCount":101},[],{"trials":37952,"activeCount":101},[],{"trials":37954,"activeCount":101},[],{"trials":37956,"activeCount":101},[],{"intervention":37958,"totalTrials":272,"cells":37959},"BIBR 1048 MS polymorph II",{"EARLY_PHASE1":37960,"PHASE1":37962,"PHASE2":37971,"PHASE3":37973,"PHASE4":37975,"NA":37977},{"trials":37961,"activeCount":101},[],{"trials":37963,"activeCount":101},[37964],{"nctId":37965,"briefTitle":37966,"status":107,"phases":37967,"primaryCompletion":8479,"start":5868,"enrollment":1865,"conditions":37968,"interventions":37969},"NCT02170974","Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.",[90],[15],[37958,37970],"BIBR 1048 MS polymorph I",{"trials":37972,"activeCount":101},[],{"trials":37974,"activeCount":101},[],{"trials":37976,"activeCount":101},[],{"trials":37978,"activeCount":101},[],{"intervention":37970,"totalTrials":272,"cells":37980},{"EARLY_PHASE1":37981,"PHASE1":37983,"PHASE2":37989,"PHASE3":37991,"PHASE4":37993,"NA":37995},{"trials":37982,"activeCount":101},[],{"trials":37984,"activeCount":101},[37985],{"nctId":37965,"briefTitle":37966,"status":107,"phases":37986,"primaryCompletion":8479,"start":5868,"enrollment":1865,"conditions":37987,"interventions":37988},[90],[15],[37958,37970],{"trials":37990,"activeCount":101},[],{"trials":37992,"activeCount":101},[],{"trials":37994,"activeCount":101},[],{"trials":37996,"activeCount":101},[],{"intervention":37998,"totalTrials":272,"cells":37999},"BEA 2180 BR solution for",{"EARLY_PHASE1":38000,"PHASE1":38002,"PHASE2":38011,"PHASE3":38013,"PHASE4":38015,"NA":38017},{"trials":38001,"activeCount":101},[],{"trials":38003,"activeCount":101},[38004],{"nctId":38005,"briefTitle":38006,"status":107,"phases":38007,"primaryCompletion":20181,"start":6911,"enrollment":2898,"conditions":38008,"interventions":38009},"NCT02254720","Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers",[90],[15],[37998,38010],"BEA 2180 BR solution for inhalation",{"trials":38012,"activeCount":101},[],{"trials":38014,"activeCount":101},[],{"trials":38016,"activeCount":101},[],{"trials":38018,"activeCount":101},[],{"intervention":38010,"totalTrials":272,"cells":38020},{"EARLY_PHASE1":38021,"PHASE1":38023,"PHASE2":38029,"PHASE3":38031,"PHASE4":38033,"NA":38035},{"trials":38022,"activeCount":101},[],{"trials":38024,"activeCount":101},[38025],{"nctId":38005,"briefTitle":38006,"status":107,"phases":38026,"primaryCompletion":20181,"start":6911,"enrollment":2898,"conditions":38027,"interventions":38028},[90],[15],[37998,38010],{"trials":38030,"activeCount":101},[],{"trials":38032,"activeCount":101},[],{"trials":38034,"activeCount":101},[],{"trials":38036,"activeCount":101},[],{"intervention":29429,"totalTrials":272,"cells":38038},{"EARLY_PHASE1":38039,"PHASE1":38041,"PHASE2":38047,"PHASE3":38049,"PHASE4":38051,"NA":38053},{"trials":38040,"activeCount":101},[],{"trials":38042,"activeCount":101},[38043],{"nctId":29424,"briefTitle":29425,"status":107,"phases":38044,"primaryCompletion":17247,"start":17247,"enrollment":448,"conditions":38045,"interventions":38046},[90],[15],[6121,29410,29429],{"trials":38048,"activeCount":101},[],{"trials":38050,"activeCount":101},[],{"trials":38052,"activeCount":101},[],{"trials":38054,"activeCount":101},[],{"intervention":38056,"totalTrials":272,"cells":38057},"BIBR 1017 BS powder",{"EARLY_PHASE1":38058,"PHASE1":38060,"PHASE2":38068,"PHASE3":38070,"PHASE4":38072,"NA":38074},{"trials":38059,"activeCount":101},[],{"trials":38061,"activeCount":101},[38062],{"nctId":38063,"briefTitle":38064,"status":107,"phases":38065,"primaryCompletion":8086,"start":8479,"enrollment":410,"conditions":38066,"interventions":38067},"NCT02184338","Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 \u002F 26% Ethanol Administered to Healthy Male Subjects",[90],[15],[38056],{"trials":38069,"activeCount":101},[],{"trials":38071,"activeCount":101},[],{"trials":38073,"activeCount":101},[],{"trials":38075,"activeCount":101},[],{"intervention":38077,"totalTrials":272,"cells":38078},"BIBB 1464 MS",{"EARLY_PHASE1":38079,"PHASE1":38081,"PHASE2":38091,"PHASE3":38093,"PHASE4":38095,"NA":38097},{"trials":38080,"activeCount":101},[],{"trials":38082,"activeCount":101},[38083],{"nctId":38084,"briefTitle":38085,"status":107,"phases":38086,"primaryCompletion":7022,"start":13117,"enrollment":19006,"conditions":38087,"interventions":38088},"NCT02229838","Safety\u002FTolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food",[90],[15],[38077,38089,38090],"BIBB 1464 MS solution","BIBB 1464 MS placebo",{"trials":38092,"activeCount":101},[],{"trials":38094,"activeCount":101},[],{"trials":38096,"activeCount":101},[],{"trials":38098,"activeCount":101},[],{"intervention":38089,"totalTrials":272,"cells":38100},{"EARLY_PHASE1":38101,"PHASE1":38103,"PHASE2":38109,"PHASE3":38111,"PHASE4":38113,"NA":38115},{"trials":38102,"activeCount":101},[],{"trials":38104,"activeCount":101},[38105],{"nctId":38084,"briefTitle":38085,"status":107,"phases":38106,"primaryCompletion":7022,"start":13117,"enrollment":19006,"conditions":38107,"interventions":38108},[90],[15],[38077,38089,38090],{"trials":38110,"activeCount":101},[],{"trials":38112,"activeCount":101},[],{"trials":38114,"activeCount":101},[],{"trials":38116,"activeCount":101},[],{"intervention":38090,"totalTrials":272,"cells":38118},{"EARLY_PHASE1":38119,"PHASE1":38121,"PHASE2":38127,"PHASE3":38129,"PHASE4":38131,"NA":38133},{"trials":38120,"activeCount":101},[],{"trials":38122,"activeCount":101},[38123],{"nctId":38084,"briefTitle":38085,"status":107,"phases":38124,"primaryCompletion":7022,"start":13117,"enrollment":19006,"conditions":38125,"interventions":38126},[90],[15],[38077,38089,38090],{"trials":38128,"activeCount":101},[],{"trials":38130,"activeCount":101},[],{"trials":38132,"activeCount":101},[],{"trials":38134,"activeCount":101},[],{"intervention":38136,"totalTrials":272,"cells":38137},"ESR 1150 CL, Capsule,",{"EARLY_PHASE1":38138,"PHASE1":38140,"PHASE2":38149,"PHASE3":38151,"PHASE4":38153,"NA":38155},{"trials":38139,"activeCount":101},[],{"trials":38141,"activeCount":101},[38142],{"nctId":38143,"briefTitle":38144,"status":107,"phases":38145,"primaryCompletion":7114,"start":11123,"enrollment":392,"conditions":38146,"interventions":38147},"NCT02183259","Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers",[90],[15],[38136,38148],"ESR 1150 CL, solution, intravenous",{"trials":38150,"activeCount":101},[],{"trials":38152,"activeCount":101},[],{"trials":38154,"activeCount":101},[],{"trials":38156,"activeCount":101},[],{"intervention":38148,"totalTrials":272,"cells":38158},{"EARLY_PHASE1":38159,"PHASE1":38161,"PHASE2":38167,"PHASE3":38169,"PHASE4":38171,"NA":38173},{"trials":38160,"activeCount":101},[],{"trials":38162,"activeCount":101},[38163],{"nctId":38143,"briefTitle":38144,"status":107,"phases":38164,"primaryCompletion":7114,"start":11123,"enrollment":392,"conditions":38165,"interventions":38166},[90],[15],[38136,38148],{"trials":38168,"activeCount":101},[],{"trials":38170,"activeCount":101},[],{"trials":38172,"activeCount":101},[],{"trials":38174,"activeCount":101},[],{"intervention":38176,"totalTrials":272,"cells":38177},"Afatinib healthy",{"EARLY_PHASE1":38178,"PHASE1":38180,"PHASE2":38190,"PHASE3":38192,"PHASE4":38194,"NA":38196},{"trials":38179,"activeCount":101},[],{"trials":38181,"activeCount":101},[38182],{"nctId":38183,"briefTitle":38184,"status":107,"phases":38185,"primaryCompletion":474,"completion":474,"start":9842,"enrollment":357,"conditions":38186,"interventions":38187},"NCT02096718","Afatinib in Subjects With Kidney Dysfunction",[90],[2550],[38176,38188,38189],"Afatinib severe renally impaired","Afatinib moderate renally impaired",{"trials":38191,"activeCount":101},[],{"trials":38193,"activeCount":101},[],{"trials":38195,"activeCount":101},[],{"trials":38197,"activeCount":101},[],{"intervention":38188,"totalTrials":272,"cells":38199},{"EARLY_PHASE1":38200,"PHASE1":38202,"PHASE2":38208,"PHASE3":38210,"PHASE4":38212,"NA":38214},{"trials":38201,"activeCount":101},[],{"trials":38203,"activeCount":101},[38204],{"nctId":38183,"briefTitle":38184,"status":107,"phases":38205,"primaryCompletion":474,"completion":474,"start":9842,"enrollment":357,"conditions":38206,"interventions":38207},[90],[2550],[38176,38188,38189],{"trials":38209,"activeCount":101},[],{"trials":38211,"activeCount":101},[],{"trials":38213,"activeCount":101},[],{"trials":38215,"activeCount":101},[],{"intervention":38189,"totalTrials":272,"cells":38217},{"EARLY_PHASE1":38218,"PHASE1":38220,"PHASE2":38226,"PHASE3":38228,"PHASE4":38230,"NA":38232},{"trials":38219,"activeCount":101},[],{"trials":38221,"activeCount":101},[38222],{"nctId":38183,"briefTitle":38184,"status":107,"phases":38223,"primaryCompletion":474,"completion":474,"start":9842,"enrollment":357,"conditions":38224,"interventions":38225},[90],[2550],[38176,38188,38189],{"trials":38227,"activeCount":101},[],{"trials":38229,"activeCount":101},[],{"trials":38231,"activeCount":101},[],{"trials":38233,"activeCount":101},[],{"intervention":20406,"totalTrials":272,"cells":38235},{"EARLY_PHASE1":38236,"PHASE1":38238,"PHASE2":38244,"PHASE3":38246,"PHASE4":38248,"NA":38250},{"trials":38237,"activeCount":101},[],{"trials":38239,"activeCount":101},[38240],{"nctId":20401,"briefTitle":20402,"status":107,"phases":38241,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":38242,"interventions":38243},[90],[15],[3981,4011,4013,4014,1241,20406,20407],{"trials":38245,"activeCount":101},[],{"trials":38247,"activeCount":101},[],{"trials":38249,"activeCount":101},[],{"trials":38251,"activeCount":101},[],{"intervention":20407,"totalTrials":272,"cells":38253},{"EARLY_PHASE1":38254,"PHASE1":38256,"PHASE2":38262,"PHASE3":38264,"PHASE4":38266,"NA":38268},{"trials":38255,"activeCount":101},[],{"trials":38257,"activeCount":101},[38258],{"nctId":20401,"briefTitle":20402,"status":107,"phases":38259,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":38260,"interventions":38261},[90],[15],[3981,4011,4013,4014,1241,20406,20407],{"trials":38263,"activeCount":101},[],{"trials":38265,"activeCount":101},[],{"trials":38267,"activeCount":101},[],{"trials":38269,"activeCount":101},[],{"intervention":38271,"totalTrials":272,"cells":38272},"14C-Tipranavir",{"EARLY_PHASE1":38273,"PHASE1":38275,"PHASE2":38283,"PHASE3":38285,"PHASE4":38287,"NA":38289},{"trials":38274,"activeCount":101},[],{"trials":38276,"activeCount":101},[38277],{"nctId":38278,"briefTitle":38279,"status":107,"phases":38280,"primaryCompletion":5879,"start":5879,"conditions":38281,"interventions":38282},"NCT02253797","Pharmacokinetics of Tipranavir\u002FRitonavir and Its Metabolites in Healthy Male Subjects",[90],[15],[38271,4008,4010],{"trials":38284,"activeCount":101},[],{"trials":38286,"activeCount":101},[],{"trials":38288,"activeCount":101},[],{"trials":38290,"activeCount":101},[],{"intervention":38292,"totalTrials":272,"cells":38293},"Aggrenox®",{"EARLY_PHASE1":38294,"PHASE1":38296,"PHASE2":38304,"PHASE3":38306,"PHASE4":38308,"NA":38310},{"trials":38295,"activeCount":101},[],{"trials":38297,"activeCount":101},[38298],{"nctId":38299,"briefTitle":38300,"status":107,"phases":38301,"primaryCompletion":6594,"start":6738,"enrollment":37,"conditions":38302,"interventions":38303},"NCT02278302","Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers",[90],[15],[38292],{"trials":38305,"activeCount":101},[],{"trials":38307,"activeCount":101},[],{"trials":38309,"activeCount":101},[],{"trials":38311,"activeCount":101},[],{"intervention":38313,"totalTrials":272,"cells":38314},"BI 44847 solution, low dose",{"EARLY_PHASE1":38315,"PHASE1":38317,"PHASE2":38328,"PHASE3":38330,"PHASE4":38332,"NA":38334},{"trials":38316,"activeCount":101},[],{"trials":38318,"activeCount":101},[38319],{"nctId":38320,"briefTitle":38321,"status":107,"phases":38322,"primaryCompletion":6116,"start":7573,"enrollment":439,"conditions":38323,"interventions":38324},"NCT02211937","Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers",[90],[15],[38313,38325,38326,38327],"BI 44847 suspension, high dose","BI 44847 tablet, low dose","BI 44847 tablet, high dose",{"trials":38329,"activeCount":101},[],{"trials":38331,"activeCount":101},[],{"trials":38333,"activeCount":101},[],{"trials":38335,"activeCount":101},[],{"intervention":38325,"totalTrials":272,"cells":38337},{"EARLY_PHASE1":38338,"PHASE1":38340,"PHASE2":38346,"PHASE3":38348,"PHASE4":38350,"NA":38352},{"trials":38339,"activeCount":101},[],{"trials":38341,"activeCount":101},[38342],{"nctId":38320,"briefTitle":38321,"status":107,"phases":38343,"primaryCompletion":6116,"start":7573,"enrollment":439,"conditions":38344,"interventions":38345},[90],[15],[38313,38325,38326,38327],{"trials":38347,"activeCount":101},[],{"trials":38349,"activeCount":101},[],{"trials":38351,"activeCount":101},[],{"trials":38353,"activeCount":101},[],{"intervention":38326,"totalTrials":272,"cells":38355},{"EARLY_PHASE1":38356,"PHASE1":38358,"PHASE2":38364,"PHASE3":38366,"PHASE4":38368,"NA":38370},{"trials":38357,"activeCount":101},[],{"trials":38359,"activeCount":101},[38360],{"nctId":38320,"briefTitle":38321,"status":107,"phases":38361,"primaryCompletion":6116,"start":7573,"enrollment":439,"conditions":38362,"interventions":38363},[90],[15],[38313,38325,38326,38327],{"trials":38365,"activeCount":101},[],{"trials":38367,"activeCount":101},[],{"trials":38369,"activeCount":101},[],{"trials":38371,"activeCount":101},[],{"intervention":38327,"totalTrials":272,"cells":38373},{"EARLY_PHASE1":38374,"PHASE1":38376,"PHASE2":38382,"PHASE3":38384,"PHASE4":38386,"NA":38388},{"trials":38375,"activeCount":101},[],{"trials":38377,"activeCount":101},[38378],{"nctId":38320,"briefTitle":38321,"status":107,"phases":38379,"primaryCompletion":6116,"start":7573,"enrollment":439,"conditions":38380,"interventions":38381},[90],[15],[38313,38325,38326,38327],{"trials":38383,"activeCount":101},[],{"trials":38385,"activeCount":101},[],{"trials":38387,"activeCount":101},[],{"trials":38389,"activeCount":101},[],{"intervention":4588,"totalTrials":272,"cells":38391},{"EARLY_PHASE1":38392,"PHASE1":38394,"PHASE2":38400,"PHASE3":38402,"PHASE4":38404,"NA":38406},{"trials":38393,"activeCount":101},[],{"trials":38395,"activeCount":101},[38396],{"nctId":4579,"briefTitle":4580,"status":4581,"phases":38397,"primaryCompletion":4583,"completion":4584,"start":4337,"enrollment":4585,"conditions":38398,"interventions":38399},[90],[2057],[2059,4588],{"trials":38401,"activeCount":101},[],{"trials":38403,"activeCount":101},[],{"trials":38405,"activeCount":101},[],{"trials":38407,"activeCount":101},[],{"intervention":38409,"totalTrials":272,"cells":38410},"BI 456906 - Formulation A",{"EARLY_PHASE1":38411,"PHASE1":38413,"PHASE2":38426,"PHASE3":38428,"PHASE4":38430,"NA":38432},{"trials":38412,"activeCount":101},[],{"trials":38414,"activeCount":101},[38415],{"nctId":38416,"briefTitle":38417,"status":107,"phases":38418,"primaryCompletion":38419,"completion":38420,"start":38421,"enrollment":357,"conditions":38422,"interventions":38423},"NCT06772532","A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body",[90],"2025-05-29","2025-06-10","2025-02-10",[15],[38409,38424,38425],"BI 456906 - Formulation B","BI 456906 - Formulation C",{"trials":38427,"activeCount":101},[],{"trials":38429,"activeCount":101},[],{"trials":38431,"activeCount":101},[],{"trials":38433,"activeCount":101},[],{"intervention":38424,"totalTrials":272,"cells":38435},{"EARLY_PHASE1":38436,"PHASE1":38438,"PHASE2":38444,"PHASE3":38446,"PHASE4":38448,"NA":38450},{"trials":38437,"activeCount":101},[],{"trials":38439,"activeCount":101},[38440],{"nctId":38416,"briefTitle":38417,"status":107,"phases":38441,"primaryCompletion":38419,"completion":38420,"start":38421,"enrollment":357,"conditions":38442,"interventions":38443},[90],[15],[38409,38424,38425],{"trials":38445,"activeCount":101},[],{"trials":38447,"activeCount":101},[],{"trials":38449,"activeCount":101},[],{"trials":38451,"activeCount":101},[],{"intervention":38425,"totalTrials":272,"cells":38453},{"EARLY_PHASE1":38454,"PHASE1":38456,"PHASE2":38462,"PHASE3":38464,"PHASE4":38466,"NA":38468},{"trials":38455,"activeCount":101},[],{"trials":38457,"activeCount":101},[38458],{"nctId":38416,"briefTitle":38417,"status":107,"phases":38459,"primaryCompletion":38419,"completion":38420,"start":38421,"enrollment":357,"conditions":38460,"interventions":38461},[90],[15],[38409,38424,38425],{"trials":38463,"activeCount":101},[],{"trials":38465,"activeCount":101},[],{"trials":38467,"activeCount":101},[],{"trials":38469,"activeCount":101},[],{"intervention":38471,"totalTrials":272,"cells":38472},"BI 1060469 Healthy",{"EARLY_PHASE1":38473,"PHASE1":38475,"PHASE2":38484,"PHASE3":38486,"PHASE4":38488,"NA":38490},{"trials":38474,"activeCount":101},[],{"trials":38476,"activeCount":101},[38477],{"nctId":38478,"briefTitle":38479,"status":107,"phases":38480,"primaryCompletion":7092,"completion":7092,"start":9842,"enrollment":12,"conditions":38481,"interventions":38482},"NCT02126865","Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients",[90],[30],[38471,38483],"BI 1060469 asthmatics",{"trials":38485,"activeCount":101},[],{"trials":38487,"activeCount":101},[],{"trials":38489,"activeCount":101},[],{"trials":38491,"activeCount":101},[],{"intervention":38483,"totalTrials":272,"cells":38493},{"EARLY_PHASE1":38494,"PHASE1":38496,"PHASE2":38502,"PHASE3":38504,"PHASE4":38506,"NA":38508},{"trials":38495,"activeCount":101},[],{"trials":38497,"activeCount":101},[38498],{"nctId":38478,"briefTitle":38479,"status":107,"phases":38499,"primaryCompletion":7092,"completion":7092,"start":9842,"enrollment":12,"conditions":38500,"interventions":38501},[90],[30],[38471,38483],{"trials":38503,"activeCount":101},[],{"trials":38505,"activeCount":101},[],{"trials":38507,"activeCount":101},[],{"trials":38509,"activeCount":101},[],{"intervention":38511,"totalTrials":272,"cells":38512},"BIIF 1149 BS - single rising doses",{"EARLY_PHASE1":38513,"PHASE1":38515,"PHASE2":38523,"PHASE3":38525,"PHASE4":38527,"NA":38529},{"trials":38514,"activeCount":101},[],{"trials":38516,"activeCount":101},[38517],{"nctId":38518,"briefTitle":38519,"status":107,"phases":38520,"primaryCompletion":13117,"start":6453,"enrollment":1208,"conditions":38521,"interventions":38522},"NCT02199899","Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers",[90],[15],[38511],{"trials":38524,"activeCount":101},[],{"trials":38526,"activeCount":101},[],{"trials":38528,"activeCount":101},[],{"trials":38530,"activeCount":101},[],{"intervention":28331,"totalTrials":272,"cells":38532},{"EARLY_PHASE1":38533,"PHASE1":38535,"PHASE2":38541,"PHASE3":38543,"PHASE4":38545,"NA":38547},{"trials":38534,"activeCount":101},[],{"trials":38536,"activeCount":101},[38537],{"nctId":28325,"briefTitle":28326,"status":107,"phases":38538,"primaryCompletion":6223,"start":4413,"enrollment":2382,"conditions":38539,"interventions":38540},[90],[15],[28330,9335,28331],{"trials":38542,"activeCount":101},[],{"trials":38544,"activeCount":101},[],{"trials":38546,"activeCount":101},[],{"trials":38548,"activeCount":101},[],{"intervention":38550,"totalTrials":272,"cells":38551},"Tadalafil",{"EARLY_PHASE1":38552,"PHASE1":38554,"PHASE2":38562,"PHASE3":38564,"PHASE4":38566,"NA":38568},{"trials":38553,"activeCount":101},[],{"trials":38555,"activeCount":101},[38556],{"nctId":38557,"briefTitle":38558,"status":107,"phases":38559,"primaryCompletion":4461,"start":4462,"enrollment":5242,"conditions":38560,"interventions":38561},"NCT02253862","Pharmacokinetic of Tadalafil Co-administered With Tipranavir\u002FRitonavir to Healthy Male Volunteers",[90],[15],[38550,4008,4010],{"trials":38563,"activeCount":101},[],{"trials":38565,"activeCount":101},[],{"trials":38567,"activeCount":101},[],{"trials":38569,"activeCount":101},[],{"intervention":10652,"totalTrials":272,"cells":38571},{"EARLY_PHASE1":38572,"PHASE1":38574,"PHASE2":38580,"PHASE3":38582,"PHASE4":38584,"NA":38586},{"trials":38573,"activeCount":101},[],{"trials":38575,"activeCount":101},[38576],{"nctId":10645,"briefTitle":10646,"status":107,"phases":38577,"primaryCompletion":10648,"completion":10648,"start":10649,"enrollment":7301,"conditions":38578,"interventions":38579},[90],[15],[10638,10652,10653],{"trials":38581,"activeCount":101},[],{"trials":38583,"activeCount":101},[],{"trials":38585,"activeCount":101},[],{"trials":38587,"activeCount":101},[],{"intervention":10653,"totalTrials":272,"cells":38589},{"EARLY_PHASE1":38590,"PHASE1":38592,"PHASE2":38598,"PHASE3":38600,"PHASE4":38602,"NA":38604},{"trials":38591,"activeCount":101},[],{"trials":38593,"activeCount":101},[38594],{"nctId":10645,"briefTitle":10646,"status":107,"phases":38595,"primaryCompletion":10648,"completion":10648,"start":10649,"enrollment":7301,"conditions":38596,"interventions":38597},[90],[15],[10638,10652,10653],{"trials":38599,"activeCount":101},[],{"trials":38601,"activeCount":101},[],{"trials":38603,"activeCount":101},[],{"trials":38605,"activeCount":101},[],{"intervention":38607,"totalTrials":272,"cells":38608},"Diclofenac Sodium",{"EARLY_PHASE1":38609,"PHASE1":38611,"PHASE2":38621,"PHASE3":38623,"PHASE4":38625,"NA":38627},{"trials":38610,"activeCount":101},[],{"trials":38612,"activeCount":101},[38613],{"nctId":38614,"briefTitle":38615,"status":107,"phases":38616,"primaryCompletion":18653,"completion":18653,"start":618,"enrollment":410,"conditions":38617,"interventions":38618},"NCT03074162","Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers",[90],[15],[38607,38619,38620],"Diclofenac & Capsaicin","Diclofenac Sodium Topical Gel",{"trials":38622,"activeCount":101},[],{"trials":38624,"activeCount":101},[],{"trials":38626,"activeCount":101},[],{"trials":38628,"activeCount":101},[],{"intervention":38619,"totalTrials":272,"cells":38630},{"EARLY_PHASE1":38631,"PHASE1":38633,"PHASE2":38639,"PHASE3":38641,"PHASE4":38643,"NA":38645},{"trials":38632,"activeCount":101},[],{"trials":38634,"activeCount":101},[38635],{"nctId":38614,"briefTitle":38615,"status":107,"phases":38636,"primaryCompletion":18653,"completion":18653,"start":618,"enrollment":410,"conditions":38637,"interventions":38638},[90],[15],[38607,38619,38620],{"trials":38640,"activeCount":101},[],{"trials":38642,"activeCount":101},[],{"trials":38644,"activeCount":101},[],{"trials":38646,"activeCount":101},[],{"intervention":38620,"totalTrials":272,"cells":38648},{"EARLY_PHASE1":38649,"PHASE1":38651,"PHASE2":38657,"PHASE3":38659,"PHASE4":38661,"NA":38663},{"trials":38650,"activeCount":101},[],{"trials":38652,"activeCount":101},[38653],{"nctId":38614,"briefTitle":38615,"status":107,"phases":38654,"primaryCompletion":18653,"completion":18653,"start":618,"enrollment":410,"conditions":38655,"interventions":38656},[90],[15],[38607,38619,38620],{"trials":38658,"activeCount":101},[],{"trials":38660,"activeCount":101},[],{"trials":38662,"activeCount":101},[],{"trials":38664,"activeCount":101},[],{"intervention":9905,"totalTrials":272,"cells":38666},{"EARLY_PHASE1":38667,"PHASE1":38669,"PHASE2":38675,"PHASE3":38677,"PHASE4":38679,"NA":38681},{"trials":38668,"activeCount":101},[],{"trials":38670,"activeCount":101},[38671],{"nctId":9899,"briefTitle":9900,"status":107,"phases":38672,"primaryCompletion":6155,"start":9902,"enrollment":1672,"conditions":38673,"interventions":38674},[90],[15],[9872,9905,9370],{"trials":38676,"activeCount":101},[],{"trials":38678,"activeCount":101},[],{"trials":38680,"activeCount":101},[],{"trials":38682,"activeCount":101},[],{"intervention":38684,"totalTrials":272,"cells":38685},"BIBT 986 BS - low",{"EARLY_PHASE1":38686,"PHASE1":38688,"PHASE2":38697,"PHASE3":38699,"PHASE4":38701,"NA":38703},{"trials":38687,"activeCount":101},[],{"trials":38689,"activeCount":101},[38690],{"nctId":38691,"briefTitle":38692,"status":107,"phases":38693,"primaryCompletion":21078,"start":6081,"enrollment":401,"conditions":38694,"interventions":38695},"NCT02254083","Tolerability and Pharmacokinetics\u002F-Dynamics of BIBT 986 BS in Healthy Male Subjects",[90],[15],[38684,38696],"BIBT 986 BS - high",{"trials":38698,"activeCount":101},[],{"trials":38700,"activeCount":101},[],{"trials":38702,"activeCount":101},[],{"trials":38704,"activeCount":101},[],{"intervention":38696,"totalTrials":272,"cells":38706},{"EARLY_PHASE1":38707,"PHASE1":38709,"PHASE2":38715,"PHASE3":38717,"PHASE4":38719,"NA":38721},{"trials":38708,"activeCount":101},[],{"trials":38710,"activeCount":101},[38711],{"nctId":38691,"briefTitle":38692,"status":107,"phases":38712,"primaryCompletion":21078,"start":6081,"enrollment":401,"conditions":38713,"interventions":38714},[90],[15],[38684,38696],{"trials":38716,"activeCount":101},[],{"trials":38718,"activeCount":101},[],{"trials":38720,"activeCount":101},[],{"trials":38722,"activeCount":101},[],{"intervention":38724,"totalTrials":272,"cells":38725},"BI 764198, formulation 1",{"EARLY_PHASE1":38726,"PHASE1":38728,"PHASE2":38739,"PHASE3":38741,"PHASE4":38743,"NA":38745},{"trials":38727,"activeCount":101},[],{"trials":38729,"activeCount":101},[38730],{"nctId":38731,"briefTitle":38732,"status":107,"phases":38733,"primaryCompletion":465,"completion":38734,"start":593,"enrollment":401,"conditions":38735,"interventions":38736},"NCT06955754","A Study in Healthy People to Test How 3 Different Formulations of BI 764198 Are Taken up in the Body and How This is Influenced by Food",[90],"2025-07-14",[15],[38724,38737,38738],"BI 764198, formulation 2","BI 764198, formulation 3",{"trials":38740,"activeCount":101},[],{"trials":38742,"activeCount":101},[],{"trials":38744,"activeCount":101},[],{"trials":38746,"activeCount":101},[],{"intervention":38737,"totalTrials":272,"cells":38748},{"EARLY_PHASE1":38749,"PHASE1":38751,"PHASE2":38757,"PHASE3":38759,"PHASE4":38761,"NA":38763},{"trials":38750,"activeCount":101},[],{"trials":38752,"activeCount":101},[38753],{"nctId":38731,"briefTitle":38732,"status":107,"phases":38754,"primaryCompletion":465,"completion":38734,"start":593,"enrollment":401,"conditions":38755,"interventions":38756},[90],[15],[38724,38737,38738],{"trials":38758,"activeCount":101},[],{"trials":38760,"activeCount":101},[],{"trials":38762,"activeCount":101},[],{"trials":38764,"activeCount":101},[],{"intervention":38738,"totalTrials":272,"cells":38766},{"EARLY_PHASE1":38767,"PHASE1":38769,"PHASE2":38775,"PHASE3":38777,"PHASE4":38779,"NA":38781},{"trials":38768,"activeCount":101},[],{"trials":38770,"activeCount":101},[38771],{"nctId":38731,"briefTitle":38732,"status":107,"phases":38772,"primaryCompletion":465,"completion":38734,"start":593,"enrollment":401,"conditions":38773,"interventions":38774},[90],[15],[38724,38737,38738],{"trials":38776,"activeCount":101},[],{"trials":38778,"activeCount":101},[],{"trials":38780,"activeCount":101},[],{"trials":38782,"activeCount":101},[],{"intervention":38784,"totalTrials":272,"cells":38785},"Dose group 1 - 50 mg BI 1358894",{"EARLY_PHASE1":38786,"PHASE1":38788,"PHASE2":38800,"PHASE3":38802,"PHASE4":38804,"NA":38806},{"trials":38787,"activeCount":101},[],{"trials":38789,"activeCount":101},[38790],{"nctId":38791,"briefTitle":38792,"status":107,"phases":38793,"primaryCompletion":38794,"completion":38794,"start":38795,"enrollment":380,"conditions":38796,"interventions":38797},"NCT03875001","A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men",[90],"2019-07-20","2019-03-25",[15],[38784,38798,38799],"Dose group 2 - 100 mg BI 1358894","Dose group 3 - 200 mg BI 1358894",{"trials":38801,"activeCount":101},[],{"trials":38803,"activeCount":101},[],{"trials":38805,"activeCount":101},[],{"trials":38807,"activeCount":101},[],{"intervention":38798,"totalTrials":272,"cells":38809},{"EARLY_PHASE1":38810,"PHASE1":38812,"PHASE2":38818,"PHASE3":38820,"PHASE4":38822,"NA":38824},{"trials":38811,"activeCount":101},[],{"trials":38813,"activeCount":101},[38814],{"nctId":38791,"briefTitle":38792,"status":107,"phases":38815,"primaryCompletion":38794,"completion":38794,"start":38795,"enrollment":380,"conditions":38816,"interventions":38817},[90],[15],[38784,38798,38799],{"trials":38819,"activeCount":101},[],{"trials":38821,"activeCount":101},[],{"trials":38823,"activeCount":101},[],{"trials":38825,"activeCount":101},[],{"intervention":38799,"totalTrials":272,"cells":38827},{"EARLY_PHASE1":38828,"PHASE1":38830,"PHASE2":38836,"PHASE3":38838,"PHASE4":38840,"NA":38842},{"trials":38829,"activeCount":101},[],{"trials":38831,"activeCount":101},[38832],{"nctId":38791,"briefTitle":38792,"status":107,"phases":38833,"primaryCompletion":38794,"completion":38794,"start":38795,"enrollment":380,"conditions":38834,"interventions":38835},[90],[15],[38784,38798,38799],{"trials":38837,"activeCount":101},[],{"trials":38839,"activeCount":101},[],{"trials":38841,"activeCount":101},[],{"trials":38843,"activeCount":101},[],{"intervention":38845,"totalTrials":272,"cells":38846},"BI 730357 mixed with [C-14]BI 730357 BS",{"EARLY_PHASE1":38847,"PHASE1":38849,"PHASE2":38857,"PHASE3":38859,"PHASE4":38861,"NA":38863},{"trials":38848,"activeCount":101},[],{"trials":38850,"activeCount":101},[38851],{"nctId":38852,"briefTitle":38853,"status":107,"phases":38854,"primaryCompletion":27218,"completion":27218,"start":27434,"enrollment":1512,"conditions":38855,"interventions":38856},"NCT03664011","A Study in Healthy Men to Test How BI 730357 is Processed by the Body",[90],[15],[38845],{"trials":38858,"activeCount":101},[],{"trials":38860,"activeCount":101},[],{"trials":38862,"activeCount":101},[],{"trials":38864,"activeCount":101},[],{"intervention":38866,"totalTrials":272,"cells":38867},"Ambroxol hydrochloride soft pastille",{"EARLY_PHASE1":38868,"PHASE1":38870,"PHASE2":38879,"PHASE3":38881,"PHASE4":38883,"NA":38885},{"trials":38869,"activeCount":101},[],{"trials":38871,"activeCount":101},[38872],{"nctId":38873,"briefTitle":38874,"status":107,"phases":38875,"primaryCompletion":6095,"completion":6095,"start":390,"conditions":38876,"interventions":38877},"NCT02572609","Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride",[90],[15],[38866,38878],"Mucosolvan ® adult syrup",{"trials":38880,"activeCount":101},[],{"trials":38882,"activeCount":101},[],{"trials":38884,"activeCount":101},[],{"trials":38886,"activeCount":101},[],{"intervention":38878,"totalTrials":272,"cells":38888},{"EARLY_PHASE1":38889,"PHASE1":38891,"PHASE2":38897,"PHASE3":38899,"PHASE4":38901,"NA":38903},{"trials":38890,"activeCount":101},[],{"trials":38892,"activeCount":101},[38893],{"nctId":38873,"briefTitle":38874,"status":107,"phases":38894,"primaryCompletion":6095,"completion":6095,"start":390,"conditions":38895,"interventions":38896},[90],[15],[38866,38878],{"trials":38898,"activeCount":101},[],{"trials":38900,"activeCount":101},[],{"trials":38902,"activeCount":101},[],{"trials":38904,"activeCount":101},[],{"intervention":38906,"totalTrials":272,"cells":38907},"Salmeterol Diskus low",{"EARLY_PHASE1":38908,"PHASE1":38910,"PHASE2":38921,"PHASE3":38923,"PHASE4":38925,"NA":38927},{"trials":38909,"activeCount":101},[],{"trials":38911,"activeCount":101},[38912],{"nctId":38913,"briefTitle":38914,"status":107,"phases":38915,"primaryCompletion":6782,"start":8086,"enrollment":1982,"conditions":38916,"interventions":38917},"NCT02254226","Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers",[90],[15],[38906,38918,38919,38920],"Salmeterol Diskus high","Salmeterol MDI low","Salmeterol MDI high",{"trials":38922,"activeCount":101},[],{"trials":38924,"activeCount":101},[],{"trials":38926,"activeCount":101},[],{"trials":38928,"activeCount":101},[],{"intervention":38918,"totalTrials":272,"cells":38930},{"EARLY_PHASE1":38931,"PHASE1":38933,"PHASE2":38939,"PHASE3":38941,"PHASE4":38943,"NA":38945},{"trials":38932,"activeCount":101},[],{"trials":38934,"activeCount":101},[38935],{"nctId":38913,"briefTitle":38914,"status":107,"phases":38936,"primaryCompletion":6782,"start":8086,"enrollment":1982,"conditions":38937,"interventions":38938},[90],[15],[38906,38918,38919,38920],{"trials":38940,"activeCount":101},[],{"trials":38942,"activeCount":101},[],{"trials":38944,"activeCount":101},[],{"trials":38946,"activeCount":101},[],{"intervention":38919,"totalTrials":272,"cells":38948},{"EARLY_PHASE1":38949,"PHASE1":38951,"PHASE2":38957,"PHASE3":38959,"PHASE4":38961,"NA":38963},{"trials":38950,"activeCount":101},[],{"trials":38952,"activeCount":101},[38953],{"nctId":38913,"briefTitle":38914,"status":107,"phases":38954,"primaryCompletion":6782,"start":8086,"enrollment":1982,"conditions":38955,"interventions":38956},[90],[15],[38906,38918,38919,38920],{"trials":38958,"activeCount":101},[],{"trials":38960,"activeCount":101},[],{"trials":38962,"activeCount":101},[],{"trials":38964,"activeCount":101},[],{"intervention":38920,"totalTrials":272,"cells":38966},{"EARLY_PHASE1":38967,"PHASE1":38969,"PHASE2":38975,"PHASE3":38977,"PHASE4":38979,"NA":38981},{"trials":38968,"activeCount":101},[],{"trials":38970,"activeCount":101},[38971],{"nctId":38913,"briefTitle":38914,"status":107,"phases":38972,"primaryCompletion":6782,"start":8086,"enrollment":1982,"conditions":38973,"interventions":38974},[90],[15],[38906,38918,38919,38920],{"trials":38976,"activeCount":101},[],{"trials":38978,"activeCount":101},[],{"trials":38980,"activeCount":101},[],{"trials":38982,"activeCount":101},[],{"intervention":27709,"totalTrials":272,"cells":38984},{"EARLY_PHASE1":38985,"PHASE1":38987,"PHASE2":38993,"PHASE3":38995,"PHASE4":38997,"NA":38999},{"trials":38986,"activeCount":101},[],{"trials":38988,"activeCount":101},[38989],{"nctId":27702,"briefTitle":27703,"status":107,"phases":38990,"primaryCompletion":27705,"completion":2822,"start":27706,"enrollment":912,"conditions":38991,"interventions":38992},[90],[2057],[27709,27709,3578],{"trials":38994,"activeCount":101},[],{"trials":38996,"activeCount":101},[],{"trials":38998,"activeCount":101},[],{"trials":39000,"activeCount":101},[],{"intervention":39002,"totalTrials":272,"cells":39003},"BI 1005273 s.c.",{"EARLY_PHASE1":39004,"PHASE1":39006,"PHASE2":39017,"PHASE3":39019,"PHASE4":39021,"NA":39023},{"trials":39005,"activeCount":101},[],{"trials":39007,"activeCount":101},[39008],{"nctId":39009,"briefTitle":39010,"status":107,"phases":39011,"primaryCompletion":420,"completion":420,"start":9491,"enrollment":3791,"conditions":39012,"interventions":39013},"NCT01650155","Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.",[90],[15],[39002,39014,39015,39016],"BI 105273 i.v. Placebo","BI 1005273 s.c. Placebo","BI 1005273 i.v.",{"trials":39018,"activeCount":101},[],{"trials":39020,"activeCount":101},[],{"trials":39022,"activeCount":101},[],{"trials":39024,"activeCount":101},[],{"intervention":39014,"totalTrials":272,"cells":39026},{"EARLY_PHASE1":39027,"PHASE1":39029,"PHASE2":39035,"PHASE3":39037,"PHASE4":39039,"NA":39041},{"trials":39028,"activeCount":101},[],{"trials":39030,"activeCount":101},[39031],{"nctId":39009,"briefTitle":39010,"status":107,"phases":39032,"primaryCompletion":420,"completion":420,"start":9491,"enrollment":3791,"conditions":39033,"interventions":39034},[90],[15],[39002,39014,39015,39016],{"trials":39036,"activeCount":101},[],{"trials":39038,"activeCount":101},[],{"trials":39040,"activeCount":101},[],{"trials":39042,"activeCount":101},[],{"intervention":39015,"totalTrials":272,"cells":39044},{"EARLY_PHASE1":39045,"PHASE1":39047,"PHASE2":39053,"PHASE3":39055,"PHASE4":39057,"NA":39059},{"trials":39046,"activeCount":101},[],{"trials":39048,"activeCount":101},[39049],{"nctId":39009,"briefTitle":39010,"status":107,"phases":39050,"primaryCompletion":420,"completion":420,"start":9491,"enrollment":3791,"conditions":39051,"interventions":39052},[90],[15],[39002,39014,39015,39016],{"trials":39054,"activeCount":101},[],{"trials":39056,"activeCount":101},[],{"trials":39058,"activeCount":101},[],{"trials":39060,"activeCount":101},[],{"intervention":39016,"totalTrials":272,"cells":39062},{"EARLY_PHASE1":39063,"PHASE1":39065,"PHASE2":39071,"PHASE3":39073,"PHASE4":39075,"NA":39077},{"trials":39064,"activeCount":101},[],{"trials":39066,"activeCount":101},[39067],{"nctId":39009,"briefTitle":39010,"status":107,"phases":39068,"primaryCompletion":420,"completion":420,"start":9491,"enrollment":3791,"conditions":39069,"interventions":39070},[90],[15],[39002,39014,39015,39016],{"trials":39072,"activeCount":101},[],{"trials":39074,"activeCount":101},[],{"trials":39076,"activeCount":101},[],{"trials":39078,"activeCount":101},[],{"intervention":39080,"totalTrials":272,"cells":39081},"Meloxicam - low dose",{"EARLY_PHASE1":39082,"PHASE1":39084,"PHASE2":39094,"PHASE3":39096,"PHASE4":39098,"NA":39100},{"trials":39083,"activeCount":101},[],{"trials":39085,"activeCount":101},[39086],{"nctId":39087,"briefTitle":39088,"status":107,"phases":39089,"primaryCompletion":7132,"start":2121,"enrollment":380,"conditions":39090,"interventions":39091},"NCT02181322","Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range",[90],[15],[39080,39092,39093],"Meloxicam - medium dose","Meloxicam - high dose",{"trials":39095,"activeCount":101},[],{"trials":39097,"activeCount":101},[],{"trials":39099,"activeCount":101},[],{"trials":39101,"activeCount":101},[],{"intervention":39092,"totalTrials":272,"cells":39103},{"EARLY_PHASE1":39104,"PHASE1":39106,"PHASE2":39112,"PHASE3":39114,"PHASE4":39116,"NA":39118},{"trials":39105,"activeCount":101},[],{"trials":39107,"activeCount":101},[39108],{"nctId":39087,"briefTitle":39088,"status":107,"phases":39109,"primaryCompletion":7132,"start":2121,"enrollment":380,"conditions":39110,"interventions":39111},[90],[15],[39080,39092,39093],{"trials":39113,"activeCount":101},[],{"trials":39115,"activeCount":101},[],{"trials":39117,"activeCount":101},[],{"trials":39119,"activeCount":101},[],{"intervention":39093,"totalTrials":272,"cells":39121},{"EARLY_PHASE1":39122,"PHASE1":39124,"PHASE2":39130,"PHASE3":39132,"PHASE4":39134,"NA":39136},{"trials":39123,"activeCount":101},[],{"trials":39125,"activeCount":101},[39126],{"nctId":39087,"briefTitle":39088,"status":107,"phases":39127,"primaryCompletion":7132,"start":2121,"enrollment":380,"conditions":39128,"interventions":39129},[90],[15],[39080,39092,39093],{"trials":39131,"activeCount":101},[],{"trials":39133,"activeCount":101},[],{"trials":39135,"activeCount":101},[],{"trials":39137,"activeCount":101},[],{"intervention":18943,"totalTrials":272,"cells":39139},{"EARLY_PHASE1":39140,"PHASE1":39142,"PHASE2":39148,"PHASE3":39150,"PHASE4":39152,"NA":39154},{"trials":39141,"activeCount":101},[],{"trials":39143,"activeCount":101},[39144],{"nctId":18937,"briefTitle":18938,"status":107,"phases":39145,"primaryCompletion":18940,"completion":18940,"start":4351,"enrollment":956,"conditions":39146,"interventions":39147},[90],[15],[18943,4176],{"trials":39149,"activeCount":101},[],{"trials":39151,"activeCount":101},[],{"trials":39153,"activeCount":101},[],{"trials":39155,"activeCount":101},[],{"intervention":18844,"totalTrials":272,"cells":39157},{"EARLY_PHASE1":39158,"PHASE1":39160,"PHASE2":39166,"PHASE3":39168,"PHASE4":39170,"NA":39172},{"trials":39159,"activeCount":101},[],{"trials":39161,"activeCount":101},[39162],{"nctId":18837,"briefTitle":18838,"status":107,"phases":39163,"primaryCompletion":18840,"completion":18840,"start":18841,"enrollment":1126,"conditions":39164,"interventions":39165},[90],[15],[18844,4095],{"trials":39167,"activeCount":101},[],{"trials":39169,"activeCount":101},[],{"trials":39171,"activeCount":101},[],{"trials":39173,"activeCount":101},[],{"intervention":39175,"totalTrials":272,"cells":39176},"EE\u002FNET",{"EARLY_PHASE1":39177,"PHASE1":39179,"PHASE2":39187,"PHASE3":39189,"PHASE4":39191,"NA":39193},{"trials":39178,"activeCount":101},[],{"trials":39180,"activeCount":101},[39181],{"nctId":39182,"briefTitle":39183,"status":107,"phases":39184,"primaryCompletion":2182,"start":6065,"enrollment":177,"conditions":39185,"interventions":39186},"NCT02182791","Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol\u002FNorethindrone in HIV-1 Infected Women",[90],[27],[2186,39175],{"trials":39188,"activeCount":101},[],{"trials":39190,"activeCount":101},[],{"trials":39192,"activeCount":101},[],{"trials":39194,"activeCount":101},[],{"intervention":39196,"totalTrials":272,"cells":39197},"Formulation B: Pramipexole Slow release (SR)",{"EARLY_PHASE1":39198,"PHASE1":39200,"PHASE2":39215,"PHASE3":39217,"PHASE4":39219,"NA":39221},{"trials":39199,"activeCount":101},[],{"trials":39201,"activeCount":101},[39202],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39205,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39206,"interventions":39207},"NCT02261090","Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers",[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],"Formulation C: Pramipexole Slow release","Formulation D: Pramipexole Slow release","Formulation E: Pramipexole Slow release","Formulation F: Pramipexole Slow release","Formulation G: Pramipexole Slow release","Formulation H: Pramipexole Slow release","Pramipexole immediate release (IR)",{"trials":39216,"activeCount":101},[],{"trials":39218,"activeCount":101},[],{"trials":39220,"activeCount":101},[],{"trials":39222,"activeCount":101},[],{"intervention":39208,"totalTrials":272,"cells":39224},{"EARLY_PHASE1":39225,"PHASE1":39227,"PHASE2":39233,"PHASE3":39235,"PHASE4":39237,"NA":39239},{"trials":39226,"activeCount":101},[],{"trials":39228,"activeCount":101},[39229],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39230,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39231,"interventions":39232},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"trials":39234,"activeCount":101},[],{"trials":39236,"activeCount":101},[],{"trials":39238,"activeCount":101},[],{"trials":39240,"activeCount":101},[],{"intervention":39209,"totalTrials":272,"cells":39242},{"EARLY_PHASE1":39243,"PHASE1":39245,"PHASE2":39251,"PHASE3":39253,"PHASE4":39255,"NA":39257},{"trials":39244,"activeCount":101},[],{"trials":39246,"activeCount":101},[39247],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39248,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39249,"interventions":39250},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"trials":39252,"activeCount":101},[],{"trials":39254,"activeCount":101},[],{"trials":39256,"activeCount":101},[],{"trials":39258,"activeCount":101},[],{"intervention":39210,"totalTrials":272,"cells":39260},{"EARLY_PHASE1":39261,"PHASE1":39263,"PHASE2":39269,"PHASE3":39271,"PHASE4":39273,"NA":39275},{"trials":39262,"activeCount":101},[],{"trials":39264,"activeCount":101},[39265],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39266,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39267,"interventions":39268},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"trials":39270,"activeCount":101},[],{"trials":39272,"activeCount":101},[],{"trials":39274,"activeCount":101},[],{"trials":39276,"activeCount":101},[],{"intervention":39211,"totalTrials":272,"cells":39278},{"EARLY_PHASE1":39279,"PHASE1":39281,"PHASE2":39287,"PHASE3":39289,"PHASE4":39291,"NA":39293},{"trials":39280,"activeCount":101},[],{"trials":39282,"activeCount":101},[39283],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39284,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39285,"interventions":39286},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"trials":39288,"activeCount":101},[],{"trials":39290,"activeCount":101},[],{"trials":39292,"activeCount":101},[],{"trials":39294,"activeCount":101},[],{"intervention":39212,"totalTrials":272,"cells":39296},{"EARLY_PHASE1":39297,"PHASE1":39299,"PHASE2":39305,"PHASE3":39307,"PHASE4":39309,"NA":39311},{"trials":39298,"activeCount":101},[],{"trials":39300,"activeCount":101},[39301],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39302,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39303,"interventions":39304},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"trials":39306,"activeCount":101},[],{"trials":39308,"activeCount":101},[],{"trials":39310,"activeCount":101},[],{"trials":39312,"activeCount":101},[],{"intervention":39213,"totalTrials":272,"cells":39314},{"EARLY_PHASE1":39315,"PHASE1":39317,"PHASE2":39323,"PHASE3":39325,"PHASE4":39327,"NA":39329},{"trials":39316,"activeCount":101},[],{"trials":39318,"activeCount":101},[39319],{"nctId":39203,"briefTitle":39204,"status":107,"phases":39320,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":39321,"interventions":39322},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"trials":39324,"activeCount":101},[],{"trials":39326,"activeCount":101},[],{"trials":39328,"activeCount":101},[],{"trials":39330,"activeCount":101},[],{"intervention":9399,"totalTrials":272,"cells":39332},{"EARLY_PHASE1":39333,"PHASE1":39335,"PHASE2":39341,"PHASE3":39343,"PHASE4":39345,"NA":39347},{"trials":39334,"activeCount":101},[],{"trials":39336,"activeCount":101},[39337],{"nctId":9393,"briefTitle":9394,"status":107,"phases":39338,"primaryCompletion":9396,"start":4441,"enrollment":380,"conditions":39339,"interventions":39340},[90],[15],[9399,528],{"trials":39342,"activeCount":101},[],{"trials":39344,"activeCount":101},[],{"trials":39346,"activeCount":101},[],{"trials":39348,"activeCount":101},[],{"intervention":39350,"totalTrials":272,"cells":39351},"Dabigatran etexilate generation I",{"EARLY_PHASE1":39352,"PHASE1":39354,"PHASE2":39363,"PHASE3":39365,"PHASE4":39367,"NA":39369},{"trials":39353,"activeCount":101},[],{"trials":39355,"activeCount":101},[39356],{"nctId":39357,"briefTitle":39358,"status":107,"phases":39359,"primaryCompletion":6223,"start":5906,"enrollment":3565,"conditions":39360,"interventions":39361},"NCT02171520","Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers",[90],[15],[39350,39362],"Dabigatran etexilate generation II",{"trials":39364,"activeCount":101},[],{"trials":39366,"activeCount":101},[],{"trials":39368,"activeCount":101},[],{"trials":39370,"activeCount":101},[],{"intervention":39362,"totalTrials":272,"cells":39372},{"EARLY_PHASE1":39373,"PHASE1":39375,"PHASE2":39381,"PHASE3":39383,"PHASE4":39385,"NA":39387},{"trials":39374,"activeCount":101},[],{"trials":39376,"activeCount":101},[39377],{"nctId":39357,"briefTitle":39358,"status":107,"phases":39378,"primaryCompletion":6223,"start":5906,"enrollment":3565,"conditions":39379,"interventions":39380},[90],[15],[39350,39362],{"trials":39382,"activeCount":101},[],{"trials":39384,"activeCount":101},[],{"trials":39386,"activeCount":101},[],{"trials":39388,"activeCount":101},[],{"intervention":39390,"totalTrials":272,"cells":39391},"[14C]- BIBW 2992 MA2",{"EARLY_PHASE1":39392,"PHASE1":39394,"PHASE2":39402,"PHASE3":39404,"PHASE4":39406,"NA":39408},{"trials":39393,"activeCount":101},[],{"trials":39395,"activeCount":101},[39396],{"nctId":39397,"briefTitle":39398,"status":107,"phases":39399,"primaryCompletion":11588,"start":2145,"enrollment":155,"conditions":39400,"interventions":39401},"NCT02171689","Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male Volunteers",[90],[15],[39390],{"trials":39403,"activeCount":101},[],{"trials":39405,"activeCount":101},[],{"trials":39407,"activeCount":101},[],{"trials":39409,"activeCount":101},[],{"intervention":39411,"totalTrials":272,"cells":39412},"BI 425809 mixed with [C-14] BI425809",{"EARLY_PHASE1":39413,"PHASE1":39415,"PHASE2":39425,"PHASE3":39427,"PHASE4":39429,"NA":39431},{"trials":39414,"activeCount":101},[],{"trials":39416,"activeCount":101},[39417],{"nctId":39418,"briefTitle":39419,"status":107,"phases":39420,"primaryCompletion":39421,"completion":39421,"start":39422,"enrollment":1512,"conditions":39423,"interventions":39424},"NCT03654170","A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body",[90],"2018-11-12","2018-09-11",[15],[39411],{"trials":39426,"activeCount":101},[],{"trials":39428,"activeCount":101},[],{"trials":39430,"activeCount":101},[],{"trials":39432,"activeCount":101},[],{"intervention":6033,"totalTrials":272,"cells":39434},{"EARLY_PHASE1":39435,"PHASE1":39437,"PHASE2":39443,"PHASE3":39445,"PHASE4":39447,"NA":39449},{"trials":39436,"activeCount":101},[],{"trials":39438,"activeCount":101},[39439],{"nctId":6026,"briefTitle":6027,"status":107,"phases":39440,"primaryCompletion":6029,"start":6030,"enrollment":188,"conditions":39441,"interventions":39442},[90],[15],[6033,6034,5982,6035],{"trials":39444,"activeCount":101},[],{"trials":39446,"activeCount":101},[],{"trials":39448,"activeCount":101},[],{"trials":39450,"activeCount":101},[],{"intervention":6034,"totalTrials":272,"cells":39452},{"EARLY_PHASE1":39453,"PHASE1":39455,"PHASE2":39461,"PHASE3":39463,"PHASE4":39465,"NA":39467},{"trials":39454,"activeCount":101},[],{"trials":39456,"activeCount":101},[39457],{"nctId":6026,"briefTitle":6027,"status":107,"phases":39458,"primaryCompletion":6029,"start":6030,"enrollment":188,"conditions":39459,"interventions":39460},[90],[15],[6033,6034,5982,6035],{"trials":39462,"activeCount":101},[],{"trials":39464,"activeCount":101},[],{"trials":39466,"activeCount":101},[],{"trials":39468,"activeCount":101},[],{"intervention":39470,"totalTrials":272,"cells":39471},"BI 1060469, iFF, Test",{"EARLY_PHASE1":39472,"PHASE1":39474,"PHASE2":39484,"PHASE3":39486,"PHASE4":39488,"NA":39490},{"trials":39473,"activeCount":101},[],{"trials":39475,"activeCount":101},[39476],{"nctId":39477,"briefTitle":39478,"status":107,"phases":39479,"primaryCompletion":2002,"completion":2002,"start":4119,"enrollment":993,"conditions":39480,"interventions":39481},"NCT02438696","Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects",[90],[15],[39470,39470,39482,39483,39483,39470,39482,39470,39470,39482,39483,39482,39482,39483,39483,39470,39483,39482],"BI 1060469, TF1, Reference","BI 1060469, TF2, Test",{"trials":39485,"activeCount":101},[],{"trials":39487,"activeCount":101},[],{"trials":39489,"activeCount":101},[],{"trials":39491,"activeCount":101},[],{"intervention":39482,"totalTrials":272,"cells":39493},{"EARLY_PHASE1":39494,"PHASE1":39496,"PHASE2":39502,"PHASE3":39504,"PHASE4":39506,"NA":39508},{"trials":39495,"activeCount":101},[],{"trials":39497,"activeCount":101},[39498],{"nctId":39477,"briefTitle":39478,"status":107,"phases":39499,"primaryCompletion":2002,"completion":2002,"start":4119,"enrollment":993,"conditions":39500,"interventions":39501},[90],[15],[39470,39470,39482,39483,39483,39470,39482,39470,39470,39482,39483,39482,39482,39483,39483,39470,39483,39482],{"trials":39503,"activeCount":101},[],{"trials":39505,"activeCount":101},[],{"trials":39507,"activeCount":101},[],{"trials":39509,"activeCount":101},[],{"intervention":39483,"totalTrials":272,"cells":39511},{"EARLY_PHASE1":39512,"PHASE1":39514,"PHASE2":39520,"PHASE3":39522,"PHASE4":39524,"NA":39526},{"trials":39513,"activeCount":101},[],{"trials":39515,"activeCount":101},[39516],{"nctId":39477,"briefTitle":39478,"status":107,"phases":39517,"primaryCompletion":2002,"completion":2002,"start":4119,"enrollment":993,"conditions":39518,"interventions":39519},[90],[15],[39470,39470,39482,39483,39483,39470,39482,39470,39470,39482,39483,39482,39482,39483,39483,39470,39483,39482],{"trials":39521,"activeCount":101},[],{"trials":39523,"activeCount":101},[],{"trials":39525,"activeCount":101},[],{"trials":39527,"activeCount":101},[],{"intervention":39529,"totalTrials":272,"cells":39530},"EU-sourced Otezla®",{"EARLY_PHASE1":39531,"PHASE1":39533,"PHASE2":39544,"PHASE3":39546,"PHASE4":39548,"NA":39550},{"trials":39532,"activeCount":101},[],{"trials":39534,"activeCount":101},[39535],{"nctId":39536,"briefTitle":39537,"status":162,"phases":39538,"primaryCompletion":39539,"completion":39539,"start":18755,"enrollment":1672,"conditions":39540,"interventions":39541},"NCT04811573","A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food",[90],"2021-08-18",[15],[39529,39542,39543],"US-sourced Otezla®","Japan-sourced Otezla®",{"trials":39545,"activeCount":101},[],{"trials":39547,"activeCount":101},[],{"trials":39549,"activeCount":101},[],{"trials":39551,"activeCount":101},[],{"intervention":39542,"totalTrials":272,"cells":39553},{"EARLY_PHASE1":39554,"PHASE1":39556,"PHASE2":39562,"PHASE3":39564,"PHASE4":39566,"NA":39568},{"trials":39555,"activeCount":101},[],{"trials":39557,"activeCount":101},[39558],{"nctId":39536,"briefTitle":39537,"status":162,"phases":39559,"primaryCompletion":39539,"completion":39539,"start":18755,"enrollment":1672,"conditions":39560,"interventions":39561},[90],[15],[39529,39542,39543],{"trials":39563,"activeCount":101},[],{"trials":39565,"activeCount":101},[],{"trials":39567,"activeCount":101},[],{"trials":39569,"activeCount":101},[],{"intervention":39543,"totalTrials":272,"cells":39571},{"EARLY_PHASE1":39572,"PHASE1":39574,"PHASE2":39580,"PHASE3":39582,"PHASE4":39584,"NA":39586},{"trials":39573,"activeCount":101},[],{"trials":39575,"activeCount":101},[39576],{"nctId":39536,"briefTitle":39537,"status":162,"phases":39577,"primaryCompletion":39539,"completion":39539,"start":18755,"enrollment":1672,"conditions":39578,"interventions":39579},[90],[15],[39529,39542,39543],{"trials":39581,"activeCount":101},[],{"trials":39583,"activeCount":101},[],{"trials":39585,"activeCount":101},[],{"trials":39587,"activeCount":101},[],{"intervention":39589,"totalTrials":272,"cells":39590},"BI 653048 BS H3PO4",{"EARLY_PHASE1":39591,"PHASE1":39593,"PHASE2":39604,"PHASE3":39606,"PHASE4":39608,"NA":39610},{"trials":39592,"activeCount":101},[],{"trials":39594,"activeCount":101},[39595],{"nctId":39596,"briefTitle":39597,"status":107,"phases":39598,"primaryCompletion":3732,"start":9443,"enrollment":39599,"conditions":39600,"interventions":39601},"NCT02217631","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers",[90],140,[15],[39589,39602,39603],"Prednisolone low dose","Prednisolone high dose",{"trials":39605,"activeCount":101},[],{"trials":39607,"activeCount":101},[],{"trials":39609,"activeCount":101},[],{"trials":39611,"activeCount":101},[],{"intervention":39602,"totalTrials":272,"cells":39613},{"EARLY_PHASE1":39614,"PHASE1":39616,"PHASE2":39622,"PHASE3":39624,"PHASE4":39626,"NA":39628},{"trials":39615,"activeCount":101},[],{"trials":39617,"activeCount":101},[39618],{"nctId":39596,"briefTitle":39597,"status":107,"phases":39619,"primaryCompletion":3732,"start":9443,"enrollment":39599,"conditions":39620,"interventions":39621},[90],[15],[39589,39602,39603],{"trials":39623,"activeCount":101},[],{"trials":39625,"activeCount":101},[],{"trials":39627,"activeCount":101},[],{"trials":39629,"activeCount":101},[],{"intervention":39603,"totalTrials":272,"cells":39631},{"EARLY_PHASE1":39632,"PHASE1":39634,"PHASE2":39640,"PHASE3":39642,"PHASE4":39644,"NA":39646},{"trials":39633,"activeCount":101},[],{"trials":39635,"activeCount":101},[39636],{"nctId":39596,"briefTitle":39597,"status":107,"phases":39637,"primaryCompletion":3732,"start":9443,"enrollment":39599,"conditions":39638,"interventions":39639},[90],[15],[39589,39602,39603],{"trials":39641,"activeCount":101},[],{"trials":39643,"activeCount":101},[],{"trials":39645,"activeCount":101},[],{"trials":39647,"activeCount":101},[],{"intervention":19400,"totalTrials":272,"cells":39649},{"EARLY_PHASE1":39650,"PHASE1":39652,"PHASE2":39658,"PHASE3":39660,"PHASE4":39662,"NA":39664},{"trials":39651,"activeCount":101},[],{"trials":39653,"activeCount":101},[39654],{"nctId":19392,"briefTitle":19393,"status":107,"phases":39655,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":439,"conditions":39656,"interventions":39657},[90],[15],[19400,19360,19390],{"trials":39659,"activeCount":101},[],{"trials":39661,"activeCount":101},[],{"trials":39663,"activeCount":101},[],{"trials":39665,"activeCount":101},[],{"intervention":39667,"totalTrials":272,"cells":39668},"BI 765883",{"EARLY_PHASE1":39669,"PHASE1":39671,"PHASE2":39682,"PHASE3":39684,"PHASE4":39686,"NA":39688},{"trials":39670,"activeCount":101},[],{"trials":39672,"activeCount":101},[39673],{"nctId":39674,"briefTitle":39675,"status":162,"phases":39676,"primaryCompletion":28834,"completion":39677,"start":922,"enrollment":155,"conditions":39678,"interventions":39679},"NCT06528093","A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy",[90],"2025-06-19",[3553],[39667,39680,39681],"gemcitabine","nab-paclitaxel",{"trials":39683,"activeCount":101},[],{"trials":39685,"activeCount":101},[],{"trials":39687,"activeCount":101},[],{"trials":39689,"activeCount":101},[],{"intervention":39681,"totalTrials":272,"cells":39691},{"EARLY_PHASE1":39692,"PHASE1":39694,"PHASE2":39700,"PHASE3":39702,"PHASE4":39704,"NA":39706},{"trials":39693,"activeCount":101},[],{"trials":39695,"activeCount":101},[39696],{"nctId":39674,"briefTitle":39675,"status":162,"phases":39697,"primaryCompletion":28834,"completion":39677,"start":922,"enrollment":155,"conditions":39698,"interventions":39699},[90],[3553],[39667,39680,39681],{"trials":39701,"activeCount":101},[],{"trials":39703,"activeCount":101},[],{"trials":39705,"activeCount":101},[],{"trials":39707,"activeCount":101},[],{"intervention":30314,"totalTrials":272,"cells":39709},{"EARLY_PHASE1":39710,"PHASE1":39712,"PHASE2":39718,"PHASE3":39720,"PHASE4":39722,"NA":39724},{"trials":39711,"activeCount":101},[],{"trials":39713,"activeCount":101},[39714],{"nctId":30309,"briefTitle":30310,"status":600,"phases":39715,"primaryCompletion":419,"completion":419,"start":10024,"enrollment":101,"conditions":39716,"interventions":39717},[90],[15],[30314,19212,30315],{"trials":39719,"activeCount":101},[],{"trials":39721,"activeCount":101},[],{"trials":39723,"activeCount":101},[],{"trials":39725,"activeCount":101},[],{"intervention":30315,"totalTrials":272,"cells":39727},{"EARLY_PHASE1":39728,"PHASE1":39730,"PHASE2":39736,"PHASE3":39738,"PHASE4":39740,"NA":39742},{"trials":39729,"activeCount":101},[],{"trials":39731,"activeCount":101},[39732],{"nctId":30309,"briefTitle":30310,"status":600,"phases":39733,"primaryCompletion":419,"completion":419,"start":10024,"enrollment":101,"conditions":39734,"interventions":39735},[90],[15],[30314,19212,30315],{"trials":39737,"activeCount":101},[],{"trials":39739,"activeCount":101},[],{"trials":39741,"activeCount":101},[],{"trials":39743,"activeCount":101},[],{"intervention":39745,"totalTrials":272,"cells":39746},"Merck Glucophage® high dose",{"EARLY_PHASE1":39747,"PHASE1":39749,"PHASE2":39760,"PHASE3":39762,"PHASE4":39764,"NA":39766},{"trials":39748,"activeCount":101},[],{"trials":39750,"activeCount":101},[39751],{"nctId":39752,"briefTitle":39753,"status":107,"phases":39754,"primaryCompletion":9404,"start":1989,"enrollment":37,"conditions":39755,"interventions":39756},"NCT02183571","Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects",[90],[15],[39745,39757,39758,39759],"BMS Glucophage® high dose","Merck Glucophage® low dose","BMS Glucophage® low dose",{"trials":39761,"activeCount":101},[],{"trials":39763,"activeCount":101},[],{"trials":39765,"activeCount":101},[],{"trials":39767,"activeCount":101},[],{"intervention":39757,"totalTrials":272,"cells":39769},{"EARLY_PHASE1":39770,"PHASE1":39772,"PHASE2":39778,"PHASE3":39780,"PHASE4":39782,"NA":39784},{"trials":39771,"activeCount":101},[],{"trials":39773,"activeCount":101},[39774],{"nctId":39752,"briefTitle":39753,"status":107,"phases":39775,"primaryCompletion":9404,"start":1989,"enrollment":37,"conditions":39776,"interventions":39777},[90],[15],[39745,39757,39758,39759],{"trials":39779,"activeCount":101},[],{"trials":39781,"activeCount":101},[],{"trials":39783,"activeCount":101},[],{"trials":39785,"activeCount":101},[],{"intervention":39758,"totalTrials":272,"cells":39787},{"EARLY_PHASE1":39788,"PHASE1":39790,"PHASE2":39796,"PHASE3":39798,"PHASE4":39800,"NA":39802},{"trials":39789,"activeCount":101},[],{"trials":39791,"activeCount":101},[39792],{"nctId":39752,"briefTitle":39753,"status":107,"phases":39793,"primaryCompletion":9404,"start":1989,"enrollment":37,"conditions":39794,"interventions":39795},[90],[15],[39745,39757,39758,39759],{"trials":39797,"activeCount":101},[],{"trials":39799,"activeCount":101},[],{"trials":39801,"activeCount":101},[],{"trials":39803,"activeCount":101},[],{"intervention":39759,"totalTrials":272,"cells":39805},{"EARLY_PHASE1":39806,"PHASE1":39808,"PHASE2":39814,"PHASE3":39816,"PHASE4":39818,"NA":39820},{"trials":39807,"activeCount":101},[],{"trials":39809,"activeCount":101},[39810],{"nctId":39752,"briefTitle":39753,"status":107,"phases":39811,"primaryCompletion":9404,"start":1989,"enrollment":37,"conditions":39812,"interventions":39813},[90],[15],[39745,39757,39758,39759],{"trials":39815,"activeCount":101},[],{"trials":39817,"activeCount":101},[],{"trials":39819,"activeCount":101},[],{"trials":39821,"activeCount":101},[],{"intervention":39823,"totalTrials":272,"cells":39824},"BILR 355 BS, solution",{"EARLY_PHASE1":39825,"PHASE1":39827,"PHASE2":39836,"PHASE3":39838,"PHASE4":39840,"NA":39842},{"trials":39826,"activeCount":101},[],{"trials":39828,"activeCount":101},[39829],{"nctId":39830,"briefTitle":39831,"status":107,"phases":39832,"primaryCompletion":6413,"start":11733,"enrollment":1218,"conditions":39833,"interventions":39834},"NCT02253914","Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers",[90],[15],[39823,39835,4010],"BILR 355 BS,",{"trials":39837,"activeCount":101},[],{"trials":39839,"activeCount":101},[],{"trials":39841,"activeCount":101},[],{"trials":39843,"activeCount":101},[],{"intervention":39835,"totalTrials":272,"cells":39845},{"EARLY_PHASE1":39846,"PHASE1":39848,"PHASE2":39854,"PHASE3":39856,"PHASE4":39858,"NA":39860},{"trials":39847,"activeCount":101},[],{"trials":39849,"activeCount":101},[39850],{"nctId":39830,"briefTitle":39831,"status":107,"phases":39851,"primaryCompletion":6413,"start":11733,"enrollment":1218,"conditions":39852,"interventions":39853},[90],[15],[39823,39835,4010],{"trials":39855,"activeCount":101},[],{"trials":39857,"activeCount":101},[],{"trials":39859,"activeCount":101},[],{"trials":39861,"activeCount":101},[],{"intervention":39863,"totalTrials":272,"cells":39864},"Reference",{"EARLY_PHASE1":39865,"PHASE1":39867,"PHASE2":39878,"PHASE3":39880,"PHASE4":39882,"NA":39884},{"trials":39866,"activeCount":101},[],{"trials":39868,"activeCount":101},[39869],{"nctId":39870,"briefTitle":39871,"status":107,"phases":39872,"primaryCompletion":18912,"completion":18912,"start":39873,"enrollment":380,"conditions":39874,"interventions":39875},"NCT05428436","A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food",[90],"2022-08-15",[15],[39863,39876,39877],"Test treatment 1","Test treatment 2",{"trials":39879,"activeCount":101},[],{"trials":39881,"activeCount":101},[],{"trials":39883,"activeCount":101},[],{"trials":39885,"activeCount":101},[],{"intervention":39876,"totalTrials":272,"cells":39887},{"EARLY_PHASE1":39888,"PHASE1":39890,"PHASE2":39896,"PHASE3":39898,"PHASE4":39900,"NA":39902},{"trials":39889,"activeCount":101},[],{"trials":39891,"activeCount":101},[39892],{"nctId":39870,"briefTitle":39871,"status":107,"phases":39893,"primaryCompletion":18912,"completion":18912,"start":39873,"enrollment":380,"conditions":39894,"interventions":39895},[90],[15],[39863,39876,39877],{"trials":39897,"activeCount":101},[],{"trials":39899,"activeCount":101},[],{"trials":39901,"activeCount":101},[],{"trials":39903,"activeCount":101},[],{"intervention":39877,"totalTrials":272,"cells":39905},{"EARLY_PHASE1":39906,"PHASE1":39908,"PHASE2":39914,"PHASE3":39916,"PHASE4":39918,"NA":39920},{"trials":39907,"activeCount":101},[],{"trials":39909,"activeCount":101},[39910],{"nctId":39870,"briefTitle":39871,"status":107,"phases":39911,"primaryCompletion":18912,"completion":18912,"start":39873,"enrollment":380,"conditions":39912,"interventions":39913},[90],[15],[39863,39876,39877],{"trials":39915,"activeCount":101},[],{"trials":39917,"activeCount":101},[],{"trials":39919,"activeCount":101},[],{"trials":39921,"activeCount":101},[],{"intervention":27924,"totalTrials":272,"cells":39923},{"EARLY_PHASE1":39924,"PHASE1":39926,"PHASE2":39932,"PHASE3":39934,"PHASE4":39936,"NA":39938},{"trials":39925,"activeCount":101},[],{"trials":39927,"activeCount":101},[39928],{"nctId":27919,"briefTitle":27920,"status":107,"phases":39929,"primaryCompletion":9381,"start":3990,"enrollment":291,"conditions":39930,"interventions":39931},[90],[15],[27924,27925,361,27926],{"trials":39933,"activeCount":101},[],{"trials":39935,"activeCount":101},[],{"trials":39937,"activeCount":101},[],{"trials":39939,"activeCount":101},[],{"intervention":27925,"totalTrials":272,"cells":39941},{"EARLY_PHASE1":39942,"PHASE1":39944,"PHASE2":39950,"PHASE3":39952,"PHASE4":39954,"NA":39956},{"trials":39943,"activeCount":101},[],{"trials":39945,"activeCount":101},[39946],{"nctId":27919,"briefTitle":27920,"status":107,"phases":39947,"primaryCompletion":9381,"start":3990,"enrollment":291,"conditions":39948,"interventions":39949},[90],[15],[27924,27925,361,27926],{"trials":39951,"activeCount":101},[],{"trials":39953,"activeCount":101},[],{"trials":39955,"activeCount":101},[],{"trials":39957,"activeCount":101},[],{"intervention":28772,"totalTrials":272,"cells":39959},{"EARLY_PHASE1":39960,"PHASE1":39962,"PHASE2":39968,"PHASE3":39970,"PHASE4":39972,"NA":39974},{"trials":39961,"activeCount":101},[],{"trials":39963,"activeCount":101},[39964],{"nctId":28766,"briefTitle":28767,"status":107,"phases":39965,"primaryCompletion":745,"completion":745,"start":28769,"enrollment":10951,"conditions":39966,"interventions":39967},[90],[15],[3794,28772,28773],{"trials":39969,"activeCount":101},[],{"trials":39971,"activeCount":101},[],{"trials":39973,"activeCount":101},[],{"trials":39975,"activeCount":101},[],{"intervention":28773,"totalTrials":272,"cells":39977},{"EARLY_PHASE1":39978,"PHASE1":39980,"PHASE2":39986,"PHASE3":39988,"PHASE4":39990,"NA":39992},{"trials":39979,"activeCount":101},[],{"trials":39981,"activeCount":101},[39982],{"nctId":28766,"briefTitle":28767,"status":107,"phases":39983,"primaryCompletion":745,"completion":745,"start":28769,"enrollment":10951,"conditions":39984,"interventions":39985},[90],[15],[3794,28772,28773],{"trials":39987,"activeCount":101},[],{"trials":39989,"activeCount":101},[],{"trials":39991,"activeCount":101},[],{"trials":39993,"activeCount":101},[],{"intervention":39995,"totalTrials":272,"cells":39996},"BI 207127 + faldaprevir",{"EARLY_PHASE1":39997,"PHASE1":39999,"PHASE2":40007,"PHASE3":40009,"PHASE4":40011,"NA":40013},{"trials":39998,"activeCount":101},[],{"trials":40000,"activeCount":101},[40001],{"nctId":40002,"briefTitle":40003,"status":107,"phases":40004,"primaryCompletion":409,"completion":409,"start":446,"enrollment":132,"conditions":40005,"interventions":40006},"NCT01737996","Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects",[90],[15],[39995],{"trials":40008,"activeCount":101},[],{"trials":40010,"activeCount":101},[],{"trials":40012,"activeCount":101},[],{"trials":40014,"activeCount":101},[],{"intervention":40016,"totalTrials":272,"cells":40017},"Tamsulosin hydrochloride, very low dose",{"EARLY_PHASE1":40018,"PHASE1":40020,"PHASE2":40032,"PHASE3":40034,"PHASE4":40036,"NA":40038},{"trials":40019,"activeCount":101},[],{"trials":40021,"activeCount":101},[40022],{"nctId":40023,"briefTitle":40024,"status":107,"phases":40025,"primaryCompletion":11581,"start":6782,"enrollment":410,"conditions":40026,"interventions":40028},"NCT02266524","Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders",[90],[40027],"Urination Disorders",[40016,40029,40030,40031],"Tamsulosin hydrochloride, low dose","Tamsulosin hydrochloride, medium dose","Tamsulosin hydrochloride, high dose",{"trials":40033,"activeCount":101},[],{"trials":40035,"activeCount":101},[],{"trials":40037,"activeCount":101},[],{"trials":40039,"activeCount":101},[],{"intervention":40029,"totalTrials":272,"cells":40041},{"EARLY_PHASE1":40042,"PHASE1":40044,"PHASE2":40050,"PHASE3":40052,"PHASE4":40054,"NA":40056},{"trials":40043,"activeCount":101},[],{"trials":40045,"activeCount":101},[40046],{"nctId":40023,"briefTitle":40024,"status":107,"phases":40047,"primaryCompletion":11581,"start":6782,"enrollment":410,"conditions":40048,"interventions":40049},[90],[40027],[40016,40029,40030,40031],{"trials":40051,"activeCount":101},[],{"trials":40053,"activeCount":101},[],{"trials":40055,"activeCount":101},[],{"trials":40057,"activeCount":101},[],{"intervention":40030,"totalTrials":272,"cells":40059},{"EARLY_PHASE1":40060,"PHASE1":40062,"PHASE2":40068,"PHASE3":40070,"PHASE4":40072,"NA":40074},{"trials":40061,"activeCount":101},[],{"trials":40063,"activeCount":101},[40064],{"nctId":40023,"briefTitle":40024,"status":107,"phases":40065,"primaryCompletion":11581,"start":6782,"enrollment":410,"conditions":40066,"interventions":40067},[90],[40027],[40016,40029,40030,40031],{"trials":40069,"activeCount":101},[],{"trials":40071,"activeCount":101},[],{"trials":40073,"activeCount":101},[],{"trials":40075,"activeCount":101},[],{"intervention":40031,"totalTrials":272,"cells":40077},{"EARLY_PHASE1":40078,"PHASE1":40080,"PHASE2":40086,"PHASE3":40088,"PHASE4":40090,"NA":40092},{"trials":40079,"activeCount":101},[],{"trials":40081,"activeCount":101},[40082],{"nctId":40023,"briefTitle":40024,"status":107,"phases":40083,"primaryCompletion":11581,"start":6782,"enrollment":410,"conditions":40084,"interventions":40085},[90],[40027],[40016,40029,40030,40031],{"trials":40087,"activeCount":101},[],{"trials":40089,"activeCount":101},[],{"trials":40091,"activeCount":101},[],{"trials":40093,"activeCount":101},[],{"intervention":40095,"totalTrials":272,"cells":40096},"BI 10773 - single rising dose",{"EARLY_PHASE1":40097,"PHASE1":40099,"PHASE2":40107,"PHASE3":40109,"PHASE4":40111,"NA":40113},{"trials":40098,"activeCount":101},[],{"trials":40100,"activeCount":101},[40101],{"nctId":40102,"briefTitle":40103,"status":107,"phases":40104,"primaryCompletion":6223,"start":4413,"enrollment":410,"conditions":40105,"interventions":40106},"NCT02182453","Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers",[90],[15],[40095],{"trials":40108,"activeCount":101},[],{"trials":40110,"activeCount":101},[],{"trials":40112,"activeCount":101},[],{"trials":40114,"activeCount":101},[],{"intervention":19846,"totalTrials":272,"cells":40116},{"EARLY_PHASE1":40117,"PHASE1":40119,"PHASE2":40125,"PHASE3":40127,"PHASE4":40129,"NA":40131},{"trials":40118,"activeCount":101},[],{"trials":40120,"activeCount":101},[40121],{"nctId":19838,"briefTitle":19839,"status":107,"phases":40122,"primaryCompletion":19841,"completion":19842,"start":19843,"enrollment":331,"conditions":40123,"interventions":40124},[90],[33],[19846,3845,19847,19848,19849],{"trials":40126,"activeCount":101},[],{"trials":40128,"activeCount":101},[],{"trials":40130,"activeCount":101},[],{"trials":40132,"activeCount":101},[],{"intervention":19847,"totalTrials":272,"cells":40134},{"EARLY_PHASE1":40135,"PHASE1":40137,"PHASE2":40143,"PHASE3":40145,"PHASE4":40147,"NA":40149},{"trials":40136,"activeCount":101},[],{"trials":40138,"activeCount":101},[40139],{"nctId":19838,"briefTitle":19839,"status":107,"phases":40140,"primaryCompletion":19841,"completion":19842,"start":19843,"enrollment":331,"conditions":40141,"interventions":40142},[90],[33],[19846,3845,19847,19848,19849],{"trials":40144,"activeCount":101},[],{"trials":40146,"activeCount":101},[],{"trials":40148,"activeCount":101},[],{"trials":40150,"activeCount":101},[],{"intervention":19848,"totalTrials":272,"cells":40152},{"EARLY_PHASE1":40153,"PHASE1":40155,"PHASE2":40161,"PHASE3":40163,"PHASE4":40165,"NA":40167},{"trials":40154,"activeCount":101},[],{"trials":40156,"activeCount":101},[40157],{"nctId":19838,"briefTitle":19839,"status":107,"phases":40158,"primaryCompletion":19841,"completion":19842,"start":19843,"enrollment":331,"conditions":40159,"interventions":40160},[90],[33],[19846,3845,19847,19848,19849],{"trials":40162,"activeCount":101},[],{"trials":40164,"activeCount":101},[],{"trials":40166,"activeCount":101},[],{"trials":40168,"activeCount":101},[],{"intervention":19849,"totalTrials":272,"cells":40170},{"EARLY_PHASE1":40171,"PHASE1":40173,"PHASE2":40179,"PHASE3":40181,"PHASE4":40183,"NA":40185},{"trials":40172,"activeCount":101},[],{"trials":40174,"activeCount":101},[40175],{"nctId":19838,"briefTitle":19839,"status":107,"phases":40176,"primaryCompletion":19841,"completion":19842,"start":19843,"enrollment":331,"conditions":40177,"interventions":40178},[90],[33],[19846,3845,19847,19848,19849],{"trials":40180,"activeCount":101},[],{"trials":40182,"activeCount":101},[],{"trials":40184,"activeCount":101},[],{"trials":40186,"activeCount":101},[],{"intervention":40188,"totalTrials":272,"cells":40189},"BI 1815368 formulation 1",{"EARLY_PHASE1":40190,"PHASE1":40192,"PHASE2":40202,"PHASE3":40204,"PHASE4":40206,"NA":40208},{"trials":40191,"activeCount":101},[],{"trials":40193,"activeCount":101},[40194],{"nctId":40195,"briefTitle":40196,"status":107,"phases":40197,"primaryCompletion":20261,"completion":20261,"start":40198,"enrollment":716,"conditions":40199,"interventions":40200},"NCT05337592","A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food",[90],"2022-06-14",[15],[40188,40201],"BI 1815368 formulation 2",{"trials":40203,"activeCount":101},[],{"trials":40205,"activeCount":101},[],{"trials":40207,"activeCount":101},[],{"trials":40209,"activeCount":101},[],{"intervention":40201,"totalTrials":272,"cells":40211},{"EARLY_PHASE1":40212,"PHASE1":40214,"PHASE2":40220,"PHASE3":40222,"PHASE4":40224,"NA":40226},{"trials":40213,"activeCount":101},[],{"trials":40215,"activeCount":101},[40216],{"nctId":40195,"briefTitle":40196,"status":107,"phases":40217,"primaryCompletion":20261,"completion":20261,"start":40198,"enrollment":716,"conditions":40218,"interventions":40219},[90],[15],[40188,40201],{"trials":40221,"activeCount":101},[],{"trials":40223,"activeCount":101},[],{"trials":40225,"activeCount":101},[],{"trials":40227,"activeCount":101},[],{"intervention":13250,"totalTrials":272,"cells":40229},{"EARLY_PHASE1":40230,"PHASE1":40232,"PHASE2":40238,"PHASE3":40240,"PHASE4":40242,"NA":40244},{"trials":40231,"activeCount":101},[],{"trials":40233,"activeCount":101},[40234],{"nctId":13245,"briefTitle":13246,"status":107,"phases":40235,"primaryCompletion":3731,"completion":420,"start":9842,"enrollment":716,"conditions":40236,"interventions":40237},[90],[15],[13238,13250,13251],{"trials":40239,"activeCount":101},[],{"trials":40241,"activeCount":101},[],{"trials":40243,"activeCount":101},[],{"trials":40245,"activeCount":101},[],{"intervention":40247,"totalTrials":272,"cells":40248},"Spesolimap",{"EARLY_PHASE1":40249,"PHASE1":40251,"PHASE2":40260,"PHASE3":40262,"PHASE4":40264,"NA":40266},{"trials":40250,"activeCount":101},[],{"trials":40252,"activeCount":101},[40253],{"nctId":40254,"briefTitle":40255,"status":107,"phases":40256,"primaryCompletion":18774,"completion":40257,"start":714,"enrollment":2235,"conditions":40258,"interventions":40259},"NCT04390568","A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body",[90],"2021-06-04",[15],[40247],{"trials":40261,"activeCount":101},[],{"trials":40263,"activeCount":101},[],{"trials":40265,"activeCount":101},[],{"trials":40267,"activeCount":101},[],{"intervention":40269,"totalTrials":272,"cells":40270},"SD I",{"EARLY_PHASE1":40271,"PHASE1":40273,"PHASE2":40282,"PHASE3":40284,"PHASE4":40286,"NA":40288},{"trials":40272,"activeCount":101},[],{"trials":40274,"activeCount":101},[40275],{"nctId":40276,"briefTitle":40277,"status":107,"phases":40278,"primaryCompletion":11733,"start":21078,"enrollment":8304,"conditions":40279,"interventions":40280},"NCT02199860","Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers",[90],[15],[40269,40281],"SD II",{"trials":40283,"activeCount":101},[],{"trials":40285,"activeCount":101},[],{"trials":40287,"activeCount":101},[],{"trials":40289,"activeCount":101},[],{"intervention":40281,"totalTrials":272,"cells":40291},{"EARLY_PHASE1":40292,"PHASE1":40294,"PHASE2":40300,"PHASE3":40302,"PHASE4":40304,"NA":40306},{"trials":40293,"activeCount":101},[],{"trials":40295,"activeCount":101},[40296],{"nctId":40276,"briefTitle":40277,"status":107,"phases":40297,"primaryCompletion":11733,"start":21078,"enrollment":8304,"conditions":40298,"interventions":40299},[90],[15],[40269,40281],{"trials":40301,"activeCount":101},[],{"trials":40303,"activeCount":101},[],{"trials":40305,"activeCount":101},[],{"trials":40307,"activeCount":101},[],{"intervention":20639,"totalTrials":272,"cells":40309},{"EARLY_PHASE1":40310,"PHASE1":40312,"PHASE2":40318,"PHASE3":40320,"PHASE4":40322,"NA":40324},{"trials":40311,"activeCount":101},[],{"trials":40313,"activeCount":101},[40314],{"nctId":20634,"briefTitle":20635,"status":107,"phases":40315,"primaryCompletion":9538,"start":390,"enrollment":6702,"conditions":40316,"interventions":40317},[90],[15],[20639,20621],{"trials":40319,"activeCount":101},[],{"trials":40321,"activeCount":101},[],{"trials":40323,"activeCount":101},[],{"trials":40325,"activeCount":101},[],{"intervention":40327,"totalTrials":272,"cells":40328},"Dabigatran etexilate plus dronedarone",{"EARLY_PHASE1":40329,"PHASE1":40331,"PHASE2":40339,"PHASE3":40341,"PHASE4":40343,"NA":40345},{"trials":40330,"activeCount":101},[],{"trials":40332,"activeCount":101},[40333],{"nctId":40334,"briefTitle":40335,"status":107,"phases":40336,"primaryCompletion":9348,"start":9332,"enrollment":448,"conditions":40337,"interventions":40338},"NCT01306162","Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects",[90],[15],[40327,6561,40327,40327,40327],{"trials":40340,"activeCount":101},[],{"trials":40342,"activeCount":101},[],{"trials":40344,"activeCount":101},[],{"trials":40346,"activeCount":101},[],{"intervention":40348,"totalTrials":272,"cells":40349},"nintedanib 25 mg",{"EARLY_PHASE1":40350,"PHASE1":40352,"PHASE2":40362,"PHASE3":40364,"PHASE4":40366,"NA":40368},{"trials":40351,"activeCount":101},[],{"trials":40353,"activeCount":101},[40354],{"nctId":40355,"briefTitle":40356,"status":107,"phases":40357,"primaryCompletion":21151,"completion":21151,"start":40358,"enrollment":1672,"conditions":40359,"interventions":40360},"NCT04938453","A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule",[90],"2021-07-14",[15],[40348,40361],"nintedanib 100 mg",{"trials":40363,"activeCount":101},[],{"trials":40365,"activeCount":101},[],{"trials":40367,"activeCount":101},[],{"trials":40369,"activeCount":101},[],{"intervention":40361,"totalTrials":272,"cells":40371},{"EARLY_PHASE1":40372,"PHASE1":40374,"PHASE2":40380,"PHASE3":40382,"PHASE4":40384,"NA":40386},{"trials":40373,"activeCount":101},[],{"trials":40375,"activeCount":101},[40376],{"nctId":40355,"briefTitle":40356,"status":107,"phases":40377,"primaryCompletion":21151,"completion":21151,"start":40358,"enrollment":1672,"conditions":40378,"interventions":40379},[90],[15],[40348,40361],{"trials":40381,"activeCount":101},[],{"trials":40383,"activeCount":101},[],{"trials":40385,"activeCount":101},[],{"trials":40387,"activeCount":101},[],{"intervention":40389,"totalTrials":272,"cells":40390},"BI 60732",{"EARLY_PHASE1":40391,"PHASE1":40393,"PHASE2":40401,"PHASE3":40403,"PHASE4":40405,"NA":40407},{"trials":40392,"activeCount":101},[],{"trials":40394,"activeCount":101},[40395],{"nctId":40396,"briefTitle":40397,"status":107,"phases":40398,"primaryCompletion":3991,"start":1989,"enrollment":37,"conditions":40399,"interventions":40400},"NCT02244203","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers",[90],[15],[40389],{"trials":40402,"activeCount":101},[],{"trials":40404,"activeCount":101},[],{"trials":40406,"activeCount":101},[],{"trials":40408,"activeCount":101},[],{"intervention":21215,"totalTrials":272,"cells":40410},{"EARLY_PHASE1":40411,"PHASE1":40413,"PHASE2":40419,"PHASE3":40421,"PHASE4":40423,"NA":40425},{"trials":40412,"activeCount":101},[],{"trials":40414,"activeCount":101},[40415],{"nctId":21208,"briefTitle":21209,"status":107,"phases":40416,"primaryCompletion":723,"completion":723,"start":21211,"enrollment":448,"conditions":40417,"interventions":40418},[90],[21213],[21215,1130,1130],{"trials":40420,"activeCount":101},[],{"trials":40422,"activeCount":101},[],{"trials":40424,"activeCount":101},[],{"trials":40426,"activeCount":101},[],{"intervention":40428,"totalTrials":272,"cells":40429},"BI 638683 or placebo",{"EARLY_PHASE1":40430,"PHASE1":40432,"PHASE2":40440,"PHASE3":40442,"PHASE4":40444,"NA":40446},{"trials":40431,"activeCount":101},[],{"trials":40433,"activeCount":101},[40434],{"nctId":40435,"briefTitle":40436,"status":107,"phases":40437,"primaryCompletion":9396,"start":7703,"enrollment":8304,"conditions":40438,"interventions":40439},"NCT01195688","Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects",[90],[15],[40428],{"trials":40441,"activeCount":101},[],{"trials":40443,"activeCount":101},[],{"trials":40445,"activeCount":101},[],{"trials":40447,"activeCount":101},[],{"intervention":40449,"totalTrials":272,"cells":40450},"BIBT 986 BS - single rising dose",{"EARLY_PHASE1":40451,"PHASE1":40453,"PHASE2":40461,"PHASE3":40463,"PHASE4":40465,"NA":40467},{"trials":40452,"activeCount":101},[],{"trials":40454,"activeCount":101},[40455],{"nctId":40456,"briefTitle":40457,"status":107,"phases":40458,"primaryCompletion":6189,"start":6495,"enrollment":4433,"conditions":40459,"interventions":40460},"NCT02254057","Tolerability and Pharmacokinetics\u002F-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects",[90],[15],[40449],{"trials":40462,"activeCount":101},[],{"trials":40464,"activeCount":101},[],{"trials":40466,"activeCount":101},[],{"trials":40468,"activeCount":101},[],{"intervention":40470,"totalTrials":272,"cells":40471},"TPV - Room condition",{"EARLY_PHASE1":40472,"PHASE1":40474,"PHASE2":40483,"PHASE3":40485,"PHASE4":40487,"NA":40489},{"trials":40473,"activeCount":101},[],{"trials":40475,"activeCount":101},[40476],{"nctId":40477,"briefTitle":40478,"status":107,"phases":40479,"primaryCompletion":1115,"start":7300,"enrollment":357,"conditions":40480,"interventions":40481},"NCT02253888","Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers",[90],[15],[40470,40482,4010],"TPV - Refrigerated conditions",{"trials":40484,"activeCount":101},[],{"trials":40486,"activeCount":101},[],{"trials":40488,"activeCount":101},[],{"trials":40490,"activeCount":101},[],{"intervention":40482,"totalTrials":272,"cells":40492},{"EARLY_PHASE1":40493,"PHASE1":40495,"PHASE2":40501,"PHASE3":40503,"PHASE4":40505,"NA":40507},{"trials":40494,"activeCount":101},[],{"trials":40496,"activeCount":101},[40497],{"nctId":40477,"briefTitle":40478,"status":107,"phases":40498,"primaryCompletion":1115,"start":7300,"enrollment":357,"conditions":40499,"interventions":40500},[90],[15],[40470,40482,4010],{"trials":40502,"activeCount":101},[],{"trials":40504,"activeCount":101},[],{"trials":40506,"activeCount":101},[],{"trials":40508,"activeCount":101},[],{"intervention":40510,"totalTrials":272,"cells":40511},"BIBR 796 BS, low dose",{"EARLY_PHASE1":40512,"PHASE1":40514,"PHASE2":40524,"PHASE3":40526,"PHASE4":40528,"NA":40530},{"trials":40513,"activeCount":101},[],{"trials":40515,"activeCount":101},[40516],{"nctId":40517,"briefTitle":40518,"status":107,"phases":40519,"primaryCompletion":2163,"start":8538,"enrollment":380,"conditions":40520,"interventions":40521},"NCT02211170","Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects",[90],[15],[40510,40522,40523],"BIBR 796 BS, high dose","Lipopolysaccharide",{"trials":40525,"activeCount":101},[],{"trials":40527,"activeCount":101},[],{"trials":40529,"activeCount":101},[],{"trials":40531,"activeCount":101},[],{"intervention":40522,"totalTrials":272,"cells":40533},{"EARLY_PHASE1":40534,"PHASE1":40536,"PHASE2":40542,"PHASE3":40544,"PHASE4":40546,"NA":40548},{"trials":40535,"activeCount":101},[],{"trials":40537,"activeCount":101},[40538],{"nctId":40517,"briefTitle":40518,"status":107,"phases":40539,"primaryCompletion":2163,"start":8538,"enrollment":380,"conditions":40540,"interventions":40541},[90],[15],[40510,40522,40523],{"trials":40543,"activeCount":101},[],{"trials":40545,"activeCount":101},[],{"trials":40547,"activeCount":101},[],{"trials":40549,"activeCount":101},[],{"intervention":40523,"totalTrials":272,"cells":40551},{"EARLY_PHASE1":40552,"PHASE1":40554,"PHASE2":40560,"PHASE3":40562,"PHASE4":40564,"NA":40566},{"trials":40553,"activeCount":101},[],{"trials":40555,"activeCount":101},[40556],{"nctId":40517,"briefTitle":40518,"status":107,"phases":40557,"primaryCompletion":2163,"start":8538,"enrollment":380,"conditions":40558,"interventions":40559},[90],[15],[40510,40522,40523],{"trials":40561,"activeCount":101},[],{"trials":40563,"activeCount":101},[],{"trials":40565,"activeCount":101},[],{"trials":40567,"activeCount":101},[],{"intervention":40569,"totalTrials":272,"cells":40570},"BIIL 284 oral solution",{"EARLY_PHASE1":40571,"PHASE1":40573,"PHASE2":40582,"PHASE3":40584,"PHASE4":40586,"NA":40588},{"trials":40572,"activeCount":101},[],{"trials":40574,"activeCount":101},[40575],{"nctId":40576,"briefTitle":40577,"status":107,"phases":40578,"primaryCompletion":7114,"start":6064,"enrollment":10951,"conditions":40579,"interventions":40580},"NCT02265302","Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males",[90],[15],[40569,40581],"BIIL 284 wetability improved formulation (WIF)",{"trials":40583,"activeCount":101},[],{"trials":40585,"activeCount":101},[],{"trials":40587,"activeCount":101},[],{"trials":40589,"activeCount":101},[],{"intervention":40581,"totalTrials":272,"cells":40591},{"EARLY_PHASE1":40592,"PHASE1":40594,"PHASE2":40600,"PHASE3":40602,"PHASE4":40604,"NA":40606},{"trials":40593,"activeCount":101},[],{"trials":40595,"activeCount":101},[40596],{"nctId":40576,"briefTitle":40577,"status":107,"phases":40597,"primaryCompletion":7114,"start":6064,"enrollment":10951,"conditions":40598,"interventions":40599},[90],[15],[40569,40581],{"trials":40601,"activeCount":101},[],{"trials":40603,"activeCount":101},[],{"trials":40605,"activeCount":101},[],{"trials":40607,"activeCount":101},[],{"intervention":19288,"totalTrials":272,"cells":40609},{"EARLY_PHASE1":40610,"PHASE1":40612,"PHASE2":40618,"PHASE3":40620,"PHASE4":40622,"NA":40624},{"trials":40611,"activeCount":101},[],{"trials":40613,"activeCount":101},[40614],{"nctId":19282,"briefTitle":19283,"status":162,"phases":40615,"primaryCompletion":19285,"completion":19285,"start":198,"enrollment":231,"conditions":40616,"interventions":40617},[90],[15],[19260,19288,19289],{"trials":40619,"activeCount":101},[],{"trials":40621,"activeCount":101},[],{"trials":40623,"activeCount":101},[],{"trials":40625,"activeCount":101},[],{"intervention":19289,"totalTrials":272,"cells":40627},{"EARLY_PHASE1":40628,"PHASE1":40630,"PHASE2":40636,"PHASE3":40638,"PHASE4":40640,"NA":40642},{"trials":40629,"activeCount":101},[],{"trials":40631,"activeCount":101},[40632],{"nctId":19282,"briefTitle":19283,"status":162,"phases":40633,"primaryCompletion":19285,"completion":19285,"start":198,"enrollment":231,"conditions":40634,"interventions":40635},[90],[15],[19260,19288,19289],{"trials":40637,"activeCount":101},[],{"trials":40639,"activeCount":101},[],{"trials":40641,"activeCount":101},[],{"trials":40643,"activeCount":101},[],{"intervention":20090,"totalTrials":272,"cells":40645},{"EARLY_PHASE1":40646,"PHASE1":40648,"PHASE2":40654,"PHASE3":40656,"PHASE4":40658,"NA":40660},{"trials":40647,"activeCount":101},[],{"trials":40649,"activeCount":101},[40650],{"nctId":20085,"briefTitle":20086,"status":107,"phases":40651,"primaryCompletion":4120,"completion":4120,"start":474,"enrollment":392,"conditions":40652,"interventions":40653},[90],[15],[929,4166,20090],{"trials":40655,"activeCount":101},[],{"trials":40657,"activeCount":101},[],{"trials":40659,"activeCount":101},[],{"trials":40661,"activeCount":101},[],{"intervention":432,"totalTrials":272,"cells":40663},{"EARLY_PHASE1":40664,"PHASE1":40666,"PHASE2":40672,"PHASE3":40674,"PHASE4":40676,"NA":40678},{"trials":40665,"activeCount":101},[],{"trials":40667,"activeCount":101},[40668],{"nctId":425,"briefTitle":426,"status":107,"phases":40669,"primaryCompletion":428,"completion":428,"start":429,"enrollment":357,"conditions":40670,"interventions":40671},[90],[15],[432,73,361,362],{"trials":40673,"activeCount":101},[],{"trials":40675,"activeCount":101},[],{"trials":40677,"activeCount":101},[],{"trials":40679,"activeCount":101},[],{"intervention":29985,"totalTrials":272,"cells":40681},{"EARLY_PHASE1":40682,"PHASE1":40684,"PHASE2":40690,"PHASE3":40692,"PHASE4":40694,"NA":40696},{"trials":40683,"activeCount":101},[],{"trials":40685,"activeCount":101},[40686],{"nctId":29979,"briefTitle":29980,"status":107,"phases":40687,"primaryCompletion":6156,"start":7151,"enrollment":1418,"conditions":40688,"interventions":40689},[90],[15],[29984,29985,4468,29986],{"trials":40691,"activeCount":101},[],{"trials":40693,"activeCount":101},[],{"trials":40695,"activeCount":101},[],{"trials":40697,"activeCount":101},[],{"intervention":29986,"totalTrials":272,"cells":40699},{"EARLY_PHASE1":40700,"PHASE1":40702,"PHASE2":40708,"PHASE3":40710,"PHASE4":40712,"NA":40714},{"trials":40701,"activeCount":101},[],{"trials":40703,"activeCount":101},[40704],{"nctId":29979,"briefTitle":29980,"status":107,"phases":40705,"primaryCompletion":6156,"start":7151,"enrollment":1418,"conditions":40706,"interventions":40707},[90],[15],[29984,29985,4468,29986],{"trials":40709,"activeCount":101},[],{"trials":40711,"activeCount":101},[],{"trials":40713,"activeCount":101},[],{"trials":40715,"activeCount":101},[],{"intervention":18960,"totalTrials":272,"cells":40717},{"EARLY_PHASE1":40718,"PHASE1":40720,"PHASE2":40726,"PHASE3":40728,"PHASE4":40730,"NA":40732},{"trials":40719,"activeCount":101},[],{"trials":40721,"activeCount":101},[40722],{"nctId":18953,"briefTitle":18954,"status":107,"phases":40723,"primaryCompletion":18956,"completion":18956,"start":18957,"enrollment":392,"conditions":40724,"interventions":40725},[90],[15],[18960,4176],{"trials":40727,"activeCount":101},[],{"trials":40729,"activeCount":101},[],{"trials":40731,"activeCount":101},[],{"trials":40733,"activeCount":101},[],{"intervention":40735,"totalTrials":272,"cells":40736},"BI 1356 BS, low dose",{"EARLY_PHASE1":40737,"PHASE1":40739,"PHASE2":40749,"PHASE3":40751,"PHASE4":40753,"NA":40755},{"trials":40738,"activeCount":101},[],{"trials":40740,"activeCount":101},[40741],{"nctId":40742,"briefTitle":40743,"status":107,"phases":40744,"primaryCompletion":4005,"start":3978,"enrollment":2772,"conditions":40745,"interventions":40746},"NCT02183415","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes",[90],[21],[40735,40747,40748],"BI 1356 BS, medium dose","BI 1356 BS, high dose",{"trials":40750,"activeCount":101},[],{"trials":40752,"activeCount":101},[],{"trials":40754,"activeCount":101},[],{"trials":40756,"activeCount":101},[],{"intervention":40747,"totalTrials":272,"cells":40758},{"EARLY_PHASE1":40759,"PHASE1":40761,"PHASE2":40767,"PHASE3":40769,"PHASE4":40771,"NA":40773},{"trials":40760,"activeCount":101},[],{"trials":40762,"activeCount":101},[40763],{"nctId":40742,"briefTitle":40743,"status":107,"phases":40764,"primaryCompletion":4005,"start":3978,"enrollment":2772,"conditions":40765,"interventions":40766},[90],[21],[40735,40747,40748],{"trials":40768,"activeCount":101},[],{"trials":40770,"activeCount":101},[],{"trials":40772,"activeCount":101},[],{"trials":40774,"activeCount":101},[],{"intervention":40748,"totalTrials":272,"cells":40776},{"EARLY_PHASE1":40777,"PHASE1":40779,"PHASE2":40785,"PHASE3":40787,"PHASE4":40789,"NA":40791},{"trials":40778,"activeCount":101},[],{"trials":40780,"activeCount":101},[40781],{"nctId":40742,"briefTitle":40743,"status":107,"phases":40782,"primaryCompletion":4005,"start":3978,"enrollment":2772,"conditions":40783,"interventions":40784},[90],[21],[40735,40747,40748],{"trials":40786,"activeCount":101},[],{"trials":40788,"activeCount":101},[],{"trials":40790,"activeCount":101},[],{"trials":40792,"activeCount":101},[],{"intervention":40794,"totalTrials":272,"cells":40795},"ESR 1150 CL",{"EARLY_PHASE1":40796,"PHASE1":40798,"PHASE2":40806,"PHASE3":40808,"PHASE4":40810,"NA":40812},{"trials":40797,"activeCount":101},[],{"trials":40799,"activeCount":101},[40800],{"nctId":40801,"briefTitle":40802,"status":162,"phases":40803,"primaryCompletion":6594,"start":8538,"enrollment":291,"conditions":40804,"interventions":40805},"NCT02209688","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects",[90],[15],[40794],{"trials":40807,"activeCount":101},[],{"trials":40809,"activeCount":101},[],{"trials":40811,"activeCount":101},[],{"trials":40813,"activeCount":101},[],{"intervention":40815,"totalTrials":272,"cells":40816},"BI 201335 NA 120 mg",{"EARLY_PHASE1":40817,"PHASE1":40819,"PHASE2":40828,"PHASE3":40830,"PHASE4":40832,"NA":40834},{"trials":40818,"activeCount":101},[],{"trials":40820,"activeCount":101},[40821],{"nctId":40822,"briefTitle":40823,"status":107,"phases":40824,"primaryCompletion":3730,"completion":3730,"start":517,"enrollment":123,"conditions":40825,"interventions":40826},"NCT01704846","Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules",[90],[9764],[40815,40815,40827,40827],"BI 201335 NA 40 mg",{"trials":40829,"activeCount":101},[],{"trials":40831,"activeCount":101},[],{"trials":40833,"activeCount":101},[],{"trials":40835,"activeCount":101},[],{"intervention":40827,"totalTrials":272,"cells":40837},{"EARLY_PHASE1":40838,"PHASE1":40840,"PHASE2":40846,"PHASE3":40848,"PHASE4":40850,"NA":40852},{"trials":40839,"activeCount":101},[],{"trials":40841,"activeCount":101},[40842],{"nctId":40822,"briefTitle":40823,"status":107,"phases":40843,"primaryCompletion":3730,"completion":3730,"start":517,"enrollment":123,"conditions":40844,"interventions":40845},[90],[9764],[40815,40815,40827,40827],{"trials":40847,"activeCount":101},[],{"trials":40849,"activeCount":101},[],{"trials":40851,"activeCount":101},[],{"trials":40853,"activeCount":101},[],{"intervention":19298,"totalTrials":272,"cells":40855},{"EARLY_PHASE1":40856,"PHASE1":40858,"PHASE2":40864,"PHASE3":40866,"PHASE4":40868,"NA":40870},{"trials":40857,"activeCount":101},[],{"trials":40859,"activeCount":101},[40860],{"nctId":19291,"briefTitle":19292,"status":107,"phases":40861,"primaryCompletion":19294,"completion":19294,"start":19295,"enrollment":188,"conditions":40862,"interventions":40863},[90],[15],[19260,19298],{"trials":40865,"activeCount":101},[],{"trials":40867,"activeCount":101},[],{"trials":40869,"activeCount":101},[],{"trials":40871,"activeCount":101},[],{"intervention":40873,"totalTrials":272,"cells":40874},"Quinidine sulfate",{"EARLY_PHASE1":40875,"PHASE1":40877,"PHASE2":40886,"PHASE3":40888,"PHASE4":40890,"NA":40892},{"trials":40876,"activeCount":101},[],{"trials":40878,"activeCount":101},[40879],{"nctId":40880,"briefTitle":40881,"status":162,"phases":40882,"primaryCompletion":4507,"start":9418,"enrollment":331,"conditions":40883,"interventions":40884},"NCT02171546","Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers",[90],[15],[6561,40873,40885],"Fexofenadine",{"trials":40887,"activeCount":101},[],{"trials":40889,"activeCount":101},[],{"trials":40891,"activeCount":101},[],{"trials":40893,"activeCount":101},[],{"intervention":40885,"totalTrials":272,"cells":40895},{"EARLY_PHASE1":40896,"PHASE1":40898,"PHASE2":40904,"PHASE3":40906,"PHASE4":40908,"NA":40910},{"trials":40897,"activeCount":101},[],{"trials":40899,"activeCount":101},[40900],{"nctId":40880,"briefTitle":40881,"status":162,"phases":40901,"primaryCompletion":4507,"start":9418,"enrollment":331,"conditions":40902,"interventions":40903},[90],[15],[6561,40873,40885],{"trials":40905,"activeCount":101},[],{"trials":40907,"activeCount":101},[],{"trials":40909,"activeCount":101},[],{"trials":40911,"activeCount":101},[],{"intervention":40913,"totalTrials":272,"cells":40914},"[14C] BILL 284 BS",{"EARLY_PHASE1":40915,"PHASE1":40917,"PHASE2":40925,"PHASE3":40927,"PHASE4":40929,"NA":40931},{"trials":40916,"activeCount":101},[],{"trials":40918,"activeCount":101},[40919],{"nctId":40920,"briefTitle":40921,"status":107,"phases":40922,"primaryCompletion":6207,"start":6207,"enrollment":1512,"conditions":40923,"interventions":40924},"NCT02266550","Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers",[90],[15],[40913],{"trials":40926,"activeCount":101},[],{"trials":40928,"activeCount":101},[],{"trials":40930,"activeCount":101},[],{"trials":40932,"activeCount":101},[],{"intervention":19409,"totalTrials":272,"cells":40934},{"EARLY_PHASE1":40935,"PHASE1":40937,"PHASE2":40943,"PHASE3":40945,"PHASE4":40947,"NA":40949},{"trials":40936,"activeCount":101},[],{"trials":40938,"activeCount":101},[40939],{"nctId":19402,"briefTitle":19403,"status":107,"phases":40940,"primaryCompletion":19405,"completion":19405,"start":19406,"enrollment":1429,"conditions":40941,"interventions":40942},[90],[15],[19409,19360],{"trials":40944,"activeCount":101},[],{"trials":40946,"activeCount":101},[],{"trials":40948,"activeCount":101},[],{"trials":40950,"activeCount":101},[],{"intervention":40952,"totalTrials":272,"cells":40953},"Dabigatran etexilate pellets",{"EARLY_PHASE1":40954,"PHASE1":40956,"PHASE2":40965,"PHASE3":40967,"PHASE4":40969,"NA":40971},{"trials":40955,"activeCount":101},[],{"trials":40957,"activeCount":101},[40958],{"nctId":40959,"briefTitle":40960,"status":107,"phases":40961,"primaryCompletion":9411,"start":2003,"enrollment":357,"conditions":40962,"interventions":40963},"NCT02171611","Bioavailability of Different Applications of Dabigatran in Healthy Volunteers",[90],[15],[40952,40964,6561],"Dabigatran etexilate powder",{"trials":40966,"activeCount":101},[],{"trials":40968,"activeCount":101},[],{"trials":40970,"activeCount":101},[],{"trials":40972,"activeCount":101},[],{"intervention":40964,"totalTrials":272,"cells":40974},{"EARLY_PHASE1":40975,"PHASE1":40977,"PHASE2":40983,"PHASE3":40985,"PHASE4":40987,"NA":40989},{"trials":40976,"activeCount":101},[],{"trials":40978,"activeCount":101},[40979],{"nctId":40959,"briefTitle":40960,"status":107,"phases":40980,"primaryCompletion":9411,"start":2003,"enrollment":357,"conditions":40981,"interventions":40982},[90],[15],[40952,40964,6561],{"trials":40984,"activeCount":101},[],{"trials":40986,"activeCount":101},[],{"trials":40988,"activeCount":101},[],{"trials":40990,"activeCount":101},[],{"intervention":40992,"totalTrials":272,"cells":40993},"BI 905681",{"EARLY_PHASE1":40994,"PHASE1":40996,"PHASE2":41005,"PHASE3":41007,"PHASE4":41009,"NA":41011},{"trials":40995,"activeCount":101},[],{"trials":40997,"activeCount":101},[40998],{"nctId":40999,"briefTitle":41000,"status":107,"phases":41001,"primaryCompletion":25962,"completion":41002,"start":28533,"enrollment":3454,"conditions":41003,"interventions":41004},"NCT04147247","A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread",[90],"2021-05-27",[33],[40992],{"trials":41006,"activeCount":101},[],{"trials":41008,"activeCount":101},[],{"trials":41010,"activeCount":101},[],{"trials":41012,"activeCount":101},[],{"intervention":4486,"totalTrials":272,"cells":41014},{"EARLY_PHASE1":41015,"PHASE1":41017,"PHASE2":41023,"PHASE3":41025,"PHASE4":41027,"NA":41029},{"trials":41016,"activeCount":101},[],{"trials":41018,"activeCount":101},[41019],{"nctId":4481,"briefTitle":4482,"status":107,"phases":41020,"primaryCompletion":4462,"start":3978,"enrollment":291,"conditions":41021,"interventions":41022},[90],[15],[4486,4487,4488,4489,1538],{"trials":41024,"activeCount":101},[],{"trials":41026,"activeCount":101},[],{"trials":41028,"activeCount":101},[],{"trials":41030,"activeCount":101},[],{"intervention":4487,"totalTrials":272,"cells":41032},{"EARLY_PHASE1":41033,"PHASE1":41035,"PHASE2":41041,"PHASE3":41043,"PHASE4":41045,"NA":41047},{"trials":41034,"activeCount":101},[],{"trials":41036,"activeCount":101},[41037],{"nctId":4481,"briefTitle":4482,"status":107,"phases":41038,"primaryCompletion":4462,"start":3978,"enrollment":291,"conditions":41039,"interventions":41040},[90],[15],[4486,4487,4488,4489,1538],{"trials":41042,"activeCount":101},[],{"trials":41044,"activeCount":101},[],{"trials":41046,"activeCount":101},[],{"trials":41048,"activeCount":101},[],{"intervention":4488,"totalTrials":272,"cells":41050},{"EARLY_PHASE1":41051,"PHASE1":41053,"PHASE2":41059,"PHASE3":41061,"PHASE4":41063,"NA":41065},{"trials":41052,"activeCount":101},[],{"trials":41054,"activeCount":101},[41055],{"nctId":4481,"briefTitle":4482,"status":107,"phases":41056,"primaryCompletion":4462,"start":3978,"enrollment":291,"conditions":41057,"interventions":41058},[90],[15],[4486,4487,4488,4489,1538],{"trials":41060,"activeCount":101},[],{"trials":41062,"activeCount":101},[],{"trials":41064,"activeCount":101},[],{"trials":41066,"activeCount":101},[],{"intervention":4489,"totalTrials":272,"cells":41068},{"EARLY_PHASE1":41069,"PHASE1":41071,"PHASE2":41077,"PHASE3":41079,"PHASE4":41081,"NA":41083},{"trials":41070,"activeCount":101},[],{"trials":41072,"activeCount":101},[41073],{"nctId":4481,"briefTitle":4482,"status":107,"phases":41074,"primaryCompletion":4462,"start":3978,"enrollment":291,"conditions":41075,"interventions":41076},[90],[15],[4486,4487,4488,4489,1538],{"trials":41078,"activeCount":101},[],{"trials":41080,"activeCount":101},[],{"trials":41082,"activeCount":101},[],{"trials":41084,"activeCount":101},[],{"intervention":41086,"totalTrials":272,"cells":41087},"BI 730460",{"EARLY_PHASE1":41088,"PHASE1":41090,"PHASE2":41100,"PHASE3":41102,"PHASE4":41104,"NA":41106},{"trials":41089,"activeCount":101},[],{"trials":41091,"activeCount":101},[41092],{"nctId":41093,"briefTitle":41094,"status":162,"phases":41095,"primaryCompletion":41096,"completion":41096,"start":41097,"enrollment":410,"conditions":41098,"interventions":41099},"NCT03483077","This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.",[90],"2019-03-21","2018-10-09",[15],[41086],{"trials":41101,"activeCount":101},[],{"trials":41103,"activeCount":101},[],{"trials":41105,"activeCount":101},[],{"trials":41107,"activeCount":101},[],{"intervention":41109,"totalTrials":272,"cells":41110},"BI 1291583 mixed with [C-14] BI 1291583",{"EARLY_PHASE1":41111,"PHASE1":41113,"PHASE2":41123,"PHASE3":41125,"PHASE4":41127,"NA":41129},{"trials":41112,"activeCount":101},[],{"trials":41114,"activeCount":101},[41115],{"nctId":41116,"briefTitle":41117,"status":107,"phases":41118,"primaryCompletion":41119,"completion":41119,"start":41120,"enrollment":155,"conditions":41121,"interventions":41122},"NCT05833035","A Study in Healthy Men to Test How BI 1291583 is Processed in the Body",[90],"2023-07-05","2023-04-24",[15],[41109],{"trials":41124,"activeCount":101},[],{"trials":41126,"activeCount":101},[],{"trials":41128,"activeCount":101},[],{"trials":41130,"activeCount":101},[],{"intervention":11323,"totalTrials":272,"cells":41132},{"EARLY_PHASE1":41133,"PHASE1":41135,"PHASE2":41141,"PHASE3":41143,"PHASE4":41145,"NA":41147},{"trials":41134,"activeCount":101},[],{"trials":41136,"activeCount":101},[41137],{"nctId":11318,"briefTitle":11319,"status":107,"phases":41138,"primaryCompletion":2145,"start":4461,"enrollment":448,"conditions":41139,"interventions":41140},[90],[15],[5945,7155,11323],{"trials":41142,"activeCount":101},[],{"trials":41144,"activeCount":101},[],{"trials":41146,"activeCount":101},[],{"trials":41148,"activeCount":101},[],{"intervention":41150,"totalTrials":272,"cells":41151},"BI 1356 BS PIB - low dose",{"EARLY_PHASE1":41152,"PHASE1":41154,"PHASE2":41166,"PHASE3":41168,"PHASE4":41170,"NA":41172},{"trials":41153,"activeCount":101},[],{"trials":41155,"activeCount":101},[41156],{"nctId":41157,"briefTitle":41158,"status":107,"phases":41159,"primaryCompletion":5843,"start":3978,"enrollment":380,"conditions":41160,"interventions":41161},"NCT02180503","Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS",[90],[15],[41150,41162,41163,41164,41165],"BI 1356 BS tablet - low dose","BI 1356 BS PIB - high dose","BI 1356 BS tablet - high dose","BI 1356 BS tablet - high dose with food",{"trials":41167,"activeCount":101},[],{"trials":41169,"activeCount":101},[],{"trials":41171,"activeCount":101},[],{"trials":41173,"activeCount":101},[],{"intervention":41162,"totalTrials":272,"cells":41175},{"EARLY_PHASE1":41176,"PHASE1":41178,"PHASE2":41184,"PHASE3":41186,"PHASE4":41188,"NA":41190},{"trials":41177,"activeCount":101},[],{"trials":41179,"activeCount":101},[41180],{"nctId":41157,"briefTitle":41158,"status":107,"phases":41181,"primaryCompletion":5843,"start":3978,"enrollment":380,"conditions":41182,"interventions":41183},[90],[15],[41150,41162,41163,41164,41165],{"trials":41185,"activeCount":101},[],{"trials":41187,"activeCount":101},[],{"trials":41189,"activeCount":101},[],{"trials":41191,"activeCount":101},[],{"intervention":41163,"totalTrials":272,"cells":41193},{"EARLY_PHASE1":41194,"PHASE1":41196,"PHASE2":41202,"PHASE3":41204,"PHASE4":41206,"NA":41208},{"trials":41195,"activeCount":101},[],{"trials":41197,"activeCount":101},[41198],{"nctId":41157,"briefTitle":41158,"status":107,"phases":41199,"primaryCompletion":5843,"start":3978,"enrollment":380,"conditions":41200,"interventions":41201},[90],[15],[41150,41162,41163,41164,41165],{"trials":41203,"activeCount":101},[],{"trials":41205,"activeCount":101},[],{"trials":41207,"activeCount":101},[],{"trials":41209,"activeCount":101},[],{"intervention":41164,"totalTrials":272,"cells":41211},{"EARLY_PHASE1":41212,"PHASE1":41214,"PHASE2":41220,"PHASE3":41222,"PHASE4":41224,"NA":41226},{"trials":41213,"activeCount":101},[],{"trials":41215,"activeCount":101},[41216],{"nctId":41157,"briefTitle":41158,"status":107,"phases":41217,"primaryCompletion":5843,"start":3978,"enrollment":380,"conditions":41218,"interventions":41219},[90],[15],[41150,41162,41163,41164,41165],{"trials":41221,"activeCount":101},[],{"trials":41223,"activeCount":101},[],{"trials":41225,"activeCount":101},[],{"trials":41227,"activeCount":101},[],{"intervention":41165,"totalTrials":272,"cells":41229},{"EARLY_PHASE1":41230,"PHASE1":41232,"PHASE2":41238,"PHASE3":41240,"PHASE4":41242,"NA":41244},{"trials":41231,"activeCount":101},[],{"trials":41233,"activeCount":101},[41234],{"nctId":41157,"briefTitle":41158,"status":107,"phases":41235,"primaryCompletion":5843,"start":3978,"enrollment":380,"conditions":41236,"interventions":41237},[90],[15],[41150,41162,41163,41164,41165],{"trials":41239,"activeCount":101},[],{"trials":41241,"activeCount":101},[],{"trials":41243,"activeCount":101},[],{"trials":41245,"activeCount":101},[],{"intervention":11849,"totalTrials":272,"cells":41247},{"EARLY_PHASE1":41248,"PHASE1":41250,"PHASE2":41256,"PHASE3":41258,"PHASE4":41260,"NA":41262},{"trials":41249,"activeCount":101},[],{"trials":41251,"activeCount":101},[41252],{"nctId":11843,"briefTitle":11844,"status":107,"phases":41253,"primaryCompletion":6207,"start":6738,"enrollment":439,"conditions":41254,"interventions":41255},[90],[15],[11836,11848,11849],{"trials":41257,"activeCount":101},[],{"trials":41259,"activeCount":101},[],{"trials":41261,"activeCount":101},[],{"trials":41263,"activeCount":101},[],{"intervention":41265,"totalTrials":272,"cells":41266},"BIBW 2992 MA2",{"EARLY_PHASE1":41267,"PHASE1":41269,"PHASE2":41277,"PHASE3":41279,"PHASE4":41281,"NA":41283},{"trials":41268,"activeCount":101},[],{"trials":41270,"activeCount":101},[41271],{"nctId":41272,"briefTitle":41273,"status":107,"phases":41274,"primaryCompletion":9404,"start":2649,"enrollment":210,"conditions":41275,"interventions":41276},"NCT02171715","BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers",[90],[15],[41265,41265,41265],{"trials":41278,"activeCount":101},[],{"trials":41280,"activeCount":101},[],{"trials":41282,"activeCount":101},[],{"trials":41284,"activeCount":101},[],{"intervention":19196,"totalTrials":272,"cells":41286},{"EARLY_PHASE1":41287,"PHASE1":41289,"PHASE2":41295,"PHASE3":41297,"PHASE4":41299,"NA":41301},{"trials":41288,"activeCount":101},[],{"trials":41290,"activeCount":101},[41291],{"nctId":19190,"briefTitle":19191,"status":107,"phases":41292,"primaryCompletion":784,"completion":784,"start":19193,"enrollment":956,"conditions":41293,"interventions":41294},[90],[15],[4109,19196,19197,19198,19199],{"trials":41296,"activeCount":101},[],{"trials":41298,"activeCount":101},[],{"trials":41300,"activeCount":101},[],{"trials":41302,"activeCount":101},[],{"intervention":19197,"totalTrials":272,"cells":41304},{"EARLY_PHASE1":41305,"PHASE1":41307,"PHASE2":41313,"PHASE3":41315,"PHASE4":41317,"NA":41319},{"trials":41306,"activeCount":101},[],{"trials":41308,"activeCount":101},[41309],{"nctId":19190,"briefTitle":19191,"status":107,"phases":41310,"primaryCompletion":784,"completion":784,"start":19193,"enrollment":956,"conditions":41311,"interventions":41312},[90],[15],[4109,19196,19197,19198,19199],{"trials":41314,"activeCount":101},[],{"trials":41316,"activeCount":101},[],{"trials":41318,"activeCount":101},[],{"trials":41320,"activeCount":101},[],{"intervention":19198,"totalTrials":272,"cells":41322},{"EARLY_PHASE1":41323,"PHASE1":41325,"PHASE2":41331,"PHASE3":41333,"PHASE4":41335,"NA":41337},{"trials":41324,"activeCount":101},[],{"trials":41326,"activeCount":101},[41327],{"nctId":19190,"briefTitle":19191,"status":107,"phases":41328,"primaryCompletion":784,"completion":784,"start":19193,"enrollment":956,"conditions":41329,"interventions":41330},[90],[15],[4109,19196,19197,19198,19199],{"trials":41332,"activeCount":101},[],{"trials":41334,"activeCount":101},[],{"trials":41336,"activeCount":101},[],{"trials":41338,"activeCount":101},[],{"intervention":19199,"totalTrials":272,"cells":41340},{"EARLY_PHASE1":41341,"PHASE1":41343,"PHASE2":41349,"PHASE3":41351,"PHASE4":41353,"NA":41355},{"trials":41342,"activeCount":101},[],{"trials":41344,"activeCount":101},[41345],{"nctId":19190,"briefTitle":19191,"status":107,"phases":41346,"primaryCompletion":784,"completion":784,"start":19193,"enrollment":956,"conditions":41347,"interventions":41348},[90],[15],[4109,19196,19197,19198,19199],{"trials":41350,"activeCount":101},[],{"trials":41352,"activeCount":101},[],{"trials":41354,"activeCount":101},[],{"trials":41356,"activeCount":101},[],{"intervention":41358,"totalTrials":272,"cells":41359},"BI 201335 NA soft gelatin",{"EARLY_PHASE1":41360,"PHASE1":41362,"PHASE2":41371,"PHASE3":41373,"PHASE4":41375,"NA":41377},{"trials":41361,"activeCount":101},[],{"trials":41363,"activeCount":101},[41364],{"nctId":41365,"briefTitle":41366,"status":107,"phases":41367,"primaryCompletion":3991,"start":5905,"enrollment":155,"conditions":41368,"interventions":41369},"NCT02182349","Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers",[90],[15],[41358,41370],"[14C]-BI 201335 NA radiolabelled drug",{"trials":41372,"activeCount":101},[],{"trials":41374,"activeCount":101},[],{"trials":41376,"activeCount":101},[],{"trials":41378,"activeCount":101},[],{"intervention":41370,"totalTrials":272,"cells":41380},{"EARLY_PHASE1":41381,"PHASE1":41383,"PHASE2":41389,"PHASE3":41391,"PHASE4":41393,"NA":41395},{"trials":41382,"activeCount":101},[],{"trials":41384,"activeCount":101},[41385],{"nctId":41365,"briefTitle":41366,"status":107,"phases":41386,"primaryCompletion":3991,"start":5905,"enrollment":155,"conditions":41387,"interventions":41388},[90],[15],[41358,41370],{"trials":41390,"activeCount":101},[],{"trials":41392,"activeCount":101},[],{"trials":41394,"activeCount":101},[],{"trials":41396,"activeCount":101},[],{"intervention":28959,"totalTrials":272,"cells":41398},{"EARLY_PHASE1":41399,"PHASE1":41401,"PHASE2":41407,"PHASE3":41409,"PHASE4":41411,"NA":41413},{"trials":41400,"activeCount":101},[],{"trials":41402,"activeCount":101},[41403],{"nctId":28954,"briefTitle":28955,"status":107,"phases":41404,"primaryCompletion":6949,"start":2163,"enrollment":2898,"conditions":41405,"interventions":41406},[90],[15],[28959,28941],{"trials":41408,"activeCount":101},[],{"trials":41410,"activeCount":101},[],{"trials":41412,"activeCount":101},[],{"trials":41414,"activeCount":101},[],{"intervention":19796,"totalTrials":272,"cells":41416},{"EARLY_PHASE1":41417,"PHASE1":41419,"PHASE2":41425,"PHASE3":41427,"PHASE4":41429,"NA":41431},{"trials":41418,"activeCount":101},[],{"trials":41420,"activeCount":101},[41421],{"nctId":19791,"briefTitle":19792,"status":107,"phases":41422,"primaryCompletion":400,"start":9411,"enrollment":331,"conditions":41423,"interventions":41424},[90],[15],[3994,3994,19796,19797,19797,19797],{"trials":41426,"activeCount":101},[],{"trials":41428,"activeCount":101},[],{"trials":41430,"activeCount":101},[],{"trials":41432,"activeCount":101},[],{"intervention":19797,"totalTrials":272,"cells":41434},{"EARLY_PHASE1":41435,"PHASE1":41437,"PHASE2":41443,"PHASE3":41445,"PHASE4":41447,"NA":41449},{"trials":41436,"activeCount":101},[],{"trials":41438,"activeCount":101},[41439],{"nctId":19791,"briefTitle":19792,"status":107,"phases":41440,"primaryCompletion":400,"start":9411,"enrollment":331,"conditions":41441,"interventions":41442},[90],[15],[3994,3994,19796,19797,19797,19797],{"trials":41444,"activeCount":101},[],{"trials":41446,"activeCount":101},[],{"trials":41448,"activeCount":101},[],{"trials":41450,"activeCount":101},[],{"intervention":41452,"totalTrials":272,"cells":41453},"afatinib 20mg",{"EARLY_PHASE1":41454,"PHASE1":41456,"PHASE2":41468,"PHASE3":41470,"PHASE4":41472,"NA":41474},{"trials":41455,"activeCount":101},[],{"trials":41457,"activeCount":101},[41458],{"nctId":41459,"briefTitle":41460,"status":107,"phases":41461,"primaryCompletion":41462,"completion":41462,"start":41463,"enrollment":5242,"conditions":41464,"interventions":41465},"NCT01214616","BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours",[90],"2013-05-01","2010-10-01",[33],[41452,41466,41467],"afatinib 40mg","vinorelbine IV 25 or 20mg\u002Fm2",{"trials":41469,"activeCount":101},[],{"trials":41471,"activeCount":101},[],{"trials":41473,"activeCount":101},[],{"trials":41475,"activeCount":101},[],{"intervention":41466,"totalTrials":272,"cells":41477},{"EARLY_PHASE1":41478,"PHASE1":41480,"PHASE2":41486,"PHASE3":41488,"PHASE4":41490,"NA":41492},{"trials":41479,"activeCount":101},[],{"trials":41481,"activeCount":101},[41482],{"nctId":41459,"briefTitle":41460,"status":107,"phases":41483,"primaryCompletion":41462,"completion":41462,"start":41463,"enrollment":5242,"conditions":41484,"interventions":41485},[90],[33],[41452,41466,41467],{"trials":41487,"activeCount":101},[],{"trials":41489,"activeCount":101},[],{"trials":41491,"activeCount":101},[],{"trials":41493,"activeCount":101},[],{"intervention":41467,"totalTrials":272,"cells":41495},{"EARLY_PHASE1":41496,"PHASE1":41498,"PHASE2":41504,"PHASE3":41506,"PHASE4":41508,"NA":41510},{"trials":41497,"activeCount":101},[],{"trials":41499,"activeCount":101},[41500],{"nctId":41459,"briefTitle":41460,"status":107,"phases":41501,"primaryCompletion":41462,"completion":41462,"start":41463,"enrollment":5242,"conditions":41502,"interventions":41503},[90],[33],[41452,41466,41467],{"trials":41505,"activeCount":101},[],{"trials":41507,"activeCount":101},[],{"trials":41509,"activeCount":101},[],{"trials":41511,"activeCount":101},[],{"intervention":41513,"totalTrials":272,"cells":41514},"Sirolimus",{"EARLY_PHASE1":41515,"PHASE1":41517,"PHASE2":41525,"PHASE3":41527,"PHASE4":41529,"NA":41531},{"trials":41516,"activeCount":101},[],{"trials":41518,"activeCount":101},[41519],{"nctId":41520,"briefTitle":41521,"status":107,"phases":41522,"primaryCompletion":420,"completion":420,"start":9443,"enrollment":1891,"conditions":41523,"interventions":41524},"NCT00993499","Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and\u002For Disease Progression Following Prior Erlotinib or Gefitinib",[90],[36],[1129,41513],{"trials":41526,"activeCount":101},[],{"trials":41528,"activeCount":101},[],{"trials":41530,"activeCount":101},[],{"trials":41532,"activeCount":101},[],{"intervention":41534,"totalTrials":272,"cells":41535},"BI 691751 fasted",{"EARLY_PHASE1":41536,"PHASE1":41538,"PHASE2":41547,"PHASE3":41549,"PHASE4":41551,"NA":41553},{"trials":41537,"activeCount":101},[],{"trials":41539,"activeCount":101},[41540],{"nctId":41541,"briefTitle":41542,"status":600,"phases":41543,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":101,"conditions":41544,"interventions":41545},"NCT02175238","Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects",[90],[15],[41534,41546],"BI 691751 after high fat breakfast",{"trials":41548,"activeCount":101},[],{"trials":41550,"activeCount":101},[],{"trials":41552,"activeCount":101},[],{"trials":41554,"activeCount":101},[],{"intervention":41546,"totalTrials":272,"cells":41556},{"EARLY_PHASE1":41557,"PHASE1":41559,"PHASE2":41565,"PHASE3":41567,"PHASE4":41569,"NA":41571},{"trials":41558,"activeCount":101},[],{"trials":41560,"activeCount":101},[41561],{"nctId":41541,"briefTitle":41542,"status":600,"phases":41562,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":101,"conditions":41563,"interventions":41564},[90],[15],[41534,41546],{"trials":41566,"activeCount":101},[],{"trials":41568,"activeCount":101},[],{"trials":41570,"activeCount":101},[],{"trials":41572,"activeCount":101},[],{"intervention":968,"totalTrials":272,"cells":41574},{"EARLY_PHASE1":41575,"PHASE1":41577,"PHASE2":41583,"PHASE3":41585,"PHASE4":41587,"NA":41589},{"trials":41576,"activeCount":101},[],{"trials":41578,"activeCount":101},[41579],{"nctId":960,"briefTitle":961,"status":107,"phases":41580,"primaryCompletion":963,"completion":964,"start":965,"enrollment":132,"conditions":41581,"interventions":41582},[90],[15],[911,968,969,970,971],{"trials":41584,"activeCount":101},[],{"trials":41586,"activeCount":101},[],{"trials":41588,"activeCount":101},[],{"trials":41590,"activeCount":101},[],{"intervention":41592,"totalTrials":272,"cells":41593},"BIIX 1 XX inhalation solution",{"EARLY_PHASE1":41594,"PHASE1":41596,"PHASE2":41604,"PHASE3":41606,"PHASE4":41608,"NA":41610},{"trials":41595,"activeCount":101},[],{"trials":41597,"activeCount":101},[41598],{"nctId":41599,"briefTitle":41600,"status":107,"phases":41601,"primaryCompletion":2182,"start":6438,"enrollment":1631,"conditions":41602,"interventions":41603},"NCT02198287","Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers",[90],[15],[41592],{"trials":41605,"activeCount":101},[],{"trials":41607,"activeCount":101},[],{"trials":41609,"activeCount":101},[],{"trials":41611,"activeCount":101},[],{"intervention":41613,"totalTrials":272,"cells":41614},"Nintedanib high dose",{"EARLY_PHASE1":41615,"PHASE1":41617,"PHASE2":41627,"PHASE3":41629,"PHASE4":41631,"NA":41633},{"trials":41616,"activeCount":101},[],{"trials":41618,"activeCount":101},[41619],{"nctId":41620,"briefTitle":41621,"status":107,"phases":41622,"primaryCompletion":475,"completion":603,"start":2506,"enrollment":357,"conditions":41623,"interventions":41624},"NCT01594125","Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma",[90],[9690],[41613,41625,41626,41626,41613],"Nintedanib low dose","Nintedanib medium dose",{"trials":41628,"activeCount":101},[],{"trials":41630,"activeCount":101},[],{"trials":41632,"activeCount":101},[],{"trials":41634,"activeCount":101},[],{"intervention":41625,"totalTrials":272,"cells":41636},{"EARLY_PHASE1":41637,"PHASE1":41639,"PHASE2":41645,"PHASE3":41647,"PHASE4":41649,"NA":41651},{"trials":41638,"activeCount":101},[],{"trials":41640,"activeCount":101},[41641],{"nctId":41620,"briefTitle":41621,"status":107,"phases":41642,"primaryCompletion":475,"completion":603,"start":2506,"enrollment":357,"conditions":41643,"interventions":41644},[90],[9690],[41613,41625,41626,41626,41613],{"trials":41646,"activeCount":101},[],{"trials":41648,"activeCount":101},[],{"trials":41650,"activeCount":101},[],{"trials":41652,"activeCount":101},[],{"intervention":41626,"totalTrials":272,"cells":41654},{"EARLY_PHASE1":41655,"PHASE1":41657,"PHASE2":41663,"PHASE3":41665,"PHASE4":41667,"NA":41669},{"trials":41656,"activeCount":101},[],{"trials":41658,"activeCount":101},[41659],{"nctId":41620,"briefTitle":41621,"status":107,"phases":41660,"primaryCompletion":475,"completion":603,"start":2506,"enrollment":357,"conditions":41661,"interventions":41662},[90],[9690],[41613,41625,41626,41626,41613],{"trials":41664,"activeCount":101},[],{"trials":41666,"activeCount":101},[],{"trials":41668,"activeCount":101},[],{"trials":41670,"activeCount":101},[],{"intervention":41672,"totalTrials":272,"cells":41673},"Heparin-Natrium-5000-ratiopharm",{"EARLY_PHASE1":41674,"PHASE1":41676,"PHASE2":41685,"PHASE3":41687,"PHASE4":41689,"NA":41691},{"trials":41675,"activeCount":101},[],{"trials":41677,"activeCount":101},[41678],{"nctId":41679,"briefTitle":41680,"status":107,"phases":41681,"primaryCompletion":41682,"completion":41682,"start":25327,"enrollment":357,"conditions":41683,"interventions":41684},"NCT04419493","A Study in Healthy Men to Compare 2 Different Formulations of Alteplase",[90],"2021-06-21",[15],[2126,2126,41672],{"trials":41686,"activeCount":101},[],{"trials":41688,"activeCount":101},[],{"trials":41690,"activeCount":101},[],{"trials":41692,"activeCount":101},[],{"intervention":41694,"totalTrials":272,"cells":41695},"BIIL 284 BS - rising dose",{"EARLY_PHASE1":41696,"PHASE1":41698,"PHASE2":41706,"PHASE3":41708,"PHASE4":41710,"NA":41712},{"trials":41697,"activeCount":101},[],{"trials":41699,"activeCount":101},[41700],{"nctId":41701,"briefTitle":41702,"status":107,"phases":41703,"primaryCompletion":7022,"start":13117,"enrollment":1418,"conditions":41704,"interventions":41705},"NCT02273414","Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers",[90],[15],[41694],{"trials":41707,"activeCount":101},[],{"trials":41709,"activeCount":101},[],{"trials":41711,"activeCount":101},[],{"trials":41713,"activeCount":101},[],{"intervention":2412,"totalTrials":272,"cells":41715},{"EARLY_PHASE1":41716,"PHASE1":41718,"PHASE2":41724,"PHASE3":41726,"PHASE4":41728,"NA":41730},{"trials":41717,"activeCount":101},[],{"trials":41719,"activeCount":101},[41720],{"nctId":2404,"briefTitle":2405,"status":107,"phases":41721,"primaryCompletion":2407,"completion":2408,"start":2409,"enrollment":188,"conditions":41722,"interventions":41723},[90],[15],[2370,2412],{"trials":41725,"activeCount":101},[],{"trials":41727,"activeCount":101},[],{"trials":41729,"activeCount":101},[],{"trials":41731,"activeCount":101},[],{"intervention":6044,"totalTrials":272,"cells":41733},{"EARLY_PHASE1":41734,"PHASE1":41736,"PHASE2":41742,"PHASE3":41744,"PHASE4":41746,"NA":41748},{"trials":41735,"activeCount":101},[],{"trials":41737,"activeCount":101},[41738],{"nctId":6037,"briefTitle":6038,"status":107,"phases":41739,"primaryCompletion":6040,"start":6041,"enrollment":401,"conditions":41740,"interventions":41741},[90],[15],[6044,6045,6046,6047,6048,5982],{"trials":41743,"activeCount":101},[],{"trials":41745,"activeCount":101},[],{"trials":41747,"activeCount":101},[],{"trials":41749,"activeCount":101},[],{"intervention":6045,"totalTrials":272,"cells":41751},{"EARLY_PHASE1":41752,"PHASE1":41754,"PHASE2":41760,"PHASE3":41762,"PHASE4":41764,"NA":41766},{"trials":41753,"activeCount":101},[],{"trials":41755,"activeCount":101},[41756],{"nctId":6037,"briefTitle":6038,"status":107,"phases":41757,"primaryCompletion":6040,"start":6041,"enrollment":401,"conditions":41758,"interventions":41759},[90],[15],[6044,6045,6046,6047,6048,5982],{"trials":41761,"activeCount":101},[],{"trials":41763,"activeCount":101},[],{"trials":41765,"activeCount":101},[],{"trials":41767,"activeCount":101},[],{"intervention":6046,"totalTrials":272,"cells":41769},{"EARLY_PHASE1":41770,"PHASE1":41772,"PHASE2":41778,"PHASE3":41780,"PHASE4":41782,"NA":41784},{"trials":41771,"activeCount":101},[],{"trials":41773,"activeCount":101},[41774],{"nctId":6037,"briefTitle":6038,"status":107,"phases":41775,"primaryCompletion":6040,"start":6041,"enrollment":401,"conditions":41776,"interventions":41777},[90],[15],[6044,6045,6046,6047,6048,5982],{"trials":41779,"activeCount":101},[],{"trials":41781,"activeCount":101},[],{"trials":41783,"activeCount":101},[],{"trials":41785,"activeCount":101},[],{"intervention":6047,"totalTrials":272,"cells":41787},{"EARLY_PHASE1":41788,"PHASE1":41790,"PHASE2":41796,"PHASE3":41798,"PHASE4":41800,"NA":41802},{"trials":41789,"activeCount":101},[],{"trials":41791,"activeCount":101},[41792],{"nctId":6037,"briefTitle":6038,"status":107,"phases":41793,"primaryCompletion":6040,"start":6041,"enrollment":401,"conditions":41794,"interventions":41795},[90],[15],[6044,6045,6046,6047,6048,5982],{"trials":41797,"activeCount":101},[],{"trials":41799,"activeCount":101},[],{"trials":41801,"activeCount":101},[],{"trials":41803,"activeCount":101},[],{"intervention":6048,"totalTrials":272,"cells":41805},{"EARLY_PHASE1":41806,"PHASE1":41808,"PHASE2":41814,"PHASE3":41816,"PHASE4":41818,"NA":41820},{"trials":41807,"activeCount":101},[],{"trials":41809,"activeCount":101},[41810],{"nctId":6037,"briefTitle":6038,"status":107,"phases":41811,"primaryCompletion":6040,"start":6041,"enrollment":401,"conditions":41812,"interventions":41813},[90],[15],[6044,6045,6046,6047,6048,5982],{"trials":41815,"activeCount":101},[],{"trials":41817,"activeCount":101},[],{"trials":41819,"activeCount":101},[],{"trials":41821,"activeCount":101},[],{"intervention":6056,"totalTrials":272,"cells":41823},{"EARLY_PHASE1":41824,"PHASE1":41826,"PHASE2":41832,"PHASE3":41834,"PHASE4":41836,"NA":41838},{"trials":41825,"activeCount":101},[],{"trials":41827,"activeCount":101},[41828],{"nctId":6050,"briefTitle":6051,"status":107,"phases":41829,"primaryCompletion":5880,"start":6053,"enrollment":410,"conditions":41830,"interventions":41831},[90],[15],[6056,6057,6058,6059,5982],{"trials":41833,"activeCount":101},[],{"trials":41835,"activeCount":101},[],{"trials":41837,"activeCount":101},[],{"trials":41839,"activeCount":101},[],{"intervention":6057,"totalTrials":272,"cells":41841},{"EARLY_PHASE1":41842,"PHASE1":41844,"PHASE2":41850,"PHASE3":41852,"PHASE4":41854,"NA":41856},{"trials":41843,"activeCount":101},[],{"trials":41845,"activeCount":101},[41846],{"nctId":6050,"briefTitle":6051,"status":107,"phases":41847,"primaryCompletion":5880,"start":6053,"enrollment":410,"conditions":41848,"interventions":41849},[90],[15],[6056,6057,6058,6059,5982],{"trials":41851,"activeCount":101},[],{"trials":41853,"activeCount":101},[],{"trials":41855,"activeCount":101},[],{"trials":41857,"activeCount":101},[],{"intervention":6058,"totalTrials":272,"cells":41859},{"EARLY_PHASE1":41860,"PHASE1":41862,"PHASE2":41868,"PHASE3":41870,"PHASE4":41872,"NA":41874},{"trials":41861,"activeCount":101},[],{"trials":41863,"activeCount":101},[41864],{"nctId":6050,"briefTitle":6051,"status":107,"phases":41865,"primaryCompletion":5880,"start":6053,"enrollment":410,"conditions":41866,"interventions":41867},[90],[15],[6056,6057,6058,6059,5982],{"trials":41869,"activeCount":101},[],{"trials":41871,"activeCount":101},[],{"trials":41873,"activeCount":101},[],{"trials":41875,"activeCount":101},[],{"intervention":6059,"totalTrials":272,"cells":41877},{"EARLY_PHASE1":41878,"PHASE1":41880,"PHASE2":41886,"PHASE3":41888,"PHASE4":41890,"NA":41892},{"trials":41879,"activeCount":101},[],{"trials":41881,"activeCount":101},[41882],{"nctId":6050,"briefTitle":6051,"status":107,"phases":41883,"primaryCompletion":5880,"start":6053,"enrollment":410,"conditions":41884,"interventions":41885},[90],[15],[6056,6057,6058,6059,5982],{"trials":41887,"activeCount":101},[],{"trials":41889,"activeCount":101},[],{"trials":41891,"activeCount":101},[],{"trials":41893,"activeCount":101},[],{"intervention":41895,"totalTrials":272,"cells":41896},"IVAX Warfarin",{"EARLY_PHASE1":41897,"PHASE1":41899,"PHASE2":41908,"PHASE3":41910,"PHASE4":41912,"NA":41914},{"trials":41898,"activeCount":101},[],{"trials":41900,"activeCount":101},[41901],{"nctId":41902,"briefTitle":41903,"status":107,"phases":41904,"primaryCompletion":4412,"start":5856,"enrollment":448,"conditions":41905,"interventions":41906},"NCT02171494","Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers",[90],[15],[41895,41907],"BMS Coumadin",{"trials":41909,"activeCount":101},[],{"trials":41911,"activeCount":101},[],{"trials":41913,"activeCount":101},[],{"trials":41915,"activeCount":101},[],{"intervention":41907,"totalTrials":272,"cells":41917},{"EARLY_PHASE1":41918,"PHASE1":41920,"PHASE2":41926,"PHASE3":41928,"PHASE4":41930,"NA":41932},{"trials":41919,"activeCount":101},[],{"trials":41921,"activeCount":101},[41922],{"nctId":41902,"briefTitle":41903,"status":107,"phases":41923,"primaryCompletion":4412,"start":5856,"enrollment":448,"conditions":41924,"interventions":41925},[90],[15],[41895,41907],{"trials":41927,"activeCount":101},[],{"trials":41929,"activeCount":101},[],{"trials":41931,"activeCount":101},[],{"trials":41933,"activeCount":101},[],{"intervention":41935,"totalTrials":272,"cells":41936},"BI 144807 high dose",{"EARLY_PHASE1":41937,"PHASE1":41939,"PHASE2":41948,"PHASE3":41950,"PHASE4":41952,"NA":41954},{"trials":41938,"activeCount":101},[],{"trials":41940,"activeCount":101},[41941],{"nctId":41942,"briefTitle":41943,"status":107,"phases":41944,"primaryCompletion":611,"completion":611,"start":3762,"enrollment":536,"conditions":41945,"interventions":41946},"NCT01897597","Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions",[90],[15],[41935,41947,41947,41947,41947,41947,41935],"BI 144807 intermediate dose",{"trials":41949,"activeCount":101},[],{"trials":41951,"activeCount":101},[],{"trials":41953,"activeCount":101},[],{"trials":41955,"activeCount":101},[],{"intervention":41947,"totalTrials":272,"cells":41957},{"EARLY_PHASE1":41958,"PHASE1":41960,"PHASE2":41966,"PHASE3":41968,"PHASE4":41970,"NA":41972},{"trials":41959,"activeCount":101},[],{"trials":41961,"activeCount":101},[41962],{"nctId":41942,"briefTitle":41943,"status":107,"phases":41963,"primaryCompletion":611,"completion":611,"start":3762,"enrollment":536,"conditions":41964,"interventions":41965},[90],[15],[41935,41947,41947,41947,41947,41947,41935],{"trials":41967,"activeCount":101},[],{"trials":41969,"activeCount":101},[],{"trials":41971,"activeCount":101},[],{"trials":41973,"activeCount":101},[],{"intervention":6902,"totalTrials":272,"cells":41975},{"EARLY_PHASE1":41976,"PHASE1":41978,"PHASE2":41984,"PHASE3":41986,"PHASE4":41988,"NA":41990},{"trials":41977,"activeCount":101},[],{"trials":41979,"activeCount":101},[41980],{"nctId":6897,"briefTitle":6898,"status":107,"phases":41981,"primaryCompletion":4462,"start":5843,"enrollment":956,"conditions":41982,"interventions":41983},[90],[15],[6890,6902,6903,6904,6905],{"trials":41985,"activeCount":101},[],{"trials":41987,"activeCount":101},[],{"trials":41989,"activeCount":101},[],{"trials":41991,"activeCount":101},[],{"intervention":6903,"totalTrials":272,"cells":41993},{"EARLY_PHASE1":41994,"PHASE1":41996,"PHASE2":42002,"PHASE3":42004,"PHASE4":42006,"NA":42008},{"trials":41995,"activeCount":101},[],{"trials":41997,"activeCount":101},[41998],{"nctId":6897,"briefTitle":6898,"status":107,"phases":41999,"primaryCompletion":4462,"start":5843,"enrollment":956,"conditions":42000,"interventions":42001},[90],[15],[6890,6902,6903,6904,6905],{"trials":42003,"activeCount":101},[],{"trials":42005,"activeCount":101},[],{"trials":42007,"activeCount":101},[],{"trials":42009,"activeCount":101},[],{"intervention":6904,"totalTrials":272,"cells":42011},{"EARLY_PHASE1":42012,"PHASE1":42014,"PHASE2":42020,"PHASE3":42022,"PHASE4":42024,"NA":42026},{"trials":42013,"activeCount":101},[],{"trials":42015,"activeCount":101},[42016],{"nctId":6897,"briefTitle":6898,"status":107,"phases":42017,"primaryCompletion":4462,"start":5843,"enrollment":956,"conditions":42018,"interventions":42019},[90],[15],[6890,6902,6903,6904,6905],{"trials":42021,"activeCount":101},[],{"trials":42023,"activeCount":101},[],{"trials":42025,"activeCount":101},[],{"trials":42027,"activeCount":101},[],{"intervention":6905,"totalTrials":272,"cells":42029},{"EARLY_PHASE1":42030,"PHASE1":42032,"PHASE2":42038,"PHASE3":42040,"PHASE4":42042,"NA":42044},{"trials":42031,"activeCount":101},[],{"trials":42033,"activeCount":101},[42034],{"nctId":6897,"briefTitle":6898,"status":107,"phases":42035,"primaryCompletion":4462,"start":5843,"enrollment":956,"conditions":42036,"interventions":42037},[90],[15],[6890,6902,6903,6904,6905],{"trials":42039,"activeCount":101},[],{"trials":42041,"activeCount":101},[],{"trials":42043,"activeCount":101},[],{"trials":42045,"activeCount":101},[],{"intervention":42047,"totalTrials":272,"cells":42048},"tenofovir\u002FBI 201335",{"EARLY_PHASE1":42049,"PHASE1":42051,"PHASE2":42059,"PHASE3":42061,"PHASE4":42063,"NA":42065},{"trials":42050,"activeCount":101},[],{"trials":42052,"activeCount":101},[42053],{"nctId":42054,"briefTitle":42055,"status":107,"phases":42056,"primaryCompletion":2030,"start":9340,"enrollment":401,"conditions":42057,"interventions":42058},"NCT01340196","Drug Drug Interaction of BI 201335 and Tenofovir",[90],[27],[42047],{"trials":42060,"activeCount":101},[],{"trials":42062,"activeCount":101},[],{"trials":42064,"activeCount":101},[],{"trials":42066,"activeCount":101},[],{"intervention":42068,"totalTrials":272,"cells":42069},"Linagliptin, low dose",{"EARLY_PHASE1":42070,"PHASE1":42072,"PHASE2":42082,"PHASE3":42084,"PHASE4":42086,"NA":42088},{"trials":42071,"activeCount":101},[],{"trials":42073,"activeCount":101},[42074],{"nctId":42075,"briefTitle":42076,"status":107,"phases":42077,"primaryCompletion":400,"start":3991,"enrollment":188,"conditions":42078,"interventions":42079},"NCT02183480","Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers",[90],[15],[42068,42080,42081],"Linagliptin, medium dose","Linagliptin, high dose",{"trials":42083,"activeCount":101},[],{"trials":42085,"activeCount":101},[],{"trials":42087,"activeCount":101},[],{"trials":42089,"activeCount":101},[],{"intervention":42080,"totalTrials":272,"cells":42091},{"EARLY_PHASE1":42092,"PHASE1":42094,"PHASE2":42100,"PHASE3":42102,"PHASE4":42104,"NA":42106},{"trials":42093,"activeCount":101},[],{"trials":42095,"activeCount":101},[42096],{"nctId":42075,"briefTitle":42076,"status":107,"phases":42097,"primaryCompletion":400,"start":3991,"enrollment":188,"conditions":42098,"interventions":42099},[90],[15],[42068,42080,42081],{"trials":42101,"activeCount":101},[],{"trials":42103,"activeCount":101},[],{"trials":42105,"activeCount":101},[],{"trials":42107,"activeCount":101},[],{"intervention":42081,"totalTrials":272,"cells":42109},{"EARLY_PHASE1":42110,"PHASE1":42112,"PHASE2":42118,"PHASE3":42120,"PHASE4":42122,"NA":42124},{"trials":42111,"activeCount":101},[],{"trials":42113,"activeCount":101},[42114],{"nctId":42075,"briefTitle":42076,"status":107,"phases":42115,"primaryCompletion":400,"start":3991,"enrollment":188,"conditions":42116,"interventions":42117},[90],[15],[42068,42080,42081],{"trials":42119,"activeCount":101},[],{"trials":42121,"activeCount":101},[],{"trials":42123,"activeCount":101},[],{"trials":42125,"activeCount":101},[],{"intervention":2510,"totalTrials":272,"cells":42127},{"EARLY_PHASE1":42128,"PHASE1":42130,"PHASE2":42136,"PHASE3":42138,"PHASE4":42140,"NA":42142},{"trials":42129,"activeCount":101},[],{"trials":42131,"activeCount":101},[42132],{"nctId":2503,"briefTitle":2504,"status":107,"phases":42133,"primaryCompletion":2001,"completion":2001,"start":2506,"enrollment":2507,"conditions":42134,"interventions":42135},[90],[15],[2441,2441,2441,2441,2441,2510,2441,2441,2441],{"trials":42137,"activeCount":101},[],{"trials":42139,"activeCount":101},[],{"trials":42141,"activeCount":101},[],{"trials":42143,"activeCount":101},[],{"intervention":42145,"totalTrials":272,"cells":42146},"BILR 355 - Treatment A",{"EARLY_PHASE1":42147,"PHASE1":42149,"PHASE2":42161,"PHASE3":42163,"PHASE4":42165,"NA":42167},{"trials":42148,"activeCount":101},[],{"trials":42150,"activeCount":101},[42151],{"nctId":42152,"briefTitle":42153,"status":107,"phases":42154,"primaryCompletion":20181,"start":1990,"enrollment":2382,"conditions":42155,"interventions":42156},"NCT02253940","Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers",[90],[15],[42145,42157,42158,42159,42160,4010],"BILR 355 - Treatment B","BILR 355 - Treatment C","BILR 355 - Treatment D","BILR 355 - Treatment E",{"trials":42162,"activeCount":101},[],{"trials":42164,"activeCount":101},[],{"trials":42166,"activeCount":101},[],{"trials":42168,"activeCount":101},[],{"intervention":42157,"totalTrials":272,"cells":42170},{"EARLY_PHASE1":42171,"PHASE1":42173,"PHASE2":42179,"PHASE3":42181,"PHASE4":42183,"NA":42185},{"trials":42172,"activeCount":101},[],{"trials":42174,"activeCount":101},[42175],{"nctId":42152,"briefTitle":42153,"status":107,"phases":42176,"primaryCompletion":20181,"start":1990,"enrollment":2382,"conditions":42177,"interventions":42178},[90],[15],[42145,42157,42158,42159,42160,4010],{"trials":42180,"activeCount":101},[],{"trials":42182,"activeCount":101},[],{"trials":42184,"activeCount":101},[],{"trials":42186,"activeCount":101},[],{"intervention":42158,"totalTrials":272,"cells":42188},{"EARLY_PHASE1":42189,"PHASE1":42191,"PHASE2":42197,"PHASE3":42199,"PHASE4":42201,"NA":42203},{"trials":42190,"activeCount":101},[],{"trials":42192,"activeCount":101},[42193],{"nctId":42152,"briefTitle":42153,"status":107,"phases":42194,"primaryCompletion":20181,"start":1990,"enrollment":2382,"conditions":42195,"interventions":42196},[90],[15],[42145,42157,42158,42159,42160,4010],{"trials":42198,"activeCount":101},[],{"trials":42200,"activeCount":101},[],{"trials":42202,"activeCount":101},[],{"trials":42204,"activeCount":101},[],{"intervention":42159,"totalTrials":272,"cells":42206},{"EARLY_PHASE1":42207,"PHASE1":42209,"PHASE2":42215,"PHASE3":42217,"PHASE4":42219,"NA":42221},{"trials":42208,"activeCount":101},[],{"trials":42210,"activeCount":101},[42211],{"nctId":42152,"briefTitle":42153,"status":107,"phases":42212,"primaryCompletion":20181,"start":1990,"enrollment":2382,"conditions":42213,"interventions":42214},[90],[15],[42145,42157,42158,42159,42160,4010],{"trials":42216,"activeCount":101},[],{"trials":42218,"activeCount":101},[],{"trials":42220,"activeCount":101},[],{"trials":42222,"activeCount":101},[],{"intervention":42160,"totalTrials":272,"cells":42224},{"EARLY_PHASE1":42225,"PHASE1":42227,"PHASE2":42233,"PHASE3":42235,"PHASE4":42237,"NA":42239},{"trials":42226,"activeCount":101},[],{"trials":42228,"activeCount":101},[42229],{"nctId":42152,"briefTitle":42153,"status":107,"phases":42230,"primaryCompletion":20181,"start":1990,"enrollment":2382,"conditions":42231,"interventions":42232},[90],[15],[42145,42157,42158,42159,42160,4010],{"trials":42234,"activeCount":101},[],{"trials":42236,"activeCount":101},[],{"trials":42238,"activeCount":101},[],{"trials":42240,"activeCount":101},[],{"intervention":42242,"totalTrials":272,"cells":42243},"Tipranavir (TPV) low",{"EARLY_PHASE1":42244,"PHASE1":42246,"PHASE2":42257,"PHASE3":42259,"PHASE4":42261,"NA":42263},{"trials":42245,"activeCount":101},[],{"trials":42247,"activeCount":101},[42248],{"nctId":42249,"briefTitle":42250,"status":107,"phases":42251,"primaryCompletion":6030,"start":6015,"enrollment":123,"conditions":42252,"interventions":42253},"NCT02249416","Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers",[90],[15],[42242,42254,42255,42256,7579],"Ritonavir (RTV) low","Tipranavir (TPV) high","Ritonavir (RTV) high",{"trials":42258,"activeCount":101},[],{"trials":42260,"activeCount":101},[],{"trials":42262,"activeCount":101},[],{"trials":42264,"activeCount":101},[],{"intervention":42254,"totalTrials":272,"cells":42266},{"EARLY_PHASE1":42267,"PHASE1":42269,"PHASE2":42275,"PHASE3":42277,"PHASE4":42279,"NA":42281},{"trials":42268,"activeCount":101},[],{"trials":42270,"activeCount":101},[42271],{"nctId":42249,"briefTitle":42250,"status":107,"phases":42272,"primaryCompletion":6030,"start":6015,"enrollment":123,"conditions":42273,"interventions":42274},[90],[15],[42242,42254,42255,42256,7579],{"trials":42276,"activeCount":101},[],{"trials":42278,"activeCount":101},[],{"trials":42280,"activeCount":101},[],{"trials":42282,"activeCount":101},[],{"intervention":42255,"totalTrials":272,"cells":42284},{"EARLY_PHASE1":42285,"PHASE1":42287,"PHASE2":42293,"PHASE3":42295,"PHASE4":42297,"NA":42299},{"trials":42286,"activeCount":101},[],{"trials":42288,"activeCount":101},[42289],{"nctId":42249,"briefTitle":42250,"status":107,"phases":42290,"primaryCompletion":6030,"start":6015,"enrollment":123,"conditions":42291,"interventions":42292},[90],[15],[42242,42254,42255,42256,7579],{"trials":42294,"activeCount":101},[],{"trials":42296,"activeCount":101},[],{"trials":42298,"activeCount":101},[],{"trials":42300,"activeCount":101},[],{"intervention":42256,"totalTrials":272,"cells":42302},{"EARLY_PHASE1":42303,"PHASE1":42305,"PHASE2":42311,"PHASE3":42313,"PHASE4":42315,"NA":42317},{"trials":42304,"activeCount":101},[],{"trials":42306,"activeCount":101},[42307],{"nctId":42249,"briefTitle":42250,"status":107,"phases":42308,"primaryCompletion":6030,"start":6015,"enrollment":123,"conditions":42309,"interventions":42310},[90],[15],[42242,42254,42255,42256,7579],{"trials":42312,"activeCount":101},[],{"trials":42314,"activeCount":101},[],{"trials":42316,"activeCount":101},[],{"trials":42318,"activeCount":101},[],{"intervention":42320,"totalTrials":272,"cells":42321},"PPX ER",{"EARLY_PHASE1":42322,"PHASE1":42324,"PHASE2":42332,"PHASE3":42334,"PHASE4":42336,"NA":42338},{"trials":42323,"activeCount":101},[],{"trials":42325,"activeCount":101},[42326],{"nctId":42327,"briefTitle":42328,"status":107,"phases":42329,"primaryCompletion":3754,"start":4392,"enrollment":1865,"conditions":42330,"interventions":42331},"NCT01119443","Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers",[90],[15],[42320,42320],{"trials":42333,"activeCount":101},[],{"trials":42335,"activeCount":101},[],{"trials":42337,"activeCount":101},[],{"trials":42339,"activeCount":101},[],{"intervention":42341,"totalTrials":272,"cells":42342},"AbGn168 intravenous",{"EARLY_PHASE1":42343,"PHASE1":42345,"PHASE2":42354,"PHASE3":42356,"PHASE4":42358,"NA":42360},{"trials":42344,"activeCount":101},[],{"trials":42346,"activeCount":101},[42347],{"nctId":42348,"briefTitle":42349,"status":107,"phases":42350,"primaryCompletion":12600,"start":2032,"enrollment":2382,"conditions":42351,"interventions":42352},"NCT00848055","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis",[90],[114],[42341,42341,42341,42341,42341,42341,42341,42353],"AbGn168 subcutaneous",{"trials":42355,"activeCount":101},[],{"trials":42357,"activeCount":101},[],{"trials":42359,"activeCount":101},[],{"trials":42361,"activeCount":101},[],{"intervention":42353,"totalTrials":272,"cells":42363},{"EARLY_PHASE1":42364,"PHASE1":42366,"PHASE2":42372,"PHASE3":42374,"PHASE4":42376,"NA":42378},{"trials":42365,"activeCount":101},[],{"trials":42367,"activeCount":101},[42368],{"nctId":42348,"briefTitle":42349,"status":107,"phases":42369,"primaryCompletion":12600,"start":2032,"enrollment":2382,"conditions":42370,"interventions":42371},[90],[114],[42341,42341,42341,42341,42341,42341,42341,42353],{"trials":42373,"activeCount":101},[],{"trials":42375,"activeCount":101},[],{"trials":42377,"activeCount":101},[],{"trials":42379,"activeCount":101},[],{"intervention":42381,"totalTrials":272,"cells":42382},"Aggrenox alone",{"EARLY_PHASE1":42383,"PHASE1":42385,"PHASE2":42395,"PHASE3":42397,"PHASE4":42399,"NA":42401},{"trials":42384,"activeCount":101},[],{"trials":42386,"activeCount":101},[42387],{"nctId":42388,"briefTitle":42389,"status":107,"phases":42390,"primaryCompletion":9340,"start":6132,"enrollment":123,"conditions":42391,"interventions":42392},"NCT01303445","Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers",[90],[15],[42381,42393,42393,42394],"Aggrenox and omeprazole","Omeprazole alone",{"trials":42396,"activeCount":101},[],{"trials":42398,"activeCount":101},[],{"trials":42400,"activeCount":101},[],{"trials":42402,"activeCount":101},[],{"intervention":42393,"totalTrials":272,"cells":42404},{"EARLY_PHASE1":42405,"PHASE1":42407,"PHASE2":42413,"PHASE3":42415,"PHASE4":42417,"NA":42419},{"trials":42406,"activeCount":101},[],{"trials":42408,"activeCount":101},[42409],{"nctId":42388,"briefTitle":42389,"status":107,"phases":42410,"primaryCompletion":9340,"start":6132,"enrollment":123,"conditions":42411,"interventions":42412},[90],[15],[42381,42393,42393,42394],{"trials":42414,"activeCount":101},[],{"trials":42416,"activeCount":101},[],{"trials":42418,"activeCount":101},[],{"trials":42420,"activeCount":101},[],{"intervention":42394,"totalTrials":272,"cells":42422},{"EARLY_PHASE1":42423,"PHASE1":42425,"PHASE2":42431,"PHASE3":42433,"PHASE4":42435,"NA":42437},{"trials":42424,"activeCount":101},[],{"trials":42426,"activeCount":101},[42427],{"nctId":42388,"briefTitle":42389,"status":107,"phases":42428,"primaryCompletion":9340,"start":6132,"enrollment":123,"conditions":42429,"interventions":42430},[90],[15],[42381,42393,42393,42394],{"trials":42432,"activeCount":101},[],{"trials":42434,"activeCount":101},[],{"trials":42436,"activeCount":101},[],{"trials":42438,"activeCount":101},[],{"intervention":42440,"totalTrials":272,"cells":42441},"131I-Sibrotuzumab",{"EARLY_PHASE1":42442,"PHASE1":42444,"PHASE2":42452,"PHASE3":42454,"PHASE4":42456,"NA":42458},{"trials":42443,"activeCount":101},[],{"trials":42445,"activeCount":101},[42446],{"nctId":42447,"briefTitle":42448,"status":162,"phases":42449,"primaryCompletion":20755,"start":5880,"enrollment":1340,"conditions":42450,"interventions":42451},"NCT02209727","Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",[90],[36],[42440],{"trials":42453,"activeCount":101},[],{"trials":42455,"activeCount":101},[],{"trials":42457,"activeCount":101},[],{"trials":42459,"activeCount":101},[],{"intervention":42461,"totalTrials":272,"cells":42462},"Saquinavir-sgc",{"EARLY_PHASE1":42463,"PHASE1":42465,"PHASE2":42473,"PHASE3":42475,"PHASE4":42477,"NA":42479},{"trials":42464,"activeCount":101},[],{"trials":42466,"activeCount":101},[42467],{"nctId":42468,"briefTitle":42469,"status":162,"phases":42470,"primaryCompletion":8538,"start":9235,"enrollment":166,"conditions":42471,"interventions":42472},"NCT02184286","Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients",[90],[27],[2186,42461],{"trials":42474,"activeCount":101},[],{"trials":42476,"activeCount":101},[],{"trials":42478,"activeCount":101},[],{"trials":42480,"activeCount":101},[],{"intervention":42482,"totalTrials":272,"cells":42483},"BIBF 1120 + PLD 30 mg\u002Fm2 + CBDCA AUC5 mg\u002FmL*min",{"EARLY_PHASE1":42484,"PHASE1":42486,"PHASE2":42497,"PHASE3":42499,"PHASE4":42501,"NA":42503},{"trials":42485,"activeCount":101},[],{"trials":42487,"activeCount":101},[42488],{"nctId":42489,"briefTitle":42490,"status":107,"phases":42491,"primaryCompletion":42492,"completion":4325,"start":42493,"enrollment":2442,"conditions":42494,"interventions":42495},"NCT01314105","BIBF 1120 + Carboplatin\u002FPegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer",[90],"2013-07-29","2011-03-15",[1187,1188],[42482,42496,42482],"BIBF 1120+ PLD 30 mg\u002Fm2 + CBDCA AUC5 mg\u002FmL*min",{"trials":42498,"activeCount":101},[],{"trials":42500,"activeCount":101},[],{"trials":42502,"activeCount":101},[],{"trials":42504,"activeCount":101},[],{"intervention":42496,"totalTrials":272,"cells":42506},{"EARLY_PHASE1":42507,"PHASE1":42509,"PHASE2":42515,"PHASE3":42517,"PHASE4":42519,"NA":42521},{"trials":42508,"activeCount":101},[],{"trials":42510,"activeCount":101},[42511],{"nctId":42489,"briefTitle":42490,"status":107,"phases":42512,"primaryCompletion":42492,"completion":4325,"start":42493,"enrollment":2442,"conditions":42513,"interventions":42514},[90],[1187,1188],[42482,42496,42482],{"trials":42516,"activeCount":101},[],{"trials":42518,"activeCount":101},[],{"trials":42520,"activeCount":101},[],{"trials":42522,"activeCount":101},[],{"intervention":42524,"totalTrials":272,"cells":42525},"BI 894416 Reference Formulation",{"EARLY_PHASE1":42526,"PHASE1":42528,"PHASE2":42542,"PHASE3":42544,"PHASE4":42546,"NA":42548},{"trials":42527,"activeCount":101},[],{"trials":42529,"activeCount":101},[42530],{"nctId":42531,"briefTitle":42532,"status":162,"phases":42533,"primaryCompletion":42534,"completion":42534,"start":42535,"enrollment":380,"conditions":42536,"interventions":42537},"NCT04232839","A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body",[90],"2020-11-30","2020-02-25",[15],[42524,42538,42539,42540,42541],"BI 894416 Formulation A2","BI 894416 Formulation C2","BI 894416 Formulation D2","BI 894416 Formulation F2",{"trials":42543,"activeCount":101},[],{"trials":42545,"activeCount":101},[],{"trials":42547,"activeCount":101},[],{"trials":42549,"activeCount":101},[],{"intervention":42538,"totalTrials":272,"cells":42551},{"EARLY_PHASE1":42552,"PHASE1":42554,"PHASE2":42560,"PHASE3":42562,"PHASE4":42564,"NA":42566},{"trials":42553,"activeCount":101},[],{"trials":42555,"activeCount":101},[42556],{"nctId":42531,"briefTitle":42532,"status":162,"phases":42557,"primaryCompletion":42534,"completion":42534,"start":42535,"enrollment":380,"conditions":42558,"interventions":42559},[90],[15],[42524,42538,42539,42540,42541],{"trials":42561,"activeCount":101},[],{"trials":42563,"activeCount":101},[],{"trials":42565,"activeCount":101},[],{"trials":42567,"activeCount":101},[],{"intervention":42539,"totalTrials":272,"cells":42569},{"EARLY_PHASE1":42570,"PHASE1":42572,"PHASE2":42578,"PHASE3":42580,"PHASE4":42582,"NA":42584},{"trials":42571,"activeCount":101},[],{"trials":42573,"activeCount":101},[42574],{"nctId":42531,"briefTitle":42532,"status":162,"phases":42575,"primaryCompletion":42534,"completion":42534,"start":42535,"enrollment":380,"conditions":42576,"interventions":42577},[90],[15],[42524,42538,42539,42540,42541],{"trials":42579,"activeCount":101},[],{"trials":42581,"activeCount":101},[],{"trials":42583,"activeCount":101},[],{"trials":42585,"activeCount":101},[],{"intervention":42540,"totalTrials":272,"cells":42587},{"EARLY_PHASE1":42588,"PHASE1":42590,"PHASE2":42596,"PHASE3":42598,"PHASE4":42600,"NA":42602},{"trials":42589,"activeCount":101},[],{"trials":42591,"activeCount":101},[42592],{"nctId":42531,"briefTitle":42532,"status":162,"phases":42593,"primaryCompletion":42534,"completion":42534,"start":42535,"enrollment":380,"conditions":42594,"interventions":42595},[90],[15],[42524,42538,42539,42540,42541],{"trials":42597,"activeCount":101},[],{"trials":42599,"activeCount":101},[],{"trials":42601,"activeCount":101},[],{"trials":42603,"activeCount":101},[],{"intervention":42541,"totalTrials":272,"cells":42605},{"EARLY_PHASE1":42606,"PHASE1":42608,"PHASE2":42614,"PHASE3":42616,"PHASE4":42618,"NA":42620},{"trials":42607,"activeCount":101},[],{"trials":42609,"activeCount":101},[42610],{"nctId":42531,"briefTitle":42532,"status":162,"phases":42611,"primaryCompletion":42534,"completion":42534,"start":42535,"enrollment":380,"conditions":42612,"interventions":42613},[90],[15],[42524,42538,42539,42540,42541],{"trials":42615,"activeCount":101},[],{"trials":42617,"activeCount":101},[],{"trials":42619,"activeCount":101},[],{"trials":42621,"activeCount":101},[],{"intervention":42623,"totalTrials":272,"cells":42624},"Arm A",{"EARLY_PHASE1":42625,"PHASE1":42627,"PHASE2":42636,"PHASE3":42638,"PHASE4":42640,"NA":42642},{"trials":42626,"activeCount":101},[],{"trials":42628,"activeCount":101},[42629],{"nctId":42630,"briefTitle":42631,"status":107,"phases":42632,"primaryCompletion":12600,"start":10775,"enrollment":439,"conditions":42633,"interventions":42634},"NCT00756223","Phase I Study of BI 831266 in Patients With Advanced Solid Tumours",[90],[33],[42623,42635],"Arm B",{"trials":42637,"activeCount":101},[],{"trials":42639,"activeCount":101},[],{"trials":42641,"activeCount":101},[],{"trials":42643,"activeCount":101},[],{"intervention":42635,"totalTrials":272,"cells":42645},{"EARLY_PHASE1":42646,"PHASE1":42648,"PHASE2":42654,"PHASE3":42656,"PHASE4":42658,"NA":42660},{"trials":42647,"activeCount":101},[],{"trials":42649,"activeCount":101},[42650],{"nctId":42630,"briefTitle":42631,"status":107,"phases":42651,"primaryCompletion":12600,"start":10775,"enrollment":439,"conditions":42652,"interventions":42653},[90],[33],[42623,42635],{"trials":42655,"activeCount":101},[],{"trials":42657,"activeCount":101},[],{"trials":42659,"activeCount":101},[],{"trials":42661,"activeCount":101},[],{"intervention":30450,"totalTrials":272,"cells":42663},{"EARLY_PHASE1":42664,"PHASE1":42666,"PHASE2":42672,"PHASE3":42674,"PHASE4":42676,"NA":42678},{"trials":42665,"activeCount":101},[],{"trials":42667,"activeCount":101},[42668],{"nctId":30445,"briefTitle":30446,"status":107,"phases":42669,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":716,"conditions":42670,"interventions":42671},[90],[15],[30450,30451,30452,30438,30453,30438],{"trials":42673,"activeCount":101},[],{"trials":42675,"activeCount":101},[],{"trials":42677,"activeCount":101},[],{"trials":42679,"activeCount":101},[],{"intervention":30451,"totalTrials":272,"cells":42681},{"EARLY_PHASE1":42682,"PHASE1":42684,"PHASE2":42690,"PHASE3":42692,"PHASE4":42694,"NA":42696},{"trials":42683,"activeCount":101},[],{"trials":42685,"activeCount":101},[42686],{"nctId":30445,"briefTitle":30446,"status":107,"phases":42687,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":716,"conditions":42688,"interventions":42689},[90],[15],[30450,30451,30452,30438,30453,30438],{"trials":42691,"activeCount":101},[],{"trials":42693,"activeCount":101},[],{"trials":42695,"activeCount":101},[],{"trials":42697,"activeCount":101},[],{"intervention":30452,"totalTrials":272,"cells":42699},{"EARLY_PHASE1":42700,"PHASE1":42702,"PHASE2":42708,"PHASE3":42710,"PHASE4":42712,"NA":42714},{"trials":42701,"activeCount":101},[],{"trials":42703,"activeCount":101},[42704],{"nctId":30445,"briefTitle":30446,"status":107,"phases":42705,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":716,"conditions":42706,"interventions":42707},[90],[15],[30450,30451,30452,30438,30453,30438],{"trials":42709,"activeCount":101},[],{"trials":42711,"activeCount":101},[],{"trials":42713,"activeCount":101},[],{"trials":42715,"activeCount":101},[],{"intervention":30453,"totalTrials":272,"cells":42717},{"EARLY_PHASE1":42718,"PHASE1":42720,"PHASE2":42726,"PHASE3":42728,"PHASE4":42730,"NA":42732},{"trials":42719,"activeCount":101},[],{"trials":42721,"activeCount":101},[42722],{"nctId":30445,"briefTitle":30446,"status":107,"phases":42723,"primaryCompletion":516,"completion":516,"start":4474,"enrollment":716,"conditions":42724,"interventions":42725},[90],[15],[30450,30451,30452,30438,30453,30438],{"trials":42727,"activeCount":101},[],{"trials":42729,"activeCount":101},[],{"trials":42731,"activeCount":101},[],{"trials":42733,"activeCount":101},[],{"intervention":42735,"totalTrials":272,"cells":42736},"ritonavir + afatinib",{"EARLY_PHASE1":42737,"PHASE1":42739,"PHASE2":42747,"PHASE3":42749,"PHASE4":42751,"NA":42753},{"trials":42738,"activeCount":101},[],{"trials":42740,"activeCount":101},[42741],{"nctId":42742,"briefTitle":42743,"status":107,"phases":42744,"primaryCompletion":6095,"start":2648,"enrollment":380,"conditions":42745,"interventions":42746},"NCT01426958","Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects",[90],[15],[2633,42735,42735],{"trials":42748,"activeCount":101},[],{"trials":42750,"activeCount":101},[],{"trials":42752,"activeCount":101},[],{"trials":42754,"activeCount":101},[],{"intervention":42756,"totalTrials":272,"cells":42757},"BI 137882",{"EARLY_PHASE1":42758,"PHASE1":42760,"PHASE2":42768,"PHASE3":42770,"PHASE4":42772,"NA":42774},{"trials":42759,"activeCount":101},[],{"trials":42761,"activeCount":101},[42762],{"nctId":42763,"briefTitle":42764,"status":162,"phases":42765,"primaryCompletion":2648,"start":9348,"enrollment":2382,"conditions":42766,"interventions":42767},"NCT01348165","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers",[90],[15],[42756],{"trials":42769,"activeCount":101},[],{"trials":42771,"activeCount":101},[],{"trials":42773,"activeCount":101},[],{"trials":42775,"activeCount":101},[],{"intervention":42777,"totalTrials":272,"cells":42778},"amlodipine\u002Ftelmisartan\u002Fcombination",{"EARLY_PHASE1":42779,"PHASE1":42781,"PHASE2":42789,"PHASE3":42791,"PHASE4":42793,"NA":42795},{"trials":42780,"activeCount":101},[],{"trials":42782,"activeCount":101},[42783],{"nctId":42784,"briefTitle":42785,"status":107,"phases":42786,"primaryCompletion":4441,"start":4442,"enrollment":1865,"conditions":42787,"interventions":42788},"NCT01181011","Telmisartan, Amlodipine and Combination in Healthy Subjects",[90],[15],[42777],{"trials":42790,"activeCount":101},[],{"trials":42792,"activeCount":101},[],{"trials":42794,"activeCount":101},[],{"trials":42796,"activeCount":101},[],{"intervention":42798,"totalTrials":272,"cells":42799},"BIIF 1149 BS",{"EARLY_PHASE1":42800,"PHASE1":42802,"PHASE2":42810,"PHASE3":42812,"PHASE4":42814,"NA":42816},{"trials":42801,"activeCount":101},[],{"trials":42803,"activeCount":101},[42804],{"nctId":42805,"briefTitle":42806,"status":107,"phases":42807,"primaryCompletion":8538,"start":6246,"enrollment":380,"conditions":42808,"interventions":42809},"NCT02209714","Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers",[90],[15],[42798],{"trials":42811,"activeCount":101},[],{"trials":42813,"activeCount":101},[],{"trials":42815,"activeCount":101},[],{"trials":42817,"activeCount":101},[],{"intervention":30484,"totalTrials":272,"cells":42819},{"EARLY_PHASE1":42820,"PHASE1":42822,"PHASE2":42828,"PHASE3":42830,"PHASE4":42832,"NA":42834},{"trials":42821,"activeCount":101},[],{"trials":42823,"activeCount":101},[42824],{"nctId":30479,"briefTitle":30480,"status":107,"phases":42825,"primaryCompletion":6401,"start":2112,"enrollment":380,"conditions":42826,"interventions":42827},[90],[15],[30484,30472],{"trials":42829,"activeCount":101},[],{"trials":42831,"activeCount":101},[],{"trials":42833,"activeCount":101},[],{"trials":42835,"activeCount":101},[],{"intervention":42837,"totalTrials":272,"cells":42838},"BI 113608 PIB bid",{"EARLY_PHASE1":42839,"PHASE1":42841,"PHASE2":42850,"PHASE3":42852,"PHASE4":42854,"NA":42856},{"trials":42840,"activeCount":101},[],{"trials":42842,"activeCount":101},[42843],{"nctId":42844,"briefTitle":42845,"status":107,"phases":42846,"primaryCompletion":408,"completion":408,"start":2001,"enrollment":410,"conditions":42847,"interventions":42848},"NCT01681277","Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers",[90],[15],[42837,42837,42837,42849],"BI 113608 PIB qd",{"trials":42851,"activeCount":101},[],{"trials":42853,"activeCount":101},[],{"trials":42855,"activeCount":101},[],{"trials":42857,"activeCount":101},[],{"intervention":42849,"totalTrials":272,"cells":42859},{"EARLY_PHASE1":42860,"PHASE1":42862,"PHASE2":42868,"PHASE3":42870,"PHASE4":42872,"NA":42874},{"trials":42861,"activeCount":101},[],{"trials":42863,"activeCount":101},[42864],{"nctId":42844,"briefTitle":42845,"status":107,"phases":42865,"primaryCompletion":408,"completion":408,"start":2001,"enrollment":410,"conditions":42866,"interventions":42867},[90],[15],[42837,42837,42837,42849],{"trials":42869,"activeCount":101},[],{"trials":42871,"activeCount":101},[],{"trials":42873,"activeCount":101},[],{"trials":42875,"activeCount":101},[],{"intervention":42877,"totalTrials":272,"cells":42878},"Nerandomilast 18 mg - adult formulation",{"EARLY_PHASE1":42879,"PHASE1":42881,"PHASE2":42893,"PHASE3":42895,"PHASE4":42897,"NA":42899},{"trials":42880,"activeCount":101},[],{"trials":42882,"activeCount":101},[42883],{"nctId":42884,"briefTitle":42885,"status":107,"phases":42886,"primaryCompletion":42887,"completion":42888,"start":42889,"enrollment":956,"conditions":42890,"interventions":42891},"NCT06624072","A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food",[90],"2024-11-22","2024-11-30","2024-10-15",[15],[42877,42892],"Nerandomilast 1 mg - paediatric formulation",{"trials":42894,"activeCount":101},[],{"trials":42896,"activeCount":101},[],{"trials":42898,"activeCount":101},[],{"trials":42900,"activeCount":101},[],{"intervention":42892,"totalTrials":272,"cells":42902},{"EARLY_PHASE1":42903,"PHASE1":42905,"PHASE2":42911,"PHASE3":42913,"PHASE4":42915,"NA":42917},{"trials":42904,"activeCount":101},[],{"trials":42906,"activeCount":101},[42907],{"nctId":42884,"briefTitle":42885,"status":107,"phases":42908,"primaryCompletion":42887,"completion":42888,"start":42889,"enrollment":956,"conditions":42909,"interventions":42910},[90],[15],[42877,42892],{"trials":42912,"activeCount":101},[],{"trials":42914,"activeCount":101},[],{"trials":42916,"activeCount":101},[],{"trials":42918,"activeCount":101},[],{"intervention":42920,"totalTrials":272,"cells":42921},"Telmisartan film-coated",{"EARLY_PHASE1":42922,"PHASE1":42924,"PHASE2":42933,"PHASE3":42935,"PHASE4":42937,"NA":42939},{"trials":42923,"activeCount":101},[],{"trials":42925,"activeCount":101},[42926],{"nctId":42927,"briefTitle":42928,"status":107,"phases":42929,"primaryCompletion":2032,"start":5856,"enrollment":1208,"conditions":42930,"interventions":42931},"NCT02261129","Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers",[90],[15],[42920,42932],"Telmisartan uncoated",{"trials":42934,"activeCount":101},[],{"trials":42936,"activeCount":101},[],{"trials":42938,"activeCount":101},[],{"trials":42940,"activeCount":101},[],{"intervention":42932,"totalTrials":272,"cells":42942},{"EARLY_PHASE1":42943,"PHASE1":42945,"PHASE2":42951,"PHASE3":42953,"PHASE4":42955,"NA":42957},{"trials":42944,"activeCount":101},[],{"trials":42946,"activeCount":101},[42947],{"nctId":42927,"briefTitle":42928,"status":107,"phases":42948,"primaryCompletion":2032,"start":5856,"enrollment":1208,"conditions":42949,"interventions":42950},[90],[15],[42920,42932],{"trials":42952,"activeCount":101},[],{"trials":42954,"activeCount":101},[],{"trials":42956,"activeCount":101},[],{"trials":42958,"activeCount":101},[],{"intervention":11060,"totalTrials":272,"cells":42960},{"EARLY_PHASE1":42961,"PHASE1":42963,"PHASE2":42969,"PHASE3":42971,"PHASE4":42973,"NA":42975},{"trials":42962,"activeCount":101},[],{"trials":42964,"activeCount":101},[42965],{"nctId":11055,"briefTitle":11056,"status":107,"phases":42966,"primaryCompletion":390,"start":2648,"enrollment":380,"conditions":42967,"interventions":42968},[90],[15],[11060,11034],{"trials":42970,"activeCount":101},[],{"trials":42972,"activeCount":101},[],{"trials":42974,"activeCount":101},[],{"trials":42976,"activeCount":101},[],{"intervention":19804,"totalTrials":272,"cells":42978},{"EARLY_PHASE1":42979,"PHASE1":42981,"PHASE2":42987,"PHASE3":42989,"PHASE4":42991,"NA":42993},{"trials":42980,"activeCount":101},[],{"trials":42982,"activeCount":101},[42983],{"nctId":19799,"briefTitle":19800,"status":107,"phases":42984,"primaryCompletion":1114,"start":7573,"enrollment":4273,"conditions":42985,"interventions":42986},[90],[15],[19804,3994],{"trials":42988,"activeCount":101},[],{"trials":42990,"activeCount":101},[],{"trials":42992,"activeCount":101},[],{"trials":42994,"activeCount":101},[],{"intervention":451,"totalTrials":272,"cells":42996},{"EARLY_PHASE1":42997,"PHASE1":42999,"PHASE2":43005,"PHASE3":43007,"PHASE4":43009,"NA":43011},{"trials":42998,"activeCount":101},[],{"trials":43000,"activeCount":101},[43001],{"nctId":443,"briefTitle":444,"status":107,"phases":43002,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":43003,"interventions":43004},[90],[15],[73,451,413,413,451,73],{"trials":43006,"activeCount":101},[],{"trials":43008,"activeCount":101},[],{"trials":43010,"activeCount":101},[],{"trials":43012,"activeCount":101},[],{"intervention":43014,"totalTrials":272,"cells":43015},"Desipramine",{"EARLY_PHASE1":43016,"PHASE1":43018,"PHASE2":43027,"PHASE3":43029,"PHASE4":43031,"NA":43033},{"trials":43017,"activeCount":101},[],{"trials":43019,"activeCount":101},[43020],{"nctId":43021,"briefTitle":43022,"status":107,"phases":43023,"primaryCompletion":6029,"start":6030,"enrollment":380,"conditions":43024,"interventions":43025},"NCT02273466","Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects",[90],[15],[43014,43026],"Crobenetine",{"trials":43028,"activeCount":101},[],{"trials":43030,"activeCount":101},[],{"trials":43032,"activeCount":101},[],{"trials":43034,"activeCount":101},[],{"intervention":43026,"totalTrials":272,"cells":43036},{"EARLY_PHASE1":43037,"PHASE1":43039,"PHASE2":43045,"PHASE3":43047,"PHASE4":43049,"NA":43051},{"trials":43038,"activeCount":101},[],{"trials":43040,"activeCount":101},[43041],{"nctId":43021,"briefTitle":43022,"status":107,"phases":43042,"primaryCompletion":6029,"start":6030,"enrollment":380,"conditions":43043,"interventions":43044},[90],[15],[43014,43026],{"trials":43046,"activeCount":101},[],{"trials":43048,"activeCount":101},[],{"trials":43050,"activeCount":101},[],{"trials":43052,"activeCount":101},[],{"intervention":43054,"totalTrials":272,"cells":43055},"[14C] BI 1356 as oral (p.o.) solution",{"EARLY_PHASE1":43056,"PHASE1":43058,"PHASE2":43067,"PHASE3":43069,"PHASE4":43071,"NA":43073},{"trials":43057,"activeCount":101},[],{"trials":43059,"activeCount":101},[43060],{"nctId":43061,"briefTitle":43062,"status":107,"phases":43063,"primaryCompletion":6911,"start":2145,"enrollment":188,"conditions":43064,"interventions":43065},"NCT02183610","Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers",[90],[15],[43054,43066],"[14C] BI 1356 solution for i.v.",{"trials":43068,"activeCount":101},[],{"trials":43070,"activeCount":101},[],{"trials":43072,"activeCount":101},[],{"trials":43074,"activeCount":101},[],{"intervention":43066,"totalTrials":272,"cells":43076},{"EARLY_PHASE1":43077,"PHASE1":43079,"PHASE2":43085,"PHASE3":43087,"PHASE4":43089,"NA":43091},{"trials":43078,"activeCount":101},[],{"trials":43080,"activeCount":101},[43081],{"nctId":43061,"briefTitle":43062,"status":107,"phases":43082,"primaryCompletion":6911,"start":2145,"enrollment":188,"conditions":43083,"interventions":43084},[90],[15],[43054,43066],{"trials":43086,"activeCount":101},[],{"trials":43088,"activeCount":101},[],{"trials":43090,"activeCount":101},[],{"trials":43092,"activeCount":101},[],{"intervention":10921,"totalTrials":272,"cells":43094},{"EARLY_PHASE1":43095,"PHASE1":43097,"PHASE2":43103,"PHASE3":43105,"PHASE4":43107,"NA":43109},{"trials":43096,"activeCount":101},[],{"trials":43098,"activeCount":101},[43099],{"nctId":10916,"briefTitle":10917,"status":107,"phases":43100,"primaryCompletion":419,"completion":419,"start":5233,"enrollment":448,"conditions":43101,"interventions":43102},[90],[15],[10896,10921,10922],{"trials":43104,"activeCount":101},[],{"trials":43106,"activeCount":101},[],{"trials":43108,"activeCount":101},[],{"trials":43110,"activeCount":101},[],{"intervention":28900,"totalTrials":272,"cells":43112},{"EARLY_PHASE1":43113,"PHASE1":43115,"PHASE2":43121,"PHASE3":43123,"PHASE4":43125,"NA":43127},{"trials":43114,"activeCount":101},[],{"trials":43116,"activeCount":101},[43117],{"nctId":28895,"briefTitle":28896,"status":107,"phases":43118,"primaryCompletion":5992,"start":7132,"enrollment":23663,"conditions":43119,"interventions":43120},[90],[15],[6228,6227,28900,28901],{"trials":43122,"activeCount":101},[],{"trials":43124,"activeCount":101},[],{"trials":43126,"activeCount":101},[],{"trials":43128,"activeCount":101},[],{"intervention":28901,"totalTrials":272,"cells":43130},{"EARLY_PHASE1":43131,"PHASE1":43133,"PHASE2":43139,"PHASE3":43141,"PHASE4":43143,"NA":43145},{"trials":43132,"activeCount":101},[],{"trials":43134,"activeCount":101},[43135],{"nctId":28895,"briefTitle":28896,"status":107,"phases":43136,"primaryCompletion":5992,"start":7132,"enrollment":23663,"conditions":43137,"interventions":43138},[90],[15],[6228,6227,28900,28901],{"trials":43140,"activeCount":101},[],{"trials":43142,"activeCount":101},[],{"trials":43144,"activeCount":101},[],{"trials":43146,"activeCount":101},[],{"intervention":6952,"totalTrials":272,"cells":43148},{"EARLY_PHASE1":43149,"PHASE1":43151,"PHASE2":43157,"PHASE3":43159,"PHASE4":43161,"NA":43163},{"trials":43150,"activeCount":101},[],{"trials":43152,"activeCount":101},[43153],{"nctId":6946,"briefTitle":6947,"status":107,"phases":43154,"primaryCompletion":6949,"start":2162,"enrollment":956,"conditions":43155,"interventions":43156},[90],[15],[6476,6952,6953],{"trials":43158,"activeCount":101},[],{"trials":43160,"activeCount":101},[],{"trials":43162,"activeCount":101},[],{"trials":43164,"activeCount":101},[],{"intervention":43166,"totalTrials":272,"cells":43167},"Methadone",{"EARLY_PHASE1":43168,"PHASE1":43170,"PHASE2":43178,"PHASE3":43180,"PHASE4":43182,"NA":43184},{"trials":43169,"activeCount":101},[],{"trials":43171,"activeCount":101},[43172],{"nctId":43173,"briefTitle":43174,"status":107,"phases":43175,"primaryCompletion":17247,"start":6782,"enrollment":956,"conditions":43176,"interventions":43177},"NCT02245451","Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers",[90],[15],[4008,4010,43166],{"trials":43179,"activeCount":101},[],{"trials":43181,"activeCount":101},[],{"trials":43183,"activeCount":101},[],{"trials":43185,"activeCount":101},[],{"intervention":43187,"totalTrials":272,"cells":43188},"Digoxin plus BI 10773",{"EARLY_PHASE1":43189,"PHASE1":43191,"PHASE2":43199,"PHASE3":43201,"PHASE4":43203,"NA":43205},{"trials":43190,"activeCount":101},[],{"trials":43192,"activeCount":101},[43193],{"nctId":43194,"briefTitle":43195,"status":107,"phases":43196,"primaryCompletion":9340,"start":9332,"enrollment":1672,"conditions":43197,"interventions":43198},"NCT01306175","Drug Interaction Study of Digoxin and BI 10773",[90],[15],[43187,2393],{"trials":43200,"activeCount":101},[],{"trials":43202,"activeCount":101},[],{"trials":43204,"activeCount":101},[],{"trials":43206,"activeCount":101},[],{"intervention":43208,"totalTrials":272,"cells":43209},"BIBW 2992 low (20mg) dosage",{"EARLY_PHASE1":43210,"PHASE1":43212,"PHASE2":43225,"PHASE3":43227,"PHASE4":43229,"NA":43231},{"trials":43211,"activeCount":101},[],{"trials":43213,"activeCount":101},[43214],{"nctId":43215,"briefTitle":43216,"status":107,"phases":43217,"primaryCompletion":3730,"completion":3730,"start":5905,"enrollment":1106,"conditions":43218,"interventions":43219},"NCT00906698","Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and\u002For HER2",[90],[33],[43208,43220,43221,43222,43223,43224],"BIBW 2992 medium (40mg) dosage","BIBW 2992 high (50mg) dosage","Vinorelbine per os 60 mg\u002Fm²","Vinorelbine per os 80 mg\u002Fm²","Vinorelbine i.v. 25 mg\u002Fm²",{"trials":43226,"activeCount":101},[],{"trials":43228,"activeCount":101},[],{"trials":43230,"activeCount":101},[],{"trials":43232,"activeCount":101},[],{"intervention":43220,"totalTrials":272,"cells":43234},{"EARLY_PHASE1":43235,"PHASE1":43237,"PHASE2":43243,"PHASE3":43245,"PHASE4":43247,"NA":43249},{"trials":43236,"activeCount":101},[],{"trials":43238,"activeCount":101},[43239],{"nctId":43215,"briefTitle":43216,"status":107,"phases":43240,"primaryCompletion":3730,"completion":3730,"start":5905,"enrollment":1106,"conditions":43241,"interventions":43242},[90],[33],[43208,43220,43221,43222,43223,43224],{"trials":43244,"activeCount":101},[],{"trials":43246,"activeCount":101},[],{"trials":43248,"activeCount":101},[],{"trials":43250,"activeCount":101},[],{"intervention":43221,"totalTrials":272,"cells":43252},{"EARLY_PHASE1":43253,"PHASE1":43255,"PHASE2":43261,"PHASE3":43263,"PHASE4":43265,"NA":43267},{"trials":43254,"activeCount":101},[],{"trials":43256,"activeCount":101},[43257],{"nctId":43215,"briefTitle":43216,"status":107,"phases":43258,"primaryCompletion":3730,"completion":3730,"start":5905,"enrollment":1106,"conditions":43259,"interventions":43260},[90],[33],[43208,43220,43221,43222,43223,43224],{"trials":43262,"activeCount":101},[],{"trials":43264,"activeCount":101},[],{"trials":43266,"activeCount":101},[],{"trials":43268,"activeCount":101},[],{"intervention":43222,"totalTrials":272,"cells":43270},{"EARLY_PHASE1":43271,"PHASE1":43273,"PHASE2":43279,"PHASE3":43281,"PHASE4":43283,"NA":43285},{"trials":43272,"activeCount":101},[],{"trials":43274,"activeCount":101},[43275],{"nctId":43215,"briefTitle":43216,"status":107,"phases":43276,"primaryCompletion":3730,"completion":3730,"start":5905,"enrollment":1106,"conditions":43277,"interventions":43278},[90],[33],[43208,43220,43221,43222,43223,43224],{"trials":43280,"activeCount":101},[],{"trials":43282,"activeCount":101},[],{"trials":43284,"activeCount":101},[],{"trials":43286,"activeCount":101},[],{"intervention":43223,"totalTrials":272,"cells":43288},{"EARLY_PHASE1":43289,"PHASE1":43291,"PHASE2":43297,"PHASE3":43299,"PHASE4":43301,"NA":43303},{"trials":43290,"activeCount":101},[],{"trials":43292,"activeCount":101},[43293],{"nctId":43215,"briefTitle":43216,"status":107,"phases":43294,"primaryCompletion":3730,"completion":3730,"start":5905,"enrollment":1106,"conditions":43295,"interventions":43296},[90],[33],[43208,43220,43221,43222,43223,43224],{"trials":43298,"activeCount":101},[],{"trials":43300,"activeCount":101},[],{"trials":43302,"activeCount":101},[],{"trials":43304,"activeCount":101},[],{"intervention":43224,"totalTrials":272,"cells":43306},{"EARLY_PHASE1":43307,"PHASE1":43309,"PHASE2":43315,"PHASE3":43317,"PHASE4":43319,"NA":43321},{"trials":43308,"activeCount":101},[],{"trials":43310,"activeCount":101},[43311],{"nctId":43215,"briefTitle":43216,"status":107,"phases":43312,"primaryCompletion":3730,"completion":3730,"start":5905,"enrollment":1106,"conditions":43313,"interventions":43314},[90],[33],[43208,43220,43221,43222,43223,43224],{"trials":43316,"activeCount":101},[],{"trials":43318,"activeCount":101},[],{"trials":43320,"activeCount":101},[],{"trials":43322,"activeCount":101},[],{"intervention":43324,"totalTrials":272,"cells":43325},"KUC 7483 CL - single rising dose",{"EARLY_PHASE1":43326,"PHASE1":43328,"PHASE2":43336,"PHASE3":43338,"PHASE4":43340,"NA":43342},{"trials":43327,"activeCount":101},[],{"trials":43329,"activeCount":101},[43330],{"nctId":43331,"briefTitle":43332,"status":107,"phases":43333,"primaryCompletion":9276,"start":8479,"enrollment":380,"conditions":43334,"interventions":43335},"NCT02259764","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers",[90],[15],[43324],{"trials":43337,"activeCount":101},[],{"trials":43339,"activeCount":101},[],{"trials":43341,"activeCount":101},[],{"trials":43343,"activeCount":101},[],{"intervention":43345,"totalTrials":272,"cells":43346},"Ethanolic Solution From HFA134a-MDI - low",{"EARLY_PHASE1":43347,"PHASE1":43349,"PHASE2":43360,"PHASE3":43362,"PHASE4":43364,"NA":43366},{"trials":43348,"activeCount":101},[],{"trials":43350,"activeCount":101},[43351],{"nctId":43352,"briefTitle":43353,"status":107,"phases":43354,"primaryCompletion":7114,"start":11123,"enrollment":1672,"conditions":43355,"interventions":43356},"NCT02264145","The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers",[90],[15],[43345,43357,43358,43359],"Ethanolic Solution From HFA134a-MDI - medium","Ethanolic Solution From HFA134a-MDI - high","Ethanolic Solution From Respimat®",{"trials":43361,"activeCount":101},[],{"trials":43363,"activeCount":101},[],{"trials":43365,"activeCount":101},[],{"trials":43367,"activeCount":101},[],{"intervention":43357,"totalTrials":272,"cells":43369},{"EARLY_PHASE1":43370,"PHASE1":43372,"PHASE2":43378,"PHASE3":43380,"PHASE4":43382,"NA":43384},{"trials":43371,"activeCount":101},[],{"trials":43373,"activeCount":101},[43374],{"nctId":43352,"briefTitle":43353,"status":107,"phases":43375,"primaryCompletion":7114,"start":11123,"enrollment":1672,"conditions":43376,"interventions":43377},[90],[15],[43345,43357,43358,43359],{"trials":43379,"activeCount":101},[],{"trials":43381,"activeCount":101},[],{"trials":43383,"activeCount":101},[],{"trials":43385,"activeCount":101},[],{"intervention":43358,"totalTrials":272,"cells":43387},{"EARLY_PHASE1":43388,"PHASE1":43390,"PHASE2":43396,"PHASE3":43398,"PHASE4":43400,"NA":43402},{"trials":43389,"activeCount":101},[],{"trials":43391,"activeCount":101},[43392],{"nctId":43352,"briefTitle":43353,"status":107,"phases":43393,"primaryCompletion":7114,"start":11123,"enrollment":1672,"conditions":43394,"interventions":43395},[90],[15],[43345,43357,43358,43359],{"trials":43397,"activeCount":101},[],{"trials":43399,"activeCount":101},[],{"trials":43401,"activeCount":101},[],{"trials":43403,"activeCount":101},[],{"intervention":43359,"totalTrials":272,"cells":43405},{"EARLY_PHASE1":43406,"PHASE1":43408,"PHASE2":43414,"PHASE3":43416,"PHASE4":43418,"NA":43420},{"trials":43407,"activeCount":101},[],{"trials":43409,"activeCount":101},[43410],{"nctId":43352,"briefTitle":43353,"status":107,"phases":43411,"primaryCompletion":7114,"start":11123,"enrollment":1672,"conditions":43412,"interventions":43413},[90],[15],[43345,43357,43358,43359],{"trials":43415,"activeCount":101},[],{"trials":43417,"activeCount":101},[],{"trials":43419,"activeCount":101},[],{"trials":43421,"activeCount":101},[],{"intervention":21922,"totalTrials":272,"cells":43423},{"EARLY_PHASE1":43424,"PHASE1":43426,"PHASE2":43432,"PHASE3":43434,"PHASE4":43436,"NA":43438},{"trials":43425,"activeCount":101},[],{"trials":43427,"activeCount":101},[43428],{"nctId":21916,"briefTitle":21917,"status":162,"phases":43429,"primaryCompletion":6884,"start":2182,"enrollment":155,"conditions":43430,"interventions":43431},[90],[27],[2186,21921,21922],{"trials":43433,"activeCount":101},[],{"trials":43435,"activeCount":101},[],{"trials":43437,"activeCount":101},[],{"trials":43439,"activeCount":101},[],{"intervention":6069,"totalTrials":272,"cells":43441},{"EARLY_PHASE1":43442,"PHASE1":43444,"PHASE2":43450,"PHASE3":43452,"PHASE4":43454,"NA":43456},{"trials":43443,"activeCount":101},[],{"trials":43445,"activeCount":101},[43446],{"nctId":6061,"briefTitle":6062,"status":107,"phases":43447,"primaryCompletion":6064,"start":6065,"enrollment":188,"conditions":43448,"interventions":43449},[90],[15],[6068,6069,5982],{"trials":43451,"activeCount":101},[],{"trials":43453,"activeCount":101},[],{"trials":43455,"activeCount":101},[],{"trials":43457,"activeCount":101},[],{"intervention":43459,"totalTrials":272,"cells":43460},"BI 1356 - Tablet TFII",{"EARLY_PHASE1":43461,"PHASE1":43463,"PHASE2":43473,"PHASE3":43475,"PHASE4":43477,"NA":43479},{"trials":43462,"activeCount":101},[],{"trials":43464,"activeCount":101},[43465],{"nctId":43466,"briefTitle":43467,"status":107,"phases":43468,"primaryCompletion":1114,"start":9902,"enrollment":380,"conditions":43469,"interventions":43470},"NCT02183363","Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers",[90],[15],[43459,43471,43472],"BI 1356 - Tablet iFF","BI 1356 - Tablet TFIIb",{"trials":43474,"activeCount":101},[],{"trials":43476,"activeCount":101},[],{"trials":43478,"activeCount":101},[],{"trials":43480,"activeCount":101},[],{"intervention":43471,"totalTrials":272,"cells":43482},{"EARLY_PHASE1":43483,"PHASE1":43485,"PHASE2":43491,"PHASE3":43493,"PHASE4":43495,"NA":43497},{"trials":43484,"activeCount":101},[],{"trials":43486,"activeCount":101},[43487],{"nctId":43466,"briefTitle":43467,"status":107,"phases":43488,"primaryCompletion":1114,"start":9902,"enrollment":380,"conditions":43489,"interventions":43490},[90],[15],[43459,43471,43472],{"trials":43492,"activeCount":101},[],{"trials":43494,"activeCount":101},[],{"trials":43496,"activeCount":101},[],{"trials":43498,"activeCount":101},[],{"intervention":43472,"totalTrials":272,"cells":43500},{"EARLY_PHASE1":43501,"PHASE1":43503,"PHASE2":43509,"PHASE3":43511,"PHASE4":43513,"NA":43515},{"trials":43502,"activeCount":101},[],{"trials":43504,"activeCount":101},[43505],{"nctId":43466,"briefTitle":43467,"status":107,"phases":43506,"primaryCompletion":1114,"start":9902,"enrollment":380,"conditions":43507,"interventions":43508},[90],[15],[43459,43471,43472],{"trials":43510,"activeCount":101},[],{"trials":43512,"activeCount":101},[],{"trials":43514,"activeCount":101},[],{"trials":43516,"activeCount":101},[],{"intervention":10027,"totalTrials":272,"cells":43518},{"EARLY_PHASE1":43519,"PHASE1":43521,"PHASE2":43527,"PHASE3":43529,"PHASE4":43531,"NA":43533},{"trials":43520,"activeCount":101},[],{"trials":43522,"activeCount":101},[43523],{"nctId":10021,"briefTitle":10022,"status":107,"phases":43524,"primaryCompletion":10024,"completion":10024,"start":516,"enrollment":132,"conditions":43525,"interventions":43526},[90],[15],[4479,4479,10027,10028],{"trials":43528,"activeCount":101},[],{"trials":43530,"activeCount":101},[],{"trials":43532,"activeCount":101},[],{"trials":43534,"activeCount":101},[],{"intervention":10028,"totalTrials":272,"cells":43536},{"EARLY_PHASE1":43537,"PHASE1":43539,"PHASE2":43545,"PHASE3":43547,"PHASE4":43549,"NA":43551},{"trials":43538,"activeCount":101},[],{"trials":43540,"activeCount":101},[43541],{"nctId":10021,"briefTitle":10022,"status":107,"phases":43542,"primaryCompletion":10024,"completion":10024,"start":516,"enrollment":132,"conditions":43543,"interventions":43544},[90],[15],[4479,4479,10027,10028],{"trials":43546,"activeCount":101},[],{"trials":43548,"activeCount":101},[],{"trials":43550,"activeCount":101},[],{"trials":43552,"activeCount":101},[],{"intervention":43554,"totalTrials":272,"cells":43555},"BI 163538 XX",{"EARLY_PHASE1":43556,"PHASE1":43558,"PHASE2":43566,"PHASE3":43568,"PHASE4":43570,"NA":43572},{"trials":43557,"activeCount":101},[],{"trials":43559,"activeCount":101},[43560],{"nctId":43561,"briefTitle":43562,"status":107,"phases":43563,"primaryCompletion":517,"completion":517,"start":4038,"enrollment":410,"conditions":43564,"interventions":43565},"NCT01587391","Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX",[90],[15],[43554],{"trials":43567,"activeCount":101},[],{"trials":43569,"activeCount":101},[],{"trials":43571,"activeCount":101},[],{"trials":43573,"activeCount":101},[],{"intervention":19718,"totalTrials":272,"cells":43575},{"EARLY_PHASE1":43576,"PHASE1":43578,"PHASE2":43584,"PHASE3":43586,"PHASE4":43588,"NA":43590},{"trials":43577,"activeCount":101},[],{"trials":43579,"activeCount":101},[43580],{"nctId":19713,"briefTitle":19714,"status":107,"phases":43581,"primaryCompletion":6235,"start":6472,"enrollment":3436,"conditions":43582,"interventions":43583},[90],[15],[19700,19718,19719],{"trials":43585,"activeCount":101},[],{"trials":43587,"activeCount":101},[],{"trials":43589,"activeCount":101},[],{"trials":43591,"activeCount":101},[],{"intervention":43593,"totalTrials":272,"cells":43594},"BI 764198 - Formula A",{"EARLY_PHASE1":43595,"PHASE1":43597,"PHASE2":43609,"PHASE3":43611,"PHASE4":43613,"NA":43615},{"trials":43596,"activeCount":101},[],{"trials":43598,"activeCount":101},[43599],{"nctId":43600,"briefTitle":43601,"status":107,"phases":43602,"primaryCompletion":30141,"completion":30141,"start":43603,"enrollment":1865,"conditions":43604,"interventions":43605},"NCT04656288","A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood",[90],"2021-01-15",[15],[43593,43606,43607,43608],"BI 764198 - Formula B","BI 764198 - Formula C","BI 764198 - Formula D",{"trials":43610,"activeCount":101},[],{"trials":43612,"activeCount":101},[],{"trials":43614,"activeCount":101},[],{"trials":43616,"activeCount":101},[],{"intervention":43606,"totalTrials":272,"cells":43618},{"EARLY_PHASE1":43619,"PHASE1":43621,"PHASE2":43627,"PHASE3":43629,"PHASE4":43631,"NA":43633},{"trials":43620,"activeCount":101},[],{"trials":43622,"activeCount":101},[43623],{"nctId":43600,"briefTitle":43601,"status":107,"phases":43624,"primaryCompletion":30141,"completion":30141,"start":43603,"enrollment":1865,"conditions":43625,"interventions":43626},[90],[15],[43593,43606,43607,43608],{"trials":43628,"activeCount":101},[],{"trials":43630,"activeCount":101},[],{"trials":43632,"activeCount":101},[],{"trials":43634,"activeCount":101},[],{"intervention":43607,"totalTrials":272,"cells":43636},{"EARLY_PHASE1":43637,"PHASE1":43639,"PHASE2":43645,"PHASE3":43647,"PHASE4":43649,"NA":43651},{"trials":43638,"activeCount":101},[],{"trials":43640,"activeCount":101},[43641],{"nctId":43600,"briefTitle":43601,"status":107,"phases":43642,"primaryCompletion":30141,"completion":30141,"start":43603,"enrollment":1865,"conditions":43643,"interventions":43644},[90],[15],[43593,43606,43607,43608],{"trials":43646,"activeCount":101},[],{"trials":43648,"activeCount":101},[],{"trials":43650,"activeCount":101},[],{"trials":43652,"activeCount":101},[],{"intervention":43608,"totalTrials":272,"cells":43654},{"EARLY_PHASE1":43655,"PHASE1":43657,"PHASE2":43663,"PHASE3":43665,"PHASE4":43667,"NA":43669},{"trials":43656,"activeCount":101},[],{"trials":43658,"activeCount":101},[43659],{"nctId":43600,"briefTitle":43601,"status":107,"phases":43660,"primaryCompletion":30141,"completion":30141,"start":43603,"enrollment":1865,"conditions":43661,"interventions":43662},[90],[15],[43593,43606,43607,43608],{"trials":43664,"activeCount":101},[],{"trials":43666,"activeCount":101},[],{"trials":43668,"activeCount":101},[],{"trials":43670,"activeCount":101},[],{"intervention":19607,"totalTrials":272,"cells":43672},{"EARLY_PHASE1":43673,"PHASE1":43675,"PHASE2":43681,"PHASE3":43683,"PHASE4":43685,"NA":43687},{"trials":43674,"activeCount":101},[],{"trials":43676,"activeCount":101},[43677],{"nctId":19602,"briefTitle":19603,"status":107,"phases":43678,"primaryCompletion":7300,"start":17247,"enrollment":1237,"conditions":43679,"interventions":43680},[90],[15],[11653,4008,19607,19608],{"trials":43682,"activeCount":101},[],{"trials":43684,"activeCount":101},[],{"trials":43686,"activeCount":101},[],{"trials":43688,"activeCount":101},[],{"intervention":19608,"totalTrials":272,"cells":43690},{"EARLY_PHASE1":43691,"PHASE1":43693,"PHASE2":43699,"PHASE3":43701,"PHASE4":43703,"NA":43705},{"trials":43692,"activeCount":101},[],{"trials":43694,"activeCount":101},[43695],{"nctId":19602,"briefTitle":19603,"status":107,"phases":43696,"primaryCompletion":7300,"start":17247,"enrollment":1237,"conditions":43697,"interventions":43698},[90],[15],[11653,4008,19607,19608],{"trials":43700,"activeCount":101},[],{"trials":43702,"activeCount":101},[],{"trials":43704,"activeCount":101},[],{"trials":43706,"activeCount":101},[],{"intervention":18705,"totalTrials":272,"cells":43708},{"EARLY_PHASE1":43709,"PHASE1":43711,"PHASE2":43717,"PHASE3":43719,"PHASE4":43721,"NA":43723},{"trials":43710,"activeCount":101},[],{"trials":43712,"activeCount":101},[43713],{"nctId":18697,"briefTitle":18698,"status":107,"phases":43714,"primaryCompletion":18700,"completion":18701,"start":18702,"enrollment":2382,"conditions":43715,"interventions":43716},[90],[15],[18705,4436,4095],{"trials":43718,"activeCount":101},[],{"trials":43720,"activeCount":101},[],{"trials":43722,"activeCount":101},[],{"trials":43724,"activeCount":101},[],{"intervention":11654,"totalTrials":272,"cells":43726},{"EARLY_PHASE1":43727,"PHASE1":43729,"PHASE2":43735,"PHASE3":43737,"PHASE4":43739,"NA":43741},{"trials":43728,"activeCount":101},[],{"trials":43730,"activeCount":101},[43731],{"nctId":11646,"briefTitle":11647,"status":107,"phases":43732,"primaryCompletion":11649,"start":11650,"enrollment":1891,"conditions":43733,"interventions":43734},[90],[15],[11653,11654,11632,4010],{"trials":43736,"activeCount":101},[],{"trials":43738,"activeCount":101},[],{"trials":43740,"activeCount":101},[],{"trials":43742,"activeCount":101},[],{"intervention":30491,"totalTrials":272,"cells":43744},{"EARLY_PHASE1":43745,"PHASE1":43747,"PHASE2":43753,"PHASE3":43755,"PHASE4":43757,"NA":43759},{"trials":43746,"activeCount":101},[],{"trials":43748,"activeCount":101},[43749],{"nctId":30486,"briefTitle":30487,"status":107,"phases":43750,"primaryCompletion":6701,"start":6005,"enrollment":392,"conditions":43751,"interventions":43752},[90],[15],[30491,30492,30472],{"trials":43754,"activeCount":101},[],{"trials":43756,"activeCount":101},[],{"trials":43758,"activeCount":101},[],{"trials":43760,"activeCount":101},[],{"intervention":30492,"totalTrials":272,"cells":43762},{"EARLY_PHASE1":43763,"PHASE1":43765,"PHASE2":43771,"PHASE3":43773,"PHASE4":43775,"NA":43777},{"trials":43764,"activeCount":101},[],{"trials":43766,"activeCount":101},[43767],{"nctId":30486,"briefTitle":30487,"status":107,"phases":43768,"primaryCompletion":6701,"start":6005,"enrollment":392,"conditions":43769,"interventions":43770},[90],[15],[30491,30492,30472],{"trials":43772,"activeCount":101},[],{"trials":43774,"activeCount":101},[],{"trials":43776,"activeCount":101},[],{"trials":43778,"activeCount":101},[],{"intervention":43780,"totalTrials":272,"cells":43781},"Fluvoxamine",{"EARLY_PHASE1":43782,"PHASE1":43784,"PHASE2":43796,"PHASE3":43798,"PHASE4":43800,"NA":43802},{"trials":43783,"activeCount":101},[],{"trials":43785,"activeCount":101},[43786],{"nctId":43787,"briefTitle":43788,"status":107,"phases":43789,"primaryCompletion":43790,"completion":43791,"start":5378,"enrollment":392,"conditions":43792,"interventions":43793},"NCT02853136","Influence of Fluvoxamine on the Pharmacokinetics of BI 409306",[90],"2016-10-17","2016-10-25",[15],[43780,43794,43795],"BI 409306 - Powder for oral solution","BI 409306 - film coated",{"trials":43797,"activeCount":101},[],{"trials":43799,"activeCount":101},[],{"trials":43801,"activeCount":101},[],{"trials":43803,"activeCount":101},[],{"intervention":43794,"totalTrials":272,"cells":43805},{"EARLY_PHASE1":43806,"PHASE1":43808,"PHASE2":43814,"PHASE3":43816,"PHASE4":43818,"NA":43820},{"trials":43807,"activeCount":101},[],{"trials":43809,"activeCount":101},[43810],{"nctId":43787,"briefTitle":43788,"status":107,"phases":43811,"primaryCompletion":43790,"completion":43791,"start":5378,"enrollment":392,"conditions":43812,"interventions":43813},[90],[15],[43780,43794,43795],{"trials":43815,"activeCount":101},[],{"trials":43817,"activeCount":101},[],{"trials":43819,"activeCount":101},[],{"trials":43821,"activeCount":101},[],{"intervention":43795,"totalTrials":272,"cells":43823},{"EARLY_PHASE1":43824,"PHASE1":43826,"PHASE2":43832,"PHASE3":43834,"PHASE4":43836,"NA":43838},{"trials":43825,"activeCount":101},[],{"trials":43827,"activeCount":101},[43828],{"nctId":43787,"briefTitle":43788,"status":107,"phases":43829,"primaryCompletion":43790,"completion":43791,"start":5378,"enrollment":392,"conditions":43830,"interventions":43831},[90],[15],[43780,43794,43795],{"trials":43833,"activeCount":101},[],{"trials":43835,"activeCount":101},[],{"trials":43837,"activeCount":101},[],{"trials":43839,"activeCount":101},[],{"intervention":43841,"totalTrials":272,"cells":43842},"99mTc - labelled hMAb BIWA 4",{"EARLY_PHASE1":43843,"PHASE1":43845,"PHASE2":43857,"PHASE3":43859,"PHASE4":43861,"NA":43863},{"trials":43844,"activeCount":101},[],{"trials":43846,"activeCount":101},[43847],{"nctId":43848,"briefTitle":43849,"status":107,"phases":43850,"primaryCompletion":2121,"start":6453,"enrollment":1116,"conditions":43851,"interventions":43852},"NCT02204033","Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer",[90],[3766],[43841,43853,43854,43855,43856],"186 Re - labelled hMAb BIWA 4","unlabelled hMAb BIWA 4 - low dose","unlabelled hMAb BIWA 4 - medium dose","unlabelled hMAb BIWA 4 - high dose",{"trials":43858,"activeCount":101},[],{"trials":43860,"activeCount":101},[],{"trials":43862,"activeCount":101},[],{"trials":43864,"activeCount":101},[],{"intervention":43853,"totalTrials":272,"cells":43866},{"EARLY_PHASE1":43867,"PHASE1":43869,"PHASE2":43875,"PHASE3":43877,"PHASE4":43879,"NA":43881},{"trials":43868,"activeCount":101},[],{"trials":43870,"activeCount":101},[43871],{"nctId":43848,"briefTitle":43849,"status":107,"phases":43872,"primaryCompletion":2121,"start":6453,"enrollment":1116,"conditions":43873,"interventions":43874},[90],[3766],[43841,43853,43854,43855,43856],{"trials":43876,"activeCount":101},[],{"trials":43878,"activeCount":101},[],{"trials":43880,"activeCount":101},[],{"trials":43882,"activeCount":101},[],{"intervention":43854,"totalTrials":272,"cells":43884},{"EARLY_PHASE1":43885,"PHASE1":43887,"PHASE2":43893,"PHASE3":43895,"PHASE4":43897,"NA":43899},{"trials":43886,"activeCount":101},[],{"trials":43888,"activeCount":101},[43889],{"nctId":43848,"briefTitle":43849,"status":107,"phases":43890,"primaryCompletion":2121,"start":6453,"enrollment":1116,"conditions":43891,"interventions":43892},[90],[3766],[43841,43853,43854,43855,43856],{"trials":43894,"activeCount":101},[],{"trials":43896,"activeCount":101},[],{"trials":43898,"activeCount":101},[],{"trials":43900,"activeCount":101},[],{"intervention":43855,"totalTrials":272,"cells":43902},{"EARLY_PHASE1":43903,"PHASE1":43905,"PHASE2":43911,"PHASE3":43913,"PHASE4":43915,"NA":43917},{"trials":43904,"activeCount":101},[],{"trials":43906,"activeCount":101},[43907],{"nctId":43848,"briefTitle":43849,"status":107,"phases":43908,"primaryCompletion":2121,"start":6453,"enrollment":1116,"conditions":43909,"interventions":43910},[90],[3766],[43841,43853,43854,43855,43856],{"trials":43912,"activeCount":101},[],{"trials":43914,"activeCount":101},[],{"trials":43916,"activeCount":101},[],{"trials":43918,"activeCount":101},[],{"intervention":43856,"totalTrials":272,"cells":43920},{"EARLY_PHASE1":43921,"PHASE1":43923,"PHASE2":43929,"PHASE3":43931,"PHASE4":43933,"NA":43935},{"trials":43922,"activeCount":101},[],{"trials":43924,"activeCount":101},[43925],{"nctId":43848,"briefTitle":43849,"status":107,"phases":43926,"primaryCompletion":2121,"start":6453,"enrollment":1116,"conditions":43927,"interventions":43928},[90],[3766],[43841,43853,43854,43855,43856],{"trials":43930,"activeCount":101},[],{"trials":43932,"activeCount":101},[],{"trials":43934,"activeCount":101},[],{"trials":43936,"activeCount":101},[],{"intervention":43938,"totalTrials":272,"cells":43939},"Catapres-TTS-1",{"EARLY_PHASE1":43940,"PHASE1":43942,"PHASE2":43952,"PHASE3":43954,"PHASE4":43956,"NA":43958},{"trials":43941,"activeCount":101},[],{"trials":43943,"activeCount":101},[43944],{"nctId":43945,"briefTitle":43946,"status":107,"phases":43947,"primaryCompletion":4391,"completion":4391,"start":9824,"enrollment":37,"conditions":43948,"interventions":43949},"NCT02096744","Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers",[90],[15],[43938,43950,43950,43951,43938,43951],"Intervention 1: Catapres-TTS-3","Intervention 2: Catapres-TTS-3",{"trials":43953,"activeCount":101},[],{"trials":43955,"activeCount":101},[],{"trials":43957,"activeCount":101},[],{"trials":43959,"activeCount":101},[],{"intervention":43950,"totalTrials":272,"cells":43961},{"EARLY_PHASE1":43962,"PHASE1":43964,"PHASE2":43970,"PHASE3":43972,"PHASE4":43974,"NA":43976},{"trials":43963,"activeCount":101},[],{"trials":43965,"activeCount":101},[43966],{"nctId":43945,"briefTitle":43946,"status":107,"phases":43967,"primaryCompletion":4391,"completion":4391,"start":9824,"enrollment":37,"conditions":43968,"interventions":43969},[90],[15],[43938,43950,43950,43951,43938,43951],{"trials":43971,"activeCount":101},[],{"trials":43973,"activeCount":101},[],{"trials":43975,"activeCount":101},[],{"trials":43977,"activeCount":101},[],{"intervention":43951,"totalTrials":272,"cells":43979},{"EARLY_PHASE1":43980,"PHASE1":43982,"PHASE2":43988,"PHASE3":43990,"PHASE4":43992,"NA":43994},{"trials":43981,"activeCount":101},[],{"trials":43983,"activeCount":101},[43984],{"nctId":43945,"briefTitle":43946,"status":107,"phases":43985,"primaryCompletion":4391,"completion":4391,"start":9824,"enrollment":37,"conditions":43986,"interventions":43987},[90],[15],[43938,43950,43950,43951,43938,43951],{"trials":43989,"activeCount":101},[],{"trials":43991,"activeCount":101},[],{"trials":43993,"activeCount":101},[],{"trials":43995,"activeCount":101},[],{"intervention":43997,"totalTrials":272,"cells":43998},"Ranitidine hydrochloride ODT",{"EARLY_PHASE1":43999,"PHASE1":44001,"PHASE2":44011,"PHASE3":44013,"PHASE4":44015,"NA":44017},{"trials":44000,"activeCount":101},[],{"trials":44002,"activeCount":101},[44003],{"nctId":44004,"briefTitle":44005,"status":107,"phases":44006,"primaryCompletion":5905,"start":9411,"enrollment":331,"conditions":44007,"interventions":44008},"NCT02195804","Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers",[90],[15],[43997,44009,44010],"Ranitidine hydrochloride ODT RM","Ranitidine hydrochloride",{"trials":44012,"activeCount":101},[],{"trials":44014,"activeCount":101},[],{"trials":44016,"activeCount":101},[],{"trials":44018,"activeCount":101},[],{"intervention":44009,"totalTrials":272,"cells":44020},{"EARLY_PHASE1":44021,"PHASE1":44023,"PHASE2":44029,"PHASE3":44031,"PHASE4":44033,"NA":44035},{"trials":44022,"activeCount":101},[],{"trials":44024,"activeCount":101},[44025],{"nctId":44004,"briefTitle":44005,"status":107,"phases":44026,"primaryCompletion":5905,"start":9411,"enrollment":331,"conditions":44027,"interventions":44028},[90],[15],[43997,44009,44010],{"trials":44030,"activeCount":101},[],{"trials":44032,"activeCount":101},[],{"trials":44034,"activeCount":101},[],{"trials":44036,"activeCount":101},[],{"intervention":44010,"totalTrials":272,"cells":44038},{"EARLY_PHASE1":44039,"PHASE1":44041,"PHASE2":44047,"PHASE3":44049,"PHASE4":44051,"NA":44053},{"trials":44040,"activeCount":101},[],{"trials":44042,"activeCount":101},[44043],{"nctId":44004,"briefTitle":44005,"status":107,"phases":44044,"primaryCompletion":5905,"start":9411,"enrollment":331,"conditions":44045,"interventions":44046},[90],[15],[43997,44009,44010],{"trials":44048,"activeCount":101},[],{"trials":44050,"activeCount":101},[],{"trials":44052,"activeCount":101},[],{"trials":44054,"activeCount":101},[],{"intervention":44056,"totalTrials":272,"cells":44057},"TPV oral solution",{"EARLY_PHASE1":44058,"PHASE1":44060,"PHASE2":44070,"PHASE3":44072,"PHASE4":44074,"NA":44076},{"trials":44059,"activeCount":101},[],{"trials":44061,"activeCount":101},[44062],{"nctId":44063,"briefTitle":44064,"status":107,"phases":44065,"primaryCompletion":3754,"start":2146,"enrollment":44066,"conditions":44067,"interventions":44068},"NCT00076999","Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children",[90],115,[27],[44056,44056,44069,44069],"RTV oral solution",{"trials":44071,"activeCount":101},[],{"trials":44073,"activeCount":101},[],{"trials":44075,"activeCount":101},[],{"trials":44077,"activeCount":101},[],{"intervention":44069,"totalTrials":272,"cells":44079},{"EARLY_PHASE1":44080,"PHASE1":44082,"PHASE2":44088,"PHASE3":44090,"PHASE4":44092,"NA":44094},{"trials":44081,"activeCount":101},[],{"trials":44083,"activeCount":101},[44084],{"nctId":44063,"briefTitle":44064,"status":107,"phases":44085,"primaryCompletion":3754,"start":2146,"enrollment":44066,"conditions":44086,"interventions":44087},[90],[27],[44056,44056,44069,44069],{"trials":44089,"activeCount":101},[],{"trials":44091,"activeCount":101},[],{"trials":44093,"activeCount":101},[],{"trials":44095,"activeCount":101},[],{"intervention":44097,"totalTrials":272,"cells":44098},"BI 1015550 Single Dose",{"EARLY_PHASE1":44099,"PHASE1":44101,"PHASE2":44111,"PHASE3":44113,"PHASE4":44115,"NA":44117},{"trials":44100,"activeCount":101},[],{"trials":44102,"activeCount":101},[44103],{"nctId":44104,"briefTitle":44105,"status":107,"phases":44106,"primaryCompletion":44107,"completion":44107,"start":30771,"enrollment":331,"conditions":44108,"interventions":44109},"NCT03230487","This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body",[90],"2018-01-16",[15],[44097,44110],"BI 1015550 Multiple Dose",{"trials":44112,"activeCount":101},[],{"trials":44114,"activeCount":101},[],{"trials":44116,"activeCount":101},[],{"trials":44118,"activeCount":101},[],{"intervention":44110,"totalTrials":272,"cells":44120},{"EARLY_PHASE1":44121,"PHASE1":44123,"PHASE2":44129,"PHASE3":44131,"PHASE4":44133,"NA":44135},{"trials":44122,"activeCount":101},[],{"trials":44124,"activeCount":101},[44125],{"nctId":44104,"briefTitle":44105,"status":107,"phases":44126,"primaryCompletion":44107,"completion":44107,"start":30771,"enrollment":331,"conditions":44127,"interventions":44128},[90],[15],[44097,44110],{"trials":44130,"activeCount":101},[],{"trials":44132,"activeCount":101},[],{"trials":44134,"activeCount":101},[],{"trials":44136,"activeCount":101},[],{"intervention":44138,"totalTrials":272,"cells":44139},"BI 1021958 bid",{"EARLY_PHASE1":44140,"PHASE1":44142,"PHASE2":44151,"PHASE3":44153,"PHASE4":44155,"NA":44157},{"trials":44141,"activeCount":101},[],{"trials":44143,"activeCount":101},[44144],{"nctId":44145,"briefTitle":44146,"status":107,"phases":44147,"primaryCompletion":9593,"completion":9593,"start":9491,"enrollment":6117,"conditions":44148,"interventions":44149},"NCT01629849","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects",[90],[15,30],[44138,44150],"BI 1021958 qd",{"trials":44152,"activeCount":101},[],{"trials":44154,"activeCount":101},[],{"trials":44156,"activeCount":101},[],{"trials":44158,"activeCount":101},[],{"intervention":44150,"totalTrials":272,"cells":44160},{"EARLY_PHASE1":44161,"PHASE1":44163,"PHASE2":44169,"PHASE3":44171,"PHASE4":44173,"NA":44175},{"trials":44162,"activeCount":101},[],{"trials":44164,"activeCount":101},[44165],{"nctId":44145,"briefTitle":44146,"status":107,"phases":44166,"primaryCompletion":9593,"completion":9593,"start":9491,"enrollment":6117,"conditions":44167,"interventions":44168},[90],[15,30],[44138,44150],{"trials":44170,"activeCount":101},[],{"trials":44172,"activeCount":101},[],{"trials":44174,"activeCount":101},[],{"trials":44176,"activeCount":101},[],{"intervention":44178,"totalTrials":272,"cells":44179},"Treatment 1",{"EARLY_PHASE1":44180,"PHASE1":44182,"PHASE2":44192,"PHASE3":44194,"PHASE4":44196,"NA":44198},{"trials":44181,"activeCount":101},[],{"trials":44183,"activeCount":101},[44184],{"nctId":44185,"briefTitle":44186,"status":107,"phases":44187,"primaryCompletion":6738,"start":6391,"enrollment":392,"conditions":44188,"interventions":44189},"NCT02276352","Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers",[90],[15],[44178,44190,44191],"Treatment 2","Treatment 3",{"trials":44193,"activeCount":101},[],{"trials":44195,"activeCount":101},[],{"trials":44197,"activeCount":101},[],{"trials":44199,"activeCount":101},[],{"intervention":44190,"totalTrials":272,"cells":44201},{"EARLY_PHASE1":44202,"PHASE1":44204,"PHASE2":44210,"PHASE3":44212,"PHASE4":44214,"NA":44216},{"trials":44203,"activeCount":101},[],{"trials":44205,"activeCount":101},[44206],{"nctId":44185,"briefTitle":44186,"status":107,"phases":44207,"primaryCompletion":6738,"start":6391,"enrollment":392,"conditions":44208,"interventions":44209},[90],[15],[44178,44190,44191],{"trials":44211,"activeCount":101},[],{"trials":44213,"activeCount":101},[],{"trials":44215,"activeCount":101},[],{"trials":44217,"activeCount":101},[],{"intervention":44191,"totalTrials":272,"cells":44219},{"EARLY_PHASE1":44220,"PHASE1":44222,"PHASE2":44228,"PHASE3":44230,"PHASE4":44232,"NA":44234},{"trials":44221,"activeCount":101},[],{"trials":44223,"activeCount":101},[44224],{"nctId":44185,"briefTitle":44186,"status":107,"phases":44225,"primaryCompletion":6738,"start":6391,"enrollment":392,"conditions":44226,"interventions":44227},[90],[15],[44178,44190,44191],{"trials":44229,"activeCount":101},[],{"trials":44231,"activeCount":101},[],{"trials":44233,"activeCount":101},[],{"trials":44235,"activeCount":101},[],{"intervention":4132,"totalTrials":272,"cells":44237},{"EARLY_PHASE1":44238,"PHASE1":44240,"PHASE2":44246,"PHASE3":44248,"PHASE4":44250,"NA":44252},{"trials":44239,"activeCount":101},[],{"trials":44241,"activeCount":101},[44242],{"nctId":4125,"briefTitle":4126,"status":107,"phases":44243,"primaryCompletion":4128,"start":4129,"enrollment":410,"conditions":44244,"interventions":44245},[90],[15],[1242,4132,4133,4134],{"trials":44247,"activeCount":101},[],{"trials":44249,"activeCount":101},[],{"trials":44251,"activeCount":101},[],{"trials":44253,"activeCount":101},[],{"intervention":4133,"totalTrials":272,"cells":44255},{"EARLY_PHASE1":44256,"PHASE1":44258,"PHASE2":44264,"PHASE3":44266,"PHASE4":44268,"NA":44270},{"trials":44257,"activeCount":101},[],{"trials":44259,"activeCount":101},[44260],{"nctId":4125,"briefTitle":4126,"status":107,"phases":44261,"primaryCompletion":4128,"start":4129,"enrollment":410,"conditions":44262,"interventions":44263},[90],[15],[1242,4132,4133,4134],{"trials":44265,"activeCount":101},[],{"trials":44267,"activeCount":101},[],{"trials":44269,"activeCount":101},[],{"trials":44271,"activeCount":101},[],{"intervention":4134,"totalTrials":272,"cells":44273},{"EARLY_PHASE1":44274,"PHASE1":44276,"PHASE2":44282,"PHASE3":44284,"PHASE4":44286,"NA":44288},{"trials":44275,"activeCount":101},[],{"trials":44277,"activeCount":101},[44278],{"nctId":4125,"briefTitle":4126,"status":107,"phases":44279,"primaryCompletion":4128,"start":4129,"enrollment":410,"conditions":44280,"interventions":44281},[90],[15],[1242,4132,4133,4134],{"trials":44283,"activeCount":101},[],{"trials":44285,"activeCount":101},[],{"trials":44287,"activeCount":101},[],{"trials":44289,"activeCount":101},[],{"intervention":44291,"totalTrials":272,"cells":44292},"BI 671800 HEA delayed release (enteric coated)",{"EARLY_PHASE1":44293,"PHASE1":44295,"PHASE2":44305,"PHASE3":44307,"PHASE4":44309,"NA":44311},{"trials":44294,"activeCount":101},[],{"trials":44296,"activeCount":101},[44297],{"nctId":44298,"briefTitle":44299,"status":107,"phases":44300,"primaryCompletion":3732,"start":6811,"enrollment":1081,"conditions":44301,"interventions":44302},"NCT02222233","Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers",[90],[15],[44291,44303,44304],"BI 671800 HEA solution","BI 671800 HEA particulate",{"trials":44306,"activeCount":101},[],{"trials":44308,"activeCount":101},[],{"trials":44310,"activeCount":101},[],{"trials":44312,"activeCount":101},[],{"intervention":44303,"totalTrials":272,"cells":44314},{"EARLY_PHASE1":44315,"PHASE1":44317,"PHASE2":44323,"PHASE3":44325,"PHASE4":44327,"NA":44329},{"trials":44316,"activeCount":101},[],{"trials":44318,"activeCount":101},[44319],{"nctId":44298,"briefTitle":44299,"status":107,"phases":44320,"primaryCompletion":3732,"start":6811,"enrollment":1081,"conditions":44321,"interventions":44322},[90],[15],[44291,44303,44304],{"trials":44324,"activeCount":101},[],{"trials":44326,"activeCount":101},[],{"trials":44328,"activeCount":101},[],{"trials":44330,"activeCount":101},[],{"intervention":44304,"totalTrials":272,"cells":44332},{"EARLY_PHASE1":44333,"PHASE1":44335,"PHASE2":44341,"PHASE3":44343,"PHASE4":44345,"NA":44347},{"trials":44334,"activeCount":101},[],{"trials":44336,"activeCount":101},[44337],{"nctId":44298,"briefTitle":44299,"status":107,"phases":44338,"primaryCompletion":3732,"start":6811,"enrollment":1081,"conditions":44339,"interventions":44340},[90],[15],[44291,44303,44304],{"trials":44342,"activeCount":101},[],{"trials":44344,"activeCount":101},[],{"trials":44346,"activeCount":101},[],{"trials":44348,"activeCount":101},[],{"intervention":30460,"totalTrials":272,"cells":44350},{"EARLY_PHASE1":44351,"PHASE1":44353,"PHASE2":44359,"PHASE3":44361,"PHASE4":44363,"NA":44365},{"trials":44352,"activeCount":101},[],{"trials":44354,"activeCount":101},[44355],{"nctId":30455,"briefTitle":30456,"status":107,"phases":44356,"primaryCompletion":4391,"completion":5233,"start":10024,"enrollment":716,"conditions":44357,"interventions":44358},[90],[15],[30438,30460,30461,30462,30438,30460],{"trials":44360,"activeCount":101},[],{"trials":44362,"activeCount":101},[],{"trials":44364,"activeCount":101},[],{"trials":44366,"activeCount":101},[],{"intervention":30461,"totalTrials":272,"cells":44368},{"EARLY_PHASE1":44369,"PHASE1":44371,"PHASE2":44377,"PHASE3":44379,"PHASE4":44381,"NA":44383},{"trials":44370,"activeCount":101},[],{"trials":44372,"activeCount":101},[44373],{"nctId":30455,"briefTitle":30456,"status":107,"phases":44374,"primaryCompletion":4391,"completion":5233,"start":10024,"enrollment":716,"conditions":44375,"interventions":44376},[90],[15],[30438,30460,30461,30462,30438,30460],{"trials":44378,"activeCount":101},[],{"trials":44380,"activeCount":101},[],{"trials":44382,"activeCount":101},[],{"trials":44384,"activeCount":101},[],{"intervention":30462,"totalTrials":272,"cells":44386},{"EARLY_PHASE1":44387,"PHASE1":44389,"PHASE2":44395,"PHASE3":44397,"PHASE4":44399,"NA":44401},{"trials":44388,"activeCount":101},[],{"trials":44390,"activeCount":101},[44391],{"nctId":30455,"briefTitle":30456,"status":107,"phases":44392,"primaryCompletion":4391,"completion":5233,"start":10024,"enrollment":716,"conditions":44393,"interventions":44394},[90],[15],[30438,30460,30461,30462,30438,30460],{"trials":44396,"activeCount":101},[],{"trials":44398,"activeCount":101},[],{"trials":44400,"activeCount":101},[],{"trials":44402,"activeCount":101},[],{"intervention":12483,"totalTrials":272,"cells":44404},{"EARLY_PHASE1":44405,"PHASE1":44407,"PHASE2":44413,"PHASE3":44415,"PHASE4":44417,"NA":44419},{"trials":44406,"activeCount":101},[],{"trials":44408,"activeCount":101},[44409],{"nctId":12477,"briefTitle":12478,"status":107,"phases":44410,"primaryCompletion":9348,"start":6133,"enrollment":1208,"conditions":44411,"interventions":44412},[90],[15],[12482,12482,12483,12483],{"trials":44414,"activeCount":101},[],{"trials":44416,"activeCount":101},[],{"trials":44418,"activeCount":101},[],{"trials":44420,"activeCount":101},[],{"intervention":19551,"totalTrials":272,"cells":44422},{"EARLY_PHASE1":44423,"PHASE1":44425,"PHASE2":44431,"PHASE3":44433,"PHASE4":44435,"NA":44437},{"trials":44424,"activeCount":101},[],{"trials":44426,"activeCount":101},[44427],{"nctId":19546,"briefTitle":19547,"status":107,"phases":44428,"primaryCompletion":390,"completion":9538,"start":3990,"enrollment":9606,"conditions":44429,"interventions":44430},[90],[33],[19551,2007],{"trials":44432,"activeCount":101},[],{"trials":44434,"activeCount":101},[],{"trials":44436,"activeCount":101},[],{"trials":44438,"activeCount":101},[],{"intervention":44440,"totalTrials":272,"cells":44441},"Meloxicam, low dose",{"EARLY_PHASE1":44442,"PHASE1":44444,"PHASE2":44454,"PHASE3":44456,"PHASE4":44458,"NA":44460},{"trials":44443,"activeCount":101},[],{"trials":44445,"activeCount":101},[44446],{"nctId":44447,"briefTitle":44448,"status":107,"phases":44449,"primaryCompletion":6029,"start":5993,"enrollment":380,"conditions":44450,"interventions":44451},"NCT02181309","Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers",[90],[15],[44440,44452,44453],"Meloxicam, medium dose","Meloxicam, high dose",{"trials":44455,"activeCount":101},[],{"trials":44457,"activeCount":101},[],{"trials":44459,"activeCount":101},[],{"trials":44461,"activeCount":101},[],{"intervention":44452,"totalTrials":272,"cells":44463},{"EARLY_PHASE1":44464,"PHASE1":44466,"PHASE2":44472,"PHASE3":44474,"PHASE4":44476,"NA":44478},{"trials":44465,"activeCount":101},[],{"trials":44467,"activeCount":101},[44468],{"nctId":44447,"briefTitle":44448,"status":107,"phases":44469,"primaryCompletion":6029,"start":5993,"enrollment":380,"conditions":44470,"interventions":44471},[90],[15],[44440,44452,44453],{"trials":44473,"activeCount":101},[],{"trials":44475,"activeCount":101},[],{"trials":44477,"activeCount":101},[],{"trials":44479,"activeCount":101},[],{"intervention":44453,"totalTrials":272,"cells":44481},{"EARLY_PHASE1":44482,"PHASE1":44484,"PHASE2":44490,"PHASE3":44492,"PHASE4":44494,"NA":44496},{"trials":44483,"activeCount":101},[],{"trials":44485,"activeCount":101},[44486],{"nctId":44447,"briefTitle":44448,"status":107,"phases":44487,"primaryCompletion":6029,"start":5993,"enrollment":380,"conditions":44488,"interventions":44489},[90],[15],[44440,44452,44453],{"trials":44491,"activeCount":101},[],{"trials":44493,"activeCount":101},[],{"trials":44495,"activeCount":101},[],{"trials":44497,"activeCount":101},[],{"intervention":13384,"totalTrials":272,"cells":44499},{"EARLY_PHASE1":44500,"PHASE1":44502,"PHASE2":44508,"PHASE3":44510,"PHASE4":44512,"NA":44514},{"trials":44501,"activeCount":101},[],{"trials":44503,"activeCount":101},[44504],{"nctId":13379,"briefTitle":13380,"status":107,"phases":44505,"primaryCompletion":12159,"completion":12159,"start":4473,"enrollment":132,"conditions":44506,"interventions":44507},[90],[15],[13384,13385,13386,13387],{"trials":44509,"activeCount":101},[],{"trials":44511,"activeCount":101},[],{"trials":44513,"activeCount":101},[],{"trials":44515,"activeCount":101},[],{"intervention":13386,"totalTrials":272,"cells":44517},{"EARLY_PHASE1":44518,"PHASE1":44520,"PHASE2":44526,"PHASE3":44528,"PHASE4":44530,"NA":44532},{"trials":44519,"activeCount":101},[],{"trials":44521,"activeCount":101},[44522],{"nctId":13379,"briefTitle":13380,"status":107,"phases":44523,"primaryCompletion":12159,"completion":12159,"start":4473,"enrollment":132,"conditions":44524,"interventions":44525},[90],[15],[13384,13385,13386,13387],{"trials":44527,"activeCount":101},[],{"trials":44529,"activeCount":101},[],{"trials":44531,"activeCount":101},[],{"trials":44533,"activeCount":101},[],{"intervention":13387,"totalTrials":272,"cells":44535},{"EARLY_PHASE1":44536,"PHASE1":44538,"PHASE2":44544,"PHASE3":44546,"PHASE4":44548,"NA":44550},{"trials":44537,"activeCount":101},[],{"trials":44539,"activeCount":101},[44540],{"nctId":13379,"briefTitle":13380,"status":107,"phases":44541,"primaryCompletion":12159,"completion":12159,"start":4473,"enrollment":132,"conditions":44542,"interventions":44543},[90],[15],[13384,13385,13386,13387],{"trials":44545,"activeCount":101},[],{"trials":44547,"activeCount":101},[],{"trials":44549,"activeCount":101},[],{"trials":44551,"activeCount":101},[],{"intervention":44553,"totalTrials":272,"cells":44554},"BILB 1941 ZW - single rising dose part",{"EARLY_PHASE1":44555,"PHASE1":44557,"PHASE2":44567,"PHASE3":44569,"PHASE4":44571,"NA":44573},{"trials":44556,"activeCount":101},[],{"trials":44558,"activeCount":101},[44559],{"nctId":44560,"briefTitle":44561,"status":107,"phases":44562,"primaryCompletion":9276,"start":2112,"enrollment":37,"conditions":44563,"interventions":44564},"NCT02256787","Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food",[90],[15],[44553,44565,44566],"BILB 1941 ZW - solution","BILB 1941 ZW -",{"trials":44568,"activeCount":101},[],{"trials":44570,"activeCount":101},[],{"trials":44572,"activeCount":101},[],{"trials":44574,"activeCount":101},[],{"intervention":44565,"totalTrials":272,"cells":44576},{"EARLY_PHASE1":44577,"PHASE1":44579,"PHASE2":44585,"PHASE3":44587,"PHASE4":44589,"NA":44591},{"trials":44578,"activeCount":101},[],{"trials":44580,"activeCount":101},[44581],{"nctId":44560,"briefTitle":44561,"status":107,"phases":44582,"primaryCompletion":9276,"start":2112,"enrollment":37,"conditions":44583,"interventions":44584},[90],[15],[44553,44565,44566],{"trials":44586,"activeCount":101},[],{"trials":44588,"activeCount":101},[],{"trials":44590,"activeCount":101},[],{"trials":44592,"activeCount":101},[],{"intervention":44566,"totalTrials":272,"cells":44594},{"EARLY_PHASE1":44595,"PHASE1":44597,"PHASE2":44603,"PHASE3":44605,"PHASE4":44607,"NA":44609},{"trials":44596,"activeCount":101},[],{"trials":44598,"activeCount":101},[44599],{"nctId":44560,"briefTitle":44561,"status":107,"phases":44600,"primaryCompletion":9276,"start":2112,"enrollment":37,"conditions":44601,"interventions":44602},[90],[15],[44553,44565,44566],{"trials":44604,"activeCount":101},[],{"trials":44606,"activeCount":101},[],{"trials":44608,"activeCount":101},[],{"trials":44610,"activeCount":101},[],{"intervention":44612,"totalTrials":272,"cells":44613},"BIIF 1149 BS - single rising dose",{"EARLY_PHASE1":44614,"PHASE1":44616,"PHASE2":44624,"PHASE3":44626,"PHASE4":44628,"NA":44630},{"trials":44615,"activeCount":101},[],{"trials":44617,"activeCount":101},[44618],{"nctId":44619,"briefTitle":44620,"status":107,"phases":44621,"primaryCompletion":7394,"start":6246,"enrollment":410,"conditions":44622,"interventions":44623},"NCT02203487","Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers",[90],[15],[44612],{"trials":44625,"activeCount":101},[],{"trials":44627,"activeCount":101},[],{"trials":44629,"activeCount":101},[],{"trials":44631,"activeCount":101},[],{"intervention":11856,"totalTrials":272,"cells":44633},{"EARLY_PHASE1":44634,"PHASE1":44636,"PHASE2":44642,"PHASE3":44644,"PHASE4":44646,"NA":44648},{"trials":44635,"activeCount":101},[],{"trials":44637,"activeCount":101},[44638],{"nctId":11851,"briefTitle":11852,"status":107,"phases":44639,"primaryCompletion":6438,"start":11123,"enrollment":380,"conditions":44640,"interventions":44641},[90],[15],[11856,11836],{"trials":44643,"activeCount":101},[],{"trials":44645,"activeCount":101},[],{"trials":44647,"activeCount":101},[],{"trials":44649,"activeCount":101},[],{"intervention":5665,"totalTrials":272,"cells":44651},{"EARLY_PHASE1":44652,"PHASE1":44654,"PHASE2":44660,"PHASE3":44662,"PHASE4":44664,"NA":44666},{"trials":44653,"activeCount":101},[],{"trials":44655,"activeCount":101},[44656],{"nctId":5659,"briefTitle":5660,"status":107,"phases":44657,"primaryCompletion":5662,"completion":5662,"start":4337,"enrollment":3454,"conditions":44658,"interventions":44659},[90],[15],[5652,5665,5666],{"trials":44661,"activeCount":101},[],{"trials":44663,"activeCount":101},[],{"trials":44665,"activeCount":101},[],{"trials":44667,"activeCount":101},[],{"intervention":5666,"totalTrials":272,"cells":44669},{"EARLY_PHASE1":44670,"PHASE1":44672,"PHASE2":44678,"PHASE3":44680,"PHASE4":44682,"NA":44684},{"trials":44671,"activeCount":101},[],{"trials":44673,"activeCount":101},[44674],{"nctId":5659,"briefTitle":5660,"status":107,"phases":44675,"primaryCompletion":5662,"completion":5662,"start":4337,"enrollment":3454,"conditions":44676,"interventions":44677},[90],[15],[5652,5665,5666],{"trials":44679,"activeCount":101},[],{"trials":44681,"activeCount":101},[],{"trials":44683,"activeCount":101},[],{"trials":44685,"activeCount":101},[],{"intervention":44687,"totalTrials":272,"cells":44688},"Epinastine nasal",{"EARLY_PHASE1":44689,"PHASE1":44691,"PHASE2":44699,"PHASE3":44701,"PHASE4":44703,"NA":44705},{"trials":44690,"activeCount":101},[],{"trials":44692,"activeCount":101},[44693],{"nctId":44694,"briefTitle":44695,"status":107,"phases":44696,"primaryCompletion":7132,"start":6584,"enrollment":291,"conditions":44697,"interventions":44698},"NCT02260037","Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal",[90],[15],[44687],{"trials":44700,"activeCount":101},[],{"trials":44702,"activeCount":101},[],{"trials":44704,"activeCount":101},[],{"trials":44706,"activeCount":101},[],{"intervention":44708,"totalTrials":272,"cells":44709},"Lacidipine and Telmisartan fixed dose combination (FDC)",{"EARLY_PHASE1":44710,"PHASE1":44712,"PHASE2":44720,"PHASE3":44722,"PHASE4":44724,"NA":44726},{"trials":44711,"activeCount":101},[],{"trials":44713,"activeCount":101},[44714],{"nctId":44715,"briefTitle":44716,"status":107,"phases":44717,"primaryCompletion":6206,"start":6207,"enrollment":188,"conditions":44718,"interventions":44719},"NCT02209649","Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects",[90],[15],[44708,8703,6121],{"trials":44721,"activeCount":101},[],{"trials":44723,"activeCount":101},[],{"trials":44725,"activeCount":101},[],{"trials":44727,"activeCount":101},[],{"intervention":10400,"totalTrials":272,"cells":44729},{"EARLY_PHASE1":44730,"PHASE1":44732,"PHASE2":44738,"PHASE3":44740,"PHASE4":44742,"NA":44744},{"trials":44731,"activeCount":101},[],{"trials":44733,"activeCount":101},[44734],{"nctId":10395,"briefTitle":10396,"status":107,"phases":44735,"primaryCompletion":6189,"start":6494,"enrollment":448,"conditions":44736,"interventions":44737},[90],[15],[10400,10401,10368],{"trials":44739,"activeCount":101},[],{"trials":44741,"activeCount":101},[],{"trials":44743,"activeCount":101},[],{"trials":44745,"activeCount":101},[],{"intervention":10401,"totalTrials":272,"cells":44747},{"EARLY_PHASE1":44748,"PHASE1":44750,"PHASE2":44756,"PHASE3":44758,"PHASE4":44760,"NA":44762},{"trials":44749,"activeCount":101},[],{"trials":44751,"activeCount":101},[44752],{"nctId":10395,"briefTitle":10396,"status":107,"phases":44753,"primaryCompletion":6189,"start":6494,"enrollment":448,"conditions":44754,"interventions":44755},[90],[15],[10400,10401,10368],{"trials":44757,"activeCount":101},[],{"trials":44759,"activeCount":101},[],{"trials":44761,"activeCount":101},[],{"trials":44763,"activeCount":101},[],{"intervention":28002,"totalTrials":272,"cells":44765},{"EARLY_PHASE1":44766,"PHASE1":44768,"PHASE2":44774,"PHASE3":44776,"PHASE4":44778,"NA":44780},{"trials":44767,"activeCount":101},[],{"trials":44769,"activeCount":101},[44770],{"nctId":27997,"briefTitle":27998,"status":162,"phases":44771,"primaryCompletion":6189,"start":6375,"enrollment":401,"conditions":44772,"interventions":44773},[90],[15],[27978,27978,27978,28002],{"trials":44775,"activeCount":101},[],{"trials":44777,"activeCount":101},[],{"trials":44779,"activeCount":101},[],{"trials":44781,"activeCount":101},[],{"intervention":11016,"totalTrials":272,"cells":44783},{"EARLY_PHASE1":44784,"PHASE1":44786,"PHASE2":44792,"PHASE3":44794,"PHASE4":44796,"NA":44798},{"trials":44785,"activeCount":101},[],{"trials":44787,"activeCount":101},[44788],{"nctId":11011,"briefTitle":11012,"status":107,"phases":44789,"primaryCompletion":2122,"start":2163,"enrollment":401,"conditions":44790,"interventions":44791},[90],[15],[6121,11008,11016],{"trials":44793,"activeCount":101},[],{"trials":44795,"activeCount":101},[],{"trials":44797,"activeCount":101},[],{"trials":44799,"activeCount":101},[],{"intervention":44801,"totalTrials":272,"cells":44802},"TPV low 1",{"EARLY_PHASE1":44803,"PHASE1":44805,"PHASE2":44820,"PHASE3":44822,"PHASE4":44824,"NA":44826},{"trials":44804,"activeCount":101},[],{"trials":44806,"activeCount":101},[44807],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44810,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44811,"interventions":44812},"NCT02251132","Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers",[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],"TPV low 2","TPV medium","TPV high 1","TPV high 2","RTV low","Ritonavir high","Radiolabelled erythromycin",{"trials":44821,"activeCount":101},[],{"trials":44823,"activeCount":101},[],{"trials":44825,"activeCount":101},[],{"trials":44827,"activeCount":101},[],{"intervention":44813,"totalTrials":272,"cells":44829},{"EARLY_PHASE1":44830,"PHASE1":44832,"PHASE2":44838,"PHASE3":44840,"PHASE4":44842,"NA":44844},{"trials":44831,"activeCount":101},[],{"trials":44833,"activeCount":101},[44834],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44835,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44836,"interventions":44837},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44839,"activeCount":101},[],{"trials":44841,"activeCount":101},[],{"trials":44843,"activeCount":101},[],{"trials":44845,"activeCount":101},[],{"intervention":44814,"totalTrials":272,"cells":44847},{"EARLY_PHASE1":44848,"PHASE1":44850,"PHASE2":44856,"PHASE3":44858,"PHASE4":44860,"NA":44862},{"trials":44849,"activeCount":101},[],{"trials":44851,"activeCount":101},[44852],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44853,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44854,"interventions":44855},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44857,"activeCount":101},[],{"trials":44859,"activeCount":101},[],{"trials":44861,"activeCount":101},[],{"trials":44863,"activeCount":101},[],{"intervention":44815,"totalTrials":272,"cells":44865},{"EARLY_PHASE1":44866,"PHASE1":44868,"PHASE2":44874,"PHASE3":44876,"PHASE4":44878,"NA":44880},{"trials":44867,"activeCount":101},[],{"trials":44869,"activeCount":101},[44870],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44871,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44872,"interventions":44873},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44875,"activeCount":101},[],{"trials":44877,"activeCount":101},[],{"trials":44879,"activeCount":101},[],{"trials":44881,"activeCount":101},[],{"intervention":44816,"totalTrials":272,"cells":44883},{"EARLY_PHASE1":44884,"PHASE1":44886,"PHASE2":44892,"PHASE3":44894,"PHASE4":44896,"NA":44898},{"trials":44885,"activeCount":101},[],{"trials":44887,"activeCount":101},[44888],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44889,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44890,"interventions":44891},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44893,"activeCount":101},[],{"trials":44895,"activeCount":101},[],{"trials":44897,"activeCount":101},[],{"trials":44899,"activeCount":101},[],{"intervention":44817,"totalTrials":272,"cells":44901},{"EARLY_PHASE1":44902,"PHASE1":44904,"PHASE2":44910,"PHASE3":44912,"PHASE4":44914,"NA":44916},{"trials":44903,"activeCount":101},[],{"trials":44905,"activeCount":101},[44906],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44907,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44908,"interventions":44909},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44911,"activeCount":101},[],{"trials":44913,"activeCount":101},[],{"trials":44915,"activeCount":101},[],{"trials":44917,"activeCount":101},[],{"intervention":44818,"totalTrials":272,"cells":44919},{"EARLY_PHASE1":44920,"PHASE1":44922,"PHASE2":44928,"PHASE3":44930,"PHASE4":44932,"NA":44934},{"trials":44921,"activeCount":101},[],{"trials":44923,"activeCount":101},[44924],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44925,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44926,"interventions":44927},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44929,"activeCount":101},[],{"trials":44931,"activeCount":101},[],{"trials":44933,"activeCount":101},[],{"trials":44935,"activeCount":101},[],{"intervention":44819,"totalTrials":272,"cells":44937},{"EARLY_PHASE1":44938,"PHASE1":44940,"PHASE2":44946,"PHASE3":44948,"PHASE4":44950,"NA":44952},{"trials":44939,"activeCount":101},[],{"trials":44941,"activeCount":101},[44942],{"nctId":44808,"briefTitle":44809,"status":107,"phases":44943,"primaryCompletion":5880,"start":6053,"enrollment":5407,"conditions":44944,"interventions":44945},[90],[15],[44801,44813,44814,44815,44816,44817,44818,44819],{"trials":44947,"activeCount":101},[],{"trials":44949,"activeCount":101},[],{"trials":44951,"activeCount":101},[],{"trials":44953,"activeCount":101},[],{"intervention":44955,"totalTrials":272,"cells":44956},"Flibanserin plus Digoxin",{"EARLY_PHASE1":44957,"PHASE1":44959,"PHASE2":44967,"PHASE3":44969,"PHASE4":44971,"NA":44973},{"trials":44958,"activeCount":101},[],{"trials":44960,"activeCount":101},[44961],{"nctId":44962,"briefTitle":44963,"status":107,"phases":44964,"primaryCompletion":1967,"start":3754,"enrollment":380,"conditions":44965,"interventions":44966},"NCT01134965","to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers",[90],[15],[44955,2393],{"trials":44968,"activeCount":101},[],{"trials":44970,"activeCount":101},[],{"trials":44972,"activeCount":101},[],{"trials":44974,"activeCount":101},[],{"intervention":44976,"totalTrials":272,"cells":44977},"BI 1015550 6 mg",{"EARLY_PHASE1":44978,"PHASE1":44980,"PHASE2":44989,"PHASE3":44991,"PHASE4":44993,"NA":44995},{"trials":44979,"activeCount":101},[],{"trials":44981,"activeCount":101},[44982],{"nctId":44983,"briefTitle":44984,"status":107,"phases":44985,"primaryCompletion":4104,"completion":4104,"start":44986,"enrollment":401,"conditions":44987,"interventions":44988},"NCT03542344","This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.",[90],"2018-06-04",[15],[44976],{"trials":44990,"activeCount":101},[],{"trials":44992,"activeCount":101},[],{"trials":44994,"activeCount":101},[],{"trials":44996,"activeCount":101},[],{"intervention":44998,"totalTrials":272,"cells":44999},"NVP ER 300 mg (KCR 20%) Medium Release",{"EARLY_PHASE1":45000,"PHASE1":45002,"PHASE2":45020,"PHASE3":45022,"PHASE4":45024,"NA":45026},{"trials":45001,"activeCount":101},[],{"trials":45003,"activeCount":101},[45004],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45007,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45008,"interventions":45009},"NCT02192463","Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers",[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],"NVP ER 300 mg (KCR 25%) Medium Release","NVP ER 300 mg (KCR 30%) Slow Release","NVP ER 400 mg (KCR 25%) Medium Release","NVP ER 300 mg (KCR 40%) Slow Release","NVP ER 300 mg (ECR 20%) Fast Release","NVP ER 400 mg (KCR 20%) Medium Release","NVP ER 400 mg (KCR 30%) Slow Release","NVP ER 400 mg (KCR 40%) Slow Release","NVP ER 400 mg (ECR 20%) Fast Release","Nevirapine immediate release (IR) 200 mg",{"trials":45021,"activeCount":101},[],{"trials":45023,"activeCount":101},[],{"trials":45025,"activeCount":101},[],{"trials":45027,"activeCount":101},[],{"intervention":45010,"totalTrials":272,"cells":45029},{"EARLY_PHASE1":45030,"PHASE1":45032,"PHASE2":45038,"PHASE3":45040,"PHASE4":45042,"NA":45044},{"trials":45031,"activeCount":101},[],{"trials":45033,"activeCount":101},[45034],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45035,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45036,"interventions":45037},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45039,"activeCount":101},[],{"trials":45041,"activeCount":101},[],{"trials":45043,"activeCount":101},[],{"trials":45045,"activeCount":101},[],{"intervention":45011,"totalTrials":272,"cells":45047},{"EARLY_PHASE1":45048,"PHASE1":45050,"PHASE2":45056,"PHASE3":45058,"PHASE4":45060,"NA":45062},{"trials":45049,"activeCount":101},[],{"trials":45051,"activeCount":101},[45052],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45053,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45054,"interventions":45055},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45057,"activeCount":101},[],{"trials":45059,"activeCount":101},[],{"trials":45061,"activeCount":101},[],{"trials":45063,"activeCount":101},[],{"intervention":45012,"totalTrials":272,"cells":45065},{"EARLY_PHASE1":45066,"PHASE1":45068,"PHASE2":45074,"PHASE3":45076,"PHASE4":45078,"NA":45080},{"trials":45067,"activeCount":101},[],{"trials":45069,"activeCount":101},[45070],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45071,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45072,"interventions":45073},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45075,"activeCount":101},[],{"trials":45077,"activeCount":101},[],{"trials":45079,"activeCount":101},[],{"trials":45081,"activeCount":101},[],{"intervention":45013,"totalTrials":272,"cells":45083},{"EARLY_PHASE1":45084,"PHASE1":45086,"PHASE2":45092,"PHASE3":45094,"PHASE4":45096,"NA":45098},{"trials":45085,"activeCount":101},[],{"trials":45087,"activeCount":101},[45088],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45089,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45090,"interventions":45091},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45093,"activeCount":101},[],{"trials":45095,"activeCount":101},[],{"trials":45097,"activeCount":101},[],{"trials":45099,"activeCount":101},[],{"intervention":45014,"totalTrials":272,"cells":45101},{"EARLY_PHASE1":45102,"PHASE1":45104,"PHASE2":45110,"PHASE3":45112,"PHASE4":45114,"NA":45116},{"trials":45103,"activeCount":101},[],{"trials":45105,"activeCount":101},[45106],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45107,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45108,"interventions":45109},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45111,"activeCount":101},[],{"trials":45113,"activeCount":101},[],{"trials":45115,"activeCount":101},[],{"trials":45117,"activeCount":101},[],{"intervention":45015,"totalTrials":272,"cells":45119},{"EARLY_PHASE1":45120,"PHASE1":45122,"PHASE2":45128,"PHASE3":45130,"PHASE4":45132,"NA":45134},{"trials":45121,"activeCount":101},[],{"trials":45123,"activeCount":101},[45124],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45125,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45126,"interventions":45127},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45129,"activeCount":101},[],{"trials":45131,"activeCount":101},[],{"trials":45133,"activeCount":101},[],{"trials":45135,"activeCount":101},[],{"intervention":45016,"totalTrials":272,"cells":45137},{"EARLY_PHASE1":45138,"PHASE1":45140,"PHASE2":45146,"PHASE3":45148,"PHASE4":45150,"NA":45152},{"trials":45139,"activeCount":101},[],{"trials":45141,"activeCount":101},[45142],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45143,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45144,"interventions":45145},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45147,"activeCount":101},[],{"trials":45149,"activeCount":101},[],{"trials":45151,"activeCount":101},[],{"trials":45153,"activeCount":101},[],{"intervention":45017,"totalTrials":272,"cells":45155},{"EARLY_PHASE1":45156,"PHASE1":45158,"PHASE2":45164,"PHASE3":45166,"PHASE4":45168,"NA":45170},{"trials":45157,"activeCount":101},[],{"trials":45159,"activeCount":101},[45160],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45161,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45162,"interventions":45163},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45165,"activeCount":101},[],{"trials":45167,"activeCount":101},[],{"trials":45169,"activeCount":101},[],{"trials":45171,"activeCount":101},[],{"intervention":45018,"totalTrials":272,"cells":45173},{"EARLY_PHASE1":45174,"PHASE1":45176,"PHASE2":45182,"PHASE3":45184,"PHASE4":45186,"NA":45188},{"trials":45175,"activeCount":101},[],{"trials":45177,"activeCount":101},[45178],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45179,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45180,"interventions":45181},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45183,"activeCount":101},[],{"trials":45185,"activeCount":101},[],{"trials":45187,"activeCount":101},[],{"trials":45189,"activeCount":101},[],{"intervention":45019,"totalTrials":272,"cells":45191},{"EARLY_PHASE1":45192,"PHASE1":45194,"PHASE2":45200,"PHASE3":45202,"PHASE4":45204,"NA":45206},{"trials":45193,"activeCount":101},[],{"trials":45195,"activeCount":101},[45196],{"nctId":45005,"briefTitle":45006,"status":107,"phases":45197,"primaryCompletion":11588,"start":6156,"enrollment":3182,"conditions":45198,"interventions":45199},[90],[15],[44998,45010,45011,45012,45013,45014,45015,45016,45017,45018,45019],{"trials":45201,"activeCount":101},[],{"trials":45203,"activeCount":101},[],{"trials":45205,"activeCount":101},[],{"trials":45207,"activeCount":101},[],{"intervention":45209,"totalTrials":272,"cells":45210},"BI 411034",{"EARLY_PHASE1":45211,"PHASE1":45213,"PHASE2":45221,"PHASE3":45223,"PHASE4":45225,"NA":45227},{"trials":45212,"activeCount":101},[],{"trials":45214,"activeCount":101},[45215],{"nctId":45216,"briefTitle":45217,"status":107,"phases":45218,"primaryCompletion":18693,"completion":18693,"start":11814,"enrollment":31,"conditions":45219,"interventions":45220},"NCT01581684","Safety Tolerability and Pharmacokinetic of BI 411034",[90],[15],[45209,45209,45209,45209,45209,45209,45209,45209],{"trials":45222,"activeCount":101},[],{"trials":45224,"activeCount":101},[],{"trials":45226,"activeCount":101},[],{"trials":45228,"activeCount":101},[],{"intervention":45230,"totalTrials":272,"cells":45231},"0.02 mcg tiotropium solution",{"EARLY_PHASE1":45232,"PHASE1":45234,"PHASE2":45247,"PHASE3":45249,"PHASE4":45251,"NA":45253},{"trials":45233,"activeCount":101},[],{"trials":45235,"activeCount":101},[45236],{"nctId":45237,"briefTitle":45238,"status":107,"phases":45239,"primaryCompletion":7114,"start":7553,"enrollment":410,"conditions":45240,"interventions":45241},"NCT02177305","Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers",[90],[15],[45230,45242,45243,45244,45245,45246],"0.04 mcg tiotropium solution","0.08 mcg tiotropium solution","0.16 mcg tiotropium solution","0.28 mcg tiotropium solution","0.40 mcg tiotropium solution",{"trials":45248,"activeCount":101},[],{"trials":45250,"activeCount":101},[],{"trials":45252,"activeCount":101},[],{"trials":45254,"activeCount":101},[],{"intervention":45242,"totalTrials":272,"cells":45256},{"EARLY_PHASE1":45257,"PHASE1":45259,"PHASE2":45265,"PHASE3":45267,"PHASE4":45269,"NA":45271},{"trials":45258,"activeCount":101},[],{"trials":45260,"activeCount":101},[45261],{"nctId":45237,"briefTitle":45238,"status":107,"phases":45262,"primaryCompletion":7114,"start":7553,"enrollment":410,"conditions":45263,"interventions":45264},[90],[15],[45230,45242,45243,45244,45245,45246],{"trials":45266,"activeCount":101},[],{"trials":45268,"activeCount":101},[],{"trials":45270,"activeCount":101},[],{"trials":45272,"activeCount":101},[],{"intervention":45243,"totalTrials":272,"cells":45274},{"EARLY_PHASE1":45275,"PHASE1":45277,"PHASE2":45283,"PHASE3":45285,"PHASE4":45287,"NA":45289},{"trials":45276,"activeCount":101},[],{"trials":45278,"activeCount":101},[45279],{"nctId":45237,"briefTitle":45238,"status":107,"phases":45280,"primaryCompletion":7114,"start":7553,"enrollment":410,"conditions":45281,"interventions":45282},[90],[15],[45230,45242,45243,45244,45245,45246],{"trials":45284,"activeCount":101},[],{"trials":45286,"activeCount":101},[],{"trials":45288,"activeCount":101},[],{"trials":45290,"activeCount":101},[],{"intervention":45244,"totalTrials":272,"cells":45292},{"EARLY_PHASE1":45293,"PHASE1":45295,"PHASE2":45301,"PHASE3":45303,"PHASE4":45305,"NA":45307},{"trials":45294,"activeCount":101},[],{"trials":45296,"activeCount":101},[45297],{"nctId":45237,"briefTitle":45238,"status":107,"phases":45298,"primaryCompletion":7114,"start":7553,"enrollment":410,"conditions":45299,"interventions":45300},[90],[15],[45230,45242,45243,45244,45245,45246],{"trials":45302,"activeCount":101},[],{"trials":45304,"activeCount":101},[],{"trials":45306,"activeCount":101},[],{"trials":45308,"activeCount":101},[],{"intervention":45245,"totalTrials":272,"cells":45310},{"EARLY_PHASE1":45311,"PHASE1":45313,"PHASE2":45319,"PHASE3":45321,"PHASE4":45323,"NA":45325},{"trials":45312,"activeCount":101},[],{"trials":45314,"activeCount":101},[45315],{"nctId":45237,"briefTitle":45238,"status":107,"phases":45316,"primaryCompletion":7114,"start":7553,"enrollment":410,"conditions":45317,"interventions":45318},[90],[15],[45230,45242,45243,45244,45245,45246],{"trials":45320,"activeCount":101},[],{"trials":45322,"activeCount":101},[],{"trials":45324,"activeCount":101},[],{"trials":45326,"activeCount":101},[],{"intervention":45246,"totalTrials":272,"cells":45328},{"EARLY_PHASE1":45329,"PHASE1":45331,"PHASE2":45337,"PHASE3":45339,"PHASE4":45341,"NA":45343},{"trials":45330,"activeCount":101},[],{"trials":45332,"activeCount":101},[45333],{"nctId":45237,"briefTitle":45238,"status":107,"phases":45334,"primaryCompletion":7114,"start":7553,"enrollment":410,"conditions":45335,"interventions":45336},[90],[15],[45230,45242,45243,45244,45245,45246],{"trials":45338,"activeCount":101},[],{"trials":45340,"activeCount":101},[],{"trials":45342,"activeCount":101},[],{"trials":45344,"activeCount":101},[],{"intervention":45346,"totalTrials":272,"cells":45347},"vicadrostat \u002F empagliflozin combination 1",{"EARLY_PHASE1":45348,"PHASE1":45350,"PHASE2":45360,"PHASE3":45362,"PHASE4":45364,"NA":45366},{"trials":45349,"activeCount":101},[],{"trials":45351,"activeCount":101},[45352],{"nctId":45353,"briefTitle":45354,"status":107,"phases":45355,"primaryCompletion":4217,"completion":4217,"start":45356,"enrollment":132,"conditions":45357,"interventions":45358},"NCT07133399","A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood",[90],"2025-09-08",[15],[45346,45359],"vicadrostat \u002F empagliflozin 2",{"trials":45361,"activeCount":101},[],{"trials":45363,"activeCount":101},[],{"trials":45365,"activeCount":101},[],{"trials":45367,"activeCount":101},[],{"intervention":45359,"totalTrials":272,"cells":45369},{"EARLY_PHASE1":45370,"PHASE1":45372,"PHASE2":45378,"PHASE3":45380,"PHASE4":45382,"NA":45384},{"trials":45371,"activeCount":101},[],{"trials":45373,"activeCount":101},[45374],{"nctId":45353,"briefTitle":45354,"status":107,"phases":45375,"primaryCompletion":4217,"completion":4217,"start":45356,"enrollment":132,"conditions":45376,"interventions":45377},[90],[15],[45346,45359],{"trials":45379,"activeCount":101},[],{"trials":45381,"activeCount":101},[],{"trials":45383,"activeCount":101},[],{"trials":45385,"activeCount":101},[],{"intervention":45387,"totalTrials":272,"cells":45388},"BI 653048 H3PO4 solution",{"EARLY_PHASE1":45389,"PHASE1":45391,"PHASE2":45401,"PHASE3":45403,"PHASE4":45405,"NA":45407},{"trials":45390,"activeCount":101},[],{"trials":45392,"activeCount":101},[45393],{"nctId":45394,"briefTitle":45395,"status":107,"phases":45396,"primaryCompletion":5905,"start":10775,"enrollment":1429,"conditions":45397,"interventions":45398},"NCT02217644","Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers",[90],[15],[45387,45399,45400],"BI 653048 H3PO4 low dose","BI 653048 H3PO4 high dose",{"trials":45402,"activeCount":101},[],{"trials":45404,"activeCount":101},[],{"trials":45406,"activeCount":101},[],{"trials":45408,"activeCount":101},[],{"intervention":45399,"totalTrials":272,"cells":45410},{"EARLY_PHASE1":45411,"PHASE1":45413,"PHASE2":45419,"PHASE3":45421,"PHASE4":45423,"NA":45425},{"trials":45412,"activeCount":101},[],{"trials":45414,"activeCount":101},[45415],{"nctId":45394,"briefTitle":45395,"status":107,"phases":45416,"primaryCompletion":5905,"start":10775,"enrollment":1429,"conditions":45417,"interventions":45418},[90],[15],[45387,45399,45400],{"trials":45420,"activeCount":101},[],{"trials":45422,"activeCount":101},[],{"trials":45424,"activeCount":101},[],{"trials":45426,"activeCount":101},[],{"intervention":45400,"totalTrials":272,"cells":45428},{"EARLY_PHASE1":45429,"PHASE1":45431,"PHASE2":45437,"PHASE3":45439,"PHASE4":45441,"NA":45443},{"trials":45430,"activeCount":101},[],{"trials":45432,"activeCount":101},[45433],{"nctId":45394,"briefTitle":45395,"status":107,"phases":45434,"primaryCompletion":5905,"start":10775,"enrollment":1429,"conditions":45435,"interventions":45436},[90],[15],[45387,45399,45400],{"trials":45438,"activeCount":101},[],{"trials":45440,"activeCount":101},[],{"trials":45442,"activeCount":101},[],{"trials":45444,"activeCount":101},[],{"intervention":45446,"totalTrials":272,"cells":45447},"BILR 355 BS \u002F1B, current low dose formulation",{"EARLY_PHASE1":45448,"PHASE1":45450,"PHASE2":45463,"PHASE3":45465,"PHASE4":45467,"NA":45469},{"trials":45449,"activeCount":101},[],{"trials":45451,"activeCount":101},[45452],{"nctId":45453,"briefTitle":45454,"status":107,"phases":45455,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":45456,"interventions":45457},"NCT02259868","Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects",[90],[15],[45446,45458,45459,45460,45461,45462,4010],"BILR 355 BS \u002F1B, current high dose formulation","BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation","BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation","BILR 355 BS - Suspension low dose","BILR 355 BS - Suspension high dose",{"trials":45464,"activeCount":101},[],{"trials":45466,"activeCount":101},[],{"trials":45468,"activeCount":101},[],{"trials":45470,"activeCount":101},[],{"intervention":45458,"totalTrials":272,"cells":45472},{"EARLY_PHASE1":45473,"PHASE1":45475,"PHASE2":45481,"PHASE3":45483,"PHASE4":45485,"NA":45487},{"trials":45474,"activeCount":101},[],{"trials":45476,"activeCount":101},[45477],{"nctId":45453,"briefTitle":45454,"status":107,"phases":45478,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":45479,"interventions":45480},[90],[15],[45446,45458,45459,45460,45461,45462,4010],{"trials":45482,"activeCount":101},[],{"trials":45484,"activeCount":101},[],{"trials":45486,"activeCount":101},[],{"trials":45488,"activeCount":101},[],{"intervention":45459,"totalTrials":272,"cells":45490},{"EARLY_PHASE1":45491,"PHASE1":45493,"PHASE2":45499,"PHASE3":45501,"PHASE4":45503,"NA":45505},{"trials":45492,"activeCount":101},[],{"trials":45494,"activeCount":101},[45495],{"nctId":45453,"briefTitle":45454,"status":107,"phases":45496,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":45497,"interventions":45498},[90],[15],[45446,45458,45459,45460,45461,45462,4010],{"trials":45500,"activeCount":101},[],{"trials":45502,"activeCount":101},[],{"trials":45504,"activeCount":101},[],{"trials":45506,"activeCount":101},[],{"intervention":45460,"totalTrials":272,"cells":45508},{"EARLY_PHASE1":45509,"PHASE1":45511,"PHASE2":45517,"PHASE3":45519,"PHASE4":45521,"NA":45523},{"trials":45510,"activeCount":101},[],{"trials":45512,"activeCount":101},[45513],{"nctId":45453,"briefTitle":45454,"status":107,"phases":45514,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":45515,"interventions":45516},[90],[15],[45446,45458,45459,45460,45461,45462,4010],{"trials":45518,"activeCount":101},[],{"trials":45520,"activeCount":101},[],{"trials":45522,"activeCount":101},[],{"trials":45524,"activeCount":101},[],{"intervention":45461,"totalTrials":272,"cells":45526},{"EARLY_PHASE1":45527,"PHASE1":45529,"PHASE2":45535,"PHASE3":45537,"PHASE4":45539,"NA":45541},{"trials":45528,"activeCount":101},[],{"trials":45530,"activeCount":101},[45531],{"nctId":45453,"briefTitle":45454,"status":107,"phases":45532,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":45533,"interventions":45534},[90],[15],[45446,45458,45459,45460,45461,45462,4010],{"trials":45536,"activeCount":101},[],{"trials":45538,"activeCount":101},[],{"trials":45540,"activeCount":101},[],{"trials":45542,"activeCount":101},[],{"intervention":45462,"totalTrials":272,"cells":45544},{"EARLY_PHASE1":45545,"PHASE1":45547,"PHASE2":45553,"PHASE3":45555,"PHASE4":45557,"NA":45559},{"trials":45546,"activeCount":101},[],{"trials":45548,"activeCount":101},[45549],{"nctId":45453,"briefTitle":45454,"status":107,"phases":45550,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":45551,"interventions":45552},[90],[15],[45446,45458,45459,45460,45461,45462,4010],{"trials":45554,"activeCount":101},[],{"trials":45556,"activeCount":101},[],{"trials":45558,"activeCount":101},[],{"trials":45560,"activeCount":101},[],{"intervention":28079,"totalTrials":272,"cells":45562},{"EARLY_PHASE1":45563,"PHASE1":45565,"PHASE2":45571,"PHASE3":45573,"PHASE4":45575,"NA":45577},{"trials":45564,"activeCount":101},[],{"trials":45566,"activeCount":101},[45567],{"nctId":28074,"briefTitle":28075,"status":107,"phases":45568,"primaryCompletion":3730,"completion":3730,"start":2001,"enrollment":956,"conditions":45569,"interventions":45570},[90],[15],[28079,27403,27403,27403,28080,27403],{"trials":45572,"activeCount":101},[],{"trials":45574,"activeCount":101},[],{"trials":45576,"activeCount":101},[],{"trials":45578,"activeCount":101},[],{"intervention":28080,"totalTrials":272,"cells":45580},{"EARLY_PHASE1":45581,"PHASE1":45583,"PHASE2":45589,"PHASE3":45591,"PHASE4":45593,"NA":45595},{"trials":45582,"activeCount":101},[],{"trials":45584,"activeCount":101},[45585],{"nctId":28074,"briefTitle":28075,"status":107,"phases":45586,"primaryCompletion":3730,"completion":3730,"start":2001,"enrollment":956,"conditions":45587,"interventions":45588},[90],[15],[28079,27403,27403,27403,28080,27403],{"trials":45590,"activeCount":101},[],{"trials":45592,"activeCount":101},[],{"trials":45594,"activeCount":101},[],{"trials":45596,"activeCount":101},[],{"intervention":18982,"totalTrials":272,"cells":45598},{"EARLY_PHASE1":45599,"PHASE1":45601,"PHASE2":45607,"PHASE3":45609,"PHASE4":45611,"NA":45613},{"trials":45600,"activeCount":101},[],{"trials":45602,"activeCount":101},[45603],{"nctId":18976,"briefTitle":18977,"status":162,"phases":45604,"primaryCompletion":18979,"completion":18979,"start":1713,"enrollment":993,"conditions":45605,"interventions":45606},[90],[15],[18982,4176],{"trials":45608,"activeCount":101},[],{"trials":45610,"activeCount":101},[],{"trials":45612,"activeCount":101},[],{"trials":45614,"activeCount":101},[],{"intervention":45616,"totalTrials":272,"cells":45617},"BIIX 1 XX - single rising dose",{"EARLY_PHASE1":45618,"PHASE1":45620,"PHASE2":45628,"PHASE3":45630,"PHASE4":45632,"NA":45634},{"trials":45619,"activeCount":101},[],{"trials":45621,"activeCount":101},[45622],{"nctId":45623,"briefTitle":45624,"status":107,"phases":45625,"primaryCompletion":7084,"start":6064,"enrollment":380,"conditions":45626,"interventions":45627},"NCT02199873","Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers",[90],[15],[45616],{"trials":45629,"activeCount":101},[],{"trials":45631,"activeCount":101},[],{"trials":45633,"activeCount":101},[],{"trials":45635,"activeCount":101},[],{"intervention":45637,"totalTrials":272,"cells":45638},"BIBX 245 CL - fed",{"EARLY_PHASE1":45639,"PHASE1":45641,"PHASE2":45650,"PHASE3":45652,"PHASE4":45654,"NA":45656},{"trials":45640,"activeCount":101},[],{"trials":45642,"activeCount":101},[45643],{"nctId":45644,"briefTitle":45645,"status":107,"phases":45646,"primaryCompletion":6064,"start":7250,"enrollment":155,"conditions":45647,"interventions":45648},"NCT02264197","Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects",[90],[15],[45637,45649],"BIBX 245 CL- fasted",{"trials":45651,"activeCount":101},[],{"trials":45653,"activeCount":101},[],{"trials":45655,"activeCount":101},[],{"trials":45657,"activeCount":101},[],{"intervention":45649,"totalTrials":272,"cells":45659},{"EARLY_PHASE1":45660,"PHASE1":45662,"PHASE2":45668,"PHASE3":45670,"PHASE4":45672,"NA":45674},{"trials":45661,"activeCount":101},[],{"trials":45663,"activeCount":101},[45664],{"nctId":45644,"briefTitle":45645,"status":107,"phases":45665,"primaryCompletion":6064,"start":7250,"enrollment":155,"conditions":45666,"interventions":45667},[90],[15],[45637,45649],{"trials":45669,"activeCount":101},[],{"trials":45671,"activeCount":101},[],{"trials":45673,"activeCount":101},[],{"trials":45675,"activeCount":101},[],{"intervention":45677,"totalTrials":272,"cells":45678},"KUC 7483 CL, immediate release",{"EARLY_PHASE1":45679,"PHASE1":45681,"PHASE2":45691,"PHASE3":45693,"PHASE4":45695,"NA":45697},{"trials":45680,"activeCount":101},[],{"trials":45682,"activeCount":101},[45683],{"nctId":45684,"briefTitle":45685,"status":107,"phases":45686,"primaryCompletion":6445,"start":11649,"enrollment":912,"conditions":45687,"interventions":45688},"NCT02259920","Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers",[90],[15],[45677,45689,45690],"KUC 7483 CL, particulate formulation","KUC 7483 CL, solution formulation",{"trials":45692,"activeCount":101},[],{"trials":45694,"activeCount":101},[],{"trials":45696,"activeCount":101},[],{"trials":45698,"activeCount":101},[],{"intervention":45689,"totalTrials":272,"cells":45700},{"EARLY_PHASE1":45701,"PHASE1":45703,"PHASE2":45709,"PHASE3":45711,"PHASE4":45713,"NA":45715},{"trials":45702,"activeCount":101},[],{"trials":45704,"activeCount":101},[45705],{"nctId":45684,"briefTitle":45685,"status":107,"phases":45706,"primaryCompletion":6445,"start":11649,"enrollment":912,"conditions":45707,"interventions":45708},[90],[15],[45677,45689,45690],{"trials":45710,"activeCount":101},[],{"trials":45712,"activeCount":101},[],{"trials":45714,"activeCount":101},[],{"trials":45716,"activeCount":101},[],{"intervention":45690,"totalTrials":272,"cells":45718},{"EARLY_PHASE1":45719,"PHASE1":45721,"PHASE2":45727,"PHASE3":45729,"PHASE4":45731,"NA":45733},{"trials":45720,"activeCount":101},[],{"trials":45722,"activeCount":101},[45723],{"nctId":45684,"briefTitle":45685,"status":107,"phases":45724,"primaryCompletion":6445,"start":11649,"enrollment":912,"conditions":45725,"interventions":45726},[90],[15],[45677,45689,45690],{"trials":45728,"activeCount":101},[],{"trials":45730,"activeCount":101},[],{"trials":45732,"activeCount":101},[],{"trials":45734,"activeCount":101},[],{"intervention":29587,"totalTrials":272,"cells":45736},{"EARLY_PHASE1":45737,"PHASE1":45739,"PHASE2":45745,"PHASE3":45747,"PHASE4":45749,"NA":45751},{"trials":45738,"activeCount":101},[],{"trials":45740,"activeCount":101},[45741],{"nctId":29582,"briefTitle":29583,"status":107,"phases":45742,"primaryCompletion":6074,"start":21407,"enrollment":1340,"conditions":45743,"interventions":45744},[90],[15],[29567,29587,29588],{"trials":45746,"activeCount":101},[],{"trials":45748,"activeCount":101},[],{"trials":45750,"activeCount":101},[],{"trials":45752,"activeCount":101},[],{"intervention":29588,"totalTrials":272,"cells":45754},{"EARLY_PHASE1":45755,"PHASE1":45757,"PHASE2":45763,"PHASE3":45765,"PHASE4":45767,"NA":45769},{"trials":45756,"activeCount":101},[],{"trials":45758,"activeCount":101},[45759],{"nctId":29582,"briefTitle":29583,"status":107,"phases":45760,"primaryCompletion":6074,"start":21407,"enrollment":1340,"conditions":45761,"interventions":45762},[90],[15],[29567,29587,29588],{"trials":45764,"activeCount":101},[],{"trials":45766,"activeCount":101},[],{"trials":45768,"activeCount":101},[],{"trials":45770,"activeCount":101},[],{"intervention":45772,"totalTrials":272,"cells":45773},"Tiotropium, solution ampoules",{"EARLY_PHASE1":45774,"PHASE1":45776,"PHASE2":45784,"PHASE3":45786,"PHASE4":45788,"NA":45790},{"trials":45775,"activeCount":101},[],{"trials":45777,"activeCount":101},[45778],{"nctId":45779,"briefTitle":45780,"status":107,"phases":45781,"primaryCompletion":7114,"start":6065,"enrollment":380,"conditions":45782,"interventions":45783},"NCT02172339","The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects",[90],[2550],[45772],{"trials":45785,"activeCount":101},[],{"trials":45787,"activeCount":101},[],{"trials":45789,"activeCount":101},[],{"trials":45791,"activeCount":101},[],{"intervention":45793,"totalTrials":272,"cells":45794},"BI 836909",{"EARLY_PHASE1":45795,"PHASE1":45797,"PHASE2":45807,"PHASE3":45809,"PHASE4":45811,"NA":45813},{"trials":45796,"activeCount":101},[],{"trials":45798,"activeCount":101},[45799],{"nctId":45800,"briefTitle":45801,"status":107,"phases":45802,"primaryCompletion":45803,"completion":45804,"start":11546,"enrollment":2789,"conditions":45805,"interventions":45806},"NCT02514239","Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients",[90],"2018-07-17","2020-07-02",[30743],[45793],{"trials":45808,"activeCount":101},[],{"trials":45810,"activeCount":101},[],{"trials":45812,"activeCount":101},[],{"trials":45814,"activeCount":101},[],{"intervention":45816,"totalTrials":272,"cells":45817},"BI 456906 formulation A",{"EARLY_PHASE1":45818,"PHASE1":45820,"PHASE2":45831,"PHASE3":45833,"PHASE4":45835,"NA":45837},{"trials":45819,"activeCount":101},[],{"trials":45821,"activeCount":101},[45822],{"nctId":45823,"briefTitle":45824,"status":107,"phases":45825,"primaryCompletion":30891,"completion":45826,"start":45827,"enrollment":401,"conditions":45828,"interventions":45829},"NCT07071974","A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body",[90],"2025-10-28","2025-07-28",[15],[45816,45830],"BI 456906 formulation B2",{"trials":45832,"activeCount":101},[],{"trials":45834,"activeCount":101},[],{"trials":45836,"activeCount":101},[],{"trials":45838,"activeCount":101},[],{"intervention":45830,"totalTrials":272,"cells":45840},{"EARLY_PHASE1":45841,"PHASE1":45843,"PHASE2":45849,"PHASE3":45851,"PHASE4":45853,"NA":45855},{"trials":45842,"activeCount":101},[],{"trials":45844,"activeCount":101},[45845],{"nctId":45823,"briefTitle":45824,"status":107,"phases":45846,"primaryCompletion":30891,"completion":45826,"start":45827,"enrollment":401,"conditions":45847,"interventions":45848},[90],[15],[45816,45830],{"trials":45850,"activeCount":101},[],{"trials":45852,"activeCount":101},[],{"trials":45854,"activeCount":101},[],{"trials":45856,"activeCount":101},[],{"intervention":45858,"totalTrials":272,"cells":45859},"BIBR 1048 MS low",{"EARLY_PHASE1":45860,"PHASE1":45862,"PHASE2":45874,"PHASE3":45876,"PHASE4":45878,"NA":45880},{"trials":45861,"activeCount":101},[],{"trials":45863,"activeCount":101},[45864],{"nctId":45865,"briefTitle":45866,"status":107,"phases":45867,"primaryCompletion":13117,"start":9235,"enrollment":2382,"conditions":45868,"interventions":45869},"NCT02170831","Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers",[90],[15],[45858,45870,45871,45872,45873],"BIBR 1048 MS medium 1","BIBR 1048 MS medium 2","BIBR 1048 MS high","BIBR 1048 MS placebo",{"trials":45875,"activeCount":101},[],{"trials":45877,"activeCount":101},[],{"trials":45879,"activeCount":101},[],{"trials":45881,"activeCount":101},[],{"intervention":45870,"totalTrials":272,"cells":45883},{"EARLY_PHASE1":45884,"PHASE1":45886,"PHASE2":45892,"PHASE3":45894,"PHASE4":45896,"NA":45898},{"trials":45885,"activeCount":101},[],{"trials":45887,"activeCount":101},[45888],{"nctId":45865,"briefTitle":45866,"status":107,"phases":45889,"primaryCompletion":13117,"start":9235,"enrollment":2382,"conditions":45890,"interventions":45891},[90],[15],[45858,45870,45871,45872,45873],{"trials":45893,"activeCount":101},[],{"trials":45895,"activeCount":101},[],{"trials":45897,"activeCount":101},[],{"trials":45899,"activeCount":101},[],{"intervention":45871,"totalTrials":272,"cells":45901},{"EARLY_PHASE1":45902,"PHASE1":45904,"PHASE2":45910,"PHASE3":45912,"PHASE4":45914,"NA":45916},{"trials":45903,"activeCount":101},[],{"trials":45905,"activeCount":101},[45906],{"nctId":45865,"briefTitle":45866,"status":107,"phases":45907,"primaryCompletion":13117,"start":9235,"enrollment":2382,"conditions":45908,"interventions":45909},[90],[15],[45858,45870,45871,45872,45873],{"trials":45911,"activeCount":101},[],{"trials":45913,"activeCount":101},[],{"trials":45915,"activeCount":101},[],{"trials":45917,"activeCount":101},[],{"intervention":45872,"totalTrials":272,"cells":45919},{"EARLY_PHASE1":45920,"PHASE1":45922,"PHASE2":45928,"PHASE3":45930,"PHASE4":45932,"NA":45934},{"trials":45921,"activeCount":101},[],{"trials":45923,"activeCount":101},[45924],{"nctId":45865,"briefTitle":45866,"status":107,"phases":45925,"primaryCompletion":13117,"start":9235,"enrollment":2382,"conditions":45926,"interventions":45927},[90],[15],[45858,45870,45871,45872,45873],{"trials":45929,"activeCount":101},[],{"trials":45931,"activeCount":101},[],{"trials":45933,"activeCount":101},[],{"trials":45935,"activeCount":101},[],{"intervention":45873,"totalTrials":272,"cells":45937},{"EARLY_PHASE1":45938,"PHASE1":45940,"PHASE2":45946,"PHASE3":45948,"PHASE4":45950,"NA":45952},{"trials":45939,"activeCount":101},[],{"trials":45941,"activeCount":101},[45942],{"nctId":45865,"briefTitle":45866,"status":107,"phases":45943,"primaryCompletion":13117,"start":9235,"enrollment":2382,"conditions":45944,"interventions":45945},[90],[15],[45858,45870,45871,45872,45873],{"trials":45947,"activeCount":101},[],{"trials":45949,"activeCount":101},[],{"trials":45951,"activeCount":101},[],{"trials":45953,"activeCount":101},[],{"intervention":45955,"totalTrials":272,"cells":45956},"Metformin Single",{"EARLY_PHASE1":45957,"PHASE1":45959,"PHASE2":45969,"PHASE3":45971,"PHASE4":45973,"NA":45975},{"trials":45958,"activeCount":101},[],{"trials":45960,"activeCount":101},[45961],{"nctId":45962,"briefTitle":45963,"status":107,"phases":45964,"primaryCompletion":6095,"completion":6095,"start":2030,"enrollment":3551,"conditions":45965,"interventions":45966},"NCT01383356","Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin\u002FMetformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet",[90],[21],[45955,45967,45968],"Linagliptin\u002FMetformin Combo","Linagliptin Single",{"trials":45970,"activeCount":101},[],{"trials":45972,"activeCount":101},[],{"trials":45974,"activeCount":101},[],{"trials":45976,"activeCount":101},[],{"intervention":45967,"totalTrials":272,"cells":45978},{"EARLY_PHASE1":45979,"PHASE1":45981,"PHASE2":45987,"PHASE3":45989,"PHASE4":45991,"NA":45993},{"trials":45980,"activeCount":101},[],{"trials":45982,"activeCount":101},[45983],{"nctId":45962,"briefTitle":45963,"status":107,"phases":45984,"primaryCompletion":6095,"completion":6095,"start":2030,"enrollment":3551,"conditions":45985,"interventions":45986},[90],[21],[45955,45967,45968],{"trials":45988,"activeCount":101},[],{"trials":45990,"activeCount":101},[],{"trials":45992,"activeCount":101},[],{"trials":45994,"activeCount":101},[],{"intervention":45968,"totalTrials":272,"cells":45996},{"EARLY_PHASE1":45997,"PHASE1":45999,"PHASE2":46005,"PHASE3":46007,"PHASE4":46009,"NA":46011},{"trials":45998,"activeCount":101},[],{"trials":46000,"activeCount":101},[46001],{"nctId":45962,"briefTitle":45963,"status":107,"phases":46002,"primaryCompletion":6095,"completion":6095,"start":2030,"enrollment":3551,"conditions":46003,"interventions":46004},[90],[21],[45955,45967,45968],{"trials":46006,"activeCount":101},[],{"trials":46008,"activeCount":101},[],{"trials":46010,"activeCount":101},[],{"trials":46012,"activeCount":101},[],{"intervention":18991,"totalTrials":272,"cells":46014},{"EARLY_PHASE1":46015,"PHASE1":46017,"PHASE2":46023,"PHASE3":46025,"PHASE4":46027,"NA":46029},{"trials":46016,"activeCount":101},[],{"trials":46018,"activeCount":101},[46019],{"nctId":18984,"briefTitle":18985,"status":107,"phases":46020,"primaryCompletion":18987,"completion":18987,"start":18988,"enrollment":188,"conditions":46021,"interventions":46022},[90],[15],[4176,18991,4176],{"trials":46024,"activeCount":101},[],{"trials":46026,"activeCount":101},[],{"trials":46028,"activeCount":101},[],{"trials":46030,"activeCount":101},[],{"intervention":46032,"totalTrials":272,"cells":46033},"meloxicam rapid release tablet, 12mg, UH AC62MU",{"EARLY_PHASE1":46034,"PHASE1":46036,"PHASE2":46044,"PHASE3":46046,"PHASE4":46048,"NA":46050},{"trials":46035,"activeCount":101},[],{"trials":46037,"activeCount":101},[46038],{"nctId":46039,"briefTitle":46040,"status":107,"phases":46041,"primaryCompletion":9235,"start":2182,"enrollment":155,"conditions":46042,"interventions":46043},"NCT02183103","Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects",[90],[15],[46032],{"trials":46045,"activeCount":101},[],{"trials":46047,"activeCount":101},[],{"trials":46049,"activeCount":101},[],{"trials":46051,"activeCount":101},[],{"intervention":46053,"totalTrials":272,"cells":46054},"hMAb BIWA 4",{"EARLY_PHASE1":46055,"PHASE1":46057,"PHASE2":46065,"PHASE3":46067,"PHASE4":46069,"NA":46071},{"trials":46056,"activeCount":101},[],{"trials":46058,"activeCount":101},[46059],{"nctId":46060,"briefTitle":46061,"status":107,"phases":46062,"primaryCompletion":7419,"start":6206,"enrollment":1340,"conditions":46063,"interventions":46064},"NCT02204059","Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer",[90],[36],[46053],{"trials":46066,"activeCount":101},[],{"trials":46068,"activeCount":101},[],{"trials":46070,"activeCount":101},[],{"trials":46072,"activeCount":101},[],{"intervention":27548,"totalTrials":272,"cells":46074},{"EARLY_PHASE1":46075,"PHASE1":46077,"PHASE2":46083,"PHASE3":46085,"PHASE4":46087,"NA":46089},{"trials":46076,"activeCount":101},[],{"trials":46078,"activeCount":101},[46079],{"nctId":27541,"briefTitle":27542,"status":107,"phases":46080,"primaryCompletion":27544,"completion":27544,"start":27545,"enrollment":380,"conditions":46081,"interventions":46082},[90],[15],[2393,969,27548,27548,970,27548,971],{"trials":46084,"activeCount":101},[],{"trials":46086,"activeCount":101},[],{"trials":46088,"activeCount":101},[],{"trials":46090,"activeCount":101},[],{"intervention":19619,"totalTrials":272,"cells":46092},{"EARLY_PHASE1":46093,"PHASE1":46095,"PHASE2":46101,"PHASE3":46103,"PHASE4":46105,"NA":46107},{"trials":46094,"activeCount":101},[],{"trials":46096,"activeCount":101},[46097],{"nctId":19614,"briefTitle":19615,"status":107,"phases":46098,"primaryCompletion":7300,"start":15139,"enrollment":1116,"conditions":46099,"interventions":46100},[90],[15],[11653,4010,19619],{"trials":46102,"activeCount":101},[],{"trials":46104,"activeCount":101},[],{"trials":46106,"activeCount":101},[],{"trials":46108,"activeCount":101},[],{"intervention":46110,"totalTrials":272,"cells":46111},"BIIL 284 BS, low dose, pediatric patients",{"EARLY_PHASE1":46112,"PHASE1":46114,"PHASE2":46127,"PHASE3":46129,"PHASE4":46131,"NA":46133},{"trials":46113,"activeCount":101},[],{"trials":46115,"activeCount":101},[46116],{"nctId":46117,"briefTitle":46118,"status":107,"phases":46119,"primaryCompletion":6495,"start":6041,"enrollment":1535,"conditions":46120,"interventions":46121},"NCT02265679","Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients",[90],[1724],[46110,46122,46123,46124,46125,46126],"BIIL 284 BS, medium dose, pediatric patients","BIIL 284 BS, high dose, pediatric patients","BIIL 284 BS, low dose, adult patients","BIIL 284 BS, medium dose, adult patients","BIIL 284 BS, high dose, adult patients",{"trials":46128,"activeCount":101},[],{"trials":46130,"activeCount":101},[],{"trials":46132,"activeCount":101},[],{"trials":46134,"activeCount":101},[],{"intervention":46122,"totalTrials":272,"cells":46136},{"EARLY_PHASE1":46137,"PHASE1":46139,"PHASE2":46145,"PHASE3":46147,"PHASE4":46149,"NA":46151},{"trials":46138,"activeCount":101},[],{"trials":46140,"activeCount":101},[46141],{"nctId":46117,"briefTitle":46118,"status":107,"phases":46142,"primaryCompletion":6495,"start":6041,"enrollment":1535,"conditions":46143,"interventions":46144},[90],[1724],[46110,46122,46123,46124,46125,46126],{"trials":46146,"activeCount":101},[],{"trials":46148,"activeCount":101},[],{"trials":46150,"activeCount":101},[],{"trials":46152,"activeCount":101},[],{"intervention":46123,"totalTrials":272,"cells":46154},{"EARLY_PHASE1":46155,"PHASE1":46157,"PHASE2":46163,"PHASE3":46165,"PHASE4":46167,"NA":46169},{"trials":46156,"activeCount":101},[],{"trials":46158,"activeCount":101},[46159],{"nctId":46117,"briefTitle":46118,"status":107,"phases":46160,"primaryCompletion":6495,"start":6041,"enrollment":1535,"conditions":46161,"interventions":46162},[90],[1724],[46110,46122,46123,46124,46125,46126],{"trials":46164,"activeCount":101},[],{"trials":46166,"activeCount":101},[],{"trials":46168,"activeCount":101},[],{"trials":46170,"activeCount":101},[],{"intervention":46124,"totalTrials":272,"cells":46172},{"EARLY_PHASE1":46173,"PHASE1":46175,"PHASE2":46181,"PHASE3":46183,"PHASE4":46185,"NA":46187},{"trials":46174,"activeCount":101},[],{"trials":46176,"activeCount":101},[46177],{"nctId":46117,"briefTitle":46118,"status":107,"phases":46178,"primaryCompletion":6495,"start":6041,"enrollment":1535,"conditions":46179,"interventions":46180},[90],[1724],[46110,46122,46123,46124,46125,46126],{"trials":46182,"activeCount":101},[],{"trials":46184,"activeCount":101},[],{"trials":46186,"activeCount":101},[],{"trials":46188,"activeCount":101},[],{"intervention":46125,"totalTrials":272,"cells":46190},{"EARLY_PHASE1":46191,"PHASE1":46193,"PHASE2":46199,"PHASE3":46201,"PHASE4":46203,"NA":46205},{"trials":46192,"activeCount":101},[],{"trials":46194,"activeCount":101},[46195],{"nctId":46117,"briefTitle":46118,"status":107,"phases":46196,"primaryCompletion":6495,"start":6041,"enrollment":1535,"conditions":46197,"interventions":46198},[90],[1724],[46110,46122,46123,46124,46125,46126],{"trials":46200,"activeCount":101},[],{"trials":46202,"activeCount":101},[],{"trials":46204,"activeCount":101},[],{"trials":46206,"activeCount":101},[],{"intervention":46126,"totalTrials":272,"cells":46208},{"EARLY_PHASE1":46209,"PHASE1":46211,"PHASE2":46217,"PHASE3":46219,"PHASE4":46221,"NA":46223},{"trials":46210,"activeCount":101},[],{"trials":46212,"activeCount":101},[46213],{"nctId":46117,"briefTitle":46118,"status":107,"phases":46214,"primaryCompletion":6495,"start":6041,"enrollment":1535,"conditions":46215,"interventions":46216},[90],[1724],[46110,46122,46123,46124,46125,46126],{"trials":46218,"activeCount":101},[],{"trials":46220,"activeCount":101},[],{"trials":46222,"activeCount":101},[],{"trials":46224,"activeCount":101},[],{"intervention":10257,"totalTrials":272,"cells":46226},{"EARLY_PHASE1":46227,"PHASE1":46229,"PHASE2":46235,"PHASE3":46237,"PHASE4":46239,"NA":46241},{"trials":46228,"activeCount":101},[],{"trials":46230,"activeCount":101},[46231],{"nctId":10252,"briefTitle":10253,"status":162,"phases":46232,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":401,"conditions":46233,"interventions":46234},[90],[15],[10257,10258,4047,10259],{"trials":46236,"activeCount":101},[],{"trials":46238,"activeCount":101},[],{"trials":46240,"activeCount":101},[],{"trials":46242,"activeCount":101},[],{"intervention":10258,"totalTrials":272,"cells":46244},{"EARLY_PHASE1":46245,"PHASE1":46247,"PHASE2":46253,"PHASE3":46255,"PHASE4":46257,"NA":46259},{"trials":46246,"activeCount":101},[],{"trials":46248,"activeCount":101},[46249],{"nctId":10252,"briefTitle":10253,"status":162,"phases":46250,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":401,"conditions":46251,"interventions":46252},[90],[15],[10257,10258,4047,10259],{"trials":46254,"activeCount":101},[],{"trials":46256,"activeCount":101},[],{"trials":46258,"activeCount":101},[],{"trials":46260,"activeCount":101},[],{"intervention":10259,"totalTrials":272,"cells":46262},{"EARLY_PHASE1":46263,"PHASE1":46265,"PHASE2":46271,"PHASE3":46273,"PHASE4":46275,"NA":46277},{"trials":46264,"activeCount":101},[],{"trials":46266,"activeCount":101},[46267],{"nctId":10252,"briefTitle":10253,"status":162,"phases":46268,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":401,"conditions":46269,"interventions":46270},[90],[15],[10257,10258,4047,10259],{"trials":46272,"activeCount":101},[],{"trials":46274,"activeCount":101},[],{"trials":46276,"activeCount":101},[],{"trials":46278,"activeCount":101},[],{"intervention":46280,"totalTrials":272,"cells":46281},"Nevirapine Immediate Release",{"EARLY_PHASE1":46282,"PHASE1":46284,"PHASE2":46293,"PHASE3":46295,"PHASE4":46297,"NA":46299},{"trials":46283,"activeCount":101},[],{"trials":46285,"activeCount":101},[46286],{"nctId":46287,"briefTitle":46288,"status":107,"phases":46289,"primaryCompletion":2001,"completion":2001,"start":5905,"enrollment":1468,"conditions":46290,"interventions":46291},"NCT00905489","A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.",[90],[27],[46280,46292],"Nevirapine Extended Release",{"trials":46294,"activeCount":101},[],{"trials":46296,"activeCount":101},[],{"trials":46298,"activeCount":101},[],{"trials":46300,"activeCount":101},[],{"intervention":46292,"totalTrials":272,"cells":46302},{"EARLY_PHASE1":46303,"PHASE1":46305,"PHASE2":46311,"PHASE3":46313,"PHASE4":46315,"NA":46317},{"trials":46304,"activeCount":101},[],{"trials":46306,"activeCount":101},[46307],{"nctId":46287,"briefTitle":46288,"status":107,"phases":46308,"primaryCompletion":2001,"completion":2001,"start":5905,"enrollment":1468,"conditions":46309,"interventions":46310},[90],[27],[46280,46292],{"trials":46312,"activeCount":101},[],{"trials":46314,"activeCount":101},[],{"trials":46316,"activeCount":101},[],{"trials":46318,"activeCount":101},[],{"intervention":19315,"totalTrials":272,"cells":46320},{"EARLY_PHASE1":46321,"PHASE1":46323,"PHASE2":46329,"PHASE3":46331,"PHASE4":46333,"NA":46335},{"trials":46322,"activeCount":101},[],{"trials":46324,"activeCount":101},[46325],{"nctId":19308,"briefTitle":19309,"status":107,"phases":46326,"primaryCompletion":19311,"completion":19311,"start":19312,"enrollment":401,"conditions":46327,"interventions":46328},[90],[15],[19315,19260],{"trials":46330,"activeCount":101},[],{"trials":46332,"activeCount":101},[],{"trials":46334,"activeCount":101},[],{"trials":46336,"activeCount":101},[],{"intervention":46338,"totalTrials":272,"cells":46339},"BI 1744 CL, low dose",{"EARLY_PHASE1":46340,"PHASE1":46342,"PHASE2":46351,"PHASE3":46353,"PHASE4":46355,"NA":46357},{"trials":46341,"activeCount":101},[],{"trials":46343,"activeCount":101},[46344],{"nctId":46345,"briefTitle":46346,"status":107,"phases":46347,"primaryCompletion":9381,"start":3991,"enrollment":132,"conditions":46348,"interventions":46349},"NCT02171832","Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function",[90],[15,550],[46338,46350],"BI 1744 CL, high dose",{"trials":46352,"activeCount":101},[],{"trials":46354,"activeCount":101},[],{"trials":46356,"activeCount":101},[],{"trials":46358,"activeCount":101},[],{"intervention":46350,"totalTrials":272,"cells":46360},{"EARLY_PHASE1":46361,"PHASE1":46363,"PHASE2":46369,"PHASE3":46371,"PHASE4":46373,"NA":46375},{"trials":46362,"activeCount":101},[],{"trials":46364,"activeCount":101},[46365],{"nctId":46345,"briefTitle":46346,"status":107,"phases":46366,"primaryCompletion":9381,"start":3991,"enrollment":132,"conditions":46367,"interventions":46368},[90],[15,550],[46338,46350],{"trials":46370,"activeCount":101},[],{"trials":46372,"activeCount":101},[],{"trials":46374,"activeCount":101},[],{"trials":46376,"activeCount":101},[],{"intervention":46378,"totalTrials":272,"cells":46379},"BI 1181181 high dose",{"EARLY_PHASE1":46380,"PHASE1":46382,"PHASE2":46391,"PHASE3":46393,"PHASE4":46395,"NA":46397},{"trials":46381,"activeCount":101},[],{"trials":46383,"activeCount":101},[46384],{"nctId":46385,"briefTitle":46386,"status":107,"phases":46387,"primaryCompletion":4391,"completion":4391,"start":10024,"enrollment":448,"conditions":46388,"interventions":46389},"NCT02106247","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers",[90],[15],[46378,46390],"BI 1181181 low dose",{"trials":46392,"activeCount":101},[],{"trials":46394,"activeCount":101},[],{"trials":46396,"activeCount":101},[],{"trials":46398,"activeCount":101},[],{"intervention":46390,"totalTrials":272,"cells":46400},{"EARLY_PHASE1":46401,"PHASE1":46403,"PHASE2":46409,"PHASE3":46411,"PHASE4":46413,"NA":46415},{"trials":46402,"activeCount":101},[],{"trials":46404,"activeCount":101},[46405],{"nctId":46385,"briefTitle":46386,"status":107,"phases":46406,"primaryCompletion":4391,"completion":4391,"start":10024,"enrollment":448,"conditions":46407,"interventions":46408},[90],[15],[46378,46390],{"trials":46410,"activeCount":101},[],{"trials":46412,"activeCount":101},[],{"trials":46414,"activeCount":101},[],{"trials":46416,"activeCount":101},[],{"intervention":46418,"totalTrials":272,"cells":46419},"BI695501 Prefilled syringe",{"EARLY_PHASE1":46420,"PHASE1":46422,"PHASE2":46434,"PHASE3":46436,"PHASE4":46438,"NA":46440},{"trials":46421,"activeCount":101},[],{"trials":46423,"activeCount":101},[46424],{"nctId":46425,"briefTitle":46426,"status":107,"phases":46427,"primaryCompletion":46428,"completion":46429,"start":46430,"enrollment":12783,"conditions":46431,"interventions":46432},"NCT02899338","Pharmacokinetics and Safety of BI 695501",[90],"2017-02-09","2017-02-23","2016-09-21",[15],[46418,46433],"BI695501Autoinjector",{"trials":46435,"activeCount":101},[],{"trials":46437,"activeCount":101},[],{"trials":46439,"activeCount":101},[],{"trials":46441,"activeCount":101},[],{"intervention":46433,"totalTrials":272,"cells":46443},{"EARLY_PHASE1":46444,"PHASE1":46446,"PHASE2":46452,"PHASE3":46454,"PHASE4":46456,"NA":46458},{"trials":46445,"activeCount":101},[],{"trials":46447,"activeCount":101},[46448],{"nctId":46425,"briefTitle":46426,"status":107,"phases":46449,"primaryCompletion":46428,"completion":46429,"start":46430,"enrollment":12783,"conditions":46450,"interventions":46451},[90],[15],[46418,46433],{"trials":46453,"activeCount":101},[],{"trials":46455,"activeCount":101},[],{"trials":46457,"activeCount":101},[],{"trials":46459,"activeCount":101},[],{"intervention":19116,"totalTrials":272,"cells":46461},{"EARLY_PHASE1":46462,"PHASE1":46464,"PHASE2":46470,"PHASE3":46472,"PHASE4":46474,"NA":46476},{"trials":46463,"activeCount":101},[],{"trials":46465,"activeCount":101},[46466],{"nctId":19111,"briefTitle":19112,"status":107,"phases":46467,"primaryCompletion":6471,"start":4129,"enrollment":281,"conditions":46468,"interventions":46469},[90],[15],[19116,19059],{"trials":46471,"activeCount":101},[],{"trials":46473,"activeCount":101},[],{"trials":46475,"activeCount":101},[],{"trials":46477,"activeCount":101},[],{"intervention":29135,"totalTrials":272,"cells":46479},{"EARLY_PHASE1":46480,"PHASE1":46482,"PHASE2":46488,"PHASE3":46490,"PHASE4":46492,"NA":46494},{"trials":46481,"activeCount":101},[],{"trials":46483,"activeCount":101},[46484],{"nctId":29130,"briefTitle":29131,"status":107,"phases":46485,"primaryCompletion":6374,"start":5879,"enrollment":97,"conditions":46486,"interventions":46487},[90],[15],[4008,4010,10041,29135],{"trials":46489,"activeCount":101},[],{"trials":46491,"activeCount":101},[],{"trials":46493,"activeCount":101},[],{"trials":46495,"activeCount":101},[],{"intervention":46497,"totalTrials":272,"cells":46498},"BIBR 1048 MS dose 1",{"EARLY_PHASE1":46499,"PHASE1":46501,"PHASE2":46513,"PHASE3":46515,"PHASE4":46517,"NA":46519},{"trials":46500,"activeCount":101},[],{"trials":46502,"activeCount":101},[46503],{"nctId":46504,"briefTitle":46505,"status":107,"phases":46506,"primaryCompletion":7114,"start":11123,"enrollment":2382,"conditions":46507,"interventions":46508},"NCT02170116","Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers",[90],[15],[46497,46509,46510,46511,46512],"BIBR 1048 MS dose 2","BIBR 1048 MS dose 3","BIBR 1048 MS dose 4","BIBR 1048 MS dose 5",{"trials":46514,"activeCount":101},[],{"trials":46516,"activeCount":101},[],{"trials":46518,"activeCount":101},[],{"trials":46520,"activeCount":101},[],{"intervention":46509,"totalTrials":272,"cells":46522},{"EARLY_PHASE1":46523,"PHASE1":46525,"PHASE2":46531,"PHASE3":46533,"PHASE4":46535,"NA":46537},{"trials":46524,"activeCount":101},[],{"trials":46526,"activeCount":101},[46527],{"nctId":46504,"briefTitle":46505,"status":107,"phases":46528,"primaryCompletion":7114,"start":11123,"enrollment":2382,"conditions":46529,"interventions":46530},[90],[15],[46497,46509,46510,46511,46512],{"trials":46532,"activeCount":101},[],{"trials":46534,"activeCount":101},[],{"trials":46536,"activeCount":101},[],{"trials":46538,"activeCount":101},[],{"intervention":46510,"totalTrials":272,"cells":46540},{"EARLY_PHASE1":46541,"PHASE1":46543,"PHASE2":46549,"PHASE3":46551,"PHASE4":46553,"NA":46555},{"trials":46542,"activeCount":101},[],{"trials":46544,"activeCount":101},[46545],{"nctId":46504,"briefTitle":46505,"status":107,"phases":46546,"primaryCompletion":7114,"start":11123,"enrollment":2382,"conditions":46547,"interventions":46548},[90],[15],[46497,46509,46510,46511,46512],{"trials":46550,"activeCount":101},[],{"trials":46552,"activeCount":101},[],{"trials":46554,"activeCount":101},[],{"trials":46556,"activeCount":101},[],{"intervention":46511,"totalTrials":272,"cells":46558},{"EARLY_PHASE1":46559,"PHASE1":46561,"PHASE2":46567,"PHASE3":46569,"PHASE4":46571,"NA":46573},{"trials":46560,"activeCount":101},[],{"trials":46562,"activeCount":101},[46563],{"nctId":46504,"briefTitle":46505,"status":107,"phases":46564,"primaryCompletion":7114,"start":11123,"enrollment":2382,"conditions":46565,"interventions":46566},[90],[15],[46497,46509,46510,46511,46512],{"trials":46568,"activeCount":101},[],{"trials":46570,"activeCount":101},[],{"trials":46572,"activeCount":101},[],{"trials":46574,"activeCount":101},[],{"intervention":46512,"totalTrials":272,"cells":46576},{"EARLY_PHASE1":46577,"PHASE1":46579,"PHASE2":46585,"PHASE3":46587,"PHASE4":46589,"NA":46591},{"trials":46578,"activeCount":101},[],{"trials":46580,"activeCount":101},[46581],{"nctId":46504,"briefTitle":46505,"status":107,"phases":46582,"primaryCompletion":7114,"start":11123,"enrollment":2382,"conditions":46583,"interventions":46584},[90],[15],[46497,46509,46510,46511,46512],{"trials":46586,"activeCount":101},[],{"trials":46588,"activeCount":101},[],{"trials":46590,"activeCount":101},[],{"trials":46592,"activeCount":101},[],{"intervention":46594,"totalTrials":272,"cells":46595},"C: BI 10773 \u002F metformin",{"EARLY_PHASE1":46596,"PHASE1":46598,"PHASE2":46608,"PHASE3":46610,"PHASE4":46612,"NA":46614},{"trials":46597,"activeCount":101},[],{"trials":46599,"activeCount":101},[46600],{"nctId":46601,"briefTitle":46602,"status":107,"phases":46603,"primaryCompletion":9396,"start":12600,"enrollment":401,"conditions":46604,"interventions":46605},"NCT01211197","Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability",[90],[21],[46594,46606,46607],"B: BI 10773 tablet and metformin","A: BI 10773 \u002F metformin",{"trials":46609,"activeCount":101},[],{"trials":46611,"activeCount":101},[],{"trials":46613,"activeCount":101},[],{"trials":46615,"activeCount":101},[],{"intervention":46606,"totalTrials":272,"cells":46617},{"EARLY_PHASE1":46618,"PHASE1":46620,"PHASE2":46626,"PHASE3":46628,"PHASE4":46630,"NA":46632},{"trials":46619,"activeCount":101},[],{"trials":46621,"activeCount":101},[46622],{"nctId":46601,"briefTitle":46602,"status":107,"phases":46623,"primaryCompletion":9396,"start":12600,"enrollment":401,"conditions":46624,"interventions":46625},[90],[21],[46594,46606,46607],{"trials":46627,"activeCount":101},[],{"trials":46629,"activeCount":101},[],{"trials":46631,"activeCount":101},[],{"trials":46633,"activeCount":101},[],{"intervention":46607,"totalTrials":272,"cells":46635},{"EARLY_PHASE1":46636,"PHASE1":46638,"PHASE2":46644,"PHASE3":46646,"PHASE4":46648,"NA":46650},{"trials":46637,"activeCount":101},[],{"trials":46639,"activeCount":101},[46640],{"nctId":46601,"briefTitle":46602,"status":107,"phases":46641,"primaryCompletion":9396,"start":12600,"enrollment":401,"conditions":46642,"interventions":46643},[90],[21],[46594,46606,46607],{"trials":46645,"activeCount":101},[],{"trials":46647,"activeCount":101},[],{"trials":46649,"activeCount":101},[],{"trials":46651,"activeCount":101},[],{"intervention":46653,"totalTrials":272,"cells":46654},"Ambroxol hydrochloride - lozenge",{"EARLY_PHASE1":46655,"PHASE1":46657,"PHASE2":46666,"PHASE3":46668,"PHASE4":46670,"NA":46672},{"trials":46656,"activeCount":101},[],{"trials":46658,"activeCount":101},[46659],{"nctId":46660,"briefTitle":46661,"status":107,"phases":46662,"primaryCompletion":13117,"start":6391,"enrollment":1672,"conditions":46663,"interventions":46664},"NCT02194296","Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers",[90],[15],[46653,46665],"Ambroxol hydrochloride - syrup",{"trials":46667,"activeCount":101},[],{"trials":46669,"activeCount":101},[],{"trials":46671,"activeCount":101},[],{"trials":46673,"activeCount":101},[],{"intervention":46665,"totalTrials":272,"cells":46675},{"EARLY_PHASE1":46676,"PHASE1":46678,"PHASE2":46684,"PHASE3":46686,"PHASE4":46688,"NA":46690},{"trials":46677,"activeCount":101},[],{"trials":46679,"activeCount":101},[46680],{"nctId":46660,"briefTitle":46661,"status":107,"phases":46681,"primaryCompletion":13117,"start":6391,"enrollment":1672,"conditions":46682,"interventions":46683},[90],[15],[46653,46665],{"trials":46685,"activeCount":101},[],{"trials":46687,"activeCount":101},[],{"trials":46689,"activeCount":101},[],{"trials":46691,"activeCount":101},[],{"intervention":20761,"totalTrials":272,"cells":46693},{"EARLY_PHASE1":46694,"PHASE1":46696,"PHASE2":46702,"PHASE3":46704,"PHASE4":46706,"NA":46708},{"trials":46695,"activeCount":101},[],{"trials":46697,"activeCount":101},[46698],{"nctId":20752,"briefTitle":20753,"status":107,"phases":46699,"primaryCompletion":20755,"start":5887,"enrollment":2123,"conditions":46700,"interventions":46701},[90],[15],[20745,20758,20759,20760,20761],{"trials":46703,"activeCount":101},[],{"trials":46705,"activeCount":101},[],{"trials":46707,"activeCount":101},[],{"trials":46709,"activeCount":101},[],{"intervention":46711,"totalTrials":272,"cells":46712},"Part 1: BI 1265162 - intravenous",{"EARLY_PHASE1":46713,"PHASE1":46715,"PHASE2":46725,"PHASE3":46727,"PHASE4":46729,"NA":46731},{"trials":46714,"activeCount":101},[],{"trials":46716,"activeCount":101},[46717],{"nctId":46718,"briefTitle":46719,"status":162,"phases":46720,"primaryCompletion":46721,"completion":46721,"start":3434,"enrollment":112,"conditions":46722,"interventions":46723},"NCT04267276","A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body",[90],"2020-04-02",[10409],[46711,46724],"Part 2: BI 1265162 -",{"trials":46726,"activeCount":101},[],{"trials":46728,"activeCount":101},[],{"trials":46730,"activeCount":101},[],{"trials":46732,"activeCount":101},[],{"intervention":46724,"totalTrials":272,"cells":46734},{"EARLY_PHASE1":46735,"PHASE1":46737,"PHASE2":46743,"PHASE3":46745,"PHASE4":46747,"NA":46749},{"trials":46736,"activeCount":101},[],{"trials":46738,"activeCount":101},[46739],{"nctId":46718,"briefTitle":46719,"status":162,"phases":46740,"primaryCompletion":46721,"completion":46721,"start":3434,"enrollment":112,"conditions":46741,"interventions":46742},[90],[10409],[46711,46724],{"trials":46744,"activeCount":101},[],{"trials":46746,"activeCount":101},[],{"trials":46748,"activeCount":101},[],{"trials":46750,"activeCount":101},[],{"intervention":46752,"totalTrials":272,"cells":46753},"BI 660848",{"EARLY_PHASE1":46754,"PHASE1":46756,"PHASE2":46764,"PHASE3":46766,"PHASE4":46768,"NA":46770},{"trials":46755,"activeCount":101},[],{"trials":46757,"activeCount":101},[46758],{"nctId":46759,"briefTitle":46760,"status":162,"phases":46761,"primaryCompletion":9396,"start":1980,"enrollment":716,"conditions":46762,"interventions":46763},"NCT01145014","To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).",[90],[6596,15],[46752,46752,46752,46752,46752,46752,46752,46752,46752,46752,46752],{"trials":46765,"activeCount":101},[],{"trials":46767,"activeCount":101},[],{"trials":46769,"activeCount":101},[],{"trials":46771,"activeCount":101},[],{"intervention":46773,"totalTrials":272,"cells":46774},"BI 655088",{"EARLY_PHASE1":46775,"PHASE1":46777,"PHASE2":46786,"PHASE3":46788,"PHASE4":46790,"NA":46792},{"trials":46776,"activeCount":101},[],{"trials":46778,"activeCount":101},[46779],{"nctId":46780,"briefTitle":46781,"status":107,"phases":46782,"primaryCompletion":46783,"completion":46783,"start":18678,"enrollment":4433,"conditions":46784,"interventions":46785},"NCT02696616","Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers",[90],"2019-02-14",[15],[46773],{"trials":46787,"activeCount":101},[],{"trials":46789,"activeCount":101},[],{"trials":46791,"activeCount":101},[],{"trials":46793,"activeCount":101},[],{"intervention":19009,"totalTrials":272,"cells":46795},{"EARLY_PHASE1":46796,"PHASE1":46798,"PHASE2":46804,"PHASE3":46806,"PHASE4":46808,"NA":46810},{"trials":46797,"activeCount":101},[],{"trials":46799,"activeCount":101},[46800],{"nctId":19000,"briefTitle":19001,"status":107,"phases":46801,"primaryCompletion":19003,"completion":19004,"start":19005,"enrollment":19006,"conditions":46802,"interventions":46803},[90],[7303],[4176,19009],{"trials":46805,"activeCount":101},[],{"trials":46807,"activeCount":101},[],{"trials":46809,"activeCount":101},[],{"trials":46811,"activeCount":101},[],{"intervention":46813,"totalTrials":272,"cells":46814},"Rosuvastatin + BI 1323495",{"EARLY_PHASE1":46815,"PHASE1":46817,"PHASE2":46827,"PHASE3":46829,"PHASE4":46831,"NA":46833},{"trials":46816,"activeCount":101},[],{"trials":46818,"activeCount":101},[46819],{"nctId":46820,"briefTitle":46821,"status":107,"phases":46822,"primaryCompletion":228,"completion":228,"start":46823,"enrollment":1865,"conditions":46824,"interventions":46825},"NCT04257032","A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood",[90],"2020-02-13",[15],[969,46813,6561,46826],"Dabigatran etexilate + BI 1323495",{"trials":46828,"activeCount":101},[],{"trials":46830,"activeCount":101},[],{"trials":46832,"activeCount":101},[],{"trials":46834,"activeCount":101},[],{"intervention":46826,"totalTrials":272,"cells":46836},{"EARLY_PHASE1":46837,"PHASE1":46839,"PHASE2":46845,"PHASE3":46847,"PHASE4":46849,"NA":46851},{"trials":46838,"activeCount":101},[],{"trials":46840,"activeCount":101},[46841],{"nctId":46820,"briefTitle":46821,"status":107,"phases":46842,"primaryCompletion":228,"completion":228,"start":46823,"enrollment":1865,"conditions":46843,"interventions":46844},[90],[15],[969,46813,6561,46826],{"trials":46846,"activeCount":101},[],{"trials":46848,"activeCount":101},[],{"trials":46850,"activeCount":101},[],{"trials":46852,"activeCount":101},[],{"intervention":46854,"totalTrials":272,"cells":46855},"750 milligram Xentuzumab",{"EARLY_PHASE1":46856,"PHASE1":46858,"PHASE2":46870,"PHASE3":46872,"PHASE4":46874,"NA":46876},{"trials":46857,"activeCount":101},[],{"trials":46859,"activeCount":101},[46860],{"nctId":46861,"briefTitle":46862,"status":107,"phases":46863,"primaryCompletion":46864,"completion":3409,"start":46865,"enrollment":3454,"conditions":46866,"interventions":46867},"NCT02145741","Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours",[90],"2015-07-01","2014-06-11",[33],[46854,46868,46869],"1000 milligram Xentuzumab","1400 milligram Xentuzumab",{"trials":46871,"activeCount":101},[],{"trials":46873,"activeCount":101},[],{"trials":46875,"activeCount":101},[],{"trials":46877,"activeCount":101},[],{"intervention":46868,"totalTrials":272,"cells":46879},{"EARLY_PHASE1":46880,"PHASE1":46882,"PHASE2":46888,"PHASE3":46890,"PHASE4":46892,"NA":46894},{"trials":46881,"activeCount":101},[],{"trials":46883,"activeCount":101},[46884],{"nctId":46861,"briefTitle":46862,"status":107,"phases":46885,"primaryCompletion":46864,"completion":3409,"start":46865,"enrollment":3454,"conditions":46886,"interventions":46887},[90],[33],[46854,46868,46869],{"trials":46889,"activeCount":101},[],{"trials":46891,"activeCount":101},[],{"trials":46893,"activeCount":101},[],{"trials":46895,"activeCount":101},[],{"intervention":46869,"totalTrials":272,"cells":46897},{"EARLY_PHASE1":46898,"PHASE1":46900,"PHASE2":46906,"PHASE3":46908,"PHASE4":46910,"NA":46912},{"trials":46899,"activeCount":101},[],{"trials":46901,"activeCount":101},[46902],{"nctId":46861,"briefTitle":46862,"status":107,"phases":46903,"primaryCompletion":46864,"completion":3409,"start":46865,"enrollment":3454,"conditions":46904,"interventions":46905},[90],[33],[46854,46868,46869],{"trials":46907,"activeCount":101},[],{"trials":46909,"activeCount":101},[],{"trials":46911,"activeCount":101},[],{"trials":46913,"activeCount":101},[],{"intervention":20768,"totalTrials":272,"cells":46915},{"EARLY_PHASE1":46916,"PHASE1":46918,"PHASE2":46924,"PHASE3":46926,"PHASE4":46928,"NA":46930},{"trials":46917,"activeCount":101},[],{"trials":46919,"activeCount":101},[46920],{"nctId":20763,"briefTitle":20764,"status":162,"phases":46921,"primaryCompletion":20755,"start":5887,"enrollment":342,"conditions":46922,"interventions":46923},[90],[15],[20745,20758,20759,20760,20768],{"trials":46925,"activeCount":101},[],{"trials":46927,"activeCount":101},[],{"trials":46929,"activeCount":101},[],{"trials":46931,"activeCount":101},[],{"intervention":46933,"totalTrials":272,"cells":46934},"BI 2536 BS, intravenous",{"EARLY_PHASE1":46935,"PHASE1":46937,"PHASE2":46945,"PHASE3":46947,"PHASE4":46949,"NA":46951},{"trials":46936,"activeCount":101},[],{"trials":46938,"activeCount":101},[46939],{"nctId":46940,"briefTitle":46941,"status":107,"phases":46942,"primaryCompletion":6116,"start":8479,"enrollment":8304,"conditions":46943,"interventions":46944},"NCT02211872","BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit",[90],[33],[46933],{"trials":46946,"activeCount":101},[],{"trials":46948,"activeCount":101},[],{"trials":46950,"activeCount":101},[],{"trials":46952,"activeCount":101},[],{"intervention":4520,"totalTrials":272,"cells":46954},{"EARLY_PHASE1":46955,"PHASE1":46957,"PHASE2":46963,"PHASE3":46965,"PHASE4":46967,"NA":46969},{"trials":46956,"activeCount":101},[],{"trials":46958,"activeCount":101},[46959],{"nctId":4513,"briefTitle":4514,"status":107,"phases":46960,"primaryCompletion":4516,"start":4517,"enrollment":380,"conditions":46961,"interventions":46962},[90],[15],[4520,1538],{"trials":46964,"activeCount":101},[],{"trials":46966,"activeCount":101},[],{"trials":46968,"activeCount":101},[],{"trials":46970,"activeCount":101},[],{"intervention":46972,"totalTrials":272,"cells":46973},"BI 207127 middle dose +SOC",{"EARLY_PHASE1":46974,"PHASE1":46976,"PHASE2":46986,"PHASE3":46988,"PHASE4":46990,"NA":46992},{"trials":46975,"activeCount":101},[],{"trials":46977,"activeCount":101},[46978],{"nctId":46979,"briefTitle":46980,"status":107,"phases":46981,"primaryCompletion":6132,"start":9411,"enrollment":3939,"conditions":46982,"interventions":46983},"NCT00905632","4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients",[90],[4040],[46972,46984,46985],"BI 207127 high dose+SOC","BI 207127 low dose + SOC",{"trials":46987,"activeCount":101},[],{"trials":46989,"activeCount":101},[],{"trials":46991,"activeCount":101},[],{"trials":46993,"activeCount":101},[],{"intervention":46984,"totalTrials":272,"cells":46995},{"EARLY_PHASE1":46996,"PHASE1":46998,"PHASE2":47004,"PHASE3":47006,"PHASE4":47008,"NA":47010},{"trials":46997,"activeCount":101},[],{"trials":46999,"activeCount":101},[47000],{"nctId":46979,"briefTitle":46980,"status":107,"phases":47001,"primaryCompletion":6132,"start":9411,"enrollment":3939,"conditions":47002,"interventions":47003},[90],[4040],[46972,46984,46985],{"trials":47005,"activeCount":101},[],{"trials":47007,"activeCount":101},[],{"trials":47009,"activeCount":101},[],{"trials":47011,"activeCount":101},[],{"intervention":46985,"totalTrials":272,"cells":47013},{"EARLY_PHASE1":47014,"PHASE1":47016,"PHASE2":47022,"PHASE3":47024,"PHASE4":47026,"NA":47028},{"trials":47015,"activeCount":101},[],{"trials":47017,"activeCount":101},[47018],{"nctId":46979,"briefTitle":46980,"status":107,"phases":47019,"primaryCompletion":6132,"start":9411,"enrollment":3939,"conditions":47020,"interventions":47021},[90],[4040],[46972,46984,46985],{"trials":47023,"activeCount":101},[],{"trials":47025,"activeCount":101},[],{"trials":47027,"activeCount":101},[],{"trials":47029,"activeCount":101},[],{"intervention":47031,"totalTrials":272,"cells":47032},"ASA\u002FER-DP",{"EARLY_PHASE1":47033,"PHASE1":47035,"PHASE2":47043,"PHASE3":47045,"PHASE4":47047,"NA":47049},{"trials":47034,"activeCount":101},[],{"trials":47036,"activeCount":101},[47037],{"nctId":47038,"briefTitle":47039,"status":107,"phases":47040,"primaryCompletion":5868,"start":6445,"enrollment":380,"conditions":47041,"interventions":47042},"NCT02262793","Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects",[90],[15],[7281,47031],{"trials":47044,"activeCount":101},[],{"trials":47046,"activeCount":101},[],{"trials":47048,"activeCount":101},[],{"trials":47050,"activeCount":101},[],{"intervention":27404,"totalTrials":272,"cells":47052},{"EARLY_PHASE1":47053,"PHASE1":47055,"PHASE2":47061,"PHASE3":47063,"PHASE4":47065,"NA":47067},{"trials":47054,"activeCount":101},[],{"trials":47056,"activeCount":101},[47057],{"nctId":27398,"briefTitle":27399,"status":107,"phases":47058,"primaryCompletion":379,"completion":379,"start":3730,"enrollment":1672,"conditions":47059,"interventions":47060},[90],[15],[27403,27403,27403,5264,27404],{"trials":47062,"activeCount":101},[],{"trials":47064,"activeCount":101},[],{"trials":47066,"activeCount":101},[],{"trials":47068,"activeCount":101},[],{"intervention":47070,"totalTrials":272,"cells":47071},"14C-BI 409306",{"EARLY_PHASE1":47072,"PHASE1":47074,"PHASE2":47084,"PHASE3":47086,"PHASE4":47088,"NA":47090},{"trials":47073,"activeCount":101},[],{"trials":47075,"activeCount":101},[47076],{"nctId":47077,"briefTitle":47078,"status":107,"phases":47079,"primaryCompletion":47080,"completion":47080,"start":47081,"enrollment":1512,"conditions":47082,"interventions":47083},"NCT02597998","Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers",[90],"2015-12-11","2015-09-15",[15],[47070],{"trials":47085,"activeCount":101},[],{"trials":47087,"activeCount":101},[],{"trials":47089,"activeCount":101},[],{"trials":47091,"activeCount":101},[],{"intervention":47093,"totalTrials":272,"cells":47094},"Cilobradine, low, film-coated",{"EARLY_PHASE1":47095,"PHASE1":47097,"PHASE2":47107,"PHASE3":47109,"PHASE4":47111,"NA":47113},{"trials":47096,"activeCount":101},[],{"trials":47098,"activeCount":101},[47099],{"nctId":47100,"briefTitle":47101,"status":107,"phases":47102,"primaryCompletion":6445,"start":2112,"enrollment":9700,"conditions":47103,"interventions":47104},"NCT02264015","Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers",[90],[15],[47093,47105,47106],"Cilobradine, high, film-coated","Moxifloxacin, film-coated",{"trials":47108,"activeCount":101},[],{"trials":47110,"activeCount":101},[],{"trials":47112,"activeCount":101},[],{"trials":47114,"activeCount":101},[],{"intervention":47105,"totalTrials":272,"cells":47116},{"EARLY_PHASE1":47117,"PHASE1":47119,"PHASE2":47125,"PHASE3":47127,"PHASE4":47129,"NA":47131},{"trials":47118,"activeCount":101},[],{"trials":47120,"activeCount":101},[47121],{"nctId":47100,"briefTitle":47101,"status":107,"phases":47122,"primaryCompletion":6445,"start":2112,"enrollment":9700,"conditions":47123,"interventions":47124},[90],[15],[47093,47105,47106],{"trials":47126,"activeCount":101},[],{"trials":47128,"activeCount":101},[],{"trials":47130,"activeCount":101},[],{"trials":47132,"activeCount":101},[],{"intervention":47106,"totalTrials":272,"cells":47134},{"EARLY_PHASE1":47135,"PHASE1":47137,"PHASE2":47143,"PHASE3":47145,"PHASE4":47147,"NA":47149},{"trials":47136,"activeCount":101},[],{"trials":47138,"activeCount":101},[47139],{"nctId":47100,"briefTitle":47101,"status":107,"phases":47140,"primaryCompletion":6445,"start":2112,"enrollment":9700,"conditions":47141,"interventions":47142},[90],[15],[47093,47105,47106],{"trials":47144,"activeCount":101},[],{"trials":47146,"activeCount":101},[],{"trials":47148,"activeCount":101},[],{"trials":47150,"activeCount":101},[],{"intervention":47152,"totalTrials":272,"cells":47153},"Enoxaparin prefilled syringes",{"EARLY_PHASE1":47154,"PHASE1":47156,"PHASE2":47164,"PHASE3":47166,"PHASE4":47168,"NA":47170},{"trials":47155,"activeCount":101},[],{"trials":47157,"activeCount":101},[47158],{"nctId":47159,"briefTitle":47160,"status":107,"phases":47161,"primaryCompletion":5856,"start":6223,"enrollment":993,"conditions":47162,"interventions":47163},"NCT02171559","Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers",[90],[15],[47152,6561],{"trials":47165,"activeCount":101},[],{"trials":47167,"activeCount":101},[],{"trials":47169,"activeCount":101},[],{"trials":47171,"activeCount":101},[],{"intervention":27629,"totalTrials":272,"cells":47173},{"EARLY_PHASE1":47174,"PHASE1":47176,"PHASE2":47182,"PHASE3":47184,"PHASE4":47186,"NA":47188},{"trials":47175,"activeCount":101},[],{"trials":47177,"activeCount":101},[47178],{"nctId":27621,"briefTitle":27622,"status":600,"phases":47179,"primaryCompletion":27624,"completion":27625,"start":27626,"enrollment":101,"conditions":47180,"interventions":47181},[90],[15],[4066,27629],{"trials":47183,"activeCount":101},[],{"trials":47185,"activeCount":101},[],{"trials":47187,"activeCount":101},[],{"trials":47189,"activeCount":101},[],{"intervention":47191,"totalTrials":272,"cells":47192},"R1: Reference Product X",{"EARLY_PHASE1":47193,"PHASE1":47195,"PHASE2":47215,"PHASE3":47217,"PHASE4":47219,"NA":47221},{"trials":47194,"activeCount":101},[],{"trials":47196,"activeCount":101},[47197],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47200,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47201,"interventions":47202},"NCT04926246","A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body",[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],"T1: Test Product M","T2: Test Product N","T3: Test Product O","T4: Test Product O","R2: Reference Product Y","T5: Test Product P","T6: Test Product P","T7: Test Product Q","R3: Reference Product Z","T8: Test Product S","T9: Test Product S","T10: Test Product U",{"trials":47216,"activeCount":101},[],{"trials":47218,"activeCount":101},[],{"trials":47220,"activeCount":101},[],{"trials":47222,"activeCount":101},[],{"intervention":47203,"totalTrials":272,"cells":47224},{"EARLY_PHASE1":47225,"PHASE1":47227,"PHASE2":47233,"PHASE3":47235,"PHASE4":47237,"NA":47239},{"trials":47226,"activeCount":101},[],{"trials":47228,"activeCount":101},[47229],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47230,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47231,"interventions":47232},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47234,"activeCount":101},[],{"trials":47236,"activeCount":101},[],{"trials":47238,"activeCount":101},[],{"trials":47240,"activeCount":101},[],{"intervention":47204,"totalTrials":272,"cells":47242},{"EARLY_PHASE1":47243,"PHASE1":47245,"PHASE2":47251,"PHASE3":47253,"PHASE4":47255,"NA":47257},{"trials":47244,"activeCount":101},[],{"trials":47246,"activeCount":101},[47247],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47248,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47249,"interventions":47250},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47252,"activeCount":101},[],{"trials":47254,"activeCount":101},[],{"trials":47256,"activeCount":101},[],{"trials":47258,"activeCount":101},[],{"intervention":47205,"totalTrials":272,"cells":47260},{"EARLY_PHASE1":47261,"PHASE1":47263,"PHASE2":47269,"PHASE3":47271,"PHASE4":47273,"NA":47275},{"trials":47262,"activeCount":101},[],{"trials":47264,"activeCount":101},[47265],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47266,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47267,"interventions":47268},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47270,"activeCount":101},[],{"trials":47272,"activeCount":101},[],{"trials":47274,"activeCount":101},[],{"trials":47276,"activeCount":101},[],{"intervention":47206,"totalTrials":272,"cells":47278},{"EARLY_PHASE1":47279,"PHASE1":47281,"PHASE2":47287,"PHASE3":47289,"PHASE4":47291,"NA":47293},{"trials":47280,"activeCount":101},[],{"trials":47282,"activeCount":101},[47283],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47284,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47285,"interventions":47286},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47288,"activeCount":101},[],{"trials":47290,"activeCount":101},[],{"trials":47292,"activeCount":101},[],{"trials":47294,"activeCount":101},[],{"intervention":47207,"totalTrials":272,"cells":47296},{"EARLY_PHASE1":47297,"PHASE1":47299,"PHASE2":47305,"PHASE3":47307,"PHASE4":47309,"NA":47311},{"trials":47298,"activeCount":101},[],{"trials":47300,"activeCount":101},[47301],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47302,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47303,"interventions":47304},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47306,"activeCount":101},[],{"trials":47308,"activeCount":101},[],{"trials":47310,"activeCount":101},[],{"trials":47312,"activeCount":101},[],{"intervention":47208,"totalTrials":272,"cells":47314},{"EARLY_PHASE1":47315,"PHASE1":47317,"PHASE2":47323,"PHASE3":47325,"PHASE4":47327,"NA":47329},{"trials":47316,"activeCount":101},[],{"trials":47318,"activeCount":101},[47319],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47320,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47321,"interventions":47322},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47324,"activeCount":101},[],{"trials":47326,"activeCount":101},[],{"trials":47328,"activeCount":101},[],{"trials":47330,"activeCount":101},[],{"intervention":47209,"totalTrials":272,"cells":47332},{"EARLY_PHASE1":47333,"PHASE1":47335,"PHASE2":47341,"PHASE3":47343,"PHASE4":47345,"NA":47347},{"trials":47334,"activeCount":101},[],{"trials":47336,"activeCount":101},[47337],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47338,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47339,"interventions":47340},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47342,"activeCount":101},[],{"trials":47344,"activeCount":101},[],{"trials":47346,"activeCount":101},[],{"trials":47348,"activeCount":101},[],{"intervention":47210,"totalTrials":272,"cells":47350},{"EARLY_PHASE1":47351,"PHASE1":47353,"PHASE2":47359,"PHASE3":47361,"PHASE4":47363,"NA":47365},{"trials":47352,"activeCount":101},[],{"trials":47354,"activeCount":101},[47355],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47356,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47357,"interventions":47358},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47360,"activeCount":101},[],{"trials":47362,"activeCount":101},[],{"trials":47364,"activeCount":101},[],{"trials":47366,"activeCount":101},[],{"intervention":47211,"totalTrials":272,"cells":47368},{"EARLY_PHASE1":47369,"PHASE1":47371,"PHASE2":47377,"PHASE3":47379,"PHASE4":47381,"NA":47383},{"trials":47370,"activeCount":101},[],{"trials":47372,"activeCount":101},[47373],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47374,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47375,"interventions":47376},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47378,"activeCount":101},[],{"trials":47380,"activeCount":101},[],{"trials":47382,"activeCount":101},[],{"trials":47384,"activeCount":101},[],{"intervention":47212,"totalTrials":272,"cells":47386},{"EARLY_PHASE1":47387,"PHASE1":47389,"PHASE2":47395,"PHASE3":47397,"PHASE4":47399,"NA":47401},{"trials":47388,"activeCount":101},[],{"trials":47390,"activeCount":101},[47391],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47392,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47393,"interventions":47394},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47396,"activeCount":101},[],{"trials":47398,"activeCount":101},[],{"trials":47400,"activeCount":101},[],{"trials":47402,"activeCount":101},[],{"intervention":47213,"totalTrials":272,"cells":47404},{"EARLY_PHASE1":47405,"PHASE1":47407,"PHASE2":47413,"PHASE3":47415,"PHASE4":47417,"NA":47419},{"trials":47406,"activeCount":101},[],{"trials":47408,"activeCount":101},[47409],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47410,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47411,"interventions":47412},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47414,"activeCount":101},[],{"trials":47416,"activeCount":101},[],{"trials":47418,"activeCount":101},[],{"trials":47420,"activeCount":101},[],{"intervention":47214,"totalTrials":272,"cells":47422},{"EARLY_PHASE1":47423,"PHASE1":47425,"PHASE2":47431,"PHASE3":47433,"PHASE4":47435,"NA":47437},{"trials":47424,"activeCount":101},[],{"trials":47426,"activeCount":101},[47427],{"nctId":47198,"briefTitle":47199,"status":107,"phases":47428,"primaryCompletion":20672,"completion":20672,"start":34648,"enrollment":291,"conditions":47429,"interventions":47430},[90],[15],[47191,47203,47204,47205,47206,47207,47208,47209,47210,47211,47212,47213,47214],{"trials":47432,"activeCount":101},[],{"trials":47434,"activeCount":101},[],{"trials":47436,"activeCount":101},[],{"trials":47438,"activeCount":101},[],{"intervention":47440,"totalTrials":272,"cells":47441},"Nevirapine suspension, into Enterion™",{"EARLY_PHASE1":47442,"PHASE1":47444,"PHASE2":47453,"PHASE3":47455,"PHASE4":47457,"NA":47459},{"trials":47443,"activeCount":101},[],{"trials":47445,"activeCount":101},[47446],{"nctId":47447,"briefTitle":47448,"status":107,"phases":47449,"primaryCompletion":4005,"start":7300,"enrollment":251,"conditions":47450,"interventions":47451},"NCT02191189","Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males",[90],[15],[47440,47452],"Nevirapine suspension",{"trials":47454,"activeCount":101},[],{"trials":47456,"activeCount":101},[],{"trials":47458,"activeCount":101},[],{"trials":47460,"activeCount":101},[],{"intervention":47452,"totalTrials":272,"cells":47462},{"EARLY_PHASE1":47463,"PHASE1":47465,"PHASE2":47471,"PHASE3":47473,"PHASE4":47475,"NA":47477},{"trials":47464,"activeCount":101},[],{"trials":47466,"activeCount":101},[47467],{"nctId":47447,"briefTitle":47448,"status":107,"phases":47468,"primaryCompletion":4005,"start":7300,"enrollment":251,"conditions":47469,"interventions":47470},[90],[15],[47440,47452],{"trials":47472,"activeCount":101},[],{"trials":47474,"activeCount":101},[],{"trials":47476,"activeCount":101},[],{"trials":47478,"activeCount":101},[],{"intervention":47480,"totalTrials":272,"cells":47481},"Ibuprofen syrup",{"EARLY_PHASE1":47482,"PHASE1":47484,"PHASE2":47493,"PHASE3":47495,"PHASE4":47497,"NA":47499},{"trials":47483,"activeCount":101},[],{"trials":47485,"activeCount":101},[47486],{"nctId":47487,"briefTitle":47488,"status":107,"phases":47489,"primaryCompletion":7553,"start":7084,"enrollment":380,"conditions":47490,"interventions":47491},"NCT02182960","Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers",[90],[15],[47480,47492],"Brufen syrup",{"trials":47494,"activeCount":101},[],{"trials":47496,"activeCount":101},[],{"trials":47498,"activeCount":101},[],{"trials":47500,"activeCount":101},[],{"intervention":47492,"totalTrials":272,"cells":47502},{"EARLY_PHASE1":47503,"PHASE1":47505,"PHASE2":47511,"PHASE3":47513,"PHASE4":47515,"NA":47517},{"trials":47504,"activeCount":101},[],{"trials":47506,"activeCount":101},[47507],{"nctId":47487,"briefTitle":47488,"status":107,"phases":47508,"primaryCompletion":7553,"start":7084,"enrollment":380,"conditions":47509,"interventions":47510},[90],[15],[47480,47492],{"trials":47512,"activeCount":101},[],{"trials":47514,"activeCount":101},[],{"trials":47516,"activeCount":101},[],{"trials":47518,"activeCount":101},[],{"intervention":47520,"totalTrials":272,"cells":47521},"BIBT 986 BS",{"EARLY_PHASE1":47522,"PHASE1":47524,"PHASE2":47532,"PHASE3":47534,"PHASE4":47536,"NA":47538},{"trials":47523,"activeCount":101},[],{"trials":47525,"activeCount":101},[47526],{"nctId":47527,"briefTitle":47528,"status":107,"phases":47529,"primaryCompletion":8479,"start":6871,"enrollment":97,"conditions":47530,"interventions":47531},"NCT02254070","Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment",[90],[15],[47520],{"trials":47533,"activeCount":101},[],{"trials":47535,"activeCount":101},[],{"trials":47537,"activeCount":101},[],{"trials":47539,"activeCount":101},[],{"intervention":27357,"totalTrials":272,"cells":47541},{"EARLY_PHASE1":47542,"PHASE1":47544,"PHASE2":47550,"PHASE3":47552,"PHASE4":47554,"NA":47556},{"trials":47543,"activeCount":101},[],{"trials":47545,"activeCount":101},[47546],{"nctId":27352,"briefTitle":27353,"status":107,"phases":47547,"primaryCompletion":6738,"start":13117,"enrollment":1512,"conditions":47548,"interventions":47549},[90],[15],[6024,27357],{"trials":47551,"activeCount":101},[],{"trials":47553,"activeCount":101},[],{"trials":47555,"activeCount":101},[],{"trials":47557,"activeCount":101},[],{"intervention":47559,"totalTrials":272,"cells":47560},"Ambroxol hydrochloride - soft pastille",{"EARLY_PHASE1":47561,"PHASE1":47563,"PHASE2":47573,"PHASE3":47575,"PHASE4":47577,"NA":47579},{"trials":47562,"activeCount":101},[],{"trials":47564,"activeCount":101},[47565],{"nctId":47566,"briefTitle":47567,"status":107,"phases":47568,"primaryCompletion":17247,"start":9276,"enrollment":380,"conditions":47569,"interventions":47570},"NCT02194270","Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers",[90],[15],[47559,47571,47572],"Ambroxol hydrochloride - syrup - low dose","Ambroxol hydrochloride - syrup - high dose",{"trials":47574,"activeCount":101},[],{"trials":47576,"activeCount":101},[],{"trials":47578,"activeCount":101},[],{"trials":47580,"activeCount":101},[],{"intervention":47571,"totalTrials":272,"cells":47582},{"EARLY_PHASE1":47583,"PHASE1":47585,"PHASE2":47591,"PHASE3":47593,"PHASE4":47595,"NA":47597},{"trials":47584,"activeCount":101},[],{"trials":47586,"activeCount":101},[47587],{"nctId":47566,"briefTitle":47567,"status":107,"phases":47588,"primaryCompletion":17247,"start":9276,"enrollment":380,"conditions":47589,"interventions":47590},[90],[15],[47559,47571,47572],{"trials":47592,"activeCount":101},[],{"trials":47594,"activeCount":101},[],{"trials":47596,"activeCount":101},[],{"trials":47598,"activeCount":101},[],{"intervention":47572,"totalTrials":272,"cells":47600},{"EARLY_PHASE1":47601,"PHASE1":47603,"PHASE2":47609,"PHASE3":47611,"PHASE4":47613,"NA":47615},{"trials":47602,"activeCount":101},[],{"trials":47604,"activeCount":101},[47605],{"nctId":47566,"briefTitle":47567,"status":107,"phases":47606,"primaryCompletion":17247,"start":9276,"enrollment":380,"conditions":47607,"interventions":47608},[90],[15],[47559,47571,47572],{"trials":47610,"activeCount":101},[],{"trials":47612,"activeCount":101},[],{"trials":47614,"activeCount":101},[],{"trials":47616,"activeCount":101},[],{"intervention":4527,"totalTrials":272,"cells":47618},{"EARLY_PHASE1":47619,"PHASE1":47621,"PHASE2":47627,"PHASE3":47629,"PHASE4":47631,"NA":47633},{"trials":47620,"activeCount":101},[],{"trials":47622,"activeCount":101},[47623],{"nctId":4522,"briefTitle":4523,"status":107,"phases":47624,"primaryCompletion":4516,"start":1114,"enrollment":123,"conditions":47625,"interventions":47626},[90],[15],[4527,4528,1538,4529,4456],{"trials":47628,"activeCount":101},[],{"trials":47630,"activeCount":101},[],{"trials":47632,"activeCount":101},[],{"trials":47634,"activeCount":101},[],{"intervention":4528,"totalTrials":272,"cells":47636},{"EARLY_PHASE1":47637,"PHASE1":47639,"PHASE2":47645,"PHASE3":47647,"PHASE4":47649,"NA":47651},{"trials":47638,"activeCount":101},[],{"trials":47640,"activeCount":101},[47641],{"nctId":4522,"briefTitle":4523,"status":107,"phases":47642,"primaryCompletion":4516,"start":1114,"enrollment":123,"conditions":47643,"interventions":47644},[90],[15],[4527,4528,1538,4529,4456],{"trials":47646,"activeCount":101},[],{"trials":47648,"activeCount":101},[],{"trials":47650,"activeCount":101},[],{"trials":47652,"activeCount":101},[],{"intervention":4529,"totalTrials":272,"cells":47654},{"EARLY_PHASE1":47655,"PHASE1":47657,"PHASE2":47663,"PHASE3":47665,"PHASE4":47667,"NA":47669},{"trials":47656,"activeCount":101},[],{"trials":47658,"activeCount":101},[47659],{"nctId":4522,"briefTitle":4523,"status":107,"phases":47660,"primaryCompletion":4516,"start":1114,"enrollment":123,"conditions":47661,"interventions":47662},[90],[15],[4527,4528,1538,4529,4456],{"trials":47664,"activeCount":101},[],{"trials":47666,"activeCount":101},[],{"trials":47668,"activeCount":101},[],{"trials":47670,"activeCount":101},[],{"intervention":47672,"totalTrials":272,"cells":47673},"BI 754132",{"EARLY_PHASE1":47674,"PHASE1":47676,"PHASE2":47687,"PHASE3":47689,"PHASE4":47691,"NA":47693},{"trials":47675,"activeCount":101},[],{"trials":47677,"activeCount":101},[47678],{"nctId":47679,"briefTitle":47680,"status":162,"phases":47681,"primaryCompletion":47682,"completion":47682,"start":47683,"enrollment":392,"conditions":47684,"interventions":47686},"NCT04002310","A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy",[90],"2022-08-09","2019-07-26",[47685],"Macular Degeneration",[47672],{"trials":47688,"activeCount":101},[],{"trials":47690,"activeCount":101},[],{"trials":47692,"activeCount":101},[],{"trials":47694,"activeCount":101},[],{"intervention":47696,"totalTrials":272,"cells":47697},"BIBR 1048 MS - low dose",{"EARLY_PHASE1":47698,"PHASE1":47700,"PHASE2":47710,"PHASE3":47712,"PHASE4":47714,"NA":47716},{"trials":47699,"activeCount":101},[],{"trials":47701,"activeCount":101},[47702],{"nctId":47703,"briefTitle":47704,"status":107,"phases":47705,"primaryCompletion":2181,"start":6246,"enrollment":1982,"conditions":47706,"interventions":47707},"NCT02170740","Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects",[90],[15],[47696,47708,47709],"BIBR 1048 MS - high dose","BIBR 1048 MS + Pantoprazole",{"trials":47711,"activeCount":101},[],{"trials":47713,"activeCount":101},[],{"trials":47715,"activeCount":101},[],{"trials":47717,"activeCount":101},[],{"intervention":47708,"totalTrials":272,"cells":47719},{"EARLY_PHASE1":47720,"PHASE1":47722,"PHASE2":47728,"PHASE3":47730,"PHASE4":47732,"NA":47734},{"trials":47721,"activeCount":101},[],{"trials":47723,"activeCount":101},[47724],{"nctId":47703,"briefTitle":47704,"status":107,"phases":47725,"primaryCompletion":2181,"start":6246,"enrollment":1982,"conditions":47726,"interventions":47727},[90],[15],[47696,47708,47709],{"trials":47729,"activeCount":101},[],{"trials":47731,"activeCount":101},[],{"trials":47733,"activeCount":101},[],{"trials":47735,"activeCount":101},[],{"intervention":47709,"totalTrials":272,"cells":47737},{"EARLY_PHASE1":47738,"PHASE1":47740,"PHASE2":47746,"PHASE3":47748,"PHASE4":47750,"NA":47752},{"trials":47739,"activeCount":101},[],{"trials":47741,"activeCount":101},[47742],{"nctId":47703,"briefTitle":47704,"status":107,"phases":47743,"primaryCompletion":2181,"start":6246,"enrollment":1982,"conditions":47744,"interventions":47745},[90],[15],[47696,47708,47709],{"trials":47747,"activeCount":101},[],{"trials":47749,"activeCount":101},[],{"trials":47751,"activeCount":101},[],{"trials":47753,"activeCount":101},[],{"intervention":29021,"totalTrials":272,"cells":47755},{"EARLY_PHASE1":47756,"PHASE1":47758,"PHASE2":47764,"PHASE3":47766,"PHASE4":47768,"NA":47770},{"trials":47757,"activeCount":101},[],{"trials":47759,"activeCount":101},[47760],{"nctId":29015,"briefTitle":29016,"status":107,"phases":47761,"primaryCompletion":20695,"completion":20695,"start":29018,"enrollment":956,"conditions":47762,"interventions":47763},[90],[15],[29021,19905],{"trials":47765,"activeCount":101},[],{"trials":47767,"activeCount":101},[],{"trials":47769,"activeCount":101},[],{"trials":47771,"activeCount":101},[],{"intervention":47773,"totalTrials":272,"cells":47774},"BI 1774 CL",{"EARLY_PHASE1":47775,"PHASE1":47777,"PHASE2":47785,"PHASE3":47787,"PHASE4":47789,"NA":47791},{"trials":47776,"activeCount":101},[],{"trials":47778,"activeCount":101},[47779],{"nctId":47780,"briefTitle":47781,"status":107,"phases":47782,"primaryCompletion":9381,"start":3990,"enrollment":210,"conditions":47783,"interventions":47784},"NCT02172118","BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function",[90],[15],[47773],{"trials":47786,"activeCount":101},[],{"trials":47788,"activeCount":101},[],{"trials":47790,"activeCount":101},[],{"trials":47792,"activeCount":101},[],{"intervention":3901,"totalTrials":272,"cells":47794},{"EARLY_PHASE1":47795,"PHASE1":47797,"PHASE2":47803,"PHASE3":47805,"PHASE4":47807,"NA":47809},{"trials":47796,"activeCount":101},[],{"trials":47798,"activeCount":101},[47799],{"nctId":3894,"briefTitle":3895,"status":162,"phases":47800,"primaryCompletion":3869,"completion":3869,"start":3897,"enrollment":956,"conditions":47801,"interventions":47802},[90],[3899],[3859,3901],{"trials":47804,"activeCount":101},[],{"trials":47806,"activeCount":101},[],{"trials":47808,"activeCount":101},[],{"trials":47810,"activeCount":101},[],{"intervention":47812,"totalTrials":272,"cells":47813},"BI 1181181 healthy elderly",{"EARLY_PHASE1":47814,"PHASE1":47816,"PHASE2":47825,"PHASE3":47827,"PHASE4":47829,"NA":47831},{"trials":47815,"activeCount":101},[],{"trials":47817,"activeCount":101},[47818],{"nctId":47819,"briefTitle":47820,"status":162,"phases":47821,"primaryCompletion":1125,"completion":1125,"start":475,"enrollment":448,"conditions":47822,"interventions":47823},"NCT02254161","Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male\u002FFemale Volunteers",[90],[15],[47812,47824],"BI 1181181 Healthy young",{"trials":47826,"activeCount":101},[],{"trials":47828,"activeCount":101},[],{"trials":47830,"activeCount":101},[],{"trials":47832,"activeCount":101},[],{"intervention":47824,"totalTrials":272,"cells":47834},{"EARLY_PHASE1":47835,"PHASE1":47837,"PHASE2":47843,"PHASE3":47845,"PHASE4":47847,"NA":47849},{"trials":47836,"activeCount":101},[],{"trials":47838,"activeCount":101},[47839],{"nctId":47819,"briefTitle":47820,"status":162,"phases":47840,"primaryCompletion":1125,"completion":1125,"start":475,"enrollment":448,"conditions":47841,"interventions":47842},[90],[15],[47812,47824],{"trials":47844,"activeCount":101},[],{"trials":47846,"activeCount":101},[],{"trials":47848,"activeCount":101},[],{"trials":47850,"activeCount":101},[],{"intervention":30567,"totalTrials":272,"cells":47852},{"EARLY_PHASE1":47853,"PHASE1":47855,"PHASE2":47861,"PHASE3":47863,"PHASE4":47865,"NA":47867},{"trials":47854,"activeCount":101},[],{"trials":47856,"activeCount":101},[47857],{"nctId":30562,"briefTitle":30563,"status":107,"phases":47858,"primaryCompletion":2122,"start":2181,"enrollment":1218,"conditions":47859,"interventions":47860},[90],[15],[30567,30536,30568,30569],{"trials":47862,"activeCount":101},[],{"trials":47864,"activeCount":101},[],{"trials":47866,"activeCount":101},[],{"trials":47868,"activeCount":101},[],{"intervention":30568,"totalTrials":272,"cells":47870},{"EARLY_PHASE1":47871,"PHASE1":47873,"PHASE2":47879,"PHASE3":47881,"PHASE4":47883,"NA":47885},{"trials":47872,"activeCount":101},[],{"trials":47874,"activeCount":101},[47875],{"nctId":30562,"briefTitle":30563,"status":107,"phases":47876,"primaryCompletion":2122,"start":2181,"enrollment":1218,"conditions":47877,"interventions":47878},[90],[15],[30567,30536,30568,30569],{"trials":47880,"activeCount":101},[],{"trials":47882,"activeCount":101},[],{"trials":47884,"activeCount":101},[],{"trials":47886,"activeCount":101},[],{"intervention":30569,"totalTrials":272,"cells":47888},{"EARLY_PHASE1":47889,"PHASE1":47891,"PHASE2":47897,"PHASE3":47899,"PHASE4":47901,"NA":47903},{"trials":47890,"activeCount":101},[],{"trials":47892,"activeCount":101},[47893],{"nctId":30562,"briefTitle":30563,"status":107,"phases":47894,"primaryCompletion":2122,"start":2181,"enrollment":1218,"conditions":47895,"interventions":47896},[90],[15],[30567,30536,30568,30569],{"trials":47898,"activeCount":101},[],{"trials":47900,"activeCount":101},[],{"trials":47902,"activeCount":101},[],{"trials":47904,"activeCount":101},[],{"intervention":20414,"totalTrials":272,"cells":47906},{"EARLY_PHASE1":47907,"PHASE1":47909,"PHASE2":47915,"PHASE3":47917,"PHASE4":47919,"NA":47921},{"trials":47908,"activeCount":101},[],{"trials":47910,"activeCount":101},[47911],{"nctId":20409,"briefTitle":20410,"status":107,"phases":47912,"primaryCompletion":6910,"start":8479,"enrollment":380,"conditions":47913,"interventions":47914},[90],[15],[3981,20414],{"trials":47916,"activeCount":101},[],{"trials":47918,"activeCount":101},[],{"trials":47920,"activeCount":101},[],{"trials":47922,"activeCount":101},[],{"intervention":9936,"totalTrials":272,"cells":47924},{"EARLY_PHASE1":47925,"PHASE1":47927,"PHASE2":47933,"PHASE3":47935,"PHASE4":47937,"NA":47939},{"trials":47926,"activeCount":101},[],{"trials":47928,"activeCount":101},[47929],{"nctId":9931,"briefTitle":9932,"status":107,"phases":47930,"primaryCompletion":5905,"start":9404,"enrollment":1672,"conditions":47931,"interventions":47932},[90],[15],[9936,9872,413],{"trials":47934,"activeCount":101},[],{"trials":47936,"activeCount":101},[],{"trials":47938,"activeCount":101},[],{"trials":47940,"activeCount":101},[],{"intervention":47942,"totalTrials":272,"cells":47943},"Low dose of BIBT 986 CL, per i.v.",{"EARLY_PHASE1":47944,"PHASE1":47946,"PHASE2":47957,"PHASE3":47959,"PHASE4":47961,"NA":47963},{"trials":47945,"activeCount":101},[],{"trials":47947,"activeCount":101},[47948],{"nctId":47949,"briefTitle":47950,"status":107,"phases":47951,"primaryCompletion":21078,"start":8108,"enrollment":1208,"conditions":47952,"interventions":47953},"NCT02259881","Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers",[90],[15],[47942,47954,47955,47956],"Medium dose of BIBT 986 CL, per i.v.","High dose of BIBT 986 CL, per i.v.","Lipopolysaccharide (LPS), single i.v. bolus",{"trials":47958,"activeCount":101},[],{"trials":47960,"activeCount":101},[],{"trials":47962,"activeCount":101},[],{"trials":47964,"activeCount":101},[],{"intervention":47954,"totalTrials":272,"cells":47966},{"EARLY_PHASE1":47967,"PHASE1":47969,"PHASE2":47975,"PHASE3":47977,"PHASE4":47979,"NA":47981},{"trials":47968,"activeCount":101},[],{"trials":47970,"activeCount":101},[47971],{"nctId":47949,"briefTitle":47950,"status":107,"phases":47972,"primaryCompletion":21078,"start":8108,"enrollment":1208,"conditions":47973,"interventions":47974},[90],[15],[47942,47954,47955,47956],{"trials":47976,"activeCount":101},[],{"trials":47978,"activeCount":101},[],{"trials":47980,"activeCount":101},[],{"trials":47982,"activeCount":101},[],{"intervention":47955,"totalTrials":272,"cells":47984},{"EARLY_PHASE1":47985,"PHASE1":47987,"PHASE2":47993,"PHASE3":47995,"PHASE4":47997,"NA":47999},{"trials":47986,"activeCount":101},[],{"trials":47988,"activeCount":101},[47989],{"nctId":47949,"briefTitle":47950,"status":107,"phases":47990,"primaryCompletion":21078,"start":8108,"enrollment":1208,"conditions":47991,"interventions":47992},[90],[15],[47942,47954,47955,47956],{"trials":47994,"activeCount":101},[],{"trials":47996,"activeCount":101},[],{"trials":47998,"activeCount":101},[],{"trials":48000,"activeCount":101},[],{"intervention":47956,"totalTrials":272,"cells":48002},{"EARLY_PHASE1":48003,"PHASE1":48005,"PHASE2":48011,"PHASE3":48013,"PHASE4":48015,"NA":48017},{"trials":48004,"activeCount":101},[],{"trials":48006,"activeCount":101},[48007],{"nctId":47949,"briefTitle":47950,"status":107,"phases":48008,"primaryCompletion":21078,"start":8108,"enrollment":1208,"conditions":48009,"interventions":48010},[90],[15],[47942,47954,47955,47956],{"trials":48012,"activeCount":101},[],{"trials":48014,"activeCount":101},[],{"trials":48016,"activeCount":101},[],{"trials":48018,"activeCount":101},[],{"intervention":27637,"totalTrials":272,"cells":48020},{"EARLY_PHASE1":48021,"PHASE1":48023,"PHASE2":48029,"PHASE3":48031,"PHASE4":48033,"NA":48035},{"trials":48022,"activeCount":101},[],{"trials":48024,"activeCount":101},[48025],{"nctId":27631,"briefTitle":27632,"status":107,"phases":48026,"primaryCompletion":2540,"completion":2540,"start":27634,"enrollment":3565,"conditions":48027,"interventions":48028},[90],[15],[4066,27637],{"trials":48030,"activeCount":101},[],{"trials":48032,"activeCount":101},[],{"trials":48034,"activeCount":101},[],{"trials":48036,"activeCount":101},[],{"intervention":48038,"totalTrials":272,"cells":48039},"Dabigatran etexilate tablet E1",{"EARLY_PHASE1":48040,"PHASE1":48042,"PHASE2":48056,"PHASE3":48058,"PHASE4":48060,"NA":48062},{"trials":48041,"activeCount":101},[],{"trials":48043,"activeCount":101},[48044],{"nctId":48045,"briefTitle":48046,"status":107,"phases":48047,"primaryCompletion":48048,"completion":48049,"start":28294,"enrollment":1418,"conditions":48050,"interventions":48051},"NCT02710630","Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects",[90],"2016-05-11","2016-06-10",[15],[48038,48052,48053,48054,48055,6561],"Dabigatran etexilate tablet D1","Dabigatran etexilate tablet C1","Dabigatran etexilate tablet B1","Dabigatran etexilate tablet A1",{"trials":48057,"activeCount":101},[],{"trials":48059,"activeCount":101},[],{"trials":48061,"activeCount":101},[],{"trials":48063,"activeCount":101},[],{"intervention":48052,"totalTrials":272,"cells":48065},{"EARLY_PHASE1":48066,"PHASE1":48068,"PHASE2":48074,"PHASE3":48076,"PHASE4":48078,"NA":48080},{"trials":48067,"activeCount":101},[],{"trials":48069,"activeCount":101},[48070],{"nctId":48045,"briefTitle":48046,"status":107,"phases":48071,"primaryCompletion":48048,"completion":48049,"start":28294,"enrollment":1418,"conditions":48072,"interventions":48073},[90],[15],[48038,48052,48053,48054,48055,6561],{"trials":48075,"activeCount":101},[],{"trials":48077,"activeCount":101},[],{"trials":48079,"activeCount":101},[],{"trials":48081,"activeCount":101},[],{"intervention":48053,"totalTrials":272,"cells":48083},{"EARLY_PHASE1":48084,"PHASE1":48086,"PHASE2":48092,"PHASE3":48094,"PHASE4":48096,"NA":48098},{"trials":48085,"activeCount":101},[],{"trials":48087,"activeCount":101},[48088],{"nctId":48045,"briefTitle":48046,"status":107,"phases":48089,"primaryCompletion":48048,"completion":48049,"start":28294,"enrollment":1418,"conditions":48090,"interventions":48091},[90],[15],[48038,48052,48053,48054,48055,6561],{"trials":48093,"activeCount":101},[],{"trials":48095,"activeCount":101},[],{"trials":48097,"activeCount":101},[],{"trials":48099,"activeCount":101},[],{"intervention":48054,"totalTrials":272,"cells":48101},{"EARLY_PHASE1":48102,"PHASE1":48104,"PHASE2":48110,"PHASE3":48112,"PHASE4":48114,"NA":48116},{"trials":48103,"activeCount":101},[],{"trials":48105,"activeCount":101},[48106],{"nctId":48045,"briefTitle":48046,"status":107,"phases":48107,"primaryCompletion":48048,"completion":48049,"start":28294,"enrollment":1418,"conditions":48108,"interventions":48109},[90],[15],[48038,48052,48053,48054,48055,6561],{"trials":48111,"activeCount":101},[],{"trials":48113,"activeCount":101},[],{"trials":48115,"activeCount":101},[],{"trials":48117,"activeCount":101},[],{"intervention":48055,"totalTrials":272,"cells":48119},{"EARLY_PHASE1":48120,"PHASE1":48122,"PHASE2":48128,"PHASE3":48130,"PHASE4":48132,"NA":48134},{"trials":48121,"activeCount":101},[],{"trials":48123,"activeCount":101},[48124],{"nctId":48045,"briefTitle":48046,"status":107,"phases":48125,"primaryCompletion":48048,"completion":48049,"start":28294,"enrollment":1418,"conditions":48126,"interventions":48127},[90],[15],[48038,48052,48053,48054,48055,6561],{"trials":48129,"activeCount":101},[],{"trials":48131,"activeCount":101},[],{"trials":48133,"activeCount":101},[],{"trials":48135,"activeCount":101},[],{"intervention":19129,"totalTrials":272,"cells":48137},{"EARLY_PHASE1":48138,"PHASE1":48140,"PHASE2":48146,"PHASE3":48148,"PHASE4":48150,"NA":48152},{"trials":48139,"activeCount":101},[],{"trials":48141,"activeCount":101},[48142],{"nctId":19124,"briefTitle":19125,"status":107,"phases":48143,"primaryCompletion":10775,"start":4413,"enrollment":4433,"conditions":48144,"interventions":48145},[90],[18],[19059,19129,5860],{"trials":48147,"activeCount":101},[],{"trials":48149,"activeCount":101},[],{"trials":48151,"activeCount":101},[],{"trials":48153,"activeCount":101},[],{"intervention":48155,"totalTrials":272,"cells":48156},"BI 44370 BS",{"EARLY_PHASE1":48157,"PHASE1":48159,"PHASE2":48167,"PHASE3":48169,"PHASE4":48171,"NA":48173},{"trials":48158,"activeCount":101},[],{"trials":48160,"activeCount":101},[48161],{"nctId":48162,"briefTitle":48163,"status":107,"phases":48164,"primaryCompletion":4412,"start":5856,"enrollment":155,"conditions":48165,"interventions":48166},"NCT02215772","Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers",[90],[15],[48155],{"trials":48168,"activeCount":101},[],{"trials":48170,"activeCount":101},[],{"trials":48172,"activeCount":101},[],{"trials":48174,"activeCount":101},[],{"intervention":48176,"totalTrials":272,"cells":48177},"iCF1(T1) 25 milligram BI 425809",{"EARLY_PHASE1":48178,"PHASE1":48180,"PHASE2":48192,"PHASE3":48194,"PHASE4":48196,"NA":48198},{"trials":48179,"activeCount":101},[],{"trials":48181,"activeCount":101},[48182],{"nctId":48183,"briefTitle":48184,"status":107,"phases":48185,"primaryCompletion":48186,"completion":48186,"start":48187,"enrollment":392,"conditions":48188,"interventions":48189},"NCT03817476","A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood",[90],"2019-05-28","2019-02-11",[15],[48176,48190,48191],"iCF2(T2) 25 milligram BI 425809","TF2(R) 25 milligram BI 425809",{"trials":48193,"activeCount":101},[],{"trials":48195,"activeCount":101},[],{"trials":48197,"activeCount":101},[],{"trials":48199,"activeCount":101},[],{"intervention":48190,"totalTrials":272,"cells":48201},{"EARLY_PHASE1":48202,"PHASE1":48204,"PHASE2":48210,"PHASE3":48212,"PHASE4":48214,"NA":48216},{"trials":48203,"activeCount":101},[],{"trials":48205,"activeCount":101},[48206],{"nctId":48183,"briefTitle":48184,"status":107,"phases":48207,"primaryCompletion":48186,"completion":48186,"start":48187,"enrollment":392,"conditions":48208,"interventions":48209},[90],[15],[48176,48190,48191],{"trials":48211,"activeCount":101},[],{"trials":48213,"activeCount":101},[],{"trials":48215,"activeCount":101},[],{"trials":48217,"activeCount":101},[],{"intervention":48191,"totalTrials":272,"cells":48219},{"EARLY_PHASE1":48220,"PHASE1":48222,"PHASE2":48228,"PHASE3":48230,"PHASE4":48232,"NA":48234},{"trials":48221,"activeCount":101},[],{"trials":48223,"activeCount":101},[48224],{"nctId":48183,"briefTitle":48184,"status":107,"phases":48225,"primaryCompletion":48186,"completion":48186,"start":48187,"enrollment":392,"conditions":48226,"interventions":48227},[90],[15],[48176,48190,48191],{"trials":48229,"activeCount":101},[],{"trials":48231,"activeCount":101},[],{"trials":48233,"activeCount":101},[],{"trials":48235,"activeCount":101},[],{"intervention":21451,"totalTrials":272,"cells":48237},{"EARLY_PHASE1":48238,"PHASE1":48240,"PHASE2":48246,"PHASE3":48248,"PHASE4":48250,"NA":48252},{"trials":48239,"activeCount":101},[],{"trials":48241,"activeCount":101},[48242],{"nctId":21444,"briefTitle":21445,"status":107,"phases":48243,"primaryCompletion":581,"completion":21447,"start":21448,"enrollment":1918,"conditions":48244,"interventions":48245},[90],[33,2629],[21155,21451,21452,21453,21454,21451],{"trials":48247,"activeCount":101},[],{"trials":48249,"activeCount":101},[],{"trials":48251,"activeCount":101},[],{"trials":48253,"activeCount":101},[],{"intervention":21453,"totalTrials":272,"cells":48255},{"EARLY_PHASE1":48256,"PHASE1":48258,"PHASE2":48264,"PHASE3":48266,"PHASE4":48268,"NA":48270},{"trials":48257,"activeCount":101},[],{"trials":48259,"activeCount":101},[48260],{"nctId":21444,"briefTitle":21445,"status":107,"phases":48261,"primaryCompletion":581,"completion":21447,"start":21448,"enrollment":1918,"conditions":48262,"interventions":48263},[90],[33,2629],[21155,21451,21452,21453,21454,21451],{"trials":48265,"activeCount":101},[],{"trials":48267,"activeCount":101},[],{"trials":48269,"activeCount":101},[],{"trials":48271,"activeCount":101},[],{"intervention":21454,"totalTrials":272,"cells":48273},{"EARLY_PHASE1":48274,"PHASE1":48276,"PHASE2":48282,"PHASE3":48284,"PHASE4":48286,"NA":48288},{"trials":48275,"activeCount":101},[],{"trials":48277,"activeCount":101},[48278],{"nctId":21444,"briefTitle":21445,"status":107,"phases":48279,"primaryCompletion":581,"completion":21447,"start":21448,"enrollment":1918,"conditions":48280,"interventions":48281},[90],[33,2629],[21155,21451,21452,21453,21454,21451],{"trials":48283,"activeCount":101},[],{"trials":48285,"activeCount":101},[],{"trials":48287,"activeCount":101},[],{"trials":48289,"activeCount":101},[],{"intervention":48291,"totalTrials":272,"cells":48292},"Tipranavir oral solution",{"EARLY_PHASE1":48293,"PHASE1":48295,"PHASE2":48305,"PHASE3":48307,"PHASE4":48309,"NA":48311},{"trials":48294,"activeCount":101},[],{"trials":48296,"activeCount":101},[48297],{"nctId":48298,"briefTitle":48299,"status":107,"phases":48300,"primaryCompletion":11649,"start":6374,"enrollment":357,"conditions":48301,"interventions":48302},"NCT02251158","Bioavailability of Tipranavir\u002FRitonavir Paediatric Solution Compared to Tipranavir\u002FRitonavir Capsules in Healthy Female and Male Subjects",[90],[15],[48291,4008,48303,48304],"Ritonavir oral solution","Ritonavir soft gel",{"trials":48306,"activeCount":101},[],{"trials":48308,"activeCount":101},[],{"trials":48310,"activeCount":101},[],{"trials":48312,"activeCount":101},[],{"intervention":48303,"totalTrials":272,"cells":48314},{"EARLY_PHASE1":48315,"PHASE1":48317,"PHASE2":48323,"PHASE3":48325,"PHASE4":48327,"NA":48329},{"trials":48316,"activeCount":101},[],{"trials":48318,"activeCount":101},[48319],{"nctId":48298,"briefTitle":48299,"status":107,"phases":48320,"primaryCompletion":11649,"start":6374,"enrollment":357,"conditions":48321,"interventions":48322},[90],[15],[48291,4008,48303,48304],{"trials":48324,"activeCount":101},[],{"trials":48326,"activeCount":101},[],{"trials":48328,"activeCount":101},[],{"trials":48330,"activeCount":101},[],{"intervention":48304,"totalTrials":272,"cells":48332},{"EARLY_PHASE1":48333,"PHASE1":48335,"PHASE2":48341,"PHASE3":48343,"PHASE4":48345,"NA":48347},{"trials":48334,"activeCount":101},[],{"trials":48336,"activeCount":101},[48337],{"nctId":48298,"briefTitle":48299,"status":107,"phases":48338,"primaryCompletion":11649,"start":6374,"enrollment":357,"conditions":48339,"interventions":48340},[90],[15],[48291,4008,48303,48304],{"trials":48342,"activeCount":101},[],{"trials":48344,"activeCount":101},[],{"trials":48346,"activeCount":101},[],{"trials":48348,"activeCount":101},[],{"intervention":48350,"totalTrials":272,"cells":48351},"linagliptin QD (once daily) for 7 days",{"EARLY_PHASE1":48352,"PHASE1":48354,"PHASE2":48362,"PHASE3":48364,"PHASE4":48366,"NA":48368},{"trials":48353,"activeCount":101},[],{"trials":48355,"activeCount":101},[48356],{"nctId":48357,"briefTitle":48358,"status":107,"phases":48359,"primaryCompletion":4442,"start":5905,"enrollment":1991,"conditions":48360,"interventions":48361},"NCT00935220","Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients",[90],[21],[48350],{"trials":48363,"activeCount":101},[],{"trials":48365,"activeCount":101},[],{"trials":48367,"activeCount":101},[],{"trials":48369,"activeCount":101},[],{"intervention":48371,"totalTrials":272,"cells":48372},"Lasolvan",{"EARLY_PHASE1":48373,"PHASE1":48375,"PHASE2":48386,"PHASE3":48388,"PHASE4":48390,"NA":48392},{"trials":48374,"activeCount":101},[],{"trials":48376,"activeCount":101},[48377],{"nctId":48378,"briefTitle":48379,"status":107,"phases":48380,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":380,"conditions":48381,"interventions":48382},"NCT02036775","Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers",[90],[15],[48371,48371,48371,48371,48383,48383,48383,48384,48384,48385,48371,48371,48384,48383,48384,48384,48383,48383],"Lasolvan effervescent","Lasolvan prolonged-release hard","Lasolvan prolonged-released",{"trials":48387,"activeCount":101},[],{"trials":48389,"activeCount":101},[],{"trials":48391,"activeCount":101},[],{"trials":48393,"activeCount":101},[],{"intervention":48383,"totalTrials":272,"cells":48395},{"EARLY_PHASE1":48396,"PHASE1":48398,"PHASE2":48404,"PHASE3":48406,"PHASE4":48408,"NA":48410},{"trials":48397,"activeCount":101},[],{"trials":48399,"activeCount":101},[48400],{"nctId":48378,"briefTitle":48379,"status":107,"phases":48401,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":380,"conditions":48402,"interventions":48403},[90],[15],[48371,48371,48371,48371,48383,48383,48383,48384,48384,48385,48371,48371,48384,48383,48384,48384,48383,48383],{"trials":48405,"activeCount":101},[],{"trials":48407,"activeCount":101},[],{"trials":48409,"activeCount":101},[],{"trials":48411,"activeCount":101},[],{"intervention":48384,"totalTrials":272,"cells":48413},{"EARLY_PHASE1":48414,"PHASE1":48416,"PHASE2":48422,"PHASE3":48424,"PHASE4":48426,"NA":48428},{"trials":48415,"activeCount":101},[],{"trials":48417,"activeCount":101},[48418],{"nctId":48378,"briefTitle":48379,"status":107,"phases":48419,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":380,"conditions":48420,"interventions":48421},[90],[15],[48371,48371,48371,48371,48383,48383,48383,48384,48384,48385,48371,48371,48384,48383,48384,48384,48383,48383],{"trials":48423,"activeCount":101},[],{"trials":48425,"activeCount":101},[],{"trials":48427,"activeCount":101},[],{"trials":48429,"activeCount":101},[],{"intervention":48385,"totalTrials":272,"cells":48431},{"EARLY_PHASE1":48432,"PHASE1":48434,"PHASE2":48440,"PHASE3":48442,"PHASE4":48444,"NA":48446},{"trials":48433,"activeCount":101},[],{"trials":48435,"activeCount":101},[48436],{"nctId":48378,"briefTitle":48379,"status":107,"phases":48437,"primaryCompletion":9842,"completion":9842,"start":9824,"enrollment":380,"conditions":48438,"interventions":48439},[90],[15],[48371,48371,48371,48371,48383,48383,48383,48384,48384,48385,48371,48371,48384,48383,48384,48384,48383,48383],{"trials":48441,"activeCount":101},[],{"trials":48443,"activeCount":101},[],{"trials":48445,"activeCount":101},[],{"trials":48447,"activeCount":101},[],{"intervention":48449,"totalTrials":272,"cells":48450},"BI-409306 25 milligram (mg) SD",{"EARLY_PHASE1":48451,"PHASE1":48453,"PHASE2":48466,"PHASE3":48468,"PHASE4":48470,"NA":48472},{"trials":48452,"activeCount":101},[],{"trials":48454,"activeCount":101},[48455],{"nctId":48456,"briefTitle":48457,"status":107,"phases":48458,"primaryCompletion":48459,"completion":48459,"start":48460,"enrollment":7524,"conditions":48461,"interventions":48462},"NCT01841112","Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers",[90],"2013-07-18","2013-04-22",[15],[48449,48463,48464,48465],"BI-409306 50 mg SD","BI-409306 100 mg SD","BI-409306 100 mg MD",{"trials":48467,"activeCount":101},[],{"trials":48469,"activeCount":101},[],{"trials":48471,"activeCount":101},[],{"trials":48473,"activeCount":101},[],{"intervention":48463,"totalTrials":272,"cells":48475},{"EARLY_PHASE1":48476,"PHASE1":48478,"PHASE2":48484,"PHASE3":48486,"PHASE4":48488,"NA":48490},{"trials":48477,"activeCount":101},[],{"trials":48479,"activeCount":101},[48480],{"nctId":48456,"briefTitle":48457,"status":107,"phases":48481,"primaryCompletion":48459,"completion":48459,"start":48460,"enrollment":7524,"conditions":48482,"interventions":48483},[90],[15],[48449,48463,48464,48465],{"trials":48485,"activeCount":101},[],{"trials":48487,"activeCount":101},[],{"trials":48489,"activeCount":101},[],{"trials":48491,"activeCount":101},[],{"intervention":48464,"totalTrials":272,"cells":48493},{"EARLY_PHASE1":48494,"PHASE1":48496,"PHASE2":48502,"PHASE3":48504,"PHASE4":48506,"NA":48508},{"trials":48495,"activeCount":101},[],{"trials":48497,"activeCount":101},[48498],{"nctId":48456,"briefTitle":48457,"status":107,"phases":48499,"primaryCompletion":48459,"completion":48459,"start":48460,"enrollment":7524,"conditions":48500,"interventions":48501},[90],[15],[48449,48463,48464,48465],{"trials":48503,"activeCount":101},[],{"trials":48505,"activeCount":101},[],{"trials":48507,"activeCount":101},[],{"trials":48509,"activeCount":101},[],{"intervention":48465,"totalTrials":272,"cells":48511},{"EARLY_PHASE1":48512,"PHASE1":48514,"PHASE2":48520,"PHASE3":48522,"PHASE4":48524,"NA":48526},{"trials":48513,"activeCount":101},[],{"trials":48515,"activeCount":101},[48516],{"nctId":48456,"briefTitle":48457,"status":107,"phases":48517,"primaryCompletion":48459,"completion":48459,"start":48460,"enrollment":7524,"conditions":48518,"interventions":48519},[90],[15],[48449,48463,48464,48465],{"trials":48521,"activeCount":101},[],{"trials":48523,"activeCount":101},[],{"trials":48525,"activeCount":101},[],{"trials":48527,"activeCount":101},[],{"intervention":27234,"totalTrials":272,"cells":48529},{"EARLY_PHASE1":48530,"PHASE1":48532,"PHASE2":48538,"PHASE3":48540,"PHASE4":48542,"NA":48544},{"trials":48531,"activeCount":101},[],{"trials":48533,"activeCount":101},[48534],{"nctId":27227,"briefTitle":27228,"status":107,"phases":48535,"primaryCompletion":27230,"completion":27230,"start":27231,"enrollment":956,"conditions":48536,"interventions":48537},[90],[15],[27234,949,27235,27236],{"trials":48539,"activeCount":101},[],{"trials":48541,"activeCount":101},[],{"trials":48543,"activeCount":101},[],{"trials":48545,"activeCount":101},[],{"intervention":27236,"totalTrials":272,"cells":48547},{"EARLY_PHASE1":48548,"PHASE1":48550,"PHASE2":48556,"PHASE3":48558,"PHASE4":48560,"NA":48562},{"trials":48549,"activeCount":101},[],{"trials":48551,"activeCount":101},[48552],{"nctId":27227,"briefTitle":27228,"status":107,"phases":48553,"primaryCompletion":27230,"completion":27230,"start":27231,"enrollment":956,"conditions":48554,"interventions":48555},[90],[15],[27234,949,27235,27236],{"trials":48557,"activeCount":101},[],{"trials":48559,"activeCount":101},[],{"trials":48561,"activeCount":101},[],{"trials":48563,"activeCount":101},[],{"intervention":29535,"totalTrials":272,"cells":48565},{"EARLY_PHASE1":48566,"PHASE1":48568,"PHASE2":48574,"PHASE3":48576,"PHASE4":48578,"NA":48580},{"trials":48567,"activeCount":101},[],{"trials":48569,"activeCount":101},[48570],{"nctId":29530,"briefTitle":29531,"status":107,"phases":48571,"primaryCompletion":2145,"start":4498,"enrollment":448,"conditions":48572,"interventions":48573},[90],[15],[29535,29516],{"trials":48575,"activeCount":101},[],{"trials":48577,"activeCount":101},[],{"trials":48579,"activeCount":101},[],{"trials":48581,"activeCount":101},[],{"intervention":48583,"totalTrials":272,"cells":48584},"BI 1810631 - trial formulation 1",{"EARLY_PHASE1":48585,"PHASE1":48587,"PHASE2":48599,"PHASE3":48601,"PHASE4":48603,"NA":48605},{"trials":48586,"activeCount":101},[],{"trials":48588,"activeCount":101},[48589],{"nctId":48590,"briefTitle":48591,"status":107,"phases":48592,"primaryCompletion":48593,"completion":48593,"start":48594,"enrollment":912,"conditions":48595,"interventions":48596},"NCT05380947","A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood",[90],"2022-09-13","2022-06-23",[15],[48583,48597,48598],"BI 1810631 - new formulation","Rabeprazole sodium",{"trials":48600,"activeCount":101},[],{"trials":48602,"activeCount":101},[],{"trials":48604,"activeCount":101},[],{"trials":48606,"activeCount":101},[],{"intervention":48597,"totalTrials":272,"cells":48608},{"EARLY_PHASE1":48609,"PHASE1":48611,"PHASE2":48617,"PHASE3":48619,"PHASE4":48621,"NA":48623},{"trials":48610,"activeCount":101},[],{"trials":48612,"activeCount":101},[48613],{"nctId":48590,"briefTitle":48591,"status":107,"phases":48614,"primaryCompletion":48593,"completion":48593,"start":48594,"enrollment":912,"conditions":48615,"interventions":48616},[90],[15],[48583,48597,48598],{"trials":48618,"activeCount":101},[],{"trials":48620,"activeCount":101},[],{"trials":48622,"activeCount":101},[],{"trials":48624,"activeCount":101},[],{"intervention":48598,"totalTrials":272,"cells":48626},{"EARLY_PHASE1":48627,"PHASE1":48629,"PHASE2":48635,"PHASE3":48637,"PHASE4":48639,"NA":48641},{"trials":48628,"activeCount":101},[],{"trials":48630,"activeCount":101},[48631],{"nctId":48590,"briefTitle":48591,"status":107,"phases":48632,"primaryCompletion":48593,"completion":48593,"start":48594,"enrollment":912,"conditions":48633,"interventions":48634},[90],[15],[48583,48597,48598],{"trials":48636,"activeCount":101},[],{"trials":48638,"activeCount":101},[],{"trials":48640,"activeCount":101},[],{"trials":48642,"activeCount":101},[],{"intervention":48644,"totalTrials":272,"cells":48645},"quinidine",{"EARLY_PHASE1":48646,"PHASE1":48648,"PHASE2":48656,"PHASE3":48658,"PHASE4":48660,"NA":48662},{"trials":48647,"activeCount":101},[],{"trials":48649,"activeCount":101},[48650],{"nctId":48651,"briefTitle":48652,"status":107,"phases":48653,"primaryCompletion":9404,"start":2003,"enrollment":331,"conditions":48654,"interventions":48655},"NCT02171624","Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate",[90],[15],[1685,48644],{"trials":48657,"activeCount":101},[],{"trials":48659,"activeCount":101},[],{"trials":48661,"activeCount":101},[],{"trials":48663,"activeCount":101},[],{"intervention":48665,"totalTrials":272,"cells":48666},"BI 1323495,",{"EARLY_PHASE1":48667,"PHASE1":48669,"PHASE2":48679,"PHASE3":48681,"PHASE4":48683,"NA":48685},{"trials":48668,"activeCount":101},[],{"trials":48670,"activeCount":101},[48671],{"nctId":48672,"briefTitle":48673,"status":107,"phases":48674,"primaryCompletion":48675,"completion":48675,"start":48676,"enrollment":188,"conditions":48677,"interventions":48678},"NCT03802331","A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men",[90],"2019-03-03","2019-01-28",[15],[48665],{"trials":48680,"activeCount":101},[],{"trials":48682,"activeCount":101},[],{"trials":48684,"activeCount":101},[],{"trials":48686,"activeCount":101},[],{"intervention":30344,"totalTrials":272,"cells":48688},{"EARLY_PHASE1":48689,"PHASE1":48691,"PHASE2":48697,"PHASE3":48699,"PHASE4":48701,"NA":48703},{"trials":48690,"activeCount":101},[],{"trials":48692,"activeCount":101},[48693],{"nctId":30339,"briefTitle":30340,"status":107,"phases":48694,"primaryCompletion":3731,"completion":3731,"start":10024,"enrollment":716,"conditions":48695,"interventions":48696},[90],[15],[30344,30344,30345,30346,30347,13251],{"trials":48698,"activeCount":101},[],{"trials":48700,"activeCount":101},[],{"trials":48702,"activeCount":101},[],{"trials":48704,"activeCount":101},[],{"intervention":30345,"totalTrials":272,"cells":48706},{"EARLY_PHASE1":48707,"PHASE1":48709,"PHASE2":48715,"PHASE3":48717,"PHASE4":48719,"NA":48721},{"trials":48708,"activeCount":101},[],{"trials":48710,"activeCount":101},[48711],{"nctId":30339,"briefTitle":30340,"status":107,"phases":48712,"primaryCompletion":3731,"completion":3731,"start":10024,"enrollment":716,"conditions":48713,"interventions":48714},[90],[15],[30344,30344,30345,30346,30347,13251],{"trials":48716,"activeCount":101},[],{"trials":48718,"activeCount":101},[],{"trials":48720,"activeCount":101},[],{"trials":48722,"activeCount":101},[],{"intervention":30346,"totalTrials":272,"cells":48724},{"EARLY_PHASE1":48725,"PHASE1":48727,"PHASE2":48733,"PHASE3":48735,"PHASE4":48737,"NA":48739},{"trials":48726,"activeCount":101},[],{"trials":48728,"activeCount":101},[48729],{"nctId":30339,"briefTitle":30340,"status":107,"phases":48730,"primaryCompletion":3731,"completion":3731,"start":10024,"enrollment":716,"conditions":48731,"interventions":48732},[90],[15],[30344,30344,30345,30346,30347,13251],{"trials":48734,"activeCount":101},[],{"trials":48736,"activeCount":101},[],{"trials":48738,"activeCount":101},[],{"trials":48740,"activeCount":101},[],{"intervention":30347,"totalTrials":272,"cells":48742},{"EARLY_PHASE1":48743,"PHASE1":48745,"PHASE2":48751,"PHASE3":48753,"PHASE4":48755,"NA":48757},{"trials":48744,"activeCount":101},[],{"trials":48746,"activeCount":101},[48747],{"nctId":30339,"briefTitle":30340,"status":107,"phases":48748,"primaryCompletion":3731,"completion":3731,"start":10024,"enrollment":716,"conditions":48749,"interventions":48750},[90],[15],[30344,30344,30345,30346,30347,13251],{"trials":48752,"activeCount":101},[],{"trials":48754,"activeCount":101},[],{"trials":48756,"activeCount":101},[],{"trials":48758,"activeCount":101},[],{"intervention":30643,"totalTrials":272,"cells":48760},{"EARLY_PHASE1":48761,"PHASE1":48763,"PHASE2":48769,"PHASE3":48771,"PHASE4":48773,"NA":48775},{"trials":48762,"activeCount":101},[],{"trials":48764,"activeCount":101},[48765],{"nctId":30638,"briefTitle":30639,"status":107,"phases":48766,"primaryCompletion":420,"completion":420,"start":4473,"enrollment":7524,"conditions":48767,"interventions":48768},[90],[15],[4123,30643,30644,30645],{"trials":48770,"activeCount":101},[],{"trials":48772,"activeCount":101},[],{"trials":48774,"activeCount":101},[],{"trials":48776,"activeCount":101},[],{"intervention":30644,"totalTrials":272,"cells":48778},{"EARLY_PHASE1":48779,"PHASE1":48781,"PHASE2":48787,"PHASE3":48789,"PHASE4":48791,"NA":48793},{"trials":48780,"activeCount":101},[],{"trials":48782,"activeCount":101},[48783],{"nctId":30638,"briefTitle":30639,"status":107,"phases":48784,"primaryCompletion":420,"completion":420,"start":4473,"enrollment":7524,"conditions":48785,"interventions":48786},[90],[15],[4123,30643,30644,30645],{"trials":48788,"activeCount":101},[],{"trials":48790,"activeCount":101},[],{"trials":48792,"activeCount":101},[],{"trials":48794,"activeCount":101},[],{"intervention":30645,"totalTrials":272,"cells":48796},{"EARLY_PHASE1":48797,"PHASE1":48799,"PHASE2":48805,"PHASE3":48807,"PHASE4":48809,"NA":48811},{"trials":48798,"activeCount":101},[],{"trials":48800,"activeCount":101},[48801],{"nctId":30638,"briefTitle":30639,"status":107,"phases":48802,"primaryCompletion":420,"completion":420,"start":4473,"enrollment":7524,"conditions":48803,"interventions":48804},[90],[15],[4123,30643,30644,30645],{"trials":48806,"activeCount":101},[],{"trials":48808,"activeCount":101},[],{"trials":48810,"activeCount":101},[],{"trials":48812,"activeCount":101},[],{"intervention":20202,"totalTrials":272,"cells":48814},{"EARLY_PHASE1":48815,"PHASE1":48817,"PHASE2":48823,"PHASE3":48825,"PHASE4":48827,"NA":48829},{"trials":48816,"activeCount":101},[],{"trials":48818,"activeCount":101},[48819],{"nctId":20197,"briefTitle":20198,"status":107,"phases":48820,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":48821,"interventions":48822},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":48824,"activeCount":101},[],{"trials":48826,"activeCount":101},[],{"trials":48828,"activeCount":101},[],{"trials":48830,"activeCount":101},[],{"intervention":20203,"totalTrials":272,"cells":48832},{"EARLY_PHASE1":48833,"PHASE1":48835,"PHASE2":48841,"PHASE3":48843,"PHASE4":48845,"NA":48847},{"trials":48834,"activeCount":101},[],{"trials":48836,"activeCount":101},[48837],{"nctId":20197,"briefTitle":20198,"status":107,"phases":48838,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":48839,"interventions":48840},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":48842,"activeCount":101},[],{"trials":48844,"activeCount":101},[],{"trials":48846,"activeCount":101},[],{"trials":48848,"activeCount":101},[],{"intervention":19220,"totalTrials":272,"cells":48850},{"EARLY_PHASE1":48851,"PHASE1":48853,"PHASE2":48859,"PHASE3":48861,"PHASE4":48863,"NA":48865},{"trials":48852,"activeCount":101},[],{"trials":48854,"activeCount":101},[48855],{"nctId":19214,"briefTitle":19215,"status":107,"phases":48856,"primaryCompletion":19217,"completion":19217,"start":230,"enrollment":1512,"conditions":48857,"interventions":48858},[90],[15],[4109,19220],{"trials":48860,"activeCount":101},[],{"trials":48862,"activeCount":101},[],{"trials":48864,"activeCount":101},[],{"trials":48866,"activeCount":101},[],{"intervention":19228,"totalTrials":272,"cells":48868},{"EARLY_PHASE1":48869,"PHASE1":48871,"PHASE2":48877,"PHASE3":48879,"PHASE4":48881,"NA":48883},{"trials":48870,"activeCount":101},[],{"trials":48872,"activeCount":101},[48873],{"nctId":19222,"briefTitle":19223,"status":107,"phases":48874,"primaryCompletion":18773,"completion":18773,"start":19225,"enrollment":401,"conditions":48875,"interventions":48876},[90],[15],[19228,19229,19230,19231,4109],{"trials":48878,"activeCount":101},[],{"trials":48880,"activeCount":101},[],{"trials":48882,"activeCount":101},[],{"trials":48884,"activeCount":101},[],{"intervention":19229,"totalTrials":272,"cells":48886},{"EARLY_PHASE1":48887,"PHASE1":48889,"PHASE2":48895,"PHASE3":48897,"PHASE4":48899,"NA":48901},{"trials":48888,"activeCount":101},[],{"trials":48890,"activeCount":101},[48891],{"nctId":19222,"briefTitle":19223,"status":107,"phases":48892,"primaryCompletion":18773,"completion":18773,"start":19225,"enrollment":401,"conditions":48893,"interventions":48894},[90],[15],[19228,19229,19230,19231,4109],{"trials":48896,"activeCount":101},[],{"trials":48898,"activeCount":101},[],{"trials":48900,"activeCount":101},[],{"trials":48902,"activeCount":101},[],{"intervention":19230,"totalTrials":272,"cells":48904},{"EARLY_PHASE1":48905,"PHASE1":48907,"PHASE2":48913,"PHASE3":48915,"PHASE4":48917,"NA":48919},{"trials":48906,"activeCount":101},[],{"trials":48908,"activeCount":101},[48909],{"nctId":19222,"briefTitle":19223,"status":107,"phases":48910,"primaryCompletion":18773,"completion":18773,"start":19225,"enrollment":401,"conditions":48911,"interventions":48912},[90],[15],[19228,19229,19230,19231,4109],{"trials":48914,"activeCount":101},[],{"trials":48916,"activeCount":101},[],{"trials":48918,"activeCount":101},[],{"trials":48920,"activeCount":101},[],{"intervention":19231,"totalTrials":272,"cells":48922},{"EARLY_PHASE1":48923,"PHASE1":48925,"PHASE2":48931,"PHASE3":48933,"PHASE4":48935,"NA":48937},{"trials":48924,"activeCount":101},[],{"trials":48926,"activeCount":101},[48927],{"nctId":19222,"briefTitle":19223,"status":107,"phases":48928,"primaryCompletion":18773,"completion":18773,"start":19225,"enrollment":401,"conditions":48929,"interventions":48930},[90],[15],[19228,19229,19230,19231,4109],{"trials":48932,"activeCount":101},[],{"trials":48934,"activeCount":101},[],{"trials":48936,"activeCount":101},[],{"trials":48938,"activeCount":101},[],{"intervention":48940,"totalTrials":272,"cells":48941},"low dose BI 201335 NA soft gelatine",{"EARLY_PHASE1":48942,"PHASE1":48944,"PHASE2":48955,"PHASE3":48957,"PHASE4":48959,"NA":48961},{"trials":48943,"activeCount":101},[],{"trials":48945,"activeCount":101},[48946],{"nctId":48947,"briefTitle":48948,"status":107,"phases":48949,"primaryCompletion":4129,"start":4507,"enrollment":1237,"conditions":48950,"interventions":48951},"NCT02182284","Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers",[90],[15],[48940,48952,48953,48954],"high dose BI 201335 NA soft gelatine","low dose BI 201335 NA powder in bottle","high dose BI 201335 NA powder in bottle",{"trials":48956,"activeCount":101},[],{"trials":48958,"activeCount":101},[],{"trials":48960,"activeCount":101},[],{"trials":48962,"activeCount":101},[],{"intervention":48952,"totalTrials":272,"cells":48964},{"EARLY_PHASE1":48965,"PHASE1":48967,"PHASE2":48973,"PHASE3":48975,"PHASE4":48977,"NA":48979},{"trials":48966,"activeCount":101},[],{"trials":48968,"activeCount":101},[48969],{"nctId":48947,"briefTitle":48948,"status":107,"phases":48970,"primaryCompletion":4129,"start":4507,"enrollment":1237,"conditions":48971,"interventions":48972},[90],[15],[48940,48952,48953,48954],{"trials":48974,"activeCount":101},[],{"trials":48976,"activeCount":101},[],{"trials":48978,"activeCount":101},[],{"trials":48980,"activeCount":101},[],{"intervention":48953,"totalTrials":272,"cells":48982},{"EARLY_PHASE1":48983,"PHASE1":48985,"PHASE2":48991,"PHASE3":48993,"PHASE4":48995,"NA":48997},{"trials":48984,"activeCount":101},[],{"trials":48986,"activeCount":101},[48987],{"nctId":48947,"briefTitle":48948,"status":107,"phases":48988,"primaryCompletion":4129,"start":4507,"enrollment":1237,"conditions":48989,"interventions":48990},[90],[15],[48940,48952,48953,48954],{"trials":48992,"activeCount":101},[],{"trials":48994,"activeCount":101},[],{"trials":48996,"activeCount":101},[],{"trials":48998,"activeCount":101},[],{"intervention":48954,"totalTrials":272,"cells":49000},{"EARLY_PHASE1":49001,"PHASE1":49003,"PHASE2":49009,"PHASE3":49011,"PHASE4":49013,"NA":49015},{"trials":49002,"activeCount":101},[],{"trials":49004,"activeCount":101},[49005],{"nctId":48947,"briefTitle":48948,"status":107,"phases":49006,"primaryCompletion":4129,"start":4507,"enrollment":1237,"conditions":49007,"interventions":49008},[90],[15],[48940,48952,48953,48954],{"trials":49010,"activeCount":101},[],{"trials":49012,"activeCount":101},[],{"trials":49014,"activeCount":101},[],{"trials":49016,"activeCount":101},[],{"intervention":49018,"totalTrials":272,"cells":49019},"Meloxicam gel",{"EARLY_PHASE1":49020,"PHASE1":49022,"PHASE2":49030,"PHASE3":49032,"PHASE4":49034,"NA":49036},{"trials":49021,"activeCount":101},[],{"trials":49023,"activeCount":101},[49024],{"nctId":49025,"briefTitle":49026,"status":107,"phases":49027,"primaryCompletion":11123,"start":7084,"enrollment":188,"conditions":49028,"interventions":49029},"NCT02183077","Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects",[90],[15],[49018,6498],{"trials":49031,"activeCount":101},[],{"trials":49033,"activeCount":101},[],{"trials":49035,"activeCount":101},[],{"trials":49037,"activeCount":101},[],{"intervention":49039,"totalTrials":272,"cells":49040},"Zongertinib manufacturer 1",{"EARLY_PHASE1":49041,"PHASE1":49043,"PHASE2":49053,"PHASE3":49055,"PHASE4":49057,"NA":49059},{"trials":49042,"activeCount":101},[],{"trials":49044,"activeCount":101},[49045],{"nctId":49046,"briefTitle":49047,"status":107,"phases":49048,"primaryCompletion":49049,"completion":42,"start":4245,"enrollment":37,"conditions":49050,"interventions":49051},"NCT06360081","A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers",[90],"2024-06-30",[15],[49039,49052],"Zongertinib manufacturer 2",{"trials":49054,"activeCount":101},[],{"trials":49056,"activeCount":101},[],{"trials":49058,"activeCount":101},[],{"trials":49060,"activeCount":101},[],{"intervention":49052,"totalTrials":272,"cells":49062},{"EARLY_PHASE1":49063,"PHASE1":49065,"PHASE2":49071,"PHASE3":49073,"PHASE4":49075,"NA":49077},{"trials":49064,"activeCount":101},[],{"trials":49066,"activeCount":101},[49067],{"nctId":49046,"briefTitle":49047,"status":107,"phases":49068,"primaryCompletion":49049,"completion":42,"start":4245,"enrollment":37,"conditions":49069,"interventions":49070},[90],[15],[49039,49052],{"trials":49072,"activeCount":101},[],{"trials":49074,"activeCount":101},[],{"trials":49076,"activeCount":101},[],{"trials":49078,"activeCount":101},[],{"intervention":49080,"totalTrials":272,"cells":49081},"Single rising doses of BI 1744 CL, solution for oral inhalation",{"EARLY_PHASE1":49082,"PHASE1":49084,"PHASE2":49093,"PHASE3":49095,"PHASE4":49097,"NA":49099},{"trials":49083,"activeCount":101},[],{"trials":49085,"activeCount":101},[49086],{"nctId":49087,"briefTitle":49088,"status":107,"phases":49089,"primaryCompletion":6140,"start":6155,"enrollment":448,"conditions":49090,"interventions":49091},"NCT02259959","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers",[90],[15],[49080,49092],"Tiotropium, fixed dose, solution for oral inhalation",{"trials":49094,"activeCount":101},[],{"trials":49096,"activeCount":101},[],{"trials":49098,"activeCount":101},[],{"trials":49100,"activeCount":101},[],{"intervention":49092,"totalTrials":272,"cells":49102},{"EARLY_PHASE1":49103,"PHASE1":49105,"PHASE2":49111,"PHASE3":49113,"PHASE4":49115,"NA":49117},{"trials":49104,"activeCount":101},[],{"trials":49106,"activeCount":101},[49107],{"nctId":49087,"briefTitle":49088,"status":107,"phases":49108,"primaryCompletion":6140,"start":6155,"enrollment":448,"conditions":49109,"interventions":49110},[90],[15],[49080,49092],{"trials":49112,"activeCount":101},[],{"trials":49114,"activeCount":101},[],{"trials":49116,"activeCount":101},[],{"trials":49118,"activeCount":101},[],{"intervention":2569,"totalTrials":272,"cells":49120},{"EARLY_PHASE1":49121,"PHASE1":49123,"PHASE2":49129,"PHASE3":49131,"PHASE4":49133,"NA":49135},{"trials":49122,"activeCount":101},[],{"trials":49124,"activeCount":101},[49125],{"nctId":2562,"briefTitle":2563,"status":107,"phases":49126,"primaryCompletion":2565,"completion":2565,"start":2566,"enrollment":155,"conditions":49127,"interventions":49128},[90],[15],[2441,2569],{"trials":49130,"activeCount":101},[],{"trials":49132,"activeCount":101},[],{"trials":49134,"activeCount":101},[],{"trials":49136,"activeCount":101},[],{"intervention":49138,"totalTrials":272,"cells":49139},"BI 905677",{"EARLY_PHASE1":49140,"PHASE1":49142,"PHASE2":49151,"PHASE3":49153,"PHASE4":49155,"NA":49157},{"trials":49141,"activeCount":101},[],{"trials":49143,"activeCount":101},[49144],{"nctId":49145,"briefTitle":49146,"status":162,"phases":49147,"primaryCompletion":1646,"completion":1646,"start":49148,"enrollment":3398,"conditions":49149,"interventions":49150},"NCT03604445","This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)",[90],"2018-08-08",[33],[49138],{"trials":49152,"activeCount":101},[],{"trials":49154,"activeCount":101},[],{"trials":49156,"activeCount":101},[],{"trials":49158,"activeCount":101},[],{"intervention":49160,"totalTrials":272,"cells":49161},"BHT 0.1%",{"EARLY_PHASE1":49162,"PHASE1":49164,"PHASE2":49173,"PHASE3":49175,"PHASE4":49177,"NA":49179},{"trials":49163,"activeCount":101},[],{"trials":49165,"activeCount":101},[49166],{"nctId":49167,"briefTitle":49168,"status":107,"phases":49169,"primaryCompletion":1980,"start":399,"enrollment":9606,"conditions":49170,"interventions":49171},"NCT02220673","Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)",[90],[30],[49160,49172],"BHT 0.5%",{"trials":49174,"activeCount":101},[],{"trials":49176,"activeCount":101},[],{"trials":49178,"activeCount":101},[],{"trials":49180,"activeCount":101},[],{"intervention":49172,"totalTrials":272,"cells":49182},{"EARLY_PHASE1":49183,"PHASE1":49185,"PHASE2":49191,"PHASE3":49193,"PHASE4":49195,"NA":49197},{"trials":49184,"activeCount":101},[],{"trials":49186,"activeCount":101},[49187],{"nctId":49167,"briefTitle":49168,"status":107,"phases":49188,"primaryCompletion":1980,"start":399,"enrollment":9606,"conditions":49189,"interventions":49190},[90],[30],[49160,49172],{"trials":49192,"activeCount":101},[],{"trials":49194,"activeCount":101},[],{"trials":49196,"activeCount":101},[],{"trials":49198,"activeCount":101},[],{"intervention":7603,"totalTrials":272,"cells":49200},{"EARLY_PHASE1":49201,"PHASE1":49203,"PHASE2":49209,"PHASE3":49211,"PHASE4":49213,"NA":49215},{"trials":49202,"activeCount":101},[],{"trials":49204,"activeCount":101},[49205],{"nctId":7598,"briefTitle":7599,"status":107,"phases":49206,"primaryCompletion":2146,"start":6081,"enrollment":3575,"conditions":49207,"interventions":49208},[90],[15],[7603,7604,7605,7606,7607,7591],{"trials":49210,"activeCount":101},[],{"trials":49212,"activeCount":101},[],{"trials":49214,"activeCount":101},[],{"trials":49216,"activeCount":101},[],{"intervention":7604,"totalTrials":272,"cells":49218},{"EARLY_PHASE1":49219,"PHASE1":49221,"PHASE2":49227,"PHASE3":49229,"PHASE4":49231,"NA":49233},{"trials":49220,"activeCount":101},[],{"trials":49222,"activeCount":101},[49223],{"nctId":7598,"briefTitle":7599,"status":107,"phases":49224,"primaryCompletion":2146,"start":6081,"enrollment":3575,"conditions":49225,"interventions":49226},[90],[15],[7603,7604,7605,7606,7607,7591],{"trials":49228,"activeCount":101},[],{"trials":49230,"activeCount":101},[],{"trials":49232,"activeCount":101},[],{"trials":49234,"activeCount":101},[],{"intervention":7605,"totalTrials":272,"cells":49236},{"EARLY_PHASE1":49237,"PHASE1":49239,"PHASE2":49245,"PHASE3":49247,"PHASE4":49249,"NA":49251},{"trials":49238,"activeCount":101},[],{"trials":49240,"activeCount":101},[49241],{"nctId":7598,"briefTitle":7599,"status":107,"phases":49242,"primaryCompletion":2146,"start":6081,"enrollment":3575,"conditions":49243,"interventions":49244},[90],[15],[7603,7604,7605,7606,7607,7591],{"trials":49246,"activeCount":101},[],{"trials":49248,"activeCount":101},[],{"trials":49250,"activeCount":101},[],{"trials":49252,"activeCount":101},[],{"intervention":7606,"totalTrials":272,"cells":49254},{"EARLY_PHASE1":49255,"PHASE1":49257,"PHASE2":49263,"PHASE3":49265,"PHASE4":49267,"NA":49269},{"trials":49256,"activeCount":101},[],{"trials":49258,"activeCount":101},[49259],{"nctId":7598,"briefTitle":7599,"status":107,"phases":49260,"primaryCompletion":2146,"start":6081,"enrollment":3575,"conditions":49261,"interventions":49262},[90],[15],[7603,7604,7605,7606,7607,7591],{"trials":49264,"activeCount":101},[],{"trials":49266,"activeCount":101},[],{"trials":49268,"activeCount":101},[],{"trials":49270,"activeCount":101},[],{"intervention":7607,"totalTrials":272,"cells":49272},{"EARLY_PHASE1":49273,"PHASE1":49275,"PHASE2":49281,"PHASE3":49283,"PHASE4":49285,"NA":49287},{"trials":49274,"activeCount":101},[],{"trials":49276,"activeCount":101},[49277],{"nctId":7598,"briefTitle":7599,"status":107,"phases":49278,"primaryCompletion":2146,"start":6081,"enrollment":3575,"conditions":49279,"interventions":49280},[90],[15],[7603,7604,7605,7606,7607,7591],{"trials":49282,"activeCount":101},[],{"trials":49284,"activeCount":101},[],{"trials":49286,"activeCount":101},[],{"trials":49288,"activeCount":101},[],{"intervention":6121,"totalTrials":1208,"cells":49290},{"EARLY_PHASE1":49291,"PHASE1":49293,"PHASE2":49381,"PHASE3":49393,"PHASE4":49460,"NA":49518},{"trials":49292,"activeCount":101},[],{"trials":49294,"activeCount":101},[49295,49299,49303,49307,49311,49315,49319,49323,49329,49333,49339,49343,49347,49351,49355,49361,49365,49369,49373,49377],{"nctId":31480,"briefTitle":31481,"status":107,"phases":49296,"primaryCompletion":9752,"start":9340,"enrollment":1208,"conditions":49297,"interventions":49298},[90],[15],[31473,6121,31485],{"nctId":29288,"briefTitle":29289,"status":107,"phases":49300,"primaryCompletion":9418,"start":4516,"enrollment":357,"conditions":49301,"interventions":49302},[90],[15],[29281,6121,10908],{"nctId":29417,"briefTitle":29418,"status":107,"phases":49304,"primaryCompletion":7618,"start":9276,"enrollment":357,"conditions":49305,"interventions":49306},[90],[15],[6121,29410,29422],{"nctId":32940,"briefTitle":32941,"status":107,"phases":49308,"primaryCompletion":9418,"start":6140,"enrollment":6117,"conditions":49309,"interventions":49310},[90],[15],[32933,6121,10908],{"nctId":6113,"briefTitle":6114,"status":107,"phases":49312,"primaryCompletion":4517,"start":6116,"enrollment":6117,"conditions":49313,"interventions":49314},[90],[15],[6120,6121,6106,6106],{"nctId":6203,"briefTitle":6204,"status":107,"phases":49316,"primaryCompletion":6206,"start":6207,"enrollment":132,"conditions":49317,"interventions":49318},[90],[15],[6196,6121,6210],{"nctId":28552,"briefTitle":28553,"status":107,"phases":49320,"primaryCompletion":5843,"start":3978,"enrollment":2400,"conditions":49321,"interventions":49322},[90],[15],[28557,6121,6994],{"nctId":49324,"briefTitle":49325,"status":107,"phases":49326,"primaryCompletion":11123,"start":7084,"enrollment":251,"conditions":49327,"interventions":49328},"NCT02218684","Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects",[90],[15],[6121,8703],{"nctId":10903,"briefTitle":10904,"status":107,"phases":49330,"primaryCompletion":9418,"start":6140,"enrollment":6117,"conditions":49331,"interventions":49332},[90],[15],[10896,6121,10908],{"nctId":49334,"briefTitle":49335,"status":107,"phases":49336,"primaryCompletion":11588,"start":4498,"enrollment":2887,"conditions":49337,"interventions":49338},"NCT02259816","Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers",[90],[15],[6121,10908],{"nctId":29294,"briefTitle":29295,"status":107,"phases":49340,"primaryCompletion":3763,"start":8911,"enrollment":357,"conditions":49341,"interventions":49342},[90],[15],[29299,6121,10908],{"nctId":36267,"briefTitle":36268,"status":107,"phases":49344,"primaryCompletion":4412,"start":6224,"enrollment":1208,"conditions":49345,"interventions":49346},[90],[15],[36260,6121],{"nctId":29424,"briefTitle":29425,"status":107,"phases":49348,"primaryCompletion":17247,"start":17247,"enrollment":448,"conditions":49349,"interventions":49350},[90],[15],[6121,29410,29429],{"nctId":6123,"briefTitle":6124,"status":107,"phases":49352,"primaryCompletion":4517,"start":6116,"enrollment":6117,"conditions":49353,"interventions":49354},[90],[15],[6120,6121,6106,6106],{"nctId":49356,"briefTitle":49357,"status":107,"phases":49358,"primaryCompletion":6438,"start":7553,"enrollment":1982,"conditions":49359,"interventions":49360},"NCT02203500","Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects",[90],[15],[8703,6121],{"nctId":44715,"briefTitle":44716,"status":107,"phases":49362,"primaryCompletion":6206,"start":6207,"enrollment":188,"conditions":49363,"interventions":49364},[90],[15],[44708,8703,6121],{"nctId":11011,"briefTitle":11012,"status":107,"phases":49366,"primaryCompletion":2122,"start":2163,"enrollment":401,"conditions":49367,"interventions":49368},[90],[15],[6121,11008,11016],{"nctId":47038,"briefTitle":47039,"status":107,"phases":49370,"primaryCompletion":5868,"start":6445,"enrollment":380,"conditions":49371,"interventions":49372},[90],[15],[7281,47031],{"nctId":6442,"briefTitle":6443,"status":107,"phases":49374,"primaryCompletion":6445,"start":6446,"enrollment":380,"conditions":49375,"interventions":49376},[90],[15],[6121,6420],{"nctId":6137,"briefTitle":6138,"status":107,"phases":49378,"primaryCompletion":6140,"start":4517,"enrollment":331,"conditions":49379,"interventions":49380},[90],[15],[6121,6106],{"trials":49382,"activeCount":101},[49383,49389],{"nctId":49384,"briefTitle":49385,"status":107,"phases":49386,"primaryCompletion":6140,"start":6156,"enrollment":2772,"conditions":49387,"interventions":49388},"NCT02242344","Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension",[91],[24],[6121],{"nctId":6232,"briefTitle":6233,"status":107,"phases":49390,"primaryCompletion":1115,"completion":1115,"start":6235,"enrollment":6236,"conditions":49391,"interventions":49392},[91],[24],[6121,6196,6239],{"trials":49394,"activeCount":101},[49395,49399,49403,49407,49411,49415,49419,49425,49429,49433,49437,49441,49445,49452,49456],{"nctId":11578,"briefTitle":11579,"status":107,"phases":49396,"primaryCompletion":6911,"completion":6911,"start":11581,"enrollment":1771,"conditions":49397,"interventions":49398},[92],[24],[10922,6121],{"nctId":11585,"briefTitle":11586,"status":107,"phases":49400,"primaryCompletion":11588,"completion":11588,"start":5842,"enrollment":993,"conditions":49401,"interventions":49402},[92],[24],[6121,10922],{"nctId":6243,"briefTitle":6244,"status":107,"phases":49404,"primaryCompletion":6246,"start":6064,"enrollment":6247,"conditions":49405,"interventions":49406},[92],[24],[6121,6196],{"nctId":12578,"briefTitle":12579,"status":107,"phases":49408,"primaryCompletion":2122,"start":2181,"enrollment":7301,"conditions":49409,"interventions":49410},[92],[24],[12563,6121],{"nctId":11022,"briefTitle":11023,"status":107,"phases":49412,"primaryCompletion":3763,"completion":3763,"start":6156,"enrollment":11025,"conditions":49413,"interventions":49414},[92],[24,11027],[7281,9343],{"nctId":12714,"briefTitle":12715,"status":107,"phases":49416,"primaryCompletion":9381,"start":2003,"enrollment":12717,"conditions":49417,"interventions":49418},[92],[24],[12224,7281,12703],{"nctId":49420,"briefTitle":49421,"status":107,"phases":49422,"primaryCompletion":7419,"start":6262,"enrollment":1672,"conditions":49423,"interventions":49424},"NCT02206659","Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension",[92],[24],[6121],{"nctId":7472,"briefTitle":7473,"status":107,"phases":49426,"primaryCompletion":2112,"completion":2112,"start":7475,"enrollment":7476,"conditions":49427,"interventions":49428},[92],[24,21],[7281,7461],{"nctId":7111,"briefTitle":7112,"status":107,"phases":49430,"primaryCompletion":7114,"start":6065,"enrollment":7115,"conditions":49431,"interventions":49432},[92],[24],[6121,7100],{"nctId":12721,"briefTitle":12722,"status":107,"phases":49434,"primaryCompletion":2030,"start":12600,"enrollment":12724,"conditions":49435,"interventions":49436},[92],[24],[12727,6121],{"nctId":6152,"briefTitle":6153,"status":107,"phases":49438,"primaryCompletion":6155,"start":6156,"enrollment":6157,"conditions":49439,"interventions":49440},[92],[24],[6121,6106],{"nctId":11986,"briefTitle":11987,"status":107,"phases":49442,"primaryCompletion":7022,"start":5923,"enrollment":11989,"conditions":49443,"interventions":49444},[92],[24],[6121,11992],{"nctId":49446,"briefTitle":49447,"status":107,"phases":49448,"primaryCompletion":7114,"start":6065,"enrollment":49449,"conditions":49450,"interventions":49451},"NCT02177409","Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension",[92],431,[24],[6121],{"nctId":17684,"briefTitle":17685,"status":107,"phases":49453,"primaryCompletion":7114,"start":6065,"enrollment":17687,"conditions":49454,"interventions":49455},[92],[24],[6121,17673],{"nctId":12226,"briefTitle":12227,"status":107,"phases":49457,"primaryCompletion":6224,"start":4516,"enrollment":12229,"conditions":49458,"interventions":49459},[92],[24],[12207,7281],{"trials":49461,"activeCount":101},[49462,49466,49470,49474,49478,49482,49490,49494,49498,49502,49506,49510,49514],{"nctId":6272,"briefTitle":6273,"status":107,"phases":49463,"primaryCompletion":4392,"start":5905,"enrollment":6275,"conditions":49464,"interventions":49465},[93],[24],[6121,6121,6196],{"nctId":6163,"briefTitle":6164,"status":107,"phases":49467,"completion":5868,"start":6081,"enrollment":8,"conditions":49468,"interventions":49469},[93],[21,24],[6121,6106],{"nctId":6279,"briefTitle":6280,"status":107,"phases":49471,"primaryCompletion":5993,"start":2181,"enrollment":6282,"conditions":49472,"interventions":49473},[93],[24],[6121,6285,6196],{"nctId":7121,"briefTitle":7122,"status":107,"phases":49475,"primaryCompletion":4462,"completion":4462,"start":7124,"enrollment":7125,"conditions":49476,"interventions":49477},[93],[2203,24],[6121,7100],{"nctId":7273,"briefTitle":7274,"status":107,"phases":49479,"primaryCompletion":7276,"start":7277,"enrollment":7278,"conditions":49480,"interventions":49481},[93],[24,2203],[7281,7282],{"nctId":49483,"briefTitle":49484,"status":162,"phases":49485,"primaryCompletion":49486,"completion":49486,"start":49487,"enrollment":210,"conditions":49488,"interventions":49489},"NCT00274105","SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients",[93],"2004-10-01","2001-03-01",[24,6534],[7281],{"nctId":7129,"briefTitle":7130,"status":107,"phases":49491,"primaryCompletion":6375,"start":7132,"enrollment":7133,"conditions":49492,"interventions":49493},[93],[24],[6121,7100],{"nctId":6169,"briefTitle":6170,"status":107,"phases":49495,"primaryCompletion":6172,"start":6173,"enrollment":6174,"conditions":49496,"interventions":49497},[93],[24],[6121,6106],{"nctId":6178,"briefTitle":6179,"status":107,"phases":49499,"primaryCompletion":4413,"start":6015,"enrollment":6181,"conditions":49500,"interventions":49501},[93],[662],[6121,6184,6106],{"nctId":8864,"briefTitle":8865,"status":107,"phases":49503,"primaryCompletion":6494,"start":6029,"enrollment":380,"conditions":49504,"interventions":49505},[93],[15],[6121,8851],{"nctId":7615,"briefTitle":7616,"status":162,"phases":49507,"primaryCompletion":7618,"start":5869,"enrollment":380,"conditions":49508,"interventions":49509},[93],[24],[6121,7591],{"nctId":7482,"briefTitle":7483,"status":107,"phases":49511,"primaryCompletion":6494,"start":2163,"enrollment":7485,"conditions":49512,"interventions":49513},[93],[24],[6121,7488,7489],{"nctId":6186,"briefTitle":6187,"status":107,"phases":49515,"primaryCompletion":2146,"completion":2146,"start":6189,"enrollment":6190,"conditions":49516,"interventions":49517},[93],[24],[6121,6106],{"trials":49519,"activeCount":101},[49520,49528,49535,49542,49549,49557,49564,49571,49578,49588,49596,49603,49614,49621],{"nctId":49521,"briefTitle":49522,"status":107,"phases":49523,"primaryCompletion":9418,"start":3978,"enrollment":49524,"conditions":49525,"interventions":49526},"NCT02242396","A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)",[],5248,[24],[6121,49527],"Telmisartan hydrochlorothiazide",{"nctId":49529,"briefTitle":49530,"status":107,"phases":49531,"primaryCompletion":6910,"start":6390,"enrollment":49532,"conditions":49533,"interventions":49534},"NCT02245464","Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension",[],13066,[24],[6121],{"nctId":49536,"briefTitle":49537,"status":107,"phases":49538,"primaryCompletion":7300,"start":9276,"enrollment":49539,"conditions":49540,"interventions":49541},"NCT02242851","Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients",[],5018,[24],[6121],{"nctId":49543,"briefTitle":49544,"status":107,"phases":49545,"primaryCompletion":3754,"start":6156,"enrollment":49546,"conditions":49547,"interventions":49548},"NCT00659581","J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation",[],21471,[24],[6121],{"nctId":49550,"briefTitle":49551,"status":107,"phases":49552,"primaryCompletion":1990,"start":7151,"enrollment":49553,"conditions":49554,"interventions":49555},"NCT02242877","TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic\u002FDiastolic Hypertension Patients Aged 55 or Older",[],3320,[24],[6121,49556],"Telmisartan combined with hydrochlorothiazide",{"nctId":49558,"briefTitle":49559,"status":107,"phases":49560,"primaryCompletion":5880,"start":2122,"enrollment":49561,"conditions":49562,"interventions":49563},"NCT02238262","Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals",[],2318,[24],[6121],{"nctId":49565,"briefTitle":49566,"status":107,"phases":49567,"primaryCompletion":2122,"start":9235,"enrollment":49568,"conditions":49569,"interventions":49570},"NCT02187705","Micardis® in Patients With Essential Hypertension",[],1688,[24],[6121],{"nctId":49572,"briefTitle":49573,"status":107,"phases":49574,"primaryCompletion":4391,"completion":4391,"start":6132,"enrollment":49575,"conditions":49576,"interventions":49577},"NCT01316419","Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension",[],2089,[24],[6121,12224],{"nctId":49579,"briefTitle":49580,"status":107,"phases":49581,"primaryCompletion":6132,"start":6811,"enrollment":49582,"conditions":49583,"interventions":49584},"NCT02248896","Antihypertensive Medications and the Risk of Sepsis",[],1129062,[24],[6121,49585,49586,49587],"Other angiotensin-receptor blockers","Angiotensin-converting enzyme inhibitors","Other major antihypertensive medication classes",{"nctId":49589,"briefTitle":49590,"status":107,"phases":49591,"primaryCompletion":5843,"start":6782,"enrollment":49592,"conditions":49593,"interventions":49594},"NCT02242383","Evaluation of Efficacy and Tolerability of Micardis® \u002F MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension",[],13248,[24],[6121,49595],"Telmisartan in combination with hydrochlorothiazide",{"nctId":49597,"briefTitle":49598,"status":107,"phases":49599,"primaryCompletion":1114,"start":7574,"enrollment":49600,"conditions":49601,"interventions":49602},"NCT00946829","Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise",[],18299,[24],[7281],{"nctId":49604,"briefTitle":49605,"status":107,"phases":49606,"primaryCompletion":9538,"start":9332,"enrollment":49607,"conditions":49608,"interventions":49609},"NCT02215733","The Use of Angiotensin Receptor Blockers and the Risk of Cancer",[],1165781,[30613],[49610,49611,49612,49613,6121],"ARB","ACEI","Beta-blockers","Diuretics",{"nctId":49615,"briefTitle":49616,"status":107,"phases":49617,"primaryCompletion":5880,"start":9235,"enrollment":49618,"conditions":49619,"interventions":49620},"NCT02200575","Pharmacovigilance and Patient Compliance in Hypertensive Patients",[],10333,[24],[6121],{"nctId":49622,"briefTitle":49623,"status":107,"phases":49624,"primaryCompletion":6911,"start":5869,"enrollment":49625,"conditions":49626,"interventions":49627},"NCT02242838","Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension",[],6336,[24],[6121],{"intervention":5860,"totalTrials":31,"cells":49629},{"EARLY_PHASE1":49630,"PHASE1":49632,"PHASE2":49654,"PHASE3":49692,"PHASE4":49887,"NA":49949},{"trials":49631,"activeCount":101},[],{"trials":49633,"activeCount":101},[49634,49638,49642,49646],{"nctId":34515,"briefTitle":34516,"status":107,"phases":49635,"primaryCompletion":6390,"start":2162,"enrollment":392,"conditions":49636,"interventions":49637},[90],[15],[34508,34520,5860],{"nctId":20521,"briefTitle":20522,"status":107,"phases":49639,"primaryCompletion":2030,"start":6132,"enrollment":448,"conditions":49640,"interventions":49641},[90],[15],[5860,5860,6304,6304],{"nctId":19124,"briefTitle":19125,"status":107,"phases":49643,"primaryCompletion":10775,"start":4413,"enrollment":4433,"conditions":49644,"interventions":49645},[90],[18],[19059,19129,5860],{"nctId":49647,"briefTitle":49648,"status":107,"phases":49649,"primaryCompletion":49650,"completion":49650,"start":49651,"enrollment":188,"conditions":49652,"interventions":49653},"NCT02969317","Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg\u002F 5 μg) in Chinese COPD Patients",[90],"2017-06-15","2017-02-24",[18],[5860,5959],{"trials":49655,"activeCount":101},[49656,49660,49664,49668,49674,49678,49684,49688],{"nctId":19729,"briefTitle":19730,"status":107,"phases":49657,"primaryCompletion":6911,"start":3978,"enrollment":11163,"conditions":49658,"interventions":49659},[91],[18],[19700,5899],{"nctId":11605,"briefTitle":11606,"status":107,"phases":49661,"primaryCompletion":6494,"start":6030,"enrollment":6702,"conditions":49662,"interventions":49663},[91],[18],[11610,5860,11596],{"nctId":5853,"briefTitle":5854,"status":107,"phases":49665,"primaryCompletion":5856,"start":4516,"enrollment":5857,"conditions":49666,"interventions":49667},[91],[18],[5860,5832,5861,5862,5863],{"nctId":49669,"briefTitle":49670,"status":107,"phases":49671,"primaryCompletion":9418,"start":11588,"enrollment":44066,"conditions":49672,"interventions":49673},"NCT00365560","An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma",[91],[30],[5899],{"nctId":19735,"briefTitle":19736,"status":107,"phases":49675,"primaryCompletion":6413,"start":6235,"enrollment":3398,"conditions":49676,"interventions":49677},[91],[18],[19700,5860],{"nctId":49679,"briefTitle":49680,"status":107,"phases":49681,"primaryCompletion":4391,"completion":4391,"start":4473,"enrollment":231,"conditions":49682,"interventions":49683},"NCT02030535","Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers",[91],[18],[5900,5899,5899,5900],{"nctId":19751,"briefTitle":19752,"status":107,"phases":49685,"primaryCompletion":4498,"start":11642,"enrollment":6311,"conditions":49686,"interventions":49687},[91],[18],[19700,5899],{"nctId":5865,"briefTitle":5866,"status":107,"phases":49689,"primaryCompletion":5868,"start":5869,"enrollment":5870,"conditions":49690,"interventions":49691},[91],[18],[5860,5832],{"trials":49693,"activeCount":101},[49694,49702,49706,49710,49714,49720,49724,49731,49737,49744,49753,49760,49769,49777,49781,49788,49795,49802,49809,49813,49820,49824,49828,49832,49836,49845,49849,49856,49862,49868,49875,49881],{"nctId":49695,"briefTitle":49696,"status":107,"phases":49697,"primaryCompletion":378,"completion":378,"start":5296,"enrollment":49698,"conditions":49699,"interventions":49700},"NCT01431287","Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",[92],2539,[18],[49701,49701,5899,5899,5900],"tiotropium + olodaterol",{"nctId":5876,"briefTitle":5877,"status":107,"phases":49703,"completion":5879,"start":5880,"enrollment":448,"conditions":49704,"interventions":49705},[92],[18],[5860,5832],{"nctId":11329,"briefTitle":11330,"status":107,"phases":49707,"primaryCompletion":11332,"completion":11332,"start":5932,"enrollment":2586,"conditions":49708,"interventions":49709},[92],[18],[5860,11335,5860,5945],{"nctId":5884,"briefTitle":5885,"status":107,"phases":49711,"primaryCompletion":5843,"start":5887,"enrollment":410,"conditions":49712,"interventions":49713},[92],[18],[5860,5832],{"nctId":49715,"briefTitle":49716,"status":107,"phases":49717,"primaryCompletion":6081,"start":6701,"enrollment":220,"conditions":49718,"interventions":49719},"NCT00274521","Tiotropium (Spiriva) Rehabilitation Study",[92],[18],[5860],{"nctId":5891,"briefTitle":5892,"status":107,"phases":49721,"primaryCompletion":603,"completion":1125,"start":4474,"enrollment":5894,"conditions":49722,"interventions":49723},[92],[18],[5897,5898,5899,5900,5900,5899,5897,5898],{"nctId":49725,"briefTitle":49726,"status":107,"phases":49727,"primaryCompletion":2649,"start":6911,"enrollment":49728,"conditions":49729,"interventions":49730},"NCT00387088","Tiotropium \u002F Respimat One Year Study in COPD.",[92],3991,[18],[5860],{"nctId":49732,"briefTitle":49733,"status":107,"phases":49734,"primaryCompletion":5879,"start":6494,"enrollment":5956,"conditions":49735,"interventions":49736},"NCT00281567","Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[5860],{"nctId":49738,"briefTitle":49739,"status":107,"phases":49740,"primaryCompletion":6446,"completion":6446,"start":6029,"enrollment":49741,"conditions":49742,"interventions":49743},"NCT00274053","Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD",[92],555,[18],[5899],{"nctId":49745,"briefTitle":49746,"status":107,"phases":49747,"primaryCompletion":49748,"completion":49749,"start":49750,"enrollment":6773,"conditions":49751,"interventions":49752},"NCT02629965","Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients",[92],"2017-03-24","2017-04-17","2016-02-12",[18],[5899,5900,5899],{"nctId":49754,"briefTitle":49755,"status":107,"phases":49756,"primaryCompletion":4474,"completion":4474,"start":2001,"enrollment":49757,"conditions":49758,"interventions":49759},"NCT01696058","Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®",[92],1137,[18],[5860,5860,5959],{"nctId":49761,"briefTitle":49762,"status":107,"phases":49763,"primaryCompletion":378,"completion":378,"start":9538,"enrollment":49764,"conditions":49765,"interventions":49766},"NCT01533935","Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.",[92],291,[18],[49767,49768,5860,5959],"Tiotropium + Olodaterol","tiotropium + Olodaterol",{"nctId":49770,"briefTitle":49771,"status":107,"phases":49772,"primaryCompletion":49773,"completion":49773,"start":49774,"enrollment":12,"conditions":49775,"interventions":49776},"NCT00239447","Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD",[92],"2004-04-29","2002-11-26",[18],[5860],{"nctId":15675,"briefTitle":15676,"status":107,"phases":49778,"primaryCompletion":11650,"completion":11650,"start":6495,"enrollment":15678,"conditions":49779,"interventions":49780},[92],[18],[5860,15664],{"nctId":49782,"briefTitle":49783,"status":107,"phases":49784,"primaryCompletion":6081,"start":7132,"enrollment":49785,"conditions":49786,"interventions":49787},"NCT00274547","Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],1829,[18],[5860],{"nctId":49789,"briefTitle":49790,"status":107,"phases":49791,"primaryCompletion":611,"completion":611,"start":5296,"enrollment":49792,"conditions":49793,"interventions":49794},"NCT01431274","Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",[92],2624,[18],[49701,5899,5900,5899,49701],{"nctId":49796,"briefTitle":49797,"status":107,"phases":49798,"primaryCompletion":6401,"start":5879,"enrollment":49799,"conditions":49800,"interventions":49801},"NCT00239460","Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD",[92],196,[18],[5860],{"nctId":49803,"briefTitle":49804,"status":107,"phases":49805,"primaryCompletion":4129,"start":8108,"enrollment":49806,"conditions":49807,"interventions":49808},"NCT00144339","Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients",[92],5993,[18],[5899],{"nctId":5902,"briefTitle":5903,"status":107,"phases":49810,"primaryCompletion":5905,"start":5906,"enrollment":2235,"conditions":49811,"interventions":49812},[92],[18],[5909,5832,5860],{"nctId":49814,"briefTitle":49815,"status":107,"phases":49816,"primaryCompletion":419,"completion":475,"start":378,"enrollment":49817,"conditions":49818,"interventions":49819},"NCT01964352","Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)",[92],813,[18],[5899,5900,5899,5899,5900],{"nctId":5911,"briefTitle":5912,"status":107,"phases":49821,"primaryCompletion":5914,"start":5915,"enrollment":5916,"conditions":49822,"interventions":49823},[92],[18],[5860,5832],{"nctId":5920,"briefTitle":5921,"status":107,"phases":49825,"primaryCompletion":2122,"start":5923,"enrollment":5924,"conditions":49826,"interventions":49827},[92],[18],[5860,5832],{"nctId":17066,"briefTitle":17067,"status":107,"phases":49829,"primaryCompletion":2002,"completion":437,"start":9824,"enrollment":17069,"conditions":49830,"interventions":49831},[92],[18],[17072,17055,5899],{"nctId":5928,"briefTitle":5929,"status":162,"phases":49833,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5933,"conditions":49834,"interventions":49835},[92],[18],[5936,5832,5937,5860],{"nctId":49837,"briefTitle":49838,"status":107,"phases":49839,"primaryCompletion":49840,"completion":5955,"start":49841,"enrollment":49842,"conditions":49843,"interventions":49844},"NCT02296138","Comparing the Efficacy of Tiotropium + Olodaterol (5\u002F5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.",[92],"2017-03-08","2015-01-13",7903,[18],[5900,5899,5899],{"nctId":5939,"briefTitle":5940,"status":162,"phases":49846,"primaryCompletion":5931,"completion":5931,"start":5932,"enrollment":5942,"conditions":49847,"interventions":49848},[92],[18],[5945,5946,5832,5860],{"nctId":49850,"briefTitle":49851,"status":107,"phases":49852,"primaryCompletion":419,"completion":475,"start":378,"enrollment":49853,"conditions":49854,"interventions":49855},"NCT02006732","Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)",[92],809,[18],[5900,5899],{"nctId":49857,"briefTitle":49858,"status":107,"phases":49859,"primaryCompletion":6374,"completion":6374,"start":6053,"enrollment":8109,"conditions":49860,"interventions":49861},"NCT00274014","Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders",[92],[18],[5860],{"nctId":49863,"briefTitle":49864,"status":107,"phases":49865,"primaryCompletion":9515,"completion":9515,"start":3753,"enrollment":735,"conditions":49866,"interventions":49867},"NCT01559116","Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease",[92],[18],[49701,5899,5900,5899,49701],{"nctId":49869,"briefTitle":49870,"status":107,"phases":49871,"primaryCompletion":6445,"completion":6445,"start":5993,"enrollment":49872,"conditions":49873,"interventions":49874},"NCT00277264","Spiriva® Assessment of FEV1 (SAFE)",[92],914,[18],[5860],{"nctId":49876,"briefTitle":49755,"status":107,"phases":49877,"primaryCompletion":9515,"completion":9515,"start":2001,"enrollment":49878,"conditions":49879,"interventions":49880},"NCT01694771",[92],1134,[18],[5860,5959,5860],{"nctId":49882,"briefTitle":49883,"status":107,"phases":49884,"primaryCompletion":378,"completion":378,"start":3753,"enrollment":1252,"conditions":49885,"interventions":49886},"NCT01533922","Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients",[92],[18],[5860,5959,49701,49767],{"trials":49888,"activeCount":101},[49889,49893,49901,49905,49911,49915,49919,49928,49932,49938,49945],{"nctId":7222,"briefTitle":7223,"status":107,"phases":49890,"primaryCompletion":6471,"start":2145,"enrollment":7225,"conditions":49891,"interventions":49892},[93],[18],[5899,7202],{"nctId":49894,"briefTitle":49895,"status":107,"phases":49896,"primaryCompletion":49897,"completion":5967,"start":49898,"enrollment":11,"conditions":49899,"interventions":49900},"NCT02853123","Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients",[93],"2017-07-24","2016-09-22",[18],[5860,5959,5860],{"nctId":5950,"briefTitle":5951,"status":107,"phases":49902,"primaryCompletion":5953,"completion":5954,"start":5955,"enrollment":5956,"conditions":49903,"interventions":49904},[93],[18],[5860,5959,5960,5832],{"nctId":49906,"briefTitle":49907,"status":107,"phases":49908,"primaryCompletion":9593,"completion":9593,"start":390,"enrollment":39599,"conditions":49909,"interventions":49910},"NCT01483625","Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection",[93],[18],[5899],{"nctId":8476,"briefTitle":8477,"status":107,"phases":49912,"primaryCompletion":8479,"completion":8479,"start":5869,"enrollment":8480,"conditions":49913,"interventions":49914},[93],[18],[5860,8463],{"nctId":5962,"briefTitle":5963,"status":107,"phases":49916,"primaryCompletion":5965,"completion":5966,"start":5967,"enrollment":5968,"conditions":49917,"interventions":49918},[93],[18],[5860,5959,5960,5832],{"nctId":49920,"briefTitle":49921,"status":107,"phases":49922,"primaryCompletion":49923,"completion":49923,"start":49924,"enrollment":49925,"conditions":49926,"interventions":49927},"NCT00144196","12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)",[93],"2005-07-25","2004-03-11",224,[18],[5899],{"nctId":8885,"briefTitle":8886,"status":107,"phases":49929,"primaryCompletion":8888,"start":8889,"enrollment":7301,"conditions":49930,"interventions":49931},[93],[18],[5899,8872],{"nctId":49933,"briefTitle":49934,"status":107,"phases":49935,"primaryCompletion":390,"completion":390,"start":17427,"enrollment":22,"conditions":49936,"interventions":49937},"NCT01072396","Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease",[93],[18],[5860],{"nctId":49939,"briefTitle":49940,"status":107,"phases":49941,"primaryCompletion":1967,"start":6155,"enrollment":49942,"conditions":49943,"interventions":49944},"NCT00523991","Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).",[93],457,[18],[5899],{"nctId":9064,"briefTitle":9065,"status":107,"phases":49946,"primaryCompletion":9067,"completion":9068,"start":9069,"enrollment":9070,"conditions":49947,"interventions":49948},[93],[18],[9051,5860,5959],{"trials":49950,"activeCount":101},[49951,49958,49965,49972,49981,49988,49998],{"nctId":49952,"briefTitle":49953,"status":107,"phases":49954,"primaryCompletion":6472,"start":6375,"enrollment":49955,"conditions":49956,"interventions":49957},"NCT02196194","A Prescription-Event Monitoring (PEM) Study of Tiotropium",[],13891,[18],[5860],{"nctId":49959,"briefTitle":49960,"status":107,"phases":49961,"primaryCompletion":3732,"start":19461,"enrollment":49962,"conditions":49963,"interventions":49964},"NCT00624377","Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice",[],2031,[18],[5860],{"nctId":49966,"briefTitle":49967,"status":107,"phases":49968,"primaryCompletion":6471,"start":6155,"enrollment":49969,"conditions":49970,"interventions":49971},"NCT00615992","Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines",[],754,[18],[5860],{"nctId":49973,"briefTitle":49974,"status":107,"phases":49975,"primaryCompletion":49976,"completion":49976,"start":5433,"enrollment":49977,"conditions":49978,"interventions":49979},"NCT04249310","Early Intervention Efficacy in COPD",[],"2020-08-12",6788,[18],[49980,5860],"Tiotropium\u002FOlodaterol",{"nctId":49982,"briefTitle":49983,"status":107,"phases":49984,"primaryCompletion":4507,"start":6116,"enrollment":49985,"conditions":49986,"interventions":49987},"NCT02172560","A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler",[],441,[18],[5860],{"nctId":49989,"briefTitle":49990,"status":107,"phases":49991,"primaryCompletion":49992,"completion":49992,"start":49993,"enrollment":2102,"conditions":49994,"interventions":49995},"NCT05501639","Exacerbation Risk in Asthma",[],"2021-11-02","2021-05-14",[30],[5899,49996,49997],"long-acting β2-agonists","inhaled corticosteroids",{"nctId":49999,"briefTitle":50000,"status":107,"phases":50001,"primaryCompletion":50002,"completion":50002,"start":18912,"enrollment":50003,"conditions":50004,"interventions":50005},"NCT05402020","Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan",[],"2023-02-13",17018,[18],[5860,50006,5959,50007],"Inhaled corticosteroids","Long-acting β2-agonists",{"intervention":361,"totalTrials":2789,"cells":50009},{"EARLY_PHASE1":50010,"PHASE1":50012,"PHASE2":50076,"PHASE3":50086,"PHASE4":50188,"NA":50215},{"trials":50011,"activeCount":101},[],{"trials":50013,"activeCount":101},[50014,50018,50022,50026,50030,50034,50038,50042,50046,50050,50054,50058,50062,50066,50072],{"nctId":27476,"briefTitle":27477,"status":107,"phases":50015,"primaryCompletion":4392,"start":6811,"enrollment":8,"conditions":50016,"interventions":50017},[90],[15],[27469,361,413],{"nctId":28172,"briefTitle":28173,"status":107,"phases":50019,"primaryCompletion":456,"completion":456,"start":4038,"enrollment":132,"conditions":50020,"interventions":50021},[90],[15],[28165,413,361],{"nctId":352,"briefTitle":353,"status":107,"phases":50023,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":50024,"interventions":50025},[90],[15],[360,73,361,362],{"nctId":27260,"briefTitle":27261,"status":107,"phases":50027,"primaryCompletion":9443,"start":400,"enrollment":401,"conditions":50028,"interventions":50029},[90],[15],[460,361],{"nctId":9372,"briefTitle":9373,"status":107,"phases":50031,"primaryCompletion":400,"start":3991,"enrollment":401,"conditions":50032,"interventions":50033},[90],[15],[528,361],{"nctId":30211,"briefTitle":30212,"status":107,"phases":50035,"primaryCompletion":5233,"completion":5233,"start":10024,"enrollment":2400,"conditions":50036,"interventions":50037},[90],[15],[30204,361,30216],{"nctId":27489,"briefTitle":27490,"status":107,"phases":50039,"primaryCompletion":4392,"start":6811,"enrollment":8,"conditions":50040,"interventions":50041},[90],[15],[27469,361,413],{"nctId":27919,"briefTitle":27920,"status":107,"phases":50043,"primaryCompletion":9381,"start":3990,"enrollment":291,"conditions":50044,"interventions":50045},[90],[15],[27924,27925,361,27926],{"nctId":27495,"briefTitle":27496,"status":107,"phases":50047,"primaryCompletion":5233,"completion":5233,"start":10024,"enrollment":6702,"conditions":50048,"interventions":50049},[90],[15],[361,413,27469],{"nctId":425,"briefTitle":426,"status":107,"phases":50051,"primaryCompletion":428,"completion":428,"start":429,"enrollment":357,"conditions":50052,"interventions":50053},[90],[15],[432,73,361,362],{"nctId":27501,"briefTitle":27502,"status":107,"phases":50055,"primaryCompletion":3732,"start":6811,"enrollment":10951,"conditions":50056,"interventions":50057},[90],[15],[27469,361,413],{"nctId":10464,"briefTitle":10465,"status":107,"phases":50059,"primaryCompletion":4473,"completion":4473,"start":517,"enrollment":331,"conditions":50060,"interventions":50061},[90],[21],[361,6659],{"nctId":30218,"briefTitle":30219,"status":107,"phases":50063,"primaryCompletion":5233,"completion":5233,"start":9842,"enrollment":6702,"conditions":50064,"interventions":50065},[90],[15],[361,30204,30216],{"nctId":50067,"briefTitle":50068,"status":107,"phases":50069,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":448,"conditions":50070,"interventions":50071},"NCT01947153","Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.",[90],[15],[413,361,413,361],{"nctId":479,"briefTitle":480,"status":107,"phases":50073,"primaryCompletion":482,"completion":483,"start":484,"enrollment":37,"conditions":50074,"interventions":50075},[90],[15],[73,361],{"trials":50077,"activeCount":101},[50078,50082],{"nctId":10772,"briefTitle":10773,"status":107,"phases":50079,"primaryCompletion":10775,"start":6224,"enrollment":10776,"conditions":50080,"interventions":50081},[91],[21],[606,361],{"nctId":10472,"briefTitle":10473,"status":107,"phases":50083,"primaryCompletion":3763,"start":6156,"enrollment":7429,"conditions":50084,"interventions":50085},[91],[21],[361,361,361,6659],{"trials":50087,"activeCount":101},[50088,50092,50096,50103,50110,50117,50124,50128,50132,50138,50142,50148,50155,50162,50166,50170,50177,50181],{"nctId":577,"briefTitle":578,"status":107,"phases":50089,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":50090,"interventions":50091},[92],[21],[413,586,361,73],{"nctId":10480,"briefTitle":10481,"status":107,"phases":50093,"primaryCompletion":2506,"start":3732,"enrollment":10483,"conditions":50094,"interventions":50095},[92],[21],[6659,361],{"nctId":50097,"briefTitle":50098,"status":107,"phases":50099,"primaryCompletion":7338,"completion":7338,"start":7703,"enrollment":50100,"conditions":50101,"interventions":50102},"NCT01204294","Comprehensive Add on Study in Japan",[92],574,[21],[361,361,413,413,361,361,361],{"nctId":50104,"briefTitle":50105,"status":107,"phases":50106,"primaryCompletion":9411,"start":4129,"enrollment":50107,"conditions":50108,"interventions":50109},"NCT00602472","BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes",[92],1058,[21],[6633],{"nctId":50111,"briefTitle":50112,"status":107,"phases":50113,"primaryCompletion":5296,"start":3990,"enrollment":50114,"conditions":50115,"interventions":50116},"NCT00954447","Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes",[92],1263,[21],[361],{"nctId":50118,"briefTitle":50119,"status":107,"phases":50120,"primaryCompletion":9411,"start":4129,"enrollment":50121,"conditions":50122,"interventions":50123},"NCT00621140","Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control",[92],503,[21],[6633],{"nctId":6625,"briefTitle":6626,"status":107,"phases":50125,"primaryCompletion":6628,"completion":6628,"start":6629,"enrollment":6630,"conditions":50126,"interventions":50127},[92],[21],[6633,6634,6614,6635],{"nctId":6637,"briefTitle":6638,"status":107,"phases":50129,"primaryCompletion":6640,"completion":6641,"start":6642,"enrollment":6643,"conditions":50130,"interventions":50131},[92],[21],[361,6646,6647,6648,6649,6650],{"nctId":50133,"briefTitle":50134,"status":107,"phases":50135,"primaryCompletion":2506,"start":12600,"enrollment":2858,"conditions":50136,"interventions":50137},"NCT01214239","Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control",[92],[21],[361],{"nctId":6652,"briefTitle":6653,"status":107,"phases":50139,"primaryCompletion":4442,"start":6223,"enrollment":6655,"conditions":50140,"interventions":50141},[92],[21],[361,6658,6659],{"nctId":50143,"briefTitle":50144,"status":107,"phases":50145,"primaryCompletion":2030,"start":3732,"enrollment":10483,"conditions":50146,"interventions":50147},"NCT01084005","Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes",[92],[21],[6633],{"nctId":50149,"briefTitle":50150,"status":107,"phases":50151,"primaryCompletion":391,"completion":391,"start":7703,"enrollment":50152,"conditions":50153,"interventions":50154},"NCT01194830","Efficacy and Safety of Linagliptin (BI 1356) in Black\u002FAfrican Americans With Type 2 Diabetes With a MTT Sub-study",[92],234,[21],[361],{"nctId":50156,"briefTitle":50157,"status":107,"phases":50158,"primaryCompletion":4038,"completion":4038,"start":12600,"enrollment":50159,"conditions":50160,"interventions":50161},"NCT01215097","Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy",[92],306,[21],[361],{"nctId":6661,"briefTitle":6662,"status":107,"phases":50163,"primaryCompletion":611,"completion":611,"start":2648,"enrollment":6664,"conditions":50164,"interventions":50165},[92],[21],[6667,6668,6669,6670,6669,6669,6670,6670,6671,6672,6669,6673,6671,6671,6633,6670,6614,6674,6614,6675,6614,6671,6674,6675,6614],{"nctId":18000,"briefTitle":18001,"status":107,"phases":50167,"primaryCompletion":18003,"completion":18003,"start":18004,"enrollment":18005,"conditions":50168,"interventions":50169},[92],[21],[361,17989,17989,17989,18008,17989],{"nctId":50171,"briefTitle":50172,"status":107,"phases":50173,"primaryCompletion":9411,"start":4507,"enrollment":50174,"conditions":50175,"interventions":50176},"NCT00601250","Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes",[92],701,[21],[6633,6633],{"nctId":18374,"briefTitle":18375,"status":107,"phases":50178,"primaryCompletion":18377,"completion":18378,"start":18379,"enrollment":18380,"conditions":50179,"interventions":50180},[92],[21],[6633,18363],{"nctId":50182,"briefTitle":50183,"status":107,"phases":50184,"primaryCompletion":3753,"start":9443,"enrollment":50185,"conditions":50186,"interventions":50187},"NCT00996658","Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone",[92],278,[21],[361],{"trials":50189,"activeCount":101},[50190,50194,50198,50206],{"nctId":6679,"briefTitle":6680,"status":107,"phases":50191,"primaryCompletion":409,"completion":409,"start":390,"enrollment":6682,"conditions":50192,"interventions":50193},[93],[21],[6685,6614,384,384,6633],{"nctId":7335,"briefTitle":7336,"status":107,"phases":50195,"primaryCompletion":379,"completion":379,"start":7338,"enrollment":7339,"conditions":50196,"interventions":50197},[93],[21],[384,6633,6685,6685],{"nctId":50199,"briefTitle":50200,"status":107,"phases":50201,"primaryCompletion":754,"completion":50202,"start":50203,"enrollment":5968,"conditions":50204,"interventions":50205},"NCT02240680","Linagliptin as Add on to Basal Insulin in the Elderly",[93],"2017-04-25","2014-09-23",[21],[6633],{"nctId":50207,"briefTitle":50208,"status":107,"phases":50209,"primaryCompletion":50210,"completion":50210,"start":50211,"enrollment":50212,"conditions":50213,"interventions":50214},"NCT01897532","Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)",[93],"2018-01-18","2013-07-10",6991,[21],[361],{"trials":50216,"activeCount":101},[50217,50224,50233,50239],{"nctId":50218,"briefTitle":50219,"status":107,"phases":50220,"primaryCompletion":4120,"completion":4120,"start":9842,"enrollment":50221,"conditions":50222,"interventions":50223},"NCT02140645","Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy",[],166613,[21],[6633],{"nctId":50225,"briefTitle":50226,"status":107,"phases":50227,"primaryCompletion":50228,"completion":50228,"start":50229,"enrollment":50230,"conditions":50231,"interventions":50232},"NCT03338803","Real World Glycemic Effectiveness of Linagliptin",[],"2018-02-02","2017-11-21",11001,[21],[361],{"nctId":50234,"briefTitle":50235,"status":162,"phases":50236,"primaryCompletion":4474,"completion":4474,"start":2506,"enrollment":7196,"conditions":50237,"interventions":50238},"NCT01826370","Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus",[],[21],[361],{"nctId":50240,"briefTitle":50241,"status":162,"phases":50242,"primaryCompletion":50243,"completion":50243,"start":50244,"enrollment":1468,"conditions":50245,"interventions":50246},"NCT04180813","Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose",[],"2021-07-11","2020-03-04",[21],[361,27773],{"intervention":4010,"totalTrials":2789,"cells":50248},{"EARLY_PHASE1":50249,"PHASE1":50251,"PHASE2":50387,"PHASE3":50413,"PHASE4":50433,"NA":50435},{"trials":50250,"activeCount":101},[],{"trials":50252,"activeCount":101},[50253,50261,50267,50271,50277,50283,50287,50291,50295,50299,50303,50307,50311,50315,50319,50323,50327,50331,50335,50339,50343,50347,50351,50355,50359,50363,50367,50371,50375,50379,50383],{"nctId":50254,"briefTitle":50255,"status":107,"phases":50256,"primaryCompletion":50257,"start":50258,"enrollment":380,"conditions":50259,"interventions":50260},"NCT02249442","Study to Determine the Pharmacokinetics on TPV\u002Fr in Subjects With Mild and Moderate Hepatic Insufficiency",[90],"2004-06-01","2003-10-01",[2526],[4008,4010],{"nctId":50262,"briefTitle":50263,"status":107,"phases":50264,"primaryCompletion":7151,"start":5842,"enrollment":956,"conditions":50265,"interventions":50266},"NCT02253875","Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers",[90],[15],[4008,4010,4013],{"nctId":9749,"briefTitle":9750,"status":107,"phases":50268,"primaryCompletion":9752,"start":2030,"enrollment":177,"conditions":50269,"interventions":50270},[90],[27],[6505,4010,4042],{"nctId":50272,"briefTitle":50273,"status":107,"phases":50274,"primaryCompletion":9381,"start":400,"enrollment":210,"conditions":50275,"interventions":50276},"NCT02171754","Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers",[90],[15],[1129,4010],{"nctId":50278,"briefTitle":50279,"status":107,"phases":50280,"primaryCompletion":5906,"start":6471,"enrollment":132,"conditions":50281,"interventions":50282},"NCT02244190","Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers",[90],[15],[4008,4008,4010],{"nctId":11639,"briefTitle":11640,"status":107,"phases":50284,"primaryCompletion":11642,"start":6782,"enrollment":3454,"conditions":50285,"interventions":50286},[90],[15],[4008,4010,11632],{"nctId":28671,"briefTitle":28672,"status":107,"phases":50288,"primaryCompletion":2111,"start":5842,"enrollment":1865,"conditions":50289,"interventions":50290},[90],[15],[987,4008,4010],{"nctId":4002,"briefTitle":4003,"status":107,"phases":50292,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":50293,"interventions":50294},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":19588,"briefTitle":19589,"status":107,"phases":50296,"primaryCompletion":7300,"start":7618,"enrollment":5205,"conditions":50297,"interventions":50298},[90],[15],[11653,19593,4010],{"nctId":35756,"briefTitle":35757,"status":107,"phases":50300,"primaryCompletion":11588,"start":4498,"enrollment":410,"conditions":50301,"interventions":50302},[90],[15],[35749,35761,35762,35763,4010],{"nctId":19595,"briefTitle":19596,"status":107,"phases":50304,"primaryCompletion":1115,"start":11581,"enrollment":1237,"conditions":50305,"interventions":50306},[90],[15],[11653,4010,19600],{"nctId":37299,"briefTitle":37300,"status":107,"phases":50308,"primaryCompletion":11649,"start":6082,"enrollment":31,"conditions":50309,"interventions":50310},[90],[15],[37292,37304,37305,37306,37307,37308,37309,37310,37311,4010],{"nctId":37726,"briefTitle":37727,"status":107,"phases":50312,"primaryCompletion":1114,"start":9902,"enrollment":993,"conditions":50313,"interventions":50314},[90],[15],[4008,4010,37719],{"nctId":37944,"briefTitle":37945,"status":107,"phases":50316,"primaryCompletion":2145,"start":6156,"enrollment":1237,"conditions":50317,"interventions":50318},[90],[15],[4008,4010,37937],{"nctId":38278,"briefTitle":38279,"status":107,"phases":50320,"primaryCompletion":5879,"start":5879,"conditions":50321,"interventions":50322},[90],[15],[38271,4008,4010],{"nctId":38557,"briefTitle":38558,"status":107,"phases":50324,"primaryCompletion":4461,"start":4462,"enrollment":5242,"conditions":50325,"interventions":50326},[90],[15],[38550,4008,4010],{"nctId":12393,"briefTitle":12394,"status":107,"phases":50328,"primaryCompletion":7574,"start":6495,"enrollment":380,"conditions":50329,"interventions":50330},[90],[15],[4008,4010,12398],{"nctId":39830,"briefTitle":39831,"status":107,"phases":50332,"primaryCompletion":6413,"start":11733,"enrollment":1218,"conditions":50333,"interventions":50334},[90],[15],[39823,39835,4010],{"nctId":40477,"briefTitle":40478,"status":107,"phases":50336,"primaryCompletion":1115,"start":7300,"enrollment":357,"conditions":50337,"interventions":50338},[90],[15],[40470,40482,4010],{"nctId":42152,"briefTitle":42153,"status":107,"phases":50340,"primaryCompletion":20181,"start":1990,"enrollment":2382,"conditions":50341,"interventions":50342},[90],[15],[42145,42157,42158,42159,42160,4010],{"nctId":29044,"briefTitle":29045,"status":107,"phases":50344,"primaryCompletion":5869,"start":6472,"enrollment":380,"conditions":50345,"interventions":50346},[90],[15],[4008,4010,29031],{"nctId":7538,"briefTitle":7539,"status":107,"phases":50348,"primaryCompletion":6374,"start":6472,"enrollment":380,"conditions":50349,"interventions":50350},[90],[15],[4008,4010,7531],{"nctId":43173,"briefTitle":43174,"status":107,"phases":50352,"primaryCompletion":17247,"start":6782,"enrollment":956,"conditions":50353,"interventions":50354},[90],[15],[4008,4010,43166],{"nctId":11646,"briefTitle":11647,"status":107,"phases":50356,"primaryCompletion":11649,"start":11650,"enrollment":1891,"conditions":50357,"interventions":50358},[90],[15],[11653,11654,11632,4010],{"nctId":45453,"briefTitle":45454,"status":107,"phases":50360,"primaryCompletion":1981,"start":1115,"enrollment":3791,"conditions":50361,"interventions":50362},[90],[15],[45446,45458,45459,45460,45461,45462,4010],{"nctId":10073,"briefTitle":10074,"status":107,"phases":50364,"primaryCompletion":10076,"start":10077,"enrollment":448,"conditions":50365,"interventions":50366},[90],[2526],[4008,4010,10080,9801],{"nctId":19614,"briefTitle":19615,"status":107,"phases":50368,"primaryCompletion":7300,"start":15139,"enrollment":1116,"conditions":50369,"interventions":50370},[90],[15],[11653,4010,19619],{"nctId":29130,"briefTitle":29131,"status":107,"phases":50372,"primaryCompletion":6374,"start":5879,"enrollment":97,"conditions":50373,"interventions":50374},[90],[15],[4008,4010,10041,29135],{"nctId":9925,"briefTitle":9926,"status":107,"phases":50376,"primaryCompletion":4413,"start":6471,"enrollment":188,"conditions":50377,"interventions":50378},[90],[15],[9872,4010],{"nctId":6500,"briefTitle":6501,"status":107,"phases":50380,"primaryCompletion":4413,"start":3763,"enrollment":342,"conditions":50381,"interventions":50382},[90],[15],[4008,4010,6505,6484],{"nctId":6868,"briefTitle":6869,"status":107,"phases":50384,"primaryCompletion":5879,"start":6871,"enrollment":1672,"conditions":50385,"interventions":50386},[90],[15],[4008,4010,6845],{"trials":50388,"activeCount":101},[50389,50393,50397,50401,50407],{"nctId":10863,"briefTitle":10864,"status":107,"phases":50390,"primaryCompletion":2163,"start":6453,"enrollment":392,"conditions":50391,"interventions":50392},[91],[27],[4008,4010,10868,7579,10854,10869],{"nctId":20779,"briefTitle":20780,"status":107,"phases":50394,"primaryCompletion":6584,"start":6438,"enrollment":1991,"conditions":50395,"interventions":50396},[91],[27],[20745,20758,4010,20784,20785],{"nctId":21890,"briefTitle":21891,"status":107,"phases":50398,"primaryCompletion":21893,"start":21894,"enrollment":11245,"conditions":50399,"interventions":50400},[91],[27],[18356,18357,21881,21897,21898],{"nctId":50402,"briefTitle":50403,"status":107,"phases":50404,"primaryCompletion":5906,"start":4516,"enrollment":1468,"conditions":50405,"interventions":50406},"NCT00530920","Tipranavir\u002FRitonavir Low Dose Pharmacokinetics in Treatment Naive Patients",[91],[27],[18356,18357],{"nctId":50408,"briefTitle":50409,"status":162,"phases":50410,"primaryCompletion":6140,"start":11588,"enrollment":1044,"conditions":50411,"interventions":50412},"NCT02229760","Effect of Steady State TPV\u002Fr on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV",[90,91],[27],[4008,4010],{"trials":50414,"activeCount":101},[50415,50419,50423,50429],{"nctId":12510,"briefTitle":12511,"status":107,"phases":50416,"primaryCompletion":5856,"start":7574,"enrollment":12513,"conditions":50417,"interventions":50418},[92],[27],[4008,4010,12499],{"nctId":11513,"briefTitle":11514,"status":162,"phases":50420,"primaryCompletion":5856,"start":6140,"enrollment":2382,"conditions":50421,"interventions":50422},[92],[27],[4008,6505,4010],{"nctId":50424,"briefTitle":50425,"status":162,"phases":50426,"primaryCompletion":4412,"start":6116,"enrollment":281,"conditions":50427,"interventions":50428},"NCT00447902","Safety and Antiviral Activity of TPV in HCV and\u002For HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation",[92],[27],[18356,18357],{"nctId":18351,"briefTitle":18352,"status":162,"phases":50430,"primaryCompletion":4412,"start":9902,"enrollment":1116,"conditions":50431,"interventions":50432},[92],[27],[18356,18357,18340],{"trials":50434,"activeCount":101},[],{"trials":50436,"activeCount":101},[50437,50443,50449],{"nctId":50438,"briefTitle":50439,"status":107,"phases":50440,"primaryCompletion":9752,"completion":9752,"start":400,"enrollment":331,"conditions":50441,"interventions":50442},"NCT00976950","A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.",[],[27],[4008,18357],{"nctId":50444,"briefTitle":50445,"status":5515,"phases":50446,"primaryCompletion":3978,"start":6413,"conditions":50447,"interventions":50448},"NCT00097799","Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection",[],[27],[4008,4010],{"nctId":50450,"briefTitle":50451,"status":107,"phases":50452,"primaryCompletion":2649,"start":11588,"enrollment":7524,"conditions":50453,"interventions":50454},"NCT00531206","Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.",[],[27],[4008,4010],{"intervention":6561,"totalTrials":2789,"cells":50456},{"EARLY_PHASE1":50457,"PHASE1":50459,"PHASE2":50578,"PHASE3":50628,"PHASE4":50673,"NA":50684},{"trials":50458,"activeCount":101},[],{"trials":50460,"activeCount":101},[50461,50465,50469,50477,50481,50485,50491,50495,50501,50507,50514,50518,50522,50526,50533,50537,50541,50545,50552,50558,50562,50566,50570,50574],{"nctId":29316,"briefTitle":29317,"status":107,"phases":50462,"primaryCompletion":456,"completion":456,"start":2506,"enrollment":448,"conditions":50463,"interventions":50464},[90],[15],[1685,29309,29309,1685,1685],{"nctId":34240,"briefTitle":34241,"status":107,"phases":50466,"primaryCompletion":34243,"completion":34244,"start":154,"enrollment":448,"conditions":50467,"interventions":50468},[90],[19351],[34247,34233],{"nctId":50470,"briefTitle":50471,"status":107,"phases":50472,"primaryCompletion":723,"completion":723,"start":50473,"enrollment":188,"conditions":50474,"interventions":50475},"NCT03086356","Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State",[90],"2017-05-10",[10409],[6561,50476],"Idarucizumab",{"nctId":6556,"briefTitle":6557,"status":107,"phases":50478,"primaryCompletion":2145,"start":4498,"enrollment":380,"conditions":50479,"interventions":50480},[90],[15],[6561,6549],{"nctId":34843,"briefTitle":34844,"status":107,"phases":50482,"primaryCompletion":2111,"start":6156,"enrollment":380,"conditions":50483,"interventions":50484},[90],[15],[6561,34836],{"nctId":50486,"briefTitle":50487,"status":107,"phases":50488,"primaryCompletion":10024,"completion":10024,"start":4473,"enrollment":1631,"conditions":50489,"interventions":50490},"NCT02044367","Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers",[90],[15],[6561,6561,6561],{"nctId":27388,"briefTitle":27389,"status":107,"phases":50492,"primaryCompletion":3991,"start":5905,"enrollment":380,"conditions":50493,"interventions":50494},[90],[15],[6561,5264],{"nctId":50496,"briefTitle":50497,"status":107,"phases":50498,"primaryCompletion":11588,"start":2111,"enrollment":380,"conditions":50499,"interventions":50500},"NCT02171052","Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers",[90],[15],[6561,2393],{"nctId":50502,"briefTitle":50503,"status":107,"phases":50504,"primaryCompletion":4462,"start":11642,"enrollment":380,"conditions":50505,"interventions":50506},"NCT02170571","Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function",[90],[2526],[6561],{"nctId":50508,"briefTitle":50509,"status":107,"phases":50510,"primaryCompletion":7508,"completion":18902,"start":50511,"enrollment":9807,"conditions":50512,"interventions":50513},"NCT03070171","Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects",[90],"2017-03-21",[15],[1685],{"nctId":29322,"briefTitle":29323,"status":107,"phases":50515,"primaryCompletion":525,"completion":525,"start":446,"enrollment":410,"conditions":50516,"interventions":50517},[90],[15],[1685,1685,29327,29327,29327,1685],{"nctId":27270,"briefTitle":27271,"status":107,"phases":50519,"primaryCompletion":3991,"start":5905,"enrollment":380,"conditions":50520,"interventions":50521},[90],[15],[6561,460],{"nctId":40334,"briefTitle":40335,"status":107,"phases":50523,"primaryCompletion":9348,"start":9332,"enrollment":448,"conditions":50524,"interventions":50525},[90],[15],[40327,6561,40327,40327,40327],{"nctId":50527,"briefTitle":50528,"status":107,"phases":50529,"primaryCompletion":516,"completion":516,"start":517,"enrollment":2442,"conditions":50530,"interventions":50532},"NCT01711853","Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.",[90],[50531],"Renal Insufficiency, Chronic",[34247],{"nctId":40880,"briefTitle":40881,"status":162,"phases":50534,"primaryCompletion":4507,"start":9418,"enrollment":331,"conditions":50535,"interventions":50536},[90],[15],[6561,40873,40885],{"nctId":40959,"briefTitle":40960,"status":107,"phases":50538,"primaryCompletion":9411,"start":2003,"enrollment":357,"conditions":50539,"interventions":50540},[90],[15],[40952,40964,6561],{"nctId":29038,"briefTitle":29039,"status":107,"phases":50542,"primaryCompletion":6223,"start":4413,"enrollment":1672,"conditions":50543,"interventions":50544},[90],[15],[6561,29031],{"nctId":50546,"briefTitle":50547,"status":107,"phases":50548,"primaryCompletion":9348,"start":4441,"enrollment":112,"conditions":50549,"interventions":50551},"NCT01241539","Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis",[90],[662,50550],"Kidney Failure, Chronic",[6561,6561,6561],{"nctId":50553,"briefTitle":50554,"status":107,"phases":50555,"primaryCompletion":9340,"start":6133,"enrollment":5466,"conditions":50556,"interventions":50557},"NCT01290757","Bioequivalence of Two Different Capsule Types of Dabigatran",[90],[15],[6561,6561],{"nctId":46820,"briefTitle":46821,"status":107,"phases":50559,"primaryCompletion":228,"completion":228,"start":46823,"enrollment":1865,"conditions":50560,"interventions":50561},[90],[15],[969,46813,6561,46826],{"nctId":47159,"briefTitle":47160,"status":107,"phases":50563,"primaryCompletion":5856,"start":6223,"enrollment":993,"conditions":50564,"interventions":50565},[90],[15],[47152,6561],{"nctId":1677,"briefTitle":1678,"status":107,"phases":50567,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":177,"conditions":50568,"interventions":50569},[90],[15],[1685,1595],{"nctId":48045,"briefTitle":48046,"status":107,"phases":50571,"primaryCompletion":48048,"completion":48049,"start":28294,"enrollment":1418,"conditions":50572,"interventions":50573},[90],[15],[48038,48052,48053,48054,48055,6561],{"nctId":48651,"briefTitle":48652,"status":107,"phases":50575,"primaryCompletion":9404,"start":2003,"enrollment":331,"conditions":50576,"interventions":50577},[90],[15],[1685,48644],{"trials":50579,"activeCount":101},[50580,50588,50596,50602,50609,50615,50622],{"nctId":50581,"briefTitle":50582,"status":107,"phases":50583,"primaryCompletion":4517,"start":5843,"enrollment":50584,"conditions":50585,"interventions":50587},"NCT00246025","A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.",[91],512,[10350,50586],"Venous Thrombosis",[6561,6561,34247],{"nctId":50589,"briefTitle":50590,"status":107,"phases":50591,"primaryCompletion":9443,"start":4128,"enrollment":50592,"conditions":50593,"interventions":50595},"NCT00621855","RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome",[91],1878,[50594],"Coronary Disease",[1685,1685,1685,1685],{"nctId":50597,"briefTitle":50598,"status":107,"phases":50599,"primaryCompletion":5283,"completion":5283,"start":3732,"enrollment":392,"conditions":50600,"interventions":50601},"NCT01083732","Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to \u003C 12 Years of Age",[91],[10299],[1685],{"nctId":50603,"briefTitle":50604,"status":162,"phases":50605,"primaryCompletion":2649,"start":11649,"enrollment":50606,"conditions":50607,"interventions":50608},"NCT00157248","Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048",[91],361,[6098,2092],[1685,1685,1685,1685],{"nctId":50610,"briefTitle":50611,"status":107,"phases":50612,"primaryCompletion":6911,"start":5842,"enrollment":12724,"conditions":50613,"interventions":50614},"NCT01136408","A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin",[91],[6098],[6561,6561,4094],{"nctId":50616,"briefTitle":50617,"status":107,"phases":50618,"primaryCompletion":18735,"start":50619,"enrollment":1340,"conditions":50620,"interventions":50621},"NCT00844415","Safety and Tolerability of Dabigatran Etexilate in Adolescents",[91],"2009-06-01",[10299],[1685],{"nctId":50623,"briefTitle":50624,"status":600,"phases":50625,"primaryCompletion":2031,"completion":2031,"start":3730,"enrollment":101,"conditions":50626,"interventions":50627},"NCT01773174","Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to \u003C 2 Years of Age",[91],[10299],[1685],{"trials":50629,"activeCount":101},[50630,50638,50642,50646,50650,50657,50661,50665],{"nctId":50631,"briefTitle":50632,"status":107,"phases":50633,"primaryCompletion":17709,"completion":50634,"start":50635,"enrollment":5680,"conditions":50636,"interventions":50637},"NCT02197416","Safety of Dabigatran Etexilate in Blood Clot Prevention in Children",[92],"2019-11-19","2014-09-29",[10299,16151],[1685],{"nctId":16144,"briefTitle":16145,"status":107,"phases":50639,"primaryCompletion":16147,"completion":16147,"start":16148,"enrollment":16149,"conditions":50640,"interventions":50641},[92],[2092,16151],[16133,16153,1685],{"nctId":10320,"briefTitle":10321,"status":107,"phases":50643,"primaryCompletion":400,"start":4128,"enrollment":10323,"conditions":50644,"interventions":50645},[92],[10299],[10285,6561],{"nctId":10327,"briefTitle":10328,"status":107,"phases":50647,"primaryCompletion":2145,"start":8086,"enrollment":10330,"conditions":50648,"interventions":50649},[92],[10332,10333],[1685,1685,2105],{"nctId":50651,"briefTitle":50652,"status":107,"phases":50653,"primaryCompletion":9348,"start":6471,"enrollment":50654,"conditions":50655,"interventions":50656},"NCT00680186","Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)",[92],2589,[10332],[4094,6561],{"nctId":17706,"briefTitle":17707,"status":107,"phases":50658,"primaryCompletion":17709,"completion":17710,"start":17711,"enrollment":17712,"conditions":50659,"interventions":50660},[92],[10299],[1685,17695],{"nctId":10345,"briefTitle":10346,"status":107,"phases":50662,"primaryCompletion":4498,"start":8086,"enrollment":10348,"conditions":50663,"interventions":50664},[92],[10350,10332],[2105,1685,1685],{"nctId":50666,"briefTitle":50667,"status":107,"phases":50668,"primaryCompletion":50669,"completion":50669,"start":50670,"enrollment":641,"conditions":50671,"interventions":50672},"NCT02913326","A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)",[92],"2018-06-22","2016-12-13",[10332],[6561,4094],{"trials":50674,"activeCount":101},[50675],{"nctId":50676,"briefTitle":50677,"status":107,"phases":50678,"primaryCompletion":379,"completion":379,"start":4442,"enrollment":4815,"conditions":50679,"interventions":50683},"NCT01184989","Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate",[93],[50680,50681,50682],"Arthroplasty, Replacement","Prevention of Venous Thromboembolism","Moderate Renal Impairment (CrCl 30-50 mL\u002FMin)",[6561],{"trials":50685,"activeCount":101},[50686,50696,50702],{"nctId":50687,"briefTitle":50688,"status":107,"phases":50689,"primaryCompletion":50690,"completion":50690,"start":50691,"enrollment":50692,"conditions":50693,"interventions":50694},"NCT02240667","Drug Persistence\u002FAdherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)",[],"2017-12-31","2014-09-18",1506,[6098],[6561,50695],"Vitamin K antagonists",{"nctId":50697,"briefTitle":50698,"status":600,"phases":50699,"primaryCompletion":1236,"completion":1236,"start":10517,"enrollment":101,"conditions":50700,"interventions":50701},"NCT05536791","A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot",[],[10299],[34247],{"nctId":50703,"briefTitle":50704,"status":107,"phases":50705,"primaryCompletion":50706,"completion":50706,"start":50707,"enrollment":50708,"conditions":50709,"interventions":50710},"NCT03006341","Validation of Predictors of OAC Initiation Using EMR Data",[],"2017-05-09","2017-02-28",140187,[6098],[6561,4094],{"intervention":4008,"totalTrials":2887,"cells":50712},{"EARLY_PHASE1":50713,"PHASE1":50715,"PHASE2":50797,"PHASE3":50824,"PHASE4":50853,"NA":50855},{"trials":50714,"activeCount":101},[],{"trials":50716,"activeCount":101},[50717,50721,50725,50729,50733,50737,50741,50745,50749,50753,50757,50761,50765,50769,50773,50777,50781,50785,50789,50793],{"nctId":50254,"briefTitle":50255,"status":107,"phases":50718,"primaryCompletion":50257,"start":50258,"enrollment":380,"conditions":50719,"interventions":50720},[90],[2526],[4008,4010],{"nctId":50262,"briefTitle":50263,"status":107,"phases":50722,"primaryCompletion":7151,"start":5842,"enrollment":956,"conditions":50723,"interventions":50724},[90],[15],[4008,4010,4013],{"nctId":50278,"briefTitle":50279,"status":107,"phases":50726,"primaryCompletion":5906,"start":6471,"enrollment":132,"conditions":50727,"interventions":50728},[90],[15],[4008,4008,4010],{"nctId":11639,"briefTitle":11640,"status":107,"phases":50730,"primaryCompletion":11642,"start":6782,"enrollment":3454,"conditions":50731,"interventions":50732},[90],[15],[4008,4010,11632],{"nctId":28671,"briefTitle":28672,"status":107,"phases":50734,"primaryCompletion":2111,"start":5842,"enrollment":1865,"conditions":50735,"interventions":50736},[90],[15],[987,4008,4010],{"nctId":4002,"briefTitle":4003,"status":107,"phases":50738,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":50739,"interventions":50740},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":37726,"briefTitle":37727,"status":107,"phases":50742,"primaryCompletion":1114,"start":9902,"enrollment":993,"conditions":50743,"interventions":50744},[90],[15],[4008,4010,37719],{"nctId":37944,"briefTitle":37945,"status":107,"phases":50746,"primaryCompletion":2145,"start":6156,"enrollment":1237,"conditions":50747,"interventions":50748},[90],[15],[4008,4010,37937],{"nctId":38278,"briefTitle":38279,"status":107,"phases":50750,"primaryCompletion":5879,"start":5879,"conditions":50751,"interventions":50752},[90],[15],[38271,4008,4010],{"nctId":38557,"briefTitle":38558,"status":107,"phases":50754,"primaryCompletion":4461,"start":4462,"enrollment":5242,"conditions":50755,"interventions":50756},[90],[15],[38550,4008,4010],{"nctId":12393,"briefTitle":12394,"status":107,"phases":50758,"primaryCompletion":7574,"start":6495,"enrollment":380,"conditions":50759,"interventions":50760},[90],[15],[4008,4010,12398],{"nctId":29044,"briefTitle":29045,"status":107,"phases":50762,"primaryCompletion":5869,"start":6472,"enrollment":380,"conditions":50763,"interventions":50764},[90],[15],[4008,4010,29031],{"nctId":7538,"briefTitle":7539,"status":107,"phases":50766,"primaryCompletion":6374,"start":6472,"enrollment":380,"conditions":50767,"interventions":50768},[90],[15],[4008,4010,7531],{"nctId":43173,"briefTitle":43174,"status":107,"phases":50770,"primaryCompletion":17247,"start":6782,"enrollment":956,"conditions":50771,"interventions":50772},[90],[15],[4008,4010,43166],{"nctId":19602,"briefTitle":19603,"status":107,"phases":50774,"primaryCompletion":7300,"start":17247,"enrollment":1237,"conditions":50775,"interventions":50776},[90],[15],[11653,4008,19607,19608],{"nctId":10073,"briefTitle":10074,"status":107,"phases":50778,"primaryCompletion":10076,"start":10077,"enrollment":448,"conditions":50779,"interventions":50780},[90],[2526],[4008,4010,10080,9801],{"nctId":29130,"briefTitle":29131,"status":107,"phases":50782,"primaryCompletion":6374,"start":5879,"enrollment":97,"conditions":50783,"interventions":50784},[90],[15],[4008,4010,10041,29135],{"nctId":6500,"briefTitle":6501,"status":107,"phases":50786,"primaryCompletion":4413,"start":3763,"enrollment":342,"conditions":50787,"interventions":50788},[90],[15],[4008,4010,6505,6484],{"nctId":48298,"briefTitle":48299,"status":107,"phases":50790,"primaryCompletion":11649,"start":6374,"enrollment":357,"conditions":50791,"interventions":50792},[90],[15],[48291,4008,48303,48304],{"nctId":6868,"briefTitle":6869,"status":107,"phases":50794,"primaryCompletion":5879,"start":6871,"enrollment":1672,"conditions":50795,"interventions":50796},[90],[15],[4008,4010,6845],{"trials":50798,"activeCount":101},[50799,50808,50812,50816,50820],{"nctId":50800,"briefTitle":50801,"status":107,"phases":50802,"primaryCompletion":50803,"start":50804,"enrollment":50805,"conditions":50806,"interventions":50807},"NCT00275444","3 TPV\u002FRTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study",[91],"2003-01-20","2002-03-29",216,[27],[4008],{"nctId":10863,"briefTitle":10864,"status":107,"phases":50809,"primaryCompletion":2163,"start":6453,"enrollment":392,"conditions":50810,"interventions":50811},[91],[27],[4008,4010,10868,7579,10854,10869],{"nctId":21890,"briefTitle":21891,"status":107,"phases":50813,"primaryCompletion":21893,"start":21894,"enrollment":11245,"conditions":50814,"interventions":50815},[91],[27],[18356,18357,21881,21897,21898],{"nctId":50402,"briefTitle":50403,"status":107,"phases":50817,"primaryCompletion":5906,"start":4516,"enrollment":1468,"conditions":50818,"interventions":50819},[91],[27],[18356,18357],{"nctId":50408,"briefTitle":50409,"status":162,"phases":50821,"primaryCompletion":6140,"start":11588,"enrollment":1044,"conditions":50822,"interventions":50823},[90,91],[27],[4008,4010],{"trials":50825,"activeCount":101},[50826,50830,50834,50838,50845,50849],{"nctId":12510,"briefTitle":12511,"status":107,"phases":50827,"primaryCompletion":5856,"start":7574,"enrollment":12513,"conditions":50828,"interventions":50829},[92],[27],[4008,4010,12499],{"nctId":11513,"briefTitle":11514,"status":162,"phases":50831,"primaryCompletion":5856,"start":6140,"enrollment":2382,"conditions":50832,"interventions":50833},[92],[27],[4008,6505,4010],{"nctId":50424,"briefTitle":50425,"status":162,"phases":50835,"primaryCompletion":4412,"start":6116,"enrollment":281,"conditions":50836,"interventions":50837},[92],[27],[18356,18357],{"nctId":50839,"briefTitle":50840,"status":107,"phases":50841,"primaryCompletion":5906,"start":6005,"enrollment":50842,"conditions":50843,"interventions":50844},"NCT00146328","Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects",[91,92],997,[27],[4008],{"nctId":12517,"briefTitle":12518,"status":107,"phases":50846,"primaryCompletion":4412,"start":6081,"enrollment":12520,"conditions":50847,"interventions":50848},[92],[27],[4008,12523],{"nctId":18351,"briefTitle":18352,"status":162,"phases":50850,"primaryCompletion":4412,"start":9902,"enrollment":1116,"conditions":50851,"interventions":50852},[92],[27],[18356,18357,18340],{"trials":50854,"activeCount":101},[],{"trials":50856,"activeCount":101},[50857,50863,50869,50873,50879,50883,50889],{"nctId":50858,"briefTitle":50859,"status":107,"phases":50860,"primaryCompletion":9411,"start":4517,"enrollment":331,"conditions":50861,"interventions":50862},"NCT00615290","Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy",[],[27],[18356],{"nctId":50864,"briefTitle":50865,"status":5515,"phases":50866,"primaryCompletion":4413,"start":6445,"conditions":50867,"interventions":50868},"NCT00933205","An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.",[],[27],[4008],{"nctId":50438,"briefTitle":50439,"status":107,"phases":50870,"primaryCompletion":9752,"completion":9752,"start":400,"enrollment":331,"conditions":50871,"interventions":50872},[],[27],[4008,18357],{"nctId":50874,"briefTitle":50875,"status":600,"phases":50876,"primaryCompletion":9381,"start":4413,"enrollment":101,"conditions":50877,"interventions":50878},"NCT00805857","Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort",[],[27],[4008],{"nctId":50444,"briefTitle":50445,"status":5515,"phases":50880,"primaryCompletion":3978,"start":6413,"conditions":50881,"interventions":50882},[],[27],[4008,4010],{"nctId":50884,"briefTitle":50885,"status":5515,"phases":50886,"primaryCompletion":10024,"completion":10024,"start":21078,"conditions":50887,"interventions":50888},"NCT00062660","Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection",[],[27],[4008],{"nctId":50450,"briefTitle":50451,"status":107,"phases":50890,"primaryCompletion":2649,"start":11588,"enrollment":7524,"conditions":50891,"interventions":50892},[],[27],[4008,4010],{"intervention":1492,"totalTrials":448,"cells":50894},{"EARLY_PHASE1":50895,"PHASE1":50897,"PHASE2":50925,"PHASE3":50973,"PHASE4":51036,"NA":51062},{"trials":50896,"activeCount":101},[],{"trials":50898,"activeCount":101},[50899,50903,50907,50911,50917,50921],{"nctId":2623,"briefTitle":2624,"status":107,"phases":50900,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":912,"conditions":50901,"interventions":50902},[90],[2629,2630],[2632,2633,2616,2632,2633,2633],{"nctId":27276,"briefTitle":27277,"status":107,"phases":50904,"primaryCompletion":2648,"start":9752,"enrollment":210,"conditions":50905,"interventions":50906},[90],[15],[1492,1492,460],{"nctId":21437,"briefTitle":21438,"status":107,"phases":50908,"primaryCompletion":21440,"completion":21440,"start":19380,"enrollment":132,"conditions":50909,"interventions":50910},[90],[36],[21155,1492],{"nctId":50912,"briefTitle":50913,"status":107,"phases":50914,"primaryCompletion":7338,"start":9332,"enrollment":1418,"conditions":50915,"interventions":50916},"NCT01298063","Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib",[90],[550,15],[1492,1492,1492],{"nctId":42742,"briefTitle":42743,"status":107,"phases":50918,"primaryCompletion":6095,"start":2648,"enrollment":380,"conditions":50919,"interventions":50920},[90],[15],[2633,42735,42735],{"nctId":3741,"briefTitle":3742,"status":107,"phases":50922,"primaryCompletion":603,"completion":3744,"start":516,"enrollment":3551,"conditions":50923,"interventions":50924},[90],[33],[1472,1492],{"trials":50926,"activeCount":101},[50927,50931,50941,50951,50955,50959,50967],{"nctId":1485,"briefTitle":1486,"status":107,"phases":50928,"primaryCompletion":1488,"completion":1488,"start":1489,"enrollment":380,"conditions":50929,"interventions":50930},[91],[36],[1492,1071],{"nctId":50932,"briefTitle":50933,"status":107,"phases":50934,"primaryCompletion":50935,"completion":1663,"start":50936,"enrollment":50937,"conditions":50938,"interventions":50939},"NCT01466660","LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung",[91],"2016-04-08","2011-12-13",319,[2693],[1492,50940],"gefitinib",{"nctId":50942,"briefTitle":50943,"status":107,"phases":50944,"primaryCompletion":50945,"completion":50945,"start":50946,"enrollment":37,"conditions":50947,"interventions":50950},"NCT02372006","Trial of Afatinib in Pediatric Tumours",[90,91],"2020-08-05","2015-04-29",[50948,50949],"Neuroectodermal Tumors","Rhabdomyosarcoma",[2633],{"nctId":10616,"briefTitle":10617,"status":107,"phases":50952,"primaryCompletion":10619,"completion":10619,"start":10620,"enrollment":392,"conditions":50953,"interventions":50954},[91],[36],[2633,10600],{"nctId":12156,"briefTitle":12157,"status":107,"phases":50956,"primaryCompletion":12159,"completion":3731,"start":391,"enrollment":10776,"conditions":50957,"interventions":50958},[91],[2629,938],[12162,12163,2633,2633],{"nctId":50960,"briefTitle":50961,"status":107,"phases":50962,"primaryCompletion":50963,"completion":27945,"start":5443,"enrollment":331,"conditions":50964,"interventions":50966},"NCT02780687","Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy",[91],"2018-09-24",[50965],"Urologic Neoplasms",[1492],{"nctId":50968,"briefTitle":50969,"status":107,"phases":50970,"primaryCompletion":390,"start":9443,"enrollment":2789,"conditions":50971,"interventions":50972},"NCT01003899","A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB\u002FIV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]",[91],[36],[2633],{"trials":50974,"activeCount":101},[50975,50981,50985,50989,50998,51005,51016,51024,51028],{"nctId":50976,"briefTitle":50977,"status":107,"phases":50978,"primaryCompletion":5283,"completion":5283,"start":9824,"enrollment":177,"conditions":50979,"interventions":50980},"NCT02044380","Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations",[92],[36],[1492],{"nctId":12275,"briefTitle":12276,"status":107,"phases":50982,"primaryCompletion":12278,"completion":12279,"start":12280,"enrollment":12281,"conditions":50983,"interventions":50984},[92],[3766,3767],[1492,12264],{"nctId":12404,"briefTitle":12405,"status":107,"phases":50986,"primaryCompletion":7092,"completion":7092,"start":379,"enrollment":2382,"conditions":50987,"interventions":50988},[92],[36],[2633,12386],{"nctId":50990,"briefTitle":50991,"status":162,"phases":50992,"primaryCompletion":50993,"completion":50993,"start":50994,"enrollment":50995,"conditions":50996,"interventions":50997},"NCT01345669","LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy",[92],"2016-09-12","2011-10-17",617,[3766],[1492],{"nctId":50999,"briefTitle":51000,"status":162,"phases":51001,"primaryCompletion":27525,"completion":27525,"start":51002,"enrollment":448,"conditions":51003,"interventions":51004},"NCT02131155","LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy",[92],"2014-07-17",[3766],[1492],{"nctId":51006,"briefTitle":51007,"status":107,"phases":51008,"primaryCompletion":51009,"completion":51010,"start":51011,"enrollment":51012,"conditions":51013,"interventions":51014},"NCT01523587","LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy",[92],"2013-10-21","2017-12-27","2012-03-05",795,[36],[2633,51015],"erlotinib",{"nctId":51017,"briefTitle":51018,"status":107,"phases":51019,"primaryCompletion":2664,"completion":2664,"start":51020,"enrollment":51021,"conditions":51022,"interventions":51023},"NCT01953913","Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation",[92],"2013-09-30",542,[36],[1492],{"nctId":12285,"briefTitle":12286,"status":107,"phases":51025,"primaryCompletion":12288,"completion":12289,"start":12290,"enrollment":12291,"conditions":51026,"interventions":51027},[92],[3766],[12264,1492],{"nctId":51029,"briefTitle":51030,"status":107,"phases":51031,"primaryCompletion":2466,"completion":2466,"start":51032,"enrollment":51033,"conditions":51034,"interventions":51035},"NCT01853826","An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)",[92],"2013-07-17",481,[36],[1492],{"trials":51037,"activeCount":101},[51038,51046,51054],{"nctId":51039,"briefTitle":51040,"status":162,"phases":51041,"primaryCompletion":6640,"completion":6640,"start":51042,"enrollment":272,"conditions":51043,"interventions":51045},"NCT02695290","Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)",[93],"2016-03-17",[36,51044],"ErbB Receptors",[1492],{"nctId":51047,"briefTitle":51048,"status":107,"phases":51049,"primaryCompletion":51050,"completion":3508,"start":51051,"enrollment":123,"conditions":51052,"interventions":51053},"NCT02208843","Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation",[93],"2017-05-17","2014-10-02",[36],[1492],{"nctId":51055,"briefTitle":51056,"status":107,"phases":51057,"primaryCompletion":1655,"completion":51058,"start":51059,"enrollment":439,"conditions":51060,"interventions":51061},"NCT02514174","Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older",[93],"2019-04-25","2015-08-18",[36,51044],[1492],{"trials":51063,"activeCount":101},[51064,51073,51079,51085,51091,51099,51108,51114,51122,51130,51139],{"nctId":51065,"briefTitle":51066,"status":107,"phases":51067,"primaryCompletion":887,"completion":887,"start":51068,"enrollment":4219,"conditions":51069,"interventions":51071},"NCT04750824","Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.",[],"2020-10-15",[51070],"Non-squamous, Non-Small Cell Lung Cancer",[1492,51072],"other systemic therapy",{"nctId":51074,"briefTitle":51075,"status":5481,"phases":51076,"conditions":51077,"interventions":51078},"NCT05107193","Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)",[],[2057],[2633],{"nctId":51080,"briefTitle":51081,"status":5515,"phases":51082,"conditions":51083,"interventions":51084},"NCT01931306","Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)",[],[36],[1492],{"nctId":51086,"briefTitle":51087,"status":5515,"phases":51088,"primaryCompletion":9824,"completion":9824,"start":9491,"conditions":51089,"interventions":51090},"NCT01649284","Afatinib Expanded Access Program",[],[36],[2633],{"nctId":51092,"briefTitle":51093,"status":107,"phases":51094,"primaryCompletion":51095,"completion":51095,"start":51096,"enrollment":16953,"conditions":51097,"interventions":51098},"NCT02047903","GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations",[],"2018-12-31","2014-03-05",[36],[1492],{"nctId":51100,"briefTitle":51101,"status":107,"phases":51102,"primaryCompletion":51103,"completion":51104,"start":51105,"enrollment":716,"conditions":51106,"interventions":51107},"NCT04206787","The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer",[],"2023-12-18","2023-12-22","2020-05-20",[51070],[1492],{"nctId":51109,"briefTitle":51110,"status":107,"phases":51111,"primaryCompletion":4118,"completion":4118,"start":4441,"enrollment":3755,"conditions":51112,"interventions":51113},"NCT01251653","A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel",[],[33],[1492,1492,5355,39680],{"nctId":51115,"briefTitle":51116,"status":107,"phases":51117,"primaryCompletion":51118,"completion":51118,"start":51119,"enrollment":1429,"conditions":51120,"interventions":51121},"NCT02440854","Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings",[],"2021-02-17","2016-02-16",[36],[2633],{"nctId":51123,"briefTitle":51124,"status":107,"phases":51125,"primaryCompletion":51126,"completion":51126,"start":51127,"enrollment":7763,"conditions":51128,"interventions":51129},"NCT04795245","Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma",[],"2023-10-16","2021-08-26",[51070],[2633],{"nctId":51131,"briefTitle":51132,"status":107,"phases":51133,"primaryCompletion":51134,"completion":51134,"start":51135,"enrollment":3182,"conditions":51136,"interventions":51137},"NCT03370770","Afatinib Osimertinib Sequencing NIS",[],"2019-11-28","2017-12-28",[36],[1492,51138],"Osimertinib",{"nctId":51140,"briefTitle":51141,"status":107,"phases":51142,"primaryCompletion":51143,"completion":51143,"start":51144,"enrollment":51145,"conditions":51146,"interventions":51147},"NCT04179890","The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib",[],"2021-07-22","2019-12-17",462,[51070],[1492,51148,51149,51138,1492,51138],"Erlotinib","Gefitinib",{"intervention":1129,"totalTrials":1116,"cells":51151},{"EARLY_PHASE1":51152,"PHASE1":51154,"PHASE2":51235,"PHASE3":51299,"PHASE4":51324,"NA":51326},{"trials":51153,"activeCount":101},[],{"trials":51155,"activeCount":101},[51156,51163,51167,51171,51175,51181,51187,51191,51197,51201,51207,51215,51219,51225,51231],{"nctId":51157,"briefTitle":51158,"status":107,"phases":51159,"primaryCompletion":51160,"start":11701,"enrollment":112,"conditions":51161,"interventions":51162},"NCT02171650","BIBW 2992 in Patients With Advanced Solid Tumors",[90],"2006-05-01",[33],[1129],{"nctId":2635,"briefTitle":2636,"status":107,"phases":51164,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":392,"conditions":51165,"interventions":51166},[90],[2629],[1040,1129],{"nctId":50272,"briefTitle":50273,"status":107,"phases":51168,"primaryCompletion":9381,"start":400,"enrollment":210,"conditions":51169,"interventions":51170},[90],[15],[1129,4010],{"nctId":9590,"briefTitle":9591,"status":107,"phases":51172,"primaryCompletion":9593,"completion":5233,"start":9443,"enrollment":2507,"conditions":51173,"interventions":51174},[90],[33],[1129,1119],{"nctId":51176,"briefTitle":51177,"status":107,"phases":51178,"primaryCompletion":19461,"start":11581,"enrollment":536,"conditions":51179,"interventions":51180},"NCT02171741","Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors",[90],[33],[1129,2731],{"nctId":51182,"briefTitle":51183,"status":107,"phases":51184,"primaryCompletion":6116,"start":8086,"enrollment":231,"conditions":51185,"interventions":51186},"NCT02171702","Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours",[90],[33],[1129],{"nctId":9597,"briefTitle":9598,"status":107,"phases":51188,"primaryCompletion":3990,"start":7573,"enrollment":1865,"conditions":51189,"interventions":51190},[90],[33],[1129,1119],{"nctId":51192,"briefTitle":51193,"status":107,"phases":51194,"primaryCompletion":4128,"start":7300,"enrollment":2382,"conditions":51195,"interventions":51196},"NCT02171676","BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors",[90],[33],[2731,1129],{"nctId":41520,"briefTitle":41521,"status":107,"phases":51198,"primaryCompletion":420,"completion":420,"start":9443,"enrollment":1891,"conditions":51199,"interventions":51200},[90],[36],[1129,41513],{"nctId":51202,"briefTitle":51203,"status":107,"phases":51204,"primaryCompletion":6911,"start":8086,"enrollment":357,"conditions":51205,"interventions":51206},"NCT02171728","Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors",[90],[33],[1129],{"nctId":51208,"briefTitle":51209,"status":107,"phases":51210,"primaryCompletion":51211,"completion":51211,"start":51212,"enrollment":4433,"conditions":51213,"interventions":51214},"NCT00716417","Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin\u002FPaclitaxel or Cisplatin\u002F5-FU in Patients With Advanced Solid Tumours",[90],"2010-07-01","2008-07-01",[33],[1129,1129],{"nctId":3727,"briefTitle":3728,"status":107,"phases":51216,"primaryCompletion":3730,"completion":3731,"start":3732,"enrollment":3733,"conditions":51217,"interventions":51218},[90],[36],[1472,1472,1129,1129],{"nctId":51220,"briefTitle":51221,"status":107,"phases":51222,"primaryCompletion":7151,"start":2146,"enrollment":2887,"conditions":51223,"interventions":51224},"NCT02171637","Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors",[90],[33],[1129],{"nctId":51226,"briefTitle":51227,"status":107,"phases":51228,"primaryCompletion":7151,"start":6401,"enrollment":2789,"conditions":51229,"interventions":51230},"NCT02171663","Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors",[90],[33],[1129],{"nctId":1122,"briefTitle":1123,"status":107,"phases":51232,"primaryCompletion":1125,"completion":1125,"start":1114,"enrollment":1126,"conditions":51233,"interventions":51234},[90],[33],[1120,1010,1129,1120,1130,1120,1010,1131,1129,1129],{"trials":51236,"activeCount":101},[51237,51243,51250,51254,51258,51262,51268,51272,51278,51282,51289,51293],{"nctId":51238,"briefTitle":51239,"status":107,"phases":51240,"primaryCompletion":3990,"start":6911,"enrollment":1991,"conditions":51241,"interventions":51242},"NCT00431067","Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy",[91],[2629],[1129],{"nctId":51244,"briefTitle":51245,"status":107,"phases":51246,"primaryCompletion":2506,"start":2032,"enrollment":2507,"conditions":51247,"interventions":51248},"NCT00796549","BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients",[91],[36],[51249],"BiBW 2992",{"nctId":2645,"briefTitle":2646,"status":107,"phases":51251,"primaryCompletion":2648,"start":2649,"enrollment":993,"conditions":51252,"interventions":51253},[91],[2629],[2652,1129,2616],{"nctId":3750,"briefTitle":3751,"status":107,"phases":51255,"primaryCompletion":3753,"start":3754,"enrollment":3755,"conditions":51256,"interventions":51257},[91],[3060],[1129,1472],{"nctId":3759,"briefTitle":3760,"status":107,"phases":51259,"primaryCompletion":3732,"completion":3762,"start":3763,"enrollment":3764,"conditions":51260,"interventions":51261},[91],[3766,3767],[1129,1472],{"nctId":51263,"briefTitle":51264,"status":107,"phases":51265,"primaryCompletion":17427,"completion":2002,"start":3763,"enrollment":747,"conditions":51266,"interventions":51267},"NCT00525148","LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations",[91],[36],[1129],{"nctId":23720,"briefTitle":23721,"status":107,"phases":51269,"primaryCompletion":23723,"completion":20008,"start":23724,"enrollment":1458,"conditions":51270,"interventions":51271},[91],[3671],[1129,23711,23727],{"nctId":51273,"briefTitle":51274,"status":107,"phases":51275,"primaryCompletion":9411,"start":6910,"enrollment":2235,"conditions":51276,"interventions":51277},"NCT00425854","An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer",[91],[2629],[1129],{"nctId":22282,"briefTitle":22283,"status":107,"phases":51279,"primaryCompletion":17427,"start":7573,"enrollment":1865,"conditions":51280,"interventions":51281},[91],[2629],[1129,1129,21452,21452],{"nctId":51283,"briefTitle":51284,"status":162,"phases":51285,"primaryCompletion":51286,"start":10076,"enrollment":1672,"conditions":51287,"interventions":51288},"NCT00748709","Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and\u002For HER2 Gene Amplification.",[91],"2010-11-01",[33],[1129],{"nctId":9713,"briefTitle":9714,"status":107,"phases":51290,"primaryCompletion":2032,"start":4461,"enrollment":3970,"conditions":51291,"interventions":51292},[91],[9651],[1119,1129,9718],{"nctId":51294,"briefTitle":51295,"status":107,"phases":51296,"primaryCompletion":9340,"start":2003,"enrollment":123,"conditions":51297,"interventions":51298},"NCT00875433","Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours",[91],[33],[1129],{"trials":51300,"activeCount":101},[51301,51305,51312,51316,51320],{"nctId":2660,"briefTitle":2661,"status":107,"phases":51302,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":51303,"interventions":51304},[92],[2629],[1129,2616,2669,2669],{"nctId":51306,"briefTitle":51307,"status":107,"phases":51308,"primaryCompletion":4474,"completion":4474,"start":6471,"enrollment":51309,"conditions":51310,"interventions":51311},"NCT00656136","BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)",[92],585,[36],[1129],{"nctId":1765,"briefTitle":1766,"status":107,"phases":51313,"primaryCompletion":1768,"completion":1769,"start":1770,"enrollment":1771,"conditions":51314,"interventions":51315},[92],[36,1773],[1011,1129,1009],{"nctId":17424,"briefTitle":17425,"status":107,"phases":51317,"primaryCompletion":4474,"completion":9688,"start":17427,"enrollment":17428,"conditions":51318,"interventions":51319},[92],[36],[17413,1129],{"nctId":17939,"briefTitle":17940,"status":107,"phases":51321,"primaryCompletion":17942,"completion":17943,"start":17944,"enrollment":17945,"conditions":51322,"interventions":51323},[92],[36,1773],[17928,1129],{"trials":51325,"activeCount":101},[],{"trials":51327,"activeCount":101},[51328],{"nctId":51329,"briefTitle":51330,"status":5515,"phases":51331,"conditions":51332,"interventions":51333},"NCT01209650","LUX Lung Special Access Scheme Australia Named Patient Use (NPU)",[],[36],[1129],{"intervention":413,"totalTrials":993,"cells":51335},{"EARLY_PHASE1":51336,"PHASE1":51338,"PHASE2":51412,"PHASE3":51426,"PHASE4":51448,"NA":51458},{"trials":51337,"activeCount":101},[],{"trials":51339,"activeCount":101},[51340,51344,51348,51352,51356,51360,51364,51368,51372,51376,51380,51384,51388,51392,51396,51400,51404,51408],{"nctId":27476,"briefTitle":27477,"status":107,"phases":51341,"primaryCompletion":4392,"start":6811,"enrollment":8,"conditions":51342,"interventions":51343},[90],[15],[27469,361,413],{"nctId":27521,"briefTitle":27522,"status":107,"phases":51345,"primaryCompletion":7193,"completion":27524,"start":27525,"enrollment":357,"conditions":51346,"interventions":51347},[90],[15],[2393,971,413,969,2393,971,970,969],{"nctId":20067,"briefTitle":20068,"status":107,"phases":51349,"primaryCompletion":5233,"completion":5233,"start":9842,"enrollment":401,"conditions":51350,"interventions":51351},[90],[15],[384,4166,4166,384],{"nctId":28172,"briefTitle":28173,"status":107,"phases":51353,"primaryCompletion":456,"completion":456,"start":4038,"enrollment":132,"conditions":51354,"interventions":51355},[90],[15],[28165,413,361],{"nctId":9359,"briefTitle":9360,"status":107,"phases":51357,"primaryCompletion":2003,"start":2649,"enrollment":401,"conditions":51358,"interventions":51359},[90],[15],[528,413],{"nctId":375,"briefTitle":376,"status":107,"phases":51361,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":51362,"interventions":51363},[90],[15],[383,384,384,383,385,385],{"nctId":28316,"briefTitle":28317,"status":107,"phases":51365,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":51366,"interventions":51367},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":27489,"briefTitle":27490,"status":107,"phases":51369,"primaryCompletion":4392,"start":6811,"enrollment":8,"conditions":51370,"interventions":51371},[90],[15],[27469,361,413],{"nctId":405,"briefTitle":406,"status":107,"phases":51373,"primaryCompletion":408,"completion":408,"start":409,"enrollment":410,"conditions":51374,"interventions":51375},[90],[15],[73,413,73,414,413,414,73,413,414],{"nctId":27495,"briefTitle":27496,"status":107,"phases":51377,"primaryCompletion":5233,"completion":5233,"start":10024,"enrollment":6702,"conditions":51378,"interventions":51379},[90],[15],[361,413,27469],{"nctId":416,"briefTitle":417,"status":107,"phases":51381,"primaryCompletion":419,"completion":419,"start":420,"enrollment":357,"conditions":51382,"interventions":51383},[90],[15],[384,423,383],{"nctId":27501,"briefTitle":27502,"status":107,"phases":51385,"primaryCompletion":3732,"start":6811,"enrollment":10951,"conditions":51386,"interventions":51387},[90],[15],[27469,361,413],{"nctId":434,"briefTitle":435,"status":107,"phases":51389,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":51390,"interventions":51391},[90],[15],[73,413,73,413],{"nctId":443,"briefTitle":444,"status":107,"phases":51393,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":51394,"interventions":51395},[90],[15],[73,451,413,413,451,73],{"nctId":50067,"briefTitle":50068,"status":107,"phases":51397,"primaryCompletion":4473,"completion":4473,"start":378,"enrollment":448,"conditions":51398,"interventions":51399},[90],[15],[413,361,413,361],{"nctId":471,"briefTitle":472,"status":107,"phases":51401,"primaryCompletion":474,"completion":474,"start":475,"enrollment":357,"conditions":51402,"interventions":51403},[90],[15],[384,423,383],{"nctId":29350,"briefTitle":29351,"status":107,"phases":51405,"primaryCompletion":4462,"start":1981,"enrollment":401,"conditions":51406,"interventions":51407},[90],[15],[413,29337],{"nctId":9931,"briefTitle":9932,"status":107,"phases":51409,"primaryCompletion":5905,"start":9404,"enrollment":1672,"conditions":51410,"interventions":51411},[90],[15],[9936,9872,413],{"trials":51413,"activeCount":101},[51414,51418,51422],{"nctId":23233,"briefTitle":23234,"status":107,"phases":51415,"primaryCompletion":3763,"start":4498,"enrollment":5968,"conditions":51416,"interventions":51417},[91],[21],[23224,23238,23239,413],{"nctId":9461,"briefTitle":9462,"status":107,"phases":51419,"primaryCompletion":9443,"start":4412,"enrollment":9464,"conditions":51420,"interventions":51421},[91],[21],[528,384],{"nctId":9472,"briefTitle":9473,"status":107,"phases":51423,"primaryCompletion":9348,"start":2003,"enrollment":9475,"conditions":51424,"interventions":51425},[91],[21],[528,413,528,606],{"trials":51427,"activeCount":101},[51428,51432,51436,51440,51444],{"nctId":577,"briefTitle":578,"status":107,"phases":51429,"primaryCompletion":580,"completion":581,"start":582,"enrollment":583,"conditions":51430,"interventions":51431},[92],[21],[413,586,361,73],{"nctId":50097,"briefTitle":50098,"status":107,"phases":51433,"primaryCompletion":7338,"completion":7338,"start":7703,"enrollment":50100,"conditions":51434,"interventions":51435},[92],[21],[361,361,413,413,361,361,361],{"nctId":9956,"briefTitle":9957,"status":107,"phases":51437,"primaryCompletion":1980,"start":2032,"enrollment":9959,"conditions":51438,"interventions":51439},[92],[21],[9872,9962,9963,413,384],{"nctId":9528,"briefTitle":9529,"status":107,"phases":51441,"primaryCompletion":379,"completion":379,"start":9348,"enrollment":9531,"conditions":51442,"interventions":51443},[92],[21],[413,528,528],{"nctId":18192,"briefTitle":18193,"status":107,"phases":51445,"primaryCompletion":2030,"start":5905,"enrollment":18195,"conditions":51446,"interventions":51447},[92],[21],[18181,18198,413],{"trials":51449,"activeCount":101},[51450,51454],{"nctId":6679,"briefTitle":6680,"status":107,"phases":51451,"primaryCompletion":409,"completion":409,"start":390,"enrollment":6682,"conditions":51452,"interventions":51453},[93],[21],[6685,6614,384,384,6633],{"nctId":7335,"briefTitle":7336,"status":107,"phases":51455,"primaryCompletion":379,"completion":379,"start":7338,"enrollment":7339,"conditions":51456,"interventions":51457},[93],[21],[384,6633,6685,6685],{"trials":51459,"activeCount":101},[51460],{"nctId":763,"briefTitle":764,"status":600,"phases":51461,"primaryCompletion":766,"completion":766,"start":767,"enrollment":101,"conditions":51462,"interventions":51463},[],[21,662],[383,384,770],{"intervention":5959,"totalTrials":993,"cells":51465},{"EARLY_PHASE1":51466,"PHASE1":51468,"PHASE2":51474,"PHASE3":51490,"PHASE4":51576,"NA":51594},{"trials":51467,"activeCount":101},[],{"trials":51469,"activeCount":101},[51470],{"nctId":49647,"briefTitle":49648,"status":107,"phases":51471,"primaryCompletion":49650,"completion":49650,"start":49651,"enrollment":188,"conditions":51472,"interventions":51473},[90],[18],[5860,5959],{"trials":51475,"activeCount":101},[51476,51482,51486],{"nctId":51477,"briefTitle":51478,"status":107,"phases":51479,"primaryCompletion":1990,"start":4005,"enrollment":132,"conditions":51480,"interventions":51481},"NCT00928668","Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma",[91],[30],[5959,5959,5959,5959],{"nctId":49679,"briefTitle":49680,"status":107,"phases":51483,"primaryCompletion":4391,"completion":4391,"start":4473,"enrollment":231,"conditions":51484,"interventions":51485},[91],[18],[5900,5899,5899,5900],{"nctId":26502,"briefTitle":26503,"status":600,"phases":51487,"start":391,"enrollment":101,"conditions":51488,"interventions":51489},[91],[30],[5959,5959,5959,5959,5959,5959,5959,26493,26493,26493,26493,26493,26493,26493,26507,26507,26507,26507,26507,26507,26507],{"trials":51491,"activeCount":101},[51492,51496,51500,51504,51508,51512,51516,51523,51530,51534,51538,51542,51546,51550,51556,51560,51564,51568,51572],{"nctId":49695,"briefTitle":49696,"status":107,"phases":51493,"primaryCompletion":378,"completion":378,"start":5296,"enrollment":49698,"conditions":51494,"interventions":51495},[92],[18],[49701,49701,5899,5899,5900],{"nctId":5891,"briefTitle":5892,"status":107,"phases":51497,"primaryCompletion":603,"completion":1125,"start":4474,"enrollment":5894,"conditions":51498,"interventions":51499},[92],[18],[5897,5898,5899,5900,5900,5899,5897,5898],{"nctId":11614,"briefTitle":11615,"status":107,"phases":51501,"primaryCompletion":9396,"start":2649,"enrollment":11617,"conditions":51502,"interventions":51503},[92],[18],[5959,5959,11596],{"nctId":49745,"briefTitle":49746,"status":107,"phases":51505,"primaryCompletion":49748,"completion":49749,"start":49750,"enrollment":6773,"conditions":51506,"interventions":51507},[92],[18],[5899,5900,5899],{"nctId":49754,"briefTitle":49755,"status":107,"phases":51509,"primaryCompletion":4474,"completion":4474,"start":2001,"enrollment":49757,"conditions":51510,"interventions":51511},[92],[18],[5860,5860,5959],{"nctId":49761,"briefTitle":49762,"status":107,"phases":51513,"primaryCompletion":378,"completion":378,"start":9538,"enrollment":49764,"conditions":51514,"interventions":51515},[92],[18],[49767,49768,5860,5959],{"nctId":51517,"briefTitle":51518,"status":107,"phases":51519,"primaryCompletion":7703,"start":1989,"enrollment":51520,"conditions":51521,"interventions":51522},"NCT00782509","12 \u002F 48 wk Pivotal PFT vs PBO in COPD II",[92],644,[18],[5959,5959],{"nctId":51524,"briefTitle":51525,"status":107,"phases":51526,"primaryCompletion":7703,"start":10775,"enrollment":51527,"conditions":51528,"interventions":51529},"NCT00782210","12 \u002F 48 Week Pivotal PFT vs PBO in COPD I",[92],625,[18],[5959,5959],{"nctId":49789,"briefTitle":49790,"status":107,"phases":51531,"primaryCompletion":611,"completion":611,"start":5296,"enrollment":49792,"conditions":51532,"interventions":51533},[92],[18],[49701,5899,5900,5899,49701],{"nctId":49814,"briefTitle":49815,"status":107,"phases":51535,"primaryCompletion":419,"completion":475,"start":378,"enrollment":49817,"conditions":51536,"interventions":51537},[92],[18],[5899,5900,5899,5899,5900],{"nctId":11621,"briefTitle":11622,"status":107,"phases":51539,"primaryCompletion":9396,"start":1989,"enrollment":11624,"conditions":51540,"interventions":51541},[92],[18],[5959,5959,11596],{"nctId":13512,"briefTitle":13513,"status":107,"phases":51543,"primaryCompletion":9340,"start":6811,"enrollment":13515,"conditions":51544,"interventions":51545},[92],[18],[5959,5959,5959,13501],{"nctId":13519,"briefTitle":13520,"status":107,"phases":51547,"primaryCompletion":9340,"start":6811,"enrollment":1458,"conditions":51548,"interventions":51549},[92],[18],[5959,5959,5959,13524],{"nctId":51551,"briefTitle":51552,"status":107,"phases":51553,"primaryCompletion":611,"completion":611,"start":9538,"enrollment":25,"conditions":51554,"interventions":51555},"NCT01536262","Japan Long-term Safety for Tiotropium Plus Olodaterol",[92],[18],[49767,49767,5959],{"nctId":49837,"briefTitle":49838,"status":107,"phases":51557,"primaryCompletion":49840,"completion":5955,"start":49841,"enrollment":49842,"conditions":51558,"interventions":51559},[92],[18],[5900,5899,5899],{"nctId":49850,"briefTitle":49851,"status":107,"phases":51561,"primaryCompletion":419,"completion":475,"start":378,"enrollment":49853,"conditions":51562,"interventions":51563},[92],[18],[5900,5899],{"nctId":49863,"briefTitle":49864,"status":107,"phases":51565,"primaryCompletion":9515,"completion":9515,"start":3753,"enrollment":735,"conditions":51566,"interventions":51567},[92],[18],[49701,5899,5900,5899,49701],{"nctId":49876,"briefTitle":49755,"status":107,"phases":51569,"primaryCompletion":9515,"completion":9515,"start":2001,"enrollment":49878,"conditions":51570,"interventions":51571},[92],[18],[5860,5959,5860],{"nctId":49882,"briefTitle":49883,"status":107,"phases":51573,"primaryCompletion":378,"completion":378,"start":3753,"enrollment":1252,"conditions":51574,"interventions":51575},[92],[18],[5860,5959,49701,49767],{"trials":51577,"activeCount":101},[51578,51582,51586,51590],{"nctId":49894,"briefTitle":49895,"status":107,"phases":51579,"primaryCompletion":49897,"completion":5967,"start":49898,"enrollment":11,"conditions":51580,"interventions":51581},[93],[18],[5860,5959,5860],{"nctId":5950,"briefTitle":5951,"status":107,"phases":51583,"primaryCompletion":5953,"completion":5954,"start":5955,"enrollment":5956,"conditions":51584,"interventions":51585},[93],[18],[5860,5959,5960,5832],{"nctId":5962,"briefTitle":5963,"status":107,"phases":51587,"primaryCompletion":5965,"completion":5966,"start":5967,"enrollment":5968,"conditions":51588,"interventions":51589},[93],[18],[5860,5959,5960,5832],{"nctId":9064,"briefTitle":9065,"status":107,"phases":51591,"primaryCompletion":9067,"completion":9068,"start":9069,"enrollment":9070,"conditions":51592,"interventions":51593},[93],[18],[9051,5860,5959],{"trials":51595,"activeCount":101},[51596,51605],{"nctId":51597,"briefTitle":51598,"status":107,"phases":51599,"primaryCompletion":51600,"completion":51600,"start":10406,"enrollment":51601,"conditions":51602,"interventions":51603},"NCT03030638","Drug Utilization Study for Olodaterol",[],"2018-03-31",27606,[18],[5959,51604],"Indacaterol",{"nctId":49999,"briefTitle":50000,"status":107,"phases":51606,"primaryCompletion":50002,"completion":50002,"start":18912,"enrollment":50003,"conditions":51607,"interventions":51608},[],[18],[5860,50006,5959,50007],{"intervention":8680,"totalTrials":1865,"cells":51610},{"EARLY_PHASE1":51611,"PHASE1":51613,"PHASE2":51615,"PHASE3":51624,"PHASE4":51683,"NA":51734},{"trials":51612,"activeCount":101},[],{"trials":51614,"activeCount":101},[],{"trials":51616,"activeCount":101},[51617],{"nctId":51618,"briefTitle":51619,"status":107,"phases":51620,"primaryCompletion":6446,"completion":6446,"start":6189,"enrollment":51621,"conditions":51622,"interventions":51623},"NCT00239486","Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)",[91],109,[11724],[8680],{"trials":51625,"activeCount":101},[51626,51632,51636,51643,51650,51654,51660,51666,51672,51676],{"nctId":51627,"briefTitle":51628,"status":107,"phases":51629,"primaryCompletion":5905,"completion":5905,"start":6471,"enrollment":50159,"conditions":51630,"interventions":51631},"NCT00654498","Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)",[92],[11724],[8680],{"nctId":12369,"briefTitle":12370,"status":107,"phases":51633,"primaryCompletion":2162,"start":2182,"enrollment":650,"conditions":51634,"interventions":51635},[92],[6934],[8680,12358],{"nctId":51637,"briefTitle":51638,"status":107,"phases":51639,"primaryCompletion":3754,"start":19461,"enrollment":51640,"conditions":51641,"interventions":51642},"NCT00577460","Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD",[92],391,[6934],[8680],{"nctId":51644,"briefTitle":51645,"status":107,"phases":51646,"primaryCompletion":3754,"start":4507,"enrollment":51647,"conditions":51648,"interventions":51649},"NCT00601523","Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).",[92],511,[6934],[8680],{"nctId":12375,"briefTitle":12376,"status":107,"phases":51651,"primaryCompletion":8479,"completion":8479,"start":5879,"enrollment":12378,"conditions":51652,"interventions":51653},[92],[6934],[8680,12358],{"nctId":51655,"briefTitle":51656,"status":107,"phases":51657,"primaryCompletion":17247,"completion":17247,"start":6446,"enrollment":1771,"conditions":51658,"interventions":51659},"NCT00133198","Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)",[92],[11724],[8680],{"nctId":51661,"briefTitle":51662,"status":107,"phases":51663,"primaryCompletion":17247,"start":2112,"enrollment":49925,"conditions":51664,"interventions":51665},"NCT00152958","A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)",[92],[11724],[8680],{"nctId":51667,"briefTitle":51668,"status":107,"phases":51669,"primaryCompletion":2181,"start":11123,"enrollment":2800,"conditions":51670,"interventions":51671},"NCT02177357","Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients",[92],[6934],[8680],{"nctId":17244,"briefTitle":17245,"status":107,"phases":51673,"primaryCompletion":17247,"completion":17247,"start":6081,"enrollment":3551,"conditions":51674,"interventions":51675},[92],[11724],[17250,17233],{"nctId":51677,"briefTitle":51678,"status":107,"phases":51679,"primaryCompletion":6446,"completion":6446,"start":6189,"enrollment":51680,"conditions":51681,"interventions":51682},"NCT00275457","Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients",[92],346,[11724],[17250],{"trials":51684,"activeCount":101},[51685,51691,51698,51705,51711,51715,51721,51727],{"nctId":51686,"briefTitle":51687,"status":107,"phases":51688,"primaryCompletion":8911,"start":6911,"enrollment":25618,"conditions":51689,"interventions":51690},"NCT00375284","A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS",[93],[11724],[8680],{"nctId":51692,"briefTitle":51693,"status":107,"phases":51694,"primaryCompletion":1114,"start":2145,"enrollment":51695,"conditions":51696,"interventions":51697},"NCT00349531","A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS",[93],369,[11724],[8680],{"nctId":51699,"briefTitle":51700,"status":107,"phases":51701,"primaryCompletion":5906,"start":4461,"enrollment":19136,"conditions":51702,"interventions":51704},"NCT00297778","Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms",[93],[6934,51703],"Depression",[8680],{"nctId":51706,"briefTitle":51707,"status":107,"phases":51708,"primaryCompletion":4517,"start":2145,"enrollment":25618,"conditions":51709,"interventions":51710},"NCT00356096","Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances",[93],[11724,51703],[17250],{"nctId":8674,"briefTitle":8675,"status":107,"phases":51712,"primaryCompletion":7394,"start":6064,"enrollment":8677,"conditions":51713,"interventions":51714},[93],[6934],[8680,8661],{"nctId":51716,"briefTitle":51717,"status":107,"phases":51718,"primaryCompletion":9404,"start":4498,"enrollment":13118,"conditions":51719,"interventions":51720},"NCT00321854","Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)",[93],[6934],[17250],{"nctId":51722,"briefTitle":51723,"status":107,"phases":51724,"primaryCompletion":5856,"start":6910,"enrollment":698,"conditions":51725,"interventions":51726},"NCT00402233","A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients",[93],[6934],[8680],{"nctId":51728,"briefTitle":51729,"status":107,"phases":51730,"primaryCompletion":6224,"start":1114,"enrollment":51731,"conditions":51732,"interventions":51733},"NCT00472199","Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)",[93],331,[11724],[8680],{"trials":51735,"activeCount":101},[51736,51743,51750,51757,51764,51773,51780,51786,51793],{"nctId":51737,"briefTitle":51738,"status":107,"phases":51739,"primaryCompletion":7573,"start":7151,"enrollment":51740,"conditions":51741,"interventions":51742},"NCT02248142","Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)",[],1029,[11724],[8680],{"nctId":51744,"briefTitle":51745,"status":107,"phases":51746,"primaryCompletion":2146,"start":7574,"enrollment":51747,"conditions":51748,"interventions":51749},"NCT02248207","Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease",[],1293,[6934],[8680],{"nctId":51751,"briefTitle":51752,"status":107,"phases":51753,"primaryCompletion":6207,"start":7553,"enrollment":51754,"conditions":51755,"interventions":51756},"NCT02248220","Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease",[],657,[6934],[8680],{"nctId":51758,"briefTitle":51759,"status":107,"phases":51760,"primaryCompletion":4462,"start":11733,"enrollment":51761,"conditions":51762,"interventions":51763},"NCT02248181","Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease",[],442,[6934],[8680],{"nctId":51765,"briefTitle":51766,"status":107,"phases":51767,"primaryCompletion":51768,"completion":51768,"start":51769,"enrollment":51770,"conditions":51771,"interventions":51772},"NCT00349310","Profile of Depressive Symptoms in Parkinsons Disease",[],"2006-10-01","2006-04-01",1018,[6934,51703],[8680],{"nctId":51774,"briefTitle":51775,"status":107,"phases":51776,"primaryCompletion":9538,"completion":9538,"start":9348,"enrollment":51777,"conditions":51778,"interventions":51779},"NCT01361009","a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients",[],2017,[6934],[17250],{"nctId":51781,"briefTitle":51738,"status":107,"phases":51782,"primaryCompletion":6910,"start":6156,"enrollment":51783,"conditions":51784,"interventions":51785},"NCT02248155",[],2644,[11724],[8680],{"nctId":51787,"briefTitle":51788,"status":107,"phases":51789,"primaryCompletion":7573,"start":5992,"enrollment":51790,"conditions":51791,"interventions":51792},"NCT02248168","Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease",[],1449,[6934],[8680],{"nctId":51794,"briefTitle":51795,"status":107,"phases":51796,"primaryCompletion":10775,"start":4129,"enrollment":51797,"conditions":51798,"interventions":51799},"NCT02236728","Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole",[],497,[6934],[8680],{"intervention":2186,"totalTrials":439,"cells":51801},{"EARLY_PHASE1":51802,"PHASE1":51804,"PHASE2":51842,"PHASE3":51854,"PHASE4":51874,"NA":51922},{"trials":51803,"activeCount":101},[],{"trials":51805,"activeCount":101},[51806,51812,51816,51822,51826,51830,51834,51838],{"nctId":51807,"briefTitle":51808,"status":107,"phases":51809,"enrollment":357,"conditions":51810,"interventions":51811},"NCT00000649","An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count \u003C 400\u002Fmm3)",[90],[27],[2186,7579],{"nctId":32333,"briefTitle":32334,"status":107,"phases":51813,"primaryCompletion":6224,"start":6471,"enrollment":8,"conditions":51814,"interventions":51815},[90],[15],[32326,32338,32339,2186],{"nctId":51817,"briefTitle":51818,"status":107,"phases":51819,"primaryCompletion":13117,"start":6438,"enrollment":1991,"conditions":51820,"interventions":51821},"NCT02184091","Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine",[90],[2550,2526],[2186],{"nctId":21781,"briefTitle":21782,"status":107,"phases":51823,"enrollment":380,"conditions":51824,"interventions":51825},[90],[27],[21786,2186,10869],{"nctId":39182,"briefTitle":39183,"status":107,"phases":51827,"primaryCompletion":2182,"start":6065,"enrollment":177,"conditions":51828,"interventions":51829},[90],[27],[2186,39175],{"nctId":42468,"briefTitle":42469,"status":162,"phases":51831,"primaryCompletion":8538,"start":9235,"enrollment":166,"conditions":51832,"interventions":51833},[90],[27],[2186,42461],{"nctId":21916,"briefTitle":21917,"status":162,"phases":51835,"primaryCompletion":6884,"start":2182,"enrollment":155,"conditions":51836,"interventions":51837},[90],[27],[2186,21921,21922],{"nctId":29050,"briefTitle":29051,"status":107,"phases":51839,"enrollment":448,"conditions":51840,"interventions":51841},[90],[27],[29055,2186,29031],{"trials":51843,"activeCount":101},[51844,51850],{"nctId":51845,"briefTitle":51846,"status":107,"phases":51847,"enrollment":7476,"conditions":51848,"interventions":51849},"NCT00002324","The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease",[91],[27],[2186,7579],{"nctId":10871,"briefTitle":10872,"status":107,"phases":51851,"primaryCompletion":6413,"completion":6413,"start":5993,"enrollment":260,"conditions":51852,"interventions":51853},[91],[27],[2186,10854,7579],{"trials":51855,"activeCount":101},[51856,51860,51864,51868],{"nctId":10879,"briefTitle":10880,"status":107,"phases":51857,"primaryCompletion":7003,"start":2182,"enrollment":10882,"conditions":51858,"interventions":51859},[92],[27],[2186,7579,10854],{"nctId":10886,"briefTitle":10887,"status":107,"phases":51861,"enrollment":5690,"conditions":51862,"interventions":51863},[92],[27],[2186,10854],{"nctId":7570,"briefTitle":7571,"status":107,"phases":51865,"primaryCompletion":7573,"completion":7573,"start":7574,"enrollment":7575,"conditions":51866,"interventions":51867},[92],[7577],[2186,7579,7559],{"nctId":51869,"briefTitle":51870,"status":107,"phases":51871,"conditions":51872,"interventions":51873},"NCT00002166","An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease",[92],[27],[2186],{"trials":51875,"activeCount":101},[51876,51886,51893,51899,51906,51910,51914,51918],{"nctId":51877,"briefTitle":51878,"status":107,"phases":51879,"primaryCompletion":51880,"start":51881,"enrollment":956,"conditions":51882,"interventions":51884},"NCT00144261","An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects",[93],"2006-12-01","2003-11-01",[27,51883],"Metabolism, Lipids",[51885],"nevirapine",{"nctId":51887,"briefTitle":51888,"status":107,"phases":51889,"primaryCompletion":7276,"start":51890,"enrollment":5205,"conditions":51891,"interventions":51892},"NCT00144248","A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions",[93],"2004-06-25",[27,2526],[51885],{"nctId":51894,"briefTitle":51895,"status":107,"phases":51896,"primaryCompletion":6374,"completion":6374,"start":6029,"enrollment":1081,"conditions":51897,"interventions":51898},"NCT00273988","Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults",[93],[7577],[51885],{"nctId":51900,"briefTitle":51901,"status":107,"phases":51902,"primaryCompletion":6401,"completion":6401,"start":7132,"enrollment":5568,"conditions":51903,"interventions":51905},"NCT00274001","Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients",[93],[27,51904],"Quality of Life",[2186],{"nctId":2178,"briefTitle":2179,"status":107,"phases":51907,"primaryCompletion":2181,"start":2182,"enrollment":2183,"conditions":51908,"interventions":51909},[93],[27],[2186,323],{"nctId":7583,"briefTitle":7584,"status":107,"phases":51911,"primaryCompletion":2145,"completion":2145,"start":6871,"enrollment":231,"conditions":51912,"interventions":51913},[93],[7577],[2186,7579,7559],{"nctId":6881,"briefTitle":6882,"status":107,"phases":51915,"primaryCompletion":6884,"start":6701,"enrollment":380,"conditions":51916,"interventions":51917},[93],[27],[6845,2186],{"nctId":7550,"briefTitle":7551,"status":107,"phases":51919,"primaryCompletion":7114,"start":7553,"enrollment":2442,"conditions":51920,"interventions":51921},[93],[27],[2186,7531],{"trials":51923,"activeCount":101},[51924,51930,51936],{"nctId":51925,"briefTitle":51926,"status":107,"phases":51927,"primaryCompletion":6445,"start":6871,"enrollment":51761,"conditions":51928,"interventions":51929},"NCT02191215","Clinical and Therapeutic Evaluation of the Infection by HIV\u002FAIDS",[],[7577],[2186],{"nctId":51931,"briefTitle":51932,"status":107,"phases":51933,"enrollment":123,"conditions":51934,"interventions":51935},"NCT00002323","A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell",[94],[27],[2186,7579],{"nctId":51937,"briefTitle":51938,"status":107,"phases":51939,"primaryCompletion":5856,"start":7151,"enrollment":51940,"conditions":51941,"interventions":51942},"NCT00310843","Case-Control Viramune (Nevirapine) Toxicogenomics Study",[],889,[27],[2186],{"intervention":5978,"totalTrials":2442,"cells":51944},{"EARLY_PHASE1":51945,"PHASE1":51947,"PHASE2":51953,"PHASE3":51979,"PHASE4":52014,"NA":52041},{"trials":51946,"activeCount":101},[],{"trials":51948,"activeCount":101},[51949],{"nctId":19093,"briefTitle":19094,"status":107,"phases":51950,"primaryCompletion":2145,"start":6156,"enrollment":410,"conditions":51951,"interventions":51952},[90],[15],[19059,5978],{"trials":51954,"activeCount":101},[51955,51961,51965,51969,51973],{"nctId":51956,"briefTitle":51957,"status":107,"phases":51958,"primaryCompletion":2001,"completion":2001,"start":2648,"enrollment":3436,"conditions":51959,"interventions":51960},"NCT01383499","A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma",[91],[30],[5978,5978,5978,5978],{"nctId":19741,"briefTitle":19742,"status":107,"phases":51962,"primaryCompletion":19744,"completion":19744,"start":19745,"enrollment":19746,"conditions":51963,"interventions":51964},[91],[18],[19700,19749],{"nctId":7157,"briefTitle":7158,"status":107,"phases":51966,"primaryCompletion":5856,"start":2145,"enrollment":7160,"conditions":51967,"interventions":51968},[91],[30],[5978,7139],{"nctId":26542,"briefTitle":26543,"status":107,"phases":51970,"primaryCompletion":1989,"start":4413,"enrollment":11419,"conditions":51971,"interventions":51972},[91],[18],[26533,26547],{"nctId":51974,"briefTitle":51975,"status":107,"phases":51976,"primaryCompletion":9340,"start":1980,"enrollment":3389,"conditions":51977,"interventions":51978},"NCT01122680","Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma",[91],[30],[5978,26547,26547],{"trials":51980,"activeCount":101},[51981,51987,51993,52000,52006],{"nctId":51982,"briefTitle":51983,"status":107,"phases":51984,"primaryCompletion":11650,"completion":11650,"start":7003,"enrollment":2442,"conditions":51985,"interventions":51986},"NCT00274027","Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)",[92],[18],[26547],{"nctId":51988,"briefTitle":51989,"status":107,"phases":51990,"primaryCompletion":6156,"completion":6156,"start":6375,"enrollment":50152,"conditions":51991,"interventions":51992},"NCT00157235","Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients",[92],[18],[5978],{"nctId":51994,"briefTitle":51995,"status":107,"phases":51996,"primaryCompletion":6189,"start":5992,"enrollment":51997,"conditions":51998,"interventions":51999},"NCT00274573","Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity",[92],1639,[18],[5978],{"nctId":52001,"briefTitle":52002,"status":107,"phases":52003,"primaryCompletion":5843,"completion":5843,"start":5879,"enrollment":7476,"conditions":52004,"interventions":52005},"NCT00144326","A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[92],[18],[19749],{"nctId":52007,"briefTitle":52008,"status":107,"phases":52009,"primaryCompletion":52010,"start":52011,"enrollment":19939,"conditions":52012,"interventions":52013},"NCT00274508","Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients",[92],"2003-01-07","2000-10-10",[18],[26547],{"trials":52015,"activeCount":101},[52016,52023,52030,52037],{"nctId":52017,"briefTitle":52018,"status":107,"phases":52019,"primaryCompletion":6446,"completion":6446,"start":8108,"enrollment":52020,"conditions":52021,"interventions":52022},"NCT00239408","Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).",[93],311,[18],[26547],{"nctId":52024,"briefTitle":52025,"status":107,"phases":52026,"primaryCompletion":52027,"completion":52027,"start":18693,"enrollment":269,"conditions":52028,"interventions":52029},"NCT01663987","Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1",[93],"2014-05-01",[18],[26547],{"nctId":52031,"briefTitle":52032,"status":107,"phases":52033,"primaryCompletion":52034,"completion":52034,"start":18693,"enrollment":269,"conditions":52035,"interventions":52036},"NCT01662986","Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2",[93],"2014-04-01",[18],[26547],{"nctId":5972,"briefTitle":5973,"status":107,"phases":52038,"primaryCompletion":4392,"start":4507,"enrollment":5975,"conditions":52039,"interventions":52040},[93],[18],[5978,5832],{"trials":52042,"activeCount":101},[52043,52050,52058,52065],{"nctId":52044,"briefTitle":52045,"status":107,"phases":52046,"primaryCompletion":6374,"start":20755,"enrollment":52047,"conditions":52048,"interventions":52049},"NCT02172495","Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice",[],4700,[18],[5978],{"nctId":52051,"briefTitle":52052,"status":162,"phases":52053,"primaryCompletion":52054,"completion":52054,"start":52055,"enrollment":1340,"conditions":52056,"interventions":52057},"NCT05362487","Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug",[],"2023-01-18","2022-08-05",[18],[5978],{"nctId":52059,"briefTitle":52060,"status":107,"phases":52061,"primaryCompletion":6374,"start":20755,"enrollment":52062,"conditions":52063,"interventions":52064},"NCT02172482","Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[],63127,[18],[5978],{"nctId":52066,"briefTitle":52067,"status":107,"phases":52068,"primaryCompletion":1990,"start":4005,"enrollment":52069,"conditions":52070,"interventions":52071},"NCT02172521","Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation",[],1536,[18],[5978],{"intervention":6498,"totalTrials":5242,"cells":52073},{"EARLY_PHASE1":52074,"PHASE1":52076,"PHASE2":52105,"PHASE3":52107,"PHASE4":52131,"NA":52147},{"trials":52075,"activeCount":101},[],{"trials":52077,"activeCount":101},[52078,52082,52086,52092,52096],{"nctId":6491,"briefTitle":6492,"status":107,"phases":52079,"primaryCompletion":6494,"start":6495,"enrollment":401,"conditions":52080,"interventions":52081},[90],[15],[6498,6484],{"nctId":11681,"briefTitle":11682,"status":107,"phases":52083,"primaryCompletion":7114,"start":11123,"enrollment":188,"conditions":52084,"interventions":52085},[90],[15],[11674,6498],{"nctId":52087,"briefTitle":52088,"status":107,"phases":52089,"primaryCompletion":2649,"start":10775,"enrollment":1512,"conditions":52090,"interventions":52091},"NCT02183181","Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers",[90],[15],[6498,6498],{"nctId":49025,"briefTitle":49026,"status":107,"phases":52093,"primaryCompletion":11123,"start":7084,"enrollment":188,"conditions":52094,"interventions":52095},[90],[15],[49018,6498],{"nctId":52097,"briefTitle":52098,"status":107,"phases":52099,"primaryCompletion":52100,"completion":52101,"start":52102,"enrollment":1982,"conditions":52103,"interventions":52104},"NCT03684265","A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets",[90],"2018-10-30","2018-11-06","2018-10-05",[15],[6498,6498],{"trials":52106,"activeCount":101},[],{"trials":52108,"activeCount":101},[52109,52113,52117,52121,52125],{"nctId":11691,"briefTitle":11692,"status":107,"phases":52110,"primaryCompletion":6413,"completion":6413,"start":5868,"enrollment":11694,"conditions":52111,"interventions":52112},[92],[6609],[11674,6498],{"nctId":15161,"briefTitle":15162,"status":107,"phases":52114,"primaryCompletion":5915,"start":15164,"enrollment":7093,"conditions":52115,"interventions":52116},[92],[15166],[15150,6498,15168],{"nctId":16928,"briefTitle":16929,"status":107,"phases":52118,"primaryCompletion":6390,"start":7553,"enrollment":16931,"conditions":52119,"interventions":52120},[92],[6609],[6498,16917],{"nctId":11698,"briefTitle":11699,"status":107,"phases":52122,"primaryCompletion":11701,"completion":11702,"start":11703,"enrollment":2800,"conditions":52123,"interventions":52124},[92],[10667],[11674,6498],{"nctId":52126,"briefTitle":52127,"status":107,"phases":52128,"completion":5879,"start":20755,"enrollment":8109,"conditions":52129,"interventions":52130},"NCT00042068","A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis",[92],[10667],[6498],{"trials":52132,"activeCount":101},[52133,52137,52141],{"nctId":6581,"briefTitle":6582,"status":107,"phases":52134,"primaryCompletion":6030,"start":6584,"enrollment":6585,"conditions":52135,"interventions":52136},[93],[6587],[6498,6549,6589],{"nctId":6602,"briefTitle":6603,"status":107,"phases":52138,"primaryCompletion":6605,"start":6606,"enrollment":6607,"conditions":52139,"interventions":52140},[93],[6609],[6549,6498],{"nctId":52142,"briefTitle":52143,"status":107,"phases":52144,"primaryCompletion":5923,"start":7553,"enrollment":357,"conditions":52145,"interventions":52146},"NCT02183116","A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee",[93],[6609],[6498],{"trials":52148,"activeCount":101},[52149,52156,52162,52169],{"nctId":52150,"briefTitle":52151,"status":107,"phases":52152,"primaryCompletion":6155,"start":2112,"enrollment":52153,"conditions":52154,"interventions":52155},"NCT02184065","Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases",[],22639,[10667],[6498],{"nctId":52157,"briefTitle":52158,"status":107,"phases":52159,"primaryCompletion":15139,"start":5879,"enrollment":10776,"conditions":52160,"interventions":52161},"NCT02184052","Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions",[],[10667],[6498],{"nctId":52163,"briefTitle":52164,"status":107,"phases":52165,"primaryCompletion":6040,"start":7003,"enrollment":52166,"conditions":52167,"interventions":52168},"NCT02182739","Observational Study of Meloxicam in Any Labeled Indication",[],13039,[10667],[6498],{"nctId":52170,"briefTitle":52171,"status":107,"phases":52172,"primaryCompletion":9276,"start":6041,"enrollment":52173,"conditions":52174,"interventions":52175},"NCT02180516","Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome",[],9984,[10667],[6498,52176],"Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac",{"intervention":4094,"totalTrials":5242,"cells":52178},{"EARLY_PHASE1":52179,"PHASE1":52181,"PHASE2":52203,"PHASE3":52213,"PHASE4":52238,"NA":52244},{"trials":52180,"activeCount":101},[],{"trials":52182,"activeCount":101},[52183,52187,52191,52195,52199],{"nctId":33824,"briefTitle":33825,"status":107,"phases":52184,"primaryCompletion":1967,"start":1980,"enrollment":392,"conditions":52185,"interventions":52186},[90],[15],[33817,33829,33817,4094],{"nctId":9893,"briefTitle":9894,"status":107,"phases":52188,"primaryCompletion":4412,"start":5906,"enrollment":392,"conditions":52189,"interventions":52190},[90],[15],[4094,9872],{"nctId":4087,"briefTitle":4088,"status":107,"phases":52192,"primaryCompletion":4090,"completion":4090,"start":4091,"enrollment":912,"conditions":52193,"interventions":52194},[90],[15],[1242,4094,4013,2393,4095],{"nctId":4115,"briefTitle":4116,"status":600,"phases":52196,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":101,"conditions":52197,"interventions":52198},[90],[15],[4013,4094,4123,1242,4013,4123,1242,1242,4094,4123,2393,2393],{"nctId":4160,"briefTitle":4161,"status":107,"phases":52200,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":52201,"interventions":52202},[90],[15],[927,4044,4076,4165,928,4166,4167],{"trials":52204,"activeCount":101},[52205,52209],{"nctId":25575,"briefTitle":25576,"status":107,"phases":52206,"primaryCompletion":8086,"start":5869,"enrollment":10931,"conditions":52207,"interventions":52208},[91],[6098],[25566,25566,25566,25566,25566,25566,4165,25580,25580,25580],{"nctId":50610,"briefTitle":50611,"status":107,"phases":52210,"primaryCompletion":6911,"start":5842,"enrollment":12724,"conditions":52211,"interventions":52212},[91],[6098],[6561,6561,4094],{"trials":52214,"activeCount":101},[52215,52219,52223,52227,52234],{"nctId":16122,"briefTitle":16123,"status":107,"phases":52216,"primaryCompletion":9411,"start":7151,"enrollment":16125,"conditions":52217,"interventions":52218},[92],[10332],[16111,4165],{"nctId":13161,"briefTitle":13162,"status":107,"phases":52220,"primaryCompletion":9404,"start":4462,"enrollment":13164,"conditions":52221,"interventions":52222},[92],[6098,2092],[4165,13150,13167],{"nctId":50651,"briefTitle":50652,"status":107,"phases":52224,"primaryCompletion":9348,"start":6471,"enrollment":50654,"conditions":52225,"interventions":52226},[92],[10332],[4094,6561],{"nctId":52228,"briefTitle":52229,"status":107,"phases":52230,"primaryCompletion":12600,"start":4498,"enrollment":52231,"conditions":52232,"interventions":52233},"NCT00329238","Secondary Prevention of Venous Thrombo Embolism (VTE).",[92],2867,[10332],[29142,4094],{"nctId":50666,"briefTitle":50667,"status":107,"phases":52235,"primaryCompletion":50669,"completion":50669,"start":50670,"enrollment":641,"conditions":52236,"interventions":52237},[92],[10332],[6561,4094],{"trials":52239,"activeCount":101},[52240],{"nctId":7190,"briefTitle":7191,"status":107,"phases":52241,"primaryCompletion":7193,"completion":7194,"start":7195,"enrollment":7196,"conditions":52242,"interventions":52243},[93],[6098],[4094,6522],{"trials":52245,"activeCount":101},[52246,52250,52260,52272],{"nctId":50703,"briefTitle":50704,"status":107,"phases":52247,"primaryCompletion":50706,"completion":50706,"start":50707,"enrollment":50708,"conditions":52248,"interventions":52249},[],[6098],[6561,4094],{"nctId":52251,"briefTitle":52252,"status":107,"phases":52253,"primaryCompletion":52254,"completion":52255,"start":52256,"enrollment":52257,"conditions":52258,"interventions":52259},"NCT03254134","Comparative Effectiveness and Safety Between Warfarin and Dabigatran",[],"2017-10-30","2017-11-03","2017-10-20",22490,[6098],[4094,29142],{"nctId":52261,"briefTitle":52262,"status":107,"phases":52263,"primaryCompletion":52254,"completion":52264,"start":52265,"enrollment":52266,"conditions":52267,"interventions":52268},"NCT03254147","Medical Need of OAC Reversal",[],"2017-11-10","2017-10-15",53969,[6098],[4165,28330,52269,52270,52271],"Apixaban","Edoxaban","Rivaroxaban",{"nctId":52273,"briefTitle":52274,"status":107,"phases":52275,"primaryCompletion":22224,"completion":22224,"start":52276,"enrollment":52277,"conditions":52278,"interventions":52279},"NCT02631057","Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan",[],"2016-09-01",4313,[6098],[29142,4094],{"intervention":2393,"totalTrials":956,"cells":52281},{"EARLY_PHASE1":52282,"PHASE1":52284,"PHASE2":52342,"PHASE3":52344,"PHASE4":52346,"NA":52348},{"trials":52283,"activeCount":101},[],{"trials":52285,"activeCount":101},[52286,52290,52294,52298,52302,52306,52310,52314,52318,52322,52326,52330,52334,52338],{"nctId":27521,"briefTitle":27522,"status":107,"phases":52287,"primaryCompletion":7193,"completion":27524,"start":27525,"enrollment":357,"conditions":52288,"interventions":52289},[90],[15],[2393,971,413,969,2393,971,970,969],{"nctId":9887,"briefTitle":9888,"status":107,"phases":52291,"primaryCompletion":5856,"start":4413,"enrollment":1672,"conditions":52292,"interventions":52293},[90],[15],[2393,9872],{"nctId":4002,"briefTitle":4003,"status":107,"phases":52295,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":52296,"interventions":52297},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":50496,"briefTitle":50497,"status":107,"phases":52299,"primaryCompletion":11588,"start":2111,"enrollment":380,"conditions":52300,"interventions":52301},[90],[15],[6561,2393],{"nctId":28316,"briefTitle":28317,"status":107,"phases":52303,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":52304,"interventions":52305},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":2386,"briefTitle":2387,"status":107,"phases":52307,"primaryCompletion":2389,"completion":2390,"start":1217,"enrollment":177,"conditions":52308,"interventions":52309},[90],[15],[2370,969,2393],{"nctId":4068,"briefTitle":4069,"status":107,"phases":52311,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":28,"conditions":52312,"interventions":52313},[90],[15],[4075,927,4076,4077],{"nctId":4087,"briefTitle":4088,"status":107,"phases":52315,"primaryCompletion":4090,"completion":4090,"start":4091,"enrollment":912,"conditions":52316,"interventions":52317},[90],[15],[1242,4094,4013,2393,4095],{"nctId":43194,"briefTitle":43195,"status":107,"phases":52319,"primaryCompletion":9340,"start":9332,"enrollment":1672,"conditions":52320,"interventions":52321},[90],[15],[43187,2393],{"nctId":4115,"briefTitle":4116,"status":600,"phases":52323,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":101,"conditions":52324,"interventions":52325},[90],[15],[4013,4094,4123,1242,4013,4123,1242,1242,4094,4123,2393,2393],{"nctId":44962,"briefTitle":44963,"status":107,"phases":52327,"primaryCompletion":1967,"start":3754,"enrollment":380,"conditions":52328,"interventions":52329},[90],[15],[44955,2393],{"nctId":27541,"briefTitle":27542,"status":107,"phases":52331,"primaryCompletion":27544,"completion":27544,"start":27545,"enrollment":380,"conditions":52332,"interventions":52333},[90],[15],[2393,969,27548,27548,970,27548,971],{"nctId":4160,"briefTitle":4161,"status":107,"phases":52335,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":52336,"interventions":52337},[90],[15],[927,4044,4076,4165,928,4166,4167],{"nctId":20197,"briefTitle":20198,"status":107,"phases":52339,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":52340,"interventions":52341},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":52343,"activeCount":101},[],{"trials":52345,"activeCount":101},[],{"trials":52347,"activeCount":101},[],{"trials":52349,"activeCount":101},[52350],{"nctId":52351,"briefTitle":52352,"status":107,"phases":52353,"primaryCompletion":964,"completion":2702,"start":52354,"enrollment":1865,"conditions":52355,"interventions":52356},"NCT05741372","A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis",[94],"2023-09-07",[2968],[969,2393,52357,971],"Metformin hydrochlorid",{"intervention":12224,"totalTrials":912,"cells":52359},{"EARLY_PHASE1":52360,"PHASE1":52362,"PHASE2":52388,"PHASE3":52390,"PHASE4":52412,"NA":52423},{"trials":52361,"activeCount":101},[],{"trials":52363,"activeCount":101},[52364,52368,52372,52376,52380,52384],{"nctId":29288,"briefTitle":29289,"status":107,"phases":52365,"primaryCompletion":9418,"start":4516,"enrollment":357,"conditions":52366,"interventions":52367},[90],[15],[29281,6121,10908],{"nctId":32940,"briefTitle":32941,"status":107,"phases":52369,"primaryCompletion":9418,"start":6140,"enrollment":6117,"conditions":52370,"interventions":52371},[90],[15],[32933,6121,10908],{"nctId":10903,"briefTitle":10904,"status":107,"phases":52373,"primaryCompletion":9418,"start":6140,"enrollment":6117,"conditions":52374,"interventions":52375},[90],[15],[10896,6121,10908],{"nctId":49334,"briefTitle":49335,"status":107,"phases":52377,"primaryCompletion":11588,"start":4498,"enrollment":2887,"conditions":52378,"interventions":52379},[90],[15],[6121,10908],{"nctId":29294,"briefTitle":29295,"status":107,"phases":52381,"primaryCompletion":3763,"start":8911,"enrollment":357,"conditions":52382,"interventions":52383},[90],[15],[29299,6121,10908],{"nctId":28889,"briefTitle":28890,"status":107,"phases":52385,"primaryCompletion":20181,"start":6911,"enrollment":380,"conditions":52386,"interventions":52387},[90],[15],[6227,6228,12224],{"trials":52389,"activeCount":101},[],{"trials":52391,"activeCount":101},[52392,52396,52400,52404,52408],{"nctId":12218,"briefTitle":12219,"status":107,"phases":52393,"primaryCompletion":5856,"start":4516,"enrollment":12221,"conditions":52394,"interventions":52395},[92],[24],[12207,12224],{"nctId":12714,"briefTitle":12715,"status":107,"phases":52397,"primaryCompletion":9381,"start":2003,"enrollment":12717,"conditions":52398,"interventions":52399},[92],[24],[12224,7281,12703],{"nctId":16697,"briefTitle":16698,"status":107,"phases":52401,"primaryCompletion":603,"completion":603,"start":3762,"enrollment":1928,"conditions":52402,"interventions":52403},[92],[24],[16686,16686,12224],{"nctId":13333,"briefTitle":13334,"status":107,"phases":52405,"primaryCompletion":4412,"start":9418,"enrollment":13336,"conditions":52406,"interventions":52407},[92],[24],[13322,12224],{"nctId":13340,"briefTitle":13341,"status":107,"phases":52409,"primaryCompletion":5856,"start":4516,"enrollment":13343,"conditions":52410,"interventions":52411},[92],[24],[13322,12224],{"trials":52413,"activeCount":101},[52414],{"nctId":52415,"briefTitle":52416,"status":107,"phases":52417,"primaryCompletion":52418,"start":52419,"enrollment":1218,"conditions":52420,"interventions":52422},"NCT00242814","Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities",[93],"2007-03-29","2005-11-03",[24,52421],"Metabolic Syndrome X",[6478,10908],{"trials":52424,"activeCount":101},[52425],{"nctId":49572,"briefTitle":49573,"status":107,"phases":52426,"primaryCompletion":4391,"completion":4391,"start":6132,"enrollment":49575,"conditions":52427,"interventions":52428},[],[24],[6121,12224],{"intervention":29142,"totalTrials":188,"cells":52430},{"EARLY_PHASE1":52431,"PHASE1":52433,"PHASE2":52453,"PHASE3":52461,"PHASE4":52467,"NA":52469},{"trials":52432,"activeCount":101},[],{"trials":52434,"activeCount":101},[52435,52441,52445,52449],{"nctId":52436,"briefTitle":52437,"status":107,"phases":52438,"primaryCompletion":3731,"completion":3731,"start":4473,"enrollment":1429,"conditions":52439,"interventions":52440},"NCT02028780","Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects",[90],[15],[50476,28330,50476],{"nctId":28325,"briefTitle":28326,"status":107,"phases":52442,"primaryCompletion":6223,"start":4413,"enrollment":2382,"conditions":52443,"interventions":52444},[90],[15],[28330,9335,28331],{"nctId":30371,"briefTitle":30372,"status":107,"phases":52446,"primaryCompletion":378,"completion":378,"start":2001,"enrollment":13515,"conditions":52447,"interventions":52448},[90],[15],[29142,30357],{"nctId":29137,"briefTitle":29138,"status":107,"phases":52450,"primaryCompletion":11588,"start":2111,"enrollment":380,"conditions":52451,"interventions":52452},[90],[15],[29142,10041],{"trials":52454,"activeCount":101},[52455],{"nctId":52456,"briefTitle":52457,"status":107,"phases":52458,"primaryCompletion":9688,"completion":5283,"start":420,"enrollment":155,"conditions":52459,"interventions":52460},"NCT02223260","Tolerability , PK\u002FPD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children \u003C 1 Year of Age",[91],[10299],[28330],{"trials":52462,"activeCount":101},[52463],{"nctId":52228,"briefTitle":52229,"status":107,"phases":52464,"primaryCompletion":12600,"start":4498,"enrollment":52231,"conditions":52465,"interventions":52466},[92],[10332],[29142,4094],{"trials":52468,"activeCount":101},[],{"trials":52470,"activeCount":101},[52471,52478,52482,52486,52490,52497],{"nctId":52472,"briefTitle":52473,"status":162,"phases":52474,"primaryCompletion":52475,"completion":52475,"start":4442,"enrollment":20964,"conditions":52476,"interventions":52477},"NCT01153698","Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery",[],"2011-12-21",[10299,50680],[28330],{"nctId":52251,"briefTitle":52252,"status":107,"phases":52479,"primaryCompletion":52254,"completion":52255,"start":52256,"enrollment":52257,"conditions":52480,"interventions":52481},[],[6098],[4094,29142],{"nctId":52261,"briefTitle":52262,"status":107,"phases":52483,"primaryCompletion":52254,"completion":52264,"start":52265,"enrollment":52266,"conditions":52484,"interventions":52485},[],[6098],[4165,28330,52269,52270,52271],{"nctId":52273,"briefTitle":52274,"status":107,"phases":52487,"primaryCompletion":22224,"completion":22224,"start":52276,"enrollment":52277,"conditions":52488,"interventions":52489},[],[6098],[29142,4094],{"nctId":52491,"briefTitle":52492,"status":107,"phases":52493,"primaryCompletion":52494,"completion":52494,"start":824,"enrollment":2090,"conditions":52495,"interventions":52496},"NCT03258645","This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke",[],"2019-06-17",[6098],[29142],{"nctId":52498,"briefTitle":52499,"status":107,"phases":52500,"primaryCompletion":52501,"completion":52501,"start":52502,"enrollment":52503,"conditions":52504,"interventions":52505},"NCT04532528","ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years",[],"2023-05-08","2020-08-27",897,[6098],[29142],{"intervention":969,"totalTrials":281,"cells":52507},{"EARLY_PHASE1":52508,"PHASE1":52510,"PHASE2":52552,"PHASE3":52554,"PHASE4":52556,"NA":52558},{"trials":52509,"activeCount":101},[],{"trials":52511,"activeCount":101},[52512,52516,52520,52524,52528,52532,52536,52540,52544,52548],{"nctId":27521,"briefTitle":27522,"status":107,"phases":52513,"primaryCompletion":7193,"completion":27524,"start":27525,"enrollment":357,"conditions":52514,"interventions":52515},[90],[15],[2393,971,413,969,2393,971,970,969],{"nctId":28316,"briefTitle":28317,"status":107,"phases":52517,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":52518,"interventions":52519},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":2386,"briefTitle":2387,"status":107,"phases":52521,"primaryCompletion":2389,"completion":2390,"start":1217,"enrollment":177,"conditions":52522,"interventions":52523},[90],[15],[2370,969,2393],{"nctId":28246,"briefTitle":28247,"status":107,"phases":52525,"primaryCompletion":28249,"completion":28250,"start":28251,"enrollment":392,"conditions":52526,"interventions":52527},[90],[15],[969,362,971],{"nctId":4068,"briefTitle":4069,"status":107,"phases":52529,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":28,"conditions":52530,"interventions":52531},[90],[15],[4075,927,4076,4077],{"nctId":960,"briefTitle":961,"status":107,"phases":52533,"primaryCompletion":963,"completion":964,"start":965,"enrollment":132,"conditions":52534,"interventions":52535},[90],[15],[911,968,969,970,971],{"nctId":18962,"briefTitle":18963,"status":107,"phases":52537,"primaryCompletion":1864,"completion":1864,"start":697,"enrollment":1982,"conditions":52538,"interventions":52539},[90],[15],[969,4176],{"nctId":27541,"briefTitle":27542,"status":107,"phases":52541,"primaryCompletion":27544,"completion":27544,"start":27545,"enrollment":380,"conditions":52542,"interventions":52543},[90],[15],[2393,969,27548,27548,970,27548,971],{"nctId":46820,"briefTitle":46821,"status":107,"phases":52545,"primaryCompletion":228,"completion":228,"start":46823,"enrollment":1865,"conditions":52546,"interventions":52547},[90],[15],[969,46813,6561,46826],{"nctId":10036,"briefTitle":10037,"status":107,"phases":52549,"primaryCompletion":409,"completion":409,"start":9614,"enrollment":5205,"conditions":52550,"interventions":52551},[90],[15],[949,10041,4479,969,4479],{"trials":52553,"activeCount":101},[],{"trials":52555,"activeCount":101},[],{"trials":52557,"activeCount":101},[],{"trials":52559,"activeCount":101},[52560],{"nctId":52351,"briefTitle":52352,"status":107,"phases":52561,"primaryCompletion":964,"completion":2702,"start":52354,"enrollment":1865,"conditions":52562,"interventions":52563},[94],[2968],[969,2393,52357,971],{"intervention":1241,"totalTrials":281,"cells":52565},{"EARLY_PHASE1":52566,"PHASE1":52568,"PHASE2":52598,"PHASE3":52600,"PHASE4":52614,"NA":52616},{"trials":52567,"activeCount":101},[],{"trials":52569,"activeCount":101},[52570,52574,52578,52582,52586,52590,52594],{"nctId":4002,"briefTitle":4003,"status":107,"phases":52571,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":52572,"interventions":52573},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":10382,"briefTitle":10383,"status":107,"phases":52575,"primaryCompletion":9688,"completion":9688,"start":5275,"enrollment":448,"conditions":52576,"interventions":52577},[90],[15],[10368,1241,10368],{"nctId":4035,"briefTitle":4036,"status":107,"phases":52579,"primaryCompletion":516,"completion":419,"start":4038,"enrollment":716,"conditions":52580,"interventions":52581},[90],[4040],[927,4042,4043,4044,4045,4045,927,4044,4046,4042,4042,4047,4047,4042,4047,4048,4048,4048,4046,4048,4044,4045,4047,927,4042,4047,4048],{"nctId":20401,"briefTitle":20402,"status":107,"phases":52583,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":52584,"interventions":52585},[90],[15],[3981,4011,4013,4014,1241,20406,20407],{"nctId":1231,"briefTitle":1232,"status":107,"phases":52587,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":52588,"interventions":52589},[90],[1228,539],[1195,1240,1241,1242],{"nctId":4160,"briefTitle":4161,"status":107,"phases":52591,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":52592,"interventions":52593},[90],[15],[927,4044,4076,4165,928,4166,4167],{"nctId":20197,"briefTitle":20198,"status":107,"phases":52595,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":52596,"interventions":52597},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":52599,"activeCount":101},[],{"trials":52601,"activeCount":101},[52602,52606,52610],{"nctId":14407,"briefTitle":14408,"status":107,"phases":52603,"primaryCompletion":7574,"start":7084,"enrollment":14410,"conditions":52604,"interventions":52605},[92],[13290],[14396,14413,14414,14415,1241],{"nctId":10428,"briefTitle":10429,"status":107,"phases":52607,"primaryCompletion":10431,"completion":10432,"start":10407,"enrollment":10433,"conditions":52608,"interventions":52609},[92],[10435,10436],[10438,4044],{"nctId":10440,"briefTitle":10441,"status":107,"phases":52611,"primaryCompletion":9824,"completion":9824,"start":9515,"enrollment":10443,"conditions":52612,"interventions":52613},[92],[10445,10446],[10448,10438,10438,4044,10448,4044,10438,10448],{"trials":52615,"activeCount":101},[],{"trials":52617,"activeCount":101},[52618],{"nctId":4190,"briefTitle":4191,"status":107,"phases":52619,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":1564,"conditions":52620,"interventions":52621},[94],[2968],[1241,4011,4013,4198,1242],{"intervention":9095,"totalTrials":1081,"cells":52623},{"EARLY_PHASE1":52624,"PHASE1":52626,"PHASE2":52644,"PHASE3":52652,"PHASE4":52654,"NA":52660},{"trials":52625,"activeCount":101},[],{"trials":52627,"activeCount":101},[52628,52632,52636,52640],{"nctId":28107,"briefTitle":28108,"status":107,"phases":52629,"primaryCompletion":4119,"completion":4119,"start":4118,"enrollment":1237,"conditions":52630,"interventions":52631},[90],[6741],[28112,28100],{"nctId":34997,"briefTitle":34998,"status":107,"phases":52633,"primaryCompletion":7151,"start":5842,"enrollment":5870,"conditions":52634,"interventions":52635},[90],[15],[9095,34990,35002],{"nctId":28118,"briefTitle":28119,"status":107,"phases":52637,"primaryCompletion":28121,"completion":28121,"start":28122,"enrollment":1237,"conditions":52638,"interventions":52639},[90],[6741],[28112,28125],{"nctId":36015,"briefTitle":36016,"status":107,"phases":52641,"primaryCompletion":2032,"start":5856,"enrollment":380,"conditions":52642,"interventions":52643},[90],[15],[9095,36008],{"trials":52645,"activeCount":101},[52646],{"nctId":52647,"briefTitle":52648,"status":107,"phases":52649,"primaryCompletion":409,"completion":409,"start":446,"enrollment":6682,"conditions":52650,"interventions":52651},"NCT01726270","An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms",[91],[6704],[28112],{"trials":52653,"activeCount":101},[],{"trials":52655,"activeCount":101},[52656],{"nctId":9089,"briefTitle":9090,"status":107,"phases":52657,"primaryCompletion":6390,"start":6065,"enrollment":9092,"conditions":52658,"interventions":52659},[93],[6741],[9095,9076],{"trials":52661,"activeCount":101},[52662,52669,52676,52683],{"nctId":52663,"briefTitle":52664,"status":107,"phases":52665,"primaryCompletion":21078,"start":6375,"enrollment":52666,"conditions":52667,"interventions":52668},"NCT02244320","Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)",[],4150,[6741],[9095],{"nctId":52670,"briefTitle":52671,"status":107,"phases":52672,"primaryCompletion":1981,"start":15139,"enrollment":52673,"conditions":52674,"interventions":52675},"NCT02245529","Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia",[],982,[6741],[9095],{"nctId":52677,"briefTitle":52678,"status":107,"phases":52679,"primaryCompletion":19461,"start":6156,"enrollment":52680,"conditions":52681,"interventions":52682},"NCT02245555","Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia",[],1060,[6741],[9095],{"nctId":52684,"briefTitle":52685,"status":107,"phases":52686,"primaryCompletion":6374,"start":21078,"enrollment":52687,"conditions":52688,"interventions":52689},"NCT02245503","Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)",[],7391,[6741],[9095],{"intervention":49701,"totalTrials":1081,"cells":52691},{"EARLY_PHASE1":52692,"PHASE1":52694,"PHASE2":52696,"PHASE3":52698,"PHASE4":52730,"NA":52743},{"trials":52693,"activeCount":101},[],{"trials":52695,"activeCount":101},[],{"trials":52697,"activeCount":101},[],{"trials":52699,"activeCount":101},[52700,52704,52708,52712,52716,52722,52726],{"nctId":49695,"briefTitle":49696,"status":107,"phases":52701,"primaryCompletion":378,"completion":378,"start":5296,"enrollment":49698,"conditions":52702,"interventions":52703},[92],[18],[49701,49701,5899,5899,5900],{"nctId":49761,"briefTitle":49762,"status":107,"phases":52705,"primaryCompletion":378,"completion":378,"start":9538,"enrollment":49764,"conditions":52706,"interventions":52707},[92],[18],[49767,49768,5860,5959],{"nctId":49789,"briefTitle":49790,"status":107,"phases":52709,"primaryCompletion":611,"completion":611,"start":5296,"enrollment":49792,"conditions":52710,"interventions":52711},[92],[18],[49701,5899,5900,5899,49701],{"nctId":51551,"briefTitle":51552,"status":107,"phases":52713,"primaryCompletion":611,"completion":611,"start":9538,"enrollment":25,"conditions":52714,"interventions":52715},[92],[18],[49767,49767,5959],{"nctId":52717,"briefTitle":52718,"status":107,"phases":52719,"primaryCompletion":611,"completion":611,"start":9538,"enrollment":25618,"conditions":52720,"interventions":52721},"NCT01525615","A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD",[92],[18],[17072,49701],{"nctId":49863,"briefTitle":49864,"status":107,"phases":52723,"primaryCompletion":9515,"completion":9515,"start":3753,"enrollment":735,"conditions":52724,"interventions":52725},[92],[18],[49701,5899,5900,5899,49701],{"nctId":49882,"briefTitle":49883,"status":107,"phases":52727,"primaryCompletion":378,"completion":378,"start":3753,"enrollment":1252,"conditions":52728,"interventions":52729},[92],[18],[5860,5959,49701,49767],{"trials":52731,"activeCount":101},[52732],{"nctId":52733,"briefTitle":52734,"status":107,"phases":52735,"primaryCompletion":52736,"completion":52737,"start":52738,"enrollment":52739,"conditions":52740,"interventions":52741},"NCT04223843","A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale",[93],"2020-09-07","2020-09-29","2020-01-08",213,[18],[52742],"Tiotropium + olodaterol",{"trials":52744,"activeCount":101},[52745,52755],{"nctId":52746,"briefTitle":52747,"status":107,"phases":52748,"primaryCompletion":52749,"completion":52749,"start":52750,"enrollment":52751,"conditions":52752,"interventions":52753},"NCT04011475","A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA\u002FLAMA or LAMA Treatment",[],"2020-10-31","2019-12-29",1617,[18],[49767,52754,8585],"Other LABA\u002FLAMA",{"nctId":52756,"briefTitle":52757,"status":107,"phases":52758,"primaryCompletion":52759,"completion":52759,"start":52760,"enrollment":52761,"conditions":52762,"interventions":52763},"NCT05169424","A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)",[],"2021-12-27","2021-12-17",9117,[18],[49767,52764],"Fluticasone Furoate + Umeclidinium + Vilanterol",{"intervention":4013,"totalTrials":1081,"cells":52766},{"EARLY_PHASE1":52767,"PHASE1":52769,"PHASE2":52807,"PHASE3":52809,"PHASE4":52811,"NA":52813},{"trials":52768,"activeCount":101},[],{"trials":52770,"activeCount":101},[52771,52775,52779,52783,52787,52791,52795,52799,52803],{"nctId":50262,"briefTitle":50263,"status":107,"phases":52772,"primaryCompletion":7151,"start":5842,"enrollment":956,"conditions":52773,"interventions":52774},[90],[15],[4008,4010,4013],{"nctId":919,"briefTitle":920,"status":107,"phases":52776,"primaryCompletion":922,"completion":922,"start":923,"enrollment":401,"conditions":52777,"interventions":52778},[90],[15],[926,927,928,929],{"nctId":4002,"briefTitle":4003,"status":107,"phases":52780,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":52781,"interventions":52782},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":20401,"briefTitle":20402,"status":107,"phases":52784,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":52785,"interventions":52786},[90],[15],[3981,4011,4013,4014,1241,20406,20407],{"nctId":10015,"briefTitle":10016,"status":107,"phases":52788,"primaryCompletion":9593,"completion":9593,"start":2001,"enrollment":956,"conditions":52789,"interventions":52790},[90],[15],[9996,9996,928,9996],{"nctId":4087,"briefTitle":4088,"status":107,"phases":52792,"primaryCompletion":4090,"completion":4090,"start":4091,"enrollment":912,"conditions":52793,"interventions":52794},[90],[15],[1242,4094,4013,2393,4095],{"nctId":4115,"briefTitle":4116,"status":600,"phases":52796,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":101,"conditions":52797,"interventions":52798},[90],[15],[4013,4094,4123,1242,4013,4123,1242,1242,4094,4123,2393,2393],{"nctId":4160,"briefTitle":4161,"status":107,"phases":52800,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":52801,"interventions":52802},[90],[15],[927,4044,4076,4165,928,4166,4167],{"nctId":20197,"briefTitle":20198,"status":107,"phases":52804,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":52805,"interventions":52806},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":52808,"activeCount":101},[],{"trials":52810,"activeCount":101},[],{"trials":52812,"activeCount":101},[],{"trials":52814,"activeCount":101},[52815],{"nctId":4190,"briefTitle":4191,"status":107,"phases":52816,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":1564,"conditions":52817,"interventions":52818},[94],[2968],[1241,4011,4013,4198,1242],{"intervention":7579,"totalTrials":1340,"cells":52820},{"EARLY_PHASE1":52821,"PHASE1":52823,"PHASE2":52833,"PHASE3":52847,"PHASE4":52857,"NA":52863},{"trials":52822,"activeCount":101},[],{"trials":52824,"activeCount":101},[52825,52829],{"nctId":51807,"briefTitle":51808,"status":107,"phases":52826,"enrollment":357,"conditions":52827,"interventions":52828},[90],[27],[2186,7579],{"nctId":42249,"briefTitle":42250,"status":107,"phases":52830,"primaryCompletion":6030,"start":6015,"enrollment":123,"conditions":52831,"interventions":52832},[90],[15],[42242,42254,42255,42256,7579],{"trials":52834,"activeCount":101},[52835,52839,52843],{"nctId":10863,"briefTitle":10864,"status":107,"phases":52836,"primaryCompletion":2163,"start":6453,"enrollment":392,"conditions":52837,"interventions":52838},[91],[27],[4008,4010,10868,7579,10854,10869],{"nctId":51845,"briefTitle":51846,"status":107,"phases":52840,"enrollment":7476,"conditions":52841,"interventions":52842},[91],[27],[2186,7579],{"nctId":10871,"briefTitle":10872,"status":107,"phases":52844,"primaryCompletion":6413,"completion":6413,"start":5993,"enrollment":260,"conditions":52845,"interventions":52846},[91],[27],[2186,10854,7579],{"trials":52848,"activeCount":101},[52849,52853],{"nctId":10879,"briefTitle":10880,"status":107,"phases":52850,"primaryCompletion":7003,"start":2182,"enrollment":10882,"conditions":52851,"interventions":52852},[92],[27],[2186,7579,10854],{"nctId":7570,"briefTitle":7571,"status":107,"phases":52854,"primaryCompletion":7573,"completion":7573,"start":7574,"enrollment":7575,"conditions":52855,"interventions":52856},[92],[7577],[2186,7579,7559],{"trials":52858,"activeCount":101},[52859],{"nctId":7583,"briefTitle":7584,"status":107,"phases":52860,"primaryCompletion":2145,"completion":2145,"start":6871,"enrollment":231,"conditions":52861,"interventions":52862},[93],[7577],[2186,7579,7559],{"trials":52864,"activeCount":101},[52865],{"nctId":51931,"briefTitle":51932,"status":107,"phases":52866,"enrollment":123,"conditions":52867,"interventions":52868},[94],[27],[2186,7579],{"intervention":52870,"totalTrials":1340,"cells":52871},"Micardis®",{"EARLY_PHASE1":52872,"PHASE1":52874,"PHASE2":52876,"PHASE3":52886,"PHASE4":52888,"NA":52890},{"trials":52873,"activeCount":101},[],{"trials":52875,"activeCount":101},[],{"trials":52877,"activeCount":101},[52878],{"nctId":52879,"briefTitle":52880,"status":107,"phases":52881,"primaryCompletion":5843,"start":17247,"enrollment":2183,"conditions":52882,"interventions":52884},"NCT00146289","The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects",[91],[539,52883],"Insulin Resistance",[52885],"MICARDIS®",{"trials":52887,"activeCount":101},[],{"trials":52889,"activeCount":101},[],{"trials":52891,"activeCount":101},[52892,52899,52907,52914,52922,52929,52936,52944],{"nctId":52893,"briefTitle":52894,"status":107,"phases":52895,"primaryCompletion":2122,"start":6438,"enrollment":52896,"conditions":52897,"interventions":52898},"NCT02176850","Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension",[],19870,[24],[52870],{"nctId":52900,"briefTitle":52901,"status":107,"phases":52902,"primaryCompletion":5992,"start":7003,"enrollment":52903,"conditions":52904,"interventions":52905},"NCT02202525","Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension",[],2148,[24],[52870,52906],"Other hypertensives",{"nctId":52908,"briefTitle":52909,"status":107,"phases":52910,"primaryCompletion":5887,"start":2121,"enrollment":52911,"conditions":52912,"interventions":52913},"NCT02242331","Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure",[],19805,[24],[52870],{"nctId":52915,"briefTitle":52916,"status":107,"phases":52917,"primaryCompletion":1990,"start":4005,"enrollment":52918,"conditions":52919,"interventions":52920},"NCT02242825","Study to Evaluate the Effect of Micardis® \u002F MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus",[],8148,[24],[52870,52921],"MicardisPlus®",{"nctId":52923,"briefTitle":52924,"status":107,"phases":52925,"primaryCompletion":4461,"start":5869,"enrollment":52926,"conditions":52927,"interventions":52928},"NCT02262637","Micardis® \u002F MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)",[],4814,[24],[52870,52921],{"nctId":52930,"briefTitle":52931,"status":107,"phases":52932,"primaryCompletion":1990,"start":4005,"enrollment":52933,"conditions":52934,"interventions":52935},"NCT02242864","Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure",[],1527,[24],[52870,52921],{"nctId":52937,"briefTitle":52938,"status":107,"phases":52939,"primaryCompletion":5879,"start":7574,"enrollment":52940,"conditions":52941,"interventions":52942},"NCT02242357","Study to Evaluate Efficacy and Tolerability of Micardis®\u002FMicardis® Plus in Patients With Hypertension",[],14553,[24],[52870,52943],"Micardis® Plus",{"nctId":52945,"briefTitle":52946,"status":107,"phases":52947,"primaryCompletion":4462,"start":7574,"enrollment":27725,"conditions":52948,"interventions":52949},"NCT02262611","Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)",[],[24],[52870,52921],{"intervention":2095,"totalTrials":155,"cells":52951},{"EARLY_PHASE1":52952,"PHASE1":52954,"PHASE2":52960,"PHASE3":52962,"PHASE4":52980,"NA":52982},{"trials":52953,"activeCount":101},[],{"trials":52955,"activeCount":101},[52956],{"nctId":41679,"briefTitle":41680,"status":107,"phases":52957,"primaryCompletion":41682,"completion":41682,"start":25327,"enrollment":357,"conditions":52958,"interventions":52959},[90],[15],[2126,2126,41672],{"trials":52961,"activeCount":101},[],{"trials":52963,"activeCount":101},[52964,52968,52976],{"nctId":2085,"briefTitle":2086,"status":107,"phases":52965,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":2090,"conditions":52966,"interventions":52967},[92],[2092],[2094,2095],{"nctId":52969,"briefTitle":52970,"status":107,"phases":52971,"primaryCompletion":52972,"completion":52972,"start":52973,"enrollment":641,"conditions":52974,"interventions":52975},"NCT02930837","Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset",[92],"2017-12-11","2016-11-15",[2092],[2095],{"nctId":2118,"briefTitle":2119,"status":107,"phases":52977,"primaryCompletion":2121,"start":2122,"enrollment":2123,"conditions":52978,"interventions":52979},[92],[632],[2074,2126,2127],{"trials":52981,"activeCount":101},[],{"trials":52983,"activeCount":101},[52984,52991,52998,53005],{"nctId":52985,"briefTitle":52986,"status":107,"phases":52987,"primaryCompletion":2003,"start":2111,"enrollment":52988,"conditions":52989,"interventions":52990},"NCT02229890","An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke",[],593,[2092],[2095],{"nctId":52992,"briefTitle":52993,"status":162,"phases":52994,"primaryCompletion":7114,"start":7924,"enrollment":241,"conditions":52995,"interventions":52996},"NCT02235389","A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)",[],[632],[2126,52997],"Standard therapy",{"nctId":52999,"briefTitle":53000,"status":107,"phases":53001,"primaryCompletion":2145,"start":8108,"enrollment":53002,"conditions":53003,"interventions":53004},"NCT02229812","Safe Implementation of Thrombolysis in Stroke - Monitoring Study",[],6475,[2092],[2095],{"nctId":53006,"briefTitle":53007,"status":107,"phases":53008,"primaryCompletion":53009,"completion":53009,"start":19339,"enrollment":53010,"conditions":53011,"interventions":53013},"NCT04260347","SITS-IVT in Patients >80 Years Study",[],"2022-12-31",1655,[53012],"Ischaemic Stroke",[2126],{"intervention":50476,"totalTrials":112,"cells":53015},{"EARLY_PHASE1":53016,"PHASE1":53018,"PHASE2":53028,"PHASE3":53030,"PHASE4":53061,"NA":53063},{"trials":53017,"activeCount":101},[],{"trials":53019,"activeCount":101},[53020,53024],{"nctId":52436,"briefTitle":52437,"status":107,"phases":53021,"primaryCompletion":3731,"completion":3731,"start":4473,"enrollment":1429,"conditions":53022,"interventions":53023},[90],[15],[50476,28330,50476],{"nctId":50470,"briefTitle":50471,"status":107,"phases":53025,"primaryCompletion":723,"completion":723,"start":50473,"enrollment":188,"conditions":53026,"interventions":53027},[90],[10409],[6561,50476],{"trials":53029,"activeCount":101},[],{"trials":53031,"activeCount":101},[53032,53041,53048,53055],{"nctId":53033,"briefTitle":53034,"status":107,"phases":53035,"primaryCompletion":22125,"completion":53036,"start":53037,"enrollment":50121,"conditions":53038,"interventions":53039},"NCT02104947","Reversal of Dabigatran Anticoagulant Effect With Idarucizumab",[92],"2016-10-20","2014-05-06",[30368],[53040],"idarucizumab",{"nctId":53042,"briefTitle":53043,"status":107,"phases":53044,"primaryCompletion":19424,"completion":19424,"start":53045,"enrollment":272,"conditions":53046,"interventions":53047},"NCT02831660","CU Programme of Idarucizumab for Japanese Patients",[92],"2016-07-22",[30368],[53040],{"nctId":53049,"briefTitle":53050,"status":107,"phases":53051,"primaryCompletion":53052,"completion":53052,"start":22224,"enrollment":272,"conditions":53053,"interventions":53054},"NCT02815670","Reversal Dabigatran Anticoagulant Effect With Idarucizumab",[92],"2019-10-19",[30368],[50476],{"nctId":53056,"briefTitle":53057,"status":107,"phases":53058,"primaryCompletion":45804,"completion":45804,"start":5954,"enrollment":2442,"conditions":53059,"interventions":53060},"NCT03343704","This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding",[92],[30368],[50476],{"trials":53062,"activeCount":101},[],{"trials":53064,"activeCount":101},[53065],{"nctId":53066,"briefTitle":53067,"status":600,"phases":53068,"primaryCompletion":53069,"completion":53070,"start":53071,"enrollment":101,"conditions":53072,"interventions":53073},"NCT02798107","Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients",[],"2019-05-23","2019-05-24","2019-05-20",[30368],[53040],{"intervention":53075,"totalTrials":112,"cells":53076},"pramipexole immediate release",{"EARLY_PHASE1":53077,"PHASE1":53079,"PHASE2":53092,"PHASE3":53100,"PHASE4":53125,"NA":53127},{"trials":53078,"activeCount":101},[],{"trials":53080,"activeCount":101},[53081,53085],{"nctId":39203,"briefTitle":39204,"status":107,"phases":53082,"primaryCompletion":9276,"start":6235,"enrollment":177,"conditions":53083,"interventions":53084},[90],[15],[39196,39208,39209,39210,39211,39212,39213,39214],{"nctId":53086,"briefTitle":53087,"status":107,"phases":53088,"primaryCompletion":6133,"start":9396,"enrollment":380,"conditions":53089,"interventions":53090},"NCT01214109","Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers",[90],[15],[53091,53091,53075,53075],"pramipexole extended release",{"trials":53093,"activeCount":101},[53094],{"nctId":53095,"briefTitle":53096,"status":107,"phases":53097,"primaryCompletion":5905,"start":4507,"enrollment":8304,"conditions":53098,"interventions":53099},"NCT00558467","Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria",[91],[14871],[53075],{"trials":53101,"activeCount":101},[53102,53111,53118],{"nctId":53103,"briefTitle":53104,"status":107,"phases":53105,"primaryCompletion":5906,"start":4516,"enrollment":53106,"conditions":53107,"interventions":53108},"NCT00558025","Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease",[92],156,[6934],[53109,53110],"Pramipexole Extended Release","Pramipexole Immediate Release",{"nctId":53112,"briefTitle":53113,"status":107,"phases":53114,"primaryCompletion":7338,"completion":7338,"start":4442,"enrollment":53115,"conditions":53116,"interventions":53117},"NCT01191944","Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients",[92],475,[6934],[53075,53091],{"nctId":53119,"briefTitle":53120,"status":107,"phases":53121,"primaryCompletion":399,"start":9418,"enrollment":53122,"conditions":53123,"interventions":53124},"NCT00560508","A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period",[91,92],112,[6934],[53110,53109],{"trials":53126,"activeCount":101},[],{"trials":53128,"activeCount":101},[53129],{"nctId":53130,"briefTitle":53131,"status":107,"phases":53132,"primaryCompletion":6471,"completion":6471,"enrollment":1949,"conditions":53133,"interventions":53134},"NCT00651183","Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment",[],[6934],[53135],"Pramipexole immediate release",{"intervention":2731,"totalTrials":112,"cells":53137},{"EARLY_PHASE1":53138,"PHASE1":53140,"PHASE2":53158,"PHASE3":53160,"PHASE4":53170,"NA":53172},{"trials":53139,"activeCount":101},[],{"trials":53141,"activeCount":101},[53142,53146,53150,53154],{"nctId":5212,"briefTitle":5213,"status":107,"phases":53143,"primaryCompletion":5215,"completion":5216,"start":5217,"enrollment":1081,"conditions":53144,"interventions":53145},[90],[36],[78,2731],{"nctId":51176,"briefTitle":51177,"status":107,"phases":53147,"primaryCompletion":19461,"start":11581,"enrollment":536,"conditions":53148,"interventions":53149},[90],[33],[1129,2731],{"nctId":51192,"briefTitle":51193,"status":107,"phases":53151,"primaryCompletion":4128,"start":7300,"enrollment":2382,"conditions":53152,"interventions":53153},[90],[33],[2731,1129],{"nctId":5251,"briefTitle":5252,"status":107,"phases":53155,"primaryCompletion":5254,"completion":5254,"start":5255,"enrollment":177,"conditions":53156,"interventions":53157},[90],[36],[2731,78,78,78,78],{"trials":53159,"activeCount":101},[],{"trials":53161,"activeCount":101},[53162,53166],{"nctId":5348,"briefTitle":5349,"status":162,"phases":53163,"primaryCompletion":5351,"completion":5351,"start":5352,"enrollment":188,"conditions":53164,"interventions":53165},[92],[36],[5355,5355,3401],{"nctId":2719,"briefTitle":2720,"status":600,"phases":53167,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":101,"conditions":53168,"interventions":53169},[92],[2726,2727,2728],[2675,1461,2730,2731],{"trials":53171,"activeCount":101},[],{"trials":53173,"activeCount":101},[53174],{"nctId":51109,"briefTitle":51110,"status":107,"phases":53175,"primaryCompletion":4118,"completion":4118,"start":4441,"enrollment":3755,"conditions":53176,"interventions":53177},[],[33],[1492,1492,5355,39680],{"intervention":971,"totalTrials":1512,"cells":53179},{"EARLY_PHASE1":53180,"PHASE1":53182,"PHASE2":53204,"PHASE3":53206,"PHASE4":53208,"NA":53210},{"trials":53181,"activeCount":101},[],{"trials":53183,"activeCount":101},[53184,53188,53192,53196,53200],{"nctId":27521,"briefTitle":27522,"status":107,"phases":53185,"primaryCompletion":7193,"completion":27524,"start":27525,"enrollment":357,"conditions":53186,"interventions":53187},[90],[15],[2393,971,413,969,2393,971,970,969],{"nctId":28316,"briefTitle":28317,"status":107,"phases":53189,"primaryCompletion":28319,"completion":28319,"start":28320,"enrollment":1535,"conditions":53190,"interventions":53191},[90],[15],[2393,971,413,969,9335,27235,28323,459],{"nctId":28246,"briefTitle":28247,"status":107,"phases":53193,"primaryCompletion":28249,"completion":28250,"start":28251,"enrollment":392,"conditions":53194,"interventions":53195},[90],[15],[969,362,971],{"nctId":960,"briefTitle":961,"status":107,"phases":53197,"primaryCompletion":963,"completion":964,"start":965,"enrollment":132,"conditions":53198,"interventions":53199},[90],[15],[911,968,969,970,971],{"nctId":27541,"briefTitle":27542,"status":107,"phases":53201,"primaryCompletion":27544,"completion":27544,"start":27545,"enrollment":380,"conditions":53202,"interventions":53203},[90],[15],[2393,969,27548,27548,970,27548,971],{"trials":53205,"activeCount":101},[],{"trials":53207,"activeCount":101},[],{"trials":53209,"activeCount":101},[],{"trials":53211,"activeCount":101},[53212],{"nctId":52351,"briefTitle":52352,"status":107,"phases":53213,"primaryCompletion":964,"completion":2702,"start":52354,"enrollment":1865,"conditions":53214,"interventions":53215},[94],[2968],[969,2393,52357,971],{"intervention":8703,"totalTrials":1512,"cells":53217},{"EARLY_PHASE1":53218,"PHASE1":53220,"PHASE2":53234,"PHASE3":53236,"PHASE4":53245,"NA":53251},{"trials":53219,"activeCount":101},[],{"trials":53221,"activeCount":101},[53222,53226,53230],{"nctId":49324,"briefTitle":49325,"status":107,"phases":53223,"primaryCompletion":11123,"start":7084,"enrollment":251,"conditions":53224,"interventions":53225},[90],[15],[6121,8703],{"nctId":49356,"briefTitle":49357,"status":107,"phases":53227,"primaryCompletion":6438,"start":7553,"enrollment":1982,"conditions":53228,"interventions":53229},[90],[15],[8703,6121],{"nctId":44715,"briefTitle":44716,"status":107,"phases":53231,"primaryCompletion":6206,"start":6207,"enrollment":188,"conditions":53232,"interventions":53233},[90],[15],[44708,8703,6121],{"trials":53235,"activeCount":101},[],{"trials":53237,"activeCount":101},[53238],{"nctId":53239,"briefTitle":53240,"status":107,"phases":53241,"primaryCompletion":17270,"start":53242,"enrollment":231,"conditions":53243,"interventions":53244},"NCT02177331","Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension",[92],"1995-06",[24],[8703],{"trials":53246,"activeCount":101},[53247],{"nctId":8697,"briefTitle":8698,"status":107,"phases":53248,"primaryCompletion":6594,"start":8700,"enrollment":1982,"conditions":53249,"interventions":53250},[93],[24],[8703,8684],{"trials":53252,"activeCount":101},[53253],{"nctId":53254,"briefTitle":53255,"status":162,"phases":53256,"primaryCompletion":6949,"start":7250,"enrollment":53257,"conditions":53258,"interventions":53259},"NCT02240641","Effect of Caldine® on Renal Function in Balanced Hypertension",[],5417,[24],[8703,49613,53260,53261,53262,53263],"antihypertensive drugs","alpha blockers","Angiotensin-Converting Enzyme Inhibitors","beta blockers",{"intervention":53109,"totalTrials":166,"cells":53265},{"EARLY_PHASE1":53266,"PHASE1":53268,"PHASE2":53274,"PHASE3":53276,"PHASE4":53290,"NA":53292},{"trials":53267,"activeCount":101},[],{"trials":53269,"activeCount":101},[53270],{"nctId":53086,"briefTitle":53087,"status":107,"phases":53271,"primaryCompletion":6133,"start":9396,"enrollment":380,"conditions":53272,"interventions":53273},[90],[15],[53091,53091,53075,53075],{"trials":53275,"activeCount":101},[],{"trials":53277,"activeCount":101},[53278,53282,53286],{"nctId":53103,"briefTitle":53104,"status":107,"phases":53279,"primaryCompletion":5906,"start":4516,"enrollment":53106,"conditions":53280,"interventions":53281},[92],[6934],[53109,53110],{"nctId":53112,"briefTitle":53113,"status":107,"phases":53283,"primaryCompletion":7338,"completion":7338,"start":4442,"enrollment":53115,"conditions":53284,"interventions":53285},[92],[6934],[53075,53091],{"nctId":53119,"briefTitle":53120,"status":107,"phases":53287,"primaryCompletion":399,"start":9418,"enrollment":53122,"conditions":53288,"interventions":53289},[91,92],[6934],[53110,53109],{"trials":53291,"activeCount":101},[],{"trials":53293,"activeCount":101},[53294],{"nctId":53295,"briefTitle":53296,"status":107,"phases":53297,"primaryCompletion":5296,"start":3732,"enrollment":18786,"conditions":53298,"interventions":53299},"NCT01097421","Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease",[],[6934],[53109],{"intervention":52921,"totalTrials":166,"cells":53301},{"EARLY_PHASE1":53302,"PHASE1":53304,"PHASE2":53306,"PHASE3":53308,"PHASE4":53310,"NA":53312},{"trials":53303,"activeCount":101},[],{"trials":53305,"activeCount":101},[],{"trials":53307,"activeCount":101},[],{"trials":53309,"activeCount":101},[],{"trials":53311,"activeCount":101},[],{"trials":53313,"activeCount":101},[53314,53318,53322,53326,53330],{"nctId":52915,"briefTitle":52916,"status":107,"phases":53315,"primaryCompletion":1990,"start":4005,"enrollment":52918,"conditions":53316,"interventions":53317},[],[24],[52870,52921],{"nctId":52923,"briefTitle":52924,"status":107,"phases":53319,"primaryCompletion":4461,"start":5869,"enrollment":52926,"conditions":53320,"interventions":53321},[],[24],[52870,52921],{"nctId":52930,"briefTitle":52931,"status":107,"phases":53323,"primaryCompletion":1990,"start":4005,"enrollment":52933,"conditions":53324,"interventions":53325},[],[24],[52870,52921],{"nctId":52945,"briefTitle":52946,"status":107,"phases":53327,"primaryCompletion":4462,"start":7574,"enrollment":27725,"conditions":53328,"interventions":53329},[],[24],[52870,52921],{"nctId":53331,"briefTitle":53332,"status":107,"phases":53333,"primaryCompletion":7573,"start":6156,"enrollment":53334,"conditions":53335,"interventions":53336},"NCT02243566","Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)",[],2707,[24],[52921],{"intervention":14372,"totalTrials":1564,"cells":53338},{"EARLY_PHASE1":53339,"PHASE1":53341,"PHASE2":53343,"PHASE3":53345,"PHASE4":53351,"NA":53353},{"trials":53340,"activeCount":101},[],{"trials":53342,"activeCount":101},[],{"trials":53344,"activeCount":101},[],{"trials":53346,"activeCount":101},[53347],{"nctId":14366,"briefTitle":14367,"status":107,"phases":53348,"completion":7151,"start":7381,"enrollment":14369,"conditions":53349,"interventions":53350},[92],[632],[14355,14372],{"trials":53352,"activeCount":101},[],{"trials":53354,"activeCount":101},[53355,53362,53369],{"nctId":53356,"briefTitle":53357,"status":107,"phases":53358,"primaryCompletion":5662,"completion":5662,"start":3515,"enrollment":53359,"conditions":53360,"interventions":53361},"NCT05395338","1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients",[],12551,[2092],[14372],{"nctId":53363,"briefTitle":53364,"status":107,"phases":53365,"primaryCompletion":2565,"completion":2565,"start":5662,"enrollment":53366,"conditions":53367,"interventions":53368},"NCT05395351","Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization",[],113035,[2092],[14372],{"nctId":53370,"briefTitle":53371,"status":107,"phases":53372,"primaryCompletion":53373,"completion":53373,"start":53374,"enrollment":53375,"conditions":53376,"interventions":53377},"NCT05401149","Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients",[],"2022-12-14","2022-07-18",3058,[2092],[14372],{"intervention":4011,"totalTrials":1564,"cells":53379},{"EARLY_PHASE1":53380,"PHASE1":53382,"PHASE2":53396,"PHASE3":53398,"PHASE4":53400,"NA":53402},{"trials":53381,"activeCount":101},[],{"trials":53383,"activeCount":101},[53384,53388,53392],{"nctId":4002,"briefTitle":4003,"status":107,"phases":53385,"primaryCompletion":2145,"start":4005,"enrollment":1237,"conditions":53386,"interventions":53387},[90],[15],[4008,4009,4010,1241,4011,4012,4013,4014,1242,4015,2393,2393],{"nctId":20401,"briefTitle":20402,"status":107,"phases":53389,"primaryCompletion":4462,"start":1981,"enrollment":1672,"conditions":53390,"interventions":53391},[90],[15],[3981,4011,4013,4014,1241,20406,20407],{"nctId":20197,"briefTitle":20198,"status":107,"phases":53393,"primaryCompletion":5856,"start":4413,"enrollment":97,"conditions":53394,"interventions":53395},[90],[15],[3995,1241,4011,4012,4013,4014,20202,20203,2393],{"trials":53397,"activeCount":101},[],{"trials":53399,"activeCount":101},[],{"trials":53401,"activeCount":101},[],{"trials":53403,"activeCount":101},[53404],{"nctId":4190,"briefTitle":4191,"status":107,"phases":53405,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":1564,"conditions":53406,"interventions":53407},[94],[2968],[1241,4011,4013,4198,1242],{"intervention":19719,"totalTrials":1564,"cells":53409},{"EARLY_PHASE1":53410,"PHASE1":53412,"PHASE2":53418,"PHASE3":53420,"PHASE4":53422,"NA":53432},{"trials":53411,"activeCount":101},[],{"trials":53413,"activeCount":101},[53414],{"nctId":19713,"briefTitle":19714,"status":107,"phases":53415,"primaryCompletion":6235,"start":6472,"enrollment":3436,"conditions":53416,"interventions":53417},[90],[15],[19700,19718,19719],{"trials":53419,"activeCount":101},[],{"trials":53421,"activeCount":101},[],{"trials":53423,"activeCount":101},[53424],{"nctId":53425,"briefTitle":53426,"status":107,"phases":53427,"primaryCompletion":6374,"completion":6374,"start":6189,"enrollment":53428,"conditions":53429,"interventions":53430},"NCT00274079","SPIRIVA in Ususal Care",[93],395,[18],[53431],"SPIRIVA",{"trials":53433,"activeCount":101},[53434,53441],{"nctId":53435,"briefTitle":53436,"status":107,"phases":53437,"primaryCompletion":7573,"start":6156,"enrollment":53438,"conditions":53439,"interventions":53440},"NCT02172547","Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.",[],10821,[18],[19719],{"nctId":53442,"briefTitle":53443,"status":107,"phases":53444,"primaryCompletion":20912,"completion":10432,"start":10170,"enrollment":53445,"conditions":53446,"interventions":53447},"NCT02489981","Specific Use-result Surveillance of Spiriva Respimat in Asthmatics",[],359,[30],[19719],{"intervention":39680,"totalTrials":1564,"cells":53449},{"EARLY_PHASE1":53450,"PHASE1":53452,"PHASE2":53458,"PHASE3":53464,"PHASE4":53470,"NA":53472},{"trials":53451,"activeCount":101},[],{"trials":53453,"activeCount":101},[53454],{"nctId":39674,"briefTitle":39675,"status":162,"phases":53455,"primaryCompletion":28834,"completion":39677,"start":922,"enrollment":155,"conditions":53456,"interventions":53457},[90],[3553],[39667,39680,39681],{"trials":53459,"activeCount":101},[53460],{"nctId":4388,"briefTitle":4389,"status":107,"phases":53461,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":4219,"conditions":53462,"interventions":53463},[91],[1187],[1120,2730,3662,4395,2007],{"trials":53465,"activeCount":101},[53466],{"nctId":2719,"briefTitle":2720,"status":600,"phases":53467,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":101,"conditions":53468,"interventions":53469},[92],[2726,2727,2728],[2675,1461,2730,2731],{"trials":53471,"activeCount":101},[],{"trials":53473,"activeCount":101},[53474],{"nctId":51109,"briefTitle":51110,"status":107,"phases":53475,"primaryCompletion":4118,"completion":4118,"start":4441,"enrollment":3755,"conditions":53476,"interventions":53477},[],[33],[1492,1492,5355,39680],{"intervention":53479,"totalTrials":1564,"cells":53480},"Spiolto® Respimat®",{"EARLY_PHASE1":53481,"PHASE1":53483,"PHASE2":53485,"PHASE3":53487,"PHASE4":53489,"NA":53491},{"trials":53482,"activeCount":101},[],{"trials":53484,"activeCount":101},[],{"trials":53486,"activeCount":101},[],{"trials":53488,"activeCount":101},[],{"trials":53490,"activeCount":101},[],{"trials":53492,"activeCount":101},[53493,53501,53511,53520],{"nctId":53494,"briefTitle":53495,"status":107,"phases":53496,"primaryCompletion":648,"completion":648,"start":53497,"enrollment":53498,"conditions":53499,"interventions":53500},"NCT03663569","A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler",[],"2018-08-15",4819,[18],[53479],{"nctId":53502,"briefTitle":53503,"status":107,"phases":53504,"primaryCompletion":53505,"completion":53506,"start":53507,"enrollment":53508,"conditions":53509,"interventions":53510},"NCT03165045","Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)",[],"2019-02-04","2019-03-24","2017-05-26",1351,[18],[53479],{"nctId":53512,"briefTitle":53513,"status":107,"phases":53514,"primaryCompletion":18957,"completion":853,"start":53515,"enrollment":53516,"conditions":53517,"interventions":53518},"NCT03954132","Spiolto® Respimat® (Tiotropium\u002FOlodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)",[],"2019-06-07",469,[18],[53479,53519],"Triple-Therapy",{"nctId":53521,"briefTitle":53522,"status":107,"phases":53523,"primaryCompletion":53524,"completion":53524,"start":19348,"enrollment":50159,"conditions":53525,"interventions":53526},"NCT03003494","Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy",[],"2018-07-30",[18],[53479],{"intervention":53528,"totalTrials":1044,"cells":53529},"Atrovent®",{"EARLY_PHASE1":53530,"PHASE1":53532,"PHASE2":53534,"PHASE3":53536,"PHASE4":53538,"NA":53548},{"trials":53531,"activeCount":101},[],{"trials":53533,"activeCount":101},[],{"trials":53535,"activeCount":101},[],{"trials":53537,"activeCount":101},[],{"trials":53539,"activeCount":101},[53540],{"nctId":53541,"briefTitle":53542,"status":107,"phases":53543,"primaryCompletion":21078,"start":8108,"enrollment":53544,"conditions":53545,"interventions":53547},"NCT02238210","Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy",[93],230,[53546],"Cold",[53528],{"trials":53549,"activeCount":101},[53550,53557],{"nctId":53551,"briefTitle":53552,"status":107,"phases":53553,"primaryCompletion":7132,"start":7003,"enrollment":3389,"conditions":53554,"interventions":53555},"NCT02238184","Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)",[],[18],[53528,53556],"Ventilat®",{"nctId":53558,"briefTitle":53559,"status":107,"phases":53560,"primaryCompletion":8538,"start":7022,"enrollment":6263,"conditions":53561,"interventions":53562},"NCT02236715","Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease",[],[18],[53528],{"intervention":53564,"totalTrials":1044,"cells":53565},"Synvisc®",{"EARLY_PHASE1":53566,"PHASE1":53568,"PHASE2":53570,"PHASE3":53572,"PHASE4":53574,"NA":53576},{"trials":53567,"activeCount":101},[],{"trials":53569,"activeCount":101},[],{"trials":53571,"activeCount":101},[],{"trials":53573,"activeCount":101},[],{"trials":53575,"activeCount":101},[],{"trials":53577,"activeCount":101},[53578,53584,53590],{"nctId":53579,"briefTitle":53580,"status":107,"phases":53581,"primaryCompletion":11650,"start":6029,"enrollment":1991,"conditions":53582,"interventions":53583},"NCT02195492","Retrospective Follow-up of Synvisc® in Active Patients With Knee Osteoarthritis",[],[6609],[53564],{"nctId":53585,"briefTitle":53586,"status":107,"phases":53587,"primaryCompletion":11650,"start":6029,"enrollment":401,"conditions":53588,"interventions":53589},"NCT02195557","Retrospective Follow-up Study of Synvisc® in Patients With Knee Osteoarthritis",[],[6609],[53564],{"nctId":53591,"briefTitle":53592,"status":107,"phases":53593,"primaryCompletion":2163,"start":7553,"enrollment":2507,"conditions":53594,"interventions":53595},"NCT02195544","Use of Synvisc® in Knee Osteoarthritis - Survey on Practice",[],[6609],[53564],{"intervention":53597,"totalTrials":1044,"cells":53598},"Sifrol®",{"EARLY_PHASE1":53599,"PHASE1":53601,"PHASE2":53603,"PHASE3":53605,"PHASE4":53607,"NA":53609},{"trials":53600,"activeCount":101},[],{"trials":53602,"activeCount":101},[],{"trials":53604,"activeCount":101},[],{"trials":53606,"activeCount":101},[],{"trials":53608,"activeCount":101},[],{"trials":53610,"activeCount":101},[53611,53618,53625],{"nctId":53612,"briefTitle":53613,"status":107,"phases":53614,"primaryCompletion":8108,"start":6030,"enrollment":53615,"conditions":53616,"interventions":53617},"NCT02231255","Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease",[],1216,[6934],[53597],{"nctId":53619,"briefTitle":53620,"status":107,"phases":53621,"primaryCompletion":4412,"start":6140,"enrollment":53622,"conditions":53623,"interventions":53624},"NCT00721279","Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome",[],549,[11724],[53597],{"nctId":53626,"briefTitle":53627,"status":107,"phases":53628,"primaryCompletion":5993,"start":2162,"enrollment":53629,"conditions":53630,"interventions":53631},"NCT02231294","The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease",[],1464,[6934],[53597],{"intervention":6101,"totalTrials":1044,"cells":53633},{"EARLY_PHASE1":53634,"PHASE1":53636,"PHASE2":53638,"PHASE3":53640,"PHASE4":53642,"NA":53648},{"trials":53635,"activeCount":101},[],{"trials":53637,"activeCount":101},[],{"trials":53639,"activeCount":101},[],{"trials":53641,"activeCount":101},[],{"trials":53643,"activeCount":101},[53644],{"nctId":6092,"briefTitle":6093,"status":107,"phases":53645,"primaryCompletion":5233,"completion":5233,"start":6095,"enrollment":6096,"conditions":53646,"interventions":53647},[93],[6098],[6100,6101,6102,6101],{"trials":53649,"activeCount":101},[53650,53659],{"nctId":53651,"briefTitle":53652,"status":107,"phases":53653,"primaryCompletion":53654,"completion":53654,"start":53655,"enrollment":53656,"conditions":53657,"interventions":53658},"NCT01774370","SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea",[],"2017-02-17","2013-01-14",3182,[6098],[6101],{"nctId":53660,"briefTitle":53661,"status":107,"phases":53662,"primaryCompletion":53663,"completion":53663,"start":53664,"enrollment":53665,"conditions":53666,"interventions":53667},"NCT02849509","Patient Convenience Study- NIS RELATE",[],"2017-12-30","2016-06-20",1313,[6098],[6101,53668],"Vitamin K antagonist",{"intervention":53670,"totalTrials":1044,"cells":53671},"Alesion®",{"EARLY_PHASE1":53672,"PHASE1":53674,"PHASE2":53676,"PHASE3":53678,"PHASE4":53680,"NA":53682},{"trials":53673,"activeCount":101},[],{"trials":53675,"activeCount":101},[],{"trials":53677,"activeCount":101},[],{"trials":53679,"activeCount":101},[],{"trials":53681,"activeCount":101},[],{"trials":53683,"activeCount":101},[53684,53691,53698],{"nctId":53685,"briefTitle":53686,"status":107,"phases":53687,"primaryCompletion":4498,"start":6446,"enrollment":53688,"conditions":53689,"interventions":53690},"NCT02238223","Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet",[],2001,[11866],[53670],{"nctId":53692,"briefTitle":53693,"status":107,"phases":53694,"primaryCompletion":6471,"start":7300,"enrollment":53695,"conditions":53696,"interventions":53697},"NCT02238236","Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema\u002FDermatitis, Urticaria and Pruritus",[],3793,[11866],[53670],{"nctId":53699,"briefTitle":53700,"status":107,"phases":53701,"primaryCompletion":6140,"start":5843,"enrollment":25,"conditions":53702,"interventions":53704},"NCT02238249","Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria",[],[53703],"Urticaria",[53670],{"intervention":6478,"totalTrials":1044,"cells":53706},{"EARLY_PHASE1":53707,"PHASE1":53709,"PHASE2":53711,"PHASE3":53713,"PHASE4":53715,"NA":53725},{"trials":53708,"activeCount":101},[],{"trials":53710,"activeCount":101},[],{"trials":53712,"activeCount":101},[],{"trials":53714,"activeCount":101},[],{"trials":53716,"activeCount":101},[53717,53721],{"nctId":52415,"briefTitle":52416,"status":107,"phases":53718,"primaryCompletion":52418,"start":52419,"enrollment":1218,"conditions":53719,"interventions":53720},[93],[24,52421],[6478,10908],{"nctId":6468,"briefTitle":6469,"status":107,"phases":53722,"primaryCompletion":6471,"start":6472,"enrollment":6473,"conditions":53723,"interventions":53724},[93],[2092],[6476,6476,6477,6477,6478,6478,6479,6479,6420,6420,6480,6480],{"trials":53726,"activeCount":101},[53727],{"nctId":53728,"briefTitle":53729,"status":107,"phases":53730,"primaryCompletion":6811,"start":9404,"enrollment":1170,"conditions":53731,"interventions":53732},"NCT00879411","Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients",[],[24],[6478],{"intervention":50007,"totalTrials":1044,"cells":53734},{"EARLY_PHASE1":53735,"PHASE1":53737,"PHASE2":53739,"PHASE3":53741,"PHASE4":53743,"NA":53745},{"trials":53736,"activeCount":101},[],{"trials":53738,"activeCount":101},[],{"trials":53740,"activeCount":101},[],{"trials":53742,"activeCount":101},[],{"trials":53744,"activeCount":101},[],{"trials":53746,"activeCount":101},[53747,53751,53755],{"nctId":49989,"briefTitle":49990,"status":107,"phases":53748,"primaryCompletion":49992,"completion":49992,"start":49993,"enrollment":2102,"conditions":53749,"interventions":53750},[],[30],[5899,49996,49997],{"nctId":49999,"briefTitle":50000,"status":107,"phases":53752,"primaryCompletion":50002,"completion":50002,"start":18912,"enrollment":50003,"conditions":53753,"interventions":53754},[],[18],[5860,50006,5959,50007],{"nctId":53756,"briefTitle":53757,"status":107,"phases":53758,"primaryCompletion":53759,"completion":53759,"start":18912,"enrollment":53760,"conditions":53761,"interventions":53762},"NCT05393245","Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data",[],"2022-12-07",19467,[18],[53763,53764,50007],"Tiotropium+Olodaterol","Long-acting muscarinic antagonists",{"intervention":53766,"totalTrials":1044,"cells":53767},"Atrovent® inhalets",{"EARLY_PHASE1":53768,"PHASE1":53770,"PHASE2":53772,"PHASE3":53774,"PHASE4":53776,"NA":53778},{"trials":53769,"activeCount":101},[],{"trials":53771,"activeCount":101},[],{"trials":53773,"activeCount":101},[],{"trials":53775,"activeCount":101},[],{"trials":53777,"activeCount":101},[],{"trials":53779,"activeCount":101},[53780,53786,53793],{"nctId":53781,"briefTitle":53782,"status":107,"phases":53783,"primaryCompletion":5880,"start":2163,"enrollment":51680,"conditions":53784,"interventions":53785},"NCT02238171","Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease",[],[18],[53766],{"nctId":53787,"briefTitle":53788,"status":107,"phases":53789,"primaryCompletion":6246,"start":7114,"enrollment":7485,"conditions":53790,"interventions":53791},"NCT02238132","Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease",[],[18],[53792],"ATROVENT® inhalets",{"nctId":53794,"briefTitle":53795,"status":107,"phases":53796,"primaryCompletion":6005,"start":7022,"enrollment":53797,"conditions":53798,"interventions":53799},"NCT02238158","Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease",[],595,[18],[53766],{"intervention":17072,"totalTrials":1044,"cells":53801},{"EARLY_PHASE1":53802,"PHASE1":53804,"PHASE2":53806,"PHASE3":53808,"PHASE4":53818,"NA":53820},{"trials":53803,"activeCount":101},[],{"trials":53805,"activeCount":101},[],{"trials":53807,"activeCount":101},[],{"trials":53809,"activeCount":101},[53810,53814],{"nctId":17066,"briefTitle":17067,"status":107,"phases":53811,"primaryCompletion":2002,"completion":437,"start":9824,"enrollment":17069,"conditions":53812,"interventions":53813},[92],[18],[17072,17055,5899],{"nctId":52717,"briefTitle":52718,"status":107,"phases":53815,"primaryCompletion":611,"completion":611,"start":9538,"enrollment":25618,"conditions":53816,"interventions":53817},[92],[18],[17072,49701],{"trials":53819,"activeCount":101},[],{"trials":53821,"activeCount":101},[53822],{"nctId":53756,"briefTitle":53757,"status":107,"phases":53823,"primaryCompletion":53759,"completion":53759,"start":18912,"enrollment":53760,"conditions":53824,"interventions":53825},[],[18],[53763,53764,50007],{"intervention":12316,"totalTrials":1075,"cells":53827},{"EARLY_PHASE1":53828,"PHASE1":53830,"PHASE2":53832,"PHASE3":53838,"PHASE4":53840,"NA":53842},{"trials":53829,"activeCount":101},[],{"trials":53831,"activeCount":101},[],{"trials":53833,"activeCount":101},[53834],{"nctId":12308,"briefTitle":12309,"status":107,"phases":53835,"primaryCompletion":6207,"start":7924,"enrollment":12311,"conditions":53836,"interventions":53837},[91],[12313],[12315,12299,12316],{"trials":53839,"activeCount":101},[],{"trials":53841,"activeCount":101},[],{"trials":53843,"activeCount":101},[53844],{"nctId":53845,"briefTitle":53846,"status":107,"phases":53847,"primaryCompletion":53848,"completion":53848,"start":53849,"enrollment":11419,"conditions":53850,"interventions":53851},"NCT02910167","Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima",[],"2017-02-20","2016-10-15",[6575,22079],[53852,12316,53852,12316],"Hyoscine n-butylbromide",{"intervention":53854,"totalTrials":1075,"cells":53855},"Tiotropium bromide + Olodaterol",{"EARLY_PHASE1":53856,"PHASE1":53858,"PHASE2":53860,"PHASE3":53862,"PHASE4":53864,"NA":53866},{"trials":53857,"activeCount":101},[],{"trials":53859,"activeCount":101},[],{"trials":53861,"activeCount":101},[],{"trials":53863,"activeCount":101},[],{"trials":53865,"activeCount":101},[],{"trials":53867,"activeCount":101},[53868,53877],{"nctId":53869,"briefTitle":53870,"status":107,"phases":53871,"primaryCompletion":53872,"completion":53872,"start":53873,"enrollment":53874,"conditions":53875,"interventions":53876},"NCT04926233","Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study",[],"2020-04-14","2019-11-15",1371146,[18],[53854],{"nctId":53878,"briefTitle":53879,"status":107,"phases":53880,"primaryCompletion":3879,"completion":3879,"start":53881,"enrollment":53882,"conditions":53883,"interventions":53885},"NCT04138758","Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA\u002FICS",[],"2019-11-01",42953,[53884],"COPD",[53854,53886],"LABA\u002FICS",{"intervention":53888,"totalTrials":1075,"cells":53889},"Berodual® Respimat® solution for inhalation",{"EARLY_PHASE1":53890,"PHASE1":53892,"PHASE2":53894,"PHASE3":53896,"PHASE4":53898,"NA":53900},{"trials":53891,"activeCount":101},[],{"trials":53893,"activeCount":101},[],{"trials":53895,"activeCount":101},[],{"trials":53897,"activeCount":101},[],{"trials":53899,"activeCount":101},[],{"trials":53901,"activeCount":101},[53902,53909],{"nctId":53903,"briefTitle":53904,"status":107,"phases":53905,"primaryCompletion":6413,"start":6401,"enrollment":53906,"conditions":53907,"interventions":53908},"NCT02231372","Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease",[],4602,[18],[53888],{"nctId":53910,"briefTitle":53904,"status":107,"phases":53911,"primaryCompletion":9276,"start":2112,"enrollment":53912,"conditions":53913,"interventions":53914},"NCT02231359",[],2006,[18],[53888],{"intervention":53916,"totalTrials":1075,"cells":53917},"Trazenta",{"EARLY_PHASE1":53918,"PHASE1":53920,"PHASE2":53922,"PHASE3":53924,"PHASE4":53926,"NA":53928},{"trials":53919,"activeCount":101},[],{"trials":53921,"activeCount":101},[],{"trials":53923,"activeCount":101},[],{"trials":53925,"activeCount":101},[],{"trials":53927,"activeCount":101},[],{"trials":53929,"activeCount":101},[53930,53939],{"nctId":53931,"briefTitle":53932,"status":107,"phases":53933,"primaryCompletion":53934,"completion":53934,"start":53935,"enrollment":53936,"conditions":53937,"interventions":53938},"NCT01904383","PMS of Trazenta on the Long-term Use as Add-on Therapy",[],"2018-10-04","2013-07-01",4057,[21],[53916],{"nctId":53940,"briefTitle":53941,"status":107,"phases":53942,"primaryCompletion":53943,"completion":53944,"start":2627,"enrollment":53945,"conditions":53946,"interventions":53947},"NCT01650259","Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus",[],"2017-09-05","2017-09-14",4876,[21],[53948,53916],"OAD",{"intervention":53950,"totalTrials":1075,"cells":53951},"Atrovent® - inhalets",{"EARLY_PHASE1":53952,"PHASE1":53954,"PHASE2":53956,"PHASE3":53958,"PHASE4":53960,"NA":53962},{"trials":53953,"activeCount":101},[],{"trials":53955,"activeCount":101},[],{"trials":53957,"activeCount":101},[],{"trials":53959,"activeCount":101},[],{"trials":53961,"activeCount":101},[],{"trials":53963,"activeCount":101},[53964,53971],{"nctId":53965,"briefTitle":53966,"status":107,"phases":53967,"primaryCompletion":5887,"start":7419,"enrollment":53968,"conditions":53969,"interventions":53970},"NCT02233894","Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease",[],526,[18],[53950],{"nctId":53972,"briefTitle":53973,"status":107,"phases":53974,"primaryCompletion":6015,"start":7003,"enrollment":53975,"conditions":53976,"interventions":53977},"NCT02233881","Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease",[],4222,[18],[53950],{"intervention":53979,"totalTrials":1075,"cells":53980},"Viramune®",{"EARLY_PHASE1":53981,"PHASE1":53983,"PHASE2":53985,"PHASE3":53987,"PHASE4":53989,"NA":53991},{"trials":53982,"activeCount":101},[],{"trials":53984,"activeCount":101},[],{"trials":53986,"activeCount":101},[],{"trials":53988,"activeCount":101},[],{"trials":53990,"activeCount":101},[],{"trials":53992,"activeCount":101},[53993,54000],{"nctId":53994,"briefTitle":53995,"status":107,"phases":53996,"primaryCompletion":6911,"start":5887,"enrollment":53997,"conditions":53998,"interventions":53999},"NCT02191293","Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®",[],228,[27],[53979],{"nctId":54001,"briefTitle":54002,"status":107,"phases":54003,"primaryCompletion":8479,"start":5993,"enrollment":1106,"conditions":54004,"interventions":54005},"NCT02191319","Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens",[],[27],[53979],{"intervention":54007,"totalTrials":1075,"cells":54008},"Berodual®",{"EARLY_PHASE1":54009,"PHASE1":54011,"PHASE2":54013,"PHASE3":54015,"PHASE4":54017,"NA":54019},{"trials":54010,"activeCount":101},[],{"trials":54012,"activeCount":101},[],{"trials":54014,"activeCount":101},[],{"trials":54016,"activeCount":101},[],{"trials":54018,"activeCount":101},[],{"trials":54020,"activeCount":101},[54021,54028],{"nctId":54022,"briefTitle":54023,"status":107,"phases":54024,"primaryCompletion":5880,"start":2181,"enrollment":54025,"conditions":54026,"interventions":54027},"NCT02232594","Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease",[],834,[18],[54007],{"nctId":54029,"briefTitle":54030,"status":107,"phases":54031,"primaryCompletion":6246,"start":6438,"enrollment":54032,"conditions":54033,"interventions":54034},"NCT02231437","Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease",[],3488,[18],[54007],{"intervention":8585,"totalTrials":1075,"cells":54036},{"EARLY_PHASE1":54037,"PHASE1":54039,"PHASE2":54041,"PHASE3":54043,"PHASE4":54045,"NA":54051},{"trials":54038,"activeCount":101},[],{"trials":54040,"activeCount":101},[],{"trials":54042,"activeCount":101},[],{"trials":54044,"activeCount":101},[],{"trials":54046,"activeCount":101},[54047],{"nctId":8577,"briefTitle":8578,"status":107,"phases":54048,"primaryCompletion":8580,"completion":8580,"start":109,"enrollment":507,"conditions":54049,"interventions":54050},[93],[18],[8564,8583,8584,8585],{"trials":54052,"activeCount":101},[54053],{"nctId":52746,"briefTitle":52747,"status":107,"phases":54054,"primaryCompletion":52749,"completion":52749,"start":52750,"enrollment":52751,"conditions":54055,"interventions":54056},[],[18],[49767,52754,8585],{"intervention":54058,"totalTrials":1075,"cells":54059},"Long-acting Muscarinic Antagonists",{"EARLY_PHASE1":54060,"PHASE1":54062,"PHASE2":54064,"PHASE3":54066,"PHASE4":54068,"NA":54070},{"trials":54061,"activeCount":101},[],{"trials":54063,"activeCount":101},[],{"trials":54065,"activeCount":101},[],{"trials":54067,"activeCount":101},[],{"trials":54069,"activeCount":101},[],{"trials":54071,"activeCount":101},[54072,54081],{"nctId":54073,"briefTitle":54074,"status":107,"phases":54075,"primaryCompletion":54076,"completion":54076,"start":734,"enrollment":54077,"conditions":54078,"interventions":54079},"NCT04172701","A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)",[],"2020-12-31",9284,[18],[54058,54080],"Inhaled corticosteroid",{"nctId":53756,"briefTitle":53757,"status":107,"phases":54082,"primaryCompletion":53759,"completion":53759,"start":18912,"enrollment":53760,"conditions":54083,"interventions":54084},[],[18],[53763,53764,50007],{"intervention":54080,"totalTrials":1075,"cells":54086},{"EARLY_PHASE1":54087,"PHASE1":54089,"PHASE2":54091,"PHASE3":54093,"PHASE4":54095,"NA":54097},{"trials":54088,"activeCount":101},[],{"trials":54090,"activeCount":101},[],{"trials":54092,"activeCount":101},[],{"trials":54094,"activeCount":101},[],{"trials":54096,"activeCount":101},[],{"trials":54098,"activeCount":101},[54099,54103],{"nctId":54073,"briefTitle":54074,"status":107,"phases":54100,"primaryCompletion":54076,"completion":54076,"start":734,"enrollment":54077,"conditions":54101,"interventions":54102},[],[18],[54058,54080],{"nctId":54104,"briefTitle":54105,"status":107,"phases":54106,"primaryCompletion":54107,"completion":54107,"start":16147,"enrollment":54108,"conditions":54109,"interventions":54110},"NCT03611777","The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.",[],"2020-01-31",901,[18],[54080],{"intervention":17227,"totalTrials":1075,"cells":54112},{"EARLY_PHASE1":54113,"PHASE1":54115,"PHASE2":54117,"PHASE3":54119,"PHASE4":54125,"NA":54127},{"trials":54114,"activeCount":101},[],{"trials":54116,"activeCount":101},[],{"trials":54118,"activeCount":101},[],{"trials":54120,"activeCount":101},[54121],{"nctId":17220,"briefTitle":17221,"status":107,"phases":54122,"primaryCompletion":10024,"completion":10024,"start":611,"enrollment":401,"conditions":54123,"interventions":54124},[92],[17224,17225],[17227,17209,17227,17227],{"trials":54126,"activeCount":101},[],{"trials":54128,"activeCount":101},[54129],{"nctId":54130,"briefTitle":54131,"status":162,"phases":54132,"primaryCompletion":6413,"start":6081,"enrollment":54133,"conditions":54134,"interventions":54135},"NCT02229799","Protocol for Post Marketing Surveillance of Actilyse Vial",[],265,[2092],[17227],{"intervention":54137,"totalTrials":1075,"cells":54138},"Ventilat® - metered dose inhaler",{"EARLY_PHASE1":54139,"PHASE1":54141,"PHASE2":54143,"PHASE3":54145,"PHASE4":54147,"NA":54149},{"trials":54140,"activeCount":101},[],{"trials":54142,"activeCount":101},[],{"trials":54144,"activeCount":101},[],{"trials":54146,"activeCount":101},[],{"trials":54148,"activeCount":101},[],{"trials":54150,"activeCount":101},[54151,54157],{"nctId":54152,"briefTitle":54153,"status":107,"phases":54154,"primaryCompletion":6584,"start":6207,"enrollment":53797,"conditions":54155,"interventions":54156},"NCT02233907","Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease",[],[18],[54137],{"nctId":54158,"briefTitle":54159,"status":107,"phases":54160,"primaryCompletion":5880,"start":2181,"enrollment":54161,"conditions":54162,"interventions":54163},"NCT02233920","Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis",[],716,[18],[54137],{"intervention":54165,"totalTrials":1075,"cells":54166},"ALNA®",{"EARLY_PHASE1":54167,"PHASE1":54169,"PHASE2":54171,"PHASE3":54173,"PHASE4":54175,"NA":54177},{"trials":54168,"activeCount":101},[],{"trials":54170,"activeCount":101},[],{"trials":54172,"activeCount":101},[],{"trials":54174,"activeCount":101},[],{"trials":54176,"activeCount":101},[],{"trials":54178,"activeCount":101},[54179,54186],{"nctId":54180,"briefTitle":54181,"status":107,"phases":54182,"primaryCompletion":6040,"start":6053,"enrollment":54183,"conditions":54184,"interventions":54185},"NCT02244268","Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia",[],3629,[6741],[54165],{"nctId":54187,"briefTitle":54188,"status":107,"phases":54189,"primaryCompletion":5868,"start":11733,"enrollment":54190,"conditions":54191,"interventions":54192},"NCT02244333","Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)",[],4575,[6741],[54165],{"intervention":50940,"totalTrials":1075,"cells":54194},{"EARLY_PHASE1":54195,"PHASE1":54197,"PHASE2":54199,"PHASE3":54205,"PHASE4":54207,"NA":54209},{"trials":54196,"activeCount":101},[],{"trials":54198,"activeCount":101},[],{"trials":54200,"activeCount":101},[54201],{"nctId":50932,"briefTitle":50933,"status":107,"phases":54202,"primaryCompletion":50935,"completion":1663,"start":50936,"enrollment":50937,"conditions":54203,"interventions":54204},[91],[2693],[1492,50940],{"trials":54206,"activeCount":101},[],{"trials":54208,"activeCount":101},[],{"trials":54210,"activeCount":101},[54211],{"nctId":51140,"briefTitle":51141,"status":107,"phases":54212,"primaryCompletion":51143,"completion":51143,"start":51144,"enrollment":51145,"conditions":54213,"interventions":54214},[],[51070],[1492,51148,51149,51138,1492,51138],{"intervention":49613,"totalTrials":1075,"cells":54216},{"EARLY_PHASE1":54217,"PHASE1":54219,"PHASE2":54221,"PHASE3":54223,"PHASE4":54225,"NA":54227},{"trials":54218,"activeCount":101},[],{"trials":54220,"activeCount":101},[],{"trials":54222,"activeCount":101},[],{"trials":54224,"activeCount":101},[],{"trials":54226,"activeCount":101},[],{"trials":54228,"activeCount":101},[54229,54233],{"nctId":53254,"briefTitle":53255,"status":162,"phases":54230,"primaryCompletion":6949,"start":7250,"enrollment":53257,"conditions":54231,"interventions":54232},[],[24],[8703,49613,53260,53261,53262,53263],{"nctId":49604,"briefTitle":49605,"status":107,"phases":54234,"primaryCompletion":9538,"start":9332,"enrollment":49607,"conditions":54235,"interventions":54236},[],[30613],[49610,49611,49612,49613,6121],{"intervention":53262,"totalTrials":1075,"cells":54238},{"EARLY_PHASE1":54239,"PHASE1":54241,"PHASE2":54243,"PHASE3":54245,"PHASE4":54247,"NA":54249},{"trials":54240,"activeCount":101},[],{"trials":54242,"activeCount":101},[],{"trials":54244,"activeCount":101},[],{"trials":54246,"activeCount":101},[],{"trials":54248,"activeCount":101},[],{"trials":54250,"activeCount":101},[54251,54255],{"nctId":53254,"briefTitle":53255,"status":162,"phases":54252,"primaryCompletion":6949,"start":7250,"enrollment":53257,"conditions":54253,"interventions":54254},[],[24],[8703,49613,53260,53261,53262,53263],{"nctId":49579,"briefTitle":49580,"status":107,"phases":54256,"primaryCompletion":6132,"start":6811,"enrollment":49582,"conditions":54257,"interventions":54258},[],[24],[6121,49585,49586,49587],{"intervention":8284,"totalTrials":1075,"cells":54260},{"EARLY_PHASE1":54261,"PHASE1":54263,"PHASE2":54265,"PHASE3":54267,"PHASE4":54269,"NA":54275},{"trials":54262,"activeCount":101},[],{"trials":54264,"activeCount":101},[],{"trials":54266,"activeCount":101},[],{"trials":54268,"activeCount":101},[],{"trials":54270,"activeCount":101},[54271],{"nctId":8278,"briefTitle":8279,"status":107,"phases":54272,"primaryCompletion":6413,"completion":6413,"start":7574,"enrollment":8281,"conditions":54273,"interventions":54274},[93],[24,21],[8284,8265],{"trials":54276,"activeCount":101},[54277],{"nctId":49550,"briefTitle":49551,"status":107,"phases":54278,"primaryCompletion":1990,"start":7151,"enrollment":49553,"conditions":54279,"interventions":54280},[],[24],[6121,49556],{"intervention":54282,"totalTrials":1075,"cells":54283},"tiotropium-bromide",{"EARLY_PHASE1":54284,"PHASE1":54286,"PHASE2":54288,"PHASE3":54297,"PHASE4":54299,"NA":54301},{"trials":54285,"activeCount":101},[],{"trials":54287,"activeCount":101},[],{"trials":54289,"activeCount":101},[54290],{"nctId":54291,"briefTitle":54292,"status":107,"phases":54293,"primaryCompletion":474,"completion":474,"start":9491,"enrollment":54294,"conditions":54295,"interventions":54296},"NCT01634113","Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma",[91],102,[30],[54282,54282],{"trials":54298,"activeCount":101},[],{"trials":54300,"activeCount":101},[],{"trials":54302,"activeCount":101},[54303],{"nctId":54304,"briefTitle":54305,"status":107,"phases":54306,"completion":4516,"enrollment":7575,"conditions":54307,"interventions":54308},"NCT00613574","RUSSE \u002F Russian Spiriva® Safety & Efficacy Study",[],[53884],[54282],{"intervention":49997,"totalTrials":1075,"cells":54310},{"EARLY_PHASE1":54311,"PHASE1":54313,"PHASE2":54315,"PHASE3":54317,"PHASE4":54319,"NA":54321},{"trials":54312,"activeCount":101},[],{"trials":54314,"activeCount":101},[],{"trials":54316,"activeCount":101},[],{"trials":54318,"activeCount":101},[],{"trials":54320,"activeCount":101},[],{"trials":54322,"activeCount":101},[54323,54327],{"nctId":49989,"briefTitle":49990,"status":107,"phases":54324,"primaryCompletion":49992,"completion":49992,"start":49993,"enrollment":2102,"conditions":54325,"interventions":54326},[],[30],[5899,49996,49997],{"nctId":49999,"briefTitle":50000,"status":107,"phases":54328,"primaryCompletion":50002,"completion":50002,"start":18912,"enrollment":50003,"conditions":54329,"interventions":54330},[],[18],[5860,50006,5959,50007],{"intervention":51015,"totalTrials":1075,"cells":54332},{"EARLY_PHASE1":54333,"PHASE1":54335,"PHASE2":54337,"PHASE3":54339,"PHASE4":54345,"NA":54347},{"trials":54334,"activeCount":101},[],{"trials":54336,"activeCount":101},[],{"trials":54338,"activeCount":101},[],{"trials":54340,"activeCount":101},[54341],{"nctId":51006,"briefTitle":51007,"status":107,"phases":54342,"primaryCompletion":51009,"completion":51010,"start":51011,"enrollment":51012,"conditions":54343,"interventions":54344},[92],[36],[2633,51015],{"trials":54346,"activeCount":101},[],{"trials":54348,"activeCount":101},[54349],{"nctId":51140,"briefTitle":51141,"status":107,"phases":54350,"primaryCompletion":51143,"completion":51143,"start":51144,"enrollment":51145,"conditions":54351,"interventions":54352},[],[51070],[1492,51148,51149,51138,1492,51138],{"intervention":54354,"totalTrials":1075,"cells":54355},"Berodual® Respimat® - inhaler",{"EARLY_PHASE1":54356,"PHASE1":54358,"PHASE2":54360,"PHASE3":54362,"PHASE4":54364,"NA":54366},{"trials":54357,"activeCount":101},[],{"trials":54359,"activeCount":101},[],{"trials":54361,"activeCount":101},[],{"trials":54363,"activeCount":101},[],{"trials":54365,"activeCount":101},[],{"trials":54367,"activeCount":101},[54368,54375],{"nctId":54369,"briefTitle":54370,"status":107,"phases":54371,"primaryCompletion":2111,"start":4462,"enrollment":54372,"conditions":54373,"interventions":54374},"NCT02231320","Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease",[],236,[18],[54354],{"nctId":54376,"briefTitle":54377,"status":107,"phases":54378,"primaryCompletion":6156,"start":5843,"enrollment":2800,"conditions":54379,"interventions":54380},"NCT02231346","Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease",[],[18],[54354],{"intervention":29984,"totalTrials":1075,"cells":54382},{"EARLY_PHASE1":54383,"PHASE1":54385,"PHASE2":54391,"PHASE3":54393,"PHASE4":54395,"NA":54397},{"trials":54384,"activeCount":101},[],{"trials":54386,"activeCount":101},[54387],{"nctId":29979,"briefTitle":29980,"status":107,"phases":54388,"primaryCompletion":6156,"start":7151,"enrollment":1418,"conditions":54389,"interventions":54390},[90],[15],[29984,29985,4468,29986],{"trials":54392,"activeCount":101},[],{"trials":54394,"activeCount":101},[],{"trials":54396,"activeCount":101},[],{"trials":54398,"activeCount":101},[54399],{"nctId":54400,"briefTitle":54401,"status":107,"phases":54402,"primaryCompletion":4412,"start":4517,"enrollment":1068,"conditions":54403,"interventions":54404},"NCT00614302","Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population",[],[27],[29984],{"intervention":54406,"totalTrials":1075,"cells":54407},"Dabigatran 150 mg",{"EARLY_PHASE1":54408,"PHASE1":54410,"PHASE2":54412,"PHASE3":54418,"PHASE4":54420,"NA":54422},{"trials":54409,"activeCount":101},[],{"trials":54411,"activeCount":101},[],{"trials":54413,"activeCount":101},[54414],{"nctId":25917,"briefTitle":25918,"status":107,"phases":54415,"primaryCompletion":4442,"start":2649,"enrollment":231,"conditions":54416,"interventions":54417},[91],[25921],[25908,25923,25924],{"trials":54419,"activeCount":101},[],{"trials":54421,"activeCount":101},[],{"trials":54423,"activeCount":101},[54424],{"nctId":54425,"briefTitle":54426,"status":107,"phases":54427,"primaryCompletion":4120,"completion":4120,"start":4391,"enrollment":54428,"conditions":54429,"interventions":54430},"NCT02149303","Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa",[],191,[6098,30368],[54431,54406],"Dabigatran 75 mg",{"intervention":8583,"totalTrials":1075,"cells":54433},{"EARLY_PHASE1":54434,"PHASE1":54436,"PHASE2":54438,"PHASE3":54440,"PHASE4":54442,"NA":54448},{"trials":54435,"activeCount":101},[],{"trials":54437,"activeCount":101},[],{"trials":54439,"activeCount":101},[],{"trials":54441,"activeCount":101},[],{"trials":54443,"activeCount":101},[54444],{"nctId":8577,"briefTitle":8578,"status":107,"phases":54445,"primaryCompletion":8580,"completion":8580,"start":109,"enrollment":507,"conditions":54446,"interventions":54447},[93],[18],[8564,8583,8584,8585],{"trials":54449,"activeCount":101},[54450],{"nctId":54451,"briefTitle":54452,"status":600,"phases":54453,"primaryCompletion":54454,"completion":54455,"start":54456,"enrollment":101,"conditions":54457,"interventions":54458},"NCT04402515","Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)",[],"2022-01-15","2022-01-31","2021-10-28",[18],[54459,8583],"TIO\u002FOLO",{"intervention":54461,"totalTrials":1075,"cells":54462},"Spiolto Respimat",{"EARLY_PHASE1":54463,"PHASE1":54465,"PHASE2":54467,"PHASE3":54469,"PHASE4":54471,"NA":54473},{"trials":54464,"activeCount":101},[],{"trials":54466,"activeCount":101},[],{"trials":54468,"activeCount":101},[],{"trials":54470,"activeCount":101},[],{"trials":54472,"activeCount":101},[],{"trials":54474,"activeCount":101},[54475,54485],{"nctId":54476,"briefTitle":54477,"status":107,"phases":54478,"primaryCompletion":54479,"completion":54480,"start":54481,"enrollment":54482,"conditions":54483,"interventions":54484},"NCT02675517","Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice",[],"2017-03-10","2017-04-11","2016-01-13",1737,[18],[54461],{"nctId":54486,"briefTitle":54487,"status":162,"phases":54488,"primaryCompletion":54489,"completion":54489,"start":6640,"enrollment":1928,"conditions":54490,"interventions":54491},"NCT02720757","Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)",[],"2017-12-14",[18],[54461],{"intervention":54493,"totalTrials":1075,"cells":54494},"Micardis® plus",{"EARLY_PHASE1":54495,"PHASE1":54497,"PHASE2":54499,"PHASE3":54501,"PHASE4":54503,"NA":54505},{"trials":54496,"activeCount":101},[],{"trials":54498,"activeCount":101},[],{"trials":54500,"activeCount":101},[],{"trials":54502,"activeCount":101},[],{"trials":54504,"activeCount":101},[],{"trials":54506,"activeCount":101},[54507,54514],{"nctId":54508,"briefTitle":54509,"status":107,"phases":54510,"primaryCompletion":8108,"start":20755,"enrollment":54511,"conditions":54512,"interventions":54513},"NCT02238275","Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension",[],8135,[24],[54493],{"nctId":52937,"briefTitle":52938,"status":107,"phases":54515,"primaryCompletion":5879,"start":7574,"enrollment":52940,"conditions":54516,"interventions":54517},[],[24],[52870,52943],{"intervention":8806,"totalTrials":1075,"cells":54519},{"EARLY_PHASE1":54520,"PHASE1":54522,"PHASE2":54524,"PHASE3":54526,"PHASE4":54528,"NA":54534},{"trials":54521,"activeCount":101},[],{"trials":54523,"activeCount":101},[],{"trials":54525,"activeCount":101},[],{"trials":54527,"activeCount":101},[],{"trials":54529,"activeCount":101},[54530],{"nctId":8800,"briefTitle":8801,"status":107,"phases":54531,"primaryCompletion":6856,"completion":8803,"start":1654,"enrollment":716,"conditions":54532,"interventions":54533},[93],[18],[8806,8787],{"trials":54535,"activeCount":101},[54536],{"nctId":54537,"briefTitle":54538,"status":107,"phases":54539,"primaryCompletion":54540,"completion":54540,"start":1856,"enrollment":54541,"conditions":54542,"interventions":54543},"NCT03964220","Impact of Tiotropium Add-on Therapy in Patients With Asthma",[],"2019-09-20",7857,[30],[8806,54544],"Inhaled Corticosteroid\u002FLong-acting beta-agonist",{"intervention":881,"totalTrials":1075,"cells":54546},{"EARLY_PHASE1":54547,"PHASE1":54549,"PHASE2":54551,"PHASE3":54553,"PHASE4":54555,"NA":54557},{"trials":54548,"activeCount":101},[],{"trials":54550,"activeCount":101},[],{"trials":54552,"activeCount":101},[],{"trials":54554,"activeCount":101},[],{"trials":54556,"activeCount":101},[],{"trials":54558,"activeCount":101},[54559,54563],{"nctId":873,"briefTitle":874,"status":107,"phases":54560,"primaryCompletion":876,"completion":876,"start":877,"enrollment":878,"conditions":54561,"interventions":54562},[],[21],[73,881],{"nctId":902,"briefTitle":903,"status":107,"phases":54564,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":54565,"interventions":54566},[],[21],[383,881],{"intervention":27773,"totalTrials":1075,"cells":54568},{"EARLY_PHASE1":54569,"PHASE1":54571,"PHASE2":54577,"PHASE3":54579,"PHASE4":54581,"NA":54583},{"trials":54570,"activeCount":101},[],{"trials":54572,"activeCount":101},[54573],{"nctId":27768,"briefTitle":27769,"status":107,"phases":54574,"primaryCompletion":2032,"start":4412,"enrollment":3398,"conditions":54575,"interventions":54576},[90],[15],[27737,27773],{"trials":54578,"activeCount":101},[],{"trials":54580,"activeCount":101},[],{"trials":54582,"activeCount":101},[],{"trials":54584,"activeCount":101},[54585],{"nctId":50240,"briefTitle":50241,"status":162,"phases":54586,"primaryCompletion":50243,"completion":50243,"start":50244,"enrollment":1468,"conditions":54587,"interventions":54588},[],[21],[361,27773],{"intervention":4198,"totalTrials":1075,"cells":54590},{"EARLY_PHASE1":54591,"PHASE1":54593,"PHASE2":54599,"PHASE3":54601,"PHASE4":54603,"NA":54605},{"trials":54592,"activeCount":101},[],{"trials":54594,"activeCount":101},[54595],{"nctId":4160,"briefTitle":4161,"status":107,"phases":54596,"primaryCompletion":474,"completion":474,"start":419,"enrollment":380,"conditions":54597,"interventions":54598},[90],[15],[927,4044,4076,4165,928,4166,4167],{"trials":54600,"activeCount":101},[],{"trials":54602,"activeCount":101},[],{"trials":54604,"activeCount":101},[],{"trials":54606,"activeCount":101},[54607],{"nctId":4190,"briefTitle":4191,"status":107,"phases":54608,"primaryCompletion":4193,"completion":4194,"start":4195,"enrollment":1564,"conditions":54609,"interventions":54610},[94],[2968],[1241,4011,4013,4198,1242],{"intervention":51138,"totalTrials":1075,"cells":54612},{"EARLY_PHASE1":54613,"PHASE1":54615,"PHASE2":54617,"PHASE3":54619,"PHASE4":54621,"NA":54623},{"trials":54614,"activeCount":101},[],{"trials":54616,"activeCount":101},[],{"trials":54618,"activeCount":101},[],{"trials":54620,"activeCount":101},[],{"trials":54622,"activeCount":101},[],{"trials":54624,"activeCount":101},[54625,54629],{"nctId":51131,"briefTitle":51132,"status":107,"phases":54626,"primaryCompletion":51134,"completion":51134,"start":51135,"enrollment":3182,"conditions":54627,"interventions":54628},[],[36],[1492,51138],{"nctId":51140,"briefTitle":51141,"status":107,"phases":54630,"primaryCompletion":51143,"completion":51143,"start":51144,"enrollment":51145,"conditions":54631,"interventions":54632},[],[51070],[1492,51148,51149,51138,1492,51138],{"intervention":54634,"totalTrials":272,"cells":54635},"Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids",{"EARLY_PHASE1":54636,"PHASE1":54638,"PHASE2":54640,"PHASE3":54642,"PHASE4":54644,"NA":54646},{"trials":54637,"activeCount":101},[],{"trials":54639,"activeCount":101},[],{"trials":54641,"activeCount":101},[],{"trials":54643,"activeCount":101},[],{"trials":54645,"activeCount":101},[],{"trials":54647,"activeCount":101},[54648],{"nctId":54649,"briefTitle":54650,"status":107,"phases":54651,"primaryCompletion":39421,"completion":39421,"start":54652,"enrollment":54653,"conditions":54654,"interventions":54655},"NCT03724877","Effectiveness of Triple Therapy in COPD",[],"2018-11-10",8853,[18],[54634,54656],"Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists",{"intervention":54656,"totalTrials":272,"cells":54658},{"EARLY_PHASE1":54659,"PHASE1":54661,"PHASE2":54663,"PHASE3":54665,"PHASE4":54667,"NA":54669},{"trials":54660,"activeCount":101},[],{"trials":54662,"activeCount":101},[],{"trials":54664,"activeCount":101},[],{"trials":54666,"activeCount":101},[],{"trials":54668,"activeCount":101},[],{"trials":54670,"activeCount":101},[54671],{"nctId":54649,"briefTitle":54650,"status":107,"phases":54672,"primaryCompletion":39421,"completion":39421,"start":54652,"enrollment":54653,"conditions":54673,"interventions":54674},[],[18],[54634,54656],{"intervention":51072,"totalTrials":272,"cells":54676},{"EARLY_PHASE1":54677,"PHASE1":54679,"PHASE2":54681,"PHASE3":54683,"PHASE4":54685,"NA":54687},{"trials":54678,"activeCount":101},[],{"trials":54680,"activeCount":101},[],{"trials":54682,"activeCount":101},[],{"trials":54684,"activeCount":101},[],{"trials":54686,"activeCount":101},[],{"trials":54688,"activeCount":101},[54689],{"nctId":51065,"briefTitle":51066,"status":107,"phases":54690,"primaryCompletion":887,"completion":887,"start":51068,"enrollment":4219,"conditions":54691,"interventions":54692},[],[51070],[1492,51072],{"intervention":54694,"totalTrials":272,"cells":54695},"Cymbalta",{"EARLY_PHASE1":54696,"PHASE1":54698,"PHASE2":54700,"PHASE3":54702,"PHASE4":54704,"NA":54706},{"trials":54697,"activeCount":101},[],{"trials":54699,"activeCount":101},[],{"trials":54701,"activeCount":101},[],{"trials":54703,"activeCount":101},[],{"trials":54705,"activeCount":101},[],{"trials":54707,"activeCount":101},[54708],{"nctId":54709,"briefTitle":54710,"status":107,"phases":54711,"primaryCompletion":9443,"start":2145,"enrollment":757,"conditions":54712,"interventions":54713},"NCT02215798","Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients",[],[6596],[54694],{"intervention":53556,"totalTrials":272,"cells":54715},{"EARLY_PHASE1":54716,"PHASE1":54718,"PHASE2":54720,"PHASE3":54722,"PHASE4":54724,"NA":54726},{"trials":54717,"activeCount":101},[],{"trials":54719,"activeCount":101},[],{"trials":54721,"activeCount":101},[],{"trials":54723,"activeCount":101},[],{"trials":54725,"activeCount":101},[],{"trials":54727,"activeCount":101},[54728],{"nctId":53551,"briefTitle":53552,"status":107,"phases":54729,"primaryCompletion":7132,"start":7003,"enrollment":3389,"conditions":54730,"interventions":54731},[],[18],[53528,53556],{"intervention":54733,"totalTrials":272,"cells":54734},"Telmisartan or Telmisartan and Hydrochlorthiazide",{"EARLY_PHASE1":54735,"PHASE1":54737,"PHASE2":54739,"PHASE3":54741,"PHASE4":54743,"NA":54745},{"trials":54736,"activeCount":101},[],{"trials":54738,"activeCount":101},[],{"trials":54740,"activeCount":101},[],{"trials":54742,"activeCount":101},[],{"trials":54744,"activeCount":101},[],{"trials":54746,"activeCount":101},[54747],{"nctId":54748,"briefTitle":54749,"status":107,"phases":54750,"primaryCompletion":6133,"start":4392,"enrollment":1252,"conditions":54751,"interventions":54752},"NCT01108809","Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients",[],[24],[54733],{"intervention":53852,"totalTrials":272,"cells":54754},{"EARLY_PHASE1":54755,"PHASE1":54757,"PHASE2":54759,"PHASE3":54761,"PHASE4":54763,"NA":54765},{"trials":54756,"activeCount":101},[],{"trials":54758,"activeCount":101},[],{"trials":54760,"activeCount":101},[],{"trials":54762,"activeCount":101},[],{"trials":54764,"activeCount":101},[],{"trials":54766,"activeCount":101},[54767],{"nctId":53845,"briefTitle":53846,"status":107,"phases":54768,"primaryCompletion":53848,"completion":53848,"start":53849,"enrollment":11419,"conditions":54769,"interventions":54770},[],[6575,22079],[53852,12316,53852,12316],{"intervention":54772,"totalTrials":272,"cells":54773},"Pradaxa®",{"EARLY_PHASE1":54774,"PHASE1":54776,"PHASE2":54778,"PHASE3":54780,"PHASE4":54782,"NA":54784},{"trials":54775,"activeCount":101},[],{"trials":54777,"activeCount":101},[],{"trials":54779,"activeCount":101},[],{"trials":54781,"activeCount":101},[],{"trials":54783,"activeCount":101},[],{"trials":54785,"activeCount":101},[54786],{"nctId":54787,"briefTitle":54788,"status":107,"phases":54789,"primaryCompletion":54790,"completion":18377,"start":18902,"enrollment":54791,"conditions":54792,"interventions":54793},"NCT03187197","Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation",[],"2018-06-30",1315,[6098],[54772],{"intervention":54795,"totalTrials":272,"cells":54796},"Spiriva (tiotropium bromide) inhalation",{"EARLY_PHASE1":54797,"PHASE1":54799,"PHASE2":54801,"PHASE3":54803,"PHASE4":54805,"NA":54807},{"trials":54798,"activeCount":101},[],{"trials":54800,"activeCount":101},[],{"trials":54802,"activeCount":101},[],{"trials":54804,"activeCount":101},[],{"trials":54806,"activeCount":101},[],{"trials":54808,"activeCount":101},[54809],{"nctId":54810,"briefTitle":54811,"status":107,"phases":54812,"primaryCompletion":6140,"start":11581,"enrollment":54813,"conditions":54814,"interventions":54815},"NCT02177318","Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease",[],3588,[18],[54795],{"intervention":54817,"totalTrials":272,"cells":54818},"Spiolto",{"EARLY_PHASE1":54819,"PHASE1":54821,"PHASE2":54823,"PHASE3":54825,"PHASE4":54827,"NA":54829},{"trials":54820,"activeCount":101},[],{"trials":54822,"activeCount":101},[],{"trials":54824,"activeCount":101},[],{"trials":54826,"activeCount":101},[],{"trials":54828,"activeCount":101},[],{"trials":54830,"activeCount":101},[54831],{"nctId":54832,"briefTitle":54833,"status":107,"phases":54834,"primaryCompletion":52100,"completion":54835,"start":54836,"enrollment":54837,"conditions":54838,"interventions":54839},"NCT02850978","Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease",[],"2018-11-30","2016-08-23",1335,[18],[54817],{"intervention":54841,"totalTrials":272,"cells":54842},"Second line (2L) afatinib",{"EARLY_PHASE1":54843,"PHASE1":54845,"PHASE2":54847,"PHASE3":54849,"PHASE4":54851,"NA":54853},{"trials":54844,"activeCount":101},[],{"trials":54846,"activeCount":101},[],{"trials":54848,"activeCount":101},[],{"trials":54850,"activeCount":101},[],{"trials":54852,"activeCount":101},[],{"trials":54854,"activeCount":101},[54855],{"nctId":54856,"briefTitle":54857,"status":107,"phases":54858,"primaryCompletion":298,"completion":298,"start":54859,"enrollment":10417,"conditions":54860,"interventions":54862},"NCT04552535","A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung",[],"2020-05-08",[54861],"Squamous Non-small Cell Lung Cancer",[54841,54863],"Second line chemotherapy",{"intervention":54863,"totalTrials":272,"cells":54865},{"EARLY_PHASE1":54866,"PHASE1":54868,"PHASE2":54870,"PHASE3":54872,"PHASE4":54874,"NA":54876},{"trials":54867,"activeCount":101},[],{"trials":54869,"activeCount":101},[],{"trials":54871,"activeCount":101},[],{"trials":54873,"activeCount":101},[],{"trials":54875,"activeCount":101},[],{"trials":54877,"activeCount":101},[54878],{"nctId":54856,"briefTitle":54857,"status":107,"phases":54879,"primaryCompletion":298,"completion":298,"start":54859,"enrollment":10417,"conditions":54880,"interventions":54881},[],[54861],[54841,54863],{"intervention":49527,"totalTrials":272,"cells":54883},{"EARLY_PHASE1":54884,"PHASE1":54886,"PHASE2":54888,"PHASE3":54890,"PHASE4":54892,"NA":54894},{"trials":54885,"activeCount":101},[],{"trials":54887,"activeCount":101},[],{"trials":54889,"activeCount":101},[],{"trials":54891,"activeCount":101},[],{"trials":54893,"activeCount":101},[],{"trials":54895,"activeCount":101},[54896],{"nctId":49521,"briefTitle":49522,"status":107,"phases":54897,"primaryCompletion":9418,"start":3978,"enrollment":49524,"conditions":54898,"interventions":54899},[],[24],[6121,49527],{"intervention":54901,"totalTrials":272,"cells":54902},"No Treatment",{"EARLY_PHASE1":54903,"PHASE1":54905,"PHASE2":54907,"PHASE3":54909,"PHASE4":54911,"NA":54913},{"trials":54904,"activeCount":101},[],{"trials":54906,"activeCount":101},[],{"trials":54908,"activeCount":101},[],{"trials":54910,"activeCount":101},[],{"trials":54912,"activeCount":101},[],{"trials":54914,"activeCount":101},[54915],{"nctId":54916,"briefTitle":54917,"status":107,"phases":54918,"primaryCompletion":53663,"completion":53663,"start":54919,"enrollment":54920,"conditions":54921,"interventions":54922},"NCT03064841","Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China",[],"2017-03-09",1537,[828],[54901],{"intervention":54924,"totalTrials":272,"cells":54925},"NOAC",{"EARLY_PHASE1":54926,"PHASE1":54928,"PHASE2":54930,"PHASE3":54932,"PHASE4":54934,"NA":54936},{"trials":54927,"activeCount":101},[],{"trials":54929,"activeCount":101},[],{"trials":54931,"activeCount":101},[],{"trials":54933,"activeCount":101},[],{"trials":54935,"activeCount":101},[],{"trials":54937,"activeCount":101},[54938],{"nctId":54939,"briefTitle":54940,"status":107,"phases":54941,"primaryCompletion":230,"completion":230,"start":54942,"enrollment":54943,"conditions":54944,"interventions":54945},"NCT03285373","This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain",[],"2017-11-29",1008,[6098],[54924],{"intervention":54947,"totalTrials":272,"cells":54948},"oral antidiabetic drugs",{"EARLY_PHASE1":54949,"PHASE1":54951,"PHASE2":54953,"PHASE3":54955,"PHASE4":54957,"NA":54959},{"trials":54950,"activeCount":101},[],{"trials":54952,"activeCount":101},[],{"trials":54954,"activeCount":101},[],{"trials":54956,"activeCount":101},[],{"trials":54958,"activeCount":101},[],{"trials":54960,"activeCount":101},[54961],{"nctId":54962,"briefTitle":54963,"status":107,"phases":54964,"primaryCompletion":54965,"completion":54965,"start":54965,"enrollment":54966,"conditions":54967,"interventions":54968},"NCT03092752","Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV",[],"2017-03-01",162116,[21],[54947],{"intervention":54970,"totalTrials":272,"cells":54971},"alpha-adrenergic blocker",{"EARLY_PHASE1":54972,"PHASE1":54974,"PHASE2":54976,"PHASE3":54978,"PHASE4":54980,"NA":54982},{"trials":54973,"activeCount":101},[],{"trials":54975,"activeCount":101},[],{"trials":54977,"activeCount":101},[],{"trials":54979,"activeCount":101},[],{"trials":54981,"activeCount":101},[],{"trials":54983,"activeCount":101},[54984],{"nctId":54985,"briefTitle":54986,"status":107,"phases":54987,"primaryCompletion":6871,"start":2181,"enrollment":54988,"conditions":54989,"interventions":54990},"NCT02244307","Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade",[],4561,[6741],[54970],{"intervention":50695,"totalTrials":272,"cells":54992},{"EARLY_PHASE1":54993,"PHASE1":54995,"PHASE2":54997,"PHASE3":54999,"PHASE4":55001,"NA":55003},{"trials":54994,"activeCount":101},[],{"trials":54996,"activeCount":101},[],{"trials":54998,"activeCount":101},[],{"trials":55000,"activeCount":101},[],{"trials":55002,"activeCount":101},[],{"trials":55004,"activeCount":101},[55005],{"nctId":50687,"briefTitle":50688,"status":107,"phases":55006,"primaryCompletion":50690,"completion":50690,"start":50691,"enrollment":50692,"conditions":55007,"interventions":55008},[],[6098],[6561,50695],{"intervention":55010,"totalTrials":272,"cells":55011},"Spiriva Respimat",{"EARLY_PHASE1":55012,"PHASE1":55014,"PHASE2":55016,"PHASE3":55018,"PHASE4":55020,"NA":55022},{"trials":55013,"activeCount":101},[],{"trials":55015,"activeCount":101},[],{"trials":55017,"activeCount":101},[],{"trials":55019,"activeCount":101},[],{"trials":55021,"activeCount":101},[],{"trials":55023,"activeCount":101},[55024],{"nctId":55025,"briefTitle":55026,"status":107,"phases":55027,"primaryCompletion":55028,"completion":5241,"start":55029,"enrollment":32181,"conditions":55030,"interventions":55031},"NCT03188120","Specific Use-Result of Spiriva Respimat® in Asthmatics",[],"2018-09-22","2017-07-04",[30],[55010],{"intervention":770,"totalTrials":272,"cells":55033},{"EARLY_PHASE1":55034,"PHASE1":55036,"PHASE2":55038,"PHASE3":55040,"PHASE4":55042,"NA":55044},{"trials":55035,"activeCount":101},[],{"trials":55037,"activeCount":101},[],{"trials":55039,"activeCount":101},[],{"trials":55041,"activeCount":101},[],{"trials":55043,"activeCount":101},[],{"trials":55045,"activeCount":101},[55046],{"nctId":763,"briefTitle":764,"status":600,"phases":55047,"primaryCompletion":766,"completion":766,"start":767,"enrollment":101,"conditions":55048,"interventions":55049},[],[21,662],[383,384,770],{"intervention":55051,"totalTrials":272,"cells":55052},"Dabigatran vs. Rivaroxaban",{"EARLY_PHASE1":55053,"PHASE1":55055,"PHASE2":55057,"PHASE3":55059,"PHASE4":55061,"NA":55063},{"trials":55054,"activeCount":101},[],{"trials":55056,"activeCount":101},[],{"trials":55058,"activeCount":101},[],{"trials":55060,"activeCount":101},[],{"trials":55062,"activeCount":101},[],{"trials":55064,"activeCount":101},[55065],{"nctId":55066,"briefTitle":55067,"status":107,"phases":55068,"primaryCompletion":55069,"completion":55069,"start":55070,"enrollment":55071,"conditions":55072,"interventions":55073},"NCT03026556","The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis",[],"2017-08-23","2016-12-29",42534,[6098],[55051,55074],"Dabigatran vs. Apixaban",{"intervention":55074,"totalTrials":272,"cells":55076},{"EARLY_PHASE1":55077,"PHASE1":55079,"PHASE2":55081,"PHASE3":55083,"PHASE4":55085,"NA":55087},{"trials":55078,"activeCount":101},[],{"trials":55080,"activeCount":101},[],{"trials":55082,"activeCount":101},[],{"trials":55084,"activeCount":101},[],{"trials":55086,"activeCount":101},[],{"trials":55088,"activeCount":101},[55089],{"nctId":55066,"briefTitle":55067,"status":107,"phases":55090,"primaryCompletion":55069,"completion":55069,"start":55070,"enrollment":55071,"conditions":55091,"interventions":55092},[],[6098],[55051,55074],{"intervention":55094,"totalTrials":272,"cells":55095},"Atrovent® Inhalation Solution",{"EARLY_PHASE1":55096,"PHASE1":55098,"PHASE2":55100,"PHASE3":55102,"PHASE4":55104,"NA":55106},{"trials":55097,"activeCount":101},[],{"trials":55099,"activeCount":101},[],{"trials":55101,"activeCount":101},[],{"trials":55103,"activeCount":101},[],{"trials":55105,"activeCount":101},[],{"trials":55107,"activeCount":101},[55108],{"nctId":55109,"briefTitle":55110,"status":107,"phases":55111,"primaryCompletion":6041,"start":7419,"enrollment":55112,"conditions":55113,"interventions":55114},"NCT02238197","Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease",[],477,[18],[55094],{"intervention":55116,"totalTrials":272,"cells":55117},"OFEV",{"EARLY_PHASE1":55118,"PHASE1":55120,"PHASE2":55122,"PHASE3":55124,"PHASE4":55126,"NA":55128},{"trials":55119,"activeCount":101},[],{"trials":55121,"activeCount":101},[],{"trials":55123,"activeCount":101},[],{"trials":55125,"activeCount":101},[],{"trials":55127,"activeCount":101},[],{"trials":55129,"activeCount":101},[55130],{"nctId":55131,"briefTitle":55132,"status":5515,"phases":55133,"conditions":55134,"interventions":55135},"NCT03843892","An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities",[],[2599],[55116],{"intervention":55137,"totalTrials":272,"cells":55138},"Telmisartan or Telmisartan + Hydrochlorothiazide",{"EARLY_PHASE1":55139,"PHASE1":55141,"PHASE2":55143,"PHASE3":55145,"PHASE4":55147,"NA":55149},{"trials":55140,"activeCount":101},[],{"trials":55142,"activeCount":101},[],{"trials":55144,"activeCount":101},[],{"trials":55146,"activeCount":101},[],{"trials":55148,"activeCount":101},[],{"trials":55150,"activeCount":101},[55151],{"nctId":55152,"briefTitle":55153,"status":107,"phases":55154,"primaryCompletion":9381,"start":9404,"enrollment":55155,"conditions":55156,"interventions":55157},"NCT00890084","Telmisartan Tab Hypertension",[],2913,[24],[55137],{"intervention":51604,"totalTrials":272,"cells":55159},{"EARLY_PHASE1":55160,"PHASE1":55162,"PHASE2":55164,"PHASE3":55166,"PHASE4":55168,"NA":55170},{"trials":55161,"activeCount":101},[],{"trials":55163,"activeCount":101},[],{"trials":55165,"activeCount":101},[],{"trials":55167,"activeCount":101},[],{"trials":55169,"activeCount":101},[],{"trials":55171,"activeCount":101},[55172],{"nctId":51597,"briefTitle":51598,"status":107,"phases":55173,"primaryCompletion":51600,"completion":51600,"start":10406,"enrollment":51601,"conditions":55174,"interventions":55175},[],[18],[5959,51604],{"intervention":789,"totalTrials":272,"cells":55177},{"EARLY_PHASE1":55178,"PHASE1":55180,"PHASE2":55182,"PHASE3":55184,"PHASE4":55186,"NA":55188},{"trials":55179,"activeCount":101},[],{"trials":55181,"activeCount":101},[],{"trials":55183,"activeCount":101},[],{"trials":55185,"activeCount":101},[],{"trials":55187,"activeCount":101},[],{"trials":55189,"activeCount":101},[55190],{"nctId":781,"briefTitle":782,"status":107,"phases":55191,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":55192,"interventions":55193},[],[21],[73,789],{"intervention":799,"totalTrials":272,"cells":55195},{"EARLY_PHASE1":55196,"PHASE1":55198,"PHASE2":55200,"PHASE3":55202,"PHASE4":55204,"NA":55206},{"trials":55197,"activeCount":101},[],{"trials":55199,"activeCount":101},[],{"trials":55201,"activeCount":101},[],{"trials":55203,"activeCount":101},[],{"trials":55205,"activeCount":101},[],{"trials":55207,"activeCount":101},[55208],{"nctId":791,"briefTitle":792,"status":107,"phases":55209,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":55210,"interventions":55211},[],[21],[73,799],{"intervention":55213,"totalTrials":272,"cells":55214},"Drug: Berodual®",{"EARLY_PHASE1":55215,"PHASE1":55217,"PHASE2":55219,"PHASE3":55221,"PHASE4":55223,"NA":55225},{"trials":55216,"activeCount":101},[],{"trials":55218,"activeCount":101},[],{"trials":55220,"activeCount":101},[],{"trials":55222,"activeCount":101},[],{"trials":55224,"activeCount":101},[],{"trials":55226,"activeCount":101},[55227],{"nctId":55228,"briefTitle":55229,"status":107,"phases":55230,"primaryCompletion":6246,"start":6438,"enrollment":16267,"conditions":55231,"interventions":55232},"NCT02231424","Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease",[],[18],[55213],{"intervention":52754,"totalTrials":272,"cells":55234},{"EARLY_PHASE1":55235,"PHASE1":55237,"PHASE2":55239,"PHASE3":55241,"PHASE4":55243,"NA":55245},{"trials":55236,"activeCount":101},[],{"trials":55238,"activeCount":101},[],{"trials":55240,"activeCount":101},[],{"trials":55242,"activeCount":101},[],{"trials":55244,"activeCount":101},[],{"trials":55246,"activeCount":101},[55247],{"nctId":52746,"briefTitle":52747,"status":107,"phases":55248,"primaryCompletion":52749,"completion":52749,"start":52750,"enrollment":52751,"conditions":55249,"interventions":55250},[],[18],[49767,52754,8585],{"intervention":52764,"totalTrials":272,"cells":55252},{"EARLY_PHASE1":55253,"PHASE1":55255,"PHASE2":55257,"PHASE3":55259,"PHASE4":55261,"NA":55263},{"trials":55254,"activeCount":101},[],{"trials":55256,"activeCount":101},[],{"trials":55258,"activeCount":101},[],{"trials":55260,"activeCount":101},[],{"trials":55262,"activeCount":101},[],{"trials":55264,"activeCount":101},[55265],{"nctId":52756,"briefTitle":52757,"status":107,"phases":55266,"primaryCompletion":52759,"completion":52759,"start":52760,"enrollment":52761,"conditions":55267,"interventions":55268},[],[18],[49767,52764],{"intervention":55270,"totalTrials":272,"cells":55271},"Telmisartan and hydrochlorothiazide",{"EARLY_PHASE1":55272,"PHASE1":55274,"PHASE2":55276,"PHASE3":55278,"PHASE4":55280,"NA":55282},{"trials":55273,"activeCount":101},[],{"trials":55275,"activeCount":101},[],{"trials":55277,"activeCount":101},[],{"trials":55279,"activeCount":101},[],{"trials":55281,"activeCount":101},[],{"trials":55283,"activeCount":101},[55284],{"nctId":55285,"briefTitle":55286,"status":107,"phases":55287,"primaryCompletion":20181,"start":6156,"enrollment":55288,"conditions":55289,"interventions":55290},"NCT02248129","Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide",[],4255,[24],[55270],{"intervention":55292,"totalTrials":272,"cells":55293},"Respimat",{"EARLY_PHASE1":55294,"PHASE1":55296,"PHASE2":55298,"PHASE3":55300,"PHASE4":55302,"NA":55304},{"trials":55295,"activeCount":101},[],{"trials":55297,"activeCount":101},[],{"trials":55299,"activeCount":101},[],{"trials":55301,"activeCount":101},[],{"trials":55303,"activeCount":101},[],{"trials":55305,"activeCount":101},[55306],{"nctId":55307,"briefTitle":55308,"status":107,"phases":55309,"primaryCompletion":46823,"completion":46823,"start":696,"enrollment":55310,"conditions":55311,"interventions":55312},"NCT04011735","Re-usable Respimat® Soft MistTM Inhaler Study",[],262,[18],[55292],{"intervention":55314,"totalTrials":272,"cells":55315},"Olodaterol\u002FTiotropium Bromide",{"EARLY_PHASE1":55316,"PHASE1":55318,"PHASE2":55320,"PHASE3":55322,"PHASE4":55324,"NA":55326},{"trials":55317,"activeCount":101},[],{"trials":55319,"activeCount":101},[],{"trials":55321,"activeCount":101},[],{"trials":55323,"activeCount":101},[],{"trials":55325,"activeCount":101},[],{"trials":55327,"activeCount":101},[55328],{"nctId":55329,"briefTitle":55330,"status":107,"phases":55331,"primaryCompletion":55332,"completion":55332,"start":55333,"enrollment":55334,"conditions":55335,"interventions":55336},"NCT03979807","A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[],"2019-06-11","2019-06-10",11296,[18],[55314,55337],"Umeclidinium\u002F Vilanterol",{"intervention":55337,"totalTrials":272,"cells":55339},{"EARLY_PHASE1":55340,"PHASE1":55342,"PHASE2":55344,"PHASE3":55346,"PHASE4":55348,"NA":55350},{"trials":55341,"activeCount":101},[],{"trials":55343,"activeCount":101},[],{"trials":55345,"activeCount":101},[],{"trials":55347,"activeCount":101},[],{"trials":55349,"activeCount":101},[],{"trials":55351,"activeCount":101},[55352],{"nctId":55329,"briefTitle":55330,"status":107,"phases":55353,"primaryCompletion":55332,"completion":55332,"start":55333,"enrollment":55334,"conditions":55354,"interventions":55355},[],[18],[55314,55337],{"intervention":52997,"totalTrials":272,"cells":55357},{"EARLY_PHASE1":55358,"PHASE1":55360,"PHASE2":55362,"PHASE3":55364,"PHASE4":55366,"NA":55368},{"trials":55359,"activeCount":101},[],{"trials":55361,"activeCount":101},[],{"trials":55363,"activeCount":101},[],{"trials":55365,"activeCount":101},[],{"trials":55367,"activeCount":101},[],{"trials":55369,"activeCount":101},[55370],{"nctId":52992,"briefTitle":52993,"status":162,"phases":55371,"primaryCompletion":7114,"start":7924,"enrollment":241,"conditions":55372,"interventions":55373},[],[632],[2126,52997],{"intervention":55375,"totalTrials":272,"cells":55376},"Twynsta",{"EARLY_PHASE1":55377,"PHASE1":55379,"PHASE2":55381,"PHASE3":55383,"PHASE4":55385,"NA":55387},{"trials":55378,"activeCount":101},[],{"trials":55380,"activeCount":101},[],{"trials":55382,"activeCount":101},[],{"trials":55384,"activeCount":101},[],{"trials":55386,"activeCount":101},[],{"trials":55388,"activeCount":101},[55389],{"nctId":55390,"briefTitle":55391,"status":107,"phases":55392,"primaryCompletion":55393,"completion":55394,"start":55395,"enrollment":55396,"conditions":55397,"interventions":55398},"NCT01243268","A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy",[],"2016-06-27","2016-08-18","2010-12-21",674,[24],[55375],{"intervention":55400,"totalTrials":272,"cells":55401},"Tiotropium and Olodaterol",{"EARLY_PHASE1":55402,"PHASE1":55404,"PHASE2":55406,"PHASE3":55408,"PHASE4":55410,"NA":55412},{"trials":55403,"activeCount":101},[],{"trials":55405,"activeCount":101},[],{"trials":55407,"activeCount":101},[],{"trials":55409,"activeCount":101},[],{"trials":55411,"activeCount":101},[],{"trials":55413,"activeCount":101},[55414],{"nctId":55415,"briefTitle":55416,"status":107,"phases":55417,"primaryCompletion":3879,"completion":3879,"start":53881,"enrollment":55418,"conditions":55419,"interventions":55420},"NCT04184297","Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy",[],27190,[18],[55400,55421],"Long-acting beta2-agonist and Inhaled corticosteroids",{"intervention":55421,"totalTrials":272,"cells":55423},{"EARLY_PHASE1":55424,"PHASE1":55426,"PHASE2":55428,"PHASE3":55430,"PHASE4":55432,"NA":55434},{"trials":55425,"activeCount":101},[],{"trials":55427,"activeCount":101},[],{"trials":55429,"activeCount":101},[],{"trials":55431,"activeCount":101},[],{"trials":55433,"activeCount":101},[],{"trials":55435,"activeCount":101},[55436],{"nctId":55415,"briefTitle":55416,"status":107,"phases":55437,"primaryCompletion":3879,"completion":3879,"start":53881,"enrollment":55418,"conditions":55438,"interventions":55439},[],[18],[55400,55421],{"intervention":55441,"totalTrials":272,"cells":55442},"DOAC or VKA",{"EARLY_PHASE1":55443,"PHASE1":55445,"PHASE2":55447,"PHASE3":55449,"PHASE4":55451,"NA":55453},{"trials":55444,"activeCount":101},[],{"trials":55446,"activeCount":101},[],{"trials":55448,"activeCount":101},[],{"trials":55450,"activeCount":101},[],{"trials":55452,"activeCount":101},[],{"trials":55454,"activeCount":101},[55455],{"nctId":55456,"briefTitle":55457,"status":107,"phases":55458,"primaryCompletion":55459,"completion":55459,"start":20127,"enrollment":13118,"conditions":55460,"interventions":55461},"NCT03134911","Health-related Quality of Life in Patients on Anticoagulants",[],"2018-01-31",[6098],[55441,55462],"VKA",{"intervention":55462,"totalTrials":272,"cells":55464},{"EARLY_PHASE1":55465,"PHASE1":55467,"PHASE2":55469,"PHASE3":55471,"PHASE4":55473,"NA":55475},{"trials":55466,"activeCount":101},[],{"trials":55468,"activeCount":101},[],{"trials":55470,"activeCount":101},[],{"trials":55472,"activeCount":101},[],{"trials":55474,"activeCount":101},[],{"trials":55476,"activeCount":101},[55477],{"nctId":55456,"briefTitle":55457,"status":107,"phases":55478,"primaryCompletion":55459,"completion":55459,"start":20127,"enrollment":13118,"conditions":55479,"interventions":55480},[],[6098],[55441,55462],{"intervention":55482,"totalTrials":272,"cells":55483},"Furoate\u002FUmeclidinium\u002FVilanterol",{"EARLY_PHASE1":55484,"PHASE1":55486,"PHASE2":55488,"PHASE3":55490,"PHASE4":55492,"NA":55494},{"trials":55485,"activeCount":101},[],{"trials":55487,"activeCount":101},[],{"trials":55489,"activeCount":101},[],{"trials":55491,"activeCount":101},[],{"trials":55493,"activeCount":101},[],{"trials":55495,"activeCount":101},[55496],{"nctId":55497,"briefTitle":55498,"status":107,"phases":55499,"primaryCompletion":55500,"completion":55500,"start":55501,"enrollment":55502,"conditions":55503,"interventions":55504},"NCT05127304","A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol",[],"2022-02-03","2021-02-26",11316,[18],[55482,55505],"Tiotropium Bromide\u002FOlodaterol",{"intervention":55505,"totalTrials":272,"cells":55507},{"EARLY_PHASE1":55508,"PHASE1":55510,"PHASE2":55512,"PHASE3":55514,"PHASE4":55516,"NA":55518},{"trials":55509,"activeCount":101},[],{"trials":55511,"activeCount":101},[],{"trials":55513,"activeCount":101},[],{"trials":55515,"activeCount":101},[],{"trials":55517,"activeCount":101},[],{"trials":55519,"activeCount":101},[55520],{"nctId":55497,"briefTitle":55498,"status":107,"phases":55521,"primaryCompletion":55500,"completion":55500,"start":55501,"enrollment":55502,"conditions":55522,"interventions":55523},[],[18],[55482,55505],{"intervention":55525,"totalTrials":272,"cells":55526},"Telmisartan 80mg",{"EARLY_PHASE1":55527,"PHASE1":55529,"PHASE2":55531,"PHASE3":55533,"PHASE4":55535,"NA":55537},{"trials":55528,"activeCount":101},[],{"trials":55530,"activeCount":101},[],{"trials":55532,"activeCount":101},[],{"trials":55534,"activeCount":101},[],{"trials":55536,"activeCount":101},[],{"trials":55538,"activeCount":101},[55539],{"nctId":55540,"briefTitle":55541,"status":107,"phases":55542,"primaryCompletion":6095,"completion":6095,"start":6811,"enrollment":55543,"conditions":55544,"interventions":55545},"NCT01050062","Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use",[],1452,[24],[55525,55546,55547],"Telmisartan 40mg","Hydrochlorothiazide 12.5mg",{"intervention":55546,"totalTrials":272,"cells":55549},{"EARLY_PHASE1":55550,"PHASE1":55552,"PHASE2":55554,"PHASE3":55556,"PHASE4":55558,"NA":55560},{"trials":55551,"activeCount":101},[],{"trials":55553,"activeCount":101},[],{"trials":55555,"activeCount":101},[],{"trials":55557,"activeCount":101},[],{"trials":55559,"activeCount":101},[],{"trials":55561,"activeCount":101},[55562],{"nctId":55540,"briefTitle":55541,"status":107,"phases":55563,"primaryCompletion":6095,"completion":6095,"start":6811,"enrollment":55543,"conditions":55564,"interventions":55565},[],[24],[55525,55546,55547],{"intervention":55547,"totalTrials":272,"cells":55567},{"EARLY_PHASE1":55568,"PHASE1":55570,"PHASE2":55572,"PHASE3":55574,"PHASE4":55576,"NA":55578},{"trials":55569,"activeCount":101},[],{"trials":55571,"activeCount":101},[],{"trials":55573,"activeCount":101},[],{"trials":55575,"activeCount":101},[],{"trials":55577,"activeCount":101},[],{"trials":55579,"activeCount":101},[55580],{"nctId":55540,"briefTitle":55541,"status":107,"phases":55581,"primaryCompletion":6095,"completion":6095,"start":6811,"enrollment":55543,"conditions":55582,"interventions":55583},[],[24],[55525,55546,55547],{"intervention":49980,"totalTrials":272,"cells":55585},{"EARLY_PHASE1":55586,"PHASE1":55588,"PHASE2":55590,"PHASE3":55592,"PHASE4":55594,"NA":55596},{"trials":55587,"activeCount":101},[],{"trials":55589,"activeCount":101},[],{"trials":55591,"activeCount":101},[],{"trials":55593,"activeCount":101},[],{"trials":55595,"activeCount":101},[],{"trials":55597,"activeCount":101},[55598],{"nctId":49973,"briefTitle":49974,"status":107,"phases":55599,"primaryCompletion":49976,"completion":49976,"start":5433,"enrollment":49977,"conditions":55600,"interventions":55601},[],[18],[49980,5860],{"intervention":55603,"totalTrials":272,"cells":55604},"Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor",{"EARLY_PHASE1":55605,"PHASE1":55607,"PHASE2":55609,"PHASE3":55611,"PHASE4":55613,"NA":55615},{"trials":55606,"activeCount":101},[],{"trials":55608,"activeCount":101},[],{"trials":55610,"activeCount":101},[],{"trials":55612,"activeCount":101},[],{"trials":55614,"activeCount":101},[],{"trials":55616,"activeCount":101},[55617],{"nctId":55618,"briefTitle":55619,"status":107,"phases":55620,"primaryCompletion":55621,"completion":55621,"start":18914,"enrollment":55622,"conditions":55623,"interventions":55624},"NCT03817463","A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes",[],"2021-12-10",327624,[21],[55603,55625],"Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor",{"intervention":55625,"totalTrials":272,"cells":55627},{"EARLY_PHASE1":55628,"PHASE1":55630,"PHASE2":55632,"PHASE3":55634,"PHASE4":55636,"NA":55638},{"trials":55629,"activeCount":101},[],{"trials":55631,"activeCount":101},[],{"trials":55633,"activeCount":101},[],{"trials":55635,"activeCount":101},[],{"trials":55637,"activeCount":101},[],{"trials":55639,"activeCount":101},[55640],{"nctId":55618,"briefTitle":55619,"status":107,"phases":55641,"primaryCompletion":55621,"completion":55621,"start":18914,"enrollment":55622,"conditions":55642,"interventions":55643},[],[21],[55603,55625],{"intervention":53260,"totalTrials":272,"cells":55645},{"EARLY_PHASE1":55646,"PHASE1":55648,"PHASE2":55650,"PHASE3":55652,"PHASE4":55654,"NA":55656},{"trials":55647,"activeCount":101},[],{"trials":55649,"activeCount":101},[],{"trials":55651,"activeCount":101},[],{"trials":55653,"activeCount":101},[],{"trials":55655,"activeCount":101},[],{"trials":55657,"activeCount":101},[55658],{"nctId":53254,"briefTitle":53255,"status":162,"phases":55659,"primaryCompletion":6949,"start":7250,"enrollment":53257,"conditions":55660,"interventions":55661},[],[24],[8703,49613,53260,53261,53262,53263],{"intervention":53261,"totalTrials":272,"cells":55663},{"EARLY_PHASE1":55664,"PHASE1":55666,"PHASE2":55668,"PHASE3":55670,"PHASE4":55672,"NA":55674},{"trials":55665,"activeCount":101},[],{"trials":55667,"activeCount":101},[],{"trials":55669,"activeCount":101},[],{"trials":55671,"activeCount":101},[],{"trials":55673,"activeCount":101},[],{"trials":55675,"activeCount":101},[55676],{"nctId":53254,"briefTitle":53255,"status":162,"phases":55677,"primaryCompletion":6949,"start":7250,"enrollment":53257,"conditions":55678,"interventions":55679},[],[24],[8703,49613,53260,53261,53262,53263],{"intervention":53263,"totalTrials":272,"cells":55681},{"EARLY_PHASE1":55682,"PHASE1":55684,"PHASE2":55686,"PHASE3":55688,"PHASE4":55690,"NA":55692},{"trials":55683,"activeCount":101},[],{"trials":55685,"activeCount":101},[],{"trials":55687,"activeCount":101},[],{"trials":55689,"activeCount":101},[],{"trials":55691,"activeCount":101},[],{"trials":55693,"activeCount":101},[55694],{"nctId":53254,"briefTitle":53255,"status":162,"phases":55695,"primaryCompletion":6949,"start":7250,"enrollment":53257,"conditions":55696,"interventions":55697},[],[24],[8703,49613,53260,53261,53262,53263],{"intervention":55699,"totalTrials":272,"cells":55700},"subjects treated with telmisartan\u002Fhydrochlorothiazide",{"EARLY_PHASE1":55701,"PHASE1":55703,"PHASE2":55705,"PHASE3":55707,"PHASE4":55709,"NA":55711},{"trials":55702,"activeCount":101},[],{"trials":55704,"activeCount":101},[],{"trials":55706,"activeCount":101},[],{"trials":55708,"activeCount":101},[],{"trials":55710,"activeCount":101},[],{"trials":55712,"activeCount":101},[55713],{"nctId":55714,"briefTitle":55715,"status":600,"phases":55716,"primaryCompletion":55717,"completion":55717,"start":55718,"enrollment":101,"conditions":55719,"interventions":55720},"NCT03205137","Comparison of the Medication Adherence of Patients Treated With Telmisartan\u002FHydrochlorothiazide or Telmisartan\u002FAmlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice",[],"2022-07-11","2022-06-01",[24],[55699,55721,55722,55723],"Subjects treated with Telmisartan and amlodipine","subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group","subjects treated with telmisartan+amlodipine double pill",{"intervention":55721,"totalTrials":272,"cells":55725},{"EARLY_PHASE1":55726,"PHASE1":55728,"PHASE2":55730,"PHASE3":55732,"PHASE4":55734,"NA":55736},{"trials":55727,"activeCount":101},[],{"trials":55729,"activeCount":101},[],{"trials":55731,"activeCount":101},[],{"trials":55733,"activeCount":101},[],{"trials":55735,"activeCount":101},[],{"trials":55737,"activeCount":101},[55738],{"nctId":55714,"briefTitle":55715,"status":600,"phases":55739,"primaryCompletion":55717,"completion":55717,"start":55718,"enrollment":101,"conditions":55740,"interventions":55741},[],[24],[55699,55721,55722,55723],{"intervention":55722,"totalTrials":272,"cells":55743},{"EARLY_PHASE1":55744,"PHASE1":55746,"PHASE2":55748,"PHASE3":55750,"PHASE4":55752,"NA":55754},{"trials":55745,"activeCount":101},[],{"trials":55747,"activeCount":101},[],{"trials":55749,"activeCount":101},[],{"trials":55751,"activeCount":101},[],{"trials":55753,"activeCount":101},[],{"trials":55755,"activeCount":101},[55756],{"nctId":55714,"briefTitle":55715,"status":600,"phases":55757,"primaryCompletion":55717,"completion":55717,"start":55718,"enrollment":101,"conditions":55758,"interventions":55759},[],[24],[55699,55721,55722,55723],{"intervention":55723,"totalTrials":272,"cells":55761},{"EARLY_PHASE1":55762,"PHASE1":55764,"PHASE2":55766,"PHASE3":55768,"PHASE4":55770,"NA":55772},{"trials":55763,"activeCount":101},[],{"trials":55765,"activeCount":101},[],{"trials":55767,"activeCount":101},[],{"trials":55769,"activeCount":101},[],{"trials":55771,"activeCount":101},[],{"trials":55773,"activeCount":101},[55774],{"nctId":55714,"briefTitle":55715,"status":600,"phases":55775,"primaryCompletion":55717,"completion":55717,"start":55718,"enrollment":101,"conditions":55776,"interventions":55777},[],[24],[55699,55721,55722,55723],{"intervention":55779,"totalTrials":272,"cells":55780},"MOBEC",{"EARLY_PHASE1":55781,"PHASE1":55783,"PHASE2":55785,"PHASE3":55787,"PHASE4":55789,"NA":55791},{"trials":55782,"activeCount":101},[],{"trials":55784,"activeCount":101},[],{"trials":55786,"activeCount":101},[],{"trials":55788,"activeCount":101},[],{"trials":55790,"activeCount":101},[],{"trials":55792,"activeCount":101},[55793],{"nctId":55794,"briefTitle":55795,"status":107,"phases":55796,"primaryCompletion":6040,"start":6701,"enrollment":55797,"conditions":55798,"interventions":55799},"NCT02182726","Postmarketing Surveillance Study With MOBEC®",[],4760,[6609],[55779],{"intervention":55801,"totalTrials":272,"cells":55802},"JARDIANCE 10mg",{"EARLY_PHASE1":55803,"PHASE1":55805,"PHASE2":55807,"PHASE3":55809,"PHASE4":55811,"NA":55813},{"trials":55804,"activeCount":101},[],{"trials":55806,"activeCount":101},[],{"trials":55808,"activeCount":101},[],{"trials":55810,"activeCount":101},[],{"trials":55812,"activeCount":101},[],{"trials":55814,"activeCount":101},[55815],{"nctId":55816,"briefTitle":55817,"status":107,"phases":55818,"primaryCompletion":55819,"completion":55819,"start":20913,"enrollment":55820,"conditions":55821,"interventions":55822},"NCT02848833","JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus",[],"2020-04-17",3368,[21],[55801,55823],"JARDIANCE 25mg",{"intervention":55823,"totalTrials":272,"cells":55825},{"EARLY_PHASE1":55826,"PHASE1":55828,"PHASE2":55830,"PHASE3":55832,"PHASE4":55834,"NA":55836},{"trials":55827,"activeCount":101},[],{"trials":55829,"activeCount":101},[],{"trials":55831,"activeCount":101},[],{"trials":55833,"activeCount":101},[],{"trials":55835,"activeCount":101},[],{"trials":55837,"activeCount":101},[55838],{"nctId":55816,"briefTitle":55817,"status":107,"phases":55839,"primaryCompletion":55819,"completion":55819,"start":20913,"enrollment":55820,"conditions":55840,"interventions":55841},[],[21],[55801,55823],{"intervention":55843,"totalTrials":272,"cells":55844},"Spiriva® Respimat®",{"EARLY_PHASE1":55845,"PHASE1":55847,"PHASE2":55849,"PHASE3":55851,"PHASE4":55853,"NA":55855},{"trials":55846,"activeCount":101},[],{"trials":55848,"activeCount":101},[],{"trials":55850,"activeCount":101},[],{"trials":55852,"activeCount":101},[],{"trials":55854,"activeCount":101},[],{"trials":55856,"activeCount":101},[55857],{"nctId":55858,"briefTitle":55859,"status":107,"phases":55860,"primaryCompletion":4120,"completion":4120,"start":4391,"enrollment":55861,"conditions":55862,"interventions":55863},"NCT02173769","Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy",[],1845,[18],[55843,55864],"Striverdi® Respimat®",{"intervention":55864,"totalTrials":272,"cells":55866},{"EARLY_PHASE1":55867,"PHASE1":55869,"PHASE2":55871,"PHASE3":55873,"PHASE4":55875,"NA":55877},{"trials":55868,"activeCount":101},[],{"trials":55870,"activeCount":101},[],{"trials":55872,"activeCount":101},[],{"trials":55874,"activeCount":101},[],{"trials":55876,"activeCount":101},[],{"trials":55878,"activeCount":101},[55879],{"nctId":55858,"briefTitle":55859,"status":107,"phases":55880,"primaryCompletion":4120,"completion":4120,"start":4391,"enrollment":55861,"conditions":55881,"interventions":55882},[],[18],[55843,55864],{"intervention":809,"totalTrials":272,"cells":55884},{"EARLY_PHASE1":55885,"PHASE1":55887,"PHASE2":55889,"PHASE3":55891,"PHASE4":55893,"NA":55895},{"trials":55886,"activeCount":101},[],{"trials":55888,"activeCount":101},[],{"trials":55890,"activeCount":101},[],{"trials":55892,"activeCount":101},[],{"trials":55894,"activeCount":101},[],{"trials":55896,"activeCount":101},[55897],{"nctId":801,"briefTitle":802,"status":107,"phases":55898,"primaryCompletion":804,"completion":804,"start":805,"enrollment":806,"conditions":55899,"interventions":55900},[],[21],[73,809,810,811],{"intervention":810,"totalTrials":272,"cells":55902},{"EARLY_PHASE1":55903,"PHASE1":55905,"PHASE2":55907,"PHASE3":55909,"PHASE4":55911,"NA":55913},{"trials":55904,"activeCount":101},[],{"trials":55906,"activeCount":101},[],{"trials":55908,"activeCount":101},[],{"trials":55910,"activeCount":101},[],{"trials":55912,"activeCount":101},[],{"trials":55914,"activeCount":101},[55915],{"nctId":801,"briefTitle":802,"status":107,"phases":55916,"primaryCompletion":804,"completion":804,"start":805,"enrollment":806,"conditions":55917,"interventions":55918},[],[21],[73,809,810,811],{"intervention":811,"totalTrials":272,"cells":55920},{"EARLY_PHASE1":55921,"PHASE1":55923,"PHASE2":55925,"PHASE3":55927,"PHASE4":55929,"NA":55931},{"trials":55922,"activeCount":101},[],{"trials":55924,"activeCount":101},[],{"trials":55926,"activeCount":101},[],{"trials":55928,"activeCount":101},[],{"trials":55930,"activeCount":101},[],{"trials":55932,"activeCount":101},[55933],{"nctId":801,"briefTitle":802,"status":107,"phases":55934,"primaryCompletion":804,"completion":804,"start":805,"enrollment":806,"conditions":55935,"interventions":55936},[],[21],[73,809,810,811],{"intervention":55938,"totalTrials":272,"cells":55939},"Afatinib dimaleate",{"EARLY_PHASE1":55940,"PHASE1":55942,"PHASE2":55944,"PHASE3":55946,"PHASE4":55948,"NA":55950},{"trials":55941,"activeCount":101},[],{"trials":55943,"activeCount":101},[],{"trials":55945,"activeCount":101},[],{"trials":55947,"activeCount":101},[],{"trials":55949,"activeCount":101},[],{"trials":55951,"activeCount":101},[55952],{"nctId":55953,"briefTitle":55954,"status":107,"phases":55955,"primaryCompletion":55956,"completion":55956,"start":55957,"enrollment":55958,"conditions":55959,"interventions":55960},"NCT02131259","Long-term Observation PMS for Afatinib",[],"2016-12-28","2014-05-07",1605,[36],[55938],{"intervention":55962,"totalTrials":272,"cells":55963},"ALNA®OCAS®",{"EARLY_PHASE1":55964,"PHASE1":55966,"PHASE2":55968,"PHASE3":55970,"PHASE4":55972,"NA":55974},{"trials":55965,"activeCount":101},[],{"trials":55967,"activeCount":101},[],{"trials":55969,"activeCount":101},[],{"trials":55971,"activeCount":101},[],{"trials":55973,"activeCount":101},[],{"trials":55975,"activeCount":101},[55976],{"nctId":55977,"briefTitle":55978,"status":107,"phases":55979,"primaryCompletion":7151,"start":11581,"enrollment":55980,"conditions":55981,"interventions":55982},"NCT02245542","The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS\u002FBPH)",[],5775,[6741],[55962],{"intervention":53948,"totalTrials":272,"cells":55984},{"EARLY_PHASE1":55985,"PHASE1":55987,"PHASE2":55989,"PHASE3":55991,"PHASE4":55993,"NA":55995},{"trials":55986,"activeCount":101},[],{"trials":55988,"activeCount":101},[],{"trials":55990,"activeCount":101},[],{"trials":55992,"activeCount":101},[],{"trials":55994,"activeCount":101},[],{"trials":55996,"activeCount":101},[55997],{"nctId":53940,"briefTitle":53941,"status":107,"phases":55998,"primaryCompletion":53943,"completion":53944,"start":2627,"enrollment":53945,"conditions":55999,"interventions":56000},[],[21],[53948,53916],{"intervention":56002,"totalTrials":272,"cells":56003},"Motens®",{"EARLY_PHASE1":56004,"PHASE1":56006,"PHASE2":56008,"PHASE3":56010,"PHASE4":56012,"NA":56014},{"trials":56005,"activeCount":101},[],{"trials":56007,"activeCount":101},[],{"trials":56009,"activeCount":101},[],{"trials":56011,"activeCount":101},[],{"trials":56013,"activeCount":101},[],{"trials":56015,"activeCount":101},[56016],{"nctId":56017,"briefTitle":56018,"status":107,"phases":56019,"primaryCompletion":7022,"start":6064,"enrollment":56020,"conditions":56021,"interventions":56022},"NCT02235415","Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension",[],24526,[24],[56002],{"intervention":56024,"totalTrials":272,"cells":56025},"Metalyse weight-adjusted",{"EARLY_PHASE1":56026,"PHASE1":56028,"PHASE2":56030,"PHASE3":56032,"PHASE4":56034,"NA":56036},{"trials":56027,"activeCount":101},[],{"trials":56029,"activeCount":101},[],{"trials":56031,"activeCount":101},[],{"trials":56033,"activeCount":101},[],{"trials":56035,"activeCount":101},[],{"trials":56037,"activeCount":101},[56038],{"nctId":56039,"briefTitle":56040,"status":107,"phases":56041,"primaryCompletion":11650,"start":6701,"enrollment":56042,"conditions":56043,"interventions":56044},"NCT02194153","Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse",[],351,[632],[56024],{"intervention":56046,"totalTrials":272,"cells":56047},"Prizbind®",{"EARLY_PHASE1":56048,"PHASE1":56050,"PHASE2":56052,"PHASE3":56054,"PHASE4":56056,"NA":56058},{"trials":56049,"activeCount":101},[],{"trials":56051,"activeCount":101},[],{"trials":56053,"activeCount":101},[],{"trials":56055,"activeCount":101},[],{"trials":56057,"activeCount":101},[],{"trials":56059,"activeCount":101},[56060],{"nctId":56061,"briefTitle":56062,"status":107,"phases":56063,"primaryCompletion":1917,"completion":1917,"start":7507,"enrollment":56064,"conditions":56065,"interventions":56066},"NCT02946931","All-Case Surveillance of Prizbind®",[],1402,[30368],[56046],{"intervention":56068,"totalTrials":272,"cells":56069},"Spevigo®",{"EARLY_PHASE1":56070,"PHASE1":56072,"PHASE2":56074,"PHASE3":56076,"PHASE4":56078,"NA":56080},{"trials":56071,"activeCount":101},[],{"trials":56073,"activeCount":101},[],{"trials":56075,"activeCount":101},[],{"trials":56077,"activeCount":101},[],{"trials":56079,"activeCount":101},[],{"trials":56081,"activeCount":101},[56082],{"nctId":56083,"briefTitle":56084,"status":600,"phases":56085,"primaryCompletion":56086,"completion":56086,"start":56087,"enrollment":101,"conditions":56088,"interventions":56089},"NCT06886009","Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis",[],"2029-06-08","2026-03-31",[146],[56068],{"intervention":56091,"totalTrials":272,"cells":56092},"Metalyse",{"EARLY_PHASE1":56093,"PHASE1":56095,"PHASE2":56097,"PHASE3":56099,"PHASE4":56101,"NA":56103},{"trials":56094,"activeCount":101},[],{"trials":56096,"activeCount":101},[],{"trials":56098,"activeCount":101},[],{"trials":56100,"activeCount":101},[],{"trials":56102,"activeCount":101},[],{"trials":56104,"activeCount":101},[56105],{"nctId":56106,"briefTitle":56107,"status":107,"phases":56108,"primaryCompletion":1989,"start":6081,"enrollment":56109,"conditions":56110,"interventions":56111},"NCT02206646","Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction",[],987,[632],[56091],{"intervention":56113,"totalTrials":272,"cells":56114},"Atrovent® Inhaletten",{"EARLY_PHASE1":56115,"PHASE1":56117,"PHASE2":56119,"PHASE3":56121,"PHASE4":56123,"NA":56125},{"trials":56116,"activeCount":101},[],{"trials":56118,"activeCount":101},[],{"trials":56120,"activeCount":101},[],{"trials":56122,"activeCount":101},[],{"trials":56124,"activeCount":101},[],{"trials":56126,"activeCount":101},[56127],{"nctId":56128,"briefTitle":56129,"status":107,"phases":56130,"primaryCompletion":6246,"start":6438,"enrollment":9475,"conditions":56131,"interventions":56132},"NCT02238145","Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease",[],[18],[56113],{"intervention":52906,"totalTrials":272,"cells":56134},{"EARLY_PHASE1":56135,"PHASE1":56137,"PHASE2":56139,"PHASE3":56141,"PHASE4":56143,"NA":56145},{"trials":56136,"activeCount":101},[],{"trials":56138,"activeCount":101},[],{"trials":56140,"activeCount":101},[],{"trials":56142,"activeCount":101},[],{"trials":56144,"activeCount":101},[],{"trials":56146,"activeCount":101},[56147],{"nctId":52900,"briefTitle":52901,"status":107,"phases":56148,"primaryCompletion":5992,"start":7003,"enrollment":52903,"conditions":56149,"interventions":56150},[],[24],[52870,52906],{"intervention":56152,"totalTrials":272,"cells":56153},"Prazaxa",{"EARLY_PHASE1":56154,"PHASE1":56156,"PHASE2":56158,"PHASE3":56160,"PHASE4":56162,"NA":56164},{"trials":56155,"activeCount":101},[],{"trials":56157,"activeCount":101},[],{"trials":56159,"activeCount":101},[],{"trials":56161,"activeCount":101},[],{"trials":56163,"activeCount":101},[],{"trials":56165,"activeCount":101},[56166],{"nctId":56167,"briefTitle":56168,"status":107,"phases":56169,"primaryCompletion":56170,"completion":56170,"start":56171,"enrollment":56172,"conditions":56173,"interventions":56174},"NCT01491178","Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation",[],"2016-08-02","2011-12-12",6772,[6098],[56152],{"intervention":56176,"totalTrials":272,"cells":56177},"GIOTRIF 20mg",{"EARLY_PHASE1":56178,"PHASE1":56180,"PHASE2":56182,"PHASE3":56184,"PHASE4":56186,"NA":56188},{"trials":56179,"activeCount":101},[],{"trials":56181,"activeCount":101},[],{"trials":56183,"activeCount":101},[],{"trials":56185,"activeCount":101},[],{"trials":56187,"activeCount":101},[],{"trials":56189,"activeCount":101},[56190],{"nctId":56191,"briefTitle":56192,"status":107,"phases":56193,"primaryCompletion":775,"completion":775,"start":18661,"enrollment":56194,"conditions":56195,"interventions":56196},"NCT02285361","GIOTRIF rPMS in Korean Patients With NSCLC",[],1272,[36],[56176,56197,56198],"GIOTRIF 40mg","GIOTRIF 30mg",{"intervention":56197,"totalTrials":272,"cells":56200},{"EARLY_PHASE1":56201,"PHASE1":56203,"PHASE2":56205,"PHASE3":56207,"PHASE4":56209,"NA":56211},{"trials":56202,"activeCount":101},[],{"trials":56204,"activeCount":101},[],{"trials":56206,"activeCount":101},[],{"trials":56208,"activeCount":101},[],{"trials":56210,"activeCount":101},[],{"trials":56212,"activeCount":101},[56213],{"nctId":56191,"briefTitle":56192,"status":107,"phases":56214,"primaryCompletion":775,"completion":775,"start":18661,"enrollment":56194,"conditions":56215,"interventions":56216},[],[36],[56176,56197,56198],{"intervention":56198,"totalTrials":272,"cells":56218},{"EARLY_PHASE1":56219,"PHASE1":56221,"PHASE2":56223,"PHASE3":56225,"PHASE4":56227,"NA":56229},{"trials":56220,"activeCount":101},[],{"trials":56222,"activeCount":101},[],{"trials":56224,"activeCount":101},[],{"trials":56226,"activeCount":101},[],{"trials":56228,"activeCount":101},[],{"trials":56230,"activeCount":101},[56231],{"nctId":56191,"briefTitle":56192,"status":107,"phases":56232,"primaryCompletion":775,"completion":775,"start":18661,"enrollment":56194,"conditions":56233,"interventions":56234},[],[36],[56176,56197,56198],{"intervention":56236,"totalTrials":272,"cells":56237},"Gladem",{"EARLY_PHASE1":56238,"PHASE1":56240,"PHASE2":56242,"PHASE3":56244,"PHASE4":56246,"NA":56248},{"trials":56239,"activeCount":101},[],{"trials":56241,"activeCount":101},[],{"trials":56243,"activeCount":101},[],{"trials":56245,"activeCount":101},[],{"trials":56247,"activeCount":101},[],{"trials":56249,"activeCount":101},[56250],{"nctId":56251,"briefTitle":56252,"status":107,"phases":56253,"primaryCompletion":7574,"start":6949,"enrollment":56254,"conditions":56255,"interventions":56257},"NCT02231268","Observational Study to Assess a 6-months Treatment With Gladem",[],546,[56256],"Depressive Disorder",[56236],{"intervention":54431,"totalTrials":272,"cells":56259},{"EARLY_PHASE1":56260,"PHASE1":56262,"PHASE2":56264,"PHASE3":56266,"PHASE4":56268,"NA":56270},{"trials":56261,"activeCount":101},[],{"trials":56263,"activeCount":101},[],{"trials":56265,"activeCount":101},[],{"trials":56267,"activeCount":101},[],{"trials":56269,"activeCount":101},[],{"trials":56271,"activeCount":101},[56272],{"nctId":54425,"briefTitle":54426,"status":107,"phases":56273,"primaryCompletion":4120,"completion":4120,"start":4391,"enrollment":54428,"conditions":56274,"interventions":56275},[],[6098,30368],[54431,54406],{"intervention":56277,"totalTrials":272,"cells":56278},"L - Antineoplastic and immunomodulating agents",{"EARLY_PHASE1":56279,"PHASE1":56281,"PHASE2":56283,"PHASE3":56285,"PHASE4":56287,"NA":56289},{"trials":56280,"activeCount":101},[],{"trials":56282,"activeCount":101},[],{"trials":56284,"activeCount":101},[],{"trials":56286,"activeCount":101},[],{"trials":56288,"activeCount":101},[],{"trials":56290,"activeCount":101},[56291],{"nctId":56292,"briefTitle":56293,"status":107,"phases":56294,"primaryCompletion":56295,"completion":56295,"start":19441,"enrollment":3509,"conditions":56296,"interventions":56297},"NCT03281200","Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain",[],"2018-06-07",[1397],[56277,56298,56299,56300,56301],"L01 - Antineoplastic agents","L01X - Other antineoplastic agents","L01XE - Protein kinase inhibitors","L01XE31 - Nintedanib",{"intervention":56298,"totalTrials":272,"cells":56303},{"EARLY_PHASE1":56304,"PHASE1":56306,"PHASE2":56308,"PHASE3":56310,"PHASE4":56312,"NA":56314},{"trials":56305,"activeCount":101},[],{"trials":56307,"activeCount":101},[],{"trials":56309,"activeCount":101},[],{"trials":56311,"activeCount":101},[],{"trials":56313,"activeCount":101},[],{"trials":56315,"activeCount":101},[56316],{"nctId":56292,"briefTitle":56293,"status":107,"phases":56317,"primaryCompletion":56295,"completion":56295,"start":19441,"enrollment":3509,"conditions":56318,"interventions":56319},[],[1397],[56277,56298,56299,56300,56301],{"intervention":56299,"totalTrials":272,"cells":56321},{"EARLY_PHASE1":56322,"PHASE1":56324,"PHASE2":56326,"PHASE3":56328,"PHASE4":56330,"NA":56332},{"trials":56323,"activeCount":101},[],{"trials":56325,"activeCount":101},[],{"trials":56327,"activeCount":101},[],{"trials":56329,"activeCount":101},[],{"trials":56331,"activeCount":101},[],{"trials":56333,"activeCount":101},[56334],{"nctId":56292,"briefTitle":56293,"status":107,"phases":56335,"primaryCompletion":56295,"completion":56295,"start":19441,"enrollment":3509,"conditions":56336,"interventions":56337},[],[1397],[56277,56298,56299,56300,56301],{"intervention":56300,"totalTrials":272,"cells":56339},{"EARLY_PHASE1":56340,"PHASE1":56342,"PHASE2":56344,"PHASE3":56346,"PHASE4":56348,"NA":56350},{"trials":56341,"activeCount":101},[],{"trials":56343,"activeCount":101},[],{"trials":56345,"activeCount":101},[],{"trials":56347,"activeCount":101},[],{"trials":56349,"activeCount":101},[],{"trials":56351,"activeCount":101},[56352],{"nctId":56292,"briefTitle":56293,"status":107,"phases":56353,"primaryCompletion":56295,"completion":56295,"start":19441,"enrollment":3509,"conditions":56354,"interventions":56355},[],[1397],[56277,56298,56299,56300,56301],{"intervention":56301,"totalTrials":272,"cells":56357},{"EARLY_PHASE1":56358,"PHASE1":56360,"PHASE2":56362,"PHASE3":56364,"PHASE4":56366,"NA":56368},{"trials":56359,"activeCount":101},[],{"trials":56361,"activeCount":101},[],{"trials":56363,"activeCount":101},[],{"trials":56365,"activeCount":101},[],{"trials":56367,"activeCount":101},[],{"trials":56369,"activeCount":101},[56370],{"nctId":56292,"briefTitle":56293,"status":107,"phases":56371,"primaryCompletion":56295,"completion":56295,"start":19441,"enrollment":3509,"conditions":56372,"interventions":56373},[],[1397],[56277,56298,56299,56300,56301],{"intervention":56375,"totalTrials":272,"cells":56376},"LABA and the LAMA tiotropium",{"EARLY_PHASE1":56377,"PHASE1":56379,"PHASE2":56381,"PHASE3":56383,"PHASE4":56385,"NA":56387},{"trials":56378,"activeCount":101},[],{"trials":56380,"activeCount":101},[],{"trials":56382,"activeCount":101},[],{"trials":56384,"activeCount":101},[],{"trials":56386,"activeCount":101},[],{"trials":56388,"activeCount":101},[56389],{"nctId":56390,"briefTitle":56391,"status":107,"phases":56392,"primaryCompletion":50690,"completion":50690,"start":18652,"enrollment":56393,"conditions":56394,"interventions":56395},"NCT03376295","Comparative Effectiveness of COPD Treatments",[],3954,[18],[56375,56396],"LABA and an ICS",{"intervention":56396,"totalTrials":272,"cells":56398},{"EARLY_PHASE1":56399,"PHASE1":56401,"PHASE2":56403,"PHASE3":56405,"PHASE4":56407,"NA":56409},{"trials":56400,"activeCount":101},[],{"trials":56402,"activeCount":101},[],{"trials":56404,"activeCount":101},[],{"trials":56406,"activeCount":101},[],{"trials":56408,"activeCount":101},[],{"trials":56410,"activeCount":101},[56411],{"nctId":56390,"briefTitle":56391,"status":107,"phases":56412,"primaryCompletion":50690,"completion":50690,"start":18652,"enrollment":56393,"conditions":56413,"interventions":56414},[],[18],[56375,56396],{"intervention":839,"totalTrials":272,"cells":56416},{"EARLY_PHASE1":56417,"PHASE1":56419,"PHASE2":56421,"PHASE3":56423,"PHASE4":56425,"NA":56427},{"trials":56418,"activeCount":101},[],{"trials":56420,"activeCount":101},[],{"trials":56422,"activeCount":101},[],{"trials":56424,"activeCount":101},[],{"trials":56426,"activeCount":101},[],{"trials":56428,"activeCount":101},[56429],{"nctId":831,"briefTitle":832,"status":107,"phases":56430,"primaryCompletion":834,"completion":834,"start":835,"enrollment":836,"conditions":56431,"interventions":56432},[],[21],[73,839],{"intervention":56434,"totalTrials":272,"cells":56435},"telmisartan\u002Ftelmisartan + HCTZ",{"EARLY_PHASE1":56436,"PHASE1":56438,"PHASE2":56440,"PHASE3":56442,"PHASE4":56444,"NA":56446},{"trials":56437,"activeCount":101},[],{"trials":56439,"activeCount":101},[],{"trials":56441,"activeCount":101},[],{"trials":56443,"activeCount":101},[],{"trials":56445,"activeCount":101},[],{"trials":56447,"activeCount":101},[56448],{"nctId":56449,"briefTitle":56450,"status":107,"phases":56451,"primaryCompletion":1114,"start":17247,"enrollment":56452,"conditions":56453,"interventions":56454},"NCT00904215","An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension",[],1095,[24],[56434],{"intervention":56456,"totalTrials":272,"cells":56457},"Lendormin D",{"EARLY_PHASE1":56458,"PHASE1":56460,"PHASE2":56462,"PHASE3":56464,"PHASE4":56466,"NA":56468},{"trials":56459,"activeCount":101},[],{"trials":56461,"activeCount":101},[],{"trials":56463,"activeCount":101},[],{"trials":56465,"activeCount":101},[],{"trials":56467,"activeCount":101},[],{"trials":56469,"activeCount":101},[56470],{"nctId":56471,"briefTitle":56472,"status":107,"phases":56473,"primaryCompletion":4461,"start":1115,"enrollment":56474,"conditions":56475,"interventions":56476},"NCT02224014","Lendormin D® Tablet (Drug Use Result Survey)",[],485,[11071],[56456],{"intervention":52269,"totalTrials":272,"cells":56478},{"EARLY_PHASE1":56479,"PHASE1":56481,"PHASE2":56483,"PHASE3":56485,"PHASE4":56487,"NA":56489},{"trials":56480,"activeCount":101},[],{"trials":56482,"activeCount":101},[],{"trials":56484,"activeCount":101},[],{"trials":56486,"activeCount":101},[],{"trials":56488,"activeCount":101},[],{"trials":56490,"activeCount":101},[56491],{"nctId":52261,"briefTitle":52262,"status":107,"phases":56492,"primaryCompletion":52254,"completion":52264,"start":52265,"enrollment":52266,"conditions":56493,"interventions":56494},[],[6098],[4165,28330,52269,52270,52271],{"intervention":52270,"totalTrials":272,"cells":56496},{"EARLY_PHASE1":56497,"PHASE1":56499,"PHASE2":56501,"PHASE3":56503,"PHASE4":56505,"NA":56507},{"trials":56498,"activeCount":101},[],{"trials":56500,"activeCount":101},[],{"trials":56502,"activeCount":101},[],{"trials":56504,"activeCount":101},[],{"trials":56506,"activeCount":101},[],{"trials":56508,"activeCount":101},[56509],{"nctId":52261,"briefTitle":52262,"status":107,"phases":56510,"primaryCompletion":52254,"completion":52264,"start":52265,"enrollment":52266,"conditions":56511,"interventions":56512},[],[6098],[4165,28330,52269,52270,52271],{"intervention":52271,"totalTrials":272,"cells":56514},{"EARLY_PHASE1":56515,"PHASE1":56517,"PHASE2":56519,"PHASE3":56521,"PHASE4":56523,"NA":56525},{"trials":56516,"activeCount":101},[],{"trials":56518,"activeCount":101},[],{"trials":56520,"activeCount":101},[],{"trials":56522,"activeCount":101},[],{"trials":56524,"activeCount":101},[],{"trials":56526,"activeCount":101},[56527],{"nctId":52261,"briefTitle":52262,"status":107,"phases":56528,"primaryCompletion":52254,"completion":52264,"start":52265,"enrollment":52266,"conditions":56529,"interventions":56530},[],[6098],[4165,28330,52269,52270,52271],{"intervention":56532,"totalTrials":272,"cells":56533},"Observational",{"EARLY_PHASE1":56534,"PHASE1":56536,"PHASE2":56538,"PHASE3":56540,"PHASE4":56542,"NA":56544},{"trials":56535,"activeCount":101},[],{"trials":56537,"activeCount":101},[],{"trials":56539,"activeCount":101},[],{"trials":56541,"activeCount":101},[],{"trials":56543,"activeCount":101},[],{"trials":56545,"activeCount":101},[56546],{"nctId":56547,"briefTitle":56548,"status":107,"phases":56549,"primaryCompletion":877,"completion":877,"start":56550,"enrollment":56551,"conditions":56552,"interventions":56553},"NCT02061748","The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage",[],"2014-10-28",38499,[6098],[56532],{"intervention":56555,"totalTrials":272,"cells":56556},"IV rtPA",{"EARLY_PHASE1":56557,"PHASE1":56559,"PHASE2":56561,"PHASE3":56563,"PHASE4":56565,"NA":56567},{"trials":56558,"activeCount":101},[],{"trials":56560,"activeCount":101},[],{"trials":56562,"activeCount":101},[],{"trials":56564,"activeCount":101},[],{"trials":56566,"activeCount":101},[],{"trials":56568,"activeCount":101},[56569],{"nctId":56570,"briefTitle":56571,"status":107,"phases":56572,"primaryCompletion":8580,"completion":8580,"start":56573,"enrollment":56574,"conditions":56575,"interventions":56576},"NCT04290494","Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;",[],"2020-09-21",42188,[2092],[56555],{"intervention":56578,"totalTrials":272,"cells":56579},"Empagliflozin\u002FLinagliptin",{"EARLY_PHASE1":56580,"PHASE1":56582,"PHASE2":56584,"PHASE3":56586,"PHASE4":56588,"NA":56590},{"trials":56581,"activeCount":101},[],{"trials":56583,"activeCount":101},[],{"trials":56585,"activeCount":101},[],{"trials":56587,"activeCount":101},[],{"trials":56589,"activeCount":101},[],{"trials":56591,"activeCount":101},[56592],{"nctId":56593,"briefTitle":56594,"status":107,"phases":56595,"primaryCompletion":56596,"completion":20695,"start":56597,"enrollment":56598,"conditions":56599,"interventions":56600},"NCT05130463","Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus",[],"2024-04-08","2022-03-22",1053,[21],[56578],{"intervention":54459,"totalTrials":272,"cells":56602},{"EARLY_PHASE1":56603,"PHASE1":56605,"PHASE2":56607,"PHASE3":56609,"PHASE4":56611,"NA":56613},{"trials":56604,"activeCount":101},[],{"trials":56606,"activeCount":101},[],{"trials":56608,"activeCount":101},[],{"trials":56610,"activeCount":101},[],{"trials":56612,"activeCount":101},[],{"trials":56614,"activeCount":101},[56615],{"nctId":54451,"briefTitle":54452,"status":600,"phases":56616,"primaryCompletion":54454,"completion":54455,"start":54456,"enrollment":101,"conditions":56617,"interventions":56618},[],[18],[54459,8583],{"intervention":858,"totalTrials":272,"cells":56620},{"EARLY_PHASE1":56621,"PHASE1":56623,"PHASE2":56625,"PHASE3":56627,"PHASE4":56629,"NA":56631},{"trials":56622,"activeCount":101},[],{"trials":56624,"activeCount":101},[],{"trials":56626,"activeCount":101},[],{"trials":56628,"activeCount":101},[],{"trials":56630,"activeCount":101},[],{"trials":56632,"activeCount":101},[56633],{"nctId":850,"briefTitle":851,"status":107,"phases":56634,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":56635,"interventions":56636},[],[21],[73,858,859],{"intervention":859,"totalTrials":272,"cells":56638},{"EARLY_PHASE1":56639,"PHASE1":56641,"PHASE2":56643,"PHASE3":56645,"PHASE4":56647,"NA":56649},{"trials":56640,"activeCount":101},[],{"trials":56642,"activeCount":101},[],{"trials":56644,"activeCount":101},[],{"trials":56646,"activeCount":101},[],{"trials":56648,"activeCount":101},[],{"trials":56650,"activeCount":101},[56651],{"nctId":850,"briefTitle":851,"status":107,"phases":56652,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":56653,"interventions":56654},[],[21],[73,858,859],{"intervention":56656,"totalTrials":272,"cells":56657},"Tiotropium bromide plus Olodaterol",{"EARLY_PHASE1":56658,"PHASE1":56660,"PHASE2":56662,"PHASE3":56664,"PHASE4":56666,"NA":56668},{"trials":56659,"activeCount":101},[],{"trials":56661,"activeCount":101},[],{"trials":56663,"activeCount":101},[],{"trials":56665,"activeCount":101},[],{"trials":56667,"activeCount":101},[],{"trials":56669,"activeCount":101},[56670],{"nctId":56671,"briefTitle":56672,"status":107,"phases":56673,"primaryCompletion":56674,"completion":56674,"start":56675,"enrollment":56676,"conditions":56677,"interventions":56678},"NCT04672941","Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece",[],"2022-02-21","2021-02-16",1396,[18],[56656],{"intervention":49585,"totalTrials":272,"cells":56680},{"EARLY_PHASE1":56681,"PHASE1":56683,"PHASE2":56685,"PHASE3":56687,"PHASE4":56689,"NA":56691},{"trials":56682,"activeCount":101},[],{"trials":56684,"activeCount":101},[],{"trials":56686,"activeCount":101},[],{"trials":56688,"activeCount":101},[],{"trials":56690,"activeCount":101},[],{"trials":56692,"activeCount":101},[56693],{"nctId":49579,"briefTitle":49580,"status":107,"phases":56694,"primaryCompletion":6132,"start":6811,"enrollment":49582,"conditions":56695,"interventions":56696},[],[24],[6121,49585,49586,49587],{"intervention":49587,"totalTrials":272,"cells":56698},{"EARLY_PHASE1":56699,"PHASE1":56701,"PHASE2":56703,"PHASE3":56705,"PHASE4":56707,"NA":56709},{"trials":56700,"activeCount":101},[],{"trials":56702,"activeCount":101},[],{"trials":56704,"activeCount":101},[],{"trials":56706,"activeCount":101},[],{"trials":56708,"activeCount":101},[],{"trials":56710,"activeCount":101},[56711],{"nctId":49579,"briefTitle":49580,"status":107,"phases":56712,"primaryCompletion":6132,"start":6811,"enrollment":49582,"conditions":56713,"interventions":56714},[],[24],[6121,49585,49586,49587],{"intervention":49595,"totalTrials":272,"cells":56716},{"EARLY_PHASE1":56717,"PHASE1":56719,"PHASE2":56721,"PHASE3":56723,"PHASE4":56725,"NA":56727},{"trials":56718,"activeCount":101},[],{"trials":56720,"activeCount":101},[],{"trials":56722,"activeCount":101},[],{"trials":56724,"activeCount":101},[],{"trials":56726,"activeCount":101},[],{"trials":56728,"activeCount":101},[56729],{"nctId":49589,"briefTitle":49590,"status":107,"phases":56730,"primaryCompletion":5843,"start":6782,"enrollment":49592,"conditions":56731,"interventions":56732},[],[24],[6121,49595],{"intervention":56734,"totalTrials":272,"cells":56735},"Non-Nucleoside Reverse Transcriptase Inhibitors",{"EARLY_PHASE1":56736,"PHASE1":56738,"PHASE2":56740,"PHASE3":56742,"PHASE4":56744,"NA":56746},{"trials":56737,"activeCount":101},[],{"trials":56739,"activeCount":101},[],{"trials":56741,"activeCount":101},[],{"trials":56743,"activeCount":101},[],{"trials":56745,"activeCount":101},[],{"trials":56747,"activeCount":101},[56748],{"nctId":56749,"briefTitle":56750,"status":107,"phases":56751,"primaryCompletion":7151,"start":6235,"enrollment":24749,"conditions":56752,"interventions":56753},"NCT02191202","Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression",[],[27],[56734],{"intervention":870,"totalTrials":272,"cells":56755},{"EARLY_PHASE1":56756,"PHASE1":56758,"PHASE2":56760,"PHASE3":56762,"PHASE4":56764,"NA":56766},{"trials":56757,"activeCount":101},[],{"trials":56759,"activeCount":101},[],{"trials":56761,"activeCount":101},[],{"trials":56763,"activeCount":101},[],{"trials":56765,"activeCount":101},[],{"trials":56767,"activeCount":101},[56768],{"nctId":861,"briefTitle":862,"status":107,"phases":56769,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":56770,"interventions":56771},[],[868],[73,870,871],{"intervention":871,"totalTrials":272,"cells":56773},{"EARLY_PHASE1":56774,"PHASE1":56776,"PHASE2":56778,"PHASE3":56780,"PHASE4":56782,"NA":56784},{"trials":56775,"activeCount":101},[],{"trials":56777,"activeCount":101},[],{"trials":56779,"activeCount":101},[],{"trials":56781,"activeCount":101},[],{"trials":56783,"activeCount":101},[],{"trials":56785,"activeCount":101},[56786],{"nctId":861,"briefTitle":862,"status":107,"phases":56787,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":56788,"interventions":56789},[],[868],[73,870,871],{"intervention":56791,"totalTrials":272,"cells":56792},"inhaled bronchodilator",{"EARLY_PHASE1":56793,"PHASE1":56795,"PHASE2":56797,"PHASE3":56799,"PHASE4":56801,"NA":56803},{"trials":56794,"activeCount":101},[],{"trials":56796,"activeCount":101},[],{"trials":56798,"activeCount":101},[],{"trials":56800,"activeCount":101},[],{"trials":56802,"activeCount":101},[],{"trials":56804,"activeCount":101},[56805],{"nctId":56806,"briefTitle":56807,"status":107,"phases":56808,"primaryCompletion":6053,"start":6391,"enrollment":56809,"conditions":56810,"interventions":56811},"NCT02176564","Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease",[],2639,[18],[56791],{"intervention":53668,"totalTrials":272,"cells":56813},{"EARLY_PHASE1":56814,"PHASE1":56816,"PHASE2":56818,"PHASE3":56820,"PHASE4":56822,"NA":56824},{"trials":56815,"activeCount":101},[],{"trials":56817,"activeCount":101},[],{"trials":56819,"activeCount":101},[],{"trials":56821,"activeCount":101},[],{"trials":56823,"activeCount":101},[],{"trials":56825,"activeCount":101},[56826],{"nctId":53660,"briefTitle":53661,"status":107,"phases":56827,"primaryCompletion":53663,"completion":53663,"start":53664,"enrollment":53665,"conditions":56828,"interventions":56829},[],[6098],[6101,53668],{"intervention":56831,"totalTrials":272,"cells":56832},"Viramune",{"EARLY_PHASE1":56833,"PHASE1":56835,"PHASE2":56837,"PHASE3":56839,"PHASE4":56841,"NA":56843},{"trials":56834,"activeCount":101},[],{"trials":56836,"activeCount":101},[],{"trials":56838,"activeCount":101},[],{"trials":56840,"activeCount":101},[],{"trials":56842,"activeCount":101},[],{"trials":56844,"activeCount":101},[56845],{"nctId":56846,"briefTitle":56847,"status":107,"phases":56848,"primaryCompletion":6015,"start":6206,"enrollment":2586,"conditions":56849,"interventions":56850},"NCT02191332","Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen",[],[27],[56831],{"intervention":56852,"totalTrials":272,"cells":56853},"T80\u002FA5\u002FH12.5 FDC",{"EARLY_PHASE1":56854,"PHASE1":56856,"PHASE2":56858,"PHASE3":56860,"PHASE4":56862,"NA":56864},{"trials":56855,"activeCount":101},[],{"trials":56857,"activeCount":101},[],{"trials":56859,"activeCount":101},[],{"trials":56861,"activeCount":101},[],{"trials":56863,"activeCount":101},[],{"trials":56865,"activeCount":101},[56866],{"nctId":56867,"briefTitle":56868,"status":107,"phases":56869,"primaryCompletion":19186,"completion":19186,"start":56870,"enrollment":56871,"conditions":56872,"interventions":56873},"NCT03021265","To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension",[],"2017-01-20",676,[24],[56852],{"intervention":56875,"totalTrials":272,"cells":56876},"Berotec® N 100 µg Metered-dose Inhaler",{"EARLY_PHASE1":56877,"PHASE1":56879,"PHASE2":56881,"PHASE3":56883,"PHASE4":56885,"NA":56887},{"trials":56878,"activeCount":101},[],{"trials":56880,"activeCount":101},[],{"trials":56882,"activeCount":101},[],{"trials":56884,"activeCount":101},[],{"trials":56886,"activeCount":101},[],{"trials":56888,"activeCount":101},[56889],{"nctId":56890,"briefTitle":56891,"status":107,"phases":56892,"primaryCompletion":7394,"start":2163,"enrollment":56893,"conditions":56894,"interventions":56895},"NCT02244216","Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease",[],2914,[18],[56875],{"intervention":53519,"totalTrials":272,"cells":56897},{"EARLY_PHASE1":56898,"PHASE1":56900,"PHASE2":56902,"PHASE3":56904,"PHASE4":56906,"NA":56908},{"trials":56899,"activeCount":101},[],{"trials":56901,"activeCount":101},[],{"trials":56903,"activeCount":101},[],{"trials":56905,"activeCount":101},[],{"trials":56907,"activeCount":101},[],{"trials":56909,"activeCount":101},[56910],{"nctId":53512,"briefTitle":53513,"status":107,"phases":56911,"primaryCompletion":18957,"completion":853,"start":53515,"enrollment":53516,"conditions":56912,"interventions":56913},[],[18],[53479,53519],{"intervention":52176,"totalTrials":272,"cells":56915},{"EARLY_PHASE1":56916,"PHASE1":56918,"PHASE2":56920,"PHASE3":56922,"PHASE4":56924,"NA":56926},{"trials":56917,"activeCount":101},[],{"trials":56919,"activeCount":101},[],{"trials":56921,"activeCount":101},[],{"trials":56923,"activeCount":101},[],{"trials":56925,"activeCount":101},[],{"trials":56927,"activeCount":101},[56928],{"nctId":52170,"briefTitle":52171,"status":107,"phases":56929,"primaryCompletion":9276,"start":6041,"enrollment":52173,"conditions":56930,"interventions":56931},[],[10667],[6498,52176],{"intervention":56933,"totalTrials":272,"cells":56934},"Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation",{"EARLY_PHASE1":56935,"PHASE1":56937,"PHASE2":56939,"PHASE3":56941,"PHASE4":56943,"NA":56945},{"trials":56936,"activeCount":101},[],{"trials":56938,"activeCount":101},[],{"trials":56940,"activeCount":101},[],{"trials":56942,"activeCount":101},[],{"trials":56944,"activeCount":101},[],{"trials":56946,"activeCount":101},[56947],{"nctId":56948,"briefTitle":56949,"status":107,"phases":56950,"primaryCompletion":56951,"completion":56951,"start":56952,"enrollment":10665,"conditions":56953,"interventions":56954},"NCT01937390","Observational Study of Adherence to LABA \u002F LAMA in Chronic Obstructive Pulmonary Disease (COPD)",[],"2016-10-22","2011-11-06",[18],[56933,56955,56956,56957],"Indacterol 300 µg","Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard","Indacterol 150 µg",{"intervention":56955,"totalTrials":272,"cells":56959},{"EARLY_PHASE1":56960,"PHASE1":56962,"PHASE2":56964,"PHASE3":56966,"PHASE4":56968,"NA":56970},{"trials":56961,"activeCount":101},[],{"trials":56963,"activeCount":101},[],{"trials":56965,"activeCount":101},[],{"trials":56967,"activeCount":101},[],{"trials":56969,"activeCount":101},[],{"trials":56971,"activeCount":101},[56972],{"nctId":56948,"briefTitle":56949,"status":107,"phases":56973,"primaryCompletion":56951,"completion":56951,"start":56952,"enrollment":10665,"conditions":56974,"interventions":56975},[],[18],[56933,56955,56956,56957],{"intervention":56956,"totalTrials":272,"cells":56977},{"EARLY_PHASE1":56978,"PHASE1":56980,"PHASE2":56982,"PHASE3":56984,"PHASE4":56986,"NA":56988},{"trials":56979,"activeCount":101},[],{"trials":56981,"activeCount":101},[],{"trials":56983,"activeCount":101},[],{"trials":56985,"activeCount":101},[],{"trials":56987,"activeCount":101},[],{"trials":56989,"activeCount":101},[56990],{"nctId":56948,"briefTitle":56949,"status":107,"phases":56991,"primaryCompletion":56951,"completion":56951,"start":56952,"enrollment":10665,"conditions":56992,"interventions":56993},[],[18],[56933,56955,56956,56957],{"intervention":56957,"totalTrials":272,"cells":56995},{"EARLY_PHASE1":56996,"PHASE1":56998,"PHASE2":57000,"PHASE3":57002,"PHASE4":57004,"NA":57006},{"trials":56997,"activeCount":101},[],{"trials":56999,"activeCount":101},[],{"trials":57001,"activeCount":101},[],{"trials":57003,"activeCount":101},[],{"trials":57005,"activeCount":101},[],{"trials":57007,"activeCount":101},[57008],{"nctId":56948,"briefTitle":56949,"status":107,"phases":57009,"primaryCompletion":56951,"completion":56951,"start":56952,"enrollment":10665,"conditions":57010,"interventions":57011},[],[18],[56933,56955,56956,56957],{"intervention":57013,"totalTrials":272,"cells":57014},"PraxbindTM",{"EARLY_PHASE1":57015,"PHASE1":57017,"PHASE2":57019,"PHASE3":57021,"PHASE4":57023,"NA":57025},{"trials":57016,"activeCount":101},[],{"trials":57018,"activeCount":101},[],{"trials":57020,"activeCount":101},[],{"trials":57022,"activeCount":101},[],{"trials":57024,"activeCount":101},[],{"trials":57026,"activeCount":101},[57027],{"nctId":57028,"briefTitle":57029,"status":107,"phases":57030,"primaryCompletion":1488,"completion":1488,"start":57031,"enrollment":166,"conditions":57032,"interventions":57033},"NCT03359889","PraxbindTM India PMS Program",[],"2018-12-26",[10332],[57013],{"intervention":57035,"totalTrials":272,"cells":57036},"treatment",{"EARLY_PHASE1":57037,"PHASE1":57039,"PHASE2":57041,"PHASE3":57043,"PHASE4":57045,"NA":57047},{"trials":57038,"activeCount":101},[],{"trials":57040,"activeCount":101},[],{"trials":57042,"activeCount":101},[],{"trials":57044,"activeCount":101},[],{"trials":57046,"activeCount":101},[],{"trials":57048,"activeCount":101},[57049],{"nctId":57050,"briefTitle":57051,"status":107,"phases":57052,"primaryCompletion":5768,"completion":5768,"start":18003,"enrollment":57053,"conditions":57054,"interventions":57055},"NCT02392455","VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)",[],817,[36],[57035],{"intervention":52357,"totalTrials":272,"cells":57057},{"EARLY_PHASE1":57058,"PHASE1":57060,"PHASE2":57062,"PHASE3":57064,"PHASE4":57066,"NA":57068},{"trials":57059,"activeCount":101},[],{"trials":57061,"activeCount":101},[],{"trials":57063,"activeCount":101},[],{"trials":57065,"activeCount":101},[],{"trials":57067,"activeCount":101},[],{"trials":57069,"activeCount":101},[57070],{"nctId":52351,"briefTitle":52352,"status":107,"phases":57071,"primaryCompletion":964,"completion":2702,"start":52354,"enrollment":1865,"conditions":57072,"interventions":57073},[94],[2968],[969,2393,52357,971],{"intervention":57075,"totalTrials":272,"cells":57076},"Prazaxa®",{"EARLY_PHASE1":57077,"PHASE1":57079,"PHASE2":57081,"PHASE3":57083,"PHASE4":57085,"NA":57087},{"trials":57078,"activeCount":101},[],{"trials":57080,"activeCount":101},[],{"trials":57082,"activeCount":101},[],{"trials":57084,"activeCount":101},[],{"trials":57086,"activeCount":101},[],{"trials":57088,"activeCount":101},[57089],{"nctId":57090,"briefTitle":57091,"status":107,"phases":57092,"primaryCompletion":19225,"completion":57093,"start":5332,"enrollment":57094,"conditions":57095,"interventions":57096},"NCT03175198","Japanese Pradaxa PMS, Long Term",[],"2021-01-12",5660,[6098],[57075],{"intervention":57098,"totalTrials":272,"cells":57099},"JARDIANCE DUO®",{"EARLY_PHASE1":57100,"PHASE1":57102,"PHASE2":57104,"PHASE3":57106,"PHASE4":57108,"NA":57110},{"trials":57101,"activeCount":101},[],{"trials":57103,"activeCount":101},[],{"trials":57105,"activeCount":101},[],{"trials":57107,"activeCount":101},[],{"trials":57109,"activeCount":101},[],{"trials":57111,"activeCount":101},[57112],{"nctId":57113,"briefTitle":57114,"status":107,"phases":57115,"primaryCompletion":3813,"completion":3813,"start":6628,"enrollment":10740,"conditions":57116,"interventions":57117},"NCT03642717","Regulatory Request NIS in Korea",[],[21],[57098],{"intervention":54544,"totalTrials":272,"cells":57119},{"EARLY_PHASE1":57120,"PHASE1":57122,"PHASE2":57124,"PHASE3":57126,"PHASE4":57128,"NA":57130},{"trials":57121,"activeCount":101},[],{"trials":57123,"activeCount":101},[],{"trials":57125,"activeCount":101},[],{"trials":57127,"activeCount":101},[],{"trials":57129,"activeCount":101},[],{"trials":57131,"activeCount":101},[57132],{"nctId":54537,"briefTitle":54538,"status":107,"phases":57133,"primaryCompletion":54540,"completion":54540,"start":1856,"enrollment":54541,"conditions":57134,"interventions":57135},[],[30],[8806,54544],{"intervention":57137,"totalTrials":272,"cells":57138},"Micamlo",{"EARLY_PHASE1":57139,"PHASE1":57141,"PHASE2":57143,"PHASE3":57145,"PHASE4":57147,"NA":57149},{"trials":57140,"activeCount":101},[],{"trials":57142,"activeCount":101},[],{"trials":57144,"activeCount":101},[],{"trials":57146,"activeCount":101},[],{"trials":57148,"activeCount":101},[],{"trials":57150,"activeCount":101},[57151],{"nctId":57152,"briefTitle":57153,"status":107,"phases":57154,"primaryCompletion":9515,"completion":9515,"start":9348,"enrollment":57155,"conditions":57156,"interventions":57157},"NCT01353274","Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension",[],1157,[24],[57137],{"intervention":57159,"totalTrials":272,"cells":57160},"MaxSpiolto® Respimat® 160 Characters...",{"EARLY_PHASE1":57161,"PHASE1":57163,"PHASE2":57165,"PHASE3":57167,"PHASE4":57169,"NA":57171},{"trials":57162,"activeCount":101},[],{"trials":57164,"activeCount":101},[],{"trials":57166,"activeCount":101},[],{"trials":57168,"activeCount":101},[],{"trials":57170,"activeCount":101},[],{"trials":57172,"activeCount":101},[57173],{"nctId":57174,"briefTitle":57175,"status":107,"phases":57176,"primaryCompletion":57177,"completion":57178,"start":57179,"enrollment":57180,"conditions":57181,"interventions":57182},"NCT03419962","Greek NIS Spiolto ELLACTO",[],"2018-11-09","2019-04-03","2018-03-19",1360,[18],[57159],{"intervention":57184,"totalTrials":272,"cells":57185},"Mirapex LA",{"EARLY_PHASE1":57186,"PHASE1":57188,"PHASE2":57190,"PHASE3":57192,"PHASE4":57194,"NA":57196},{"trials":57187,"activeCount":101},[],{"trials":57189,"activeCount":101},[],{"trials":57191,"activeCount":101},[],{"trials":57193,"activeCount":101},[],{"trials":57195,"activeCount":101},[],{"trials":57197,"activeCount":101},[57198],{"nctId":57199,"briefTitle":57200,"status":107,"phases":57201,"primaryCompletion":4391,"completion":4391,"start":9538,"enrollment":57202,"conditions":57203,"interventions":57204},"NCT01525641","Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease",[],615,[6934],[57184],{"intervention":57206,"totalTrials":272,"cells":57207},"TRADIANCE® Combination Tablets AP",{"EARLY_PHASE1":57208,"PHASE1":57210,"PHASE2":57212,"PHASE3":57214,"PHASE4":57216,"NA":57218},{"trials":57209,"activeCount":101},[],{"trials":57211,"activeCount":101},[],{"trials":57213,"activeCount":101},[],{"trials":57215,"activeCount":101},[],{"trials":57217,"activeCount":101},[],{"trials":57219,"activeCount":101},[57220],{"nctId":57221,"briefTitle":57222,"status":107,"phases":57223,"primaryCompletion":18754,"completion":1251,"start":18815,"enrollment":57224,"conditions":57225,"interventions":57226},"NCT03761797","A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes",[],1164,[21],[57206,57227],"TRADIANCE® Combination Tablets BP",{"intervention":57227,"totalTrials":272,"cells":57229},{"EARLY_PHASE1":57230,"PHASE1":57232,"PHASE2":57234,"PHASE3":57236,"PHASE4":57238,"NA":57240},{"trials":57231,"activeCount":101},[],{"trials":57233,"activeCount":101},[],{"trials":57235,"activeCount":101},[],{"trials":57237,"activeCount":101},[],{"trials":57239,"activeCount":101},[],{"trials":57241,"activeCount":101},[57242],{"nctId":57221,"briefTitle":57222,"status":107,"phases":57243,"primaryCompletion":18754,"completion":1251,"start":18815,"enrollment":57224,"conditions":57244,"interventions":57245},[],[21],[57206,57227],{"intervention":891,"totalTrials":272,"cells":57247},{"EARLY_PHASE1":57248,"PHASE1":57250,"PHASE2":57252,"PHASE3":57254,"PHASE4":57256,"NA":57258},{"trials":57249,"activeCount":101},[],{"trials":57251,"activeCount":101},[],{"trials":57253,"activeCount":101},[],{"trials":57255,"activeCount":101},[],{"trials":57257,"activeCount":101},[],{"trials":57259,"activeCount":101},[57260],{"nctId":883,"briefTitle":884,"status":107,"phases":57261,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":57262,"interventions":57263},[],[21],[383,891],{"intervention":57265,"totalTrials":272,"cells":57266},"Zentiva®",{"EARLY_PHASE1":57267,"PHASE1":57269,"PHASE2":57271,"PHASE3":57273,"PHASE4":57275,"NA":57277},{"trials":57268,"activeCount":101},[],{"trials":57270,"activeCount":101},[],{"trials":57272,"activeCount":101},[],{"trials":57274,"activeCount":101},[],{"trials":57276,"activeCount":101},[],{"trials":57278,"activeCount":101},[57279],{"nctId":57280,"briefTitle":57281,"status":107,"phases":57282,"primaryCompletion":57283,"completion":30404,"start":57284,"enrollment":8304,"conditions":57285,"interventions":57286},"NCT05278104","A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)",[94],"2024-10-23","2023-09-14",[3926],[57265],{"intervention":57288,"totalTrials":272,"cells":57289},"Vahelva® Respimat®",{"EARLY_PHASE1":57290,"PHASE1":57292,"PHASE2":57294,"PHASE3":57296,"PHASE4":57298,"NA":57300},{"trials":57291,"activeCount":101},[],{"trials":57293,"activeCount":101},[],{"trials":57295,"activeCount":101},[],{"trials":57297,"activeCount":101},[],{"trials":57299,"activeCount":101},[],{"trials":57301,"activeCount":101},[57302],{"nctId":57303,"briefTitle":57304,"status":107,"phases":57305,"primaryCompletion":4252,"completion":4252,"start":111,"enrollment":57306,"conditions":57307,"interventions":57308},"NCT02864407","Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease",[],3223,[18],[57288],{"intervention":49610,"totalTrials":272,"cells":57310},{"EARLY_PHASE1":57311,"PHASE1":57313,"PHASE2":57315,"PHASE3":57317,"PHASE4":57319,"NA":57321},{"trials":57312,"activeCount":101},[],{"trials":57314,"activeCount":101},[],{"trials":57316,"activeCount":101},[],{"trials":57318,"activeCount":101},[],{"trials":57320,"activeCount":101},[],{"trials":57322,"activeCount":101},[57323],{"nctId":49604,"briefTitle":49605,"status":107,"phases":57324,"primaryCompletion":9538,"start":9332,"enrollment":49607,"conditions":57325,"interventions":57326},[],[30613],[49610,49611,49612,49613,6121],{"intervention":49611,"totalTrials":272,"cells":57328},{"EARLY_PHASE1":57329,"PHASE1":57331,"PHASE2":57333,"PHASE3":57335,"PHASE4":57337,"NA":57339},{"trials":57330,"activeCount":101},[],{"trials":57332,"activeCount":101},[],{"trials":57334,"activeCount":101},[],{"trials":57336,"activeCount":101},[],{"trials":57338,"activeCount":101},[],{"trials":57340,"activeCount":101},[57341],{"nctId":49604,"briefTitle":49605,"status":107,"phases":57342,"primaryCompletion":9538,"start":9332,"enrollment":49607,"conditions":57343,"interventions":57344},[],[30613],[49610,49611,49612,49613,6121],{"intervention":49612,"totalTrials":272,"cells":57346},{"EARLY_PHASE1":57347,"PHASE1":57349,"PHASE2":57351,"PHASE3":57353,"PHASE4":57355,"NA":57357},{"trials":57348,"activeCount":101},[],{"trials":57350,"activeCount":101},[],{"trials":57352,"activeCount":101},[],{"trials":57354,"activeCount":101},[],{"trials":57356,"activeCount":101},[],{"trials":57358,"activeCount":101},[57359],{"nctId":49604,"briefTitle":49605,"status":107,"phases":57360,"primaryCompletion":9538,"start":9332,"enrollment":49607,"conditions":57361,"interventions":57362},[],[30613],[49610,49611,49612,49613,6121],{"intervention":57364,"totalTrials":272,"cells":57365},"Secotex®",{"EARLY_PHASE1":57366,"PHASE1":57368,"PHASE2":57370,"PHASE3":57372,"PHASE4":57374,"NA":57376},{"trials":57367,"activeCount":101},[],{"trials":57369,"activeCount":101},[],{"trials":57371,"activeCount":101},[],{"trials":57373,"activeCount":101},[],{"trials":57375,"activeCount":101},[],{"trials":57377,"activeCount":101},[57378],{"nctId":57379,"briefTitle":57380,"status":107,"phases":57381,"primaryCompletion":8086,"start":6445,"enrollment":57382,"conditions":57383,"interventions":57384},"NCT02244346","Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)",[],811,[6741],[57364],{"intervention":57386,"totalTrials":272,"cells":57387},"Low dose of Telmisartan, once daily",{"EARLY_PHASE1":57388,"PHASE1":57390,"PHASE2":57392,"PHASE3":57394,"PHASE4":57396,"NA":57398},{"trials":57389,"activeCount":101},[],{"trials":57391,"activeCount":101},[],{"trials":57393,"activeCount":101},[],{"trials":57395,"activeCount":101},[],{"trials":57397,"activeCount":101},[],{"trials":57399,"activeCount":101},[57400],{"nctId":57401,"briefTitle":57402,"status":107,"phases":57403,"primaryCompletion":6053,"start":6206,"enrollment":57404,"conditions":57405,"interventions":57406},"NCT02200094","Micardis®. Observational Study in Patients With Essential Hypertension",[],4532,[24],[57386,57407],"High dose of Telmisartan, once daily",{"intervention":57407,"totalTrials":272,"cells":57409},{"EARLY_PHASE1":57410,"PHASE1":57412,"PHASE2":57414,"PHASE3":57416,"PHASE4":57418,"NA":57420},{"trials":57411,"activeCount":101},[],{"trials":57413,"activeCount":101},[],{"trials":57415,"activeCount":101},[],{"trials":57417,"activeCount":101},[],{"trials":57419,"activeCount":101},[],{"trials":57421,"activeCount":101},[57422],{"nctId":57401,"briefTitle":57402,"status":107,"phases":57423,"primaryCompletion":6053,"start":6206,"enrollment":57404,"conditions":57424,"interventions":57425},[],[24],[57386,57407],{"intervention":57427,"totalTrials":272,"cells":57428},"Trajenta",{"EARLY_PHASE1":57429,"PHASE1":57431,"PHASE2":57433,"PHASE3":57435,"PHASE4":57437,"NA":57439},{"trials":57430,"activeCount":101},[],{"trials":57432,"activeCount":101},[],{"trials":57434,"activeCount":101},[],{"trials":57436,"activeCount":101},[],{"trials":57438,"activeCount":101},[],{"trials":57440,"activeCount":101},[57441],{"nctId":57442,"briefTitle":57443,"status":107,"phases":57444,"primaryCompletion":18686,"completion":18686,"start":57445,"enrollment":57446,"conditions":57447,"interventions":57448},"NCT01707147","A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus",[],"2012-11-16",3219,[21],[57427],{"intervention":57450,"totalTrials":272,"cells":57451},"METALYSE®",{"EARLY_PHASE1":57452,"PHASE1":57454,"PHASE2":57456,"PHASE3":57458,"PHASE4":57460,"NA":57462},{"trials":57453,"activeCount":101},[],{"trials":57455,"activeCount":101},[],{"trials":57457,"activeCount":101},[],{"trials":57459,"activeCount":101},[],{"trials":57461,"activeCount":101},[],{"trials":57463,"activeCount":101},[57464],{"nctId":57465,"briefTitle":57466,"status":107,"phases":57467,"primaryCompletion":4005,"start":11581,"enrollment":123,"conditions":57468,"interventions":57469},"NCT02191670","Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation",[],[632],[57450],{"intervention":53886,"totalTrials":272,"cells":57471},{"EARLY_PHASE1":57472,"PHASE1":57474,"PHASE2":57476,"PHASE3":57478,"PHASE4":57480,"NA":57482},{"trials":57473,"activeCount":101},[],{"trials":57475,"activeCount":101},[],{"trials":57477,"activeCount":101},[],{"trials":57479,"activeCount":101},[],{"trials":57481,"activeCount":101},[],{"trials":57483,"activeCount":101},[57484],{"nctId":53878,"briefTitle":53879,"status":107,"phases":57485,"primaryCompletion":3879,"completion":3879,"start":53881,"enrollment":53882,"conditions":57486,"interventions":57487},[],[53884],[53854,53886],{"intervention":57489,"totalTrials":272,"cells":57490},"Trajenta duo",{"EARLY_PHASE1":57491,"PHASE1":57493,"PHASE2":57495,"PHASE3":57497,"PHASE4":57499,"NA":57501},{"trials":57492,"activeCount":101},[],{"trials":57494,"activeCount":101},[],{"trials":57496,"activeCount":101},[],{"trials":57498,"activeCount":101},[],{"trials":57500,"activeCount":101},[],{"trials":57502,"activeCount":101},[57503],{"nctId":57504,"briefTitle":57505,"status":107,"phases":57506,"primaryCompletion":240,"completion":57507,"start":57508,"enrollment":57509,"conditions":57510,"interventions":57511},"NCT01903356","A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea",[],"2017-06-10","2013-07-11",724,[21],[57489],{"intervention":57513,"totalTrials":272,"cells":57514},"Non-vitamin K antagonist oral anticoagulant",{"EARLY_PHASE1":57515,"PHASE1":57517,"PHASE2":57519,"PHASE3":57521,"PHASE4":57523,"NA":57525},{"trials":57516,"activeCount":101},[],{"trials":57518,"activeCount":101},[],{"trials":57520,"activeCount":101},[],{"trials":57522,"activeCount":101},[],{"trials":57524,"activeCount":101},[],{"trials":57526,"activeCount":101},[57527],{"nctId":57528,"briefTitle":57529,"status":107,"phases":57530,"primaryCompletion":57531,"completion":57531,"start":57532,"enrollment":8344,"conditions":57533,"interventions":57534},"NCT03993119","This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain",[],"2020-08-20","2019-07-30",[6098],[57513],{"intervention":57536,"totalTrials":272,"cells":57537},"Mirapexin®",{"EARLY_PHASE1":57538,"PHASE1":57540,"PHASE2":57542,"PHASE3":57544,"PHASE4":57546,"NA":57548},{"trials":57539,"activeCount":101},[],{"trials":57541,"activeCount":101},[],{"trials":57543,"activeCount":101},[],{"trials":57545,"activeCount":101},[],{"trials":57547,"activeCount":101},[],{"trials":57549,"activeCount":101},[57550],{"nctId":57551,"briefTitle":57552,"status":107,"phases":57553,"primaryCompletion":9396,"start":399,"enrollment":57554,"conditions":57555,"interventions":57556},"NCT02236741","The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia",[],26814,[573],[57536]]